<SEC-DOCUMENT>0001213900-21-018061.txt : 20210329
<SEC-HEADER>0001213900-21-018061.hdr.sgml : 20210329
<ACCEPTANCE-DATETIME>20210326193931
ACCESSION NUMBER:		0001213900-21-018061
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		117
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210329
DATE AS OF CHANGE:		20210326

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Clene Inc.
		CENTRAL INDEX KEY:			0001822791
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39834
		FILM NUMBER:		21779113

	BUSINESS ADDRESS:	
		STREET 1:		6550 SOUTH MILLROCK DRIVE, SUITE G50
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84121
		BUSINESS PHONE:		801-676-9695

	MAIL ADDRESS:	
		STREET 1:		6550 SOUTH MILLROCK DRIVE, SUITE G50
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Chelsea Worldwide Inc.
		DATE OF NAME CHANGE:	20200827
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>f10k2020_cleneinc.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>FORM
10-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9746;
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal year ended <B><U>December 31, 2020</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
<B>TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the transition period from _____________ to _____________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number: <B><U>01-39834</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>Clene
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>85-2828339</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction of <BR>
    incorporation or organization)</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer<BR>
    Identification No.)</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6550
                                         South Millrock Drive, Suite G50</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Salt
        Lake City, Utah</B></FONT></P></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>84121</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>(801) 676 9695</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 51%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title
    of each class</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading
    Symbol(s)</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    of each exchange on which registered</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock, $0.0001 par value</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CLNN</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Nasdaq Capital Market</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants,
    to acquire one-half of one share of Common Stock for $11.50 per share</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CLNNW</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Nasdaq Capital Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(g) of the Act: <B>None.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; No
&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes
&#9744; No &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and
(2) has been subject to such filing requirements for the past 90 days. Yes &#9746; No &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant
to Rule 405 of Regulation S-T (&sect; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit such files). Yes &#9746; No &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo;
&ldquo;smaller reporting company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; width: 25%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</FONT></TD>
    <TD STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 25%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</FONT></TD>
    <TD STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
    filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    Growth Company</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&rsquo;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The common stock of the registrant has been traded on the Nasdaq
Capital Market under the symbol &ldquo;CLNN&rdquo; since December 31, 2020, which is the business day following the consummation
of the business combination among the registrant and Tottenham Acquisition I Limited, which traded on the Nasdaq Capital Market
under the symbol &ldquo;TOTA.&rdquo; The aggregate market value of TOTA&rsquo;s common stock held by non-affiliates of TOTA, based
on the closing price of TOTA&rsquo;s common stock on the Nasdaq Capital Market as of June 30, 2020, the last business day of TOTA&rsquo;s
most recently completed second fiscal quarter, was approximately $23.3 million, based on the closing price of TOTA&rsquo;s common
stock on the Nasdaq Capital Market of $10.79 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares outstanding of the Registrant&rsquo;s shares of common stock as of March 25, 2021 was 59,526,171.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DOCUMENTS
INCORPORATED BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
portions of the registrant&rsquo;s definitive proxy statement, in connection with its 2021 annual meeting of stockholders, to
be filed within 120 days after the end of fiscal year ended December 31, 2020, are incorporated by reference into Part III of
this Annual Report on Form 10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CLENE
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Annual
Report on Form 10-K for the Year Ended December 31, 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A HREF="#a_001">PART
    I</A></B></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1</B></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 0.35in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; width: 14%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_002">ITEM
    1.</A> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0in; padding-bottom: 0in; width: 76%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_002">BUSINESS</A></FONT></TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0in; padding-bottom: 0in; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.35in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_003">ITEM
    1A.</A> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_003">RISK
    FACTORS</A></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 0.35in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_004">ITEM
    1B.</A> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_004">UNRESOLVED
    STAFF COMMENTS</A></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.35in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_005">ITEM
    2.</A> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_005">PROPERTIES</A></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 0.35in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_006">ITEM
    3.</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_006">LEGAL
    PROCEEDINGS</A></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.35in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_007">ITEM
    4.</A> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_007">MINE
    SAFETY DISCLOSURES</A></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 0.35in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0in; padding-bottom: 0in">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0in; padding-bottom: 0in">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A HREF="#a_008">PART
    II</A></B></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>77</B></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 0.35in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_009">ITEM
    5.</A> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_009">MARKET
    FOR REGISTRANT&rsquo;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</A></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.35in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_010">ITEM
    6.</A> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_010">SELECTED
    FINANCIAL DATA</A></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 0.35in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_011">ITEM
    7.</A> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_011">MANAGEMENT&rsquo;S
    DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</A></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.35in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_012">ITEM
    7A.</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_012">QUANTITATIVE
    AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</A></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 0.35in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_013">ITEM
    8.</A> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_013">FINANCIAL
    STATEMENTS AND SUPPLEMENTARY DATA</A></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">95</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.35in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_014">ITEM
    9.</A> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_014">CHANGES
    IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</A></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0in; padding-bottom: 0in">96</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 0.35in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_015">ITEM
    9A.</A> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_015">CONTROLS
    AND PROCEDURES</A></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.35in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_016">ITEM
    9B.</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_016">OTHER
    INFORMATION</A></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 0.35in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0in; padding-bottom: 0in">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0in; padding-bottom: 0in">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A HREF="#a_017">PART
    III</A></B></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>99</B></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 0.35in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_018">ITEM
    10.</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_018">DIRECTORS,
    EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</A></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.35in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_019">ITEM
    11.</A> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_019">EXECUTIVE
    COMPENSATION</A></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 0.35in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_020">ITEM
    12.</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_020">SECURITY
    OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</A></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.35in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_021">ITEM
    13.</A> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_021">CERTAIN
    RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</A></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 0.35in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_022">ITEM
    14.</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_022">PRINCIPAL
    ACCOUNTANT FEES AND SERVICES</A></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.35in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0in; padding-bottom: 0in">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0in; padding-bottom: 0in">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A HREF="#a_023">PART
    IV</A></B></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>100</B></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.35in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_024">ITEM
    15.</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_024">EXHIBITS
    AND FINANCIAL STATEMENT SCHEDULES</A></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 0.35in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0in; padding-bottom: 0in">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0in; padding-bottom: 0in">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A HREF="#a_025">EXHIBIT
    INDEX</A></B></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>101</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_001"></A>PART
I</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Throughout this Annual Report on Form 10-K (the &ldquo;Annual
Report&rdquo;), the &ldquo;Company,&rdquo; and references to &ldquo;we,&rdquo; &ldquo;us,&rdquo; or similar such references should
be understood to be references to the combined company, Clene Inc. When this Annual Report references &ldquo;Clene&rdquo; and describes
the business of Clene, it refers to the business of Clene Nanomedicine, Inc. and its subsidiaries, prior to the consummation of
the business combination (referred to throughout as the &ldquo;Reverse Recapitalization&rdquo;). Following the date of the Reverse
Recapitalization, references to &ldquo;Clene&rdquo; should be understood to reference Clene Inc. Given that the Reverse Recapitalization
is accounted for as a reverse recapitalization, as described in more detail below, and the accounting acquirer is Clene Nanomedicine,
Inc., the post-Reverse Recapitalization financial statements included in this Annual Report show the consolidated balances and
transactions of the Company and Clene as well as comparative financial information of Clene (the acquirer for accounting purposes).</I></Font></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CAUTIONARY
STATEMENT REGARDING FORWARD LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, or the Securities
Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). The statements contained
in this Annual Report that are not purely historical are forward-looking statements. Our forward-looking statements include, but
are not limited to, statements regarding our or our management team&rsquo;s expectations, hopes, beliefs, intentions or strategies
regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events
or circumstances, including any underlying assumptions, are forward-looking statements. The words &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo;
&ldquo;contemplate,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intends,&rdquo;
&ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;plan,&rdquo; &ldquo;possible,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo;
&ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo; and similar expressions may identify forward-looking
statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in
this Annual Report may include, for example, statements about:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
benefits of the Reverse Recapitalization;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         future financial performance of the Company;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         clinical results of our drug candidates;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         likelihood of commercial success for our drug candidates;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                         in the market for our services;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion
                                         plans and opportunities; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
                                         factors detailed under the section entitled &ldquo;<I>Risk Factors</I>.&rdquo;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
forward-looking statements are based on information available as of the date of this Annual Report, the information incorporated
herein by reference and our management&rsquo;s current expectations, forecasts and assumptions, and involve a number of judgments,
risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing our views as of any
subsequent date. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the
date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable
securities laws.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different
from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
outcome of any legal proceedings that may be instituted against us following the consummation of the Reverse Recapitalization;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         inability to maintain the listing of our Common Stock or warrants on The Nasdaq Stock
                                         Market;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to demonstrate the efficacy and safety of our drug candidates;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         clinical results for our drug candidates, which may not support further development or
                                         marketing approval;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actions
                                         of regulatory agencies, which may affect the initiation, timing and progress of clinical
                                         trials and marketing approval;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to achieve commercial success for our marketed products and drug candidates,
                                         if approved;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to obtain and maintain protection of intellectual property for our technology
                                         and drugs;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         reliance on third parties to conduct drug development, manufacturing and other services;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         limited operating history and our ability to obtain additional funding for operations
                                         and to complete the licensing or development and commercialization of our drug candidates;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         impact of the COVID-19 pandemic on our clinical development, commercial and other operations;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                         in applicable laws or regulations;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         possibility that we may be adversely affected by other economic, business, and/or competitive
                                         factors; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
                                         risks and uncertainties set forth in the section entitled &ldquo;<I>Risk Factors</I>&rdquo;.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_002"></A>ITEM
1. BUSINESS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Overview</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean surfaced
nanotechnology (CSN) therapeutics. CSN therapeutics are comprised of atoms of transition elements that when assembled in nanocrystalline
form, possess unusually high, unique catalytic activities not present in those same elements in bulk form. These nanocatalytic
activities drive, support, and maintain beneficial metabolic and energetic intercellular reactions within diseased, stressed,
and damaged cells.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Our patent-protected, proprietary position affords us the potential
to develop a broad and deep pipeline of novel&nbsp;CSN therapeutics to address a range of diseases with high impact on human health.
We began in 2013 by innovating an electrochemistry drug development platform that draws from advances in nanotechnology, plasma
and quantum physics, material science, and biochemistry. Our platform process results in nanocrystals with faceted surfaces that
are free of the chemical surface modifications that accompany other production methods. Many traditional methods of nanoparticle
synthesis involve the unavoidable deposition of potentially toxic organic residues and stabilizing surfactants on the particle
surfaces. Synthesizing stable nanocrystals that are both nontoxic and highly catalytic has overcome this significant hurdle in
harnessing transition metal catalytic activity for therapeutic use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clean-surfaced nanocrystals exhibit catalytic activities many-fold higher than other commercially available nanoparticles, produced
using various techniques, that we have comparatively evaluated. We have multiple drug assets currently in development for applications
in neurology, infectious disease, and oncology. Our efforts are currently focused on addressing the high unmet medical needs in
two areas: first, those related to central nervous system disorders including Multiple Sclerosis (&ldquo;<U>MS</U>&rdquo;), Parkinson&rsquo;s
Disease (&ldquo;<U>PD</U>&rdquo;) and Amyotrophic Lateral Sclerosis (&ldquo;<U>ALS</U>&rdquo;); and second, those related to the
pandemic caused by COVID-19, a highly infectious viral respiratory disease with serious and sometimes fatal co-morbidities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
Clene Approach</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Clene approach to drug development is <I>innovation focused</I> and <I>scientifically driven</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Innovation
focused</I> &mdash; There are a significant number of diseases with high impact on human health that
have proven exceedingly challenging for traditional small-molecule or biologic drug development approaches. Our approach involves
the innovation of highly active therapeutic nanocatalysts with novel mechanisms of action that result from proprietary advances
in nanotechnology, plasma and quantum physics, biochemistry, and materials science. This platform affords us the ability to make
new drug modalities targeting a wide range of diseases that have eluded intervention using traditional small molecule or monoclonal
antibody approaches.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Scientifically
                                         driven </I>&mdash; Clear scientific rationale and sound experimental design drive our
                                         discoveries, from basic science to clinical trials. We believe we have established ourselves
                                         as an industry leader in position for the development of therapeutic catalytic nanocrystals.
                                         We have deep knowledge of the chemical properties, safety profiles, and catalytic abilities
                                         of transitional metal nanocrystals and have proven abilities to produce concentrated,
                                         stable, highly active, clean-surfaced nanocrystal suspensions using efficient, &ldquo;green,&rdquo;
                                         scalable processes. In so doing, we are establishing, new classes of nanomedicines with
                                         the potential to address some of the most serious diseases affecting human health.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Strategy
and Leadership</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
management team is key to the successful execution of this strategic plan and fulfillment of our business model. Our exceptional
team brings extensive expertise and industry experience to their roles in leading the company skillfully and effectively. The
members of the executive team have established track records in scientific innovation, early and late-stage pharmaceutical development,
commercialization, marketing, and the generation and protection of intellectual property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
innovation of CSN therapeutic candidates places us at the forefront of novel drug development for a host of high impact, high
unmet need human diseases. As we lead the development of CSN therapeutics, our business strategy can be encapsulated by the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>First
                                         mover advantage&nbsp;&mdash; </I>We believe that our proprietary knowledge of the processes
                                         needed to manufacture clean-surfaced, highly faceted, catalytically active nanocrystals,
                                         and of the resulting toxicological and physicochemical properties associated with these
                                         nanocrystals, places us in a leadership position in the innovation and development of
                                         new candidate therapeutics for diseases that have proven to be extremely difficult to
                                         target using traditional methods.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Wide
                                         range of applicability&nbsp;&mdash;</I> Energy metabolism is a fundamental mechanism
                                         in all living cells, and CSN therapeutics that improve cellular bioenergetic efficiencies
                                         have the potential to be applied to many different disease states and cell types. An
                                         advantage of this approach is that a single drug candidate can be developed to hit multiple
                                         targets in multiple diseased cell types, presently being investigated across multiple
                                         clinical trials with our lead asset, CNM-Au8, through its clinical development program.
                                         We continue to explore ways in which the unique mechanisms of action of CSN therapeutics
                                         can be applied across different diseases.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Flexibility
                                         and tunability&nbsp;&mdash; </I>Nanocatalytic activities are determined by the shape,
                                         faceting, size, and chemical composition of nanocrystals. Our CSN platform has demonstrated
                                         flexibility in its ability to make, for instance, both pure gold and gold-platinum nanocrystals
                                         of consistent and reproducible shapes and sizes, in addition to making solutions of ionic
                                         zinc and silver. Because of the ease with which new single elemental and composite nanocrystals
                                         can be made of varying shapes and sizes using our proprietary techniques, we plan to
                                         continue developing a wide range of CSN therapeutics to generate a deep pipeline of drug
                                         candidates to treat a host of different diseases.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Intellectual
Property, Trade Secrets and Manufacturing</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are the sole inventors of our manufacturing processes, devices, and drugs. These inventions are protected by a comprehensive intellectual
property portfolio of over 100 patents issued worldwide, with over 30 additional patents pending. See &ldquo;&mdash; <I>Intellectual
Property</I>&rdquo; for more details. The patents relate to (1)&nbsp;the devices that manufacture our CSN therapeutic drug candidates,
(2)&nbsp;the processes involved in the use of these devices, (3)&nbsp;the drug candidates manufactured in these devices, and (4)&nbsp;methods
of use for the drug candidates. In addition to filings for U.S. and foreign patents, we will continue to protect and maintain
our proprietary position by the use of trademarks, trade secrets, copyright protection, and continued technological innovation.
For example, years of intensive research and development were invested in fine-tuning our production and delivery processes to
the point where we expect to be able to consistently, reliably, and affordably produce our drug candidates, including CNM-Au8,
to meet large scale needs. We believe that any attempts to reverse engineer or otherwise replicate our discoveries would be extraordinarily
challenging for potential competitors without violating our intellectual property protections.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also focused on building out a robust and relevant trade secret portfolio. Our trade secret portfolio largely relates to the
liquid handling and processing of our water-based products from start to finish. In the case of our lead asset, CNM-Au8, highly
purified water containing at least one processing enhancer enters the production device where it is exposed to a plasma-conditioning
step. The exact nature of the plasma conditioning affects additional constituents that can become part of the flowing water thus
affecting the subsequent crystal growth processes. Likewise, many details of the electrode design, configuration and operation
also affect the electrochemical crystal growth processes that occur at each electrode set. Similarly, many design and operational
aspects of each trough device directly affect the electrochemical crystal growth processes that occur at each electrode set. Finally,
various aspects of liquid handling subsequent to crystal growth, such as concentration and filling, are critical so as not to
introduce any contaminates into the liquid, which could alter the surfaces of the nanocrystals, thus adding toxicity and/or adversely
affecting efficacy of the biological catalysis processes. We continue to explore additional ways to expand our trade secret portfolio
in various aspects of the design, production, control and manufacture of our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
manufacturing facility meets rigorous international Good Manufacturing Processes (&ldquo;<U>GMP</U>&rdquo;) standards in producing
our CSN therapeutics. Furthermore, we have the space and know-how to expand and scale up production as we continue to meet increased
demands for our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Products</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
CSN therapeutic candidates aim to address high unmet medical needs in several disease areas including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disease
                                         modification of <B>central nervous system disorders</B>, including MS, PD and ALS;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         treatment of <B>infectious diseases</B>, including COVID-19;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">accelerated
                                         <B>wound healing and scar formation</B>; and,</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         treatment of <B>selected cancer types</B>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the development of faceted, clean-surfaced nanocrystals, our electro-crystal-chemistry platform can produce ionic
solutions of various transition elements including silver, zinc, and others&nbsp;&mdash; elements which have proven historical
utility in the treatment of disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CNM-Au8</B>,
                                         our lead asset, is a highly concentrated aqueous suspension of clean-surfaced, highly
                                         faceted nanocrystalline gold (&ldquo;Au&rdquo;). CNM-Au8&rsquo;s nanocatalytic mechanisms
                                         target the bioenergetic deficits, oxidative stress, and accumulation of misfolded proteins
                                         that are common to many neurodegenerative diseases. CNM-Au8 is hypothesized to act as
                                         a neuroprotective and remyelinating therapy in neurodegenerative disease states in order
                                         to: 1) drive, support, and maintain beneficial metabolic and energetic intracellular
                                         reactions within diseased, stressed, and/or damaged cells, 2) directly catalyze the reduction
                                         of harmful, reactive oxygen species, and 3) promote protein homeostasis via activation
                                         of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded
                                         and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.
                                         We believe that CNM-Au8 is the only drug candidate in development with these unique nanocatalytic
                                         mechanisms of action. Nonclinical toxicology studies have demonstrated no adverse effect
                                         levels (&ldquo;NOAELs&rdquo;) even up to maximum feasible dosing levels for oral administration.
                                         <I>In vitro</I> and in <I>vivo</I> pharmacology studies have demonstrated that CNM-Au8
                                         treatment enhances remyelination and neuroprotection in numerous models of MS, PD, and
                                         ALS. A Phase 1 First-In-Human study did not reveal safety or tolerability concerns for
                                         CNM-Au8 in healthy human volunteers dosed in accordance with the study protocol. There
                                         are four Phase&nbsp;2 clinical studies presently underway evaluating the efficacy and
                                         safety of CNM-Au8 for the treatment of MS, PD, and ALS, an Expanded Access Program for
                                         ALS, and one Phase 3 registrational clinical trial underway that has the potential to
                                         fully support a New Drug Application (NDA) for the treatment of ALS, each of which is
                                         discussed in detail below.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CNM-ZnAg
                                         </B>is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn<SUP>2+</SUP>)
                                         and silver (Ag<SUP>+</SUP>) ions under development to treat disease-causing infections,
                                         such as COVID-19, and to provide immune support for symptom resolution. Zn<SUP>2+ </SUP>and
                                         Ag<SUP>+</SUP> ions are produced in aqueous solutions using our electrochemistry manufacturing
                                         platform; combining Zn<SUP>2+ </SUP>and Ag<SUP>+</SUP> ions made in this manner leads
                                         to enhanced bioavailability of the ions and potentially, synergistic immune system effects.
                                         One clinical study commenced in February, 2021 in Brazil, to determine ZnAg efficacy
                                         for the treatment of symptomatic subjects with COVID-19 to prevent hospitalization.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CNM-AgZn-17
                                         </B>is a gel polymer suspension of Ag<SUP>+ </SUP>and Zn<SUP>2+</SUP> under development
                                         for treatment of infectious diseases and to support wound healing. We have demonstrated
                                         in <I>in vitro</I> assays that CNM-AgZn17 has broad-based anti-viral and anti-bacterial
                                         activity against common and antibiotic resistant pathogens such as Methicillin-resistant
                                         <I>Staphylococcus aureus</I>. We have also shown enhanced wound healing benefits in animal
                                         models of diabetic wound healing and decreased scar formation following burns. We anticipate
                                         filing an Investigational New Drug (IND) application with the FDA and subsequently plan
                                         to initiate a Phase 1 dermal First-In-Human safety study with CNM-AgZn17 in 2022.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CNM-PtAu7
                                         </B>is a gold-platinum combination nanocrystal with the potential to be an effective
                                         treatment for oncology indications. We have demonstrated <I>in vitro</I> up-regulation
                                         of pro-apoptotic and down-regulation of anti-apoptotic genes in the human breast cancer
                                         cell lines EFM-19 and MT-3 using CNM-PtAu7. We have further demonstrated down-regulation
                                         of genes associated with the electron transport chain activity which may relate to changes
                                         in tumorigenesis activity. We anticipate initiating standard animal toxicology programs
                                         in late 2022 with an IND filing planned between 2023&nbsp;&ndash; 2024, subject to evaluation
                                         of the safety and efficacy learnings from the preclinical oncology assays and toxicology
                                         findings.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Supplements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
patented electrochemistry manufacturing platform further enables us to develop very low concentration dietary supplements to advance
the health and well-being of broad populations. These dietary supplements can vary greatly and include nanocrystals of varying
composition, shapes and sizes as well as ionic solutions with diverse metallic constituents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dietary
supplements are marketed and distributed through our wholly owned subsidiary, dOrbital, Inc. (&ldquo;dOrbital&rdquo;), or through
an exclusive license with 4Life Research LLC (&ldquo;4Life&rdquo;). These include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>rMetx</B><SUP>&trade;
                                         </SUP>(ZnAg Immune Boost) by dOrbital; rMetx<SUP>&trade;</SUP> is an aqueous zinc-silver ion
                                         dietary (mineral) supplement made using our electrochemistry manufacturing platform with
                                         bioactive immune-supporting properties. rMetx<SUP>&trade;</SUP> is sold through dOrbital,
                                         and, a substantially similar product under the tradename, Zinc Factor<SUP>&trade;</SUP>, is
                                         sold by 4Life Research LLC (&ldquo;4Life&rdquo;), an international supplier of health
                                         supplements and a related party, under a supply agreement.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>KHC46
                                         (</B>Gold Factor<SUP>&trade;</SUP>) by 4Life: KHC46 is an aqueous gold dietary (mineral) supplement
                                         of very low-concentration Au nanoparticles produced using our electrochemistry manufacturing
                                         platform. KHC46 has different production methods and uses different devices resulting
                                         in different physiochemical properties from our lead drug candidate, CNM-Au8. KHC46 is
                                         licensed exclusively to 4Life for worldwide marketing and distribution.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Clinical
Development Pipeline</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have four Phase 2 clinical studies presently underway for the treatment of neurodegenerative disorders including MS, ALS, and
PD, one Expanded Access Program for ALS patients, one Phase 3 registrational clinical trial presently underway for disease-modification
in ALS, and a Phase&nbsp;2 clinical study for the treatment of COVID-19, which has received regulatory approval for conduct in
Brazil. In addition, we anticipate launching a clinical study for the treatment of PD in late 2021. The chart below reflects the
respective stages of our main drug candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Our
CSN Therapeutics Platform</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed a new pharmaceutical technology, CSN therapeutics. By uniting concepts from electrochemistry, nanotechnology, plasma
and quantum physics, material science, and biochemistry, we have created and refined a proprietary electrocrystallization method
that results in a single component or multiple components in nanocrystals of the transition elements that are clean-surfaced,
highly faceted, and biologically catalytically active. These nanocrystals can be concentrated as aqueous suspensions and orally
administered. We are further able to produce ionic solutions of various transitions elements utilizing our electrochemistry manufacturing
platform. Once in the gastrointestinal system, nanocrystals pass into the blood stream, and accumulate in organs such as the liver,
kidneys, and spleen, with lower amounts crossing the blood brain barrier and reaching the brain, spinal cord, and cerebrospinal
fluid. Nanocrystals can remain active within the body for days before they are eliminated via the hepatobiliary-fecal system as
well as via the urinary system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
inside the body, CSN therapeutics cross cellular membranes and enter cells where they directly donate and receive electrons within
biological systems. In this way, each nanocrystal acts as a potent nanocatalyst, that can drive, support, and maintain beneficial
metabolic and energetic intercellular reactions within diseased, stressed, and damaged cells. These catalytic, nanocrystal-based
therapeutic drugs represent an entirely new approach to drug development, substantially differing from the standard paradigm of
small-molecule drugs and large-molecule biologics. Unlike traditional pharmacological approaches, which are limited to single
targets or specific signaling pathways, our technology platform has produced metallic nanocrystals that are beneficial through
multi-modal activities in multiple cell types across multiple diseases. By utilizing intracellular medicinal catalysts to support
bioenergetic reactions within cells, we believe this technology represents a revolutionary advance in the treatment of the underlying
pathophysiology of neurodegeneration and related diseases associated with bioenergetic failure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Figure
1 below shows examples of the kinds of nanocrystals that can be produced using our CSN therapeutic platform.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
1. Representative CSN Therapeutic Nanocrystals</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_002.jpg" ALT="" STYLE="height: 265px; width: 850px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Figure
1. Representative transmission electron micrographs of the commonly observed crystalline shapes of gold nanocrystals (CNM-Au8)
resulting from our CSN therapeutic platform. Insets are wireframes illustrating each classic shape: A, pentagonal bipyramid; B,
tetrahedron; and C, hexagonal bipyramid. These nanocrystals are 10-13 nm in diameter.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Nanocatalysis</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
catalyst lowers the activation energy of a chemical reaction in such a way as to accelerate the rate of the reaction, without
being consumed in the reaction. In doing so, it does not change the equilibrium of the substrates and products, and it can catalyze
both forward and reverse reactions until homeostasis, or a balance of substrates and products, has been achieved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Several
industrial uses of metal nanocatalysts have been discovered, but to our knowledge, we are the only company currently developing
nanocatalysts to directly modulate biological systems as therapeutic drug candidates. Prior to our invention of the CSN therapeutic
platform, the methods employed to make stable nanoparticles required the use of organic solvents or capping agents, which would
contaminate the surfaces of the nanoparticles and were substantially difficult to remove. There are multiple conflicting reports
in the literature regarding the toxicity of these nanoparticles, ranging from reportedly non-toxic to highly toxic to living organisms.
We believe this lack of consistency may have been due to the varying degrees to which different nanoparticle preparations were
contaminated with organic reagents, leading to observed toxic effects. Because our electrocrystal chemistry method does not involve
the use of any organic solvents or reduction chemicals, we have observed that our nanocrystals possess substantially higher catalytic
activity in living organisms than those reported for nanoparticles made using other methods. All of the toxicology studies completed
with our lead asset, CNM-Au8, have resulted in NOAEL findings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transition
metal nanocatalysts are surface catalysts. Unlike enzymes, which are protein catalysts that lower activation energies using active
site binding pockets, metal nanocatalysts carry out their catalytic activities on their surfaces, where they act as exceptionally
efficient electron donors and receivers. For this reason, unmodified, clean surfaces that are free of contaminating chemicals
are extremely important for catalytic activity. The facets and vertices of the nanocrystals serve as the surface areas where electron
exchange can take place. Metal nanocatalysts have been shown to have a variety of different catalytic activities, including superoxide
dismutase, peroxidase, and catalase-like activities for reducing reactive oxygen species, to reactions involving the oxidation
of glucose, ascorbic acid, or the energetic metabolite, nicotinamide adenine dinucleotide (&ldquo;NAD&rdquo;). Figure 2 is an
illustration of nanocatalysis, showing a single gold nanocrystal converting molecules of nicotinamide adenine dinucleotide hydride
(&ldquo;NADH&rdquo;) in the background into NAD in the foreground. Gold nanocrystals have been described as electron reservoirs
because their surfaces can readily accept as well as donate thousands of electrons per second in order to catalyze biochemical
reactions, allowing them to accelerate reaction rates to extraordinarily high levels. For example, the conversion of NADH to NAD
is usually very slow at room temperature. Upon addition of our gold nanocrystal suspension CNM-Au8, we have observed the very
rapid conversion of NADH into NAD. Importantly, the NAD reaction drives adenosine triphosphate (ATP) production in both the mitochondrion
as well as in the cytoplasm, via a reaction called glycolysis. ATP is the universal currency of energy in all living things; without
the ability to convert NADH to NAD and vice versa, cells would be quickly depleted of ATP energy stores and die. CSN therapeutics
capture the natural, extraordinary nanocatalytic activities of clean-surfaced, faceted nanocrystals to produce metabolites of
high energetic or protective value to the cell.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
2. Nanocatalysis Mechanism Representation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_003.jpg" ALT="" STYLE="height: 531px; width: 850px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Figure
2. Illustration of nanocatalytic activity (Not to scale). A pentagonal bipyramidal gold nanocrystal is shown with its electron
cloud to represent the ability of the nanocrystal to rapidly exchange electrons with substrates interacting with its surface.
In the background, NADH molecules drawn as dark chemical ball-and-stick figures are catalytically converted into NAD in the foreground
as bright pink ball-and-stick figures. A pink and blue mitochondrion on the left can use available NAD for the generation of ATP
(Illustrated by Ella Maru).</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
Focus on Central Nervous System Disorders</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over
the past several decades, traditional small molecule and biologic drug development approaches have suffered serious setbacks in
the attempts to address nervous system disorders. A likely contributor to these setbacks is the multifactorial mechanisms underlying
these diseases themselves, which are sufficiently complex they may not be amenable to &ldquo;one drug-one target&rdquo; disease
modification. In the face of these failures, we believe our new paradigm of nanocrystal drug development, producing novel drugs
with unique nanocatalytic, multi-modal mechanisms of action, is advantageous.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Multiple
lines of evidence now point to bioenergetic failure as a key contributor to neurodegenerative disease. Neurons, and their associated
support cells, in particular oligodendrocytes, are amongst the highest energy-consuming cells in the body: the brain represents
only two percent of human body weight, yet it consumes over twenty-percent of the body&rsquo;s metabolic energy. As humans age,
our cell&rsquo;s ability to convert food into energy in the form of ATP becomes less efficient. Eventually, the nervous system&rsquo;s
demand for ATP surpasses the cells&rsquo; ability to supply it, and as a consequence, neurons begin to fail and subsequently die.
Genetic and environmental factors determine which neuronal types are most susceptible to bioenergetic failure in any individual.
In PD, dopaminergic and other neuronal cell types manifest mitochondrial failure, leading to impaired energy production. In ALS,
mitochondrial dysfunction is considered a hallmark of both sporadic and familial ALS, and several genetic causal variants of ALS
have been linked to dysregulated neuronal energy metabolism. In MS, the cells capable of remyelinating damaged axons have been
shown to be under metabolic stress, rendering them incapable of undergoing the energetically demanding process of repairing damaged
myelin.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
work has shown that CNM-Au8 nanocrystals cross the blood brain barrier to potentially protect multiple central nervous system
cell types. In multiple preclinical studies, we have demonstrated these central nervous system cells may benefit from nanocatalysis
in several ways: oligodendrocytes receive an energetic boost sufficient to drive myelin production; dopaminergic, hippocampal,
and cortical neurons improve energy metabolism sufficient to enhance survival and maintain function in response to multiple disease-relevant
stressors. Human astrocytes derived from patients with ALS have the capacity to kill motor neurons when grown in a co-culture,
and these motor neurons exhibit markedly reduced toxicity when co-cultures are treated with CNM-Au8. By their very nature, faceted
clean-surfaced nanocrystals with nanocatalytic capabilities circumvent many of the challenges that have plagued the central nervous
system pharmaceutical drug development field in the past. Importantly, the mechanism by which they act through nanocatalysis produces
several useful energetic metabolites while reducing the presence of harmful ones. These mechanisms are well suited to address
the complex failures that occur in neurodegenerative diseases on multiple levels and within multiple central nervous system cell
types.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
innovation of CSN therapeutics is that we are positioned to address the most significant challenge posed by numerous central nervous
system diseases. Unlike the &ldquo;one drug-one target&rdquo; model, faceted clean surfaced nanocrystals act by multiple mechanisms
to enhance the cellular bioenergetic state, while simultaneously and independently reducing oxidative stress and stimulating protein
homeostasis inside central nervous system cells. Each nanocrystal is capable of exchanging thousands of electrons per second,
potentially addressing deficits in diseased central nervous system cells in a manner that does not further deplete the cells of
their internal energy stores. Our data demonstrate CSN therapeutics thereby support cells and replenish cellular bioenergetic
deficiencies. In other words, CSN therapeutics support the cells of the central nervous system with the basic building blocks
of energy they require to function normally.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Market
Potential of CSN Therapeutics for Neurodegenerative Diseases</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the urgent demand for treatments and the tremendous market opportunities for neurodegenerative disease therapeutics, effective
treatments are limited. Currently, there are no existing therapies that either promote remyelination or have been demonstrated
to improve function in people with non-active, progressive MS. People with non-active, progressive MS account for approximately
one-third of all MS cases and they suffer progressive loss of function, severely reduced quality of life and shortened life spans.
Further, the current FDA-approved therapeutic agents for ALS have very limited disease-modifying effects. And, there are no currently
available disease-modifying therapies for PD. All of the existing PD therapies are limited to symptomatic improvement and none
have been shown to prevent or slow the loss of dopaminergic neurons. If the clinical studies presently underway provide evidence
of remyelination or demonstrate improved neurological function, CSN therapeutics will have significant commercial sales potential
in treating MS, PD, or ALS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
a single approved MS drug worldwide has been approved to show an effect on remyelination and neuroprotection. CNM-Au8&rsquo;s
effects on remyelination and neuroprotection for central nervous system disorders, together with the urgent market demand for
safe and effective treatments, provides us with a global unique first-mover-advantage with significant market potential for the
treatment of central nervous system diseases. Our most advanced CSN therapeutic candidate, CNM-Au8, has been developed to address
the significant unmet medical needs in the treatment of the central nervous system disorders, MS, PD, and ALS. MS, PD, and ALS
each severely impact healthspan and lifespan of those who suffer from these disorders, resulting in significant demand for disease-modifying
treatments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>CNM-Au8
and Restoration of Bioenergetic Metabolism in MS, ALS, and PD</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Overview</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CNM-Au8
is a concentrated, orally-delivered suspension of pure gold nanocrystals in pharmaceutical grade water buffered with sodium bicarbonate.
A single 60 milliliter, 30 milligram dose contains over one quadrillion nanocrystals. The median ferret diameter of CNM-Au8 nanocrystals
is approximately 13 nanometers with each nanocrystal consisting of an estimated 30,000 to 70,000 gold atoms. CNM-Au8&rsquo;s nanocatalytic
mechanism, directly donating and/or receiving electrons, enhances intracellular bioenergetic reaction rates without requiring
associated energetic investment from cells, thus increasing cells&rsquo; net energetic capacity. CNM-Au8 treatment results in
improved bioenergetic metabolism within cells of the central nervous system. Through this mechanism, CNM-Au8 may protect multiple
neuronal and glial populations including oligodendrocytes and/or neurons from oxidative, inflammatory, hypoxic, and excitotoxic
insults, potentially resulting in enhanced myelination and improved neuronal survival while preserving neurite processes and synapse
integrity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Standard
ICH M3(R2) toxicology studies were conducted on CNM-Au8 in three animal species, which yielded no toxicity findings resulting
in a NOAEL finding up to maximum feasible dosing. A First-in-Humans Phase 1 Clinical Trial of orally administered single and multiple
ascending doses of CNM-Au8 was then carried out in 86 healthy human volunteers. All doses (up to 90 mg/day) of CNM-Au8 were well-tolerated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CNM-Au8
has received regulatory approval to proceed to Phase 2 clinical studies designed to assess the safety and efficacy of CNM-Au8
for brain metabolite target engagement and functional and physiologic improvements indicative of remyelination, and neuroprotection.
Details for each clinical trial of CNM-Au8 are given below in the <I>Clinical Development Plan</I> section for each indication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Mechanism
of Action</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CNM-Au8
acts through nanocatalysis to improve the bioenergetics, reduce harmful reactive oxygen species, and induce protein homeostatsis,
via the heat shock protein-1 pathway in nervous system cells. These unique mechanism of actions lead to a cascade of beneficial
effects as summarized in Figure 3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
3. Nanocatalytic Biological Mechanism of Action</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_004.jpg" ALT="" STYLE="height: 388px; width: 850px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Figure
3. CNM-Au8 mediated nanocatalysis enhances cellular energetic capacity and decreases oxidative stress, resulting in increased
NAD and ATP production as well as increased proteostatic activity via the heat shock factor 1 pathway. Together, these activities
lead to a cascade of enhanced disease responses in neurons, oligodendrocytes, and astrocytes, cell types that are most vulnerable
to energetic deficiencies. CNM-Au8 thereby mediates remyelination and neuroprotective effects in neurodegenerative diseases such
as MS, ALS, and PD.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
of the key metabolites catalyzed by CNM-Au8 is nicotinamide adenine dinucleotide (&ldquo;NAD<SUP>+</SUP>&rdquo;) (Fig. 4). NAD<SUP>+
</SUP>and its reduced partner NADH are vital for driving cellular energy ATP-generating reactions in living cells (Fig. 4A). Brain
imaging studies have shown the ratio of NAD<SUP>+</SUP> to NADH typically decreases with aging. Lowered NAD<SUP>+</SUP> levels
in both the blood and brain have been associated with neurological diseases such as schizophrenia, multiple sclerosis, Parkinson&rsquo;s
Disease, and Huntington&rsquo;s Disease. Boosting NAD<SUP>+</SUP> activity in neurodegenerative disease preclinical models has
consistently demonstrated beneficial anti-aging and neuroprotective effects. CNM-Au8 exhibits higher catalytic activity for directly
oxidizing NADH into NAD than any other commercially available gold nanoparticle we have tested (Fig. 4C, D). We have shown that
treating cultured nervous system cells with CNM-Au8 increases their intracellular pools of NAD<SUP>+</SUP> and ATP, demonstrating
that CNM-Au8 increases the energetic capacity of central nervous system cells (Fig. 4E, F). This optimization of ATP (Fig. 4F)
allows oligodendrocytes to increase myelin production, as well as help numerous other types of central nervous system cells resist
environmental and disease-related stressors that would otherwise cause them to die.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
statistical analyses shown in Figure 4 were conducted by one-way analysis of variance (ANOVA) to compare means of each treatment
group to mean of the vehicle control (corrected for multiple comparisons). The p-value (Fig.&nbsp;4E, F) represents the probability
of obtaining test results at least as extreme as the results observed in the assay, under the general assumption that there is
no difference between the groups (the null hypothesis). The lower (smaller) the p-value, the greater the statistical significance
of the observation, and the less likely the null hypothesis is true. The scientific community and regulatory authorities, such
as the FDA, conventionally regard p-values of 0.05 or less to be significant when replicated in independent clinical studies.
Consistently statistically significant preclinical results, such as those described here, are used to support investigative new
drug applications to investigate the clinical effects of an investigational product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
significant stressor shared by many neurodegenerative diseases is the accumulation of harmful reactive oxygen species (&ldquo;ROS&rdquo;)
within neurons as their energetic demands begin to exceed their ability to produce enough ATP to carry out normal functions. Chronic
oxidative stress, caused by accumulation of ROS, can overwhelm the mitochondrial systems that normally tightly regulate ROS levels.
Accumulation of excess ROS damages cell membranes, allows calcium ion imbalances, and eventually leads to cell death.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
4. NAD Oxidation and Biological Effects on ATP and NAD+</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_005.jpg" ALT="" STYLE="height: 614px; width: 850px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Figure
4. Bioenergetic nanocatalysis by CNM-Au8. A, The NAD-NADH reduction-oxidation couple plays a key role in both ATP-generating reactions,
glycolysis and mitochondrial electron transport chain (&ldquo;ETC&rdquo;) oxidative phosphorylation. B, Ultraviolet-visible light
spectroscopy was used to show the catalytic activity of CNM-Au8 with time. As the reaction progresses, NADH is consumed, as demonstrated
by the decrease in the NADH absorbance peak at 340 nm, while NAD+ is generated, as shown by the corresponding increase in the
NAD+ absorbance peak at 260 nm. C, the rate of decay of the NADH absorbance peak is greater for CNM-Au8 than it is for citrate-reduced
gold, nanoparticles of 10 nm (orange) and 30 nm (red) diameters (purchased from the National Institute of Standards and Technology),
indicating that CNM-Au8 has a catalytic rate at least three-fold higher than NIST comparators under the same reaction conditions.
D, Catalytic rate of CNM-Au8 is demonstrably superior to several commercially available gold nanoparticles. Sigma Aldrich provides
reactant-free, &ldquo;citrate reduced&rdquo; gold nanoparticles, in which extra procedures are used to clean the surfaces of reactants.
&ldquo;Citrate&rdquo; gold nanoparticles may still have residual reactants present in the suspensions. E, Intracellular NAD+ levels
increase in response to CNM-Au8 treatment in primary rodent neuron-glial co-cultures. F, Intracellular ATP levels increase in
primary rodent oligodendrocyte cultures in response to CNM-Au8 treatment. Panels E-F, quantities shown are group means +/&minus;
SEM. One-way ANOVA, corrected for multiple comparisons, was used to compare means of each treatment group to mean of the vehicle
control; a&nbsp;statistically significant difference between treatment and vehicle is denoted by asterisks: *p &lt; 0.05; **p
&lt; 0.01.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to boosting NAD+ levels inside nervous system cells, CNM-Au8 directly acts to reduce ROS by directly catalyzing their
reduction (Fig. 5). CNM-Au8 possesses anti-oxidative catalytic activity and has been demonstrated to directly reduce oxygen radicals
in a superoxide dismutase-like manner, as well as convert hydrogen peroxide into water and oxygen in a catalase-like manner (Fig.
5A, B). Anti-oxidative activity for CNM-Au8 has been demonstrated in primary mouse oligodendrocyte cultures, in which basal levels
of ROS were reduced with treatment (Fig. 5C). In a Parkinson&rsquo;s Disease <I>in vitro</I> model, ROS generated by treating
primary rodent dopaminergic cells with the neurotoxin 1-methyl-4-phenylpyridinium (&ldquo;MPP&rdquo;) was lowered in response
to CNM-Au8 treatment in the presence of MPP (Fig. 5D). The statistical analyses shown in Figure 5 were conducted by one-way analysis
of variance (ANOVA) to compare means of each treatment group to mean of the vehicle control (corrected for multiple comparisons).
The p-value (Fig.&nbsp;5C, D) represents the probability of obtaining test results at least as extreme as the results observed
in the assay, under the general assumption that there is no difference between the groups (the null hypothesis).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previous
drug development efforts for neurodegenerative diseases have included numerous antioxidants, all of which failed to show disease-modifying
effects. We believe CNM-Au8 remains in a different class&nbsp;from standard antioxidants because, to our knowledge, no other antioxidant
demonstrates catalytic ability to increase bioenergetic metabolites NAD+ and ATP, while independently catalytically decreasing
reactive oxygen species.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
5. Reduction of Reactive Oxygen Species</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_006.jpg" ALT="" STYLE="height: 385px; width: 850px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_007.jpg" ALT="" STYLE="height: 478px; width: 850px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Figure
5. CNM-Au8 is a catalytically active antioxidant. A, SOD-like activity of CNM-Au8 on superoxide radicals was measured using a
colorimetric SOD assay kit (Cayman Chemical). B, Decay of the absorbance peak of hydrogen peroxide (H2O2) as the dismutation of
H2O2 takes place in the presence of CNM-Au8 (green) or comparator AuNPs of similar diameter (red) or no gold (black). C,D, Neurotoxin
(MPP+) induced mitochondrial stress and death of dopaminergic neurons in primary E15 rat co-cultures is prevented by CNM-Au8 (green),
as determined by TH+ cell number (not shown), reduction of ROS as measured as by the fraction of dopaminergic (&ldquo;TH&rdquo;)
cells fluorescing with CELLROX Green signal, a marker of cytosolic oxidizing environment (C), and increased mitochondrial membrane
potential (Mitotracker Red CMXRos) (D). Panels C-D, quantities shown are group means +/&minus; SEM. One-way ANOVA, corrected for
multiple comparisons was used to compare means of each treatment group of MPP with CNM-Au8 treatment to the mean of the MPP (4&mu;M)
alone treatment group; a statistically significant difference between each CNM-Au8 treatment group and MPP alone is denoted by
asterisks: *p &lt; 0.05; **p &lt; 0.01, ***p &lt; 0.001; ****p &lt; 0.000. Untreated &ldquo;Control&rdquo; group is included to
demonstrate the significant effect of MPP treatment to increase levels of ROS in TH neurons in Panel C and reduce mitochondrial
membrane potential in Panel D, which was not included in the ANOVA analysis.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previous
drug development efforts in the neurodegenerative disease space have targeted misfolded protein aggregates as toxic drivers of
disease; for example, alpha-synuclein in PD, amyloid beta in Alzheimer&rsquo;s Disease, and TAR DNA binding protein 43 (&ldquo;TDP-43&rdquo;)
in ALS. An important component of the mechanism of action of CNM-Au8 is its ability to dose-dependently reduce aggregated alpha-synuclein
and TDP-43 in cellular models of PD and ALS, respectively (Fig. 6). We believe this activity is, at least in part, attributable
to the robust induction of twenty gene transcripts of the Heat Shock Factor 1 pathway, which we observed in oligodendrocytes in
response to CNM-Au8 treatment (Robinson, et al. Nanocatalytic activity of clean-surfaced, faceted nanocrystalline gold enhances
remyelination in animal models of multiple sclerosis. Sci Rep 10, 1936 (2020)) as well as due to an indirect cellular response
to NAD upregulation, which has been shown to activate autophagic and proteostatic responses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
summary, CNM-Au8 exhibits a novel mechanism of action via its nanocatalytic activities, involving:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enhancement
                                         of bioenergetic metabolism via increased production of NAD+ and ATP</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduction
                                         of oxidative stress, and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enhancement
                                         of proteostatic, autophagic responses that reduce accumulation of toxic protein aggregates
                                         that are hallmarks of neurodegenerative diseases.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
6. Reduction in Misfolded Protein Aggregates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_008.jpg" ALT="" STYLE="height: 478px; width: 850px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Figure
6. CNM-Au8 reduces accumulation of protein aggregates in cellular models of PD and ALS. A) Primary culture of E15 rat mesencephalic
neurons were pre-treated with vehicle, CNM-Au8, or positive control BDNF for 48h on day 4 of culture. 6-OHDA (20 uM) was added
for 48 h then fixed and stained for anti-TH and anti- a-syn. B, Rat spinal motor neurons were cultured and treated with vehicle,
glutamate (5 uM) or glutamate (5 uM) and CNM-Au8, then fixed and stained for anti-neurofilament, anti-TDP-43, and Hoechst. Group
means plotted +/-&nbsp;SEM.&nbsp;* p &lt;0.05; ** p &lt; 0.01; *** p &lt; 0.001; **** p&lt; 0.0001; treatment vs. vehicle, one-way
ANOVA corrected for multiple comparisons.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Safety
and Tolerability of CNM-Au8</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
completed a Phase 1 First-In-Human study of CNM-Au8 in 2016 to demonstrate it was safe for further clinical development, and to
assess the pharmacokinetic profile at different dosing concentrations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Trial
design.</I> The Phase 1 First-In-Human study of CNM-Au8 was a randomized, placebo-controlled, double-blind, escalating single-
and multiple-dose study to evaluate the safety, tolerability, and pharmacokinetics of CNM-Au8 in healthy male and female volunteers.
There were two phases to this study: a single-ascending dose (&ldquo;SAD&rdquo;) phase and a multiple-ascending dose (&ldquo;MAD&rdquo;)
phase. The SAD Phase was conducted first followed by the MAD Phase of the study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Single
                                         Ascending Dose: 40 subjects were randomized to CNM-Au8 (n=30) or placebo (n=10) at a
                                         3:1&nbsp;ratio in single dose escalating cohorts who received CNM-Au8 at 15 mg, 30 mg,
                                         60 mg, or 90 mg with follow-up study duration for each subject of 18&nbsp;days.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Multiple
                                         Ascending Dose: 46 subjects were randomized to CNM-Au8 (n=35) or placebo (n=11) in multiple
                                         dose cohorts who received CNM-Au8 at 15mg, 30 mg, 60 mg, and 90 mg with the duration
                                         of treatment at 21&nbsp;days and follow-up of each subject was up to 50&nbsp;days.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Safety</I>.
Safety assessments revealed no significant findings. All doses used in this study were determined to be well-tolerated based on
the frequency of reported treatment emergent adverse events (&ldquo;TEAEs&rdquo;). TEAEs occurred more frequently on placebo (86%)
than in the CNM-Au8 dosing groups in both the SAD and MAD phases combined (75%). No subjects discontinued the study due to TEAEs
and no serious adverse events (&ldquo;SAEs&rdquo;) were reported across any treatment group. The most frequently reported TEAEs
were almost entirely of Grade 1 (mild) severity and transient. The most frequently reported TEAEs consisted of headaches, somnolence,
fatigue, abdominal pain, diarrhea, nausea, and dizziness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Pharmacokinetics.
</I>PK analyses from the MAD Phase showed that at the end of 21&nbsp;days, the maximum concentration of gold in blood was determined
to be 1.53 ng/mL, 1.98 ng/mL, 2.35 ng/mL, and 3.33 ng/mL for each group dosed with 15, 30, 60, or 90 mg respectively. Pharmacokinetic
(PK) analyses demonstrated that CNM-Au8 has a half-life of 14-21&nbsp;days. The end-of-study drug exposure levels in humans either
matched or exceeded the equivalent exposure that demonstrated neuroprotection and remyelination efficacy in animal models.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Conclusion</I>.
The First-In-Human safety results demonstrated no safety signals following dosing with CNM-Au8 at or above clinically used doses
and drug exposure levels in humans either matched or exceeded the equivalent exposure that demonstrated neuroprotection and remyelination
efficacy in animal models.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
successful completion of Phase 1 studies of CNM-Au8, we progressed CNM-Au8 into multiple Phase 2 studies designed to test the
efficacy of CNM-Au8 in specific disease indications. Based on the safety findings and the strength of our preclinical
remyelination and neuroprotection data, we have initiated four Phase 2 studies in central nervous system disorders including
MS, PD, and ALS. We have also partnered with a major academic institution to implement a Phase 3 registrational clinical
program with CNM-Au8 for the treatment of ALS. We are accumulating increasing human safety exposure in our ongoing Phase 2
and Phase 3 clinical programs. To date, on a blinded basis we have seen no concerning or dose-limiting safety signals, and
two independent data safety monitoring boards overseeing our randomized double-blind placebo controlled trials have
recommended continuing the conduct of the trials following unblinded evaluation of the safety data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Multiple
Sclerosis</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>MS
Market Opportunity</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Multiple
sclerosis is an inflammatory and degenerative disorder of the central nervous system involving immune-mediated destruction of
the brain, optic nerves, and spinal cord. MS results from autoimmune attacks on the myelin sheath, the protective covering wrapping
the axons of neurons. When myelin is destroyed by autoinflammatory immune attacks, neurons become damaged and can ultimately die,
leading to motor symptoms, cognitive disability, visual impairment and other neurological impairments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MS
typically begins between the ages from 20 to 40, and it is the leading cause of non-traumatic disability in young adults. Women
are affected approximately three-times as often as men, except in individuals with the less common, primary-progressive form of
the disease, where there is no gender preponderance. MS is the most common inflammatory demyelinating disease, with a prevalence
that varies considerably, from high levels in North America and Europe to low rates in Eastern Asia and sub-Saharan Africa.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
diagnosis of multiple sclerosis is predominantly a clinical one that is aided by radiological tests (e.g.,&nbsp;magnetic resonance
imaging). Other diagnostic methods include blood tests, evoked potential tests, lumbar puncture, and optical coherence tomography,
which is a new technology for examining the effects of multiple sclerosis on the health of nerve cells and axons in the retina.
Utilizing magnetic resonance imaging, a new diagnostic classification for multiple sclerosis &mdash; clinically isolated syndrome
has been included in the updated 2017 International (McDonald) Criteria. Ongoing improvements in diagnostic technologies may increase
the number of patients diagnosed with multiple sclerosis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>MS
Current Therapies and Limitations</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the currently available drugs for treating multiple sclerosis either treat the symptoms caused by MS or act to reduce the degree
of autoimmune-mediated inflammation. These drugs are typically referred to as disease-modifying therapies (&ldquo;DMTs&rdquo;).
Nearly all of the current approved DMTs are approved for the treatment of relapsing forms of MS (&ldquo;RMS&rdquo;). They commonly
act via immunosuppression or via immunomodulation, and thereby act to minimize autoimmune-associated attacks on myelin. Immunomodulatory
DMTs reduce the risk of having an inflammatory attack, referred to as a &ldquo;relapse&rdquo;, and can slow the development of
disability in those patients having attacks (i.e., &ldquo;active&rdquo; patients). As a corollary, DMTs may possibly diminish
the risk of conversion of relapsing MS to secondary progressive multiple sclerosis (&ldquo;SPMS&rdquo;). The newer DMTs have been
shown to substantially reduce autoimmune-mediated attacks and to delay the progression of the disease in active patients. However,
there are no drugs available which can reduce the ongoing loss of function (i.e., disease progression) in non-active (those no
longer having attacks) MS patients. None of the approved DMTs have been shown to clinically improve remyelination of damaged and
demyelinated axons in MS lesions. Currently available DMTs for the treatment of MS include: <I>Injectable medications</I>, Avonex
(interferon beta-1a), Betaseron (interferon beta-1b), Extavia (interferon beta-1b), Copaxone (glatiramer acetate), Plegridy (peginterferon
beta-1a), Rebif (interferon beta-1a), Glatiramer acetate generic equivalent (Glatiramer Acetate Injection, Glatopa (glatiramer
acetate); <I>Oral medications</I>, Aubagio (teriflunomide), Gilenya (fingolimod), Tecfidera (dimethyl fumarate), Mavenclad (cladribine),
Mayzent (siponimod)<I>; Infusion medications</I>, Lemtrada (alemtuzumab), Novantrone (mitoxantrone), Ocrevus (ocrelizumab), and
Tysabri (natalizumab). Advances in MS treatment with new B-cell depleting therapies, including ocrelizumab, have largely ameliorated
inflammatory disease activity as measured by the reduction in risk of having relapses and the lack of occurrence of new gadolinium
enhancing (inflammatory) lesions, as detected by MRI. However, despite the stabilization of MS disease activity in active MS patients
by these agents for these MS patients, significant improvement in overall function has not been shown. Importantly, for the DMTs
that have been approved to date, efficacy and safety are generally inversely correlated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is an increasing demand for better treatment strategies. Although current drugs for multiple sclerosis can reduce the risk of
an inflammatory attack and slow down the progression of the disease in some MS patients, patients&rsquo; responses to drugs can
be variable and suboptimal. For non-active MS patients, there is no available DMT that can substantially alter their progressive
worsening. Also, the side effects of current MS drugs range from mild to serious, which may lead to reduced patient adherence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Potential
Advantages of CNM-Au8 for MS</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that CNM-Au8 has the potential to be a global first-in-class remyelinating and neuroprotective disease-modifying nanotherapeutic
drug for MS. CNM-Au8 supports neurologic functions by enhancing bioenergetic activities in neurons and oligodendrocytes that have
been attacked by the disease. Unlike the current immunomodulating MS DMTs, CNM-Au8 is thought to act to directly support neuroprotection
and remyelination by improving bioenergetics, reducing harmful reactive oxygen species and inducing protective heat shock protein
mechanisms. CNM-Au8 is administered orally, penetrates the blood brain barrier, and to date has a favorable safety, tolerability,
and toxicology profile. Used alternately or in conjunction with standard immunomodulatory DMTs, CNM-Au8 treatment may improve
patients&rsquo; quality of life and potentially reverse disease progression because of its enhancing bioenergetic activities in
neurons and oligodendrocytes that have been attacked by the disease, even in patients whose inflammatory attacks are well-controlled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Summary
of Nonclinical Pharmacology Myelination Studies for MS</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Myelination
is a complex process resulting in the wrapping of axons by oligodendrocyte (&ldquo;OL&rdquo;) membranes containing specialized
proteins and lipids. The resulting myelin sheath provides metabolic support to the axon and facilitates axonal electrical conduction,
which in turn allows for central nervous system processing of motor, sensory, and higher order cognitive functions. During active
myelination, OLs synthesize on the order of 100,000 proteins per minute and several thousand new lipid molecules per second, reflecting
the significant energetic investment needed for biomass generation, and making this cell type among the most energetically demanding
in the body. In MS, myelin is destroyed by autoimmune-mediated inflammatory attacks, and neurons whose axons were once protected
and supported by myelin become damaged and can ultimately die. OL precursor cells are known to be present near MS lesions and
can play a role in remyelination, but studies have shown that these cells are energetically compromised and remyelination is suboptimal
in most central nervous system lesions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bioenergetic
deficits have been noted in the brains of living patients with MS using <SUP>31</SUP>Phosphorus magnetic resonance spectroscopy
(&ldquo;<SUP>31</SUP>P-MRS&rdquo;). In autopsied brains from MS patients, oligodendrocyte precursor cells near MS lesions displayed
impaired mitochondrial complex activity and other energetic deficits. These bioenergetic deficits play key roles in MS disease
progression. CNM-Au8 is uniquely designed to directly address these important pathophysiological mechanisms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
investigated the ability of CNM-Au8 to address OL energetic deficits, to induce remyelination and to restore functional activities
and motor behaviors in a comprehensive remyelination preclinical program involving multiple <I>in vitro</I> and <I>in vivo</I>
assays to determine CNM-Au8 efficacy. This work has been published as a peer-reviewed publication in Scientific Reports and is
briefly summarized here.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>In
vitro</I> experiments on primary OL precursor cells demonstrated robust induction of myelin production by CNM-Au8. RNASeq analyses
of CNM-Au8 treated OL precursors cells demonstrated that multiple transcripts for known myelination genes are upregulated, and
that glycolytic activity and ATP production are also increased. Several <I>in vivo</I> experiments were also conducted to demonstrate
that orally delivered CNM-Au8 results in increased remyelination in the brains and spinal cords of animals treated with cuprizone
or lysolecithin, two agents that are known to strip neurons of myelin via different mechanisms (Robinson et al. <I>Sci Rep</I>.
2020 Feb 11;10(1):1936). As fully described in the peer-reviewed publication by Robinson et al. both orally delivered cuprizone,
or stereotactically injected lysolecithin are commonly used techniques to cause demyelination of the corpus callosum or spinal
cord, respectively. Cuprizone, which is administered to rodents by including this agent in their chow, is a copper chelating agent
that specifically causes mature oligodendrocyte death within multiple brain regions, including the corpus callosum. Maximal demyelination
due to cuprizone feeding typically occurs within five weeks, which can be visually monitored and quantified using transmission
electron microscopy. Lysolecithin injection results in the rapid degradation of myelin within a localized area of the spinal cord,
observable using Luxol Fast Blue or toluidine staining for myelin with light microscopy, or also with transmission electron microscopy
of the lesion, within a day of injury, allowing for the observation of remyelination within the induced lesion within the following
weeks. Remyelination of the corpus callosum or spinal cord using either technique requires the migration of surviving oligodendrocyte
precursor cells to the sites of demyelination, differentiation of these cells into mature myelinating oligodendrocytes, and rapid
generation of specialized proteins and lipids for formation of new myelin membrane wraps around axons in this energetically demanding
process. Multiple independent <I>in vivo</I> remyelination assays, using either cuprizone or lysolecithin as demyelination agents,
were performed to demonstrate the remyelinating ability of CNM-Au8. For example, CNM-Au8 was provided either prophylactically,
at the same time as the start of cuprizone feeding, or only after two weeks of cuprizone feeding, therapeutically, in order to
allow demyelination to start to take place prior to administration of CNM-Au8. In both contexts, CNM-Au8 demonstrated greater
recovery of myelin in affected brain areas than vehicle-treated controls. Furthermore, animals that were provided with CNM-Au8
only after full demyelination (five complete weeks of cuprizone treatment) had taken place displayed evidence of higher levels
of mature myelin marker expression in their brains than vehicle controls, indicating that CNM-Au8 was not blocking the action
of cuprizone but rather inducing recovery by stimulating the differentiation of oligodendrocytes. Similar results were confirmed
by the lysolecithin experiments, which indicated that myelin destroyed by a completely different mechanism could be recovered
with the daily oral administration of CNM-Au8 for one or two weeks after focal demyelination by lysolecithin. Treatment with CNM-Au8
significantly improved not only the quantifiable detection of myelinated axons in the brains of experimental animals, but also
mouse behaviors and functional movements in the open field test and kinematic assays. For example, quantitation of the number
of myelinated versus unmyelinated axons in 587 transmission electron microscope images, averaging 84 images per treatment group
(with 15 mice per treatment group, seven treatment groups total), demonstrated a statistically significant (p&nbsp;&lt;&nbsp;0.0001
using one-way ANOVA corrected for multiple comparisons) recovery of remyelinated axons in therapeutically treated animals who
were dosed with CNM-Au8 by gavage compared to vehicle treated, cuprizone-fed controls. In independent demyelination model studies
using lysolecithin, lesioned animals treated with CNM-Au8 exhibited a 43% mean increase in myelinated axons within lesions post-LPC
injection compared to vehicle controls (p = 0.15, unpaired t-test comparing CNM-Au8 treated rats to vehicle treated controls).
Finally, in a cuprizone-mediated demyelination model study of both gross and fine motor behaviors, the group of animals receiving
therapeutically delivered CNM-Au8 displayed detectable improvements in behaviors in both open field and fine motor kinetics assessments.
Principal component analysis of gait metrics showed no statistical difference (p = 0.47) between CNM-Au8 treated, cuprizone-fed
animals compared to the sham treated group, whereas there was a detectable difference in vehicle-treated, cuprizone-fed animals
and sham controls (p&nbsp;=&nbsp;0.032; 2-way ANOVA) by the end of study at week 6. Figure 7 shows examples of the observed induction
of myelination by CNM-Au8 from selected in <I>vitro</I> and in vivo experiments reported in Robinson et al. These studies were
fully funded by Clene and were the result of collaborations among academic researchers from Northwestern University, George Washington
University, and various other academic consultants and employees of Clene.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
7. Remyelination Summary</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_009.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Figure
7. A summary of myelinating activities of CNM-Au8. Top row, Left: illustration of the demyelination (red) of a neuron&rsquo;s
axon (yellow) that occurs in MS. Right: Illustration of restored myelination along the axon (blue) provided by the OL (blue cell).
Middle row: isolated primary mouse OL precursors treated with vehicle control (left), 3 &mu;g/mL CNM-Au8, or positive control
and myelin-inducing agent tri-iodothyronine (&ldquo;T3&rdquo;). Cells are fixed and stained for Myelin Basic Protein (&ldquo;MBP&rdquo;),
a marker of mature myelin in red, and the nuclear stain DAPI in blue, to reveal the presence of all OL precursor cells in the
field of view. Many more cells expressing MBP are seen in the CNM-Au8 treated cells compared to vehicle-treated cells. Bottom
row: transmission electron images of slices of corpus callosum of mice treated with, left to right: no cuprizone, cuprizone for
five weeks, CNM-Au8 for five weeks, or cuprizone for five weeks and CNM-Au8 for the last three of the five weeks. Myelin can be
seen as dark rings in each micrograph. Cuprizone treatment destroys myelin, while CNM-Au8 treatment alone does not change myelin.
CNM-Au8 treatment of cuprizone-treated animals results in the recovery of myelin in the brains of these animals.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Clinical
Development of CNM-Au8 as a Disease-Modifying Drug for MS</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on safety findings in our Phase 1 clinical study of CNM-Au8 and our robust preclinical remyelination data, we have launched two
Phase 2 clinical studies to investigate the effects of CNM-Au8 in MS patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>VISIONARY-MS</U></FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
VISIONARY-MS study, launched in December&nbsp;2018, is an ongoing double-blind, randomized, placebo-controlled Phase 2 trial evaluating
the efficacy and safety of two doses of CNM-Au8 as a remyelinating and neuroprotective treatment in people who have stable relapsing
MS with chronic visual impairment. Enrolled participants must have chronic optic neuropathy, defined as visual impairment with
no episodes of acute optic neuritis within the six months prior to enrollment, and stable (non-active) disease, defined as no
MS relapses within the three months prior to entry. Concomitant immunomodulatory MS DMTs are allowed. Participants are randomized
to low-dose CNM-Au8 (15 mg/day), high-dose CNM-Au8 (30 mg/day), or matching placebo. The primary endpoint is improvement in low
contrast letter acuity (&ldquo;LCLA&rdquo;) from baseline to week 24.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contrast
is the quantity of lightness or darkness contained by an object in comparison to its background. The smallest difference in contrast
distinguished by the eye is known as the contrast threshold, usually reported as its reciprocal value, which is also known as
contrast sensitivity (1/contrast threshold). Therefore, if a large amount of contrast is necessary for a patient to identify an
object, they have poor contrast sensitivity and will have a low numerical value for this measurement. Contrast sensitivity can
be thought of as a spectrum, in that black letters on a white background will be easier for any individual to discern than lower-contrast
grey on white letter chart, regardless of whether or not visual abnormalities are present. The contrast threshold is the minimum
amount of contrast necessary for an individual to discern an object from its background, and for people with MS the contrast threshold
has been found to be higher than that of healthy individuals, even when visual acuity is equal between the two groups. contrast
sensitivity is on a spectrum and may elicit more subtle changes in the contrast threshold that will be missed by high contrast
visual acuity. LCLA tests low-contrast vision at various spatial frequencies that may be particularly affected by damage to specific
inter-neural connections in the complex visual pathway.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the VISIONARY-MS study, all participants remain in the double-blind, placebo-controlled treatment period through week 48, until
the last participant completes week 24. In this way, double-blind, placebo-controlled data will be generated for most patients
in the study through week 48, improving the study&rsquo;s ability to assess the long-term effects of CNM-Au8 on clinical endpoints.
The study is presently being conducted across eight clinical sites in Australia, and site expansion into North America is presently
underway. Health Canada and the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) have both approved conduct of the trial
within Canada and the United&nbsp;States, respectively. Incremental clinical research site initiation is subject to ongoing COVID-19
related research restrictions. As of February 26, 2021, 56 participants were enrolled in the VISIONARY-MS study with exposure
to the investigational product up to 48-weeks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary,
interim, blinded efficacy results from VISIONARY-MS were reported as an invited oral presentation at the Joint NAIMS-IMSVISUAL
Symposium at the Americas Committee for Treatment and Research in Multiple Sclerosis (&ldquo;ACTRIMS&rdquo;) Forum 2020 held February
27-29 in West Palm Beach, Florida. Results from the first 34 enrolled participants up to week 36 demonstrate clinically-relevant
median improvements in LCLA and the three remaining modified Multiple Sclerosis Functional Composite sub-scales (&ldquo;(m)MSFC&rdquo;),
including Symbol Digit Modalities Test (SDMT, cognition), 9-Hole Peg Test (9HPT, upper extremity function), and Timed 25-foot
Walk (T25FWT, gait) in the population, as a whole. Updated preliminary, interim, blinded efficacy results were presented at the
8<SUP>th</SUP> Joint ACTRIMS-ECTRIMS meeting, called MS Virtual, on September 11<SUP>th</SUP>, 2020, and at the ACTRIMS Forum
2021 on February 26, 2021. These updated blinded interim analyses compared changes in Multiple Sclerosis Functional Composite
(MSFC) scores over the study treatment period to the baseline values of study participants with mild disease, as defined by Baseline
Expanded Disability Status Scale (EDSS) scores of 1.5 or less. Notably, baseline scores for these participants demonstrate less
neurological impairment than those of the overall study population, providing a valid comparator group. Changes in the four MSFC
sub-scales (LCLA, SDMT, 9HPT, and T25FW) were compared to baseline scores of the comparator group with mild disease. These comparisons
were performed at each study time-point (Weeks 12, 24, and 36). At each visit, the overall study population (randomized 2:1 active
CNM-Au8 to placebo) showed notable increasing mean improvements in overall MSFC scores and key MSFC sub-scales compared to the
comparator group (mixed-effects model; p&lt;0.0001 vs. baseline). We believe these data support CNM-Au8&rsquo;s potential to drive
meaningful neurological improvements in MS patients. Further, we believe these observations are notable given the expected long-term
decline in LCLA, SDMT, 9HPT, and T25FW amongst MS patients reported from data sets including from the MS Outcome Assessments Consortium
(&ldquo;MSOAC&rdquo;) (Goldman et al. Neurology. 2019 Nov 19;93(21):e1921-e1931). MSOAC includes prospectively acquired RMS patient-level
data from fourteen separate MS clinical trials including over 12,776 participants combined into a single database and followed
for up to 24-months. When LCLA, SDMT, 9HPT, and T25FW were analyzed as a multidimensional measure rather than individually, progression
on any one of these performance measures was more sensitive than the commonly used MS Expanded Disability Status Scale (EDSS),
and demonstrated long-term declines in RMS patients. The increasing mean improvements observed across the entire study population
(CNM-Au8 and placebo) may suggest a clinical effect CNM-Au8 when contrasted with the anticipated decline reported in publications
from the MSOAC data. Figure 8 represents a summary of the observed average change in an integrated MSFC average 6-component Z-score
of the change from Baseline by each 12-week study interval across all study participants in VISIONARY-MS (e.g., low dose, high
dose, placebo) for all visits recorded as of 13-January-2021 and indicate continuing improvement over the course of the study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
8. VISIONARY-MS Mean (m)MSFC Z-Score Change vs. Baseline</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_010.jpg" ALT="" STYLE="height: 394px; width: 850px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Glanzman,
R., H. Beadnall, M. T. Hotchkin, A. Klistorner, M. Barnett, R. Sergott, A. Rynders, K. S. Ho, and Mark G. Mortenson. &ldquo;Update
to a Phase 2 clinical trial of catalytic gold nanocrystals, CNM-Au8, for the treatment of chronic optic neuropathy.&rdquo; Presented
at the ACTRIMS Forum 2021, February 26, 2021.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Available
blinded safety data from VISIONARY-MS indicate that CNM-Au8 is well-tolerated with most adverse events characterized as mild in
severity. No serious adverse events related to the investigational product (e.g.,&nbsp;placebo, CNM-Au8) have been reported to
date. The most frequently reported adverse events include headache, upper respiratory infection, and sore throat. The full unblinded
results from the study are anticipated in the first half of 2022, subject to ongoing COVID-19 related research restrictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>REPAIR-MS
and REPAIR-PD</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
Phase 2, central nervous system imaging trials, REPAIR-MS and REPAIR-PD, were initiated to demonstrate central nervous system
target engagement by measuring the effects of orally delivered CNM-Au8 on brain energy metabolites in patients with MS and PD
<I>in vivo.</I> These bioenergetic metabolites are measured non-invasively and semi-quantitatively by utilizing <SUP>31</SUP>P-MRS
imaging with a 7 Tesla (7T) MRI scanner. The REPAIR studies are being conducted at the University of Texas Southwestern, a center
with specialized capabilities for conducting and analyzing 7T <SUP>31</SUP>P-MRS imaging studies. Both REPAIR studies were approved
for clinical conduct by the FDA and commenced in December&nbsp;2019 (REPAIR-PD)/January&nbsp;2020 (REPAIR-MS) with full data availability
anticipated in the second half of 2021 for both REPAIR-PD and REPAIR-MS, subject to ongoing COVID-19 related research restrictions.
As of February 25, 2021, twelve participants were enrolled in REPAIR-PD study with exposure to CNM-Au8 up to 21-weeks, and ten
participants were enrolled in the REPAIR-MS study with exposure to CNM-Au8 up to 18-weeks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
interim analysis of data from study completers as of mid-July&nbsp;2020 from these ongoing trials was conducted and reported at
the 8<SUP>th</SUP> Joint ACTRIMS-ECTRIMS (MS Virtual 2020) meeting held September 11<SUP>th</SUP>, 2020. A full volume head coil
was used to collect whole brain spectral waveforms in ~600 voxels with a spatial resolution of 2 cm<SUP>3</SUP> for the following
metabolites: NAD pool (both NAD+ and NADH together), ATP, phosphocreatine, extracellular and intracellular inorganic phosphate,
uridine diphosphate glucose, phosphocholine, phosphoethanolamine, glycerophosphocholine, and glycerophosphoethanolamine. A partial
volume head coil was used in the same patient cohort to measure occipito-parietal levels of individual NAD+ and NADH phosphorous
metabolites to determine the ratio of NAD+/NADH. Results for 4 MS and 6 PD completers (all competed subjects prior to a COVID-19
related research pause) were analyzed. Percent change from baseline (&ldquo;BL&rdquo;) at the end-of-study (&ldquo;EOS&rdquo;)
visit was highly correlated to BL levels for key bioenergetic markers. Overall, the data indicate that CNM-Au8 normalized the
levels of multiple bioenergetic metabolites measured. Patients with whole-brain NAD levels less than the BL mean significantly
increased NAD levels at the EOS visit, while patients with whole-brain BL NAD levels greater than the mean normalized levels to
the BL mean. Importantly, this relationship was observed for total NAD levels (r<SUP>2</SUP>&nbsp;=&nbsp;0.6585; p = 0.0044),
&szlig;-ATP (r<SUP>2</SUP> = 0.8705; p &lt; 0.0001), and several other <SUP>31</SUP>P metabolites, indicating a homeostatic effect
of CNM-Au8 on brain bioenergetics. In the 4 MS patients, there were marked correlations for NAD (r<SUP>2</SUP>&nbsp;=&nbsp;0.9241;
p = 0.039), &szlig;-ATP (r<SUP>2</SUP> = 0.968; p=0.016), and several other phosphorous metabolites. These preliminary results
reflect target engagement in the brains of PD and MS patients, and provide the first clinical evidence to support the catalytic
effects of CNM-Au8 on brain bioenergetic metabolites. Figure 9 below illustrates the changes in NAD/NADH ratio via the partial
volume coil assay and correlations in mean &szlig;-ATP levels versus baseline values for the full volume coil.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
9. Interim Data from All Completers in REPAIR-MS and REPAIR-PD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Left,
Change in NAD+/NADH Ratio by Subject. Right, Normalization of Brain &szlig;-ATP by Subject</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_011.jpg" ALT="" STYLE="height: 385px; width: 850px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A subsequent updated
interim analysis of MS participants was presented at the ACTRIMS Forum 2021 on February 26, 2021, specific to the 5 MS participants
who have completed the <SUP>31</SUP>P-MRS imaging. Among those who completed the study, the data indicate that CNM-Au8 increased
the ratio of NAD+/NADH in the brains of MS subjects, resulting in normalized levels of multiple bioenergetic metabolites measured
including ATP. Patients with whole-brain &alpha;-ATP and &gamma;-ATP levels less than the BL mean significantly increased these
levels at the EOS visit, while patients with whole-brain BL &alpha;-ATP and &gamma;-ATP levels greater than the mean normalized
levels to the BL mean, indicating a homeostatic effect of CNM-Au8 on brain bioenergetics (r<SUP>2</SUP> = 0.94 [&alpha;-ATP] and
0.96 [&gamma;-ATP]; p &lt; 0.01) (Figure 10).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
10. Updated Interim Data from All Completers in REPAIR-MS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Left,
Change in NAD+/NADH Ratio by Subject. Center and Right, Normalization of Brain ATP by Subject</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_012.jpg" ALT="" STYLE="height: 376px; width: 850px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Parkinson&rsquo;s
Disease</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>PD
Market Opportunities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parkinson&rsquo;s
disease (PD) is a chronic, progressive neurodegenerative disorder involving the progressive loss of dopaminergic neurons in the
<I>substantia nigra</I> area of the midbrain. The degeneration of dopaminergic neurons leads to resting tremor, bradykinesia,
limb rigidity, and gait and balance problems as well as increasingly recognized cognitive loss and behavioral changes due to more
generalized neuronal loss. Both genetic and environmental factors are thought to contribute to the development of PD in addition
to ageing, which is the most significant risk factor for developing the disease. Approximately one in one hundred individuals
over the age of 60 is affected by PD.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>PD
Current Therapies and Limitations</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
there are a number of approved Parkinson&rsquo;s therapies, such as dopamine agonists, COMT and MAO-B inhibitors, and deep brain
stimulation, these treatments are limited to symptomatic improvement. No treatment is currently available to prevent the destruction
of dopaminergic neurons. The inexorable progression of loss of dopaminergic innervation leads to progressively worsening symptoms
with &ldquo;on&rdquo; (dyskinesias) and &ldquo;off&rdquo; (rigidity) symptoms that become increasingly difficult to manage. In
addition, long-term use of levodopa, a commonly-prescribed dopamine precursor used to treat Parkinsonian symptoms, often results
in dyskinesia that in itself becomes disabling. Despite an enormous effort over the past several decades, no disease-modifying
or neuroprotective therapeutic for PD is available. A therapeutic that alters or slows the clinical progression, and thus improves
PD healthspan and lifespan, would address a very significant unmet need.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuronal
bioenergetic failure underlies PD, as evidenced by the observed impaired mitochondrial and lysosomal functioning, neuronal sensitivity
to glutamate toxicity, accumulation of oxidative stress, autophagic failure in clearing misfolded proteins, and loss of synapse
integrity associated with this disease. As such, improvement of cellular bioenergetic efficiency, as is possible with CNM-Au8,
represents an important and previously unaddressed therapeutic target for this disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Potential
Advantages of CNM-Au8 for PD</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that CNM-Au8 has the potential to be a global first-in-class&nbsp;disease modifying nanotherapeutic drug for PD. While
current therapies for PD are designed to stimulate surviving dopaminergic neurons in order to elicit partial functional effects,
none of them prevent the inexorable degeneration of dopaminergic neurons to change the course of disease progression. Our nonclinical
studies demonstrate that CNM-Au8 is robustly neuroprotective of dopaminergic neurons across a variety of disease-relevant insults
created using a variety of toxins and stressors. In addition, CNM-Au8 may have a tolerability profile superior to existing approved
products like commonly used drugs for PD, such as levodopa/carbidopa that result in risk of dyskinesias after long-term use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Summary
of Nonclinical Pharmacology and General Neuroprotection Studies for PD</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excitotoxic
injury, oxidative stress, and the accumulation of misfolded alpha-synuclein are hallmarks of the failing bioenergetic pathways
associated with PD. In order to determine whether CNM-Au8 could act as a neuroprotective agent for PD, we conducted a series of
<I>in vitro</I> and <I>in vivo</I> studies designed to test efficacy of CNM-Au8 in protecting various neuronal cell types from
a variety of PD relevant disease-related stressors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
potential of CNM-Au8 to confer neuroprotection in PD disease-specific cellular models was first demonstrated <I>in vitro</I>.
Primary rat dopaminergic cells were challenged with 1-methyl-4-phenyl-1,2,3,6-tatrahydropyridine, (MPTP, which is metabolized
to its active form MPP+) or alternatively with 6-hydroxydopamine (6-OHDA), which are both toxins specific to dopaminergic neurons.
Treatment of primary neuronal-glial cocultures with CNM-Au8 increased the numbers of surviving dopaminergic neurons in response
to either toxin in a dose-dependent manner, as well as affected overall improvement in neuronal health by a variety of metrics,
including preservation of neurite network, reduction in oxidative stress, increase in mitochondrial staining, and reduction in
alpha-synuclein aggregates. The activity of CNM-Au8 was then tested in the standard 6-OHDA-unilateral lesion model of PD. Lesioned
rats, and a sham control group, were orally administered vehicle or CNM-Au8 for 4-weeks (2-weeks post-lesion) or 6-weeks (one-day
post lesion) following the establishment of a lesion in the striatum. Significant functional improvements due to CNM-Au8 treatment
was demonstrated in both the behavioral apomorphine-induced rotation and cylinder paw placement tests. In addition, larger numbers
of surviving dopaminergic neurons were detected in the striatum of CNM-Au8-treated lesioned animals compared to vehicle controls.
These studies independently demonstrated that CNM-Au8 treatment has robust neuroprotective properties in preclinical models of
PD.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Clinical
Development of CNM-Au8 as a Disease-Modifying Drug for PD</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>REPAIR-PD</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
initiated the Phase 2 REPAIR-PD study to determine CNS target engagement by measuring the effects of orally delivered CNM-Au8
on brain energy metabolites in patients with PD as discussed previously. The REPAIR-PD study is being conducted at the University
of Texas Southwestern. The REPAIR-PD study was approved for clinical conduct by the U.S. Food and Drug Administration (FDA) and
commenced in December&nbsp;2019. The REPAIR-PD study is anticipated to conclude in the second half of 2021 subject to COVID-19
related research restrictions. As of February 25, 2021, twelve participants were enrolled in the REPAIR-PD study with exposure
up to 21-weeks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July&nbsp;2020, an interim analysis of data from completers of these ongoing trials was conducted. A full volume coil was used
to collect whole brain spectral waveforms in ~600 voxels with a spatial resolution of 2 cm<SUP>3</SUP> for the following metabolites:
NAD pool (both NAD+ and NADH together), ATP, phosphocreatine, extracellular and intracellular inorganic phosphate, uridine diphosphate
glucose, phosphocholine, phosphoethanolamine, glycerophosphocholine, and glycerophosphoethanolamine. A partial volume coil was
used on the same patient cohort to measure combined occipital and parietal levels of NAD+ and NADH phosphorous metabolites to
determine the ratio of NAD+/NADH. Results for 4 MS and 6 PD completers (all competed subjects prior to a COVID-19 related research
pause) were analyzed. These data suggest that CNM-Au8 was able to normalize the levels of all bioenergetic metabolites measured.
Percent change from BL at the EOS visit was highly correlated to BL levels for key bioenergetic markers. Patients with NAD levels
less than the BL mean significantly increased whole-brain NAD levels at the EOS visit, while patients with BL NAD levels greater
than the mean normalized levels to the BL mean. Importantly, this relationship was observed for total NAD levels (r<SUP>2</SUP>
= 0.6585; p = 0.0044), &szlig;-ATP (r<SUP>2</SUP> = 0.8705; p &lt; 0.0001), and several other <SUP>31</SUP>P metabolites, indicating
a homeostatic effect of CNM-Au8 on brain bioenergetics. These preliminary results robustly demonstrate target engagement in the
brains of PD patients, and provide the first clinical evidence demonstrating the catalytic effects of CNM-Au8 on brain bioenergetic
metabolites. For details, please see the &ldquo;&mdash; REPAIR-MS and REPAIR-PD&rdquo; section and Figure 9 above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>RESCUE-PD</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
second Phase 2 clinical study is planned to investigate the effects of CNM-Au8 on slowing or preventing disease progression in
PD patients. This study, the RESCUE-PD study, will follow patients with PD to determine the effects of CNM-Au8 on stabilizing
disease activity as a neuroprotective therapeutic. The RESCUE-PD study is planned to commence in late&nbsp;2022, with results
anticipated within 24-36 months following study initiation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Amyotrophic
Lateral Sclerosis</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>ALS
Market Opportunities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amyotrophic
lateral sclerosis is an adult-onset, progressive, and fatal neurodegenerative disorder of the neuromuscular system resulting in
muscle weakness and paralysis leading to death as early as three to five years after initial diagnosis. ALS involves the progressive
degeneration of motor neurons in the spinal cord and brain, which are responsible for controlling voluntary muscle movement. In
ALS, this progressive loss of motor neurons leads to muscle weakness, loss of muscle mass, and inability to control movement.
Although there are two FDA approved drugs for ALS, riluzole and edaravone, neither treatment substantially halts or reverses the
progressive nature of this disease. The onset of disease for the majority of individuals with ALS occurs between 40 and 60&nbsp;years
old and is more common in men. After the age of 65, the difference in incidence between males and females decreases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>ALS
Current Therapies and Limitations</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
ALS treatment therapies are largely palliative, aiming only to provide temporary relief from symptoms without addressing the underlying
disease progression. For example, one approach to the loss of respiratory function, which is the most common cause of ALS-related
death, is non-invasive ventilation. Despite the great need for an effective disease-modifying treatment, and significant research
efforts by the pharmaceutical industry to meet this need, there have been limited clinical successes and no curative therapies
approved to date. There are two FDA-approved therapeutic agents for the treatment of ALS: riluzole, an anti-glutamatergic agent,
and edaravone, a free-radical scavenger. However, both of these treatments are acknowledged to have limited disease-modifying
effects, as riluzole extends participant lifespans by an average of only two to three months, while edaravone slows the decline
of the ALSFRS-R score, a clinical measure of functional decline, in only a small subset of participants who are at an early stage
of disease. There is clearly an urgent unmet need for the development of safe and effective disease-modifying therapeutics for
ALS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Potential
Advantages of CNM-Au8 for ALS</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that CNM-Au8 has the potential to be a first-in-class&nbsp;disease modifying nanotherapeutic drug for ALS. In a human
induced pluripotent stem cell (&ldquo;iPSC&rdquo;) model of ALS, CNM-Au8 demonstrated clearly superior human motor neuron protection
compared to riluzole. Furthermore, oral delivery of CNM-Au8 to ALS model mice extended the median lifespan of these animals by
over three times the lifespan extension attributed to edaravone or riluzole treatment reported in the literature. While the mechanism
of action of edaravone shares one similar component with CNM-Au8, namely, reduction of oxidative stress, we believe the important
difference in activity lies in CNM-Au8&rsquo;s demonstrated potential to enhance bioenergetic activity in diseased neurons as
well as to significantly reduce oxidative stress. Furthermore, we believe the complex nature of many of the neurodegenerative
diseases, including ALS, calls for a therapeutic drug with multimodal activity that can act to enhance the bioenergetic profile
of multiple central nervous system cell types; for this, CNM-Au8 may be uniquely suited to address the therapeutic challenges
posed by such complicated and devastating diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Summary
of Nonclinical Pharmacology Neuroprotection Studies for ALS</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motor
neurons progressively degenerate during the course of ALS. To demonstrate neuroprotection of motor neurons by CNM-Au8, <I>in vitro
</I>neuroprotection assays were first used. Rat motor neurons were challenged with glutamate to induce excitotoxicity, or with
amyloid beta 1-42 peptide (&ldquo;A-beta&rdquo;), which is toxic to motor neurons. In Alzheimer&rsquo;s Disease, A-beta aggregates
participate in the formation of amyloid plaques. CNM-Au8 treatment of motor neurons challenged with glutamate or with A-beta increased
numbers of surviving motor neurons and preserved neurite networks in a dose-dependent manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregation
of misfolded proteins that display neurotoxic properties is a hallmark of many neurodegenerative diseases, including ALS. Accumulation
of mis-localized, cytoplasmic TAR DNA-binding protein 43 (&ldquo;TDP-43&rdquo;) in motor neurons is associated with over 90% of
ALS cases, and TDP-43 aggregates have been shown to disrupt cellular functions in motor neurons. In neuron-glial co-culture assays,
application of glutamate or A-beta to rat motor neurons causes TDP-43 aggregates to accumulate in the cytoplasm of motor neurons.
Treatment of the glutamate- or A-beta-challenged motor neurons with CNM-Au8 significantly reduced the accumulation of TDP-43 aggregates
in a dose-dependent manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to animal models, iPSCs have emerged as a new technique for neurodegenerative disease modeling using human-derived cells.
iPSCs can be generated from a human skin or blood samples, and then differentiated <I>in vitro</I> into astrocytes and motor neurons.
Using this technique, ALS patient-derived astrocytes were shown to be toxic to normal healthy human motor neurons. Introduction
of CNM-Au8 to these toxic ALS patient astrocyte-motor neuron co-cultures resulted in a significant, dose-dependent rescue of human
motor neurons and preservation of motor neuron neurite networks. Collectively, these results indicated that CNM-Au8 exerts motor
neuron protection effects in several different models, including in response to excitotoxic stress, A-beta toxicity, and toxic
astrocytes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
investigate the efficacy of CNM-Au8 in an <I>in vivo</I> model of ALS, two studies were conducted in separate transgenic
(SOD1<SUP>G93A</SUP>) mouse model strains that model the human SOD1 familial form of ALS. In a study using rapidly
progressing SOD1<SUP>G93A</SUP> animals, CNM-Au8 treated animals showed significant reduction of brainstem atrophy and
brainstem vacuolization normally seen in untreated SOD1<SUP>G93A</SUP> mice. In the study using slower-progressing
SOD1<SUP>G93A </SUP>animals, CNM-Au8 treated animals showed significant treatment effects in a number of behavioral and
functional tests, including overall clinical score, weights hold, static rod orientation time, and average wheel-running
velocity. Median survival of CNM-Au8 treated animals significantly exceeded vehicle-treated controls by 23&nbsp;days
(approximately 20% of the animal&rsquo;s expected life-span).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Clinical
Development of CNM-Au8 as a Disease-Modifying Drug for ALS</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Orphan
Drug Status for ALS</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. FDA granted orphan drug development status to CNM-Au8 for the treatment of ALS in May&nbsp;2019. Following FDA orphan drug
designation, sponsors may qualify for seven-year FDA-administered Orphan Drug Exclusivity, partial tax credits for research and
development expenses, potential research and development grants, waived FDA fees, and protocol assistance from the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>RESCUE-ALS</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RESCUE-ALS
is a Phase 2, randomized, double-blind, placebo-controlled study of the efficacy, safety, pharmacokinetics, and pharmacodynamics
of CNM-Au8 in ALS patients. As of September 7<SUP>th</SUP>,&nbsp;2020, the study was fully enrolled with 42 participants. In the
study, patients will be randomized 1:1 to either receive 30 mg of CNM-Au8 once daily or matching placebo over a 36-week double-blind
treatment period. Efficacy will be assessed as the change in motor neuron loss as measured by electromyography (e.g., MUNIX, the
primary endpoint; and secondary endpoints, including MScanFit, MUSIX, Split Hand Index, and the Neurophysiology Index). Exploratory
endpoints include standard clinical, safety, and quality of life assessments. The study is being conducted at two sites in Australia
and led by ALS clinicians who are experts in electrophysiology techniques. As of February 25, 2021, the study had over-enrolled
with 45 of 42 planned participants in the RESCUE-ALS study with exposure to the investigational product up to 36-weeks. Twelve
participants had enrolled in the long-term open-label extension following completion of the week 36 end-of-study visit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RESCUE-ALS
is being substantially funded by FightMND who provided Clene with a grant of AUD$1.37 million. In general, the grant terms from
Fight MND include repayment of funds received in the event of commercialization of CNM-Au8 for the treatment of ALS in Australia
from future net sales proceeds up to a mid single-digit multiplier of the original grant amount of AUD $1.37M. Funding is disbursed
based on the achievement of performance milestones related to patient enrollment targets. All intellectual property rights from
the study activities will be owned by the company. Results of this study are anticipated in the second half of 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Healey-ALS
Platform Trial</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September of 2019, the Sean M. Healey&nbsp;&amp; AMG Center (&ldquo;Healey Center&rdquo;) for ALS at Massachusetts General Hospital
selected CNM-Au8 as one of the first three drugs for inclusion in the first Platform Trial for the treatment of ALS. The Healey
Center Platform Trial for ALS will test promising experimental therapeutics with a design that allows for the testing of multiple
drugs simultaneously in order to rapidly identify and accelerate the development of novel therapies for ALS, while offering the
advantages of reduced trial time, reduced costs and increased patient participation. The trial includes substantial financial
support from philanthropic donors and the Healey Center, and provides access to 54 expert ALS clinical trial sites across the
United&nbsp;States from the Northeast Amyotrophic Lateral Sclerosis (&ldquo;NEALS&rdquo;) consortium.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trial is a Phase 3, multicenter, double-blind, placebo controlled registrational clinical trial to assess the safety, efficacy,
pharmacokinetics, and pharmacodynamics of CNM-Au8 in treating ALS. Participants will be randomized 3:1 between active treatment
and placebo with active treatment equally distributed between low dose (30&nbsp;mg) CNM-Au8 and high dose (60 mg) CNM-Au8. The
primary endpoint is rate of change in ALSFRS-R score from baseline to week 24, with secondary endpoints of changes in slow vital
capacity and hand-held dynamometry measurements. Exploratory endpoints include a combined joint-rank score based on survival and
change in ALSFRS-R score from baseline to week 24, voice pathology measurements, and biofluid-based pharmacodynamic and metabolic
markers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clene
will contribute a direct fee to the Healey ALS Center toward the clinical conduct of this trial; there will be no additional licensing
fees or milestone requirements. Clene will own all CNM-Au8 data while placebo data will be shared across the different treatment
regimens within the platform trial. Study enrollment commenced in August&nbsp;2020. Results for CNM-Au8 are anticipated in the
first half of&nbsp;2022 subject to the achievement of enrollment targets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>CNM-Au8
Expanded Access Program</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on interest in the potential of CNM-Au8 to delay disease progression in ALS patients, clinical experts at Massachusetts General
Hospital requested early access to use CNM-Au8 in an Expanded Access Program (&ldquo;EAP&rdquo;). An EAP is a potential pathway
for a patient with an immediately life-threatening condition or serious disease or condition to gain access to an investigational
medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory
alternative therapy options are available. To qualify an EAP within the United&nbsp;States the following should apply, (i)&nbsp;a
patient has a serious disease or condition, or whose life is immediately threatened by their disease or condition, (ii)&nbsp;there
is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition, (iii)&nbsp;patient
enrollment in a clinical trial is not possible, (iv)&nbsp;potential patient benefit justifies the potential risks of treatment,
and (iv)&nbsp;providing the investigational medical product will not interfere with investigational trials that could support
a medical product&rsquo;s development or marketing approval for the treatment indication. The EAP is conducted under a study protocol
filed with the FDA and commenced in August&nbsp;2019. The EAP will collect safety and pharmacokinetic data in ALS patients not
otherwise eligible for clinical studies due to standard inclusion and exclusion criteria. As of February 25, 2021, 37 participants
had been enrolled in the EAP with exposure up to 69-weeks. An EAP provides additional safety data for FDA review and will be considered
as part of the safety data package for CNM-Au8, and may provide supportive long-term safety data with respect to an NDA submission
should the Healey ALS platform trial result in a statistically significant treatment benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>REPAIR-ALS</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
REPAIR-ALS Phase 2 study is modeled after the REPAIR-MS and REPAIR-PD studies, discussed previously, and will investigate the
effects of CNM-Au8 on improvement of bioenergetics and brain cellular membrane markers by non-invasively measuring brain levels
of these markers utilizing <SUP>31</SUP>P-MRS. The REPAIR-ALS study has been approved for clinical conduct by the U.S. Food and
Drug Administration (FDA) and is planned to commence following completion of the REPAIR-MS and REPAIR-PD programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Additional
CSN Therapeutics in the Pipeline</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three
other drug candidates are at various IND-enabling stages of research. Utilizing our CSN therapeutic drug development platform,
we have developed additional drug candidates based on the transition elements silver and zinc (CNM-ZnAg) for anti-viral/anti-bacterial
and wound healing applications (CNM-AgZn17), and gold and platinum (CNM-PtAu7) for oncology applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>CNM-ZnAg,
a Broad Spectrum Anti-viral and Anti-Bacterial agent in Development for Treatment of COVID-19</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CNM-ZnAg
was developed for use as an orally deliverable, broad-spectrum antiviral and antibacterial agent. It is formulated as an ionic
solution of zinc (Zn<SUP>+2</SUP>) and silver (Ag<SUP>+</SUP>) with a limited presence (&lt;1%) of silver Ag<SUP>0</SUP> nanoparticles,
all generated using the CSN platform in a manner that does not involve traditional inorganic synthesis methods utilized to generate
zinc and silver compounds. The rationale for integrating a zinc-silver ionic solution was premised on the recognized historical
activity of both Zn and Ag (as independent entities) for antimicrobial and antiviral disease treatment. Initial development studies
both internally as well as externally from other labs revealed that when Zn<SUP>2+</SUP> and Ag<SUP>+</SUP> are administered together,
they exhibit synergistic antiviral and antibacterial properties that are not observed when Zn<SUP>2+</SUP> or Ag<SUP>+</SUP>,
or Ag<SUP>0</SUP> nanoparticles are administered singly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the human body, zinc is an essential structural component of &lt;750 zinc finger transcription factors, and is a catalytic component
of approximately&nbsp;2000 enzymes, encompassing all known enzyme classes. Most significantly, zinc is essential for the proper
function of the immune system, and is specifically involved in multiple steps in the antiviral response. Zinc has demonstrated
direct antiviral properties; in addition, zinc stimulates both innate and acquired antiviral responses. Thus, zinc-based treatments
are hypothesized to support systemic immunity, while also acting to specifically inhibit viral replication, viral protein processing,
and/or viral-infection-related symptoms. Silver has long been studied for its anti-infective activity. Silver&rsquo;s microbial-treatment
properties have been documented for centuries, and silver has been the most extensively studied metal for the purpose of fighting
infections and preventing food spoilage. Prophylaxis of silver nitrate against gonococcal ophthalmia neonatorum with silver ions
was considered the standard of care in many countries until the end of the 20<SUP>th</SUP> century, prior to the advent of antibiotics.
Independent research had demonstrated silver nanoparticles have been shown to be active against several types of viruses including
human immunodeficiency virus, hepatitis B virus, herpes simplex virus, respiratory syncytial virus, and monkey pox virus. Silver
nanoparticles and silver ions reduce viral infectivity when added concomitantly with the virus inocula, possibly by blocking interaction
of the virus with the host cell.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
standard toxicology program based on ICH M3(R2) guidelines has been completed for CNM-ZnAg. The toxicity of CNM-ZnAg was evaluated
at high concentrations up to the maximum feasible dose administered via oral gavage up to four times daily for 28&nbsp;days in
rats and 7&nbsp;days in canines. Across all studies, there were no deaths, no test-article-related clinical observations, and
no effects on: body weight, food consumption, hematology endpoints, clinical pathology findings, blood coagulation times, urinalysis,
or urine chemistry. Standard i<I>n vivo</I> genotoxicity studies in rodents, including a 2-day COMET assay and a 28-day evaluation
of micronucleated reticulocytes, revealed no test-article effects on genotoxicity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
seven-day human tolerability study of the dietary supplement was previously conducted by an antecedent company to determine the
safety and tolerability in forty (40) healthy human volunteers. There were no self-reported adverse events and laboratory assessments
indicated no significant changes from baseline in body weight, blood pressure, heart rate, liver enzymes (AST/ALT), blood glucose,
or blood lipids (total cholesterol, LDL/HDL, triglycerides). There were no safety findings associated with administration of the
dietary supplement over the 7-day dosing period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Clinical
Development of CNM-ZnAg as a Therapeutic Treatment for COVID-19</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COVID-19
is a rapidly emerging respiratory disease, resulting in substantial morbidity and mortality. Symptoms of COVID-19 are highly variable,
with most infected individuals presenting with varying degrees of respiratory distress, fever, cough, sore throat, malaise, myalgias,
nausea, diarrhea, anosmia, and ageusia. The median incubation period, from exposure to symptom onset, is approximately 4 to 5&nbsp;days,
and 97.5% of patients who are symptomatic will have symptoms within 11.5&nbsp;days after infection. Severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) is the viral infection which causes COVID-19. Due to the international infection rates and potentially
serious nature of this disease, COVID-19 was characterized as a pandemic by the World Health Organization on March 11, 2020. A
CDC summary of PCR-positive COVID-19 cases in the U.S. as of May 30<SUP>t</SUP>, 2020 showed approximately 28% were known to be
symptomatic, 14% had been hospitalized, 2% were admitted to an intensive care unit, and 5% died.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
reduce disease impact on public health, a strategy of identifying, isolating, and quarantining infected or exposed individuals
has been put in place to slow or stop transmission; however, these preventative activities, while necessary, do not alleviate
the disease burden of individuals who have already become infected. The anti-viral therapy remdesivir is approved by the FDA for
emergency use within the U.S. for treatment of hospitalized patients with COVID-19, however, the therapeutic benefit demonstrated
in clinical trials was modest, and access has been limited regionally. Outside of the hospital setting, there are no therapies
proven to reduce the severity or duration of COVID-19 infection. Further, the timeline and efficacy for vaccine development remains
uncertain. Therefore, there is a significant unmet medical need to urgently decrease the morbidity and improve time to recovery
in COVID-19 infected individuals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of exigent worldwide need, Clene determined to rapidly develop CNM-ZnAg as a candidate treatment for COVID-19 based on the hypothesis
that CNM-ZnAg may provide immune support benefits. On a limited basis, a dietary supplement version of ZnAg has been provided
under 21 CFR 111 to support immune health. Preliminary uncontrolled observational case series with the dietary supplement yielded
results suggesting oral administration of ZnAg to individuals with PCR-confirmed, COVID-19 infections may improve subject well-being
and limit the duration of the disease. Results from a large case-series study of a COVID-19 outbreak in a US-based industrial
food processing facility and its associated congregate housing are described below. Sixty-two (62) company employees and managers
voluntarily received the ZnAg dietary supplement orally daily (while in quarantine and in congregate housing), completed a standardized
daily symptom survey, and underwent repeated SARS-CoV-2 PCR testing prior to ZnAg treatment initiation and again following 7&nbsp;days
of ZnAg supplement intake. The study population was of predominantly Hispanic ethnicity (74%). The mean age was 33.6 (10.8) years,
with 84% male. Twenty-seven (27) subjects were identified prior to supplement intake as SARS-CoV-2 positive by PCR testing. Amongst
subjects with PCR+ confirmed SARS-CoV-2 at treatment start, 44% transitioned to PCR negative following 7-days of supplement administration
(Fig. 11A). Amongst the 35 SARS-CoV-2 PCR negative subjects prior to treatment initiation, 88% remained SARS-CoV-2 negative by
repeat PCR testing after 7-days of treatment. Amongst the 27 SARS-CoV-2 positive individuals, 24 reported symptoms consistent
with COVID-19, generally self-reported as mild-to-moderate intensity. Symptom resolution (Fig. 10A), and PCR detected viral clearance
(Fig. 11C) decreased rapidly following ZnAg treatment initiation consistent with a marked improvement in participants&rsquo; global
impression of change (Fig. 11B). The rate of symptomatic resolution (~75%) by Day 7 appears qualitatively greater than the placebo
improvement rate (~50%) from a study completed in a comparable COVID-19 non-hospitalized symptomatic patient population (Fig.
11D, Skipper et al. Ann Intern Me. 2020 Jul 16;M20-4207).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
11. PCR Status and Symptomatic Changes in Food Processing Facility Workers Infected with, or Exposed to, COVID-19</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_013.jpg" ALT="" STYLE="height: 291px; width: 700px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_014.jpg" ALT="" STYLE="height: 373px; width: 700px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the potential for a clinical effect together with no identified safety signals from animal toxicology or initial human tolerability
studies, we are planning to investigate CNM-ZnAg in a randomized, placebo-controlled clinical trial to determine the efficacy
and safety of CNM-ZnAg for symptomatic improvement of COVID-19. This clinical study intended for 276 patients launched in Brazil
in February 2021. Brazil represents a geography with a significant number of COVID-19 cases, robust clinical infrastructure and
clinical trial experience, reasonable economic costs, and limited competition for participants for the enrollment of COVID-19
clinical research. The study is a randomized double-blind placebo-controlled study of CNM-ZnAg to decrease the incidence of hospitalization
(primary endpoint) at Day 28 and improve the time to symptom resolution (secondary endpoint) in PCR confirmed SARS-CoV-19 subjects
aged 40 and over. The study will evaluate two different doses of CNM-ZnAg, for which will be combined for analyses versus placebo.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>CNM-AgZn17
for Wound-Healing and Burn Treatment</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CNM-AgZn17
consists of an ionic solution of silver and zinc in a polymer gel formulation for topical application to the skin. We have demonstrated
in <I>in vitro</I> assays that CNM-AgZn17 has broad-based anti-viral and anti-bacterial activity against common and antibiotic
resistant pathogens such as Methicillin-resistant <I>Staphylococcus aureus</I>. We have also shown enhanced wound healing benefits
in animal models of diabetic wound healing and less scar formation from during burn healing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are presently completing a standard toxicology program in animals to demonstrate safety in order to advance to first-in-human
dosing studies. We have progressed to GLP dermal toxicity studies for topical applications expected to complete in 2022. Subject
to regulatory filings of these toxicology findings and other results, we anticipate initiating a standard Phase 1 dermal First-In-Human
safety study with CNM-AgZn17 with single-ascending dose and multiple-ascending dose cohorts by late 2022. The goal of this study
will be to demonstrate safety sufficient to advance to Phase 2 clinical programs with CNM-AgZn17. Given the multiple preclinical
benefits demonstrated to date with CNM-AgZn17, we envision a clinical program focused on healing burn and/or surgical wounds,
which is anticipated to initiate in 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>CNM-PtAu7&nbsp;&mdash;
Our Oncology Targeted Nanotherapeutic</U></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CNM-PtAu7
is a suspension of novel nanocrystals comprised of alloyed gold and platinum. We have demonstrated that treatment of human breast
cancer cell lines EFM-19 and MT-3 with CNM-PtAu7 induces the expression of pro-apoptotic genes and represses the expression of
anti-apoptotic genes, consistent with an anti-oncogenic effect. We have further demonstrated down-regulation of genes associated
with the electron transport chain activity, which may also suppress tumorigenic activity. Further investigations related to the
anti-tumor effects of CNM-PtAu7 are planned in additional malignant cell lines. CNM-PtAu7 has been patented in all major markets
worldwide including the United&nbsp;States, Europe, China, Singapore, and Japan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Overview</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are deeply invested in our research and development (&ldquo;R&amp;D&rdquo;) program. Our R&amp;D activities are essential to attaining
and sustaining the position as a recognized global leader in the development of CSN therapeutics. Our R&amp;D plan is to continue
the innovation of novel nanocatalysts and ionic suspensions of metallic transition elements with recognized medicinal value and
underexplored, or as yet undiscovered, physicochemical and catalytic properties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed in-house all of the technologies that are critical to our R&amp;D processes, and guard those technologies with
appropriate intellectual property protections, and will continue to do so. We conduct our research activities through an in-house
R&amp;D team at our facility in Maryland, and engage in external clinical research collaborations to support our R&amp;D activities
as well.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Internal
R&amp;D</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
internal or in-house R&amp;D activities are executed by a group of experienced research scientists, materials scientists, engineers,
molecular biologists, medical doctors, clinical trial operational specialists, and a management team with deep expertise in the
biopharmaceutical industry. Our in-house R&amp;D team has a full range of capabilities ranging from drug discovery to preclinical
development to and the design and implementation of clinical trials. We believe our R&amp;D team is experienced, qualified, and
will enable us to achieve our long-term goal of developing and commercializing innovative CSN therapeutics for patients worldwide.
Our in-house R&amp;D operates functionally through four sub-teams: (1)&nbsp;our research engineering team, (2)&nbsp;biological
science discovery team, (3)&nbsp;nonclinical development team, and (4)&nbsp;clinical development team which work collaboratively
to ensure the success of our R&amp;D efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research engineering team is responsible for the development and optimization of new CSN therapeutic candidates along with developing
the technical processes and infrastructure to ensure reproducible CMC batch production of our CSN therapeutic candidates. Members
of our research engineering team have PhDs and/or master&rsquo;s degrees in chemistry, material science and engineering, electrical
engineering, and solid-state physics. Our research engineering team leader has a degree in electrical engineering and has been
instrumental in the design of our electro-crystal-chemistry platform including the various continuous flows through apparatuses
we use to produce our CSN therapeutics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
biological science discovery team is responsible for the initial characterization of CSN therapeutics, conducting biological assays,
and assessing the activity and toxicity of drug candidates through <I>in vitro</I> and <I>in vivo </I>assays. Our biological discovery
team assesses the CSN therapeutic candidates once initial development has been completed by our research engineering team. This
team is led by an experienced research scientist who is a medical doctor and has a PhD in molecular science. Our biological discovery
team collaborates closely with our research engineering team to refine our CSN candidate selection, for instance based on structural
characteristics, in order to optimize the biological effects of our CSN candidate therapeutics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
nonclinical development team is responsible for developing a complete dataset of nonclinical animal pharmacology, toxicology,
and safety studies, which is sufficient to support regulatory filings with human research ethics committees and government regulatory
authorities in order to obtain approval for use in human studies. Our nonclinical development team works collaboratively with
our biological science discovery team and clinical development team to translate our findings into animals and prepare for eventual
studies in patients. This team also leads our external collaboration research activities with universities and academic experts.
Our nonclinical development team is led by a research scientist with a PhD in Developmental Biology from Stanford University and
a Master of Science degree in Genetics from the University of Cambridge where she was a Marshall Scholar. She is also an adjunct
faculty member of the University of Utah School of Medicine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clinical development team is led by our chief medical officer, who is a board-certified neurologist and Fellow of the American
Academy of Neurology. Once our CSN therapeutic candidates have demonstrated sufficient safety and toxicology results to advance
to human studies, the clinical development team designs, implements, and oversees the operational conduct of our clinical trials.
The clinical trials are designed to prove our CSN therapeutics are safe and effective in the treatment of diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Outsourced
R&amp;D Activities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
line with industry practice, we also outsource certain R&amp;D activities to key academic partners, nonclinical research organizations,
and to third-party clinical research organizations (&ldquo;<B>CROs</B>&rdquo;). We have collaborated with experts at key academic
universities which have myelination and neuroprotection expertise. These university collaborators have conducted animal experiments
to demonstrate the effects of CNM-Au8 treatment on remyelination and neuroprotection in animals and in cell-based <I>in vitro
</I>assays. To support our research efforts, we have partnered with academic experts at The Johns Hopkins University in ALS, Cambridge
University for myelination-related experiments, Northwestern University for myelination-related experiments, the George Washington
University for myelination-related experiments, and the University of Edinburgh for myelination-related research. In general,
we outsource the majority of toxicology, pharmacology, and toxicokinetic studies to expert nonclinical CROs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
provide maximum flexibility and efficiency to operations, we engage industry-leading CROs to manage, conduct and support our clinical
studies and to supplement our internal R&amp;D teams&rsquo; capabilities. We apply a rigorous process to selecting CROs to conduct
research studies for us; selection is based on the quality, reputation, and research experience in the field of central nervous
system disorders. In addition to the scope, depth and quality of the service and product offerings of the CROs, for clinical trial
management, we place emphasis on the ability of the CROs to facilitate optimal site selection, to recruit patients in a timely
manner, and to conduct complex clinical trials efficiently. Our CROs are widely recognized within their functional areas of research.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
enter into separate agreements with CROs and our external partners for each clinical trial or nonclinical research project. All
CROs and other external research collaborators were all independent third parties. Principal terms of the service agreements with
our key CROs and external partners are summarized as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Services.
                                         The CRO, nonclinical research organization, or academic site implements and manages the
                                         study in accordance with the protocol designed by us as specified in the service agreement.</I></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Term</I>.
                                         The CRO, nonclinical research organization, or academic site is required to support the
                                         clinical trial or nonclinical studies within the prescribed time limit until the end
                                         of the clinical trial.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&#9679;</I></FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Payments.
                                         </I>We are required to make payments to our partners in accordance with the payment schedule
                                         agreed by the parties.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&#9679;</I></FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Intellectual
                                         property rights. We own intellectual property rights arising from the research activities
                                         related to our background intellectual property.</I></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Risk
                                         allocation.</I> Each party indemnifies the other party for losses caused by its fault
                                         or gross negligence. We indemnify the CRO and external partners for theoretical risks
                                         related to CNM-Au8.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
monitor and evaluate our CROs and external research partners with various activities including site visits, ongoing project team
reviews, and/or assessments by third party assessors. We strive to achieve clinical trial excellence by maintaining strong quality
control measures. We perform core functions such as clinical development strategy formulation and protocol design in house, and
exercise control and oversight over key functions of clinical trial management. We conduct regular site visits to oversee site
initiation, patient recruitment, and data quality monitoring, except when precluded by COVID-19 related research restrictions.
We also engage third party consultants to perform clinical trial audits. Data quality is further assessed by in-house data review,
including medical review, document review, and monitoring report review. We will not work with a vendor who does not have processes
established surrounding data privacy and safeguards to ensure compliance through the clinical trial. We have maintained a stable
relationship with our CROs and other external research partners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Clinical
Trial Management</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
support our clinical trials, our internal clinical trials team designs, implements, collects and analyzes data for our clinical
trials. When additional services are required to support a clinical trial, we conduct a feasibility and qualification assessment
for potential vendors and CROs. These vendors are vetted through review of their current operational structure and established
procedures, knowledge, and experience about the study, indication, or population, and past feedback from participating clinical
sites. Our internal clinical development team supervises CROs on key clinical activities, such as patient eligibility review,
medical data review, and SAE review, to ensure that the performance of these CROs complies with our protocols and applicable laws,
which in turn protects the integrity and authenticity of the data from our clinical trials. Our internal clinical development
team holds meetings with CROs to evaluate the CRO&rsquo;s performance by following up on clinical progress and resolving potential
issues and risks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Financial
Grants</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have been awarded grants from various organizations, including the U.S. Congressionally Directed Medical Research Program administered
by the Department of Defense, the National Multiple Sclerosis Society, and FightMND, a not-for-profit registered charity in Australia,
who together have issued us grants totaling approximately $2.6 million. We also receive indirect financial support for one of
the clinical studies in which we participate, the Healey ALS Platform Trial, administered by the Massachusetts General Hospital,
which is conducting a study of our CNM-Au8 drug candidate along with other drugs in a platform trial, at significantly lower costs
to us than we would otherwise incur if we were to conduct a comparably designed study on our own at reasonable market rates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
grants include the following terms:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Congressionally Directed Medical Research Program administered by the Department of Defense
                                         is an award for $1.25M for additional preclinical work in specific ALS models, which
                                         was awarded to us in December&nbsp;2019. At the time of this Annual Report we had not
                                         yet finalized contracting with the Department of Defense.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         NMSS grant is for a total of $339,000 for biomarker analyses of the VISIONARY-MS study.
                                         The grant was awarded to us in September&nbsp;2019 and includes terms related to repayment
                                         of funds received in the event of commercialization of CNM-Au8 for the treatment of MS
                                         based on achievement of sales milestones up to a mid single-digit multiplier of the original
                                         grant amount. Funding is milestone based on the achievement of analytical validation
                                         and reporting to the NMSS. All intellectual property rights from grant related activities
                                         vest in the company.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         FightMND grant is for AUD $1.37M and was awarded to us in August&nbsp;2019. The grant
                                         includes terms related to repayment of funds received in the event of commercialization
                                         of CNM-Au8 for the treatment of ALS in Australia from future net sales proceeds up to
                                         a mid single-digit multiplier of the original grant amount. Funding is milestone based
                                         on the achievement of performance milestones related to patient enrollment targets. All
                                         intellectual property rights from grant related activities will be owned by the company.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Michael J. Fox Foundation grant was awarded to us in January 2021. The grant provides for preclinical research funding for an in
vivo rodent model with CNM-Au8 treatment in well characterized alpha-synuclein over-expression, and additional research in human
induced pluripotent stem cell derived neurons with commonly recognized Parkinson&rsquo;s genetic defects. Funding is milestone
based and all intellectual property rights from grant related activities will be owned by the company.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Manufacturing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
manufacture CSN therapeutics at our own production facility based in Maryland, USA based on novel manufacturing processes and
devices that were entirely invented by us. Our Maryland manufacturing facility is compliant with GMP where we operate an ISO8
level clean room that contains the specialized electro-crystal-chemistry devices, or continuous flow trough apparatuses, that
we have invented and patented to produce our CSN therapeutics from highly pure raw materials. At our present operating scale,
we produce in-process gold nanocrystal suspension, the active pharmaceutical ingredient (API) for our lead asset, CNM-Au8, on
an ongoing basis. Our current API production capabilities are fully sufficient to meet our needs for both research and development
and supply for our ongoing Phase&nbsp;2 and Phase 3 clinical trials, and we believe our processes can be scaled to achieve commercially
viable quantities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
years of intensive research and development we have fine-tuned our production and delivery processes to the point where we can
consistently, reliably, and affordably produce our core drug candidates, including CNM-Au8. We have also invested considerable
time and substantial resources in perfecting the handling and storage systems in a manner that maintains stability and efficacy
of our nanocrystal suspensions. In general, the manufacturing process for CSN therapeutics involves the following steps:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sufficient
                                         quantities of processing enhancers (e.g., sodium bicarbonate, others) are dissolved in
                                         highly purified water. The resulting mixture is referred to as &ldquo;process water.&rdquo;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         process water is transferred to the conditioning portion of the trough apparatus at a
                                         constant nominal rate, where the process water is exposed to an atmospheric plasma in
                                         each trough apparatus, creating &ldquo;conditioned water.&rdquo;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         conditioned water then flows into the electrochemical crystal growth portion of the trough
                                         apparatus, at a constant rate, where the conditioned water is exposed to a series of
                                         pairs of wire electrodes. The flow of the conditioned water is controlled, and the electrodes
                                         are continuously monitored and controlled by computerized, automated controllers.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         electrodes are slowly advanced at a nominal rate to ensure that the conditioned water
                                         is exposed to the same electrochemical processing conditions to ensure batch-to-batch
                                         reproducibility, thus maintaining consistent size and shapes of the nanocrystals in each
                                         nanocrystal suspension.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In-process
                                         bulk product, API, containing elemental nanocrystals, is continuously produced. The in-process
                                         bulk product is collected into large containers.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         nominal concentration of active drug ingredients is achieved by executing a concentration
                                         step where in-process API is treated by a proprietary concentration procedure.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         concentrated product is verified to adhere to physiochemical release specifications.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         concentrated bulk suspension is subsequently filtered during filling to remove any microbiological
                                         contaminants and volumetrically filled into single unit containers. The final drug candidate
                                         is assayed to ensure it meets release specifications.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed plans to expand our production capacity at our Maryland facility in order to supply additional planned Phase 3
clinical studies following evaluation of the Phase 2 clinical trial results. We have the technical expertise and capabilities
to expand capacity to support eventual commercialization. During Part 1 of this planned expansion, we will more than triple the
number of continuous flow trough apparatus and increase our storage capacity within our existing clean room environment. During
Part 2 of our planned expansion, we will scale our production capacity by more than doubling our clean-room area along with the
addition of more continuous flow trough apparatus and storage reservoirs. At the completion of this planned expansion we believe
we will have sufficient capacity to support multiple Phase 3 studies in addition to enabling initial commercial supply of CNM-Au8.
We also have initiated design studies to significantly scale our production processes as demand for our products increases to
supply commercial marketing needs. We believe our current production environment has established Clene as the leading world-class
manufacturer of clean surfaced nanocrystal therapeutics, and following the completion of our planned expansion, our facilities,
equipment, and processes will comply with international practices and support our long term strategic plans, taking into consideration
quality, costs, manageability, expandability and controls.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License
Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2018, we established a license agreement and an exclusive supply agreement with 4Life, an international supplier of health supplements
and one of our shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
this license agreement, we granted to 4Life an exclusive and royalty-bearing license in relation to products that are very low
concentration silver, gold, and other similar very low-concentration non-pharmaceutical supplement products produced by our electro-crystal-chemistry
technology platform. This exclusive grant does not include ZnAg, for which 4Life has a non-exclusive right. 4Life is allowed to
develop, make, manufacture, use, sell and commercialize the licensed products worldwide within the field of dietary supplements
and certain non-pharmaceutical products for human use, internally or externally, which contain metallic-based constituents that
are formed by our electrochemistry manufacturing techniques. 4Life will use its reasonably diligent commercial efforts to introduce
the products to certain commercial markets following regulatory approval for their sale as nutritional mineral supplements. The
initial term of this license agreement commenced on August 31, 2018 and will continue until five years after 4Life&rsquo;s introduction
of the first nutritional supplement licensed product into the marketplace, which occurred on July 1, 2020. The license agreement
may be renewed for additional five year periods by mutual agreement. Upon expiration of the license agreement the exclusive provisions
in the agreement will convert to non-exclusive. The license agreement may only terminate by mutual agreement between the parties,
or upon breach by either party that results in termination of the agreement under applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
an exclusive supply agreement, 4Life will purchase the licensed products exclusively from us and we will sell the licensed products
exclusively through 4Life, except for ZnAg which is not exclusively sold through 4Life. Upon the occurrence of certain future
events, 4Life can achieve the right to exclusively manufacture the licensed products under the license agreement, other than ZnAg
for which this right does not apply. The initial term of the exclusive supply agreement commenced on August 31, 2018 and will
continue until five years after the minimum sales commencement date, which both parties anticipate will be in April&nbsp;2021.
The exclusive supply agreement may be renewed for additional five year periods by mutual agreement. 4Life may terminate the exclusive
supply agreement for cause, which is stated to include repudiation, uncured material breach, insolvency, bankruptcy, general assignment
for benefit of creditors, failure to provide reasonable assurances of financial and operational capacity, prolonged unremedied
force majeure, and failure to proper notify of change in control. Clene may terminate the exclusive supply agreement in the event
of a repudiation, uncured material breach, insolvency, bankruptcy or general assignment for benefit of creditors by 4Life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the time of commercial sales, single-digit royalty payments are owed to us by 4Life based on the size of 4Life&rsquo;s basket
of total product sales. Royalties are payable quarterly under the license agreement until termination of the license agreement.
In addition, 4Life will pay us our fully encumbered manufacturing expenses plus a guaranteed double-digit margin. We began supplying
KHC46 (Gold Factor<SUP>&trade;</SUP>) and a low dose zinc-silver solution (Zinc Factor&trade;) during the first half of 2020 under
this license agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not licensed our electrochemistry platform, any CSN therapeutics or any drug candidates to any other parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Competition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the industry of the treatment for central nervous system diseases is quite competitive and subject to frequent changes, there
are currently no existing therapies that claim effects on remyelination and neurodegeneration in patients. CNM-Au8&rsquo;s core
effects of remyelination and neuroprotection provide us a globally unique first-mover-advantage for the treatment of central nervous
system diseases. Together with our expanded intellectual property portfolio, we believe that it would be challenging for any potential
competitors entering into the market of remyelination and neuroprotection focused therapeutics to replicate our efforts without
violating our intellectual property protections.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intellectual
Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
intellectual property is protected through extensive global patents, institutional expertise and experience, and specialized technical
know-how, which enable us to maintain our leading position in the development of CSN therapeutics for high-medical need diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have over 100 issued patents worldwide and over 30 patents pending worldwide. We have world-wide rights to protect and
thus commercialize our CSN therapeutics and believe that our issued, and pending patents, provide sufficient protection to secure
the future commercial potential of our CSN therapeutics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed and obtained patents in the United&nbsp;States (US); Australia (AU); Brazil (BR); Canada (CA); China (CN); European
Patent Office (EP), including Switzerland (CH), Germany (DE), Denmark (DK), Finland (FI), France (FR), Great Britain (CB), Ireland
(IE), Italy (IT), Netherlands (NL), Norway (NO), Spain (ES), and Sweden (SE); Egypt (EG); India (IN); Indonesia (ID); Israel (IL);
Japan (JP); Korea (KR); Mexico (MX); New Zealand (NZ); Philippines (PH); Russia (RU); Singapore (SG); and the United Arab Emirates
(AE); with multiple fundamental patent families protecting our CSN therapeutics. The following table lists the material granted
patent families in connection with our CSN therapeutics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 28%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 23%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jurisdiction</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 23%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application
    Date (US)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 23%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant
    Date (US)</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continuous
    methods for treating liquids and manufacturing certain constituents (e.g., nanoparticles) in liquids, apparatuses and nanoparticles
    and nanoparticle/liquid solution(s) resulting therefrom (these patents relate to CNM-Au8 and ZnAg)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Issued:
                                         </I>US (3), CA, AU, CN, ID, IL, IN, JP, KR, MX, PH.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Granted:
        </I>EPO</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Pending:
        </I>US</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
                                         7, 2010</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
        15, 2013</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
        11, 2017</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
        13, 2010</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
        27, 2013</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
                                         31, 2013</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
        29, 2017</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
        9, 2018</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
        24,&nbsp;2013</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
        12, 2016</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration
dates for these patents will occur in 2028 in the applicable foreign jurisdictions and in 2030 in the US*</FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continuous,
    semi-continuous and batch methods for treating liquids and manufacturing certain constituents (e.g.,&nbsp;nanoparticles) in
    liquids, apparatuses and nanoparticles and nanoparticle/liquid solution(s) and colloids resulting therefrom (these patents
    relate to CNM-Au8 and ZnAg)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Issued:
                                         </I>US (2), AU, CA, CN, EP, IN, IS, JP, KR, SG, RU; CH, DE, DK, FI, FR, IE, NL, NO, SE,
                                         GB.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Allowed:
        US</I></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Pending:
IN, EP</I></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
                                         12, 2011</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August&nbsp;25,
        2014</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
                                         30, 2015</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
        31, 2018</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration
dates for these patents will occur in 2030 in the US and the applicable foreign jurisdictions*</FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Novel
    gold-based nanocrystals for medical treatments and electrochemical manufacturing processes therefor (these patents relate
    to CNM-Au8)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Issued:
                                         </I>US (2), AE, AU (3), CA, CN, ID, IN, IL, JP (3), KR (3), MX, RU, SG; CH, DE, DK, ES,
                                         FI, FR, GB, IE, IT, NL, NO, SE.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Allowed:
        US, AU</I></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Pending:
</I>BR, JP, MX, PH (2)</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    28, 2012</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
                                         28, 2017</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration
dates for these patents will occur in 2030 in the US and the applicable foreign jurisdictions*</FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Novel
    gold-platinum based bi-metallic nanocrystal suspensions, electrochemical manufacturing processes therefor and uses for the
    same (these patents do not relate to any specifically named product candidates herein)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Issued:
                                         </I>US, AE, AU, CA, CN, ID, IL, IN, JP, KR, MX, NZ, RU, SG; CH, DE, DK, ES, FI, FR, GB,
                                         IE, IT, NL, NO, SE.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Pending:
</I>BR, EG, PH</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    16, 2013</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
                                         12, 2016</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration
dates for these patents will occur in 2030 in the US and in 2032 in the applicable foreign jurisdictions*</FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods
    and treatment for certain demyelination and dysmyelination-based disorders and/or promoting remyelination (these patents relate
    to CNM-Au8)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Issued:
                                         </I>AU, PH, RU, SG.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Granted:
        </I>EPO</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Allowed:
        </I>ID, KR, MX, NZ&nbsp;(2)</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Pending:
</I>CA, CN, IN, IL, JP, SG</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NA</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NA</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration
        dates for these patents will occur in 2033 in the US and the applicable foreign jurisdictions*</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 15%; font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expiration
                                         dates do not include possible patent extensions for certain countries</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not been involved in any proceedings in respect of, and we had not received notice of any claims of infringement
of, any intellectual property rights that may be threatened or pending, in which we may be a claimant or a respondent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Government
Regulation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate,
among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling,
packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring, and post-approval
reporting of drugs such as those Clene is developing. Clene, along with third-party contractors, are required to comply with the
various preclinical, clinical, and commercial approval requirements of the governing regulatory agencies of the countries in which
Clene wishes to conduct studies or seek approval or licensure of CNM-Au8 or any future drug candidate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>FDA
Drug Approval Process</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United&nbsp;States, the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act (&ldquo;FDCA&rdquo;) and implementing
regulations. The process required by the FDA before drug candidates may be marketed in the United&nbsp;States generally involves
the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
                                         of preclinical laboratory tests and animal studies performed in accordance with the FDA&rsquo;s
                                         current Good Laboratory Practices regulations;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
                                         to the FDA of an investigational new drug (&ldquo;IND&rdquo;) application, which must
                                         become effective before clinical trials may begin and must be updated annually or when
                                         significant changes are made;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
                                         by an independent review board whose role is to review the research before the trial
                                         is commenced and continuously throughout the trial to assure the protection of the rights
                                         and welfare of the human subjects. These boards are often called &ldquo;institutional
                                         review boards&rdquo; (&ldquo;IRB&rdquo;);</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
                                         of adequate and well-controlled human clinical trials to establish the safety and efficacy
                                         of the proposed drug candidate for its intended purpose;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparation
                                         of and submission to the FDA of a new drug application (&ldquo;NDA&rdquo;) after completion
                                         of all pivotal clinical trials that includes substantial evidence of safety and efficacy
                                         from results of nonclinical testing and clinical trials;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                         determination by the FDA within 60&nbsp;days of its receipt of a NDA to file the application
                                         for review;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
                                         completion of an FDA pre-approval inspection of the manufacturing facility or facilities
                                         at which the proposed product is produced to assess compliance with GMP and to assure
                                         that the facilities, methods, and controls are adequate to preserve the drug candidate&rsquo;s
                                         continued safety, purity and potency, and of selected clinical investigation sites to
                                         assess compliance with Good Clinical Practices (&ldquo;GCP&rdquo;);</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
                                         completion of an FDA Advisory Committee review, if applicable; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
                                         review and approval of the NDA to permit commercial marketing of the product for particular
                                         indications for use in the United&nbsp;States.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Preclinical
and Clinical Development</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to beginning the first clinical trial with a drug candidate in the United&nbsp;States, Clene must submit an IND application to
the FDA. An IND application is a request for authorization from the FDA to administer an investigational new drug product to humans.
The central focus of an IND submission is the general investigational plan and the protocol(s) for clinical studies. The IND also
includes results of animal and <I>in vitro</I> studies assessing the toxicology, pharmacokinetics (&ldquo;PK&rdquo;), pharmacology,
and pharmacodynamic (&ldquo;PD&rdquo;) characteristics of the drug candidate; chemistry, manufacturing, and controls (&ldquo;CMC&rdquo;)
information; and any available human data or literature to support the use of the investigational product. An IND must become
effective before human clinical trials may begin. The IND automatically becomes effective 30&nbsp;days after receipt by the FDA,
unless the FDA, within the 30-day time period, raises safety concerns or other questions about the proposed clinical trial. In
such a case, the IND may be placed on clinical hold until the IND sponsor and the FDA resolve the outstanding concerns or questions.
Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators
in accordance with Good Clinical Practice (GCP) and regulations governing the protection of human research subjects, including
the requirement that all research subjects provide voluntary informed consent for their participation in any clinical study. Clinical
trials are conducted under clinical study protocols detailing, among other things, the objectives of the study, the parameters
to be used in monitoring safety, and the effectiveness criteria to be evaluated. A separate submission to the existing IND must
be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. For
new indications, a separate new IND may be required. An Institutional Review Board (IRB) must review and approve the plan for
any clinical trial and its informed consent form before the clinical trial begins. and must monitor the study until completed.
Often each institution or clinical site has its own IRB. The IRB is responsible for ensuring that human subject&rsquo;s rights
and privacy are maintained. Regulatory authorities, the IRB, or the sponsor may suspend a clinical trial at any time on various
grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely
to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the
clinical study sponsor, known as a data safety monitoring board (DSMB), which provides authorization for whether or not a study
may move forward at designated check points based on access to certain data from the study. The DSMB may halt the clinical trial
if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy.
There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.
For purposes of NDA approval, human clinical trials are typically conducted in three sequential phases (which may overlap or be
combined).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                         1&nbsp;&mdash; The investigational product is initially introduced into a small number of
                                         healthy human subjects or patients with the target disease or condition. These studies
                                         are generally designed to test the safety, dosage tolerance, absorption, metabolism,
                                         distribution, and elimination of the investigational product in humans, the side effects
                                         associated with increasing doses, and, if possible, to gain early evidence on effectiveness.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                         2&nbsp;&mdash; The investigational product is administered to a larger, but still limited
                                         patient population with a specified disease or condition to evaluate the preliminary
                                         efficacy (usually based on a biomarker of disease), optimal dosages, and to identify
                                         possible adverse side effects and safety risks. Multiple Phase&nbsp;2 clinical trials
                                         may be conducted to obtain information prior to beginning larger, confirmatory Phase&nbsp;3
                                         clinical trials.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                         3&nbsp;&mdash; The investigational product is administered to an expanded patient population
                                         to provide statistically significant evidence of relevant clinical efficacy and to further
                                         test for safety, and potentially further evaluate different dosages, generally at multiple
                                         geographically dispersed clinical trial sites. These clinical trials are intended to
                                         establish the overall risk/benefit ratio of the investigational product and to provide
                                         an adequate basis for product approval by health authorities.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to
gain more information about the product. These studies, termed Phase 4 studies, may be implemented as a condition of approval
of the NDA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information
about the biological characteristics of the drug candidate, and must finalize a process for manufacturing the product in commercial
quantities in accordance with current GMP requirements. The manufacturing process must be capable of consistently producing quality
batches of the drug candidate and, among other things, must develop methods for testing the identity, strength, quality and purity
of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted
to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug
companies such as Clene are subject to legal requirements restricting, or imposing penalties for, the employment or use of
individuals who have been debarred or excluded under various laws, including the provisions of 21 U.S.C. &sect;&sect; 335a,
335b, or 335c, 42 U.S.C. &sect; 1320a-7, in connection with making materially false or fraudulent statements to FDA, the
offering or making of any prohibited payment, gratuity or other thing of value to personnel of the FDA or any other
Governmental Entity, or other acts, statements, or omissions subject to FDA&rsquo;s policy titled &ldquo;Fraud, Untrue
Statements of Material Facts, Bribery, and Illegal Gratuities&rdquo; set forth in 56 Fed. Reg. 46191 (September 10, 1991),
Employment of such individuals, or the occurrence of such violations in the development and regulatory application process
may prevent or delay any approval of a company&rsquo;s new drug application.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>NDA
Submission, Review and Approval</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
successful completion of all required testing in accordance with all applicable regulatory requirements, the results of nonclinical
studies and clinical trials are submitted to the FDA as part of a New Drug Application (NDA) requesting approval to market the
product for one or more indications. The NDA must include all relevant data available from pertinent preclinical and clinical
studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to
the product&rsquo;s CMC, and proposed labeling, among other things. The submission of a NDA requires payment of a substantial
application user fee to FDA (unless a waiver or exemption applies).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
an NDA has been submitted, the FDA&rsquo;s goal is to review standard applications within ten months after it accepts the application
for filing (a 60-day process), or, if the application qualifies for priority review, six months after the FDA accepts the application
for filing. In both standard and priority reviews, the review process can be significantly extended by FDA requests for additional
information or clarification. The FDA reviews an NDA to determine, among other things, whether a product is safe and effective
and the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&rsquo;s
continued safety and efficacy. The FDA may convene an advisory committee to provide clinical insight on application review questions.
Before approving an NDA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA
will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with GMP
requirements and adequate to assure consistent production of the product within required specifications. Additionally, before
approving a NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines
that the application, manufacturing processes, or manufacturing facilities are not acceptable, it will outline the deficiencies
in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional
information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the FDA evaluates a NDA and conducts inspections of manufacturing facilities where the investigational product and/or its drug
substance will be produced, the FDA may issue an approval letter or a Complete Response Letter. An approval letter authorizes
commercial marketing of the product with specific prescribing information for specific indications. A Complete Response Letter
will describe all of the deficiencies that the FDA has identified in the NDA, except that, where the FDA determines that the data
supporting the application are inadequate to support approval, the FDA may issue the Complete Response Letter without first conducting
required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the Complete Response Letter,
the FDA may recommend actions that the applicant might undertake to resolve any findings and place the NDA in condition for approval,
including requests for additional information or clarification. The FDA may delay or refuse approval of a NDA if applicable regulatory
criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to
monitor safety or efficacy of a product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations
on the indicated uses for which such product may be marketed. For example, the FDA may approve the NDA with a Risk Evaluation
and Mitigation Strategy (&ldquo;REMS&rdquo;), to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy
to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such
medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure
safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition
approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once
approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained
or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and
surveillance to further assess and monitor the product&rsquo;s safety and effectiveness after commercialization, and may limit
further marketing of the product based on the results of these post-marketing studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Expedited
Development and Review Programs</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
marketing application for a drug candidate submitted to the FDA for approval may be eligible for FDA programs intended to expedite
the FDA review and approval process, such as priority review, fast track designation, breakthrough therapy, and accelerated approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative
therapy exists or to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition
compared to marketed products. For products containing new molecular entities, priority review designation means the FDA&rsquo;s
goal is to take action on the marketing application within six months of the 60-day filing date (compared with ten months under
standard review).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended
to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need by
providing a therapy where none exists or a therapy that may be potentially superior to existing therapy based on efficacy or safety
factors. Fast track designation provides opportunities for more-frequent interactions with the FDA review team to expedite development
and review of the product. The FDA may also review sections of the NDA for a fast track product on a rolling basis before the
complete application is submitted, if the sponsor and FDA agree on a schedule for the submission of the application sections,
and the sponsor pays any required user fees upon submission of the first section of the NDA. The review clock does not begin until
the final section of the NDA is submitted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the provisions of the Food and Drug Administration Safety and Innovation Act (&ldquo;FDASIA&rdquo;) enacted in
July&nbsp;2012, a sponsor can request designation of a drug candidate as a &ldquo;breakthrough therapy.&rdquo; A breakthrough
therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening
disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing
therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.
Drugs designated as breakthrough therapies are also eligible for accelerated approval. The FDA must take certain actions, such
as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval
of a breakthrough therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive
accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to
predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that
is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account
the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of
accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical
studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. In addition,
the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely
impact the timing of the commercial launch of the product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions
for qualification or decide that the time period for FDA review and approval will not be shortened. Furthermore, priority review,
fast track designation, breakthrough therapy designation, and accelerated approval do not change the standards for approval but
may expedite the development or approval process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Orphan
Drug Designation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition, which is a
disease or condition that affects fewer than 200,000 individuals in the United&nbsp;States, or more than 200,000 individuals in
the United&nbsp;States for which there is no reasonable expectation that the cost of developing and making available in the United&nbsp;States
a drug for this type of disease or condition will be recovered from sales in the United&nbsp;States for that drug. Orphan designation
must be requested before submitting an NDA. After the FDA grants orphan designation, the generic identity of the therapeutic agent
and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation in and of itself does not convey any
advantage in, or automatically shorten the duration of, the regulatory review or approval process. However, a drug granted orphan
status allows the sponsor to receive tax credits and a user fee waiver.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a product that has orphan designation subsequently receives the first FDA approval for the disease for which it has such designation,
the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including
a full NDA, to market the same product for the same indication for seven years, except in limited circumstances, such as a showing
of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent FDA from approving
a different drug for the same disease or condition, or the same drug for a different disease or condition. A designated orphan
product may not receive orphan exclusivity if it is approved for a use that is broader than the indication for which it received
orphan designation. In addition, exclusive marketing rights in the United&nbsp;States may be lost if the FDA later determines
that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of
the product to meet the needs of patients with the rare disease or condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Post-Approval
Requirements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
products manufactured or distributed by Clene pursuant to FDA approvals are subject to pervasive and continuing regulation by
the FDA, including, among other things, requirements relating to quality control and quality assurance, record-keeping, reporting
of adverse events, periodic reporting, product sampling, and distribution, and advertising and promotion of the product. After
approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to FDA review
and approval. There also are continuing user fee requirements, under which FDA assesses an annual program fee for each product
identified in an approved NDA. Manufacturers and their subcontractors are required to register their establishments and list the
drugs they manufacture with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA
and certain state agencies for compliance with GMPs, which impose certain procedural and documentation requirements upon Clene.
Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior
FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from GMPs and
impose reporting requirements upon Clene and any third-party manufacturers or packagers that it may decide to use. Accordingly,
manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain compliance
with GMP and other aspects of regulatory compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after
the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated
severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions
to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety
risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include,
among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
                                         on the marketing or manufacturing of a product, mandated modification of promotional
                                         materials or issuance of corrective information, issuance by FDA or other regulatory
                                         authorities of safety alerts, Dear Healthcare Provider letters, press releases or other
                                         communications containing warnings or other safety information about the product, or
                                         complete withdrawal of the product from the market or product recalls;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
                                         warning or untitled letters or holds on post-approval clinical studies;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
                                         of the FDA to approve pending applications or supplements to approved applications, or
                                         suspension or revocation of existing product approvals;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
                                         seizure or detention, or refusal of the FDA to permit the import or export of products;
                                         or</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions,
                                         consent decrees or the imposition of civil or criminal penalties.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating
to safety, efficacy, and conditions of use of the drug that are approved by the FDA and in accordance with the provisions of the
approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.
Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising,
and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described
in the product&rsquo;s labeling and that differ from those tested by Clene and approved by the FDA. Such off-label uses are common
across medical specialties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Physicians
may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate
the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&rsquo;s communications
on the subject of off-label use of their products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
U.S. Healthcare Laws and Compliance Requirements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United&nbsp;States, Clene&rsquo;s current and future operations are subject to regulation by various federal, state and local
authorities in addition to the FDA, including but not limited to, the Centers for Medicare and Medicaid Services (&ldquo;CMS&rdquo;),
which is part of the U.S. Department of Health and Human Services (&ldquo;HHS&rdquo;), as well as other divisions of HHS (such
as the Office of Inspector General, Office for Civil Rights and the Health Resources and Service Administration), the U.S. Department
of Justice (&ldquo;DOJ&rdquo;) and individual U.S. Attorney offices within the DOJ, and state and local governments. For example,
Clene&rsquo;s clinical research, sales, marketing and scientific/educational grant programs have to comply with the anti-fraud
and abuse provisions of the Social Security Act (such as the Anti-Kickback Statute), the false claims laws, the anti-fraud provisions
of and the privacy and security provisions of regulations implementing the Health Insurance Portability and Accountability Act
(&ldquo;HIPAA&rdquo;), the Drug Supply Chain Security Act, and similar state laws, each as amended, as applicable. Clene&rsquo;s
business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party
payors, patients, and customers may be subject to healthcare laws, regulations and enforcement by the federal government and by
authorities in the states and foreign jurisdictions in which Clene conducts its business. Such laws include, without limitation,
state and federal anti-kickback, fraud and abuse, patient brokering, false claims, privacy and security, price reporting, drug
distribution, and physician sunshine laws. Some of Clene&rsquo;s pre-commercial activities are subject to some of these laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying,
soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return
for purchasing, leasing, ordering or arranging for the purchase, lease or order of any item or service reimbursable, in whole
or in part, under Medicare, Medicaid, or other federal healthcare programs. The term remuneration has been interpreted broadly
to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between therapeutic product
manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. There are a number of statutory exceptions
and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly
and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing, or recommending
may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of
a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback
Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all
of its facts and circumstances. Clene&rsquo;s practices may not in all cases meet all of the criteria for protection under a statutory
exception or regulatory safe harbor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the intent standard under the Anti-Kickback Statute was amended by the Patient Protection and Affordable Care Act, as amended
by the Health Care and Education Reconciliation Act of 2010 (&ldquo;Affordable Care Act&rdquo;), to a stricter standard such that
a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed
a violation. Violations of the Anti-Kickback Statute can result in significant civil and criminal fines and penalties, imprisonment,
and exclusion from federal healthcare programs. In addition, the Affordable Care Act codified case law that a claim including
items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for
purposes of the federal False Claims Act (&ldquo;FCA&rdquo;) (discussed below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal false claims and civil monetary penalty laws, including the FCA, which imposes significant penalties and can be enforced
by private citizens through civil qui tam actions, prohibit any person or entity from, among other things, knowingly presenting,
or causing to be presented, a false or fraudulent claim for payment to, or approval by, the federal government, including federal
healthcare programs, such as Medicare and Medicaid, knowingly making, using, or causing to be made or used a false record or statement
material to a false or fraudulent claim to the federal government, or knowingly making a false statement to improperly avoid,
decrease or conceal an obligation to pay money to the federal government. A claim includes &ldquo;any request or demand&rdquo;
for money or property presented to the U.S. government. For instance, historically, pharmaceutical and other healthcare companies
have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers
would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because
of the companies&rsquo; marketing of the product for unapproved, off-label, and thus generally non-reimbursable, uses. Penalties
for federal civil False Claims Act violations may include up to three times the actual damages sustained by the government, plus
significant mandatory civil penalties, and exclusion from participation in federal healthcare programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA
created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing, or attempting
to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money
or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors,
willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or
covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in
connection with the delivery of or payment for healthcare benefits, items or services. Like the Anti-Kickback Statute, the Affordable
Care Act amended the intent standard for certain healthcare fraud statutes under HIPAA such that a person or entity no longer
needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clene
may be subject to data privacy and security regulations by both the federal government and the states in which Clene conducts
its business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&ldquo;HITECH&rdquo;),
and its implementing regulations, imposes requirements relating to the privacy, security and transmission of individually identifiable
health information. Among other things, HITECH makes HIPAA&rsquo;s privacy and security standards directly applicable to business
associates, which are independent contractors or agents of covered entities that create, receive, maintain, or transmit protected
health information in connection with providing a service on behalf of, to or for a covered entity. HITECH also created four new
tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates,
and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA
and seek attorneys&rsquo; fees and costs associated with pursuing federal civil actions. In addition, many state laws govern the
privacy and security of health information in specified circumstances, many of which differ from each other in significant ways,
are often not pre-empted by HIPAA, and may have a more prohibitive effect than HIPAA, thus complicating compliance efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the federal Physician Payments Sunshine Act (the &ldquo;Sunshine Act&rdquo;), and its implementing regulations, require that certain
manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the
Children&rsquo;s Health Insurance Program (with certain exceptions) report annually to CMS information related to certain payments
or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request
of, or designated on behalf of, the physicians and teaching hospitals and to report annually certain ownership and investment
interests held by physicians and their immediate family members. Failure to report accurately could result in penalties. In addition,
many states have similar statutes or regulations to the above federal laws that may be broader in scope and may apply regardless
of payor. Clene may also be subject to state laws that require pharmaceutical companies to comply with the pharmaceutical industry&rsquo;s
voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, and/or state laws
that require drug manufacturers to report information related to payments and other transfers of value to physicians and other
healthcare providers, drug pricing or marketing expenditures. These laws may differ from each other in significant ways further
complicating compliance efforts. Additionally, to the extent that Clene has business operations in foreign countries or sell any
of Clene&rsquo;s products in foreign countries and jurisdictions, including Canada or the E.U., Clene may be subject to additional
regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clene
may someday develop products that, once approved, may be administered by a physician. Under currently applicable U.S. law, certain
products not usually self-administered (including injectable drugs) may be eligible for coverage under Medicare through Medicare
Part B. Medicare Part B is part of original Medicare, the federal health care program that provides health care benefits to the
aged and disabled, and covers outpatient services and supplies, including certain biopharmaceutical products, that are medically
necessary to treat a beneficiary&rsquo;s health condition. As a condition of receiving Medicare Part B reimbursement for a manufacturer&rsquo;s
eligible drugs, the manufacturer is required to participate in other government healthcare programs, including the Medicaid Drug
Rebate Program and the 340B Drug Pricing Program. The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter
into and have in effect a national rebate agreement with the Secretary of HHS as a condition for states to receive federal matching
funds for the manufacturer&rsquo;s outpatient drugs furnished to Medicaid patients. Under the 340B Drug Pricing Program, the manufacturer
must extend discounts to entities that participate in the program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such
as average sales price (&ldquo;ASP&rdquo;) and best price. Penalties may apply in some cases when such metrics are not submitted
accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government
healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries
where they may be sold at lower prices than in the United&nbsp;States. It is difficult to predict how Medicare coverage and reimbursement
policies will be applied to Clene&rsquo;s products in the future and coverage and reimbursement under different federal healthcare
programs are not always consistent. Medicare reimbursement rates may also reflect budgetary constraints placed on the Medicare
program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to distribute products commercially, Clene must comply with state laws that require the registration of manufacturers and
wholesale distributors of drug products in a state, including, in certain states, manufacturers and distributors who ship products
into the state even if such manufacturers or distributors have no place of business within the state. The federal government as
well as some states also impose requirements on manufacturers and distributors to maintain records regarding the history of products
in the chain of distribution. Federal law requires manufacturers to provide product tracing information to subsequent supply chain
partners. The federal Drug Supply Chain Security Act (&ldquo;DSCSA&rdquo;) governs the system of tracing certain prescription
drugs as they are distributed in the U.S. A goal of the DSCSA is to protect consumers from drugs that may be counterfeit, contaminated,
stolen, or adulterated. The law requires manufacturers to, prior to or at the time of each transfer of ownership of a drug, provide
the subsequent owner with transaction history, transaction information, and a transaction statement. In the event of a recall
or an inquiry regarding a potentially illegitimate product, manufacturers must be able to provide information regarding the transaction
history and transaction information of their products. Violations of the DSCSA may result in fines or imprisonment. In addition,
many states regulate manufacturers and enforce recordkeeping and licensure requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Several
states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs,
file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other
activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from
providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing, and
to prohibit certain other sales and marketing practices. All of Clene&rsquo;s activities are potentially subject to federal and
state consumer protection and unfair competition laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ensuring
business arrangements with third parties comply with applicable healthcare laws and regulations is a costly endeavor. If Clene&rsquo;s
operations are found to be in violation of any of the federal and state healthcare laws described above or any other current or
future governmental regulations that apply to Clene, it may be subject to penalties, including without limitation, civil, criminal
and/or administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government programs,
such as Medicare and Medicaid, injunctions, private &ldquo;qui tam&rdquo; actions brought by individual whistleblowers in the
name of the government, or refusal to allow Clene to enter into government contracts, contractual damages, reputational harm,
administrative burdens, diminished profits and future earnings, additional reporting obligations and oversight if Clene becomes
subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the
curtailment or restructuring of Clene&rsquo;s operations, any of which could adversely affect its ability to operate its business
and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Coverage,
Pricing and Reimbursement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
uncertainty exists as to the coverage and reimbursement status of any drug candidates for which Clene may obtain regulatory approval.
In the United&nbsp;States and in foreign markets, sales of any products for which Clene receives regulatory approval for commercial
sale will depend, in part, on the extent to which third-party payors provide coverage and establish adequate reimbursement levels
for such products. In the United&nbsp;States, third-party payors include federal and state healthcare programs, private managed
care providers, health insurers and other organizations. Adequate coverage and reimbursement from governmental healthcare programs,
such as Medicare and Medicaid in the United&nbsp;States, and commercial payors are critical to new product acceptance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clene&rsquo;s
ability to commercialize any products successfully also will depend in part on the extent to which coverage and reimbursement
for these products and related treatments will be available from third-party payors, which decide which therapeutics they will
pay for and establish reimbursement levels. Coverage and reimbursement by a third-party payor may depend upon a number of factors,
including the third-party payor&rsquo;s determination that use of a therapeutic is:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                         covered benefit under its health plan;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">safe,
                                         effective and medically necessary;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">appropriate
                                         for the specific patient;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cost-effective;
                                         and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">neither
                                         experimental nor investigational.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clene
cannot be sure that coverage or reimbursement will be available for any product that Clene commercializes and, if coverage and
reimbursement are available, what the level of reimbursement will be. Coverage may also be more limited than the purposes for
which the product is approved by the FDA or comparable foreign regulatory authorities. Reimbursement may impact the demand for,
or the price of, any product for which Clene obtains regulatory approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
payors are increasingly challenging the price, examining the medical necessity, and reviewing the cost-effectiveness, of medical
products, therapies and services, in addition to questioning their safety and efficacy. Obtaining reimbursement for Clene&rsquo;s
products may be particularly difficult because of the higher prices often associated with branded drugs and drugs administered
under the supervision of a physician. Clene may need to conduct expensive pharmacoeconomic studies in order to demonstrate the
medical necessity and cost-effectiveness of its products, in addition to the costs required to obtain FDA approvals. Clene&rsquo;s
drug candidates may not be considered medically necessary or cost-effective by payors. Obtaining coverage and reimbursement approval
of a product from a government or other third-party payor is a time-consuming and costly process that could require Clene to provide
to each payor supporting scientific, clinical and cost-effectiveness data for the use of Clene&rsquo;s product on a payor-by-payor
basis, with no assurance that coverage and adequate reimbursement will be obtained. A payor&rsquo;s decision to provide coverage
for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&rsquo;s determination to
provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party
reimbursement may not be available to enable Clene to maintain price levels sufficient to realize an appropriate return on its
investment in product development. If reimbursement is not available or is available only at limited levels, Clene may not be
able to successfully commercialize any drug candidate that it successfully develops.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Different
pricing and reimbursement schemes exist in other countries. In the E.U., governments influence the price of biopharmaceutical
products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the
cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only
be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may
require the completion of clinical trials that compare the cost effectiveness of a particular drug candidate to currently available
therapies. Other member states allow companies to establish their own prices for medicines, but monitor and control company profits.
The downward pressure on health care costs has become intense. As a result, increasingly high barriers are being erected to the
entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure
on pricing within a country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
marketability of any drug candidates for which Clene receives regulatory approval for commercial sale may suffer if the government
and third-party payors fail to provide adequate coverage and reimbursement. In addition, political and economic pressures as well
as legislative changes in the United&nbsp;States has increased, and Clene expects will continue to increase, the pressure on drug
pricing. The downward pressure on the rise in healthcare costs in general, particularly prescription medicines, medical devices
and surgical procedures and other treatments, has become very intense. Coverage policies and third-party reimbursement rates may
change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which Clene receives
regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Healthcare
Reform</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United&nbsp;States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory
changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of drug candidates,
restrict or regulate post-approval activities, and affect the ability to profitably sell drug candidates for which marketing approval
is obtained. Among policy makers and payors in the United&nbsp;States and elsewhere, there is significant interest in promoting
changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access.
In the United&nbsp;States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly
affected by major legislative initiatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, the Affordable Care Act has substantially changed healthcare financing and delivery by both governmental and private
insurers. Among the Affordable Care Act provisions of importance to the pharmaceutical and biotechnology industries, in addition
to those otherwise described above, are the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                         annual, nondeductible fee on any entity that manufactures or imports certain specified
                                         branded prescription drugs and biologic agents apportioned among these entities according
                                         to their market share in some government healthcare programs;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                         increase in the statutory minimum rebates a manufacturer must pay under the Medicaid
                                         Drug Rebate Program to 23.1% and 13% of the average manufacturer price for most branded
                                         and generic drugs, respectively, and capped the total rebate amount for innovator drugs
                                         at 100% of the Average Manufacturer Price (&ldquo;AMP&rdquo;);</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                         to the Medicare Part D coverage gap discount program, in which manufacturers must agree
                                         to offer 50% point-of-sale discounts, which through subsequent legislative amendments,
                                         has been increased to 70%, starting in 2019, off negotiated prices of applicable branded
                                         drugs to eligible beneficiaries during their coverage gap period, as a condition for
                                         the manufacturers&rsquo; outpatient drugs to be covered under Medicare Part D;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">extension
                                         of manufacturers&rsquo; Medicaid rebate liability to covered outpatient drugs dispensed
                                         to individuals who are enrolled in Medicaid managed care organizations;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion
                                         of eligibility criteria for Medicaid programs by, among other things, allowing states
                                         to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility
                                         categories for individuals with income at or below 133% of the federal poverty level,
                                         thereby potentially increasing manufacturers&rsquo; Medicaid rebate liability;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion
                                         of the entities eligible for discounts under the 340B Drug Discount Program;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                         new Patient-Centered Outcomes Research Institute to oversee, identify priorities in,
                                         and conduct comparative clinical effectiveness research, along with funding for such
                                         research;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion
                                         of healthcare fraud and abuse laws, including the FCA and the Anti-Kickback Statute,
                                         new government investigative powers, and enhanced penalties for noncompliance;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                         new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate
                                         Program are calculated for drugs that are inhaled, infused, instilled, implanted, or
                                         injected;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
                                         to report certain financial arrangements with physicians and teaching hospitals;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                         requirement to annually report certain information regarding drug samples that manufacturers
                                         and distributors provide to physicians;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishment
                                         of a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and
                                         service delivery models to lower Medicare and Medicaid spending; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                         licensure framework for follow on biologic products.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the provisions of the Affordable Care Act have yet to be implemented, and there have been legal and political challenges to
certain aspects of the Affordable Care Act. Clene anticipates that the Affordable Care Act, if substantially maintained in its
current form, will continue to result in additional downward pressure on coverage and the price that it receives for any approved
product, and could seriously harm its business. Any reduction in reimbursement from Medicare and other government programs may
result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare
reforms may prevent Clene from being able to generate revenue, attain profitability, or commercialize its products. Such reforms
could have an adverse effect on anticipated revenue from drug candidates that Clene may successfully develop and for which it
may obtain regulatory approval and may affect its overall financial condition and ability to develop drug candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further
legislation or regulation could be passed that could harm Clene&rsquo;s business, financial condition and results of operations.
Other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, in August&nbsp;2011,
President Obama signed into law the Budget Control Act of 2011, which, among other things, included aggregate reductions to Medicare
payments to providers of 2% per fiscal year, which went into effect beginning on April 1, 2013 and will stay in effect through
2027 unless additional Congressional action is taken. In January&nbsp;2013, the American Taxpayer Relief Act of 2012 was signed
into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging
centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments
to providers from three to five years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
there has been increasing legislative and enforcement interest in the United&nbsp;States with respect to specialty drug pricing
practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal legislation designed
to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review
the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies
for drugs. Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative
measures to control drug costs. Individual states in the United&nbsp;States have also become increasingly active in passing legislation
and implementing regulations designed to control biopharmaceutical product pricing, including price or patient reimbursement constraints,
discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases,
designed to encourage importation from other countries and bulk purchasing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
Foreign Corrupt Practices Act</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Foreign Corrupt Practices Act (&ldquo;FCPA&rdquo;), prohibits any U.S. individual or business from paying, offering, or authorizing
payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the
purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or
retaining business. The FCPA also obligates companies whose securities are listed in the United&nbsp;States to comply with accounting
provisions requiring Clene to maintain books and records that accurately and fairly reflect all transactions of the corporation,
including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international
operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Additional
Regulation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational
Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect Clene&rsquo;s business.
These and other laws govern Clene&rsquo;s use, handling and disposal of various biological, and chemical substances used in, and
wastes generated by, Clene&rsquo;s operations. If Clene&rsquo;s operations result in contamination of the environment or expose
individuals to hazardous substances, Clene could be liable for damages and governmental fines. Clene believes that it is in material
compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect
on its business. Clene cannot predict, however, how changes in these laws may affect its future operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
Regulations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clene
is also subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices,
environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances. Clene may incur
significant costs to comply with such laws and regulations now or in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Human Capital</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 1, 2021,
we had a total of 74 employees, 63 of which were full-time, located in Utah and Maryland. The table below sets forth our employees
by role:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Department</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Count of Employees</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Manufacturing</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">20</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">27</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Microbiology Lab</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Quality Control&nbsp;&amp; Bioanalytics</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Research and Development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Senior Management</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">Clinical</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Quality Assurance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">Finance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Human Resources</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Information Technology</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">74</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">100</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">%</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of our employees are represented by a labor union or are covered by a collective bargaining agreement, and we believe that we
have good relations with our employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
mailing address for our principal executive office is 6550 South Millrock Drive, Suite G50, Salt Lake City, Utah 84121, and our
telephone number is (801) 676-9695. Our website address is http:// https://clene.com. The information contained in or accessible
from our website is not incorporated into this Annual Report, and you should not consider it part of this Annual Report. We have
included our website address in this Annual Report solely as an inactive textual reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Executive
Officers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name</FONT></TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Age</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Position</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 30%; text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Robert
    Etherington</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: center; font-family: Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">54</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 59%; text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">President, Chief Executive
    Officer and Director</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Mark
    Mortenson</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">62</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Science Officer</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Robert
    Glanzman</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">64</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Medical Officer</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Ted
    (Tae Heum) Jeong</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">50</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Robert
Etherington.&nbsp;</I>Mr. Etherington has been Clene&rsquo;s president, chief executive officer and director since April&nbsp;2013
and is in charge of overall management, business, and strategy of Clene. Mr. Etherington has over 28&nbsp;years of experience
in commercialization of pharmaceuticals and biotech products. Mr. Etherington began his pharmaceutical career with a number of
sales and marketing roles at Parke-Davis, a division of Pfizer, culminating in a Team Leader position over the drug Lipitor. He
left Pfizer in 2000 to be the founding Director of Marketing during the IPO year of Swiss-based, Actelion Pharmaceuticals, focused
in cardiopulmonary disease. Mr. Etherington has served on the board of BioUtah, an independent trade association serving the life
science industry in the State of Utah, including a term as vice-chair, chairman and executive chair, since June&nbsp;2016. Mr.
Etherington has also been a director of Corsair LLC, a privately held biotechnology company, since March&nbsp;2018. Mr. Etherington
obtained a bachelor&rsquo;s degree of art from Brigham Young University in August&nbsp;1990. He received his master&rsquo;s degree
of business administration from Brigham Young University in April&nbsp;1992, majored in business with a pharmaceutical healthcare
emphasis. Mr. Etherington also completed the alumnus-granting General Management Program in Harvard University in June&nbsp;2011.
Mr. Etherington was selected to serve on the board of directors because, as CEO of Clene, he provides valuable operational and
strategic insights to the board&rsquo;s decision-making process. The board also values and benefits from Mr. Etherington&rsquo;s
experience in the pharmaceutical industry.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Mark
Mortenson.&nbsp;</I>Mr. Mortenson is Clene&rsquo;s co-founder and chief science officer of Clene. Mr. Mortenson is the co-inventor
of the technology platform developed to produce clean-surface nanocrystal (CSN&trade;) therapeutics, as well as the inventor/co-inventor
on 30 other US patents and hundreds of corresponding foreign patents. Mr. Mortenson is a former chief patent counsel responsible
for approximately 5,500 patents and patent applications in the United&nbsp;States and 44 foreign countries, and is the former
chief operating officer of research, development, and manufacturing for an advanced materials-based company of over 300 employees.
Mr. Mortenson received his bachelor&rsquo;s degrees in physics and in ceramic engineering from Alfred University in 1980, his
master&rsquo;s degree in material science from Pennsylvania State University in 1982, and his Juris Doctor from George Washington
University in 1986.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Robert
Glanzman.&nbsp;</I>Dr.&nbsp;Glanzman has been Clene&rsquo;s Chief Medical Officer since July&nbsp;2019. Dr.&nbsp;Glanzman is board
certified in neurology, and a Fellow of the American Academy of Neurology. Dr.&nbsp;Glanzman spent seven years as Assistant Clinical
Professor at Michigan State University, where he maintained clinical practice, taught residents and acted as principal investigator
for numerous clinical trials. Dr.&nbsp;Glanzman spent eight years at Pfizer as Senior Medical Director and Team Leader of the
medical affairs team for interferon beta-1a (Rebif). In 2007, he moved to Novartis where he oversaw the successful Phase III development
of fingolimod (Gilenya) and the commercial launch of interferon beta-1b (Extavia), in the US. In 2009, he was recruited by the
Roche Group as Global Development Team Leader for the ocrelizumab (Ocrevus) program from the end of Phase II through the initiation
of Phase III, in 2012. Following this, he held positions of increasing responsibilities at Purdue Pharmaceuticals, Nektar Therapeutics
and, from December&nbsp;2015 to June&nbsp;2019, was Chief Medical Officer of GeNeuro S.A. Dr.&nbsp;Glanzman has co-authored numerous
peer-reviewed publications. Dr.&nbsp;Glanzman received a bachelor&rsquo;s degree of science in biology from the University of
North Carolina at Charlotte in 1982. He obtained a doctorate in medicine from the Wake Forest University School of Medicine in
1987. Dr.&nbsp;Glanzman&rsquo;s clinical training includes an internship in internal medicine at the NY Medical College, completed
in 1988, a residency in neurology at the University of Michigan, completed in 1991, and a fellowship in diagnostic nuclear medicine
at Duke University, completed in June&nbsp;1992.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dr.&nbsp;Ted
(Tae Heum) Jeong.&nbsp;</I>Dr.&nbsp;Jeong has been Clene&rsquo;s chief financial officer since December&nbsp;2020. Dr.&nbsp;Jeong
has more than 20&nbsp;years of experience as a venture capitalist and a financial executive. He is a managing partner at KSV Global
Innovations, a growth-stage investment firm which he co-founded in 2018. Before becoming CFO of Clene, Dr.&nbsp;Jeong was CFO
of Rexahn Pharmaceuticals, Inc. (Nasdaq: REXN), an oncology and CNS-focused biopharmaceutical company, from 2002 to 2018, where
he completed equity financings totaling more than $170 million and was also responsible for forming strategic alliances and executing
license deals in the U.S., Europe, and Asia. From 1997 to 2002, he served as the Senior Investment Manager at Hyundai Venture
Investment Corporation, a subsidiary of the Hyundai Motors conglomerate and one of the largest venture capital firms in South
Korea, where he operated two of the first healthcare venture capital funds in Korea. From 2019 to 2021, he also served on the
board of directors of Neurobo Pharmaceuticals (Nasdaq: NRBO), where he was chair of the audit committee. Dr.&nbsp;Jeong received
his bachelor&rsquo;s and master&rsquo;s degrees of science in chemistry from Pohang University of Science&nbsp;&amp; Technology.
He also holds a master of science in finance degree from Johns Hopkins University, and a doctorate of management from the University
of Maryland.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_003"></A>ITEM
1A. RISK FACTORS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>An
investment in our securities carries a significant degree of risk. You should carefully consider the following risks, as well
as the other information contained in this Annual Report, including our historical financial statements and related notes included
elsewhere in this Annual Report, before you decide to purchase our securities. Any one of these risks and uncertainties has the
potential to cause material adverse effects on our business, prospects, financial condition and operating results which could
cause actual results to differ materially from any forward-looking statements expressed by us and a significant decrease in the
value of our Common Shares and Warrants. Refer to &ldquo;Cautionary Statement Regarding Forward-Looking Statements.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Relating to Our Business and Industry</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
depend substantially on the successful commercialization of our drug candidates in the future, which may fail to materialize or
experience significant delays.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a new biopharmaceutical business, we currently do not have any drugs available for commercial sales nor do we have any drugs that
have been approved for sale by the regulatory authorities. We have invested a significant portion of our efforts and financial
resources in research and development of our leading drug candidate, CNM-Au8, which in early-stage studies has shown potential
for the treatment of patients with multiple sclerosis (&ldquo;<U>MS</U>&rdquo;), amyotrophic lateral sclerosis (&ldquo;<U>ALS</U>&rdquo;)
and Parkinson&rsquo;s disease (&ldquo;<U>PD</U>&rdquo;). Our ability to generate significant revenue and become profitable in
the future depends substantially on the future sales generated by CNM-Au8 and our drug candidates, which in turn depends on the
successful research and development (&ldquo;<U>R&amp;D</U>&rdquo;), regulatory approval, commercialization and sale of our drug
candidates presently under clinical development for the treatment of patients with neurological disorders. We are also developing
new drugs based on our technology that have not yet entered into human studies. The ultimate success of our drug candidates is
subject to us achieving certain milestones, including without limitation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying, assessing, acquiring and obtaining evidence of biological activity of new drug candidates to treat certain diseases;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining satisfactory evidence of safety of these drug candidates in animal toxicology studies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining regulatory approval for the conduct of, successful enrollment in, and completion of, clinical trials of our drug candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining satisfactory proof of the clinical efficacy and safety of our drug candidates from these clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining approvals and marketing authorizations from regulatory authorities for our drug candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing sustainable and scalable manufacturing processes to produce these drug candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully expanding manufacturing processes to support global commercialization capacity of our drug candidates; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching and commercializing drug candidates for which we have obtained regulatory approvals and marketing authorizations, either directly or with a collaborator or distributor.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we do not achieve one or more of these milestones in a timely manner, or at all, we could experience significant delays in our
ability to obtain approval for and/or to successfully commercialize our drug candidates, which would materially harm our business
and we may not be able to generate sufficient revenues and cash flows to continue our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we are able to generate revenues from the future sales of our drug candidates, we may not become profitable and may need to
obtain additional funding to continue operations. Any required funding may not be available on favorable terms or at all. If we
fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our
operations at planned levels and be forced to reduce our operations. Even if we do achieve profitability, we may not be able to
sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease our
value significantly and could impair our ability to raise capital, expand our business or continue our operations, which in turn
may adversely affect our business, financial condition, and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
currently do not generate revenue from the commercial sales of drug candidates and we may not become profitable when expected,
or at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
main business is the research and development, and if successful, sales of drug candidates. As all of our drug candidates are
still in the R&amp;D stage, we currently do not generate revenue from the sale of drug candidates, and have recorded continued
losses. We generate a small amount of revenue related to supply agreements for dietary (mineral) supplements and from sales of
another product, however, such revenue is not expected to be a major contributor to revenue in the future. If we fail to commercialize
our drug candidates as planned due to failures to complete clinical trials, obtain regulatory approval, conduct commercial scale
manufacturing or for any other reason, we may experience significant delays or failure in generating revenue and realizing profit
from the commercial sale of our drug candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
we expect to incur significant costs in the future, in particular for the R&amp;D and commercialization of our drug candidates.
Our R&amp;D expenses amounted to $15.2 million, $9.6 million and $6.6 million, respectively, in 2020, 2019 and 2018, respectively.
As drug candidates presently undergoing preclinical research enter into the clinical trial stage, costs associated with such drug
candidates may increase significantly. In the future, as we move more drug candidates into the clinical trial stage, conduct more
clinical trials for commercialized products to broaden their use, and carries out commercial production of our drug candidates,
the costs associated with such operations may increase significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
we operate in the highly competitive pharmaceutical market, we compete to commercialize our drug candidates ahead of our competitors,
putting us under pressure to incur R&amp;D and other expenses with a potential negative impact on our short-term profitability.
On the other hand, our commercialized drug candidates may fail to realize their sales potential as expected due to competition,
insufficient market demand, product defects, or any other reason. Therefore, even after we start to generate revenue from the
sales of our commercialized drug candidates in the future, we may still not be profitable for an extended period of time or at
all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have incurred significant net losses and net operating cash outflows since our inception.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Investment in biopharmaceutical
drug development is highly speculative. It entails substantial upfront capital expenditures and significant risk that a drug candidate
might fail to gain regulatory approval or become commercially viable. We continue to incur significant expenses related to our
ongoing operations. We have incurred substantial losses since our inception. During 2020, 2019 and 2018, we recorded a loss for
the year of $19.3 million, $16.2 million and $11.7 million, respectively. As of December 31, 2020, we had an accumulated deficit
of $153.6 million. For details, see <I>Item 7. Management&rsquo;s Discussion and Analysis of Financial Condition and Results of
Operations.</I> Substantially all of our operating losses have resulted from costs incurred in connection with our R&amp;D programs
and administrative expenses associated with our operations, and we expect that our R&amp;D expenses will continue to increase in
the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to incur losses for the foreseeable future, and we expect these losses to increase as we continue to expand
our development of, and seeks regulatory approvals for, our drug candidates, and we continue to build up our commercialization
and sales workforce in anticipation of the future roll-out of our late-stage drug candidates. Typically, it takes many years to
develop one new drug from the drug discovery stage to the time it is available for treating patients. In addition, we will continue
to incur costs associated with operating as a public company and in support of our growth as a development-stage or commercial-stage
pharmaceutical company. The size of our future net losses will depend, in part, on the number and scope of our drug development
programs and the associated costs of those programs, the cost of commercializing any approved products, our ability to generate
revenues and the timing and amount of milestones and other payments we make or receive through arrangements with third parties.
If any of our drug candidates fails in clinical trials or does not gain regulatory approval, or if approved, fails to achieve
market acceptance, we may never become profitable. Our failure to become and remain profitable would decrease our value significantly
and impair our ability to raise capital, maintain our R&amp;D efforts, expand our business or continue our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our ability to continue as a going
concern requires that we obtain sufficient funding to finance our operations, which may not be available on acceptable terms, or
at all. A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our drug development
or commercialization efforts.</I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31,
2020, we had cash totaling $59.3 million and an accumulated deficit of $153.6 million. During 2020, we incurred a net loss totaling
$19.3 million, and used cash in operating activities totaling $18.9 million. We expect to continue to incur losses and use cash
in operating activities in 2021 and for the foreseeable future. We expect that the cash on hand as of December 31, 2020 will be
sufficient to fund our operations for a period extending beyond twelve months from the date the consolidated financial statements
are issued. For details, please see <I>Item 7. Management&rsquo;s Discussion and Analysis of Financial Condition and Results of
Operations &mdash; Liquidity and Capital Resources</I>. Our ability to continue as a going concern requires that we obtain sufficient
funding to finance our operations until our drug candidates begin generating sufficient revenue. As part of our ongoing business
plans, we will continue seeking funding through equity financing and may seek debt financing or other capital sources. We may not
be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the
rights of our shareholders. If we are unable to raise capital when needed or on acceptable terms, we would be forced to delay,
reduce or eliminate research and development programs and commercialization efforts. These factors, among others, may raise substantial
doubt about our ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have a limited operating history, which may make it difficult to evaluate our current business and predict our future performance.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a biopharmaceutical company formed in December&nbsp;2012 focusing on the discovery and development of innovative drugs for
the treatment of neurological diseases and other disorders. Our limited operating history, particularly in light of the rapidly
evolving nanocrystal therapies field, may make it difficult to evaluate our current business and predict our future performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a relatively new business, we have not yet demonstrated an ability to manufacture drugs at a commercial scale, or arrange for
a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. We
have not had any product approved for commercial sale and have not generated any revenue from product sales. Consequently, any
assessment you make about our current business or future success or viability may not be as accurate as it could be if we had
a longer operating history and had been able to reduce some of the uncertainties as set out above. Further, our limited financial
track record, without any revenue yet from our expected future principal business, may be of limited reference value for your
assessment of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may encounter difficulties in managing our growth and expanding our operations successfully.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
we seek to advance our drug candidates through clinical trials, we will need to expand our development, regulatory, compliance,
manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities for us. As our operations
expand, we expect that we will need to manage additional relationships with various strategic partners, suppliers and other third
parties. Future growth will impose significant added responsibilities on members of management. Our future financial performance
and our ability to commercialize our drug candidates and to compete effectively will depend, in part, on our ability to manage
any future growth effectively. To that end, we must be able to manage our development efforts and clinical trials effectively
and hire, train and integrate additional management, administrative, and sales and marketing personnel. We may not be able to
accomplish these tasks, and our failure to accomplish any of them could prevent us from successful growth and could harm our future
business, financial condition and operating results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes
in government regulation or in practices relating to the pharmaceutical and biotechnology industries, including potential healthcare
reform, could decrease the need for our drug candidates, or make it more difficult to obtain regulatory approvals for our drug
candidates and commercialize them.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
recent years, the U.S. Congress, the President, executive branch agencies, and state legislatures have considered various types
of healthcare reform to control growing healthcare costs. Similar reform movements have occurred in parts of Europe and Asia.
Healthcare reform legislation could also increase the costs of drug development and commercialization that could limit the profits
to be made from the development of new drugs. This could adversely affect R&amp;D expenditures by pharmaceutical and biotechnology
companies, which could in turn decrease the business opportunities available to us in the U.S. and other countries. We are unable
to predict what reform proposals will be adopted in the future, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we, or any CRO we may engage, fails to comply with environmental, health and safety laws and regulations, we could become subject
to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and certain of the third parties we contract with, such as our contract research organizations, or CROs, are subject to numerous
environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use,
storage, treatment, and disposal of hazardous materials and wastes. In addition, our planned construction projects can only be
put into operation after certain regulatory procedures have been completed with the relevant administrative authorities in charge
of environmental protection, health and safety. Our operations involve the use of hazardous and flammable materials, including
chemicals and biological materials. Our operations also may produce hazardous waste products at some future time. We generally
contract with third parties for the disposal of these materials and wastes. We cannot entirely eliminate the risk of contamination
or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could
be held liable for any resulting damages, and any liability could exceed our resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we maintain workers&rsquo; compensation insurance to cover the costs and expenses we may incur due to injuries to our employees
resulting from the use of or exposure to hazardous materials, this insurance may not provide adequate coverage against potential
liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in
connection with our storage, use or disposal of biological or hazardous materials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the environmental, health and safety laws and regulations applicable to us and our third-party contractors may change
and impose stricter requirements in the future. As a result, we may be required to incur substantial costs to comply with future
environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development
or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other
sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
internal computer systems, or those used by any CRO or other contractors or consultants we may engage, may fail or suffer security
breaches.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants
are vulnerable to damage from computer viruses and unauthorized access. Although, to our knowledge, we have not experienced any
material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations,
it could result in a material disruption of our development programs and business operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we collect and store sensitive data, including, among other things, legally protected patient
health information, personally identifiable information about our employees, intellectual property, and proprietary business information.
We manage and maintains our applications and data utilizing on-site systems and outsourced vendors. These applications and data
encompass a wide variety of business-critical information including research and development information, commercial information,
and business and financial information. Because information systems, networks and other technologies are critical to many of our
operating activities, shutdowns or service disruptions of our systems or those of the vendors that provide information systems,
networks or other services to us pose increasing risks. Such disruptions may be caused by events such as computer hacking, phishing
attacks, ransomware, dissemination of computer viruses, worms and other destructive or disruptive software, denial of service
attacks and other malicious activity, as well as power outages, natural disasters (including extreme weather), terrorist attacks
or other similar events. Such events could have an adverse impact on us and our business, including loss of data and damage to
equipment and data. In addition, system redundancy may be ineffective or inadequate, and our disaster recovery planning may not
be sufficient to cover all eventualities. Significant events could result in a disruption of our operations, damage to our reputation
or a loss of revenues. In addition, we may not have adequate insurance coverage to compensate for any losses associated with such
events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
could be subject to risks caused by misappropriation, misuse, leakage, falsification or intentional or accidental release or loss
of information maintained in our information systems and networks and those of our vendors, including personal information of
our employees and patients, and company and vendor confidential data. In addition, outside parties may attempt to penetrate our
systems or those of our vendors or fraudulently induce our personnel or the personnel of our vendors to disclose sensitive information
in order to gain access to our data and/or systems. Like other companies, we have on occasion experienced, and will continue to
experience, threats to our data and systems, including malicious codes and viruses, phishing and other cyber-attacks. The number
and complexity of these threats continue to increase over time. If a material breach of our information technology systems or
those of our vendors occurs, the market perception of the effectiveness of our security measures could be harmed and our reputation
and credibility could be damaged. We could be required to expend significant amounts of money and other resources to repair or
replace information systems or networks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we could be subject to regulatory actions and/or claims made by individuals and/or groups in private litigation involving
privacy issues related to data collection and use practices and other data privacy laws and regulations, including claims for
misuse or inappropriate disclosure of data, as well as unfair or deceptive practices. Although we develop and maintain systems
and controls designed to prevent these events from occurring, and we have a process to identify and mitigate threats, the development
and maintenance of these systems, controls and processes is costly and requires ongoing monitoring and updating as technologies
change and efforts to overcome security measures become increasingly sophisticated. Moreover, despite our efforts, the possibility
of these events occurring cannot be eliminated entirely. As we outsource more of our information systems to vendors, engages in
more electronic transactions with payers and patients and relies more on cloud-based information systems, the related security
risks will increase and we will need to expend additional resources to protect our technology and information systems.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
manufacture all of our drug candidates ourselves, and intend to manufacture most, if not all, of any approved drugs ourselves
as well.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have manufacturing facilities in the U.S. and may build additional manufacturing facilities in other markets to expand
our manufacturing capacity. These facilities may encounter unanticipated delays and expenses due to a number of factors, including
regulatory requirements. If construction, regulatory evaluation, and/or approval of our new facilities is delayed, we may not
be able to manufacture sufficient quantities of our drug candidates, if approved, which would limit our development and commercialization
activities and our opportunities for growth. Cost overruns associated with constructing or maintaining our facilities could require
us to raise additional funds from other sources, which may not be available on favorable terms or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Much
of the equipment used in our manufacturing process was developed and built by us, and it would be difficult or even impossible
to purchase or create suitable replacements in a short period of time. Further, for much of this equipment we have an insufficient
amount of or no spare parts available. Were certain equipment, some of which is critical to the production of our drug candidates,
to become damaged, lost, or otherwise unusable, we would have to construct new parts, which could take a considerable time, causing
a temporary halt to at least a portion of our production operations in the meantime. Further, we are constantly seeking to further
fine-tune and develop our advanced manufacturing techniques and process controls to fully utilize our facilities. Advances in
manufacturing techniques may render our facilities and equipment inadequate, in which case we may lose competitive advantage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
produce our drug candidates in the quantities that we believe will be required to meet anticipated market demand, if approved,
we will need to increase or &ldquo;scale up&rdquo; the production process by a significant factor over current levels of production.
A significant part of the scaling up process will include seeking for ways to increase the automation and semi-automation of our
production process, which will require additional research and development, investment, potential new regulatory approvals, and
cooperation with third parties, some of which may not be successful. If we are unable or delayed in scaling up, or if the cost
of doing so is not economically feasible for us, we may not be able to produce our approved drug candidates in a sufficient quantity
to meet future demand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Delays
in completing and receiving regulatory approvals for our manufacturing facilities could delay our development plans or commercialization
efforts.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
manufacturing facilities will be subject to ongoing, periodic inspection by various regulatory authorities, including the U.S.
Food and Drug Administration (&ldquo;<B>FDA</B>&rdquo;), European Medicines Agency (&ldquo;<B>EMA</B>&rdquo;), China&rsquo;s National
Medical Products Administration (&ldquo;<B>NMPA</B>&rdquo;), Health Canada, and the Australian Therapeutics Goods Administration
(&ldquo;<B>TGA</B>&rdquo;) or other comparable regulatory agencies to ensure compliance with good manufacturing practices (&ldquo;<B>GMP</B>&rdquo;).
Our failure to follow and document our adherence to such GMP or other regulatory requirements may lead to significant delays in
the availability of products for clinical or, in the future, commercial use, and may result in the termination of or a hold on
a clinical trial, or may delay or prevent filing or approval of marketing applications for our drug candidates or the commercialization
of our drugs, if approved. We also may encounter problems with the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieving
                                         adequate or clinical-grade materials that meet FDA, EMA, NMPA, Health Canada, TGA or
                                         other comparable regulatory agency standards or specifications with consistent and acceptable
                                         production yield and costs;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shortages
                                         of qualified personnel, raw materials or key contractors; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ongoing
                                         compliance with GMP and other requirements of the FDA, EMA, NMPA, TGA or other comparable
                                         regulatory agencies.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to comply with applicable regulations could also result in sanctions being imposed on us, including fines, injunctions, civil
penalties, a requirement to suspend or put on hold one or more of our clinical trials, failure of regulatory authorities to grant
marketing approval of our drug candidates, delays, suspension or withdrawal of approvals, supply disruptions, license revocation,
seizures, or recalls of our drug candidates, operating restrictions and civil or criminal prosecutions, any of which could harm
our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Damage
to, destruction of or interruption of production at our manufacturing facilities would negatively affect our business and prospects.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our manufacturing facilities or the equipment in them is damaged or destroyed, we may not be able to quickly or inexpensively
replace our manufacturing capacity or replace it at all. In the event of a temporary or protracted loss of the facilities or equipment,
we might not be able to transfer manufacturing to a third party. Even if we could transfer manufacturing to a third party, the
shift would likely be expensive and time-consuming, particularly since the new facility would need to comply with the necessary
regulatory requirements and we would need regulatory agency approval before selling any of our future approved drugs manufactured
at that new facility. Such an event could delay our clinical trials or reduce our product sales if and when we are able to commercialize
one or more of our drug candidates. Any interruption in manufacturing operations at our manufacturing facilities could result
in our inability to satisfy the demands of our clinical trials or commercialization. Any disruption that impedes our ability to
manufacture our drugs in a timely manner could materially harm our business, financial condition and operating results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
we maintain insurance coverage against damage to our property and equipment in amounts we believe are reasonable. However, our
insurance coverage may not reimburse us, or may not be sufficient to reimburse us, for any expenses or losses we may suffer. We
may be unable to meet the requirements for our drugs if there were a catastrophic event or failure of our manufacturing facilities
or processes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
future success depends on our ability to retain key executives and to attract, train, retain and motivate qualified and highly
skilled personnel.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are highly dependent on Mark Mortenson, our co-founder and chief science officer, Rob Etherington, CEO, President and a Director,
and the other principal members of our management and scientific teams. Although we have formal employment agreements with select
executive officers, these agreements do not prevent our executives from terminating their employment with us at any time. Further,
Mr. Etherington and Mr. Mortenson have not entered into formal employment agreements with us. We do not maintain &ldquo;key person&rdquo;
insurance for any of our executives or other employees. The loss of the services of any of these persons could impede the achievement
of our research, development and commercialization objectives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recruiting
and retaining qualified scientific, technical, clinical, and manufacturing and sales and marketing personnel in the future will
also be critical to our success. In addition, we rely on consultants and advisors, including scientific and clinical advisors,
to assist us in formulating our discovery, clinical development, operations, and commercialization strategy. The loss of the services
of our executive officers or other key employees and consultants could impede the achievement of our research, development, and
commercialization objectives and seriously harm our ability to successfully implement our business strategy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
benefit from certain tax and financial incentives, the expiration of or changes to which could adversely affect our profitability.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
benefit from certain tax treatments, as well as tax concessions in relation to our research and development costs. We receive
refundable tax credits through the R&amp;D tax credits in the United&nbsp;States, Australia, and the state of Maryland. In the
United&nbsp;States, the R&amp;D credit is used to offset federal employment taxes on our United&nbsp;States payroll. In Australia,
we receive a refundable tax offset of 43.5% of R&amp;D deductions. In Maryland, we receive the Basic Research and Development
Tax credit of 3% of the lesser of eligible R&amp;D expenses and the Maryland Base Amount, which is used to offset state income taxes and may be applied
against following years&rsquo; taxes until the credit is used or the credit may be carried forward for seven years. We also receive a tax exemption in Maryland
for state personal property and sales tax, as well as the Maryland enterprise zone hiring and job creation tax credits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, current or future tax treatments, tax concessions, tax allowances and financial incentives applicable to us may be changed,
terminated, or otherwise become unavailable due to many factors, including changes in government policy or administrative decisions
by the relevant government authorities. Due to potential changes in government policies, we cannot be certain of the level of
government grants we will receive in the future. Our post-tax profitability and cash flows may be adversely affected as a result
of one or more of these or other factors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
financial position and operations may be adversely affected by the COVID-19 outbreak.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
outbreak of the respiratory illness COVID-19 caused by a strain of novel coronavirus, SARS-Cov-2, has spread worldwide, causing
many governments to implement measures to slow the spread of the outbreak through quarantines, strict travel restrictions, heightened
border scrutiny, and other measures. The outbreak and government measures taken in response have had a significant impact, both
direct and indirect, on businesses and commerce. The future progression of the outbreak and its effects on our business and operations
are uncertain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and our CROs and clinical sites may experience disruptions in supply of drug candidates and/or procuring items that are essential
for our research and development activities, including raw materials used in the manufacturing of our drug candidates, medical
and laboratory supplies used in our clinical trials or preclinical studies or animals that are used for preclinical testing, in
each case, for which there may be shortages because of ongoing efforts to address the outbreak. Any disruption in the supply chain
from the recent COVID-19 outbreak, or any potential future outbreak could have a material adverse effect on our clinical trial
plans and business operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we have enrolled, and will seek to enroll, patients in our clinical trials at sites located in many areas affected by COVID-19
and, as a result, our trials may be impacted. In addition, even if sites are actively recruiting, we may face difficulties recruiting
or retaining patients in our ongoing and planned clinical trials if patients are affected by the virus or are fearful of visiting
or traveling to clinical trial sites because of the outbreak. Prolonged delays or closure to enrollment in our trials or patient
discontinuations could have a material adverse impact on our clinical trial plans and timelines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
response to the COVID-19 pandemic may redirect resources with respect to regulatory and intellectual property matters in a way
that would adversely affect our ability to obtain regulatory approvals and protect our intellectual property. In addition, we
may face impediments to regulatory meetings and approvals due to measures intended to limit in-person interactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
negative impact that the COVID-19 outbreak has on the ability of our suppliers to provide materials for our drug candidates or
on recruiting or retaining patients in our clinical trials or our ability to collect patient data could cause costly delays to
clinical trial activities, which could adversely affect our ability to obtain regulatory approval for and to commercialize our
drug candidates, increase our operating expenses, and have a material adverse effect on our financial results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
COVID-19 pandemic has significantly impacted economies worldwide, which could result in adverse effects on our business and operations.
We cannot be certain what the overall impact of the COVID-19 pandemic will be on our business. It has the potential to adversely
affect our business, financial condition, results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial
time to new compliance initiatives.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, and particularly after we are no longer an emerging growth company, we will incur significant legal, accounting
and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act of 2002 and rules subsequently
implemented by the SEC and the Nasdaq Global Market have imposed various requirements on public companies, including establishing
and maintaining effective disclosure and financial controls and corporate governance practices. Our management and other personnel
will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase
our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect
that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability
insurance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We have identified material weaknesses in our internal control
over financial reporting. If we fail to remediate the material weakness, or if we experience additional material weaknesses in
the future or otherwise fails to maintain an effective system of internal controls in the future, we may not be able to accurately
or timely report our financial condition or results of operations, which may adversely affect investor confidence in us and, as
a result, the value of our Common Stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
internal control over financial reporting is necessary for us to provide reliable financial reports and, together with adequate
disclosure controls and procedures, is designed to prevent fraud. Any failure to implement required new or improved controls,
or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations. In addition, any
testing by us, as and when required, conducted in connection with Section&nbsp;404 of the Sarbanes-Oxley Act or any subsequent
testing by our independent registered public accounting firm, as and when required, may reveal deficiencies in our internal control
over financial reporting that are deemed to be significant deficiencies or material weaknesses or that may require prospective
or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal
controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect
on the trading price of our Common Stock.</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the audit of our financial statements for the year ended December 31, 2020, 2019 and 2018, our management identified material weaknesses
in our internal control over financial reporting. A material weakness is a deficiency, or combination of deficiencies, in internal
control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim
financial statements will not be prevented or detected on a timely basis. The material weaknesses identified relate to the fact
that we did not design or maintain an effective control environment commensurate with our financial reporting requirements, including
(a)&nbsp;lack of a sufficient number of trained professionals with an appropriate level of accounting knowledge, training and experience
to appropriately analyze, record and disclose accounting matters timely and accurately, and (b)&nbsp;lack of structures, reporting
lines and appropriate authorities and responsibilities to achieve financial reporting objectives. This deficiency in our control
environment contributed to the following additional deficiencies (each of which individually represents a material weakness) in
our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">we did not design and maintain formal accounting policies, procedures and controls to achieve complete, accurate and timely financial accounting, reporting and disclosures, including controls over the preparation and review of account reconciliations and journal entries;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">we did not design and maintain effective controls over segregation of duties related to manual journal entries. Specifically, certain personnel have the ability to both prepare and post manual journal entries without an independent review by someone without the ability to prepare and post manual journal entries;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">we did not design and maintain formal accounting policies, processes and controls to analyze, account for and disclose complex transactions. Specifically, we did not design and maintain controls to analyze, account for and disclose warrants to purchase preferred stock and convertible promissory notes with embedded derivatives, including ensuring complete and accurate data was used in the valuations; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">we did not design and maintain effective controls over certain information technology general controls for IT systems that are relevant to the preparation of the financial statements. Specifically, we did not design and maintain: (a)&nbsp;user access controls to ensure appropriate segregation of duties and that adequately restrict user and privileged access to financial applications, programs, and data to appropriate personnel, (b)&nbsp;program change management controls to ensure that IT program and data changes affecting financial IT applications and underlying accounting records are identified, tested, authorized and implemented appropriately, (c)&nbsp;computer operations controls to ensure that data backups are authorized and monitored, and (d)&nbsp;testing and approval controls for program development to ensure that new software development is aligned with business and IT requirements.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
control deficiencies identified resulted in the misstatement of our redeemable convertible preferred stock warrant liability,
accrued liabilities, general and administrative expenses, Australian research and development credit, and amounts and classification
within our statement of cash flows and related financial disclosures, which led to a restatement of our 2017 financial statements.
Additionally, each of the control deficiencies described above could result in a misstatement of one or more account balances
or disclosures that would result in a material misstatement to the annual or interim consolidated financial statements that would
not be prevented or detected. Accordingly, our management has determined that each of the control deficiencies described above
constitute a material weakness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To remedy the identified
material weaknesses, we have implemented and continue to implement, several measures, including, among others:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">hiring additional competent and qualified accounting and reporting personnel with appropriate knowledge and experience of U.S. GAAP and SEC financial reporting requirements;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">establishing and designing internal financial reporting structures and authorizing certain departments or capable and responsible persons to be in charge of the overall financial management and financial objectives;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">establishing an ongoing program to provide sufficient additional training to our accounting staff, especially training related to U.S. GAAP and SEC financial reporting requirements;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">designing and preparing accounting policies in accordance with relevant rules, especially in relation to complex and major transactions;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">updating our internal staff manual and ensuring effective segregation of duties for our accounting staff in relation to manual journal entries; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">upgrading our internal IT systems to facilitate financial management and reporting procedures.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we have begun to implement measures to address the material weaknesses, the implementation of these measures may not fully address
the material weaknesses and deficiencies in our internal control over financial reporting, and we cannot conclude that these matters
have been fully remedied. Further, in the future we may determine that we have additional material weaknesses. Our failure to
remediate the material weaknesses or failure to identify and address any other material weaknesses or control deficiencies could
result in inaccuracies in our financial statements and could also impair our ability to comply with applicable financial reporting
requirements and related regulatory filings on a timely basis, which could cause investors to lose confidence in our reported
financial information, which may result in volatility in and a decline in the market price of our securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Pursuant to Section&nbsp;404, after the Reverse Recapitalization,
we, as the surviving entity, are required to furnish a report by our management on the effectiveness of our internal control over
financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered
public accounting firm. However, while we remain an emerging growth company, we will not be required to include an attestation
report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance
with Section&nbsp;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control
over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources,
potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over
financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning
as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite
our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude within
the prescribed timeframe that our internal control over financial reporting is effective as required by Section&nbsp;404. This
could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>There
is significant uncertainty associated with our drug candidates and their viability as a commercial product.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Metallic
nanocrystal therapeutic candidates, such as our lead product, CNM-Au8, are considered emerging and novel investigational products
for the potential treatment of neurological diseases and other disorders. We are developing CNM-Au8 for the treatment of neurological
disorders such as MS, ALS, and PD through remyelination and/or neuroprotection mechanisms related to catalysis of certain biological
reactions. There are currently no approved remyelination therapies and the evidence for an effect of neuroprotection treatments
on these indications is thus far limited. Since there is limited clinical trial data and precedent for the development of nanocrystal
therapies that promote remyelination and neuroprotection to treat these indications, there is a substantial risk that the design
or outcomes of our clinical trials will not be satisfactory to support regulatory approval. In addition, there are generally limited
or no regulatory precedents concerning metallic nanocrystal drug marketing authorization, or a regulatory framework to appropriately
differentiate approved nanocrystal product labeling. Our lead metallic nanocrystal drug candidate, CNM-Au8, contains nanocrystals
made entirely of high purity gold alone. It is unclear how regulatory authorities will identify or classify the active moiety
of CNM-Au8, including whether it is classified as a new chemical entity or comparable designation. The inability to obtain sufficiently
differentiated active moiety classification from gold generically could potential limit CNM-Au8 and our drug candidates from ever
achieving profitability.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
the mechanisms of action for nanocrystal therapies are not thoroughly understood, and adverse events or side effects may be observed
in clinical studies and reported by medical practitioners in connection with patient usage in the future. If those adverse events
or side effects prove significant, they may hamper the ability of our drug candidates to pass through clinical trials or they
may outweigh the benefits that patients derive from using our drug candidates, both of which could potentially prevent our drug
candidates from ever achieving profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
drug candidates are not metabolized and may accumulate in the body following long-term usage, making the long-term effects of
taking our drug candidates for substantial periods of time uncertain. While all of the current toxicology studies of our drug
candidates have resulted in no-adverse-effect levels as the date of this Annual Report, we have not completed reproductive or
carcinogenicity studies, which we are required to complete in the future. Any negative results from these studies could materially
and adversely affect our business, results of operations, financial condition and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
the results of clinical trials for nanocrystal therapies could reveal a high and unacceptable severity and prevalence of undesirable
side effects. Any such side effects could adversely impact our ability to obtain regulatory approvals. For example, the FDA, NMPA,
TGA, EMA or other comparable authorities could order us to suspend or terminate our studies or to cease further clinical development
of or deny approval of our drug candidates. In addition, any adverse drug-related side effects could affect patient recruitment
or the ability of enrolled patients to complete trials or may result in potential product liability claims. Any of these occurrences
may harm our business, financial condition and prospects significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have not previously obtained any regulatory approval for a drug candidate and we may be unable to obtain, or may be delayed in
obtaining regulatory approval for any of our drug candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is substantially dependent on our ability to complete the development of, obtain regulatory approval for and successfully
commercialize drug candidates in a timely manner. We cannot commercialize drug candidates without obtaining regulatory approval
to market each drug from the FDA, NMPA, Health Canada, TGA, EMA and other comparable regulatory authorities. The time required
to obtain approval from regulatory authorities is unpredictable but typically takes years following the commencement of pre-clinical
studies and clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities.
In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during
the course of a drug candidate&rsquo;s clinical development and may vary among jurisdictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
drug candidates could fail to receive regulatory approval for many reasons, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
                                         to begin or complete clinical trials due to disagreements with regulatory authorities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
                                         to begin or complete clinical trials due to inability to recruit sufficient numbers of
                                         study participants;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
                                         to demonstrate that a drug candidate is safe and effective or is safe, pure and potent
                                         for our proposed indication;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
                                         of clinical trial results to meet the level of statistical significance required for
                                         approval;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">data
                                         integrity issues related to our clinical trials;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disagreement
                                         with our interpretation of data from preclinical studies or clinical trials;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                         in approval policies or regulations that render our preclinical and clinical data insufficient
                                         for approval or require us to amend our clinical trial protocols;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                         requests for additional analysis, reports, data, nonclinical studies and clinical trials,
                                         or questions regarding interpretations of data and results and the emergence of new information
                                         regarding our drug candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">insufficient
                                         data from the clinical trials of our drug candidates to obtain regulatory approval;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
                                         by us or our investigators to conduct a clinical trial in accordance with regulatory
                                         requirements or our clinical trial protocols; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
                                         sites, investigators or other participants in our clinical trials deviating from a trial
                                         protocol, failing to conduct the trial in accordance with regulatory requirements, or
                                         dropping out of a trial.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA, NMPA, TGA, EMA or a comparable regulatory authority may require more information, including additional preclinical or clinical
data, to support approval, which may delay or prevent approval and our commercialization plans, or we may decide to abandon the
development program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
or unexpected adverse events, or changes in regulatory requirements and guidance may also occur, and we may need to amend clinical
trial protocols submitted to applicable regulatory authorities to reflect these changes. Amendments may require us to resubmit
clinical trial protocols to institutional review boards (&ldquo;<B>IRBs</B>&rdquo;) or human research ethics committees (&ldquo;<B>HREC</B>&rdquo;)
for re-examination, which may impact the costs, timing or successful completion of a clinical trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we experience delays in the completion of, or the termination of, a clinical trial of any of our drug candidates, the commercial
prospects of that drug candidate will be harmed, and our ability to generate product sales revenues from any of those drug candidates
will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our drug candidate
development and approval process, and jeopardize our ability to commence product sales and generate related revenues for that
product. Any of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of
the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the
denial of regulatory approval of our drug candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to successfully identify, discover, develop or in-license new drug candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot guarantee that we will be successful in identifying potential drug candidates for clinical development for a number of
reasons. For example, our research methodology may be unsuccessful in identifying potential drug candidates or those we identify
may be shown to have harmful side effects or other characteristics that make them unmarketable or unlikely to receive regulatory
approval. we have devoted significant resources to discovery efforts through our proprietary electro-crystal-chemistry drug development
platform, and we cannot guarantee that we will be successful in identifying additional potential drug candidates, or that we will
be able to successfully identify and in-license new drug candidates with high potential from other parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
programs to pursue the development of our drug candidates for additional indications and to identify new drug candidates and drug
targets require substantial technical, financial, and human resources. our research programs may initially show promise in identifying
potential indications and/or drug candidates, yet fail to yield results for clinical development for a number of reasons, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         research methodology used may not be successful in identifying potential indications,
                                         and/or drug candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
                                         drug candidates may, after further study, be shown to have harmful adverse effects or
                                         other characteristics that indicate they are unlikely to be effective drugs; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
                                         may take greater human and financial resources to identify additional therapeutic opportunities
                                         for our drug candidates or to develop suitable potential drug candidates through internal
                                         research programs than we will possess, thereby limiting our ability to diversify and
                                         expand our drug portfolio.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
there is no assurance that we will ever be able to identify additional therapeutic opportunities for our drug candidates or to
develop suitable potential drug candidates through internal research programs, which could materially and adversely affect our
future growth and prospects. we may focus our efforts and resources on potential drug candidates or other potential programs that
ultimately prove to be unsuccessful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Pre-clinical
and clinical development of drug candidates involves a lengthy and expensive process with an uncertain outcome, and we are unable
to predict if or when we will successfully develop or commercialize any of our drug candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is a risk of failure for each of our drug candidates. It is difficult to predict when or if any of our drug candidates will prove
effective and safe in humans or will receive regulatory approval. Before obtaining regulatory approval from regulatory authorities
for the sale of any of our drug candidates, we must complete pre-clinical studies and then conduct extensive clinical trials to
demonstrate the safety and efficacy of our drug candidates in humans. our internal discovery programs for some of our drug candidates
are at an early stage of development and will require significant investment and regulatory approvals prior to commercialization.
We are not permitted to market or promote any of our drug candidates until we receive regulatory approval from the FDA, NMPA,
TGA, EMA or comparable regulatory authorities, and we may never receive such regulatory approval for any of our drug candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
could encounter regulatory delays if a clinical trial is suspended or terminated by us or, as applicable, by the institutional
review boards or the ethics committees of the institutions in which such trials are being conducted, by the data safety monitoring
board, which is an independent group of experts that is formed to monitor clinical trials while ongoing, or by the FDA, NMPA,
TGA, EMA or other regulatory authorities. Such authorities may impose a suspension or termination due to a number of factors,
including: a failure to conduct the clinical trial in accordance with regulatory requirements or the applicable clinical protocols,
inspection of the clinical trial operations or trial site by the FDA, NMPA, TGA, EMA or other regulatory authorities that results
in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from
using a drug, changes in governmental regulations or administrative actions, or lack of adequate funding to continue the clinical
trial. Many of the factors that cause a delay in the commencement or completion of clinical trials may also ultimately lead to
the denial of regulatory approval of our drug candidates. Further, the FDA, NMPA, TGA, EMA or other regulatory authorities may
disagree with our clinical trial design or our interpretation of data from clinical trials, or may change the requirements for
approval even after it has reviewed and commented on the design for our clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-clinical
studies and clinical trials are expensive, difficult to design and implement, and can take many years to complete. Moreover, pre-clinical
and clinical data are often susceptible to varying interpretations and analysis, and many companies that have believed their drug
candidates performed satisfactorily in pre-clinical studies and clinical trials have nonetheless failed to obtain regulatory approval
of their drug candidates. Future clinical trials of our drug candidates may not be successful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencement
of clinical trials is subject to finalizing the trial design based on ongoing discussions with the FDA, NMPA, TGA, EMA and/or
other regulatory authorities. The FDA, NMPA, TGA, EMA and other regulatory authorities could change their position on the acceptability
of trial designs or clinical endpoints, which could require us to complete additional clinical trials or impose approval conditions
that we do not currently expect. Successful completion of our clinical trials is a prerequisite to submitting an NDA (or analogous
filing) to the FDA, NMPA, TGA, EMA and/or other regulatory authorities for each drug candidate and, consequently, the ultimate
approval and commercial marketing of our drug candidates. We do not know whether the clinical trials for our drug candidates will
be completed on schedule, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Results
of earlier clinical trials may not be predictive of results of later-stage clinical trials.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of pre-clinical studies and early clinical trials of our drug candidates may not be predictive of the results of later-stage
clinical trials. Drug candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite
having progressed through pre-clinical studies and initial clinical trials. Future clinical trial results may not be favorable
for these and other reasons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some cases, there can be significant variability in the safety and/or efficacy results between different trials of the same drug
candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type
of the patient populations, including genetic differences, patient adherence to the dosing regimen, and the rate of dropout among
clinical trial participants. As drug candidates are developed through pre-clinical to early- to late-stage clinical trials towards
approval and commercialization, it is customary that various aspects of the development program, such as manufacturing and formulation,
are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve
these intended objectives. In the case of any trials we conduct, results may differ from earlier trials due to the larger number
of clinical trial sites and additional countries and languages involved in such trials. Any of these changes could make the results
of planned clinical trials or other future clinical trials we may initiate less predictable and could cause our drug candidates
to perform differently, which could delay completion of clinical trials, delay approval of our drug candidates, and/or jeopardize
our ability to commence commercialization of our drug candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Clinical
trials of our drug candidates may fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities, or may
not otherwise produce positive results, which may cause us to incur additional costs or experience delays in completing, or ultimately
be unable to complete, the development and commercialization of our drug candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
obtaining regulatory approval for the sale of our drug candidates, we must conduct extensive clinical trials to demonstrate the
safety and efficacy of our drug candidates in humans. We may experience numerous unexpected events during, or as a result of,
clinical trials that could delay or prevent us from receiving regulatory approval or commercializing our drug candidates, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators,
                                         IRBs, or HRECs may not authorize us or our investigators to commence a clinical trial
                                         or conduct a clinical trial at a prospective trial site;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         inability to reach agreements on acceptable terms with prospective CROs, clinical trial
                                         vendors, and trial sites, the terms of which can be subject to extensive negotiation
                                         and may vary significantly among different CROs and trial sites;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
                                         issues, including problems with manufacturing, supply quality, compliance with GMP, or
                                         obtaining from third parties sufficient quantities of a drug candidate for use in a clinical
                                         trial;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
                                         trials of our drug candidates may produce negative or inconclusive results, and we may
                                         decide, or regulators may require us, to conduct additional clinical trials or abandon
                                         drug development programs;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         number of patients required for clinical trials of our drug candidates may be larger
                                         than we anticipate;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         third-party contractors, including clinical investigators, may fail to comply with regulatory
                                         requirements or meet their contractual obligations to us in a timely manner, or at all;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         may not investigate, may not be able to license, or may be unable to properly conduct
                                         companion diagnostic tests to identify patients who are likely to benefit from treatment
                                         with our drug candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         might have to suspend or terminate clinical trials of our drug candidates for various
                                         reasons, including a finding of a lack of clinical response or other unexpected characteristics
                                         or a finding that participants are being exposed to unacceptable health risks;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators,
                                         IRBs or HRECs may require that we or our investigators suspend or terminate clinical
                                         research or not rely on the results of clinical research for various reasons, including
                                         non-compliance with regulatory requirements;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         cost of clinical trials of our drug candidates may be greater than we anticipate;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         supply or quality of our drug candidates or other materials necessary to conduct clinical
                                         trials of our drug candidates may be insufficient or inadequate; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         drug candidates may have undesirable side effects or unexpected characteristics, causing
                                         us or our investigators, regulators, institutional review boards or ethics committees
                                         to suspend or terminate the clinical trials, or reports may arise from pre-clinical studies
                                         or clinical trials of other therapies that raise safety or efficacy concerns about our
                                         drug candidates.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are required to conduct additional clinical trials or other testing of our drug candidates beyond those that we currently contemplate,
if we are unable to successfully complete clinical trials of our drug candidates or other testing, if the results of these trials
or tests are not positive or are only modestly positive or if they raise safety concerns, we may (i)&nbsp;be delayed in obtaining
regulatory approval for our drug candidates; (ii)&nbsp;not obtain regulatory approval at all; (iii)&nbsp;obtain approval for indications
that are not as broad as intended; (iv)&nbsp;have the drug removed from the market after obtaining regulatory approval; (v)&nbsp;be
subject to additional post-marketing testing requirements; (vi)&nbsp;be subject to restrictions on how the drug is distributed
or used; or (vii)&nbsp;be unable to obtain reimbursement for use of the drug.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
clinical trial delays may also increase our development costs and could shorten any periods during which we have the exclusive
right to commercialize our drug candidates or allow our competitors to bring drugs to market before we do. This could impair our
ability to commercialize our drug candidates and may harm our business and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we encounter difficulties enrolling patients in clinical trials, clinical trials of our drug candidates may be delayed or otherwise
adversely affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll
a sufficient number of patients who remain in the trial until our conclusion. we may experience difficulties in patient enrollment
in our clinical trials for a variety of reasons, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         size and nature of the patient population;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         design of the trial, including the patient eligibility criteria defined in the protocol;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         size of the study population required for analysis of the trial&rsquo;s primary endpoints;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         proximity of patients to trial sites;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to recruit clinical trial investigators with the appropriate competencies and
                                         experience;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing
                                         clinical trials for similar therapies or other new therapeutics;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinicians&rsquo;
                                         and patients&rsquo; perceptions as to the potential advantages and side effects of the
                                         drug candidate being studied in relation to other available therapies, including any
                                         new drugs or treatments that may be approved for the indications we are investigating;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to obtain and maintain patient consents;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         risk that patients enrolled in clinical trials will not complete a clinical trial; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         availability of approved therapies that are similar in mechanism to our drug candidates.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
of our timely completion of clinical trials would delay the approval and commercialization of our drug candidates, impair the
commercial performance of our drug candidates, and consequently harm our business and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are not able to obtain, or experiences delays in obtaining, required regulatory approvals, we will not be able to commercialize
our drug candidates, and our ability to generate revenue will be materially impaired.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
obtaining regulatory approvals for the commercial sale of any drug candidate for a target indication, we must demonstrate in preclinical
studies and well-controlled clinical trials, and, with respect to approval in the U.S., to the satisfaction of the FDA, that the
drug candidate is safe and effective for use for that target indication and that the manufacturing facilities, processes and controls
are adequate. In addition to preclinical and clinical data, the New Drug Application (&ldquo;<B>NDA</B>&rdquo;) must include significant
information regarding the chemistry, manufacturing, and controls for the drug candidate. Obtaining approval of an NDA is a lengthy,
expensive and uncertain process, and approval may not be obtained. After we submits an NDA to the FDA, the FDA decides whether
to accept or reject the submission for filing. We cannot be certain that any submissions will be accepted for filing and review
by the&nbsp;FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not yet demonstrated an ability to file for or receive regulatory approval for our drug candidates. For example, we do not
have experience in preparing the required materials for regulatory submission or navigating the regulatory approval process. As
a result, our ability to successfully submit an NDA and obtain regulatory approval for our drug candidates may involve more inherent
risk, take longer, and cost more than it would if we were a company with experience in obtaining regulatory approvals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
authorities outside of the U.S., such as the NMPA and EMA, also have requirements for approval of drugs for commercial sale with
which we must comply prior to marketing in those areas. Regulatory requirements can vary widely from country to country and could
delay or prevent the introduction of our drug candidates. Clinical trials conducted in one country may not be accepted by regulatory
authorities in other countries, and obtaining regulatory approval in one country does not mean that regulatory approval will be
obtained in any other country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval
processes vary among countries and can involve additional product testing and validation, and additional administrative review
periods. Seeking non-U.S. regulatory approval could require additional nonclinical studies or clinical trials, which could be
costly and time consuming. The non-U.S. regulatory approval process may include all of the risks associated with obtaining FDA
approval. For all of these reasons, we may not obtain non-U.S. regulatory approvals on a timely basis, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process to develop, obtain regulatory approval for and commercialize drug candidates is long, complex and costly both inside and
outside the United&nbsp;States, and approval is never guaranteed. Even if our drug candidates were to successfully obtain approval
from the regulatory authorities, any approval might significantly limit the approved indications for use, or require that precautions,
contraindications or warnings be included on the product labeling, or require expensive and time-consuming post-approval clinical
trials or surveillance as conditions of approval. Following any approval for commercial sale of our drug candidates, certain changes
to the drug, such as changes in manufacturing processes and additional labeling claims, may be subject to additional review and
approval by the FDA, NMPA, TGA, EMA and comparable regulatory authorities. Also, regulatory approval for any of our drug candidates
may be withdrawn. If we are unable to obtain regulatory approval for our drug candidates in one or more jurisdictions, or any
approval contains significant limitations, our target market will be reduced and our ability to realize the full market potential
of our drug candidates will be harmed. Furthermore, we may not be able to obtain sufficient funding or generate sufficient revenue
and cash flows to continue the development of any other drug candidate in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Favorable
designations may not be granted, or if granted, be withdrawn later, for any of our drug candidates, and may not lead to faster
development or regulatory review or approval.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have Fast Track Designation or, Breakthrough Therapy Designation, but may seek one or more of such designations
in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address
unmet medical need for that condition, the drug sponsor may apply for FDA Fast Track Designation. The FDA has broad discretion
whether or not to grant this designation. Even if we believe a particular drug candidate is eligible for this designation, we
cannot assure that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not experience a development,
review or approval process faster than conventional FDA procedures. The FDA may withdraw a Fast Track Designation if it believes
that the designation is no longer supported by data from our clinical development program. Many drugs that have received Fast
Track Designation have failed to obtain approval from the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Breakthrough Therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious
or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial
improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed
early in clinical development. For drugs that have been designated as Breakthrough Therapies, interaction and communication between
the FDA and the sponsor can help to identify the most efficient path for development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designation
as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe, after completing early clinical
trials, that one of our drug candidates meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and
instead decide not to grant that designation. In any event, the receipt of a Breakthrough Therapy Designation for a drug candidate
may not result in a faster development, review or approval process compared to drugs considered for approval under conventional
FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our drug candidates qualify
as Breakthrough Therapies, the FDA may later decide that such drug candidates no longer meet the conditions for qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. FDA granted orphan drug development status to our lead drug candidate, CNM-Au8, for the treatment of ALS in May&nbsp;2019.
Regulatory authorities in some jurisdictions, including the U.S. and the European Union, may designate drugs for relatively small
patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug
intended to treat a rare disease or condition, which is generally defined as a disease with a patient population of fewer than
200,000 individuals in the U.S., or that affects more than 200,000 individuals in the U.S. and for which there is no reasonable
expectation that costs of research and development of the product for the indication can be recovered by sales of the product
in the U.S. Generally, if a drug with an orphan drug designation subsequently receives the first regulatory approval for the indication
for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes the FDA or EMA,
from approving another marketing application for the same drug for the same indication during the period of exclusivity. The applicable
period is seven years in the United&nbsp;States and 10&nbsp;years in the European Union. The European exclusivity period can be
reduced to six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable
so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or the EMA determines that the
request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to
meet the needs of patients with the rare disease or condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we have obtained orphan drug exclusivity for CNM-Au8 for the treatment of ALS in the U.S., and may obtain the same exclusivity
for other drug candidates or indication, that exclusivity may not effectively protect the drug candidate from competition because
different drugs can be approved for the same condition and the same drugs can be approved for a different condition but used off-label
for any orphan indication we may obtain. Even after an orphan drug is approved, the FDA can subsequently approve a drug that is
otherwise the same drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown
to be safer, more effective, or makes a major contribution to patient care.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Any
of our future approved drug candidates will be subject to ongoing or additional regulatory obligations and continued regulatory
review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory
requirements or experiences unanticipated problems with our drug candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of our future approved drug candidates will be subject to ongoing or additional regulatory requirements for manufacturing, labeling,
packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety,
efficacy, and other post-market information, including both federal and state requirements in the U.S. and requirements of comparable
regulatory authorities in European Union, China, Australia and other markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturers
and manufacturers&rsquo; facilities are required to comply with extensive FDA, NMPA, TGA, EMA and other comparable regulatory
authority requirements ensuring that quality control and manufacturing procedures conform to GMP. As such, we will be subject
to continual review and inspections to assess compliance with GMP and adherence to commitments made in any NDA, other marketing
application, and previous responses to any inspection observations if we were to build manufacturing facilities in the future.
Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance,
including manufacturing, production, and quality control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
approvals that we receive for our drug candidates may be subject to limitations on the approved indicated uses for which the drug
may be marketed or to the conditions of approval, which could adversely affect the drug&rsquo;s commercial potential or contain
requirements for potentially costly post-marketing testing and surveillance to monitor the safety and efficacy of the drug candidate.
The FDA, NMPA, TGA, EMA or a comparable regulatory authority may also require a risk evaluation mitigation strategy program as
a condition of approval of our drug candidates or following approval. In addition, if the FDA, NMPA, TGA, EMA or a comparable
regulatory authority approves our drug candidates, we will have to comply with requirements, including, for example, submissions
of safety and other post-marketing information and reports, registration, as well as continued compliance with GMP and good clinical
practice GCP, for any clinical trials that we conduct post-approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and other regulatory authorities strictly regulate the marketing, labeling, advertising and promotion of products that are
placed on the market. Drugs may be promoted only for their approved indications and for use in accordance with the provisions
of the approved label. The FDA, NMPA, TGA, EMA and other regulatory authorities actively enforce the laws and regulations prohibiting
the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant
liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we are able to commercialize any approved drug candidates, the drugs may become subject to national or other third-party reimbursement
practices or unfavorable pricing regulations, which could harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
regulations that govern regulatory approvals, pricing and reimbursement for new therapeutic products vary widely from country
to country. In Europe, Canada, Australia, China, and some markets outside China, prescription pharmaceutical pricing remains subject
to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for
a drug in a particular country, but then be subject to price regulations that delay our commercial launch of the drug and negatively
impact our revenues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to commercialize any approved drug candidates successfully also will depend in part on the extent to which reimbursement
for these drugs and related treatments will be available from government health administration authorities, private health insurers,
and other organizations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
primary trend in the global healthcare industry is cost containment. Government authorities and these third-party payers have
attempted to control costs by limiting coverage and the amount of reimbursement for particular medications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S., no uniform policy of coverage and reimbursement for drugs exists among third-party payers. As a result, obtaining coverage
and reimbursement approval of a drug from a government or other third-party payer is a time-consuming and costly process that
could require us to provide to each payer supporting scientific, clinical, and cost-effectiveness data for the use of our future
approved drugs on a payer-by-payer basis, with no assurance that coverage and adequate reimbursement will be obtained. Even if
we obtain coverage for a given drug, the resulting reimbursement rates might not be adequate for us to achieve or sustain profitability
or may require co-payments that patients find unacceptably high. Additionally, third-party payers may not cover, or provide adequate
reimbursement for, long-term follow-up evaluations required following the use of our future approved drug candidates. Patients
are unlikely to use any of our future approved drugs unless coverage is provided and reimbursement is adequate to cover a significant
portion of the cost of the drug. Because some of our drug candidates may have a higher cost of goods than conventional small molecule
therapies, and may require long-term follow-up evaluations, the risk that coverage and reimbursement rates may be inadequate for
us to achieve profitability may be greater.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increasingly,
third-party payers are requiring that companies provide them with predetermined discounts from list prices and are challenging
the prices charged for medical products. We cannot assure that reimbursement will be available for any approved drug candidate
that we commercializes and, if reimbursement is available, what the level of reimbursement will be. Reimbursement may impact the
demand for, or the price of, any approved drug candidate that we commercialize. If reimbursement is not available or is available
only to limited levels, we may not be able to successfully commercialize any drug candidate that it successfully develops.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
may be significant delays in obtaining reimbursement for approved drug candidates, and coverage may be more limited than the purposes
for which the drug candidates are approved by the FDA, NMPA, TGA, EMA or other comparable regulatory authorities. Moreover, eligibility
for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research,
development, manufacture, sale and distribution. Interim payments for new drugs, if applicable, may also not be sufficient to
cover our costs and may not be made permanent. Payment rates may vary according to the use of the drug and the clinical setting
in which it is used, may be based on payments allowed for lower cost drugs that are already reimbursed, and may be incorporated
into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government
healthcare programs or private payers and by any future weakening of laws that presently restrict imports of drugs from countries
where they may be sold at lower prices than in the U.S. our inability to promptly obtain coverage and profitable payment rates
from both government-funded and private payers for any future approved drug candidates and any new drugs that we develop could
have a material adverse effect on our business, operating results and overall financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to seek approval alone or in conjunction with partners to market our drug candidates in the U.S., China, European Union,
Australia, Canada, and other jurisdictions. In China, Australia, Canada, and the European Union, the pricing of drugs is subject
to governmental control, and it can take considerable time after obtaining marketing regulatory approval to get the future approved
drugs reimbursed. Market acceptance and sales of any of our future approved drug candidates will depend significantly on the availability
of adequate coverage and reimbursement from third-party payers for drugs and may be affected by existing and future healthcare
reform measures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
drug candidates approved in the future may fail to achieve the degree of market acceptance by physicians, patients, third-party
payers and others in the medical community necessary for commercial success and the market opportunity for the drug candidate
may be smaller than we estimate.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future approved drug candidates may fail to gain sufficient market acceptance by physicians, patients, third-party payers and
others in the medical community. For example, current multiple sclerosis treatments are well established in the medical community,
and physicians may continue to rely on these treatments to the exclusion of our drug candidates that are in clinical trials for
the same or similar indications. In addition, physicians, patients, and third-party payers may prefer other novel products to
ours. If our drug candidates do not achieve an adequate level of acceptance, we may not generate significant product sales revenues
and we may not become profitable. The degree of market acceptance of our drug candidates, if approved for commercial sale, will
depend on a number of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         clinical indications for which our drug candidates are approved;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
                                         physicians, hospitals, treatment centers and patients consider our drug candidates as
                                         a safe and effective treatment;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         potential and perceived advantages of our drug candidates over alternative treatments;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         prevalence and severity of any side effects;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
                                         labeling or product insert requirements of regulatory authorities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
                                         or warnings contained in the labeling approved by regulatory authorities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         timing of market introduction of our drug candidates as well as competitive drugs;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         cost of treatment in relation to alternative treatments;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         availability of adequate coverage, reimbursement and pricing by third-party payers and
                                         government authorities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         willingness of patients to pay out-of-pocket in the absence of coverage and reimbursement
                                         by third-party payers and government authorities; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         effectiveness of our sales and marketing efforts.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any approved drug candidates that we commercialize fail to achieve market acceptance among physicians, patients, hospitals, treatment
centers or others in the medical community, we will not be able to generate significant revenue. Even if our future approved drug
candidates achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies
are introduced that are more favorably received than our drug candidates, are more cost-effective or render our drug candidates
obsolete.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
our drug candidates cause, or are perceived to cause, undesirable side effects, it can result in delays or failure to receive
regulatory approval or limitations on the commercial profile of an approved label.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undesirable
side effects caused by our drug candidates could cause either us or regulatory authorities to interrupt, delay or halt clinical
trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, NMPA, TGA, EMA or
other regulatory authorities. If the results of the ongoing clinical trials of our drug candidates reveal a high and unacceptable
severity and prevalence of undesirable side effects, the clinical trials of our drug candidates could be suspended or terminated
and the FDA, NMPA, TGA, EMA or comparable regulatory authorities could order us to cease further development of or deny approval
of our drug candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or
the ability of enrolled patients to complete the clinical trial or result in potential product liability claims. Any of these
occurrences may harm our business, financial condition and prospects significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials assess a sample of the potential patient population. With a limited number of patients and a limited duration of exposure,
rare and severe side effects of our drug candidates may only be uncovered with a significantly larger number of patients exposed
to the drug candidates. If our drug candidates receive regulatory approval and we or others discover undesirable side effects
caused by such drugs (or any other similar drugs) or that such drug candidates are less effective than previously believed, a
number of potentially significant negative consequences could result, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         FDA, NMPA, TGA, EMA or other comparable regulatory authorities may withdraw or limit
                                         their approval of such drug candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         FDA, NMPA, TGA, EMA or other comparable regulatory authorities may require the addition
                                         of labeling statements, such as a &ldquo;boxed&rdquo; warning or a contra-indication;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         may be required to create a medication guide outlining the risks of such side effects
                                         for distribution to patients;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         may be required to change the way such drug candidates are distributed or administered,
                                         conduct additional clinical trials or change the labeling of our drug candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         FDA, NMPA, TGA, EMA or other comparable regulatory authorities may require the development
                                         of risk evaluation and mitigation strategies and plans to mitigate risks, which could
                                         include medication guides, physician communication plans, or elements to assure safe
                                         use, such as restricted distribution methods, patient registries and other risk minimization
                                         tools;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         may be subject to regulatory investigations and government enforcement actions;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         may decide to remove such drug candidates from the marketplace;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         could be sued and held liable for injury caused to individuals exposed to or taking our
                                         drugs; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         reputation may suffer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these events could prevent us from achieving or maintaining market acceptance of the affected drug candidates and could substantially
increase the costs of commercializing our drugs, if approved, and significantly impact our ability to successfully commercialize
our drugs and generate revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Adverse
drug reactions and negative results from off-label use of our products could materially harm our business reputation, product
brand name, financial condition and expose us to liability.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Products
distributed or sold in the pharmaceutical market may be subject to off-label drug use. Off-label drug use is prescribing a product
for an indication, patient population, dosage strength or frequency, or other condition of use that is not in accordance with
regulatory approved usage and labeling. Even though the FDA, NMPA, TGA, EMA and other comparable regulatory authorities actively
enforce the laws and regulations prohibiting the promotion of off-label use, there remains the risk that our products are subject
to off-label drug use and is prescribed in a patient population or dosage that has not been approved by competent authorities.
Off-label use of our products may be less effective or entirely ineffective and may cause adverse drug reactions. Any of these
occurrences can create negative publicity and significantly harm our business reputation, product brand name, commercial operations,
and financial condition, including our share price. These occurrences may also expose us to liability and cause, or lead to, a
delay in the progress of our clinical trials and may also ultimately result in failure to obtain regulatory approval for our drug
candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>As
a company, we have no experience in launching and marketing drugs. If we are unable to develop sales, marketing and distribution
capabilities or enter into sales, marketing and distribution agreements or arrangements with third parties, we may not be successful
in commercializing any drugs and generate drug candidate sales revenue.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not yet demonstrated an ability to launch and commercialize any of our drug candidates. As a result, our ability to successfully
commercialize any approved drugs may involve more inherent risk, take longer, and cost more than it would if we were a company
with prior experience launching and marketing drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will have to compete with other pharmaceutical and biopharmaceutical
companies to recruit, hire, train and retain marketing and sales personnel. We must either develop internal sales, marketing, and
commercial distribution capabilities for any or all of our approved drugs or pursue collaborative arrangements regarding the sales
and marketing of our approved drugs. However, there can be no assurance that we will be able to develop such distribution capabilities
or establish or maintain such collaborative arrangements, or if we are able to do so, that they will have effective sales forces.
Any revenue we receive will depend upon the efforts of such third parties. we would have little or no control over the marketing
and sales efforts of such third parties, and our revenue from product sales may be lower than if we had commercialized our approved
drugs by ourselves. We also face competition in our search for third parties to assist it with the sales and marketing efforts
for our approved drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, we may not be able to generate product sales revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
face substantial competition from other pharmaceutical and biotechnology companies, and our operating results may suffer if we
fail to compete effectively.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development and commercialization of new drugs is highly competitive. We face competition from major pharmaceutical companies,
specialty pharmaceutical companies, and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology
companies that currently market and sell drugs or are pursuing the development of drugs for the treatment of neurological diseases
and other disorders for which we are commercializing our drugs or developing our drug candidates. Potential competitors also include
academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent
protection and establish collaborative arrangements for research, development, manufacturing, and commercialization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial opportunity could be reduced or eliminated if our competitors develop and commercialize drugs that are safer, more
effective, have fewer or less severe side effects, are more convenient, or are less expensive than any drugs that we commercialize
or may develop. Our competitors may also obtain approval from the FDA, NMPA, TGA, EMA or other comparable regulatory authorities
for their drugs more rapidly than we may obtain approval for our drugs, which could result in our competitors establishing a strong
market position before we are able to enter the market and/or could slow our regulatory approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the companies against which we are competing or against which we may compete in the future have significantly greater financial
resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining
regulatory approvals, and marketing approved drugs than we do. Mergers and acquisitions in the pharmaceutical and biotechnology
industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage
companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established
companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing
clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary
for, our programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject, directly or indirectly, to applicable anti-kickback, false claims laws, physician payment transparency laws, fraud
and abuse laws or similar healthcare and security laws and regulations in the U.S. and other jurisdictions, which could expose
us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
providers, physicians and others play a primary role in the recommendation and prescription of any products for which we obtain
regulatory approval. If we obtain FDA approval for any of our drug candidates and begin commercializing those drugs in the U.S.,
our operations may be subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback
Statute, the federal False Claims Act, and physician payment sunshine laws and regulations. These laws may impact, among other
things, our proposed sales, marketing, and education programs. In addition, we may be subject to patient privacy regulation by
both the federal government and the states in which we conduct our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we are subject to state and non-U.S. equivalents of each of the healthcare laws described above, among others, some of which may
be broader in scope and may apply to healthcare services reimbursed by any source, not just governmental payers, including private
insurers. In addition, some states have passed laws that require pharmaceutical companies to comply with the April&nbsp;2003 Office
of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and/or other voluntary industry codes of conduct.
Several states also impose other marketing restrictions or require pharmaceutical companies to make marketing or price disclosures
to the state. There are ambiguities as to what is required to comply with these state requirements, and if we fail to comply with
applicable state law requirements, we could be subject to penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Violations
of fraud and abuse laws may be punishable by criminal and/or civil sanctions, including penalties, fines and/or exclusion or suspension
from federal and state healthcare programs such as Medicare and Medicaid and debarment from contracting with the U.S. government.
In addition, private individuals have the ability to bring actions on behalf of the U.S. government under the federal False Claims
Act as well as under the false claims laws of several states.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Neither the U.S. government nor the U.S. courts have provided
definitive guidance on limitations to potential liability under the fraud and abuse laws as they may apply to our business. Law
enforcement authorities are increasingly focused on enforcing these laws, often using new and creative legal theories, and it is
possible that some of our practices may be challenged under these laws. Efforts to ensure that our business arrangements with third
parties will comply with applicable healthcare laws and regulations will involve substantial costs. Regardless of the compliance
efforts, it is possible that governmental authorities will conclude that our business practices may not comply with current or
future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If any
such actions are instituted against us, defending against such actions, even if successful, would distract the company and key
personnel from our core mission and impose potentially significant costs. If we are not successful in defending ourselves or asserting
our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative
penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid, and other federal
healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations,
any of which could adversely affect our ability to operate our business and our results of operations. In addition, the approval
and commercialization of any of our approved drugs outside the U.S. will also likely subject us to non-U.S. equivalents of the
healthcare laws mentioned above, among other non-U.S. laws, as well as the U.S. Foreign Corrupt Practices Act (FCPA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the physicians or other providers or entities with whom we expect to do business are found to be not in compliance with
applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded
healthcare programs, which may also adversely affect our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Any
failure to perform proper quality control and quality assurance would have a material adverse effect on our business and financial
results.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacturing of our drug candidates and future approved drugs is subject to applicable laws, regulations, and GMP. These regulations
govern manufacturing processes and procedures, including record keeping and the implementation and operation of quality management
systems to control and assure the quality of investigational products and products approved for sale. We apply stringent quality
controls at each stage of our production process to comply with these requirements. We perform extensive tests throughout the
manufacturing processes to ensure the safety and effectiveness of our drug candidates. We may, however, detect instances in which
an unreleased product was produced without adherence to our manufacturing procedures or the raw material used in our production
process was not collected to store in accordance with the GMP or other regulations, resulting in a determination that the implicated
products should be destroyed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if we fail to comply with relevant quality control requirements under laws and GMP, we could experience a disruption
in the supply of our products, which could delay or prevent further sales of such products, which could have a material adverse
effect on our business and financial results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, quality issues may arise during scale-up activities. If we are unable to successfully ensure consistent and high quality
of our products during large-volume production, the sales of our products may not be able to be promoted, which could have a material
adverse effect on our business and financial results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may explore the licensing of commercialization rights or other forms of collaboration worldwide, which will expose us to additional
risks.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-U.S.
markets are an important component of our growth strategy. we initially intend to focus on opportunities in the U.S., European
Union, Canada, Australia, Japan, and China, in particular. If we fail to obtain licenses or enter into collaboration arrangements
with third parties in these or other markets, or if these parties are not successful, our revenue-generating growth potential
will be adversely affected. Moreover, international business relationships subject us to additional risks that may materially
adversely affect our ability to attain or sustain profitable operations, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">efforts
                                         to enter into collaboration or licensing arrangements with third parties in connection
                                         with our international sales, marketing, and distribution efforts may increase our expenses
                                         or divert our management&rsquo;s attention from the acquisition or development of our
                                         drug candidates;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
                                         of effective enforcement of contractual provisions in local jurisdictions;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">differing
                                         regulatory requirements for drug approvals and marketing internationally;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                         in a specific market&rsquo;s political and cultural climate or economic condition;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
                                         third-party patent rights or potentially reduced protection for intellectual property
                                         rights;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unexpected
                                         changes in tariffs, trade barriers, and regulatory requirements;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic
                                         weakness, including inflation;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
                                         with tax, employment, immigration, and labor laws for employees traveling abroad;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         effects of applicable non-U.S. tax structures and potentially adverse tax consequences;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">currency
                                         fluctuations, which could result in increased operating expenses and reduced revenue;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">production
                                         shortages resulting from any events affecting raw material supply or manufacturing capabilities
                                         abroad;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">workforce
                                         uncertainty and labor unrest;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
                                         of our employees and contracted third parties to comply with Office of Foreign Asset
                                         Control rules and regulations and the Foreign Corrupt Practices Act; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">business
                                         interruptions resulting from geo-political actions, including war and terrorism, or natural
                                         disasters, including earthquakes, volcanoes, typhoons, floods, hurricanes, and fires.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
and other risks may materially and adversely affect our ability to attain or sustain revenue from international markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Illegal
and/or parallel imports and counterfeit pharmaceutical products may reduce demand for our future approved drug candidates and
could have a negative impact on our reputation and business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
importation, whether authorized by governmental policy or illegally, of competing products from countries where government price
controls or other market dynamics result in lower prices may adversely affect the demand for our future approved drugs and, in
turn, may adversely affect our sales and profitability where we commercialize our products. Unapproved foreign imports of prescription
drugs are illegal under the current laws of the U.S., China, European Union, Australia and other jurisdictions. However, illegal
imports may continue to occur or even increase as the ability of patients to obtain these lower priced imports continues to grow.
Furthermore, cross-border imports from lower-priced markets (parallel imports) into higher-priced markets could harm sales of
our future approved drugs and exert commercial pressure on pricing within one or more markets. In addition, competent government
authorities may expand consumers&rsquo; ability to import lower priced versions of our future approved products or competing products
from outside the countries where we operate. Any future legislation or regulations that increase consumer access to lower priced
medicines from outside the countries where we operate could have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Certain
products distributed or sold in the pharmaceutical market may be manufactured without proper licenses or approvals, or are fraudulently
mislabeled with respect to their content or manufacturers. These products are generally referred to as counterfeit pharmaceutical
products. The counterfeit pharmaceutical product control and enforcement system, particularly in developing markets such as China,
may be inadequate to discourage or eliminate the manufacturing and sale of counterfeit pharmaceutical products imitating our products.
Since counterfeit pharmaceutical products in many cases have very similar appearances compared with the authentic pharmaceutical
products but are generally sold at lower prices, counterfeits of our products can quickly erode the demand for our future approved
drugs. Our reputation and business could suffer harm as a result of counterfeit pharmaceutical products sold under our or our
collaborators&rsquo; brand name(s). In addition, theft of inventory at warehouses, plants or while in-transit, which are not properly
stored and which are sold through unauthorized channels, could adversely impact patient safety, as well as our reputation and
business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
rely on third parties to conduct our preclinical studies and clinical trials and we must work effectively with collaborators to
develop our drug candidates. If these third parties do not successfully carry out their contractual duties or meet expected deadlines,
we may not be able to obtain regulatory approval for or commercialize our drug candidates and our business could be substantially
harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely upon and plan to continue to rely upon third-party CROs and third-party vendors to monitor, collect samples, analyze samples,
report data, and manage data for our ongoing preclinical and clinical programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We&nbsp;rely
on these parties for execution of our preclinical studies and clinical trials, and controls only certain aspects of their activities.
Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol,
legal and regulatory requirements, and scientific standards, and our reliance on the CROs does not relieve us of our regulatory
responsibilities. We, our CROs and third-party vendors supporting our clinical programs, and our clinical investigators, are required
to comply with GCPs, which are regulations and guidelines enforced by the FDA, NMPA, TGA, EMA, and other comparable regulatory
authorities for all of our drugs in clinical development. If we or any of our CROs or clinical investigators fails to comply with
applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, NMPA, TGA, EMA or comparable
regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. In addition,
our pivotal clinical trials must be conducted with product produced under GMP. our failure to comply with these regulations may
require it to repeat clinical trials, which would delay the regulatory approval process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our relationships with these third-parties terminates, we may not be able to enter into arrangements with alternative CROs
or vendors, or to do so on commercially reasonable terms. In addition, our CROs are not our employees, and except for remedies
available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources
to our ongoing clinical and nonclinical programs. If CROs do not successfully carry out their contractual duties or obligations
or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they or our clinical
investigators obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements, or for other
reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or
successfully commercialize our drug candidates. As a result, our results of operations and the commercial prospects for our approved
drugs would be harmed, our costs could increase and our ability to generate revenues could be delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Switching
or adding additional CROs involves additional cost and delays, which can materially influence our ability to meet our desired
clinical development timelines. There can be no assurance that we will not encounter similar challenges or delays in the future
or that these delays or challenges will not have a material adverse effect on our business, financial condition and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future revenues are dependent on our ability to work effectively with collaborators to develop our drug candidates, including
to obtain regulatory approval. Our arrangements with collaborators will be critical to successfully bringing products to market
and commercializing them. We relies on collaborators in various respects, including to undertake research and development programs,
conduct clinical trials, manage or assist with the regulatory filings and approval process, and to assist with our commercialization
efforts. We do not control our collaborators; therefore, we cannot ensure that these third parties will adequately and timely
perform all of their obligations to us. If they fail to complete the remaining studies successfully, or at all, it could delay,
adversely affect or prevent regulatory approval. We cannot guarantee the satisfactory performance of any of our collaborators
and if any of our collaborators breach or terminate their agreements with us, we may not be able to successfully commercialize
the licensed product which could materially and adversely affect our business, financial condition, cash flows and results of
operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
third-party CROs and third-party vendors may also be impacted by the COVID-19 outbreak. See &ldquo;&mdash;&nbsp;<I>Our financial
position and operations may be adversely affected by the COVID-19 outbreak</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have entered into research collaborations and may form or seek collaborations or strategic alliances or enter into licensing arrangements
in the future, and we may not realize the benefits of such collaborations, alliances, or licensing arrangements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may form or seek strategic alliances, create joint ventures
or collaborations, or enter into licensing arrangements with third parties that we believe will complement or augment our development
and commercialization efforts with respect to our drug candidates and any future drug candidates that we may develop. Any of these
relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities
that dilute our existing shareholders, or disrupt our management and business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into collaborative research arrangements with some of the world&rsquo;s leading academic institutions and research
centers and are working with key scientists in the field of central nervous system disorders. </FONT>We face significant competition
in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful
in our efforts to establish a strategic partnership or other alternative arrangements for our drug candidates because they may
be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our drug candidates
as having the requisite potential to demonstrate safety and efficacy or commercial viability. If and when we collaborate with
a third party for development and commercialization of a drug candidate, we can expect to relinquish some or all of the control
over the future success of that drug candidate to the third party. For any drug candidates that we may seek to in-license from
third parties, we may face significant competition from other pharmaceutical or biotechnology companies with greater resources
or capabilities than we have, and any agreement that we do enter may not result in the anticipated benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
collaborations involving our drugs are subject to numerous risks, which may include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                         have significant discretion in determining the efforts and resources that they will apply
                                         to a collaboration;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                         may not pursue development and commercialization of our drug candidates or may elect
                                         not to continue or renew development or commercialization programs based on clinical
                                         trial results, changes in their strategic focus due to the acquisition of competitive
                                         drugs, availability of funding, or other external factors, such as a business combination
                                         that diverts resources or creates competing priorities;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                         may delay clinical trials, provide insufficient funding for a clinical trial, stop a
                                         clinical trial, abandon a drug candidate, repeat or conduct new clinical trials, or require
                                         a new formulation of a drug candidate for clinical testing;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                         could independently develop, or develop with third parties, drugs that compete directly
                                         or indirectly with our drugs;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                         collaborator with marketing and distribution rights to one or more drugs may not commit
                                         sufficient resources to their marketing and distribution;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                         may not properly develop, maintain, or defend our intellectual property rights or may
                                         use our intellectual property or proprietary information in a way that gives rise to
                                         actual or threatened litigation that could jeopardize or invalidate our intellectual
                                         property or proprietary information or expose us to potential liability;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
                                         may arise between us and a collaborator that cause the delay or termination of the research,
                                         development, or commercialization of our drug candidates, or that result in costly litigation
                                         or arbitration that diverts management attention and resources;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborations
may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization
of the applicable drug candidates; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                         may own or co-own intellectual property covering our drugs that results from our collaborating
                                         with them, and in such cases, we would not have the exclusive right to commercialize
                                         such intellectual property.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, we may not be able to realize the benefit of current or future research collaborations, strategic partnerships, or the
potential licensing of third-party drugs if we are unable to successfully integrate such products with our existing operations
and company culture, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that,
following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction.
If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have
to curtail the development of a drug candidate, reduce or delay our development program or one or more of our other development
programs, delay our potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures
and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or
commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available
to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to
undertake the necessary development and commercialization activities, we may not be able to further develop our drug candidates
or bring them to market and generate product sales revenue, which would harm our business prospects, financial condition and results
of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
business depends on the use of raw materials, and a decrease in the supply, or an increase in the cost of these raw materials
could materially and adversely affect our business, financial condition and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In order to manufacture our products, we must obtain sufficient
quantities of high-quality raw materials at commercially acceptable prices and in a timely manner. Certain critical raw materials,
such as wires made of high-purity gold and other transition elements, are available from a limited number of suppliers in the market.
As a result, any disruption in production or inability of our suppliers to produce adequate quantities to meet our needs could
impair our ability to operate our business on a day-to-day basis and to continue our research and development of future drug candidates.
Moreover, we expect our demand for such materials to increase as we expand our business scale and commercialize our products, and
we cannot guarantee that current suppliers have the capacity to meet our demand. We are also exposed to the risk of increased material
costs, which we may not be able to pass on to customers and as a result, we could have lower profitability. In addition, although
we have implemented quality inspection procedures on such materials before they are used in our manufacturing processes and also
require our suppliers to maintain high quality standards, we cannot guarantee that we will be able to secure sufficient quantities
of raw materials at high quality standards, nor detect all quality issues in the supplies we use. For example, should the highly
purified water that we utilize be compromised in any way, it could render entire batches unusable or, depending on the nature of
the impurity, potentially dangerous to patients. We cannot assure you that third parties will be able to maintain and renew all
licenses, permits, and approvals necessary for their operations or comply with all applicable laws and regulations. Failure to
do so by them may lead to interruption in their business operations, which in turn may result in shortages of the raw materials
utilized by us. If we are unable to obtain adequate raw materials and the quality of our products suffer as a result, we may have
to delay clinical trials and regulatory filings, recall our products, be subject to product liability claims, fail to comply with
continuing regulatory requirements, and incur significant costs to rectify such issues, which may have a material and adverse effect
on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to obtain and maintain sufficient patent protection for our drug candidates through intellectual property rights,
or if the scope of such intellectual property rights obtained is not sufficiently broad, third parties could develop and commercialize
products similar or identical to our products, and our ability to commercialize our approved drugs successfully may be adversely
affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends in large part on our ability to protect our proprietary technology, drug candidates in clinical studies, and approved
drugs on market (if approved) from competition by obtaining, maintaining and enforcing our intellectual property rights, including
patent rights. We seek to protect the drug candidates and technology that it considers commercially important by filing patent
applications in most important commercial markets, including the U.S., the People&rsquo;s Republic of China (&ldquo;<B>PRC</B>&rdquo;),
Europe, Canada, Japan, Korea, and other countries, relying on trade secrets or pharmaceutical regulatory protection or employing
a combination of these methods. However, the patent prosecution process is expensive, time-consuming and complex, and we may not
be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or
in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output
before it is too late to obtain patent protection. As a result, we may not be able to prevent competitors from developing and
commercializing competitive drugs in all such fields and territories.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
may be invalidated and patent applications may not be granted for a number of reasons, including known or unknown prior art, deficiencies
in the patent application or the lack of novelty of the underlying invention or technology. Although we enter into non-disclosure
and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development
output, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants,
advisors and any other third parties, any of these parties may breach such agreements and disclose such output before a patent
application is filed, thereby jeopardizing our ability to seek patent protection. In addition, publications of discoveries in
the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions
are typically not published until 18 months after filing, or in some cases, not at all. Therefore, we cannot be certain that it
was the first to make the inventions claimed in our patents or pending patent applications or that it was the first to file for
patent protection of such inventions. Furthermore, the PRC, EPO, and the U.S. have adopted the &ldquo;first-to-file&rdquo; system
under which whoever first files a patent application will be awarded the patent if all other patentability requirements are met.
Under the first-to-file system, third parties may be granted a patent relating to a technology which we invented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
coverage sought by the claims in a patent application can be significantly reduced before the patent is issued, and the scope
of the claims can be reinterpreted after issuance. Even if patent applications we license or own currently or in the future issue
as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third
parties from competing with us, or otherwise provide us with any competitive advantage. In addition, the patent position of biotechnology
and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject
of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and commercial value of our patent
rights are highly uncertain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of a patent is not conclusive as to our inventorship, scope, validity, or enforceability, and our patents may be challenged
in the courts or patent offices in any country. We may be subject to a third-party preissuance submission of prior art to the
U.S. Patent and Trademark Office, or USPTO, or become involved in opposition, derivation, revocation, re-examination, post-grant
and <I>inter partes</I> review, or interference proceedings or similar proceedings in foreign jurisdictions challenging our patent
rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce
the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or approved drugs and compete
directly with us without payment, or result in our inability to manufacture or commercialize drug candidates and approved drugs
without infringing, misappropriating or otherwise violating third-party patent rights. Moreover, we may have to participate in
interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such
as oppositions in a foreign patent office, that challenge the priority of our invention or other features of patentability of
our patents and patent applications. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims
being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing
similar or identical technology and products, or limit the duration of the patent protection of our technology and drug candidates.
Such proceedings also may result in substantial costs and require significant time from our scientists and management, even if
the eventual outcome is favorable to us. Consequently, we do not know whether any of our technology or drug candidates will be
protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent
our patents by developing similar or alternative technologies or products in a non-infringing manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
although various extensions may be available, the life of a patent and the protection it affords, is limited. For example, approved
therapies may face competition from generic medications after the related patents have expired, or if they are challenged and
invalidated even before their expiry. Manufacturers of generic drugs may challenge the scope, validity or enforceability of our
patents in court, and we may not be successful in enforcing or defending those intellectual property rights and, as a result,
may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any potential
sales of that product. The issued patents and pending patent applications, if issued, for our drug candidates are expected to
expire on various dates as described in &ldquo;Business&nbsp;&mdash; Intellectual Property&rdquo; of this Annual Report. Upon
the expiration of our issued patents or patents that may issue from our pending patent applications, we will not be able to assert
such patent rights against potential competitors and our business and results of operations may be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such
drug candidates might expire before or shortly after such drugs are commercialized. As a result, our patents and patent applications
may not provide it with sufficient rights to exclude others from commercializing products similar or identical to our products.
Moreover, some of our patents and patent applications may in the future be co-owned with third parties. If we are unable to obtain
an exclusive license to any such third-party co-owners&rsquo; interest in such patents or patent applications, such co-owners
may be able to license their rights to other third parties, including our competitors, and our competitors could market competing
products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such
patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse
effect on our competitive position, business, financial conditions, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to protect our intellectual property rights throughout the world or prevent unfair competition by third parties.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing,
prosecuting, maintaining, and defending patents on drug candidates in all countries throughout the world could be prohibitively
expensive for us, and our intellectual property rights in some non-U.S. countries can have a different scope and strength than
do those in the U.S. In addition, the laws of certain non-U.S. countries do not protect intellectual property rights to the same
extent as the laws of the U.S. Consequently, we may not be able to prevent third parties from practicing our inventions in all
countries outside the U.S., or from selling or importing drugs made using our inventions in and into the U.S. or non-U.S. jurisdictions.
Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own drugs
and further, may export otherwise infringing drugs to non-U.S. jurisdictions where we have patent protection, but where enforcement
rights are not as strong as those in the U.S. These drugs may compete with our future approved drugs and our patent rights or
other intellectual property rights may not be effective or adequate to prevent them from competing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and
unsuccessful. our patent rights relating to our drugs could be found invalid or unenforceable if challenged in court or before
the U.S. Patent and Trademark Office or comparable non-U.S. authority.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may infringe our patent rights or misappropriate or otherwise violate our intellectual property rights. To counter infringement
or unauthorized use, litigation may be necessary in the future to enforce or defend our intellectual property rights, protect
our trade secrets or determine the validity and scope of our own intellectual property rights or the proprietary rights of others.
Enforcement or defense of intellectual property rights can be expensive and time consuming. Any claims that we assert against
perceived infringers could also provoke these parties to assert counterclaims against us alleging that we infringe their intellectual
property rights. Many of our current and potential competitors have the ability to dedicate substantially greater resources to
enforce and/or defend their intellectual property rights than we can. Accordingly, despite our efforts, we may not be able to
prevent third parties from infringing upon or misappropriating our intellectual property. An adverse result in any litigation
proceeding could put our patents, as well as any patents that may issue in the future from our pending patent applications, at
risk of being invalidated, held unenforceable or interpreted narrowly. Furthermore, because of the substantial amount of discovery
required in connection with intellectual property litigation, there is a risk that some of our confidential information could
be compromised by disclosure during this type of litigation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
patent litigation in the U.S., defendant counterclaims in district courts or in the patent trademark and appeal board (PTAB) alleging
invalidity or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity
or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the U.S. or abroad,
even outside the context of litigation. Such mechanisms include ex parte re-examination, inter partes review, post-grant review,
derivation and equivalent proceedings in non-U.S. jurisdictions, such as opposition proceedings. Such proceedings could result
in revocation or amendment to our patents in such a way that they no longer cover and protect our drug candidates. The outcome
following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity of our patents, for
example, we cannot be certain that there is no invalidating prior art of which we, our patent counsel, and the patent examiner
were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we
would lose at least part, and perhaps all, of the patent protection on our drug candidates. Such a loss of patent protection could
have a material adverse impact on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to prevent misappropriation of our trade secrets or confidential information, particularly in countries where
the laws may not protect those rights as fully as in the U.S. Furthermore, because of the substantial amount of discovery required
in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised
by disclosure during this type of litigation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are sued for infringing the intellectual property rights of third parties, such litigation could be costly and time consuming
and could prevent or delay us from developing or commercializing our drug candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends in part on our avoiding infringement of the patents and other intellectual property rights of third
parties. We are aware of other issued patents belonging to third parties that exist in fields in which we are developing our drug
candidates. There may also be third-party patents or patent applications of which we are currently unaware, and given the dynamic
area in which we operate, additional patents are likely to be issued that relate to some aspects of our business. There is a substantial
amount of litigation and other claims and proceedings involving patent and other intellectual property rights in the biotechnology
and pharmaceutical industries generally. As the biotechnology and pharmaceutical industries expand and more patents are issued,
the risk increases that our drug candidates may give rise to claims of infringement of the patent rights of others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
parties may assert that we are using technology in violation of their patent or other proprietary rights. Defense of these claims,
regardless of their merit, could involve substantial litigation expense and divert our technical personnel, management personnel,
or both from their normal responsibilities. If third parties bring successful claims against us for infringement of their intellectual
property rights, we may be subject to injunctive or other equitable relief, which could prevent us from developing and commercializing
one or more of our drug candidates. We may also have to pay substantial damages, including treble damages and attorneys&rsquo;
fees in the case of willful infringement, or redesign our infringing drug candidates, which may be impossible or require substantial
time and cost. In the event of an adverse result in any such litigation, or even in the absence of litigation, we may need to
obtain licenses from third parties to advance our research or allow commercialization of our drug candidates. Any such license
might not be available on reasonable terms or at all. In the event that we are unable to obtain such a license, we would be unable
to further develop and commercialize one or more of our drug candidates, which could harm our business significantly. We may also
elect to enter into license agreements in order to settle patent infringement claims or to resolve disputes prior to litigation,
and any such license agreements may require us to pay royalties and other fees that could significantly harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Intellectual property litigation
may lead to unfavorable publicity that harms our reputation and increases our operating losses, causing the market price of our
Common Stock to decline.</I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the course of any intellectual property litigation, there could be public announcements of the results of hearings, motions or
other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could
have a substantial adverse effect on the market price of the ordinary shares. Such litigation or proceedings could substantially
increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or
distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings.
Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because
of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other
proceedings could have a material adverse effect on our ability to compete in the marketplace.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other
requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance
with these requirements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
maintenance fees on any issued patent are due to be paid to the USPTO and most foreign jurisdictions either annually or in several
stages over the lifetime of the patent. The USPTO and various non-U.S. governmental patent agencies require compliance with a
number of procedural, documentary, fee payment, and other similar provisions during the patent application process. Although an
inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules,
there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting
in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment
or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment
of fees, and failure to properly legalize and submit formal documents. In any such event, our competitors might be able to enter
the market, which would have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we do not obtain patent term extension and data exclusivity for any drug candidates it may develop, our business may be materially
harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depending
upon the timing, duration, and specifics of any FDA marketing approval of any drug candidates we may develop, one or more of our
U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action
of 1984, or Hatch Waxman Amendments. The Hatch Waxman Amendments permit a patent extension term of up to five years as compensation
for patent term lost during clinical trials and the FDA regulatory review process. A comparable extension right may exist in other
foreign jurisdictions as well. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&nbsp;years
from the date of drug approval, only one patent may be extended and only those claims covering the approved drug, a method for
using it, or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example,
failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines,
failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the
applicable time period or the scope of patent protection afforded could be less than we request. In addition, no patent term extension
system has been established in the PRC beyond the new pilot program, and implementation of the pilot program may not occur quickly.
As a result, the patents we have in the PRC are not yet eligible to be extended for patent term lost during clinical trials and
the regulatory review process. If we are unable to obtain patent term extension or term of any such extension is less than we
request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial
condition, results of operations, and prospects could be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes
in patent law could diminish the value of patents in general, thereby impairing our ability to protect our drug candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The U.S. has recently
enacted and is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme court rulings have narrowed the
scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In
addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created
uncertainty with respect to the value of patents once obtained, if any. Depending on decisions by the U.S. Congress, the federal
courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability
to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. There could be similar
changes in the laws of foreign jurisdictions that may impact the value of our patent rights or other intellectual property rights.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to our
issued patents and pending patent applications, we rely on trade secrets, including unpatented know-how, technology, and other
proprietary information, to maintain our competitive position and to protect our drug candidates. We seek to protect these trade
secrets, in part, by entering into non-disclosure and confidentiality agreements with parties that have access to them, such as
our employees, corporate collaborators, outside scientific collaborators, sponsored researchers, consultants, advisors and other
third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants.
However, any of these parties may breach such agreements and disclose our proprietary information, and we may not be able to obtain
adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be
difficult, expensive, time-consuming, and the outcome is unpredictable. If any of our trade secrets were to be lawfully obtained
or independently developed by a competitor, we would have no right to prevent them from using that technology or information to
compete with us and our competitive position would be harmed.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject to claims that our employees have wrongfully used or disclosed the alleged trade secrets of their former employers.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our employees, including our senior management, were previously employed at other biotechnology or pharmaceutical companies,
including our competitors or potential competitors. Some of these employees, including each member of our senior management, executed
proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try
to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject
to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary
information, of any such employee&rsquo;s former employer. we are not aware of any threatened or pending claims related to these
matters or concerning the agreements with our senior management, but in the future litigation may be necessary to defend against
such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual
property rights, or personnel. Even if we are successful in defending against such claims, litigation could result in substantial
costs and be a distraction to management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Intellectual
property rights do not necessarily protect us from all potential threats to our competitive advantages.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have
limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples
are illustrative:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
                                         may be able to make compounds that are similar to our drug candidates but that are not
                                         covered by the claims of the patents that we own or may in the future exclusively license;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         might not have been the first to make the inventions covered by the issued patents or
                                         pending patent applications that it owns or may in the future exclusively license, which
                                         could result in the patent applications not issuing or being invalidated after issuing;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         might not have been the first to file patent applications covering certain of our inventions,
                                         which could prevent the issuance of the patent applications or cause them to be invalidated
                                         after issuance;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
                                         may independently develop similar or alternative technologies or duplicate any of our
                                         technologies without infringing our intellectual property rights;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
                                         is possible that our pending patent applications will not lead to issued patents;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issued
                                         patents that we own or have exclusively licensed may not provide it with any competitive
                                         advantages, or may be held invalid or unenforceable, as a result of legal challenges
                                         by our competitors;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         may obtain patents for certain drug candidates many years before it receives NDA approval
                                         for these drugs, and because patents have a limited life, which may begin to run prior
                                         to the commercial sale of the related drugs, limiting the commercial value of our patents;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         competitors might conduct research and development activities in countries where we does
                                         not have patent rights and then use the information learned from such activities to develop
                                         competitive drugs for commercialization in our major markets;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         may fail to develop additional proprietary technologies that are patentable;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         may fail to apply for or obtain adequate intellectual property protection in all the
                                         jurisdictions in which it operates; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         patents of others may have an adverse effect on our business, for example by preventing
                                         we from commercializing one or more of our drug candidates for one or more indications.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                         of the aforementioned threats to our competitive advantage could have a material adverse
                                         effect on our business.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to the Reverse Recapitalization
and Integration of Businesses</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will incur significant increased expenses and administrative burdens as a public company, which could have an adverse effect on
our business, financial condition and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a newly public company, we will face increased legal, accounting, administrative and other costs and expenses as a public company
that we did not incur as a private company. The Sarbanes-Oxley Act of 2002 (the &ldquo;Sarbanes-Oxley Act&rdquo;), including the
requirements of Section&nbsp;404, as well as rules and regulations subsequently implemented by the SEC, the Dodd-Frank Wall Street
Reform and Consumer Protection Act of 2010 and the rules and regulations promulgated and to be promulgated thereunder, the PCAOB
and the securities exchanges, impose additional reporting and other obligations on public companies. Compliance with public company
requirements will increase costs and make certain activities more time-consuming. A number of those requirements will require
us to carry out activities we have not done previously. In addition, additional expenses associated with SEC reporting requirements
will be incurred. Furthermore, if any issues in complying with those requirements are identified (for example, if the auditors
identify a material weakness or significant deficiency in the internal control over financial reporting), we could incur additional
costs rectifying those issues, and the existence of those issues could adversely affect our reputation or investor perceptions
of it. It may also be more expensive to obtain director and officer liability insurance. Risks associated with our status as a
public company may make it more difficult to attract and retain qualified persons to serve on the board of directors or as executive
officers. The additional reporting and other obligations imposed by these rules and regulations will increase legal and financial
compliance costs and the costs of related legal, accounting and administrative activities. These increased costs will require
us to divert a significant amount of money that could otherwise be used to expand the business and achieve strategic objectives.
Advocacy efforts by shareholders and third parties may also prompt additional changes in governance and reporting requirements,
which could further increase costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
qualify as an emerging growth company within the meaning of the Securities Act, and if we take advantage of certain exemptions
from disclosure requirements available to emerging growth companies, it could make our securities less attractive to investors
and may make it more difficult to compare our performance to the performance of other public companies.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We qualify as an &ldquo;emerging
growth company&rdquo; as defined in Section&nbsp;2(a)(19) of the Securities Act, as modified by the JOBS Act. As such, we are eligible
for and intend to take advantage of certain exemptions from various reporting requirements applicable to other public companies
that are not emerging growth companies for as long as we continue to be an emerging growth company, including (i)&nbsp;the exemption
from the auditor attestation requirements with respect to internal control over financial reporting under Section&nbsp;404(b) of
the Sarbanes-Oxley Act, (ii)&nbsp;the exemptions from say-on-pay, say-on-frequency and say-on-golden parachute voting requirements
and (iii)&nbsp;reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We
will remain an emerging growth company until the earliest of (i)&nbsp;the last day of the fiscal year in which the market value
of the shares of our Common Stock that are held by non-affiliates exceeds $700 million as of June 30 of that fiscal year, (ii)&nbsp;the
last day of the fiscal year in which we have total annual gross revenue of $1.07 billion or more during such fiscal year, (iii)&nbsp;the
date on which we have issued more than $1 billion in non-convertible debt in the prior three-year period or (iv)&nbsp;the last
day of the fiscal year following the fifth anniversary of the date of the first sale of common stocks in TOTA&rsquo;s IPO.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards
apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting
standards that have different effective dates for public and private companies until the earlier of the date we (i)&nbsp;are no
longer an emerging growth company or (ii)&nbsp;affirmatively and irrevocably opt out of the extended transition period provided
in the JOBS Act. As a result, we will not be subject to the same new or revised accounting standards as other public companies
that are not emerging growth companies and our financial statements may not be comparable to other public companies that comply
with new or revised accounting pronouncements as of public company effective dates. We may choose to early adopt any new or revised
accounting standards whenever such early adoption is permitted for private companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
even after we no longer qualify as an emerging growth company, we may still qualify as a &ldquo;smaller reporting company,&rdquo;
which would allow us to take advantage of many of the same exemptions from disclosure requirements, including reduced disclosure
obligations regarding executive compensation in our periodic reports and proxy statements. In addition, if we are a smaller reporting
company with less than $100 million in annual revenue, we would not be required to comply with the auditor attestation requirements
of Section&nbsp;404 of the Sarbanes-Oxley Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot predict if investors will find our common shares less attractive because we may rely on these exemptions. If some investors
find our common shares less attractive as a result, there may be a less of an active trading market for our common shares and
our share price may be more volatile.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Provisions in our amended and restated
certificate of incorporation and amended and restated bylaws that went into effect upon the consummation of the Reverse Recapitalization
could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our Common Stock.</I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provisions in our amended
and restated certificate of incorporation and amended and restated bylaws may discourage, delay or prevent a merger, acquisition
or other change in control that shareholders may consider favorable, including transactions in which shareholders might otherwise
receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future
for shares of our Common Stock, thereby depressing the market price of our Common Stock. Such provisions including the following:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                         classified board of directors with three-year&nbsp;staggered terms, which could delay
                                         the ability of shareholders to change the membership of a majority of our board of directors;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         ability of our board of directors to issue shares of preferred stock and to determine
                                         the price and other terms of those shares, including preferences and voting rights, without
                                         shareholder approval, which could be used to significantly dilute the ownership of a
                                         hostile acquiror;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         requirement for the affirmative vote of holders of at least 66&#8532;% of the voting
                                         power of all of the then-outstanding&nbsp;shares of the voting stock, voting together
                                         as a single class, to amend the provisions of our amended and restated certificate of
                                         incorporation or our amended and restated bylaws, which may inhibit the ability of an
                                         acquiror to effect such amendments to facilitate an unsolicited takeover attempt;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         exclusive right of our board of directors to elect a director to fill a vacancy created
                                         by the expansion of our board of directors or the resignation, death or removal of a
                                         director, which prevents shareholders from being able to fill vacancies on our board
                                         of directors for a period of time; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         requirement that a special meeting of shareholders may be called only by the board of
                                         directors, the chairman of our board of directors or our Chief Executive Officer, which
                                         could delay the ability of our shareholders to force consideration of a proposal or to
                                         take action, including the removal of directors.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These and other provisions
in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for shareholders
or potential acquirors to obtain control of our board of directors or initiate actions that are opposed by our then-current&nbsp;board
of directors, including the ability to delay or impede a merger, tender offer or proxy contest. The existence of these provisions
could negatively affect the price of our Common Stock and limit opportunities for shareholders to realize value in a corporate
transaction.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
can be no assurance that we will be able to comply with the continued listing standards of Nasdaq.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">If
Nasdaq delists our shares of Common Stock or warrants from trading on its exchange for failure to meet Nasdaq&rsquo;s listing
standards, we and our shareholders could face significant material adverse consequences including:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                         limited availability of market quotations for our securities;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
                                         liquidity for our securities;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">a determination that our Common Stock is a &ldquo;penny stock&rdquo;
which will require brokers trading in our Common Stock to adhere to more stringent rules and possibly result in a reduced level
of trading activity in the secondary trading market for our securities;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                         limited amount of news and analyst coverage; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                         decreased ability to issue additional securities or obtain additional financing in the
                                         future.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The price of our Common Stock and
warrants may be volatile.</I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
stock markets in general and the markets for biotechnology stocks have experienced extreme volatility. The market for the common
stock of smaller companies such as ours is characterized by significant price volatility when compared to the shares of larger,
more established companies that trade on a national securities exchange and have large public floats, and our share price is more
volatile than the shares of such larger, more established companies for the indefinite future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The
price of our Common Stock and warrants may fluctuate due to a variety of factors, including:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                         in the industries in which we operate;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">variations
                                         in our operating performance and the performance of our competitors in general;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">material
                                         and adverse impact of the COVID-19 pandemic on the markets and the broader global economy;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
                                         or anticipated fluctuations in our quarterly or annual operating results;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">publication
                                         of research reports by securities analysts about us or our competitors or our industry,
                                         such as occurred in February&nbsp;2021;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         public&rsquo;s reaction to our press releases, our other public announcements and our
                                         filings with the SEC;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         failure or the failure of our competitors to meet analysts&rsquo; projections or guidance
                                         that we or our competitors may give to the market;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
                                         and departures of key personnel;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                         in laws and regulations affecting our business;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">commencement
                                         of, or involvement in, litigation involving us;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                         in our capital structure, such as future issuances of securities or the incurrence of
                                         additional debt;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the volume of shares of our Common Stock available for public
sale; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
                                         economic and political conditions such as recessions, interest rates, fuel prices, foreign
                                         currency fluctuations, international tariffs, social, political and economic risks, pandemics
                                         and acts of war or terrorism.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
market and industry factors may materially reduce the market price of our Common Stock and our warrants regardless of our operating
performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Future offerings of debt or equity
securities by us may adversely affect the market price of our Common Stock.</I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In
the future, we may attempt to obtain financing or to further increase our capital resources by issuing additional shares of our
Common Stock or offering debt or other equity securities, including commercial paper, medium-term notes, senior or subordinated
notes, debt securities convertible into equity or shares of preferred stock. Future acquisitions could require substantial additional
capital in excess of cash from operations. We would expect to obtain the capital required for acquisitions through a combination
of additional issuances of equity, corporate indebtedness and/or cash from operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Issuing additional
shares of our Common Stock or other equity securities or securities convertible into equity may dilute the economic and voting
rights of our existing shareholders or reduce the market price of our Common Stock or both. Upon liquidation, holders of such debt
securities and preferred shares, if issued, and lenders with respect to other borrowings would receive a distribution of our available
assets prior to the holders of our Common Stock. Debt securities convertible into equity could be subject to adjustments in the
conversion ratio pursuant to which certain events may increase the number of equity securities issuable upon conversion. Preferred
shares, if issued, could have a preference with respect to liquidating distributions or a preference with respect to dividend payments
that could limit our ability to pay dividends to the holders of our Common Stock. Our decision to issue securities in any future
offering will depend on market conditions and other factors beyond our control, which may adversely affect the amount, timing and
nature of our future offerings.</P>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_004"></A>ITEM
1B. UNRESOLVED STAFF COMMENTS</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_005"></A>ITEM
2. PROPERTIES</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">To date, we do not have any owned properties. We have leased
a number of properties from independent third parties in the United&nbsp;States. We utilize our Salt Lake City location for our
headquarters functions including finance, clinical development, clinical operations, translational medicine, and business operations.
We lease property in North East, Maryland, the United&nbsp;States for our manufacturing and R&amp;D activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary sets forth the details of our leased properties:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EOS
at Millrock Park, LLC (leased Salt Lake City, Utah offices) for approximately&nbsp;5200 square feet, expiring April&nbsp;2027
with an option to extend thereafter.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upper
Chesapeake Flex One, LLC (leased North East, Maryland facility) for approximately 21,000 square feet, expiring October&nbsp;2026
with an option to extend thereafter.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_006"></A>ITEM
3. LEGAL PROCEEDINGS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be subject to legal proceedings, investigations and claims incidental to the conduct of our business from time to time. We
are not currently a party to any material litigation or other legal proceedings brought against us. We are also not aware of any
legal proceeding, investigation or claim, or other legal exposure that has a more than remote possibility of having a material
adverse effect on our business, financial condition or results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_007"></A>ITEM
4. MINE SAFETY DISCLOSURES</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_008"></A>PART
II</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_009"></A>ITEM
5. MARKET FOR REGISTRANT&rsquo;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shares of our Common
Stock and warrants began trading on Nasdaq under the symbol &ldquo;CLNN,&rdquo; and &ldquo;CLNNW,&rdquo; respectively, on December
31, 2020. We have not paid any cash dividends on our shares of Common Stock to date. Historical market price information regarding
our Common Stock is not provided because, as of the date of this Annual Report, there has been no established public market for
either our Common Stock or warrants for a full quarterly period or any interim period for which financial statements are included,
or required to be included, in this Annual Report.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is the present intention of our board of directors to retain all earnings, if any, for use in our business operations and, accordingly,
our board does not anticipate declaring any dividends in the foreseeable future. The payment of cash dividends in the future will
be dependent upon our revenues and earnings, if any, capital requirements and general financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Holders
of Record</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify">As of March 25, 2021, there were 59,526,171 issued and outstanding
shares of our Common Stock held by 189 stockholders of record. The number of record holders was determined from the records of
our transfer agent and does not include beneficial owners of shares of Common Stock whose shares are held in the names of various
security brokers, dealers, and registered clearing agencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Sales of Unregistered Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><B><I>PIPE Investment</I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company entered into
subscription agreements with various investors for the private placement of Common Stock (the &ldquo;Private Placement&rdquo;),
all of which closed shortly before the closing of the Reverse Recapitalization. Under the Private Placement, 2,239,500 shares of
Common Stock (the &ldquo;PIPE Shares&rdquo;) were sold, resulting in net proceeds of $22.2 million. Pursuant to the subscription
agreements, investors in the Private Placement also received warrants to purchase a number of shares equal to one-half (1/2) of
the number of PIPE Shares, totaling 1,119,750 shares of PubCo Common Stock, at an exercise price of $0.01 per share for each of
the PIPE Shares (the &ldquo;PIPE Warrants&rdquo;), subject to a 180-day holding period. On February 16, 2021, the Company filed
a registration statement on Form S-1 to register the PIPE Shares and the Common Stock underlying the PIPE Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Plan-Related Issuances</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify">Since January 1, 2018, we granted to our employees, consultants,
and other service providers options to purchase an aggregate of 2,259,788 shares of our common stock under our 2014 Stock Plan
(&ldquo;2014 Plan&rdquo;), at exercise prices ranging from $0.7918 to $7.99 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Between August 23, 2018 and August 31, 2018, we issued and sold
to an investor warrants to purchase an aggregate of 399,690 shares of our Series C preferred stock, for an exercise price of $0.0007
per share. We received aggregate consideration of $288.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Preferred Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Between August 23,
2018 and July 31, 2019, we issued and sold to investors an aggregate of 7,264,519 shares of our Series C preferred stock for prices
ranging from $0.0007 to $4.1699 per share. We received aggregate consideration of $28,175,545.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Between August 10,
2020 and November 18, 2020, we issued and sold to investors an aggregate of 9,394,057 shares of our Series D preferred stock for
prices ranging from $4.1418 to $4.6018 per share. We received aggregate consideration of $42,540,558.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
of Proceeds</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Purchases
of Equity Securities by the Issuer and Affiliated Purchasers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_010"></A>ITEM
6. SELECTED FINANCIAL DATA</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_011"></A>ITEM
7. MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>The following discussion
and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial
statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion and other parts of this Annual
Report on Form&nbsp;10-K contain forward-looking statements reflecting our current expectations, estimates and assumptions concerning
events and financial trends that may affect our future operating results or financial position. Actual results and the timing of
events may differ materially from those contained in these forward-looking statements due to a number of factors, including those
discussed in the sections titled &ldquo;Risk Factors&rdquo; and &ldquo;Cautionary Note Regarding Forward-Looking Statements&rdquo;
appearing elsewhere in this Annual Report on Form 10-K. Unless the context otherwise requires, for purposes of this section, the
terms &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;the Company&rdquo; or &ldquo;our&rdquo; are intended to mean the business and
operations of Clene Inc. and its consolidated subsidiaries.</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Business
Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel, clean-surfaced
nano (CSN) therapeutics. CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystalline
form, possess unusually high, unique catalytic activities not present in those same elements in bulk form. These nanocatalytic
activities drive, support, and maintain beneficial metabolic and energetic intercellular reactions within diseased, stressed,
and damaged cells.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our patent-protected,
proprietary position affords us the potential to develop a broad and deep pipeline of novel&nbsp;CSN therapeutics to address a
range of diseases with high impact on human health. We began in 2013 by innovating an electrochemistry drug development platform
that draws from advances in nanotechnology, plasma and quantum physics, material science, and biochemistry. Our platform process
results in nanocrystals with faceted structures and surfaces that are free of the chemical surface modifications that accompany
other production methods. Many traditional methods of nanoparticle synthesis involve the unavoidable deposition of potentially
toxic organic residues and stabilizing surfactants on the particle surfaces. Synthesizing stable nanocrystals that are both nontoxic
and highly catalytic has overcome this significant hurdle in harnessing transition metal catalytic activity for human therapeutic
use.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clean-surfaced nanocrystals exhibit catalytic activities many fold higher than multiple other commercially available nanoparticles,
produced using various techniques, that we have comparatively evaluated. We now have multiple drug assets currently in development
and/or clinical trials for applications in neurology, infectious disease, and oncology. Our development and clinical efforts are
currently focused on addressing the high unmet medical needs in two areas: first, those related to central nervous system disorders
including Multiple Sclerosis (&ldquo;<B>MS</B>&rdquo;), Parkinson&rsquo;s Disease (&ldquo;<B>PD</B>&rdquo;) and Amyotrophic Lateral
Sclerosis (&ldquo;<B>ALS</B>&rdquo;); and second, those related to the pandemic caused by COVID-19, a highly infectious viral
respiratory disease with serious and sometimes fatal co-morbidities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 30, 2020, Chelsea Worldwide, Inc., our predecessor company, consummated the previously announced business combination
(referred to as the &ldquo;<B>Reverse Recapitalization</B>&rdquo;) pursuant to a merger agreement, dated as of September 1, 2020
(the &ldquo;<B>Merger Agreement</B>&rdquo;), by and among Clene Nanomedicine, Inc. (&ldquo;<B>Clene Nanomedicine</B>&rdquo;),
Tottenham Acquisition I Limited (&ldquo;<B>Tottenham</B>&rdquo; or &ldquo;<B>TOTA</B>&rdquo;), the public entity prior to the
Reverse Recapitalization, Chelsea Worldwide Inc., a Delaware corporation and wholly owned subsidiary of Tottenham (&ldquo;<B>PubCo</B>&rdquo;),
Creative Worldwide Inc., a Delaware corporation and wholly owned subsidiary of PubCo (&ldquo;<B>Merger Sub</B>&rdquo;), and Fortis
Advisors LLC, a Delaware limited liability company as the representative of our shareholders (&ldquo;<B>Shareholders&rsquo; Representative</B>&rdquo;).
Prior to the Reincorporation Merger discussed below, Tottenham was incorporated in the British Virgin Islands as a blank check
company for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization
or other similar business combination with one or more businesses or entities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The
Reverse Recapitalization was effected in two steps: (i) Tottenham was reincorporated to the state of Delaware by merging with
and into PubCo (the &ldquo;<B>Reincorporation Merger</B>&rdquo;); (ii) promptly following the Reincorporation Merger, Merger Sub
was merged with and into Clene Nanomedicine, resulting in Clene Nanomedicine being a wholly owned subsidiary of PubCo (the &ldquo;<B>Acquisition
Merger</B>&rdquo;). On the Closing Date, PubCo changed its name from Chelsea Worldwide Inc. to Clene Inc. and listed its shares
of common stock, par value $0.0001 per share (&ldquo;Common Stock&rdquo;) on Nasdaq under the symbol &ldquo;CLNN.&rdquo; As a
result of the Reverse Recapitalization, Clene Nanomedicine became a wholly owned direct subsidiary of Clene Inc. For periods prior
to the closing of the Reverse Recapitalization on December 30, 2020, the disclosure in Management&rsquo;s Discussion and Analysis
of Financial Condition and Results of Operations has been updated to give effect to the Reverse Recapitalization.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 16, 2021,
we filed a registration statement on Form S-1 to register 4,541,481 shares of Common Stock underlying outstanding warrants that
we had previously issued. The SEC has not yet declared this registration statement to be effective. We will receive an aggregate
gross proceed of $30.7 million if all of these warrants are exercised. In addition, the registration statement on Form S-1 will
register the sale by certain selling stockholders of 23,251,553 shares of our Common Stock. We will not receive any proceeds from
the sales by the selling shareholders. In conjunction with the preparation of the registration statement on Form S-1, we incurred
offering costs of $27,000, which will be recognized as an expense within general and administrative expenses on consolidated statement
of operations in the first quarter of 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have no drugs approved by the US Food and Drug
Administration (FDA) for commercial sale and have not generated any revenue from drug sales. We have never been profitable and
have incurred operating losses in each year since inception. We began supplying low dose dietary supplements to 4Life, LLC, one
of our shareholders, and had minimal direct sales of our rMetx<SUP>&trade;</SUP> ZnAg Immune Boost dietary supplement product.
Our total operating losses were $20.2 million and $16.3 million for the years ended December 31, 2020 and 2019, respectively. Substantially
all of our operating losses resulted from research and development expenses and administrative expenses. As of December 31, 2020
we had an accumulated deficit of $153.6 million.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue investing in product development, sales and marketing and customer support for our products and expect to incur
additional losses in the future to fund our operations and conduct product research and development. We also recognize the need
to raise additional capital to fully implement our business plan. The long-term continuation of our business plan is dependent
upon the generation of sufficient revenues from our products to offset expenses and capital expenditures. In the event that we
do not generate sufficient revenues and are unable to obtain funding, we will be forced to delay, reduce, or eliminate some or
all of our research and development programs, product portfolio expansion, commercialization efforts or capital expenditures,
which could adversely affect our business prospects, ability to meet long-term liquidity needs or we may be unable to continue
operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Impact
of the COVID-19 Coronavirus Pandemic</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The COVID-19 pandemic,
which began in December&nbsp;2019 and has spread worldwide, has caused many governments to implement measures to slow the spread
of the outbreak. The outbreak and government measures taken in response have had a significant impact, both direct and indirect,
on businesses and commerce, as worker shortages have occurred, supply chains have been disrupted, and facilities and production
have been suspended. The future progression of the pandemic and its effects on our business and operations remain uncertain. The
COVID-19 pandemic may affect our ability to initiate and complete preclinical studies, delay the initiation of future clinical
trials, disrupt regulatory activities, or have other adverse effects on our business and operations. In particular, we and our
clinical research organizations (&ldquo;CROs&rdquo;) may face disruptions that may affect our ability to initiate and complete
preclinical studies, cause manufacturing disruptions, or create delays at clinical trial sites. The pandemic has already caused
significant disruptions in the financial markets, and may continue to cause such disruptions, which could impact our ability to
raise additional funds to support our operations. Moreover, the pandemic has significantly impacted economies worldwide and could
result in adverse effects on our business and operations.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are monitoring the
potential impact of the COVID-19 pandemic on our business and financial statements. While the COVID-19 pandemic has led to various
research restrictions and paused certain of our clinical trials, these impacts have been temporary and to date we have not experienced
material business disruptions or incurred impairment losses in the carrying values of our assets as a result of the pandemic. We
are not aware of any specific related event or circumstance that would require us to revise the estimates reflected in our financial
statements. The extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and
financial condition, including planned and future clinical trials and research and development costs, will depend on future developments
that are highly uncertain, including as a result of new information that may emerge concerning COVID-19, the actions taken to contain
or treat it, and the duration and intensity of the related effects.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reverse
Recapitalization with Tottenham and Clene Nanomedicine</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 30, 2020, we completed the previously announced Reverse Recapitalization, pursuant to which Tottenham was reincorporated
and merged with and into PubCo with PubCo surviving the merger in connection with the Reincorporation Merger and the Merger Sub
was merged with and into Clene Nanomedicine, resulting in Clene Nanomedicine being a wholly owned subsidiary of PubCo. On the
closing of the Reverse Recapitalization, PubCo changed its name from Chelsea Worldwide Inc. to Clene Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the closing of the
Reverse Recapitalization, Clene Inc. acquired 100% of the issued and outstanding Clene Nanomedicine common stock, in exchange for
54,339,012 shares of Clene Inc. Common Stock issued to the Clene Nanomedicine common shareholders, among which 2,716,958 shares
of the Clene Inc. Common Stock are to be issued and held in escrow to satisfy any indemnification obligations incurred under the
Merger Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the closing of the
Reverse Recapitalization, each stock option of Clene Nanomedicine common stock was cancelled and the holders thereof in exchange
received 0.1320 newly issued stock options of our Common Stock, which is 95% of the exchange ratio determined in the Merger Agreement.
Pursuant to the Merger Agreement, we issued 370,101 of restricted stock units (&ldquo;RSUs&rdquo;) to the option holders which
complements the 5% closing payment shares held in escrow for Clene Nanomedicine common shareholders discussed above. In addition,
we issued 1,136,961 RSUs to option holders to complement the earn-out payments that would contingently be issued to certain current
Clene Nanomedicine&rsquo;s shareholders upon the achievement of milestones. See &ldquo;Earn-out Share&rdquo; for the milestones
detail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Immediately after giving
effect to the Reverse Recapitalization and the PIPE offering discussed in below, there were 59,526,171 shares of Common Stock issued
and outstanding, and warrants to purchase 5,566,363 shares of Common Stock issued and outstanding.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transaction was accounted for as a &ldquo;reverse recapitalization&rdquo; and Tottenham was treated as the &ldquo;acquired&rdquo;
company for accounting purposes. Accordingly, for accounting purposes, the Reverse Recapitalization was treated as the equivalent
of Clene Nanomedicine issuing shares for the net assets of Tottenham, accompanied by a recapitalization. The net assets of Tottenham
were recorded at historical costs, with no goodwill or other intangible assets recorded. Reported amounts from operations included
herein prior to the Reverse Recapitalization are those of Clene Nanomedicine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
PIPE Offering</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Prior to the completion
of the Reverse Recapitalization on December 30, 2020, we entered into subscription agreements on December 28, 2020, with various
investors (the &ldquo;<B>PIPE</B>&rdquo;). Pursuant to the subscription agreements, we issued 2,239,500 shares of our Common Stock
(the &ldquo;<B>PIPE Shares</B>&rdquo;) at a price of $10.00 per share with net proceeds of $22.2 million. The purpose of the PIPE
is to fund general corporate expenses. In addition, investors in the PIPE offering will also receive warrants to purchase a number
of shares equal to one-half (1/2) of the number of PIPE Shares, for an aggregate total of 1,119,750 shares of our Common Stock,
at an exercise price of $0.01 per share (the &ldquo;<B>PIPE Warrants</B>&rdquo;), subject to a 180-day holding period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
of Presentation and Consolidation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted
in the United States of America (&ldquo;<B>GAAP</B>&rdquo;) and include the accounts of the Company and its wholly owned subsidiaries,
Clene Nanomedicine, a subsidiary incorporated in Delaware, Clene Australia Pty Ltd (&ldquo;<B>Clene Australia</B>&rdquo;), a subsidiary
incorporated in Australia, and dOrbital, Inc., a subsidiary incorporated in Delaware, after elimination of all significant intercompany
accounts and transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Key
Factors Affecting Our Results of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
results of operations, financial condition and the period-to-period comparability of our financial results are principally affected
by the following factors:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Earn-out
Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the Reverse Recapitalization, certain of Clene Nanomedicine&rsquo;s current shareholders and Tottenham&rsquo;s former officers
and directors and the Sponsor (collectively, the &ldquo;<B>Initial Shareholders</B>&rdquo;) are entitled to receive earn-out payments
(collectively, referred to as &ldquo;<B>Earn-out Shares</B>&rdquo;) based on achieving milestones discussed below. The earn-out
payments (the &ldquo;<B>Contingent Earn-out</B>&rdquo;) have been classified as liabilities in the consolidated balance sheets
as of December 31, 2020 and will be initially measured at fair value and remeasured subsequently in each reporting period. The
change in fair value of the contingent earn-out will be recorded in the consolidated statements of operations and comprehensive
loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Clene
Nanomedicine contingent earn-out provision includes (i) Milestone 1 that is based on achieving a certain volume-weighted
average price of the shares of the Company Common Stock within three years after the closing of the Reverse Recapitalization
or the change of control price equaling or exceeding a certain price if a change of control transaction occurs within the
three years following the closing of the Reverse Recapitalization, (ii) Milestone 2 that is based on achieving a certain
volume-weighted average price of the shares of the Company Common Stock within five years after the closing of the Reverse
Recapitalization or the change of control price equaling or exceeding a certain price if a change of control transaction
occurs within the five years following the closing of the Reverse Recapitalization, and (iii) Milestone 3 that is based on
completing by December 30, 2021 a randomized placebo-controlled study for treatment of COVID-19 coronavirus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Initial Shareholders
contingent earn-out provision includes Milestone 1 and Milestone 2 listed above. Upon the consummation of the Reverse Recapitalization,
Clene Nanomedicine and the Initial Shareholders are entitled to receive up to 8,346,185 and 750,000 shares of the Company&rsquo;s
Common Stock, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The estimated fair
value of the contingent consideration was determined using a Monte Carlo simulation that simulated the future path of the Company&rsquo;s
stock price over the earn-out period. The assumptions utilized in the calculation are based on the achievement of certain stock
price milestones including projected stock price, volatility, and risk-free rate. For potential payments related to a product development
milestone, the fair value was determined based on the Company&rsquo;s expectations of achieving such a milestone and the simulated
estimated stock price on the expected date of achievement.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contingent
earn-out payments involve certain assumptions requiring significant judgment and actual results may differ from assumed and estimated
amounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The discovery and development
of novel drug candidates require a significant investment of resources over a prolonged period of time, and a core part of our
strategy is to continue making sustained investments in this area. As a result of this commitment, our pipeline of drug candidates
has been advancing and expanding, with two clinical-stage drug candidates currently being investigated.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that our research and development expenses will increase significantly due to the increase in clinical trial expenses
incurred to develop our drug candidates, expenses incurred for payments to CROs, principal investigators and clinical trial sites,
costs of materials to support our clinical trials and preclinical studies, costs associated with preclinical activities, share
awards granted to our research and development personnel and salaries for our expanding research and development personnel headcount.
Our research and development expenses are affected by the timing and advancement of our existing product pipeline as well as the
timing and quantity of new drug programs commenced.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, we have dedicated significant resources to our research and development activities. Our research and development expenses
were $15.2 million and $9.6 million, representing 74.8%, and 58.6% of our total operating expenses in 2020 and 2019, respectively.
As we continue to advance our clinical programs for our drug products, we expect our research and development expenses to increase
in absolute amounts and to continue to represent a significant percentage of our total operating expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Funding
for Our Operations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, we have dedicated substantially all of our resources to the development of our drug candidates. We have financed
our operations principally through proceeds from the issuance of preferred stock, issuance of common stock upon exercise of common
stock options, convertible promissory notes, issuances of notes payable, and the consummation of the Reverse Recapitalization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception and through the date of this Annual Report, we have funded our operations primarily with proceeds from the following
sources:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 42pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 18pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">gross
                                         proceeds of $87.2 million from sales of our preferred stock and other equity financing;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 42pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 18pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">gross
                                         proceeds of $28.1 million from borrowings under convertible promissory notes;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 42pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 18pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">gross
                                         proceeds of $0.6 million through external lenders; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 42pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 18pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">gross cash proceeds of $31.7 million through the Reverse Recapitalization
and the PIPE offering.</P></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2021, we
filed a registration statement on Form S-1 to register 4,541,481 shares of Common Stock underlying outstanding warrants. We will
receive aggregate gross proceeds of $30.7 million if all of these are exercised. In addition, we received $0.5 million from a Michael
J. Fox Foundation grant in January 2021 which provides for our preclinical research funding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have also been awarded
grants from various other organizations, including the U.S. Congressionally Directed Medical Research Program administered by the
Department of Defense, the National Multiple Sclerosis Society, and FightMND, a not-for-profit registered charity in Australia,
who together have issued us grants totaling approximately $2.6 million. We also receive indirect financial support for one of the
clinical studies in which we participate, the Healey ALS Platform Trial, administered by the Massachusetts General Hospital, which
is conducting a study of our CNM-Au8 drug candidate along with other drugs in a platform trial, at significantly lower costs to
us than we would otherwise incur if we were to conduct a comparably designed study on our own at reasonable market rates.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The net cash used in our operating activities was $18.9 million
and $13.2 million for the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020, we had cash of $59.3 million.
We expect that the cash on hand as of December 31, 2020 will be sufficient to fund our operations for a period extending beyond
twelve months from the date the consolidated financial statements are issued. We have based this estimate on assumptions that may
prove to be wrong, and we may exhaust our available capital resources sooner than we anticipate. See &ldquo;&mdash; <I>Liquidity
and Capital Resources</I>.&rdquo; We expect our expenses to increase significantly in connection with our ongoing activities, particularly
as we advance the clinical development of our clinical-stage drug products and continue research and development of our preclinical
drug products and initiate additional clinical trials of, and seek regulatory approval for, these and other future drug products.
As we continue to grow and expand, we will incur more expenses relating to regulatory compliance and sales and marketing personnel
as we prepare to commence commercialization once we obtain regulatory approval of our drug products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>General and Administrative Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our administrative
expenses consist primarily of staff costs, agency and consulting fees, utilities, rent and general office expenses, and share grants.
We recorded administrative expenses of $5.2 million and $6.8 million for the years ended December 31, 2020 and 2019, respectively.
We anticipate that our administrative expenses will further increase in future periods to support increases in our research and
development activities and as we continue to rapidly advance the clinical programs of our drug products and expect to commercialize
our products once we receive regulatory approval. These increases will likely include increased headcount, increased share compensation
charges, expanded infrastructure and increased insurance expenses. We also anticipate increasing legal, compliance, accounting
and investor and public relations expenses associated with being a public company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Grants and Government Tax Incentives</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">We received grants issued by non-government entities related
to income which have future related costs expected to be incurred and require us to comply with conditions attached to the grants.
These non-government grants related to income are recognized in profit or loss as an offset to research and development expenses
when funding has been received and related costs have been incurred. We received tax incentives from the Australian government
in the form of cash subsidies for research and development activities related to clinical trial activities conducted by our Australian
subsidiary, which are recognized as other income upon compliance with certain conditions. We recognized $0.8 million and $0.1 million
of grant funding against research and development expenses for the years ended December 31, 2020 and 2019, respectively. We recognized
$3.2 million and $0.6 million of other income for the years ended December 31, 2020 and 2019, respectively, that we classified
as Australia research and development credit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Commercialization
of Our Drug Candidates</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business and results of operations depend on our ability to commercialize our drug candidates, if approved for marketing. Our
pipeline is comprised of four drug candidates ranging from pre-clinical to late-stage clinical programs, including two drug candidates
at the clinical stage or IND stage. Although we currently do not have any drug candidates approved for commercial sale and have
not generated any revenue from drug product sales, we expect to commercialize one or more of our drug products in the coming years
as they move toward the final stages of development. While we began selling our ZnAg Immune Boost product online in May&nbsp;2020,
we anticipate revenue generated from sales of this dietary supplement will be small compared to our operating expenses as well
as the revenue we expect to generate from future sales of our drug candidates for which we are currently conducting clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Components
of Results of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Revenue</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
all our drug candidates are still at clinical stage, we did not generate any revenue for the year ended December 31, 2019. We
generated an immaterial amount of revenue for the year ended December 31, 2020, which we separate as product revenue and royalty
revenue. Product revenue is generated under our dietary supplement segment from 4Life, LLC, a related party, related to supply
agreements for the low dose mineral supplement KHC46 and a low dose zinc-silver solution, two dietary (mineral) supplements that
we began supplying during this period. We also generated minimal product revenue from sales of rMetx<SUP>&trade;</SUP> ZnAg Immune
Boost during this period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalty
revenue is paid to us by 4Life, LLC, under an exclusive and royalty-bearing license agreement relating to sales of KHC46 only.
For more details on this agreement, see <I>Item 1. Business &mdash; License Arrangements.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Operating
Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Research
and Development Expenses</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are charged to operations as incurred. We account for nonrefundable advance payments for goods and services
that will be used in future research and development activities initially as an asset and then as expenses when the goods have
been received or when the service has been performed rather than when the payment is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had research and development expenses for the years ended December 31, 2020 and 2019 of $15.2 million and $9.6 million, respectively.
Research and development expenses consist of costs incurred by us for the discovery and development of our drug candidates. Research
and development costs include payroll and personnel expenses, including salaries and related benefits and stock-based compensation
for employees engaged in research and development functions, clinical trial supplies, fees for clinical trial services, consulting
costs, and allocated overhead, including rent, equipment, utilities, depreciation, insurance, and facilities maintenance costs.
We expect our research and development expenses to increase as more of our drug candidates progress through their clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
substantially all of our research and development expenses relate to CNM-Au8, our lead asset. Drug candidates in later stages
of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily
due to per patient clinical trial site fees for larger studies, the costs of opening and monitoring clinical sites, CRO activity,
and manufacturing expenses. We expect that our research and development expenses will increase in connection with our clinical
development activities in the near term and in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trial costs, including clinical trial supplies and fees for clinical trial services, are charged to research and development expense
as incurred. Our clinical trial accrual process seeks to account for expenses resulting from obligations under contracts with
CROs, consultants, and under clinical site agreements in connection with conducting clinical trials. The financial terms of these
contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match
the periods over which materials or services are provided to us under such contracts. We reflect the appropriate trial expenses
in the consolidated financial statements by matching the appropriate expenses with the period in which services and efforts are
expended. In the event advance payments are made to a CRO, the payments will be recorded as a prepaid asset, which will be expensed
over the period of time the contracted services are performed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>General
and Administrative Expenses</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist of employee salary and benefits, share-based compensation expenses, professional fees for
legal, consulting and audit services and business development activities, facility, travel expenses, rental fees and other administrative
expenses. We expect our general and administrative expenses to increase as we continue to grow and expand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
Income (Expenses)</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income (expenses) consists of interest expenses, interest income, gains from the termination of a lease arrangement, changes in
fair value of preferred stock warrant liability, changes in fair value of derivative liability, change in fair value of contingent
earn-out, a research and development credit received from the Australian government, foreign exchange gain, loss on disposal of
assets, and loss on extinguishment of convertible notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Comparison
of the Years Ended December 31, 2020 and 2019</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our results of operations for the years ended December 31, 2020 and 2019:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-style: italic">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-style: italic; text-align: center">(in thousands)</TD><TD STYLE="font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Product revenue</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">176</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Royalty revenue</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">30</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Total revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">206</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 0.25in">Cost of revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,204</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,563</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,151</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,769</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">20,420</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">16,332</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20,214</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,332</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Other income (expenses):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(950</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(88</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Gain on termination of lease</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">51</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Change in fair value of preferred stock warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(14,615</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(361</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Change in fair value of derivative liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Change in fair value of Clene Nanomedicine contingent earn-out</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,659</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Change in fair value of Initial Shareholder contingent earn-out</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,465</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Australia research and development credit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,210</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">599</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Loss on extinguishment of convertibles notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(540</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Other income, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">34</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">27</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Total other income (expense), net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,343</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">177</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss before income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,871</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,155</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Income tax expense</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(406</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(19,277</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,155</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Other comprehensive income (loss):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Foreign currency translation adjustments</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">284</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Total other comprehensive income (loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">284</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(18,993</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(16,158</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Revenue</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We generated revenue
of $0.2 million for the year ended December 31, 2020 while no revenue was generated for 2019. $0.2 million of our revenue for the
year ended December 31, 2020 was product revenue from supply agreements with a related party for KHC46 and a low dose zinc-silver
solution, two dietary supplements that we began supplying during this period. We also generated minimal product revenue from sales
of rMetx<SUP>&trade;</SUP> ZnAg Immune Boost during this period. In addition, $30 thousand of our revenue during the same period
was royalty revenue from a license agreement with the same related party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Operating
Expenses</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cost
of Sales</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incurred cost of sales of $0.1 million for the year ended December 31, 2020 relating to production and distribution costs for
the sales of our KHC46 and low dose zinc-silver solution dietary supplement products through supply agreements we have entered
into with a related party while no cost of sales was incurred for 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research
and Development Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses were $15.2 million for the year ended December 31, 2020 compared to $9.6 million for 2019. During these
periods, substantially all of our research and development expenses were related to the development and clinical trials of CNM-Au8.
This increase of $5.6 million, or 59.0%, was primarily due to the progression of our drug candidates through the clinical development
process, including increased enrollment into the REPAIR-PD and the REPAIR-MS studies, and calendar payments due for our participation
in the Healey-ALS Platform Trial. These efforts resulted in greater associated costs and manufacturing expenses in support of
these trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General
and Administrative Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">General
and administrative expenses were $5.2 million for the year ended December 31, 2020 compared to $6.8 million for 2019. This decrease
of $1.6 million, or 23.9% was primarily due to decreased expenses relating to efforts to list our shares on an international public
exchange during 2019, which were subsequently abandoned. For the year ended December 31, 2020, we had a small increase in employee
salary and benefits, shares based-compensation expenses due to the growth of our business and professional expenses related to
fund raising activities.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Other
Income (Expenses)</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income (expenses), net for the years ended December 31, 2020 and 2019 included the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) recognized interest
expense of $1.0 million and $0.1 million, respectively, due to an increase in the fair value of the Company&rsquo;s notes payable.
As of December 31, 2020, the fair value of the Company&rsquo;s notes payable is determined based on the closing price of CLNN shares
listed on the Nasdaq.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) recognized expense
of $14.6 million and $0.4 million relating to the changes in fair value of preferred stock warrant liability, respectively. The
increase of $14.2 million in association with the changes in fair value of preferred stock warrant liability was primarily a result
of the increase in the value of outstanding warrants as the estimated value of our company and the likelihood of a liquidation
event increased due to consideration of the Reverse Recapitalization. Upon the consummation of the Reverse Recapitalization, we
determined that the warrants qualify for classification as permanent equity and we reclassified the resulting warrant liability
to additional paid-in capital. No change in fair value of preferred stock warrant liability will be recorded going forward.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iii) recognized Clene
Nanomedicine contingent earn-out liability of $64.7 million upon the closing of the Reverse Recapitalization and subsequently remeasured
the contingent earn-out liability to the fair value of $52.1 million at the reporting date. The change in fair value of our Clene
Nanomedicine contingent earn-out of $12.6 million was primarily a result of the decrease of the closing price of CLNN shares listed
on the Nasdaq for $9.01 per share on December 31, 2020 from $10.82 per share on December 30, 2020 when we recognized the Clene
Nanomedicine contingent earn-out liability at inception.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iv) recognized Initial
Shareholders contingent earn-out liability of $7.4 million upon the closing of the Reverse Recapitalization and subsequently remeasured
the contingent earn-out liability to the fair value of $5.9 million at the reporting date. The change in fair value of our Initial
Shareholders contingent earn-out of $1.5 million was primarily a result of the decrease of the closing price of CLNN shares listed
on the Nasdaq for $9.01 per share on December 31, 2020 from $10.82 per share on December 30, 2020 when we recognized the Initial
Shareholders contingent earn-out liability at inception.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(v) recognized income
of $3.2 million and $0.6 million relating to a research and development credit received from the Australian government, respectively.
We recognized Australian research and development credit in an amount equal to the qualifying expenses incurred in each period
multiplied by the applicable reimbursement percentage. The increase in research and development credit is the result of increased
research and development activities during the year ended December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(vi) recognized expense
of $0.5 million due to loss of extinguishment of convertible notes, while not recording any similar expenses in 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Comprehensive Loss</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the
foregoing, we incurred a comprehensive loss of $19.0 million for the year ended December 31, 2020 compared to a comprehensive loss
of $16.2 million for 2019.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Taxation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>United&nbsp;States</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are incorporated
in Delaware in the U.S. and subject to statutory U.S. federal corporate income tax at a rate of 21% for the years ended December
31, 2020 and 2019. We are also subject to state income tax in Utah and Maryland, at a rate of 4.95% and 8.25%, respectively, for
the years ended December 31, 2020 and 2019. We recorded a full valuation allowance against our net deferred tax assets due to the
uncertainty as to whether such assets will be realized resulting from our three-year cumulative loss position and the uncertainty
surrounding our ability to generate pre-tax income in the foreseeable future. This valuation allowance was $22.1 million and $16.8
million as of December 31, 2020 and 2019, respectively.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Australia</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our wholly owned subsidiary,
Clene Australia Pty Ltd, was established in Australia on March 5, 2018 and is subject to corporate income tax at a rate of 27.5%.
Clene Australia total income tax expense was $0.4 million for the year ended December 31, 2020. In 2019, Clene Australia had no
taxable income and therefore, no provision for income taxes was required. We recorded $3.2 million as other income in 2020 for
a refund of research and development credits pertaining to Clene Australia Pty Ltd for the 2020 and 2019 tax year. We recorded
$0.6 million as other income in 2019 for a refund of research and development credits pertaining to Clene Australia Pty Ltd for
the 2018 tax year.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JOBS
Act</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
JOBS Act permits an emerging growth company (&ldquo;<B>EGC</B>&rdquo;) such as us to take advantage of an extended transition
period to comply with new or revised accounting standards applicable to public companies. We have elected to use the extended
transition period under the JOBS Act until the earlier of the date we (1)&nbsp;are no longer an emerging growth company or (2)&nbsp;affirmatively
and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our consolidated financial statements
may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will remain an emerging
growth company until the earliest to occur of: (1)&nbsp;the last day of the fiscal year in which we have more than $1.07 billion
in annual revenue; (2)&nbsp;the date on which we are deemed to be a &ldquo;large accelerated filer,&rdquo; which would occur if
the market value of our equity securities held by non-affiliates exceeds US$700 million as of the last business day of our most
recently completed second fiscal quarter; (3)&nbsp;the date on which we have issued more than $1.0 billion in non-convertible debt
securities during the prior three-year period; and (4)&nbsp;the last day of the fiscal year ending after the fifth anniversary
of Tottenham&rsquo;s initial public offering, or August 6, 2023.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for public companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Smaller
Reporting Company Status</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a Smaller Reporting
Company (&ldquo;<B>SRC</B>&rdquo;) as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage
of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements.
We will remain a smaller reporting company until (1) the market value of our Common Stock held by non-affiliates exceeds $250 million
as of the end of the second fiscal quarter and our annual revenues exceed $100 million during the previous fiscal year, or (2)
the market value of our Common Stock held by non-affiliates exceeds $700 million as of the end of the second fiscal quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
and Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Since inception, we have
incurred annual net losses from our operations. Substantially all of our losses have resulted from the funding of our research
and development programs and general and administrative expenses associated with our operations. We incurred net losses of $19.3
million and $16.2 million for the years ended December 31, 2020 and 2019, respectively. Our loss from operations was $20.2 million
and $16.3 million for the years ended December 31, 2020 and 2019, respectively. We have financed our operations principally through
proceeds from the sale of preferred stock, the sale of preferred stock warrants and the sale of convertible notes that have converted
into shares of preferred stock, and through the funds we raised from the consummation of the Reverse Recapitalization and the PIPE
offering. During the years ended December 31, 2020 and 2019, we raised an aggregate of $69.5 million and $5.5 million, respectively,
consisting of net proceeds from issuances of preferred stock, common stock upon exercise of common stock options, convertible promissory
notes, notes payable, the Reverse Recapitalization and the PIPE offering. In February 2021, we filed a registration statement on
Form S-1 to register 4,541,481 shares of Common Stock underlying outstanding warrants. We will receive aggregate gross proceeds
of $30.7 million if all of these are exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The net cash used in
our operating activities was $18.9 million and $13.2 million for the years ended December 31, 2020 and 2019, respectively. As of
December 31, 2020, we had cash of $59.3 million. We expect that the cash on hand as of December 31, 2020 will be sufficient to
fund our operations for a period extending beyond twelve months from the date the consolidated financial statements are issued.
We have based this estimate on assumptions that may prove to be wrong, and we may exhaust our available capital resources sooner
than we anticipate. We expect our expenses to increase significantly in connection with our ongoing activities, particularly as
we advance the clinical development of our clinical-stage drug products and continue research and development of our preclinical
drug products and initiate additional clinical trials of, and seek regulatory approval for, these and other future drug products.
As we continue to grow and expand, we will incur more expenses relating to regulatory compliance and sales and marketing personnel
as we prepare to commence commercialization once we obtain regulatory approval of our drug products.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to continue
as a going concern may require obtaining additional funding to finance operations. As part of our ongoing business plans, we will
continue seeking funding through equity financing and may seek debt financing or other capital sources. We may not be able to obtain
financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of our shareholders.
If we are unable to raise capital when needed or on acceptable terms, we would be forced to delay, reduce or eliminate research
and development programs and commercialization efforts.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information regarding our cash flows for relevant periods:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.25in; padding-left: 0.25in; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.25in; padding-left: 0.25in; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.25in; padding-left: 0.25in; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-style: italic; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-style: italic; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(in
    thousands)</FONT></TD><TD STYLE="font-style: italic; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.25in; padding-left: 0.25in; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    cash used in operating activities</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(18,929</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(13,197</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.25in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    cash used in investing activities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(387</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(294</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.25in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    cash provided by financing activities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">69,534</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,503</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    effect of foreign exchange rate changes</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">269</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    increase (decrease) in cash</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif">$<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">50,487</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif">$<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(7,989</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Use
of Funds</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our primary use of
cash in all periods presented was to fund our research and development, regulatory and other clinical trial costs, and related
supporting administration. Our prepaid expenses and other current assets, accounts payable and accrued expense balances in all
periods presented were affected by the timing of vendor invoicing and payments, and impacted the cash provided by, or used in,
operations. We have no commitments for capital expenditures as of the end
of the latest fiscal period.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Operating
Activities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities was $18.9 million of cash for the year ended December 31, 2020, which resulted from a net loss of $19.3 million, adjusted
for (i)&nbsp;non-cash items of $3.7 million, which primarily consisted of depreciation expense of $1.0 million, stock-based compensation
expenses of $0.8 million, changes in the fair value of preferred stock warrant liability of $14.6 million, changes in fair value
of the Clene Nanomedicine contingent earn-out of $12.6 million, changes in fair value of the Initial Shareholders contingent earn-out
of $1.5 million, loss on extinguishment of convertible notes of $0.5 million and increase in interest accrued on notes payable
and accretion of debt discount of $0.9 million, and (ii)&nbsp;a net decrease in operating assets and liabilities of $3.3 million.
The net decrease in operating assets and liabilities was primarily attributable to an increase in inventory of $0.2 million, an
increase in prepaid expenses and other current assets of $2.9 million due to the increase in Australia research and development
credit receivable and prepayments to CROs and other vendors, $0.3 million decrease in accounts payable, $0.2 million increase in
income tax payable related to the Australian entity, $0.3 million decrease in accrued liabilities due to the timing of vendor invoicing
and payments, $0.1 million decrease in payable to related parties, $0.3 million increase in deferred income tax, $0.1 million increase
in deferred revenue from related parties, and $0.1 million decrease in operating lease obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $13.2 million of cash for the year ended December 31, 2019, which resulted from a net loss
of $16.2 million, adjusted for (i)&nbsp;non-cash items of $1.8 million, which primarily consisted of depreciation of $0.8 million,
stock-based compensation expenses of $0.4 million and changes in fair value of preferred stock warrant liability of $0.4 million,
and (ii)&nbsp;a net increase in operating assets and liabilities of $1.2 million. The net increase in operating assets and liabilities
was primarily attributable to (1)&nbsp;an increase in accrued liabilities of $1.9 million relating to accrued professional fees,
(2)&nbsp;a decrease in prepaid expenses and other current assets of $0.4 million relating to prepayments for clinical studies,
and (3)&nbsp;a decrease in payment of operating lease obligations of $0.2 million relating to our leased office space.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Investing
Activities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities was $0.4 million and $0.3 million for the years ended December 31, 2020 and 2019, respectively,
which in each instance was related to purchases of property and equipment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Financing
Activities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by financing activities was $69.5 million
for the year ended December 31, 2020, which primarily resulted from (i) funds raised in connection with the Reverse Recapitalization,
net of transaction costs, of $5.6 million, (ii) net proceeds from the PIPE transaction of $22.2 million, (iii) proceeds from the
issuance of Series D preferred Stock, net of issuance costs, of $35.1 million, (iv)&nbsp;proceeds from the issuance of convertible
notes payable of $6.1 million, (v)&nbsp;proceeds from the issuance of notes payable of $0.6 million and (vi) proceeds from issuance
of common stock upon exercise of common stock options of $0.1 million partially offset by payments on our finance lease obligations
of $0.2 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $5.5 million for the year ended December 31, 2019, which primarily resulted from (i)&nbsp;proceeds
from issuance of Series C Preferred Stock, net of issuance costs, of $8.1 million and (ii)&nbsp;proceeds from the issuance of
notes payable of $0.6 million and was partially offset by (a)&nbsp;payments of notes payable of $3.0 million and (b)&nbsp;payments
of finance lease obligations of $0.2 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Debt
Obligations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February&nbsp;2019,
we entered into a loan agreement with the Department of Housing and Community Development, a principal department of the State
of Maryland, pursuant to which Maryland agreed to provide a $0.5 million term loan. Amounts outstanding under the loan bear simple
interest at an annual rate of 8.00%. Repayment of the full balance outstanding is due on February 22, 2034. This loan establishes
&ldquo;Phantom Shares,&rdquo; based on 119,906 shares of our common stock (based on 863,110 Series C Preferred Shares prior to
the <FONT STYLE="font-family: Times New Roman, Times, Serif">Reverse Recapitalization</FONT>), determined at issuance. The Loan
Agreement states the repayment amount is to be the greater of the balance of principal and accrued interest or the Phantom Shares
value. We determined that the note should be accounted for at fair value. We record the fair value of the debt at the end of each
reporting period. In order to value the note, we consider the amount of the simple interest expense that would be due and consider
the value of Phantom Shares. Upon the closing of the Reverse Recapitalization and as of December 31, 2020, the fair value of the
Maryland note payable is now determined based on the closing price of CLNN shares listed on the Nasdaq. Expenses of $0.5 million
and $34 thousand were recognized during the years ended December 31, 2020 and 2019, respectively. The fair value of $1.1 million
and $0.5 million of principal and accrued interest is included in long-term notes payable as of December 31, 2020 and December
31, 2019, respectively.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April&nbsp;2019,
the Company entered into a loan agreement (the &ldquo;2019 Cecil Loan&rdquo;) with Cecil County, Maryland (&ldquo;Cecil&rdquo;).
Pursuant to the 2019 Cecil Loan, Cecil agreed to provide a $0.1 million term loan. Amounts outstanding under the 2019 Cecil Loan
bear simple interest at an annual rate of 8.00%. Under the 2019 Cecil Loan, the Company has agreed to affirmative and negative
covenants to which it will remain subject until maturity. These covenants include providing information about the Company and its
operations; limitations on the Company&rsquo;s ability to retire, repurchase, or redeem the Company&rsquo;s common or preferred
stock, options, and warrants other than per the terms of the securities; and limitations on the Company&rsquo;s ability to pay
dividends of cash or property. There are no financial covenants associated with the Loan Agreement. Events of default under the
Loan Agreement include failure to make payments when due, insolvency events, failure to comply with covenants, and material adverse
effects with respect to the Company. The Company is not in violation of any affirmative or negative covenants. Repayment of the
full balance outstanding is due on April 30, 2034. The 2019 Cecil Loan establishes &ldquo;Phantom Shares,&rdquo; based on 23,981
shares of the Company&rsquo;s common stock (based on 172,622 Series C Preferred Shares prior to the <FONT STYLE="font-family: Times New Roman, Times, Serif">Reverse
Recapitalization</FONT>), determined at issuance. The 2019 Cecil Loan states the repayment amount is to be the greater of the balance
of principal and accrued interest or the Phantom Share value. The Company determined that the note should be accounted for at fair
value. The Company records the fair value of the debt at the end of each reporting period. Upon the closing of the Reverse Recapitalization
and as of December 31, 2020, the fair value of the 2019 Cecil Loan is now determined based on the closing price of CLNN shares
listed on the Nasdaq. In order to value the note, the Company considers the amount of the simple interest expense that would be
due and considers the value of Phantom Shares. Expense of $0.1 million and $6 thousand was recognized during the years ended December
31, 2020 and 2019, respectively. The fair value of $0.2 million and $0.1 million of principal and accrued interest is included
in long-term notes payable as of December 31, 2020 and December 31, 2019, respectively.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February through
July&nbsp;2020, we issued convertible promissory notes (the &ldquo;2020 Convertible Notes&rdquo;) in an aggregate principal amount
of $6.1 million, bearing interest at an annual rate of 5%. The 2020 Convertible Notes were convertible at the earlier of (i)&nbsp;one
year, at which point the notes would be convertible into Series C preferred shares at the Series C preferred share issuance price,
and (ii)&nbsp;next equity financing of no less than $10.0 million, at which point the notes would be convertible into shares issued
in the next equity financing at 90% of the per share issuance price of the next equity financing. The redemption feature at the
next equity financing met the requirements of an embedded derivative to be bifurcated and recorded at fair value. We bifurcated
the embedded feature at issuance and recorded a derivative liability of $0.7 million at inception in conjunction with a discount
on debt to be amortized over the life of the note. We recognized interest expense of $0.2 million, including amortization of debt
discount of $0.2 million during the year ended December 31, 2020, in connection with the 2020 Convertible Notes. We also identified
two other embedded features in these convertible promissory notes that were not bifurcated, which were the conversion into Series
C preferred shares upon maturity and the redemption upon a liquidation event. On August 11, 2020, in connection with our issuance
and sale of Series D Preferred Stock prior to the <FONT STYLE="font-family: Times New Roman, Times, Serif">Reverse Recapitalization</FONT>,
all of the outstanding principal and accrued interest under the 2020 Convertible Notes, totaling $6.9 million, was automatically
converted into 1,497,135 shares of Series D Preferred Stock at a price equal to 90% of $4.60 per share, the per share price paid
in cash by investors in the Series D preferred stock financing. We accounted for the conversion of the 2020 Convertible Notes as
a debt extinguishment and recognized a loss on extinguishment of debt of $0.5 million within other income (expense), net in the
consolidated statement of operations and comprehensive loss. As of the date of conversion, the unamortized discount on the 2020
Convertible Notes was $0.5 million. The loss on extinguishment was calculated as the difference between (i) the fair value of the
1,497,135 shares of Series D Preferred Stock issued to settle the 2020 Convertible Notes of $6.9 million and (ii) the carrying
value of the 2020 Convertible Notes, including the principal balance of the 2020 Convertible Notes of $6.1 million and accrued
but unpaid interest of $76 thousand, net of the unamortized debt discount of $5.7 million, plus the then-current fair value of
derivative liability associated with the 2020 Convertible Notes at the time of the extinguishment of $0.7 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May&nbsp;2020, the
Company entered into a note payable in the amount of $0.6 million (the &ldquo;PPP Note&rdquo;) under the Paycheck Protection Program
of the CARES Act (the &ldquo;PPP&rdquo;). As amended, the PPP permits forgiveness of amounts loaned for payments of payroll and
other qualifying expenses within 24 weeks of receipt of loaned funds, given that at least 60% of the total loan is used for payroll.
Amounts not forgiven by the PPP have a repayment period of five years. The Company expects the full $0.6 million balance of the
PPP Note to be forgiven. The Company will record any forgiveness after approval by the issuer. Until then, the PPP balance is included
in long-term notes payable as of December 31, 2020. On January 11, 2021, the U.S. Small Business Administration notified the Company
that the Company&rsquo;s PPP loan of $0.6 million had been forgiven. As a result, we will record a gain of $0.6 million in our
consolidated statements of operations and comprehensive loss in our first quarter of 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contractual
Obligations and Commitments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth our contractual obligations as of December 31, 2020:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif;  width: 100%">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Payment
    Due by Period</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1
    - 3 years</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">3
    - 5 years</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">More
    than<BR>
5 years</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-style: italic; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="14" STYLE="font-style: italic; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">($
    in thousands)</FONT></TD><TD STYLE="font-style: italic; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 52%; text-align: left; font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Long-term debt obligations</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,949</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,949</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Finance lease liabilities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">395</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">369</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">26</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating lease
    obligations</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,979</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">755</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,161</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">63</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 4pt">Total</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,323</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,124</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,187</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,012</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have made an accounting policy election not to recognize leases with an initial term of 12 months or less within our consolidated
balance sheet and to recognize those lease payments on a straight-line basis in our consolidated statements of operations and
comprehensive loss over the lease term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
enter into agreements in the normal course of business with CROs for clinical trials and with vendors for preclinical studies
and other services and products for operating purposes, which are cancelable at any time by us, subject to payment of our remaining
obligations under binding purchase orders and, in certain cases, nominal early termination fees. These commitments are not deemed
significant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Off-Balance
Sheet Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period presented, we did not have, and we currently do not have, any off-balance sheet arrangements, such as relationships
with unconsolidated entities or financial partnerships, which are often referred to as structured finance or special purpose entities,
established for the purpose of facilitating financing transactions that are not required to be reflected on our balance sheets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Critical
Accounting Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements,
which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates,
assumptions and judgments that affect the reported amounts of assets, liabilities, revenues, costs and expenses. We evaluate our
estimates and judgments on an ongoing basis, and our actual results may differ from these estimates. We base our estimates on
historical experience, known trends and events, contractual milestones and other various factors that are believed to be reasonable
under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities
that are not readily apparent from other sources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
most critical accounting policies are summarized below. See Note 2 to the Accountant&rsquo;s Report included elsewhere in this
Annual Report for a description of our other significant accounting policies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Contingent
Earn-out</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the Reverse Recapitalization and pursuant to the Merger Agreement, we agreed to issue additional shares to Clene Nanomedicine&rsquo;s
common shareholders immediately prior to the Reverse Recapitalization and to the initial shareholders of Tottenham a certain amount
of our Common Stock upon our achieving certain milestones. In accordance with ASC 815 &ndash; <I>Derivatives and hedging</I>, the
Earn-out Shares are not indexed to our Common Stock and therefore are accounted for as a liability with the changes in fair value
recorded as a component of other income (expense), net in our consolidated statements of operations and comprehensive loss. The
contingent earn-out liabilities were initially measured at fair value upon the closing of the Reverse Recapitalization and are
subsequently remeasured to fair value at each reporting date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Our
contingent earn-out liabilities contain unobservable inputs that reflect our own assumptions. We used a Monte Carlo analysis to
simulate the future path of our stock price over the earn-out period. The assumptions utilized in the calculation are based on
the achievement of certain stock price milestones such as projected stock price, volatility and risk-free rate. For potential
payments related to the product development milestone, the fair value was determined based on our expectations of achieving such
milestone and the simulated estimated stock price on the expected date of achievement. Our significant unobservable inputs upon
the closing of the Reverse Recapitalization and as of December 31, 2020 were as follows: (i) 85% of expected stock price volatility,
(ii) risk-free interest rate of 0.4%, and (iii) expected term of 5 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We
believe our assumptions are reasonable based on available information, our experience, knowledge, and judgments. These estimates
can be affected by factors that are difficult to predict including future (i) CLNN closing price per share on the Nasdaq, (ii)
estimated stock price volatility over the earn-out period, and (iii) risk free rates. Changes in assumptions and estimates used
in our analysis, or future results that vary from assumptions used in the analysis, could affect the fair value of the contingent
earn-out and could result in material changes in future periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Valuation
of Warrants to Purchase Preferred Stock</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Reverse
Recapitalization with Tottenham, we accounted for freestanding warrants to purchase shares of preferred stock as liabilities on
the consolidated balance sheet at their estimated fair value as the underlying redeemable convertible preferred stock was considered
contingently redeemable and may obligate us to transfer assets to the holders at a future date upon the occurrence of a deemed
liquidation event. At the end of each reporting period, changes in the estimated fair value of the warrants to purchase shares
of preferred stock were recorded in change in fair value of preferred stock warrant liability in the consolidated statements of
operations and comprehensive loss. Immediately prior to the close of the Reverse Recapitalization, all of the outstanding Clene
Nanomedicine preferred stock was converted to our Common Stock and the Clene Nanomedicine preferred stock warrants to purchase
Clene Nanomedicine preferred stock were converted to warrants to purchase our Common Stock. Upon conversion, we assessed the features
of the warrants and determined that they qualify for classification as permanent equity upon the closing of the Reverse Recapitalization.
We remeasured the warrants to fair value one final time upon the close of the Reverse Recapitalization and recognized a loss of
$14.6 million for the year ended December 31, 2020, within other income, (expense), net on the consolidated statements of operations
and comprehensive loss. Upon the closing of the Reverse Recapitalization, the preferred stock warrant liability was reclassified
to additional paid-in capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2019, change in the estimated fair value of the preferred stock warrant liability was $0.4 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Our
preferred stock warrant liabilities contain unobservable inputs that reflect our own assumptions. We used a Black-Scholes valuation
model to value the preferred stock warrant liability during 2020 and <FONT STYLE="font-family: Times New Roman, Times, Serif">we
used an option pricing model to value the preferred stock warrant liability during </FONT>2019. The following table summarizes
our significant unobservable inputs as at the dates indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 9pt; text-align: center; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Prior to the</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Closing of the Business</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Combination on<BR>
        December&nbsp;30,<BR>
        2020</B></P></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As of</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>December&nbsp;31,</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2019</B></P></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Series D Preferred Stock</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Fair value</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">$10.82</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Expected term</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2.3 years</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Expect volatility</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">101%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Series C Preferred Stock</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 78%; padding-left: 0.25in; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Fair value</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: center"><FONT STYLE="font-size: 10pt">$4.1699</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Expected term</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">1 year</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Expect volatility</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">49%</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Series A Preferred Stock</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Fair value</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">$10.82</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">$3.1046</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Expected term</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2.3 years</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">1 year</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Expect volatility</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">101%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">71%</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors
determines the fair value of the preferred stock by considering a number of objective and subjective factors, including third-party
valuations, valuations of comparable companies, sales of redeemable convertible preferred stock, sales of Common Stock to unrelated
third parties, operating and financial performance, the lack of liquidity of our capital stock, and general and industry-specific
economic outlook. We estimated the volatility of our preferred stock based on comparable peer companies&rsquo; historical volatility.
The risk-free interest rate for periods within the contractual life of the warrants is based on the U.S. Treasury yield curve in
effect at the valuation date. We have no plans to declare any future dividends. The determination of the fair value of the preferred
stock warrant liability could change in future periods based upon changes in the value of our preferred stock and other assumptions,
as presented above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock-based
Compensation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We account for stock-based
compensation arrangements with employees in accordance with Accounting Standards Codification (ASC) Topic 718-10, Compensation
&mdash; Stock Compensation. ASC 718 requires the recognition of compensation expense, using a fair value-based method, for costs
related to all share-based payments including stock options. We grant equity awards under our stock-based compensation plan, which
may include stock options and restricted common stock.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Prior
to the consummation of the Reverse Recapitalization, our determination of the fair value of stock options on the date of grant
utilized the Black-Scholes option-pricing model and was impacted by Clene Nanomedicine&rsquo;s common stock price as well as changes
in assumptions regarding a number of subjective variables. These variables include, but are not limited to, the expected term
that options will remain outstanding, the expected common stock price volatility over the term of the option awards, risk-free
interest rates, and expected dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After the closing of
the Reverse Recapitalization, our board of directors determined the fair value of each share of Common Stock underlying stock-based
awards based on the closing price of our Common Stock as reported by Nasdaq on the date of grant. RSUs that have a market condition
are associated with the achievement of certain stock price milestones. The fair value of the RSUs with market conditions are determined
using a Monte Carlo valuation model. The assumptions utilized in the Monte Carlo valuation model include projected stock price,
volatility and risk-free rate based on the achievement of certain stock price milestones.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value is recognized over the period during which an
optionee is required to provide services in exchange for the option award and service-based RSUs, known as the requisite service
period (usually the vesting period), on a straight-line basis. For the RSUs with market conditions, the fair value is recognized
over the period based on the expected milestone achievement dates as the derived service period (usually the vesting period), on
a straight-line basis. For the RSUs with performance conditions, the grant date fair value of these awards is the market price
on the applicable grant date, and compensation expense will be recognized when the conditions become probable of being satisfied.
The Company will recognize a cumulative true-up adjustment once the conditions become probable of being satisfied as the related
service period had been completed in a prior period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognize stock-based
compensation expense for the portion of awards that have vested. Stock compensation expense is recorded in research and development
and general and administrative expenses based on the classification of the work performed by the grantees. Stock-based compensation
expense recognized at fair value includes the impact of estimated forfeitures. In 2017, we adopted new accounting guidance from
the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) on stock compensation, or Accounting Standards Update (&ldquo;ASU&rdquo;)
2016-09, as described in &ldquo;Recently Adopted Accounting Standards&rdquo; below and have elected to account for forfeitures
as they occur, rather than estimating expected forfeitures.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth stock-based compensation for the periods presented:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif;  width: 100%">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><P STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year
ended December 31,</FONT></P>

</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>(in thousands)</I></FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">General
    and administrative</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">281</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">161</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research
    and development</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">480</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">238</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    stock-based compensation</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">761</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">399</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2020, we had approximately $2.4 million of unrecognized stock-based compensation costs related to non-vested awards
which is expected to be recognized over a weighted-average period of 2.04 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Stock Options</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following sets forth the outstanding common stock options and related activity for the years ended December 31, 2020 and 2019:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif;  width: 100%">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Equity</B></FONT></TD><TD STYLE="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Number&nbsp;of<BR>
Options</B></FONT></TD><TD STYLE="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Weighted
    <BR> Average <BR> Exercise <BR> Price <BR> Per Share</B></FONT></TD><TD STYLE="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Weighted
    <BR> Average <BR> Remaining <BR> Term <BR> (Years)</B></FONT></TD><TD STYLE="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Instrinsic <BR> Value</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 52%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding
    - December 31, 2018</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,698,090</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.38</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.62</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">11,089</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Granted</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,440,717</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.42</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.66</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercised</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(11,878</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.83</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">31</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Forfeited</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(248,757</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.44</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding
    - December 31, 2019</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,878,172</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.83</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.36</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">18,105</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Granted</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">270,555</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">5.48</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.32</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercised</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(83,232</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.94</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">740</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Forfeited</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(32,904</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">1.65</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding
    - December 31, 2020</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,032,591</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.97</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.34</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">62,462</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Options
    vested and exercisable - December 31, 2020</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,896,034</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.55</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.86</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">52,694</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Options
    vested and exercisable - Stock options vested and expected to vest December 31, 2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,032,591</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.97</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.34</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">62,462</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the consummation
of the Reverse Recapitalization, the exercise price of the stock options granted was based on the fair market value of the common
shares of the Company as of the grant date as determined by the Board of Directors, with input from the Company&rsquo;s management.
The Board of Directors determined the fair value of the common stock at the time of grant of the options by considering a number
of objective and subjective factors, including third-party valuation reports, valuations of comparable companies, sales of redeemable
convertible Preferred Stock, sales of common stock to unrelated third parties, operating and financial performance, the lack of
liquidity of the Company&rsquo;s capital stock, and general and industry-specific economic outlook.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Stock
options are valued using the Black-Scholes option pricing model. Since the Company has limited trading history of its Common Stock,
the expected volatility is derived from the average historical stock volatilities of several unrelated public companies within
the Company&rsquo;s industry that the Company considers to be comparable to its own business over a period equivalent to the expected
term of the stock option grants. The risk-free interest rate for periods within the contractual life of the stock options is based
on the U.S. Treasury yield curve in effect at the time of the grant. The expected dividend is assumed to be zero as the Company
has never paid dividends and has no current plans to do so. The expected term represents the period that stock-based awards are
expected to be outstanding. For option grants that are considered to be &ldquo;plain vanilla,&rdquo; the Company determines the
expected term using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the
contractual life of the options. For other option grants, the Company estimates the expected term using historical data on employee
exercises and post-vesting employment termination behavior taking into account the contractual life of the award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assumptions used to calculate the value of the stock option awards granted in 2020 and 2019 are presented as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 72%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    stock price volatility</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 12%; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">75.00%
                                         - 119.30</FONT>%</TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 12%; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">75.00%</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Risk-free
    interest rate</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.39%
- 0.53%</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.46%</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    dividend yield</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">0</FONT>%</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">0%</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    term of options</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">6
years</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">6
                                         years</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average grant-date fair values of options granted for the years ended December 31, 2020 and 2019 were $2.3923 and $1.5806,
respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Restricted Stock Units</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 30, 2020,
we granted the following shares of restricted common stock under the 2020 Stock Plan:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">370,101 shares to various employees and non-employee directors, which vest on June 30, 2021, subject to the employee&rsquo;s continuous employment through such vesting date. The award represents 5% of the converted stock options under 2014 Stock Plan as a result of the Reverse Recapitalization and complements the 5% closing payment shares held in escrow for Clene Nanomedicine common shareholders. The grant-date fair value of these awards was $4.0 million.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">454,781 shares to various employees and non-employee directors, which were eligible to vest based on certain market conditions, subject to the employee&rsquo;s continuous employment through such vesting date. The award complements the Milestone 1 earn-out share entitlement of Clene Nanomedicine shareholders and vests based on the same market condition. The grant-date fair value of these awards, using a Monte Carlo simulation, was $4.3 million. Based on the outcome of the market condition as of the December 31, 2020 measurement date, no shares were vested.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">341,090 shares to various employees and non-employee directors, which were eligible to vest based on certain market conditions, subject to the employee&rsquo;s continuous employment through such vesting date. The award complements the Milestone 2 earn-out share entitlement of Clene Nanomedicine shareholders and vests based on the same market condition. The grant-date fair value of these awards, using a Monte Carlo simulation, was $3.5 million. Based on the outcome of the market condition as of the December 31, 2020 measurement date, no shares were vested.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt">341,090 shares to various employees and non-employee directors, which were
eligible vest based on certain performance conditions tied to the completion of the COVID-19 coronavirus treatment study, subject
to the employee&rsquo;s continuous employment through such vesting date. The award complements the Milestone 3 earn-out share
entitlement of Clene Nanomedicine shareholders and vests based on the same performance condition. The grant-date fair value of
these awards was $3.7 million based on a weighted average grant date fair value of $10.82 per share. The Company did not recognize
compensation expense because the occurrence of achieving this milestone was not probable. As of the December 31, 2020, no shares
were vested.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
summarizes the restricted common stock activity during the year ended December 31, 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number&nbsp;of<BR>
RSUs</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted Average Grant Date Fair Value</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 76%; padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unvested balance as of December 31, 2019</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.25in; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,507,062</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 0.25in; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unvested balance as of December 31, 2020</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,507,062</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt double">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The assumptions used
to calculate the value of the restricted stock units granted in 2020 in the Monte Carlo valuation model include projected stock
price, volatility and risk-free rate based on the achievement of certain stock price milestones. Our significant unobservable inputs
as of December 31, 2020 were as follows: (i) 85% of expected stock price volatility, (ii) risk-free interest rate of 0.4%, and
(iii) expected term of 5 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Income
Taxes</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in our
tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statement
and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to
reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. We assess the likelihood
that our deferred tax assets will be recovered from future taxable income and, to the extent we believe, based upon the weight
of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized,
a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is
evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We account for uncertainty
in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax
benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon
external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position
is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit
that may be recognized is the largest amount that is more-likely-than-not to be realized upon ultimate settlement. The provision
for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate
as well as the related net interest and penalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Accounting Pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
description of recently issued accounting pronouncements that may potentially impact our financial position and result of operations
is disclosed in Note 2 to our consolidated financial statements included elsewhere in this Annual Report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_012"></A>ITEM
7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
required by this Item is not applicable as we are electing scaled disclosure requirements available to&nbsp;Smaller&nbsp;Reporting
Companies with respect to this Item.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_013"></A>ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Index
to Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 90%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#b_001">REPORT OF INDEPENDENT REGISTERED
    PUBLIC ACCOUNTING FIRM</A></FONT></TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">F-1</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#b_002">Consolidated Balance Sheets</A></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif">F-2</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#b_003">Consolidated Statements of Operations and Comprehensive
    Loss</A></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif">F-3</TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#b_004">Consolidated Statements of Redeemable Convertible
    Preferred Stock and Stockholders&rsquo; Equity (Deficit)</A></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif">F-4</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#b_005">Consolidated Statements of Cash Flows</A></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">F-5</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#b_006">Notes to Consolidated Financial Statements</A></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">F-6</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="img_015.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="b_001"></A>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Board of Directors and Stockholders of Clene Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Opinion on the Financial Statements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have audited the accompanying consolidated balance sheets
of Clene Inc. and its subsidiaries (the &ldquo;Company&rdquo;) as of December 31, 2020 and 2019, and the related consolidated statements
of operations and comprehensive loss, of redeemable convertible preferred stock and stockholders&rsquo; equity (deficit) and of
cash flows for the years then ended, including the related notes (collectively referred to as the &ldquo;consolidated financial
statements&rdquo;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial
position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for the years then
ended in conformity with accounting principles generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Basis for Opinion</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These consolidated financial statements are the responsibility
of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s consolidated financial statements
based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States)
(PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and
the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We conducted our audits of these consolidated financial statements
in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable
assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audits included performing procedures to assess the risks
of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that
respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in
the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates
made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our
audits provide a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Emphasis of Matter</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As discussed in Note 1 to the consolidated financial statements,
the Company will require additional financing or a collaboration agreement to fund future operations. Management&rsquo;s evaluation
of the events and conditions and management&rsquo;s plans to mitigate this matter are also described in Note 1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ PricewaterhouseCoopers LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Salt Lake City, Utah</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 26, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company's auditor since 2019.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 98; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="b_002"></A>CLENE
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED
BALANCE SHEETS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Current assets:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-indent: -9pt; padding-left: 0.25in">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">59,275</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">8,788</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 0.25in">Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">191</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,523</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">661</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 27pt">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">62,989</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,477</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Right-of-use assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,029</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,081</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Property and equipment, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,225</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,319</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">TOTAL ASSETS</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">68,243</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">14,877</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,124</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">889</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,960</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,878</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Income tax payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">164</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Payable to related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">131</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Deferred revenue from related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Operating lease obligations, current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">194</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">216</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Finance lease obligations, current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">190</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Clene Nanomedicine contingent earn-out, current portion</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,924</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 27pt">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,668</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,314</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Operating lease obligations, net of current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,785</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,434</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Finance lease obligations, net of current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">205</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">389</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Notes payable, net of current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,949</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">640</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Deferred income tax</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">260</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Redeemable convertible preferred stock warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,213</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Clene Nanomedicine contingent earn-out, net of current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,129</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Initial Shareholders contingent earn-out</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,906</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">TOTAL LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">67,902</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,990</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Commitments and contingencies (Note 13)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Redeemable convertible preferred stock<SUP>(1)</SUP> (Series A, B, C and D), $0.0001 par value; 0 and 31,036,008 shares authorized as of December 31, 2020 and 2019, respectively; 0 and 27,499,837 shares issued and outstanding as of December 31, 2020 and 2019, respectively; liquidation preference of $0 and $78,875 as of December 31, 2020 and 2019, respectively</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72,661</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders&rsquo; equity (deficit): <SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Common stock, $0.0001 par value: 100,000,000 shares authorized; 59,526,171 and 17,357,505 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">153,571</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,754</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accumulated deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(153,561</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(69,571</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Accumulated other comprehensive income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">325</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">41</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">TOTAL STOCKHOLDERS&rsquo; EQUITY (DEFICIT)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">341</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(67,774</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS&rsquo; EQUITY</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">68,243</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">14,877</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 15%; font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Retroactively
                                         restated for the reverse recapitalization as described in Note 1</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>See
accompanying notes to the consolidated financial statements.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="b_003"></A>CLENE
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Revenue:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Product revenue</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">176</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Royalty revenue</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">30</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 27pt">Total revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">206</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 0.25in">Cost of revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,204</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,563</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,151</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,769</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">20,420</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">16,332</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20,214</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,332</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Other income (expense), net:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(950</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(88</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Gain on termination of lease</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">51</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Change in fair value of preferred stock warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(14,615</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(361</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Change in fair value of derivative liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Change in fair value of Clene Nanomedicine contingent earn-out</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,659</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Change in fair value of Initial Shareholders contingent earn-out</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,465</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Australia research and development credit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,210</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">599</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Loss on extinguishment of convertibles notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(540</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Other income, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">34</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">27</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total other income (expense), net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,343</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">177</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net loss before income taxes</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(18,871</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(16,155</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Income tax expense</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(406</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(19,277</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,155</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Other comprehensive income (loss):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Foreign currency translation adjustments</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">284</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total other comprehensive income (loss)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">284</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Comprehensive loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(18,993</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(16,158</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss per share-- basic and diluted (Note 19) <SUP>(1)</SUP></FONT></TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1.10</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.93</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average common shares used to compute basic and diluted net loss per share <SUP>(1)</SUP></FONT></TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">17,503,992</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">17,357,505</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 15%; font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Retroactively
                                         restated for the reverse recapitalization as described in Note 1</FONT></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>See
accompanying notes to the consolidated financial statements.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="b_004"></A>CLENE
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED
STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&rsquo; EQUITY (DEFICIT) <SUP>(1)</SUP></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 9pt; text-align: center; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Redeemable<BR>
Convertible <BR>
Preferred Stock</B></FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Common Stock</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Additional<BR>
Paid-In</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Accumulated</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Accumulated<BR>
Other<BR>
Comprehensive</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Total<BR>
Stockholders&rsquo;<BR>
Equity</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 9pt; text-align: center; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Shares</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amount</B></FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Shares</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amount</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Capital</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Deficit</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Income</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Deficit)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Balances at December 31, 2018</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 10pt">25,165,036</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 10pt">62,926</FONT></TD>
    <TD STYLE="width: 1%; border-right: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 10pt">17,345,002</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 10pt">2</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 10pt">1,345</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 10pt">(53,430</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 10pt">44</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 10pt">(52,039</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Application of ASC 842</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">14</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">14</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Issuance of Series C preferred stock, net of issuance costs</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,935,111</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">8,069</FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Exercise of Series C preferred stock warrants</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">399,690</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,666</FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Exercise of stock options</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">12,503</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Stock-based compensation expense</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">399</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">399</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Foreign currency translation adjustment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Net loss</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(16,155</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(16,155</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Balances at December 31, 2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">27,499,837</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">72,661</FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">17,357,505</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,754</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(69,571</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">41</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(67,774</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Issuance of Series D Preferred Stock, net of issuance costs of $1.3 million</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7,896,922</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">35,051</FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Issuance of Series D Preferred Stock in connection with the extinguishment of convertible promissory notes</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,497,135</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6,891</FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Exercise of stock options</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">87,613</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">78</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">78</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Conversion of redeemable convertible preferred stock into common stock in connection with the Reverse Recapitalization</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(36,893,894</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(114,603</FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">36,893,894</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">114,599</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">114,603</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Extinguishment of preferred stock warrant liability in connection with the conversion of redeemable convertible preferred stock</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">17,828</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">17,828</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Issuance of common stock upon the Reverse
    Recapitalization and the private offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4,542,995</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">31,833</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">31,833</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Offering costs in connection with the Reverse Recapitalization</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(5,911</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(5,911</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Issuance of common stock as payment of related offering costs</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">644,164</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Clene Nanomedicine contingent earn-out recognized in connection with the Reverse Recapitalization (see Note 12)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(64,713</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(64,713</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -9pt">Initial Shareholders contingent
earn-out recognized in connection with the Reverse Recapitalization (see Note 12)</P></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(7,371)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(7,371)</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Stock-based compensation expense</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">761</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">761</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Foreign currency translation adjustment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">284</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">284</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Net loss</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(19,277</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(19,277</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2pt; padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Balances at December 31, 2020</FONT></TD>
    <TD STYLE="padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-size: 10pt">59,526,171</FONT></TD>
    <TD STYLE="padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-size: 10pt">6</FONT></TD>
    <TD STYLE="padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-size: 10pt">153,571</FONT></TD>
    <TD STYLE="padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-size: 10pt">(153,561</FONT></TD>
    <TD STYLE="padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-size: 10pt">325</FONT></TD>
    <TD STYLE="padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-size: 10pt">341</FONT></TD>
    <TD STYLE="padding-bottom: 2pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 15%; font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Retroactively
                                         restated for the reverse recapitalization as described in Note 1</FONT></TD>
</TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>See
accompanying notes to the consolidated financial statements.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="b_005"></A>CLENE
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED
STATEMENTS OF CASH FLOWS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font: 6pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Cash flows from operating activities:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(19,277</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(16,155</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 27pt">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">963</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">848</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 27pt">Non-cash lease expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">108</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">153</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 27pt">Change in fair value of preferred stock warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,615</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">361</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 27pt">Change in fair value of Clene Nanomedicine contingent earn-out</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,659</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 27pt">Change in fair value of Initial Shareholders contingent earn-out</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,465</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 27pt">Stock-based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">761</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">399</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 27pt">Change in fair value of derivative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(29</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 27pt">Loss on extinguishment of convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">540</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 27pt">Gain on termination of lease</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(51</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 27pt">Accretion of debt discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">179</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 27pt">Increase in interest accrued on notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">732</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 27pt">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 0.5in">Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(163</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(28</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.5in">Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,862</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(354</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.5in">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(312</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(76</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.5in">Accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(272</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,820</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.5in">Income tax payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">164</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.5in">Payable to related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(131</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.5in">Deferred revenue from related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.5in">Deferred income tax</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">260</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.5in">Operating lease obligations</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(142</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(237</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Net cash used in operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,929</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,197</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Cash flows from investing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Purchases of property and equipment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(387</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(294</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 27pt">Net cash used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(387</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(294</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Cash flows from financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Proceeds from issuance of Series C Preferred Stock, net of issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,069</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Proceeds from exercise of stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Payments of finance lease obligations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(194</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(176</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Proceeds from the issuance of note payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">652</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">600</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Payments of notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Payment of offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,011</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Proceeds from the Reverse Recapitalization and from the private placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,833</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Proceeds from issuance of Series D Preferred Stock, net of issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,051</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Proceeds from the issuance of convertible notes payable</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,125</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 27pt">Net cash provided by financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69,534</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,503</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Effect of foreign exchange rate changes on cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">269</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Net increase (decrease) in cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,487</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,989</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cash &ndash; beginning of year</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,788</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">16,777</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Cash &ndash; end of year</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">59,275</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">8,788</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Supplemental disclosure of non-cash investing and financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Acquisition of property and equipment through finance lease</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">403</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Acquisition of right-of-use assets and leasehold improvements through operating lease</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">820</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">11</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Warrant liability settled on exercise</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,666</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Lease liability settled through termination of lease</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">348</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Issuance of derivative instrument related to convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">705</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Issuance of Series D Preferred Stock upon extinguishment of convertible promissory notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,675</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Extinguishment of derivative liability in connection with extinguishment of convertible promissory notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">676</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Deferred transaction costs in accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">546</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Deferred transaction costs in accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,354</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Conversion of redeemable convertible preferred stock into common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">114,603</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Extinguishment of preferred stock warrant liability in connection with the conversion of redeemable convertible preferred stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">17,828</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Issuance of common stock as payment of related offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6,442</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Clene Nanomedicine contingent earn-out recognized in connection with the Reverse Recapitalization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">64,713</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Initial Shareholders contingent earn-out recognized in connection with the Reverse Recapitalization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7,371</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Supplemental disclosures:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Cash paid for interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">39</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">48</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>See
accompanying notes to the consolidated financial statements.</I></FONT></P>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="b_006"></A>CLENE
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.
Nature of the Business and Basis of Presentation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clene Inc. (formerly
Chelsea Worldwide, Inc.) (the &ldquo;Company&rdquo;) is a biopharmaceutical company focused on the development of clean-surfaced
nanocrystal drugs. The Company has developed an electrocrystal chemistry drug development platform, in which nanocrystals within
a suspension are the therapeutic drug. Utilizing technology to create nanocrystal drug suspensions, the Company&rsquo;s platform
has produced multiple drug assets, of which its lead assets are currently in development for use in neurological and infectious
diseases, among others, such as a study for treatment of COVID-19 coronavirus pandemic. Secondary to the Company&rsquo;s drug development,
as part of the Company&rsquo;s identification of potential drug assets, the Company has also identified certain mineral solutions
as dietary supplements. The Company&rsquo;s dietary supplements may also be commercialized by a related party, as discussed in
Note 20.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying consolidated
financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America
(&ldquo;GAAP&rdquo;) and include the accounts of the Company and its wholly owned subsidiaries, Clene Nanomedicine, Inc. (&ldquo;Clene
Nanomedicine&rdquo;), a subsidiary incorporated in Delaware, Clene Australia Pty Ltd, a subsidiary incorporated in Australia, and
dOrbital, Inc., a subsidiary incorporated in Delaware, after elimination of all intercompany accounts and transactions. Certain
prior period balances have been reclassified to conform to the current year presentation.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Reverse
Recapitalization with Tottenham Acquisition 1 Limited</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 30, 2020 (the &ldquo;Closing Date&rdquo;), Chelsea Worldwide, Inc., our predecessor company, consummated the previously
announced business combination (referred to as the &ldquo;Reverse Recapitalization&rdquo;) pursuant to a merger agreement, dated
as of September 1, 2020 (the &ldquo;Merger Agreement&rdquo;), by and among Clene Nanomedicine, Tottenham Acquisition I Limited
(&ldquo;Tottenham&rdquo; or &ldquo;TOTA&rdquo;), Chelsea Worldwide Inc., a Delaware corporation and wholly owned subsidiary of
Tottenham (&ldquo;PubCo&rdquo;), Creative Worldwide Inc., a Delaware corporation and wholly owned subsidiary of PubCo (&ldquo;Merger
Sub&rdquo;), and Fortis Advisors LLC, a Delaware limited liability company as the representative of the Company&rsquo;s stockholders
(&ldquo;Stockholders&rsquo; Representative&rdquo;). Prior to the Reincorporation Merger discussed below, Tottenham was incorporated
in the British Virgin Islands as a blank check company for the purpose of entering into a merger, share exchange, asset acquisition,
stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Reverse Recapitalization
was effected in two steps: (i) Tottenham was reincorporated to the state of Delaware by merging with and into PubCo (the &ldquo;Reincorporation
Merger&rdquo;); (ii) promptly following the Reincorporation Merger, Merger Sub was merged with and into Clene Nanomedicine, resulting
in Clene Nanomedicine becoming a wholly owned subsidiary of PubCo (the &ldquo;Acquisition Merger&rdquo;). On the Closing Date,
PubCo changed its name from Chelsea Worldwide Inc. to Clene Inc. and listed its shares of common stock, par value $0.0001 per share
(&ldquo;Common Stock&rdquo;) on the Nasdaq under the symbol &ldquo;CLNN.&rdquo;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the consummation
of the Reverse Recapitalization, each Tottenham ordinary share issued and outstanding immediately prior to the effective time of
the Reincorporation Merger (excluding certain shares to be canceled pursuant to the Merger Agreement, any redeemed shares and any
dissenting), was automatically cancelled and cease to exist and (i) for each Tottenham ordinary share, the Company issued to each
shareholder one validly issued share of the Company&rsquo;s Common Stock; (ii) each warrant to purchase one half (1/2) of one Tottenham
Ordinary Share converted into a warrant to purchase one-half of one share of the Company&rsquo;s Common Stock; (iii) each right
exchangeable into one-tenth (1/10) of one Tottenham ordinary share converted into a right exchangeable for one-tenth (1/10) of
one share of the Company&rsquo;s Common Stock; provided, however, that no fractional shares were issued and all fractional shares
were rounded down to the nearest whole share.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On the Closing Date,
each share of Clene Nanomedicine common stock was cancelled and the holders thereof in exchange received 0.1389 newly issued shares
of Clene Inc. Common Stock, which is the exchange ratio (the &ldquo;Exchange Ratio&rdquo;). Pursuant to the Merger Agreement, 5%
of the aggregate amount of the closing payment shares, or 2,716,958 shares will be held in escrow to satisfy any indemnification
obligation incurred and will be released six months after the closing of the Reverse Recapitalization. In addition, each share
of Clene Nanomedicine&rsquo;s preferred stock outstanding immediately prior to the closing of the Reverse Recapitalization was
converted into the right to receive the Company&rsquo;s Common Stock based on the same Exchange Ratio. In addition, all outstanding
warrants exercisable for common stock in Clene Nanomedicine (other than warrants that expired, were exercised or were deemed automatically
net exercised immediately prior to the Acquisition Merger) were exchanged for warrants exercisable for the Company Common Stock
with the same terms and conditions except adjusted by the aforementioned Exchange Ratio. At the closing of the Reverse Recapitalization,
each stock option of Clene Nanomedicine common stock was cancelled and the holders thereof in exchange received 0.1320 newly issued
stock options of the Company&rsquo;s Common Stock, which is 95% of the Exchange Ratio. Pursuant to the Merger Agreement, the Company
issued 370,101 of restricted stock units (&ldquo;RSUs&rdquo;) to the option holders which complements the 5% closing payment shares
held in escrow for Clene Nanomedicine common shareholders. The modification of the stock options did not result in a material incremental
compensation expense upon closing of the Reverse Recapitalization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the Company
issued 1,136,961 RSUs to option holders to complement the earn-out payments that would contingently be issued to certain current
Clene Nanomedicine&rsquo;s shareholders upon the achievement of milestones. See Note 3 for the milestones detail.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The proceeds received from
the Reverse Recapitalization is $3.7&nbsp;million, net of offering costs of $5.9 million which excludes the fair value of common
shares issued as a payment of related offering costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
Tottenham&rsquo;s initial public offering in August 2018, Tottenham issued to Chardan Capital Markets, LLC (&ldquo;Chardan&rdquo;),
options to purchase 220,000 units at $10.00 per unit. Each of the units consists of one and one-tenth shares of Tottenham&rsquo;s
ordinary shares for $10.00 per share and one warrant to purchase one-half of one of Tottenham&rsquo;s ordinary shares at an exercise
price of $11.50 per share (the &ldquo;Chardan Unit Purchase Option&rdquo;). In connection with the Reverse Recapitalization, the
Chardan Unit Purchase Option was converted into one Company unit purchase option. The warrants included in the Chardan Unit Purchase
Option (the &ldquo;Chardan Unit Purchase Option Warrants&rdquo;) are exercisable upon the completion of the Reverse Recapitalization
and will expire five years after the consummation of the Reverse Recapitalization (i.e., December 30, 2025) (see Note 10).</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also,
in connection with the Reverse Recapitalization, 644,164 shares of the Company&rsquo;s Common stock were issued to LifeSci Capital
LLC (&ldquo;LifeSci&rdquo;), as payment for advisory services rendered in connection with the Reverse Recapitalization (see Notes
3 and 18).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transaction was
accounted for as a &ldquo;reverse recapitalization&rdquo; in accordance with accounting principles generally accepted in the United
States (&ldquo;GAAP&rdquo;). Under this method of accounting, Tottenham was treated as the &ldquo;acquired&rdquo; company for financial
reporting purposes. This determination is primarily based on the fact that subsequent to the Reverse Recapitalization, Clene Nanomedicine&rsquo;s
stockholders have a majority of the voting power of the combined company, Clene Nanomedicine comprises all of the ongoing operations
of the combined entity, Clene Nanomedicine comprises a majority of the governing body of the combined company, and Clene Nanomedicine&rsquo;s
senior management comprises all of the senior management of the combined company. Accordingly, for accounting purposes, this transaction
was treated as the equivalent of Clene Nanomedicine issuing shares for the net assets of Tottenham, accompanied by a recapitalization.
The shares and net loss per common share, prior to the Reverse Recapitalization, have been retroactively restated as shares reflecting
the Exchange Ratio established in the Reverse Recapitalization (0.1389 Clene Inc. shares for 1 Clene Nanomedicine share). The net
assets of Tottenham were recorded at historical costs, with no goodwill or other intangible assets recorded. Operations prior to
the Reverse Recapitalization are those of Clene Nanomedicine.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
PIPE Offering</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Prior to the completion
of the Reverse Recapitalization on December 30, 2020, the Company entered into a subscription agreement on December 28, 2020, with
various investors. Pursuant to the subscription agreements, the Company issued 2,239,500 shares of the Company&rsquo;s Common Stock
(the &ldquo;PIPE Shares&rdquo;) at a price of $10.00 per share with net proceeds of $22.2 million. The purpose of the PIPE is to
fund general corporate expenses. In addition, investors in the PIPE offering also received warrants to purchase a number of shares
equal to one-half (1/2) of the number of PIPE Shares, totaling 1,119,750 shares of the Company&rsquo;s Common Stock, at an exercise
price of $0.01 per share for each of the PIPE Shares (the &ldquo;PIPE Warrants&rdquo;), subject to a 180-day holding period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 3 &ndash; Reverse Recapitalization with Tottenham and Clene Nanomedicine for additional details on Reverse Recapitalization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Liquidity</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has incurred
significant losses and negative cash flows from operations since its inception. The Company incurred net losses of $19.3 million
and $16.2 million for the years ended December 31, 2020 and 2019. As of December 31, 2020, the Company&rsquo;s cash totaled $59.3
million, its accumulated deficit was $153.6 million, and the Company had net cash used in operating activities of $18.9 million.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Reverse Recapitalization, Clene Nanomedicine&rsquo;s
operations were financed through the issuance of equity instruments and the issuance of convertible promissory notes. The Company
has not generated significant revenues to date and does not anticipate generating any significant revenues unless it successfully
completes development and obtains regulatory approval for its drugs or for its COVID-19 study. The Company expects to incur additional
losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional
capital to fully implement its business plan. Additionally, we may attempt to negotiate a collaboration agreement with a third
party for development and commercialization of a drug candidate, which may provide upfront and milestone payments to reduce our
spending going forward.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects to continue investing in product development, sales and marketing and customer support for its products. The long-term
continuation of the Company&rsquo;s business plan is dependent upon the generation of sufficient revenues from its products to
offset expenses and capital expenditures. In the event that the Company does not generate sufficient revenues and is unable to
obtain funding, the Company will be forced to delay, reduce, or eliminate some or all of its research and development programs,
product portfolio expansion, commercialization efforts or capital expenditures, which could adversely affect the Company&rsquo;s
business prospects, ability to meet long-term liquidity needs or the Company may be unable to continue operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects that the cash on hand as of December 31, 2020 will be sufficient to fund its operations for a period extending
beyond twelve months from the date the consolidated financial statements are issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Impact
of the COVID-19 Coronavirus Pandemic</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
COVID-19 pandemic, which began in December&nbsp;2019 and has spread worldwide, has caused many governments to implement measures
to slow the spread of the outbreak. The outbreak and government measures taken in response have had a significant impact, both
direct and indirect, on businesses and commerce, as worker shortages have occurred, supply chains have been disrupted, and facilities
and production have been suspended. The future progression of the pandemic and its effects on the Company&rsquo;s business and
operations remain uncertain. The COVID-19 pandemic may affect the Company&rsquo;s ability to initiate and complete preclinical
studies, delay the initiation of future clinical trials, disrupt regulatory activities, or have other adverse effects on its business
and operations. In particular, the Company and its clinical research organizations (&ldquo;CROs&rdquo;) may face disruptions that
may affect the Company&rsquo;s ability to initiate and complete preclinical studies, manufacturing disruptions, and delays at
clinical trial sites. The pandemic has already caused significant disruptions in the financial markets, and may continue to cause
such disruptions, which could impact the Company&rsquo;s ability to raise additional funds to support its operations. Moreover,
the pandemic has significantly impacted economies worldwide and could result in adverse effects on the Company&rsquo;s business
and operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is monitoring the potential impact of the COVID-19 pandemic on the Company&rsquo;s business and financial statements.
While the COVID-19 pandemic has led to various research restrictions and paused certain of Clene Nanomedicine&rsquo;s clinical
trials, these impacts have been temporary and to date, the Company has not experienced material business disruptions or incurred
impairment losses in the carrying values of its assets as a result of the pandemic and the Company is not aware of any specific
related event or circumstance that would require the Company to revise the estimates reflected in these financial statements.
The extent to which the COVID-19 pandemic will directly or indirectly impact the Company&rsquo;s business, results of operations,
cash flows and financial condition, including planned and future clinical trials and research and development costs, will depend
on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19,
the actions taken to contain or treat it, and the duration and intensity of the related effects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
Summary of Significant Accounting Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Use
of Estimates</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets, liabilities and disclosure of contingent assets and liabilities at the date of the
consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and
assumptions made in the accompanying consolidated financial statements include, but are not limited to the valuation of common
stock, stock options, contingent earn-out liability, and Preferred Stock warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual
results may differ from those estimates or assumptions. Estimates are periodically reviewed in light of changes in circumstances,
facts, and experience. Changes in estimates are recorded in the period in which they become known.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Risks
and Uncertainties</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
product candidates developed by the Company require approvals from the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) or
foreign regulatory agencies prior to commercial sales. There can be no assurance that the Company&rsquo;s current and future product
candidates will receive the necessary approvals or be commercially successful. If the Company is denied approval or approval is
delayed, it will have a material adverse impact on the Company&rsquo;s business and its consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to risks common to companies in the development stage including, but not limited to, dependency on the need
for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by
physicians and patients, significant competition, and untested manufacturing capabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to certain risks and uncertainties and believes that changes in any of the following areas could have a material
adverse effect on future financial position or results of operations: ability to obtain future financing; regulatory approval
and market acceptance of, and reimbursement for, product candidates; performance of third-party clinical research organizations
and manufacturers upon which the Company relies; protection of the Company&rsquo;s intellectual property; litigation or claims
against the Company based on intellectual property, patent, product, regulatory or other factors; and the Company&rsquo;s ability
to attract and retain employees necessary to support its growth.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Concentrations
of Credit Risk</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments which potentially subject the Company to significant concentrations of credit risk consist primarily of cash. The
Company&rsquo;s cash is mainly held in financial institutions. Amounts on deposit may at times exceed federally insured limits.
The Company has not experienced any losses on its deposits of cash and does not believe that it is subject to unusual credit risk
beyond the normal credit risk associated with commercial banking relationships.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Cash and Cash Equivalents</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company considers
all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. As of December
31, 2020 and 2019, the Company has no cash equivalents and no restricted cash balances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Inventory</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Inventory is stated
at historic cost on a first -in first-out basis. The Company&rsquo;s inventory consisted of $71,000 in raw materials and $0.1 million
in finished goods as of December 31, 2020. The Company&rsquo;s inventory consisted of $28,000 in finished goods as of December
31, 2019.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Deferred
Offering Costs</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company capitalizes
certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings,
including the Reverse Recapitalization and the PIPE offering, as deferred costs until such financings are consummated. After consummation
of the equity financing, these costs are recorded in stockholders&rsquo; equity (deficit) as a reduction of proceeds generated
as a result of the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately
as a charge to operating expenses in the consolidated statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2020, the Company incurred $5.9 million of offering costs, which excludes the fair value of common shares issued as a payment
of related offering costs, to additional paid in capital in connection with the Reverse Recapitalization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During 2019, the Company
had offering costs that were directly related to its proposed initial public offering of $1.0 million. In September 2019, the Company
terminated its initial public offering registration process. Accordingly, the Company has written off deferred offering costs previously
capitalized to general and administrative expense within the accompanying consolidated statements of operations and comprehensive
loss as of December 31, 2019.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Leases</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
inception of a contract, the Company determines if a contract meets the definition of a lease. A lease is a contract, or part
of a contract, that conveys the right to control the use of identified property, plant, or equipment (an identified asset) for
a period of time in exchange for consideration. The Company determines if the contract conveys the right to control the use of
an identified asset for a period of time. The Company assesses throughout the period of use whether the Company has both of the
following: (1)&nbsp;the right to obtain substantially all of the economic benefits from use of the identified asset, and (2)&nbsp;the
right to direct the use of the identified asset. This determination is reassessed if the terms of the contract are changed. Leases
are classified as operating or finance leases based on the terms of the lease agreement and certain characteristics of the identified
asset. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of the
future lease payments.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases laboratory and office space (real estate), and certain equipment under non-cancellable operating and finance leases.
The carrying value of the Company&rsquo;s right-of-use lease assets is substantially concentrated in its real estate leases, while
the volume of lease agreements is primarily concentrated in equipment leases. The Company&rsquo;s policy is to not record leases
with an original term of twelve months or less on the consolidated balance sheets. The Company recognizes lease expense for these
short-term leases on a straight-line basis over the lease term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
lease agreements may require the Company to pay additional amounts for taxes, insurance, maintenance and other expenses, which
are generally referred to as non-lease components. Such variable non-lease components are treated as variable lease payments and
recognized in the period in which the obligation for these payments was incurred. Variable lease components and variable non-lease
components are not measured as part of the right-of-use asset and liability. Only when lease components and their associated non-lease
components are fixed are they accounted for as a single lease component and are recognized as part of a right-of-use asset and
liability. Total contract consideration is allocated to the combined fixed lease and non-lease component. This policy election
applies consistently to all asset classes under lease agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
may contain clauses for renewal at the Company&rsquo;s option. Payments to be made in option periods are recognized as part of
the right-of-use lease assets and lease liabilities when it is reasonably certain that the option to extend the lease will be
exercised, or is not at the Company&rsquo;s option. The Company determines whether the reasonably certain threshold is met by
considering contract-, asset-, market-, and entity-based factors. In the consolidated statements of earnings, operating lease
expense, which is recognized on a straight-line basis over the lease term, and the amortization of finance lease ROU assets, which
are included in plant, property, and equipment and depreciated, are included in research and development or general and administrative
expenses consistent with the leased assets&rsquo; primary use. Accretion on the liabilities for finance leases is included in
interest expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Property
and Equipment</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Property and equipment
are stated at cost less accumulated depreciation. Property and equipment consist of lab and office equipment and leasehold improvements.
Depreciation is calculated using the straight-line method over the estimated economic useful lives of the assets, which are 3-5&nbsp;years
for lab equipment and 3-7&nbsp;years for furniture and fixtures. Leasehold improvements are amortized over the lesser of the estimated
lease term or the estimated useful life of the assets. Costs for capital assets not yet placed into service are capitalized as
construction in progress and depreciated or amortized in accordance with the above useful lives once placed into service. Upon
retirement or sale, the related cost and accumulated depreciation and amortization are removed from the accounts and any resulting
gain or loss is included in the consolidated statements of operations and comprehensive loss. Maintenance and repairs that do not
improve or extend the lives of the respective assets are expensed to operations as incurred.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Impairment
of Long-Lived Assets</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived
assets are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of
the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include
significant underperformance of the business in relation to expectations, significant negative industry or economic trends and
significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate an asset group
for recoverability, the Company compares the forecasted undiscounted cash flows expected to result from the use and eventual disposition
of the asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows
expected to result from the use and eventual disposition of an asset group are less than its carrying amount. The impairment loss
would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted
cash flows using market participant assumptions. The Company did not record any impairment losses on long-lived assets during
the years ended December 31, 2020 or December 31, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Derivative
Instruments</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
convertible promissory notes issued in February through July&nbsp;2020 (&ldquo;2020 Convertible Notes&rdquo;) contained embedded
features that provide the lenders with multiple settlement alternatives. Certain of these settlement features provided the lenders
a right to a fixed number of the Company&rsquo;s shares upon conversion of the notes. Other settlement features provided the lenders
the right or the obligation to receive cash or a variable number of shares upon the completion of a capital raising transaction,
change of control or default of the Company (the &ldquo;Redemption Features&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Redemption Features of the 2020 Convertible Notes met the requirements for separate accounting and were accounted for as a single
derivative instrument (the &ldquo;2020 Derivative Instrument&rdquo;). The 2020 Derivative Instrument was recorded at fair value
at inception and was subject to re-measurement to fair value at each balance sheet date and immediately prior to the extinguishment
of derivative liability, with any changes in fair value recognized in the consolidated statements of operations and comprehensive
loss. In August 2020, in connection with the Company&rsquo;s issuance and sale of Series D Preferred Stock, all of the outstanding
principal and accrued interest under the convertible promissory notes was automatically converted into shares of Series D Preferred
Stock and the derivative liability was extinguished (see Notes 11 and 12).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Redeemable
Convertible Preferred Stock</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Reverse
Recapitalization with Tottenham, the Company recorded all shares of redeemable convertible Preferred Stock at their respective
fair values on the dates of issuance, net of issuance costs. The redeemable convertible Preferred Stock was recorded outside of
permanent equity because while it was not mandatorily redeemable, upon certain events considered not solely within the Company&rsquo;s
control, such as a merger, acquisition, or sale of all or substantially all of the Company&rsquo;s assets (each, a &ldquo;Deemed
Liquidation Event&rdquo;), the redeemable convertible Preferred Stock would become redeemable at the option of the holders of at
least a majority of the then-outstanding shares. The Company did not adjust the carrying values of the redeemable convertible Preferred
Stock to the liquidation preferences of such shares because it was uncertain whether or when a Deemed Liquidation Event would occur
that would obligate the Company to pay the liquidation preferences to holders of shares of redeemable convertible Preferred Stock.
Subsequent adjustments to the carrying values of the liquidation preferences would be made only when it becomes probable that such
a Deemed Liquidation Event will occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the Reverse Recapitalization, all shares of redeemable convertible Preferred Stock were converted into shares of the Company&rsquo;s
Common Stock. Accordingly, there was no redeemable convertible Preferred Stock outstanding as of December 31, 2020. As of December
31, 2019, the carrying value of the redeemable convertible Preferred Stock was $72.7 million (see Note 17).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Contingent Earn-out</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the Reverse Recapitalization and pursuant to the Merger Agreement, Clene Nanomedicine&rsquo;s common shareholders and Initial Shareholders
of Tottenham are entitled to receive additional shares of the Company&rsquo;s Common Stock upon the Company achieving certain milestones
described in Note 12. In accordance with ASC 815 &ndash; <I>Derivatives and hedging</I>, the earn-out shares are not indexed to
the Company&rsquo;s own stock and therefore are accounted for as a liability at the reverse recapitalization date and subsequently
remeasured at each reporting date with changes in fair value recorded as a component of other income (expense), net in the consolidated
statements of operations and comprehensive loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The estimated fair
value of the contingent consideration was determined using a Monte Carlo simulation that simulated the future path of the Company&rsquo;s
stock price over the earn-out period. The assumptions utilized in the calculation are based on the achievement of certain stock
price milestones including projected stock price, volatility, and risk-free rate. For potential payments related to a product development
milestone, the fair value was determined based on the Company&rsquo;s expectations of achieving such a milestone and the simulated
estimated stock price on the expected date of achievement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The contingent earn-out
is categorized as a Level 3 fair value measurement (see Fair Value of Financial Instruments accounting policy) because the Company
estimates projections during the earn-out period utilizing unobservable inputs, including various potential pay-out scenarios.
Contingent earn-out payments involve certain assumptions requiring significant judgment and actual results may differ from assumed
and estimated amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Preferred Stock Warrant Liability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Reverse
Recapitalization with Tottenham, the Company accounted for freestanding warrants to purchase shares of Preferred Stock as liabilities
on the balance sheet at their estimated fair value as the underlying redeemable convertible Preferred Stock was considered contingently
redeemable and may obligate the Company to transfer assets to the holders at a future date upon the occurrence of a deemed liquidation
event. At the end of each reporting period, changes in the estimated fair value of the warrants to purchase shares of Preferred
Stock were recorded in change in fair value of Preferred Stock warrant liability in the consolidated statements of operations and
comprehensive loss. Changes in the estimated fair value of the Preferred Stock warrant liability were ($14.6) million and ($0.4)
million for the years ended December 31, 2020 and 2019, respectively. In connection with the Reverse Recapitalization, all Clene
Nanomedicine Preferred Stock was converted to the Company&rsquo;s Common Stock and the Clene Nanomedicine Preferred Stock warrants
were converted to warrants to purchase the Company&rsquo;s Common Stock. The Company assessed the features of these warrants and
determined that they qualify for classification as permanent equity. Accordingly, the Company remeasured the warrants to fair value
upon the closing of the Reverse Recapitalization and reclassified the resulting warrant liability to additional paid-in capital
(See Note 16).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Common Stock Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company accounts for common stock warrants as either equity
instruments or liabilities in accordance with ASC 480, <I>Distinguishing Liabilities from Equity</I> (&ldquo;ASC 480&rdquo;), depending
on the specific terms of the warrant agreement (See Note 10).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Revenue
Recognition</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects
the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition
for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&nbsp;identify
the contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract; (iii)&nbsp;determine the transaction
price, including variable consideration, if any; (iv)&nbsp;allocate the transaction price to the performance obligations in the
contract; and (v)&nbsp;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies
the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in
exchange for the goods or services it transfers to the customer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine
which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes
as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation
is satisfied or as it is satisfied. The Company typically satisfies its performance obligations via delivery of dietary supplements
to the customer. Payments are due upon receipt for commercial transactions or a prepayment is collected for online retail sales.
The Company&rsquo;s revenue for the year ended December 31, 2020 was comprised of sales of dietary supplements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded deferred revenue of $0.1 million as of December 31, 2020 from the dietary supply agreement with the related party
discussed in Note 20. The deferred revenue is expected to be recognized in the first half of 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Grant
Funding</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company may submit
applications to receive grant funding from governmental and non-governmental entities. Grant funding received that involves no
conditions or continuing performance obligations of the Company is recognized upon receipt. Grant funding with conditions or obligations
of the Company is recognized as the conditions or obligations are fulfilled. The Company has made an accounting policy election
to record such unconditional grants, such as the Australian Research and Development Credit, as other income in the consolidated
statements of operations and comprehensive loss. Income from grants is recognized in the period during which the related qualifying
expenses are incurred, provided that the conditions under which the grants were provided have been met. The Company recognizes
Australian Research and Development Credit in an amount equal to the qualifying expenses incurred in each period multiplied by
the applicable reimbursement percentage. During the years ended December 31, 2020 and 2019, the Company recognized $3.2 million
and $0.6 million, respectively, of Australian Research and Development Credit within other income (expense), net in the consolidated
statement of operations and comprehensive loss. As of December 31, 2020 and 2019, the Company recorded $2.1 million and $0, respectively,
of Australian Research and Development Credit receivable in prepaid expenses and other current assets on the consolidated balance
sheets.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
amount received in advance of fulfilling such conditions or obligations is recorded in accrued liabilities in the consolidated
balance sheets if the conditions or obligations are expected to be met within the next twelve months. As of December 31, 2020
and 2019, the Company recorded $0.3 million and $0.1 million, respectively, of Australian Research and Development Credit received
in advance in accrued liabilities.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant
funding recognized on conditional grants is included as a reduction in research and development expenses in the consolidated statements
of operations and comprehensive loss as the conditions are tied to the Company&rsquo;s research and development efforts, and as
the arrangement between the Company and the organizations are not part of the Company&rsquo;s on-going, major, or central operations.
During the years ended December 31, 2020 and 2019, the Company recorded $0.8 million and $0.1 million, respectively of grant funding
as a reduction of research and development expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Fair
Value of Financial Instruments</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the price that would be received for
an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value
must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried
at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Level
1</B>&nbsp;&mdash; Inputs based upon quoted market prices for identical assets or liabilities in active markets at the measurement
date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Level
2</B>&nbsp;&mdash; Observable inputs other than quoted market prices included in Level 1, such as quoted prices for similar assets
and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active;
or other inputs that are observable or can be corroborated by observable market data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Level
3</B>&nbsp;&mdash; Inputs that are management&rsquo;s best estimate of what market participants would use in pricing the asset
or liability at the measurement date. The inputs are unobservable in the market and significant to the instrument&rsquo;s valuation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews the fair value hierarchy classification as of the actual date of the event or change in circumstances that caused
the transfer. There was a transfer to Level 1 from Level 3 as of December 31, 2020 for the Notes payable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 16 for information on the Company&rsquo;s assets and liabilities measured at fair value as of December 31, 2020 and 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Foreign
Currency Translation and Transactions</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
functional currency of the Company is the United&nbsp;States dollar. The Company&rsquo;s Australian subsidiary determined its
functional currency to be the Australian dollar. The Company uses the United&nbsp;States dollar as its reporting currency for
the consolidated financial statements. The results of its non-U.S. dollar based functional currency operations are translated
to U.S. dollars at the average exchange rates during the period. The Company&rsquo;s assets and liabilities are translated using
the current exchange rate as of the consolidated balance sheet date and shareholders&rsquo; equity is translated using historical
rates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
resulting from the translation of the consolidated financial statements of the Company&rsquo;s foreign functional currency subsidiaries
into U.S. dollars are excluded from the determination of net loss and are accumulated in a separate component of shareholders&rsquo;
equity. These foreign currency translation gains and losses are currently the only component of other comprehensive income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also incurs foreign exchange transaction gains and losses for purchases denominated in foreign currencies. Foreign exchange
transaction gains and losses are included in other income (expense) in the Company&rsquo;s consolidated results of operations
as incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Comprehensive
Loss</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss includes net loss as well as other changes in stockholders&rsquo; equity (deficit) that result from transactions and economic
events other than those with stockholders. The Company&rsquo;s only element of other comprehensive income (loss) in any period
presented was translation of Australian dollar denominated balances of the Company&rsquo;s Australian subsidiary to U.S. dollars
for consolidation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Net
Loss Per Share Attributable to Common Shareholders</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company calculated basic and diluted net loss per share attributable to common shareholders in conformity with the two-class method
required for companies with participating securities. The Company considered all series of redeemable convertible Preferred Stock
to have been participating securities as the holders were entitled to receive non-cumulative dividends on a pari passu basis in
the event that a dividend had been paid on common stock. See Note 19, Net Loss Per Share Attributable to Common Shareholders,
for further details on the Company&rsquo;s historical participating securities, including warrants to purchase redeemable convertible
Preferred Stock and common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the two-class method, basic net loss per share attributable to common shareholders was calculated by dividing the net loss by
the weighted-average number of shares of common stock outstanding during the period, less shares subject to repurchase. The net
loss attributable to common shareholders was not allocated to the redeemable convertible Preferred Stock as the holders of redeemable
convertible Preferred Stock did not have a contractual obligation to share in losses. Diluted net loss per share attributable
to common shareholders was computed by giving effect to all potentially dilutive common stock equivalents outstanding for the
period. For purposes of this calculation, redeemable convertible Preferred Stock, stock options to purchase common stock, early
exercised stock options, and warrants to purchase redeemable convertible Preferred Stock and common stock were considered common
shares equivalents but had been excluded from the calculation of diluted net loss per share attributable to common shareholders
as their effect was anti-dilutive. In periods in which the Company reports a net loss attributable to common shareholders, diluted
net loss per share attributable to common shareholders is the same as basic net loss per share attributable to common shareholders,
since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net
loss attributable to common shareholders during the years ended December 31, 2020 and 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Segment
Information</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has determined that its chief executive officer is the chief operating decision maker (&ldquo;CODM&rdquo;). Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the CODM in making decisions regarding resource allocation and assessing performance. The Company views its operations and
manages its business in two operating segments, the first being that of the development and commercialization of proprietary nanotechnology
drug suspensions, and the second being the development and commercialization of dietary supplements (See Note 21).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Income
Taxes</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets
and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements
or in the Company&rsquo;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between
the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences
are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company
assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes,
based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets
will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred
tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process
to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood
that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not
to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial
statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being
realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized
tax benefits, that are considered appropriate as well as the related net interest and penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock-Based
Compensation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company accounts
for stock-based compensation arrangements with employees using a fair value-based method for costs related to all share-based payments
including stock options and restricted common stock. Stock-based compensation expense is recorded in research and development and
general and administrative expenses based on the classification of the work performed by the grantees.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the Reverse Recapitalization, there was not a public market for the shares of Clene Nanomedicine, Inc. common stock. The Company&rsquo;s
determination of the fair value of stock options on the date of grant utilized the Black-Scholes option-pricing model and was
impacted by its common stock price, as determined by the Board of Directors with input from the Company&rsquo;s management, as
well as changes in assumptions regarding a number of subjective variables. These variables included, but were not limited to,
the expected term that options remained outstanding, the expected common stock price volatility over the term of the option awards,
risk-free interest rates, and expected dividends.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value was recognized over the period during which an
optionee was required to provide services in exchange for the option award and service-based RSUs, known as the requisite service
period (usually the vesting period), on a straight-line basis. For the RSUs with market conditions, the fair value is recognized
over the period based on the expected milestone achievement dates as the derived service period (usually the vesting period), on
a straight-line basis. For the RSUs with performance conditions, the grant date fair value of these awards is the market price
on the applicable grant date, and compensation expense will be recognized when the conditions become probable of being satisfied.
The Company will recognize a cumulative true-up adjustment once the conditions become probable of being satisfied as the related
service period had been completed in a prior period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stock-based compensation
expense recognized at fair value included the impact of estimated forfeitures. The Company elected to account for forfeitures as
they occurred, rather than estimating expected forfeitures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After the closing
of the Reverse Recapitalization, the Company determined the fair value of each share of Common Stock underlying stock-based awards
based on the closing price of the Company&rsquo;s Common Stock as reported by Nasdaq on the date of grant. The fair value of the
RSUs with market conditions are determined using a Monte Carlo valuation model. Forfeitures are estimated at the time of grant
and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are charged to expense as incurred. The Company accounts for nonrefundable advance payments for goods and
services that will be used in future research and development activities as expenses when the goods have been received or when
the service has been performed. Research and development expenses consist of costs incurred by the Company for the discovery and
development of the Company&rsquo;s product candidates. Research and development costs include, but are not limited to, payroll
and personnel expenses including stock-based compensation, clinical trial supplies, fees for clinical trial services, consulting
costs, and allocated overhead, including rent, equipment, and utilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Clinical
Trial Accrual</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s
clinical trial accrual process accounts for expenses resulting from obligations under contracts with CROs, consultants, and under
clinical site agreements in connection with conducting clinical trials. Clinical trial costs are charged to research and development
expense as incurred. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and
may result in payment flows that do not match the periods over which materials or services are provided to the Company under such
contracts. The Company reflects the appropriate clinical trial expense in the consolidated financial statements by matching the
appropriate expenses with the period in which services and efforts are expended. In the event advance payments are made to a CRO,
the payments will be recorded as a prepaid asset which will be amortized over the period of time the contracted services are performed.
In addition to pass-through costs, the Company generally incurs costs in clinical trials in four distinct groups as follows:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRO
Start-up&nbsp;&mdash; These costs include the initial set-up of the clinical trial and usually occurs within a few months after
the contract has been executed and includes costs which are expensed ratably over the start-up period when such period is identifiable
and expensed as incurred when no such period exists. Start-up phase activities include study initiation, site recruitment, regulatory
applications, investigator meetings, screening, preparation, pre-study visits, and training.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRO
Site and Study Management&nbsp;&mdash; These costs include medical and safety monitoring, and patient administration and data
management. These costs are usually calculated on a per patient basis and expensed ratably over the treatment period beginning
on the date that the patient enrolls.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRO
Close Down and Reporting&nbsp;&mdash; These costs include analyzing the data obtained and reporting results, which occurs after
patients have ceased treatment and the database of information collected is locked. These costs are expensed as incurred over
the course of any close down and reporting period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
Party Contracts&nbsp;&mdash; These costs include fees charged by third parties for various support services which are not provided
by CROs and include such items as lab fees, data quality review costs, and fees incurred for investigational product monitoring
and inventory control. These items are expensed ratably over any identifiable service period with the engaged third-party vendors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CRO contracts generally include pass-through fees including, but not limited to, regulatory expenses, investigator fees, travel
costs and other miscellaneous costs, including shipping and printing fees. The Company determines accrual estimates through reports
from and discussion with applicable personnel and outside services providers as to the progress or state of completion of trials,
or the services completed. The Company makes estimates of accrued expenses as of each balance sheet date in the consolidated financial
statements based on the facts and circumstances known to the Company at that time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Recently
Adopted Accounting Pronouncements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitating of the Effects of Reference Rate Reform
on Financial Reporting, which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships,
and other transactions in which the reference LIBOR or another reference rate is expected to be discontinued as a result of the
Reference Rate Reform. This ASU is intended to ease the potential burden in accounting for (or recognizing the effects of) reference
rate reform on financial reporting. The new guidance was effective immediately, and through December 31, 2022. As a result of
the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section
107(b) of the JOBS Act, ASU 2016-02 is effective for the Company for fiscal years beginning after December 15, 2020, and all interim
periods thereafter. Early adoption is permitted. The Company early adopted this guidance on March 1, 2020. The adoption of this
guidance did not have a material impact on its consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Recent
Accounting Pronouncements Not Yet Adopted</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2016, the FASB
issued ASU No. 2016-13, <I>Financial Instruments &ndash; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</I>.
The amendments in this ASU, among other things, require the measurement of all expected credit losses for financial assets held
at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions
and other organizations will now use forward-looking information to better inform their credit loss estimates. The guidance is
effective for fiscal years beginning after December 15, 2022. The Company is currently evaluating the expected impact of the new
guidance.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2018, the FASB issued ASU No. 2018-15, <I>Intangibles &ndash; Goodwill and Other &ndash; Internal-Use Software (Subtopic
350-40): Customer&rsquo;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract</I>.
The new guidance provides for the deferral of implementation costs for cloud computing arrangements and expensing those costs
over the term of the cloud services arrangement. The new guidance is effective for fiscal years beginning after December 15, 2020.
The Company is currently evaluating the expected impact of the new guidance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2019, the
FASB issued ASU No. 2019-12, <I>Income Taxes</I> (Topic 740), which amends the existing guidance relating to the accounting for
income taxes. This ASU is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles
of accounting for income taxes and to improve the consistent application of GAAP for other areas of accounting for income taxes
by clarifying and amending existing guidance. The new guidance is effective for fiscal years beginning after December 15, 2021.
The Company does not expect that the adoption of this new guidance will have a material impact on its consolidated statements.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
Reverse Recapitalization with Tottenham and Clene Nanomedicine</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 30, 2020,
the Company consummated the Reverse Recapitalization, pursuant to which Tottenham merged with and into PubCo in connection with
the Reincorporation Merger and PubCo merged with and into Clene Nanomedicine, resulting in Clene Nanomedicine becoming a wholly
owned subsidiary of PubCo. On the Closing Date, PubCo changed its name from Chelsea Worldwide, Inc. to Clene Inc. (see Note 1).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the consummation
of the Reverse Recapitalization, each Tottenham ordinary share issued and outstanding immediately prior to the effective time of
the Reincorporation Merger was automatically cancelled and ceased to exist and (i) for each Tottenham ordinary share, the Company
issued one validly issued share of the Company&rsquo;s Common Stock; (ii) each warrant to purchase one half of one Tottenham Ordinary
Share was converted into a warrant to purchase one-half of one share of the Company&rsquo;s Common Stock; and (iii) each Tottenham
right exchangeable into one-tenth (1/10) of one Tottenham ordinary share was converted into a right exchangeable for one-tenth
(1/10) of one share of the Company&rsquo;s Common Stock. As a result of the Reverse Recapitalization, all outstanding shares of
Tottenham ordinary shares of 2,303,495 held by the Initial Shareholders and Tottenham public shareholders were converted into the
same number of the Company&rsquo;s Common Stock. In addition, pursuant to the Merger Agreement, the Initial Shareholders are entitled
to receive up to 750,000 of the company common shares as earn-out shares upon the achievement of certain milestones described in
below. The contingent earn-out with the Initial Shareholders is accounted for as a contingent liability and is included in the
line item of &ldquo;Contingent Earn-out&rdquo; on the consolidated balance sheets.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with
the Merger Agreement, on the closing of the Reverse Recapitalization, each share of Clene Nanomedicine preferred stock and common
stock then issued and outstanding was automatically cancelled, extinguished and exchanged for 0.1389 newly issued shares of Clene
Inc. Common Stock. At the closing of the Reverse Recapitalization, Clene Inc. acquired 100% of the issued and outstanding Clene
Nanomedicine common stock, in exchange for 54,339,012 shares of Clene Inc. Common Stock issued to the Clene Nanomedicine common
shareholders, among which 2,716,958 shares of the Clene Inc. Common Stock are to be issued and held in escrow to satisfy any indemnification
obligations incurred under the Merger Agreement. In addition, all outstanding warrants (other than warrants that expired, were
exercised or were deemed automatically net exercised immediately prior to the Acquisition Merger) exercisable for common stock
in Clene Nanomedicine were assumed by the Company with no changes to the terms and conditions of the awards. The awards have been
retroactively restated to reflect the Exchange Ratio established in the Reverse Recapitalization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the Reverse Recapitalization, a total of 53,286,115 stock options of Clene Nanomedicine common stock was cancelled and the holders
thereof in exchange received 0.1320 newly issued stock options of Clene Inc. Common Stock for a total of 7,032,590, which is 95%
of the Exchange Ratio. Pursuant to the Merger Agreement, the Company issued RSUs to the option holders which complements the 5%
closing payment shares held in escrow for Clene Nanomedicine common shareholders. In addition, the Company issued 1,136,961 RSUs
to option holders to complement the earn-out payments that would contingently be issued to certain current Clene Nanomedicine&rsquo;s
shareholders upon the achievement of milestones described in below.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Also, in connection
with the Reverse Recapitalization, Clene Nanomedicine entered into a letter agreement with LifeSci Capital LLC (&ldquo;LifeSci&rdquo;)
on July 2, 2020, according to which LifeSci was engaged to act as Clene Nanomedicine&rsquo;s financial advisor with respect to
identifying and soliciting special purpose acquisition companies for the purpose of entering into a merger or similar transaction
with Clene Nanomedicine and its shareholders. Under this agreement, Clene Nanomedicine agreed that if it consummated a merger with
Tottenham, LifeSci would receive consideration of (i) 3% of the amount by which the total transaction consideration exceeded $350
million, plus (ii) 7% of cash and cash-equivalents received by Clene Nanomedicine from the Tottenham&rsquo;s trust account. Clene
Nanomedicine could elect to pay LifeSci either in cash, equity interests of the surviving company, or a combination of the two.
Upon the consummation of the Reverse Recapitalization, 644,164 shares of the Company&rsquo;s Common Stock were issued to LifeSci
as consideration for its services as pursuant to the letter agreement (see Note 18).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Immediately after giving
effect to the Reverse Recapitalization, there were 59,526,171 shares of Common Stock issued and outstanding, and warrants to purchase
5,566,363 shares of Common Stock issued and outstanding (see Note 10).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During Tottenham&rsquo;s
IPO, Tottenham incurred deferred underwriters&rsquo; fees which were payable to Chardan from the amounts held in the trust account
upon completion of the Reverse Recapitalization. Upon the closing of the Reverse Recapitalization, the Company paid $2.1 million
to Chardan as the settlement of the deferred underwriting and advisory fees which amount was included in the total offering costs
of the Reverse Recapitalization transaction.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2020, the Company recorded $5.9 million of offering costs, which excludes the fair value of common shares issued as a payment
of related offering costs and Chardan underwriting fees discussed above. Those offering costs were related to third-party legal,
accounting services and other professional services to consummate the Reverse Recapitalization. These offering costs are recorded
in additional paid-in capital upon the close of the Reverse Recapitalization in the Company&rsquo;s consolidated balance sheets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 28, 2020 and
prior to the close of the Reverse Recapitalization on December 30, 2020, various PIPE investors purchased 2,239,500 shares of the
Company&rsquo;s Common Stock at a price of $10.00 per share and 1,119,750 warrants with an exercise price of $0.01 per share, to
purchase one share of the Company&rsquo;s Common Stock, for net proceeds of $22.2 million (see Notes 10 and 18).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Earn-out
shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain of Clene Nanomedicine&rsquo;s
current stockholders are entitled to receive earn-out shares as follows (the &ldquo;Clene Nanomedicine Contingent Earn-Out&rdquo;):
(i) 3,333,333 shares of the Company&rsquo;s Common Stock if (A) the volume-weighted average price (&ldquo;VWAP&rdquo;) of the shares
of the Company&rsquo;s Common Stock equals or exceeds $15.00 (or any foreign currency equivalent) (the &ldquo;Milestone 1 Price&rdquo;)
in any twenty trading days within a thirty trading day period within the three years following the closing of the Reverse Recapitalization
on any securities exchange or securities market on which the shares of the Company&rsquo;s Common Stock are then traded or (B)
the change of control price equals or exceeds the Milestone 1 Price if a change of control transaction occurs within the three
years following the closing of the Reverse Recapitalization (the requirements set forth in clause (A) and (B), &ldquo;Milestone
1&rdquo;); (ii) 2,500,000 shares of the Company&rsquo;s Common Stock if (A) the VWAP of the shares of the Company&rsquo;s Common
Stock equals or exceeds $20.00 (or any foreign currency equivalent) (the &ldquo;Milestone 2 Price&rdquo;) in any twenty trading
days within a thirty trading day period within the five years following the closing of the Reverse Recapitalization on any securities
exchange or securities market on which the shares of the Company&rsquo;s Common Stock are then traded or (B) the change of control
price equals or exceeds the Milestone 2 Price if a change of control transaction occurs within the five years following the closing
of the Reverse Recapitalization (the requirements set forth in clause (A) or (B), &ldquo;Milestone 1&rdquo;); and (iii) 2,500,000
shares of the Company&rsquo;s Common Stock if Clene Nanomedicine completes a randomized placebo-controlled study for treatment
of COVID-19 which results in a statistically significant finding of clinical efficacy within twelve months after the closing of
the Reverse Recapitalization (&ldquo;Milestone 3&rdquo;). If Milestone 1 is not achieved but Milestone 2 is achieved, the Clene
Nanomedicine stockholders will receive a catch-up issuance equal to the shares issued upon satisfaction of Milestone 1. Upon the
consummation of the Reverse Recapitalization, the earn-out shares that certain Clene Nanomedicine stockholders are entitled to
receive increased by 12,852 as a result of the exercise of stock options during November 2020. Therefore, the total Clene Nanomedicine
earn-out shares has increased to 8,346,185 shares of the Company&rsquo;s Common Stock.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Initial Shareholders of Tottenham may be entitled to receive earn-out shares as follows (the &ldquo;Initial Shareholders Contingent
Earn-Out&rdquo;): (i) 375,000 shares of the Company&rsquo;s Common Stock upon satisfaction of the requirements of Milestone 1;
and (ii) another 375,000 shares of the Company&rsquo;s Common Stock upon satisfaction of the requirements of Milestone 2. If Milestone
1 is not achieved but Milestone 2 is achieved, the Initial Shareholders shall receive a catch-up issuance equal to the shares
granted upon satisfaction of the requirements of Milestone 1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clene Nanomedicine
and Initial Shareholders earn-out payments (collectively, referred to as &ldquo;Earn-out Shares&rdquo;) have been classified as
liabilities in the consolidated balance sheets as of December 31, 2020 and were initially measured at fair value on the date of
the Reverse Recapitalization and will be subsequently remeasured to fair value at each reporting date (see Note 16).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the
Reverse Recapitalization and the PIPE offering, Clene Nanomedicine&rsquo;s stockholders own approximately 91% of the Common Stock
of the Company, Tottenham public stockholders own approximately 4% of the Common Stock of the Company, and investors from the PIPE
own approximately 4% of the Common Stock of the Company, based on the number of shares of Clene Inc. Common Stock outstanding on
December 30, 2020 (in each case, not giving effect to any shares issuable upon exercise of Clene Inc. warrants, options, or earn-out
shares).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.
Prepaid expenses and other current assets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets consisted of the following as of December 31, 2020 and 2019:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Australia research and development credit receivable</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,148</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">CRO prepayments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,211</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">413</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Metals to be used in research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">191</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">112</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">57</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,523</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">661</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.
Property and Equipment, Net</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment, net consisted of the following as of December 31, 2020 and 2019:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif;  width: 100%">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(in
    thousands)</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.25in; padding-left: 0.25in; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Lab
    equipment</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,077</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,707</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.25in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Furniture
    and fixtures</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">147</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">162</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.25in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Leasehold
    improvements</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,889</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,430</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Construction
    in progress</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">490</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">410</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.25in; padding-left: 0.25in; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,603</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,709</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Less
    accumulated depreciation</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,378</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,390</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    property and equipment, net</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,225</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,319</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense related to property and equipment, net for the years ended December 31, 2020 and 2019 was approximately $1.0 million ($0.9
million in Research and Development expense and $0.1 million in General and Administrative expense) and $0.9 million ($0.8 million
in Research and Development expense and $0.1 million in General and Administrative expense), respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.
Accrued Liabilities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
liabilities consisted of the following as of December 31, 2020 and 2019:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued professional fees</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">189</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,826</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued compensation and benefits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,225</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">817</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued CRO fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">788</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">95</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Deferred grant funds</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">301</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued expense reimbursements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued transaction costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,354</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">70</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">24</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,960</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,878</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.
Leases</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted ASC 842 on January 1, 2019 using the modified retrospective approach. Upon adoption of the new leasing standards,
the Company (i) recognized an operating lease right of use asset of approximately $1.2 million and a corresponding operating lease
liability of approximately $1.7 million, which are included in the Company&rsquo;s consolidated balance sheet, and with a $14
thousand cumulative adjustment to accumulated deficit and (ii) elected the package of transition practical expedients, which allowed
the Company to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the
lease classification for any expired or existing leases and initial direct costs for existing leases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also made an accounting policy election not to recognize leases with an initial term of 12 months or less within its consolidated
balance sheets and to recognize those lease payments on a straight-line basis in its consolidated statements of operations and
comprehensive loss over the lease term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the lease commencement date, the discount rate implicit in the lease is used to discount the lease liability if readily determinable.
If not readily determinable or leases do not contain an implicit rate, the Company&rsquo;s incremental borrowing rate is used
as the discount rate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April&nbsp;2020, the Company terminated an existing operating lease for office space. At the time of termination, the Company
removed the remaining right-of-use asset of $0.3 million, lease liability of $0.3 million, and recognized a gain of $51 thousand.
Further, in April&nbsp;2020, the Company commenced a new operating lease. At the time of commencement, the Company recorded the
right-of-use asset value of $0.4 million, leasehold improvements of $0.4 million, and a lease liability of $0.8 million. The net
effect of the change in leases being an increase in right-of-use assets of $56 thousand, an increase in leasehold improvements
of $0.5 million, an increase in lease liability of $0.4 million, and a gain on termination of $51 thousand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has noncancelable operating lease arrangements primarily for office and lab space. The Company also has noncancelable
finance leases for certain lab equipment. The maturity analysis of finance and operating lease liabilities as of December 31,
2020 are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif;  width: 100%">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(in
    thousands)</FONT></TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif">Finance <FONT STYLE="font-family: Times New Roman, Times, Serif">Leases</FONT></TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif">Operating <FONT STYLE="font-family: Times New Roman, Times, Serif">Leases</FONT></TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">165</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">376</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">135</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">421</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2023</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">82</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">433</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">20</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">442</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2025</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">454</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Thereafter</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">530</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    undiscounted cash flows</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">403</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,656</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Less
    amount representing interest/discounting</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(8</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(677</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Present
    value of future lease payments</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">395</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,979</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Less
    lease obligations, current portion</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(190</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(194</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Lease
    obligations&nbsp;&ndash; long term portion</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">205</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,785</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects that, in the normal course of business, the existing leases will be renewed or replaced by similar leases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Finance
Leases</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
recorded under finance lease obligations and included with property and equipment as of December 31, 2020 and 2019 are summarized
as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif;  width: 100%">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(in
    thousands)</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 76%; text-align: left; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Lab
    equipment</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">920</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">920</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Furniture
    and fixtures</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">46</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">46</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Work
    in process</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">228</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">228</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,194</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,194</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Less
    accumulated depreciation</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(593</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(418</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">601</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">776</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2020, the Company&rsquo;s finance lease obligations had a weighted-average interest rate of 8.1% and had a weighted-average
remaining term of 2.7 years. As of December 31, 2019, the Company&rsquo;s finance lease obligations had a weighted-average interest
rate of 8.1% and had a weighted-average remaining term of 3.7 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Operating
Leases</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s balance of right-of-use assets on the face of the balance sheet pertain to operating leases. As of December 31,
2020, the Company&rsquo;s operating lease obligations had a weighted-average discount rate of 9.6% and had a weighted-average
remaining term of 6.3 years. As of December 31, 2019, the Company&rsquo;s operating lease obligations had a weighted-average discount
rate of 9.6% and a weighted-average remaining term of 6.0 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Components
of Lease Cost</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of finance and operating lease costs for the years ended December 31, 2020 and 2019 were as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif;  width: 100%">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(in
    thousands)</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Finance
    lease costs:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amortization</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">175</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">182</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest
    on lease liabilities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">37</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">29</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating
    lease costs</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">293</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">325</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Short-term
    lease costs</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">249</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">283</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Variable
    lease costs</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">92</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">103</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    lease costs</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">846</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">922</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Supplemental
Cash Flow Information</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif;  width: 100%">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(in
    thousands)</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating
    cash flows from operating leases</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(635</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(711</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating
    cash flows from finance leases</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(37</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(29</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Finance
    cash flows from finance leases</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(194</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(176</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.
Notes Payable</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February&nbsp;2019, the Company entered into a loan agreement (the &ldquo;2019 MD Loan&rdquo;) with the Department of Housing
and Community Development, a principal department of the State of Maryland (&ldquo;Maryland&rdquo;). Pursuant to the 2019 MD Loan,
Maryland agreed to provide a $0.5 million term loan. Amounts outstanding under the 2019 MD Loan bear simple interest at an annual
rate of 8.00%. Under the 2019 MD Loan, the Company has agreed to affirmative and negative covenants to which it will remain subject
until maturity. These covenants include providing information about the Company and its operations; limitations on the Company&rsquo;s
ability to retire, repurchase, or redeem the Company&rsquo;s common or preferred stock, options, and warrants other than per the
terms of the securities; and limitations on the Company&rsquo;s ability to pay dividends of cash or property. There are no financial
covenants associated with the Loan Agreement. Events of default under the Loan Agreement include failure to make payments when
due, insolvency events, failure to comply with covenants, and material adverse effects with respect to the Company. The Company
is not in violation of any affirmative or negative covenants. Repayment of the full balance outstanding is due on February 22,
2034. The 2019 MD Loan establishes &ldquo;Phantom Shares,&rdquo; based on 119,906 shares of the Company&rsquo;s common stock (based
on 863,110 Series C Preferred Shares prior to the Reverse Recapitalization), determined at issuance. The Loan Agreement states
the repayment amount is to be the greater of the balance of principal and accrued interest or the Phantom Share value. The Company
determined that the note should be accounted for at fair value. The Company records the fair value of the debt at the end of each
reporting period. In order to value the note, the Company considers the amount of the simple interest expense that would be due
and considers the value of Phantom Shares. Expense of $0.5 million and $34 thousand was recognized during the years ended December
31, 2020 and 2019, respectively. The fair value of $1.1 million and $0.5 million of principal and accrued interest is included
in long-term notes payable as of December 31, 2020 and December 31, 2019, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April&nbsp;2019,
the Company entered into a loan agreement (the &ldquo;2019 Cecil Loan&rdquo;) with Cecil County, Maryland (&ldquo;Cecil&rdquo;).
Pursuant to the 2019 Cecil Loan, Cecil agreed to provide a $0.1 million term loan. Amounts outstanding under the 2019 Cecil Loan
bear simple interest at an annual rate of 8.00%. Under the 2019 Cecil Loan, the Company has agreed to affirmative and negative
covenants to which it will remain subject until maturity. These covenants include providing information about the Company and its
operations; limitations on the Company&rsquo;s ability to retire, repurchase, or redeem the Company&rsquo;s common or preferred
stock, options, and warrants other than per the terms of the securities; and limitations on the Company&rsquo;s ability to pay
dividends of cash or property. There are no financial covenants associated with the Loan Agreement. Events of default under the
Loan Agreement include failure to make payments when due, insolvency events, failure to comply with covenants, and material adverse
effects with respect to the Company. The Company is not in violation of any affirmative or negative covenants. Repayment of the
full balance outstanding is due on April 30, 2034. The 2019 Cecil Loan establishes &ldquo;Phantom Shares,&rdquo; based on 23,981
shares of the Company&rsquo;s common stock (based on 172,622 Series C Preferred Shares prior to the Reverse Recapitalization),
determined at issuance. The 2019 Cecil Loan states the repayment amount is to be the greater of the balance of principal and accrued
interest or the Phantom Share value. The Company determined that the note should be accounted for at fair value. The Company records
the fair value of the debt at the end of each reporting period. In order to value the note, the Company considers the amount of
the simple interest expense that would be due and considers the value of Phantom Shares. Expense of $0.1 million and $6 thousand
was recognized during the years ended December 31, 2020 and 2019, respectively. The fair value of $0.2 million and $0.1 million
of principal and accrued interest is included in long-term notes payable as of December 31, 2020 and December 31, 2019, respectively.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May&nbsp;2020, the
Company entered into a note payable in the amount of $0.6 million (the &ldquo;PPP Note&rdquo;) under the Paycheck Protection Program
of the CARES Act (the &ldquo;PPP&rdquo;). As amended, the PPP permits forgiveness of amounts loaned for payments of payroll and
other qualifying expenses within 24 weeks of receipt of loaned funds, given that at least 60% of the total loan is used for payroll.
Amounts not forgiven by the PPP have a repayment period of five years. The Company expects the full $0.6 million balance of the
PPP Note to be forgiven. The Company will record any forgiveness after approval by the issuer. Until then, the PPP balance is included
in long-term notes payable as of December 31, 2020. On January 11, 2021, the U.S. Small Business Administration notified the Company
that the Company&rsquo;s PPP loan of $0.6 million had been forgiven (see Note 22).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.
Preferred Stock Warrant Liability</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Reverse
Recapitalization, the Company issued Series A Preferred Stock Warrants in 2013 in connection with certain note purchase agreements.
The warrants expire 10&nbsp;years from issuance. These warrants are exercisable at a fixed exercise price of $1.97, which is equal
to the price per share of the Series A Preferred Stock by the Company. As of December 31, 2019, these warrants were exercisable
into 1,608,672 shares of the Series A Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Reverse
Recapitalization, on April 8, 2013, the Company issued 10-year warrants to purchase units of the Company&rsquo;s most senior equity
equal to 0.50% of the Company&rsquo;s fully diluted equity at the time of exercise in connection with certain note purchase agreements.
As of December 31, 2019, these warrants were exercisable into 271,439 shares of the Company&rsquo;s most senior equity, Series
C Preferred Stock, at a fixed exercise price of $1.97 per share. On August 11, 2020, in connection with the Company&rsquo;s issuance
of Series D Preferred Stock, these warrants became exercisable into 320,441 shares of the Company&rsquo;s most senior equity, Series
D Preferred Stock, at a fixed exercise price of $1.97 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Reverse
Recapitalization, the Company classified its Preferred Stock warrants as a liability on its consolidated balance sheet because
the warrants are freestanding financial instruments that may have required to the Company to transfer assets upon exercise. The
liability associated with each of these warrants was initially recorded at fair value upon the issuance date of each warrant and
is subsequently remeasured to fair value as a component of other income (expense), net in the consolidated statement of operations
and comprehensive loss. Upon the closing of the Reverse Recapitalization (see Note 1), and as pursuant to the Merger Agreement,
all of the outstanding Clene Nanomedicine Preferred Stock was converted to the Company&rsquo;s Common Stock and the Clene Nanomedicine
Preferred Stock warrants to purchase Clene Nanomedicine Preferred Stock were converted to warrants to purchase the Company&rsquo;s
Common Stock (see Note 10). Upon conversion, the Company assessed the features of the warrants and determined that they qualify
for classification as permanent equity upon the closing of the Reverse Recapitalization. Accordingly, the Company remeasured the
warrants to fair value one final time upon the close of the Reverse Recapitalization, and recognized a loss of $14.6 million for
the year ended December 31, 2020, within other income, (expense), net on the consolidated statements of operations and comprehensive
loss. Upon the closing of the Reverse Recapitalization, the warrant liability was reclassified to additional paid-in capital (see
Notes 1 and 17).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2020, the Company does not have any Preferred Stock warrants outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2019,&nbsp;the fair value of the outstanding warrants was $3.2 million with the changes in fair value recorded
as a component of other income (expense), net on the consolidated statements of operations and comprehensive&nbsp;loss. As of
December 31, 2019, the Company had Preferred Stock warrants outstanding and exercisable as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif;  width: 100%">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expiration</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD><TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercise&nbsp;Price</FONT></TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrant</FONT>s</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD><TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Per&nbsp;Share<SUP>(1)</SUP></FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding<SUP>(1)</SUP></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 66%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    C preferred stock warrants<SUP>(2)</SUP></FONT></TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2023</FONT></TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right; width: 9%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.9658</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 9%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">271,439</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Series
    A preferred stock warrants</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2023</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.9658</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,608,672</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 15%; font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         exercise price per share and warrants outstanding, prior to the Reverse Recapitalization,
                                         have been retroactively restated as shares reflecting the Exchange Ratio established
                                         in the Reverse Recapitalization (See Note 1).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                         of December 31, 2019, the most senior equity preferred stock warrants were convertible
                                         into Series C Preferred Stock.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.
Common Stock Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2020, outstanding warrants to purchase shares of the Company&rsquo;s Common Stock consisted of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; padding-left: 9pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Date Exercisable</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number of</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Shares Issuable</B></P></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Exercise Price</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Exercisable for</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Classification</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Expiration</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; width: 28%; padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">June 2021</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">1,119,750</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">0.01</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 12%; text-align: center"><FONT STYLE="font-size: 10pt">Common Stock</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 12%; text-align: center"><FONT STYLE="font-size: 10pt">Equity</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 12%; text-align: center"><FONT STYLE="font-size: 10pt">December 2021</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">December 2020</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">2,407,500</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">11.50</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">Common Stock</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">Equity</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">December 2025</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">December 2020</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">110,000</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">11.50</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">Common Stock</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">Equity</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">December 2025</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">December 2020</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,929,113</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 10pt">1.97</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Common Stock</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Equity</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">April 2023</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Total</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 4.5pt double">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-size: 10pt">5,566,363</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 2pt; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 2pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 2pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 2pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On December 28, 2020, the Company entered into a subscription agreement
(the &ldquo;Subscription Agreement&rdquo;) with various investors for the private purchase of 2,239,500 shares of the Company&rsquo;s
Common Stock at a price of $10.00 per share with net proceeds of $22.2 million. Investors in the PIPE offering also received warrants
(&ldquo;PIPE Warrants&rdquo;) to purchase a number of shares equal to one-half (1/2) of the number of PIPE Shares, totaling 1,119,750
shares of the Company&rsquo;s Common Stock, at an exercise price of $0.01 per share. Also, pursuant to the Subscription Agreement,
the 1,119,750 PIPE Warrants are subject to a 180-day holding period. A holder of the PIPE Warrants may not exercise the PIPE Warrant
if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of the Company&rsquo;s
Common Stock outstanding immediately after giving effect to such exercise. As of December 31, 2020, none of the warrants had been
exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the Reverse Recapitalization, all of Tottenham&rsquo;s issued and outstanding warrants to purchase one-half (1/2) of one share
of Tottenham&rsquo;s ordinary shares totaling 4,815,000 shares issued in connection with Tottenham&rsquo;s initial public offering,
were automatically converted into 2,407,500 warrants to purchase the Company&rsquo;s Common Stock. The warrants became exercisable
upon the completion of the Reverse Recapitalization and will expire five years after the consummation of the Reverse Recapitalization
(i.e., December 2025). The Company may redeem those outstanding warrants, in whole and not in part, at a price of $0.01 per warrant
if, and only if, the last sales price of the Company&rsquo;s Common Stock equals or exceeds $16.50 per share for any 20 trading
days within a 30-trading day period ending three business days before the Company sends the notice of redemption. As of December
31, 2020, none of the warrants had been exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
Tottenham&rsquo;s initial public offering in August 2018, Tottenham issued to Chardan options to purchase 220,000 units at $10.00
per unit. Each of Tottenham&rsquo;s units consists of one and one-tenth shares of Tottenham&rsquo;s ordinary shares for $10.00
per share and one warrant to purchase one-half of one Tottenham ordinary share at an exercise price of $11.50 per share. In connection
with the Reverse Recapitalization, the Chardan Unit Purchase Option was converted into one Company unit purchase option. The Chardan
Unit Purchase Option Warrants are exercisable upon the completion of the Reverse Recapitalization and will expire in December
2025. As of December 31, 2020, no Chardan Unit Purchase Options were exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Reverse Recapitalization, all of the 1,929,113 outstanding Series A and Series D Preferred Stock Warrants
were converted automatically into 1,929,113 warrants to purchase shares of the Company Common Stock at $1.97 per share (See Note
9).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.
Convertible Notes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February through July 2020, the Company issued convertible promissory notes (the &ldquo;2020 Convertible Notes&rdquo;) in an aggregate
principal amount of $6.1 million, bearing interest at an annual rate of 5%. The 2020 Convertible Notes were convertible at the
earlier of (i)&nbsp;one year, at which point the notes would be convertible into Series C preferred shares at the Series C preferred
share issuance price, and (ii)&nbsp;next equity financing of no less than $10.0 million, at which point the notes would be convertible
into shares issued in the next equity financing at 90% of the per share issuance price of the next equity financing. The 2020
Convertible Notes contained redemption features that met the requirements for separate accounting and were accounted for as a
single derivative instrument. Accordingly, the 2020 derivative instrument of $0.7 million was recorded at fair value at inception
as redeemable convertible preferred stock derivative liability in the consolidated balance sheets (see Note 12).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized interest expense of $0.2 million, including amortization of debt discount of $0.2 million during the year ended
December 31, 2020, in connection with the 2020 Convertible Notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 11, 2020, in connection with the Company&rsquo;s issuance and sale of Series D Preferred Stock, all of the outstanding
principal and accrued interest under the 2020 Convertible Notes, totaling $6.9 million, was automatically converted into 1,497,135
shares of Series D Preferred Stock at a price equal to 90% of $4.60 per share, the per share price paid in cash by investors in
the Series D preferred stock financing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 119; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounted for the conversion of the 2020 Convertible Notes as a debt extinguishment and recognized a loss on extinguishment
of debt of $0.5 million within other income (expense), net in the consolidated statement of operations and comprehensive loss.
As of the date of conversion, the unamortized discount on the 2020 Convertible Notes was $0.5 million. The loss on extinguishment
was calculated as the difference between (i) the fair value of the 1,497,135 shares of Series D Preferred Stock issued to settle
the 2020 Convertible Notes of $6.9 million and (ii) the carrying value of the 2020 Convertible Notes, including the principal
balance of the 2020 Convertible Notes of $6.1 million and accrued but unpaid interest of $76 thousand, net of the unamortized
debt discount of $5.7 million, plus the then-current fair value of derivative liability associated with the 2020 Convertible Notes
at the time of the extinguishment of $0.7 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.
Derivative Instruments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Derivative
instrument in connection with the 2020 Convertible Notes</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">One of the redemption
features of the 2020 Convertible Notes met the requirements for separate accounting and was accounted for as a derivative instrument.
The 2020 Derivative Instrument was recorded at fair value, which was $0.7 million at issuance. In August 2020, in connection with
the Company&rsquo;s issuance and sale of Series D Preferred Stock, all of the outstanding principal and accrued interest under
the 2020 Convertible Notes was automatically converted into shares of Series D Preferred Stock and the derivative liability was
extinguished. Prior to the extinguishment of derivative liability, the 2020 Derivative Instrument was marked at fair value and
the Company recorded the change in the 2020 Derivative Instrument of ($29) thousand in the consolidated statements of operations
and comprehensive loss (see Note 11).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Derivative instrument in connection
with the Contingent Earn-out</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Earn-out Shares
issued in connection with the Reverse Recapitalization met the requirements for separate accounting and is therefore accounted
for as a derivative instrument. Accordingly, upon the consummation of the Reverse Recapitalization, the Company recorded a liability
in the consolidated balance sheets and a debit to additional paid-in capital for the earn-out provision associated with the Initial
Shareholders Contingent Earn-out and a debit to accumulated deficit for the earn-out provisions associated with the Clene Nanomedicine
Contingent Earn-out. The contingent shares to be issued to the Clene Nanomedicine shareholders immediately prior to the Reverse
Capitalization were treated as a deemed distribution. The contingent earn-out was subsequently remeasured to fair value at each
reporting date as a component of other income (expense), net in the Company&rsquo;s consolidated statements of operations and comprehensive
loss.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing of the Reverse Recapitalization, the Company recognized the contingent earn-out liability at its fair value of $72.1
million in the consolidated balance sheets. As of December 31, 2020, the carrying value of the contingent earn-out was $58.0 million.
During the year ended of December 31, 2020, the Company recognized a gain of $14.1 million in change in fair value of contingent
earn-out as a component of other income (expense), net in the Company&rsquo;s consolidated statements of operations and comprehensive
loss. To date, none of the milestones has been achieved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13.
Commitments and Contingencies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Litigation</B>&nbsp;&mdash;
From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business activities.
The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures
can be reasonably estimated. The Company is not aware of any current pending legal matters or claims.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14.
Income Taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not recorded income tax benefits for the net operating losses incurred during the years ended December 31, 2020 and
2019 nor for research and development tax credits and other deferred tax assets generated, due to its uncertainty of realizing
a benefit from those items.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The components of income
(loss) before income taxes for the years ended December 31, 2020 and 2019 were as follows (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">United&nbsp;States</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(18,985</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(13,812</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Foreign</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">114</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,343</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Loss before provision for income taxes</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(18,871</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(16,155</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Income tax expense
(benefit) for the years ended December 31, 2020 and 2019 were as follows (in thousands):</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>Provision for income taxes:</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Current tax expense:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; padding-left: 9pt">Federal</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">State</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 9pt">Foreign</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">146</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total current tax expense (benefit)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">146</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Deferred tax expense:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Federal</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">State</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 9pt">Foreign</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">260</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total deferred tax expense (benefit)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">260</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Total income tax expense (benefit)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">406</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A reconciliation of
the income tax computed at the U.S. federal statutory rate of 21% to the expense for income taxes for the years ended December
31, 2020 and 2019 is as follows (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Income tax expense (benefit) at federal statutory rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(3,963</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(3,393</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">State income taxes (net of federal benefit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(917</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(721</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,069</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Contingent consideration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,966</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Research and development credits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(425</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">326</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">242</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,205</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Change in valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,366</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,583</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Income tax expense (benefit)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">406</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s
effective tax rate was (2.15)% and 0.00% for the years ended December 31, 2020 and 2019, respectively. Significant components of
the Company&rsquo;s deferred tax assets (liabilities) as of December 31, 2020 and 2019 were as follows (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">Deferred tax assets (liabilities):</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 9pt">Net operating loss carryforwards</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">17,958</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">13,502</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,810</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,814</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Research &amp; development credits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,682</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">882</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Lease liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">520</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">436</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Right-of-use asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(270</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(48</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Accrued interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">160</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Non-qualified stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">146</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">130</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Accrued compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">115</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">62</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 9pt">Other</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(260</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(23</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in">Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,861</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,755</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Less: valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(22,121</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(16,755</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net deferred tax assets (liabilities)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(260</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In
assessing the realizability of deferred tax assets, management considers whether it is more-likely-than-not that some portion
or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the
generation of future taxable income during periods in which those temporary differences become deductible. Management considers
the scheduled reversal of deferred tax liabilities, projected future taxable income, carry back opportunities and tax planning
strategies in making the assessment. The Company believes it is more likely than not it will not realize the benefits of these
deductible differences and has applied a full valuation allowance against them. As the Company has no deferred tax assets in Australia,
it has recognized a deferred tax liability and expense for $0.3 million for temporary differences that will reverse in future
periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The
Company has federal and state net operating losses (NOLs) of approximately $72.2 million and $59.8 million as of December 31,
2020, respectively that, subject to limitation, may be available in future tax years to offset taxable income. Of the available
federal NOLs, approximately $38.8 million can be carried forward indefinitely but utilization is limited to 80% of the Company's
taxable income in any given tax year based on current federal tax laws. The remaining balance of $33.4 million will begin to expire
after 2034. Of the available state NOLs, approximately $39.4 million can be carried forward indefinitely but utilization is limited
to 80% of the Company's taxable income in any given tax year based on current tax laws. The remaining balance of $20.4 million
will begin to expire after 2032. Additionally, the Company has approximately $1.7 million of research and development (R&amp;D)
credit carryforwards that will begin to expire after 2034 if not utilized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the provisions
of &sect;382 of the Internal Revenue Code, substantial changes in the Company's ownership may result in limitations on the amount
of NOL carryforwards and R&amp;D credits that can be utilized in future years. NOL carryforwards and R&amp;D credits are subject
to examination in the year they are utilized regardless of whether the tax year in which they are generated has been closed by
statute. The amount subject to disallowance is limited to the amount utilized. Accordingly, the Company may be subject to examination
for prior NOLs and credits generated as such tax attributes are utilized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has not
recorded any amounts for unrecognized tax benefits as of December 31, 2020 and 2019. The Company&rsquo;s practice is to recognize
interest and penalties related to income tax matters in income tax expense. The Company had no accrual of interest and penalties
on the Company&rsquo;s balance sheets and has not recognized interest and penalties in the consolidated statements of operations
and comprehensive loss for the years ended December 31, 2020 and 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is subject to taxation in the United States and
Australia. The Company&rsquo;s tax returns from 2014 to present are subject to examination by the United States and state authorities
due to the carry forward of unutilized net operating losses and R&amp;D credits. There are currently no pending examinations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.
Stock-Based Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2020
Stock Plan</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In December 2020, in connection with the Reverse Recapitalization,
the Company&rsquo;s board of directors approved the 2020 Stock Plan (the &ldquo;2020 Stock Plan&rdquo;) and reserved 12,000,000
shares of Common Stock for issuance thereunder, all of which may be issued pursuant to incentive stock options or any other type
of award under the 2020 Stock Plan. The 2020 Stock Plan became effective immediately upon the closing of the Reverse Recapitalization.
The maximum number of shares of Common Stock that may be issued pursuant to the exercise of incentive stock options under the 2020
Stock Plan is 12,000,000. The Company&rsquo;s selected employees, officers, directors and consultants are eligible to participate
in the traditional stock option grants, stock appreciation rights, restricted stock awards, restricted stock unit awards, other
stock awards, and performance awards under the 2020 Stock Plan. The purpose of this 2020 Stock Plan is to enable the Company to
offer competitive equity compensation packages in order to attract and retain the talent necessary for the Combined Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The 2020 Stock Plan is administered by the Company&rsquo;s Board
of Directors. The exercise prices, vesting periods and other restrictions are determined at the discretion of the Company&rsquo;s
Board of Directors, except that the exercise price per share of options may not be less than 100% of the fair market value of the
Common Stock on the date of grant. Stock options awarded under the 2020 Stock Plan expire ten years after the grant date, unless
the Company&rsquo;s Board of Directors sets a shorter term. Stock options and restricted stock granted to employees, officers,
members of the Company&rsquo;s Board of Directors and consultants generally vest over a four-year period. If an option or other
award granted under the 2020 Stock Plan expires, terminates or is cancelled, the unissued shares subject to that option or award
shall again be available under the 2020 Stock Plan. If shares awarded pursuant to the 2020 Stock Plan are forfeited to or repurchased
at original cost by the Company, the number of shares forfeited or repurchased at original cost shall again be available under
the 2020 Stock Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 30, 2020, the Company granted 1,507,062 restricted
stock units under the 2020 Stock Plan. As of December 31, 2020, 10,492,938 shares remained available for future grant.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2014
Stock Plan</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the closing of the Reverse Recapitalization, the 2014 Stock Plan is administered by the Company&rsquo;s Board of Directors. Stock
options awarded under the 2014 Stock Plan expire ten years after the grant date. Stock options and restricted stock granted to
employees, officers, members of the Company&rsquo;s Board of Directors and consultants typically vest over a four-year period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of
                                                                                                                                                                                                     the Reverse Recapitalization (as described in Note 1), stock options outstanding under the 2014 Stock Plan of 53,286,115 were
                                                                                                                                                                                                     converted into 7,032,590 of stock options of the Company based on the Exchange Ratio determined in accordance with the terms
                                                                                                                                                                                                     of the Merger Agreement. The exchange of Clene Nanomedicine&rsquo;s stock options for Clene Inc. stock options was treated as
                                                                                                                                                                                                     a modification of the awards. The modification of the stock options did not result in a material incremental compensation
                                                                                                                                                                                                     expense to be recognized at the closing of the Reverse Recapitalization.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2020, the Company granted stock options for 270,555 shares under the 2014 Stock Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31,
2019, there were 6,720,065 common shares authorized for grant to employees, officers, directors, and consultants under the 2014
Stock Plan. Effective as of the closing of the Reverse Recapitalization on December 30, 2020, no additional awards may be made
under the 2014 Stock Plan and as a result, (i) any shares in respect of stock options that are expired or terminated under the
2014 Stock Plan without having been fully exercised will not be available for future awards; (ii) any shares in respect of restricted
stock that are forfeited to, or otherwise repurchased by the Company, will not be available for future awards; and (iii) any shares
of Common Stock that are tendered to the Company by a participant to exercise an award will not be available for future awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2019, the Company granted stock options for 1,440,717 shares under the 2014 Stock Plan. There were 388,283 shares
available for grant under the 2014 Stock Plan as of December 31, 2019.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation for the years ended December 31, 2020 and 2019 was approximately $0.8 million and $0.4 million, respectively, and
is recorded in research and development and general and administrative expenses in the consolidated statement of operations and
comprehensive loss as follows:</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif;  width: 100%">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(In
    thousands)</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">General
    and administrative</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">281</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">161</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research
    and development</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">480</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">238</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    stock-based compensation</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">761</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">399</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2020, the Company had approximately $2.4 million of unrecognized stock-based compensation costs related to non-vested
awards which is expected to be recognized over a weighted-average period of 2.04 years.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following sets
forth the outstanding Common Stock options and related activity for the year ended December 31, 2020 (in thousands, except share
and per share data):</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Equity</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&nbsp;of<BR> Options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <BR> Average <BR> Exercise <BR> Price <BR> Per Share</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <BR> Average <BR> Remaining <BR> Term <BR> (Years)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Instrinsic <BR> Value</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-indent: -9pt; padding-left: 9pt">Outstanding - December 31, 2018</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">5,698,090</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.38</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">6.62</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">11,089</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 0.25in">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,440,717</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.42</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.66</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 0.25in">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,878</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.83</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Forfeited</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(248,757</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1.44</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">Outstanding - December 31, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,878,172</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.83</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.36</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,105</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 0.25in">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">270,555</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.48</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.32</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 0.25in">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(83,232</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.94</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">740</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Forfeited</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(32,904</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1.65</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Outstanding - December 31, 2020</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,032,591</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">0.97</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5.34</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">62,462</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Options vested and exercisable - December 31, 2020</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5,896,034</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">0.55</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4.86</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">52,694</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Options vested and exercisable - Stock options vested and expected to vest December 31, 2020</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,032,591</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">0.97</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5.34</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">62,462</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the consummation
of the Reverse Recapitalization, the exercise price of the stock options granted was based on the fair market value of the common
shares of the Company as of the grant date as determined by the Board of Directors, with input from the Company&rsquo;s management.
The Board of Directors determined the fair value of the common stock at the time of grant of the options by considering a number
of objective and subjective factors, including third-party valuation reports, valuations of comparable companies, sales of redeemable
convertible Preferred Stock, sales of common stock to unrelated third parties, operating and financial performance, the lack of
liquidity of the Company&rsquo;s capital stock, and general and industry-specific economic outlook.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
options are valued using the Black-Scholes option pricing model. Since the Company has limited trading history of its common stock,
the expected volatility is derived from the average historical stock volatilities of several unrelated public companies within
the Company&rsquo;s industry that the Company considers to be comparable to its own business over a period equivalent to the expected
term of the stock option grants. The risk-free interest rate for periods within the contractual life of the stock options is based
on the U.S. Treasury yield curve in effect at the time of the grant. The expected dividend is assumed to be zero as the Company
has never paid dividends and has no current plans to do so. The expected term represents the period that stock-based awards are
expected to be outstanding. For option grants that are considered to be &ldquo;plain vanilla,&rdquo; the Company determines the
expected term using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the
contractual life of the options. For other option grants, the Company estimates the expected term using historical data on employee
exercises and post-vesting employment termination behavior taking into account the contractual life of the award.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assumptions used to calculate the value of the stock option awards granted in 2020 and 2019 are presented as follows:</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.25in; padding-left: 0.25in; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.25in; padding-left: 0.25in; width: 72%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    stock price volatility</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 12%; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">75.00%
- 119.30%</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 12%; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">75.00%</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.25in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Risk-free
    interest rate</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.39%
                                         - 0.53%</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.46%</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.25in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    dividend yield</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">0%</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">0%</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.25in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    term of options</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">6
years</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">6
                                         years</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>


<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average grant-date fair value of options granted during the years ended December 31, 2020 and 2019 was $2.3923 and $1.5806,
respectively.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Restricted Stock Units</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 30, 2020,
the Company granted the following shares of restricted common stock under the 2020 Stock Plan:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">370,101 shares to various employees and non-employee directors,
which vest on June 30, 2021, subject to the employee&rsquo;s continuous employment through such vesting date. The award represents
5% of the converted stock options under 2014 Stock Plan as a result of the Reverse Recapitalization and complements the 5% closing
payment shares held in escrow for Clene Nanomedicine common shareholders (as described in Note 1). The grant-date fair value of
these awards was $4.0 million.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">454,781 shares to various employees and non-employee directors, which were eligible to vest based on certain market conditions, subject to the employee&rsquo;s continuous employment through such vesting date. The award complements the Milestone 1 earn-out share entitlement of Clene Nanomedicine shareholders and vests based on the same market condition (as described in Note 3). The grant-date fair value of these awards, using a Monte Carlo simulation, was $4.3 million. Based on the outcome of the market condition as of the December 31, 2020 measurement date, no shares were vested.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">341,090 shares to various employees and non-employee directors, which were eligible to vest based on certain market conditions, subject to the employee&rsquo;s continuous employment through such vesting date. The award complements the Milestone 2 earn-out share entitlement of Clene Nanomedicine. shareholders and vests based on the same market condition (as described in Note 3). The grant-date fair value of these awards, using a Monte Carlo simulation, was $3.5 million. Based on the outcome of the market condition as of the December 31, 2020 measurement date, no shares were vested.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">341,090 shares to various employees and non-employee directors,
which were eligible vest based on certain performance conditions tied to the completion of the COVID-19 coronavirus treatment study,
subject to the employee&rsquo;s continuous employment through such vesting date. The award complements the Milestone 3 earn-out
share entitlement of Clene Nanomedicine shareholders and vests based on the same performance condition (as described in Note 3).
The grant-date fair value of these awards was $3.7 million based on a weighted average grant date fair value of $10.82 per share.
The Company did not recognize compensation expense because the occurrence of achieving this milestone was not probable. As of the
December 31, 2020 measurement date, no shares were vested.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
summarizes the restricted common stock activity during the year ended December 31, 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&nbsp;of<BR> RSUs</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Grant Date Fair Value</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Unvested balance as of December 31, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%; text-indent: -9pt; padding-left: 0.25in">Granted</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,507,062</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">10.30</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Vested</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Unvested balance as of December 31, 2020</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,507,062</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">10.30</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The assumptions used
to calculate the value of the restricted stock units granted in 2020 in the Monte Carlo valuation model include projected stock
price, volatility and risk-free rate based on the achievement of certain stock price milestones. Our significant unobservable inputs
as of December 31, 2020 were as follows: (i) 85% of expected stock price volatility, (ii) risk-free interest rate of 0.4%, and
(iii) expected term of 5 years. The weighted average grant-date fair value of RSUs granted during the years ended December 31,
2020 and 2019 was $10.3034 and $0, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The stock-based compensation
expense associated with the RSUs were immaterial for the years ended December 31, 2020 and 2019. As of December 31, 2020, total
unrecognized compensation cost related to the unvested stock-based awards was $15.5 million, which is expected to be recognized
over a weighted average period of 8 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16.
Fair Value</B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The carrying amount
of cash and accounts payable approximates fair value because of the immediate, short-term maturity of these financial instruments.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liabilities
with Fair Value Measurements on a Recurring Basis&nbsp;&mdash; </B>The following tables present the Company&rsquo;s fair value
hierarchy for its liabilities measured at fair value on a recurring basis as of December 31, 2020 and 2019 (in thousands):</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value Measurements on a Recurring Basis<BR> December&nbsp;31, 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; text-indent: -9pt; padding-left: 9pt">Notes payable</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,296</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,296</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Clene Nanomedicine contingent earn-out</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">52,053</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">52,053</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Initial Shareholders contingent earn-out</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,906</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,906</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif;  width: 100%">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="14" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fair
    Value Measurements on a Recurring Basis<BR>
December&nbsp;31, 2019</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Level
                                         1</FONT></TD><TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Level
                                         2</FONT></TD><TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Level
                                         3</FONT></TD><TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Redeemable
    convertible preferred stock warrant liability</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,213</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,213</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notes
    payable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">640</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">640</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended
December 31, 2020, there was a transfer to Level 1 from Level 3 of the Company&rsquo;s notes payable as the fair value of the notes
payable is determined based on the Company&rsquo;s stock price listed on the Nasdaq. There were no other transfers between Level
1, Level 2 or Level 3. For the years ended December 31, 2019, there were no transfers between Level 1, Level 2, or Level 3.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Valuation
of the Notes Payable</I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The carrying value
of the notes payable includes certain notes remeasured at fair value on a recurring basis in the balance sheet as of December 31,
2020 and 2019. In order to value the note, the Company considers the amount of simple interest expense that would be due and considers
the value of Phantom Shares.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 125; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to becoming a public company, the Company&rsquo;s notes payable contained unobservable inputs that reflected the Company&rsquo;s
own assumptions. Accordingly, the Company&rsquo;s notes payable were measured at fair value on a recurring basis using unobservable
inputs. Significant unobservable inputs as of December 31, 2019 were the fair value of Series C Preferred Stock of $4.1699 per
share.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31,
2020, the fair value of the Company&rsquo;s Notes payable is determined based on the closing price of $9.01 per share for CLNN
listed on the Nasdaq.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Valuation
of Warrants to Purchase Preferred Stock</I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s Preferred Stock warrant liabilities contain unobservable inputs that reflect the Company&rsquo;s own assumptions.
Accordingly, the Company&rsquo;s Preferred Stock warrant liabilities were measured at fair value on a recurring basis using unobservable
inputs. Prior to the extinguishment of the Preferred Stock warrant liabilities on December 30, 2020 and on December 31, 2019,
the Preferred Stock warrant liability was valued using a Black-Scholes valuation model.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Significant unobservable
inputs at December 30, 2020 were the fair value of Series D Preferred Stock warrants of $10.82 per share, the fair value of Series
A Preferred Stock warrants of $10.82 per share, expected term of 2.3&nbsp;years, expected volatility of Series D Preferred Stock
warrants of 101%, and expected volatility of Series A Preferred Stock warrants of 101%. Significant unobservable inputs at December
31, 2019 were the fair value of Series C Preferred Stock warrants of $4.1699 per share, the fair value of Series A Preferred Stock
warrants of $3.1046 per share, expected term of 2&nbsp;years, expected volatility of Series C Preferred Stock warrants of 49%,
and expected volatility of Series A Preferred Stock warrants of 71%.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors
determines the fair value of the Preferred Stock by considering a number of objective and subjective factors, including third-party
valuations, valuations of comparable companies, sales of redeemable convertible Preferred Stock, sales of common stock to unrelated
third parties, operating and financial performance, the lack of liquidity of the Company&rsquo;s capital stock, and general and
industry-specific economic outlook. The Company estimated the volatility of its Preferred Stock based on comparable peer companies&rsquo;
historical volatility. The risk-free interest rate for periods within the contractual life of the warrants is based on the U.S.
Treasury yield curve in effect at the valuation date. The Company has no plans to declare any future dividends. The determination
of the fair value of the Preferred Stock warrant liability could change in future periods based upon changes in the value of the
Company&rsquo;s Preferred Stock and other assumptions as presented above. The Company records any such change in fair value to
the change in fair value of Preferred Stock warrant liability expense line in the consolidated statements of operations and comprehensive
loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the closing of
the Reverse Recapitalization (see Note 1), all of the outstanding Clene Nanomedicine Preferred Stock was converted to Clene Inc.
Common Stock and the Clene Nanomedicine Preferred Stock warrants were converted to warrants for the purchase of Clene Inc. Common
Stock. Accordingly, the Preferred Stock warrant liabilities were extinguished in connection with the conversion of Clene Nanomedicine
Preferred Stock on December 30, 2020 (see Note 9).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Valuation
of the Contingent Earn-out</I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Merger
Agreement, Clene Nanomedicine&rsquo;s common shareholders immediately prior to the Reverse Recapitalization and Initial Shareholders
of Totttenham were entitled to receive additional shares of up to 8,333,333 shares and 750,000 shares of the Company&rsquo;s Common
Stock, respectively, upon the Company achieving certain milestones described in Note 3. Upon the consummation of the Reverse Recapitalization,
Clene Nanomedicine and the Initial Shareholders are entitled to receive additional shares up to 8,346,185 shares as a result of
the exercise of the stock options in November 2020, and 750,000 shares of the Company&rsquo;s Common Stock. The Clene Nanomedicine
Contingent Earn-out and the Initial Shareholders Contingent Earn-out are recorded at fair value as contingent earn-out on the closing
of the Reverse Recapitalization on December 30, 2020 and remeasured at each reporting period. As of December 31, 2020, no milestone
has been achieved.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair value of the initial contingent earn-out is determined using a Monte Carlo analysis in order to simulate the future
path of the Company&rsquo;s stock price over the earn-out period. The carrying amount of the liability may fluctuate significantly
and actual amounts paid may be materially different from the liability&rsquo;s estimated value. As of December 31, 2020, the contingent
earn-out was revalued using a similar Monte Carlo analysis. The unobservable inputs to the model were as follows:</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 72%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    stock price volatility</FONT></TD>
    <TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 12%; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">85.00</FONT>%</TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif">N/A</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Risk-free
    interest rate</FONT></TD>
    <TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.40%</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">N/A</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    term</FONT></TD>
    <TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5
                                         years</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">N/A</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of changes in the fair value of the Company&rsquo;s financial liability related to the notes payable, the
derivative instrument, the Preferred Stock warrants, and the contingent earn-out measured at fair value as of December 31, 2020
and 2019 (in thousands):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Notes Payable</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Derivative Instrument</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Preferred Stock Warrants</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Clene Nanomedicine Contingent Earn-out</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Initial Shareholders Contingent Earn-out</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%">Balance - December 31, 2018</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,518</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Issuance of notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">600</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Change in fair value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">361</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; padding-bottom: 1.5pt; text-align: left">Exercise of Series C preferred stock warrants</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,666</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Balance - December 31, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">640</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,213</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Issuance of convertible promissory notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">705</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in">Initial fair value of instrument</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64,712</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,371</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Change in fair value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">656</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(29</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,615</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,659</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,465</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Extinguishment of preferred stock warrant liability in connection with the conversion of redeemable convertible preferred stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(17,828</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1.5pt; text-align: left">Extinguishment of derivative liability in connection with extinguishment of the 2020 Convertible Notes (Note 12)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(676</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Balance - December 31, 2020</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,296</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">52,053</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5,906</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17.
Redeemable Convertible Preferred Stock</B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Reverse
Recapitalization, the Company had issued Series A, B, C, and D Preferred Stock to various investors. Preferred stock is convertible
into common stock at the option of the holder at the conversion price. The Company evaluated the Preferred Stock and concluded
that it did not meet the criteria for being classified as a liability. However, the Company had determined that the Preferred Stock
should be classified as temporary equity, as the Company might be required to redeem the outstanding Preferred Stock in cash. The
Company had concluded that a redemption event is not probable. Accordingly, the value of Preferred Stock had not been adjusted
to its redemption amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of Preferred
Stock vote together with the holders of common stock as a single class. Voting rights are in proportion to the number of votes
equal to common stock shares into which preferred shares would be converted.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Redeemable
Preferred Stock</I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Between February and
April&nbsp;2015, the Company issued 16,066,503 shares of Series A Preferred Stock to several investors, at a price of $1.9658 per
share, for proceeds of $9.5 million in cash and $18.0 million by conversion of convertible promissory notes.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December&nbsp;2016, the Company issued 4,168,815 shares of Series B Preferred Stock at a price of $4.0778 per share and a buyout
option for proceeds of $16.6 million, net of issuance costs of $0.4 million. The Agreement provided the buyer with an exclusive
right and option to acquire all of the issued and outstanding stock of the Company on a fully diluted basis at a set price and
provides for future milestone payments to be made to existing shareholders of the Company based on achievement of certain milestones
defined within the Agreement. The purchase option was not exercised and was terminated by written notice received from the buyer
on September 21, 2017. The Company allocated the total cash consideration received of $16.6 million between the Series B Preferred
Stock and the buyout option based on the relative fair value of each instrument. The $3.4 million assigned to the buyout option
was treated as a contribution and recorded into additional paid-in capital.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Between August and
October&nbsp;2018, the Company issued 4,929,718 shares of Series C Preferred Stock to several investors. The Company issued 3,849,011
shares, at a price of $4.1699 per share, for proceeds of $15.9 million in cash, net of issuance costs of $0.2 million. $1.5 million
of the proceeds were allocated to the Series C Preferred Stock Warrants issued (see Note 9). The Company issued 1,080,707 shares
upon conversion of the convertible promissory notes (see Note 11).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Between March and July&nbsp;2019,
the Company issued 2,334,801 shares of Series C Preferred Stock to several investors. The Company issued 1,935,111 shares, at a
price of $4.1699 per share, for proceeds of $8.1 million in cash, net of immaterial issuance costs. The Company issued 399,690
shares on exercise of Series C Preferred Stock Warrants (see Note 9).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 127; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020, the
Company issued 9,394,057 shares of Series D Preferred Stock to several investors. The Company issued 7,896,922 shares, at a price
of $4.6018 per share, for proceeds of $35.1 million in cash, net of $1.3 million issuance costs. In addition, in connection with
the Company&rsquo;s issuance and sale of Series D preferred stock, all of the outstanding principal and accrued interest under
the 2020 Convertible Notes was automatically converted into an aggregate of 1,497,135 shares of Series D Preferred Stock. The Company
determined the fair value of the shares issued upon conversion to be $6.9 million, based on the preferred stock financing cash
price per share (see Note 11).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Series A Preferred
Stock, Series B Preferred Stock, Series C Preferred Stock, and Series D Preferred Stock are collectively referred as the &ldquo;Preferred
Stock.&rdquo; In connection with the closing of the Reverse Recapitalization, the Preferred Stock converted into 36,893,894 shares
of Common Stock on a 1:0.1389 basis (see Note 1).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2020, there was no Preferred Stock outstanding.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
Stock consisted of the following as of December 31, 2019 (in thousands, except share amounts):</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="18" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31, 2019</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Preferred<BR>
    Shares<BR> Authorized</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Preferred<BR>
    Shares<BR> Issued and<BR> Outstanding</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Carrying<BR>
    Value</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Liquidation<BR>
    Value</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common
    Stock<BR> Issuable Upon<BR> Conversion</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 40%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Series
    A Preferred Stock</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">17,675,175</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">16,066,503</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">27,485</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">31,584</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">16,066,503</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Series
    B Preferred Stock</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,168,815</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,168,815</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">16,582</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">16,999</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,168,815</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Series
    C Preferred Stock</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,192,018</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,264,519</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">28,594</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">30,292</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,264,519</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">31,036,008</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">27,499,837</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">72,661</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">78,875</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">27,499,837</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rights and preferences of Series A, Series B, Series C, and Series D Preferred Stock are as follows:</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Voting
Rights&nbsp;&mdash; </B>The holder of each share of Series A, Series B, Series C, and Series D Preferred Stock shall have the
right to one vote for each share of common stock into which such Series A, Series B, Series C, and Series D Preferred Stock could
then be converted.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Right to Elect Directors&nbsp;&mdash;
</B>As long as the majority of the Series A Preferred Stock issued remains outstanding, its holders shall be entitled to elect
two directors of the Company. The holders of Series B Preferred Stock are entitled to elect one director of the Company. The holders
of Series C Preferred Stock are entitled to elect one director of the Company. The holders of Preferred Stock and common stock
(voting together as a single class&nbsp;and not as separate series and on as-converted basis) shall be entitled to elect any remaining
director of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Dividend Rights&nbsp;&mdash;
</B>The holders of Preferred Stock are entitled to receive, when, as and if declared by the Board of Directors, out of any assets
of the Company legally available therefore, any dividends as may be declared from time to time by the Board of Directors. No dividend
may be declared or paid on the common stock (other than dividends payable in shares of common stock) unless any and all such dividends
or distributions are distributed among all holders of common stock and Preferred Stock in proportion as if the Preferred Stock
were converted to common stock at the effective conversion rate. The debt covenants of the Company&rsquo;s outstanding note payable
prohibit the issuance of dividends, see Note 8.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Preferred Stock
Protective Provisions&nbsp;&mdash; </B>As long as Preferred Stock originally issued remains outstanding, the Company shall not
without first obtaining the approval of the holders of at least a majority of the outstanding shares of Preferred Stock: (i)&nbsp;consummate
a liquidation event or effect any other merger or consolidation, (ii)&nbsp;amend, alter, or repeal any provision of the Certificate
of Incorporation, (iii)&nbsp;increase or decrease (other than redemption or conversion) the total number of authorized shares of
common stock or Preferred Stock, (iv)&nbsp;authorize or issue any equity security having a preference over, or being on a parity
of any series of Preferred Stock, (v)&nbsp;redeem, purchase, or acquire any shares of Preferred Stock or common stock, (vi)&nbsp;pay
or declare any dividend on any shares of capital stock of the Company, other than dividends payable in shares of common stock,
(vii)&nbsp;create or hold capital stock in any subsidiary that is not wholly owned by the Company or permit any direct or indirect
subsidiary to sell, lease, transfer, exclusively license, or otherwise dispose the assets of such subsidiary.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, Series B, Series C, and Series D Preferred Stock have protective provisions that prevent the Company from amending,
altering, or repealing any provision of the Certificate of Incorporation or Bylaws to adversely alter or change the powers, preferences
or special rights without first obtaining the approval of the holders of at least a majority of the outstanding shares of Series
B, Series C, and Series D Preferred Stock, respectively.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidation
Preference&nbsp;&mdash; </B>In case of any liquidation event, either voluntary or involuntary, the holders of Series D Preferred
Stock shall be entitled to receive out of the proceeds or assets of the Company available for distribution to its shareholders
prior and in preference to any distribution of the proceeds of such liquidation event to the holders of Series C Preferred Stock,
Series B Preferred Stock, Series A Preferred Stock, and common stock by reason of their ownership thereof, an amount per share
equal to the sum of the applicable original issue price for the Series D Preferred Stock plus declared but unpaid dividends on
such share. If, upon the occurrence of such event, the proceeds thus distributed among the holders of the Series D Preferred Stock
shall be insufficient to permit the payment to such holders of the full amounts, then the entire Proceeds legally available for
distribution shall be distributed ratably among the holders of the Series D Preferred Stock in proportion to the full preferential
amount that each such holder is entitled to receive.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
case of any liquidation event, either voluntary or involuntary, the holders of Series C Preferred Stock shall be entitled to receive
out of the proceeds or assets of the Company available for distribution to its shareholders prior and in preference to any distribution
of the proceeds of such liquidation event to the holders of Series B Preferred Stock, Series A Preferred Stock, and common stock
by reason of their ownership thereof, an amount per share equal to the sum of the applicable original issue price for the Series
C Preferred Stock plus declared but unpaid dividends on such share. If, upon the occurrence of such event, the proceeds thus distributed
among the holders of the Series C Preferred Stock shall be insufficient to permit the payment to such holders of the full amounts,
then the entire Proceeds legally available for distribution shall be distributed ratably among the holders of the Series C Preferred
Stock in proportion to the full preferential amount that each such holder is entitled to receive.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In case of any liquidation
event, either voluntary or involuntary, the holders of Series B Preferred Stock shall be entitled to receive out of the proceeds
or assets of the Company available for distribution to its shareholders prior and in preference to any distribution of the proceeds
of such liquidation event to the holders of Series A Preferred Stock, and common stock by reason of their ownership thereof, an
amount per share equal to the sum of the applicable original issue price for the Series B Preferred Stock plus declared but unpaid
dividends on such share. If, upon the occurrence of such event, the proceeds thus distributed among the holders of the Series B
Preferred Stock shall be insufficient to permit the payment to such holders of the full preferential amounts, then the remaining
Proceeds legally available for distribution after distribution to holders of the Series D Preferred Stock and Series C Preferred
Stock shall be distributed ratably among the holders of the Series B Preferred Stock in proportion to the full preferential amount
that each such holder is entitled to receive.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In case of any liquidation
event, either voluntary or involuntary, the holders of Series A Preferred Stock shall be entitled to receive out of the proceeds
or assets of the Company available for distribution to its shareholders prior and in preference to any distribution of the proceeds
of such liquidation event to the holders of common stock by reason of their ownership thereof, an amount per share equal to the
sum of the applicable original issue price for the Series A Preferred Stock plus declared but unpaid dividends on such share. If,
upon the occurrence of such event, the proceeds thus distributed among the holders of the Series A Preferred Stock shall be insufficient
to permit the payment to such holders of the full preferential amounts, then the remaining Proceeds legally available for distribution
after distribution to holders of the Series D Preferred Stock, Series C Preferred Stock and Series B Preferred Stock shall be distributed
ratably among the holders of the Series A Preferred Stock in proportion to the full preferential amount that each such holder is
entitled to receive For purposes of determining the amount each holder of shares of Preferred Stock is entitled to receive in a
liquidation event, each such holder shall be deemed to have converted into shares of common stock immediately prior to the Liquidation
Event if, as a result of an actual conversion, such holder would receive, in the aggregate, an amount greater than the amount that
would be distributed otherwise.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Redemption&nbsp;&mdash;
</B>The Series A, Series B, Series C, and Series D Preferred Stock are not redeemable at the option of the holder. However, so
long as a majority of the Preferred Stock originally issued remains outstanding, the Company shall not, without first obtaining
the approval of the holders of at least a majority of the then outstanding shares of Preferred Stock, redeem, purchase, or acquire
any share or shares of Preferred Stock or common stock, except the repurchase, if any, of shares of common stock from employees,
officers, directors, consultants, or other persons performing services for the Company.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Conversion
Rights &mdash;</B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Right to Convert.&nbsp;Each share of Preferred Stock shall be convertible, at the option of the holder thereof, at any time, into such number of fully paid and non-assessable shares of common stock as is determined by dividing the applicable original issue price by the applicable conversion price. The initial conversion price per share of Series A, Series B, Series C, and Series D Preferred Stock shall be $1.9658, $4.0778, $4.1699, and $4.6018, respectively, provided, however, that the conversion price shall be subject to adjustment as set forth below.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Automatic Conversion.&nbsp;Each share of Series A, Series B, Series C, and Series D Preferred Stock shall automatically be converted into shares of common stock upon the earlier of (i)&nbsp;the closing of the sale of common stock in an underwritten public offering pursuant to a registration statement under the Securities Act of 1933, the public offering price of which is not less than $30.0 million in the aggregate, (ii)&nbsp;the date, or the occurrence of an event, specified by vote or written consent, or agreement of the holders of a majority of the then outstanding shares of Preferred Stock (voting together as a single class&nbsp;and not as separate series and on an as-converted basis), or (iii) a closing of a merger with a publicly-traded entity that has no operations other than searching for an operating company with which to merge (a &ldquo;SPAC&rdquo;) at a value per share in accordance with the restated certification incorporation, resulting in at least $30.0 million of proceeds to the Company (including any cash acquired in the merger with the SPAC).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion
Price Adjustment.&nbsp;The conversion Price of Preferred Stock shall be subject to adjustment as follows: If the Company shall
issue any additional stock (as defined in the associated agreement) without consideration or for a consideration per share less
than the Conversion Price in effect immediately prior to the issuance of such additional stock, the Conversion Price shall be
adjusted.</FONT></TD>
</TR></TABLE>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18.
Common Stock</B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2020, the Company&rsquo;s certificate of incorporation, as amended and restated, authorized the Company to issue
100,000,000 shares of the Company&rsquo;s Common Stock, par value $0.0001 per share and 1,000,000 shares of the Company&rsquo;s
Preferred Stock, par value $0.0001 per share.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s
common shareholders are entitled to one vote per share and to notice of any shareholders&rsquo; meeting. Voting, dividend and liquidation
rights of the holders of Common Stock are subject to the prior rights of holders of all classes of stock and are qualified by the
rights, powers, preferences and privileges of the holders of Preferred Stock. No distributions shall be made with respect to Common
Stock until all declared dividends to Preferred Shares have been paid or set aside for payment to the holders of Preferred Stock.
Common Stock is not redeemable at the option of the holder.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the closing of the Reverse Recapitalization, the total 2,303,495 of the Tottenham ordinary shares held by the Initial Shareholders
and public shareholders were converted into the same number of Company&rsquo;s Common Stock (see Note 3).</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the closing of the Reverse Recapitalization, 644,164 shares of the Company&rsquo;s Common Stock were issued to LifeSci as financial
advisor to the Reverse Recapitalization (see Note 3).</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 28, 2020 and
prior to the closing of the Reverse Recapitalization, various PIPE investors purchased 2,239,500 shares of the Company&rsquo;s
Common Stock at a price of $10.00 per share and 1,119,750 warrants to purchase, at an exercise price of $0.01 per share, one share
of the Company&rsquo;s Common Stock for net proceeds of $22.2 million (see Notes 1 and 3).</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31,
2020, the Company&rsquo;s common shares issued and outstanding are 59,526,171 and there are no preferred shares issued and outstanding
(see Note 17).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>19.
Net Loss Per Share Attributable to Common Shareholders</B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the computation of basic and diluted net loss per share attributable to common shareholders (in thousands,
except share and per share data):</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<BR> December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Numerator:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -0.125in; padding-left: 0.25in">Net loss attributable to common shareholders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(19,277</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(16,155</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">Denominator:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">Weighted average shares outstanding</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">17,503,992</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">17,357,505</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Net loss per share attributable to common shareholders, basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1.10</TD><TD STYLE="padding-bottom: 2pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.93</TD><TD STYLE="padding-bottom: 2pt; text-align: left">)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 130; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Included within weighted
average common shares outstanding are 1,119,750 common shares issuable upon the exercise of the PIPE warrants as the warrants are
exercisable at any time for nominal consideration, and as such, the shares are considered outstanding for the purpose of calculating
basic and diluted net loss per share attributable to common shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has not
considered the effect of the Chardan Unit Purchase Option that would convert to 242,000 shares of the Company&rsquo;s Common Stock
and warrants to purchase 110,000 shares of the Company&rsquo;s Commons Stock, in the calculation of diluted loss per share, since
the conversion of the Chardan Unit Purchase Option and the exercise of the Chardan Unit Purchase Option Warrants into the Company&rsquo;s
Commons Stock would be anti-dilutive (see Notes 1 and 10).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share
attributable to common shareholders for the periods presented because including them would have been antidilutive:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
    of<BR>
December&nbsp;31,</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Series
    C redeemable convertible preferred stock</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,264,519</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Series
    B redeemable convertible preferred stock</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,168,815</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Series
    A redeemable convertible preferred stock</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">16,066,503</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Series
    C redeemable convertible preferred stock warrants</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">271,439</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Series
    A redeemable convertible preferred stock warrants</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,608,672</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common
    stock warrants (see Note 10)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,336,613</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Options
    to purchase common stock</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,032,591</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,878,172</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chardan
    Unit Purchase Option to purchase common stock (see Note 1)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">242,000</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chardan
    Unit Purchase Option Warrants (see Notes 1 and 10)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">110,000</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Earn-out
    shares (see Note 3 and 12)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,096,185</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 4pt; vertical-align: top; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">20,817,389</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">36,258,120</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>20.
Related Party Transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Related
Party Payables</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
years prior to 2020, the Company incurred expenses for compensation for consulting services provided by a member of the Board
of Directors. These expenses were fully paid as of December 31, 2020. As of December 31, 2019, the outstanding balance of $0.1
million was recorded in accounts payable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Supply
Agreement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In August&nbsp;2018, in
conjunction with an investment made in the Company&rsquo;s Series C Preferred Stock and Series C Preferred Stock Warrants by 4Life,
LLC, an investor, the Company entered into a supply agreement with the investor. Under the terms of this agreement, the Company
granted the investor an exclusive license to pursue development of dietary supplements using certain of the Company&rsquo;s intellectual
property (IP). The exclusive rights to the IP will be for a term of 5&nbsp;years from the commencement of sales of licensed product
by the investor, with a deemed commencement date of January 1, 2023 if sales have not yet commenced, and is subject to annual minimum
sales. The agreement may be renewed for additional 5-year terms. If the investor fails to meet the annual minimum sales requirements,
the investor may pay an additional fee to maintain exclusivity or have the investor&rsquo;s license converted to non-exclusive
rights. As part of this agreement, the Company will provide non-pharmaceutical product to the investor for development efforts
and potential future production, and the investor is to pay royalties of 3% of incremental sales, as defined in the agreement.
As of December 31, 2020, the Company had sold $70 thousand of product under this agreement, as well as $62 thousand of product
not under this agreement, and received $0.1 million in advance to be applied against future sales of product under this agreement.
The Company recorded this advanced amount as deferred revenue as of December 31, 2020 within accrued liabilities, and the Company
expects to fulfil the performance obligations to release the deferred revenue in the first half of 2021 as the investor purchases
product. As of December 31, 2020, the investor has made commercial sales of their products under the agreement which the Company
recognized as royalty revenues of $30 thousand. As of and for the year ended December 31, 2019, the Company had not sold any product
under this agreement, and there were no balances outstanding due to or from the investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 131; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>21.
Geographic and Segment Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Geographic
Information</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s long-lived assets, which were composed of property and equipment, net by location was as follows (in thousands):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; padding-left: 0.125in; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
    of<BR>
December&nbsp;31,</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; padding-left: 0.125in; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">United
    States</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,997</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,908</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Australia</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">228</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">411</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    property and equipment, net</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,225</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,319</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Segment
Information</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31,
2019, the Company had a single operating segment, development and commercialization of proprietary nanotechnology drug suspensions
(&ldquo;Drugs&rdquo;). The Company identified a second segment, development and commercialization of proprietary dietary supplements
(&ldquo;Supplements&rdquo;), in January&nbsp;2020. The Company&rsquo;s chief operating decision maker, the CEO, now obtains and
reviews separate financial information for Supplements in deciding how to allocate resources to the segments and in assessing performance.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
operating results of the Company&rsquo;s Drugs and Supplements segments for the years ended December 31, 2020 and 2019 were as
follows (in thousands):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
    of<BR>
December 31,<BR>
2020</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Drugs</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Supplements</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Revenue
    from external customers</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">206</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">206</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Loss)
    Income from operations</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(20,355</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">141</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(20,214</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<BR>
December&nbsp;31,<BR>
2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Drugs</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Supplements</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Revenue from external customers</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Loss from operations</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(16,332</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(16,332</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company&rsquo;s long-lived assets, which were composed of property and equipment, net by segment was as follows (in thousands):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<BR> December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-indent: -9pt; padding-left: 9pt">Drugs</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3,990</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,319</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Supplements</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">235</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total property and equipment, net</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4,225</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4,319</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 132; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>22.
Subsequent Events</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">On
January 11, 2021, the U.S. Small Business Administration notified the Company that the PPP loan of $0.6 million was forgiven.
On that date, the Company recorded a gain on forgiveness of the PPP loan of $0.6 million in its consolidated statement of operations
and comprehensive loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 27, 2021,
the Company was awarded the Michael J. Fox Foundation grant for $0.5 million and funding is milestone based. On that date, the
grant was recorded in accrued liabilities in the consolidated balance sheets, and as the associated conditions or obligations are
met, the grant funding will be recognized as a reduction in research and development expenses in the consolidated statements of
operations and comprehensive loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 16, 2021,
the Company filed a registration statement on Form S-1 to register 4,541,481 shares of Common Stock underlying outstanding warrants
that the Company had issued, among which 2,517,500 and 904,231 warrants were originally issued by Tottenham and Clene Nanomedicine,
respectively, prior to the closing of the Reverse Recapitalization, and 1,119,750 warrants were issued as part of the PIPE offering
in connection with the closing of the Reverse Recapitalization. The Company will receive aggregate gross proceeds of $30.7 million
if all of these warrants are exercised. In addition, the registration statement on Form S-1 included 23,251,553 shares of the Common
Stock to be registered for possible sale by the selling shareholders. The Company will not receive any proceeds from the sales
by the selling shareholders. Incident to the registration of the Common Stock, the Company incurred certain offering costs, which
will be recognized as an expense within general and administrative expenses on the consolidated statement of operations and comprehensive
loss in the first quarter of 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 133; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_014"></A>ITEM
9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_015"></A>ITEM
9A. CONTROLS AND PROCEDURES</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Evaluation of Disclosure Controls and
Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the supervision
and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an
evaluation of the effectiveness of our disclosure controls and procedures as of December 31, 2020, as such term is defined in Rules
13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer
have concluded that, as of December 31, 2020, our disclosure controls and procedures were not effective due to the material weaknesses
in internal control over financial reporting described below. Notwithstanding the identified material weaknesses, management, including
our Chief Executive Officer and Chief Financial Officer, believes the consolidated financial statements included in this Annual
Report on Form 10-K fairly represent in all material respects our financial condition, results of operations and cash flows at
and for the periods presented in accordance with U.S. GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Disclosure controls
and procedures are designed to ensure that information required to be disclosed by us in the reports that we file or submit under
the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&rsquo;s rules and
forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief
Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Material Weaknesses in Internal Control
over Financial Reporting </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection
with the audit of Clene&rsquo;s financial statements as of and for the years ended December 31, 2020 and 2019, Clene&rsquo;s
management identified material weaknesses in its internal control over financial reporting. A material weakness is a
deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable
possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a
timely basis. The material weaknesses identified relate to the fact that Clene did not design or maintain an effective
control environment commensurate with its financial reporting requirements, including (a) lack of a sufficient number of
trained professionals with an appropriate level of accounting knowledge, training and experience to appropriately analyze,
record and disclose accounting matters timely and accurately, and (b) lack of structures, reporting lines and appropriate
authorities and responsibilities to achieve financial reporting objectives. This deficiency in Clene&rsquo;s control
environment contributed to the following additional deficiencies (each of which individually represents a material weakness)
in Clene&rsquo;s internal control over financial reporting:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clene did not design and maintain formal accounting policies, procedures and controls to achieve complete, accurate and timely financial accounting, reporting and disclosures, including controls over the preparation and review of account reconciliations and journal entries;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clene did not design and maintain effective controls over segregation of duties related to manual journal entries. Specifically, certain personnel have the ability to both prepare and post manual journal entries without an independent review by someone without the ability to prepare and post manual journal entries;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clene did not design and maintain formal accounting policies, processes and controls to analyze, account for and disclose complex transactions. Specifically, Clene did not design and maintain controls to analyze, account for and disclose warrants to purchase preferred stock and convertible promissory notes with embedded derivatives, including ensuring complete and accurate data was used in the valuations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clene did not design and maintain effective controls over certain information technology (&ldquo;IT&rdquo;) general controls for IT systems that are relevant to the preparation of the financial statements. Specifically, Clene did not design and maintain: (a) user access controls to ensure appropriate segregation of duties and that adequately restrict user and privileged access to financial applications, programs, and data to appropriate personnel of Clene, (b) program change management controls to ensure that IT program and data changes affecting financial IT applications and underlying accounting records are identified, tested, authorized and implemented appropriately, (c) computer operations controls to ensure that data backups are authorized and monitored, and (d) testing and approval controls for program development to ensure that new software development is aligned with business and IT requirements.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 134; Options: NewSection; Value: 96 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The control
deficiencies described above resulted in the misstatement of Clene&rsquo;s redeemable convertible preferred stock warrant
liability, accrued liabilities, general and administrative expenses, Australian research and development credit, and amounts
and classification within our statement of cash flows and related financial disclosures as of and for the year ended December
31, 2019 and in the misstatement of Clene&rsquo;s prepaid expenses and other current assets, accrued liabilities, earn-out
liabilities, redeemable convertible preferred stock warrant liability, general and administrative expenses, amounts and
classification within our statement of equity, and amounts and classification within our statement of cash flows and related
financial disclosures as of and for the year ended December 31, 2020. Additionally, each of the control deficiencies
described above could result in a misstatement of one or more account balances or disclosures that would result in a material
misstatement to the annual or interim consolidated financial statements that would not be prevented or detected. Accordingly,
Clene&rsquo;s management has determined that each of the control deficiencies described above constitute material
weaknesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Material Weakness Remediation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management is actively
engaged and committed to taking the steps necessary to remediate the control deficiencies that constituted the above material weakness.
During 2020, we made the following enhancements to our control environment:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We added finance personnel to the organization to strengthen our internal accounting team, to provide oversight, structure and reporting lines, and to provide additional review over our disclosures to include a Chief Financial Officer and a Manager of SEC Reporting;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We engaged outside consultants to assist in the design, implementation, and documentation of internal controls that address the relevant risks, are properly designed, and provide for appropriate evidence of performance of the internal control; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">We engaged outside consultants to assist us in the evaluation
of a new Enterprise Resource Planning (&ldquo; ERP&rdquo;) system in order to mitigate the internal control gaps and limitations
that cannot be addressed by the current ERP around segregation of duties, and to enhance the information technology general controls
environment.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our remediation activities
are continuing during 2021. In addition to the above actions, we expect to engage in additional activities, including, but not limited
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adding more technical accounting resources to enhance our control environment;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
    we have sufficient technical accounting resources, engaging external consultants to provide support and to assist us in our evaluation of more complex
    applications of GAAP, and to assist us with documenting and assessing our accounting policies and procedures;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Implementing a new ERP to enhance the accuracy of our financial records, enable the enforcement of systematic segregation of duties, and to improve our information technology general controls environment.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We continue to enhance
corporate oversight over process-level controls and structures to ensure that there is appropriate assignment of authority, responsibility,
and accountability to enable remediation of our material weaknesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our
remediation plan will be sufficient to remediate the identified material weakness and strengthen our internal control over financial
reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As we continue to evaluate,
and work to improve, our internal control over financial reporting, management may determine that additional measures to address
control deficiencies or modifications to the remediation plan are necessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 135; Value: 96 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Changes in Internal Control over Financial
Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are engaged in the
process of the design and implementation of our internal control over financial reporting in a manner commensurate with the scale
of our operations following the Reverse Recapitalization. During the quarter ended December 31, 2020, there were changes in our
internal control over financial reporting which are described under &ldquo;Material Weakness Remediation&rdquo; above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Management&rsquo;s Report on Internal
Control Over Financial Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This report does not
include a report of management&rsquo;s assessment regarding internal control over financial reporting (&ldquo;ICFR&rdquo;) as allowed
by the SEC for reverse acquisitions between an issuer and a private operating company when it is not possible to conduct an assessment
of the private operating company&rsquo;s ICFR in the period between the consummation date of the reverse acquisition and the date
of management&rsquo;s assessment of ICFR (see Section 215.02 of the SEC Division of Corporation Finance&rsquo;s Regulation S-K
Compliance &amp; Disclosure Interpretations). As discussed elsewhere in this Annual Report on Form 10-K, we completed the Reverse
Recapitalization among the registrant and Tottenham Acquisition I Limited on December 30, 2020. Prior to the Reverse Recapitalization,
we were a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition,
stock purchase, reorganization, or similar business combination involving one or more businesses. As a result, previously existing
internal controls are no longer applicable or comprehensive enough as of the assessment date as our operations prior to the Reverse
Recapitalization were insignificant compared to those of the consolidated entity post-Reverse Recapitalization. The design of ICFR
for the Company post-Reverse Recapitalization has required and will continue to require significant time and resources from management
and other personnel. As a result, management was unable, without incurring unreasonable effort or expense, to conduct an assessment
of our ICFR as of December 31, 2020. If management were to conduct an assessment regarding the Company&rsquo;s ICFR, however, its
scope would include the criteria set forth by the Internal Control Integrated Framework (2013) issued by the Committee of Sponsoring
Organizations of The Treadway Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_016"></A>ITEM
9B. OTHER INFORMATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 136; Value: 96 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_017"></A>PART
III</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_018"></A>ITEM
10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
required by this Item regarding the Company&rsquo;s directors and corporate governance, including information with respect to
our corporate governance guidelines, Code of Business Conduct and Ethics and beneficial ownership reporting compliance, will appear
in the Proxy Statement we will deliver to our stockholders in connection with our 2021 Annual Meeting of Stockholders. Such information
is incorporated herein by reference. Information relating to our executive officers is included in Item 1 of Part I, &ldquo;Business&mdash;Executive
Officers.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_019"></A>ITEM
11. EXECUTIVE COMPENSATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this Item will appear in the Proxy Statement we will deliver to our stockholders in connection with our
2021 Annual Meeting of Stockholders. Such information is incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_020"></A>ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this Item regarding security ownership of certain beneficial owners and management will appear in the
Proxy Statement we will deliver to our stockholders in connection with our 2021 Annual Meeting of Stockholders. Such information
is incorporated herein by reference. Information relating to securities authorized for issuance under the Company&rsquo;s equity
compensation plans is included in Part II of this Annual Report under &ldquo;Item 5&ndash;Market for Registrant&rsquo;s Common
Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_021"></A>ITEM
13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this Item will appear in the Proxy Statement we will deliver to our stockholders in connection with our
2021 Annual Meeting of Stockholders. Such information is incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_022"></A>ITEM
14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this Item will appear in the Proxy Statement we will deliver to our stockholders in connection with our
2021 Annual Meeting of Stockholders. Such information is incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 137; Value: 96 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_023"></A>PART
IV</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_024"></A>ITEM
15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         following are filed with this Annual Report:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         following financial statements are included in Item 8 of this Annual Report</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
                                         applicable</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<TD STYLE="width: 0in; font-family: Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following exhibits are filed as part of this Annual Report or are incorporated by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 138; Value: 96 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_025"></A>EXHIBIT
INDEX</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1731176/000121390020025950/fs42020_chelsea-tott.htm#T301">Merger
    Agreement, dated as of September 1, 2020 (incorporated by reference to Annex&nbsp;A-1 to the Proxy Statement/Consent Solicitation
    Statement/Prospectus on Form&nbsp;S-4 filed by the Registrant on September&nbsp;10, 2020).</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1822791/000121390021000487/ea132520ex3-1_cleneinc.htm">Amended
    and Restated Certificate of Incorporation of Clene Inc. (incorporated by reference to Exhibit&nbsp;3.1 to the Current Report
    on Form&nbsp;8-K filed by the Registrant on January 5, 2021).</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1822791/000121390021000487/ea132520ex3-2_cleneinc.htm">Bylaws
    of Clene Inc. (incorporated by reference to Exhibit 3.2 to the Current Report on Form&nbsp;8-K filed by the Registrant on
    January 5, 2021).</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/0001731176/000168316818001874/tottenham_s1-ex0403.htm" STYLE="-sec-extract: exhibit">Specimen TOTA Warrant Certificate (incorporated by reference to Exhibit 4.4 to the Tottenham Registration Statement on Form&nbsp;S-1 filed with the Securities&nbsp;&amp; Exchange Commission on July 5, 2018)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1731176/000168316818002163/tottenham_ex0401.htm">Warrant
    Agreement, dated August 1, 2018, by and between Continental Stock Transfer&nbsp;&amp; Trust Company and the Registrant (incorporated
    by reference to Exhibit 4.5 to the Current Report on Form&nbsp;8-K filed with the Securities and Exchange Commission on August
    7, 2018).</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1731176/000121390020025950/fs42020ex10-10_chelseatott.htm">Form
    of Registration Rights Agreement (incorporated by reference to Exhibit 10.10 to the Registration Statement on Form&nbsp;S-4
    filed by Chelsea Worldwide Inc. with the Securities and Exchange Commission on December 15, 2020)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1822791/000121390020037923/fs42020a4ex10-8_chelsea.htm">Escrow
    Agreement, by and among Clene Inc., Fortis Advisors LLC and Continental Stock Transfer&nbsp;&amp; Trust Company, as the escrow
    agent (incorporated by reference to Exhibit 10.8 to the Registration Statement on Form&nbsp;S-4 filed by Chelsea Worldwide
    Inc. with the Securities and Exchange Commission on December 15, 2020)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1822791/000121390020041247/fs42020a5ex10-18_chelsea.htm">Form
    of Indemnification Agreement between the Registration and its directors and executive officers (incorporated by reference
    to Exhibit 10.18 to the Registration Statement on Form&nbsp;S-4 filed by Chelsea Worldwide Inc. with the Securities and Exchange
    Commission on December 15, 2020)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1822791/000121390020031913/fs42020a2ex10-14_chelsea.htm">License
    Agreement, effective August 31, 2018, between Clene Nanomedicine, Inc. and 4Life Research, LLC (incorporated by reference
    to Exhibit 10.14 to the Registration Statement on Form&nbsp;S-4 filed by Chelsea Worldwide Inc. with the Securities and Exchange
    Commission on December 15, 2020)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1822791/000121390020031913/fs42020a2ex10-15_chelsea.htm">Exclusive
    Supply Agreement, dated August 31, 2018, between Clene Nanomedicine, Inc. and 4Life Research, LLC (incorporated by reference
    to Exhibit 10.15 to the Registration Statement on Form&nbsp;S-4 filed by Chelsea Worldwide Inc. with the Securities and Exchange
    Commission on December 15, 2020)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1822791/000121390020031913/fs42020a2ex10-16_chelsea.htm">Lease
    Agreement, dated May 9, 2016, and First Amendment of Lease Agreement, dated January 6, 2017, between Upper Chesapeake Flex
    One, LLC and Clene Nanomedicine, Inc. (incorporated by reference to Exhibit 10.16 to the Registration Statement on Form&nbsp;S-4
    filed by Chelsea Worldwide Inc. with the Securities and Exchange Commission on December 15, 2020)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1822791/000121390020031913/fs42020a2ex10-17_chelsea.htm">Clinical
    Research Support Agreement, dated September 27, 2019, between Clene Nanomedicine, Inc. and The General Hospital Corporation
    (incorporated by reference to Exhibit 10.17 to the Registration Statement on Form&nbsp;S-4 filed by Chelsea Worldwide Inc.
    with the Securities and Exchange Commission on December 15, 2020)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1822791/000121390021000487/ea132520ex10-4_cleneinc.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020
Equity Incentive Plan (Incorporated by reference to Exhibit 10.4 to the registrant&rsquo;s Registration Statement on Form 8-K
filed by the registrant on January 5, 2021)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1822791/000121390021000487/ea132520ex21-1_cleneinc.htm">Subsidiaries of Registrant (Incorporated by reference to Exhibit 21.1 to the registrant&rsquo;s Current Report on Form 8-K filed by the registrant on January 5, 2021)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="f10k2020ex31-1_cleneinc.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="f10k2020ex31-2_cleneinc.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Financial Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="f10k2020ex32-1_cleneinc.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</A></FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">32.2</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="f10k2020ex32-2_cleneinc.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.1</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">XBRL Instance Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.2</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Schema Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.3</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Calculation Linkbase Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.4</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Definition Linkbase Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.5</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Label Linkbase Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.6</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Presentation Linkbase Document</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 15%; font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Portions
    of this exhibit have been omitted pursuant to Rule 601(b)(10) of Regulation S-K. The omitted information is not material and
    would likely cause competitive harm to the registrant if publicly disclosed.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
    a management contract or a compensatory plan or agreement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 139; Value: 96 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the registrant caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CLENE INC.</B></FONT></TD></TR>
<TR>
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: March 26, 2021</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;/s/ Robert Etherington</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert Etherington</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief Executive Officer and Director</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act, this Annual Report on Form 10-K has been signed by the following persons in the capacities
and on the dated indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 40%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 40%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 18%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Robert Etherington</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief Executive Officer and Director</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 26, 2021</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert Etherington</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Ted (Tae Heum) Jeong</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 26, 2021</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ted (Tae Heum) Jeong</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Shalom Jacobovitz</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the board</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 26, 2021</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shalom Jacobovitz</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Alison Mosca</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 26, 2021</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alison Mosca</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jonathon Gay</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 26, 2021</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jonathon Gay</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ John Henry Stevens</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 26, 2021</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John Henry Stevens</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Reed Neil Wilcox</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 26, 2021</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reed Neil Wilcox</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Chidozie Ugwumba</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 26, 2021</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chidozie Ugwumba</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ David Matlin</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 26, 2021</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Matlin</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Fiona Costello</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 26, 2021</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fiona Costello</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.1pt">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">102</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>






</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>f10k2020ex31-1_cleneinc.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>CERTIFICATION</U></B></FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Robert Etherington, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this
    Annual Report on Form&nbsp;10-K&nbsp;of Clene Inc.;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
    to the period covered by this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
    material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
    presented in this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%; font-size: 10pt"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
    about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based
    on such evaluation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
    affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
    and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s
    other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
    to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
    the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
    information; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
March 26, 2021</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Robert Etherington</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert Etherington</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>f10k2020ex31-2_cleneinc.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-indent: 0; text-align: right; margin: 0"><B>Exhibit 31.2</B></P>

<P STYLE="text-indent: 0; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; background-color: white; text-indent: 0"><B><U>CERTIFICATION</U></B></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; background-color: white; text-indent: 0">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; background-color: white; text-indent: 0">I, Ted (Tae Heum) Jeong, certify that:</P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">I have reviewed this Annual Report on Form&nbsp;10-K&nbsp;of Clene Inc.;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and&nbsp;15d-15(e))&nbsp;and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; background-color: white"></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 4%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%; font-size: 10pt"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%; font-size: 10pt"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; background-color: white"></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  </TABLE>
<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; background-color: white; text-indent: 0">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; background-color: white; text-indent: 0">Date: March 26, 2021</P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; background-color: white; text-indent: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%"><FONT STYLE="font-size: 10pt">/s/ Ted (Tae Heum) Jeong&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Ted (Tae Heum) Jeong</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; background-color: white"></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>f10k2020ex32-1_cleneinc.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 32.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; background-color: white">Pursuant to the requirement set forth in
Rule&nbsp;13a-14(b)&nbsp;of the Securities Exchange Act of 1934, as amended, (the &ldquo;Exchange Act&rdquo;) and Section&nbsp;1350 of
Chapter 63 of Title 18 of the United States Code (18 U.S.C. &sect;1350),<B>&nbsp;</B>Robert Etherington, Chief Executive Officer of Clene
Inc. (the &ldquo;Company&rdquo;), hereby certifies that, to the best of his knowledge:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">The Company&rsquo;s Annual Report on Form&nbsp;10-K&nbsp;for the period ended December&nbsp;31, 2020, to which this Certification is attached as Exhibit 32.1 (the &ldquo;Annual Report&rdquo;), fully complies with the requirements of Section&nbsp;13(a) or Section&nbsp;15(d) of the Exchange Act; and</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">Dated: March 26, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%"><FONT STYLE="font-size: 10pt">/s/ Robert Etherington&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Robert Etherington</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="text-indent: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; text-align: justify; margin: 0; background-color: white">A signed original of this written statement
required by Section&nbsp;906 of 18 U.S.C. &sect;&nbsp;1350 has been provided to the Company, and will be retained by the Company and
furnished to the Securities and Exchange Commission or its staff upon request.</P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">This
certification accompanies the Form&nbsp;10-K&nbsp;to which it relates, is not deemed filed with the Securities and Exchange Commission
and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the
Exchange Act (whether made before or after the date of the Form&nbsp;10-K),&nbsp;irrespective of any general incorporation language
contained in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>f10k2020ex32-2_cleneinc.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0; font: 10pt Times New Roman, Times, Serif; background-color: white; text-indent: 0"><B>Exhibit
32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0; background-color: white; text-indent: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white; text-indent: 0"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify; background-color: white">Pursuant to the requirement set forth in
Rule&nbsp;13a-14(b)&nbsp;of the Securities Exchange Act of 1934, as amended, (the &ldquo;Exchange Act&rdquo;) and Section&nbsp;1350 of
Chapter 63 of Title 18 of the United States Code (18 U.S.C. &sect;1350),<B>&nbsp;</B>Ted (Tae Heum) Jeong, Chief Financial Officer of
Clene Inc. (the &ldquo;Company&rdquo;), hereby certifies that, to the best of his knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">The Company&rsquo;s Annual Report on Form&nbsp;10-K&nbsp;for the period ended December&nbsp;31, 2020, to which this Certification is attached as Exhibit 32.1 (the &ldquo;Annual Report&rdquo;), fully complies with the requirements of Section&nbsp;13(a) or Section&nbsp;15(d) of the Exchange Act; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0">Dated: March 26, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%"><FONT STYLE="font-size: 10pt">/s/ Ted (Tae Heum) Jeong&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Ted (Tae Heum) Jeong</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; background-color: white">Chief
Financial Officer</P>

</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0">A signed original of this written statement
required by Section&nbsp;906 of 18 U.S.C. &sect;&nbsp;1350 has been provided to the Company, and will be retained by the Company and
furnished to the Securities and Exchange Commission or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0">This certification accompanies the Form&nbsp;10-K&nbsp;to
which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any
filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the
Form&nbsp;10-K),&nbsp;irrespective of any general incorporation language contained in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>clnn-20201231.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Mar 26 16:52:33 EDT 2021 -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:pf0="http://xbrl.sec.gov/exch/2020-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:pf1="http://xbrl.sec.gov/country/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:compsci="http://compsciresources.com" xmlns:clnn="http://www.cleaninccom/20201231" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="clnn-20201231.xsd"/>
  <context id="c0_From1Jan2020To31Dec2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c1_AsOf25Mar2021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
    </entity>
    <period>
      <instant>2021-03-25</instant>
    </period>
  </context>
  <context id="c2_AsOf30Jun2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
    </entity>
    <period>
      <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="c3_AsOf31Dec2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c4_AsOf31Dec2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c5_From1Jan2020To31Dec2020_ProductMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c6_From1Jan2019To31Dec2019_ProductMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c7_From1Jan2020To31Dec2020_RoyaltyMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c8_From1Jan2019To31Dec2019_RoyaltyMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c9_From1Jan2019To31Dec2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c10_AsOf31Dec2018_RedeemableConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c11_AsOf31Dec2018_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c12_AsOf31Dec2018_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c13_AsOf31Dec2018_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c14_AsOf31Dec2018_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c15_AsOf31Dec2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c17_From1Jan2019To31Dec2019_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c19_From1Jan2019To31Dec2019_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c21_AsOf31Dec2019_RedeemableConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c22_AsOf31Dec2019_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c23_AsOf31Dec2019_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c24_AsOf31Dec2019_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c25_AsOf31Dec2019_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c27_From1Jan2020To31Dec2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c29_From1Jan2020To31Dec2020_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c31_AsOf31Dec2020_RedeemableConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c32_AsOf31Dec2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c33_AsOf31Dec2020_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c34_AsOf31Dec2020_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c35_AsOf31Dec2020_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c36_From1Jan2020To31Dec2020_ExchangeClearedMember_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis">us-gaap:ExchangeClearedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c37_From1Jan2020To31Dec2020_ExchangeClearedMember_CleneNanomedicineMember_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis">us-gaap:ExchangeClearedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneNanomedicineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c38_AsOf31Dec2020_ExchangeClearedMember_CleneNanomedicineMember_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis">us-gaap:ExchangeClearedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneNanomedicineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c39_From1Jan2020To31Dec2020_RestrictedStockUnitsRSUMember_ExchangeClearedMember_CleneNanomedicineMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis">us-gaap:ExchangeClearedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneNanomedicineMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c40_AsOf31Dec2020_RestrictedStockUnitsRSUMember_ExchangeClearedMember_CleneNanomedicineMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis">us-gaap:ExchangeClearedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneNanomedicineMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c41_From1Jan2020To31Dec2020_RestrictedStockUnitsRSUMember_CleneNanomedicineMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneNanomedicineMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c42_From1Aug2018To31Aug2018_ChardanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">clnn:ChardanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-08-01</startDate>
      <endDate>2018-08-31</endDate>
    </period>
  </context>
  <context id="c43_AsOf31Aug2018_ChardanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">clnn:ChardanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-08-31</instant>
    </period>
  </context>
  <context id="c44_From1Jan2020To31Dec2020_LifeSciCapitalLLCMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">clnn:LifeSciCapitalLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c45_From1Dec2020To28Dec2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
    </entity>
    <period>
      <startDate>2020-12-01</startDate>
      <endDate>2020-12-28</endDate>
    </period>
  </context>
  <context id="c46_AsOf28Dec2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-28</instant>
    </period>
  </context>
  <context id="c47_From1Jan2020To31Dec2020_MinimumMember_EquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c48_From1Jan2020To31Dec2020_MaximumMember_EquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c49_From1Jan2020To31Dec2020_MinimumMember_FurnitureAndFixturesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c50_From1Jan2020To31Dec2020_MaximumMember_FurnitureAndFixturesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c51_From1Jan2019To31Dec2019_RedeemablePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c52_From1Jan2020To31Dec2020_PreferredStockWarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:PreferredStockWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c53_From1Jan2019To31Dec2019_PreferredStockWarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:PreferredStockWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c54_From1Jan2020To31Dec2020_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c55_From1Jan2019To31Dec2019_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c56_AsOf31Dec2020_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c57_AsOf31Dec2019_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c58_From1Jan2020To31Dec2020_GrantFundingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">clnn:GrantFundingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c59_From1Jan2019To31Dec2019_GrantFundingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">clnn:GrantFundingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c60_From1Jan2020To31Dec2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c61_From1Jan2020To31Dec2020_CleneNanomedicineMember_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneNanomedicineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c62_From1Jan2020To31Dec2020_LifeSciCapitalLLCMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:LifeSciCapitalLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c63_AsOf31Dec2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c64_AsOf28Dec2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
    </entity>
    <period>
      <instant>2020-12-28</instant>
    </period>
  </context>
  <context id="c65_From1Jan2020To31Dec2020_CleneNanomedicineMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneNanomedicineMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c66_AsOf31Dec2020_CleneNanomedicineMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneNanomedicineMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c67_AsOf31Dec2020_TottenhamMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:TottenhamMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c68_AsOf31Dec2020_PIPE">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pf0:PIPE</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c69_From1Jan2020To31Dec2020_PropertyPlantAndEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c70_From1Jan2019To31Dec2019_PropertyPlantAndEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c71_AsOf2Jan2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
    </entity>
    <period>
      <instant>2019-01-02</instant>
    </period>
  </context>
  <context id="c72_AsOf30Apr2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
    </entity>
    <period>
      <instant>2020-04-30</instant>
    </period>
  </context>
  <context id="c73_From1Apr2020To30Apr2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
    </entity>
    <period>
      <startDate>2020-04-01</startDate>
      <endDate>2020-04-30</endDate>
    </period>
  </context>
  <context id="c74_AsOf31Dec2020_FinanceLeasesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">clnn:FinanceLeasesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c75_AsOf31Dec2020_OperatingLeasesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">clnn:OperatingLeasesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c76_AsOf31Dec2020_EquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c77_AsOf31Dec2019_EquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c78_AsOf31Dec2020_FurnitureAndFixturesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c79_AsOf31Dec2019_FurnitureAndFixturesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c80_AsOf31Dec2020_WorkInProcessMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">clnn:WorkInProcessMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c81_AsOf31Dec2019_WorkInProcessMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">clnn:WorkInProcessMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c82_AsOf28Feb2019_TwoThousandNineteenMDLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenMDLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-02-28</instant>
    </period>
  </context>
  <context id="c83_From1Feb2019To28Feb2019_TwoThousandNineteenMDLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenMDLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-02-01</startDate>
      <endDate>2019-02-28</endDate>
    </period>
  </context>
  <context id="c84_From1Jan2020To31Dec2020_TwoThousandNineteenMDLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenMDLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c85_From1Jan2019To31Dec2019_TwoThousandNineteenMDLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenMDLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c86_AsOf31Dec2020_TwoThousandNineteenMDLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenMDLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c87_AsOf31Dec2019_TwoThousandNineteenMDLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenMDLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c88_AsOf30Apr2019_TwoThousandNineteenCecilLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenCecilLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-04-30</instant>
    </period>
  </context>
  <context id="c89_From1Apr2019To30Apr2019_TwoThousandNineteenCecilLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenCecilLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-04-01</startDate>
      <endDate>2019-04-30</endDate>
    </period>
  </context>
  <context id="c90_From1Jan2020To31Dec2020_TwoThousandNineteenCecilLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenCecilLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c91_From1Jan2019To31Dec2019_TwoThousandNineteenCecilLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenCecilLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c92_AsOf31Dec2020_TwoThousandNineteenCecilLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenCecilLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c93_AsOf31Dec2019_TwoThousandNineteenCecilLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenCecilLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c94_AsOf31May2020_PaycheckProtectionProgramNoteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:PaycheckProtectionProgramNoteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c95_From1May2020To31May2020_PaycheckProtectionProgramNoteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:PaycheckProtectionProgramNoteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-05-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c96_AsOf11Jan2021_PaycheckProtectionProgramNoteMember_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:PaycheckProtectionProgramNoteMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-01-11</instant>
    </period>
  </context>
  <context id="c97_AsOf8Apr2013_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-04-08</instant>
    </period>
  </context>
  <context id="c98_From1Apr2013To8Apr2013_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-04-08</endDate>
    </period>
  </context>
  <context id="c99_AsOf31Dec2019_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c100_AsOf8Apr2013_SeriesCPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-04-08</instant>
    </period>
  </context>
  <context id="c101_AsOf31Dec2019_SeriesCPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c102_From1Jan2019To31Dec2019_SeriesCPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c103_AsOf11Aug2020_SeriesDPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-08-11</instant>
    </period>
  </context>
  <context id="c104_From4Aug2020To11Aug2020_SeriesDPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-08-04</startDate>
      <endDate>2020-08-11</endDate>
    </period>
  </context>
  <context id="c105_From1Jan2019To31Dec2019_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c106_AsOf31Dec2020_TottenhamsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:TottenhamsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c107_From1Jan2020To31Dec2020_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c108_AsOf31Dec2020_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c109_AsOf31Dec2020_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c110_AsOf31Dec2020_SeriesDPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c111_AsOf31Dec2020_WarrantsDateMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantsDateMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c112_From1Jan2020To31Dec2020_WarrantsDateMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantsDateMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c113_AsOf31Dec2020_WarrantsDate1Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantsDate1Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c114_From1Jan2020To31Dec2020_WarrantsDate1Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantsDate1Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c115_AsOf31Dec2020_December20201Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:December20201Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c116_From1Jan2020To31Dec2020_December20201Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:December20201Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c117_AsOf31Dec2020_WarrantsDate2Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantsDate2Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c118_From1Jan2020To31Dec2020_WarrantsDate2Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantsDate2Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c119_AsOf31Jul2020_ConvertibleNotesPayableMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-07-31</instant>
    </period>
  </context>
  <context id="c120_From1Feb2020To31Jul2020_ConvertibleNotesPayableMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-02-01</startDate>
      <endDate>2020-07-31</endDate>
    </period>
  </context>
  <context id="c121_From1Jan2020To31Dec2020_ConvertibleNotesPayableMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c122_From1Aug2020To11Aug2020_ConvertibleNotesPayableMember_SeriesDPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-08-01</startDate>
      <endDate>2020-08-11</endDate>
    </period>
  </context>
  <context id="c123_AsOf31Dec2020_ConvertibleNotesPayableMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c124_From1Jan2020To31Dec2020_DomesticCountryMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c125_From1Jan2020To31Dec2020_StateAndLocalJurisdictionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c126_AsOf31Dec2020_DomesticCountryMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c127_AsOf31Dec2020_StateAndLocalJurisdictionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c128_AsOf31Dec2020_StockPlan2020Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:StockPlan2020Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c129_From1Jan2020To31Dec2020_StockPlan2020Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:StockPlan2020Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c130_From1Dec2020To31Dec2020_StockPlan2020Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:StockPlan2020Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-12-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c131_AsOf31Dec2020_RestrictedStockUnitsRSUMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c132_From1Jan2020To31Dec2020_RestrictedStockUnitsRSUMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c133_From1Jan2020To31Dec2020_StockPlan2014Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:StockPlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c134_AsOf31Dec2020_StockPlan2014Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:StockPlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c135_AsOf31Dec2019_StockPlan2014Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:StockPlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c136_From1Jan2019To31Dec2019_StockPlan2014Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:StockPlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c137_From1Dec2020To30Dec2020_RestrictedStockUnitsRSUMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-12-01</startDate>
      <endDate>2020-12-30</endDate>
    </period>
  </context>
  <context id="c138_From1Jan2019To31Dec2019_RestrictedStockUnitsRSUMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c139_From1Jan2020To31Dec2020_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c140_From1Jan2019To31Dec2019_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c141_AsOf30Dec2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
    </entity>
    <period>
      <instant>2018-12-30</instant>
    </period>
  </context>
  <context id="c142_From31Dec2018To31Dec2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
    </entity>
    <period>
      <startDate>2018-12-31</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c143_From1Jan2020To31Dec2020_MinimumMember_StockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c144_From1Jan2020To31Dec2020_MaximumMember_StockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c145_From1Jan2019To31Dec2019_StockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c146_From1Jan2020To31Dec2020_StockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c147_AsOf31Dec2019_RestrictedStockUnitsRSUMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c148_From27Dec2020To30Dec2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
    </entity>
    <period>
      <startDate>2020-12-27</startDate>
      <endDate>2020-12-30</endDate>
    </period>
  </context>
  <context id="c149_AsOf31Dec2020_FairValueInputsLevel1Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c150_AsOf31Dec2020_FairValueInputsLevel2Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c151_AsOf31Dec2020_FairValueInputsLevel3Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c152_AsOf31Dec2019_FairValueInputsLevel1Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c153_AsOf31Dec2019_FairValueInputsLevel2Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c154_AsOf31Dec2019_FairValueInputsLevel3Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c155_From1Jan2020To31Dec2020_ContingentEarnoutMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:ContingentEarnoutMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c156_From1Jan2019To31Dec2019_ContingentEarnoutMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:ContingentEarnoutMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c157_AsOf31Dec2018_NotesPayableOtherPayablesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c158_AsOf31Dec2018_DerivativeInstrumentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:DerivativeInstrumentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c159_AsOf31Dec2018_PreferredStockWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:PreferredStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c160_AsOf31Dec2018_ContingentEarnoutMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:ContingentEarnoutMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c161_AsOf31Dec2018_InitialShareholdersContingentEarnoutMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:InitialShareholdersContingentEarnoutMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c162_From1Jan2019To31Dec2019_NotesPayableOtherPayablesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c163_From1Jan2019To31Dec2019_DerivativeInstrumentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:DerivativeInstrumentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c164_From1Jan2019To31Dec2019_PreferredStockWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:PreferredStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c165_From1Jan2019To31Dec2019_ContingentEarnoutMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:ContingentEarnoutMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c166_From1Jan2019To31Dec2019_InitialShareholdersContingentEarnoutMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:InitialShareholdersContingentEarnoutMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c167_AsOf31Dec2019_NotesPayableOtherPayablesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c168_AsOf31Dec2019_DerivativeInstrumentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:DerivativeInstrumentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c169_AsOf31Dec2019_PreferredStockWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:PreferredStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c170_AsOf31Dec2019_ContingentEarnoutMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:ContingentEarnoutMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c171_AsOf31Dec2019_InitialShareholdersContingentEarnoutMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:InitialShareholdersContingentEarnoutMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c172_From1Jan2020To31Dec2020_NotesPayableOtherPayablesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c173_From1Jan2020To31Dec2020_DerivativeInstrumentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:DerivativeInstrumentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c174_From1Jan2020To31Dec2020_PreferredStockWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:PreferredStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c175_From1Jan2020To31Dec2020_ContingentEarnoutMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:ContingentEarnoutMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c176_From1Jan2020To31Dec2020_InitialShareholdersContingentEarnoutMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:InitialShareholdersContingentEarnoutMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c177_AsOf31Dec2020_NotesPayableOtherPayablesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c178_AsOf31Dec2020_DerivativeInstrumentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:DerivativeInstrumentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c179_AsOf31Dec2020_PreferredStockWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:PreferredStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c180_AsOf31Dec2020_ContingentEarnoutMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:ContingentEarnoutMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c181_AsOf31Dec2020_InitialShareholdersContingentEarnoutMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:InitialShareholdersContingentEarnoutMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c182_From2Feb2015To30Apr2015_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-02-02</startDate>
      <endDate>2015-04-30</endDate>
    </period>
  </context>
  <context id="c183_AsOf30Apr2015_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-04-30</instant>
    </period>
  </context>
  <context id="c184_From2Dec2016To31Dec2016_SeriesBPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-12-02</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="c185_AsOf31Dec2016_SeriesBPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="c186_From2Aug2018To31Oct2018_InvestorMember_SeriesCPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-08-02</startDate>
      <endDate>2018-10-31</endDate>
    </period>
  </context>
  <context id="c187_From2Aug2018To31Oct2018_SeriesCPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-08-02</startDate>
      <endDate>2018-10-31</endDate>
    </period>
  </context>
  <context id="c188_AsOf31Oct2018_SeriesCPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-10-31</instant>
    </period>
  </context>
  <context id="c189_From2Mar2019To31Jul2019_InvestorMember_SeriesCPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-03-02</startDate>
      <endDate>2019-07-31</endDate>
    </period>
  </context>
  <context id="c190_From2Mar2019To31Jul2019_SeriesCPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-03-02</startDate>
      <endDate>2019-07-31</endDate>
    </period>
  </context>
  <context id="c191_AsOf31Jul2019_SeriesCPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-07-31</instant>
    </period>
  </context>
  <context id="c192_From2Aug2020To31Aug2020_InvestorMember_SeriesDPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-08-02</startDate>
      <endDate>2020-08-31</endDate>
    </period>
  </context>
  <context id="c193_From2Aug2020To31Aug2020_SeriesDPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-08-02</startDate>
      <endDate>2020-08-31</endDate>
    </period>
  </context>
  <context id="c194_AsOf31Aug2020_SeriesDPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-08-31</instant>
    </period>
  </context>
  <context id="c195_From2Aug2020To31Aug2020_ConvertibleNotesPayableMember_SeriesDPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-08-02</startDate>
      <endDate>2020-08-31</endDate>
    </period>
  </context>
  <context id="c196_From1Jan2020To31Dec2020_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c197_From1Jan2020To31Dec2020_SeriesBPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c198_From1Jan2020To31Dec2020_SeriesCPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c199_From1Jan2020To31Dec2020_SeriesDPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c200_AsOf31Dec2019_SeriesBPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c201_From1Jan2019To31Dec2019_SeriesBPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c202_AsOf31Dec2020_BoardOfDirectorsChairmanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c203_From1Aug2018To31Aug2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
    </entity>
    <period>
      <startDate>2018-08-01</startDate>
      <endDate>2018-08-31</endDate>
    </period>
  </context>
  <context id="c204_AsOf31Dec2020_US">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pf1:US</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c205_AsOf31Dec2019_US">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pf1:US</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c206_AsOf31Dec2020_AU">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pf1:AU</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c207_AsOf31Dec2019_AU">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pf1:AU</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c208_From1Jan2020To31Dec2020_DrugsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:DrugsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c209_From1Jan2020To31Dec2020_SupplementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:SupplementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c210_From1Jan2019To31Dec2019_DrugsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:DrugsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c211_From1Jan2019To31Dec2019_SupplementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:SupplementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c212_AsOf31Dec2020_DrugsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:DrugsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c213_AsOf31Dec2019_DrugsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:DrugsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c214_AsOf31Dec2020_SupplementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:SupplementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c215_AsOf31Dec2019_SupplementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:SupplementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c216_From1Jan2021To11Jan2021_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-01-11</endDate>
    </period>
  </context>
  <context id="c217_From1Jan2021To27Jan2021_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-01-27</endDate>
    </period>
  </context>
  <context id="c218_From1Feb2021To16Feb2021_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-02-01</startDate>
      <endDate>2021-02-16</endDate>
    </period>
  </context>
  <unit id="shares">
    <measure>xbrli:shares</measure>
  </unit>
  <unit id="usd">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="usdPershares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="pure">
    <measure>xbrli:pure</measure>
  </unit>
  <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:label="_TemporaryEquityCarryingAmountAttributableToParent-c3_AsOf31Dec2020_usd" xlink:href="#_TemporaryEquityCarryingAmountAttributableToParent-c3_AsOf31Dec2020_usd"/>
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="ftnt_0" xml:lang="en-US">Retroactively restated for the reverse recapitalization as described in Note 1
</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_TemporaryEquityCarryingAmountAttributableToParent-c3_AsOf31Dec2020_usd" xlink:to="ftnt_0" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_TemporaryEquityCarryingAmountAttributableToParent-c4_AsOf31Dec2019_usd" xlink:href="#_TemporaryEquityCarryingAmountAttributableToParent-c4_AsOf31Dec2019_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_TemporaryEquityCarryingAmountAttributableToParent-c4_AsOf31Dec2019_usd" xlink:to="ftnt_0" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_CommonStockValue-c3_AsOf31Dec2020_usd" xlink:href="#_CommonStockValue-c3_AsOf31Dec2020_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_CommonStockValue-c3_AsOf31Dec2020_usd" xlink:to="ftnt_0" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_CommonStockValue-c4_AsOf31Dec2019_usd" xlink:href="#_CommonStockValue-c4_AsOf31Dec2019_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_CommonStockValue-c4_AsOf31Dec2019_usd" xlink:to="ftnt_0" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_AdditionalPaidInCapital-c3_AsOf31Dec2020_usd" xlink:href="#_AdditionalPaidInCapital-c3_AsOf31Dec2020_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_AdditionalPaidInCapital-c3_AsOf31Dec2020_usd" xlink:to="ftnt_0" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_AdditionalPaidInCapital-c4_AsOf31Dec2019_usd" xlink:href="#_AdditionalPaidInCapital-c4_AsOf31Dec2019_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_AdditionalPaidInCapital-c4_AsOf31Dec2019_usd" xlink:to="ftnt_0" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_RetainedEarningsAccumulatedDeficit-c3_AsOf31Dec2020_usd" xlink:href="#_RetainedEarningsAccumulatedDeficit-c3_AsOf31Dec2020_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_RetainedEarningsAccumulatedDeficit-c3_AsOf31Dec2020_usd" xlink:to="ftnt_0" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_RetainedEarningsAccumulatedDeficit-c4_AsOf31Dec2019_usd" xlink:href="#_RetainedEarningsAccumulatedDeficit-c4_AsOf31Dec2019_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_RetainedEarningsAccumulatedDeficit-c4_AsOf31Dec2019_usd" xlink:to="ftnt_0" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_AccumulatedOtherComprehensiveIncomeLossNetOfTax-c3_AsOf31Dec2020_usd" xlink:href="#_AccumulatedOtherComprehensiveIncomeLossNetOfTax-c3_AsOf31Dec2020_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_AccumulatedOtherComprehensiveIncomeLossNetOfTax-c3_AsOf31Dec2020_usd" xlink:to="ftnt_0" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_AccumulatedOtherComprehensiveIncomeLossNetOfTax-c4_AsOf31Dec2019_usd" xlink:href="#_AccumulatedOtherComprehensiveIncomeLossNetOfTax-c4_AsOf31Dec2019_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_AccumulatedOtherComprehensiveIncomeLossNetOfTax-c4_AsOf31Dec2019_usd" xlink:to="ftnt_0" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockholdersEquity-c3_AsOf31Dec2020_usd" xlink:href="#_StockholdersEquity-c3_AsOf31Dec2020_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockholdersEquity-c3_AsOf31Dec2020_usd" xlink:to="ftnt_0" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockholdersEquity-c4_AsOf31Dec2019_usd" xlink:href="#_StockholdersEquity-c4_AsOf31Dec2019_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockholdersEquity-c4_AsOf31Dec2019_usd" xlink:to="ftnt_0" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_EarningsPerShareBasicAndDiluted-c0_From1Jan2020To31Dec2020_usdPershares" xlink:href="#_EarningsPerShareBasicAndDiluted-c0_From1Jan2020To31Dec2020_usdPershares"/>
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="ftnt_1" xml:lang="en-US">Retroactively restated for the reverse recapitalization as described in Note 1</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_EarningsPerShareBasicAndDiluted-c0_From1Jan2020To31Dec2020_usdPershares" xlink:to="ftnt_1" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_EarningsPerShareBasicAndDiluted-c9_From1Jan2019To31Dec2019_usdPershares" xlink:href="#_EarningsPerShareBasicAndDiluted-c9_From1Jan2019To31Dec2019_usdPershares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_EarningsPerShareBasicAndDiluted-c9_From1Jan2019To31Dec2019_usdPershares" xlink:to="ftnt_1" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-c0_From1Jan2020To31Dec2020_shares" xlink:href="#_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-c0_From1Jan2020To31Dec2020_shares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-c0_From1Jan2020To31Dec2020_shares" xlink:to="ftnt_1" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-c9_From1Jan2019To31Dec2019_shares" xlink:href="#_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-c9_From1Jan2019To31Dec2019_shares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-c9_From1Jan2019To31Dec2019_shares" xlink:to="ftnt_1" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_SharesOutstanding-c10_AsOf31Dec2018_RedeemableConvertiblePreferredStockMember_shares" xlink:href="#_SharesOutstanding-c10_AsOf31Dec2018_RedeemableConvertiblePreferredStockMember_shares"/>
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="ftnt_2" xml:lang="en-US">Retroactively restated for the reverse recapitalization as described in Note 1
</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_SharesOutstanding-c10_AsOf31Dec2018_RedeemableConvertiblePreferredStockMember_shares" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockholdersEquity-c10_AsOf31Dec2018_RedeemableConvertiblePreferredStockMember_usd" xlink:href="#_StockholdersEquity-c10_AsOf31Dec2018_RedeemableConvertiblePreferredStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockholdersEquity-c10_AsOf31Dec2018_RedeemableConvertiblePreferredStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_SharesOutstanding-c11_AsOf31Dec2018_CommonStockMember_shares" xlink:href="#_SharesOutstanding-c11_AsOf31Dec2018_CommonStockMember_shares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_SharesOutstanding-c11_AsOf31Dec2018_CommonStockMember_shares" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockholdersEquity-c11_AsOf31Dec2018_CommonStockMember_usd" xlink:href="#_StockholdersEquity-c11_AsOf31Dec2018_CommonStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockholdersEquity-c11_AsOf31Dec2018_CommonStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockholdersEquity-c12_AsOf31Dec2018_AdditionalPaidInCapitalMember_usd" xlink:href="#_StockholdersEquity-c12_AsOf31Dec2018_AdditionalPaidInCapitalMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockholdersEquity-c12_AsOf31Dec2018_AdditionalPaidInCapitalMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockholdersEquity-c13_AsOf31Dec2018_RetainedEarningsMember_usd" xlink:href="#_StockholdersEquity-c13_AsOf31Dec2018_RetainedEarningsMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockholdersEquity-c13_AsOf31Dec2018_RetainedEarningsMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockholdersEquity-c14_AsOf31Dec2018_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:href="#_StockholdersEquity-c14_AsOf31Dec2018_AccumulatedOtherComprehensiveIncomeMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockholdersEquity-c14_AsOf31Dec2018_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockholdersEquity-c15_AsOf31Dec2018_usd" xlink:href="#_StockholdersEquity-c15_AsOf31Dec2018_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockholdersEquity-c15_AsOf31Dec2018_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ApplicationOfASC842-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_usd" xlink:href="#_ApplicationOfASC842-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ApplicationOfASC842-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ApplicationOfASC842-c17_From1Jan2019To31Dec2019_CommonStockMember_usd" xlink:href="#_ApplicationOfASC842-c17_From1Jan2019To31Dec2019_CommonStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ApplicationOfASC842-c17_From1Jan2019To31Dec2019_CommonStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ApplicationOfASC842-c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd" xlink:href="#_ApplicationOfASC842-c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ApplicationOfASC842-c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ApplicationOfASC842-c19_From1Jan2019To31Dec2019_RetainedEarningsMember_usd" xlink:href="#_ApplicationOfASC842-c19_From1Jan2019To31Dec2019_RetainedEarningsMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ApplicationOfASC842-c19_From1Jan2019To31Dec2019_RetainedEarningsMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ApplicationOfASC842-c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:href="#_ApplicationOfASC842-c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ApplicationOfASC842-c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ApplicationOfASC842-c9_From1Jan2019To31Dec2019_usd" xlink:href="#_ApplicationOfASC842-c9_From1Jan2019To31Dec2019_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ApplicationOfASC842-c9_From1Jan2019To31Dec2019_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodSharesOther-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_shares" xlink:href="#_StockIssuedDuringPeriodSharesOther-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_shares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodSharesOther-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_shares" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_usd" xlink:href="#_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodSharesOther-c17_From1Jan2019To31Dec2019_CommonStockMember_shares" xlink:href="#_StockIssuedDuringPeriodSharesOther-c17_From1Jan2019To31Dec2019_CommonStockMember_shares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodSharesOther-c17_From1Jan2019To31Dec2019_CommonStockMember_shares" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts-c17_From1Jan2019To31Dec2019_CommonStockMember_usd" xlink:href="#_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts-c17_From1Jan2019To31Dec2019_CommonStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts-c17_From1Jan2019To31Dec2019_CommonStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts-c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd" xlink:href="#_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts-c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts-c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts-c19_From1Jan2019To31Dec2019_RetainedEarningsMember_usd" xlink:href="#_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts-c19_From1Jan2019To31Dec2019_RetainedEarningsMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts-c19_From1Jan2019To31Dec2019_RetainedEarningsMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts-c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:href="#_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts-c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts-c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts-c9_From1Jan2019To31Dec2019_usd" xlink:href="#_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts-c9_From1Jan2019To31Dec2019_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts-c9_From1Jan2019To31Dec2019_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ExerciseOfSeriesCPreferredStockWarrant-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_shares" xlink:href="#_ExerciseOfSeriesCPreferredStockWarrant-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_shares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ExerciseOfSeriesCPreferredStockWarrant-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_shares" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ExerciseOfSeriesCPreferredStockWarrants-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_usd" xlink:href="#_ExerciseOfSeriesCPreferredStockWarrants-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ExerciseOfSeriesCPreferredStockWarrants-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ExerciseOfSeriesCPreferredStockWarrant-c17_From1Jan2019To31Dec2019_CommonStockMember_shares" xlink:href="#_ExerciseOfSeriesCPreferredStockWarrant-c17_From1Jan2019To31Dec2019_CommonStockMember_shares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ExerciseOfSeriesCPreferredStockWarrant-c17_From1Jan2019To31Dec2019_CommonStockMember_shares" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ExerciseOfSeriesCPreferredStockWarrants-c17_From1Jan2019To31Dec2019_CommonStockMember_usd" xlink:href="#_ExerciseOfSeriesCPreferredStockWarrants-c17_From1Jan2019To31Dec2019_CommonStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ExerciseOfSeriesCPreferredStockWarrants-c17_From1Jan2019To31Dec2019_CommonStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ExerciseOfSeriesCPreferredStockWarrants-c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd" xlink:href="#_ExerciseOfSeriesCPreferredStockWarrants-c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ExerciseOfSeriesCPreferredStockWarrants-c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ExerciseOfSeriesCPreferredStockWarrants-c19_From1Jan2019To31Dec2019_RetainedEarningsMember_usd" xlink:href="#_ExerciseOfSeriesCPreferredStockWarrants-c19_From1Jan2019To31Dec2019_RetainedEarningsMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ExerciseOfSeriesCPreferredStockWarrants-c19_From1Jan2019To31Dec2019_RetainedEarningsMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ExerciseOfSeriesCPreferredStockWarrants-c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:href="#_ExerciseOfSeriesCPreferredStockWarrants-c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ExerciseOfSeriesCPreferredStockWarrants-c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ExerciseOfSeriesCPreferredStockWarrants-c9_From1Jan2019To31Dec2019_usd" xlink:href="#_ExerciseOfSeriesCPreferredStockWarrants-c9_From1Jan2019To31Dec2019_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ExerciseOfSeriesCPreferredStockWarrants-c9_From1Jan2019To31Dec2019_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodSharesStockOptionsExercised-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_shares" xlink:href="#_StockIssuedDuringPeriodSharesStockOptionsExercised-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_shares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodSharesStockOptionsExercised-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_shares" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueStockOptionsExercised-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_usd" xlink:href="#_StockIssuedDuringPeriodValueStockOptionsExercised-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueStockOptionsExercised-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodSharesStockOptionsExercised-c17_From1Jan2019To31Dec2019_CommonStockMember_shares" xlink:href="#_StockIssuedDuringPeriodSharesStockOptionsExercised-c17_From1Jan2019To31Dec2019_CommonStockMember_shares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodSharesStockOptionsExercised-c17_From1Jan2019To31Dec2019_CommonStockMember_shares" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueStockOptionsExercised-c17_From1Jan2019To31Dec2019_CommonStockMember_usd" xlink:href="#_StockIssuedDuringPeriodValueStockOptionsExercised-c17_From1Jan2019To31Dec2019_CommonStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueStockOptionsExercised-c17_From1Jan2019To31Dec2019_CommonStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueStockOptionsExercised-c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd" xlink:href="#_StockIssuedDuringPeriodValueStockOptionsExercised-c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueStockOptionsExercised-c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueStockOptionsExercised-c19_From1Jan2019To31Dec2019_RetainedEarningsMember_usd" xlink:href="#_StockIssuedDuringPeriodValueStockOptionsExercised-c19_From1Jan2019To31Dec2019_RetainedEarningsMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueStockOptionsExercised-c19_From1Jan2019To31Dec2019_RetainedEarningsMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueStockOptionsExercised-c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:href="#_StockIssuedDuringPeriodValueStockOptionsExercised-c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueStockOptionsExercised-c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueStockOptionsExercised-c9_From1Jan2019To31Dec2019_usd" xlink:href="#_StockIssuedDuringPeriodValueStockOptionsExercised-c9_From1Jan2019To31Dec2019_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueStockOptionsExercised-c9_From1Jan2019To31Dec2019_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_usd" xlink:href="#_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c17_From1Jan2019To31Dec2019_CommonStockMember_usd" xlink:href="#_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c17_From1Jan2019To31Dec2019_CommonStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c17_From1Jan2019To31Dec2019_CommonStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd" xlink:href="#_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c19_From1Jan2019To31Dec2019_RetainedEarningsMember_usd" xlink:href="#_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c19_From1Jan2019To31Dec2019_RetainedEarningsMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c19_From1Jan2019To31Dec2019_RetainedEarningsMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:href="#_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c9_From1Jan2019To31Dec2019_usd" xlink:href="#_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c9_From1Jan2019To31Dec2019_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c9_From1Jan2019To31Dec2019_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ForeignCurrencyTranslationAdjustment-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_usd" xlink:href="#_ForeignCurrencyTranslationAdjustment-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ForeignCurrencyTranslationAdjustment-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ForeignCurrencyTranslationAdjustment-c17_From1Jan2019To31Dec2019_CommonStockMember_usd" xlink:href="#_ForeignCurrencyTranslationAdjustment-c17_From1Jan2019To31Dec2019_CommonStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ForeignCurrencyTranslationAdjustment-c17_From1Jan2019To31Dec2019_CommonStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ForeignCurrencyTranslationAdjustment-c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd" xlink:href="#_ForeignCurrencyTranslationAdjustment-c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ForeignCurrencyTranslationAdjustment-c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ForeignCurrencyTranslationAdjustment-c19_From1Jan2019To31Dec2019_RetainedEarningsMember_usd" xlink:href="#_ForeignCurrencyTranslationAdjustment-c19_From1Jan2019To31Dec2019_RetainedEarningsMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ForeignCurrencyTranslationAdjustment-c19_From1Jan2019To31Dec2019_RetainedEarningsMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ForeignCurrencyTranslationAdjustment-c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:href="#_ForeignCurrencyTranslationAdjustment-c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ForeignCurrencyTranslationAdjustment-c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ForeignCurrencyTranslationAdjustment-c9_From1Jan2019To31Dec2019_usd" xlink:href="#_ForeignCurrencyTranslationAdjustment-c9_From1Jan2019To31Dec2019_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ForeignCurrencyTranslationAdjustment-c9_From1Jan2019To31Dec2019_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ProfitLoss-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_usd" xlink:href="#_ProfitLoss-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ProfitLoss-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ProfitLoss-c17_From1Jan2019To31Dec2019_CommonStockMember_usd" xlink:href="#_ProfitLoss-c17_From1Jan2019To31Dec2019_CommonStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ProfitLoss-c17_From1Jan2019To31Dec2019_CommonStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ProfitLoss-c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd" xlink:href="#_ProfitLoss-c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ProfitLoss-c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ProfitLoss-c19_From1Jan2019To31Dec2019_RetainedEarningsMember_usd" xlink:href="#_ProfitLoss-c19_From1Jan2019To31Dec2019_RetainedEarningsMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ProfitLoss-c19_From1Jan2019To31Dec2019_RetainedEarningsMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ProfitLoss-c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:href="#_ProfitLoss-c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ProfitLoss-c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ProfitLoss-c9_From1Jan2019To31Dec2019_usd" xlink:href="#_ProfitLoss-c9_From1Jan2019To31Dec2019_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ProfitLoss-c9_From1Jan2019To31Dec2019_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_SharesOutstanding-c21_AsOf31Dec2019_RedeemableConvertiblePreferredStockMember_shares" xlink:href="#_SharesOutstanding-c21_AsOf31Dec2019_RedeemableConvertiblePreferredStockMember_shares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_SharesOutstanding-c21_AsOf31Dec2019_RedeemableConvertiblePreferredStockMember_shares" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockholdersEquity-c21_AsOf31Dec2019_RedeemableConvertiblePreferredStockMember_usd" xlink:href="#_StockholdersEquity-c21_AsOf31Dec2019_RedeemableConvertiblePreferredStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockholdersEquity-c21_AsOf31Dec2019_RedeemableConvertiblePreferredStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_SharesOutstanding-c22_AsOf31Dec2019_CommonStockMember_shares" xlink:href="#_SharesOutstanding-c22_AsOf31Dec2019_CommonStockMember_shares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_SharesOutstanding-c22_AsOf31Dec2019_CommonStockMember_shares" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockholdersEquity-c22_AsOf31Dec2019_CommonStockMember_usd" xlink:href="#_StockholdersEquity-c22_AsOf31Dec2019_CommonStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockholdersEquity-c22_AsOf31Dec2019_CommonStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockholdersEquity-c23_AsOf31Dec2019_AdditionalPaidInCapitalMember_usd" xlink:href="#_StockholdersEquity-c23_AsOf31Dec2019_AdditionalPaidInCapitalMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockholdersEquity-c23_AsOf31Dec2019_AdditionalPaidInCapitalMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockholdersEquity-c24_AsOf31Dec2019_RetainedEarningsMember_usd" xlink:href="#_StockholdersEquity-c24_AsOf31Dec2019_RetainedEarningsMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockholdersEquity-c24_AsOf31Dec2019_RetainedEarningsMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockholdersEquity-c25_AsOf31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:href="#_StockholdersEquity-c25_AsOf31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockholdersEquity-c25_AsOf31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_shares" xlink:href="#_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_shares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_shares" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" xlink:href="#_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-c27_From1Jan2020To31Dec2020_CommonStockMember_shares" xlink:href="#_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-c27_From1Jan2020To31Dec2020_CommonStockMember_shares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-c27_From1Jan2020To31Dec2020_CommonStockMember_shares" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" xlink:href="#_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-c27_From1Jan2020To31Dec2020_CommonStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" xlink:href="#_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" xlink:href="#_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:href="#_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-c0_From1Jan2020To31Dec2020_usd" xlink:href="#_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-c0_From1Jan2020To31Dec2020_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-c0_From1Jan2020To31Dec2020_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_IssuanceOfSeriesDPreferredStockInConnectionExtinguishmentOfConvertiblePromis-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_shares" xlink:href="#_IssuanceOfSeriesDPreferredStockInConnectionExtinguishmentOfConvertiblePromis-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_shares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_IssuanceOfSeriesDPreferredStockInConnectionExtinguishmentOfConvertiblePromis-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_shares" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" xlink:href="#_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_IssuanceOfSeriesDPreferredStockInConnectionExtinguishmentOfConvertiblePromis-c27_From1Jan2020To31Dec2020_CommonStockMember_shares" xlink:href="#_IssuanceOfSeriesDPreferredStockInConnectionExtinguishmentOfConvertiblePromis-c27_From1Jan2020To31Dec2020_CommonStockMember_shares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_IssuanceOfSeriesDPreferredStockInConnectionExtinguishmentOfConvertiblePromis-c27_From1Jan2020To31Dec2020_CommonStockMember_shares" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" xlink:href="#_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis-c27_From1Jan2020To31Dec2020_CommonStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" xlink:href="#_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" xlink:href="#_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:href="#_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis-c0_From1Jan2020To31Dec2020_usd" xlink:href="#_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis-c0_From1Jan2020To31Dec2020_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis-c0_From1Jan2020To31Dec2020_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodSharesStockOptionsExercised-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_shares" xlink:href="#_StockIssuedDuringPeriodSharesStockOptionsExercised-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_shares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodSharesStockOptionsExercised-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_shares" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueStockOptionsExercised-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" xlink:href="#_StockIssuedDuringPeriodValueStockOptionsExercised-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueStockOptionsExercised-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodSharesStockOptionsExercised-c27_From1Jan2020To31Dec2020_CommonStockMember_shares" xlink:href="#_StockIssuedDuringPeriodSharesStockOptionsExercised-c27_From1Jan2020To31Dec2020_CommonStockMember_shares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodSharesStockOptionsExercised-c27_From1Jan2020To31Dec2020_CommonStockMember_shares" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueStockOptionsExercised-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" xlink:href="#_StockIssuedDuringPeriodValueStockOptionsExercised-c27_From1Jan2020To31Dec2020_CommonStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueStockOptionsExercised-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueStockOptionsExercised-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" xlink:href="#_StockIssuedDuringPeriodValueStockOptionsExercised-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueStockOptionsExercised-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueStockOptionsExercised-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" xlink:href="#_StockIssuedDuringPeriodValueStockOptionsExercised-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueStockOptionsExercised-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueStockOptionsExercised-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:href="#_StockIssuedDuringPeriodValueStockOptionsExercised-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueStockOptionsExercised-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueStockOptionsExercised-c0_From1Jan2020To31Dec2020_usd" xlink:href="#_StockIssuedDuringPeriodValueStockOptionsExercised-c0_From1Jan2020To31Dec2020_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueStockOptionsExercised-c0_From1Jan2020To31Dec2020_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_shares" xlink:href="#_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_shares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_shares" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" xlink:href="#_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection-c27_From1Jan2020To31Dec2020_CommonStockMember_shares" xlink:href="#_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection-c27_From1Jan2020To31Dec2020_CommonStockMember_shares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection-c27_From1Jan2020To31Dec2020_CommonStockMember_shares" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" xlink:href="#_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe-c27_From1Jan2020To31Dec2020_CommonStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" xlink:href="#_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" xlink:href="#_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:href="#_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe-c0_From1Jan2020To31Dec2020_usd" xlink:href="#_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe-c0_From1Jan2020To31Dec2020_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe-c0_From1Jan2020To31Dec2020_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" xlink:href="#_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" xlink:href="#_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable-c27_From1Jan2020To31Dec2020_CommonStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" xlink:href="#_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" xlink:href="#_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:href="#_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable-c0_From1Jan2020To31Dec2020_usd" xlink:href="#_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable-c0_From1Jan2020To31Dec2020_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable-c0_From1Jan2020To31Dec2020_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodSharesNewIssues-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_shares" xlink:href="#_StockIssuedDuringPeriodSharesNewIssues-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_shares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodSharesNewIssues-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_shares" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" xlink:href="#_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodSharesNewIssues-c27_From1Jan2020To31Dec2020_CommonStockMember_shares" xlink:href="#_StockIssuedDuringPeriodSharesNewIssues-c27_From1Jan2020To31Dec2020_CommonStockMember_shares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodSharesNewIssues-c27_From1Jan2020To31Dec2020_CommonStockMember_shares" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" xlink:href="#_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts-c27_From1Jan2020To31Dec2020_CommonStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" xlink:href="#_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" xlink:href="#_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:href="#_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts-c0_From1Jan2020To31Dec2020_usd" xlink:href="#_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts-c0_From1Jan2020To31Dec2020_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts-c0_From1Jan2020To31Dec2020_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueOther-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" xlink:href="#_StockIssuedDuringPeriodValueOther-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueOther-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueOther-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" xlink:href="#_StockIssuedDuringPeriodValueOther-c27_From1Jan2020To31Dec2020_CommonStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueOther-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueOther-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" xlink:href="#_StockIssuedDuringPeriodValueOther-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueOther-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueOther-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" xlink:href="#_StockIssuedDuringPeriodValueOther-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueOther-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueOther-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:href="#_StockIssuedDuringPeriodValueOther-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueOther-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueOther-c0_From1Jan2020To31Dec2020_usd" xlink:href="#_StockIssuedDuringPeriodValueOther-c0_From1Jan2020To31Dec2020_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueOther-c0_From1Jan2020To31Dec2020_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_IssuanceOfCommonStockPaymentOfRelatedOfferingCosts-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_shares" xlink:href="#_IssuanceOfCommonStockPaymentOfRelatedOfferingCosts-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_shares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_IssuanceOfCommonStockPaymentOfRelatedOfferingCosts-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_shares" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" xlink:href="#_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_IssuanceOfCommonStockPaymentOfRelatedOfferingCosts-c27_From1Jan2020To31Dec2020_CommonStockMember_shares" xlink:href="#_IssuanceOfCommonStockPaymentOfRelatedOfferingCosts-c27_From1Jan2020To31Dec2020_CommonStockMember_shares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_IssuanceOfCommonStockPaymentOfRelatedOfferingCosts-c27_From1Jan2020To31Dec2020_CommonStockMember_shares" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" xlink:href="#_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts-c27_From1Jan2020To31Dec2020_CommonStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" xlink:href="#_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" xlink:href="#_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:href="#_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts-c0_From1Jan2020To31Dec2020_usd" xlink:href="#_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts-c0_From1Jan2020To31Dec2020_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts-c0_From1Jan2020To31Dec2020_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" xlink:href="#_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" xlink:href="#_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati-c27_From1Jan2020To31Dec2020_CommonStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" xlink:href="#_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" xlink:href="#_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:href="#_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati-c0_From1Jan2020To31Dec2020_usd" xlink:href="#_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati-c0_From1Jan2020To31Dec2020_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati-c0_From1Jan2020To31Dec2020_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" xlink:href="#_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" xlink:href="#_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization-c27_From1Jan2020To31Dec2020_CommonStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" xlink:href="#_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" xlink:href="#_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:href="#_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization-c0_From1Jan2020To31Dec2020_usd" xlink:href="#_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization-c0_From1Jan2020To31Dec2020_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization-c0_From1Jan2020To31Dec2020_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" xlink:href="#_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" xlink:href="#_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c27_From1Jan2020To31Dec2020_CommonStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" xlink:href="#_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" xlink:href="#_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:href="#_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c0_From1Jan2020To31Dec2020_usd" xlink:href="#_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c0_From1Jan2020To31Dec2020_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c0_From1Jan2020To31Dec2020_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ForeignCurrencyTranslationAdjustment-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" xlink:href="#_ForeignCurrencyTranslationAdjustment-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ForeignCurrencyTranslationAdjustment-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ForeignCurrencyTranslationAdjustment-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" xlink:href="#_ForeignCurrencyTranslationAdjustment-c27_From1Jan2020To31Dec2020_CommonStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ForeignCurrencyTranslationAdjustment-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ForeignCurrencyTranslationAdjustment-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" xlink:href="#_ForeignCurrencyTranslationAdjustment-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ForeignCurrencyTranslationAdjustment-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ForeignCurrencyTranslationAdjustment-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" xlink:href="#_ForeignCurrencyTranslationAdjustment-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ForeignCurrencyTranslationAdjustment-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ForeignCurrencyTranslationAdjustment-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:href="#_ForeignCurrencyTranslationAdjustment-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ForeignCurrencyTranslationAdjustment-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ForeignCurrencyTranslationAdjustment-c0_From1Jan2020To31Dec2020_usd" xlink:href="#_ForeignCurrencyTranslationAdjustment-c0_From1Jan2020To31Dec2020_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ForeignCurrencyTranslationAdjustment-c0_From1Jan2020To31Dec2020_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ProfitLoss-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" xlink:href="#_ProfitLoss-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ProfitLoss-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ProfitLoss-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" xlink:href="#_ProfitLoss-c27_From1Jan2020To31Dec2020_CommonStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ProfitLoss-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ProfitLoss-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" xlink:href="#_ProfitLoss-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ProfitLoss-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ProfitLoss-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" xlink:href="#_ProfitLoss-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ProfitLoss-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ProfitLoss-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:href="#_ProfitLoss-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ProfitLoss-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ProfitLoss-c0_From1Jan2020To31Dec2020_usd" xlink:href="#_ProfitLoss-c0_From1Jan2020To31Dec2020_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ProfitLoss-c0_From1Jan2020To31Dec2020_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_SharesOutstanding-c31_AsOf31Dec2020_RedeemableConvertiblePreferredStockMember_shares" xlink:href="#_SharesOutstanding-c31_AsOf31Dec2020_RedeemableConvertiblePreferredStockMember_shares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_SharesOutstanding-c31_AsOf31Dec2020_RedeemableConvertiblePreferredStockMember_shares" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockholdersEquity-c31_AsOf31Dec2020_RedeemableConvertiblePreferredStockMember_usd" xlink:href="#_StockholdersEquity-c31_AsOf31Dec2020_RedeemableConvertiblePreferredStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockholdersEquity-c31_AsOf31Dec2020_RedeemableConvertiblePreferredStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_SharesOutstanding-c32_AsOf31Dec2020_CommonStockMember_shares" xlink:href="#_SharesOutstanding-c32_AsOf31Dec2020_CommonStockMember_shares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_SharesOutstanding-c32_AsOf31Dec2020_CommonStockMember_shares" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockholdersEquity-c32_AsOf31Dec2020_CommonStockMember_usd" xlink:href="#_StockholdersEquity-c32_AsOf31Dec2020_CommonStockMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockholdersEquity-c32_AsOf31Dec2020_CommonStockMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockholdersEquity-c33_AsOf31Dec2020_AdditionalPaidInCapitalMember_usd" xlink:href="#_StockholdersEquity-c33_AsOf31Dec2020_AdditionalPaidInCapitalMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockholdersEquity-c33_AsOf31Dec2020_AdditionalPaidInCapitalMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockholdersEquity-c34_AsOf31Dec2020_RetainedEarningsMember_usd" xlink:href="#_StockholdersEquity-c34_AsOf31Dec2020_RetainedEarningsMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockholdersEquity-c34_AsOf31Dec2020_RetainedEarningsMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockholdersEquity-c35_AsOf31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:href="#_StockholdersEquity-c35_AsOf31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockholdersEquity-c35_AsOf31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_NetIssuanceCosts-c0_From1Jan2020To31Dec2020_usd" xlink:href="#_NetIssuanceCosts-c0_From1Jan2020To31Dec2020_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_NetIssuanceCosts-c0_From1Jan2020To31Dec2020_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ExpirationDate-c102_From1Jan2019To31Dec2019_SeriesCPreferredStockMember" xlink:href="#_ExpirationDate-c102_From1Jan2019To31Dec2019_SeriesCPreferredStockMember"/>
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="ftnt_4" xml:lang="en-US">As of December 31, 2019, the most senior equity preferred stock warrants were convertible into Series C Preferred Stock.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ExpirationDate-c102_From1Jan2019To31Dec2019_SeriesCPreferredStockMember" xlink:to="ftnt_4" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_WarrantExercisePriceIncrease-c102_From1Jan2019To31Dec2019_SeriesCPreferredStockMember_usdPershares" xlink:href="#_WarrantExercisePriceIncrease-c102_From1Jan2019To31Dec2019_SeriesCPreferredStockMember_usdPershares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_WarrantExercisePriceIncrease-c102_From1Jan2019To31Dec2019_SeriesCPreferredStockMember_usdPershares" xlink:to="ftnt_4" order="1"/>
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="ftnt_3" xml:lang="en-US">The exercise price per share and warrants outstanding, prior to the Reverse Recapitalization, have been retroactively restated as shares reflecting the Exchange Ratio established in the Reverse Recapitalization (See Note 1).</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_WarrantExercisePriceIncrease-c102_From1Jan2019To31Dec2019_SeriesCPreferredStockMember_usdPershares" xlink:to="ftnt_3" order="2"/>
    <link:loc xlink:type="locator" xlink:label="_ClassOfWarrantOrRightOutstanding-c101_AsOf31Dec2019_SeriesCPreferredStockMember_shares" xlink:href="#_ClassOfWarrantOrRightOutstanding-c101_AsOf31Dec2019_SeriesCPreferredStockMember_shares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ClassOfWarrantOrRightOutstanding-c101_AsOf31Dec2019_SeriesCPreferredStockMember_shares" xlink:to="ftnt_4" order="1"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ClassOfWarrantOrRightOutstanding-c101_AsOf31Dec2019_SeriesCPreferredStockMember_shares" xlink:to="ftnt_3" order="2"/>
    <link:loc xlink:type="locator" xlink:label="_WarrantExercisePriceIncrease-c105_From1Jan2019To31Dec2019_SeriesAPreferredStockMember_usdPershares" xlink:href="#_WarrantExercisePriceIncrease-c105_From1Jan2019To31Dec2019_SeriesAPreferredStockMember_usdPershares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_WarrantExercisePriceIncrease-c105_From1Jan2019To31Dec2019_SeriesAPreferredStockMember_usdPershares" xlink:to="ftnt_3" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ClassOfWarrantOrRightOutstanding-c99_AsOf31Dec2019_SeriesAPreferredStockMember_shares" xlink:href="#_ClassOfWarrantOrRightOutstanding-c99_AsOf31Dec2019_SeriesAPreferredStockMember_shares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ClassOfWarrantOrRightOutstanding-c99_AsOf31Dec2019_SeriesAPreferredStockMember_shares" xlink:to="ftnt_3" order="1"/>
  </link:footnoteLink>
  <dei:DocumentType contextRef="c0_From1Jan2020To31Dec2020">10-K</dei:DocumentType>
  <dei:CurrentFiscalYearEndDate contextRef="c0_From1Jan2020To31Dec2020">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentPeriodEndDate contextRef="c0_From1Jan2020To31Dec2020">2020-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentFiscalYearFocus contextRef="c0_From1Jan2020To31Dec2020">2020</dei:DocumentFiscalYearFocus>
  <dei:EntityFileNumber contextRef="c0_From1Jan2020To31Dec2020">01-39834</dei:EntityFileNumber>
  <dei:EntityRegistrantName contextRef="c0_From1Jan2020To31Dec2020">Clene Inc.</dei:EntityRegistrantName>
  <dei:EntityIncorporationStateCountryCode contextRef="c0_From1Jan2020To31Dec2020">DE</dei:EntityIncorporationStateCountryCode>
  <dei:EntityWellKnownSeasonedIssuer contextRef="c0_From1Jan2020To31Dec2020">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityVoluntaryFilers contextRef="c0_From1Jan2020To31Dec2020">No</dei:EntityVoluntaryFilers>
  <dei:EntityCurrentReportingStatus contextRef="c0_From1Jan2020To31Dec2020">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityInteractiveDataCurrent contextRef="c0_From1Jan2020To31Dec2020">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityFilerCategory contextRef="c0_From1Jan2020To31Dec2020">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntitySmallBusiness contextRef="c0_From1Jan2020To31Dec2020">true</dei:EntitySmallBusiness>
  <dei:EntityEmergingGrowthCompany contextRef="c0_From1Jan2020To31Dec2020">true</dei:EntityEmergingGrowthCompany>
  <dei:EntityExTransitionPeriod contextRef="c0_From1Jan2020To31Dec2020">false</dei:EntityExTransitionPeriod>
  <dei:EntityShellCompany contextRef="c0_From1Jan2020To31Dec2020">false</dei:EntityShellCompany>
  <dei:AmendmentFlag contextRef="c0_From1Jan2020To31Dec2020">false</dei:AmendmentFlag>
  <dei:DocumentFiscalPeriodFocus contextRef="c0_From1Jan2020To31Dec2020">FY</dei:DocumentFiscalPeriodFocus>
  <dei:EntityCentralIndexKey contextRef="c0_From1Jan2020To31Dec2020">0001822791</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding unitRef="shares" contextRef="c1_AsOf25Mar2021" decimals="INF">59526171</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityPublicFloat unitRef="usd" contextRef="c2_AsOf30Jun2020" decimals="0">23300000</dei:EntityPublicFloat>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">59275000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">8788000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:InventoryNet unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">191000</us-gaap:InventoryNet>
  <us-gaap:InventoryNet unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">28000</us-gaap:InventoryNet>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">3523000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">661000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">62989000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">9477000</us-gaap:AssetsCurrent>
  <us-gaap:OperatingLeaseRightOfUseAsset unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">1029000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseRightOfUseAsset unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">1081000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">4225000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">4319000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:Assets unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">68243000</us-gaap:Assets>
  <us-gaap:Assets unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">14877000</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">1124000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">889000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">3960000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">2878000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:TaxesPayableCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">164000</us-gaap:TaxesPayableCurrent>
  <us-gaap:TaxesPayableCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:AccountsPayableRelatedPartiesCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:AccountsPayableRelatedPartiesCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">131000</us-gaap:AccountsPayableRelatedPartiesCurrent>
  <us-gaap:DeferredRevenueCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">112000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:OperatingLeaseLiabilityCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">194000</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:OperatingLeaseLiabilityCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">216000</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:FinanceLeaseLiabilityCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">190000</us-gaap:FinanceLeaseLiabilityCurrent>
  <us-gaap:FinanceLeaseLiabilityCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">200000</us-gaap:FinanceLeaseLiabilityCurrent>
  <us-gaap:LongTermDebtCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">5924000</us-gaap:LongTermDebtCurrent>
  <us-gaap:LongTermDebtCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">11668000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">4314000</us-gaap:LiabilitiesCurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">1785000</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">1434000</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:FinanceLeaseLiabilityNoncurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">205000</us-gaap:FinanceLeaseLiabilityNoncurrent>
  <us-gaap:FinanceLeaseLiabilityNoncurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">389000</us-gaap:FinanceLeaseLiabilityNoncurrent>
  <us-gaap:LongTermNotesPayable unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">1949000</us-gaap:LongTermNotesPayable>
  <us-gaap:LongTermNotesPayable unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">640000</us-gaap:LongTermNotesPayable>
  <us-gaap:DeferredIncomeTaxLiabilitiesNet unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">260000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
  <us-gaap:DeferredIncomeTaxLiabilitiesNet unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <clnn:RedeemableConvertiblePreferredStockWarrantLiability unitRef="usd" contextRef="c3_AsOf31Dec2020" xs:nil="true"/>
  <clnn:RedeemableConvertiblePreferredStockWarrantLiability unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">3213000</clnn:RedeemableConvertiblePreferredStockWarrantLiability>
  <clnn:ContingentEarnoutNetOfCurrentPortion unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">46129000</clnn:ContingentEarnoutNetOfCurrentPortion>
  <clnn:ContingentEarnoutNetOfCurrentPortion unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <clnn:InitialShareholdersContingentEarnout unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">5906000</clnn:InitialShareholdersContingentEarnout>
  <clnn:InitialShareholdersContingentEarnout unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:Liabilities unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">67902000</us-gaap:Liabilities>
  <us-gaap:Liabilities unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">9990000</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies unitRef="usd" contextRef="c3_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:CommitmentsAndContingencies unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="_TemporaryEquityCarryingAmountAttributableToParent-c3_AsOf31Dec2020_usd" unitRef="usd" contextRef="c3_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="_TemporaryEquityCarryingAmountAttributableToParent-c4_AsOf31Dec2019_usd" unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">72661000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:CommonStockValue id="_CommonStockValue-c3_AsOf31Dec2020_usd" unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">6000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue id="_CommonStockValue-c4_AsOf31Dec2019_usd" unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">2000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapital id="_AdditionalPaidInCapital-c3_AsOf31Dec2020_usd" unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">153571000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital id="_AdditionalPaidInCapital-c4_AsOf31Dec2019_usd" unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">1754000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="_RetainedEarningsAccumulatedDeficit-c3_AsOf31Dec2020_usd" unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">-153561000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="_RetainedEarningsAccumulatedDeficit-c4_AsOf31Dec2019_usd" unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">-69571000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="_AccumulatedOtherComprehensiveIncomeLossNetOfTax-c3_AsOf31Dec2020_usd" unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">325000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="_AccumulatedOtherComprehensiveIncomeLossNetOfTax-c4_AsOf31Dec2019_usd" unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">41000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:StockholdersEquity id="_StockholdersEquity-c3_AsOf31Dec2020_usd" unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">341000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="_StockholdersEquity-c4_AsOf31Dec2019_usd" unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">-67774000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">68243000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">14877000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare unitRef="usdPershares" contextRef="c3_AsOf31Dec2020" decimals="4">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare unitRef="usdPershares" contextRef="c4_AsOf31Dec2019" decimals="4">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized unitRef="shares" contextRef="c4_AsOf31Dec2019" decimals="INF">31036008</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued unitRef="shares" contextRef="c4_AsOf31Dec2019" decimals="INF">27499837</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding unitRef="shares" contextRef="c4_AsOf31Dec2019" decimals="INF">27499837</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityLiquidationPreference unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">0</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:TemporaryEquityLiquidationPreference unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">78875000</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c3_AsOf31Dec2020" decimals="4">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c4_AsOf31Dec2019" decimals="4">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c4_AsOf31Dec2019" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">59526171</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c4_AsOf31Dec2019" decimals="INF">17357505</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">59526171</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding unitRef="shares" contextRef="c4_AsOf31Dec2019" decimals="INF">17357505</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:Revenues unitRef="usd" contextRef="c5_From1Jan2020To31Dec2020_ProductMember" decimals="-3">176000</us-gaap:Revenues>
  <us-gaap:Revenues unitRef="usd" contextRef="c6_From1Jan2019To31Dec2019_ProductMember" xs:nil="true"/>
  <us-gaap:Revenues unitRef="usd" contextRef="c7_From1Jan2020To31Dec2020_RoyaltyMember" decimals="-3">30000</us-gaap:Revenues>
  <us-gaap:Revenues unitRef="usd" contextRef="c8_From1Jan2019To31Dec2019_RoyaltyMember" xs:nil="true"/>
  <us-gaap:Revenues unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">206000</us-gaap:Revenues>
  <us-gaap:Revenues unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <clnn:CostsOfRevenue unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">65000</clnn:CostsOfRevenue>
  <clnn:CostsOfRevenue unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">15204000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">9563000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">5151000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">6769000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">20420000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">16332000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-20214000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">-16332000</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">950000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">88000</us-gaap:InterestExpense>
  <us-gaap:GainLossOnContractTermination unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">51000</us-gaap:GainLossOnContractTermination>
  <us-gaap:GainLossOnContractTermination unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <clnn:ChangeInFairValueOfPreferredStockWarrantLiability unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-14615000</clnn:ChangeInFairValueOfPreferredStockWarrantLiability>
  <clnn:ChangeInFairValueOfPreferredStockWarrantLiability unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">-361000</clnn:ChangeInFairValueOfPreferredStockWarrantLiability>
  <us-gaap:UnrealizedGainLossOnDerivativesAndCommodityContracts unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">29000</us-gaap:UnrealizedGainLossOnDerivativesAndCommodityContracts>
  <us-gaap:UnrealizedGainLossOnDerivativesAndCommodityContracts unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <clnn:ChangeInFairValueOfContingentEarnout unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">12659000</clnn:ChangeInFairValueOfContingentEarnout>
  <clnn:ChangeInFairValueOfContingentEarnout unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <clnn:ChangeInFairValueOfInitialShareholdersContingentEarnout unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">1465000</clnn:ChangeInFairValueOfInitialShareholdersContingentEarnout>
  <clnn:ChangeInFairValueOfInitialShareholdersContingentEarnout unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <clnn:AustraliaResearchAndDevelopmentCredit unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-3210000</clnn:AustraliaResearchAndDevelopmentCredit>
  <clnn:AustraliaResearchAndDevelopmentCredit unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">-599000</clnn:AustraliaResearchAndDevelopmentCredit>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-540000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:OtherNonoperatingIncomeExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">34000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">27000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">1343000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">177000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-18871000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">-16155000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">406000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-19277000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">-16155000</us-gaap:NetIncomeLoss>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">284000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">-3000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossTax unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-284000</us-gaap:OtherComprehensiveIncomeLossTax>
  <us-gaap:OtherComprehensiveIncomeLossTax unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">3000</us-gaap:OtherComprehensiveIncomeLossTax>
  <us-gaap:ComprehensiveIncomeNetOfTax unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-18993000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">-16158000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:EarningsPerShareBasicAndDiluted id="_EarningsPerShareBasicAndDiluted-c0_From1Jan2020To31Dec2020_usdPershares" unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">-1.10</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="_EarningsPerShareBasicAndDiluted-c9_From1Jan2019To31Dec2019_usdPershares" unitRef="usdPershares" contextRef="c9_From1Jan2019To31Dec2019" decimals="2">-0.93</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-c0_From1Jan2020To31Dec2020_shares" unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">17503992</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-c9_From1Jan2019To31Dec2019_shares" unitRef="shares" contextRef="c9_From1Jan2019To31Dec2019" decimals="INF">17357505</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:SharesOutstanding id="_SharesOutstanding-c10_AsOf31Dec2018_RedeemableConvertiblePreferredStockMember_shares" unitRef="shares" contextRef="c10_AsOf31Dec2018_RedeemableConvertiblePreferredStockMember" decimals="INF">25165036</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="_StockholdersEquity-c10_AsOf31Dec2018_RedeemableConvertiblePreferredStockMember_usd" unitRef="usd" contextRef="c10_AsOf31Dec2018_RedeemableConvertiblePreferredStockMember" decimals="-3">62926000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="_SharesOutstanding-c11_AsOf31Dec2018_CommonStockMember_shares" unitRef="shares" contextRef="c11_AsOf31Dec2018_CommonStockMember" decimals="INF">17345002</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="_StockholdersEquity-c11_AsOf31Dec2018_CommonStockMember_usd" unitRef="usd" contextRef="c11_AsOf31Dec2018_CommonStockMember" decimals="-3">2000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="_StockholdersEquity-c12_AsOf31Dec2018_AdditionalPaidInCapitalMember_usd" unitRef="usd" contextRef="c12_AsOf31Dec2018_AdditionalPaidInCapitalMember" decimals="-3">1345000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="_StockholdersEquity-c13_AsOf31Dec2018_RetainedEarningsMember_usd" unitRef="usd" contextRef="c13_AsOf31Dec2018_RetainedEarningsMember" decimals="-3">-53430000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="_StockholdersEquity-c14_AsOf31Dec2018_AccumulatedOtherComprehensiveIncomeMember_usd" unitRef="usd" contextRef="c14_AsOf31Dec2018_AccumulatedOtherComprehensiveIncomeMember" decimals="-3">44000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="_StockholdersEquity-c15_AsOf31Dec2018_usd" unitRef="usd" contextRef="c15_AsOf31Dec2018" decimals="-3">-52039000</us-gaap:StockholdersEquity>
  <clnn:ApplicationOfASC842 id="_ApplicationOfASC842-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_usd" unitRef="usd" contextRef="c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember" xs:nil="true"/>
  <clnn:ApplicationOfASC842 id="_ApplicationOfASC842-c17_From1Jan2019To31Dec2019_CommonStockMember_usd" unitRef="usd" contextRef="c17_From1Jan2019To31Dec2019_CommonStockMember" xs:nil="true"/>
  <clnn:ApplicationOfASC842 id="_ApplicationOfASC842-c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd" unitRef="usd" contextRef="c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <clnn:ApplicationOfASC842 id="_ApplicationOfASC842-c19_From1Jan2019To31Dec2019_RetainedEarningsMember_usd" unitRef="usd" contextRef="c19_From1Jan2019To31Dec2019_RetainedEarningsMember" decimals="-3">14000</clnn:ApplicationOfASC842>
  <clnn:ApplicationOfASC842 id="_ApplicationOfASC842-c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd" unitRef="usd" contextRef="c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <clnn:ApplicationOfASC842 id="_ApplicationOfASC842-c9_From1Jan2019To31Dec2019_usd" unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">14000</clnn:ApplicationOfASC842>
  <us-gaap:StockIssuedDuringPeriodSharesOther id="_StockIssuedDuringPeriodSharesOther-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_shares" unitRef="shares" contextRef="c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember" decimals="INF">1935111</us-gaap:StockIssuedDuringPeriodSharesOther>
  <clnn:IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts id="_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_usd" unitRef="usd" contextRef="c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember" decimals="-3">8069000</clnn:IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts>
  <us-gaap:StockIssuedDuringPeriodSharesOther id="_StockIssuedDuringPeriodSharesOther-c17_From1Jan2019To31Dec2019_CommonStockMember_shares" unitRef="shares" contextRef="c17_From1Jan2019To31Dec2019_CommonStockMember" xs:nil="true"/>
  <clnn:IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts id="_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts-c17_From1Jan2019To31Dec2019_CommonStockMember_usd" unitRef="usd" contextRef="c17_From1Jan2019To31Dec2019_CommonStockMember" xs:nil="true"/>
  <clnn:IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts id="_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts-c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd" unitRef="usd" contextRef="c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <clnn:IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts id="_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts-c19_From1Jan2019To31Dec2019_RetainedEarningsMember_usd" unitRef="usd" contextRef="c19_From1Jan2019To31Dec2019_RetainedEarningsMember" xs:nil="true"/>
  <clnn:IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts id="_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts-c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd" unitRef="usd" contextRef="c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <clnn:IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts id="_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts-c9_From1Jan2019To31Dec2019_usd" unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <clnn:ExerciseOfSeriesCPreferredStockWarrant id="_ExerciseOfSeriesCPreferredStockWarrant-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_shares" unitRef="shares" contextRef="c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember" decimals="INF">399690</clnn:ExerciseOfSeriesCPreferredStockWarrant>
  <clnn:ExerciseOfSeriesCPreferredStockWarrants id="_ExerciseOfSeriesCPreferredStockWarrants-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_usd" unitRef="usd" contextRef="c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember" decimals="-3">1666000</clnn:ExerciseOfSeriesCPreferredStockWarrants>
  <clnn:ExerciseOfSeriesCPreferredStockWarrant id="_ExerciseOfSeriesCPreferredStockWarrant-c17_From1Jan2019To31Dec2019_CommonStockMember_shares" unitRef="shares" contextRef="c17_From1Jan2019To31Dec2019_CommonStockMember" xs:nil="true"/>
  <clnn:ExerciseOfSeriesCPreferredStockWarrants id="_ExerciseOfSeriesCPreferredStockWarrants-c17_From1Jan2019To31Dec2019_CommonStockMember_usd" unitRef="usd" contextRef="c17_From1Jan2019To31Dec2019_CommonStockMember" xs:nil="true"/>
  <clnn:ExerciseOfSeriesCPreferredStockWarrants id="_ExerciseOfSeriesCPreferredStockWarrants-c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd" unitRef="usd" contextRef="c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <clnn:ExerciseOfSeriesCPreferredStockWarrants id="_ExerciseOfSeriesCPreferredStockWarrants-c19_From1Jan2019To31Dec2019_RetainedEarningsMember_usd" unitRef="usd" contextRef="c19_From1Jan2019To31Dec2019_RetainedEarningsMember" xs:nil="true"/>
  <clnn:ExerciseOfSeriesCPreferredStockWarrants id="_ExerciseOfSeriesCPreferredStockWarrants-c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd" unitRef="usd" contextRef="c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <clnn:ExerciseOfSeriesCPreferredStockWarrants id="_ExerciseOfSeriesCPreferredStockWarrants-c9_From1Jan2019To31Dec2019_usd" unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="_StockIssuedDuringPeriodSharesStockOptionsExercised-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_shares" unitRef="shares" contextRef="c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="_StockIssuedDuringPeriodValueStockOptionsExercised-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_usd" unitRef="usd" contextRef="c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="_StockIssuedDuringPeriodSharesStockOptionsExercised-c17_From1Jan2019To31Dec2019_CommonStockMember_shares" unitRef="shares" contextRef="c17_From1Jan2019To31Dec2019_CommonStockMember" decimals="INF">12503</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="_StockIssuedDuringPeriodValueStockOptionsExercised-c17_From1Jan2019To31Dec2019_CommonStockMember_usd" unitRef="usd" contextRef="c17_From1Jan2019To31Dec2019_CommonStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="_StockIssuedDuringPeriodValueStockOptionsExercised-c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd" unitRef="usd" contextRef="c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" decimals="-3">10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="_StockIssuedDuringPeriodValueStockOptionsExercised-c19_From1Jan2019To31Dec2019_RetainedEarningsMember_usd" unitRef="usd" contextRef="c19_From1Jan2019To31Dec2019_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="_StockIssuedDuringPeriodValueStockOptionsExercised-c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd" unitRef="usd" contextRef="c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="_StockIssuedDuringPeriodValueStockOptionsExercised-c9_From1Jan2019To31Dec2019_usd" unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_usd" unitRef="usd" contextRef="c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c17_From1Jan2019To31Dec2019_CommonStockMember_usd" unitRef="usd" contextRef="c17_From1Jan2019To31Dec2019_CommonStockMember" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd" unitRef="usd" contextRef="c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" decimals="-3">399000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c19_From1Jan2019To31Dec2019_RetainedEarningsMember_usd" unitRef="usd" contextRef="c19_From1Jan2019To31Dec2019_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd" unitRef="usd" contextRef="c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c9_From1Jan2019To31Dec2019_usd" unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">399000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <clnn:ForeignCurrencyTranslationAdjustment id="_ForeignCurrencyTranslationAdjustment-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_usd" unitRef="usd" contextRef="c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember" xs:nil="true"/>
  <clnn:ForeignCurrencyTranslationAdjustment id="_ForeignCurrencyTranslationAdjustment-c17_From1Jan2019To31Dec2019_CommonStockMember_usd" unitRef="usd" contextRef="c17_From1Jan2019To31Dec2019_CommonStockMember" xs:nil="true"/>
  <clnn:ForeignCurrencyTranslationAdjustment id="_ForeignCurrencyTranslationAdjustment-c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd" unitRef="usd" contextRef="c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <clnn:ForeignCurrencyTranslationAdjustment id="_ForeignCurrencyTranslationAdjustment-c19_From1Jan2019To31Dec2019_RetainedEarningsMember_usd" unitRef="usd" contextRef="c19_From1Jan2019To31Dec2019_RetainedEarningsMember" xs:nil="true"/>
  <clnn:ForeignCurrencyTranslationAdjustment id="_ForeignCurrencyTranslationAdjustment-c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd" unitRef="usd" contextRef="c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember" decimals="-3">-3000</clnn:ForeignCurrencyTranslationAdjustment>
  <clnn:ForeignCurrencyTranslationAdjustment id="_ForeignCurrencyTranslationAdjustment-c9_From1Jan2019To31Dec2019_usd" unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">-3000</clnn:ForeignCurrencyTranslationAdjustment>
  <us-gaap:ProfitLoss id="_ProfitLoss-c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember_usd" unitRef="usd" contextRef="c16_From1Jan2019To31Dec2019_RedeemableConvertiblePreferredStockMember" xs:nil="true"/>
  <us-gaap:ProfitLoss id="_ProfitLoss-c17_From1Jan2019To31Dec2019_CommonStockMember_usd" unitRef="usd" contextRef="c17_From1Jan2019To31Dec2019_CommonStockMember" xs:nil="true"/>
  <us-gaap:ProfitLoss id="_ProfitLoss-c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd" unitRef="usd" contextRef="c18_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:ProfitLoss id="_ProfitLoss-c19_From1Jan2019To31Dec2019_RetainedEarningsMember_usd" unitRef="usd" contextRef="c19_From1Jan2019To31Dec2019_RetainedEarningsMember" decimals="-3">-16155000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="_ProfitLoss-c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd" unitRef="usd" contextRef="c20_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <us-gaap:ProfitLoss id="_ProfitLoss-c9_From1Jan2019To31Dec2019_usd" unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">-16155000</us-gaap:ProfitLoss>
  <us-gaap:SharesOutstanding id="_SharesOutstanding-c21_AsOf31Dec2019_RedeemableConvertiblePreferredStockMember_shares" unitRef="shares" contextRef="c21_AsOf31Dec2019_RedeemableConvertiblePreferredStockMember" decimals="INF">27499837</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="_StockholdersEquity-c21_AsOf31Dec2019_RedeemableConvertiblePreferredStockMember_usd" unitRef="usd" contextRef="c21_AsOf31Dec2019_RedeemableConvertiblePreferredStockMember" decimals="-3">72661000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="_SharesOutstanding-c22_AsOf31Dec2019_CommonStockMember_shares" unitRef="shares" contextRef="c22_AsOf31Dec2019_CommonStockMember" decimals="INF">17357505</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="_StockholdersEquity-c22_AsOf31Dec2019_CommonStockMember_usd" unitRef="usd" contextRef="c22_AsOf31Dec2019_CommonStockMember" decimals="-3">2000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="_StockholdersEquity-c23_AsOf31Dec2019_AdditionalPaidInCapitalMember_usd" unitRef="usd" contextRef="c23_AsOf31Dec2019_AdditionalPaidInCapitalMember" decimals="-3">1754000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="_StockholdersEquity-c24_AsOf31Dec2019_RetainedEarningsMember_usd" unitRef="usd" contextRef="c24_AsOf31Dec2019_RetainedEarningsMember" decimals="-3">-69571000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="_StockholdersEquity-c25_AsOf31Dec2019_AccumulatedOtherComprehensiveIncomeMember_usd" unitRef="usd" contextRef="c25_AsOf31Dec2019_AccumulatedOtherComprehensiveIncomeMember" decimals="-3">41000</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_shares" unitRef="shares" contextRef="c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember" decimals="INF">7896922</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" unitRef="usd" contextRef="c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember" decimals="-3">35051000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-c27_From1Jan2020To31Dec2020_CommonStockMember_shares" unitRef="shares" contextRef="c27_From1Jan2020To31Dec2020_CommonStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" unitRef="usd" contextRef="c27_From1Jan2020To31Dec2020_CommonStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" unitRef="usd" contextRef="c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-c0_From1Jan2020To31Dec2020_usd" unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <clnn:IssuanceOfSeriesDPreferredStockInConnectionExtinguishmentOfConvertiblePromis id="_IssuanceOfSeriesDPreferredStockInConnectionExtinguishmentOfConvertiblePromis-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_shares" unitRef="shares" contextRef="c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember" decimals="INF">1497135</clnn:IssuanceOfSeriesDPreferredStockInConnectionExtinguishmentOfConvertiblePromis>
  <clnn:IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis id="_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" unitRef="usd" contextRef="c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember" decimals="-3">6891000</clnn:IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis>
  <clnn:IssuanceOfSeriesDPreferredStockInConnectionExtinguishmentOfConvertiblePromis id="_IssuanceOfSeriesDPreferredStockInConnectionExtinguishmentOfConvertiblePromis-c27_From1Jan2020To31Dec2020_CommonStockMember_shares" unitRef="shares" contextRef="c27_From1Jan2020To31Dec2020_CommonStockMember" xs:nil="true"/>
  <clnn:IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis id="_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" unitRef="usd" contextRef="c27_From1Jan2020To31Dec2020_CommonStockMember" xs:nil="true"/>
  <clnn:IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis id="_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <clnn:IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis id="_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <clnn:IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis id="_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" unitRef="usd" contextRef="c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <clnn:IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis id="_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis-c0_From1Jan2020To31Dec2020_usd" unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="_StockIssuedDuringPeriodSharesStockOptionsExercised-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_shares" unitRef="shares" contextRef="c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="_StockIssuedDuringPeriodValueStockOptionsExercised-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" unitRef="usd" contextRef="c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="_StockIssuedDuringPeriodSharesStockOptionsExercised-c27_From1Jan2020To31Dec2020_CommonStockMember_shares" unitRef="shares" contextRef="c27_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">87613</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="_StockIssuedDuringPeriodValueStockOptionsExercised-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" unitRef="usd" contextRef="c27_From1Jan2020To31Dec2020_CommonStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="_StockIssuedDuringPeriodValueStockOptionsExercised-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="-3">78000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="_StockIssuedDuringPeriodValueStockOptionsExercised-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="_StockIssuedDuringPeriodValueStockOptionsExercised-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" unitRef="usd" contextRef="c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="_StockIssuedDuringPeriodValueStockOptionsExercised-c0_From1Jan2020To31Dec2020_usd" unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">78000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <clnn:ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection id="_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_shares" unitRef="shares" contextRef="c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember" decimals="INF">-36893894</clnn:ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection>
  <clnn:ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe id="_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" unitRef="usd" contextRef="c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember" decimals="-3">-114603000</clnn:ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe>
  <clnn:ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection id="_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection-c27_From1Jan2020To31Dec2020_CommonStockMember_shares" unitRef="shares" contextRef="c27_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">36893894</clnn:ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection>
  <clnn:ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe id="_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" unitRef="usd" contextRef="c27_From1Jan2020To31Dec2020_CommonStockMember" decimals="-3">4000</clnn:ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe>
  <clnn:ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe id="_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="-3">114599000</clnn:ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe>
  <clnn:ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe id="_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <clnn:ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe id="_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" unitRef="usd" contextRef="c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <clnn:ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe id="_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe-c0_From1Jan2020To31Dec2020_usd" unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">114603000</clnn:ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe>
  <clnn:ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable id="_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" unitRef="usd" contextRef="c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember" xs:nil="true"/>
  <clnn:ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable id="_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" unitRef="usd" contextRef="c27_From1Jan2020To31Dec2020_CommonStockMember" xs:nil="true"/>
  <clnn:ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable id="_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="-3">17828000</clnn:ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable>
  <clnn:ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable id="_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <clnn:ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable id="_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" unitRef="usd" contextRef="c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <clnn:ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable id="_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable-c0_From1Jan2020To31Dec2020_usd" unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">17828000</clnn:ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="_StockIssuedDuringPeriodSharesNewIssues-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_shares" unitRef="shares" contextRef="c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember" xs:nil="true"/>
  <clnn:IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts id="_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" unitRef="usd" contextRef="c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="_StockIssuedDuringPeriodSharesNewIssues-c27_From1Jan2020To31Dec2020_CommonStockMember_shares" unitRef="shares" contextRef="c27_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">4542995</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <clnn:IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts id="_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" unitRef="usd" contextRef="c27_From1Jan2020To31Dec2020_CommonStockMember" xs:nil="true"/>
  <clnn:IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts id="_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="-3">31833000</clnn:IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts>
  <clnn:IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts id="_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <clnn:IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts id="_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" unitRef="usd" contextRef="c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <clnn:IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts id="_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts-c0_From1Jan2020To31Dec2020_usd" unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">31833000</clnn:IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts>
  <us-gaap:StockIssuedDuringPeriodValueOther id="_StockIssuedDuringPeriodValueOther-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" unitRef="usd" contextRef="c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueOther id="_StockIssuedDuringPeriodValueOther-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" unitRef="usd" contextRef="c27_From1Jan2020To31Dec2020_CommonStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueOther id="_StockIssuedDuringPeriodValueOther-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="-3">-5911000</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueOther id="_StockIssuedDuringPeriodValueOther-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueOther id="_StockIssuedDuringPeriodValueOther-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" unitRef="usd" contextRef="c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueOther id="_StockIssuedDuringPeriodValueOther-c0_From1Jan2020To31Dec2020_usd" unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-5911000</us-gaap:StockIssuedDuringPeriodValueOther>
  <clnn:IssuanceOfCommonStockPaymentOfRelatedOfferingCosts id="_IssuanceOfCommonStockPaymentOfRelatedOfferingCosts-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_shares" unitRef="shares" contextRef="c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember" xs:nil="true"/>
  <clnn:IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts id="_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" unitRef="usd" contextRef="c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember" xs:nil="true"/>
  <clnn:IssuanceOfCommonStockPaymentOfRelatedOfferingCosts id="_IssuanceOfCommonStockPaymentOfRelatedOfferingCosts-c27_From1Jan2020To31Dec2020_CommonStockMember_shares" unitRef="shares" contextRef="c27_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">644164</clnn:IssuanceOfCommonStockPaymentOfRelatedOfferingCosts>
  <clnn:IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts id="_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" unitRef="usd" contextRef="c27_From1Jan2020To31Dec2020_CommonStockMember" xs:nil="true"/>
  <clnn:IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts id="_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <clnn:IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts id="_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <clnn:IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts id="_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" unitRef="usd" contextRef="c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <clnn:IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts id="_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts-c0_From1Jan2020To31Dec2020_usd" unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <clnn:ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati id="_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" unitRef="usd" contextRef="c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember" xs:nil="true"/>
  <clnn:ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati id="_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" unitRef="usd" contextRef="c27_From1Jan2020To31Dec2020_CommonStockMember" xs:nil="true"/>
  <clnn:ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati id="_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <clnn:ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati id="_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_RetainedEarningsMember" decimals="-3">-64713000</clnn:ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati>
  <clnn:ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati id="_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" unitRef="usd" contextRef="c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <clnn:ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati id="_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati-c0_From1Jan2020To31Dec2020_usd" unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-64713000</clnn:ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati>
  <clnn:ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization id="_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" unitRef="usd" contextRef="c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember" xs:nil="true"/>
  <clnn:ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization id="_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" unitRef="usd" contextRef="c27_From1Jan2020To31Dec2020_CommonStockMember" xs:nil="true"/>
  <clnn:ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization id="_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="-3">-7371000</clnn:ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization>
  <clnn:ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization id="_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <clnn:ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization id="_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" unitRef="usd" contextRef="c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <clnn:ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization id="_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization-c0_From1Jan2020To31Dec2020_usd" unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-7371000</clnn:ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" unitRef="usd" contextRef="c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" unitRef="usd" contextRef="c27_From1Jan2020To31Dec2020_CommonStockMember" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="-3">761000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" unitRef="usd" contextRef="c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-c0_From1Jan2020To31Dec2020_usd" unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">761000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <clnn:ForeignCurrencyTranslationAdjustment id="_ForeignCurrencyTranslationAdjustment-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" unitRef="usd" contextRef="c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember" xs:nil="true"/>
  <clnn:ForeignCurrencyTranslationAdjustment id="_ForeignCurrencyTranslationAdjustment-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" unitRef="usd" contextRef="c27_From1Jan2020To31Dec2020_CommonStockMember" xs:nil="true"/>
  <clnn:ForeignCurrencyTranslationAdjustment id="_ForeignCurrencyTranslationAdjustment-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <clnn:ForeignCurrencyTranslationAdjustment id="_ForeignCurrencyTranslationAdjustment-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <clnn:ForeignCurrencyTranslationAdjustment id="_ForeignCurrencyTranslationAdjustment-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" unitRef="usd" contextRef="c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember" decimals="-3">284000</clnn:ForeignCurrencyTranslationAdjustment>
  <clnn:ForeignCurrencyTranslationAdjustment id="_ForeignCurrencyTranslationAdjustment-c0_From1Jan2020To31Dec2020_usd" unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">284000</clnn:ForeignCurrencyTranslationAdjustment>
  <us-gaap:ProfitLoss id="_ProfitLoss-c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember_usd" unitRef="usd" contextRef="c26_From1Jan2020To31Dec2020_RedeemableConvertiblePreferredStockMember" xs:nil="true"/>
  <us-gaap:ProfitLoss id="_ProfitLoss-c27_From1Jan2020To31Dec2020_CommonStockMember_usd" unitRef="usd" contextRef="c27_From1Jan2020To31Dec2020_CommonStockMember" xs:nil="true"/>
  <us-gaap:ProfitLoss id="_ProfitLoss-c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember_usd" unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:ProfitLoss id="_ProfitLoss-c29_From1Jan2020To31Dec2020_RetainedEarningsMember_usd" unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_RetainedEarningsMember" decimals="-3">-19277000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="_ProfitLoss-c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" unitRef="usd" contextRef="c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <us-gaap:ProfitLoss id="_ProfitLoss-c0_From1Jan2020To31Dec2020_usd" unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-19277000</us-gaap:ProfitLoss>
  <us-gaap:SharesOutstanding id="_SharesOutstanding-c31_AsOf31Dec2020_RedeemableConvertiblePreferredStockMember_shares" unitRef="shares" contextRef="c31_AsOf31Dec2020_RedeemableConvertiblePreferredStockMember" xs:nil="true"/>
  <us-gaap:StockholdersEquity id="_StockholdersEquity-c31_AsOf31Dec2020_RedeemableConvertiblePreferredStockMember_usd" unitRef="usd" contextRef="c31_AsOf31Dec2020_RedeemableConvertiblePreferredStockMember" xs:nil="true"/>
  <us-gaap:SharesOutstanding id="_SharesOutstanding-c32_AsOf31Dec2020_CommonStockMember_shares" unitRef="shares" contextRef="c32_AsOf31Dec2020_CommonStockMember" decimals="INF">59526171</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="_StockholdersEquity-c32_AsOf31Dec2020_CommonStockMember_usd" unitRef="usd" contextRef="c32_AsOf31Dec2020_CommonStockMember" decimals="-3">6000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="_StockholdersEquity-c33_AsOf31Dec2020_AdditionalPaidInCapitalMember_usd" unitRef="usd" contextRef="c33_AsOf31Dec2020_AdditionalPaidInCapitalMember" decimals="-3">153571000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="_StockholdersEquity-c34_AsOf31Dec2020_RetainedEarningsMember_usd" unitRef="usd" contextRef="c34_AsOf31Dec2020_RetainedEarningsMember" decimals="-3">-153561000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="_StockholdersEquity-c35_AsOf31Dec2020_AccumulatedOtherComprehensiveIncomeMember_usd" unitRef="usd" contextRef="c35_AsOf31Dec2020_AccumulatedOtherComprehensiveIncomeMember" decimals="-3">325000</us-gaap:StockholdersEquity>
  <clnn:NetIssuanceCosts id="_NetIssuanceCosts-c0_From1Jan2020To31Dec2020_usd" unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-5">1300000</clnn:NetIssuanceCosts>
  <us-gaap:Depreciation unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">963000</us-gaap:Depreciation>
  <us-gaap:Depreciation unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">848000</us-gaap:Depreciation>
  <us-gaap:OtherNoncashExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">108000</us-gaap:OtherNoncashExpense>
  <us-gaap:OtherNoncashExpense unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">153000</us-gaap:OtherNoncashExpense>
  <us-gaap:FairValueAdjustmentOfWarrants unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">14615000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">361000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">761000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">399000</us-gaap:ShareBasedCompensation>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">29000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:GainLossOnTerminationOfLease unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">51000</us-gaap:GainLossOnTerminationOfLease>
  <us-gaap:GainLossOnTerminationOfLease unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:AmortizationOfDebtDiscountPremium unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">179000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:AmortizationOfDebtDiscountPremium unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <clnn:IncreaseInInterestAccruedOnNotesPayable unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">732000</clnn:IncreaseInInterestAccruedOnNotesPayable>
  <clnn:IncreaseInInterestAccruedOnNotesPayable unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">40000</clnn:IncreaseInInterestAccruedOnNotesPayable>
  <us-gaap:IncreaseDecreaseInInventories unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">163000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">28000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">2862000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">354000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-312000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">-76000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-272000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">1820000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">164000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
  <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <clnn:IncreaseDecreaseInPayableToRelatedParties unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-131000</clnn:IncreaseDecreaseInPayableToRelatedParties>
  <clnn:IncreaseDecreaseInPayableToRelatedParties unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">32000</clnn:IncreaseDecreaseInPayableToRelatedParties>
  <us-gaap:IncreaseDecreaseInDeferredRevenue unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">112000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-260000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
  <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <clnn:IncreaseDecreaseOperatingLeaseObligations unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">142000</clnn:IncreaseDecreaseOperatingLeaseObligations>
  <clnn:IncreaseDecreaseOperatingLeaseObligations unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">237000</clnn:IncreaseDecreaseOperatingLeaseObligations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-18929000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">-13197000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">387000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">294000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-387000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">-294000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">8069000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <us-gaap:ProceedsFromStockOptionsExercised unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">78000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">10000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:FinanceLeasePrincipalPayments unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">194000</us-gaap:FinanceLeasePrincipalPayments>
  <us-gaap:FinanceLeasePrincipalPayments unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">176000</us-gaap:FinanceLeasePrincipalPayments>
  <us-gaap:ProceedsFromConvertibleDebt unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">652000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromConvertibleDebt unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">600000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:RepaymentsOfNotesPayable unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:RepaymentsOfNotesPayable unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">3000000</us-gaap:RepaymentsOfNotesPayable>
  <us-gaap:PaymentsOfStockIssuanceCosts unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">4011000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <clnn:ProceedsFromThePrivatePlacementOfferingNetOfOfferingCosts unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">31833000</clnn:ProceedsFromThePrivatePlacementOfferingNetOfOfferingCosts>
  <clnn:ProceedsFromThePrivatePlacementOfferingNetOfOfferingCosts unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">35051000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:ProceedsFromIssuanceOfMediumTermNotes unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">6125000</us-gaap:ProceedsFromIssuanceOfMediumTermNotes>
  <us-gaap:ProceedsFromIssuanceOfMediumTermNotes unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">69534000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">5503000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">269000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">-1000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">50487000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">-7989000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">8788000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents unitRef="usd" contextRef="c15_AsOf31Dec2018" decimals="-3">16777000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">59275000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:FairValueOfAssetsAcquired unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:FairValueOfAssetsAcquired unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">403000</us-gaap:FairValueOfAssetsAcquired>
  <clnn:AcquisitionOfRightofuseAssetsAndLeaseholdImprovementsThroughOperatingLease unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">820000</clnn:AcquisitionOfRightofuseAssetsAndLeaseholdImprovementsThroughOperatingLease>
  <clnn:AcquisitionOfRightofuseAssetsAndLeaseholdImprovementsThroughOperatingLease unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">11000</clnn:AcquisitionOfRightofuseAssetsAndLeaseholdImprovementsThroughOperatingLease>
  <clnn:WarrantLiabilitySettledOnExercise unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <clnn:WarrantLiabilitySettledOnExercise unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">1666000</clnn:WarrantLiabilitySettledOnExercise>
  <clnn:LeaseLiabilitySettledThroughTerminationOfLease unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">348000</clnn:LeaseLiabilitySettledThroughTerminationOfLease>
  <clnn:LeaseLiabilitySettledThroughTerminationOfLease unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <clnn:IssuanceOfDerivativeInstrumentRelatedToConvertibleNotes unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">705000</clnn:IssuanceOfDerivativeInstrumentRelatedToConvertibleNotes>
  <clnn:IssuanceOfDerivativeInstrumentRelatedToConvertibleNotes unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <clnn:IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">5675000</clnn:IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes>
  <clnn:IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <clnn:ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">676000</clnn:ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN>
  <clnn:ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <clnn:DeferredTransactionCostsInAccountsPayable unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">546000</clnn:DeferredTransactionCostsInAccountsPayable>
  <clnn:DeferredTransactionCostsInAccountsPayable unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <clnn:DeferredTransactionsCostsInAccruedLiabilities unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">1354000</clnn:DeferredTransactionsCostsInAccruedLiabilities>
  <clnn:DeferredTransactionsCostsInAccruedLiabilities unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <clnn:ConversionOfRedeemableConvertiblePreferredStockIntoCommonStock unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">114603000</clnn:ConversionOfRedeemableConvertiblePreferredStockIntoCommonStock>
  <clnn:ConversionOfRedeemableConvertiblePreferredStockIntoCommonStock unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <clnn:ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemableConvertibleSreferredStock unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">17828000</clnn:ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemableConvertibleSreferredStock>
  <clnn:ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemableConvertibleSreferredStock unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <clnn:IssuanceOfCommonStockAsPaymentRelatedOfferingCosts unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">6442000</clnn:IssuanceOfCommonStockAsPaymentRelatedOfferingCosts>
  <clnn:IssuanceOfCommonStockAsPaymentRelatedOfferingCosts unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <clnn:ContingentEarnoutRecognizedConnectionWithTheReverseRecapitalization unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">64713000</clnn:ContingentEarnoutRecognizedConnectionWithTheReverseRecapitalization>
  <clnn:ContingentEarnoutRecognizedConnectionWithTheReverseRecapitalization unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <clnn:InitialShareholdersContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">7371000</clnn:InitialShareholdersContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization>
  <clnn:InitialShareholdersContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:InterestPaid unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">39000</us-gaap:InterestPaid>
  <us-gaap:InterestPaid unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">48000</us-gaap:InterestPaid>
  <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;1.
Nature of the Business and Basis of Presentation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Clene Inc. (formerly
Chelsea Worldwide, Inc.) (the &amp;#x201c;Company&amp;#x201d;) is a biopharmaceutical company focused on the development of clean-surfaced
nanocrystal drugs. The Company has developed an electrocrystal chemistry drug development platform, in which nanocrystals within
a suspension are the therapeutic drug. Utilizing technology to create nanocrystal drug suspensions, the Company&amp;#x2019;s platform
has produced multiple drug assets, of which its lead assets are currently in development for use in neurological and infectious
diseases, among others, such as a study for treatment of COVID-19 coronavirus pandemic. Secondary to the Company&amp;#x2019;s drug development,
as part of the Company&amp;#x2019;s identification of potential drug assets, the Company has also identified certain mineral solutions
as dietary supplements. The Company&amp;#x2019;s dietary supplements may also be commercialized by a related party, as discussed in
Note 20.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The accompanying consolidated
financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America
(&amp;#x201c;GAAP&amp;#x201d;) and include the accounts of the Company and its wholly owned subsidiaries, Clene Nanomedicine, Inc. (&amp;#x201c;Clene
Nanomedicine&amp;#x201d;), a subsidiary incorporated in Delaware, Clene Australia Pty Ltd, a subsidiary incorporated in Australia, and
dOrbital, Inc., a subsidiary incorporated in Delaware, after elimination of all intercompany accounts and transactions. Certain
prior period balances have been reclassified to conform to the current year presentation.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Reverse
Recapitalization with Tottenham Acquisition 1 Limited&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;On
December 30, 2020 (the &amp;#x201c;Closing Date&amp;#x201d;), Chelsea Worldwide, Inc., our predecessor company, consummated the previously
announced business combination (referred to as the &amp;#x201c;Reverse Recapitalization&amp;#x201d;) pursuant to a merger agreement, dated
as of September 1, 2020 (the &amp;#x201c;Merger Agreement&amp;#x201d;), by and among Clene Nanomedicine, Tottenham Acquisition I Limited
(&amp;#x201c;Tottenham&amp;#x201d; or &amp;#x201c;TOTA&amp;#x201d;), Chelsea Worldwide Inc., a Delaware corporation and wholly owned subsidiary of
Tottenham (&amp;#x201c;PubCo&amp;#x201d;), Creative Worldwide Inc., a Delaware corporation and wholly owned subsidiary of PubCo (&amp;#x201c;Merger
Sub&amp;#x201d;), and Fortis Advisors LLC, a Delaware limited liability company as the representative of the Company&amp;#x2019;s stockholders
(&amp;#x201c;Stockholders&amp;#x2019; Representative&amp;#x201d;). Prior to the Reincorporation Merger discussed below, Tottenham was incorporated
in the British Virgin Islands as a blank check company for the purpose of entering into a merger, share exchange, asset acquisition,
stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Reverse Recapitalization
was effected in two steps: (i) Tottenham was reincorporated to the state of Delaware by merging with and into PubCo (the &amp;#x201c;Reincorporation
Merger&amp;#x201d;); (ii) promptly following the Reincorporation Merger, Merger Sub was merged with and into Clene Nanomedicine, resulting
in Clene Nanomedicine becoming a wholly owned subsidiary of PubCo (the &amp;#x201c;Acquisition Merger&amp;#x201d;). On the Closing Date,
PubCo changed its name from Chelsea Worldwide Inc. to Clene Inc. and listed its shares of common stock, par value $0.0001 per share
(&amp;#x201c;Common Stock&amp;#x201d;) on the Nasdaq under the symbol &amp;#x201c;CLNN.&amp;#x201d;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Upon the consummation
of the Reverse Recapitalization, each Tottenham ordinary share issued and outstanding immediately prior to the effective time of
the Reincorporation Merger (excluding certain shares to be canceled pursuant to the Merger Agreement, any redeemed shares and any
dissenting), was automatically cancelled and cease to exist and (i) for each Tottenham ordinary share, the Company issued to each
shareholder one validly issued share of the Company&amp;#x2019;s Common Stock; (ii) each warrant to purchase one half (1/2) of one Tottenham
Ordinary Share converted into a warrant to purchase one-half of one share of the Company&amp;#x2019;s Common Stock; (iii) each right
exchangeable into one-tenth (1/10) of one Tottenham ordinary share converted into a right exchangeable for one-tenth (1/10) of
one share of the Company&amp;#x2019;s Common Stock; provided, however, that no fractional shares were issued and all fractional shares
were rounded down to the nearest whole share.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;On the Closing Date,
each share of Clene Nanomedicine common stock was cancelled and the holders thereof in exchange received 0.1389 newly issued shares
of Clene Inc. Common Stock, which is the exchange ratio (the &amp;#x201c;Exchange Ratio&amp;#x201d;). Pursuant to the Merger Agreement, 5%
of the aggregate amount of the closing payment shares, or 2,716,958 shares will be held in escrow to satisfy any indemnification
obligation incurred and will be released six months after the closing of the Reverse Recapitalization. In addition, each share
of Clene Nanomedicine&amp;#x2019;s preferred stock outstanding immediately prior to the closing of the Reverse Recapitalization was
converted into the right to receive the Company&amp;#x2019;s Common Stock based on the same Exchange Ratio. In addition, all outstanding
warrants exercisable for common stock in Clene Nanomedicine (other than warrants that expired, were exercised or were deemed automatically
net exercised immediately prior to the Acquisition Merger) were exchanged for warrants exercisable for the Company Common Stock
with the same terms and conditions except adjusted by the aforementioned Exchange Ratio. At the closing of the Reverse Recapitalization,
each stock option of Clene Nanomedicine common stock was cancelled and the holders thereof in exchange received 0.1320 newly issued
stock options of the Company&amp;#x2019;s Common Stock, which is 95% of the Exchange Ratio. Pursuant to the Merger Agreement, the Company
issued 370,101 of restricted stock units (&amp;#x201c;RSUs&amp;#x201d;) to the option holders which complements the 5% closing payment shares
held in escrow for Clene Nanomedicine common shareholders. The modification of the stock options did not result in a material incremental
compensation expense upon closing of the Reverse Recapitalization.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In addition, the Company
issued 1,136,961 RSUs to option holders to complement the earn-out payments that would contingently be issued to certain current
Clene Nanomedicine&amp;#x2019;s shareholders upon the achievement of milestones. See Note 3 for the milestones detail.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in&quot;&gt;The proceeds received from
the Reverse Recapitalization is $3.7&amp;#xa0;million, net of offering costs of $5.9 million which excludes the fair value of common
shares issued as a payment of related offering costs.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In connection with
Tottenham&amp;#x2019;s initial public offering in August 2018, Tottenham issued to Chardan Capital Markets, LLC (&amp;#x201c;Chardan&amp;#x201d;),
options to purchase 220,000 units at $10.00 per unit. Each of the units consists of one and one-tenth shares of Tottenham&amp;#x2019;s
ordinary shares for $10.00 per share and one warrant to purchase one-half of one of Tottenham&amp;#x2019;s ordinary shares at an exercise
price of $11.50 per share (the &amp;#x201c;Chardan Unit Purchase Option&amp;#x201d;). In connection with the Reverse Recapitalization, the
Chardan Unit Purchase Option was converted into one Company unit purchase option. The warrants included in the Chardan Unit Purchase
Option (the &amp;#x201c;Chardan Unit Purchase Option Warrants&amp;#x201d;) are exercisable upon the completion of the Reverse Recapitalization
and will expire five years after the consummation of the Reverse Recapitalization (i.e., December 30, 2025) (see Note 10).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Also,
in connection with the Reverse Recapitalization, 644,164 shares of the Company&amp;#x2019;s Common stock were issued to LifeSci Capital
LLC (&amp;#x201c;LifeSci&amp;#x201d;), as payment for advisory services rendered in connection with the Reverse Recapitalization (see Notes
3 and 18).&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The transaction was
accounted for as a &amp;#x201c;reverse recapitalization&amp;#x201d; in accordance with accounting principles generally accepted in the United
States (&amp;#x201c;GAAP&amp;#x201d;). Under this method of accounting, Tottenham was treated as the &amp;#x201c;acquired&amp;#x201d; company for financial
reporting purposes. This determination is primarily based on the fact that subsequent to the Reverse Recapitalization, Clene Nanomedicine&amp;#x2019;s
stockholders have a majority of the voting power of the combined company, Clene Nanomedicine comprises all of the ongoing operations
of the combined entity, Clene Nanomedicine comprises a majority of the governing body of the combined company, and Clene Nanomedicine&amp;#x2019;s
senior management comprises all of the senior management of the combined company. Accordingly, for accounting purposes, this transaction
was treated as the equivalent of Clene Nanomedicine issuing shares for the net assets of Tottenham, accompanied by a recapitalization.
The shares and net loss per common share, prior to the Reverse Recapitalization, have been retroactively restated as shares reflecting
the Exchange Ratio established in the Reverse Recapitalization (0.1389 Clene Inc. shares for 1 Clene Nanomedicine share). The net
assets of Tottenham were recorded at historical costs, with no goodwill or other intangible assets recorded. Operations prior to
the Reverse Recapitalization are those of Clene Nanomedicine.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;The
PIPE Offering&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in&quot;&gt;Prior to the completion
of the Reverse Recapitalization on December 30, 2020, the Company entered into a subscription agreement on December 28, 2020, with
various investors. Pursuant to the subscription agreements, the Company issued 2,239,500 shares of the Company&amp;#x2019;s Common Stock
(the &amp;#x201c;PIPE Shares&amp;#x201d;) at a price of $10.00 per share with net proceeds of $22.2 million. The purpose of the PIPE is to
fund general corporate expenses. In addition, investors in the PIPE offering also received warrants to purchase a number of shares
equal to one-half (1/2) of the number of PIPE Shares, totaling 1,119,750 shares of the Company&amp;#x2019;s Common Stock, at an exercise
price of $0.01 per share for each of the PIPE Shares (the &amp;#x201c;PIPE Warrants&amp;#x201d;), subject to a 180-day holding period.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;See
Note 3 &amp;#x2013; Reverse Recapitalization with Tottenham and Clene Nanomedicine for additional details on Reverse Recapitalization.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Liquidity&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Company has incurred
significant losses and negative cash flows from operations since its inception. The Company incurred net losses of $19.3 million
and $16.2 million for the years ended December 31, 2020 and 2019. As of December 31, 2020, the Company&amp;#x2019;s cash totaled $59.3
million, its accumulated deficit was $153.6 million, and the Company had net cash used in operating activities of $18.9 million.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Prior to the Reverse Recapitalization, Clene Nanomedicine&amp;#x2019;s
operations were financed through the issuance of equity instruments and the issuance of convertible promissory notes. The Company
has not generated significant revenues to date and does not anticipate generating any significant revenues unless it successfully
completes development and obtains regulatory approval for its drugs or for its COVID-19 study. The Company expects to incur additional
losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional
capital to fully implement its business plan. Additionally, we may attempt to negotiate a collaboration agreement with a third
party for development and commercialization of a drug candidate, which may provide upfront and milestone payments to reduce our
spending going forward.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company expects to continue investing in product development, sales and marketing and customer support for its products. The long-term
continuation of the Company&amp;#x2019;s business plan is dependent upon the generation of sufficient revenues from its products to
offset expenses and capital expenditures. In the event that the Company does not generate sufficient revenues and is unable to
obtain funding, the Company will be forced to delay, reduce, or eliminate some or all of its research and development programs,
product portfolio expansion, commercialization efforts or capital expenditures, which could adversely affect the Company&amp;#x2019;s
business prospects, ability to meet long-term liquidity needs or the Company may be unable to continue operations.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company expects that the cash on hand as of December 31, 2020 will be sufficient to fund its operations for a period extending
beyond twelve months from the date the consolidated financial statements are issued.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Impact
of the COVID-19 Coronavirus Pandemic&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
COVID-19 pandemic, which began in December&amp;#xa0;2019 and has spread worldwide, has caused many governments to implement measures
to slow the spread of the outbreak. The outbreak and government measures taken in response have had a significant impact, both
direct and indirect, on businesses and commerce, as worker shortages have occurred, supply chains have been disrupted, and facilities
and production have been suspended. The future progression of the pandemic and its effects on the Company&amp;#x2019;s business and
operations remain uncertain. The COVID-19 pandemic may affect the Company&amp;#x2019;s ability to initiate and complete preclinical
studies, delay the initiation of future clinical trials, disrupt regulatory activities, or have other adverse effects on its business
and operations. In particular, the Company and its clinical research organizations (&amp;#x201c;CROs&amp;#x201d;) may face disruptions that
may affect the Company&amp;#x2019;s ability to initiate and complete preclinical studies, manufacturing disruptions, and delays at
clinical trial sites. The pandemic has already caused significant disruptions in the financial markets, and may continue to cause
such disruptions, which could impact the Company&amp;#x2019;s ability to raise additional funds to support its operations. Moreover,
the pandemic has significantly impacted economies worldwide and could result in adverse effects on the Company&amp;#x2019;s business
and operations.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company is monitoring the potential impact of the COVID-19 pandemic on the Company&amp;#x2019;s business and financial statements.
While the COVID-19 pandemic has led to various research restrictions and paused certain of Clene Nanomedicine&amp;#x2019;s clinical
trials, these impacts have been temporary and to date, the Company has not experienced material business disruptions or incurred
impairment losses in the carrying values of its assets as a result of the pandemic and the Company is not aware of any specific
related event or circumstance that would require the Company to revise the estimates reflected in these financial statements.
The extent to which the COVID-19 pandemic will directly or indirectly impact the Company&amp;#x2019;s business, results of operations,
cash flows and financial condition, including planned and future clinical trials and research and development costs, will depend
on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19,
the actions taken to contain or treat it, and the duration and intensity of the related effects.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c36_From1Jan2020To31Dec2020_ExchangeClearedMember_CommonStockMember" decimals="INF">0.1389</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <clnn:MergerAgreementPercentage unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">0.05</clnn:MergerAgreementPercentage>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">2716958</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c37_From1Jan2020To31Dec2020_ExchangeClearedMember_CleneNanomedicineMember_CommonStockMember" decimals="INF">0.1320</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" contextRef="c38_AsOf31Dec2020_ExchangeClearedMember_CleneNanomedicineMember_CommonStockMember" decimals="2">0.95</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward unitRef="shares" contextRef="c39_From1Jan2020To31Dec2020_RestrictedStockUnitsRSUMember_ExchangeClearedMember_CleneNanomedicineMember" decimals="INF">370101</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" contextRef="c40_AsOf31Dec2020_RestrictedStockUnitsRSUMember_ExchangeClearedMember_CleneNanomedicineMember" decimals="2">0.05</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward unitRef="shares" contextRef="c41_From1Jan2020To31Dec2020_RestrictedStockUnitsRSUMember_CleneNanomedicineMember" decimals="INF">1136961</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
  <clnn:ProceedsFromReverseRecapitalizationNet unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-5">3700000</clnn:ProceedsFromReverseRecapitalizationNet>
  <us-gaap:DeferredOfferingCosts unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-5">5900000</us-gaap:DeferredOfferingCosts>
  <clnn:PurchaseOption unitRef="pure" contextRef="c42_From1Aug2018To31Aug2018_ChardanMember" decimals="0">220000</clnn:PurchaseOption>
  <clnn:PerShareUnit unitRef="pure" contextRef="c43_AsOf31Aug2018_ChardanMember" decimals="2">10.00</clnn:PerShareUnit>
  <us-gaap:SaleOfStockPricePerShare unitRef="usdPershares" contextRef="c43_AsOf31Aug2018_ChardanMember" decimals="2">10.00</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 unitRef="usdPershares" contextRef="c43_AsOf31Aug2018_ChardanMember" decimals="2">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <clnn:PaymentsForAdvisoryServicesShares unitRef="shares" contextRef="c44_From1Jan2020To31Dec2020_LifeSciCapitalLLCMember" decimals="INF">644164</clnn:PaymentsForAdvisoryServicesShares>
  <clnn:StockIssuedDuringPeriodSharesPrivatePlacement unitRef="shares" contextRef="c45_From1Dec2020To28Dec2020" decimals="INF">2239500</clnn:StockIssuedDuringPeriodSharesPrivatePlacement>
  <us-gaap:SaleOfStockPricePerShare unitRef="usdPershares" contextRef="c46_AsOf28Dec2020_CommonStockMember" decimals="2">10.00</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity unitRef="usd" contextRef="c45_From1Dec2020To28Dec2020" decimals="-5">22200000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants unitRef="shares" contextRef="c45_From1Dec2020To28Dec2020" decimals="INF">1119750</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
  <clnn:IncurredNetLosses unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-5">19300000</clnn:IncurredNetLosses>
  <clnn:IncurredNetLosses unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-5">16200000</clnn:IncurredNetLosses>
  <us-gaap:Cash unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-5">59300000</us-gaap:Cash>
  <clnn:RetainedEarningsAccumulatedDeficit1 unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-5">153600000</clnn:RetainedEarningsAccumulatedDeficit1>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-5">18900000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;2.
Summary of Significant Accounting Policies&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Use
of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets, liabilities and disclosure of contingent assets and liabilities at the date of the
consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and
assumptions made in the accompanying consolidated financial statements include, but are not limited to the valuation of common
stock, stock options, contingent earn-out liability, and Preferred Stock warrants.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual
results may differ from those estimates or assumptions. Estimates are periodically reviewed in light of changes in circumstances,
facts, and experience. Changes in estimates are recorded in the period in which they become known.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Risks
and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
product candidates developed by the Company require approvals from the U.S. Food and Drug Administration (&amp;#x201c;FDA&amp;#x201d;) or
foreign regulatory agencies prior to commercial sales. There can be no assurance that the Company&amp;#x2019;s current and future product
candidates will receive the necessary approvals or be commercially successful. If the Company is denied approval or approval is
delayed, it will have a material adverse impact on the Company&amp;#x2019;s business and its consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company is subject to risks common to companies in the development stage including, but not limited to, dependency on the need
for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by
physicians and patients, significant competition, and untested manufacturing capabilities.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company is subject to certain risks and uncertainties and believes that changes in any of the following areas could have a material
adverse effect on future financial position or results of operations: ability to obtain future financing; regulatory approval
and market acceptance of, and reimbursement for, product candidates; performance of third-party clinical research organizations
and manufacturers upon which the Company relies; protection of the Company&amp;#x2019;s intellectual property; litigation or claims
against the Company based on intellectual property, patent, product, regulatory or other factors; and the Company&amp;#x2019;s ability
to attract and retain employees necessary to support its growth.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Concentrations
of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Financial
instruments which potentially subject the Company to significant concentrations of credit risk consist primarily of cash. The
Company&amp;#x2019;s cash is mainly held in financial institutions. Amounts on deposit may at times exceed federally insured limits.
The Company has not experienced any losses on its deposits of cash and does not believe that it is subject to unusual credit risk
beyond the normal credit risk associated with commercial banking relationships.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Company considers
all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. As of December
31, 2020 and 2019, the Company has no cash equivalents and no restricted cash balances.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Inventory&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Inventory is stated
at historic cost on a first -in first-out basis. The Company&amp;#x2019;s inventory consisted of $71,000 in raw materials and $0.1 million
in finished goods as of December 31, 2020. The Company&amp;#x2019;s inventory consisted of $28,000 in finished goods as of December
31, 2019.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Deferred
Offering Costs&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Company capitalizes
certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings,
including the Reverse Recapitalization and the PIPE offering, as deferred costs until such financings are consummated. After consummation
of the equity financing, these costs are recorded in stockholders&amp;#x2019; equity (deficit) as a reduction of proceeds generated
as a result of the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately
as a charge to operating expenses in the consolidated statement of operations.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in&quot;&gt;During the year ended December
31, 2020, the Company incurred $5.9 million of offering costs, which excludes the fair value of common shares issued as a payment
of related offering costs, to additional paid in capital in connection with the Reverse Recapitalization.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;During 2019, the Company
had offering costs that were directly related to its proposed initial public offering of $1.0 million. In September 2019, the Company
terminated its initial public offering registration process. Accordingly, the Company has written off deferred offering costs previously
capitalized to general and administrative expense within the accompanying consolidated statements of operations and comprehensive
loss as of December 31, 2019.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;At
inception of a contract, the Company determines if a contract meets the definition of a lease. A lease is a contract, or part
of a contract, that conveys the right to control the use of identified property, plant, or equipment (an identified asset) for
a period of time in exchange for consideration. The Company determines if the contract conveys the right to control the use of
an identified asset for a period of time. The Company assesses throughout the period of use whether the Company has both of the
following: (1)&amp;#xa0;the right to obtain substantially all of the economic benefits from use of the identified asset, and (2)&amp;#xa0;the
right to direct the use of the identified asset. This determination is reassessed if the terms of the contract are changed. Leases
are classified as operating or finance leases based on the terms of the lease agreement and certain characteristics of the identified
asset. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of the
future lease payments.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company leases laboratory and office space (real estate), and certain equipment under non-cancellable operating and finance leases.
The carrying value of the Company&amp;#x2019;s right-of-use lease assets is substantially concentrated in its real estate leases, while
the volume of lease agreements is primarily concentrated in equipment leases. The Company&amp;#x2019;s policy is to not record leases
with an original term of twelve months or less on the consolidated balance sheets. The Company recognizes lease expense for these
short-term leases on a straight-line basis over the lease term.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Certain
lease agreements may require the Company to pay additional amounts for taxes, insurance, maintenance and other expenses, which
are generally referred to as non-lease components. Such variable non-lease components are treated as variable lease payments and
recognized in the period in which the obligation for these payments was incurred. Variable lease components and variable non-lease
components are not measured as part of the right-of-use asset and liability. Only when lease components and their associated non-lease
components are fixed are they accounted for as a single lease component and are recognized as part of a right-of-use asset and
liability. Total contract consideration is allocated to the combined fixed lease and non-lease component. This policy election
applies consistently to all asset classes under lease agreements.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Leases
may contain clauses for renewal at the Company&amp;#x2019;s option. Payments to be made in option periods are recognized as part of
the right-of-use lease assets and lease liabilities when it is reasonably certain that the option to extend the lease will be
exercised, or is not at the Company&amp;#x2019;s option. The Company determines whether the reasonably certain threshold is met by
considering contract-, asset-, market-, and entity-based factors. In the consolidated statements of earnings, operating lease
expense, which is recognized on a straight-line basis over the lease term, and the amortization of finance lease ROU assets, which
are included in plant, property, and equipment and depreciated, are included in research and development or general and administrative
expenses consistent with the leased assets&amp;#x2019; primary use. Accretion on the liabilities for finance leases is included in
interest expense.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Property
and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Property and equipment
are stated at cost less accumulated depreciation. Property and equipment consist of lab and office equipment and leasehold improvements.
Depreciation is calculated using the straight-line method over the estimated economic useful lives of the assets, which are 3-5&amp;#xa0;years
for lab equipment and 3-7&amp;#xa0;years for furniture and fixtures. Leasehold improvements are amortized over the lesser of the estimated
lease term or the estimated useful life of the assets. Costs for capital assets not yet placed into service are capitalized as
construction in progress and depreciated or amortized in accordance with the above useful lives once placed into service. Upon
retirement or sale, the related cost and accumulated depreciation and amortization are removed from the accounts and any resulting
gain or loss is included in the consolidated statements of operations and comprehensive loss. Maintenance and repairs that do not
improve or extend the lives of the respective assets are expensed to operations as incurred.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Impairment
of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Long-lived
assets are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of
the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include
significant underperformance of the business in relation to expectations, significant negative industry or economic trends and
significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate an asset group
for recoverability, the Company compares the forecasted undiscounted cash flows expected to result from the use and eventual disposition
of the asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows
expected to result from the use and eventual disposition of an asset group are less than its carrying amount. The impairment loss
would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted
cash flows using market participant assumptions. The Company did not record any impairment losses on long-lived assets during
the years ended December 31, 2020 or December 31, 2019.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Derivative
Instruments&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
convertible promissory notes issued in February through July&amp;#xa0;2020 (&amp;#x201c;2020 Convertible Notes&amp;#x201d;) contained embedded
features that provide the lenders with multiple settlement alternatives. Certain of these settlement features provided the lenders
a right to a fixed number of the Company&amp;#x2019;s shares upon conversion of the notes. Other settlement features provided the lenders
the right or the obligation to receive cash or a variable number of shares upon the completion of a capital raising transaction,
change of control or default of the Company (the &amp;#x201c;Redemption Features&amp;#x201d;).&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Redemption Features of the 2020 Convertible Notes met the requirements for separate accounting and were accounted for as a single
derivative instrument (the &amp;#x201c;2020 Derivative Instrument&amp;#x201d;). The 2020 Derivative Instrument was recorded at fair value
at inception and was subject to re-measurement to fair value at each balance sheet date and immediately prior to the extinguishment
of derivative liability, with any changes in fair value recognized in the consolidated statements of operations and comprehensive
loss. In August 2020, in connection with the Company&amp;#x2019;s issuance and sale of Series D Preferred Stock, all of the outstanding
principal and accrued interest under the convertible promissory notes was automatically converted into shares of Series D Preferred
Stock and the derivative liability was extinguished (see Notes 11 and 12).&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Redeemable
Convertible Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Prior to the Reverse
Recapitalization with Tottenham, the Company recorded all shares of redeemable convertible Preferred Stock at their respective
fair values on the dates of issuance, net of issuance costs. The redeemable convertible Preferred Stock was recorded outside of
permanent equity because while it was not mandatorily redeemable, upon certain events considered not solely within the Company&amp;#x2019;s
control, such as a merger, acquisition, or sale of all or substantially all of the Company&amp;#x2019;s assets (each, a &amp;#x201c;Deemed
Liquidation Event&amp;#x201d;), the redeemable convertible Preferred Stock would become redeemable at the option of the holders of at
least a majority of the then-outstanding shares. The Company did not adjust the carrying values of the redeemable convertible Preferred
Stock to the liquidation preferences of such shares because it was uncertain whether or when a Deemed Liquidation Event would occur
that would obligate the Company to pay the liquidation preferences to holders of shares of redeemable convertible Preferred Stock.
Subsequent adjustments to the carrying values of the liquidation preferences would be made only when it becomes probable that such
a Deemed Liquidation Event will occur.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In connection with
the Reverse Recapitalization, all shares of redeemable convertible Preferred Stock were converted into shares of the Company&amp;#x2019;s
Common Stock. Accordingly, there was no redeemable convertible Preferred Stock outstanding as of December 31, 2020. As of December
31, 2019, the carrying value of the redeemable convertible Preferred Stock was $72.7 million (see Note 17).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Contingent Earn-out&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In connection with
the Reverse Recapitalization and pursuant to the Merger Agreement, Clene Nanomedicine&amp;#x2019;s common shareholders and Initial Shareholders
of Tottenham are entitled to receive additional shares of the Company&amp;#x2019;s Common Stock upon the Company achieving certain milestones
described in Note 12. In accordance with ASC 815 &amp;#x2013; &lt;i&gt;Derivatives and hedging&lt;/i&gt;, the earn-out shares are not indexed to
the Company&amp;#x2019;s own stock and therefore are accounted for as a liability at the reverse recapitalization date and subsequently
remeasured at each reporting date with changes in fair value recorded as a component of other income (expense), net in the consolidated
statements of operations and comprehensive loss.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The estimated fair
value of the contingent consideration was determined using a Monte Carlo simulation that simulated the future path of the Company&amp;#x2019;s
stock price over the earn-out period. The assumptions utilized in the calculation are based on the achievement of certain stock
price milestones including projected stock price, volatility, and risk-free rate. For potential payments related to a product development
milestone, the fair value was determined based on the Company&amp;#x2019;s expectations of achieving such a milestone and the simulated
estimated stock price on the expected date of achievement.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The contingent earn-out
is categorized as a Level 3 fair value measurement (see Fair Value of Financial Instruments accounting policy) because the Company
estimates projections during the earn-out period utilizing unobservable inputs, including various potential pay-out scenarios.
Contingent earn-out payments involve certain assumptions requiring significant judgment and actual results may differ from assumed
and estimated amounts.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Preferred Stock Warrant Liability&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Prior to the Reverse
Recapitalization with Tottenham, the Company accounted for freestanding warrants to purchase shares of Preferred Stock as liabilities
on the balance sheet at their estimated fair value as the underlying redeemable convertible Preferred Stock was considered contingently
redeemable and may obligate the Company to transfer assets to the holders at a future date upon the occurrence of a deemed liquidation
event. At the end of each reporting period, changes in the estimated fair value of the warrants to purchase shares of Preferred
Stock were recorded in change in fair value of Preferred Stock warrant liability in the consolidated statements of operations and
comprehensive loss. Changes in the estimated fair value of the Preferred Stock warrant liability were ($14.6) million and ($0.4)
million for the years ended December 31, 2020 and 2019, respectively. In connection with the Reverse Recapitalization, all Clene
Nanomedicine Preferred Stock was converted to the Company&amp;#x2019;s Common Stock and the Clene Nanomedicine Preferred Stock warrants
were converted to warrants to purchase the Company&amp;#x2019;s Common Stock. The Company assessed the features of these warrants and
determined that they qualify for classification as permanent equity. Accordingly, the Company remeasured the warrants to fair value
upon the closing of the Reverse Recapitalization and reclassified the resulting warrant liability to additional paid-in capital
(See Note 16).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Common Stock Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The Company accounts for common stock warrants as either equity
instruments or liabilities in accordance with ASC 480, &lt;i&gt;Distinguishing Liabilities from Equity&lt;/i&gt; (&amp;#x201c;ASC 480&amp;#x201d;), depending
on the specific terms of the warrant agreement (See Note 10).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Revenue
Recognition&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Under
ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects
the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition
for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&amp;#xa0;identify
the contract(s) with a customer; (ii)&amp;#xa0;identify the performance obligations in the contract; (iii)&amp;#xa0;determine the transaction
price, including variable consideration, if any; (iv)&amp;#xa0;allocate the transaction price to the performance obligations in the
contract; and (v)&amp;#xa0;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies
the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in
exchange for the goods or services it transfers to the customer.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Once
a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine
which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes
as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation
is satisfied or as it is satisfied. The Company typically satisfies its performance obligations via delivery of dietary supplements
to the customer. Payments are due upon receipt for commercial transactions or a prepayment is collected for online retail sales.
The Company&amp;#x2019;s revenue for the year ended December 31, 2020 was comprised of sales of dietary supplements.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company recorded deferred revenue of $0.1 million as of December 31, 2020 from the dietary supply agreement with the related party
discussed in Note 20. The deferred revenue is expected to be recognized in the first half of 2021.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Grant
Funding&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Company may submit
applications to receive grant funding from governmental and non-governmental entities. Grant funding received that involves no
conditions or continuing performance obligations of the Company is recognized upon receipt. Grant funding with conditions or obligations
of the Company is recognized as the conditions or obligations are fulfilled. The Company has made an accounting policy election
to record such unconditional grants, such as the Australian Research and Development Credit, as other income in the consolidated
statements of operations and comprehensive loss. Income from grants is recognized in the period during which the related qualifying
expenses are incurred, provided that the conditions under which the grants were provided have been met. The Company recognizes
Australian Research and Development Credit in an amount equal to the qualifying expenses incurred in each period multiplied by
the applicable reimbursement percentage. During the years ended December 31, 2020 and 2019, the Company recognized $3.2 million
and $0.6 million, respectively, of Australian Research and Development Credit within other income (expense), net in the consolidated
statement of operations and comprehensive loss. As of December 31, 2020 and 2019, the Company recorded $2.1 million and $0, respectively,
of Australian Research and Development Credit receivable in prepaid expenses and other current assets on the consolidated balance
sheets.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Any
amount received in advance of fulfilling such conditions or obligations is recorded in accrued liabilities in the consolidated
balance sheets if the conditions or obligations are expected to be met within the next twelve months. As of December 31, 2020
and 2019, the Company recorded $0.3 million and $0.1 million, respectively, of Australian Research and Development Credit received
in advance in accrued liabilities.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Grant
funding recognized on conditional grants is included as a reduction in research and development expenses in the consolidated statements
of operations and comprehensive loss as the conditions are tied to the Company&amp;#x2019;s research and development efforts, and as
the arrangement between the Company and the organizations are not part of the Company&amp;#x2019;s on-going, major, or central operations.
During the years ended December 31, 2020 and 2019, the Company recorded $0.8 million and $0.1 million, respectively of grant funding
as a reduction of research and development expenses.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Fair
Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Certain
assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the price that would be received for
an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value
must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried
at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;Level
1&lt;/b&gt;&amp;#xa0;&amp;#x2014; Inputs based upon quoted market prices for identical assets or liabilities in active markets at the measurement
date.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;Level
2&lt;/b&gt;&amp;#xa0;&amp;#x2014; Observable inputs other than quoted market prices included in Level 1, such as quoted prices for similar assets
and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active;
or other inputs that are observable or can be corroborated by observable market data.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;Level
3&lt;/b&gt;&amp;#xa0;&amp;#x2014; Inputs that are management&amp;#x2019;s best estimate of what market participants would use in pricing the asset
or liability at the measurement date. The inputs are unobservable in the market and significant to the instrument&amp;#x2019;s valuation.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company reviews the fair value hierarchy classification as of the actual date of the event or change in circumstances that caused
the transfer. There was a transfer to Level 1 from Level 3 as of December 31, 2020 for the Notes payable.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;See
Note 16 for information on the Company&amp;#x2019;s assets and liabilities measured at fair value as of December 31, 2020 and 2019.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Foreign
Currency Translation and Transactions&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
functional currency of the Company is the United&amp;#xa0;States dollar. The Company&amp;#x2019;s Australian subsidiary determined its
functional currency to be the Australian dollar. The Company uses the United&amp;#xa0;States dollar as its reporting currency for
the consolidated financial statements. The results of its non-U.S. dollar based functional currency operations are translated
to U.S. dollars at the average exchange rates during the period. The Company&amp;#x2019;s assets and liabilities are translated using
the current exchange rate as of the consolidated balance sheet date and shareholders&amp;#x2019; equity is translated using historical
rates.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Adjustments
resulting from the translation of the consolidated financial statements of the Company&amp;#x2019;s foreign functional currency subsidiaries
into U.S. dollars are excluded from the determination of net loss and are accumulated in a separate component of shareholders&amp;#x2019;
equity. These foreign currency translation gains and losses are currently the only component of other comprehensive income.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company also incurs foreign exchange transaction gains and losses for purchases denominated in foreign currencies. Foreign exchange
transaction gains and losses are included in other income (expense) in the Company&amp;#x2019;s consolidated results of operations
as incurred.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Comprehensive
Loss&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Comprehensive
loss includes net loss as well as other changes in stockholders&amp;#x2019; equity (deficit) that result from transactions and economic
events other than those with stockholders. The Company&amp;#x2019;s only element of other comprehensive income (loss) in any period
presented was translation of Australian dollar denominated balances of the Company&amp;#x2019;s Australian subsidiary to U.S. dollars
for consolidation.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Net
Loss Per Share Attributable to Common Shareholders&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company calculated basic and diluted net loss per share attributable to common shareholders in conformity with the two-class method
required for companies with participating securities. The Company considered all series of redeemable convertible Preferred Stock
to have been participating securities as the holders were entitled to receive non-cumulative dividends on a pari passu basis in
the event that a dividend had been paid on common stock. See Note 19, Net Loss Per Share Attributable to Common Shareholders,
for further details on the Company&amp;#x2019;s historical participating securities, including warrants to purchase redeemable convertible
Preferred Stock and common stock.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Under
the two-class method, basic net loss per share attributable to common shareholders was calculated by dividing the net loss by
the weighted-average number of shares of common stock outstanding during the period, less shares subject to repurchase. The net
loss attributable to common shareholders was not allocated to the redeemable convertible Preferred Stock as the holders of redeemable
convertible Preferred Stock did not have a contractual obligation to share in losses. Diluted net loss per share attributable
to common shareholders was computed by giving effect to all potentially dilutive common stock equivalents outstanding for the
period. For purposes of this calculation, redeemable convertible Preferred Stock, stock options to purchase common stock, early
exercised stock options, and warrants to purchase redeemable convertible Preferred Stock and common stock were considered common
shares equivalents but had been excluded from the calculation of diluted net loss per share attributable to common shareholders
as their effect was anti-dilutive. In periods in which the Company reports a net loss attributable to common shareholders, diluted
net loss per share attributable to common shareholders is the same as basic net loss per share attributable to common shareholders,
since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net
loss attributable to common shareholders during the years ended December 31, 2020 and 2019.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Segment
Information&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company has determined that its chief executive officer is the chief operating decision maker (&amp;#x201c;CODM&amp;#x201d;). Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the CODM in making decisions regarding resource allocation and assessing performance. The Company views its operations and
manages its business in two operating segments, the first being that of the development and commercialization of proprietary nanotechnology
drug suspensions, and the second being the development and commercialization of dietary supplements (See Note 21).&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Income
Taxes&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets
and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements
or in the Company&amp;#x2019;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between
the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences
are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company
assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes,
based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets
will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred
tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process
to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood
that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not
to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial
statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being
realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized
tax benefits, that are considered appropriate as well as the related net interest and penalties.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Stock-Based
Compensation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Company accounts
for stock-based compensation arrangements with employees using a fair value-based method for costs related to all share-based payments
including stock options and restricted common stock. Stock-based compensation expense is recorded in research and development and
general and administrative expenses based on the classification of the work performed by the grantees.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Prior
to the Reverse Recapitalization, there was not a public market for the shares of Clene Nanomedicine, Inc. common stock. The Company&amp;#x2019;s
determination of the fair value of stock options on the date of grant utilized the Black-Scholes option-pricing model and was
impacted by its common stock price, as determined by the Board of Directors with input from the Company&amp;#x2019;s management, as
well as changes in assumptions regarding a number of subjective variables. These variables included, but were not limited to,
the expected term that options remained outstanding, the expected common stock price volatility over the term of the option awards,
risk-free interest rates, and expected dividends.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The fair value was recognized over the period during which an
optionee was required to provide services in exchange for the option award and service-based RSUs, known as the requisite service
period (usually the vesting period), on a straight-line basis. For the RSUs with market conditions, the fair value is recognized
over the period based on the expected milestone achievement dates as the derived service period (usually the vesting period), on
a straight-line basis. For the RSUs with performance conditions, the grant date fair value of these awards is the market price
on the applicable grant date, and compensation expense will be recognized when the conditions become probable of being satisfied.
The Company will recognize a cumulative true-up adjustment once the conditions become probable of being satisfied as the related
service period had been completed in a prior period.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Stock-based compensation
expense recognized at fair value included the impact of estimated forfeitures. The Company elected to account for forfeitures as
they occurred, rather than estimating expected forfeitures.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;After the closing
of the Reverse Recapitalization, the Company determined the fair value of each share of Common Stock underlying stock-based awards
based on the closing price of the Company&amp;#x2019;s Common Stock as reported by Nasdaq on the date of grant. The fair value of the
RSUs with market conditions are determined using a Monte Carlo valuation model. Forfeitures are estimated at the time of grant
and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Research
and Development&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Research
and development costs are charged to expense as incurred. The Company accounts for nonrefundable advance payments for goods and
services that will be used in future research and development activities as expenses when the goods have been received or when
the service has been performed. Research and development expenses consist of costs incurred by the Company for the discovery and
development of the Company&amp;#x2019;s product candidates. Research and development costs include, but are not limited to, payroll
and personnel expenses including stock-based compensation, clinical trial supplies, fees for clinical trial services, consulting
costs, and allocated overhead, including rent, equipment, and utilities.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Clinical
Trial Accrual&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Company&amp;#x2019;s
clinical trial accrual process accounts for expenses resulting from obligations under contracts with CROs, consultants, and under
clinical site agreements in connection with conducting clinical trials. Clinical trial costs are charged to research and development
expense as incurred. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and
may result in payment flows that do not match the periods over which materials or services are provided to the Company under such
contracts. The Company reflects the appropriate clinical trial expense in the consolidated financial statements by matching the
appropriate expenses with the period in which services and efforts are expended. In the event advance payments are made to a CRO,
the payments will be recorded as a prepaid asset which will be amortized over the period of time the contracted services are performed.
In addition to pass-through costs, the Company generally incurs costs in clinical trials in four distinct groups as follows:&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;CRO
Start-up&amp;#xa0;&amp;#x2014; These costs include the initial set-up of the clinical trial and usually occurs within a few months after
the contract has been executed and includes costs which are expensed ratably over the start-up period when such period is identifiable
and expensed as incurred when no such period exists. Start-up phase activities include study initiation, site recruitment, regulatory
applications, investigator meetings, screening, preparation, pre-study visits, and training.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;CRO
Site and Study Management&amp;#xa0;&amp;#x2014; These costs include medical and safety monitoring, and patient administration and data
management. These costs are usually calculated on a per patient basis and expensed ratably over the treatment period beginning
on the date that the patient enrolls.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;CRO
Close Down and Reporting&amp;#xa0;&amp;#x2014; These costs include analyzing the data obtained and reporting results, which occurs after
patients have ceased treatment and the database of information collected is locked. These costs are expensed as incurred over
the course of any close down and reporting period.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Third
Party Contracts&amp;#xa0;&amp;#x2014; These costs include fees charged by third parties for various support services which are not provided
by CROs and include such items as lab fees, data quality review costs, and fees incurred for investigational product monitoring
and inventory control. These items are expensed ratably over any identifiable service period with the engaged third-party vendors.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
CRO contracts generally include pass-through fees including, but not limited to, regulatory expenses, investigator fees, travel
costs and other miscellaneous costs, including shipping and printing fees. The Company determines accrual estimates through reports
from and discussion with applicable personnel and outside services providers as to the progress or state of completion of trials,
or the services completed. The Company makes estimates of accrued expenses as of each balance sheet date in the consolidated financial
statements based on the facts and circumstances known to the Company at that time.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Recently
Adopted Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;In
March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitating of the Effects of Reference Rate Reform
on Financial Reporting, which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships,
and other transactions in which the reference LIBOR or another reference rate is expected to be discontinued as a result of the
Reference Rate Reform. This ASU is intended to ease the potential burden in accounting for (or recognizing the effects of) reference
rate reform on financial reporting. The new guidance was effective immediately, and through December 31, 2022. As a result of
the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section
107(b) of the JOBS Act, ASU 2016-02 is effective for the Company for fiscal years beginning after December 15, 2020, and all interim
periods thereafter. Early adoption is permitted. The Company early adopted this guidance on March 1, 2020. The adoption of this
guidance did not have a material impact on its consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Recent
Accounting Pronouncements Not Yet Adopted&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In June 2016, the FASB
issued ASU No. 2016-13, &lt;i&gt;Financial Instruments &amp;#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt;.
The amendments in this ASU, among other things, require the measurement of all expected credit losses for financial assets held
at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions
and other organizations will now use forward-looking information to better inform their credit loss estimates. The guidance is
effective for fiscal years beginning after December 15, 2022. The Company is currently evaluating the expected impact of the new
guidance.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;In
August 2018, the FASB issued ASU No. 2018-15, &lt;i&gt;Intangibles &amp;#x2013; Goodwill and Other &amp;#x2013; Internal-Use Software (Subtopic
350-40): Customer&amp;#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract&lt;/i&gt;.
The new guidance provides for the deferral of implementation costs for cloud computing arrangements and expensing those costs
over the term of the cloud services arrangement. The new guidance is effective for fiscal years beginning after December 15, 2020.
The Company is currently evaluating the expected impact of the new guidance.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In December 2019, the
FASB issued ASU No. 2019-12, &lt;i&gt;Income Taxes&lt;/i&gt; (Topic 740), which amends the existing guidance relating to the accounting for
income taxes. This ASU is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles
of accounting for income taxes and to improve the consistent application of GAAP for other areas of accounting for income taxes
by clarifying and amending existing guidance. The new guidance is effective for fiscal years beginning after December 15, 2021.
The Company does not expect that the adoption of this new guidance will have a material impact on its consolidated statements.&lt;/p&gt;&lt;br/&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:UseOfEstimates contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Use
of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets, liabilities and disclosure of contingent assets and liabilities at the date of the
consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and
assumptions made in the accompanying consolidated financial statements include, but are not limited to the valuation of common
stock, stock options, contingent earn-out liability, and Preferred Stock warrants.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual
results may differ from those estimates or assumptions. Estimates are periodically reviewed in light of changes in circumstances,
facts, and experience. Changes in estimates are recorded in the period in which they become known.&lt;/font&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
  <clnn:RiskAndUncertaintiesPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Risks
and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
product candidates developed by the Company require approvals from the U.S. Food and Drug Administration (&amp;#x201c;FDA&amp;#x201d;) or
foreign regulatory agencies prior to commercial sales. There can be no assurance that the Company&amp;#x2019;s current and future product
candidates will receive the necessary approvals or be commercially successful. If the Company is denied approval or approval is
delayed, it will have a material adverse impact on the Company&amp;#x2019;s business and its consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company is subject to risks common to companies in the development stage including, but not limited to, dependency on the need
for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by
physicians and patients, significant competition, and untested manufacturing capabilities.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company is subject to certain risks and uncertainties and believes that changes in any of the following areas could have a material
adverse effect on future financial position or results of operations: ability to obtain future financing; regulatory approval
and market acceptance of, and reimbursement for, product candidates; performance of third-party clinical research organizations
and manufacturers upon which the Company relies; protection of the Company&amp;#x2019;s intellectual property; litigation or claims
against the Company based on intellectual property, patent, product, regulatory or other factors; and the Company&amp;#x2019;s ability
to attract and retain employees necessary to support its growth.&lt;/font&gt;&lt;/p&gt;</clnn:RiskAndUncertaintiesPolicyTextBlock>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Concentrations
of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Financial
instruments which potentially subject the Company to significant concentrations of credit risk consist primarily of cash. The
Company&amp;#x2019;s cash is mainly held in financial institutions. Amounts on deposit may at times exceed federally insured limits.
The Company has not experienced any losses on its deposits of cash and does not believe that it is subject to unusual credit risk
beyond the normal credit risk associated with commercial banking relationships.&lt;/font&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Company considers
all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. As of December
31, 2020 and 2019, the Company has no cash equivalents and no restricted cash balances.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:InventoryPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Inventory&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Inventory is stated
at historic cost on a first -in first-out basis. The Company&amp;#x2019;s inventory consisted of $71,000 in raw materials and $0.1 million
in finished goods as of December 31, 2020. The Company&amp;#x2019;s inventory consisted of $28,000 in finished goods as of December
31, 2019.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
  <us-gaap:InventoryRawMaterials unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">71000</us-gaap:InventoryRawMaterials>
  <us-gaap:InventoryFinishedGoods unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-5">100000</us-gaap:InventoryFinishedGoods>
  <us-gaap:InventoryFinishedGoods unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">28000</us-gaap:InventoryFinishedGoods>
  <us-gaap:DeferredChargesPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Deferred
Offering Costs&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Company capitalizes
certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings,
including the Reverse Recapitalization and the PIPE offering, as deferred costs until such financings are consummated. After consummation
of the equity financing, these costs are recorded in stockholders&amp;#x2019; equity (deficit) as a reduction of proceeds generated
as a result of the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately
as a charge to operating expenses in the consolidated statement of operations.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in&quot;&gt;During the year ended December
31, 2020, the Company incurred $5.9 million of offering costs, which excludes the fair value of common shares issued as a payment
of related offering costs, to additional paid in capital in connection with the Reverse Recapitalization.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;During 2019, the Company
had offering costs that were directly related to its proposed initial public offering of $1.0 million. In September 2019, the Company
terminated its initial public offering registration process. Accordingly, the Company has written off deferred offering costs previously
capitalized to general and administrative expense within the accompanying consolidated statements of operations and comprehensive
loss as of December 31, 2019.&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
  <clnn:ProposedPublicOfferingCost unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-5">1000000</clnn:ProposedPublicOfferingCost>
  <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;At
inception of a contract, the Company determines if a contract meets the definition of a lease. A lease is a contract, or part
of a contract, that conveys the right to control the use of identified property, plant, or equipment (an identified asset) for
a period of time in exchange for consideration. The Company determines if the contract conveys the right to control the use of
an identified asset for a period of time. The Company assesses throughout the period of use whether the Company has both of the
following: (1)&amp;#xa0;the right to obtain substantially all of the economic benefits from use of the identified asset, and (2)&amp;#xa0;the
right to direct the use of the identified asset. This determination is reassessed if the terms of the contract are changed. Leases
are classified as operating or finance leases based on the terms of the lease agreement and certain characteristics of the identified
asset. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of the
future lease payments.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company leases laboratory and office space (real estate), and certain equipment under non-cancellable operating and finance leases.
The carrying value of the Company&amp;#x2019;s right-of-use lease assets is substantially concentrated in its real estate leases, while
the volume of lease agreements is primarily concentrated in equipment leases. The Company&amp;#x2019;s policy is to not record leases
with an original term of twelve months or less on the consolidated balance sheets. The Company recognizes lease expense for these
short-term leases on a straight-line basis over the lease term.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Certain
lease agreements may require the Company to pay additional amounts for taxes, insurance, maintenance and other expenses, which
are generally referred to as non-lease components. Such variable non-lease components are treated as variable lease payments and
recognized in the period in which the obligation for these payments was incurred. Variable lease components and variable non-lease
components are not measured as part of the right-of-use asset and liability. Only when lease components and their associated non-lease
components are fixed are they accounted for as a single lease component and are recognized as part of a right-of-use asset and
liability. Total contract consideration is allocated to the combined fixed lease and non-lease component. This policy election
applies consistently to all asset classes under lease agreements.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Leases
may contain clauses for renewal at the Company&amp;#x2019;s option. Payments to be made in option periods are recognized as part of
the right-of-use lease assets and lease liabilities when it is reasonably certain that the option to extend the lease will be
exercised, or is not at the Company&amp;#x2019;s option. The Company determines whether the reasonably certain threshold is met by
considering contract-, asset-, market-, and entity-based factors. In the consolidated statements of earnings, operating lease
expense, which is recognized on a straight-line basis over the lease term, and the amortization of finance lease ROU assets, which
are included in plant, property, and equipment and depreciated, are included in research and development or general and administrative
expenses consistent with the leased assets&amp;#x2019; primary use. Accretion on the liabilities for finance leases is included in
interest expense.&lt;/font&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Property
and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Property and equipment
are stated at cost less accumulated depreciation. Property and equipment consist of lab and office equipment and leasehold improvements.
Depreciation is calculated using the straight-line method over the estimated economic useful lives of the assets, which are 3-5&amp;#xa0;years
for lab equipment and 3-7&amp;#xa0;years for furniture and fixtures. Leasehold improvements are amortized over the lesser of the estimated
lease term or the estimated useful life of the assets. Costs for capital assets not yet placed into service are capitalized as
construction in progress and depreciated or amortized in accordance with the above useful lives once placed into service. Upon
retirement or sale, the related cost and accumulated depreciation and amortization are removed from the accounts and any resulting
gain or loss is included in the consolidated statements of operations and comprehensive loss. Maintenance and repairs that do not
improve or extend the lives of the respective assets are expensed to operations as incurred.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c47_From1Jan2020To31Dec2020_MinimumMember_EquipmentMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c48_From1Jan2020To31Dec2020_MaximumMember_EquipmentMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c49_From1Jan2020To31Dec2020_MinimumMember_FurnitureAndFixturesMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c50_From1Jan2020To31Dec2020_MaximumMember_FurnitureAndFixturesMember">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraqWjSnTNF4jeT3oaMW8W5R0MkiIXXy8k2PQbBklJ1lYf+6GCuiY/lJFjk6uDeNN+gvvgD/ctbqbBhZgNg1qNU0EiFrWvY1hT6GmZd73HE7TJaI9wGp4wAxzd2UaTwEVsbp/IQFhRTHB/tg6uRHFmIlsS7md0nP83XEmRJWGf+LgrErd53annin] CSR-->
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Impairment
of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Long-lived
assets are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of
the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include
significant underperformance of the business in relation to expectations, significant negative industry or economic trends and
significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate an asset group
for recoverability, the Company compares the forecasted undiscounted cash flows expected to result from the use and eventual disposition
of the asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows
expected to result from the use and eventual disposition of an asset group are less than its carrying amount. The impairment loss
would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted
cash flows using market participant assumptions. The Company did not record any impairment losses on long-lived assets during
the years ended December 31, 2020 or December 31, 2019.&lt;/font&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:DerivativesPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Derivative
Instruments&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
convertible promissory notes issued in February through July&amp;#xa0;2020 (&amp;#x201c;2020 Convertible Notes&amp;#x201d;) contained embedded
features that provide the lenders with multiple settlement alternatives. Certain of these settlement features provided the lenders
a right to a fixed number of the Company&amp;#x2019;s shares upon conversion of the notes. Other settlement features provided the lenders
the right or the obligation to receive cash or a variable number of shares upon the completion of a capital raising transaction,
change of control or default of the Company (the &amp;#x201c;Redemption Features&amp;#x201d;).&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Redemption Features of the 2020 Convertible Notes met the requirements for separate accounting and were accounted for as a single
derivative instrument (the &amp;#x201c;2020 Derivative Instrument&amp;#x201d;). The 2020 Derivative Instrument was recorded at fair value
at inception and was subject to re-measurement to fair value at each balance sheet date and immediately prior to the extinguishment
of derivative liability, with any changes in fair value recognized in the consolidated statements of operations and comprehensive
loss. In August 2020, in connection with the Company&amp;#x2019;s issuance and sale of Series D Preferred Stock, all of the outstanding
principal and accrued interest under the convertible promissory notes was automatically converted into shares of Series D Preferred
Stock and the derivative liability was extinguished (see Notes 11 and 12).&lt;/font&gt;&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
  <us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Redeemable
Convertible Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Prior to the Reverse
Recapitalization with Tottenham, the Company recorded all shares of redeemable convertible Preferred Stock at their respective
fair values on the dates of issuance, net of issuance costs. The redeemable convertible Preferred Stock was recorded outside of
permanent equity because while it was not mandatorily redeemable, upon certain events considered not solely within the Company&amp;#x2019;s
control, such as a merger, acquisition, or sale of all or substantially all of the Company&amp;#x2019;s assets (each, a &amp;#x201c;Deemed
Liquidation Event&amp;#x201d;), the redeemable convertible Preferred Stock would become redeemable at the option of the holders of at
least a majority of the then-outstanding shares. The Company did not adjust the carrying values of the redeemable convertible Preferred
Stock to the liquidation preferences of such shares because it was uncertain whether or when a Deemed Liquidation Event would occur
that would obligate the Company to pay the liquidation preferences to holders of shares of redeemable convertible Preferred Stock.
Subsequent adjustments to the carrying values of the liquidation preferences would be made only when it becomes probable that such
a Deemed Liquidation Event will occur.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In connection with
the Reverse Recapitalization, all shares of redeemable convertible Preferred Stock were converted into shares of the Company&amp;#x2019;s
Common Stock. Accordingly, there was no redeemable convertible Preferred Stock outstanding as of December 31, 2020. As of December
31, 2019, the carrying value of the redeemable convertible Preferred Stock was $72.7 million (see Note 17).&lt;/p&gt;</us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock>
  <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock unitRef="usd" contextRef="c51_From1Jan2019To31Dec2019_RedeemablePreferredStockMember" decimals="-5">72700000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
  <clnn:ContingentEarnoutPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Contingent Earn-out&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In connection with
the Reverse Recapitalization and pursuant to the Merger Agreement, Clene Nanomedicine&amp;#x2019;s common shareholders and Initial Shareholders
of Tottenham are entitled to receive additional shares of the Company&amp;#x2019;s Common Stock upon the Company achieving certain milestones
described in Note 12. In accordance with ASC 815 &amp;#x2013; &lt;i&gt;Derivatives and hedging&lt;/i&gt;, the earn-out shares are not indexed to
the Company&amp;#x2019;s own stock and therefore are accounted for as a liability at the reverse recapitalization date and subsequently
remeasured at each reporting date with changes in fair value recorded as a component of other income (expense), net in the consolidated
statements of operations and comprehensive loss.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The estimated fair
value of the contingent consideration was determined using a Monte Carlo simulation that simulated the future path of the Company&amp;#x2019;s
stock price over the earn-out period. The assumptions utilized in the calculation are based on the achievement of certain stock
price milestones including projected stock price, volatility, and risk-free rate. For potential payments related to a product development
milestone, the fair value was determined based on the Company&amp;#x2019;s expectations of achieving such a milestone and the simulated
estimated stock price on the expected date of achievement.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The contingent earn-out
is categorized as a Level 3 fair value measurement (see Fair Value of Financial Instruments accounting policy) because the Company
estimates projections during the earn-out period utilizing unobservable inputs, including various potential pay-out scenarios.
Contingent earn-out payments involve certain assumptions requiring significant judgment and actual results may differ from assumed
and estimated amounts.&lt;/p&gt;</clnn:ContingentEarnoutPolicyTextBlock>
  <us-gaap:StockholdersEquityPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Preferred Stock Warrant Liability&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Prior to the Reverse
Recapitalization with Tottenham, the Company accounted for freestanding warrants to purchase shares of Preferred Stock as liabilities
on the balance sheet at their estimated fair value as the underlying redeemable convertible Preferred Stock was considered contingently
redeemable and may obligate the Company to transfer assets to the holders at a future date upon the occurrence of a deemed liquidation
event. At the end of each reporting period, changes in the estimated fair value of the warrants to purchase shares of Preferred
Stock were recorded in change in fair value of Preferred Stock warrant liability in the consolidated statements of operations and
comprehensive loss. Changes in the estimated fair value of the Preferred Stock warrant liability were ($14.6) million and ($0.4)
million for the years ended December 31, 2020 and 2019, respectively. In connection with the Reverse Recapitalization, all Clene
Nanomedicine Preferred Stock was converted to the Company&amp;#x2019;s Common Stock and the Clene Nanomedicine Preferred Stock warrants
were converted to warrants to purchase the Company&amp;#x2019;s Common Stock. The Company assessed the features of these warrants and
determined that they qualify for classification as permanent equity. Accordingly, the Company remeasured the warrants to fair value
upon the closing of the Reverse Recapitalization and reclassified the resulting warrant liability to additional paid-in capital
(See Note 16).&lt;/p&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
  <us-gaap:FairValueAdjustmentOfWarrants unitRef="usd" contextRef="c52_From1Jan2020To31Dec2020_PreferredStockWarrantMember" decimals="-5">14600000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants unitRef="usd" contextRef="c53_From1Jan2019To31Dec2019_PreferredStockWarrantMember" decimals="-5">400000</us-gaap:FairValueAdjustmentOfWarrants>
  <clnn:CommonStockWarrantsPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Common Stock Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The Company accounts for common stock warrants as either equity
instruments or liabilities in accordance with ASC 480, &lt;i&gt;Distinguishing Liabilities from Equity&lt;/i&gt; (&amp;#x201c;ASC 480&amp;#x201d;), depending
on the specific terms of the warrant agreement (See Note 10).&lt;/p&gt;</clnn:CommonStockWarrantsPolicyTextBlock>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Revenue
Recognition&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Under
ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects
the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition
for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&amp;#xa0;identify
the contract(s) with a customer; (ii)&amp;#xa0;identify the performance obligations in the contract; (iii)&amp;#xa0;determine the transaction
price, including variable consideration, if any; (iv)&amp;#xa0;allocate the transaction price to the performance obligations in the
contract; and (v)&amp;#xa0;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies
the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in
exchange for the goods or services it transfers to the customer.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Once
a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine
which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes
as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation
is satisfied or as it is satisfied. The Company typically satisfies its performance obligations via delivery of dietary supplements
to the customer. Payments are due upon receipt for commercial transactions or a prepayment is collected for online retail sales.
The Company&amp;#x2019;s revenue for the year ended December 31, 2020 was comprised of sales of dietary supplements.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company recorded deferred revenue of $0.1 million as of December 31, 2020 from the dietary supply agreement with the related party
discussed in Note 20. The deferred revenue is expected to be recognized in the first half of 2021.&lt;/font&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:DeferredRevenue unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-5">100000</us-gaap:DeferredRevenue>
  <clnn:GrantFundingPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Grant
Funding&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Company may submit
applications to receive grant funding from governmental and non-governmental entities. Grant funding received that involves no
conditions or continuing performance obligations of the Company is recognized upon receipt. Grant funding with conditions or obligations
of the Company is recognized as the conditions or obligations are fulfilled. The Company has made an accounting policy election
to record such unconditional grants, such as the Australian Research and Development Credit, as other income in the consolidated
statements of operations and comprehensive loss. Income from grants is recognized in the period during which the related qualifying
expenses are incurred, provided that the conditions under which the grants were provided have been met. The Company recognizes
Australian Research and Development Credit in an amount equal to the qualifying expenses incurred in each period multiplied by
the applicable reimbursement percentage. During the years ended December 31, 2020 and 2019, the Company recognized $3.2 million
and $0.6 million, respectively, of Australian Research and Development Credit within other income (expense), net in the consolidated
statement of operations and comprehensive loss. As of December 31, 2020 and 2019, the Company recorded $2.1 million and $0, respectively,
of Australian Research and Development Credit receivable in prepaid expenses and other current assets on the consolidated balance
sheets.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Any
amount received in advance of fulfilling such conditions or obligations is recorded in accrued liabilities in the consolidated
balance sheets if the conditions or obligations are expected to be met within the next twelve months. As of December 31, 2020
and 2019, the Company recorded $0.3 million and $0.1 million, respectively, of Australian Research and Development Credit received
in advance in accrued liabilities.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Grant
funding recognized on conditional grants is included as a reduction in research and development expenses in the consolidated statements
of operations and comprehensive loss as the conditions are tied to the Company&amp;#x2019;s research and development efforts, and as
the arrangement between the Company and the organizations are not part of the Company&amp;#x2019;s on-going, major, or central operations.
During the years ended December 31, 2020 and 2019, the Company recorded $0.8 million and $0.1 million, respectively of grant funding
as a reduction of research and development expenses.&lt;/font&gt;&lt;/p&gt;</clnn:GrantFundingPolicyTextBlock>
  <us-gaap:OtherOperatingIncomeExpenseNet unitRef="usd" contextRef="c54_From1Jan2020To31Dec2020_ResearchAndDevelopmentExpenseMember" decimals="-5">3200000</us-gaap:OtherOperatingIncomeExpenseNet>
  <us-gaap:OtherOperatingIncomeExpenseNet unitRef="usd" contextRef="c55_From1Jan2019To31Dec2019_ResearchAndDevelopmentExpenseMember" decimals="-5">600000</us-gaap:OtherOperatingIncomeExpenseNet>
  <us-gaap:PrepaidExpenseCurrentAndNoncurrent unitRef="usd" contextRef="c56_AsOf31Dec2020_ResearchAndDevelopmentExpenseMember" decimals="-5">2100000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
  <us-gaap:PrepaidExpenseCurrentAndNoncurrent unitRef="usd" contextRef="c57_AsOf31Dec2019_ResearchAndDevelopmentExpenseMember" decimals="0">0</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
  <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent unitRef="usd" contextRef="c56_AsOf31Dec2020_ResearchAndDevelopmentExpenseMember" decimals="-5">300000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
  <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent unitRef="usd" contextRef="c57_AsOf31Dec2019_ResearchAndDevelopmentExpenseMember" decimals="-5">100000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c58_From1Jan2020To31Dec2020_GrantFundingMember" decimals="-5">800000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c59_From1Jan2019To31Dec2019_GrantFundingMember" decimals="-5">100000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Fair
Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Certain
assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the price that would be received for
an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value
must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried
at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;Level
1&lt;/b&gt;&amp;#xa0;&amp;#x2014; Inputs based upon quoted market prices for identical assets or liabilities in active markets at the measurement
date.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;Level
2&lt;/b&gt;&amp;#xa0;&amp;#x2014; Observable inputs other than quoted market prices included in Level 1, such as quoted prices for similar assets
and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active;
or other inputs that are observable or can be corroborated by observable market data.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;Level
3&lt;/b&gt;&amp;#xa0;&amp;#x2014; Inputs that are management&amp;#x2019;s best estimate of what market participants would use in pricing the asset
or liability at the measurement date. The inputs are unobservable in the market and significant to the instrument&amp;#x2019;s valuation.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company reviews the fair value hierarchy classification as of the actual date of the event or change in circumstances that caused
the transfer. There was a transfer to Level 1 from Level 3 as of December 31, 2020 for the Notes payable.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;See
Note 16 for information on the Company&amp;#x2019;s assets and liabilities measured at fair value as of December 31, 2020 and 2019.&lt;/font&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Foreign
Currency Translation and Transactions&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
functional currency of the Company is the United&amp;#xa0;States dollar. The Company&amp;#x2019;s Australian subsidiary determined its
functional currency to be the Australian dollar. The Company uses the United&amp;#xa0;States dollar as its reporting currency for
the consolidated financial statements. The results of its non-U.S. dollar based functional currency operations are translated
to U.S. dollars at the average exchange rates during the period. The Company&amp;#x2019;s assets and liabilities are translated using
the current exchange rate as of the consolidated balance sheet date and shareholders&amp;#x2019; equity is translated using historical
rates.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Adjustments
resulting from the translation of the consolidated financial statements of the Company&amp;#x2019;s foreign functional currency subsidiaries
into U.S. dollars are excluded from the determination of net loss and are accumulated in a separate component of shareholders&amp;#x2019;
equity. These foreign currency translation gains and losses are currently the only component of other comprehensive income.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company also incurs foreign exchange transaction gains and losses for purchases denominated in foreign currencies. Foreign exchange
transaction gains and losses are included in other income (expense) in the Company&amp;#x2019;s consolidated results of operations
as incurred.&lt;/font&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Comprehensive
Loss&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Comprehensive
loss includes net loss as well as other changes in stockholders&amp;#x2019; equity (deficit) that result from transactions and economic
events other than those with stockholders. The Company&amp;#x2019;s only element of other comprehensive income (loss) in any period
presented was translation of Australian dollar denominated balances of the Company&amp;#x2019;s Australian subsidiary to U.S. dollars
for consolidation.&lt;/font&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Net
Loss Per Share Attributable to Common Shareholders&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company calculated basic and diluted net loss per share attributable to common shareholders in conformity with the two-class method
required for companies with participating securities. The Company considered all series of redeemable convertible Preferred Stock
to have been participating securities as the holders were entitled to receive non-cumulative dividends on a pari passu basis in
the event that a dividend had been paid on common stock. See Note 19, Net Loss Per Share Attributable to Common Shareholders,
for further details on the Company&amp;#x2019;s historical participating securities, including warrants to purchase redeemable convertible
Preferred Stock and common stock.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Under
the two-class method, basic net loss per share attributable to common shareholders was calculated by dividing the net loss by
the weighted-average number of shares of common stock outstanding during the period, less shares subject to repurchase. The net
loss attributable to common shareholders was not allocated to the redeemable convertible Preferred Stock as the holders of redeemable
convertible Preferred Stock did not have a contractual obligation to share in losses. Diluted net loss per share attributable
to common shareholders was computed by giving effect to all potentially dilutive common stock equivalents outstanding for the
period. For purposes of this calculation, redeemable convertible Preferred Stock, stock options to purchase common stock, early
exercised stock options, and warrants to purchase redeemable convertible Preferred Stock and common stock were considered common
shares equivalents but had been excluded from the calculation of diluted net loss per share attributable to common shareholders
as their effect was anti-dilutive. In periods in which the Company reports a net loss attributable to common shareholders, diluted
net loss per share attributable to common shareholders is the same as basic net loss per share attributable to common shareholders,
since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net
loss attributable to common shareholders during the years ended December 31, 2020 and 2019.&lt;/font&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Segment
Information&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company has determined that its chief executive officer is the chief operating decision maker (&amp;#x201c;CODM&amp;#x201d;). Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the CODM in making decisions regarding resource allocation and assessing performance. The Company views its operations and
manages its business in two operating segments, the first being that of the development and commercialization of proprietary nanotechnology
drug suspensions, and the second being the development and commercialization of dietary supplements (See Note 21).&lt;/font&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:NumberOfOperatingSegments unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">2</us-gaap:NumberOfOperatingSegments>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Income
Taxes&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets
and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements
or in the Company&amp;#x2019;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between
the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences
are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company
assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes,
based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets
will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred
tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process
to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood
that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not
to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial
statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being
realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized
tax benefits, that are considered appropriate as well as the related net interest and penalties.&lt;/font&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Stock-Based
Compensation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Company accounts
for stock-based compensation arrangements with employees using a fair value-based method for costs related to all share-based payments
including stock options and restricted common stock. Stock-based compensation expense is recorded in research and development and
general and administrative expenses based on the classification of the work performed by the grantees.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Prior
to the Reverse Recapitalization, there was not a public market for the shares of Clene Nanomedicine, Inc. common stock. The Company&amp;#x2019;s
determination of the fair value of stock options on the date of grant utilized the Black-Scholes option-pricing model and was
impacted by its common stock price, as determined by the Board of Directors with input from the Company&amp;#x2019;s management, as
well as changes in assumptions regarding a number of subjective variables. These variables included, but were not limited to,
the expected term that options remained outstanding, the expected common stock price volatility over the term of the option awards,
risk-free interest rates, and expected dividends.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The fair value was recognized over the period during which an
optionee was required to provide services in exchange for the option award and service-based RSUs, known as the requisite service
period (usually the vesting period), on a straight-line basis. For the RSUs with market conditions, the fair value is recognized
over the period based on the expected milestone achievement dates as the derived service period (usually the vesting period), on
a straight-line basis. For the RSUs with performance conditions, the grant date fair value of these awards is the market price
on the applicable grant date, and compensation expense will be recognized when the conditions become probable of being satisfied.
The Company will recognize a cumulative true-up adjustment once the conditions become probable of being satisfied as the related
service period had been completed in a prior period.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Stock-based compensation
expense recognized at fair value included the impact of estimated forfeitures. The Company elected to account for forfeitures as
they occurred, rather than estimating expected forfeitures.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;After the closing
of the Reverse Recapitalization, the Company determined the fair value of each share of Common Stock underlying stock-based awards
based on the closing price of the Company&amp;#x2019;s Common Stock as reported by Nasdaq on the date of grant. The fair value of the
RSUs with market conditions are determined using a Monte Carlo valuation model. Forfeitures are estimated at the time of grant
and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Research
and Development&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Research
and development costs are charged to expense as incurred. The Company accounts for nonrefundable advance payments for goods and
services that will be used in future research and development activities as expenses when the goods have been received or when
the service has been performed. Research and development expenses consist of costs incurred by the Company for the discovery and
development of the Company&amp;#x2019;s product candidates. Research and development costs include, but are not limited to, payroll
and personnel expenses including stock-based compensation, clinical trial supplies, fees for clinical trial services, consulting
costs, and allocated overhead, including rent, equipment, and utilities.&lt;/font&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <clnn:ClinicalTrialAccrualPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Clinical
Trial Accrual&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Company&amp;#x2019;s
clinical trial accrual process accounts for expenses resulting from obligations under contracts with CROs, consultants, and under
clinical site agreements in connection with conducting clinical trials. Clinical trial costs are charged to research and development
expense as incurred. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and
may result in payment flows that do not match the periods over which materials or services are provided to the Company under such
contracts. The Company reflects the appropriate clinical trial expense in the consolidated financial statements by matching the
appropriate expenses with the period in which services and efforts are expended. In the event advance payments are made to a CRO,
the payments will be recorded as a prepaid asset which will be amortized over the period of time the contracted services are performed.
In addition to pass-through costs, the Company generally incurs costs in clinical trials in four distinct groups as follows:&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;CRO
Start-up&amp;#xa0;&amp;#x2014; These costs include the initial set-up of the clinical trial and usually occurs within a few months after
the contract has been executed and includes costs which are expensed ratably over the start-up period when such period is identifiable
and expensed as incurred when no such period exists. Start-up phase activities include study initiation, site recruitment, regulatory
applications, investigator meetings, screening, preparation, pre-study visits, and training.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;CRO
Site and Study Management&amp;#xa0;&amp;#x2014; These costs include medical and safety monitoring, and patient administration and data
management. These costs are usually calculated on a per patient basis and expensed ratably over the treatment period beginning
on the date that the patient enrolls.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;CRO
Close Down and Reporting&amp;#xa0;&amp;#x2014; These costs include analyzing the data obtained and reporting results, which occurs after
patients have ceased treatment and the database of information collected is locked. These costs are expensed as incurred over
the course of any close down and reporting period.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Third
Party Contracts&amp;#xa0;&amp;#x2014; These costs include fees charged by third parties for various support services which are not provided
by CROs and include such items as lab fees, data quality review costs, and fees incurred for investigational product monitoring
and inventory control. These items are expensed ratably over any identifiable service period with the engaged third-party vendors.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
CRO contracts generally include pass-through fees including, but not limited to, regulatory expenses, investigator fees, travel
costs and other miscellaneous costs, including shipping and printing fees. The Company determines accrual estimates through reports
from and discussion with applicable personnel and outside services providers as to the progress or state of completion of trials,
or the services completed. The Company makes estimates of accrued expenses as of each balance sheet date in the consolidated financial
statements based on the facts and circumstances known to the Company at that time.&lt;/font&gt;&lt;/p&gt;</clnn:ClinicalTrialAccrualPolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Recently
Adopted Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;In
March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitating of the Effects of Reference Rate Reform
on Financial Reporting, which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships,
and other transactions in which the reference LIBOR or another reference rate is expected to be discontinued as a result of the
Reference Rate Reform. This ASU is intended to ease the potential burden in accounting for (or recognizing the effects of) reference
rate reform on financial reporting. The new guidance was effective immediately, and through December 31, 2022. As a result of
the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section
107(b) of the JOBS Act, ASU 2016-02 is effective for the Company for fiscal years beginning after December 15, 2020, and all interim
periods thereafter. Early adoption is permitted. The Company early adopted this guidance on March 1, 2020. The adoption of this
guidance did not have a material impact on its consolidated financial statements.&lt;/font&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <clnn:NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Recent
Accounting Pronouncements Not Yet Adopted&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In June 2016, the FASB
issued ASU No. 2016-13, &lt;i&gt;Financial Instruments &amp;#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt;.
The amendments in this ASU, among other things, require the measurement of all expected credit losses for financial assets held
at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions
and other organizations will now use forward-looking information to better inform their credit loss estimates. The guidance is
effective for fiscal years beginning after December 15, 2022. The Company is currently evaluating the expected impact of the new
guidance.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;In
August 2018, the FASB issued ASU No. 2018-15, &lt;i&gt;Intangibles &amp;#x2013; Goodwill and Other &amp;#x2013; Internal-Use Software (Subtopic
350-40): Customer&amp;#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract&lt;/i&gt;.
The new guidance provides for the deferral of implementation costs for cloud computing arrangements and expensing those costs
over the term of the cloud services arrangement. The new guidance is effective for fiscal years beginning after December 15, 2020.
The Company is currently evaluating the expected impact of the new guidance.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In December 2019, the
FASB issued ASU No. 2019-12, &lt;i&gt;Income Taxes&lt;/i&gt; (Topic 740), which amends the existing guidance relating to the accounting for
income taxes. This ASU is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles
of accounting for income taxes and to improve the consistent application of GAAP for other areas of accounting for income taxes
by clarifying and amending existing guidance. The new guidance is effective for fiscal years beginning after December 15, 2021.
The Company does not expect that the adoption of this new guidance will have a material impact on its consolidated statements.&lt;/p&gt;</clnn:NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock>
  <clnn:ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;3.
Reverse Recapitalization with Tottenham and Clene Nanomedicine&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;On December 30, 2020,
the Company consummated the Reverse Recapitalization, pursuant to which Tottenham merged with and into PubCo in connection with
the Reincorporation Merger and PubCo merged with and into Clene Nanomedicine, resulting in Clene Nanomedicine becoming a wholly
owned subsidiary of PubCo. On the Closing Date, PubCo changed its name from Chelsea Worldwide, Inc. to Clene Inc. (see Note 1).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Upon the consummation
of the Reverse Recapitalization, each Tottenham ordinary share issued and outstanding immediately prior to the effective time of
the Reincorporation Merger was automatically cancelled and ceased to exist and (i) for each Tottenham ordinary share, the Company
issued one validly issued share of the Company&amp;#x2019;s Common Stock; (ii) each warrant to purchase one half of one Tottenham Ordinary
Share was converted into a warrant to purchase one-half of one share of the Company&amp;#x2019;s Common Stock; and (iii) each Tottenham
right exchangeable into one-tenth (1/10) of one Tottenham ordinary share was converted into a right exchangeable for one-tenth
(1/10) of one share of the Company&amp;#x2019;s Common Stock. As a result of the Reverse Recapitalization, all outstanding shares of
Tottenham ordinary shares of 2,303,495 held by the Initial Shareholders and Tottenham public shareholders were converted into the
same number of the Company&amp;#x2019;s Common Stock. In addition, pursuant to the Merger Agreement, the Initial Shareholders are entitled
to receive up to 750,000 of the company common shares as earn-out shares upon the achievement of certain milestones described in
below. The contingent earn-out with the Initial Shareholders is accounted for as a contingent liability and is included in the
line item of &amp;#x201c;Contingent Earn-out&amp;#x201d; on the consolidated balance sheets.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In accordance with
the Merger Agreement, on the closing of the Reverse Recapitalization, each share of Clene Nanomedicine preferred stock and common
stock then issued and outstanding was automatically cancelled, extinguished and exchanged for 0.1389 newly issued shares of Clene
Inc. Common Stock. At the closing of the Reverse Recapitalization, Clene Inc. acquired 100% of the issued and outstanding Clene
Nanomedicine common stock, in exchange for 54,339,012 shares of Clene Inc. Common Stock issued to the Clene Nanomedicine common
shareholders, among which 2,716,958 shares of the Clene Inc. Common Stock are to be issued and held in escrow to satisfy any indemnification
obligations incurred under the Merger Agreement. In addition, all outstanding warrants (other than warrants that expired, were
exercised or were deemed automatically net exercised immediately prior to the Acquisition Merger) exercisable for common stock
in Clene Nanomedicine were assumed by the Company with no changes to the terms and conditions of the awards. The awards have been
retroactively restated to reflect the Exchange Ratio established in the Reverse Recapitalization.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In connection with
the Reverse Recapitalization, a total of 53,286,115 stock options of Clene Nanomedicine common stock was cancelled and the holders
thereof in exchange received 0.1320 newly issued stock options of Clene Inc. Common Stock for a total of 7,032,590, which is 95%
of the Exchange Ratio. Pursuant to the Merger Agreement, the Company issued RSUs to the option holders which complements the 5%
closing payment shares held in escrow for Clene Nanomedicine common shareholders. In addition, the Company issued 1,136,961 RSUs
to option holders to complement the earn-out payments that would contingently be issued to certain current Clene Nanomedicine&amp;#x2019;s
shareholders upon the achievement of milestones described in below.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Also, in connection
with the Reverse Recapitalization, Clene Nanomedicine entered into a letter agreement with LifeSci Capital LLC (&amp;#x201c;LifeSci&amp;#x201d;)
on July 2, 2020, according to which LifeSci was engaged to act as Clene Nanomedicine&amp;#x2019;s financial advisor with respect to
identifying and soliciting special purpose acquisition companies for the purpose of entering into a merger or similar transaction
with Clene Nanomedicine and its shareholders. Under this agreement, Clene Nanomedicine agreed that if it consummated a merger with
Tottenham, LifeSci would receive consideration of (i) 3% of the amount by which the total transaction consideration exceeded $350
million, plus (ii) 7% of cash and cash-equivalents received by Clene Nanomedicine from the Tottenham&amp;#x2019;s trust account. Clene
Nanomedicine could elect to pay LifeSci either in cash, equity interests of the surviving company, or a combination of the two.
Upon the consummation of the Reverse Recapitalization, 644,164 shares of the Company&amp;#x2019;s Common Stock were issued to LifeSci
as consideration for its services as pursuant to the letter agreement (see Note 18).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Immediately after giving
effect to the Reverse Recapitalization, there were 59,526,171 shares of Common Stock issued and outstanding, and warrants to purchase
5,566,363 shares of Common Stock issued and outstanding (see Note 10).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;During Tottenham&amp;#x2019;s
IPO, Tottenham incurred deferred underwriters&amp;#x2019; fees which were payable to Chardan from the amounts held in the trust account
upon completion of the Reverse Recapitalization. Upon the closing of the Reverse Recapitalization, the Company paid $2.1 million
to Chardan as the settlement of the deferred underwriting and advisory fees which amount was included in the total offering costs
of the Reverse Recapitalization transaction.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in&quot;&gt;During the year ended December
31, 2020, the Company recorded $5.9 million of offering costs, which excludes the fair value of common shares issued as a payment
of related offering costs and Chardan underwriting fees discussed above. Those offering costs were related to third-party legal,
accounting services and other professional services to consummate the Reverse Recapitalization. These offering costs are recorded
in additional paid-in capital upon the close of the Reverse Recapitalization in the Company&amp;#x2019;s consolidated balance sheets.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in&quot;&gt;On December 28, 2020 and
prior to the close of the Reverse Recapitalization on December 30, 2020, various PIPE investors purchased 2,239,500 shares of the
Company&amp;#x2019;s Common Stock at a price of $10.00 per share and 1,119,750 warrants with an exercise price of $0.01 per share, to
purchase one share of the Company&amp;#x2019;s Common Stock, for net proceeds of $22.2 million (see Notes 10 and 18).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Earn-out
shares&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Certain of Clene Nanomedicine&amp;#x2019;s
current stockholders are entitled to receive earn-out shares as follows (the &amp;#x201c;Clene Nanomedicine Contingent Earn-Out&amp;#x201d;):
(i) 3,333,333 shares of the Company&amp;#x2019;s Common Stock if (A) the volume-weighted average price (&amp;#x201c;VWAP&amp;#x201d;) of the shares
of the Company&amp;#x2019;s Common Stock equals or exceeds $15.00 (or any foreign currency equivalent) (the &amp;#x201c;Milestone 1 Price&amp;#x201d;)
in any twenty trading days within a thirty trading day period within the three years following the closing of the Reverse Recapitalization
on any securities exchange or securities market on which the shares of the Company&amp;#x2019;s Common Stock are then traded or (B)
the change of control price equals or exceeds the Milestone 1 Price if a change of control transaction occurs within the three
years following the closing of the Reverse Recapitalization (the requirements set forth in clause (A) and (B), &amp;#x201c;Milestone
1&amp;#x201d;); (ii) 2,500,000 shares of the Company&amp;#x2019;s Common Stock if (A) the VWAP of the shares of the Company&amp;#x2019;s Common
Stock equals or exceeds $20.00 (or any foreign currency equivalent) (the &amp;#x201c;Milestone 2 Price&amp;#x201d;) in any twenty trading
days within a thirty trading day period within the five years following the closing of the Reverse Recapitalization on any securities
exchange or securities market on which the shares of the Company&amp;#x2019;s Common Stock are then traded or (B) the change of control
price equals or exceeds the Milestone 2 Price if a change of control transaction occurs within the five years following the closing
of the Reverse Recapitalization (the requirements set forth in clause (A) or (B), &amp;#x201c;Milestone 1&amp;#x201d;); and (iii) 2,500,000
shares of the Company&amp;#x2019;s Common Stock if Clene Nanomedicine completes a randomized placebo-controlled study for treatment
of COVID-19 which results in a statistically significant finding of clinical efficacy within twelve months after the closing of
the Reverse Recapitalization (&amp;#x201c;Milestone 3&amp;#x201d;). If Milestone 1 is not achieved but Milestone 2 is achieved, the Clene
Nanomedicine stockholders will receive a catch-up issuance equal to the shares issued upon satisfaction of Milestone 1. Upon the
consummation of the Reverse Recapitalization, the earn-out shares that certain Clene Nanomedicine stockholders are entitled to
receive increased by 12,852 as a result of the exercise of stock options during November 2020. Therefore, the total Clene Nanomedicine
earn-out shares has increased to 8,346,185 shares of the Company&amp;#x2019;s Common Stock.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Initial Shareholders of Tottenham may be entitled to receive earn-out shares as follows (the &amp;#x201c;Initial Shareholders Contingent
Earn-Out&amp;#x201d;): (i) 375,000 shares of the Company&amp;#x2019;s Common Stock upon satisfaction of the requirements of Milestone 1;
and (ii) another 375,000 shares of the Company&amp;#x2019;s Common Stock upon satisfaction of the requirements of Milestone 2. If Milestone
1 is not achieved but Milestone 2 is achieved, the Initial Shareholders shall receive a catch-up issuance equal to the shares
granted upon satisfaction of the requirements of Milestone 1.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Clene Nanomedicine
and Initial Shareholders earn-out payments (collectively, referred to as &amp;#x201c;Earn-out Shares&amp;#x201d;) have been classified as
liabilities in the consolidated balance sheets as of December 31, 2020 and were initially measured at fair value on the date of
the Reverse Recapitalization and will be subsequently remeasured to fair value at each reporting date (see Note 16).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;As a result of the
Reverse Recapitalization and the PIPE offering, Clene Nanomedicine&amp;#x2019;s stockholders own approximately 91% of the Common Stock
of the Company, Tottenham public stockholders own approximately 4% of the Common Stock of the Company, and investors from the PIPE
own approximately 4% of the Common Stock of the Company, based on the number of shares of Clene Inc. Common Stock outstanding on
December 30, 2020 (in each case, not giving effect to any shares issuable upon exercise of Clene Inc. warrants, options, or earn-out
shares).&lt;/p&gt;&lt;br/&gt;</clnn:ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock>
  <clnn:IssuanceOfCommonStockUponReverseRecapitalization unitRef="shares" contextRef="c60_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">2303495</clnn:IssuanceOfCommonStockUponReverseRecapitalization>
  <clnn:EarnOutShare unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">750000</clnn:EarnOutShare>
  <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired unitRef="pure" contextRef="c3_AsOf31Dec2020" decimals="2">1.00</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
  <clnn:EntityCommonStockSharesOutstanding1 unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">54339012</clnn:EntityCommonStockSharesOutstanding1>
  <clnn:SharesHeldInEscrow unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">2716958</clnn:SharesHeldInEscrow>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod unitRef="shares" contextRef="c61_From1Jan2020To31Dec2020_CleneNanomedicineMember_CommonStockMember" decimals="INF">53286115</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward unitRef="shares" contextRef="c37_From1Jan2020To31Dec2020_ExchangeClearedMember_CleneNanomedicineMember_CommonStockMember" decimals="INF">7032590</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
  <clnn:ServicesLetterAgreementDescription contextRef="c62_From1Jan2020To31Dec2020_LifeSciCapitalLLCMember">(i) 3% of the amount by which the total transaction consideration exceeded $350 million, plus (ii) 7% of cash and cash-equivalents received by Clene Nanomedicine from the Tottenham&amp;#x2019;s trust account. Clene Nanomedicine could elect to pay LifeSci either in cash, equity interests of the surviving company, or a combination of the two. Upon the consummation of the Reverse Recapitalization, 644,164 shares of the Company&amp;#x2019;s Common Stock were issued to LifeSci as consideration for its services as pursuant to the letter agreement (see Note 18).</clnn:ServicesLetterAgreementDescription>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c63_AsOf31Dec2020_CommonStockMember" decimals="INF">5566363</us-gaap:CommonStockSharesIssued>
  <us-gaap:OtherUnderwritingExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-5">2100000</us-gaap:OtherUnderwritingExpense>
  <us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-5">5900000</us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees>
  <clnn:InvestorsPurchasedShares unitRef="shares" contextRef="c45_From1Dec2020To28Dec2020" decimals="INF">2239500</clnn:InvestorsPurchasedShares>
  <clnn:SharesPerShare unitRef="usdPershares" contextRef="c64_AsOf28Dec2020" decimals="2">10.00</clnn:SharesPerShare>
  <clnn:ExercisePrice unitRef="usdPershares" contextRef="c64_AsOf28Dec2020" decimals="2">0.01</clnn:ExercisePrice>
  <clnn:NetProceeds unitRef="usd" contextRef="c45_From1Dec2020To28Dec2020" decimals="-5">22200000</clnn:NetProceeds>
  <clnn:EarnoutSharesDescription contextRef="c65_From1Jan2020To31Dec2020_CleneNanomedicineMember">(i) 3,333,333 shares of the Company&amp;#x2019;s Common Stock if (A) the volume-weighted average price (&amp;#x201c;VWAP&amp;#x201d;) of the shares of the Company&amp;#x2019;s Common Stock equals or exceeds $15.00 (or any foreign currency equivalent) (the &amp;#x201c;Milestone 1 Price&amp;#x201d;) in any twenty trading days within a thirty trading day period within the three years following the closing of the Reverse Recapitalization on any securities exchange or securities market on which the shares of the Company&amp;#x2019;s Common Stock are then traded or (B) the change of control price equals or exceeds the Milestone 1 Price if a change of control transaction occurs within the three years following the closing of the Reverse Recapitalization (the requirements set forth in clause (A) and (B), &amp;#x201c;Milestone 1&amp;#x201d;); (ii) 2,500,000 shares of the Company&amp;#x2019;s Common Stock if (A) the VWAP of the shares of the Company&amp;#x2019;s Common Stock equals or exceeds $20.00 (or any foreign currency equivalent) (the &amp;#x201c;Milestone 2 Price&amp;#x201d;) in any twenty trading days within a thirty trading day period within the five years following the closing of the Reverse Recapitalization on any securities exchange or securities market on which the shares of the Company&amp;#x2019;s Common Stock are then traded or (B) the change of control price equals or exceeds the Milestone 2 Price if a change of control transaction occurs within the five years following the closing of the Reverse Recapitalization (the requirements set forth in clause (A) or (B), &amp;#x201c;Milestone 1&amp;#x201d;); and (iii) 2,500,000 shares of the Company&amp;#x2019;s Common Stock if Clene Nanomedicine completes a randomized placebo-controlled study for treatment of COVID-19 which results in a statistically significant finding of clinical efficacy within twelve months after the closing of the Reverse Recapitalization (&amp;#x201c;Milestone 3&amp;#x201d;). If Milestone 1 is not achieved but Milestone 2 is achieved, the Clene Nanomedicine stockholders will receive a catch-up issuance equal to the shares issued upon satisfaction of Milestone 1. Upon the consummation of the Reverse Recapitalization, the earn-out shares that certain Clene Nanomedicine stockholders are entitled to receive increased by 12,852 as a result of the exercise of stock options during November 2020. Therefore, the total Clene Nanomedicine earn-out shares has increased to 8,346,185 shares of the Company&amp;#x2019;s Common Stock.</clnn:EarnoutSharesDescription>
  <clnn:EarnoutSharesDescription contextRef="c0_From1Jan2020To31Dec2020">(i) 375,000 shares of the Company&amp;#x2019;s Common Stock upon satisfaction of the requirements of Milestone 1; and (ii) another 375,000 shares of the Company&amp;#x2019;s Common Stock upon satisfaction of the requirements of Milestone 2. If Milestone 1 is not achieved but Milestone 2 is achieved, the Initial Shareholders shall receive a catch-up issuance equal to the shares granted upon satisfaction of the requirements of Milestone 1.</clnn:EarnoutSharesDescription>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" contextRef="c66_AsOf31Dec2020_CleneNanomedicineMember" decimals="2">0.91</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" contextRef="c67_AsOf31Dec2020_TottenhamMember" decimals="2">0.04</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" contextRef="c68_AsOf31Dec2020_PIPE" decimals="2">0.04</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <clnn:PrepaidExpensesAndOtherCurrentAssetsTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;4.
Prepaid expenses and other current assets&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Prepaid
expenses and other current assets consisted of the following as of December 31, 2020 and 2019:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-weight: bold; border-bottom: Black 1.5pt solid&quot;&gt;(in thousands)&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt&quot;&gt;Australia research and development credit receivable&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;2,148&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -9pt; padding-left: 9pt&quot;&gt;CRO prepayments&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,211&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;413&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -9pt; padding-left: 9pt&quot;&gt;Accounts receivable&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;21&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -9pt; padding-left: 9pt&quot;&gt;Metals to be used in research and development&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;31&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;191&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt&quot;&gt;Other&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;112&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;57&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;3,523&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;661&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;</clnn:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
  <clnn:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-weight: bold; border-bottom: Black 1.5pt solid&quot;&gt;(in thousands)&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt&quot;&gt;Australia research and development credit receivable&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;2,148&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -9pt; padding-left: 9pt&quot;&gt;CRO prepayments&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,211&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;413&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -9pt; padding-left: 9pt&quot;&gt;Accounts receivable&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;21&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -9pt; padding-left: 9pt&quot;&gt;Metals to be used in research and development&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;31&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;191&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt&quot;&gt;Other&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;112&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;57&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;3,523&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;661&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</clnn:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
  <clnn:AustraliaResearchAndDevelopmentCreditReceivable unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">2148000</clnn:AustraliaResearchAndDevelopmentCreditReceivable>
  <clnn:AustraliaResearchAndDevelopmentCreditReceivable unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <clnn:CROPrepayments unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">1211000</clnn:CROPrepayments>
  <clnn:CROPrepayments unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">413000</clnn:CROPrepayments>
  <us-gaap:AccountsReceivableNet unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">21000</us-gaap:AccountsReceivableNet>
  <us-gaap:AccountsReceivableNet unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <clnn:MetalsToBeUsedInResearchAndDevelopment unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">31000</clnn:MetalsToBeUsedInResearchAndDevelopment>
  <clnn:MetalsToBeUsedInResearchAndDevelopment unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">191000</clnn:MetalsToBeUsedInResearchAndDevelopment>
  <us-gaap:OtherPrepaidExpenseCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">112000</us-gaap:OtherPrepaidExpenseCurrent>
  <us-gaap:OtherPrepaidExpenseCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">57000</us-gaap:OtherPrepaidExpenseCurrent>
  <us-gaap:PrepaidExpenseCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">3523000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PrepaidExpenseCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">661000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;5.
Property and Equipment, Net&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Property
and equipment, net consisted of the following as of December 31, 2020 and 2019:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif;  width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(in
    thousands)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.25in; padding-left: 0.25in; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Lab
    equipment&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;3,077&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2,707&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.25in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Furniture
    and fixtures&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;147&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;162&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.25in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Leasehold
    improvements&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;3,889&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;3,430&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Construction
    in progress&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;490&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;410&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.25in; padding-left: 0.25in; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;7,603&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;6,709&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Less
    accumulated depreciation&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(3,378&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(2,390&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Total
    property and equipment, net&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;4,225&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;4,319&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Depreciation
expense related to property and equipment, net for the years ended December 31, 2020 and 2019 was approximately $1.0 million ($0.9
million in Research and Development expense and $0.1 million in General and Administrative expense) and $0.9 million ($0.8 million
in Research and Development expense and $0.1 million in General and Administrative expense), respectively.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:Depreciation unitRef="usd" contextRef="c69_From1Jan2020To31Dec2020_PropertyPlantAndEquipmentMember" decimals="-5">1000000</us-gaap:Depreciation>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c69_From1Jan2020To31Dec2020_PropertyPlantAndEquipmentMember" decimals="-5">900000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c69_From1Jan2020To31Dec2020_PropertyPlantAndEquipmentMember" decimals="-5">100000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:Depreciation unitRef="usd" contextRef="c70_From1Jan2019To31Dec2019_PropertyPlantAndEquipmentMember" decimals="-5">900000</us-gaap:Depreciation>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c70_From1Jan2019To31Dec2019_PropertyPlantAndEquipmentMember" decimals="-5">800000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c70_From1Jan2019To31Dec2019_PropertyPlantAndEquipmentMember" decimals="-5">100000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif;  width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(in
    thousands)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.25in; padding-left: 0.25in; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Lab
    equipment&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;3,077&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2,707&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.25in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Furniture
    and fixtures&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;147&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;162&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.25in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Leasehold
    improvements&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;3,889&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;3,430&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Construction
    in progress&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;490&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;410&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.25in; padding-left: 0.25in; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;7,603&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;6,709&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Less
    accumulated depreciation&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(3,378&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(2,390&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Total
    property and equipment, net&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;4,225&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;4,319&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:EquipmentExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">3077000</us-gaap:EquipmentExpense>
  <us-gaap:EquipmentExpense unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">2707000</us-gaap:EquipmentExpense>
  <us-gaap:FurnitureAndFixturesGross unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">147000</us-gaap:FurnitureAndFixturesGross>
  <us-gaap:FurnitureAndFixturesGross unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">162000</us-gaap:FurnitureAndFixturesGross>
  <us-gaap:LeaseholdImprovementsGross unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">3889000</us-gaap:LeaseholdImprovementsGross>
  <us-gaap:LeaseholdImprovementsGross unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">3430000</us-gaap:LeaseholdImprovementsGross>
  <us-gaap:ConstructionInProgressGross unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">490000</us-gaap:ConstructionInProgressGross>
  <us-gaap:ConstructionInProgressGross unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">410000</us-gaap:ConstructionInProgressGross>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">7603000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">6709000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">3378000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">2390000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;6.
Accrued Liabilities&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Accrued
liabilities consisted of the following as of December 31, 2020 and 2019:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-weight: bold; border-bottom: Black 1.5pt solid&quot;&gt;(in thousands)&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt&quot;&gt;Accrued professional fees&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;189&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,826&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -9pt; padding-left: 9pt&quot;&gt;Accrued compensation and benefits&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,225&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;817&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -9pt; padding-left: 9pt&quot;&gt;Accrued CRO fees&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;788&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;95&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -9pt; padding-left: 9pt&quot;&gt;Deferred grant funds&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;301&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;80&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -9pt; padding-left: 9pt&quot;&gt;Accrued expense reimbursements&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;33&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;36&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -9pt; padding-left: 9pt&quot;&gt;Accrued transaction costs&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,354&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt&quot;&gt;Other&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;70&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;24&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;3,960&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2,878&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-weight: bold; border-bottom: Black 1.5pt solid&quot;&gt;(in thousands)&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt&quot;&gt;Accrued professional fees&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;189&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,826&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -9pt; padding-left: 9pt&quot;&gt;Accrued compensation and benefits&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,225&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;817&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -9pt; padding-left: 9pt&quot;&gt;Accrued CRO fees&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;788&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;95&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -9pt; padding-left: 9pt&quot;&gt;Deferred grant funds&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;301&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;80&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -9pt; padding-left: 9pt&quot;&gt;Accrued expense reimbursements&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;33&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;36&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -9pt; padding-left: 9pt&quot;&gt;Accrued transaction costs&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,354&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt&quot;&gt;Other&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;70&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;24&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;3,960&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2,878&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:AccruedProfessionalFeesCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">189000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">1826000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedEmployeeBenefitsCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">1225000</us-gaap:AccruedEmployeeBenefitsCurrent>
  <us-gaap:AccruedEmployeeBenefitsCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">817000</us-gaap:AccruedEmployeeBenefitsCurrent>
  <clnn:AccruedCROFees unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">788000</clnn:AccruedCROFees>
  <clnn:AccruedCROFees unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">95000</clnn:AccruedCROFees>
  <clnn:DeferredGrantFunds unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">301000</clnn:DeferredGrantFunds>
  <clnn:DeferredGrantFunds unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">80000</clnn:DeferredGrantFunds>
  <us-gaap:AccruedSalariesCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">33000</us-gaap:AccruedSalariesCurrent>
  <us-gaap:AccruedSalariesCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">36000</us-gaap:AccruedSalariesCurrent>
  <clnn:AccruedTransactionCosts unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">1354000</clnn:AccruedTransactionCosts>
  <us-gaap:OtherAccruedLiabilitiesCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">70000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">24000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">3960000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">2878000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;7.
Leases&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company adopted ASC 842 on January 1, 2019 using the modified retrospective approach. Upon adoption of the new leasing standards,
the Company (i) recognized an operating lease right of use asset of approximately $1.2 million and a corresponding operating lease
liability of approximately $1.7 million, which are included in the Company&amp;#x2019;s consolidated balance sheet, and with a $14
thousand cumulative adjustment to accumulated deficit and (ii) elected the package of transition practical expedients, which allowed
the Company to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the
lease classification for any expired or existing leases and initial direct costs for existing leases.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company also made an accounting policy election not to recognize leases with an initial term of 12 months or less within its consolidated
balance sheets and to recognize those lease payments on a straight-line basis in its consolidated statements of operations and
comprehensive loss over the lease term.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;At
the lease commencement date, the discount rate implicit in the lease is used to discount the lease liability if readily determinable.
If not readily determinable or leases do not contain an implicit rate, the Company&amp;#x2019;s incremental borrowing rate is used
as the discount rate.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;In
April&amp;#xa0;2020, the Company terminated an existing operating lease for office space. At the time of termination, the Company
removed the remaining right-of-use asset of $0.3 million, lease liability of $0.3 million, and recognized a gain of $51 thousand.
Further, in April&amp;#xa0;2020, the Company commenced a new operating lease. At the time of commencement, the Company recorded the
right-of-use asset value of $0.4 million, leasehold improvements of $0.4 million, and a lease liability of $0.8 million. The net
effect of the change in leases being an increase in right-of-use assets of $56 thousand, an increase in leasehold improvements
of $0.5 million, an increase in lease liability of $0.4 million, and a gain on termination of $51 thousand.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company has noncancelable operating lease arrangements primarily for office and lab space. The Company also has noncancelable
finance leases for certain lab equipment. The maturity analysis of finance and operating lease liabilities as of December 31,
2020 are as follows:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif;  width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(in
    thousands)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;Finance &lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Leases&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;Operating &lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Leases&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2021&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;165&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;376&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2022&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;135&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;421&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2023&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;82&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;433&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2024&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;20&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;442&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2025&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;454&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;530&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.375in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Total
    undiscounted cash flows&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;403&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2,656&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Less
    amount representing interest/discounting&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(8&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(677&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.375in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Present
    value of future lease payments&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;395&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1,979&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Less
    lease obligations, current portion&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(190&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(194&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Lease
    obligations&amp;#xa0;&amp;#x2013; long term portion&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;205&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1,785&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company expects that, in the normal course of business, the existing leases will be renewed or replaced by similar leases.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;i&gt;Finance
Leases&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Assets
recorded under finance lease obligations and included with property and equipment as of December 31, 2020 and 2019 are summarized
as follows:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif;  width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(in
    thousands)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Lab
    equipment&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;920&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;920&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Furniture
    and fixtures&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;46&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;46&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Work
    in process&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;228&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;228&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1,194&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1,194&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Less
    accumulated depreciation&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(593&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(418&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Net&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;601&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;776&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;As
of December 31, 2020, the Company&amp;#x2019;s finance lease obligations had a weighted-average interest rate of 8.1% and had a weighted-average
remaining term of 2.7 years. As of December 31, 2019, the Company&amp;#x2019;s finance lease obligations had a weighted-average interest
rate of 8.1% and had a weighted-average remaining term of 3.7 years.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;i&gt;Operating
Leases&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company&amp;#x2019;s balance of right-of-use assets on the face of the balance sheet pertain to operating leases. As of December 31,
2020, the Company&amp;#x2019;s operating lease obligations had a weighted-average discount rate of 9.6% and had a weighted-average
remaining term of 6.3 years. As of December 31, 2019, the Company&amp;#x2019;s operating lease obligations had a weighted-average discount
rate of 9.6% and a weighted-average remaining term of 6.0 years.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;i&gt;Components
of Lease Cost&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
components of finance and operating lease costs for the years ended December 31, 2020 and 2019 were as follows:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif;  width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(in
    thousands)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Finance
    lease costs:&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Amortization&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;175&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;182&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif; &quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Interest
    on lease liabilities&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;37&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;29&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Operating
    lease costs&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;293&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;325&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif; &quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Short-term
    lease costs&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;249&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;283&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Variable
    lease costs&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;92&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;103&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif; &quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Total
    lease costs&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;846&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;922&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;i&gt;Supplemental
Cash Flow Information&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif;  width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(in
    thousands)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Operating
    cash flows from operating leases&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(635&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(711&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Operating
    cash flows from finance leases&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(37&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(29&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Finance
    cash flows from finance leases&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(194&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(176&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;</us-gaap:LeasesOfLesseeDisclosureTextBlock>
  <us-gaap:OperatingLeaseRightOfUseAsset unitRef="usd" contextRef="c71_AsOf2Jan2019" decimals="-5">1200000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseLiability unitRef="usd" contextRef="c71_AsOf2Jan2019" decimals="-5">1700000</us-gaap:OperatingLeaseLiability>
  <us-gaap:CumulativeEarningsDeficit unitRef="usd" contextRef="c71_AsOf2Jan2019" decimals="-3">14000</us-gaap:CumulativeEarningsDeficit>
  <clnn:RemainingRightofuseAsset unitRef="usd" contextRef="c72_AsOf30Apr2020" decimals="-5">300000</clnn:RemainingRightofuseAsset>
  <us-gaap:OperatingLeaseLiability unitRef="usd" contextRef="c72_AsOf30Apr2020" decimals="-5">300000</us-gaap:OperatingLeaseLiability>
  <clnn:RecognizedGainOnOperatingLease unitRef="usd" contextRef="c73_From1Apr2020To30Apr2020" decimals="-3">51000</clnn:RecognizedGainOnOperatingLease>
  <clnn:DescriptionOfOperatingLease contextRef="c73_From1Apr2020To30Apr2020">the Company recorded the right-of-use asset value of $0.4 million, leasehold improvements of $0.4 million, and a lease liability of $0.8 million. The net effect of the change in leases being an increase in right-of-use assets of $56 thousand, an increase in leasehold improvements of $0.5 million, an increase in lease liability of $0.4 million, and a gain on termination of $51 thousand.</clnn:DescriptionOfOperatingLease>
  <clnn:FinanceLeaseObligationsWeightedaverageInterestRate unitRef="pure" contextRef="c3_AsOf31Dec2020" decimals="3">0.081</clnn:FinanceLeaseObligationsWeightedaverageInterestRate>
  <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c3_AsOf31Dec2020">P2Y255D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
  <clnn:FinanceLeaseObligationsWeightedaverageInterestRate unitRef="pure" contextRef="c4_AsOf31Dec2019" decimals="3">0.081</clnn:FinanceLeaseObligationsWeightedaverageInterestRate>
  <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c4_AsOf31Dec2019">P3Y255D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
  <clnn:OperatingLeaseObligationsWeightedAverageInterestRate unitRef="pure" contextRef="c3_AsOf31Dec2020" decimals="3">0.096</clnn:OperatingLeaseObligationsWeightedAverageInterestRate>
  <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c3_AsOf31Dec2020">P6Y109D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
  <clnn:OperatingLeaseObligationsWeightedAverageInterestRate unitRef="pure" contextRef="c4_AsOf31Dec2019" decimals="3">0.096</clnn:OperatingLeaseObligationsWeightedAverageInterestRate>
  <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c4_AsOf31Dec2019">P6Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif;  width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(in
    thousands)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;Finance &lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Leases&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;Operating &lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Leases&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2021&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;165&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;376&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2022&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;135&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;421&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2023&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;82&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;433&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2024&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;20&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;442&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2025&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;454&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;530&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.375in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Total
    undiscounted cash flows&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;403&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2,656&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Less
    amount representing interest/discounting&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(8&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(677&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.375in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Present
    value of future lease payments&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;395&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1,979&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Less
    lease obligations, current portion&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(190&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(194&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Lease
    obligations&amp;#xa0;&amp;#x2013; long term portion&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;205&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1,785&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent unitRef="usd" contextRef="c74_AsOf31Dec2020_FinanceLeasesMember" decimals="-3">165000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent unitRef="usd" contextRef="c75_AsOf31Dec2020_OperatingLeasesMember" decimals="-3">376000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears unitRef="usd" contextRef="c74_AsOf31Dec2020_FinanceLeasesMember" decimals="-3">135000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears unitRef="usd" contextRef="c75_AsOf31Dec2020_OperatingLeasesMember" decimals="-3">421000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears unitRef="usd" contextRef="c74_AsOf31Dec2020_FinanceLeasesMember" decimals="-3">82000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears unitRef="usd" contextRef="c75_AsOf31Dec2020_OperatingLeasesMember" decimals="-3">433000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFourYears unitRef="usd" contextRef="c74_AsOf31Dec2020_FinanceLeasesMember" decimals="-3">20000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFourYears unitRef="usd" contextRef="c75_AsOf31Dec2020_OperatingLeasesMember" decimals="-3">442000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFiveYears unitRef="usd" contextRef="c74_AsOf31Dec2020_FinanceLeasesMember" xs:nil="true"/>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFiveYears unitRef="usd" contextRef="c75_AsOf31Dec2020_OperatingLeasesMember" decimals="-3">454000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFiveYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter unitRef="usd" contextRef="c74_AsOf31Dec2020_FinanceLeasesMember" xs:nil="true"/>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter unitRef="usd" contextRef="c75_AsOf31Dec2020_OperatingLeasesMember" decimals="-3">530000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDueThereafter unitRef="usd" contextRef="c74_AsOf31Dec2020_FinanceLeasesMember" decimals="-3">403000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueThereafter>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDueThereafter unitRef="usd" contextRef="c75_AsOf31Dec2020_OperatingLeasesMember" decimals="-3">2656000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueThereafter>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments unitRef="usd" contextRef="c74_AsOf31Dec2020_FinanceLeasesMember" decimals="-3">8000</us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments unitRef="usd" contextRef="c75_AsOf31Dec2020_OperatingLeasesMember" decimals="-3">677000</us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments unitRef="usd" contextRef="c74_AsOf31Dec2020_FinanceLeasesMember" decimals="-3">395000</us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments unitRef="usd" contextRef="c75_AsOf31Dec2020_OperatingLeasesMember" decimals="-3">1979000</us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments>
  <us-gaap:CapitalLeaseObligationsCurrent unitRef="usd" contextRef="c74_AsOf31Dec2020_FinanceLeasesMember" decimals="-3">190000</us-gaap:CapitalLeaseObligationsCurrent>
  <us-gaap:CapitalLeaseObligationsCurrent unitRef="usd" contextRef="c75_AsOf31Dec2020_OperatingLeasesMember" decimals="-3">194000</us-gaap:CapitalLeaseObligationsCurrent>
  <us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities unitRef="usd" contextRef="c74_AsOf31Dec2020_FinanceLeasesMember" decimals="-3">205000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
  <us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities unitRef="usd" contextRef="c75_AsOf31Dec2020_OperatingLeasesMember" decimals="-3">1785000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
  <clnn:PropertyPlantAndEquipmentOneTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif;  width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(in
    thousands)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Lab
    equipment&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;920&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;920&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Furniture
    and fixtures&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;46&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;46&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Work
    in process&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;228&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;228&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1,194&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1,194&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Less
    accumulated depreciation&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(593&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(418&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Net&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;601&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;776&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</clnn:PropertyPlantAndEquipmentOneTextBlock>
  <clnn:FinanceLeaseLiabilityGross unitRef="usd" contextRef="c76_AsOf31Dec2020_EquipmentMember" decimals="-3">920000</clnn:FinanceLeaseLiabilityGross>
  <clnn:FinanceLeaseLiabilityGross unitRef="usd" contextRef="c77_AsOf31Dec2019_EquipmentMember" decimals="-3">920000</clnn:FinanceLeaseLiabilityGross>
  <clnn:FinanceLeaseLiabilityGross unitRef="usd" contextRef="c78_AsOf31Dec2020_FurnitureAndFixturesMember" decimals="-3">46000</clnn:FinanceLeaseLiabilityGross>
  <clnn:FinanceLeaseLiabilityGross unitRef="usd" contextRef="c79_AsOf31Dec2019_FurnitureAndFixturesMember" decimals="-3">46000</clnn:FinanceLeaseLiabilityGross>
  <clnn:FinanceLeaseLiabilityGross unitRef="usd" contextRef="c80_AsOf31Dec2020_WorkInProcessMember" decimals="-3">228000</clnn:FinanceLeaseLiabilityGross>
  <clnn:FinanceLeaseLiabilityGross unitRef="usd" contextRef="c81_AsOf31Dec2019_WorkInProcessMember" decimals="-3">228000</clnn:FinanceLeaseLiabilityGross>
  <clnn:FinanceLeaseLiabilityGross unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">1194000</clnn:FinanceLeaseLiabilityGross>
  <clnn:FinanceLeaseLiabilityGross unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">1194000</clnn:FinanceLeaseLiabilityGross>
  <clnn:AccumulatedDepreciationDepletionAndAmortizationLeases unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">-593000</clnn:AccumulatedDepreciationDepletionAndAmortizationLeases>
  <clnn:AccumulatedDepreciationDepletionAndAmortizationLeases unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">-418000</clnn:AccumulatedDepreciationDepletionAndAmortizationLeases>
  <clnn:FinanceLeaseLiabilityNet unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">601000</clnn:FinanceLeaseLiabilityNet>
  <clnn:FinanceLeaseLiabilityNet unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">776000</clnn:FinanceLeaseLiabilityNet>
  <us-gaap:LeaseCostTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif;  width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(in
    thousands)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Finance
    lease costs:&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Amortization&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;175&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;182&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif; &quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Interest
    on lease liabilities&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;37&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;29&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Operating
    lease costs&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;293&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;325&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif; &quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Short-term
    lease costs&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;249&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;283&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Variable
    lease costs&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;92&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;103&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif; &quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Total
    lease costs&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;846&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;922&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
  <us-gaap:FinanceLeaseRightOfUseAssetAmortization unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">175000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
  <us-gaap:FinanceLeaseRightOfUseAssetAmortization unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">182000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
  <us-gaap:FinanceLeaseInterestExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">37000</us-gaap:FinanceLeaseInterestExpense>
  <us-gaap:FinanceLeaseInterestExpense unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">29000</us-gaap:FinanceLeaseInterestExpense>
  <us-gaap:OperatingLeaseCost unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">293000</us-gaap:OperatingLeaseCost>
  <us-gaap:OperatingLeaseCost unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">325000</us-gaap:OperatingLeaseCost>
  <us-gaap:ShortTermLeaseCost unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">249000</us-gaap:ShortTermLeaseCost>
  <us-gaap:ShortTermLeaseCost unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">283000</us-gaap:ShortTermLeaseCost>
  <us-gaap:VariableLeaseCost unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">92000</us-gaap:VariableLeaseCost>
  <us-gaap:VariableLeaseCost unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">103000</us-gaap:VariableLeaseCost>
  <us-gaap:LeaseCost unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">846000</us-gaap:LeaseCost>
  <us-gaap:LeaseCost unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">922000</us-gaap:LeaseCost>
  <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif;  width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(in
    thousands)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Operating
    cash flows from operating leases&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(635&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(711&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Operating
    cash flows from finance leases&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(37&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(29&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Finance
    cash flows from finance leases&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(194&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(176&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
  <clnn:OperatingCashFlowsFromOperatingLeases unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">-635000</clnn:OperatingCashFlowsFromOperatingLeases>
  <clnn:OperatingCashFlowsFromOperatingLeases unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">-711000</clnn:OperatingCashFlowsFromOperatingLeases>
  <clnn:OperatingCashFlowsFromFinanceLeases unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">-37000</clnn:OperatingCashFlowsFromFinanceLeases>
  <clnn:OperatingCashFlowsFromFinanceLeases unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">-29000</clnn:OperatingCashFlowsFromFinanceLeases>
  <clnn:FinanceCashFlowsFromFinanceLeases unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">-194000</clnn:FinanceCashFlowsFromFinanceLeases>
  <clnn:FinanceCashFlowsFromFinanceLeases unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">-176000</clnn:FinanceCashFlowsFromFinanceLeases>
  <us-gaap:DebtDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;8.
Notes Payable&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;In
February&amp;#xa0;2019, the Company entered into a loan agreement (the &amp;#x201c;2019 MD Loan&amp;#x201d;) with the Department of Housing
and Community Development, a principal department of the State of Maryland (&amp;#x201c;Maryland&amp;#x201d;). Pursuant to the 2019 MD Loan,
Maryland agreed to provide a $0.5 million term loan. Amounts outstanding under the 2019 MD Loan bear simple interest at an annual
rate of 8.00%. Under the 2019 MD Loan, the Company has agreed to affirmative and negative covenants to which it will remain subject
until maturity. These covenants include providing information about the Company and its operations; limitations on the Company&amp;#x2019;s
ability to retire, repurchase, or redeem the Company&amp;#x2019;s common or preferred stock, options, and warrants other than per the
terms of the securities; and limitations on the Company&amp;#x2019;s ability to pay dividends of cash or property. There are no financial
covenants associated with the Loan Agreement. Events of default under the Loan Agreement include failure to make payments when
due, insolvency events, failure to comply with covenants, and material adverse effects with respect to the Company. The Company
is not in violation of any affirmative or negative covenants. Repayment of the full balance outstanding is due on February 22,
2034. The 2019 MD Loan establishes &amp;#x201c;Phantom Shares,&amp;#x201d; based on 119,906 shares of the Company&amp;#x2019;s common stock (based
on 863,110 Series C Preferred Shares prior to the Reverse Recapitalization), determined at issuance. The Loan Agreement states
the repayment amount is to be the greater of the balance of principal and accrued interest or the Phantom Share value. The Company
determined that the note should be accounted for at fair value. The Company records the fair value of the debt at the end of each
reporting period. In order to value the note, the Company considers the amount of the simple interest expense that would be due
and considers the value of Phantom Shares. Expense of $0.5 million and $34 thousand was recognized during the years ended December
31, 2020 and 2019, respectively. The fair value of $1.1 million and $0.5 million of principal and accrued interest is included
in long-term notes payable as of December 31, 2020 and December 31, 2019, respectively.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In April&amp;#xa0;2019,
the Company entered into a loan agreement (the &amp;#x201c;2019 Cecil Loan&amp;#x201d;) with Cecil County, Maryland (&amp;#x201c;Cecil&amp;#x201d;).
Pursuant to the 2019 Cecil Loan, Cecil agreed to provide a $0.1 million term loan. Amounts outstanding under the 2019 Cecil Loan
bear simple interest at an annual rate of 8.00%. Under the 2019 Cecil Loan, the Company has agreed to affirmative and negative
covenants to which it will remain subject until maturity. These covenants include providing information about the Company and its
operations; limitations on the Company&amp;#x2019;s ability to retire, repurchase, or redeem the Company&amp;#x2019;s common or preferred
stock, options, and warrants other than per the terms of the securities; and limitations on the Company&amp;#x2019;s ability to pay
dividends of cash or property. There are no financial covenants associated with the Loan Agreement. Events of default under the
Loan Agreement include failure to make payments when due, insolvency events, failure to comply with covenants, and material adverse
effects with respect to the Company. The Company is not in violation of any affirmative or negative covenants. Repayment of the
full balance outstanding is due on April 30, 2034. The 2019 Cecil Loan establishes &amp;#x201c;Phantom Shares,&amp;#x201d; based on 23,981
shares of the Company&amp;#x2019;s common stock (based on 172,622 Series C Preferred Shares prior to the Reverse Recapitalization),
determined at issuance. The 2019 Cecil Loan states the repayment amount is to be the greater of the balance of principal and accrued
interest or the Phantom Share value. The Company determined that the note should be accounted for at fair value. The Company records
the fair value of the debt at the end of each reporting period. In order to value the note, the Company considers the amount of
the simple interest expense that would be due and considers the value of Phantom Shares. Expense of $0.1 million and $6 thousand
was recognized during the years ended December 31, 2020 and 2019, respectively. The fair value of $0.2 million and $0.1 million
of principal and accrued interest is included in long-term notes payable as of December 31, 2020 and December 31, 2019, respectively.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In May&amp;#xa0;2020, the
Company entered into a note payable in the amount of $0.6 million (the &amp;#x201c;PPP Note&amp;#x201d;) under the Paycheck Protection Program
of the CARES Act (the &amp;#x201c;PPP&amp;#x201d;). As amended, the PPP permits forgiveness of amounts loaned for payments of payroll and
other qualifying expenses within 24 weeks of receipt of loaned funds, given that at least 60% of the total loan is used for payroll.
Amounts not forgiven by the PPP have a repayment period of five years. The Company expects the full $0.6 million balance of the
PPP Note to be forgiven. The Company will record any forgiveness after approval by the issuer. Until then, the PPP balance is included
in long-term notes payable as of December 31, 2020. On January 11, 2021, the U.S. Small Business Administration notified the Company
that the Company&amp;#x2019;s PPP loan of $0.6 million had been forgiven (see Note 22).&lt;/p&gt;&lt;br/&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:LineOfCredit unitRef="usd" contextRef="c82_AsOf28Feb2019_TwoThousandNineteenMDLoanMember" decimals="-5">500000</us-gaap:LineOfCredit>
  <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod unitRef="pure" contextRef="c83_From1Feb2019To28Feb2019_TwoThousandNineteenMDLoanMember" decimals="4">0.0800</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
  <us-gaap:DebtInstrumentMaturityDate contextRef="c83_From1Feb2019To28Feb2019_TwoThousandNineteenMDLoanMember">2034-02-22</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentDescription contextRef="c83_From1Feb2019To28Feb2019_TwoThousandNineteenMDLoanMember">The 2019 MD Loan establishes &amp;#x201c;Phantom Shares,&amp;#x201d; based on 119,906 shares of the Company&amp;#x2019;s common stock (based on 863,110 Series C Preferred Shares prior to the Reverse Recapitalization), determined at issuance.</us-gaap:DebtInstrumentDescription>
  <clnn:SimpleInterestExpense unitRef="usd" contextRef="c84_From1Jan2020To31Dec2020_TwoThousandNineteenMDLoanMember" decimals="-5">500000</clnn:SimpleInterestExpense>
  <clnn:SimpleInterestExpense unitRef="usd" contextRef="c85_From1Jan2019To31Dec2019_TwoThousandNineteenMDLoanMember" decimals="-3">34000</clnn:SimpleInterestExpense>
  <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding unitRef="usd" contextRef="c86_AsOf31Dec2020_TwoThousandNineteenMDLoanMember" decimals="-5">1100000</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
  <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding unitRef="usd" contextRef="c87_AsOf31Dec2019_TwoThousandNineteenMDLoanMember" decimals="-5">500000</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
  <us-gaap:LineOfCredit unitRef="usd" contextRef="c88_AsOf30Apr2019_TwoThousandNineteenCecilLoanMember" decimals="-5">100000</us-gaap:LineOfCredit>
  <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod unitRef="pure" contextRef="c89_From1Apr2019To30Apr2019_TwoThousandNineteenCecilLoanMember" decimals="4">0.0800</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
  <us-gaap:DebtInstrumentMaturityDate contextRef="c89_From1Apr2019To30Apr2019_TwoThousandNineteenCecilLoanMember">2034-04-30</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentDescription contextRef="c89_From1Apr2019To30Apr2019_TwoThousandNineteenCecilLoanMember">The 2019 Cecil Loan establishes &amp;#x201c;Phantom Shares,&amp;#x201d; based on 23,981 shares of the Company&amp;#x2019;s common stock (based on 172,622 Series C Preferred Shares prior to the Reverse Recapitalization), determined at issuance.</us-gaap:DebtInstrumentDescription>
  <clnn:SimpleInterestExpense unitRef="usd" contextRef="c90_From1Jan2020To31Dec2020_TwoThousandNineteenCecilLoanMember" decimals="-5">100000</clnn:SimpleInterestExpense>
  <clnn:SimpleInterestExpense unitRef="usd" contextRef="c91_From1Jan2019To31Dec2019_TwoThousandNineteenCecilLoanMember" decimals="-3">6000</clnn:SimpleInterestExpense>
  <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding unitRef="usd" contextRef="c92_AsOf31Dec2020_TwoThousandNineteenCecilLoanMember" decimals="-5">200000</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
  <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding unitRef="usd" contextRef="c93_AsOf31Dec2019_TwoThousandNineteenCecilLoanMember" decimals="-5">100000</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
  <us-gaap:NotesAndLoansPayable unitRef="usd" contextRef="c94_AsOf31May2020_PaycheckProtectionProgramNoteMember" decimals="-5">600000</us-gaap:NotesAndLoansPayable>
  <clnn:PercentageOfLoanAmountUsedToPayrollExpenses unitRef="pure" contextRef="c95_From1May2020To31May2020_PaycheckProtectionProgramNoteMember" decimals="2">0.60</clnn:PercentageOfLoanAmountUsedToPayrollExpenses>
  <us-gaap:LineOfCreditFacilityExpirationPeriod contextRef="c95_From1May2020To31May2020_PaycheckProtectionProgramNoteMember">P5Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
  <us-gaap:AccruedSalariesCurrentAndNoncurrent unitRef="usd" contextRef="c94_AsOf31May2020_PaycheckProtectionProgramNoteMember" decimals="-5">600000</us-gaap:AccruedSalariesCurrentAndNoncurrent>
  <us-gaap:NotesPayableToBank unitRef="usd" contextRef="c96_AsOf11Jan2021_PaycheckProtectionProgramNoteMember_SubsequentEventMember" decimals="-5">600000</us-gaap:NotesPayableToBank>
  <us-gaap:PreferredStockTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;9.
Preferred Stock Warrant Liability&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Prior to the Reverse
Recapitalization, the Company issued Series A Preferred Stock Warrants in 2013 in connection with certain note purchase agreements.
The warrants expire 10&amp;#xa0;years from issuance. These warrants are exercisable at a fixed exercise price of $1.97, which is equal
to the price per share of the Series A Preferred Stock by the Company. As of December 31, 2019, these warrants were exercisable
into 1,608,672 shares of the Series A Preferred Stock.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Prior to the Reverse
Recapitalization, on April 8, 2013, the Company issued 10-year warrants to purchase units of the Company&amp;#x2019;s most senior equity
equal to 0.50% of the Company&amp;#x2019;s fully diluted equity at the time of exercise in connection with certain note purchase agreements.
As of December 31, 2019, these warrants were exercisable into 271,439 shares of the Company&amp;#x2019;s most senior equity, Series
C Preferred Stock, at a fixed exercise price of $1.97 per share. On August 11, 2020, in connection with the Company&amp;#x2019;s issuance
of Series D Preferred Stock, these warrants became exercisable into 320,441 shares of the Company&amp;#x2019;s most senior equity, Series
D Preferred Stock, at a fixed exercise price of $1.97 per share.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Prior to the Reverse
Recapitalization, the Company classified its Preferred Stock warrants as a liability on its consolidated balance sheet because
the warrants are freestanding financial instruments that may have required to the Company to transfer assets upon exercise. The
liability associated with each of these warrants was initially recorded at fair value upon the issuance date of each warrant and
is subsequently remeasured to fair value as a component of other income (expense), net in the consolidated statement of operations
and comprehensive loss. Upon the closing of the Reverse Recapitalization (see Note 1), and as pursuant to the Merger Agreement,
all of the outstanding Clene Nanomedicine Preferred Stock was converted to the Company&amp;#x2019;s Common Stock and the Clene Nanomedicine
Preferred Stock warrants to purchase Clene Nanomedicine Preferred Stock were converted to warrants to purchase the Company&amp;#x2019;s
Common Stock (see Note 10). Upon conversion, the Company assessed the features of the warrants and determined that they qualify
for classification as permanent equity upon the closing of the Reverse Recapitalization. Accordingly, the Company remeasured the
warrants to fair value one final time upon the close of the Reverse Recapitalization, and recognized a loss of $14.6 million for
the year ended December 31, 2020, within other income, (expense), net on the consolidated statements of operations and comprehensive
loss. Upon the closing of the Reverse Recapitalization, the warrant liability was reclassified to additional paid-in capital (see
Notes 1 and 17).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;As
of December 31, 2020, the Company does not have any Preferred Stock warrants outstanding.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;As
of December 31, 2019,&amp;#xa0;the fair value of the outstanding warrants was $3.2 million with the changes in fair value recorded
as a component of other income (expense), net on the consolidated statements of operations and comprehensive&amp;#xa0;loss. As of
December 31, 2019, the Company had Preferred Stock warrants outstanding and exercisable as follows:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif;  width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Expiration&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; text-align: center; font-weight: bold; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Exercise&amp;#xa0;Price&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Warrant&lt;/font&gt;s&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Date&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Per&amp;#xa0;Share&lt;sup&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Outstanding&lt;sup&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; width: 66%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Series
    C preferred stock warrants&lt;sup&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 9%; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;April
    2023&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: right; width: 9%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1.9658&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: right; width: 9%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;271,439&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Series
    A preferred stock warrants&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;April 2023&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1.9658&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1,608,672&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;font: 10pt Times New Roman, Times, Serif; vertical-align: top&quot;&gt;
&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;(1)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
                                         exercise price per share and warrants outstanding, prior to the Reverse Recapitalization,
                                         have been retroactively restated as shares reflecting the Exchange Ratio established
                                         in the Reverse Recapitalization (See Note 1).&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;font: 10pt Times New Roman, Times, Serif; vertical-align: top&quot;&gt;
&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;(2)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;As
                                         of December 31, 2019, the most senior equity preferred stock warrants were convertible
                                         into Series C Preferred Stock.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;</us-gaap:PreferredStockTextBlock>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c97_AsOf8Apr2013_SeriesAPreferredStockMember">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantExercisePriceDecrease unitRef="usdPershares" contextRef="c98_From1Apr2013To8Apr2013_SeriesAPreferredStockMember" decimals="2">1.97</us-gaap:WarrantExercisePriceDecrease>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights unitRef="shares" contextRef="c99_AsOf31Dec2019_SeriesAPreferredStockMember" decimals="INF">1608672</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c100_AsOf8Apr2013_SeriesCPreferredStockMember">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" contextRef="c100_AsOf8Apr2013_SeriesCPreferredStockMember" decimals="4">0.0050</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights unitRef="shares" contextRef="c101_AsOf31Dec2019_SeriesCPreferredStockMember" decimals="INF">271439</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:WarrantExercisePriceDecrease unitRef="usdPershares" contextRef="c102_From1Jan2019To31Dec2019_SeriesCPreferredStockMember" decimals="2">1.97</us-gaap:WarrantExercisePriceDecrease>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights unitRef="shares" contextRef="c103_AsOf11Aug2020_SeriesDPreferredStockMember" decimals="INF">320441</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:WarrantExercisePriceDecrease unitRef="usdPershares" contextRef="c104_From4Aug2020To11Aug2020_SeriesDPreferredStockMember" decimals="2">1.97</us-gaap:WarrantExercisePriceDecrease>
  <us-gaap:LossRecognizedOnAssetsTransferredToSeparateAccountGross unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-5">14600000</us-gaap:LossRecognizedOnAssetsTransferredToSeparateAccountGross>
  <us-gaap:WarrantsAndRightsOutstanding unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-5">3200000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:ScheduleOfPreferredUnitsTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif;  width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Expiration&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; text-align: center; font-weight: bold; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Exercise&amp;#xa0;Price&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Warrant&lt;/font&gt;s&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Date&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Per&amp;#xa0;Share&lt;sup&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Outstanding&lt;sup&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; width: 66%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Series
    C preferred stock warrants&lt;sup&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 9%; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;April
    2023&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: right; width: 9%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1.9658&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: right; width: 9%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;271,439&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Series
    A preferred stock warrants&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;April 2023&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1.9658&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1,608,672&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfPreferredUnitsTextBlock>
  <clnn:ExpirationDate id="_ExpirationDate-c102_From1Jan2019To31Dec2019_SeriesCPreferredStockMember" contextRef="c102_From1Jan2019To31Dec2019_SeriesCPreferredStockMember">April 2023</clnn:ExpirationDate>
  <us-gaap:WarrantExercisePriceIncrease id="_WarrantExercisePriceIncrease-c102_From1Jan2019To31Dec2019_SeriesCPreferredStockMember_usdPershares" unitRef="usdPershares" contextRef="c102_From1Jan2019To31Dec2019_SeriesCPreferredStockMember" decimals="4">1.9658</us-gaap:WarrantExercisePriceIncrease>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="_ClassOfWarrantOrRightOutstanding-c101_AsOf31Dec2019_SeriesCPreferredStockMember_shares" unitRef="shares" contextRef="c101_AsOf31Dec2019_SeriesCPreferredStockMember" decimals="INF">271439</us-gaap:ClassOfWarrantOrRightOutstanding>
  <clnn:ExpirationDate contextRef="c105_From1Jan2019To31Dec2019_SeriesAPreferredStockMember">April 2023</clnn:ExpirationDate>
  <us-gaap:WarrantExercisePriceIncrease id="_WarrantExercisePriceIncrease-c105_From1Jan2019To31Dec2019_SeriesAPreferredStockMember_usdPershares" unitRef="usdPershares" contextRef="c105_From1Jan2019To31Dec2019_SeriesAPreferredStockMember" decimals="4">1.9658</us-gaap:WarrantExercisePriceIncrease>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="_ClassOfWarrantOrRightOutstanding-c99_AsOf31Dec2019_SeriesAPreferredStockMember_shares" unitRef="shares" contextRef="c99_AsOf31Dec2019_SeriesAPreferredStockMember" decimals="INF">1608672</us-gaap:ClassOfWarrantOrRightOutstanding>
  <clnn:CommonStockWarrantsDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;10.
Common Stock Warrants&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;As
of December 31, 2020, outstanding warrants to purchase shares of the Company&amp;#x2019;s Common Stock consisted of the following:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;border-bottom: black 1.5pt solid; padding-left: 9pt; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&lt;b&gt;Date Exercisable&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: black 1.5pt solid&quot;&gt;
        &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/p&gt;
        &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;Shares Issuable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: black 1.5pt solid; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: black 1.5pt solid; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&lt;b&gt;Exercisable for&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: black 1.5pt solid; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&lt;b&gt;Classification&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: black 1.5pt solid; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&lt;b&gt;Expiration&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;background-color: #CCEEFF&quot;&gt;
    &lt;td style=&quot;vertical-align: top; width: 28%; padding-left: 9pt; text-indent: -9pt&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;June 2021&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 12%; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;1,119,750&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 1%&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;$&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 12%; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;0.01&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 12%; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Common Stock&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 12%; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Equity&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 12%; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;December 2021&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td style=&quot;vertical-align: top; padding-left: 9pt; text-indent: -9pt&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;December 2020&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;2,407,500&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;$&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;11.50&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Common Stock&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Equity&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;December 2025&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;background-color: #CCEEFF&quot;&gt;
    &lt;td style=&quot;vertical-align: top; padding-left: 9pt; text-indent: -9pt&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;December 2020&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;110,000&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;$&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;11.50&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Common Stock&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Equity&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;December 2025&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td style=&quot;vertical-align: top; padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;December 2020&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; border-bottom: black 1.5pt solid&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;1,929,113&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;$&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;1.97&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Common Stock&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Equity&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;April 2023&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;background-color: #CCEEFF&quot;&gt;
    &lt;td style=&quot;vertical-align: top; padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Total&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 2pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; border-bottom: black 4.5pt double&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; border-bottom: black 4.5pt double; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;5,566,363&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 2pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 2pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 2pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 2pt; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 2pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 2pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 4pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 2pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 2pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 2pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 2pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 2pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 2pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;On December 28, 2020, the Company entered into a subscription agreement
(the &amp;#x201c;Subscription Agreement&amp;#x201d;) with various investors for the private purchase of 2,239,500 shares of the Company&amp;#x2019;s
Common Stock at a price of $10.00 per share with net proceeds of $22.2 million. Investors in the PIPE offering also received warrants
(&amp;#x201c;PIPE Warrants&amp;#x201d;) to purchase a number of shares equal to one-half (1/2) of the number of PIPE Shares, totaling 1,119,750
shares of the Company&amp;#x2019;s Common Stock, at an exercise price of $0.01 per share. Also, pursuant to the Subscription Agreement,
the 1,119,750 PIPE Warrants are subject to a 180-day holding period. A holder of the PIPE Warrants may not exercise the PIPE Warrant
if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of the Company&amp;#x2019;s
Common Stock outstanding immediately after giving effect to such exercise. As of December 31, 2020, none of the warrants had been
exercised.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In connection with
the Reverse Recapitalization, all of Tottenham&amp;#x2019;s issued and outstanding warrants to purchase one-half (1/2) of one share
of Tottenham&amp;#x2019;s ordinary shares totaling 4,815,000 shares issued in connection with Tottenham&amp;#x2019;s initial public offering,
were automatically converted into 2,407,500 warrants to purchase the Company&amp;#x2019;s Common Stock. The warrants became exercisable
upon the completion of the Reverse Recapitalization and will expire five years after the consummation of the Reverse Recapitalization
(i.e., December 2025). The Company may redeem those outstanding warrants, in whole and not in part, at a price of $0.01 per warrant
if, and only if, the last sales price of the Company&amp;#x2019;s Common Stock equals or exceeds $16.50 per share for any 20 trading
days within a 30-trading day period ending three business days before the Company sends the notice of redemption. As of December
31, 2020, none of the warrants had been exercised.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In connection with
Tottenham&amp;#x2019;s initial public offering in August 2018, Tottenham issued to Chardan options to purchase 220,000 units at $10.00
per unit. Each of Tottenham&amp;#x2019;s units consists of one and one-tenth shares of Tottenham&amp;#x2019;s ordinary shares for $10.00
per share and one warrant to purchase one-half of one Tottenham ordinary share at an exercise price of $11.50 per share. In connection
with the Reverse Recapitalization, the Chardan Unit Purchase Option was converted into one Company unit purchase option. The Chardan
Unit Purchase Option Warrants are exercisable upon the completion of the Reverse Recapitalization and will expire in December
2025. As of December 31, 2020, no Chardan Unit Purchase Options were exercised.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;In
connection with the Reverse Recapitalization, all of the 1,929,113 outstanding Series A and Series D Preferred Stock Warrants
were converted automatically into 1,929,113 warrants to purchase shares of the Company Common Stock at $1.97 per share (See Note
9).&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;</clnn:CommonStockWarrantsDisclosureTextBlock>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c64_AsOf28Dec2020" decimals="INF">2239500</us-gaap:SharesIssued>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c45_From1Dec2020To28Dec2020" decimals="-5">22200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees contextRef="c45_From1Dec2020To28Dec2020">Investors in the PIPE offering also received warrants (&amp;#x201c;PIPE Warrants&amp;#x201d;) to purchase a number of shares equal to one-half (1/2) of the number of PIPE Shares, totaling 1,119,750 shares of the Company&amp;#x2019;s Common Stock, at an exercise price of $0.01 per share. Also, pursuant to the Subscription Agreement, the 1,119,750 PIPE Warrants are subject to a 180-day holding period. A holder of the PIPE Warrants may not exercise the PIPE Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of the Company&amp;#x2019;s Common Stock outstanding immediately after giving effect to such exercise.</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c106_AsOf31Dec2020_TottenhamsMember" decimals="INF">4815000</us-gaap:SharesIssued>
  <us-gaap:ConversionOfStockSharesConverted1 unitRef="shares" contextRef="c107_From1Jan2020To31Dec2020_WarrantMember" decimals="INF">2407500</us-gaap:ConversionOfStockSharesConverted1>
  <clnn:ReverseRecapitalizationAndWillExpireYears contextRef="c107_From1Jan2020To31Dec2020_WarrantMember">P5Y</clnn:ReverseRecapitalizationAndWillExpireYears>
  <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees contextRef="c107_From1Jan2020To31Dec2020_WarrantMember">The Company may redeem those outstanding warrants, in whole and not in part, at a price of $0.01 per warrant if, and only if, the last sales price of the Company&amp;#x2019;s Common Stock equals or exceeds $16.50 per share for any 20 trading days within a 30-trading day period ending three business days before the Company sends the notice of redemption.</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
  <clnn:WarrantExercisePrice unitRef="usdPershares" contextRef="c108_AsOf31Dec2020_WarrantMember" decimals="2">0.01</clnn:WarrantExercisePrice>
  <us-gaap:PartnersCapitalAccountUnitsSoldInPublicOffering unitRef="shares" contextRef="c42_From1Aug2018To31Aug2018_ChardanMember" decimals="INF">220000</us-gaap:PartnersCapitalAccountUnitsSoldInPublicOffering>
  <us-gaap:SharesIssuedPricePerShare unitRef="usdPershares" contextRef="c43_AsOf31Aug2018_ChardanMember" decimals="2">10.00</us-gaap:SharesIssuedPricePerShare>
  <clnn:PreferredStockWarrantsOutstandingShares unitRef="shares" contextRef="c109_AsOf31Dec2020_SeriesAPreferredStockMember" decimals="INF">1929113</clnn:PreferredStockWarrantsOutstandingShares>
  <clnn:PreferredStockWarrantsOutstandingShares unitRef="shares" contextRef="c110_AsOf31Dec2020_SeriesDPreferredStockMember" decimals="INF">1929113</clnn:PreferredStockWarrantsOutstandingShares>
  <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1 unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">1929113</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 unitRef="usdPershares" contextRef="c3_AsOf31Dec2020" decimals="2">1.97</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;border-bottom: black 1.5pt solid; padding-left: 9pt; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&lt;b&gt;Date Exercisable&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: black 1.5pt solid&quot;&gt;
        &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/p&gt;
        &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;Shares Issuable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: black 1.5pt solid; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: black 1.5pt solid; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&lt;b&gt;Exercisable for&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: black 1.5pt solid; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&lt;b&gt;Classification&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: black 1.5pt solid; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&lt;b&gt;Expiration&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;background-color: #CCEEFF&quot;&gt;
    &lt;td style=&quot;vertical-align: top; width: 28%; padding-left: 9pt; text-indent: -9pt&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;June 2021&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 12%; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;1,119,750&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 1%&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;$&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 12%; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;0.01&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 12%; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Common Stock&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 12%; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Equity&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 12%; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;December 2021&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td style=&quot;vertical-align: top; padding-left: 9pt; text-indent: -9pt&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;December 2020&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;2,407,500&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;$&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;11.50&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Common Stock&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Equity&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;December 2025&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;background-color: #CCEEFF&quot;&gt;
    &lt;td style=&quot;vertical-align: top; padding-left: 9pt; text-indent: -9pt&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;December 2020&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;110,000&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;$&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;11.50&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Common Stock&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Equity&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;December 2025&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td style=&quot;vertical-align: top; padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;December 2020&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; border-bottom: black 1.5pt solid&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;1,929,113&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;$&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;1.97&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Common Stock&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Equity&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;April 2023&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;background-color: #CCEEFF&quot;&gt;
    &lt;td style=&quot;vertical-align: top; padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Total&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 2pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; border-bottom: black 4.5pt double&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; border-bottom: black 4.5pt double; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;5,566,363&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 2pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 2pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 2pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 2pt; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 2pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 2pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 4pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 2pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 2pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 2pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 2pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 2pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-bottom: 2pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <clnn:NumberOfSharesIssuable unitRef="shares" contextRef="c111_AsOf31Dec2020_WarrantsDateMember" decimals="INF">1119750</clnn:NumberOfSharesIssuable>
  <clnn:CommonStockWarrantsExercisePrice unitRef="usdPershares" contextRef="c111_AsOf31Dec2020_WarrantsDateMember" decimals="2">0.01</clnn:CommonStockWarrantsExercisePrice>
  <clnn:CommonStockWarrantsExercisable contextRef="c112_From1Jan2020To31Dec2020_WarrantsDateMember">Common Stock</clnn:CommonStockWarrantsExercisable>
  <clnn:CommonStockWarrantsClassification contextRef="c112_From1Jan2020To31Dec2020_WarrantsDateMember">Equity</clnn:CommonStockWarrantsClassification>
  <clnn:CommonStockWarrantsExpiration contextRef="c112_From1Jan2020To31Dec2020_WarrantsDateMember">December 2021</clnn:CommonStockWarrantsExpiration>
  <clnn:NumberOfSharesIssuable unitRef="shares" contextRef="c113_AsOf31Dec2020_WarrantsDate1Member" decimals="INF">2407500</clnn:NumberOfSharesIssuable>
  <clnn:CommonStockWarrantsExercisePrice unitRef="usdPershares" contextRef="c113_AsOf31Dec2020_WarrantsDate1Member" decimals="2">11.50</clnn:CommonStockWarrantsExercisePrice>
  <clnn:CommonStockWarrantsExercisable contextRef="c114_From1Jan2020To31Dec2020_WarrantsDate1Member">Common Stock</clnn:CommonStockWarrantsExercisable>
  <clnn:CommonStockWarrantsClassification contextRef="c114_From1Jan2020To31Dec2020_WarrantsDate1Member">Equity</clnn:CommonStockWarrantsClassification>
  <clnn:CommonStockWarrantsExpiration contextRef="c114_From1Jan2020To31Dec2020_WarrantsDate1Member">December 2025</clnn:CommonStockWarrantsExpiration>
  <clnn:NumberOfSharesIssuable unitRef="shares" contextRef="c115_AsOf31Dec2020_December20201Member" decimals="INF">110000</clnn:NumberOfSharesIssuable>
  <clnn:CommonStockWarrantsExercisePrice unitRef="usdPershares" contextRef="c115_AsOf31Dec2020_December20201Member" decimals="2">11.50</clnn:CommonStockWarrantsExercisePrice>
  <clnn:CommonStockWarrantsExercisable contextRef="c116_From1Jan2020To31Dec2020_December20201Member">Common Stock</clnn:CommonStockWarrantsExercisable>
  <clnn:CommonStockWarrantsClassification contextRef="c116_From1Jan2020To31Dec2020_December20201Member">Equity</clnn:CommonStockWarrantsClassification>
  <clnn:CommonStockWarrantsExpiration contextRef="c116_From1Jan2020To31Dec2020_December20201Member">December 2025</clnn:CommonStockWarrantsExpiration>
  <clnn:NumberOfSharesIssuable unitRef="shares" contextRef="c117_AsOf31Dec2020_WarrantsDate2Member" decimals="INF">1929113</clnn:NumberOfSharesIssuable>
  <clnn:CommonStockWarrantsExercisePrice unitRef="usdPershares" contextRef="c117_AsOf31Dec2020_WarrantsDate2Member" decimals="2">1.97</clnn:CommonStockWarrantsExercisePrice>
  <clnn:CommonStockWarrantsExercisable contextRef="c118_From1Jan2020To31Dec2020_WarrantsDate2Member">Common Stock</clnn:CommonStockWarrantsExercisable>
  <clnn:CommonStockWarrantsClassification contextRef="c118_From1Jan2020To31Dec2020_WarrantsDate2Member">Equity</clnn:CommonStockWarrantsClassification>
  <clnn:CommonStockWarrantsExpiration contextRef="c118_From1Jan2020To31Dec2020_WarrantsDate2Member">April 2023</clnn:CommonStockWarrantsExpiration>
  <clnn:NumberOfSharesIssuable unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">5566363</clnn:NumberOfSharesIssuable>
  <clnn:ConvertibleNotesDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;11.
Convertible Notes&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;In
February through July 2020, the Company issued convertible promissory notes (the &amp;#x201c;2020 Convertible Notes&amp;#x201d;) in an aggregate
principal amount of $6.1 million, bearing interest at an annual rate of 5%. The 2020 Convertible Notes were convertible at the
earlier of (i)&amp;#xa0;one year, at which point the notes would be convertible into Series C preferred shares at the Series C preferred
share issuance price, and (ii)&amp;#xa0;next equity financing of no less than $10.0 million, at which point the notes would be convertible
into shares issued in the next equity financing at 90% of the per share issuance price of the next equity financing. The 2020
Convertible Notes contained redemption features that met the requirements for separate accounting and were accounted for as a
single derivative instrument. Accordingly, the 2020 derivative instrument of $0.7 million was recorded at fair value at inception
as redeemable convertible preferred stock derivative liability in the consolidated balance sheets (see Note 12).&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company recognized interest expense of $0.2 million, including amortization of debt discount of $0.2 million during the year ended
December 31, 2020, in connection with the 2020 Convertible Notes.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;On
August 11, 2020, in connection with the Company&amp;#x2019;s issuance and sale of Series D Preferred Stock, all of the outstanding
principal and accrued interest under the 2020 Convertible Notes, totaling $6.9 million, was automatically converted into 1,497,135
shares of Series D Preferred Stock at a price equal to 90% of $4.60 per share, the per share price paid in cash by investors in
the Series D preferred stock financing.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company accounted for the conversion of the 2020 Convertible Notes as a debt extinguishment and recognized a loss on extinguishment
of debt of $0.5 million within other income (expense), net in the consolidated statement of operations and comprehensive loss.
As of the date of conversion, the unamortized discount on the 2020 Convertible Notes was $0.5 million. The loss on extinguishment
was calculated as the difference between (i) the fair value of the 1,497,135 shares of Series D Preferred Stock issued to settle
the 2020 Convertible Notes of $6.9 million and (ii) the carrying value of the 2020 Convertible Notes, including the principal
balance of the 2020 Convertible Notes of $6.1 million and accrued but unpaid interest of $76 thousand, net of the unamortized
debt discount of $5.7 million, plus the then-current fair value of derivative liability associated with the 2020 Convertible Notes
at the time of the extinguishment of $0.7 million.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;</clnn:ConvertibleNotesDisclosureTextBlock>
  <us-gaap:ConvertibleNotesPayable unitRef="usd" contextRef="c119_AsOf31Jul2020_ConvertibleNotesPayableMember" decimals="-5">6100000</us-gaap:ConvertibleNotesPayable>
  <us-gaap:DebtInstrumentInterestRateDuringPeriod unitRef="pure" contextRef="c120_From1Feb2020To31Jul2020_ConvertibleNotesPayableMember" decimals="2">0.05</us-gaap:DebtInstrumentInterestRateDuringPeriod>
  <clnn:DescriptionOfConvertibleNotes contextRef="c120_From1Feb2020To31Jul2020_ConvertibleNotesPayableMember">The 2020 Convertible Notes were convertible at the earlier of (i) one year, at which point the notes would be convertible into Series C preferred shares at the Series C preferred share issuance price, and (ii) next equity financing of no less than $10.0 million, at which point the notes would be convertible into shares issued in the next equity financing at 90% of the per share issuance price of the next equity financing. The 2020 Convertible Notes contained redemption features that met the requirements for separate accounting and were accounted for as a single derivative instrument. Accordingly, the 2020 derivative instrument of $0.7 million was recorded at fair value at inception as redeemable convertible preferred stock derivative liability in the consolidated balance sheets (see Note 12).</clnn:DescriptionOfConvertibleNotes>
  <us-gaap:InterestExpense unitRef="usd" contextRef="c121_From1Jan2020To31Dec2020_ConvertibleNotesPayableMember" decimals="-5">200000</us-gaap:InterestExpense>
  <us-gaap:AmortizationOfDebtDiscountPremium unitRef="usd" contextRef="c121_From1Jan2020To31Dec2020_ConvertibleNotesPayableMember" decimals="-5">200000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities unitRef="usd" contextRef="c122_From1Aug2020To11Aug2020_ConvertibleNotesPayableMember_SeriesDPreferredStockMember" decimals="-5">6900000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities unitRef="shares" contextRef="c122_From1Aug2020To11Aug2020_ConvertibleNotesPayableMember_SeriesDPreferredStockMember" decimals="INF">1497135</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <clnn:PercentageOfStock unitRef="pure" contextRef="c122_From1Aug2020To11Aug2020_ConvertibleNotesPayableMember_SeriesDPreferredStockMember" decimals="2">0.90</clnn:PercentageOfStock>
  <clnn:PreferredStockConvertibleConversionPrice unitRef="usdPershares" contextRef="c122_From1Aug2020To11Aug2020_ConvertibleNotesPayableMember_SeriesDPreferredStockMember" decimals="2">4.60</clnn:PreferredStockConvertibleConversionPrice>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt unitRef="usd" contextRef="c121_From1Jan2020To31Dec2020_ConvertibleNotesPayableMember" decimals="-5">500000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:DebtInstrumentUnamortizedDiscount unitRef="usd" contextRef="c123_AsOf31Dec2020_ConvertibleNotesPayableMember" decimals="-5">500000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <clnn:DescriptionOfConvertibleNotes contextRef="c121_From1Jan2020To31Dec2020_ConvertibleNotesPayableMember">The loss on extinguishment was calculated as the difference between (i) the fair value of the 1,497,135 shares of Series D Preferred Stock issued to settle the 2020 Convertible Notes of $6.9 million and (ii) the carrying value of the 2020 Convertible Notes, including the principal balance of the 2020 Convertible Notes of $6.1 million and accrued but unpaid interest of $76 thousand, net of the unamortized debt discount of $5.7 million, plus the then-current fair value of derivative liability associated with the 2020 Convertible Notes at the time of the extinguishment of $0.7 million.</clnn:DescriptionOfConvertibleNotes>
  <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;12.
Derivative Instruments&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;i&gt;Derivative
instrument in connection with the 2020 Convertible Notes&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;One of the redemption
features of the 2020 Convertible Notes met the requirements for separate accounting and was accounted for as a derivative instrument.
The 2020 Derivative Instrument was recorded at fair value, which was $0.7 million at issuance. In August 2020, in connection with
the Company&amp;#x2019;s issuance and sale of Series D Preferred Stock, all of the outstanding principal and accrued interest under
the 2020 Convertible Notes was automatically converted into shares of Series D Preferred Stock and the derivative liability was
extinguished. Prior to the extinguishment of derivative liability, the 2020 Derivative Instrument was marked at fair value and
the Company recorded the change in the 2020 Derivative Instrument of ($29) thousand in the consolidated statements of operations
and comprehensive loss (see Note 11).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;i&gt;Derivative instrument in connection
with the Contingent Earn-out&lt;/i&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Earn-out Shares
issued in connection with the Reverse Recapitalization met the requirements for separate accounting and is therefore accounted
for as a derivative instrument. Accordingly, upon the consummation of the Reverse Recapitalization, the Company recorded a liability
in the consolidated balance sheets and a debit to additional paid-in capital for the earn-out provision associated with the Initial
Shareholders Contingent Earn-out and a debit to accumulated deficit for the earn-out provisions associated with the Clene Nanomedicine
Contingent Earn-out. The contingent shares to be issued to the Clene Nanomedicine shareholders immediately prior to the Reverse
Capitalization were treated as a deemed distribution. The contingent earn-out was subsequently remeasured to fair value at each
reporting date as a component of other income (expense), net in the Company&amp;#x2019;s consolidated statements of operations and comprehensive
loss.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Upon
the closing of the Reverse Recapitalization, the Company recognized the contingent earn-out liability at its fair value of $72.1
million in the consolidated balance sheets. As of December 31, 2020, the carrying value of the contingent earn-out was $58.0 million.
During the year ended of December 31, 2020, the Company recognized a gain of $14.1 million in change in fair value of contingent
earn-out as a component of other income (expense), net in the Company&amp;#x2019;s consolidated statements of operations and comprehensive
loss. To date, none of the milestones has been achieved.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
  <us-gaap:DerivativeFairValueOfDerivativeNet unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-5">700000</us-gaap:DerivativeFairValueOfDerivativeNet>
  <clnn:DerivativeInstrumentsOfComprehensiveLoss unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-29000</clnn:DerivativeInstrumentsOfComprehensiveLoss>
  <us-gaap:GuarantyLiabilities unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-5">72100000</us-gaap:GuarantyLiabilities>
  <us-gaap:ReportingUnitAmountOfFairValueInExcessOfCarryingAmount unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-5">58000000</us-gaap:ReportingUnitAmountOfFairValueInExcessOfCarryingAmount>
  <us-gaap:DerivativeGainLossOnDerivativeNet unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-5">14100000</us-gaap:DerivativeGainLossOnDerivativeNet>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;13.
Commitments and Contingencies&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;Litigation&lt;/b&gt;&amp;#xa0;&amp;#x2014;
From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business activities.
The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures
can be reasonably estimated. The Company is not aware of any current pending legal matters or claims.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;14.
Income Taxes&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company has not recorded income tax benefits for the net operating losses incurred during the years ended December 31, 2020 and
2019 nor for research and development tax credits and other deferred tax assets generated, due to its uncertainty of realizing
a benefit from those items.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The components of income
(loss) before income taxes for the years ended December 31, 2020 and 2019 were as follows (in thousands):&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt&quot;&gt;United&amp;#xa0;States&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;(18,985&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;(13,812&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt&quot;&gt;Foreign&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;114&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(2,343&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt&quot;&gt;Loss before provision for income taxes&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;(18,871&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;(16,155&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Income tax expense
(benefit) for the years ended December 31, 2020 and 2019 were as follows (in thousands):&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;Provision for income taxes:&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;Current tax expense:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; padding-left: 9pt&quot;&gt;Federal&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 9pt&quot;&gt;State&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; padding-left: 9pt&quot;&gt;Foreign&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;146&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in&quot;&gt;Total current tax expense (benefit)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;146&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Deferred tax expense:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 9pt&quot;&gt;Federal&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 9pt&quot;&gt;State&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; padding-left: 9pt&quot;&gt;Foreign&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;260&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in&quot;&gt;Total deferred tax expense (benefit)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;260&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;Total income tax expense (benefit)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;406&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;A reconciliation of
the income tax computed at the U.S. federal statutory rate of 21% to the expense for income taxes for the years ended December
31, 2020 and 2019 is as follows (in thousands):&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;Income tax expense (benefit) at federal statutory rate&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;(3,963&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;(3,393&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 9pt&quot;&gt;State income taxes (net of federal benefit)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(917&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(721&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 9pt&quot;&gt;Warrant liability&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3,069&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 9pt&quot;&gt;Contingent consideration&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(2,966&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 9pt&quot;&gt;Research and development credits&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(425&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;326&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 9pt&quot;&gt;Other&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;242&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,205&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 9pt&quot;&gt;Change in valuation allowance&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;5,366&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2,583&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;Income tax expense (benefit)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;406&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Company&amp;#x2019;s
effective tax rate was (2.15)% and 0.00% for the years ended December 31, 2020 and 2019, respectively. Significant components of
the Company&amp;#x2019;s deferred tax assets (liabilities) as of December 31, 2020 and 2019 were as follows (in thousands):&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Deferred tax assets (liabilities):&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; padding-left: 9pt&quot;&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;17,958&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;13,502&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 9pt&quot;&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,810&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,814&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 9pt&quot;&gt;Research &amp;amp; development credits&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,682&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;882&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 9pt&quot;&gt;Lease liability&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;520&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;436&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 9pt&quot;&gt;Right-of-use asset&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(270&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(48&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 9pt&quot;&gt;Accrued interest&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;160&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 9pt&quot;&gt;Non-qualified stock options&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;146&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;130&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 9pt&quot;&gt;Accrued compensation&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;115&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;62&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; padding-left: 9pt&quot;&gt;Other&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(260&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(23&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in&quot;&gt;Total&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;21,861&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;16,755&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 9pt&quot;&gt;Less: valuation allowance&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(22,121&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(16,755&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;Net deferred tax assets (liabilities)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;(260&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In
assessing the realizability of deferred tax assets, management considers whether it is more-likely-than-not that some portion
or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the
generation of future taxable income during periods in which those temporary differences become deductible. Management considers
the scheduled reversal of deferred tax liabilities, projected future taxable income, carry back opportunities and tax planning
strategies in making the assessment. The Company believes it is more likely than not it will not realize the benefits of these
deductible differences and has applied a full valuation allowance against them. As the Company has no deferred tax assets in Australia,
it has recognized a deferred tax liability and expense for $0.3 million for temporary differences that will reverse in future
periods.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The
Company has federal and state net operating losses (NOLs) of approximately $72.2 million and $59.8 million as of December 31,
2020, respectively that, subject to limitation, may be available in future tax years to offset taxable income. Of the available
federal NOLs, approximately $38.8 million can be carried forward indefinitely but utilization is limited to 80% of the Company&apos;s
taxable income in any given tax year based on current federal tax laws. The remaining balance of $33.4 million will begin to expire
after 2034. Of the available state NOLs, approximately $39.4 million can be carried forward indefinitely but utilization is limited
to 80% of the Company&apos;s taxable income in any given tax year based on current tax laws. The remaining balance of $20.4 million
will begin to expire after 2032. Additionally, the Company has approximately $1.7 million of research and development (R&amp;amp;D)
credit carryforwards that will begin to expire after 2034 if not utilized.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Under the provisions
of &amp;#xa7;382 of the Internal Revenue Code, substantial changes in the Company&apos;s ownership may result in limitations on the amount
of NOL carryforwards and R&amp;amp;D credits that can be utilized in future years. NOL carryforwards and R&amp;amp;D credits are subject
to examination in the year they are utilized regardless of whether the tax year in which they are generated has been closed by
statute. The amount subject to disallowance is limited to the amount utilized. Accordingly, the Company may be subject to examination
for prior NOLs and credits generated as such tax attributes are utilized.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Company has not
recorded any amounts for unrecognized tax benefits as of December 31, 2020 and 2019. The Company&amp;#x2019;s practice is to recognize
interest and penalties related to income tax matters in income tax expense. The Company had no accrual of interest and penalties
on the Company&amp;#x2019;s balance sheets and has not recognized interest and penalties in the consolidated statements of operations
and comprehensive loss for the years ended December 31, 2020 and 2019.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Company is subject to taxation in the United States and
Australia. The Company&amp;#x2019;s tax returns from 2014 to present are subject to examination by the United States and state authorities
due to the carry forward of unutilized net operating losses and R&amp;amp;D credits. There are currently no pending examinations.&lt;/p&gt;&lt;br/&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate unitRef="pure" contextRef="c9_From1Jan2019To31Dec2019" decimals="2">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="4">-0.0215</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes unitRef="pure" contextRef="c9_From1Jan2019To31Dec2019" decimals="4">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:DeferredTaxLiabilitiesDeferredExpense unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-5">300000</us-gaap:DeferredTaxLiabilitiesDeferredExpense>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c124_From1Jan2020To31Dec2020_DomesticCountryMember" decimals="-5">-72200000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c125_From1Jan2020To31Dec2020_StateAndLocalJurisdictionMember" decimals="-5">-59800000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingLossCarryforwards unitRef="usd" contextRef="c126_AsOf31Dec2020_DomesticCountryMember" decimals="-5">38800000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance unitRef="pure" contextRef="c124_From1Jan2020To31Dec2020_DomesticCountryMember" decimals="2">0.80</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <clnn:OperatingLossExpireTerm contextRef="c124_From1Jan2020To31Dec2020_DomesticCountryMember">The remaining balance of $33.4 million will begin to expire after 2034.</clnn:OperatingLossExpireTerm>
  <clnn:RemainingBalanceOfOperatingLoss unitRef="usd" contextRef="c124_From1Jan2020To31Dec2020_DomesticCountryMember" decimals="-5">33400000</clnn:RemainingBalanceOfOperatingLoss>
  <us-gaap:OperatingLossCarryforwards unitRef="usd" contextRef="c127_AsOf31Dec2020_StateAndLocalJurisdictionMember" decimals="-5">39400000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance unitRef="pure" contextRef="c125_From1Jan2020To31Dec2020_StateAndLocalJurisdictionMember" decimals="2">0.80</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <clnn:RemainingBalanceOfOperatingLoss unitRef="usd" contextRef="c125_From1Jan2020To31Dec2020_StateAndLocalJurisdictionMember" decimals="-5">20400000</clnn:RemainingBalanceOfOperatingLoss>
  <clnn:ResearchAndDevelopmentCreditExpiryTerm contextRef="c0_From1Jan2020To31Dec2020">Additionally, the Company has approximately $1.7 million of research and development (R&amp;amp;D) credit carryforwards that will begin to expire after 2034 if not utilized.</clnn:ResearchAndDevelopmentCreditExpiryTerm>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch unitRef="usd" contextRef="c126_AsOf31Dec2020_DomesticCountryMember" decimals="-5">1700000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt&quot;&gt;United&amp;#xa0;States&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;(18,985&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;(13,812&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt&quot;&gt;Foreign&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;114&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(2,343&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt&quot;&gt;Loss before provision for income taxes&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;(18,871&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;(16,155&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-18985000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">-13812000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">114000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">-2343000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
  <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;Provision for income taxes:&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;Current tax expense:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; padding-left: 9pt&quot;&gt;Federal&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 9pt&quot;&gt;State&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; padding-left: 9pt&quot;&gt;Foreign&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;146&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in&quot;&gt;Total current tax expense (benefit)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;146&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Deferred tax expense:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 9pt&quot;&gt;Federal&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 9pt&quot;&gt;State&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; padding-left: 9pt&quot;&gt;Foreign&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;260&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in&quot;&gt;Total deferred tax expense (benefit)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;260&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;Total income tax expense (benefit)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;406&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
  <us-gaap:CurrentFederalTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:CurrentFederalTaxExpenseBenefit unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:CurrentForeignTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">146000</us-gaap:CurrentForeignTaxExpenseBenefit>
  <us-gaap:CurrentForeignTaxExpenseBenefit unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:CurrentIncomeTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">146000</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:CurrentIncomeTaxExpenseBenefit unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:DeferredForeignIncomeTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">260000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
  <us-gaap:DeferredForeignIncomeTaxExpenseBenefit unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:DeferredIncomeTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">260000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxExpenseBenefit unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;Income tax expense (benefit) at federal statutory rate&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;(3,963&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;(3,393&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 9pt&quot;&gt;State income taxes (net of federal benefit)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(917&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(721&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 9pt&quot;&gt;Warrant liability&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3,069&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 9pt&quot;&gt;Contingent consideration&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(2,966&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 9pt&quot;&gt;Research and development credits&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(425&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;326&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 9pt&quot;&gt;Other&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;242&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,205&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 9pt&quot;&gt;Change in valuation allowance&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;5,366&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2,583&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;Income tax expense (benefit)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;406&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-3963000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">-3393000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-917000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">-721000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <clnn:IncomeTaxReconciliationWarrantLiability unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">3069000</clnn:IncomeTaxReconciliationWarrantLiability>
  <clnn:IncomeTaxReconciliationWarrantLiability unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:IncomeTaxReconciliationTaxContingencies unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-2966000</us-gaap:IncomeTaxReconciliationTaxContingencies>
  <us-gaap:IncomeTaxReconciliationTaxContingencies unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <clnn:IncomeTaxReconciliationNondeductibleExpensesResearchAndDevelopment unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-425000</clnn:IncomeTaxReconciliationNondeductibleExpensesResearchAndDevelopment>
  <clnn:IncomeTaxReconciliationNondeductibleExpensesResearchAndDevelopment unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">326000</clnn:IncomeTaxReconciliationNondeductibleExpensesResearchAndDevelopment>
  <us-gaap:IncomeTaxReconciliationOtherReconcilingItems unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">242000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
  <us-gaap:IncomeTaxReconciliationOtherReconcilingItems unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">1205000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">5366000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">2583000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Deferred tax assets (liabilities):&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; padding-left: 9pt&quot;&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;17,958&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;13,502&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 9pt&quot;&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,810&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,814&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 9pt&quot;&gt;Research &amp;amp; development credits&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,682&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;882&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 9pt&quot;&gt;Lease liability&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;520&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;436&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 9pt&quot;&gt;Right-of-use asset&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(270&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(48&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 9pt&quot;&gt;Accrued interest&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;160&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 9pt&quot;&gt;Non-qualified stock options&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;146&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;130&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 9pt&quot;&gt;Accrued compensation&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;115&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;62&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; padding-left: 9pt&quot;&gt;Other&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(260&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(23&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in&quot;&gt;Total&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;21,861&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;16,755&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 9pt&quot;&gt;Less: valuation allowance&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(22,121&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(16,755&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;Net deferred tax assets (liabilities)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;(260&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">17958000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">13502000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <clnn:DeferredTaxLiabilitiesDeferredExpenseDepreciation unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">1810000</clnn:DeferredTaxLiabilitiesDeferredExpenseDepreciation>
  <clnn:DeferredTaxLiabilitiesDeferredExpenseDepreciation unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">1814000</clnn:DeferredTaxLiabilitiesDeferredExpenseDepreciation>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">1682000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">882000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <clnn:DeferredTaxLiabilitiesLeaseLiability unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">520000</clnn:DeferredTaxLiabilitiesLeaseLiability>
  <clnn:DeferredTaxLiabilitiesLeaseLiability unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">436000</clnn:DeferredTaxLiabilitiesLeaseLiability>
  <clnn:DeferredTaxAssetsRightofUseAsset unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">270000</clnn:DeferredTaxAssetsRightofUseAsset>
  <clnn:DeferredTaxAssetsRightofUseAsset unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">48000</clnn:DeferredTaxAssetsRightofUseAsset>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">160000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <clnn:DeferredTaxAssetsTaxDeferredNonqualifiedStockOptions unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">146000</clnn:DeferredTaxAssetsTaxDeferredNonqualifiedStockOptions>
  <clnn:DeferredTaxAssetsTaxDeferredNonqualifiedStockOptions unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">130000</clnn:DeferredTaxAssetsTaxDeferredNonqualifiedStockOptions>
  <clnn:DeferredTaxAssetsTaxDeferredAccruedCompensation unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">115000</clnn:DeferredTaxAssetsTaxDeferredAccruedCompensation>
  <clnn:DeferredTaxAssetsTaxDeferredAccruedCompensation unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">62000</clnn:DeferredTaxAssetsTaxDeferredAccruedCompensation>
  <us-gaap:DeferredTaxAssetsOther unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">-260000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsOther unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">-23000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsGross unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">21861000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">16755000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsValuationAllowance unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">22121000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">16755000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsNet unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">260000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsNet unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;15.
Stock-Based Compensation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;i&gt;2020
Stock Plan&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In December 2020, in connection with the Reverse Recapitalization,
the Company&amp;#x2019;s board of directors approved the 2020 Stock Plan (the &amp;#x201c;2020 Stock Plan&amp;#x201d;) and reserved 12,000,000
shares of Common Stock for issuance thereunder, all of which may be issued pursuant to incentive stock options or any other type
of award under the 2020 Stock Plan. The 2020 Stock Plan became effective immediately upon the closing of the Reverse Recapitalization.
The maximum number of shares of Common Stock that may be issued pursuant to the exercise of incentive stock options under the 2020
Stock Plan is 12,000,000. The Company&amp;#x2019;s selected employees, officers, directors and consultants are eligible to participate
in the traditional stock option grants, stock appreciation rights, restricted stock awards, restricted stock unit awards, other
stock awards, and performance awards under the 2020 Stock Plan. The purpose of this 2020 Stock Plan is to enable the Company to
offer competitive equity compensation packages in order to attract and retain the talent necessary for the Combined Company.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The 2020 Stock Plan is administered by the Company&amp;#x2019;s Board
of Directors. The exercise prices, vesting periods and other restrictions are determined at the discretion of the Company&amp;#x2019;s
Board of Directors, except that the exercise price per share of options may not be less than 100% of the fair market value of the
Common Stock on the date of grant. Stock options awarded under the 2020 Stock Plan expire ten years after the grant date, unless
the Company&amp;#x2019;s Board of Directors sets a shorter term. Stock options and restricted stock granted to employees, officers,
members of the Company&amp;#x2019;s Board of Directors and consultants generally vest over a four-year period. If an option or other
award granted under the 2020 Stock Plan expires, terminates or is cancelled, the unissued shares subject to that option or award
shall again be available under the 2020 Stock Plan. If shares awarded pursuant to the 2020 Stock Plan are forfeited to or repurchased
at original cost by the Company, the number of shares forfeited or repurchased at original cost shall again be available under
the 2020 Stock Plan.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;On December 30, 2020, the Company granted 1,507,062 restricted
stock units under the 2020 Stock Plan. As of December 31, 2020, 10,492,938 shares remained available for future grant.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;i&gt;2014
Stock Plan&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Following
the closing of the Reverse Recapitalization, the 2014 Stock Plan is administered by the Company&amp;#x2019;s Board of Directors. Stock
options awarded under the 2014 Stock Plan expire ten years after the grant date. Stock options and restricted stock granted to
employees, officers, members of the Company&amp;#x2019;s Board of Directors and consultants typically vest over a four-year period.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;As a result of
                                                                                                                                                                                                     the Reverse Recapitalization (as described in Note 1), stock options outstanding under the 2014 Stock Plan of 53,286,115 were
                                                                                                                                                                                                     converted into 7,032,590 of stock options of the Company based on the Exchange Ratio determined in accordance with the terms
                                                                                                                                                                                                     of the Merger Agreement. The exchange of Clene Nanomedicine&amp;#x2019;s stock options for Clene Inc. stock options was treated as
                                                                                                                                                                                                     a modification of the awards. The modification of the stock options did not result in a material incremental compensation
                                                                                                                                                                                                     expense to be recognized at the closing of the Reverse Recapitalization.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;During the year ended
December 31, 2020, the Company granted stock options for 270,555 shares under the 2014 Stock Plan.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;As of December 31,
2019, there were 6,720,065 common shares authorized for grant to employees, officers, directors, and consultants under the 2014
Stock Plan. Effective as of the closing of the Reverse Recapitalization on December 30, 2020, no additional awards may be made
under the 2014 Stock Plan and as a result, (i) any shares in respect of stock options that are expired or terminated under the
2014 Stock Plan without having been fully exercised will not be available for future awards; (ii) any shares in respect of restricted
stock that are forfeited to, or otherwise repurchased by the Company, will not be available for future awards; and (iii) any shares
of Common Stock that are tendered to the Company by a participant to exercise an award will not be available for future awards.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;During the year ended
December 31, 2019, the Company granted stock options for 1,440,717 shares under the 2014 Stock Plan. There were 388,283 shares
available for grant under the 2014 Stock Plan as of December 31, 2019.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Stock-based
compensation for the years ended December 31, 2020 and 2019 was approximately $0.8 million and $0.4 million, respectively, and
is recorded in research and development and general and administrative expenses in the consolidated statement of operations and
comprehensive loss as follows:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif;  width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(In
    thousands)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;General
    and administrative&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;281&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;161&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Research
    and development&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;480&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;238&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Total
    stock-based compensation&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;761&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;399&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;As
of December 31, 2020, the Company had approximately $2.4 million of unrecognized stock-based compensation costs related to non-vested
awards which is expected to be recognized over a weighted-average period of 2.04 years.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The following sets
forth the outstanding Common Stock options and related activity for the year ended December 31, 2020 (in thousands, except share
and per share data):&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-weight: bold; border-bottom: Black 1.5pt solid&quot;&gt;Equity&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Number&amp;#xa0;of&lt;br/&gt; Options&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price &lt;br/&gt; Per Share&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Term &lt;br/&gt; (Years)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Instrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 52%; text-indent: -9pt; padding-left: 9pt&quot;&gt;Outstanding - December 31, 2018&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;5,698,090&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;0.38&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;6.62&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;11,089&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: -9pt; padding-left: 0.25in&quot;&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,440,717&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.42&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.66&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: -9pt; padding-left: 0.25in&quot;&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(11,878&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;0.83&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;31&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in&quot;&gt;Forfeited&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(248,757&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;1.44&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: -9pt; padding-left: 9pt&quot;&gt;Outstanding - December 31, 2019&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6,878,172&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;0.83&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.36&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;18,105&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: -9pt; padding-left: 0.25in&quot;&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;270,555&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.48&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.32&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: -9pt; padding-left: 0.25in&quot;&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(83,232&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;0.94&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;740&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in&quot;&gt;Forfeited&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(32,904&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;1.65&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt&quot;&gt;Outstanding - December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;7,032,591&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;0.97&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;5.34&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;62,462&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt&quot;&gt;Options vested and exercisable - December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;5,896,034&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;0.55&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;4.86&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;52,694&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 9pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt&quot;&gt;Options vested and exercisable - Stock options vested and expected to vest December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;7,032,591&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;0.97&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;5.34&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;62,462&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Prior to the consummation
of the Reverse Recapitalization, the exercise price of the stock options granted was based on the fair market value of the common
shares of the Company as of the grant date as determined by the Board of Directors, with input from the Company&amp;#x2019;s management.
The Board of Directors determined the fair value of the common stock at the time of grant of the options by considering a number
of objective and subjective factors, including third-party valuation reports, valuations of comparable companies, sales of redeemable
convertible Preferred Stock, sales of common stock to unrelated third parties, operating and financial performance, the lack of
liquidity of the Company&amp;#x2019;s capital stock, and general and industry-specific economic outlook.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Stock
options are valued using the Black-Scholes option pricing model. Since the Company has limited trading history of its common stock,
the expected volatility is derived from the average historical stock volatilities of several unrelated public companies within
the Company&amp;#x2019;s industry that the Company considers to be comparable to its own business over a period equivalent to the expected
term of the stock option grants. The risk-free interest rate for periods within the contractual life of the stock options is based
on the U.S. Treasury yield curve in effect at the time of the grant. The expected dividend is assumed to be zero as the Company
has never paid dividends and has no current plans to do so. The expected term represents the period that stock-based awards are
expected to be outstanding. For option grants that are considered to be &amp;#x201c;plain vanilla,&amp;#x201d; the Company determines the
expected term using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the
contractual life of the options. For other option grants, the Company estimates the expected term using historical data on employee
exercises and post-vesting employment termination behavior taking into account the contractual life of the award.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
assumptions used to calculate the value of the stock option awards granted in 2020 and 2019 are presented as follows:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.25in; padding-left: 0.25in; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.25in; padding-left: 0.25in; width: 72%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Expected
    stock price volatility&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 12%; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;75.00%
- 119.30%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 12%; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;75.00%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.25in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Risk-free
    interest rate&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;0.39%
                                         - 0.53%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1.46%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.25in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Expected
    dividend yield&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;0%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;0%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.25in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Expected
    term of options&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;6
years&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;6
                                         years&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
weighted average grant-date fair value of options granted during the years ended December 31, 2020 and 2019 was $2.3923 and $1.5806,
respectively.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;i&gt;Restricted Stock Units&lt;/i&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;On December 30, 2020,
the Company granted the following shares of restricted common stock under the 2020 Stock Plan:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 48px&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 24px; font-size: 10pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify; font-size: 10pt&quot;&gt;&lt;p style=&quot;margin: 0pt 0; font: 10pt Times New Roman, Times, Serif&quot;&gt;370,101 shares to various employees and non-employee directors,
which vest on June 30, 2021, subject to the employee&amp;#x2019;s continuous employment through such vesting date. The award represents
5% of the converted stock options under 2014 Stock Plan as a result of the Reverse Recapitalization and complements the 5% closing
payment shares held in escrow for Clene Nanomedicine common shareholders (as described in Note 1). The grant-date fair value of
these awards was $4.0 million.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 48px&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 24px; font-size: 10pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify; font-size: 10pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;454,781 shares to various employees and non-employee directors, which were eligible to vest based on certain market conditions, subject to the employee&amp;#x2019;s continuous employment through such vesting date. The award complements the Milestone 1 earn-out share entitlement of Clene Nanomedicine shareholders and vests based on the same market condition (as described in Note 3). The grant-date fair value of these awards, using a Monte Carlo simulation, was $4.3 million. Based on the outcome of the market condition as of the December 31, 2020 measurement date, no shares were vested.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 48px&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 24px; font-size: 10pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify; font-size: 10pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;341,090 shares to various employees and non-employee directors, which were eligible to vest based on certain market conditions, subject to the employee&amp;#x2019;s continuous employment through such vesting date. The award complements the Milestone 2 earn-out share entitlement of Clene Nanomedicine. shareholders and vests based on the same market condition (as described in Note 3). The grant-date fair value of these awards, using a Monte Carlo simulation, was $3.5 million. Based on the outcome of the market condition as of the December 31, 2020 measurement date, no shares were vested.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 48px&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 24px; font-size: 10pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify; font-size: 10pt&quot;&gt;&lt;p style=&quot;margin: 0pt 0; font: 10pt Times New Roman, Times, Serif&quot;&gt;341,090 shares to various employees and non-employee directors,
which were eligible vest based on certain performance conditions tied to the completion of the COVID-19 coronavirus treatment study,
subject to the employee&amp;#x2019;s continuous employment through such vesting date. The award complements the Milestone 3 earn-out
share entitlement of Clene Nanomedicine shareholders and vests based on the same performance condition (as described in Note 3).
The grant-date fair value of these awards was $3.7 million based on a weighted average grant date fair value of $10.82 per share.
The Company did not recognize compensation expense because the occurrence of achieving this milestone was not probable. As of the
December 31, 2020 measurement date, no shares were vested.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The following table
summarizes the restricted common stock activity during the year ended December 31, 2020:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Number&amp;#xa0;of&lt;br/&gt; RSUs&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted Average Grant Date Fair Value&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;Unvested balance as of December 31, 2019&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;width: 76%; text-indent: -9pt; padding-left: 0.25in&quot;&gt;Granted&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,507,062&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;10.30&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in&quot;&gt;Vested&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt&quot;&gt;Unvested balance as of December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,507,062&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;10.30&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The assumptions used
to calculate the value of the restricted stock units granted in 2020 in the Monte Carlo valuation model include projected stock
price, volatility and risk-free rate based on the achievement of certain stock price milestones. Our significant unobservable inputs
as of December 31, 2020 were as follows: (i) 85% of expected stock price volatility, (ii) risk-free interest rate of 0.4%, and
(iii) expected term of 5 years. The weighted average grant-date fair value of RSUs granted during the years ended December 31,
2020 and 2019 was $10.3034 and $0, respectively.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in&quot;&gt;The stock-based compensation
expense associated with the RSUs were immaterial for the years ended December 31, 2020 and 2019. As of December 31, 2020, total
unrecognized compensation cost related to the unvested stock-based awards was $15.5 million, which is expected to be recognized
over a weighted average period of 8 months.&lt;/p&gt;&lt;br/&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance unitRef="shares" contextRef="c128_AsOf31Dec2020_StockPlan2020Member" decimals="INF">12000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant unitRef="shares" contextRef="c128_AsOf31Dec2020_StockPlan2020Member" decimals="INF">12000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <clnn:MinimumFairMarketValueOfOptionGrantDescription contextRef="c129_From1Jan2020To31Dec2020_StockPlan2020Member">The exercise prices, vesting periods and other restrictions are determined at the discretion of the Company&amp;#x2019;s Board of Directors, except that the exercise price per share of options may not be less than 100% of the fair market value of the Common Stock on the date of grant.</clnn:MinimumFairMarketValueOfOptionGrantDescription>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c130_From1Dec2020To31Dec2020_StockPlan2020Member">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares unitRef="shares" contextRef="c131_AsOf31Dec2020_RestrictedStockUnitsRSUMember" decimals="INF">1507062</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants unitRef="shares" contextRef="c132_From1Jan2020To31Dec2020_RestrictedStockUnitsRSUMember" decimals="INF">10492938</clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c133_From1Jan2020To31Dec2020_StockPlan2014Member">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:CommonStockOtherSharesOutstanding unitRef="shares" contextRef="c134_AsOf31Dec2020_StockPlan2014Member" decimals="INF">53286115</us-gaap:CommonStockOtherSharesOutstanding>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities unitRef="shares" contextRef="c133_From1Jan2020To31Dec2020_StockPlan2014Member" decimals="INF">7032590</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c133_From1Jan2020To31Dec2020_StockPlan2014Member" decimals="INF">270555</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <clnn:CommonSharesAuthorized unitRef="shares" contextRef="c135_AsOf31Dec2019_StockPlan2014Member" decimals="INF">6720065</clnn:CommonSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c136_From1Jan2019To31Dec2019_StockPlan2014Member" decimals="INF">1440717</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross unitRef="shares" contextRef="c136_From1Jan2019To31Dec2019_StockPlan2014Member" decimals="INF">388283</clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c133_From1Jan2020To31Dec2020_StockPlan2014Member" decimals="-5">800000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c136_From1Jan2019To31Dec2019_StockPlan2014Member" decimals="-5">400000</us-gaap:ShareBasedCompensation>
  <clnn:UnrecognizedStockbasedCompensation unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-5">2400000</clnn:UnrecognizedStockbasedCompensation>
  <clnn:weightedAverageFairValuesOfOptionsGranted unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" decimals="4">2.3923</clnn:weightedAverageFairValuesOfOptionsGranted>
  <clnn:weightedAverageFairValuesOfOptionsGranted unitRef="usdPershares" contextRef="c9_From1Jan2019To31Dec2019" decimals="4">1.5806</clnn:weightedAverageFairValuesOfOptionsGranted>
  <clnn:RestrictedStockUnitsDescription contextRef="c137_From1Dec2020To30Dec2020_RestrictedStockUnitsRSUMember">the Company granted the following shares of restricted common stock under the 2020 Stock Plan: &amp;#x25cf; 370,101 shares to various employees and non-employee directors, which vest on June 30, 2021, subject to the employee&amp;#x2019;s continuous employment through such vesting date. The award represents 5% of the converted stock options under 2014 Stock Plan as a result of the Reverse Recapitalization and complements the 5% closing payment shares held in escrow for Clene Nanomedicine common shareholders (as described in Note 1). The grant-date fair value of these awards was $4.0 million. &amp;#x25cf; 454,781 shares to various employees and non-employee directors, which were eligible to vest based on certain market conditions, subject to the employee&amp;#x2019;s continuous employment through such vesting date. The award complements the Milestone 1 earn-out share entitlement of Clene Nanomedicine shareholders and vests based on the same market condition (as described in Note 3). The grant-date fair value of these awards, using a Monte Carlo simulation, was $4.3 million. Based on the outcome of the market condition as of the December 31, 2020 measurement date, no shares were vested. &amp;#x25cf; 341,090 shares to various employees and non-employee directors, which were eligible to vest based on certain market conditions, subject to the employee&amp;#x2019;s continuous employment through such vesting date. The award complements the Milestone 2 earn-out share entitlement of Clene Nanomedicine. shareholders and vests based on the same market condition (as described in Note 3). The grant-date fair value of these awards, using a Monte Carlo simulation, was $3.5 million. Based on the outcome of the market condition as of the December 31, 2020 measurement date, no shares were vested. &amp;#x25cf; 341,090 shares to various employees and non-employee directors, which were eligible vest based on certain performance conditions tied to the completion of the COVID-19 coronavirus treatment study, subject to the employee&amp;#x2019;s continuous employment through such vesting date. The award complements the Milestone 3 earn-out share entitlement of Clene Nanomedicine shareholders and vests based on the same performance condition (as described in Note 3). The grant-date fair value of these awards was $3.7 million based on a weighted average grant date fair value of $10.82 per share. The Company did not recognize compensation expense because the occurrence of achieving this milestone was not probable. As of the December 31, 2020 measurement date, no shares were vested.</clnn:RestrictedStockUnitsDescription>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c132_From1Jan2020To31Dec2020_RestrictedStockUnitsRSUMember" decimals="2">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c132_From1Jan2020To31Dec2020_RestrictedStockUnitsRSUMember" decimals="3">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c132_From1Jan2020To31Dec2020_RestrictedStockUnitsRSUMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c132_From1Jan2020To31Dec2020_RestrictedStockUnitsRSUMember" decimals="4">10.3034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c138_From1Jan2019To31Dec2019_RestrictedStockUnitsRSUMember" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized unitRef="usd" contextRef="c131_AsOf31Dec2020_RestrictedStockUnitsRSUMember" decimals="-5">15500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerms contextRef="c132_From1Jan2020To31Dec2020_RestrictedStockUnitsRSUMember">8 months</clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerms>
  <clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm contextRef="c0_From1Jan2020To31Dec2020">P2Y14D</clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm>
  <us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif;  width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(In
    thousands)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;General
    and administrative&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;281&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;161&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Research
    and development&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;480&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;238&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Total
    stock-based compensation&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;761&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;399&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c139_From1Jan2020To31Dec2020_GeneralAndAdministrativeExpenseMember" decimals="-3">281000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c140_From1Jan2019To31Dec2019_GeneralAndAdministrativeExpenseMember" decimals="-3">161000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c54_From1Jan2020To31Dec2020_ResearchAndDevelopmentExpenseMember" decimals="-3">480000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c55_From1Jan2019To31Dec2019_ResearchAndDevelopmentExpenseMember" decimals="-3">238000</us-gaap:ShareBasedCompensation>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-weight: bold; border-bottom: Black 1.5pt solid&quot;&gt;Equity&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Number&amp;#xa0;of&lt;br/&gt; Options&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price &lt;br/&gt; Per Share&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Term &lt;br/&gt; (Years)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Instrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 52%; text-indent: -9pt; padding-left: 9pt&quot;&gt;Outstanding - December 31, 2018&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;5,698,090&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;0.38&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;6.62&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;11,089&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: -9pt; padding-left: 0.25in&quot;&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,440,717&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.42&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.66&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: -9pt; padding-left: 0.25in&quot;&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(11,878&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;0.83&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;31&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in&quot;&gt;Forfeited&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(248,757&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;1.44&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: -9pt; padding-left: 9pt&quot;&gt;Outstanding - December 31, 2019&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6,878,172&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;0.83&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.36&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;18,105&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: -9pt; padding-left: 0.25in&quot;&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;270,555&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.48&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.32&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: -9pt; padding-left: 0.25in&quot;&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(83,232&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;0.94&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;740&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in&quot;&gt;Forfeited&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(32,904&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;1.65&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt&quot;&gt;Outstanding - December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;7,032,591&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;0.97&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;5.34&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;62,462&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt&quot;&gt;Options vested and exercisable - December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;5,896,034&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;0.55&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;4.86&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;52,694&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 9pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt&quot;&gt;Options vested and exercisable - Stock options vested and expected to vest December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;7,032,591&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;0.97&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;5.34&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;62,462&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c141_AsOf30Dec2018" decimals="INF">5698090</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c141_AsOf30Dec2018" decimals="2">0.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c142_From31Dec2018To31Dec2018">P6Y226D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue unitRef="usd" contextRef="c141_AsOf30Dec2018" decimals="-3">11089000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c9_From1Jan2019To31Dec2019" decimals="INF">1440717</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c9_From1Jan2019To31Dec2019" decimals="2">2.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted contextRef="c9_From1Jan2019To31Dec2019">P9Y240D</clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted>
  <clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodIntrinsicValue unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <clnn:ShareBasedCompensationArrangementNumberOfOptionsExercised unitRef="shares" contextRef="c9_From1Jan2019To31Dec2019" decimals="INF">11878</clnn:ShareBasedCompensationArrangementNumberOfOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c9_From1Jan2019To31Dec2019" decimals="2">0.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsExercised contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" decimals="-3">31000</clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod unitRef="shares" contextRef="c9_From1Jan2019To31Dec2019" decimals="INF">248757</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c9_From1Jan2019To31Dec2019" decimals="2">1.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsForfeited contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c4_AsOf31Dec2019" decimals="INF">6878172</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c4_AsOf31Dec2019" decimals="2">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c9_From1Jan2019To31Dec2019">P6Y131D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">18105000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">270555</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">5.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted contextRef="c0_From1Jan2020To31Dec2020">P5Y116D</clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted>
  <clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodIntrinsicValue unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <clnn:ShareBasedCompensationArrangementNumberOfOptionsExercised unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">83232</clnn:ShareBasedCompensationArrangementNumberOfOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">0.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsExercised contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">740000</clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">32904</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">1.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsForfeited contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">7032591</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c3_AsOf31Dec2020" decimals="2">0.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c0_From1Jan2020To31Dec2020">P5Y124D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">62462000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">5896034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c3_AsOf31Dec2020" decimals="2">0.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c0_From1Jan2020To31Dec2020">P4Y313D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
  <clnn:InstrinsicValueOptionsVestedAndExercisableEnding unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">52694000</clnn:InstrinsicValueOptionsVestedAndExercisableEnding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">7032591</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <clnn:WeightedAverageExercisePricePerShareOptionsVestedAndExercisableStockOptionsVest unitRef="usdPershares" contextRef="c3_AsOf31Dec2020" decimals="2">0.97</clnn:WeightedAverageExercisePricePerShareOptionsVestedAndExercisableStockOptionsVest>
  <clnn:WeightedAverageRemainingTermOptionsVestedAndExercisableStockOptionsVestedAndExercisable contextRef="c0_From1Jan2020To31Dec2020">P5Y124D</clnn:WeightedAverageRemainingTermOptionsVestedAndExercisableStockOptionsVestedAndExercisable>
  <clnn:InstrinsicValueOptionsVestedAndExercisableStockOptionsVestedAndExpectedToVestEnding unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">62462000</clnn:InstrinsicValueOptionsVestedAndExercisableStockOptionsVestedAndExpectedToVestEnding>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.25in; padding-left: 0.25in; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.25in; padding-left: 0.25in; width: 72%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Expected
    stock price volatility&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 12%; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;75.00%
- 119.30%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 12%; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;75.00%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.25in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Risk-free
    interest rate&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;0.39%
                                         - 0.53%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1.46%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.25in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Expected
    dividend yield&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;0%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;0%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.25in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Expected
    term of options&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;6
years&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;6
                                         years&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c143_From1Jan2020To31Dec2020_MinimumMember_StockOptionMember" decimals="4">0.7500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c144_From1Jan2020To31Dec2020_MaximumMember_StockOptionMember" decimals="4">1.1930</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c145_From1Jan2019To31Dec2019_StockOptionMember" decimals="4">0.7500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c143_From1Jan2020To31Dec2020_MinimumMember_StockOptionMember" decimals="4">0.0039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c144_From1Jan2020To31Dec2020_MaximumMember_StockOptionMember" decimals="4">0.0053</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c145_From1Jan2019To31Dec2019_StockOptionMember" decimals="4">0.0146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c146_From1Jan2020To31Dec2020_StockOptionMember" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c145_From1Jan2019To31Dec2019_StockOptionMember" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c146_From1Jan2020To31Dec2020_StockOptionMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c145_From1Jan2019To31Dec2019_StockOptionMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Number&amp;#xa0;of&lt;br/&gt; RSUs&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted Average Grant Date Fair Value&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;Unvested balance as of December 31, 2019&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;width: 76%; text-indent: -9pt; padding-left: 0.25in&quot;&gt;Granted&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,507,062&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;10.30&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in&quot;&gt;Vested&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt&quot;&gt;Unvested balance as of December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,507,062&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;10.30&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares unitRef="shares" contextRef="c147_AsOf31Dec2019_RestrictedStockUnitsRSUMember" xs:nil="true"/>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c147_AsOf31Dec2019_RestrictedStockUnitsRSUMember" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c132_From1Jan2020To31Dec2020_RestrictedStockUnitsRSUMember" decimals="INF">1507062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c132_From1Jan2020To31Dec2020_RestrictedStockUnitsRSUMember" decimals="2">10.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares unitRef="shares" contextRef="c132_From1Jan2020To31Dec2020_RestrictedStockUnitsRSUMember" xs:nil="true"/>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c132_From1Jan2020To31Dec2020_RestrictedStockUnitsRSUMember" xs:nil="true"/>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c131_AsOf31Dec2020_RestrictedStockUnitsRSUMember" decimals="2">10.30</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;16.
Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The carrying amount
of cash and accounts payable approximates fair value because of the immediate, short-term maturity of these financial instruments.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;Liabilities
with Fair Value Measurements on a Recurring Basis&amp;#xa0;&amp;#x2014; &lt;/b&gt;The following tables present the Company&amp;#x2019;s fair value
hierarchy for its liabilities measured at fair value on a recurring basis as of December 31, 2020 and 2019 (in thousands):&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;14&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Fair Value Measurements on a Recurring Basis&lt;br/&gt; December&amp;#xa0;31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Level 1&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Level 2&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Level 3&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 52%; text-align: left; text-indent: -9pt; padding-left: 9pt&quot;&gt;Notes payable&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,296&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,296&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -9pt; padding-left: 9pt&quot;&gt;Clene Nanomedicine contingent earn-out&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;52,053&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;52,053&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -9pt; padding-left: 9pt&quot;&gt;Initial Shareholders contingent earn-out&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5,906&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5,906&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif;  width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;14&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Fair
    Value Measurements on a Recurring Basis&lt;br/&gt;
December&amp;#xa0;31, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Level
                                         1&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Level
                                         2&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Level
                                         3&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Redeemable
    convertible preferred stock warrant liability&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;3,213&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;3,213&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Notes
    payable&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;640&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;640&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;For the year ended
December 31, 2020, there was a transfer to Level 1 from Level 3 of the Company&amp;#x2019;s notes payable as the fair value of the notes
payable is determined based on the Company&amp;#x2019;s stock price listed on the Nasdaq. There were no other transfers between Level
1, Level 2 or Level 3. For the years ended December 31, 2019, there were no transfers between Level 1, Level 2, or Level 3.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Valuation
of the Notes Payable&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The carrying value
of the notes payable includes certain notes remeasured at fair value on a recurring basis in the balance sheet as of December 31,
2020 and 2019. In order to value the note, the Company considers the amount of simple interest expense that would be due and considers
the value of Phantom Shares.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Prior
to becoming a public company, the Company&amp;#x2019;s notes payable contained unobservable inputs that reflected the Company&amp;#x2019;s
own assumptions. Accordingly, the Company&amp;#x2019;s notes payable were measured at fair value on a recurring basis using unobservable
inputs. Significant unobservable inputs as of December 31, 2019 were the fair value of Series C Preferred Stock of $4.1699 per
share.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;As of December 31,
2020, the fair value of the Company&amp;#x2019;s Notes payable is determined based on the closing price of $9.01 per share for CLNN
listed on the Nasdaq.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Valuation
of Warrants to Purchase Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company&amp;#x2019;s Preferred Stock warrant liabilities contain unobservable inputs that reflect the Company&amp;#x2019;s own assumptions.
Accordingly, the Company&amp;#x2019;s Preferred Stock warrant liabilities were measured at fair value on a recurring basis using unobservable
inputs. Prior to the extinguishment of the Preferred Stock warrant liabilities on December 30, 2020 and on December 31, 2019,
the Preferred Stock warrant liability was valued using a Black-Scholes valuation model.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Significant unobservable
inputs at December 30, 2020 were the fair value of Series D Preferred Stock warrants of $10.82 per share, the fair value of Series
A Preferred Stock warrants of $10.82 per share, expected term of 2.3&amp;#xa0;years, expected volatility of Series D Preferred Stock
warrants of 101%, and expected volatility of Series A Preferred Stock warrants of 101%. Significant unobservable inputs at December
31, 2019 were the fair value of Series C Preferred Stock warrants of $4.1699 per share, the fair value of Series A Preferred Stock
warrants of $3.1046 per share, expected term of 2&amp;#xa0;years, expected volatility of Series C Preferred Stock warrants of 49%,
and expected volatility of Series A Preferred Stock warrants of 71%.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Board of Directors
determines the fair value of the Preferred Stock by considering a number of objective and subjective factors, including third-party
valuations, valuations of comparable companies, sales of redeemable convertible Preferred Stock, sales of common stock to unrelated
third parties, operating and financial performance, the lack of liquidity of the Company&amp;#x2019;s capital stock, and general and
industry-specific economic outlook. The Company estimated the volatility of its Preferred Stock based on comparable peer companies&amp;#x2019;
historical volatility. The risk-free interest rate for periods within the contractual life of the warrants is based on the U.S.
Treasury yield curve in effect at the valuation date. The Company has no plans to declare any future dividends. The determination
of the fair value of the Preferred Stock warrant liability could change in future periods based upon changes in the value of the
Company&amp;#x2019;s Preferred Stock and other assumptions as presented above. The Company records any such change in fair value to
the change in fair value of Preferred Stock warrant liability expense line in the consolidated statements of operations and comprehensive
loss.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Upon the closing of
the Reverse Recapitalization (see Note 1), all of the outstanding Clene Nanomedicine Preferred Stock was converted to Clene Inc.
Common Stock and the Clene Nanomedicine Preferred Stock warrants were converted to warrants for the purchase of Clene Inc. Common
Stock. Accordingly, the Preferred Stock warrant liabilities were extinguished in connection with the conversion of Clene Nanomedicine
Preferred Stock on December 30, 2020 (see Note 9).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Valuation
of the Contingent Earn-out&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Pursuant to the Merger
Agreement, Clene Nanomedicine&amp;#x2019;s common shareholders immediately prior to the Reverse Recapitalization and Initial Shareholders
of Totttenham were entitled to receive additional shares of up to 8,333,333 shares and 750,000 shares of the Company&amp;#x2019;s Common
Stock, respectively, upon the Company achieving certain milestones described in Note 3. Upon the consummation of the Reverse Recapitalization,
Clene Nanomedicine and the Initial Shareholders are entitled to receive additional shares up to 8,346,185 shares as a result of
the exercise of the stock options in November 2020, and 750,000 shares of the Company&amp;#x2019;s Common Stock. The Clene Nanomedicine
Contingent Earn-out and the Initial Shareholders Contingent Earn-out are recorded at fair value as contingent earn-out on the closing
of the Reverse Recapitalization on December 30, 2020 and remeasured at each reporting period. As of December 31, 2020, no milestone
has been achieved.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
estimated fair value of the initial contingent earn-out is determined using a Monte Carlo analysis in order to simulate the future
path of the Company&amp;#x2019;s stock price over the earn-out period. The carrying amount of the liability may fluctuate significantly
and actual amounts paid may be materially different from the liability&amp;#x2019;s estimated value. As of December 31, 2020, the contingent
earn-out was revalued using a similar Monte Carlo analysis. The unobservable inputs to the model were as follows:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; width: 72%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Expected
    stock price volatility&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif; width: 1%&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 12%; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;85.00&lt;/font&gt;%&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; font-family: Times New Roman, Times, Serif; width: 12%&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;N/A&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Risk-free
    interest rate&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;0.40%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;N/A&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Expected
    term&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;5
                                         years&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;N/A&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
following is a summary of changes in the fair value of the Company&amp;#x2019;s financial liability related to the notes payable, the
derivative instrument, the Preferred Stock warrants, and the contingent earn-out measured at fair value as of December 31, 2020
and 2019 (in thousands):&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: center; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;3&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Notes Payable&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: center; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;3&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Derivative Instrument&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: center; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;3&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Preferred Stock Warrants&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: center; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;3&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Clene Nanomedicine Contingent Earn-out&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: center; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;3&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Initial Shareholders Contingent Earn-out&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 40%&quot;&gt;Balance - December 31, 2018&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;4,518&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-align: left&quot;&gt;Issuance of notes payable&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;600&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-align: left&quot;&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;40&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;361&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; padding-bottom: 1.5pt; text-align: left&quot;&gt;Exercise of Series C preferred stock warrants&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(1,666&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;Balance - December 31, 2019&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;640&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3,213&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-align: left&quot;&gt;Issuance of convertible promissory notes&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;705&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in&quot;&gt;Initial fair value of instrument&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;64,712&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7,371&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-align: left&quot;&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;656&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(29&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;14,615&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(12,659&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(1,465&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.25in; text-align: left&quot;&gt;Extinguishment of preferred stock warrant liability in connection with the conversion of redeemable convertible preferred stock&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(17,828&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1.5pt; text-align: left&quot;&gt;Extinguishment of derivative liability in connection with extinguishment of the 2020 Convertible Notes (Note 12)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(676&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt&quot;&gt;Balance - December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,296&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;52,053&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;5,906&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <clnn:FairValueMeasurementWithUnobservableInputsNotesPayable unitRef="usdPershares" contextRef="c102_From1Jan2019To31Dec2019_SeriesCPreferredStockMember" decimals="4">4.1699</clnn:FairValueMeasurementWithUnobservableInputsNotesPayable>
  <clnn:NotesPayableBasedOnClosingPrice unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">9.01</clnn:NotesPayableBasedOnClosingPrice>
  <clnn:WarrantsToPurchasePreferredStock contextRef="c148_From27Dec2020To30Dec2020">Significant unobservable inputs at December 30, 2020 were the fair value of Series D Preferred Stock warrants of $10.82 per share, the fair value of Series A Preferred Stock warrants of $10.82 per share, expected term of 2.3 years, expected volatility of Series D Preferred Stock warrants of 101%, and expected volatility of Series A Preferred Stock warrants of 101%.</clnn:WarrantsToPurchasePreferredStock>
  <clnn:WarrantsToPurchasePreferredStock contextRef="c9_From1Jan2019To31Dec2019">Significant unobservable inputs at December 31, 2019 were the fair value of Series C Preferred Stock warrants of $4.1699 per share, the fair value of Series A Preferred Stock warrants of $3.1046 per share, expected term of 2 years, expected volatility of Series C Preferred Stock warrants of 49%, and expected volatility of Series A Preferred Stock warrants of 71%.</clnn:WarrantsToPurchasePreferredStock>
  <us-gaap:BusinessCombinationContingentConsiderationArrangementsDescription contextRef="c0_From1Jan2020To31Dec2020">Pursuant to the Merger Agreement, Clene Nanomedicine&amp;#x2019;s common shareholders immediately prior to the Reverse Recapitalization and Initial Shareholders of Totttenham were entitled to receive additional shares of up to 8,333,333 shares and 750,000 shares of the Company&amp;#x2019;s Common Stock, respectively, upon the Company achieving certain milestones described in Note 3. Upon the consummation of the Reverse Recapitalization, Clene Nanomedicine and the Initial Shareholders are entitled to receive additional shares up to 8,346,185 shares as a result of the exercise of the stock options in November 2020, and 750,000 shares of the Company&amp;#x2019;s Common Stock</us-gaap:BusinessCombinationContingentConsiderationArrangementsDescription>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;14&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Fair Value Measurements on a Recurring Basis&lt;br/&gt; December&amp;#xa0;31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Level 1&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Level 2&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Level 3&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 52%; text-align: left; text-indent: -9pt; padding-left: 9pt&quot;&gt;Notes payable&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,296&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,296&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -9pt; padding-left: 9pt&quot;&gt;Clene Nanomedicine contingent earn-out&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;52,053&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;52,053&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -9pt; padding-left: 9pt&quot;&gt;Initial Shareholders contingent earn-out&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5,906&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5,906&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif;  width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;14&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Fair
    Value Measurements on a Recurring Basis&lt;br/&gt;
December&amp;#xa0;31, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Level
                                         1&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Level
                                         2&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Level
                                         3&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Redeemable
    convertible preferred stock warrant liability&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;3,213&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;3,213&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Notes
    payable&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;640&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;640&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <us-gaap:NotesPayableFairValueDisclosure unitRef="usd" contextRef="c149_AsOf31Dec2020_FairValueInputsLevel1Member" decimals="-3">1296000</us-gaap:NotesPayableFairValueDisclosure>
  <us-gaap:NotesPayableFairValueDisclosure unitRef="usd" contextRef="c150_AsOf31Dec2020_FairValueInputsLevel2Member" xs:nil="true"/>
  <us-gaap:NotesPayableFairValueDisclosure unitRef="usd" contextRef="c151_AsOf31Dec2020_FairValueInputsLevel3Member" xs:nil="true"/>
  <us-gaap:NotesPayableFairValueDisclosure unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">1296000</us-gaap:NotesPayableFairValueDisclosure>
  <clnn:CleneNanomedicineContingentEarnout unitRef="usd" contextRef="c149_AsOf31Dec2020_FairValueInputsLevel1Member" xs:nil="true"/>
  <clnn:CleneNanomedicineContingentEarnout unitRef="usd" contextRef="c150_AsOf31Dec2020_FairValueInputsLevel2Member" xs:nil="true"/>
  <clnn:CleneNanomedicineContingentEarnout unitRef="usd" contextRef="c151_AsOf31Dec2020_FairValueInputsLevel3Member" decimals="-3">52053000</clnn:CleneNanomedicineContingentEarnout>
  <clnn:CleneNanomedicineContingentEarnout unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-3">52053000</clnn:CleneNanomedicineContingentEarnout>
  <clnn:InitialShareholdersContingentEarnout unitRef="usd" contextRef="c149_AsOf31Dec2020_FairValueInputsLevel1Member" xs:nil="true"/>
  <clnn:InitialShareholdersContingentEarnout unitRef="usd" contextRef="c150_AsOf31Dec2020_FairValueInputsLevel2Member" xs:nil="true"/>
  <clnn:InitialShareholdersContingentEarnout unitRef="usd" contextRef="c151_AsOf31Dec2020_FairValueInputsLevel3Member" decimals="-3">5906000</clnn:InitialShareholdersContingentEarnout>
  <clnn:RedeemableConvertiblePreferredStockWarrantLiability unitRef="usd" contextRef="c152_AsOf31Dec2019_FairValueInputsLevel1Member" xs:nil="true"/>
  <clnn:RedeemableConvertiblePreferredStockWarrantLiability unitRef="usd" contextRef="c153_AsOf31Dec2019_FairValueInputsLevel2Member" xs:nil="true"/>
  <clnn:RedeemableConvertiblePreferredStockWarrantLiability unitRef="usd" contextRef="c154_AsOf31Dec2019_FairValueInputsLevel3Member" decimals="-3">3213000</clnn:RedeemableConvertiblePreferredStockWarrantLiability>
  <us-gaap:NotesPayableFairValueDisclosure unitRef="usd" contextRef="c152_AsOf31Dec2019_FairValueInputsLevel1Member" xs:nil="true"/>
  <us-gaap:NotesPayableFairValueDisclosure unitRef="usd" contextRef="c153_AsOf31Dec2019_FairValueInputsLevel2Member" xs:nil="true"/>
  <us-gaap:NotesPayableFairValueDisclosure unitRef="usd" contextRef="c154_AsOf31Dec2019_FairValueInputsLevel3Member" decimals="-3">640000</us-gaap:NotesPayableFairValueDisclosure>
  <us-gaap:NotesPayableFairValueDisclosure unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">640000</us-gaap:NotesPayableFairValueDisclosure>
  <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; width: 72%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Expected
    stock price volatility&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif; width: 1%&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 12%; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;85.00&lt;/font&gt;%&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; font-family: Times New Roman, Times, Serif; width: 12%&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;N/A&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Risk-free
    interest rate&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;0.40%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;N/A&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Expected
    term&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;5
                                         years&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;N/A&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c155_From1Jan2020To31Dec2020_ContingentEarnoutMember" decimals="4">0.8500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c156_From1Jan2019To31Dec2019_ContingentEarnoutMember" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c155_From1Jan2020To31Dec2020_ContingentEarnoutMember" decimals="4">0.0040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c156_From1Jan2019To31Dec2019_ContingentEarnoutMember" xs:nil="true"/>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c155_From1Jan2020To31Dec2020_ContingentEarnoutMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c156_From1Jan2019To31Dec2019_ContingentEarnoutMember" xs:nil="true"/>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: center; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;3&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Notes Payable&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: center; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;3&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Derivative Instrument&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: center; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;3&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Preferred Stock Warrants&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: center; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;3&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Clene Nanomedicine Contingent Earn-out&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: center; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;3&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Initial Shareholders Contingent Earn-out&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 40%&quot;&gt;Balance - December 31, 2018&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;4,518&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-align: left&quot;&gt;Issuance of notes payable&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;600&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-align: left&quot;&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;40&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;361&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; padding-bottom: 1.5pt; text-align: left&quot;&gt;Exercise of Series C preferred stock warrants&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(1,666&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;Balance - December 31, 2019&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;640&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3,213&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-align: left&quot;&gt;Issuance of convertible promissory notes&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;705&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in&quot;&gt;Initial fair value of instrument&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;64,712&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7,371&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-align: left&quot;&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;656&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(29&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;14,615&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(12,659&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(1,465&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.25in; text-align: left&quot;&gt;Extinguishment of preferred stock warrant liability in connection with the conversion of redeemable convertible preferred stock&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(17,828&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1.5pt; text-align: left&quot;&gt;Extinguishment of derivative liability in connection with extinguishment of the 2020 Convertible Notes (Note 12)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(676&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt&quot;&gt;Balance - December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,296&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;52,053&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;5,906&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue unitRef="usd" contextRef="c157_AsOf31Dec2018_NotesPayableOtherPayablesMember" xs:nil="true"/>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue unitRef="usd" contextRef="c158_AsOf31Dec2018_DerivativeInstrumentMember" xs:nil="true"/>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue unitRef="usd" contextRef="c159_AsOf31Dec2018_PreferredStockWarrantsMember" decimals="-3">4518000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue unitRef="usd" contextRef="c160_AsOf31Dec2018_ContingentEarnoutMember" xs:nil="true"/>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue unitRef="usd" contextRef="c161_AsOf31Dec2018_InitialShareholdersContingentEarnoutMember" xs:nil="true"/>
  <clnn:FairValueOfIssuanceOfNotesPayable unitRef="usd" contextRef="c162_From1Jan2019To31Dec2019_NotesPayableOtherPayablesMember" decimals="-3">600000</clnn:FairValueOfIssuanceOfNotesPayable>
  <clnn:FairValueOfIssuanceOfNotesPayable unitRef="usd" contextRef="c163_From1Jan2019To31Dec2019_DerivativeInstrumentMember" xs:nil="true"/>
  <clnn:FairValueOfIssuanceOfNotesPayable unitRef="usd" contextRef="c164_From1Jan2019To31Dec2019_PreferredStockWarrantsMember" xs:nil="true"/>
  <clnn:FairValueOfIssuanceOfNotesPayable unitRef="usd" contextRef="c165_From1Jan2019To31Dec2019_ContingentEarnoutMember" xs:nil="true"/>
  <clnn:FairValueOfIssuanceOfNotesPayable unitRef="usd" contextRef="c166_From1Jan2019To31Dec2019_InitialShareholdersContingentEarnoutMember" xs:nil="true"/>
  <clnn:IncreseDecreaseInFairValue unitRef="usd" contextRef="c162_From1Jan2019To31Dec2019_NotesPayableOtherPayablesMember" decimals="-3">40000</clnn:IncreseDecreaseInFairValue>
  <clnn:IncreseDecreaseInFairValue unitRef="usd" contextRef="c163_From1Jan2019To31Dec2019_DerivativeInstrumentMember" xs:nil="true"/>
  <clnn:IncreseDecreaseInFairValue unitRef="usd" contextRef="c164_From1Jan2019To31Dec2019_PreferredStockWarrantsMember" decimals="-3">361000</clnn:IncreseDecreaseInFairValue>
  <clnn:IncreseDecreaseInFairValue unitRef="usd" contextRef="c165_From1Jan2019To31Dec2019_ContingentEarnoutMember" xs:nil="true"/>
  <clnn:IncreseDecreaseInFairValue unitRef="usd" contextRef="c166_From1Jan2019To31Dec2019_InitialShareholdersContingentEarnoutMember" xs:nil="true"/>
  <clnn:FairValueExerciseOfSeriesCPreferredStockWarrants unitRef="usd" contextRef="c162_From1Jan2019To31Dec2019_NotesPayableOtherPayablesMember" xs:nil="true"/>
  <clnn:FairValueExerciseOfSeriesCPreferredStockWarrants unitRef="usd" contextRef="c163_From1Jan2019To31Dec2019_DerivativeInstrumentMember" xs:nil="true"/>
  <clnn:FairValueExerciseOfSeriesCPreferredStockWarrants unitRef="usd" contextRef="c164_From1Jan2019To31Dec2019_PreferredStockWarrantsMember" decimals="-3">-1666000</clnn:FairValueExerciseOfSeriesCPreferredStockWarrants>
  <clnn:FairValueExerciseOfSeriesCPreferredStockWarrants unitRef="usd" contextRef="c165_From1Jan2019To31Dec2019_ContingentEarnoutMember" xs:nil="true"/>
  <clnn:FairValueExerciseOfSeriesCPreferredStockWarrants unitRef="usd" contextRef="c166_From1Jan2019To31Dec2019_InitialShareholdersContingentEarnoutMember" xs:nil="true"/>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue unitRef="usd" contextRef="c167_AsOf31Dec2019_NotesPayableOtherPayablesMember" decimals="-3">640000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue unitRef="usd" contextRef="c168_AsOf31Dec2019_DerivativeInstrumentMember" xs:nil="true"/>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue unitRef="usd" contextRef="c169_AsOf31Dec2019_PreferredStockWarrantsMember" decimals="-3">3213000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue unitRef="usd" contextRef="c170_AsOf31Dec2019_ContingentEarnoutMember" xs:nil="true"/>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue unitRef="usd" contextRef="c171_AsOf31Dec2019_InitialShareholdersContingentEarnoutMember" xs:nil="true"/>
  <clnn:FairValueIssuanceOfConvertiblePromissoryNotes unitRef="usd" contextRef="c172_From1Jan2020To31Dec2020_NotesPayableOtherPayablesMember" xs:nil="true"/>
  <clnn:FairValueIssuanceOfConvertiblePromissoryNotes unitRef="usd" contextRef="c173_From1Jan2020To31Dec2020_DerivativeInstrumentMember" decimals="-3">705000</clnn:FairValueIssuanceOfConvertiblePromissoryNotes>
  <clnn:FairValueIssuanceOfConvertiblePromissoryNotes unitRef="usd" contextRef="c174_From1Jan2020To31Dec2020_PreferredStockWarrantsMember" xs:nil="true"/>
  <clnn:FairValueIssuanceOfConvertiblePromissoryNotes unitRef="usd" contextRef="c175_From1Jan2020To31Dec2020_ContingentEarnoutMember" xs:nil="true"/>
  <clnn:FairValueIssuanceOfConvertiblePromissoryNotes unitRef="usd" contextRef="c176_From1Jan2020To31Dec2020_InitialShareholdersContingentEarnoutMember" xs:nil="true"/>
  <clnn:InitialFairValueOfInstrument unitRef="usd" contextRef="c172_From1Jan2020To31Dec2020_NotesPayableOtherPayablesMember" xs:nil="true"/>
  <clnn:InitialFairValueOfInstrument unitRef="usd" contextRef="c173_From1Jan2020To31Dec2020_DerivativeInstrumentMember" xs:nil="true"/>
  <clnn:InitialFairValueOfInstrument unitRef="usd" contextRef="c174_From1Jan2020To31Dec2020_PreferredStockWarrantsMember" xs:nil="true"/>
  <clnn:InitialFairValueOfInstrument unitRef="usd" contextRef="c175_From1Jan2020To31Dec2020_ContingentEarnoutMember" decimals="-3">64712000</clnn:InitialFairValueOfInstrument>
  <clnn:InitialFairValueOfInstrument unitRef="usd" contextRef="c176_From1Jan2020To31Dec2020_InitialShareholdersContingentEarnoutMember" decimals="-3">7371000</clnn:InitialFairValueOfInstrument>
  <clnn:IncreseDecreaseInFairValue unitRef="usd" contextRef="c172_From1Jan2020To31Dec2020_NotesPayableOtherPayablesMember" decimals="-3">656000</clnn:IncreseDecreaseInFairValue>
  <clnn:IncreseDecreaseInFairValue unitRef="usd" contextRef="c173_From1Jan2020To31Dec2020_DerivativeInstrumentMember" decimals="-3">-29000</clnn:IncreseDecreaseInFairValue>
  <clnn:IncreseDecreaseInFairValue unitRef="usd" contextRef="c174_From1Jan2020To31Dec2020_PreferredStockWarrantsMember" decimals="-3">14615000</clnn:IncreseDecreaseInFairValue>
  <clnn:IncreseDecreaseInFairValue unitRef="usd" contextRef="c175_From1Jan2020To31Dec2020_ContingentEarnoutMember" decimals="-3">-12659000</clnn:IncreseDecreaseInFairValue>
  <clnn:IncreseDecreaseInFairValue unitRef="usd" contextRef="c176_From1Jan2020To31Dec2020_InitialShareholdersContingentEarnoutMember" decimals="-3">-1465000</clnn:IncreseDecreaseInFairValue>
  <clnn:ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable unitRef="usd" contextRef="c172_From1Jan2020To31Dec2020_NotesPayableOtherPayablesMember" xs:nil="true"/>
  <clnn:ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable unitRef="usd" contextRef="c173_From1Jan2020To31Dec2020_DerivativeInstrumentMember" xs:nil="true"/>
  <clnn:ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable unitRef="usd" contextRef="c174_From1Jan2020To31Dec2020_PreferredStockWarrantsMember" decimals="-3">-17828000</clnn:ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable>
  <clnn:ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable unitRef="usd" contextRef="c175_From1Jan2020To31Dec2020_ContingentEarnoutMember" xs:nil="true"/>
  <clnn:ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable unitRef="usd" contextRef="c176_From1Jan2020To31Dec2020_InitialShareholdersContingentEarnoutMember" xs:nil="true"/>
  <clnn:ExtinguishmentOfDerivativeLiability unitRef="usd" contextRef="c172_From1Jan2020To31Dec2020_NotesPayableOtherPayablesMember" xs:nil="true"/>
  <clnn:ExtinguishmentOfDerivativeLiability unitRef="usd" contextRef="c173_From1Jan2020To31Dec2020_DerivativeInstrumentMember" decimals="-3">-676000</clnn:ExtinguishmentOfDerivativeLiability>
  <clnn:ExtinguishmentOfDerivativeLiability unitRef="usd" contextRef="c174_From1Jan2020To31Dec2020_PreferredStockWarrantsMember" xs:nil="true"/>
  <clnn:ExtinguishmentOfDerivativeLiability unitRef="usd" contextRef="c175_From1Jan2020To31Dec2020_ContingentEarnoutMember" xs:nil="true"/>
  <clnn:ExtinguishmentOfDerivativeLiability unitRef="usd" contextRef="c176_From1Jan2020To31Dec2020_InitialShareholdersContingentEarnoutMember" xs:nil="true"/>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue unitRef="usd" contextRef="c177_AsOf31Dec2020_NotesPayableOtherPayablesMember" decimals="-3">1296000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue unitRef="usd" contextRef="c178_AsOf31Dec2020_DerivativeInstrumentMember" xs:nil="true"/>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue unitRef="usd" contextRef="c179_AsOf31Dec2020_PreferredStockWarrantsMember" xs:nil="true"/>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue unitRef="usd" contextRef="c180_AsOf31Dec2020_ContingentEarnoutMember" decimals="-3">52053000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue unitRef="usd" contextRef="c181_AsOf31Dec2020_InitialShareholdersContingentEarnoutMember" decimals="-3">5906000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <clnn:RedeemableConvertiblePreferredStockDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;17.
Redeemable Convertible Preferred Stock&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Prior to the Reverse
Recapitalization, the Company had issued Series A, B, C, and D Preferred Stock to various investors. Preferred stock is convertible
into common stock at the option of the holder at the conversion price. The Company evaluated the Preferred Stock and concluded
that it did not meet the criteria for being classified as a liability. However, the Company had determined that the Preferred Stock
should be classified as temporary equity, as the Company might be required to redeem the outstanding Preferred Stock in cash. The
Company had concluded that a redemption event is not probable. Accordingly, the value of Preferred Stock had not been adjusted
to its redemption amount.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Holders of Preferred
Stock vote together with the holders of common stock as a single class. Voting rights are in proportion to the number of votes
equal to common stock shares into which preferred shares would be converted.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Redeemable
Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Between February and
April&amp;#xa0;2015, the Company issued 16,066,503 shares of Series A Preferred Stock to several investors, at a price of $1.9658 per
share, for proceeds of $9.5 million in cash and $18.0 million by conversion of convertible promissory notes.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;In
December&amp;#xa0;2016, the Company issued 4,168,815 shares of Series B Preferred Stock at a price of $4.0778 per share and a buyout
option for proceeds of $16.6 million, net of issuance costs of $0.4 million. The Agreement provided the buyer with an exclusive
right and option to acquire all of the issued and outstanding stock of the Company on a fully diluted basis at a set price and
provides for future milestone payments to be made to existing shareholders of the Company based on achievement of certain milestones
defined within the Agreement. The purchase option was not exercised and was terminated by written notice received from the buyer
on September 21, 2017. The Company allocated the total cash consideration received of $16.6 million between the Series B Preferred
Stock and the buyout option based on the relative fair value of each instrument. The $3.4 million assigned to the buyout option
was treated as a contribution and recorded into additional paid-in capital.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Between August and
October&amp;#xa0;2018, the Company issued 4,929,718 shares of Series C Preferred Stock to several investors. The Company issued 3,849,011
shares, at a price of $4.1699 per share, for proceeds of $15.9 million in cash, net of issuance costs of $0.2 million. $1.5 million
of the proceeds were allocated to the Series C Preferred Stock Warrants issued (see Note 9). The Company issued 1,080,707 shares
upon conversion of the convertible promissory notes (see Note 11).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Between March and July&amp;#xa0;2019,
the Company issued 2,334,801 shares of Series C Preferred Stock to several investors. The Company issued 1,935,111 shares, at a
price of $4.1699 per share, for proceeds of $8.1 million in cash, net of immaterial issuance costs. The Company issued 399,690
shares on exercise of Series C Preferred Stock Warrants (see Note 9).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In August 2020, the
Company issued 9,394,057 shares of Series D Preferred Stock to several investors. The Company issued 7,896,922 shares, at a price
of $4.6018 per share, for proceeds of $35.1 million in cash, net of $1.3 million issuance costs. In addition, in connection with
the Company&amp;#x2019;s issuance and sale of Series D preferred stock, all of the outstanding principal and accrued interest under
the 2020 Convertible Notes was automatically converted into an aggregate of 1,497,135 shares of Series D Preferred Stock. The Company
determined the fair value of the shares issued upon conversion to be $6.9 million, based on the preferred stock financing cash
price per share (see Note 11).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Series A Preferred
Stock, Series B Preferred Stock, Series C Preferred Stock, and Series D Preferred Stock are collectively referred as the &amp;#x201c;Preferred
Stock.&amp;#x201d; In connection with the closing of the Reverse Recapitalization, the Preferred Stock converted into 36,893,894 shares
of Common Stock on a 1:0.1389 basis (see Note 1).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;As
of December 31, 2020, there was no Preferred Stock outstanding.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Preferred
Stock consisted of the following as of December 31, 2019 (in thousands, except share amounts):&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;18&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;December
    31, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Preferred&lt;br/&gt;
    Shares&lt;br/&gt; Authorized&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Preferred&lt;br/&gt;
    Shares&lt;br/&gt; Issued and&lt;br/&gt; Outstanding&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Carrying&lt;br/&gt;
    Value&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Liquidation&lt;br/&gt;
    Value&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Common
    Stock&lt;br/&gt; Issuable Upon&lt;br/&gt; Conversion&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; width: 40%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Series
    A Preferred Stock&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;17,675,175&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;16,066,503&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;27,485&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;31,584&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;16,066,503&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Series
    B Preferred Stock&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;4,168,815&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;4,168,815&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;16,582&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;16,999&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;4,168,815&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Series
    C Preferred Stock&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;9,192,018&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;7,264,519&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;28,594&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;30,292&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;7,264,519&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;31,036,008&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;27,499,837&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;72,661&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;78,875&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;27,499,837&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
rights and preferences of Series A, Series B, Series C, and Series D Preferred Stock are as follows:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;Voting
Rights&amp;#xa0;&amp;#x2014; &lt;/b&gt;The holder of each share of Series A, Series B, Series C, and Series D Preferred Stock shall have the
right to one vote for each share of common stock into which such Series A, Series B, Series C, and Series D Preferred Stock could
then be converted.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;&lt;b&gt;Right to Elect Directors&amp;#xa0;&amp;#x2014;
&lt;/b&gt;As long as the majority of the Series A Preferred Stock issued remains outstanding, its holders shall be entitled to elect
two directors of the Company. The holders of Series B Preferred Stock are entitled to elect one director of the Company. The holders
of Series C Preferred Stock are entitled to elect one director of the Company. The holders of Preferred Stock and common stock
(voting together as a single class&amp;#xa0;and not as separate series and on as-converted basis) shall be entitled to elect any remaining
director of the Company.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;&lt;b&gt;Dividend Rights&amp;#xa0;&amp;#x2014;
&lt;/b&gt;The holders of Preferred Stock are entitled to receive, when, as and if declared by the Board of Directors, out of any assets
of the Company legally available therefore, any dividends as may be declared from time to time by the Board of Directors. No dividend
may be declared or paid on the common stock (other than dividends payable in shares of common stock) unless any and all such dividends
or distributions are distributed among all holders of common stock and Preferred Stock in proportion as if the Preferred Stock
were converted to common stock at the effective conversion rate. The debt covenants of the Company&amp;#x2019;s outstanding note payable
prohibit the issuance of dividends, see Note 8.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;&lt;b&gt;Preferred Stock
Protective Provisions&amp;#xa0;&amp;#x2014; &lt;/b&gt;As long as Preferred Stock originally issued remains outstanding, the Company shall not
without first obtaining the approval of the holders of at least a majority of the outstanding shares of Preferred Stock: (i)&amp;#xa0;consummate
a liquidation event or effect any other merger or consolidation, (ii)&amp;#xa0;amend, alter, or repeal any provision of the Certificate
of Incorporation, (iii)&amp;#xa0;increase or decrease (other than redemption or conversion) the total number of authorized shares of
common stock or Preferred Stock, (iv)&amp;#xa0;authorize or issue any equity security having a preference over, or being on a parity
of any series of Preferred Stock, (v)&amp;#xa0;redeem, purchase, or acquire any shares of Preferred Stock or common stock, (vi)&amp;#xa0;pay
or declare any dividend on any shares of capital stock of the Company, other than dividends payable in shares of common stock,
(vii)&amp;#xa0;create or hold capital stock in any subsidiary that is not wholly owned by the Company or permit any direct or indirect
subsidiary to sell, lease, transfer, exclusively license, or otherwise dispose the assets of such subsidiary.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;In
addition, Series B, Series C, and Series D Preferred Stock have protective provisions that prevent the Company from amending,
altering, or repealing any provision of the Certificate of Incorporation or Bylaws to adversely alter or change the powers, preferences
or special rights without first obtaining the approval of the holders of at least a majority of the outstanding shares of Series
B, Series C, and Series D Preferred Stock, respectively.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;Liquidation
Preference&amp;#xa0;&amp;#x2014; &lt;/b&gt;In case of any liquidation event, either voluntary or involuntary, the holders of Series D Preferred
Stock shall be entitled to receive out of the proceeds or assets of the Company available for distribution to its shareholders
prior and in preference to any distribution of the proceeds of such liquidation event to the holders of Series C Preferred Stock,
Series B Preferred Stock, Series A Preferred Stock, and common stock by reason of their ownership thereof, an amount per share
equal to the sum of the applicable original issue price for the Series D Preferred Stock plus declared but unpaid dividends on
such share. If, upon the occurrence of such event, the proceeds thus distributed among the holders of the Series D Preferred Stock
shall be insufficient to permit the payment to such holders of the full amounts, then the entire Proceeds legally available for
distribution shall be distributed ratably among the holders of the Series D Preferred Stock in proportion to the full preferential
amount that each such holder is entitled to receive.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;In
case of any liquidation event, either voluntary or involuntary, the holders of Series C Preferred Stock shall be entitled to receive
out of the proceeds or assets of the Company available for distribution to its shareholders prior and in preference to any distribution
of the proceeds of such liquidation event to the holders of Series B Preferred Stock, Series A Preferred Stock, and common stock
by reason of their ownership thereof, an amount per share equal to the sum of the applicable original issue price for the Series
C Preferred Stock plus declared but unpaid dividends on such share. If, upon the occurrence of such event, the proceeds thus distributed
among the holders of the Series C Preferred Stock shall be insufficient to permit the payment to such holders of the full amounts,
then the entire Proceeds legally available for distribution shall be distributed ratably among the holders of the Series C Preferred
Stock in proportion to the full preferential amount that each such holder is entitled to receive.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In case of any liquidation
event, either voluntary or involuntary, the holders of Series B Preferred Stock shall be entitled to receive out of the proceeds
or assets of the Company available for distribution to its shareholders prior and in preference to any distribution of the proceeds
of such liquidation event to the holders of Series A Preferred Stock, and common stock by reason of their ownership thereof, an
amount per share equal to the sum of the applicable original issue price for the Series B Preferred Stock plus declared but unpaid
dividends on such share. If, upon the occurrence of such event, the proceeds thus distributed among the holders of the Series B
Preferred Stock shall be insufficient to permit the payment to such holders of the full preferential amounts, then the remaining
Proceeds legally available for distribution after distribution to holders of the Series D Preferred Stock and Series C Preferred
Stock shall be distributed ratably among the holders of the Series B Preferred Stock in proportion to the full preferential amount
that each such holder is entitled to receive.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In case of any liquidation
event, either voluntary or involuntary, the holders of Series A Preferred Stock shall be entitled to receive out of the proceeds
or assets of the Company available for distribution to its shareholders prior and in preference to any distribution of the proceeds
of such liquidation event to the holders of common stock by reason of their ownership thereof, an amount per share equal to the
sum of the applicable original issue price for the Series A Preferred Stock plus declared but unpaid dividends on such share. If,
upon the occurrence of such event, the proceeds thus distributed among the holders of the Series A Preferred Stock shall be insufficient
to permit the payment to such holders of the full preferential amounts, then the remaining Proceeds legally available for distribution
after distribution to holders of the Series D Preferred Stock, Series C Preferred Stock and Series B Preferred Stock shall be distributed
ratably among the holders of the Series A Preferred Stock in proportion to the full preferential amount that each such holder is
entitled to receive For purposes of determining the amount each holder of shares of Preferred Stock is entitled to receive in a
liquidation event, each such holder shall be deemed to have converted into shares of common stock immediately prior to the Liquidation
Event if, as a result of an actual conversion, such holder would receive, in the aggregate, an amount greater than the amount that
would be distributed otherwise.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;Redemption&amp;#xa0;&amp;#x2014;
&lt;/b&gt;The Series A, Series B, Series C, and Series D Preferred Stock are not redeemable at the option of the holder. However, so
long as a majority of the Preferred Stock originally issued remains outstanding, the Company shall not, without first obtaining
the approval of the holders of at least a majority of the then outstanding shares of Preferred Stock, redeem, purchase, or acquire
any share or shares of Preferred Stock or common stock, except the repurchase, if any, of shares of common stock from employees,
officers, directors, consultants, or other persons performing services for the Company.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;Conversion
Rights &amp;#x2014;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.5in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in; font-size: 10pt&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;(a)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Right to Convert.&amp;#xa0;Each share of Preferred Stock shall be convertible, at the option of the holder thereof, at any time, into such number of fully paid and non-assessable shares of common stock as is determined by dividing the applicable original issue price by the applicable conversion price. The initial conversion price per share of Series A, Series B, Series C, and Series D Preferred Stock shall be $1.9658, $4.0778, $4.1699, and $4.6018, respectively, provided, however, that the conversion price shall be subject to adjustment as set forth below.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.5in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in; font-size: 10pt&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;(b)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Automatic Conversion.&amp;#xa0;Each share of Series A, Series B, Series C, and Series D Preferred Stock shall automatically be converted into shares of common stock upon the earlier of (i)&amp;#xa0;the closing of the sale of common stock in an underwritten public offering pursuant to a registration statement under the Securities Act of 1933, the public offering price of which is not less than $30.0 million in the aggregate, (ii)&amp;#xa0;the date, or the occurrence of an event, specified by vote or written consent, or agreement of the holders of a majority of the then outstanding shares of Preferred Stock (voting together as a single class&amp;#xa0;and not as separate series and on an as-converted basis), or (iii) a closing of a merger with a publicly-traded entity that has no operations other than searching for an operating company with which to merge (a &amp;#x201c;SPAC&amp;#x201d;) at a value per share in accordance with the restated certification incorporation, resulting in at least $30.0 million of proceeds to the Company (including any cash acquired in the merger with the SPAC).&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%&quot;&gt;&lt;tr style=&quot;vertical-align: top; text-align: justify&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;(c)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Conversion
Price Adjustment.&amp;#xa0;The conversion Price of Preferred Stock shall be subject to adjustment as follows: If the Company shall
issue any additional stock (as defined in the associated agreement) without consideration or for a consideration per share less
than the Conversion Price in effect immediately prior to the issuance of such additional stock, the Conversion Price shall be
adjusted.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;</clnn:RedeemableConvertiblePreferredStockDisclosureTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions unitRef="shares" contextRef="c182_From2Feb2015To30Apr2015_SeriesAPreferredStockMember" decimals="INF">16066503</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <us-gaap:SaleOfStockPricePerShare unitRef="usdPershares" contextRef="c183_AsOf30Apr2015_SeriesAPreferredStockMember" decimals="4">1.9658</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c182_From2Feb2015To30Apr2015_SeriesAPreferredStockMember" decimals="-5">9500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <clnn:ConversionOfSecuredPromissoryNotes unitRef="usd" contextRef="c182_From2Feb2015To30Apr2015_SeriesAPreferredStockMember" decimals="-5">18000000</clnn:ConversionOfSecuredPromissoryNotes>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions unitRef="shares" contextRef="c184_From2Dec2016To31Dec2016_SeriesBPreferredStockMember" decimals="INF">4168815</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <us-gaap:SaleOfStockPricePerShare unitRef="usdPershares" contextRef="c185_AsOf31Dec2016_SeriesBPreferredStockMember" decimals="4">4.0778</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c184_From2Dec2016To31Dec2016_SeriesBPreferredStockMember" decimals="-5">16600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <clnn:NetOfIssuanceCosts unitRef="usd" contextRef="c184_From2Dec2016To31Dec2016_SeriesBPreferredStockMember" decimals="-5">400000</clnn:NetOfIssuanceCosts>
  <clnn:CashConsiderationReceived unitRef="usd" contextRef="c184_From2Dec2016To31Dec2016_SeriesBPreferredStockMember" decimals="-5">16600000</clnn:CashConsiderationReceived>
  <us-gaap:AdditionalPaidInCapital unitRef="usd" contextRef="c185_AsOf31Dec2016_SeriesBPreferredStockMember" decimals="-5">3400000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions unitRef="shares" contextRef="c186_From2Aug2018To31Oct2018_InvestorMember_SeriesCPreferredStockMember" decimals="INF">4929718</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions unitRef="shares" contextRef="c187_From2Aug2018To31Oct2018_SeriesCPreferredStockMember" decimals="INF">3849011</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <us-gaap:SaleOfStockPricePerShare unitRef="usdPershares" contextRef="c188_AsOf31Oct2018_SeriesCPreferredStockMember" decimals="4">4.1699</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c187_From2Aug2018To31Oct2018_SeriesCPreferredStockMember" decimals="-5">15900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <clnn:NetOfIssuanceCosts unitRef="usd" contextRef="c187_From2Aug2018To31Oct2018_SeriesCPreferredStockMember" decimals="-5">200000</clnn:NetOfIssuanceCosts>
  <us-gaap:ProceedsFromIssuanceOfWarrants unitRef="usd" contextRef="c187_From2Aug2018To31Oct2018_SeriesCPreferredStockMember" decimals="-5">1500000</us-gaap:ProceedsFromIssuanceOfWarrants>
  <clnn:SharesIssuedUponConversionOfConvertiblePromissoryNote unitRef="shares" contextRef="c187_From2Aug2018To31Oct2018_SeriesCPreferredStockMember" decimals="INF">1080707</clnn:SharesIssuedUponConversionOfConvertiblePromissoryNote>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions unitRef="shares" contextRef="c189_From2Mar2019To31Jul2019_InvestorMember_SeriesCPreferredStockMember" decimals="INF">2334801</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions unitRef="shares" contextRef="c190_From2Mar2019To31Jul2019_SeriesCPreferredStockMember" decimals="INF">1935111</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <us-gaap:SaleOfStockPricePerShare unitRef="usdPershares" contextRef="c191_AsOf31Jul2019_SeriesCPreferredStockMember" decimals="4">4.1699</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c190_From2Mar2019To31Jul2019_SeriesCPreferredStockMember" decimals="-5">8100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <clnn:WarrantsSharesInExercise unitRef="shares" contextRef="c190_From2Mar2019To31Jul2019_SeriesCPreferredStockMember" decimals="INF">399690</clnn:WarrantsSharesInExercise>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions unitRef="shares" contextRef="c192_From2Aug2020To31Aug2020_InvestorMember_SeriesDPreferredStockMember" decimals="INF">9394057</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions unitRef="shares" contextRef="c193_From2Aug2020To31Aug2020_SeriesDPreferredStockMember" decimals="INF">7896922</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <us-gaap:SaleOfStockPricePerShare unitRef="usdPershares" contextRef="c194_AsOf31Aug2020_SeriesDPreferredStockMember" decimals="4">4.6018</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c193_From2Aug2020To31Aug2020_SeriesDPreferredStockMember" decimals="-5">35100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <clnn:NetOfIssuanceCosts unitRef="usd" contextRef="c193_From2Aug2020To31Aug2020_SeriesDPreferredStockMember" decimals="-5">1300000</clnn:NetOfIssuanceCosts>
  <us-gaap:ConversionOfStockSharesConverted1 unitRef="shares" contextRef="c195_From2Aug2020To31Aug2020_ConvertibleNotesPayableMember_SeriesDPreferredStockMember" decimals="INF">1497135</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:ConversionOfStockAmountConverted1 unitRef="usd" contextRef="c193_From2Aug2020To31Aug2020_SeriesDPreferredStockMember" decimals="-5">6900000</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:PreferredStockConversionBasis contextRef="c0_From1Jan2020To31Dec2020">&amp;#x201d; In connection with the closing of the Reverse Recapitalization, the Preferred Stock converted into 36,893,894 shares of Common Stock on a 1:0.1389 basis (see Note 1).</us-gaap:PreferredStockConversionBasis>
  <us-gaap:ConversionOfStockSharesConverted1 unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">36893894</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:CommonStockConvertibleConversionPriceIncrease unitRef="usdPershares" contextRef="c196_From1Jan2020To31Dec2020_SeriesAPreferredStockMember" decimals="4">1.9658</us-gaap:CommonStockConvertibleConversionPriceIncrease>
  <us-gaap:CommonStockConvertibleConversionPriceIncrease unitRef="usdPershares" contextRef="c197_From1Jan2020To31Dec2020_SeriesBPreferredStockMember" decimals="4">4.0778</us-gaap:CommonStockConvertibleConversionPriceIncrease>
  <us-gaap:CommonStockConvertibleConversionPriceIncrease unitRef="usdPershares" contextRef="c198_From1Jan2020To31Dec2020_SeriesCPreferredStockMember" decimals="4">4.1699</us-gaap:CommonStockConvertibleConversionPriceIncrease>
  <us-gaap:CommonStockConvertibleConversionPriceIncrease unitRef="usdPershares" contextRef="c199_From1Jan2020To31Dec2020_SeriesDPreferredStockMember" decimals="4">4.6018</us-gaap:CommonStockConvertibleConversionPriceIncrease>
  <us-gaap:ConversionOfStockDescription contextRef="c0_From1Jan2020To31Dec2020">Each share of Series A, Series B, Series C, and Series D Preferred Stock shall automatically be converted into shares of common stock upon the earlier of (i) the closing of the sale of common stock in an underwritten public offering pursuant to a registration statement under the Securities Act of 1933, the public offering price of which is not less than $30.0 million in the aggregate, (ii) the date, or the occurrence of an event, specified by vote or written consent, or agreement of the holders of a majority of the then outstanding shares of Preferred Stock (voting together as a single class and not as separate series and on an as-converted basis), or (iii) a closing of a merger with a publicly-traded entity that has no operations other than searching for an operating company with which to merge (a &amp;#x201c;SPAC&amp;#x201d;) at a value per share in accordance with the restated certification incorporation, resulting in at least $30.0 million of proceeds to the Company (including any cash acquired in the merger with the SPAC).</us-gaap:ConversionOfStockDescription>
  <us-gaap:TemporaryEquityTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;18&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;December
    31, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Preferred&lt;br/&gt;
    Shares&lt;br/&gt; Authorized&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Preferred&lt;br/&gt;
    Shares&lt;br/&gt; Issued and&lt;br/&gt; Outstanding&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Carrying&lt;br/&gt;
    Value&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Liquidation&lt;br/&gt;
    Value&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Common
    Stock&lt;br/&gt; Issuable Upon&lt;br/&gt; Conversion&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; width: 40%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Series
    A Preferred Stock&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;17,675,175&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;16,066,503&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;27,485&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;31,584&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;16,066,503&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Series
    B Preferred Stock&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;4,168,815&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;4,168,815&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;16,582&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;16,999&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;4,168,815&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Series
    C Preferred Stock&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;9,192,018&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;7,264,519&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;28,594&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;30,292&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;7,264,519&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;31,036,008&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;27,499,837&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;72,661&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;78,875&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;27,499,837&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:TemporaryEquityTableTextBlock>
  <us-gaap:TemporaryEquitySharesAuthorized unitRef="shares" contextRef="c99_AsOf31Dec2019_SeriesAPreferredStockMember" decimals="INF">17675175</us-gaap:TemporaryEquitySharesAuthorized>
  <clnn:TemporaryEquitySharesIssuedAndOutstanding unitRef="shares" contextRef="c105_From1Jan2019To31Dec2019_SeriesAPreferredStockMember" decimals="INF">16066503</clnn:TemporaryEquitySharesIssuedAndOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent unitRef="usd" contextRef="c99_AsOf31Dec2019_SeriesAPreferredStockMember" decimals="-3">27485000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityLiquidationPreference unitRef="usd" contextRef="c99_AsOf31Dec2019_SeriesAPreferredStockMember" decimals="-3">31584000</us-gaap:TemporaryEquityLiquidationPreference>
  <clnn:TemporaryEquitySharesCommonStockIssuableUponConversion unitRef="usd" contextRef="c99_AsOf31Dec2019_SeriesAPreferredStockMember" decimals="-3">16066503000</clnn:TemporaryEquitySharesCommonStockIssuableUponConversion>
  <us-gaap:TemporaryEquitySharesAuthorized unitRef="shares" contextRef="c200_AsOf31Dec2019_SeriesBPreferredStockMember" decimals="INF">4168815</us-gaap:TemporaryEquitySharesAuthorized>
  <clnn:TemporaryEquitySharesIssuedAndOutstanding unitRef="shares" contextRef="c201_From1Jan2019To31Dec2019_SeriesBPreferredStockMember" decimals="INF">4168815</clnn:TemporaryEquitySharesIssuedAndOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent unitRef="usd" contextRef="c200_AsOf31Dec2019_SeriesBPreferredStockMember" decimals="-3">16582000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityLiquidationPreference unitRef="usd" contextRef="c200_AsOf31Dec2019_SeriesBPreferredStockMember" decimals="-3">16999000</us-gaap:TemporaryEquityLiquidationPreference>
  <clnn:TemporaryEquitySharesCommonStockIssuableUponConversion unitRef="usd" contextRef="c200_AsOf31Dec2019_SeriesBPreferredStockMember" decimals="-3">4168815000</clnn:TemporaryEquitySharesCommonStockIssuableUponConversion>
  <us-gaap:TemporaryEquitySharesAuthorized unitRef="shares" contextRef="c101_AsOf31Dec2019_SeriesCPreferredStockMember" decimals="INF">9192018</us-gaap:TemporaryEquitySharesAuthorized>
  <clnn:TemporaryEquitySharesIssuedAndOutstanding unitRef="shares" contextRef="c102_From1Jan2019To31Dec2019_SeriesCPreferredStockMember" decimals="INF">7264519</clnn:TemporaryEquitySharesIssuedAndOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent unitRef="usd" contextRef="c101_AsOf31Dec2019_SeriesCPreferredStockMember" decimals="-3">28594000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityLiquidationPreference unitRef="usd" contextRef="c101_AsOf31Dec2019_SeriesCPreferredStockMember" decimals="-3">30292000</us-gaap:TemporaryEquityLiquidationPreference>
  <clnn:TemporaryEquitySharesCommonStockIssuableUponConversion unitRef="usd" contextRef="c101_AsOf31Dec2019_SeriesCPreferredStockMember" decimals="-3">7264519000</clnn:TemporaryEquitySharesCommonStockIssuableUponConversion>
  <clnn:TemporaryEquitySharesIssuedAndOutstanding unitRef="shares" contextRef="c9_From1Jan2019To31Dec2019" decimals="INF">27499837</clnn:TemporaryEquitySharesIssuedAndOutstanding>
  <clnn:TemporaryEquitySharesCommonStockIssuableUponConversion unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-3">27499837000</clnn:TemporaryEquitySharesCommonStockIssuableUponConversion>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;18.
Common Stock&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;As
of December 31, 2020, the Company&amp;#x2019;s certificate of incorporation, as amended and restated, authorized the Company to issue
100,000,000 shares of the Company&amp;#x2019;s Common Stock, par value $0.0001 per share and 1,000,000 shares of the Company&amp;#x2019;s
Preferred Stock, par value $0.0001 per share.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Company&amp;#x2019;s
common shareholders are entitled to one vote per share and to notice of any shareholders&amp;#x2019; meeting. Voting, dividend and liquidation
rights of the holders of Common Stock are subject to the prior rights of holders of all classes of stock and are qualified by the
rights, powers, preferences and privileges of the holders of Preferred Stock. No distributions shall be made with respect to Common
Stock until all declared dividends to Preferred Shares have been paid or set aside for payment to the holders of Preferred Stock.
Common Stock is not redeemable at the option of the holder.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;On
the closing of the Reverse Recapitalization, the total 2,303,495 of the Tottenham ordinary shares held by the Initial Shareholders
and public shareholders were converted into the same number of Company&amp;#x2019;s Common Stock (see Note 3).&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;On
the closing of the Reverse Recapitalization, 644,164 shares of the Company&amp;#x2019;s Common Stock were issued to LifeSci as financial
advisor to the Reverse Recapitalization (see Note 3).&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in&quot;&gt;On December 28, 2020 and
prior to the closing of the Reverse Recapitalization, various PIPE investors purchased 2,239,500 shares of the Company&amp;#x2019;s
Common Stock at a price of $10.00 per share and 1,119,750 warrants to purchase, at an exercise price of $0.01 per share, one share
of the Company&amp;#x2019;s Common Stock for net proceeds of $22.2 million (see Notes 1 and 3).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;As of December 31,
2020, the Company&amp;#x2019;s common shares issued and outstanding are 59,526,171 and there are no preferred shares issued and outstanding
(see Note 17).&lt;/p&gt;&lt;br/&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <clnn:PreferredStockShares unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">1000000</clnn:PreferredStockShares>
  <us-gaap:PreferredStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c3_AsOf31Dec2020" decimals="4">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <clnn:IssuanceOfCommonStockUponReverseRecapitalization unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">2303495</clnn:IssuanceOfCommonStockUponReverseRecapitalization>
  <clnn:RecapitalizationShare unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">644164</clnn:RecapitalizationShare>
  <us-gaap:SharePrice unitRef="usdPershares" contextRef="c64_AsOf28Dec2020" decimals="2">10.00</us-gaap:SharePrice>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 unitRef="usdPershares" contextRef="c64_AsOf28Dec2020" decimals="2">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:EarningsPerShareTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;19.
Net Loss Per Share Attributable to Common Shareholders&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
following table sets forth the computation of basic and diluted net loss per share attributable to common shareholders (in thousands,
except share and per share data):&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;As of&lt;br/&gt; December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Numerator:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; text-indent: -0.125in; padding-left: 0.25in&quot;&gt;Net loss attributable to common shareholders&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;(19,277&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;(16,155&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in&quot;&gt;Denominator:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in&quot;&gt;Weighted average shares outstanding&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;17,503,992&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;17,357,505&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in&quot;&gt;Net loss per share attributable to common shareholders, basic and diluted&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;(1.10&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;(0.93&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Included within weighted
average common shares outstanding are 1,119,750 common shares issuable upon the exercise of the PIPE warrants as the warrants are
exercisable at any time for nominal consideration, and as such, the shares are considered outstanding for the purpose of calculating
basic and diluted net loss per share attributable to common shareholders.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Company has not
considered the effect of the Chardan Unit Purchase Option that would convert to 242,000 shares of the Company&amp;#x2019;s Common Stock
and warrants to purchase 110,000 shares of the Company&amp;#x2019;s Commons Stock, in the calculation of diluted loss per share, since
the conversion of the Chardan Unit Purchase Option and the exercise of the Chardan Unit Purchase Option Warrants into the Company&amp;#x2019;s
Commons Stock would be anti-dilutive (see Notes 1 and 10).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share
attributable to common shareholders for the periods presented because including them would have been antidilutive:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;As
    of&lt;br/&gt;
December&amp;#xa0;31,&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Series
    C redeemable convertible preferred stock&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;7,264,519&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Series
    B redeemable convertible preferred stock&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;4,168,815&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Series
    A redeemable convertible preferred stock&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;16,066,503&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Series
    C redeemable convertible preferred stock warrants&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;271,439&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Series
    A redeemable convertible preferred stock warrants&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1,608,672&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Common
    stock warrants (see Note 10)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;4,336,613&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Options
    to purchase common stock&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;7,032,591&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;6,878,172&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Chardan
    Unit Purchase Option to purchase common stock (see Note 1)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;242,000&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Chardan
    Unit Purchase Option Warrants (see Notes 1 and 10)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;110,000&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Earn-out
    shares (see Note 3 and 12)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;9,096,185&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 4pt; vertical-align: top; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;20,817,389&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;36,258,120&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;</us-gaap:EarningsPerShareTextBlock>
  <clnn:NumberOfSharesIssuableOnExerciseOfWarrants unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">1119750</clnn:NumberOfSharesIssuableOnExerciseOfWarrants>
  <clnn:ChardanUnitPurchaseOptionToPurchaseCommonStock unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">242000</clnn:ChardanUnitPurchaseOptionToPurchaseCommonStock>
  <clnn:ChardanUnitPurchaseOptionWarrants unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">110000</clnn:ChardanUnitPurchaseOptionWarrants>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;As of&lt;br/&gt; December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Numerator:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; text-indent: -0.125in; padding-left: 0.25in&quot;&gt;Net loss attributable to common shareholders&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;(19,277&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;(16,155&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in&quot;&gt;Denominator:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in&quot;&gt;Weighted average shares outstanding&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;17,503,992&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;17,357,505&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in&quot;&gt;Net loss per share attributable to common shareholders, basic and diluted&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;(1.10&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;(0.93&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;As
    of&lt;br/&gt;
December&amp;#xa0;31,&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Series
    C redeemable convertible preferred stock&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;7,264,519&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Series
    B redeemable convertible preferred stock&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;4,168,815&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Series
    A redeemable convertible preferred stock&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;16,066,503&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Series
    C redeemable convertible preferred stock warrants&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;271,439&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Series
    A redeemable convertible preferred stock warrants&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1,608,672&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Common
    stock warrants (see Note 10)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;4,336,613&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Options
    to purchase common stock&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;7,032,591&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;6,878,172&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Chardan
    Unit Purchase Option to purchase common stock (see Note 1)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;242,000&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Chardan
    Unit Purchase Option Warrants (see Notes 1 and 10)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;110,000&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Earn-out
    shares (see Note 3 and 12)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;9,096,185&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 4pt; vertical-align: top; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;20,817,389&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;36,258,120&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <clnn:SeriesCRedeemableConvertiblePreferredStock unitRef="shares" contextRef="c9_From1Jan2019To31Dec2019" decimals="INF">7264519</clnn:SeriesCRedeemableConvertiblePreferredStock>
  <clnn:SeriesBRedeemableConvertiblePreferredStock unitRef="shares" contextRef="c9_From1Jan2019To31Dec2019" decimals="INF">4168815</clnn:SeriesBRedeemableConvertiblePreferredStock>
  <clnn:SeriesARedeemableConvertiblePreferredStock unitRef="shares" contextRef="c9_From1Jan2019To31Dec2019" decimals="INF">16066503</clnn:SeriesARedeemableConvertiblePreferredStock>
  <clnn:SeriesCRedeemableConvertiblePreferredStockWarrantsinShares unitRef="shares" contextRef="c9_From1Jan2019To31Dec2019" decimals="INF">271439</clnn:SeriesCRedeemableConvertiblePreferredStockWarrantsinShares>
  <clnn:SeriesARedeemableConvertiblePreferredStockWarrantsinShares unitRef="shares" contextRef="c9_From1Jan2019To31Dec2019" decimals="INF">1608672</clnn:SeriesARedeemableConvertiblePreferredStockWarrantsinShares>
  <clnn:CommonStockWarrants unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">4336613</clnn:CommonStockWarrants>
  <clnn:OptionsToPurchaseCommonStockinShares unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">7032591</clnn:OptionsToPurchaseCommonStockinShares>
  <clnn:OptionsToPurchaseCommonStockinShares unitRef="shares" contextRef="c9_From1Jan2019To31Dec2019" decimals="INF">6878172</clnn:OptionsToPurchaseCommonStockinShares>
  <clnn:EarnoutSharessee unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">9096185</clnn:EarnoutSharessee>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">20817389</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment unitRef="shares" contextRef="c9_From1Jan2019To31Dec2019" decimals="INF">36258120</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;20.
Related Party Transactions&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Related
Party Payables&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;During
years prior to 2020, the Company incurred expenses for compensation for consulting services provided by a member of the Board
of Directors. These expenses were fully paid as of December 31, 2020. As of December 31, 2019, the outstanding balance of $0.1
million was recorded in accounts payable.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Supply
Agreement&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in&quot;&gt;In August&amp;#xa0;2018, in
conjunction with an investment made in the Company&amp;#x2019;s Series C Preferred Stock and Series C Preferred Stock Warrants by 4Life,
LLC, an investor, the Company entered into a supply agreement with the investor. Under the terms of this agreement, the Company
granted the investor an exclusive license to pursue development of dietary supplements using certain of the Company&amp;#x2019;s intellectual
property (IP). The exclusive rights to the IP will be for a term of 5&amp;#xa0;years from the commencement of sales of licensed product
by the investor, with a deemed commencement date of January 1, 2023 if sales have not yet commenced, and is subject to annual minimum
sales. The agreement may be renewed for additional 5-year terms. If the investor fails to meet the annual minimum sales requirements,
the investor may pay an additional fee to maintain exclusivity or have the investor&amp;#x2019;s license converted to non-exclusive
rights. As part of this agreement, the Company will provide non-pharmaceutical product to the investor for development efforts
and potential future production, and the investor is to pay royalties of 3% of incremental sales, as defined in the agreement.
As of December 31, 2020, the Company had sold $70 thousand of product under this agreement, as well as $62 thousand of product
not under this agreement, and received $0.1 million in advance to be applied against future sales of product under this agreement.
The Company recorded this advanced amount as deferred revenue as of December 31, 2020 within accrued liabilities, and the Company
expects to fulfil the performance obligations to release the deferred revenue in the first half of 2021 as the investor purchases
product. As of December 31, 2020, the investor has made commercial sales of their products under the agreement which the Company
recognized as royalty revenues of $30 thousand. As of and for the year ended December 31, 2019, the Company had not sold any product
under this agreement, and there were no balances outstanding due to or from the investor.&lt;/p&gt;&lt;br/&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent unitRef="usd" contextRef="c202_AsOf31Dec2020_BoardOfDirectorsChairmanMember" decimals="-5">100000</us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c203_From1Aug2018To31Aug2018">Under the terms of this agreement, the Company granted the investor an exclusive license to pursue development of dietary supplements using certain of the Company&amp;#x2019;s intellectual property (IP). The exclusive rights to the IP will be for a term of 5 years from the commencement of sales of licensed product by the investor, with a deemed commencement date of January 1, 2023 if sales have not yet commenced, and is subject to annual minimum sales. The agreement may be renewed for additional 5-year terms. If the investor fails to meet the annual minimum sales requirements, the investor may pay an additional fee to maintain exclusivity or have the investor&amp;#x2019;s license converted to non-exclusive rights. As part of this agreement, the Company will provide non-pharmaceutical product to the investor for development efforts and potential future production, and the investor is to pay royalties of 3% of incremental sales, as defined in the agreement. As of December 31, 2020, the Company had sold $70 thousand of product under this agreement, as well as $62 thousand of product not under this agreement, and received $0.1 million in advance to be applied against future sales of product under this agreement.</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
  <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">30000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
  <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;21.
Geographic and Segment Information&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;i&gt;Geographic
Information&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company&amp;#x2019;s long-lived assets, which were composed of property and equipment, net by location was as follows (in thousands):&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-left: 0.125in; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;As
    of&lt;br/&gt;
December&amp;#xa0;31,&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-left: 0.125in; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;United
    States&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;3,997&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;3,908&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Australia&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;228&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;411&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Total
    property and equipment, net&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;4,225&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;4,319&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;i&gt;Segment
Information&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;As of December 31,
2019, the Company had a single operating segment, development and commercialization of proprietary nanotechnology drug suspensions
(&amp;#x201c;Drugs&amp;#x201d;). The Company identified a second segment, development and commercialization of proprietary dietary supplements
(&amp;#x201c;Supplements&amp;#x201d;), in January&amp;#xa0;2020. The Company&amp;#x2019;s chief operating decision maker, the CEO, now obtains and
reviews separate financial information for Supplements in deciding how to allocate resources to the segments and in assessing performance.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
operating results of the Company&amp;#x2019;s Drugs and Supplements segments for the years ended December 31, 2020 and 2019 were as
follows (in thousands):&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;As
    of&lt;br/&gt;
December 31,&lt;br/&gt;
2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Drugs&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Supplements&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Revenue
    from external customers&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;206&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;206&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(Loss)
    Income from operations&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(20,355&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;141&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(20,214&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;As of&lt;br/&gt;
December&amp;#xa0;31,&lt;br/&gt;
2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Drugs&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Supplements&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -0.125in; padding-left: 0.125in&quot;&gt;Revenue from external customers&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;width: 64%; text-align: left; text-indent: -0.125in; padding-left: 0.125in&quot;&gt;Loss from operations&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;(16,332&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;(16,332&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company&amp;#x2019;s long-lived assets, which were composed of property and equipment, net by segment was as follows (in thousands):&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;As of&lt;br/&gt; December&amp;#xa0;31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-indent: -9pt; padding-left: 9pt&quot;&gt;Drugs&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;3,990&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;4,319&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt&quot;&gt;Supplements&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;235&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&amp;#x2014;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt&quot;&gt;Total property and equipment, net&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;4,225&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;4,319&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
  <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-left: 0.125in; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;As
    of&lt;br/&gt;
December&amp;#xa0;31,&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; padding-left: 0.125in; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;United
    States&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;3,997&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;3,908&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Australia&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;228&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;411&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Total
    property and equipment, net&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;4,225&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;4,319&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c204_AsOf31Dec2020_US" decimals="-3">3997000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c205_AsOf31Dec2019_US" decimals="-3">3908000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c206_AsOf31Dec2020_AU" decimals="-3">228000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c207_AsOf31Dec2019_AU" decimals="-3">411000</us-gaap:PropertyPlantAndEquipmentNet>
  <clnn:ScheduleOfDrugsAndSupplementsSegmentsTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;As
    of&lt;br/&gt;
December 31,&lt;br/&gt;
2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Drugs&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Supplements&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Revenue
    from external customers&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;206&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;206&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom;  font-family: Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(Loss)
    Income from operations&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(20,355&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;141&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(20,214&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;As of&lt;br/&gt;
December&amp;#xa0;31,&lt;br/&gt;
2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Drugs&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Supplements&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -0.125in; padding-left: 0.125in&quot;&gt;Revenue from external customers&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;width: 64%; text-align: left; text-indent: -0.125in; padding-left: 0.125in&quot;&gt;Loss from operations&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;(16,332&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;(16,332&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</clnn:ScheduleOfDrugsAndSupplementsSegmentsTableTextBlock>
  <us-gaap:Revenues unitRef="usd" contextRef="c208_From1Jan2020To31Dec2020_DrugsMember" xs:nil="true"/>
  <us-gaap:Revenues unitRef="usd" contextRef="c209_From1Jan2020To31Dec2020_SupplementsMember" decimals="-3">206000</us-gaap:Revenues>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c208_From1Jan2020To31Dec2020_DrugsMember" decimals="-3">-20355000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c209_From1Jan2020To31Dec2020_SupplementsMember" decimals="-3">141000</us-gaap:OperatingIncomeLoss>
  <us-gaap:Revenues unitRef="usd" contextRef="c210_From1Jan2019To31Dec2019_DrugsMember" xs:nil="true"/>
  <us-gaap:Revenues unitRef="usd" contextRef="c211_From1Jan2019To31Dec2019_SupplementsMember" xs:nil="true"/>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c210_From1Jan2019To31Dec2019_DrugsMember" decimals="-3">-16332000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c211_From1Jan2019To31Dec2019_SupplementsMember" xs:nil="true"/>
  <clnn:ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;As of&lt;br/&gt; December&amp;#xa0;31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-indent: -9pt; padding-left: 9pt&quot;&gt;Drugs&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;3,990&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;4,319&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt&quot;&gt;Supplements&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;235&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&amp;#x2014;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt&quot;&gt;Total property and equipment, net&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;4,225&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;4,319&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</clnn:ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c212_AsOf31Dec2020_DrugsMember" decimals="-3">3990000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c213_AsOf31Dec2019_DrugsMember" decimals="-3">4319000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c214_AsOf31Dec2020_SupplementsMember" decimals="-3">235000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c215_AsOf31Dec2019_SupplementsMember" xs:nil="true"/>
  <us-gaap:SubsequentEventsTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;22.
Subsequent Events&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in&quot;&gt;On
January 11, 2021, the U.S. Small Business Administration notified the Company that the PPP loan of $0.6 million was forgiven.
On that date, the Company recorded a gain on forgiveness of the PPP loan of $0.6 million in its consolidated statement of operations
and comprehensive loss.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;On January 27, 2021,
the Company was awarded the Michael J. Fox Foundation grant for $0.5 million and funding is milestone based. On that date, the
grant was recorded in accrued liabilities in the consolidated balance sheets, and as the associated conditions or obligations are
met, the grant funding will be recognized as a reduction in research and development expenses in the consolidated statements of
operations and comprehensive loss.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;On February 16, 2021,
the Company filed a registration statement on Form S-1 to register 4,541,481 shares of Common Stock underlying outstanding warrants
that the Company had issued, among which 2,517,500 and 904,231 warrants were originally issued by Tottenham and Clene Nanomedicine,
respectively, prior to the closing of the Reverse Recapitalization, and 1,119,750 warrants were issued as part of the PIPE offering
in connection with the closing of the Reverse Recapitalization. The Company will receive aggregate gross proceeds of $30.7 million
if all of these warrants are exercised. In addition, the registration statement on Form S-1 included 23,251,553 shares of the Common
Stock to be registered for possible sale by the selling shareholders. The Company will not receive any proceeds from the sales
by the selling shareholders. Incident to the registration of the Common Stock, the Company incurred certain offering costs, which
will be recognized as an expense within general and administrative expenses on the consolidated statement of operations and comprehensive
loss in the first quarter of 2021.&lt;/p&gt;&lt;br/&gt;</us-gaap:SubsequentEventsTextBlock>
  <clnn:PaycheckProtectionProgramLoan unitRef="usd" contextRef="c216_From1Jan2021To11Jan2021_SubsequentEventMember" decimals="-5">600000</clnn:PaycheckProtectionProgramLoan>
  <clnn:GainOnForgivenessLoan unitRef="usd" contextRef="c216_From1Jan2021To11Jan2021_SubsequentEventMember" decimals="-5">600000</clnn:GainOnForgivenessLoan>
  <clnn:FoundationGrantCost unitRef="usd" contextRef="c217_From1Jan2021To27Jan2021_SubsequentEventMember" decimals="-5">500000</clnn:FoundationGrantCost>
  <us-gaap:SubsequentEventDescription contextRef="c218_From1Feb2021To16Feb2021_SubsequentEventMember">On February 16, 2021, the Company filed a registration statement on Form S-1 to register 4,541,481 shares of Common Stock underlying outstanding warrants that the Company had issued, among which 2,517,500 and 904,231 warrants were originally issued by Tottenham and Clene Nanomedicine, respectively, prior to the closing of the Reverse Recapitalization, and 1,119,750 warrants were issued as part of the PIPE offering in connection with the closing of the Reverse Recapitalization.</us-gaap:SubsequentEventDescription>
  <clnn:AggregateGrossProceedWarrantsExercised unitRef="usd" contextRef="c218_From1Feb2021To16Feb2021_SubsequentEventMember" decimals="-5">30700000</clnn:AggregateGrossProceedWarrantsExercised>
  <clnn:SaleOfStockholdersCommonStock unitRef="shares" contextRef="c218_From1Feb2021To16Feb2021_SubsequentEventMember" decimals="INF">23251553</clnn:SaleOfStockholdersCommonStock>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>clnn-20201231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Mar 26 16:52:33 EDT 2021 -->
<xs:schema elementFormDefault="qualified" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" targetNamespace="http://www.cleaninccom/20201231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:clnn="http://www.cleaninccom/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="clnn-20201231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="clnn-20201231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="clnn-20201231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="clnn-20201231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.cleaninccom/role/ConsolidatedBalanceSheet" id="clnn_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ConsolidatedBalanceSheet_Parentheticals" id="clnn_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ConsolidatedIncomeStatement" id="clnn_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ShareholdersEquityType2or3" id="clnn_r_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ShareholdersEquityType2or3_Parentheticals" id="clnn_r_ShareholdersEquityType2or3_Parentheticals">
        <link:definition>005 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ConsolidatedCashFlow" id="clnn_r_ConsolidatedCashFlow">
        <link:definition>006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/NatureoftheBusinessandBasisofPresentation" id="clnn_r_NatureoftheBusinessandBasisofPresentation">
        <link:definition>007 - Disclosure - Nature of the Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/SummaryofSignificantAccountingPolicies" id="clnn_r_SummaryofSignificantAccountingPolicies">
        <link:definition>008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicine" id="clnn_r_ReverseRecapitalizationwithTottenhamandCleneNanomedicine">
        <link:definition>009 - Disclosure - Reverse Recapitalization with Tottenham and Clene Nanomedicine</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/Prepaidexpensesandothercurrentassets" id="clnn_r_Prepaidexpensesandothercurrentassets">
        <link:definition>010 - Disclosure - Prepaid expenses and other current assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/PropertyandEquipmentNet" id="clnn_r_PropertyandEquipmentNet">
        <link:definition>011 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/AccruedLiabilities" id="clnn_r_AccruedLiabilities">
        <link:definition>012 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/Leases" id="clnn_r_Leases">
        <link:definition>013 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/NotesPayable" id="clnn_r_NotesPayable">
        <link:definition>014 - Disclosure - Notes Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/PreferredStockWarrantLiability" id="clnn_r_PreferredStockWarrantLiability">
        <link:definition>015 - Disclosure - Preferred Stock Warrant Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/CommonStockWarrants" id="clnn_r_CommonStockWarrants">
        <link:definition>016 - Disclosure - Common Stock Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ConvertibleNotes" id="clnn_r_ConvertibleNotes">
        <link:definition>017 - Disclosure - Convertible Notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/DerivativeInstruments" id="clnn_r_DerivativeInstruments">
        <link:definition>018 - Disclosure - Derivative Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/CommitmentsandContingencies" id="clnn_r_CommitmentsandContingencies">
        <link:definition>019 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/IncomeTaxes" id="clnn_r_IncomeTaxes">
        <link:definition>020 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/StockBasedCompensation" id="clnn_r_StockBasedCompensation">
        <link:definition>021 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/FairValue" id="clnn_r_FairValue">
        <link:definition>022 - Disclosure - Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/RedeemableConvertiblePreferredStock" id="clnn_r_RedeemableConvertiblePreferredStock">
        <link:definition>023 - Disclosure - Redeemable Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/CommonStock" id="clnn_r_CommonStock">
        <link:definition>024 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/NetLossPerShareAttributabletoCommonShareholders" id="clnn_r_NetLossPerShareAttributabletoCommonShareholders">
        <link:definition>025 - Disclosure - Net Loss Per Share Attributable to Common Shareholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/RelatedPartyTransactions" id="clnn_r_RelatedPartyTransactions">
        <link:definition>026 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/GeographicandSegmentInformation" id="clnn_r_GeographicandSegmentInformation">
        <link:definition>027 - Disclosure - Geographic and Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/SubsequentEvents" id="clnn_r_SubsequentEvents">
        <link:definition>028 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/AccountingPoliciesByPolicy" id="clnn_r_AccountingPoliciesByPolicy">
        <link:definition>029 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/PrepaidexpensesandothercurrentassetsTables" id="clnn_r_PrepaidexpensesandothercurrentassetsTables">
        <link:definition>030 - Disclosure - Prepaid expenses and other current assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/PropertyandEquipmentNetTables" id="clnn_r_PropertyandEquipmentNetTables">
        <link:definition>031 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/AccruedLiabilitiesTables" id="clnn_r_AccruedLiabilitiesTables">
        <link:definition>032 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/LeasesTables" id="clnn_r_LeasesTables">
        <link:definition>033 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/PreferredStockWarrantLiabilityTables" id="clnn_r_PreferredStockWarrantLiabilityTables">
        <link:definition>034 - Disclosure - Preferred Stock Warrant Liability (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/CommonStockWarrantsTables" id="clnn_r_CommonStockWarrantsTables">
        <link:definition>035 - Disclosure - Common Stock Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/IncomeTaxesTables" id="clnn_r_IncomeTaxesTables">
        <link:definition>036 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/StockBasedCompensationTables" id="clnn_r_StockBasedCompensationTables">
        <link:definition>037 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/FairValueTables" id="clnn_r_FairValueTables">
        <link:definition>038 - Disclosure - Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/RedeemableConvertiblePreferredStockTables" id="clnn_r_RedeemableConvertiblePreferredStockTables">
        <link:definition>039 - Disclosure - Redeemable Convertible Preferred Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/NetLossPerShareAttributabletoCommonShareholdersTables" id="clnn_r_NetLossPerShareAttributabletoCommonShareholdersTables">
        <link:definition>040 - Disclosure - Net Loss Per Share Attributable to Common Shareholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/GeographicandSegmentInformationTables" id="clnn_r_GeographicandSegmentInformationTables">
        <link:definition>041 - Disclosure - Geographic and Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/NatureoftheBusinessandBasisofPresentationDetails" id="clnn_r_NatureoftheBusinessandBasisofPresentationDetails">
        <link:definition>042 - Disclosure - Nature of the Business and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails" id="clnn_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>043 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails" id="clnn_r_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails">
        <link:definition>044 - Disclosure - Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofprepaidexpensesandothercurrentassetsTable" id="clnn_r_ScheduleofprepaidexpensesandothercurrentassetsTable">
        <link:definition>045 - Disclosure - Prepaid expenses and other current assets (Details) - Schedule of prepaid expenses and other current assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/PropertyandEquipmentNetDetails" id="clnn_r_PropertyandEquipmentNetDetails">
        <link:definition>046 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetTable" id="clnn_r_ScheduleofpropertyandequipmentnetTable">
        <link:definition>047 - Disclosure - Property and Equipment, Net (Details) - Schedule of property and equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofaccruedliabilitiesTable" id="clnn_r_ScheduleofaccruedliabilitiesTable">
        <link:definition>048 - Disclosure - Accrued Liabilities (Details) - Schedule of accrued liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/LeasesDetails" id="clnn_r_LeasesDetails">
        <link:definition>049 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofnoncancelableoperatingleasearrangementsTable" id="clnn_r_ScheduleofnoncancelableoperatingleasearrangementsTable">
        <link:definition>050 - Disclosure - Leases (Details) - Schedule of noncancelable operating lease arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleoffinanceleaseobligationsandincludedpropertyandequipmentTable" id="clnn_r_ScheduleoffinanceleaseobligationsandincludedpropertyandequipmentTable">
        <link:definition>051 - Disclosure - Leases (Details) - Schedule of finance lease obligations and included property and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleoffinanceandoperatingleasecostsTable" id="clnn_r_ScheduleoffinanceandoperatingleasecostsTable">
        <link:definition>052 - Disclosure - Leases (Details) - Schedule of finance and operating lease costs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofsupplementalcashflowinformationTable" id="clnn_r_ScheduleofsupplementalcashflowinformationTable">
        <link:definition>053 - Disclosure - Leases (Details) - Schedule of supplemental cash flow information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/NotesPayableDetails" id="clnn_r_NotesPayableDetails">
        <link:definition>054 - Disclosure - Notes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/PreferredStockWarrantLiabilityDetails" id="clnn_r_PreferredStockWarrantLiabilityDetails">
        <link:definition>055 - Disclosure - Preferred Stock Warrant Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/SchedulefairvalueoftheoutstandingwarrantsTable" id="clnn_r_SchedulefairvalueoftheoutstandingwarrantsTable">
        <link:definition>056 - Disclosure - Preferred Stock Warrant Liability (Details) - Schedule fair value of the outstanding warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/CommonStockWarrantsDetails" id="clnn_r_CommonStockWarrantsDetails">
        <link:definition>057 - Disclosure - Common Stock Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable" id="clnn_r_ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable">
        <link:definition>058 - Disclosure - Common Stock Warrants (Details) - Schedule of outstanding warrants to purchase shares of common stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ConvertibleNotesDetails" id="clnn_r_ConvertibleNotesDetails">
        <link:definition>059 - Disclosure - Convertible Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/DerivativeInstrumentsDetails" id="clnn_r_DerivativeInstrumentsDetails">
        <link:definition>060 - Disclosure - Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/IncomeTaxesDetails" id="clnn_r_IncomeTaxesDetails">
        <link:definition>061 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofcomponentsofincomelossbeforeincometaxesTable" id="clnn_r_ScheduleofcomponentsofincomelossbeforeincometaxesTable">
        <link:definition>062 - Disclosure - Income Taxes (Details) - Schedule of components of income (loss) before income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofincometaxexpensebenefitTable" id="clnn_r_ScheduleofincometaxexpensebenefitTable">
        <link:definition>063 - Disclosure - Income Taxes (Details) - Schedule of income tax expense (benefit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofincometaxreconciliationTable" id="clnn_r_ScheduleofincometaxreconciliationTable">
        <link:definition>064 - Disclosure - Income Taxes (Details) - Schedule of income tax reconciliation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofdeferredtaxassetsandliabilitiesTable" id="clnn_r_ScheduleofdeferredtaxassetsandliabilitiesTable">
        <link:definition>065 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets and liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/StockBasedCompensationDetails" id="clnn_r_StockBasedCompensationDetails">
        <link:definition>066 - Disclosure - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraqWjSnTNF4jeT3oaMW8W5R0MkiIXXy8k2PQbBklJ1lYf+6GCuiY/lJFjk6uDeNN+gvvgD/ctbqbBhZgNg1qNU0EiFrWvY1hT6GmZd73HE7TJaI9wGp4wAxzd2UaTwEVsbp/IQFhRTHB/tg6uRHFmIlGRCdDj17aZ0Z2zXZ5EK1ygtUPo1grhOt] CSR-->
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofstockbasedcompensationexpenseTable" id="clnn_r_ScheduleofstockbasedcompensationexpenseTable">
        <link:definition>067 - Disclosure - Stock-Based Compensation (Details) - Schedule of stock-based compensation expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable" id="clnn_r_ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable">
        <link:definition>068 - Disclosure - Stock-Based Compensation (Details) - Schedule of outstanding common stock options and related activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleoffairvalueofthesestockoptionsawardsgrantedTable" id="clnn_r_ScheduleoffairvalueofthesestockoptionsawardsgrantedTable">
        <link:definition>069 - Disclosure - Stock-Based Compensation (Details) - Schedule of fair value of these stock options awards granted</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofrestrictedcommonstockactivityTable" id="clnn_r_ScheduleofrestrictedcommonstockactivityTable">
        <link:definition>070 - Disclosure - Stock-Based Compensation (Details) - Schedule of restricted common stock activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/FairValueDetails" id="clnn_r_FairValueDetails">
        <link:definition>071 - Disclosure - Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable" id="clnn_r_ScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable">
        <link:definition>072 - Disclosure - Fair Value (Details) - Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleoffairvalueoftheinitialcontingentearnoutTable" id="clnn_r_ScheduleoffairvalueoftheinitialcontingentearnoutTable">
        <link:definition>073 - Disclosure - Fair Value (Details) - Schedule of fair value of the initial contingent earn-out</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleoffinancialliabilityrelatedtothenotespayablethederivativeinstrumentthePreferredStockwarrantsandthecontingentearnoutmeasuredatfairvalueTable" id="clnn_r_ScheduleoffinancialliabilityrelatedtothenotespayablethederivativeinstrumentthePreferredStockwarrantsandthecontingentearnoutmeasuredatfairvalueTable">
        <link:definition>074 - Disclosure - Fair Value (Details) - Schedule of financial liability related to the notes payable, the derivative instrument, the Preferred Stock warrants, and the contingent earn-out measured at fair value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/RedeemableConvertiblePreferredStockDetails" id="clnn_r_RedeemableConvertiblePreferredStockDetails">
        <link:definition>075 - Disclosure - Redeemable Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofPreferredStockTable" id="clnn_r_ScheduleofPreferredStockTable">
        <link:definition>076 - Disclosure - Redeemable Convertible Preferred Stock (Details) - Schedule of Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/CommonStockDetails" id="clnn_r_CommonStockDetails">
        <link:definition>077 - Disclosure - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/NetLossPerShareAttributabletoCommonShareholdersDetails" id="clnn_r_NetLossPerShareAttributabletoCommonShareholdersDetails">
        <link:definition>078 - Disclosure - Net Loss Per Share Attributable to Common Shareholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable" id="clnn_r_ScheduleofbasicanddilutednetlosspershareTable">
        <link:definition>079 - Disclosure - Net Loss Per Share Attributable to Common Shareholders (Details) - Schedule of basic and diluted net loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofdilutivesecuritieswereexcludedfromthecomputationofdilutednetlosspershareTable" id="clnn_r_ScheduleofdilutivesecuritieswereexcludedfromthecomputationofdilutednetlosspershareTable">
        <link:definition>080 - Disclosure - Net Loss Per Share Attributable to Common Shareholders (Details) - Schedule of dilutive securities were excluded from the computation of diluted net loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/RelatedPartyTransactionsDetails" id="clnn_r_RelatedPartyTransactionsDetails">
        <link:definition>081 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbylocationTable" id="clnn_r_ScheduleofpropertyandequipmentnetbylocationTable">
        <link:definition>082 - Disclosure - Geographic and Segment Information (Details) - Schedule of property and equipment, net by location</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofdrugsandsupplementssegmentsTable" id="clnn_r_ScheduleofdrugsandsupplementssegmentsTable">
        <link:definition>083 - Disclosure - Geographic and Segment Information (Details) - Schedule of drugs and supplements segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbysegmentTable" id="clnn_r_ScheduleofpropertyandequipmentnetbysegmentTable">
        <link:definition>084 - Disclosure - Geographic and Segment Information (Details) - Schedule of property and equipment, net by segment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/SubsequentEventsDetails" id="clnn_r_SubsequentEventsDetails">
        <link:definition>085 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd"/>
  <xs:element name="ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract"/>
  <xs:element name="PrepaidExpensesAndOtherCurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract"/>
  <xs:element name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfPropertyAndEquipmentNetAbstract"/>
  <xs:element name="ScheduleOfAccruedLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfAccruedLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfNoncancelableOperatingLeaseArrangementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfNoncancelableOperatingLeaseArrangementsAbstract"/>
  <xs:element name="ScheduleOfFinanceLeaseObligationsAndIncludedPropertyAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfFinanceLeaseObligationsAndIncludedPropertyAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfFinanceAndOperatingLeaseCostsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfFinanceAndOperatingLeaseCostsAbstract"/>
  <xs:element name="ScheduleOfSupplementalCashFlowInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfSupplementalCashFlowInformationAbstract"/>
  <xs:element name="ScheduleFairValueOfTheOutstandingWarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleFairValueOfTheOutstandingWarrantsAbstract"/>
  <xs:element name="CommonStockWarrantsDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CommonStockWarrantsDisclosureAbstract"/>
  <xs:element name="ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockAbstract"/>
  <xs:element name="ConvertibleNotesDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ConvertibleNotesDisclosureAbstract"/>
  <xs:element name="ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract"/>
  <xs:element name="ScheduleOfIncomeTaxExpenseBenefitAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfIncomeTaxExpenseBenefitAbstract"/>
  <xs:element name="ScheduleOfIncomeTaxReconciliationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfIncomeTaxReconciliationAbstract"/>
  <xs:element name="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfStockBasedCompensationExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfStockBasedCompensationExpenseAbstract"/>
  <xs:element name="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract"/>
  <xs:element name="ScheduleOfFairValueOfTheseStockOptionsAwardsGrantedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfFairValueOfTheseStockOptionsAwardsGrantedAbstract"/>
  <xs:element name="ScheduleOfRestrictedCommonStockActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfRestrictedCommonStockActivityAbstract"/>
  <xs:element name="ScheduleOfFairValueHierarchyOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfFairValueHierarchyOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract"/>
  <xs:element name="ScheduleOfFairValueOfTheInitialContingentEarnOutAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfFairValueOfTheInitialContingentEarnOutAbstract"/>
  <xs:element name="ScheduleOfFinancialLiabilityRelatedToTheNotesPayableTheDerivativeInstrumentThePreferredStockWarrantsAndTheContingentEarnOutMeasuredAtFairValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfFinancialLiabilityRelatedToTheNotesPayableTheDerivativeInstrumentThePreferredStockWarrantsAndTheContingentEarnOutMeasuredAtFairValueAbstract"/>
  <xs:element name="RedeemableConvertiblePreferredStockDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_RedeemableConvertiblePreferredStockDisclosureAbstract"/>
  <xs:element name="ScheduleOfPreferredStockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfPreferredStockAbstract"/>
  <xs:element name="ScheduleOfBasicAndDilutedNetLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfBasicAndDilutedNetLossPerShareAbstract"/>
  <xs:element name="ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentNetByLocationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfPropertyAndEquipmentNetByLocationAbstract"/>
  <xs:element name="ScheduleOfDrugsAndSupplementsSegmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfDrugsAndSupplementsSegmentsAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentNetBySegmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfPropertyAndEquipmentNetBySegmentAbstract"/>
  <xs:element name="CurrentTaxExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CurrentTaxExpenseAbstract"/>
  <xs:element name="DeferredTaxExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_DeferredTaxExpenseAbstract"/>
  <xs:element name="DeferredTaxAssetsLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_DeferredTaxAssetsLiabilitiesAbstract"/>
  <xs:element name="NumeratorAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_NumeratorAbstract"/>
  <xs:element name="DenominatorAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_DenominatorAbstract"/>
  <xs:element name="RedeemableConvertiblePreferredStockWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_RedeemableConvertiblePreferredStockWarrantLiability"/>
  <xs:element name="ContingentEarnoutNetOfCurrentPortion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ContingentEarnoutNetOfCurrentPortion"/>
  <xs:element name="InitialShareholdersContingentEarnout" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_InitialShareholdersContingentEarnout"/>
  <xs:element name="CostsOfRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_CostsOfRevenue"/>
  <xs:element name="ChangeInFairValueOfPreferredStockWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ChangeInFairValueOfPreferredStockWarrantLiability"/>
  <xs:element name="ChangeInFairValueOfContingentEarnout" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ChangeInFairValueOfContingentEarnout"/>
  <xs:element name="ChangeInFairValueOfInitialShareholdersContingentEarnout" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout"/>
  <xs:element name="AustraliaResearchAndDevelopmentCredit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_AustraliaResearchAndDevelopmentCredit"/>
  <xs:element name="ApplicationOfASC842" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ApplicationOfASC842"/>
  <xs:element name="IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts"/>
  <xs:element name="ExerciseOfSeriesCPreferredStockWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ExerciseOfSeriesCPreferredStockWarrants"/>
  <xs:element name="ExerciseOfSeriesCPreferredStockWarrant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ExerciseOfSeriesCPreferredStockWarrant"/>
  <xs:element name="ForeignCurrencyTranslationAdjustment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ForeignCurrencyTranslationAdjustment"/>
  <xs:element name="IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis"/>
  <xs:element name="IssuanceOfSeriesDPreferredStockInConnectionExtinguishmentOfConvertiblePromis" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_IssuanceOfSeriesDPreferredStockInConnectionExtinguishmentOfConvertiblePromis"/>
  <xs:element name="ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe"/>
  <xs:element name="ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection"/>
  <xs:element name="ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable"/>
  <xs:element name="IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts"/>
  <xs:element name="IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts"/>
  <xs:element name="IssuanceOfCommonStockPaymentOfRelatedOfferingCosts" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_IssuanceOfCommonStockPaymentOfRelatedOfferingCosts"/>
  <xs:element name="ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati"/>
  <xs:element name="ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization"/>
  <xs:element name="NetIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_NetIssuanceCosts"/>
  <xs:element name="IncreaseInInterestAccruedOnNotesPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_IncreaseInInterestAccruedOnNotesPayable"/>
  <xs:element name="IncreaseDecreaseInPayableToRelatedParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_IncreaseDecreaseInPayableToRelatedParties"/>
  <xs:element name="IncreaseDecreaseOperatingLeaseObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_IncreaseDecreaseOperatingLeaseObligations"/>
  <xs:element name="ProceedsFromThePrivatePlacementOfferingNetOfOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ProceedsFromThePrivatePlacementOfferingNetOfOfferingCosts"/>
  <xs:element name="AcquisitionOfRightofuseAssetsAndLeaseholdImprovementsThroughOperatingLease" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_AcquisitionOfRightofuseAssetsAndLeaseholdImprovementsThroughOperatingLease"/>
  <xs:element name="WarrantLiabilitySettledOnExercise" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_WarrantLiabilitySettledOnExercise"/>
  <xs:element name="LeaseLiabilitySettledThroughTerminationOfLease" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_LeaseLiabilitySettledThroughTerminationOfLease"/>
  <xs:element name="IssuanceOfDerivativeInstrumentRelatedToConvertibleNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_IssuanceOfDerivativeInstrumentRelatedToConvertibleNotes"/>
  <xs:element name="IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes"/>
  <xs:element name="ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN"/>
  <xs:element name="DeferredTransactionCostsInAccountsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_DeferredTransactionCostsInAccountsPayable"/>
  <xs:element name="DeferredTransactionsCostsInAccruedLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_DeferredTransactionsCostsInAccruedLiabilities"/>
  <xs:element name="ConversionOfRedeemableConvertiblePreferredStockIntoCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStock"/>
  <xs:element name="ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemableConvertibleSreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemableConvertibleSreferredStock"/>
  <xs:element name="IssuanceOfCommonStockAsPaymentRelatedOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_IssuanceOfCommonStockAsPaymentRelatedOfferingCosts"/>
  <xs:element name="ContingentEarnoutRecognizedConnectionWithTheReverseRecapitalization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ContingentEarnoutRecognizedConnectionWithTheReverseRecapitalization"/>
  <xs:element name="InitialShareholdersContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_InitialShareholdersContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization"/>
  <xs:element name="ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock"/>
  <xs:element name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
  <xs:element name="CommonStockWarrantsDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CommonStockWarrantsDisclosureTextBlock"/>
  <xs:element name="ConvertibleNotesDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ConvertibleNotesDisclosureTextBlock"/>
  <xs:element name="RedeemableConvertiblePreferredStockDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock"/>
  <xs:element name="RiskAndUncertaintiesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_RiskAndUncertaintiesPolicyTextBlock"/>
  <xs:element name="ContingentEarnoutPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ContingentEarnoutPolicyTextBlock"/>
  <xs:element name="CommonStockWarrantsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CommonStockWarrantsPolicyTextBlock"/>
  <xs:element name="GrantFundingPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_GrantFundingPolicyTextBlock"/>
  <xs:element name="ClinicalTrialAccrualPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ClinicalTrialAccrualPolicyTextBlock"/>
  <xs:element name="NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
  <xs:element name="PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
  <xs:element name="PropertyPlantAndEquipmentOneTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_PropertyPlantAndEquipmentOneTextBlock"/>
  <xs:element name="ScheduleOfDrugsAndSupplementsSegmentsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfDrugsAndSupplementsSegmentsTableTextBlock"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock"/>
  <xs:element name="AustraliaResearchAndDevelopmentCreditReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_AustraliaResearchAndDevelopmentCreditReceivable"/>
  <xs:element name="CROPrepayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_CROPrepayments"/>
  <xs:element name="MetalsToBeUsedInResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_MetalsToBeUsedInResearchAndDevelopment"/>
  <xs:element name="AccruedCROFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_AccruedCROFees"/>
  <xs:element name="DeferredGrantFunds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_DeferredGrantFunds"/>
  <xs:element name="AccruedTransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_AccruedTransactionCosts"/>
  <xs:element name="LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsTable"/>
  <xs:element name="LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems"/>
  <xs:element name="LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentTable"/>
  <xs:element name="LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentLineItems"/>
  <xs:element name="FinanceLeaseLiabilityGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_FinanceLeaseLiabilityGross"/>
  <xs:element name="AccumulatedDepreciationDepletionAndAmortizationLeases" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_AccumulatedDepreciationDepletionAndAmortizationLeases"/>
  <xs:element name="FinanceLeaseLiabilityNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_FinanceLeaseLiabilityNet"/>
  <xs:element name="OperatingCashFlowsFromOperatingLeases" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_OperatingCashFlowsFromOperatingLeases"/>
  <xs:element name="OperatingCashFlowsFromFinanceLeases" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_OperatingCashFlowsFromFinanceLeases"/>
  <xs:element name="FinanceCashFlowsFromFinanceLeases" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_FinanceCashFlowsFromFinanceLeases"/>
  <xs:element name="ExpirationDate" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ExpirationDate"/>
  <xs:element name="NumberOfSharesIssuable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="clnn_NumberOfSharesIssuable"/>
  <xs:element name="CommonStockWarrantsExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="clnn_CommonStockWarrantsExercisePrice"/>
  <xs:element name="CommonStockWarrantsExercisable" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CommonStockWarrantsExercisable"/>
  <xs:element name="CommonStockWarrantsClassification" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CommonStockWarrantsClassification"/>
  <xs:element name="CommonStockWarrantsExpiration" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CommonStockWarrantsExpiration"/>
  <xs:element name="IncomeTaxReconciliationWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_IncomeTaxReconciliationWarrantLiability"/>
  <xs:element name="IncomeTaxReconciliationNondeductibleExpensesResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_IncomeTaxReconciliationNondeductibleExpensesResearchAndDevelopment"/>
  <xs:element name="DeferredTaxLiabilitiesDeferredExpenseDepreciation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_DeferredTaxLiabilitiesDeferredExpenseDepreciation"/>
  <xs:element name="DeferredTaxLiabilitiesLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_DeferredTaxLiabilitiesLeaseLiability"/>
  <xs:element name="DeferredTaxAssetsRightofUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_DeferredTaxAssetsRightofUseAsset"/>
  <xs:element name="DeferredTaxAssetsTaxDeferredNonqualifiedStockOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_DeferredTaxAssetsTaxDeferredNonqualifiedStockOptions"/>
  <xs:element name="DeferredTaxAssetsTaxDeferredAccruedCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_DeferredTaxAssetsTaxDeferredAccruedCompensation"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodIntrinsicValue"/>
  <xs:element name="ShareBasedCompensationArrangementNumberOfOptionsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsExercised" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsExercised"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsForfeited" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsForfeited"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue"/>
  <xs:element name="InstrinsicValueOptionsVestedAndExercisableEnding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_InstrinsicValueOptionsVestedAndExercisableEnding"/>
  <xs:element name="WeightedAverageExercisePricePerShareOptionsVestedAndExercisableStockOptionsVest" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="clnn_WeightedAverageExercisePricePerShareOptionsVestedAndExercisableStockOptionsVest"/>
  <xs:element name="WeightedAverageRemainingTermOptionsVestedAndExercisableStockOptionsVestedAndExercisable" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_WeightedAverageRemainingTermOptionsVestedAndExercisableStockOptionsVestedAndExercisable"/>
  <xs:element name="InstrinsicValueOptionsVestedAndExercisableStockOptionsVestedAndExpectedToVestEnding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_InstrinsicValueOptionsVestedAndExercisableStockOptionsVestedAndExpectedToVestEnding"/>
  <xs:element name="StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedTable"/>
  <xs:element name="StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedLineItems"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems"/>
  <xs:element name="FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable"/>
  <xs:element name="FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems"/>
  <xs:element name="CleneNanomedicineContingentEarnout" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_CleneNanomedicineContingentEarnout"/>
  <xs:element name="FairValueOfIssuanceOfNotesPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_FairValueOfIssuanceOfNotesPayable"/>
  <xs:element name="IncreseDecreaseInFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_IncreseDecreaseInFairValue"/>
  <xs:element name="FairValueExerciseOfSeriesCPreferredStockWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_FairValueExerciseOfSeriesCPreferredStockWarrants"/>
  <xs:element name="FairValueIssuanceOfConvertiblePromissoryNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_FairValueIssuanceOfConvertiblePromissoryNotes"/>
  <xs:element name="InitialFairValueOfInstrument" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_InitialFairValueOfInstrument"/>
  <xs:element name="ExtinguishmentOfDerivativeLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ExtinguishmentOfDerivativeLiability"/>
  <xs:element name="TemporaryEquitySharesIssuedAndOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_TemporaryEquitySharesIssuedAndOutstanding"/>
  <xs:element name="TemporaryEquitySharesCommonStockIssuableUponConversion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_TemporaryEquitySharesCommonStockIssuableUponConversion"/>
  <xs:element name="SeriesCRedeemableConvertiblePreferredStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SeriesCRedeemableConvertiblePreferredStock"/>
  <xs:element name="SeriesBRedeemableConvertiblePreferredStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SeriesBRedeemableConvertiblePreferredStock"/>
  <xs:element name="SeriesARedeemableConvertiblePreferredStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SeriesARedeemableConvertiblePreferredStock"/>
  <xs:element name="SeriesCRedeemableConvertiblePreferredStockWarrantsinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SeriesCRedeemableConvertiblePreferredStockWarrantsinShares"/>
  <xs:element name="SeriesARedeemableConvertiblePreferredStockWarrantsinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares"/>
  <xs:element name="CommonStockWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CommonStockWarrants"/>
  <xs:element name="OptionsToPurchaseCommonStockinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_OptionsToPurchaseCommonStockinShares"/>
  <xs:element name="ChardanUnitPurchaseOptionToPurchaseCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ChardanUnitPurchaseOptionToPurchaseCommonStock"/>
  <xs:element name="ChardanUnitPurchaseOptionWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ChardanUnitPurchaseOptionWarrants"/>
  <xs:element name="EarnoutSharessee" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_EarnoutSharessee"/>
  <xs:element name="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable"/>
  <xs:element name="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems"/>
  <xs:element name="GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsTable"/>
  <xs:element name="GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsLineItems"/>
  <xs:element name="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable"/>
  <xs:element name="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems"/>
  <xs:element name="NatureoftheBusinessandBasisofPresentationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_NatureoftheBusinessandBasisofPresentationDetailsTable"/>
  <xs:element name="NatureoftheBusinessandBasisofPresentationDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems"/>
  <xs:element name="MergerAgreementPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_MergerAgreementPercentage"/>
  <xs:element name="ProceedsFromReverseRecapitalizationNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ProceedsFromReverseRecapitalizationNet"/>
  <xs:element name="PurchaseOption" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_PurchaseOption"/>
  <xs:element name="PerShareUnit" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="clnn_PerShareUnit"/>
  <xs:element name="PaymentsForAdvisoryServicesShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_PaymentsForAdvisoryServicesShares"/>
  <xs:element name="StockIssuedDuringPeriodSharesPrivatePlacement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_StockIssuedDuringPeriodSharesPrivatePlacement"/>
  <xs:element name="IncurredNetLosses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_IncurredNetLosses"/>
  <xs:element name="RetainedEarningsAccumulatedDeficit1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_RetainedEarningsAccumulatedDeficit1"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_SummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
  <xs:element name="ProposedPublicOfferingCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ProposedPublicOfferingCost"/>
  <xs:element name="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable"/>
  <xs:element name="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems"/>
  <xs:element name="IssuanceOfCommonStockUponReverseRecapitalization" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_IssuanceOfCommonStockUponReverseRecapitalization"/>
  <xs:element name="EarnOutShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="clnn_EarnOutShare"/>
  <xs:element name="EntityCommonStockSharesOutstanding1" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="clnn_EntityCommonStockSharesOutstanding1"/>
  <xs:element name="SharesHeldInEscrow" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SharesHeldInEscrow"/>
  <xs:element name="ServicesLetterAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ServicesLetterAgreementDescription"/>
  <xs:element name="InvestorsPurchasedShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_InvestorsPurchasedShares"/>
  <xs:element name="SharesPerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="clnn_SharesPerShare"/>
  <xs:element name="ExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="clnn_ExercisePrice"/>
  <xs:element name="NetProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_NetProceeds"/>
  <xs:element name="EarnoutSharesDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_EarnoutSharesDescription"/>
  <xs:element name="PropertyandEquipmentNetDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_PropertyandEquipmentNetDetailsTable"/>
  <xs:element name="PropertyandEquipmentNetDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_PropertyandEquipmentNetDetailsLineItems"/>
  <xs:element name="RemainingRightofuseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_RemainingRightofuseAsset"/>
  <xs:element name="RecognizedGainOnOperatingLease" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_RecognizedGainOnOperatingLease"/>
  <xs:element name="DescriptionOfOperatingLease" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_DescriptionOfOperatingLease"/>
  <xs:element name="FinanceLeaseObligationsWeightedaverageInterestRate" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="clnn_FinanceLeaseObligationsWeightedaverageInterestRate"/>
  <xs:element name="OperatingLeaseObligationsWeightedAverageInterestRate" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="clnn_OperatingLeaseObligationsWeightedAverageInterestRate"/>
  <xs:element name="NotesPayableDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_NotesPayableDetailsTable"/>
  <xs:element name="NotesPayableDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_NotesPayableDetailsLineItems"/>
  <xs:element name="SimpleInterestExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_SimpleInterestExpense"/>
  <xs:element name="PercentageOfLoanAmountUsedToPayrollExpenses" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_PercentageOfLoanAmountUsedToPayrollExpenses"/>
  <xs:element name="PreferredStockWarrantLiabilityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_PreferredStockWarrantLiabilityDetailsTable"/>
  <xs:element name="PreferredStockWarrantLiabilityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_PreferredStockWarrantLiabilityDetailsLineItems"/>
  <xs:element name="CommonStockWarrantsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_CommonStockWarrantsDetailsTable"/>
  <xs:element name="CommonStockWarrantsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CommonStockWarrantsDetailsLineItems"/>
  <xs:element name="ReverseRecapitalizationAndWillExpireYears" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ReverseRecapitalizationAndWillExpireYears"/>
  <xs:element name="WarrantExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="clnn_WarrantExercisePrice"/>
  <xs:element name="PreferredStockWarrantsOutstandingShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="clnn_PreferredStockWarrantsOutstandingShares"/>
  <xs:element name="ConvertibleNotesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_ConvertibleNotesDetailsTable"/>
  <xs:element name="ConvertibleNotesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ConvertibleNotesDetailsLineItems"/>
  <xs:element name="DescriptionOfConvertibleNotes" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_DescriptionOfConvertibleNotes"/>
  <xs:element name="PercentageOfStock" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_PercentageOfStock"/>
  <xs:element name="PreferredStockConvertibleConversionPrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_PreferredStockConvertibleConversionPrice"/>
  <xs:element name="DerivativeInstrumentsOfComprehensiveLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_DerivativeInstrumentsOfComprehensiveLoss"/>
  <xs:element name="IncomeTaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_IncomeTaxesDetailsTable"/>
  <xs:element name="IncomeTaxesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_IncomeTaxesDetailsLineItems"/>
  <xs:element name="OperatingLossExpireTerm" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_OperatingLossExpireTerm"/>
  <xs:element name="RemainingBalanceOfOperatingLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_RemainingBalanceOfOperatingLoss"/>
  <xs:element name="ResearchAndDevelopmentCreditExpiryTerm" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ResearchAndDevelopmentCreditExpiryTerm"/>
  <xs:element name="StockBasedCompensationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_StockBasedCompensationDetailsTable"/>
  <xs:element name="StockBasedCompensationDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_StockBasedCompensationDetailsLineItems"/>
  <xs:element name="MinimumFairMarketValueOfOptionGrantDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_MinimumFairMarketValueOfOptionGrantDescription"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants"/>
  <xs:element name="CommonSharesAuthorized" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="clnn_CommonSharesAuthorized"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross"/>
  <xs:element name="UnrecognizedStockbasedCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_UnrecognizedStockbasedCompensation"/>
  <xs:element name="weightedAverageFairValuesOfOptionsGranted" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_weightedAverageFairValuesOfOptionsGranted"/>
  <xs:element name="RestrictedStockUnitsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_RestrictedStockUnitsDescription"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerms" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerms"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm"/>
  <xs:element name="FairValueDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_FairValueDetailsTable"/>
  <xs:element name="FairValueDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_FairValueDetailsLineItems"/>
  <xs:element name="FairValueMeasurementWithUnobservableInputsNotesPayable" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_FairValueMeasurementWithUnobservableInputsNotesPayable"/>
  <xs:element name="NotesPayableBasedOnClosingPrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_NotesPayableBasedOnClosingPrice"/>
  <xs:element name="WarrantsToPurchasePreferredStock" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_WarrantsToPurchasePreferredStock"/>
  <xs:element name="RedeemableConvertiblePreferredStockDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_RedeemableConvertiblePreferredStockDetailsTable"/>
  <xs:element name="RedeemableConvertiblePreferredStockDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_RedeemableConvertiblePreferredStockDetailsLineItems"/>
  <xs:element name="ConversionOfSecuredPromissoryNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ConversionOfSecuredPromissoryNotes"/>
  <xs:element name="NetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_NetOfIssuanceCosts"/>
  <xs:element name="CashConsiderationReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_CashConsiderationReceived"/>
  <xs:element name="SharesIssuedUponConversionOfConvertiblePromissoryNote" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SharesIssuedUponConversionOfConvertiblePromissoryNote"/>
  <xs:element name="WarrantsSharesInExercise" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_WarrantsSharesInExercise"/>
  <xs:element name="PreferredStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_PreferredStockShares"/>
  <xs:element name="RecapitalizationShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_RecapitalizationShare"/>
  <xs:element name="NumberOfSharesIssuableOnExerciseOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_NumberOfSharesIssuableOnExerciseOfWarrants"/>
  <xs:element name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_RelatedPartyTransactionsDetailsTable"/>
  <xs:element name="RelatedPartyTransactionsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_RelatedPartyTransactionsDetailsLineItems"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_SubsequentEventsDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SubsequentEventsDetailsLineItems"/>
  <xs:element name="PaycheckProtectionProgramLoan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_PaycheckProtectionProgramLoan"/>
  <xs:element name="GainOnForgivenessLoan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_GainOnForgivenessLoan"/>
  <xs:element name="FoundationGrantCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_FoundationGrantCost"/>
  <xs:element name="AggregateGrossProceedWarrantsExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_AggregateGrossProceedWarrantsExercised"/>
  <xs:element name="SaleOfStockholdersCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SaleOfStockholdersCommonStock"/>
  <xs:element name="ChardanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ChardanMember"/>
  <xs:element name="CleneNanomedicineMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CleneNanomedicineMember"/>
  <xs:element name="ContingentEarnoutMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ContingentEarnoutMember"/>
  <xs:element name="December20201Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_December20201Member"/>
  <xs:element name="DerivativeInstrumentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_DerivativeInstrumentMember"/>
  <xs:element name="DrugsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_DrugsMember"/>
  <xs:element name="FinanceLeasesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_FinanceLeasesMember"/>
  <xs:element name="GrantFundingMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_GrantFundingMember"/>
  <xs:element name="InitialShareholdersContingentEarnoutMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_InitialShareholdersContingentEarnoutMember"/>
  <xs:element name="LifeSciCapitalLLCMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_LifeSciCapitalLLCMember"/>
  <xs:element name="OperatingLeasesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_OperatingLeasesMember"/>
  <xs:element name="PaycheckProtectionProgramNoteMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_PaycheckProtectionProgramNoteMember"/>
  <xs:element name="PreferredStockWarrantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_PreferredStockWarrantMember"/>
  <xs:element name="PreferredStockWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_PreferredStockWarrantsMember"/>
  <xs:element name="StockPlan2014Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_StockPlan2014Member"/>
  <xs:element name="StockPlan2020Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_StockPlan2020Member"/>
  <xs:element name="SupplementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SupplementsMember"/>
  <xs:element name="TottenhamMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_TottenhamMember"/>
  <xs:element name="TottenhamsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_TottenhamsMember"/>
  <xs:element name="TwoThousandNineteenCecilLoanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_TwoThousandNineteenCecilLoanMember"/>
  <xs:element name="TwoThousandNineteenMDLoanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_TwoThousandNineteenMDLoanMember"/>
  <xs:element name="WarrantsDate1Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_WarrantsDate1Member"/>
  <xs:element name="WarrantsDate2Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_WarrantsDate2Member"/>
  <xs:element name="WarrantsDateMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_WarrantsDateMember"/>
  <xs:element name="WorkInProcessMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_WorkInProcessMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>clnn-20201231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Mar 26 16:52:33 EDT 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ConsolidatedBalanceSheet" roleURI="http://www.cleaninccom/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ConsolidatedIncomeStatement" roleURI="http://www.cleaninccom/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ConsolidatedCashFlow" roleURI="http://www.cleaninccom/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofcomponentsofincomelossbeforeincometaxesTable" roleURI="http://www.cleaninccom/role/ScheduleofcomponentsofincomelossbeforeincometaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofincometaxexpensebenefitTable" roleURI="http://www.cleaninccom/role/ScheduleofincometaxexpensebenefitTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofdilutivesecuritieswereexcludedfromthecomputationofdilutednetlosspershareTable" roleURI="http://www.cleaninccom/role/ScheduleofdilutivesecuritieswereexcludedfromthecomputationofdilutednetlosspershareTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_TaxesPayableCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LongTermDebtCurrent" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermNotesPayable" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_RedeemableConvertiblePreferredStockWarrantLiability" xlink:href="clnn-20201231.xsd#clnn_RedeemableConvertiblePreferredStockWarrantLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="clnn_RedeemableConvertiblePreferredStockWarrantLiability" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_ContingentEarnoutNetOfCurrentPortion" xlink:href="clnn-20201231.xsd#clnn_ContingentEarnoutNetOfCurrentPortion"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="clnn_ContingentEarnoutNetOfCurrentPortion" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_InitialShareholdersContingentEarnout" xlink:href="clnn-20201231.xsd#clnn_InitialShareholdersContingentEarnout"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="clnn_InitialShareholdersContingentEarnout" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="3" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="clnn_CostsOfRevenue" xlink:href="clnn-20201231.xsd#clnn_CostsOfRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="clnn_CostsOfRevenue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnContractTermination" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnContractTermination"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainLossOnContractTermination" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfPreferredStockWarrantLiability" xlink:href="clnn-20201231.xsd#clnn_ChangeInFairValueOfPreferredStockWarrantLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="clnn_ChangeInFairValueOfPreferredStockWarrantLiability" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfContingentEarnout" xlink:href="clnn-20201231.xsd#clnn_ChangeInFairValueOfContingentEarnout"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="clnn_ChangeInFairValueOfContingentEarnout" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout" xlink:href="clnn-20201231.xsd#clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="clnn_AustraliaResearchAndDevelopmentCredit" xlink:href="clnn-20201231.xsd#clnn_AustraliaResearchAndDevelopmentCredit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="clnn_AustraliaResearchAndDevelopmentCredit" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossTax" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraqWjSnTNF4jeT3oaMW8W5R0MkiIXXy8k2PQbBklJ1lYf+6GCuiY/lJFjk6uDeNN+gvvgD/ctbqbBhZgNg1qNU0EiFrWvY1hT6GmZd73HE7TJaI9wGp4wAxzd2UaTwEVsbp/IQFhRTHB/tg6uRHFmIlPQ/RvbutlnsApFoSy15H2BVjyanqrmOL] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_IncreaseInInterestAccruedOnNotesPayable" xlink:href="clnn-20201231.xsd#clnn_IncreaseInInterestAccruedOnNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="clnn_IncreaseInInterestAccruedOnNotesPayable" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_IncreaseDecreaseInPayableToRelatedParties" xlink:href="clnn-20201231.xsd#clnn_IncreaseDecreaseInPayableToRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="clnn_IncreaseDecreaseInPayableToRelatedParties" order="11" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="12" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfContingentEarnout" xlink:href="clnn-20201231.xsd#clnn_ChangeInFairValueOfContingentEarnout"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="clnn_ChangeInFairValueOfContingentEarnout" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout" xlink:href="clnn-20201231.xsd#clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout" order="14" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" order="15" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="16" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnTerminationOfLease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnTerminationOfLease" order="17" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="18" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="19" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" order="20" weight="-1"/>
    <loc xlink:type="locator" xlink:label="clnn_IncreaseDecreaseOperatingLeaseObligations" xlink:href="clnn-20201231.xsd#clnn_IncreaseDecreaseOperatingLeaseObligations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="clnn_IncreaseDecreaseOperatingLeaseObligations" order="21" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_ProceedsFromThePrivatePlacementOfferingNetOfOfferingCosts" xlink:href="clnn-20201231.xsd#clnn_ProceedsFromThePrivatePlacementOfferingNetOfOfferingCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="clnn_ProceedsFromThePrivatePlacementOfferingNetOfOfferingCosts" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfMediumTermNotes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfMediumTermNotes" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofcomponentsofincomelossbeforeincometaxesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofincometaxexpensebenefitTable">
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofdilutivesecuritieswereexcludedfromthecomputationofdilutednetlosspershareTable">
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesCRedeemableConvertiblePreferredStock" xlink:href="clnn-20201231.xsd#clnn_SeriesCRedeemableConvertiblePreferredStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="clnn_SeriesCRedeemableConvertiblePreferredStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesBRedeemableConvertiblePreferredStock" xlink:href="clnn-20201231.xsd#clnn_SeriesBRedeemableConvertiblePreferredStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="clnn_SeriesBRedeemableConvertiblePreferredStock" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesARedeemableConvertiblePreferredStock" xlink:href="clnn-20201231.xsd#clnn_SeriesARedeemableConvertiblePreferredStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="clnn_SeriesARedeemableConvertiblePreferredStock" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesCRedeemableConvertiblePreferredStockWarrantsinShares" xlink:href="clnn-20201231.xsd#clnn_SeriesCRedeemableConvertiblePreferredStockWarrantsinShares"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="clnn_SeriesCRedeemableConvertiblePreferredStockWarrantsinShares" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares" xlink:href="clnn-20201231.xsd#clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrants" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="clnn_CommonStockWarrants" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_OptionsToPurchaseCommonStockinShares" xlink:href="clnn-20201231.xsd#clnn_OptionsToPurchaseCommonStockinShares"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="clnn_OptionsToPurchaseCommonStockinShares" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_ChardanUnitPurchaseOptionToPurchaseCommonStock" xlink:href="clnn-20201231.xsd#clnn_ChardanUnitPurchaseOptionToPurchaseCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="clnn_ChardanUnitPurchaseOptionToPurchaseCommonStock" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_ChardanUnitPurchaseOptionWarrants" xlink:href="clnn-20201231.xsd#clnn_ChardanUnitPurchaseOptionWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="clnn_ChardanUnitPurchaseOptionWarrants" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_EarnoutSharessee" xlink:href="clnn-20201231.xsd#clnn_EarnoutSharessee"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="clnn_EarnoutSharessee" order="10" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>clnn-20201231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Mar 26 16:52:33 EDT 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ConsolidatedBalanceSheet" roleURI="http://www.cleaninccom/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.cleaninccom/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ConsolidatedIncomeStatement" roleURI="http://www.cleaninccom/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ShareholdersEquityType2or3" roleURI="http://www.cleaninccom/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ShareholdersEquityType2or3_Parentheticals" roleURI="http://www.cleaninccom/role/ShareholdersEquityType2or3_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ConsolidatedCashFlow" roleURI="http://www.cleaninccom/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_NatureoftheBusinessandBasisofPresentation" roleURI="http://www.cleaninccom/role/NatureoftheBusinessandBasisofPresentation"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.cleaninccom/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ReverseRecapitalizationwithTottenhamandCleneNanomedicine" roleURI="http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicine"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_Prepaidexpensesandothercurrentassets" roleURI="http://www.cleaninccom/role/Prepaidexpensesandothercurrentassets"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_PropertyandEquipmentNet" roleURI="http://www.cleaninccom/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_AccruedLiabilities" roleURI="http://www.cleaninccom/role/AccruedLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_Leases" roleURI="http://www.cleaninccom/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_NotesPayable" roleURI="http://www.cleaninccom/role/NotesPayable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_PreferredStockWarrantLiability" roleURI="http://www.cleaninccom/role/PreferredStockWarrantLiability"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_CommonStockWarrants" roleURI="http://www.cleaninccom/role/CommonStockWarrants"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ConvertibleNotes" roleURI="http://www.cleaninccom/role/ConvertibleNotes"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_DerivativeInstruments" roleURI="http://www.cleaninccom/role/DerivativeInstruments"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_CommitmentsandContingencies" roleURI="http://www.cleaninccom/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_IncomeTaxes" roleURI="http://www.cleaninccom/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_StockBasedCompensation" roleURI="http://www.cleaninccom/role/StockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_FairValue" roleURI="http://www.cleaninccom/role/FairValue"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_RedeemableConvertiblePreferredStock" roleURI="http://www.cleaninccom/role/RedeemableConvertiblePreferredStock"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_CommonStock" roleURI="http://www.cleaninccom/role/CommonStock"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_NetLossPerShareAttributabletoCommonShareholders" roleURI="http://www.cleaninccom/role/NetLossPerShareAttributabletoCommonShareholders"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_RelatedPartyTransactions" roleURI="http://www.cleaninccom/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_GeographicandSegmentInformation" roleURI="http://www.cleaninccom/role/GeographicandSegmentInformation"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_SubsequentEvents" roleURI="http://www.cleaninccom/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_AccountingPoliciesByPolicy" roleURI="http://www.cleaninccom/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_PrepaidexpensesandothercurrentassetsTables" roleURI="http://www.cleaninccom/role/PrepaidexpensesandothercurrentassetsTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_PropertyandEquipmentNetTables" roleURI="http://www.cleaninccom/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_AccruedLiabilitiesTables" roleURI="http://www.cleaninccom/role/AccruedLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_LeasesTables" roleURI="http://www.cleaninccom/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_PreferredStockWarrantLiabilityTables" roleURI="http://www.cleaninccom/role/PreferredStockWarrantLiabilityTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_CommonStockWarrantsTables" roleURI="http://www.cleaninccom/role/CommonStockWarrantsTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_IncomeTaxesTables" roleURI="http://www.cleaninccom/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_StockBasedCompensationTables" roleURI="http://www.cleaninccom/role/StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_FairValueTables" roleURI="http://www.cleaninccom/role/FairValueTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_RedeemableConvertiblePreferredStockTables" roleURI="http://www.cleaninccom/role/RedeemableConvertiblePreferredStockTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_NetLossPerShareAttributabletoCommonShareholdersTables" roleURI="http://www.cleaninccom/role/NetLossPerShareAttributabletoCommonShareholdersTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_GeographicandSegmentInformationTables" roleURI="http://www.cleaninccom/role/GeographicandSegmentInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofprepaidexpensesandothercurrentassetsTable" roleURI="http://www.cleaninccom/role/ScheduleofprepaidexpensesandothercurrentassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofpropertyandequipmentnetTable" roleURI="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofaccruedliabilitiesTable" roleURI="http://www.cleaninccom/role/ScheduleofaccruedliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofnoncancelableoperatingleasearrangementsTable" roleURI="http://www.cleaninccom/role/ScheduleofnoncancelableoperatingleasearrangementsTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleoffinanceleaseobligationsandincludedpropertyandequipmentTable" roleURI="http://www.cleaninccom/role/ScheduleoffinanceleaseobligationsandincludedpropertyandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleoffinanceandoperatingleasecostsTable" roleURI="http://www.cleaninccom/role/ScheduleoffinanceandoperatingleasecostsTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofsupplementalcashflowinformationTable" roleURI="http://www.cleaninccom/role/ScheduleofsupplementalcashflowinformationTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_SchedulefairvalueoftheoutstandingwarrantsTable" roleURI="http://www.cleaninccom/role/SchedulefairvalueoftheoutstandingwarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable" roleURI="http://www.cleaninccom/role/ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofcomponentsofincomelossbeforeincometaxesTable" roleURI="http://www.cleaninccom/role/ScheduleofcomponentsofincomelossbeforeincometaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofincometaxexpensebenefitTable" roleURI="http://www.cleaninccom/role/ScheduleofincometaxexpensebenefitTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofincometaxreconciliationTable" roleURI="http://www.cleaninccom/role/ScheduleofincometaxreconciliationTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofdeferredtaxassetsandliabilitiesTable" roleURI="http://www.cleaninccom/role/ScheduleofdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofstockbasedcompensationexpenseTable" roleURI="http://www.cleaninccom/role/ScheduleofstockbasedcompensationexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable" roleURI="http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleoffairvalueofthesestockoptionsawardsgrantedTable" roleURI="http://www.cleaninccom/role/ScheduleoffairvalueofthesestockoptionsawardsgrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofrestrictedcommonstockactivityTable" roleURI="http://www.cleaninccom/role/ScheduleofrestrictedcommonstockactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable" roleURI="http://www.cleaninccom/role/ScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleoffairvalueoftheinitialcontingentearnoutTable" roleURI="http://www.cleaninccom/role/ScheduleoffairvalueoftheinitialcontingentearnoutTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleoffinancialliabilityrelatedtothenotespayablethederivativeinstrumentthePreferredStockwarrantsandthecontingentearnoutmeasuredatfairvalueTable" roleURI="http://www.cleaninccom/role/ScheduleoffinancialliabilityrelatedtothenotespayablethederivativeinstrumentthePreferredStockwarrantsandthecontingentearnoutmeasuredatfairvalueTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofPreferredStockTable" roleURI="http://www.cleaninccom/role/ScheduleofPreferredStockTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofbasicanddilutednetlosspershareTable" roleURI="http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofdilutivesecuritieswereexcludedfromthecomputationofdilutednetlosspershareTable" roleURI="http://www.cleaninccom/role/ScheduleofdilutivesecuritieswereexcludedfromthecomputationofdilutednetlosspershareTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofpropertyandequipmentnetbylocationTable" roleURI="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbylocationTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofdrugsandsupplementssegmentsTable" roleURI="http://www.cleaninccom/role/ScheduleofdrugsandsupplementssegmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofpropertyandequipmentnetbysegmentTable" roleURI="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbysegmentTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_NatureoftheBusinessandBasisofPresentationDetails" roleURI="http://www.cleaninccom/role/NatureoftheBusinessandBasisofPresentationDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails" roleURI="http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_PropertyandEquipmentNetDetails" roleURI="http://www.cleaninccom/role/PropertyandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_LeasesDetails" roleURI="http://www.cleaninccom/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_NotesPayableDetails" roleURI="http://www.cleaninccom/role/NotesPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_PreferredStockWarrantLiabilityDetails" roleURI="http://www.cleaninccom/role/PreferredStockWarrantLiabilityDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_CommonStockWarrantsDetails" roleURI="http://www.cleaninccom/role/CommonStockWarrantsDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ConvertibleNotesDetails" roleURI="http://www.cleaninccom/role/ConvertibleNotesDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_DerivativeInstrumentsDetails" roleURI="http://www.cleaninccom/role/DerivativeInstrumentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_IncomeTaxesDetails" roleURI="http://www.cleaninccom/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_StockBasedCompensationDetails" roleURI="http://www.cleaninccom/role/StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_FairValueDetails" roleURI="http://www.cleaninccom/role/FairValueDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_RedeemableConvertiblePreferredStockDetails" roleURI="http://www.cleaninccom/role/RedeemableConvertiblePreferredStockDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_CommonStockDetails" roleURI="http://www.cleaninccom/role/CommonStockDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_NetLossPerShareAttributabletoCommonShareholdersDetails" roleURI="http://www.cleaninccom/role/NetLossPerShareAttributabletoCommonShareholdersDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_RelatedPartyTransactionsDetails" roleURI="http://www.cleaninccom/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_SubsequentEventsDetails" roleURI="http://www.cleaninccom/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#DocumentAndEntityInformation" roleURI="http://www.cleaninccom/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LongTermNotesPayable" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_RedeemableConvertiblePreferredStockWarrantLiability" xlink:href="clnn-20201231.xsd#clnn_RedeemableConvertiblePreferredStockWarrantLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="clnn_RedeemableConvertiblePreferredStockWarrantLiability" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ContingentEarnoutNetOfCurrentPortion" xlink:href="clnn-20201231.xsd#clnn_ContingentEarnoutNetOfCurrentPortion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="clnn_ContingentEarnoutNetOfCurrentPortion" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_InitialShareholdersContingentEarnout" xlink:href="clnn-20201231.xsd#clnn_InitialShareholdersContingentEarnout"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="clnn_InitialShareholdersContingentEarnout" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CostsOfRevenue" xlink:href="clnn-20201231.xsd#clnn_CostsOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="clnn_CostsOfRevenue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnContractTermination" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnContractTermination"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnContractTermination" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfPreferredStockWarrantLiability" xlink:href="clnn-20201231.xsd#clnn_ChangeInFairValueOfPreferredStockWarrantLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="clnn_ChangeInFairValueOfPreferredStockWarrantLiability" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfContingentEarnout" xlink:href="clnn-20201231.xsd#clnn_ChangeInFairValueOfContingentEarnout"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="clnn_ChangeInFairValueOfContingentEarnout" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout" xlink:href="clnn-20201231.xsd#clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_AustraliaResearchAndDevelopmentCredit" xlink:href="clnn-20201231.xsd#clnn_AustraliaResearchAndDevelopmentCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="clnn_AustraliaResearchAndDevelopmentCredit" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTax" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ApplicationOfASC842" xlink:href="clnn-20201231.xsd#clnn_ApplicationOfASC842"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="clnn_ApplicationOfASC842" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="clnn_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ExerciseOfSeriesCPreferredStockWarrants" xlink:href="clnn-20201231.xsd#clnn_ExerciseOfSeriesCPreferredStockWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="clnn_ExerciseOfSeriesCPreferredStockWarrants" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ExerciseOfSeriesCPreferredStockWarrant" xlink:href="clnn-20201231.xsd#clnn_ExerciseOfSeriesCPreferredStockWarrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="clnn_ExerciseOfSeriesCPreferredStockWarrant" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe" xlink:href="clnn-20201231.xsd#clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection" xlink:href="clnn-20201231.xsd#clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable" xlink:href="clnn-20201231.xsd#clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="clnn_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="clnn_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_IssuanceOfCommonStockPaymentOfRelatedOfferingCosts" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfCommonStockPaymentOfRelatedOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="clnn_IssuanceOfCommonStockPaymentOfRelatedOfferingCosts" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati" xlink:href="clnn-20201231.xsd#clnn_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="clnn_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization" xlink:href="clnn-20201231.xsd#clnn_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="clnn_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ForeignCurrencyTranslationAdjustment" xlink:href="clnn-20201231.xsd#clnn_ForeignCurrencyTranslationAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="clnn_ForeignCurrencyTranslationAdjustment" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="clnn_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_IssuanceOfSeriesDPreferredStockInConnectionExtinguishmentOfConvertiblePromis" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfSeriesDPreferredStockInConnectionExtinguishmentOfConvertiblePromis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="clnn_IssuanceOfSeriesDPreferredStockInConnectionExtinguishmentOfConvertiblePromis" order="26" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ShareholdersEquityType2or3_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="clnn_NetIssuanceCosts" xlink:href="clnn-20201231.xsd#clnn_NetIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="clnn_NetIssuanceCosts" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfContingentEarnout" xlink:href="clnn-20201231.xsd#clnn_ChangeInFairValueOfContingentEarnout"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="clnn_ChangeInFairValueOfContingentEarnout" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout" xlink:href="clnn-20201231.xsd#clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnTerminationOfLease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnTerminationOfLease" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_IncreaseInInterestAccruedOnNotesPayable" xlink:href="clnn-20201231.xsd#clnn_IncreaseInInterestAccruedOnNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="clnn_IncreaseInInterestAccruedOnNotesPayable" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_IncreaseDecreaseInPayableToRelatedParties" xlink:href="clnn-20201231.xsd#clnn_IncreaseDecreaseInPayableToRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="clnn_IncreaseDecreaseInPayableToRelatedParties" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_IncreaseDecreaseOperatingLeaseObligations" xlink:href="clnn-20201231.xsd#clnn_IncreaseDecreaseOperatingLeaseObligations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="clnn_IncreaseDecreaseOperatingLeaseObligations" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_IncreaseDecreaseOperatingLeaseObligations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ProceedsFromThePrivatePlacementOfferingNetOfOfferingCosts" xlink:href="clnn-20201231.xsd#clnn_ProceedsFromThePrivatePlacementOfferingNetOfOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="clnn_ProceedsFromThePrivatePlacementOfferingNetOfOfferingCosts" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfMediumTermNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfMediumTermNotes" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_FairValueOfAssetsAcquired" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_AcquisitionOfRightofuseAssetsAndLeaseholdImprovementsThroughOperatingLease" xlink:href="clnn-20201231.xsd#clnn_AcquisitionOfRightofuseAssetsAndLeaseholdImprovementsThroughOperatingLease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="clnn_AcquisitionOfRightofuseAssetsAndLeaseholdImprovementsThroughOperatingLease" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantLiabilitySettledOnExercise" xlink:href="clnn-20201231.xsd#clnn_WarrantLiabilitySettledOnExercise"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="clnn_WarrantLiabilitySettledOnExercise" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_LeaseLiabilitySettledThroughTerminationOfLease" xlink:href="clnn-20201231.xsd#clnn_LeaseLiabilitySettledThroughTerminationOfLease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="clnn_LeaseLiabilitySettledThroughTerminationOfLease" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_IssuanceOfDerivativeInstrumentRelatedToConvertibleNotes" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfDerivativeInstrumentRelatedToConvertibleNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="clnn_IssuanceOfDerivativeInstrumentRelatedToConvertibleNotes" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" xlink:href="clnn-20201231.xsd#clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DeferredTransactionCostsInAccountsPayable" xlink:href="clnn-20201231.xsd#clnn_DeferredTransactionCostsInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="clnn_DeferredTransactionCostsInAccountsPayable" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DeferredTransactionsCostsInAccruedLiabilities" xlink:href="clnn-20201231.xsd#clnn_DeferredTransactionsCostsInAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="clnn_DeferredTransactionsCostsInAccruedLiabilities" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStock" xlink:href="clnn-20201231.xsd#clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStock" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemableConvertibleSreferredStock" xlink:href="clnn-20201231.xsd#clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemableConvertibleSreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemableConvertibleSreferredStock" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_IssuanceOfCommonStockAsPaymentRelatedOfferingCosts" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfCommonStockAsPaymentRelatedOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="clnn_IssuanceOfCommonStockAsPaymentRelatedOfferingCosts" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ContingentEarnoutRecognizedConnectionWithTheReverseRecapitalization" xlink:href="clnn-20201231.xsd#clnn_ContingentEarnoutRecognizedConnectionWithTheReverseRecapitalization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="clnn_ContingentEarnoutRecognizedConnectionWithTheReverseRecapitalization" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_InitialShareholdersContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization" xlink:href="clnn-20201231.xsd#clnn_InitialShareholdersContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="clnn_InitialShareholdersContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_InterestPaid" order="26" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/NatureoftheBusinessandBasisofPresentation">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicine">
    <loc xlink:type="locator" xlink:label="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract" xlink:href="clnn-20201231.xsd#clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract"/>
    <loc xlink:type="locator" xlink:label="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock" xlink:href="clnn-20201231.xsd#clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract" xlink:to="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/Prepaidexpensesandothercurrentassets">
    <loc xlink:type="locator" xlink:label="clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="clnn-20201231.xsd#clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:href="clnn-20201231.xsd#clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/PropertyandEquipmentNet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/AccruedLiabilities">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/NotesPayable">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/PreferredStockWarrantLiability">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/CommonStockWarrants">
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsDisclosureAbstract" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrantsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsDisclosureTextBlock" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrantsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockWarrantsDisclosureAbstract" xlink:to="clnn_CommonStockWarrantsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ConvertibleNotes">
    <loc xlink:type="locator" xlink:label="clnn_ConvertibleNotesDisclosureAbstract" xlink:href="clnn-20201231.xsd#clnn_ConvertibleNotesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="clnn_ConvertibleNotesDisclosureTextBlock" xlink:href="clnn-20201231.xsd#clnn_ConvertibleNotesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDisclosureAbstract" xlink:to="clnn_ConvertibleNotesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/DerivativeInstruments">
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/StockBasedCompensation">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/FairValue">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/RedeemableConvertiblePreferredStock">
    <loc xlink:type="locator" xlink:label="clnn_RedeemableConvertiblePreferredStockDisclosureAbstract" xlink:href="clnn-20201231.xsd#clnn_RedeemableConvertiblePreferredStockDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock" xlink:href="clnn-20201231.xsd#clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_RedeemableConvertiblePreferredStockDisclosureAbstract" xlink:to="clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/CommonStock">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/NetLossPerShareAttributabletoCommonShareholders">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/GeographicandSegmentInformation">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_RiskAndUncertaintiesPolicyTextBlock" xlink:href="clnn-20201231.xsd#clnn_RiskAndUncertaintiesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="clnn_RiskAndUncertaintiesPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ContingentEarnoutPolicyTextBlock" xlink:href="clnn-20201231.xsd#clnn_ContingentEarnoutPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="clnn_ContingentEarnoutPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsPolicyTextBlock" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrantsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="clnn_CommonStockWarrantsPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_GrantFundingPolicyTextBlock" xlink:href="clnn-20201231.xsd#clnn_GrantFundingPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="clnn_GrantFundingPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ClinicalTrialAccrualPolicyTextBlock" xlink:href="clnn-20201231.xsd#clnn_ClinicalTrialAccrualPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="clnn_ClinicalTrialAccrualPolicyTextBlock" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:href="clnn-20201231.xsd#clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" order="26" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/PrepaidexpensesandothercurrentassetsTables">
    <loc xlink:type="locator" xlink:label="clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="clnn-20201231.xsd#clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:href="clnn-20201231.xsd#clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/PropertyandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/AccruedLiabilitiesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_PropertyPlantAndEquipmentOneTextBlock" xlink:href="clnn-20201231.xsd#clnn_PropertyPlantAndEquipmentOneTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="clnn_PropertyPlantAndEquipmentOneTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/PreferredStockWarrantLiabilityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPreferredUnitsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPreferredUnitsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ScheduleOfPreferredUnitsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/CommonStockWarrantsTables">
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsDisclosureAbstract" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrantsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockWarrantsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/StockBasedCompensationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/FairValueTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/RedeemableConvertiblePreferredStockTables">
    <loc xlink:type="locator" xlink:label="clnn_RedeemableConvertiblePreferredStockDisclosureAbstract" xlink:href="clnn-20201231.xsd#clnn_RedeemableConvertiblePreferredStockDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_RedeemableConvertiblePreferredStockDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/NetLossPerShareAttributabletoCommonShareholdersTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/GeographicandSegmentInformationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfDrugsAndSupplementsSegmentsTableTextBlock" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfDrugsAndSupplementsSegmentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="clnn_ScheduleOfDrugsAndSupplementsSegmentsTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofprepaidexpensesandothercurrentassetsTable">
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="clnn_AustraliaResearchAndDevelopmentCreditReceivable" xlink:href="clnn-20201231.xsd#clnn_AustraliaResearchAndDevelopmentCreditReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="clnn_AustraliaResearchAndDevelopmentCreditReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CROPrepayments" xlink:href="clnn-20201231.xsd#clnn_CROPrepayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="clnn_CROPrepayments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_AccountsReceivableNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_MetalsToBeUsedInResearchAndDevelopment" xlink:href="clnn-20201231.xsd#clnn_MetalsToBeUsedInResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="clnn_MetalsToBeUsedInResearchAndDevelopment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetTable">
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_EquipmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_FurnitureAndFixturesGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_LeaseholdImprovementsGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_ConstructionInProgressGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofaccruedliabilitiesTable">
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfAccruedLiabilitiesAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfAccruedLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfAccruedLiabilitiesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfAccruedLiabilitiesAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_AccruedCROFees" xlink:href="clnn-20201231.xsd#clnn_AccruedCROFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfAccruedLiabilitiesAbstract" xlink:to="clnn_AccruedCROFees" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DeferredGrantFunds" xlink:href="clnn-20201231.xsd#clnn_DeferredGrantFunds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfAccruedLiabilitiesAbstract" xlink:to="clnn_DeferredGrantFunds" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfAccruedLiabilitiesAbstract" xlink:to="us-gaap_AccruedSalariesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_AccruedTransactionCosts" xlink:href="clnn-20201231.xsd#clnn_AccruedTransactionCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfAccruedLiabilitiesAbstract" xlink:to="clnn_AccruedTransactionCosts" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfAccruedLiabilitiesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfAccruedLiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofnoncancelableoperatingleasearrangementsTable">
    <loc xlink:type="locator" xlink:label="clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems" xlink:href="clnn-20201231.xsd#clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsTable" xlink:href="clnn-20201231.xsd#clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems" xlink:to="clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceLeasesMember" xlink:href="clnn-20201231.xsd#clnn_FinanceLeasesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="clnn_FinanceLeasesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_OperatingLeasesMember" xlink:href="clnn-20201231.xsd#clnn_OperatingLeasesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="clnn_OperatingLeasesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleoffinanceleaseobligationsandincludedpropertyandequipmentTable">
    <loc xlink:type="locator" xlink:label="clnn_LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentLineItems" xlink:href="clnn-20201231.xsd#clnn_LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentTable" xlink:href="clnn-20201231.xsd#clnn_LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentLineItems" xlink:to="clnn_LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_WorkInProcessMember" xlink:href="clnn-20201231.xsd#clnn_WorkInProcessMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="clnn_WorkInProcessMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceLeaseLiabilityGross" xlink:href="clnn-20201231.xsd#clnn_FinanceLeaseLiabilityGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentLineItems" xlink:to="clnn_FinanceLeaseLiabilityGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_AccumulatedDepreciationDepletionAndAmortizationLeases" xlink:href="clnn-20201231.xsd#clnn_AccumulatedDepreciationDepletionAndAmortizationLeases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentLineItems" xlink:to="clnn_AccumulatedDepreciationDepletionAndAmortizationLeases" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceLeaseLiabilityNet" xlink:href="clnn-20201231.xsd#clnn_FinanceLeaseLiabilityNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentLineItems" xlink:to="clnn_FinanceLeaseLiabilityNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleoffinanceandoperatingleasecostsTable">
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfFinanceAndOperatingLeaseCostsAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfFinanceAndOperatingLeaseCostsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfFinanceAndOperatingLeaseCostsAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_VariableLeaseCost" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_LeaseCost" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofsupplementalcashflowinformationTable">
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfSupplementalCashFlowInformationAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfSupplementalCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="clnn_OperatingCashFlowsFromOperatingLeases" xlink:href="clnn-20201231.xsd#clnn_OperatingCashFlowsFromOperatingLeases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfSupplementalCashFlowInformationAbstract" xlink:to="clnn_OperatingCashFlowsFromOperatingLeases" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_OperatingCashFlowsFromFinanceLeases" xlink:href="clnn-20201231.xsd#clnn_OperatingCashFlowsFromFinanceLeases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfSupplementalCashFlowInformationAbstract" xlink:to="clnn_OperatingCashFlowsFromFinanceLeases" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceCashFlowsFromFinanceLeases" xlink:href="clnn-20201231.xsd#clnn_FinanceCashFlowsFromFinanceLeases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfSupplementalCashFlowInformationAbstract" xlink:to="clnn_FinanceCashFlowsFromFinanceLeases" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/SchedulefairvalueoftheoutstandingwarrantsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredUnitsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredUnitsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPreferredUnitsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPreferredUnitsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PreferredUnitsLineItems" xlink:to="us-gaap_ScheduleOfPreferredUnitsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPreferredUnitsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ExpirationDate" xlink:href="clnn-20201231.xsd#clnn_ExpirationDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PreferredUnitsLineItems" xlink:to="clnn_ExpirationDate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PreferredUnitsLineItems" xlink:to="us-gaap_WarrantExercisePriceIncrease" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PreferredUnitsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantsDateMember" xlink:href="clnn-20201231.xsd#clnn_WarrantsDateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="clnn_WarrantsDateMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantsDate1Member" xlink:href="clnn-20201231.xsd#clnn_WarrantsDate1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="clnn_WarrantsDate1Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_December20201Member" xlink:href="clnn-20201231.xsd#clnn_December20201Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="clnn_December20201Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantsDate2Member" xlink:href="clnn-20201231.xsd#clnn_WarrantsDate2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="clnn_WarrantsDate2Member" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_NumberOfSharesIssuable" xlink:href="clnn-20201231.xsd#clnn_NumberOfSharesIssuable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="clnn_NumberOfSharesIssuable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsExercisePrice" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrantsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="clnn_CommonStockWarrantsExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsExercisable" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrantsExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="clnn_CommonStockWarrantsExercisable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsClassification" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrantsClassification"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="clnn_CommonStockWarrantsClassification" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsExpiration" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrantsExpiration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="clnn_CommonStockWarrantsExpiration" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofcomponentsofincomelossbeforeincometaxesTable">
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofincometaxexpensebenefitTable">
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfIncomeTaxExpenseBenefitAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfIncomeTaxExpenseBenefitAbstract"/>
    <loc xlink:type="locator" xlink:label="clnn_CurrentTaxExpenseAbstract" xlink:href="clnn-20201231.xsd#clnn_CurrentTaxExpenseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfIncomeTaxExpenseBenefitAbstract" xlink:to="clnn_CurrentTaxExpenseAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CurrentTaxExpenseAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CurrentTaxExpenseAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CurrentTaxExpenseAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CurrentTaxExpenseAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DeferredTaxExpenseAbstract" xlink:href="clnn-20201231.xsd#clnn_DeferredTaxExpenseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfIncomeTaxExpenseBenefitAbstract" xlink:to="clnn_DeferredTaxExpenseAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_DeferredTaxExpenseAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_DeferredTaxExpenseAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_DeferredTaxExpenseAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_DeferredTaxExpenseAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfIncomeTaxExpenseBenefitAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofincometaxreconciliationTable">
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfIncomeTaxReconciliationAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfIncomeTaxReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_IncomeTaxReconciliationWarrantLiability" xlink:href="clnn-20201231.xsd#clnn_IncomeTaxReconciliationWarrantLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="clnn_IncomeTaxReconciliationWarrantLiability" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingencies" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_IncomeTaxReconciliationNondeductibleExpensesResearchAndDevelopment" xlink:href="clnn-20201231.xsd#clnn_IncomeTaxReconciliationNondeductibleExpensesResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="clnn_IncomeTaxReconciliationNondeductibleExpensesResearchAndDevelopment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofdeferredtaxassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="clnn_DeferredTaxAssetsLiabilitiesAbstract" xlink:href="clnn-20201231.xsd#clnn_DeferredTaxAssetsLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="clnn_DeferredTaxAssetsLiabilitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_DeferredTaxAssetsLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DeferredTaxLiabilitiesDeferredExpenseDepreciation" xlink:href="clnn-20201231.xsd#clnn_DeferredTaxLiabilitiesDeferredExpenseDepreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_DeferredTaxAssetsLiabilitiesAbstract" xlink:to="clnn_DeferredTaxLiabilitiesDeferredExpenseDepreciation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_DeferredTaxAssetsLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DeferredTaxLiabilitiesLeaseLiability" xlink:href="clnn-20201231.xsd#clnn_DeferredTaxLiabilitiesLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_DeferredTaxAssetsLiabilitiesAbstract" xlink:to="clnn_DeferredTaxLiabilitiesLeaseLiability" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DeferredTaxAssetsRightofUseAsset" xlink:href="clnn-20201231.xsd#clnn_DeferredTaxAssetsRightofUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_DeferredTaxAssetsLiabilitiesAbstract" xlink:to="clnn_DeferredTaxAssetsRightofUseAsset" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_DeferredTaxAssetsLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DeferredTaxAssetsTaxDeferredNonqualifiedStockOptions" xlink:href="clnn-20201231.xsd#clnn_DeferredTaxAssetsTaxDeferredNonqualifiedStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_DeferredTaxAssetsLiabilitiesAbstract" xlink:to="clnn_DeferredTaxAssetsTaxDeferredNonqualifiedStockOptions" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DeferredTaxAssetsTaxDeferredAccruedCompensation" xlink:href="clnn-20201231.xsd#clnn_DeferredTaxAssetsTaxDeferredAccruedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_DeferredTaxAssetsLiabilitiesAbstract" xlink:to="clnn_DeferredTaxAssetsTaxDeferredAccruedCompensation" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_DeferredTaxAssetsLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_DeferredTaxAssetsLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofstockbasedcompensationexpenseTable">
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems" xlink:href="clnn-20201231.xsd#clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable" xlink:href="clnn-20201231.xsd#clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems" xlink:to="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable">
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_InstrinsicValueOptionsVestedAndExercisableEnding" xlink:href="clnn-20201231.xsd#clnn_InstrinsicValueOptionsVestedAndExercisableEnding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="clnn_InstrinsicValueOptionsVestedAndExercisableEnding" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_WeightedAverageExercisePricePerShareOptionsVestedAndExercisableStockOptionsVest" xlink:href="clnn-20201231.xsd#clnn_WeightedAverageExercisePricePerShareOptionsVestedAndExercisableStockOptionsVest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="clnn_WeightedAverageExercisePricePerShareOptionsVestedAndExercisableStockOptionsVest" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_WeightedAverageRemainingTermOptionsVestedAndExercisableStockOptionsVestedAndExercisable" xlink:href="clnn-20201231.xsd#clnn_WeightedAverageRemainingTermOptionsVestedAndExercisableStockOptionsVestedAndExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="clnn_WeightedAverageRemainingTermOptionsVestedAndExercisableStockOptionsVestedAndExercisable" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_InstrinsicValueOptionsVestedAndExercisableStockOptionsVestedAndExpectedToVestEnding" xlink:href="clnn-20201231.xsd#clnn_InstrinsicValueOptionsVestedAndExercisableStockOptionsVestedAndExpectedToVestEnding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="clnn_InstrinsicValueOptionsVestedAndExercisableStockOptionsVestedAndExpectedToVestEnding" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:href="clnn-20201231.xsd#clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodIntrinsicValue" xlink:href="clnn-20201231.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodIntrinsicValue" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised" xlink:href="clnn-20201231.xsd#clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsExercised" xlink:href="clnn-20201231.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsExercised" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue" xlink:href="clnn-20201231.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsForfeited" xlink:href="clnn-20201231.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsForfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsForfeited" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue" xlink:href="clnn-20201231.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue" order="24" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleoffairvalueofthesestockoptionsawardsgrantedTable">
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedLineItems" xlink:href="clnn-20201231.xsd#clnn_StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedTable" xlink:href="clnn-20201231.xsd#clnn_StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedLineItems" xlink:to="clnn_StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraqWjSnTNF4jeT3oaMW8W5R0MkiIXXy8k2PQbBklJ1lYf+6GCuiY/lJFjk6uDeNN+gvvgD/ctbqbBhZgNg1qNU0EiFrWvY1hT6GmZd73HE7TJaI9wGp4wAxzd2UaTwEVsbp/IQFhRTHB/tg6uRHFmIlsS7md0nP83WlMV5C3kMhF/o9PwqIS68e] CSR-->
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofrestrictedcommonstockactivityTable">
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:href="clnn-20201231.xsd#clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable" xlink:href="clnn-20201231.xsd#clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:to="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable">
    <loc xlink:type="locator" xlink:label="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems" xlink:href="clnn-20201231.xsd#clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable" xlink:href="clnn-20201231.xsd#clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems" xlink:to="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems" xlink:to="us-gaap_NotesPayableFairValueDisclosure" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CleneNanomedicineContingentEarnout" xlink:href="clnn-20201231.xsd#clnn_CleneNanomedicineContingentEarnout"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems" xlink:to="clnn_CleneNanomedicineContingentEarnout" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_InitialShareholdersContingentEarnout" xlink:href="clnn-20201231.xsd#clnn_InitialShareholdersContingentEarnout"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems" xlink:to="clnn_InitialShareholdersContingentEarnout" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_RedeemableConvertiblePreferredStockWarrantLiability" xlink:href="clnn-20201231.xsd#clnn_RedeemableConvertiblePreferredStockWarrantLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems" xlink:to="clnn_RedeemableConvertiblePreferredStockWarrantLiability" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleoffairvalueoftheinitialcontingentearnoutTable">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ContingentEarnoutMember" xlink:href="clnn-20201231.xsd#clnn_ContingentEarnoutMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="clnn_ContingentEarnoutMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleoffinancialliabilityrelatedtothenotespayablethederivativeinstrumentthePreferredStockwarrantsandthecontingentearnoutmeasuredatfairvalueTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableOtherPayablesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_NotesPayableOtherPayablesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DerivativeInstrumentMember" xlink:href="clnn-20201231.xsd#clnn_DerivativeInstrumentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="clnn_DerivativeInstrumentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_PreferredStockWarrantsMember" xlink:href="clnn-20201231.xsd#clnn_PreferredStockWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="clnn_PreferredStockWarrantsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ContingentEarnoutMember" xlink:href="clnn-20201231.xsd#clnn_ContingentEarnoutMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="clnn_ContingentEarnoutMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_InitialShareholdersContingentEarnoutMember" xlink:href="clnn-20201231.xsd#clnn_InitialShareholdersContingentEarnoutMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="clnn_InitialShareholdersContingentEarnoutMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueIssuanceOfConvertiblePromissoryNotes" xlink:href="clnn-20201231.xsd#clnn_FairValueIssuanceOfConvertiblePromissoryNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="clnn_FairValueIssuanceOfConvertiblePromissoryNotes" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_InitialFairValueOfInstrument" xlink:href="clnn-20201231.xsd#clnn_InitialFairValueOfInstrument"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_FairValueIssuanceOfConvertiblePromissoryNotes" xlink:to="clnn_InitialFairValueOfInstrument" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable" xlink:href="clnn-20201231.xsd#clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_FairValueIssuanceOfConvertiblePromissoryNotes" xlink:to="clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ExtinguishmentOfDerivativeLiability" xlink:href="clnn-20201231.xsd#clnn_ExtinguishmentOfDerivativeLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_FairValueIssuanceOfConvertiblePromissoryNotes" xlink:to="clnn_ExtinguishmentOfDerivativeLiability" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueOfIssuanceOfNotesPayable" xlink:href="clnn-20201231.xsd#clnn_FairValueOfIssuanceOfNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="clnn_FairValueOfIssuanceOfNotesPayable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_IncreseDecreaseInFairValue" xlink:href="clnn-20201231.xsd#clnn_IncreseDecreaseInFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="clnn_IncreseDecreaseInFairValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueExerciseOfSeriesCPreferredStockWarrants" xlink:href="clnn-20201231.xsd#clnn_FairValueExerciseOfSeriesCPreferredStockWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="clnn_FairValueExerciseOfSeriesCPreferredStockWarrants" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofPreferredStockTable">
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_TemporaryEquitySharesIssuedAndOutstanding" xlink:href="clnn-20201231.xsd#clnn_TemporaryEquitySharesIssuedAndOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="clnn_TemporaryEquitySharesIssuedAndOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_TemporaryEquitySharesCommonStockIssuableUponConversion" xlink:href="clnn-20201231.xsd#clnn_TemporaryEquitySharesCommonStockIssuableUponConversion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="clnn_TemporaryEquitySharesCommonStockIssuableUponConversion" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable">
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfBasicAndDilutedNetLossPerShareAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfBasicAndDilutedNetLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="clnn_NumeratorAbstract" xlink:href="clnn-20201231.xsd#clnn_NumeratorAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfBasicAndDilutedNetLossPerShareAbstract" xlink:to="clnn_NumeratorAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NumeratorAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DenominatorAbstract" xlink:href="clnn-20201231.xsd#clnn_DenominatorAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfBasicAndDilutedNetLossPerShareAbstract" xlink:to="clnn_DenominatorAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_DenominatorAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfBasicAndDilutedNetLossPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofdilutivesecuritieswereexcludedfromthecomputationofdilutednetlosspershareTable">
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesCRedeemableConvertiblePreferredStock" xlink:href="clnn-20201231.xsd#clnn_SeriesCRedeemableConvertiblePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract" xlink:to="clnn_SeriesCRedeemableConvertiblePreferredStock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesBRedeemableConvertiblePreferredStock" xlink:href="clnn-20201231.xsd#clnn_SeriesBRedeemableConvertiblePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract" xlink:to="clnn_SeriesBRedeemableConvertiblePreferredStock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesARedeemableConvertiblePreferredStock" xlink:href="clnn-20201231.xsd#clnn_SeriesARedeemableConvertiblePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract" xlink:to="clnn_SeriesARedeemableConvertiblePreferredStock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesCRedeemableConvertiblePreferredStockWarrantsinShares" xlink:href="clnn-20201231.xsd#clnn_SeriesCRedeemableConvertiblePreferredStockWarrantsinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract" xlink:to="clnn_SeriesCRedeemableConvertiblePreferredStockWarrantsinShares" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares" xlink:href="clnn-20201231.xsd#clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract" xlink:to="clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrants" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract" xlink:to="clnn_CommonStockWarrants" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_OptionsToPurchaseCommonStockinShares" xlink:href="clnn-20201231.xsd#clnn_OptionsToPurchaseCommonStockinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract" xlink:to="clnn_OptionsToPurchaseCommonStockinShares" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ChardanUnitPurchaseOptionToPurchaseCommonStock" xlink:href="clnn-20201231.xsd#clnn_ChardanUnitPurchaseOptionToPurchaseCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract" xlink:to="clnn_ChardanUnitPurchaseOptionToPurchaseCommonStock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ChardanUnitPurchaseOptionWarrants" xlink:href="clnn-20201231.xsd#clnn_ChardanUnitPurchaseOptionWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract" xlink:to="clnn_ChardanUnitPurchaseOptionWarrants" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_EarnoutSharessee" xlink:href="clnn-20201231.xsd#clnn_EarnoutSharessee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract" xlink:to="clnn_EarnoutSharessee" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbylocationTable">
    <loc xlink:type="locator" xlink:label="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems" xlink:href="clnn-20201231.xsd#clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable" xlink:href="clnn-20201231.xsd#clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems" xlink:to="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_AU" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_AU"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_AU" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofdrugsandsupplementssegmentsTable">
    <loc xlink:type="locator" xlink:label="clnn_GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsLineItems" xlink:href="clnn-20201231.xsd#clnn_GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsTable" xlink:href="clnn-20201231.xsd#clnn_GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsLineItems" xlink:to="clnn_GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DrugsMember" xlink:href="clnn-20201231.xsd#clnn_DrugsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="clnn_DrugsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SupplementsMember" xlink:href="clnn-20201231.xsd#clnn_SupplementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="clnn_SupplementsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsLineItems" xlink:to="us-gaap_Revenues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbysegmentTable">
    <loc xlink:type="locator" xlink:label="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems" xlink:href="clnn-20201231.xsd#clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable" xlink:href="clnn-20201231.xsd#clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems" xlink:to="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DrugsMember" xlink:href="clnn-20201231.xsd#clnn_DrugsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="clnn_DrugsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SupplementsMember" xlink:href="clnn-20201231.xsd#clnn_SupplementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="clnn_SupplementsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/NatureoftheBusinessandBasisofPresentationDetails">
    <loc xlink:type="locator" xlink:label="clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:href="clnn-20201231.xsd#clnn_NatureoftheBusinessandBasisofPresentationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="clnn_NatureoftheBusinessandBasisofPresentationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfFreshStartAdjustmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfFreshStartAdjustmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:to="us-gaap_TypeOfFreshStartAdjustmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfFreshStartAdjustmentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfFreshStartAdjustmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:to="us-gaap_TypeOfFreshStartAdjustmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ChardanMember" xlink:href="clnn-20201231.xsd#clnn_ChardanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="clnn_ChardanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_LifeSciCapitalLLCMember" xlink:href="clnn-20201231.xsd#clnn_LifeSciCapitalLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="clnn_LifeSciCapitalLLCMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CleneNanomedicineMember" xlink:href="clnn-20201231.xsd#clnn_CleneNanomedicineMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="clnn_CleneNanomedicineMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExchangeClearedMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExchangeClearedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfFreshStartAdjustmentDomain" xlink:to="us-gaap_ExchangeClearedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_MergerAgreementPercentage" xlink:href="clnn-20201231.xsd#clnn_MergerAgreementPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="clnn_MergerAgreementPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ProceedsFromReverseRecapitalizationNet" xlink:href="clnn-20201231.xsd#clnn_ProceedsFromReverseRecapitalizationNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="clnn_ProceedsFromReverseRecapitalizationNet" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_PurchaseOption" xlink:href="clnn-20201231.xsd#clnn_PurchaseOption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="clnn_PurchaseOption" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_PerShareUnit" xlink:href="clnn-20201231.xsd#clnn_PerShareUnit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="clnn_PerShareUnit" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_PaymentsForAdvisoryServicesShares" xlink:href="clnn-20201231.xsd#clnn_PaymentsForAdvisoryServicesShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="clnn_PaymentsForAdvisoryServicesShares" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_StockIssuedDuringPeriodSharesPrivatePlacement" xlink:href="clnn-20201231.xsd#clnn_StockIssuedDuringPeriodSharesPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="clnn_StockIssuedDuringPeriodSharesPrivatePlacement" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_IncurredNetLosses" xlink:href="clnn-20201231.xsd#clnn_IncurredNetLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="clnn_IncurredNetLosses" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_Cash" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_RetainedEarningsAccumulatedDeficit1" xlink:href="clnn-20201231.xsd#clnn_RetainedEarningsAccumulatedDeficit1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="clnn_RetainedEarningsAccumulatedDeficit1" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="20" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="clnn-20201231.xsd#clnn_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="clnn_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollateralAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_CollateralAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollateralDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_CollateralDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollateralDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_CollateralDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RedeemablePreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemablePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemablePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollateralDomain" xlink:to="us-gaap_EquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_GrantFundingMember" xlink:href="clnn-20201231.xsd#clnn_GrantFundingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="clnn_GrantFundingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_PreferredStockWarrantMember" xlink:href="clnn-20201231.xsd#clnn_PreferredStockWarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="clnn_PreferredStockWarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_InventoryRawMaterials" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_InventoryFinishedGoods" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ProposedPublicOfferingCost" xlink:href="clnn-20201231.xsd#clnn_ProposedPublicOfferingCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="clnn_ProposedPublicOfferingCost" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DeferredRevenue" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails">
    <loc xlink:type="locator" xlink:label="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" xlink:href="clnn-20201231.xsd#clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" xlink:to="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfFreshStartAdjustmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfFreshStartAdjustmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:to="us-gaap_TypeOfFreshStartAdjustmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfFreshStartAdjustmentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfFreshStartAdjustmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:to="us-gaap_TypeOfFreshStartAdjustmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CleneNanomedicineMember" xlink:href="clnn-20201231.xsd#clnn_CleneNanomedicineMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="clnn_CleneNanomedicineMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_LifeSciCapitalLLCMember" xlink:href="clnn-20201231.xsd#clnn_LifeSciCapitalLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="clnn_LifeSciCapitalLLCMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_TottenhamMember" xlink:href="clnn-20201231.xsd#clnn_TottenhamMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="clnn_TottenhamMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="exch_PIPE" xlink:href="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd#exch_PIPE"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="exch_PIPE" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExchangeClearedMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExchangeClearedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfFreshStartAdjustmentDomain" xlink:to="us-gaap_ExchangeClearedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_IssuanceOfCommonStockUponReverseRecapitalization" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfCommonStockUponReverseRecapitalization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_IssuanceOfCommonStockUponReverseRecapitalization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_EarnOutShare" xlink:href="clnn-20201231.xsd#clnn_EarnOutShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_EarnOutShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_EntityCommonStockSharesOutstanding1" xlink:href="clnn-20201231.xsd#clnn_EntityCommonStockSharesOutstanding1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_EntityCommonStockSharesOutstanding1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SharesHeldInEscrow" xlink:href="clnn-20201231.xsd#clnn_SharesHeldInEscrow"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_SharesHeldInEscrow" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ServicesLetterAgreementDescription" xlink:href="clnn-20201231.xsd#clnn_ServicesLetterAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_ServicesLetterAgreementDescription" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherUnderwritingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherUnderwritingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_OtherUnderwritingExpense" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_InvestorsPurchasedShares" xlink:href="clnn-20201231.xsd#clnn_InvestorsPurchasedShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_InvestorsPurchasedShares" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SharesPerShare" xlink:href="clnn-20201231.xsd#clnn_SharesPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_SharesPerShare" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ExercisePrice" xlink:href="clnn-20201231.xsd#clnn_ExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_ExercisePrice" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_NetProceeds" xlink:href="clnn-20201231.xsd#clnn_NetProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_NetProceeds" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_EarnoutSharesDescription" xlink:href="clnn-20201231.xsd#clnn_EarnoutSharesDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_EarnoutSharesDescription" order="19" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/PropertyandEquipmentNetDetails">
    <loc xlink:type="locator" xlink:label="clnn_PropertyandEquipmentNetDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_PropertyandEquipmentNetDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_PropertyandEquipmentNetDetailsTable" xlink:href="clnn-20201231.xsd#clnn_PropertyandEquipmentNetDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_PropertyandEquipmentNetDetailsLineItems" xlink:to="clnn_PropertyandEquipmentNetDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_PropertyandEquipmentNetDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_PropertyandEquipmentNetDetailsLineItems" xlink:to="us-gaap_Depreciation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_PropertyandEquipmentNetDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_PropertyandEquipmentNetDetailsLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CumulativeEarningsDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CumulativeEarningsDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CumulativeEarningsDeficit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_RemainingRightofuseAsset" xlink:href="clnn-20201231.xsd#clnn_RemainingRightofuseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="clnn_RemainingRightofuseAsset" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_RecognizedGainOnOperatingLease" xlink:href="clnn-20201231.xsd#clnn_RecognizedGainOnOperatingLease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="clnn_RecognizedGainOnOperatingLease" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DescriptionOfOperatingLease" xlink:href="clnn-20201231.xsd#clnn_DescriptionOfOperatingLease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="clnn_DescriptionOfOperatingLease" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceLeaseObligationsWeightedaverageInterestRate" xlink:href="clnn-20201231.xsd#clnn_FinanceLeaseObligationsWeightedaverageInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="clnn_FinanceLeaseObligationsWeightedaverageInterestRate" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_OperatingLeaseObligationsWeightedAverageInterestRate" xlink:href="clnn-20201231.xsd#clnn_OperatingLeaseObligationsWeightedAverageInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="clnn_OperatingLeaseObligationsWeightedAverageInterestRate" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/NotesPayableDetails">
    <loc xlink:type="locator" xlink:label="clnn_NotesPayableDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_NotesPayableDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_NotesPayableDetailsTable" xlink:href="clnn-20201231.xsd#clnn_NotesPayableDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="clnn_NotesPayableDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_NotesPayableDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_NotesPayableDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_TwoThousandNineteenMDLoanMember" xlink:href="clnn-20201231.xsd#clnn_TwoThousandNineteenMDLoanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="clnn_TwoThousandNineteenMDLoanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_TwoThousandNineteenCecilLoanMember" xlink:href="clnn-20201231.xsd#clnn_TwoThousandNineteenCecilLoanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="clnn_TwoThousandNineteenCecilLoanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_PaycheckProtectionProgramNoteMember" xlink:href="clnn-20201231.xsd#clnn_PaycheckProtectionProgramNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="clnn_PaycheckProtectionProgramNoteMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="us-gaap_LineOfCredit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SimpleInterestExpense" xlink:href="clnn-20201231.xsd#clnn_SimpleInterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="clnn_SimpleInterestExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesAndLoansPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAndLoansPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="us-gaap_NotesAndLoansPayable" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_PercentageOfLoanAmountUsedToPayrollExpenses" xlink:href="clnn-20201231.xsd#clnn_PercentageOfLoanAmountUsedToPayrollExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="clnn_PercentageOfLoanAmountUsedToPayrollExpenses" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationPeriod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="us-gaap_AccruedSalariesCurrentAndNoncurrent" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableToBank" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBank"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="us-gaap_NotesPayableToBank" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/PreferredStockWarrantLiabilityDetails">
    <loc xlink:type="locator" xlink:label="clnn_PreferredStockWarrantLiabilityDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_PreferredStockWarrantLiabilityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_PreferredStockWarrantLiabilityDetailsTable" xlink:href="clnn-20201231.xsd#clnn_PreferredStockWarrantLiabilityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_PreferredStockWarrantLiabilityDetailsLineItems" xlink:to="clnn_PreferredStockWarrantLiabilityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_PreferredStockWarrantLiabilityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_PreferredStockWarrantLiabilityDetailsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_PreferredStockWarrantLiabilityDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_PreferredStockWarrantLiabilityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_PreferredStockWarrantLiabilityDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LossRecognizedOnAssetsTransferredToSeparateAccountGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossRecognizedOnAssetsTransferredToSeparateAccountGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_PreferredStockWarrantLiabilityDetailsLineItems" xlink:to="us-gaap_LossRecognizedOnAssetsTransferredToSeparateAccountGross" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_PreferredStockWarrantLiabilityDetailsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/CommonStockWarrantsDetails">
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrantsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsDetailsTable" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrantsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_CommonStockWarrantsDetailsLineItems" xlink:to="clnn_CommonStockWarrantsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_CommonStockWarrantsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_CommonStockWarrantsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_CommonStockWarrantsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ChardanMember" xlink:href="clnn-20201231.xsd#clnn_ChardanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="clnn_ChardanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_TottenhamsMember" xlink:href="clnn-20201231.xsd#clnn_TottenhamsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="clnn_TottenhamsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockWarrantsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockWarrantsDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockWarrantsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockWarrantsDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ReverseRecapitalizationAndWillExpireYears" xlink:href="clnn-20201231.xsd#clnn_ReverseRecapitalizationAndWillExpireYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockWarrantsDetailsLineItems" xlink:to="clnn_ReverseRecapitalizationAndWillExpireYears" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantExercisePrice" xlink:href="clnn-20201231.xsd#clnn_WarrantExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockWarrantsDetailsLineItems" xlink:to="clnn_WarrantExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockWarrantsDetailsLineItems" xlink:to="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockWarrantsDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockWarrantsDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockWarrantsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_PreferredStockWarrantsOutstandingShares" xlink:href="clnn-20201231.xsd#clnn_PreferredStockWarrantsOutstandingShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockWarrantsDetailsLineItems" xlink:to="clnn_PreferredStockWarrantsOutstandingShares" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockWarrantsDetailsLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockWarrantsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ConvertibleNotesDetails">
    <loc xlink:type="locator" xlink:label="clnn_ConvertibleNotesDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_ConvertibleNotesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_ConvertibleNotesDetailsTable" xlink:href="clnn-20201231.xsd#clnn_ConvertibleNotesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="clnn_ConvertibleNotesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_ConvertibleNotesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_ConvertibleNotesDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DescriptionOfConvertibleNotes" xlink:href="clnn-20201231.xsd#clnn_DescriptionOfConvertibleNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="clnn_DescriptionOfConvertibleNotes" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_InterestExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_PercentageOfStock" xlink:href="clnn-20201231.xsd#clnn_PercentageOfStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="clnn_PercentageOfStock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_PreferredStockConvertibleConversionPrice" xlink:href="clnn-20201231.xsd#clnn_PreferredStockConvertibleConversionPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="clnn_PreferredStockConvertibleConversionPrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/DerivativeInstrumentsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeFairValueOfDerivativeNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DerivativeInstrumentsOfComprehensiveLoss" xlink:href="clnn-20201231.xsd#clnn_DerivativeInstrumentsOfComprehensiveLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="clnn_DerivativeInstrumentsOfComprehensiveLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GuarantyLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GuarantyLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_GuarantyLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReportingUnitAmountOfFairValueInExcessOfCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitAmountOfFairValueInExcessOfCarryingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_ReportingUnitAmountOfFairValueInExcessOfCarryingAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="clnn_IncomeTaxesDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_IncomeTaxesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_IncomeTaxesDetailsTable" xlink:href="clnn-20201231.xsd#clnn_IncomeTaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_IncomeTaxesDetailsLineItems" xlink:to="clnn_IncomeTaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_OperatingLossExpireTerm" xlink:href="clnn-20201231.xsd#clnn_OperatingLossExpireTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_IncomeTaxesDetailsLineItems" xlink:to="clnn_OperatingLossExpireTerm" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_RemainingBalanceOfOperatingLoss" xlink:href="clnn-20201231.xsd#clnn_RemainingBalanceOfOperatingLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_IncomeTaxesDetailsLineItems" xlink:to="clnn_RemainingBalanceOfOperatingLoss" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ResearchAndDevelopmentCreditExpiryTerm" xlink:href="clnn-20201231.xsd#clnn_ResearchAndDevelopmentCreditExpiryTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_IncomeTaxesDetailsLineItems" xlink:to="clnn_ResearchAndDevelopmentCreditExpiryTerm" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/StockBasedCompensationDetails">
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_StockBasedCompensationDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsTable" xlink:href="clnn-20201231.xsd#clnn_StockBasedCompensationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="clnn_StockBasedCompensationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_StockBasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_StockBasedCompensationDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_StockPlan2020Member" xlink:href="clnn-20201231.xsd#clnn_StockPlan2020Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="clnn_StockPlan2020Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_StockPlan2014Member" xlink:href="clnn-20201231.xsd#clnn_StockPlan2014Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="clnn_StockPlan2014Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_MinimumFairMarketValueOfOptionGrantDescription" xlink:href="clnn-20201231.xsd#clnn_MinimumFairMarketValueOfOptionGrantDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="clnn_MinimumFairMarketValueOfOptionGrantDescription" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants" xlink:href="clnn-20201231.xsd#clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockOtherSharesOutstanding" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonSharesAuthorized" xlink:href="clnn-20201231.xsd#clnn_CommonSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="clnn_CommonSharesAuthorized" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross" xlink:href="clnn-20201231.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_UnrecognizedStockbasedCompensation" xlink:href="clnn-20201231.xsd#clnn_UnrecognizedStockbasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="clnn_UnrecognizedStockbasedCompensation" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_weightedAverageFairValuesOfOptionsGranted" xlink:href="clnn-20201231.xsd#clnn_weightedAverageFairValuesOfOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="clnn_weightedAverageFairValuesOfOptionsGranted" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_RestrictedStockUnitsDescription" xlink:href="clnn-20201231.xsd#clnn_RestrictedStockUnitsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="clnn_RestrictedStockUnitsDescription" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerms" xlink:href="clnn-20201231.xsd#clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerms" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm" xlink:href="clnn-20201231.xsd#clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm" order="22" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/FairValueDetails">
    <loc xlink:type="locator" xlink:label="clnn_FairValueDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_FairValueDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueDetailsTable" xlink:href="clnn-20201231.xsd#clnn_FairValueDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_FairValueDetailsLineItems" xlink:to="clnn_FairValueDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_FairValueDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueMeasurementWithUnobservableInputsNotesPayable" xlink:href="clnn-20201231.xsd#clnn_FairValueMeasurementWithUnobservableInputsNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_FairValueDetailsLineItems" xlink:to="clnn_FairValueMeasurementWithUnobservableInputsNotesPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_NotesPayableBasedOnClosingPrice" xlink:href="clnn-20201231.xsd#clnn_NotesPayableBasedOnClosingPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_FairValueDetailsLineItems" xlink:to="clnn_NotesPayableBasedOnClosingPrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantsToPurchasePreferredStock" xlink:href="clnn-20201231.xsd#clnn_WarrantsToPurchasePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_FairValueDetailsLineItems" xlink:to="clnn_WarrantsToPurchasePreferredStock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_FairValueDetailsLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/RedeemableConvertiblePreferredStockDetails">
    <loc xlink:type="locator" xlink:label="clnn_RedeemableConvertiblePreferredStockDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_RedeemableConvertiblePreferredStockDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_RedeemableConvertiblePreferredStockDetailsTable" xlink:href="clnn-20201231.xsd#clnn_RedeemableConvertiblePreferredStockDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="clnn_RedeemableConvertiblePreferredStockDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_RedeemableConvertiblePreferredStockDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_RedeemableConvertiblePreferredStockDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_RedeemableConvertiblePreferredStockDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestorMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_InvestorMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ConversionOfSecuredPromissoryNotes" xlink:href="clnn-20201231.xsd#clnn_ConversionOfSecuredPromissoryNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="clnn_ConversionOfSecuredPromissoryNotes" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_NetOfIssuanceCosts" xlink:href="clnn-20201231.xsd#clnn_NetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="clnn_NetOfIssuanceCosts" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CashConsiderationReceived" xlink:href="clnn-20201231.xsd#clnn_CashConsiderationReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="clnn_CashConsiderationReceived" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="us-gaap_AdditionalPaidInCapital" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SharesIssuedUponConversionOfConvertiblePromissoryNote" xlink:href="clnn-20201231.xsd#clnn_SharesIssuedUponConversionOfConvertiblePromissoryNote"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="clnn_SharesIssuedUponConversionOfConvertiblePromissoryNote" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantsSharesInExercise" xlink:href="clnn-20201231.xsd#clnn_WarrantsSharesInExercise"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="clnn_WarrantsSharesInExercise" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConversionBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockConversionBasis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="us-gaap_PreferredStockConversionBasis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="us-gaap_CommonStockConvertibleConversionPriceIncrease" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="us-gaap_ConversionOfStockDescription" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/CommonStockDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_PreferredStockShares" xlink:href="clnn-20201231.xsd#clnn_PreferredStockShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="clnn_PreferredStockShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_IssuanceOfCommonStockUponReverseRecapitalization" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfCommonStockUponReverseRecapitalization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="clnn_IssuanceOfCommonStockUponReverseRecapitalization" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_RecapitalizationShare" xlink:href="clnn-20201231.xsd#clnn_RecapitalizationShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="clnn_RecapitalizationShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_InvestorsPurchasedShares" xlink:href="clnn-20201231.xsd#clnn_InvestorsPurchasedShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="clnn_InvestorsPurchasedShares" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SharePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_NetProceeds" xlink:href="clnn-20201231.xsd#clnn_NetProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="clnn_NetProceeds" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/NetLossPerShareAttributabletoCommonShareholdersDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="clnn_NumberOfSharesIssuableOnExerciseOfWarrants" xlink:href="clnn-20201231.xsd#clnn_NumberOfSharesIssuableOnExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="clnn_NumberOfSharesIssuableOnExerciseOfWarrants" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ChardanUnitPurchaseOptionToPurchaseCommonStock" xlink:href="clnn-20201231.xsd#clnn_ChardanUnitPurchaseOptionToPurchaseCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="clnn_ChardanUnitPurchaseOptionToPurchaseCommonStock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ChardanUnitPurchaseOptionWarrants" xlink:href="clnn-20201231.xsd#clnn_ChardanUnitPurchaseOptionWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="clnn_ChardanUnitPurchaseOptionWarrants" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="clnn_RelatedPartyTransactionsDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_RelatedPartyTransactionsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_RelatedPartyTransactionsDetailsTable" xlink:href="clnn-20201231.xsd#clnn_RelatedPartyTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_RelatedPartyTransactionsDetailsLineItems" xlink:to="clnn_RelatedPartyTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_RelatedPartyTransactionsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="clnn_SubsequentEventsDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_SubsequentEventsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_SubsequentEventsDetailsTable" xlink:href="clnn-20201231.xsd#clnn_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_SubsequentEventsDetailsLineItems" xlink:to="clnn_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_PaycheckProtectionProgramLoan" xlink:href="clnn-20201231.xsd#clnn_PaycheckProtectionProgramLoan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SubsequentEventsDetailsLineItems" xlink:to="clnn_PaycheckProtectionProgramLoan" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_GainOnForgivenessLoan" xlink:href="clnn-20201231.xsd#clnn_GainOnForgivenessLoan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SubsequentEventsDetailsLineItems" xlink:to="clnn_GainOnForgivenessLoan" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_FoundationGrantCost" xlink:href="clnn-20201231.xsd#clnn_FoundationGrantCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SubsequentEventsDetailsLineItems" xlink:to="clnn_FoundationGrantCost" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SubsequentEventDescription" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_AggregateGrossProceedWarrantsExercised" xlink:href="clnn-20201231.xsd#clnn_AggregateGrossProceedWarrantsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SubsequentEventsDetailsLineItems" xlink:to="clnn_AggregateGrossProceedWarrantsExercised" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SaleOfStockholdersCommonStock" xlink:href="clnn-20201231.xsd#clnn_SaleOfStockholdersCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SubsequentEventsDetailsLineItems" xlink:to="clnn_SaleOfStockholdersCommonStock" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="21" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>clnn-20201231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Mar 26 16:52:33 EDT 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL STOCKHOLDERS&#8217; EQUITY (DEFICIT)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">(Loss) Income from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl1" xml:lang="en-US">Net operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net loss attributable to common shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax_lbl" xml:lang="en-US">Total other comprehensive income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balances (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balances (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash &#8211; beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash &#8211; end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract" xlink:href="clnn-20201231.xsd#clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract_lbl" xml:lang="en-US">Reverse Recapitalization With Tottenham And Clene Nanomedicine [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract" xlink:to="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="clnn-20201231.xsd#clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Prepaid Expenses And Other Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Schedule of prepaid expenses and other current assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfPropertyAndEquipmentNetAbstract_lbl" xml:lang="en-US">Schedule of property and equipment, net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="clnn_ScheduleOfPropertyAndEquipmentNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract_lbl" xml:lang="en-US">Disclosure Text Block Supplement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_DisclosureTextBlockSupplementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfAccruedLiabilitiesAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfAccruedLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfAccruedLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of accrued liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfAccruedLiabilitiesAbstract" xlink:to="clnn_ScheduleOfAccruedLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockAbstract_lbl" xml:lang="en-US">Disclosure Text Block [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfNoncancelableOperatingLeaseArrangementsAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfNoncancelableOperatingLeaseArrangementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfNoncancelableOperatingLeaseArrangementsAbstract_lbl" xml:lang="en-US">Schedule of noncancelable operating lease arrangements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfNoncancelableOperatingLeaseArrangementsAbstract" xlink:to="clnn_ScheduleOfNoncancelableOperatingLeaseArrangementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xml:lang="en-US">Lease Contractual Term [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfFinanceLeaseObligationsAndIncludedPropertyAndEquipmentAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfFinanceLeaseObligationsAndIncludedPropertyAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfFinanceLeaseObligationsAndIncludedPropertyAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule of finance lease obligations and included property and equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfFinanceLeaseObligationsAndIncludedPropertyAndEquipmentAbstract" xlink:to="clnn_ScheduleOfFinanceLeaseObligationsAndIncludedPropertyAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfFinanceAndOperatingLeaseCostsAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfFinanceAndOperatingLeaseCostsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfFinanceAndOperatingLeaseCostsAbstract_lbl" xml:lang="en-US">Schedule of finance and operating lease costs [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfFinanceAndOperatingLeaseCostsAbstract" xlink:to="clnn_ScheduleOfFinanceAndOperatingLeaseCostsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfSupplementalCashFlowInformationAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfSupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfSupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Schedule of supplemental cash flow information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfSupplementalCashFlowInformationAbstract" xlink:to="clnn_ScheduleOfSupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleFairValueOfTheOutstandingWarrantsAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleFairValueOfTheOutstandingWarrantsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleFairValueOfTheOutstandingWarrantsAbstract_lbl" xml:lang="en-US">Schedule fair value of the outstanding warrants [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleFairValueOfTheOutstandingWarrantsAbstract" xlink:to="clnn_ScheduleFairValueOfTheOutstandingWarrantsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsDisclosureAbstract" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrantsDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CommonStockWarrantsDisclosureAbstract_lbl" xml:lang="en-US">Common Stock Warrants Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsDisclosureAbstract" xlink:to="clnn_CommonStockWarrantsDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockAbstract_lbl" xml:lang="en-US">Schedule of outstanding warrants to purchase shares of common stock [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockAbstract" xlink:to="clnn_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ConvertibleNotesDisclosureAbstract" xlink:href="clnn-20201231.xsd#clnn_ConvertibleNotesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ConvertibleNotesDisclosureAbstract_lbl" xml:lang="en-US">Convertible Notes Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConvertibleNotesDisclosureAbstract" xlink:to="clnn_ConvertibleNotesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract_lbl" xml:lang="en-US">Schedule of components of income (loss) before income taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract" xlink:to="clnn_ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Net loss before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfIncomeTaxExpenseBenefitAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfIncomeTaxExpenseBenefitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfIncomeTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Schedule of income tax expense (benefit) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfIncomeTaxExpenseBenefitAbstract" xlink:to="clnn_ScheduleOfIncomeTaxExpenseBenefitAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total current tax expense (benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total deferred tax expense (benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total income tax expense (benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US">Income tax expense (benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfIncomeTaxReconciliationAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfIncomeTaxReconciliationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US">Schedule of income tax reconciliation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfIncomeTaxReconciliationAbstract" xlink:to="clnn_ScheduleOfIncomeTaxReconciliationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of deferred tax assets and liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="clnn_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfStockBasedCompensationExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfStockBasedCompensationExpenseAbstract_lbl" xml:lang="en-US">Schedule of stock-based compensation expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:to="clnn_ScheduleOfStockBasedCompensationExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract_lbl" xml:lang="en-US">Schedule of outstanding common stock options and related activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Outstanding - beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Number of Options, Outstanding - ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Outstanding - beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted Average Exercise Price Per Share, Outstanding - ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Instrinsic Value, Outstanding - beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Instrinsic Value, Outstanding - ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfFairValueOfTheseStockOptionsAwardsGrantedAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfFairValueOfTheseStockOptionsAwardsGrantedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfFairValueOfTheseStockOptionsAwardsGrantedAbstract_lbl" xml:lang="en-US">Schedule of fair value of these stock options awards granted [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfFairValueOfTheseStockOptionsAwardsGrantedAbstract" xlink:to="clnn_ScheduleOfFairValueOfTheseStockOptionsAwardsGrantedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfRestrictedCommonStockActivityAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfRestrictedCommonStockActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfRestrictedCommonStockActivityAbstract_lbl" xml:lang="en-US">Schedule of restricted common stock activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfRestrictedCommonStockActivityAbstract" xlink:to="clnn_ScheduleOfRestrictedCommonStockActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Beginning balance, Number of RSUs, Unvested balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0" xml:lang="en-US">Number of RSUs, Unvested balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl1" xml:lang="en-US">Shares granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Beginning balance, Weighted Average Grant Date Fair Value, Unvested balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Grant Date Fair Value, Unvested balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfFairValueHierarchyOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfFairValueHierarchyOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfFairValueHierarchyOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract_lbl" xml:lang="en-US">Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfFairValueHierarchyOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" xlink:to="clnn_ScheduleOfFairValueHierarchyOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfFairValueOfTheInitialContingentEarnOutAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfFairValueOfTheInitialContingentEarnOutAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfFairValueOfTheInitialContingentEarnOutAbstract_lbl" xml:lang="en-US">Schedule of fair value of the initial contingent earn-out [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfFairValueOfTheInitialContingentEarnOutAbstract" xlink:to="clnn_ScheduleOfFairValueOfTheInitialContingentEarnOutAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfFinancialLiabilityRelatedToTheNotesPayableTheDerivativeInstrumentThePreferredStockWarrantsAndTheContingentEarnOutMeasuredAtFairValueAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfFinancialLiabilityRelatedToTheNotesPayableTheDerivativeInstrumentThePreferredStockWarrantsAndTheContingentEarnOutMeasuredAtFairValueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfFinancialLiabilityRelatedToTheNotesPayableTheDerivativeInstrumentThePreferredStockWarrantsAndTheContingentEarnOutMeasuredAtFairValueAbstract_lbl" xml:lang="en-US">Schedule of financial liability related to the notes payable, the derivative instrument, the Preferred Stock warrants, and the contingent earn-out measured at fair value [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfFinancialLiabilityRelatedToTheNotesPayableTheDerivativeInstrumentThePreferredStockWarrantsAndTheContingentEarnOutMeasuredAtFairValueAbstract" xlink:to="clnn_ScheduleOfFinancialLiabilityRelatedToTheNotesPayableTheDerivativeInstrumentThePreferredStockWarrantsAndTheContingentEarnOutMeasuredAtFairValueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl0" xml:lang="en-US">Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_RedeemableConvertiblePreferredStockDisclosureAbstract" xlink:href="clnn-20201231.xsd#clnn_RedeemableConvertiblePreferredStockDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_RedeemableConvertiblePreferredStockDisclosureAbstract_lbl" xml:lang="en-US">Redeemable Convertible Preferred Stock Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RedeemableConvertiblePreferredStockDisclosureAbstract" xlink:to="clnn_RedeemableConvertiblePreferredStockDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfPreferredStockAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfPreferredStockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfPreferredStockAbstract_lbl" xml:lang="en-US">Schedule of Preferred Stock [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfPreferredStockAbstract" xlink:to="clnn_ScheduleOfPreferredStockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfBasicAndDilutedNetLossPerShareAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfBasicAndDilutedNetLossPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfBasicAndDilutedNetLossPerShareAbstract_lbl" xml:lang="en-US">Schedule of basic and diluted net loss per share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfBasicAndDilutedNetLossPerShareAbstract" xlink:to="clnn_ScheduleOfBasicAndDilutedNetLossPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract_lbl" xml:lang="en-US">Schedule of dilutive securities were excluded from the computation of diluted net loss per share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract" xlink:to="clnn_ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfPropertyAndEquipmentNetByLocationAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfPropertyAndEquipmentNetByLocationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfPropertyAndEquipmentNetByLocationAbstract_lbl" xml:lang="en-US">Schedule of property and equipment, net by location [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfPropertyAndEquipmentNetByLocationAbstract" xlink:to="clnn_ScheduleOfPropertyAndEquipmentNetByLocationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfDrugsAndSupplementsSegmentsAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfDrugsAndSupplementsSegmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfDrugsAndSupplementsSegmentsAbstract_lbl" xml:lang="en-US">Schedule of drugs and supplements segments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfDrugsAndSupplementsSegmentsAbstract" xlink:to="clnn_ScheduleOfDrugsAndSupplementsSegmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfPropertyAndEquipmentNetBySegmentAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfPropertyAndEquipmentNetBySegmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfPropertyAndEquipmentNetBySegmentAbstract_lbl" xml:lang="en-US">Schedule of property and equipment, net by segment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfPropertyAndEquipmentNetBySegmentAbstract" xlink:to="clnn_ScheduleOfPropertyAndEquipmentNetBySegmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating lease right of use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Total property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Income tax payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xml:lang="en-US">Payable to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenue from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease obligations, current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance lease obligations, current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US">Clene Nanomedicine contingent earn-out, current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease obligations, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Finance lease obligations, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Notes payable, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US">Deferred income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_RedeemableConvertiblePreferredStockWarrantLiability" xlink:href="clnn-20201231.xsd#clnn_RedeemableConvertiblePreferredStockWarrantLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_RedeemableConvertiblePreferredStockWarrantLiability_lbl" xml:lang="en-US">Redeemable convertible preferred stock warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RedeemableConvertiblePreferredStockWarrantLiability" xlink:to="clnn_RedeemableConvertiblePreferredStockWarrantLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ContingentEarnoutNetOfCurrentPortion" xlink:href="clnn-20201231.xsd#clnn_ContingentEarnoutNetOfCurrentPortion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ContingentEarnoutNetOfCurrentPortion_lbl" xml:lang="en-US">Clene Nanomedicine contingent earn-out, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ContingentEarnoutNetOfCurrentPortion" xlink:to="clnn_ContingentEarnoutNetOfCurrentPortion_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_InitialShareholdersContingentEarnout" xlink:href="clnn-20201231.xsd#clnn_InitialShareholdersContingentEarnout"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_InitialShareholdersContingentEarnout_lbl" xml:lang="en-US">Initial Shareholders contingent earn-out</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialShareholdersContingentEarnout" xlink:to="clnn_InitialShareholdersContingentEarnout_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 13)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US">Redeemable convertible preferred stock (Series A, B, C and D), $0.0001 par value; 0 and 31,036,008 shares authorized as of December 31, 2020 and 2019, respectively; 0 and 27,499,837 shares issued and outstanding as of December 31, 2020 and 2019, respectively; liquidation preference of $0 and $78,875 as of December 31, 2020 and 2019, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl0" xml:lang="en-US">Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US">Redeemable convertible preferred stock, per value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US">Redeemable convertible preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl0" xml:lang="en-US">Preferred Shares Authorized (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US">Redeemable convertible preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US">Redeemable convertible preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xml:lang="en-US">Liquidation preference (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl0" xml:lang="en-US">Liquidation Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity (deficit): (1)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value: 100,000,000 shares authorized; 59,526,171 and 17,357,505 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common stock par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Common share, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenue:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenue from external customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CostsOfRevenue" xlink:href="clnn-20201231.xsd#clnn_CostsOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CostsOfRevenue_lbl" xml:lang="en-US">Cost of revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CostsOfRevenue" xlink:to="clnn_CostsOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and administrative expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense), net:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnContractTermination" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnContractTermination"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnContractTermination_lbl" xml:lang="en-US">Gain on termination of lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnContractTermination" xlink:to="us-gaap_GainLossOnContractTermination_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfPreferredStockWarrantLiability" xlink:href="clnn-20201231.xsd#clnn_ChangeInFairValueOfPreferredStockWarrantLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ChangeInFairValueOfPreferredStockWarrantLiability_lbl" xml:lang="en-US">Change in fair value of preferred stock warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangeInFairValueOfPreferredStockWarrantLiability" xlink:to="clnn_ChangeInFairValueOfPreferredStockWarrantLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts_lbl" xml:lang="en-US">Change in fair value of derivative liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts" xlink:to="us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfContingentEarnout" xlink:href="clnn-20201231.xsd#clnn_ChangeInFairValueOfContingentEarnout"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ChangeInFairValueOfContingentEarnout_lbl" xml:lang="en-US">Change in fair value of Clene Nanomedicine contingent earn-out</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangeInFairValueOfContingentEarnout" xlink:to="clnn_ChangeInFairValueOfContingentEarnout_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="clnn_ChangeInFairValueOfContingentEarnout_lbl0" xml:lang="en-US">Change in fair value of Clene Nanomedicine contingent earn-out</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangeInFairValueOfContingentEarnout" xlink:to="clnn_ChangeInFairValueOfContingentEarnout_lbl0"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout" xlink:href="clnn-20201231.xsd#clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout_lbl" xml:lang="en-US">Change in fair value of Initial Shareholders contingent earn-out</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout" xlink:to="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout_lbl0" xml:lang="en-US">Change in fair value of Initial Shareholders contingent earn-out</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout" xlink:to="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of convertibles notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl0" xml:lang="en-US">Loss on extinguishment of convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1" xml:lang="en-US">Loss on extinguishment of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xml:lang="en-US">Other comprehensive income (loss):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Foreign currency translation adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share-- basic and diluted (Note 19) (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl0" xml:lang="en-US">Net loss per share attributable to common shareholders, basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average common shares used to compute basic and diluted net loss per share (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl0" xml:lang="en-US">Weighted average shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl0"/>
    <loc xlink:type="locator" xlink:label="clnn_ApplicationOfASC842" xlink:href="clnn-20201231.xsd#clnn_ApplicationOfASC842"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ApplicationOfASC842_lbl" xml:lang="en-US">Application of ASC 842</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ApplicationOfASC842" xlink:to="clnn_ApplicationOfASC842_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts_lbl" xml:lang="en-US">Issuance of Series C preferred stock, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts" xlink:to="clnn_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of Series C preferred stock, net of issuance costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ExerciseOfSeriesCPreferredStockWarrants" xlink:href="clnn-20201231.xsd#clnn_ExerciseOfSeriesCPreferredStockWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ExerciseOfSeriesCPreferredStockWarrants_lbl" xml:lang="en-US">Exercise of Series C preferred stock warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExerciseOfSeriesCPreferredStockWarrants" xlink:to="clnn_ExerciseOfSeriesCPreferredStockWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ExerciseOfSeriesCPreferredStockWarrant" xlink:href="clnn-20201231.xsd#clnn_ExerciseOfSeriesCPreferredStockWarrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ExerciseOfSeriesCPreferredStockWarrant_lbl" xml:lang="en-US">Exercise of Series C preferred stock warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExerciseOfSeriesCPreferredStockWarrant" xlink:to="clnn_ExerciseOfSeriesCPreferredStockWarrant_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ForeignCurrencyTranslationAdjustment" xlink:href="clnn-20201231.xsd#clnn_ForeignCurrencyTranslationAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ForeignCurrencyTranslationAdjustment_lbl" xml:lang="en-US">Foreign currency translation adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ForeignCurrencyTranslationAdjustment" xlink:to="clnn_ForeignCurrencyTranslationAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of Series D Preferred Stock, net of issuance costs of $1.3 million</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of Series D Preferred Stock, net of issuance costs of $1.3 million (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Convertible shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl1" xml:lang="en-US">Stock option outstanding (post-conversion)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl1"/>
    <loc xlink:type="locator" xlink:label="clnn_NetIssuanceCosts" xlink:href="clnn-20201231.xsd#clnn_NetIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_NetIssuanceCosts_lbl" xml:lang="en-US">Net issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetIssuanceCosts" xlink:to="clnn_NetIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis_lbl" xml:lang="en-US">Issuance of Series D Preferred Stock in connection with the extinguishment of convertible promissory notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis" xlink:to="clnn_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_IssuanceOfSeriesDPreferredStockInConnectionExtinguishmentOfConvertiblePromis" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfSeriesDPreferredStockInConnectionExtinguishmentOfConvertiblePromis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_IssuanceOfSeriesDPreferredStockInConnectionExtinguishmentOfConvertiblePromis_lbl" xml:lang="en-US">Issuance of Series D Preferred Stock in connection with the extinguishment of convertible promissory notes (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IssuanceOfSeriesDPreferredStockInConnectionExtinguishmentOfConvertiblePromis" xlink:to="clnn_IssuanceOfSeriesDPreferredStockInConnectionExtinguishmentOfConvertiblePromis_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe" xlink:href="clnn-20201231.xsd#clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe_lbl" xml:lang="en-US">Conversion of redeemable convertible preferred stock into common stock in connection with the Reverse Recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe" xlink:to="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection" xlink:href="clnn-20201231.xsd#clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection_lbl" xml:lang="en-US">Conversion of redeemable convertible preferred stock into common stock in connection with the Reverse Recapitalization (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection" xlink:to="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable" xlink:href="clnn-20201231.xsd#clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable_lbl" xml:lang="en-US">Extinguishment of preferred stock warrant liability in connection with the conversion of redeemable convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable" xlink:to="clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts_lbl" xml:lang="en-US">Issuance of common stock upon the Reverse Recapitalization and the private offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts" xlink:to="clnn_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock upon the Reverse Recapitalization and the private offering (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Newly issued share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Offering costs in connection with the Reverse Recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts_lbl" xml:lang="en-US">Issuance of common stock as payment of related offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts" xlink:to="clnn_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_IssuanceOfCommonStockPaymentOfRelatedOfferingCosts" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfCommonStockPaymentOfRelatedOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_IssuanceOfCommonStockPaymentOfRelatedOfferingCosts_lbl" xml:lang="en-US">Issuance of common stock as payment of related offering costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IssuanceOfCommonStockPaymentOfRelatedOfferingCosts" xlink:to="clnn_IssuanceOfCommonStockPaymentOfRelatedOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati" xlink:href="clnn-20201231.xsd#clnn_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati_lbl" xml:lang="en-US">Clene Nanomedicine contingent earn-out recognized in connection with the Reverse Recapitalization (see Note 12)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati" xlink:to="clnn_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization" xlink:href="clnn-20201231.xsd#clnn_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization_lbl" xml:lang="en-US">Initial Shareholders contingent earn-out recognized in connection with the Reverse Recapitalization (see Note 12)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization" xlink:to="clnn_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncashExpense_lbl" xml:lang="en-US">Non-cash lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Change in fair value of preferred stock warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Total stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl1" xml:lang="en-US">Stock-based compensation (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Accretion of debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl0" xml:lang="en-US">Amortization of debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl0"/>
    <loc xlink:type="locator" xlink:label="clnn_IncreaseInInterestAccruedOnNotesPayable" xlink:href="clnn-20201231.xsd#clnn_IncreaseInInterestAccruedOnNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_IncreaseInInterestAccruedOnNotesPayable_lbl" xml:lang="en-US">Increase in interest accrued on notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncreaseInInterestAccruedOnNotesPayable" xlink:to="clnn_IncreaseInInterestAccruedOnNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xml:lang="en-US">Income tax payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_IncreaseDecreaseInPayableToRelatedParties" xlink:href="clnn-20201231.xsd#clnn_IncreaseDecreaseInPayableToRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_IncreaseDecreaseInPayableToRelatedParties_lbl" xml:lang="en-US">Payable to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncreaseDecreaseInPayableToRelatedParties" xlink:to="clnn_IncreaseDecreaseInPayableToRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Proceeds from issuance of Series C Preferred Stock, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from the issuance of note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ProceedsFromThePrivatePlacementOfferingNetOfOfferingCosts" xlink:href="clnn-20201231.xsd#clnn_ProceedsFromThePrivatePlacementOfferingNetOfOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ProceedsFromThePrivatePlacementOfferingNetOfOfferingCosts_lbl" xml:lang="en-US">Proceeds from the Reverse Recapitalization and from the private placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ProceedsFromThePrivatePlacementOfferingNetOfOfferingCosts" xlink:to="clnn_ProceedsFromThePrivatePlacementOfferingNetOfOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Proceeds from issuance of Series D Preferred Stock, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfMediumTermNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfMediumTermNotes_lbl" xml:lang="en-US">Proceeds from the issuance of convertible notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:to="us-gaap_ProceedsFromIssuanceOfMediumTermNotes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of foreign exchange rate changes on cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl" xml:lang="en-US">Acquisition of property and equipment through finance lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfAssetsAcquired" xlink:to="us-gaap_FairValueOfAssetsAcquired_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_AcquisitionOfRightofuseAssetsAndLeaseholdImprovementsThroughOperatingLease" xlink:href="clnn-20201231.xsd#clnn_AcquisitionOfRightofuseAssetsAndLeaseholdImprovementsThroughOperatingLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_AcquisitionOfRightofuseAssetsAndLeaseholdImprovementsThroughOperatingLease_lbl" xml:lang="en-US">Acquisition of right-of-use assets and leasehold improvements through operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AcquisitionOfRightofuseAssetsAndLeaseholdImprovementsThroughOperatingLease" xlink:to="clnn_AcquisitionOfRightofuseAssetsAndLeaseholdImprovementsThroughOperatingLease_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantLiabilitySettledOnExercise" xlink:href="clnn-20201231.xsd#clnn_WarrantLiabilitySettledOnExercise"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_WarrantLiabilitySettledOnExercise_lbl" xml:lang="en-US">Warrant liability settled on exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantLiabilitySettledOnExercise" xlink:to="clnn_WarrantLiabilitySettledOnExercise_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_LeaseLiabilitySettledThroughTerminationOfLease" xlink:href="clnn-20201231.xsd#clnn_LeaseLiabilitySettledThroughTerminationOfLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_LeaseLiabilitySettledThroughTerminationOfLease_lbl" xml:lang="en-US">Lease liability settled through termination of lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LeaseLiabilitySettledThroughTerminationOfLease" xlink:to="clnn_LeaseLiabilitySettledThroughTerminationOfLease_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_IssuanceOfDerivativeInstrumentRelatedToConvertibleNotes" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfDerivativeInstrumentRelatedToConvertibleNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_IssuanceOfDerivativeInstrumentRelatedToConvertibleNotes_lbl" xml:lang="en-US">Issuance of derivative instrument related to convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IssuanceOfDerivativeInstrumentRelatedToConvertibleNotes" xlink:to="clnn_IssuanceOfDerivativeInstrumentRelatedToConvertibleNotes_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes_lbl" xml:lang="en-US">Issuance of Series D Preferred Stock upon extinguishment of convertible promissory notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes" xlink:to="clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" xlink:href="clnn-20201231.xsd#clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN_lbl" xml:lang="en-US">Extinguishment of derivative liability in connection with extinguishment of convertible promissory notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" xlink:to="clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DeferredTransactionCostsInAccountsPayable" xlink:href="clnn-20201231.xsd#clnn_DeferredTransactionCostsInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DeferredTransactionCostsInAccountsPayable_lbl" xml:lang="en-US">Deferred transaction costs in accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredTransactionCostsInAccountsPayable" xlink:to="clnn_DeferredTransactionCostsInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DeferredTransactionsCostsInAccruedLiabilities" xlink:href="clnn-20201231.xsd#clnn_DeferredTransactionsCostsInAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DeferredTransactionsCostsInAccruedLiabilities_lbl" xml:lang="en-US">Deferred transaction costs in accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredTransactionsCostsInAccruedLiabilities" xlink:to="clnn_DeferredTransactionsCostsInAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStock" xlink:href="clnn-20201231.xsd#clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStock_lbl" xml:lang="en-US">Conversion of redeemable convertible preferred stock into common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStock" xlink:to="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemableConvertibleSreferredStock" xlink:href="clnn-20201231.xsd#clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemableConvertibleSreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemableConvertibleSreferredStock_lbl" xml:lang="en-US">Extinguishment of preferred stock warrant liability in connection with the conversion of redeemable convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemableConvertibleSreferredStock" xlink:to="clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemableConvertibleSreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_IssuanceOfCommonStockAsPaymentRelatedOfferingCosts" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfCommonStockAsPaymentRelatedOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_IssuanceOfCommonStockAsPaymentRelatedOfferingCosts_lbl" xml:lang="en-US">Issuance of common stock as payment of related offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IssuanceOfCommonStockAsPaymentRelatedOfferingCosts" xlink:to="clnn_IssuanceOfCommonStockAsPaymentRelatedOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ContingentEarnoutRecognizedConnectionWithTheReverseRecapitalization" xlink:href="clnn-20201231.xsd#clnn_ContingentEarnoutRecognizedConnectionWithTheReverseRecapitalization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ContingentEarnoutRecognizedConnectionWithTheReverseRecapitalization_lbl" xml:lang="en-US">Clene Nanomedicine contingent earn-out recognized in connection with the Reverse Recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ContingentEarnoutRecognizedConnectionWithTheReverseRecapitalization" xlink:to="clnn_ContingentEarnoutRecognizedConnectionWithTheReverseRecapitalization_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_InitialShareholdersContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization" xlink:href="clnn-20201231.xsd#clnn_InitialShareholdersContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_InitialShareholdersContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization_lbl" xml:lang="en-US">Initial Shareholders contingent earn-out recognized in connection with the Reverse Recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialShareholdersContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization" xlink:to="clnn_InitialShareholdersContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental disclosures:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Cash paid for interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpense_lbl0" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="clnn_AustraliaResearchAndDevelopmentCredit" xlink:href="clnn-20201231.xsd#clnn_AustraliaResearchAndDevelopmentCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="clnn_AustraliaResearchAndDevelopmentCredit_lbl" xml:lang="en-US">Australia research and development credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AustraliaResearchAndDevelopmentCredit" xlink:to="clnn_AustraliaResearchAndDevelopmentCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl" xml:lang="en-US">Change in fair value of derivative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnTerminationOfLease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xml:lang="en-US">Gain on termination of lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnTerminationOfLease" xlink:to="us-gaap_GainLossOnTerminationOfLease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xml:lang="en-US">Deferred income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_IncreaseDecreaseOperatingLeaseObligations" xlink:href="clnn-20201231.xsd#clnn_IncreaseDecreaseOperatingLeaseObligations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="clnn_IncreaseDecreaseOperatingLeaseObligations_lbl" xml:lang="en-US">Operating lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncreaseDecreaseOperatingLeaseObligations" xlink:to="clnn_IncreaseDecreaseOperatingLeaseObligations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Payments of finance lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Payments of notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payment of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Product revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyMember_lbl" xml:lang="en-US">Royalty revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US">Redeemable Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">Nature of the Business and Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock" xlink:href="clnn-20201231.xsd#clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock_lbl" xml:lang="en-US">Reverse Recapitalization with Tottenham and Clene Nanomedicine</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock" xlink:to="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:href="clnn-20201231.xsd#clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:href="clnn-20201231.xsd#clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_AustraliaResearchAndDevelopmentCreditReceivable" xlink:href="clnn-20201231.xsd#clnn_AustraliaResearchAndDevelopmentCreditReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_AustraliaResearchAndDevelopmentCreditReceivable_lbl" xml:lang="en-US">Australia research and development credit receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AustraliaResearchAndDevelopmentCreditReceivable" xlink:to="clnn_AustraliaResearchAndDevelopmentCreditReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CROPrepayments" xlink:href="clnn-20201231.xsd#clnn_CROPrepayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CROPrepayments_lbl" xml:lang="en-US">CRO prepayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CROPrepayments" xlink:to="clnn_CROPrepayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_MetalsToBeUsedInResearchAndDevelopment" xlink:href="clnn-20201231.xsd#clnn_MetalsToBeUsedInResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_MetalsToBeUsedInResearchAndDevelopment_lbl" xml:lang="en-US">Metals to be used in research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_MetalsToBeUsedInResearchAndDevelopment" xlink:to="clnn_MetalsToBeUsedInResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentExpense_lbl" xml:lang="en-US">Lab equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentExpense" xlink:to="us-gaap_EquipmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl" xml:lang="en-US">Furniture and fixtures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xml:lang="en-US">Leasehold improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressGross_lbl" xml:lang="en-US">Construction in progress</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressGross" xlink:to="us-gaap_ConstructionInProgressGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Total property and equipment, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US">Accrued compensation and benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_AccruedCROFees" xlink:href="clnn-20201231.xsd#clnn_AccruedCROFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_AccruedCROFees_lbl" xml:lang="en-US">Accrued CRO fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AccruedCROFees" xlink:to="clnn_AccruedCROFees_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DeferredGrantFunds" xlink:href="clnn-20201231.xsd#clnn_DeferredGrantFunds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DeferredGrantFunds_lbl" xml:lang="en-US">Deferred grant funds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredGrantFunds" xlink:to="clnn_DeferredGrantFunds_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Accrued expense reimbursements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_AccruedTransactionCosts" xlink:href="clnn-20201231.xsd#clnn_AccruedTransactionCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_AccruedTransactionCosts_lbl" xml:lang="en-US">Accrued transaction costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AccruedTransactionCosts" xlink:to="clnn_AccruedTransactionCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of noncancelable operating lease arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US">2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US">Total undiscounted cash flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" xml:lang="en-US">Present value of future lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_lbl" xml:lang="en-US">Lease obligations &#8211; long term portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PropertyPlantAndEquipmentOneTextBlock" xlink:href="clnn-20201231.xsd#clnn_PropertyPlantAndEquipmentOneTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_PropertyPlantAndEquipmentOneTextBlock_lbl" xml:lang="en-US">Schedule of finance lease obligations and included property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PropertyPlantAndEquipmentOneTextBlock" xlink:to="clnn_PropertyPlantAndEquipmentOneTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceLeaseLiabilityGross" xlink:href="clnn-20201231.xsd#clnn_FinanceLeaseLiabilityGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_FinanceLeaseLiabilityGross_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeaseLiabilityGross" xlink:to="clnn_FinanceLeaseLiabilityGross_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_AccumulatedDepreciationDepletionAndAmortizationLeases" xlink:href="clnn-20201231.xsd#clnn_AccumulatedDepreciationDepletionAndAmortizationLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_AccumulatedDepreciationDepletionAndAmortizationLeases_lbl" xml:lang="en-US">Less accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AccumulatedDepreciationDepletionAndAmortizationLeases" xlink:to="clnn_AccumulatedDepreciationDepletionAndAmortizationLeases_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceLeaseLiabilityNet" xlink:href="clnn-20201231.xsd#clnn_FinanceLeaseLiabilityNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_FinanceLeaseLiabilityNet_lbl" xml:lang="en-US">Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeaseLiabilityNet" xlink:to="clnn_FinanceLeaseLiabilityNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of finance and operating lease costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract_lbl" xml:lang="en-US">Finance lease costs:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Interest on lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short-term lease costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Variable lease costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xml:lang="en-US">Schedule of supplemental cash flow information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_OperatingCashFlowsFromOperatingLeases" xlink:href="clnn-20201231.xsd#clnn_OperatingCashFlowsFromOperatingLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_OperatingCashFlowsFromOperatingLeases_lbl" xml:lang="en-US">Operating cash flows from operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OperatingCashFlowsFromOperatingLeases" xlink:to="clnn_OperatingCashFlowsFromOperatingLeases_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_OperatingCashFlowsFromFinanceLeases" xlink:href="clnn-20201231.xsd#clnn_OperatingCashFlowsFromFinanceLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_OperatingCashFlowsFromFinanceLeases_lbl" xml:lang="en-US">Operating cash flows from finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OperatingCashFlowsFromFinanceLeases" xlink:to="clnn_OperatingCashFlowsFromFinanceLeases_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceCashFlowsFromFinanceLeases" xlink:href="clnn-20201231.xsd#clnn_FinanceCashFlowsFromFinanceLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_FinanceCashFlowsFromFinanceLeases_lbl" xml:lang="en-US">Finance cash flows from finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceCashFlowsFromFinanceLeases" xlink:to="clnn_FinanceCashFlowsFromFinanceLeases_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xml:lang="en-US">Preferred Stock Warrant Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPreferredUnitsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPreferredUnitsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfPreferredUnitsTextBlock_lbl" xml:lang="en-US">Schedule fair value of the outstanding warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPreferredUnitsTextBlock" xlink:to="us-gaap_ScheduleOfPreferredUnitsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ExpirationDate" xlink:href="clnn-20201231.xsd#clnn_ExpirationDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ExpirationDate_lbl" xml:lang="en-US">Expiration Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExpirationDate" xlink:to="clnn_ExpirationDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl" xml:lang="en-US">Exercise Price	Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants	Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsDisclosureTextBlock" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrantsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CommonStockWarrantsDisclosureTextBlock_lbl" xml:lang="en-US">Common Stock Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsDisclosureTextBlock" xlink:to="clnn_CommonStockWarrantsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of outstanding warrants to purchase shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_NumberOfSharesIssuable" xlink:href="clnn-20201231.xsd#clnn_NumberOfSharesIssuable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_NumberOfSharesIssuable_lbl" xml:lang="en-US">Number of Shares Issuable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NumberOfSharesIssuable" xlink:to="clnn_NumberOfSharesIssuable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsExercisePrice" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrantsExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CommonStockWarrantsExercisePrice_lbl" xml:lang="en-US">Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsExercisePrice" xlink:to="clnn_CommonStockWarrantsExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsExercisable" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrantsExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CommonStockWarrantsExercisable_lbl" xml:lang="en-US">Exercisable for</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsExercisable" xlink:to="clnn_CommonStockWarrantsExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsClassification" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrantsClassification"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CommonStockWarrantsClassification_lbl" xml:lang="en-US">Classification</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsClassification" xlink:to="clnn_CommonStockWarrantsClassification_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsExpiration" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrantsExpiration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CommonStockWarrantsExpiration_lbl" xml:lang="en-US">Expiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsExpiration" xlink:to="clnn_CommonStockWarrantsExpiration_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ConvertibleNotesDisclosureTextBlock" xlink:href="clnn-20201231.xsd#clnn_ConvertibleNotesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ConvertibleNotesDisclosureTextBlock_lbl" xml:lang="en-US">Convertible Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConvertibleNotesDisclosureTextBlock" xlink:to="clnn_ConvertibleNotesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xml:lang="en-US">Derivative Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">Schedule of components of income (loss) before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">United States</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of income tax expense (benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CurrentTaxExpenseAbstract" xlink:href="clnn-20201231.xsd#clnn_CurrentTaxExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CurrentTaxExpenseAbstract_lbl" xml:lang="en-US">Current tax expense:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CurrentTaxExpenseAbstract" xlink:to="clnn_CurrentTaxExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DeferredTaxExpenseAbstract" xlink:href="clnn-20201231.xsd#clnn_DeferredTaxExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DeferredTaxExpenseAbstract_lbl" xml:lang="en-US">Deferred tax expense:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredTaxExpenseAbstract" xlink:to="clnn_DeferredTaxExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of income tax reconciliation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Income tax expense (benefit) at federal statutory rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes (net of federal benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_IncomeTaxReconciliationWarrantLiability" xlink:href="clnn-20201231.xsd#clnn_IncomeTaxReconciliationWarrantLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_IncomeTaxReconciliationWarrantLiability_lbl" xml:lang="en-US">Warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncomeTaxReconciliationWarrantLiability" xlink:to="clnn_IncomeTaxReconciliationWarrantLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies_lbl" xml:lang="en-US">Contingent consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_IncomeTaxReconciliationNondeductibleExpensesResearchAndDevelopment" xlink:href="clnn-20201231.xsd#clnn_IncomeTaxReconciliationNondeductibleExpensesResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_IncomeTaxReconciliationNondeductibleExpensesResearchAndDevelopment_lbl" xml:lang="en-US">Research and development credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncomeTaxReconciliationNondeductibleExpensesResearchAndDevelopment" xlink:to="clnn_IncomeTaxReconciliationNondeductibleExpensesResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DeferredTaxAssetsLiabilitiesAbstract" xlink:href="clnn-20201231.xsd#clnn_DeferredTaxAssetsLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DeferredTaxAssetsLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax assets (liabilities):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredTaxAssetsLiabilitiesAbstract" xlink:to="clnn_DeferredTaxAssetsLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DeferredTaxLiabilitiesDeferredExpenseDepreciation" xlink:href="clnn-20201231.xsd#clnn_DeferredTaxLiabilitiesDeferredExpenseDepreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DeferredTaxLiabilitiesDeferredExpenseDepreciation_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredTaxLiabilitiesDeferredExpenseDepreciation" xlink:to="clnn_DeferredTaxLiabilitiesDeferredExpenseDepreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research &amp; development credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl0" xml:lang="en-US">Research and development credit carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl0"/>
    <loc xlink:type="locator" xlink:label="clnn_DeferredTaxLiabilitiesLeaseLiability" xlink:href="clnn-20201231.xsd#clnn_DeferredTaxLiabilitiesLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DeferredTaxLiabilitiesLeaseLiability_lbl" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredTaxLiabilitiesLeaseLiability" xlink:to="clnn_DeferredTaxLiabilitiesLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_lbl" xml:lang="en-US">Accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DeferredTaxAssetsTaxDeferredNonqualifiedStockOptions" xlink:href="clnn-20201231.xsd#clnn_DeferredTaxAssetsTaxDeferredNonqualifiedStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DeferredTaxAssetsTaxDeferredNonqualifiedStockOptions_lbl" xml:lang="en-US">Non-qualified stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredTaxAssetsTaxDeferredNonqualifiedStockOptions" xlink:to="clnn_DeferredTaxAssetsTaxDeferredNonqualifiedStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DeferredTaxAssetsTaxDeferredAccruedCompensation" xlink:href="clnn-20201231.xsd#clnn_DeferredTaxAssetsTaxDeferredAccruedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DeferredTaxAssetsTaxDeferredAccruedCompensation_lbl" xml:lang="en-US">Accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredTaxAssetsTaxDeferredAccruedCompensation" xlink:to="clnn_DeferredTaxAssetsTaxDeferredAccruedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of outstanding common stock options and related activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Term (Years), Outstanding - beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Number of RSUs, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US">Stock options, granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:href="clnn-20201231.xsd#clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted_lbl" xml:lang="en-US">Weighted Average Remaining Term (Years), Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodIntrinsicValue" xlink:href="clnn-20201231.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodIntrinsicValue_lbl" xml:lang="en-US">Instrinsic Value, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodIntrinsicValue" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsExercised" xlink:href="clnn-20201231.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsExercised_lbl" xml:lang="en-US">Weighted Average Remaining Term (Years), Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsExercised" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue" xlink:href="clnn-20201231.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue_lbl" xml:lang="en-US">Instrinsic Value, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsForfeited" xlink:href="clnn-20201231.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsForfeited_lbl" xml:lang="en-US">Weighted Average Remaining Term (Years) Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsForfeited" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsForfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue" xlink:href="clnn-20201231.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue_lbl" xml:lang="en-US">Instrinsic Value, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Term (Years), Outstanding - ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US">Number of Options, Options vested and exercisable ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Options vested and exercisable ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Term (Years), Options vested and exercisable ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_InstrinsicValueOptionsVestedAndExercisableEnding" xlink:href="clnn-20201231.xsd#clnn_InstrinsicValueOptionsVestedAndExercisableEnding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_InstrinsicValueOptionsVestedAndExercisableEnding_lbl" xml:lang="en-US">Instrinsic Value, Options vested and exercisable ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InstrinsicValueOptionsVestedAndExercisableEnding" xlink:to="clnn_InstrinsicValueOptionsVestedAndExercisableEnding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Options vested and exercisable - Stock options vested and expected to vest ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_WeightedAverageExercisePricePerShareOptionsVestedAndExercisableStockOptionsVest" xlink:href="clnn-20201231.xsd#clnn_WeightedAverageExercisePricePerShareOptionsVestedAndExercisableStockOptionsVest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_WeightedAverageExercisePricePerShareOptionsVestedAndExercisableStockOptionsVest_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Options vested and exercisable - Stock options vested and expected to vest ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WeightedAverageExercisePricePerShareOptionsVestedAndExercisableStockOptionsVest" xlink:to="clnn_WeightedAverageExercisePricePerShareOptionsVestedAndExercisableStockOptionsVest_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_WeightedAverageRemainingTermOptionsVestedAndExercisableStockOptionsVestedAndExercisable" xlink:href="clnn-20201231.xsd#clnn_WeightedAverageRemainingTermOptionsVestedAndExercisableStockOptionsVestedAndExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_WeightedAverageRemainingTermOptionsVestedAndExercisableStockOptionsVestedAndExercisable_lbl" xml:lang="en-US">Weighted Average Remaining Term (Years), Options vested and exercisable - Stock options vested and expected to vest ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WeightedAverageRemainingTermOptionsVestedAndExercisableStockOptionsVestedAndExercisable" xlink:to="clnn_WeightedAverageRemainingTermOptionsVestedAndExercisableStockOptionsVestedAndExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_InstrinsicValueOptionsVestedAndExercisableStockOptionsVestedAndExpectedToVestEnding" xlink:href="clnn-20201231.xsd#clnn_InstrinsicValueOptionsVestedAndExercisableStockOptionsVestedAndExpectedToVestEnding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_InstrinsicValueOptionsVestedAndExercisableStockOptionsVestedAndExpectedToVestEnding_lbl" xml:lang="en-US">Instrinsic Value, Options vested and exercisable - Stock options vested and expected to vest ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InstrinsicValueOptionsVestedAndExercisableStockOptionsVestedAndExpectedToVestEnding" xlink:to="clnn_InstrinsicValueOptionsVestedAndExercisableStockOptionsVestedAndExpectedToVestEnding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of fair value of these stock options awards granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected stock price volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Expected term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of restricted common stock activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Number of RSUs, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableFairValueDisclosure_lbl" xml:lang="en-US">Notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableFairValueDisclosure" xlink:to="us-gaap_NotesPayableFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CleneNanomedicineContingentEarnout" xlink:href="clnn-20201231.xsd#clnn_CleneNanomedicineContingentEarnout"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CleneNanomedicineContingentEarnout_lbl" xml:lang="en-US">Clene Nanomedicine contingent earn-out</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneNanomedicineContingentEarnout" xlink:to="clnn_CleneNanomedicineContingentEarnout_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl" xml:lang="en-US">Schedule of fair value of the initial contingent earn-out</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Schedule of financial liability related to the notes payable, the derivative instrument, the Preferred Stock warrants, and the contingent earn-out measured at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueOfIssuanceOfNotesPayable" xlink:href="clnn-20201231.xsd#clnn_FairValueOfIssuanceOfNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_FairValueOfIssuanceOfNotesPayable_lbl" xml:lang="en-US">Issuance of notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueOfIssuanceOfNotesPayable" xlink:to="clnn_FairValueOfIssuanceOfNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_IncreseDecreaseInFairValue" xlink:href="clnn-20201231.xsd#clnn_IncreseDecreaseInFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_IncreseDecreaseInFairValue_lbl" xml:lang="en-US">Change in fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncreseDecreaseInFairValue" xlink:to="clnn_IncreseDecreaseInFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueExerciseOfSeriesCPreferredStockWarrants" xlink:href="clnn-20201231.xsd#clnn_FairValueExerciseOfSeriesCPreferredStockWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_FairValueExerciseOfSeriesCPreferredStockWarrants_lbl" xml:lang="en-US">Exercise of Series C preferred stock warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueExerciseOfSeriesCPreferredStockWarrants" xlink:to="clnn_FairValueExerciseOfSeriesCPreferredStockWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueIssuanceOfConvertiblePromissoryNotes" xlink:href="clnn-20201231.xsd#clnn_FairValueIssuanceOfConvertiblePromissoryNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_FairValueIssuanceOfConvertiblePromissoryNotes_lbl" xml:lang="en-US">Issuance of convertible promissory notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueIssuanceOfConvertiblePromissoryNotes" xlink:to="clnn_FairValueIssuanceOfConvertiblePromissoryNotes_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_InitialFairValueOfInstrument" xlink:href="clnn-20201231.xsd#clnn_InitialFairValueOfInstrument"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_InitialFairValueOfInstrument_lbl" xml:lang="en-US">Initial fair value of instrument</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialFairValueOfInstrument" xlink:to="clnn_InitialFairValueOfInstrument_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ExtinguishmentOfDerivativeLiability" xlink:href="clnn-20201231.xsd#clnn_ExtinguishmentOfDerivativeLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ExtinguishmentOfDerivativeLiability_lbl" xml:lang="en-US">Extinguishment of derivative liability in connection with extinguishment of the 2020 Convertible Notes (Note 12)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExtinguishmentOfDerivativeLiability" xlink:to="clnn_ExtinguishmentOfDerivativeLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock" xlink:href="clnn-20201231.xsd#clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock_lbl" xml:lang="en-US">Redeemable Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock" xlink:to="clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xml:lang="en-US">Schedule of Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityTableTextBlock" xlink:to="us-gaap_TemporaryEquityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_TemporaryEquitySharesIssuedAndOutstanding" xlink:href="clnn-20201231.xsd#clnn_TemporaryEquitySharesIssuedAndOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_TemporaryEquitySharesIssuedAndOutstanding_lbl" xml:lang="en-US">Preferred Shares Issued and Outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TemporaryEquitySharesIssuedAndOutstanding" xlink:to="clnn_TemporaryEquitySharesIssuedAndOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_TemporaryEquitySharesCommonStockIssuableUponConversion" xlink:href="clnn-20201231.xsd#clnn_TemporaryEquitySharesCommonStockIssuableUponConversion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_TemporaryEquitySharesCommonStockIssuableUponConversion_lbl" xml:lang="en-US">Common Stock Issuable Upon Conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TemporaryEquitySharesCommonStockIssuableUponConversion" xlink:to="clnn_TemporaryEquitySharesCommonStockIssuableUponConversion_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss Per Share Attributable to Common Shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of basic and diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_NumeratorAbstract" xlink:href="clnn-20201231.xsd#clnn_NumeratorAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_NumeratorAbstract_lbl" xml:lang="en-US">Numerator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NumeratorAbstract" xlink:to="clnn_NumeratorAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DenominatorAbstract" xlink:href="clnn-20201231.xsd#clnn_DenominatorAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DenominatorAbstract_lbl" xml:lang="en-US">Denominator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DenominatorAbstract" xlink:to="clnn_DenominatorAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of dilutive securities were excluded from the computation of diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesCRedeemableConvertiblePreferredStock" xlink:href="clnn-20201231.xsd#clnn_SeriesCRedeemableConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SeriesCRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US">Series C redeemable convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SeriesCRedeemableConvertiblePreferredStock" xlink:to="clnn_SeriesCRedeemableConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesBRedeemableConvertiblePreferredStock" xlink:href="clnn-20201231.xsd#clnn_SeriesBRedeemableConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SeriesBRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US">Series B redeemable convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SeriesBRedeemableConvertiblePreferredStock" xlink:to="clnn_SeriesBRedeemableConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesARedeemableConvertiblePreferredStock" xlink:href="clnn-20201231.xsd#clnn_SeriesARedeemableConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SeriesARedeemableConvertiblePreferredStock_lbl" xml:lang="en-US">Series A redeemable convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SeriesARedeemableConvertiblePreferredStock" xlink:to="clnn_SeriesARedeemableConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesCRedeemableConvertiblePreferredStockWarrantsinShares" xlink:href="clnn-20201231.xsd#clnn_SeriesCRedeemableConvertiblePreferredStockWarrantsinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SeriesCRedeemableConvertiblePreferredStockWarrantsinShares_lbl" xml:lang="en-US">Series C redeemable convertible preferred stock warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SeriesCRedeemableConvertiblePreferredStockWarrantsinShares" xlink:to="clnn_SeriesCRedeemableConvertiblePreferredStockWarrantsinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares" xlink:href="clnn-20201231.xsd#clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares_lbl" xml:lang="en-US">Series A redeemable convertible preferred stock warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares" xlink:to="clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrants" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CommonStockWarrants_lbl" xml:lang="en-US">Common stock warrants (see Note 10)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrants" xlink:to="clnn_CommonStockWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_OptionsToPurchaseCommonStockinShares" xlink:href="clnn-20201231.xsd#clnn_OptionsToPurchaseCommonStockinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_OptionsToPurchaseCommonStockinShares_lbl" xml:lang="en-US">Options to purchase common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OptionsToPurchaseCommonStockinShares" xlink:to="clnn_OptionsToPurchaseCommonStockinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ChardanUnitPurchaseOptionToPurchaseCommonStock" xlink:href="clnn-20201231.xsd#clnn_ChardanUnitPurchaseOptionToPurchaseCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ChardanUnitPurchaseOptionToPurchaseCommonStock_lbl" xml:lang="en-US">Chardan Unit Purchase Option to purchase common stock (see Note 1)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChardanUnitPurchaseOptionToPurchaseCommonStock" xlink:to="clnn_ChardanUnitPurchaseOptionToPurchaseCommonStock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="clnn_ChardanUnitPurchaseOptionToPurchaseCommonStock_lbl0" xml:lang="en-US">Purchase option to common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChardanUnitPurchaseOptionToPurchaseCommonStock" xlink:to="clnn_ChardanUnitPurchaseOptionToPurchaseCommonStock_lbl0"/>
    <loc xlink:type="locator" xlink:label="clnn_ChardanUnitPurchaseOptionWarrants" xlink:href="clnn-20201231.xsd#clnn_ChardanUnitPurchaseOptionWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ChardanUnitPurchaseOptionWarrants_lbl" xml:lang="en-US">Chardan Unit Purchase Option Warrants (see Notes 1 and 10)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChardanUnitPurchaseOptionWarrants" xlink:to="clnn_ChardanUnitPurchaseOptionWarrants_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="clnn_ChardanUnitPurchaseOptionWarrants_lbl0" xml:lang="en-US">Purchase of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChardanUnitPurchaseOptionWarrants" xlink:to="clnn_ChardanUnitPurchaseOptionWarrants_lbl0"/>
    <loc xlink:type="locator" xlink:label="clnn_EarnoutSharessee" xlink:href="clnn-20201231.xsd#clnn_EarnoutSharessee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_EarnoutSharessee_lbl" xml:lang="en-US">Earn-out shares (see Note 3 and 12)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_EarnoutSharessee" xlink:to="clnn_EarnoutSharessee_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Geographic and Segment Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment, net by location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfDrugsAndSupplementsSegmentsTableTextBlock" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfDrugsAndSupplementsSegmentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ScheduleOfDrugsAndSupplementsSegmentsTableTextBlock_lbl" xml:lang="en-US">Schedule of drugs and supplements segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfDrugsAndSupplementsSegmentsTableTextBlock" xlink:to="clnn_ScheduleOfDrugsAndSupplementsSegmentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment, net by segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock" xlink:to="clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl" xml:lang="en-US">Less amount representing interest/discounting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xml:lang="en-US">Less lease obligations, current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DeferredTaxAssetsRightofUseAsset" xlink:href="clnn-20201231.xsd#clnn_DeferredTaxAssetsRightofUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="clnn_DeferredTaxAssetsRightofUseAsset_lbl" xml:lang="en-US">Right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredTaxAssetsRightofUseAsset" xlink:to="clnn_DeferredTaxAssetsRightofUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax assets (liabilities)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised" xlink:href="clnn-20201231.xsd#clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised_lbl" xml:lang="en-US">Number of Options, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised" xlink:to="clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Options, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Common stock, shares cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceLeasesMember" xlink:href="clnn-20201231.xsd#clnn_FinanceLeasesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_FinanceLeasesMember_lbl" xml:lang="en-US">Finance Leases [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeasesMember" xlink:to="clnn_FinanceLeasesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_OperatingLeasesMember" xlink:href="clnn-20201231.xsd#clnn_OperatingLeasesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_OperatingLeasesMember_lbl" xml:lang="en-US">Operating Leases [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OperatingLeasesMember" xlink:to="clnn_OperatingLeasesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Lab equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquipmentMember_lbl0" xml:lang="en-US">Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl0" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="clnn_WorkInProcessMember" xlink:href="clnn-20201231.xsd#clnn_WorkInProcessMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_WorkInProcessMember_lbl" xml:lang="en-US">Work in process [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WorkInProcessMember" xlink:to="clnn_WorkInProcessMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US">Series C preferred stock warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl0" xml:lang="en-US">Series C Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A preferred stock warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl0" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantsDateMember" xlink:href="clnn-20201231.xsd#clnn_WarrantsDateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_WarrantsDateMember_lbl" xml:lang="en-US">June 2021 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantsDateMember" xlink:to="clnn_WarrantsDateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantsDate1Member" xlink:href="clnn-20201231.xsd#clnn_WarrantsDate1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_WarrantsDate1Member_lbl" xml:lang="en-US">December 2020 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantsDate1Member" xlink:to="clnn_WarrantsDate1Member_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_December20201Member" xlink:href="clnn-20201231.xsd#clnn_December20201Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_December20201Member_lbl" xml:lang="en-US">December 2020 One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_December20201Member" xlink:to="clnn_December20201Member_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantsDate2Member" xlink:href="clnn-20201231.xsd#clnn_WarrantsDate2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_WarrantsDate2Member_lbl" xml:lang="en-US">December 2020 Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantsDate2Member" xlink:to="clnn_WarrantsDate2Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ContingentEarnoutMember" xlink:href="clnn-20201231.xsd#clnn_ContingentEarnoutMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ContingentEarnoutMember_lbl" xml:lang="en-US">Contingent earn-out [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ContingentEarnoutMember" xlink:to="clnn_ContingentEarnoutMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="clnn_ContingentEarnoutMember_lbl0" xml:lang="en-US">Contingent Earn-out [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ContingentEarnoutMember" xlink:to="clnn_ContingentEarnoutMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableOtherPayablesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableOtherPayablesMember_lbl" xml:lang="en-US">Notes Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableOtherPayablesMember" xlink:to="us-gaap_NotesPayableOtherPayablesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DerivativeInstrumentMember" xlink:href="clnn-20201231.xsd#clnn_DerivativeInstrumentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DerivativeInstrumentMember_lbl" xml:lang="en-US">Derivative Instrument [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DerivativeInstrumentMember" xlink:to="clnn_DerivativeInstrumentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PreferredStockWarrantsMember" xlink:href="clnn-20201231.xsd#clnn_PreferredStockWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_PreferredStockWarrantsMember_lbl" xml:lang="en-US">Preferred Stock Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PreferredStockWarrantsMember" xlink:to="clnn_PreferredStockWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_InitialShareholdersContingentEarnoutMember" xlink:href="clnn-20201231.xsd#clnn_InitialShareholdersContingentEarnoutMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_InitialShareholdersContingentEarnoutMember_lbl" xml:lang="en-US">Initial Shareholders Contingent Earn-out [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialShareholdersContingentEarnoutMember" xlink:to="clnn_InitialShareholdersContingentEarnoutMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US">United States [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <loc xlink:type="locator" xlink:label="country_AU" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_AU"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_AU_lbl" xml:lang="en-US">Australia [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_AU" xlink:to="country_AU_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DrugsMember" xlink:href="clnn-20201231.xsd#clnn_DrugsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DrugsMember_lbl" xml:lang="en-US">Drugs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DrugsMember" xlink:to="clnn_DrugsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SupplementsMember" xlink:href="clnn-20201231.xsd#clnn_SupplementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SupplementsMember_lbl" xml:lang="en-US">Supplements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SupplementsMember" xlink:to="clnn_SupplementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis_lbl" xml:lang="en-US">Fresh-Start Adjustments [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:to="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollateralAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollateralAxis_lbl" xml:lang="en-US">Collateral Held [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_CollateralAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_MergerAgreementPercentage" xlink:href="clnn-20201231.xsd#clnn_MergerAgreementPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_MergerAgreementPercentage_lbl" xml:lang="en-US">Merger agreement percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_MergerAgreementPercentage" xlink:to="clnn_MergerAgreementPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of shares aggregate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0" xml:lang="en-US">Senior equity equal percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xml:lang="en-US">Stock issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl0" xml:lang="en-US">Shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl0"/>
    <loc xlink:type="locator" xlink:label="clnn_ProceedsFromReverseRecapitalizationNet" xlink:href="clnn-20201231.xsd#clnn_ProceedsFromReverseRecapitalizationNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ProceedsFromReverseRecapitalizationNet_lbl" xml:lang="en-US">Net proceeds from the reverse recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ProceedsFromReverseRecapitalizationNet" xlink:to="clnn_ProceedsFromReverseRecapitalizationNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PurchaseOption" xlink:href="clnn-20201231.xsd#clnn_PurchaseOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_PurchaseOption_lbl" xml:lang="en-US">Purchase option (in Units)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PurchaseOption" xlink:to="clnn_PurchaseOption_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PerShareUnit" xlink:href="clnn-20201231.xsd#clnn_PerShareUnit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_PerShareUnit_lbl" xml:lang="en-US">Purchase option (in Dollars per unit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PerShareUnit" xlink:to="clnn_PerShareUnit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Purchase option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Initial public offering price, per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl1" xml:lang="en-US">Price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrants exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Warrants exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <loc xlink:type="locator" xlink:label="clnn_PaymentsForAdvisoryServicesShares" xlink:href="clnn-20201231.xsd#clnn_PaymentsForAdvisoryServicesShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_PaymentsForAdvisoryServicesShares_lbl" xml:lang="en-US">Advisory payment share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PaymentsForAdvisoryServicesShares" xlink:to="clnn_PaymentsForAdvisoryServicesShares_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_StockIssuedDuringPeriodSharesPrivatePlacement" xlink:href="clnn-20201231.xsd#clnn_StockIssuedDuringPeriodSharesPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_StockIssuedDuringPeriodSharesPrivatePlacement_lbl" xml:lang="en-US">Private placement shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockIssuedDuringPeriodSharesPrivatePlacement" xlink:to="clnn_StockIssuedDuringPeriodSharesPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Net proceeds from equity issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xml:lang="en-US">Warrants purchase shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl0" xml:lang="en-US">Warrants shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl0"/>
    <loc xlink:type="locator" xlink:label="clnn_IncurredNetLosses" xlink:href="clnn-20201231.xsd#clnn_IncurredNetLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_IncurredNetLosses_lbl" xml:lang="en-US">Incurred net losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncurredNetLosses" xlink:to="clnn_IncurredNetLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_RetainedEarningsAccumulatedDeficit1" xlink:href="clnn-20201231.xsd#clnn_RetainedEarningsAccumulatedDeficit1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_RetainedEarningsAccumulatedDeficit1_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RetainedEarningsAccumulatedDeficit1" xlink:to="clnn_RetainedEarningsAccumulatedDeficit1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Inventory in raw materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ProposedPublicOfferingCost" xlink:href="clnn-20201231.xsd#clnn_ProposedPublicOfferingCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ProposedPublicOfferingCost_lbl" xml:lang="en-US">Proposed public offering cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ProposedPublicOfferingCost" xlink:to="clnn_ProposedPublicOfferingCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Useful lives of asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US">Convertible preferred stock value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xml:lang="en-US">Other income and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of operating segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_IssuanceOfCommonStockUponReverseRecapitalization" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfCommonStockUponReverseRecapitalization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_IssuanceOfCommonStockUponReverseRecapitalization_lbl" xml:lang="en-US">Issuance of common stock upon the Reverse Recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IssuanceOfCommonStockUponReverseRecapitalization" xlink:to="clnn_IssuanceOfCommonStockUponReverseRecapitalization_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="clnn_IssuanceOfCommonStockUponReverseRecapitalization_lbl0" xml:lang="en-US">Issuance of common stock upon the reverse recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IssuanceOfCommonStockUponReverseRecapitalization" xlink:to="clnn_IssuanceOfCommonStockUponReverseRecapitalization_lbl0"/>
    <loc xlink:type="locator" xlink:label="clnn_EarnOutShare" xlink:href="clnn-20201231.xsd#clnn_EarnOutShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_EarnOutShare_lbl" xml:lang="en-US">Earn out share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_EarnOutShare" xlink:to="clnn_EarnOutShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xml:lang="en-US">Acquired percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_EntityCommonStockSharesOutstanding1" xlink:href="clnn-20201231.xsd#clnn_EntityCommonStockSharesOutstanding1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_EntityCommonStockSharesOutstanding1_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_EntityCommonStockSharesOutstanding1" xlink:to="clnn_EntityCommonStockSharesOutstanding1_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SharesHeldInEscrow" xlink:href="clnn-20201231.xsd#clnn_SharesHeldInEscrow"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SharesHeldInEscrow_lbl" xml:lang="en-US">Shares held in Escrow</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharesHeldInEscrow" xlink:to="clnn_SharesHeldInEscrow_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ServicesLetterAgreementDescription" xlink:href="clnn-20201231.xsd#clnn_ServicesLetterAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ServicesLetterAgreementDescription_lbl" xml:lang="en-US">Services letter agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ServicesLetterAgreementDescription" xlink:to="clnn_ServicesLetterAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherUnderwritingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherUnderwritingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherUnderwritingExpense_lbl" xml:lang="en-US">Deferred underwriting fees (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherUnderwritingExpense" xlink:to="us-gaap_OtherUnderwritingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_lbl" xml:lang="en-US">Underwriting fees (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:to="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_InvestorsPurchasedShares" xlink:href="clnn-20201231.xsd#clnn_InvestorsPurchasedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_InvestorsPurchasedShares_lbl" xml:lang="en-US">Investors purchased shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InvestorsPurchasedShares" xlink:to="clnn_InvestorsPurchasedShares_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SharesPerShare" xlink:href="clnn-20201231.xsd#clnn_SharesPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SharesPerShare_lbl" xml:lang="en-US">Shares per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharesPerShare" xlink:to="clnn_SharesPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ExercisePrice" xlink:href="clnn-20201231.xsd#clnn_ExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ExercisePrice_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExercisePrice" xlink:to="clnn_ExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_NetProceeds" xlink:href="clnn-20201231.xsd#clnn_NetProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_NetProceeds_lbl" xml:lang="en-US">Net proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetProceeds" xlink:to="clnn_NetProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_EarnoutSharesDescription" xlink:href="clnn-20201231.xsd#clnn_EarnoutSharesDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_EarnoutSharesDescription_lbl" xml:lang="en-US">Earn-out shares, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_EarnoutSharesDescription" xlink:to="clnn_EarnoutSharesDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CumulativeEarningsDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CumulativeEarningsDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CumulativeEarningsDeficit_lbl" xml:lang="en-US">Cumulative adjustment to accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CumulativeEarningsDeficit" xlink:to="us-gaap_CumulativeEarningsDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_RemainingRightofuseAsset" xlink:href="clnn-20201231.xsd#clnn_RemainingRightofuseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_RemainingRightofuseAsset_lbl" xml:lang="en-US">Remaining right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RemainingRightofuseAsset" xlink:to="clnn_RemainingRightofuseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_RecognizedGainOnOperatingLease" xlink:href="clnn-20201231.xsd#clnn_RecognizedGainOnOperatingLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_RecognizedGainOnOperatingLease_lbl" xml:lang="en-US">Recognized gain on operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RecognizedGainOnOperatingLease" xlink:to="clnn_RecognizedGainOnOperatingLease_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DescriptionOfOperatingLease" xlink:href="clnn-20201231.xsd#clnn_DescriptionOfOperatingLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DescriptionOfOperatingLease_lbl" xml:lang="en-US">Description of operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DescriptionOfOperatingLease" xlink:to="clnn_DescriptionOfOperatingLease_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceLeaseObligationsWeightedaverageInterestRate" xlink:href="clnn-20201231.xsd#clnn_FinanceLeaseObligationsWeightedaverageInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_FinanceLeaseObligationsWeightedaverageInterestRate_lbl" xml:lang="en-US">Finance lease obligations weighted-average interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeaseObligationsWeightedaverageInterestRate" xlink:to="clnn_FinanceLeaseObligationsWeightedaverageInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Finance lease weighted-average remaining term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_OperatingLeaseObligationsWeightedAverageInterestRate" xlink:href="clnn-20201231.xsd#clnn_OperatingLeaseObligationsWeightedAverageInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_OperatingLeaseObligationsWeightedAverageInterestRate_lbl" xml:lang="en-US">Operating lease obligations weighted average interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OperatingLeaseObligationsWeightedAverageInterestRate" xlink:to="clnn_OperatingLeaseObligationsWeightedAverageInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating lease weighted-average remaining term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US">Term loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Outstanding due date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xml:lang="en-US">Loan, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SimpleInterestExpense" xlink:href="clnn-20201231.xsd#clnn_SimpleInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SimpleInterestExpense_lbl" xml:lang="en-US">Simple interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SimpleInterestExpense" xlink:to="clnn_SimpleInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_lbl" xml:lang="en-US">Fair value of long-term notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:to="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesAndLoansPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAndLoansPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesAndLoansPayable_lbl" xml:lang="en-US">Note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansPayable" xlink:to="us-gaap_NotesAndLoansPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PercentageOfLoanAmountUsedToPayrollExpenses" xlink:href="clnn-20201231.xsd#clnn_PercentageOfLoanAmountUsedToPayrollExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_PercentageOfLoanAmountUsedToPayrollExpenses_lbl" xml:lang="en-US">Percentage of loan amount used for payroll expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PercentageOfLoanAmountUsedToPayrollExpenses" xlink:to="clnn_PercentageOfLoanAmountUsedToPayrollExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod_lbl" xml:lang="en-US">Repayment period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:to="us-gaap_LineOfCreditFacilityExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedSalariesCurrentAndNoncurrent_lbl" xml:lang="en-US">Payroll expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedSalariesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableToBank" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBank"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableToBank_lbl" xml:lang="en-US">Long term note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableToBank" xlink:to="us-gaap_NotesPayableToBank_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants expire</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl" xml:lang="en-US">Exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LossRecognizedOnAssetsTransferredToSeparateAccountGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossRecognizedOnAssetsTransferredToSeparateAccountGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossRecognizedOnAssetsTransferredToSeparateAccountGross_lbl" xml:lang="en-US">Recognized a loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossRecognizedOnAssetsTransferredToSeparateAccountGross" xlink:to="us-gaap_LossRecognizedOnAssetsTransferredToSeparateAccountGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Outstanding warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares, issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Common stock, net proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from private offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees_lbl" xml:lang="en-US">Warrants, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:to="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Converted shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl0" xml:lang="en-US">Aggregate of converted shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl0"/>
    <loc xlink:type="locator" xlink:label="clnn_ReverseRecapitalizationAndWillExpireYears" xlink:href="clnn-20201231.xsd#clnn_ReverseRecapitalizationAndWillExpireYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ReverseRecapitalizationAndWillExpireYears_lbl" xml:lang="en-US">Reverse Recapitalization and will expire years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ReverseRecapitalizationAndWillExpireYears" xlink:to="clnn_ReverseRecapitalizationAndWillExpireYears_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantExercisePrice" xlink:href="clnn-20201231.xsd#clnn_WarrantExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_WarrantExercisePrice_lbl" xml:lang="en-US">Warrant Exercise Price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantExercisePrice" xlink:to="clnn_WarrantExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering_lbl" xml:lang="en-US">Initial public offering purchase unit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering" xlink:to="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Ordinary price, per shares (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PreferredStockWarrantsOutstandingShares" xlink:href="clnn-20201231.xsd#clnn_PreferredStockWarrantsOutstandingShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_PreferredStockWarrantsOutstandingShares_lbl" xml:lang="en-US">Preferred stock warrants, outstanding shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PreferredStockWarrantsOutstandingShares" xlink:to="clnn_PreferredStockWarrantsOutstandingShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl" xml:lang="en-US">Conversion of warrants into common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Converted price, per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Annual debt interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DescriptionOfConvertibleNotes" xlink:href="clnn-20201231.xsd#clnn_DescriptionOfConvertibleNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DescriptionOfConvertibleNotes_lbl" xml:lang="en-US">Description of convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DescriptionOfConvertibleNotes" xlink:to="clnn_DescriptionOfConvertibleNotes_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PercentageOfStock" xlink:href="clnn-20201231.xsd#clnn_PercentageOfStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_PercentageOfStock_lbl" xml:lang="en-US">Percentage of stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PercentageOfStock" xlink:to="clnn_PercentageOfStock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PreferredStockConvertibleConversionPrice" xlink:href="clnn-20201231.xsd#clnn_PreferredStockConvertibleConversionPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US">Convertible per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PreferredStockConvertibleConversionPrice" xlink:to="clnn_PreferredStockConvertibleConversionPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Unamortized discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet_lbl" xml:lang="en-US">Issuance of derivative instrument</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeNet" xlink:to="us-gaap_DerivativeFairValueOfDerivativeNet_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DerivativeInstrumentsOfComprehensiveLoss" xlink:href="clnn-20201231.xsd#clnn_DerivativeInstrumentsOfComprehensiveLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DerivativeInstrumentsOfComprehensiveLoss_lbl" xml:lang="en-US">Derivative instruments of comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DerivativeInstrumentsOfComprehensiveLoss" xlink:to="clnn_DerivativeInstrumentsOfComprehensiveLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GuarantyLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GuarantyLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GuarantyLiabilities_lbl" xml:lang="en-US">Contingent earn-out liability fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuarantyLiabilities" xlink:to="us-gaap_GuarantyLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReportingUnitAmountOfFairValueInExcessOfCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitAmountOfFairValueInExcessOfCarryingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReportingUnitAmountOfFairValueInExcessOfCarryingAmount_lbl" xml:lang="en-US">Carrying value contingent earn-out</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReportingUnitAmountOfFairValueInExcessOfCarryingAmount" xlink:to="us-gaap_ReportingUnitAmountOfFairValueInExcessOfCarryingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US">Gain in fair value of contingent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Income tax U.S. federal statutory rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Effective tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense_lbl" xml:lang="en-US">Deferred tax liability and expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Percentage of taxable income limit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_OperatingLossExpireTerm" xlink:href="clnn-20201231.xsd#clnn_OperatingLossExpireTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_OperatingLossExpireTerm_lbl" xml:lang="en-US">Term of operating loss expiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OperatingLossExpireTerm" xlink:to="clnn_OperatingLossExpireTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_RemainingBalanceOfOperatingLoss" xlink:href="clnn-20201231.xsd#clnn_RemainingBalanceOfOperatingLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_RemainingBalanceOfOperatingLoss_lbl" xml:lang="en-US">Remaining balance of operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RemainingBalanceOfOperatingLoss" xlink:to="clnn_RemainingBalanceOfOperatingLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ResearchAndDevelopmentCreditExpiryTerm" xlink:href="clnn-20201231.xsd#clnn_ResearchAndDevelopmentCreditExpiryTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ResearchAndDevelopmentCreditExpiryTerm_lbl" xml:lang="en-US">Term of research and development credit expiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ResearchAndDevelopmentCreditExpiryTerm" xlink:to="clnn_ResearchAndDevelopmentCreditExpiryTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares available to be issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_MinimumFairMarketValueOfOptionGrantDescription" xlink:href="clnn-20201231.xsd#clnn_MinimumFairMarketValueOfOptionGrantDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_MinimumFairMarketValueOfOptionGrantDescription_lbl" xml:lang="en-US">Minimum fair market value of option grant, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_MinimumFairMarketValueOfOptionGrantDescription" xlink:to="clnn_MinimumFairMarketValueOfOptionGrantDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Expiration term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants" xlink:href="clnn-20201231.xsd#clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants_lbl" xml:lang="en-US">Shares for future grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_lbl" xml:lang="en-US">Stock option outstanding (pre-conversion)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherSharesOutstanding" xlink:to="us-gaap_CommonStockOtherSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonSharesAuthorized" xlink:href="clnn-20201231.xsd#clnn_CommonSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CommonSharesAuthorized_lbl" xml:lang="en-US">Shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonSharesAuthorized" xlink:to="clnn_CommonSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross" xlink:href="clnn-20201231.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross_lbl" xml:lang="en-US">Shares available for grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_UnrecognizedStockbasedCompensation" xlink:href="clnn-20201231.xsd#clnn_UnrecognizedStockbasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_UnrecognizedStockbasedCompensation_lbl" xml:lang="en-US">Unrecognized stock-based compensation (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_UnrecognizedStockbasedCompensation" xlink:to="clnn_UnrecognizedStockbasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_weightedAverageFairValuesOfOptionsGranted" xlink:href="clnn-20201231.xsd#clnn_weightedAverageFairValuesOfOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_weightedAverageFairValuesOfOptionsGranted_lbl" xml:lang="en-US">Fair value of options granted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_weightedAverageFairValuesOfOptionsGranted" xlink:to="clnn_weightedAverageFairValuesOfOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_RestrictedStockUnitsDescription" xlink:href="clnn-20201231.xsd#clnn_RestrictedStockUnitsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_RestrictedStockUnitsDescription_lbl" xml:lang="en-US">Restricted stock units shares,description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RestrictedStockUnitsDescription" xlink:to="clnn_RestrictedStockUnitsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant-date fair value of RSUs granted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation cost (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraqWjSnTNF4jeT3oaMW8W5R0MkiIXXy8k2PQbBklJ1lYf+6GCuiY/lJFjk6uDeNN+gvvgD/ctbqbBhZgNg1qNU0EiFrWvY1hT6GmZd73HE7TJaI9wGp4wAxzd2UaTwEVsbp/IQFhRTHB/tg6uRHFmIlsS7md0nP83WPfOVzZekE0u2CIFgrisca] CSR-->
    <loc xlink:type="locator" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerms" xlink:href="clnn-20201231.xsd#clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerms_lbl" xml:lang="en-US">Weighted average period for recognition of unrecognized compensation cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerms" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm" xlink:href="clnn-20201231.xsd#clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm_lbl" xml:lang="en-US">Weighted average period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueMeasurementWithUnobservableInputsNotesPayable" xlink:href="clnn-20201231.xsd#clnn_FairValueMeasurementWithUnobservableInputsNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_FairValueMeasurementWithUnobservableInputsNotesPayable_lbl" xml:lang="en-US">Unobservable inputs fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueMeasurementWithUnobservableInputsNotesPayable" xlink:to="clnn_FairValueMeasurementWithUnobservableInputsNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_NotesPayableBasedOnClosingPrice" xlink:href="clnn-20201231.xsd#clnn_NotesPayableBasedOnClosingPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_NotesPayableBasedOnClosingPrice_lbl" xml:lang="en-US">Notes payable based on closing price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NotesPayableBasedOnClosingPrice" xlink:to="clnn_NotesPayableBasedOnClosingPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantsToPurchasePreferredStock" xlink:href="clnn-20201231.xsd#clnn_WarrantsToPurchasePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_WarrantsToPurchasePreferredStock_lbl" xml:lang="en-US">Warrants to purchase preferred stock, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantsToPurchasePreferredStock" xlink:to="clnn_WarrantsToPurchasePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_lbl" xml:lang="en-US">Contingent earn-out, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Shares of common stock issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ConversionOfSecuredPromissoryNotes" xlink:href="clnn-20201231.xsd#clnn_ConversionOfSecuredPromissoryNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ConversionOfSecuredPromissoryNotes_lbl" xml:lang="en-US">Conversion of secured promissory notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConversionOfSecuredPromissoryNotes" xlink:to="clnn_ConversionOfSecuredPromissoryNotes_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_NetOfIssuanceCosts" xlink:href="clnn-20201231.xsd#clnn_NetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_NetOfIssuanceCosts_lbl" xml:lang="en-US">Issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetOfIssuanceCosts" xlink:to="clnn_NetOfIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CashConsiderationReceived" xlink:href="clnn-20201231.xsd#clnn_CashConsiderationReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CashConsiderationReceived_lbl" xml:lang="en-US">Cash consideration received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CashConsiderationReceived" xlink:to="clnn_CashConsiderationReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Warrants issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SharesIssuedUponConversionOfConvertiblePromissoryNote" xlink:href="clnn-20201231.xsd#clnn_SharesIssuedUponConversionOfConvertiblePromissoryNote"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SharesIssuedUponConversionOfConvertiblePromissoryNote_lbl" xml:lang="en-US">Shares issued upon conversion of convertible promissory note (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharesIssuedUponConversionOfConvertiblePromissoryNote" xlink:to="clnn_SharesIssuedUponConversionOfConvertiblePromissoryNote_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantsSharesInExercise" xlink:href="clnn-20201231.xsd#clnn_WarrantsSharesInExercise"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_WarrantsSharesInExercise_lbl" xml:lang="en-US">Warrants shares in exercise (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantsSharesInExercise" xlink:to="clnn_WarrantsSharesInExercise_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US">Aggregate of converted Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConversionBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockConversionBasis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConversionBasis_lbl" xml:lang="en-US">Shares conversion basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConversionBasis" xlink:to="us-gaap_PreferredStockConversionBasis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease_lbl" xml:lang="en-US">Conversion price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:to="us-gaap_CommonStockConvertibleConversionPriceIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockDescription_lbl" xml:lang="en-US">Conversion rights, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockDescription" xlink:to="us-gaap_ConversionOfStockDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PreferredStockShares" xlink:href="clnn-20201231.xsd#clnn_PreferredStockShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_PreferredStockShares_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PreferredStockShares" xlink:to="clnn_PreferredStockShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_RecapitalizationShare" xlink:href="clnn-20201231.xsd#clnn_RecapitalizationShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_RecapitalizationShare_lbl" xml:lang="en-US">Recapitalization share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RecapitalizationShare" xlink:to="clnn_RecapitalizationShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Shares price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_NumberOfSharesIssuableOnExerciseOfWarrants" xlink:href="clnn-20201231.xsd#clnn_NumberOfSharesIssuableOnExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_NumberOfSharesIssuableOnExerciseOfWarrants_lbl" xml:lang="en-US">Number of shares issuable on exercise of PIPE warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NumberOfSharesIssuableOnExerciseOfWarrants" xlink:to="clnn_NumberOfSharesIssuableOnExerciseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl" xml:lang="en-US">Related party transaction, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US">Commercial sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PaycheckProtectionProgramLoan" xlink:href="clnn-20201231.xsd#clnn_PaycheckProtectionProgramLoan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_PaycheckProtectionProgramLoan_lbl" xml:lang="en-US">PPP loan forgiven</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PaycheckProtectionProgramLoan" xlink:to="clnn_PaycheckProtectionProgramLoan_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_GainOnForgivenessLoan" xlink:href="clnn-20201231.xsd#clnn_GainOnForgivenessLoan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_GainOnForgivenessLoan_lbl" xml:lang="en-US">Gain on forgiveness PPP loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GainOnForgivenessLoan" xlink:to="clnn_GainOnForgivenessLoan_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FoundationGrantCost" xlink:href="clnn-20201231.xsd#clnn_FoundationGrantCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_FoundationGrantCost_lbl" xml:lang="en-US">Foundation grant amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FoundationGrantCost" xlink:to="clnn_FoundationGrantCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventDescription_lbl" xml:lang="en-US">Subsequent events, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventDescription" xlink:to="us-gaap_SubsequentEventDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_AggregateGrossProceedWarrantsExercised" xlink:href="clnn-20201231.xsd#clnn_AggregateGrossProceedWarrantsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_AggregateGrossProceedWarrantsExercised_lbl" xml:lang="en-US">Aggregate gross proceed warrants exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AggregateGrossProceedWarrantsExercised" xlink:to="clnn_AggregateGrossProceedWarrantsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SaleOfStockholdersCommonStock" xlink:href="clnn-20201231.xsd#clnn_SaleOfStockholdersCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SaleOfStockholdersCommonStock_lbl" xml:lang="en-US">Sale of stockholders common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SaleOfStockholdersCommonStock" xlink:to="clnn_SaleOfStockholdersCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_RiskAndUncertaintiesPolicyTextBlock" xlink:href="clnn-20201231.xsd#clnn_RiskAndUncertaintiesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_RiskAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US">Risks and Uncertainties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RiskAndUncertaintiesPolicyTextBlock" xlink:to="clnn_RiskAndUncertaintiesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Derivative Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock_lbl" xml:lang="en-US">Redeemable Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ContingentEarnoutPolicyTextBlock" xlink:href="clnn-20201231.xsd#clnn_ContingentEarnoutPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ContingentEarnoutPolicyTextBlock_lbl" xml:lang="en-US">Contingent Earn-out</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ContingentEarnoutPolicyTextBlock" xlink:to="clnn_ContingentEarnoutPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xml:lang="en-US">Preferred Stock Warrant Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsPolicyTextBlock" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrantsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CommonStockWarrantsPolicyTextBlock_lbl" xml:lang="en-US">Common Stock Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsPolicyTextBlock" xlink:to="clnn_CommonStockWarrantsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_GrantFundingPolicyTextBlock" xlink:href="clnn-20201231.xsd#clnn_GrantFundingPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_GrantFundingPolicyTextBlock_lbl" xml:lang="en-US">Grant Funding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GrantFundingPolicyTextBlock" xlink:to="clnn_GrantFundingPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value of Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Translation and Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Share Attributable to Common Shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ClinicalTrialAccrualPolicyTextBlock" xlink:href="clnn-20201231.xsd#clnn_ClinicalTrialAccrualPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ClinicalTrialAccrualPolicyTextBlock_lbl" xml:lang="en-US">Clinical Trial Accrual</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ClinicalTrialAccrualPolicyTextBlock" xlink:to="clnn_ClinicalTrialAccrualPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:href="clnn-20201231.xsd#clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements Not Yet Adopted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:to="clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExchangeClearedMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExchangeClearedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExchangeClearedMember_lbl" xml:lang="en-US">Exchange Ratio [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExchangeClearedMember" xlink:to="us-gaap_ExchangeClearedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CleneNanomedicineMember" xlink:href="clnn-20201231.xsd#clnn_CleneNanomedicineMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CleneNanomedicineMember_lbl" xml:lang="en-US">Clene Nanomedicine [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneNanomedicineMember" xlink:to="clnn_CleneNanomedicineMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ChardanMember" xlink:href="clnn-20201231.xsd#clnn_ChardanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ChardanMember_lbl" xml:lang="en-US">Chardan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChardanMember" xlink:to="clnn_ChardanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_LifeSciCapitalLLCMember" xlink:href="clnn-20201231.xsd#clnn_LifeSciCapitalLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_LifeSciCapitalLLCMember_lbl" xml:lang="en-US">LifeSci Capital LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LifeSciCapitalLLCMember" xlink:to="clnn_LifeSciCapitalLLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RedeemablePreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemablePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RedeemablePreferredStockMember_lbl" xml:lang="en-US">Redeemable Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemablePreferredStockMember" xlink:to="us-gaap_RedeemablePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PreferredStockWarrantMember" xlink:href="clnn-20201231.xsd#clnn_PreferredStockWarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_PreferredStockWarrantMember_lbl" xml:lang="en-US">Preferred Stock Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PreferredStockWarrantMember" xlink:to="clnn_PreferredStockWarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_GrantFundingMember" xlink:href="clnn-20201231.xsd#clnn_GrantFundingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_GrantFundingMember_lbl" xml:lang="en-US">Grant Funding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GrantFundingMember" xlink:to="clnn_GrantFundingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_TottenhamMember" xlink:href="clnn-20201231.xsd#clnn_TottenhamMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_TottenhamMember_lbl" xml:lang="en-US">Tottenham [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TottenhamMember" xlink:to="clnn_TottenhamMember_lbl"/>
    <loc xlink:type="locator" xlink:label="exch_PIPE" xlink:href="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd#exch_PIPE"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="exch_PIPE_lbl" xml:lang="en-US">PIPE Investors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="exch_PIPE" xlink:to="exch_PIPE_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US">Property, Plant and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_TwoThousandNineteenMDLoanMember" xlink:href="clnn-20201231.xsd#clnn_TwoThousandNineteenMDLoanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_TwoThousandNineteenMDLoanMember_lbl" xml:lang="en-US">2019 MD Loan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TwoThousandNineteenMDLoanMember" xlink:to="clnn_TwoThousandNineteenMDLoanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_TwoThousandNineteenCecilLoanMember" xlink:href="clnn-20201231.xsd#clnn_TwoThousandNineteenCecilLoanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_TwoThousandNineteenCecilLoanMember_lbl" xml:lang="en-US">2019 Cecil Loan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TwoThousandNineteenCecilLoanMember" xlink:to="clnn_TwoThousandNineteenCecilLoanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PaycheckProtectionProgramNoteMember" xlink:href="clnn-20201231.xsd#clnn_PaycheckProtectionProgramNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_PaycheckProtectionProgramNoteMember_lbl" xml:lang="en-US">PPP Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PaycheckProtectionProgramNoteMember" xlink:to="clnn_PaycheckProtectionProgramNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xml:lang="en-US">Series D Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_TottenhamsMember" xlink:href="clnn-20201231.xsd#clnn_TottenhamsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_TottenhamsMember_lbl" xml:lang="en-US">Tottenham&#8217;s [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TottenhamsMember" xlink:to="clnn_TottenhamsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US">2020 Convertible Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl0" xml:lang="en-US">Convertible Notes Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Federal [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_StockPlan2020Member" xlink:href="clnn-20201231.xsd#clnn_StockPlan2020Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_StockPlan2020Member_lbl" xml:lang="en-US">2020 Stock Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockPlan2020Member" xlink:to="clnn_StockPlan2020Member_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_StockPlan2014Member" xlink:href="clnn-20201231.xsd#clnn_StockPlan2014Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_StockPlan2014Member_lbl" xml:lang="en-US">2014 Stock Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockPlan2014Member" xlink:to="clnn_StockPlan2014Member_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="clnn_StockPlan2014Member_lbl0" xml:lang="en-US">Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockPlan2014Member" xlink:to="clnn_StockPlan2014Member_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestorMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board of Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xml:lang="en-US">Lease Contractual Term [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsTable" xlink:href="clnn-20201231.xsd#clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsTable_lbl" xml:lang="en-US">Leases (Details) - Schedule of noncancelable operating lease arrangements [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsTable" xlink:to="clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems" xlink:href="clnn-20201231.xsd#clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems_lbl" xml:lang="en-US">Leases (Details) - Schedule of noncancelable operating lease arrangements [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems" xlink:to="clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentTable" xlink:href="clnn-20201231.xsd#clnn_LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentTable_lbl" xml:lang="en-US">Leases (Details) - Schedule of finance lease obligations and included property and equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentTable" xlink:to="clnn_LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentLineItems" xlink:href="clnn-20201231.xsd#clnn_LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentLineItems_lbl" xml:lang="en-US">Leases (Details) - Schedule of finance lease obligations and included property and equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentLineItems" xlink:to="clnn_LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPreferredUnitsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPreferredUnitsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPreferredUnitsTable_lbl" xml:lang="en-US">Schedule of Preferred Units [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPreferredUnitsTable" xlink:to="us-gaap_ScheduleOfPreferredUnitsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredUnitsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredUnitsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredUnitsLineItems_lbl" xml:lang="en-US">Preferred Units [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredUnitsLineItems" xlink:to="us-gaap_PreferredUnitsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable" xlink:href="clnn-20201231.xsd#clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable_lbl" xml:lang="en-US">Stock-Based Compensation (Details) - Schedule of stock-based compensation expense [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable" xlink:to="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems" xlink:href="clnn-20201231.xsd#clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems_lbl" xml:lang="en-US">Stock-Based Compensation (Details) - Schedule of stock-based compensation expense [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems" xlink:to="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedTable" xlink:href="clnn-20201231.xsd#clnn_StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedTable_lbl" xml:lang="en-US">Stock-Based Compensation (Details) - Schedule of fair value of these stock options awards granted [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedTable" xlink:to="clnn_StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedLineItems" xlink:href="clnn-20201231.xsd#clnn_StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedLineItems_lbl" xml:lang="en-US">Schedule of assumptions used to calculate the fair value of stock option awards granted [Line Item]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedLineItems" xlink:to="clnn_StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable" xlink:href="clnn-20201231.xsd#clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable_lbl" xml:lang="en-US">Stock-Based Compensation (Details) - Schedule of restricted common stock activity [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable" xlink:to="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:href="clnn-20201231.xsd#clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems_lbl" xml:lang="en-US">Stock-Based Compensation (Details) - Schedule of restricted common stock activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:to="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable" xlink:href="clnn-20201231.xsd#clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable_lbl" xml:lang="en-US">Fair Value (Details) - Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable" xlink:to="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems" xlink:href="clnn-20201231.xsd#clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems_lbl" xml:lang="en-US">Fair Value (Details) - Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems" xlink:to="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_lbl" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionContingentConsiderationLineItems_lbl" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_BusinessAcquisitionContingentConsiderationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US">Temporary Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable" xlink:href="clnn-20201231.xsd#clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable_lbl" xml:lang="en-US">Geographic and Segment Information (Details) - Schedule of property and equipment, net by location [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable" xlink:to="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems" xlink:href="clnn-20201231.xsd#clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems_lbl" xml:lang="en-US">Geographic and Segment Information (Details) - Schedule of property and equipment, net by location [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems" xlink:to="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsTable" xlink:href="clnn-20201231.xsd#clnn_GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsTable_lbl" xml:lang="en-US">Geographic and Segment Information (Details) - Schedule of drugs and supplements segments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsTable" xlink:to="clnn_GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsLineItems" xlink:href="clnn-20201231.xsd#clnn_GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsLineItems_lbl" xml:lang="en-US">Geographic and Segment Information (Details) - Schedule of drugs and supplements segments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsLineItems" xlink:to="clnn_GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable" xlink:href="clnn-20201231.xsd#clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable_lbl" xml:lang="en-US">Geographic and Segment Information (Details) - Schedule of property and equipment, net by segment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable" xlink:to="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems" xlink:href="clnn-20201231.xsd#clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems_lbl" xml:lang="en-US">Geographic and Segment Information (Details) - Schedule of property and equipment, net by segment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems" xlink:to="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfFreshStartAdjustmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfFreshStartAdjustmentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfFreshStartAdjustmentDomain_lbl" xml:lang="en-US">Type of Fresh-Start Adjustment [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfFreshStartAdjustmentDomain" xlink:to="us-gaap_TypeOfFreshStartAdjustmentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:href="clnn-20201231.xsd#clnn_NatureoftheBusinessandBasisofPresentationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NatureoftheBusinessandBasisofPresentationDetailsTable_lbl" xml:lang="en-US">Nature of the Business and Basis of Presentation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="clnn_NatureoftheBusinessandBasisofPresentationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems_lbl" xml:lang="en-US">Nature of the Business and Basis of Presentation (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollateralDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollateralDomain_lbl" xml:lang="en-US">Collateral Held [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollateralDomain" xlink:to="us-gaap_CollateralDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="clnn-20201231.xsd#clnn_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="clnn_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" xlink:href="clnn-20201231.xsd#clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable_lbl" xml:lang="en-US">Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" xlink:to="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems_lbl" xml:lang="en-US">Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US">Asset Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PropertyandEquipmentNetDetailsTable" xlink:href="clnn-20201231.xsd#clnn_PropertyandEquipmentNetDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PropertyandEquipmentNetDetailsTable_lbl" xml:lang="en-US">Property and Equipment, Net (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PropertyandEquipmentNetDetailsTable" xlink:to="clnn_PropertyandEquipmentNetDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PropertyandEquipmentNetDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_PropertyandEquipmentNetDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PropertyandEquipmentNetDetailsLineItems_lbl" xml:lang="en-US">Property and Equipment, Net (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PropertyandEquipmentNetDetailsLineItems" xlink:to="clnn_PropertyandEquipmentNetDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_NotesPayableDetailsTable" xlink:href="clnn-20201231.xsd#clnn_NotesPayableDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NotesPayableDetailsTable_lbl" xml:lang="en-US">Notes Payable (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NotesPayableDetailsTable" xlink:to="clnn_NotesPayableDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_NotesPayableDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_NotesPayableDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NotesPayableDetailsLineItems_lbl" xml:lang="en-US">Notes Payable (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="clnn_NotesPayableDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PreferredStockWarrantLiabilityDetailsTable" xlink:href="clnn-20201231.xsd#clnn_PreferredStockWarrantLiabilityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PreferredStockWarrantLiabilityDetailsTable_lbl" xml:lang="en-US">Preferred Stock Warrant Liability (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PreferredStockWarrantLiabilityDetailsTable" xlink:to="clnn_PreferredStockWarrantLiabilityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PreferredStockWarrantLiabilityDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_PreferredStockWarrantLiabilityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PreferredStockWarrantLiabilityDetailsLineItems_lbl" xml:lang="en-US">Preferred Stock Warrant Liability (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PreferredStockWarrantLiabilityDetailsLineItems" xlink:to="clnn_PreferredStockWarrantLiabilityDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsDetailsTable" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrantsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CommonStockWarrantsDetailsTable_lbl" xml:lang="en-US">Common Stock Warrants (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsDetailsTable" xlink:to="clnn_CommonStockWarrantsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrantsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CommonStockWarrantsDetailsLineItems_lbl" xml:lang="en-US">Common Stock Warrants (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsDetailsLineItems" xlink:to="clnn_CommonStockWarrantsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ConvertibleNotesDetailsTable" xlink:href="clnn-20201231.xsd#clnn_ConvertibleNotesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ConvertibleNotesDetailsTable_lbl" xml:lang="en-US">Convertible Notes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConvertibleNotesDetailsTable" xlink:to="clnn_ConvertibleNotesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ConvertibleNotesDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_ConvertibleNotesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ConvertibleNotesDetailsLineItems_lbl" xml:lang="en-US">Convertible Notes (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="clnn_ConvertibleNotesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_IncomeTaxesDetailsTable" xlink:href="clnn-20201231.xsd#clnn_IncomeTaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_IncomeTaxesDetailsTable_lbl" xml:lang="en-US">Income Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncomeTaxesDetailsTable" xlink:to="clnn_IncomeTaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_IncomeTaxesDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_IncomeTaxesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_IncomeTaxesDetailsLineItems_lbl" xml:lang="en-US">Income Taxes (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncomeTaxesDetailsLineItems" xlink:to="clnn_IncomeTaxesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsTable" xlink:href="clnn-20201231.xsd#clnn_StockBasedCompensationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_StockBasedCompensationDetailsTable_lbl" xml:lang="en-US">Stock-Based Compensation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockBasedCompensationDetailsTable" xlink:to="clnn_StockBasedCompensationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_StockBasedCompensationDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_StockBasedCompensationDetailsLineItems_lbl" xml:lang="en-US">Stock-Based Compensation (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="clnn_StockBasedCompensationDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueDetailsTable" xlink:href="clnn-20201231.xsd#clnn_FairValueDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FairValueDetailsTable_lbl" xml:lang="en-US">Fair Value (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueDetailsTable" xlink:to="clnn_FairValueDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_FairValueDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FairValueDetailsLineItems_lbl" xml:lang="en-US">Fair Value (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueDetailsLineItems" xlink:to="clnn_FairValueDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_RedeemableConvertiblePreferredStockDetailsTable" xlink:href="clnn-20201231.xsd#clnn_RedeemableConvertiblePreferredStockDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_RedeemableConvertiblePreferredStockDetailsTable_lbl" xml:lang="en-US">Redeemable Convertible Preferred Stock (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RedeemableConvertiblePreferredStockDetailsTable" xlink:to="clnn_RedeemableConvertiblePreferredStockDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_RedeemableConvertiblePreferredStockDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_RedeemableConvertiblePreferredStockDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_RedeemableConvertiblePreferredStockDetailsLineItems_lbl" xml:lang="en-US">Redeemable Convertible Preferred Stock (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="clnn_RedeemableConvertiblePreferredStockDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_RelatedPartyTransactionsDetailsTable" xlink:href="clnn-20201231.xsd#clnn_RelatedPartyTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_RelatedPartyTransactionsDetailsTable_lbl" xml:lang="en-US">Related Party Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RelatedPartyTransactionsDetailsTable" xlink:to="clnn_RelatedPartyTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_RelatedPartyTransactionsDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_RelatedPartyTransactionsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_RelatedPartyTransactionsDetailsLineItems_lbl" xml:lang="en-US">Related Party Transactions (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RelatedPartyTransactionsDetailsLineItems" xlink:to="clnn_RelatedPartyTransactionsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SubsequentEventsDetailsTable" xlink:href="clnn-20201231.xsd#clnn_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SubsequentEventsDetailsTable" xlink:to="clnn_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SubsequentEventsDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_SubsequentEventsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SubsequentEventsDetailsLineItems_lbl" xml:lang="en-US">Subsequent Events (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SubsequentEventsDetailsLineItems" xlink:to="clnn_SubsequentEventsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_AccruedCROFees_lbl0" xml:lang="en-US">Accrued CRO fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AccruedCROFees" xlink:to="clnn_AccruedCROFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_AccruedTransactionCosts_lbl0" xml:lang="en-US">Accrued transaction costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AccruedTransactionCosts" xlink:to="clnn_AccruedTransactionCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_AccumulatedDepreciationDepletionAndAmortizationLeases_lbl0" xml:lang="en-US">Accumulated depreciation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AccumulatedDepreciationDepletionAndAmortizationLeases" xlink:to="clnn_AccumulatedDepreciationDepletionAndAmortizationLeases_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_AustraliaResearchAndDevelopmentCreditReceivable_lbl0" xml:lang="en-US">Australia research and development credit receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AustraliaResearchAndDevelopmentCreditReceivable" xlink:to="clnn_AustraliaResearchAndDevelopmentCreditReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_CashConsiderationReceived_lbl0" xml:lang="en-US">Cash consideration received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CashConsiderationReceived" xlink:to="clnn_CashConsiderationReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ChangeInFairValueOfContingentEarnout_lbl1" xml:lang="en-US">For the period ended Change in fair value of contingent earn-out.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangeInFairValueOfContingentEarnout" xlink:to="clnn_ChangeInFairValueOfContingentEarnout_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout_lbl1" xml:lang="en-US">Change in fair value of Initial Shareholders contingent earn-out&#xd;
..</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout" xlink:to="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_CleneNanomedicineContingentEarnout_lbl0" xml:lang="en-US">Clene Nanomedicine contingent earn-out.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneNanomedicineContingentEarnout" xlink:to="clnn_CleneNanomedicineContingentEarnout_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ClinicalTrialAccrualPolicyTextBlock_lbl0" xml:lang="en-US">Clinical Trial Accrual Policy.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ClinicalTrialAccrualPolicyTextBlock" xlink:to="clnn_ClinicalTrialAccrualPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_CommonStockWarrantsDisclosureTextBlock_lbl0" xml:lang="en-US">he entire disclosure for shareholders&apos; equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsDisclosureTextBlock" xlink:to="clnn_CommonStockWarrantsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_CommonStockWarrantsExercisePrice_lbl0" xml:lang="en-US">Exercise Price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsExercisePrice" xlink:to="clnn_CommonStockWarrantsExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_CommonStockWarrantsExpiration_lbl0" xml:lang="en-US">Expiration.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsExpiration" xlink:to="clnn_CommonStockWarrantsExpiration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_CommonStockWarrantsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for Common stock warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsPolicyTextBlock" xlink:to="clnn_CommonStockWarrantsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ContingentEarnoutPolicyTextBlock_lbl0" xml:lang="en-US">Contingent Earn-out Policy.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ContingentEarnoutPolicyTextBlock" xlink:to="clnn_ContingentEarnoutPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ContingentEarnoutRecognizedConnectionWithTheReverseRecapitalization_lbl0" xml:lang="en-US">Contingent earn-out recognized in connection with the Reverse Recapitalization.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ContingentEarnoutRecognizedConnectionWithTheReverseRecapitalization" xlink:to="clnn_ContingentEarnoutRecognizedConnectionWithTheReverseRecapitalization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati_lbl0" xml:lang="en-US">Contingent earn-out recognized in connection with the Reverse Recapitalization.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati" xlink:to="clnn_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization_lbl0" xml:lang="en-US">Contingent earn-out recognized in connection with the Reverse Recapitalization.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization" xlink:to="clnn_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStock_lbl0" xml:lang="en-US">Conversion of redeemable convertible preferred stock into common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStock" xlink:to="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ConversionOfSecuredPromissoryNotes_lbl0" xml:lang="en-US">Conversion of secured promissory notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConversionOfSecuredPromissoryNotes" xlink:to="clnn_ConversionOfSecuredPromissoryNotes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_CostsOfRevenue_lbl0" xml:lang="en-US">Cost of revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CostsOfRevenue" xlink:to="clnn_CostsOfRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_DeferredGrantFunds_lbl0" xml:lang="en-US">Deferred grant funds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredGrantFunds" xlink:to="clnn_DeferredGrantFunds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_DeferredTaxAssetsRightofUseAsset_lbl0" xml:lang="en-US">Amount of deferred tax assets right of use of assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredTaxAssetsRightofUseAsset" xlink:to="clnn_DeferredTaxAssetsRightofUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_DeferredTaxAssetsTaxDeferredAccruedCompensation_lbl0" xml:lang="en-US">Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredTaxAssetsTaxDeferredAccruedCompensation" xlink:to="clnn_DeferredTaxAssetsTaxDeferredAccruedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_DeferredTaxAssetsTaxDeferredNonqualifiedStockOptions_lbl0" xml:lang="en-US">Non-qualified stock options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredTaxAssetsTaxDeferredNonqualifiedStockOptions" xlink:to="clnn_DeferredTaxAssetsTaxDeferredNonqualifiedStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_DeferredTaxLiabilitiesDeferredExpenseDepreciation_lbl0" xml:lang="en-US">Depreciation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredTaxLiabilitiesDeferredExpenseDepreciation" xlink:to="clnn_DeferredTaxLiabilitiesDeferredExpenseDepreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_DeferredTaxLiabilitiesLeaseLiability_lbl0" xml:lang="en-US">Lease liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredTaxLiabilitiesLeaseLiability" xlink:to="clnn_DeferredTaxLiabilitiesLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_DeferredTransactionCostsInAccountsPayable_lbl0" xml:lang="en-US">Thereafter, it is classified as an expense within the current accounting period. Deferred charges often stem from a business making payments for goods and services it has not yet received, such as prepaid insurance premiums or rent.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredTransactionCostsInAccountsPayable" xlink:to="clnn_DeferredTransactionCostsInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_DeferredTransactionsCostsInAccruedLiabilities_lbl0" xml:lang="en-US">Deferred transactions costs in accrued liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredTransactionsCostsInAccruedLiabilities" xlink:to="clnn_DeferredTransactionsCostsInAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_EarnOutShare_lbl0" xml:lang="en-US">the amount of the earn out share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_EarnOutShare" xlink:to="clnn_EarnOutShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_EntityCommonStockSharesOutstanding1_lbl0" xml:lang="en-US">Indicate number of shares or other units outstanding of each of registrant&apos;s classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_EntityCommonStockSharesOutstanding1" xlink:to="clnn_EntityCommonStockSharesOutstanding1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ExerciseOfSeriesCPreferredStockWarrants_lbl0" xml:lang="en-US">Exercise of Series C preferred stock warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExerciseOfSeriesCPreferredStockWarrants" xlink:to="clnn_ExerciseOfSeriesCPreferredStockWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ExpirationDate_lbl0" xml:lang="en-US">Expiration Date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExpirationDate" xlink:to="clnn_ExpirationDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ExtinguishmentOfDerivativeLiability_lbl0" xml:lang="en-US">Extinguishment of derivative liability in connection with extinguishment of the 2020 Convertible Notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExtinguishmentOfDerivativeLiability" xlink:to="clnn_ExtinguishmentOfDerivativeLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN_lbl0" xml:lang="en-US">Extinguishment of derivative liability in connection with extinguishment of convertible promissory notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" xlink:to="clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable_lbl0" xml:lang="en-US">Extinguishment of preferred stock warrant liability in connection with the conversion of redeemable convertible preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable" xlink:to="clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemableConvertibleSreferredStock_lbl0" xml:lang="en-US">Extinguishment of preferred stock warrant liability in connection with the conversion of redeemable convertible preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemableConvertibleSreferredStock" xlink:to="clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemableConvertibleSreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_FairValueExerciseOfSeriesCPreferredStockWarrants_lbl0" xml:lang="en-US">This value for exercise of Series C preferred stock warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueExerciseOfSeriesCPreferredStockWarrants" xlink:to="clnn_FairValueExerciseOfSeriesCPreferredStockWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_FairValueIssuanceOfConvertiblePromissoryNotes_lbl0" xml:lang="en-US">This value for issuance of convertible promissory notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueIssuanceOfConvertiblePromissoryNotes" xlink:to="clnn_FairValueIssuanceOfConvertiblePromissoryNotes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_FairValueOfIssuanceOfNotesPayable_lbl0" xml:lang="en-US">This value for issuance of notes payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueOfIssuanceOfNotesPayable" xlink:to="clnn_FairValueOfIssuanceOfNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_FinanceLeaseLiabilityGross_lbl0" xml:lang="en-US">Finance lease liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeaseLiabilityGross" xlink:to="clnn_FinanceLeaseLiabilityGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_FinanceLeaseLiabilityNet_lbl0" xml:lang="en-US">Finance lease liability, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeaseLiabilityNet" xlink:to="clnn_FinanceLeaseLiabilityNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_FinanceLeaseObligationsWeightedaverageInterestRate_lbl0" xml:lang="en-US">Finance lease obligations weighted-average interest rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeaseObligationsWeightedaverageInterestRate" xlink:to="clnn_FinanceLeaseObligationsWeightedaverageInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_GrantFundingPolicyTextBlock_lbl0" xml:lang="en-US">Grant Funding Policy.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GrantFundingPolicyTextBlock" xlink:to="clnn_GrantFundingPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_IncomeTaxReconciliationNondeductibleExpensesResearchAndDevelopment_lbl0" xml:lang="en-US">Amount of research and development credits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncomeTaxReconciliationNondeductibleExpensesResearchAndDevelopment" xlink:to="clnn_IncomeTaxReconciliationNondeductibleExpensesResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_IncomeTaxReconciliationWarrantLiability_lbl0" xml:lang="en-US">Amount of income tax reconciliation warrant liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncomeTaxReconciliationWarrantLiability" xlink:to="clnn_IncomeTaxReconciliationWarrantLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_IncreaseDecreaseInPayableToRelatedParties_lbl0" xml:lang="en-US">Payable to related parties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncreaseDecreaseInPayableToRelatedParties" xlink:to="clnn_IncreaseDecreaseInPayableToRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_IncreaseDecreaseOperatingLeaseObligations_lbl0" xml:lang="en-US">Operating lease obligations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncreaseDecreaseOperatingLeaseObligations" xlink:to="clnn_IncreaseDecreaseOperatingLeaseObligations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_IncreaseInInterestAccruedOnNotesPayable_lbl0" xml:lang="en-US">Increase in interest accrued on notes payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncreaseInInterestAccruedOnNotesPayable" xlink:to="clnn_IncreaseInInterestAccruedOnNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_IncreseDecreaseInFairValue_lbl0" xml:lang="en-US">This value for change in fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncreseDecreaseInFairValue" xlink:to="clnn_IncreseDecreaseInFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_IncurredNetLosses_lbl0" xml:lang="en-US">Incurred net losses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncurredNetLosses" xlink:to="clnn_IncurredNetLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_InitialFairValueOfInstrument_lbl0" xml:lang="en-US">This value for initial fair value of instrument.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialFairValueOfInstrument" xlink:to="clnn_InitialFairValueOfInstrument_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_InitialShareholdersContingentEarnout_lbl0" xml:lang="en-US">Initial Shareholders contingent earn-out.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialShareholdersContingentEarnout" xlink:to="clnn_InitialShareholdersContingentEarnout_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_InitialShareholdersContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization_lbl0" xml:lang="en-US">Initial Shareholders contingent earn-out recognized in connection with the Reverse Recapitalization,</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialShareholdersContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization" xlink:to="clnn_InitialShareholdersContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_InvestorsPurchasedShares_lbl0" xml:lang="en-US">The amount of share investors purchased shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InvestorsPurchasedShares" xlink:to="clnn_InvestorsPurchasedShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts_lbl0" xml:lang="en-US">Issuance of common stock as payment of related offering costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts" xlink:to="clnn_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_IssuanceOfCommonStockAsPaymentRelatedOfferingCosts_lbl0" xml:lang="en-US">Issuance of common stock as payment of related offering costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IssuanceOfCommonStockAsPaymentRelatedOfferingCosts" xlink:to="clnn_IssuanceOfCommonStockAsPaymentRelatedOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts_lbl0" xml:lang="en-US">Issuance of Series C preferred stock, net of issuance costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts" xlink:to="clnn_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes_lbl0" xml:lang="en-US">Issuance of Series D Preferred Stock upon extinguishment of convertible promissory notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes" xlink:to="clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_MergerAgreementPercentage_lbl0" xml:lang="en-US">Merger agreement percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_MergerAgreementPercentage" xlink:to="clnn_MergerAgreementPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_MetalsToBeUsedInResearchAndDevelopment_lbl0" xml:lang="en-US">Metals to be used in research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_MetalsToBeUsedInResearchAndDevelopment" xlink:to="clnn_MetalsToBeUsedInResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_MinimumFairMarketValueOfOptionGrantDescription_lbl0" xml:lang="en-US">Description of minimum fair market value of option grant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_MinimumFairMarketValueOfOptionGrantDescription" xlink:to="clnn_MinimumFairMarketValueOfOptionGrantDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_NetIssuanceCosts_lbl0" xml:lang="en-US">Net Issuance Costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetIssuanceCosts" xlink:to="clnn_NetIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_NetOfIssuanceCosts_lbl0" xml:lang="en-US">Net of issuance costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetOfIssuanceCosts" xlink:to="clnn_NetOfIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_NetProceeds_lbl0" xml:lang="en-US">The amount of net proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetProceeds" xlink:to="clnn_NetProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements Not Yet Adopted Policy.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:to="clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_NotesPayableBasedOnClosingPrice_lbl0" xml:lang="en-US">Notes payable based on closing price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NotesPayableBasedOnClosingPrice" xlink:to="clnn_NotesPayableBasedOnClosingPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_NumberOfSharesIssuable_lbl0" xml:lang="en-US">Number of Shares Issuable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NumberOfSharesIssuable" xlink:to="clnn_NumberOfSharesIssuable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_NumberOfSharesIssuableOnExerciseOfWarrants_lbl0" xml:lang="en-US">Number of shares issuable on exercise of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NumberOfSharesIssuableOnExerciseOfWarrants" xlink:to="clnn_NumberOfSharesIssuableOnExerciseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_OperatingLeaseObligationsWeightedAverageInterestRate_lbl0" xml:lang="en-US">Operating lease obligations weighted average interest rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OperatingLeaseObligationsWeightedAverageInterestRate" xlink:to="clnn_OperatingLeaseObligationsWeightedAverageInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_OperatingLossExpireTerm_lbl0" xml:lang="en-US">The term of operating loss expiration.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OperatingLossExpireTerm" xlink:to="clnn_OperatingLossExpireTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_PaymentsForAdvisoryServicesShares_lbl0" xml:lang="en-US">Number of shares related to advisory services.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PaymentsForAdvisoryServicesShares" xlink:to="clnn_PaymentsForAdvisoryServicesShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_PerShareUnit_lbl0" xml:lang="en-US">Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PerShareUnit" xlink:to="clnn_PerShareUnit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_PercentageOfLoanAmountUsedToPayrollExpenses_lbl0" xml:lang="en-US">Percentage of loan amount used to payroll expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PercentageOfLoanAmountUsedToPayrollExpenses" xlink:to="clnn_PercentageOfLoanAmountUsedToPayrollExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_PreferredStockConvertibleConversionPrice_lbl0" xml:lang="en-US">Convertible per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PreferredStockConvertibleConversionPrice" xlink:to="clnn_PreferredStockConvertibleConversionPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_PreferredStockShares_lbl0" xml:lang="en-US">Preferred Stock Shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PreferredStockShares" xlink:to="clnn_PreferredStockShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_PreferredStockWarrantsOutstandingShares_lbl0" xml:lang="en-US">Preferred stock warrants, outstanding shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PreferredStockWarrantsOutstandingShares" xlink:to="clnn_PreferredStockWarrantsOutstandingShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl0" xml:lang="en-US">Prepaid Expenses And Other Current Assets [TableTextBlock]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl0" xml:lang="en-US">The entire disclosure for Prepaid expenses and other current assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ProceedsFromReverseRecapitalizationNet_lbl0" xml:lang="en-US">Amount of cash inflow from the reverse recapitalization net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ProceedsFromReverseRecapitalizationNet" xlink:to="clnn_ProceedsFromReverseRecapitalizationNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ProceedsFromThePrivatePlacementOfferingNetOfOfferingCosts_lbl0" xml:lang="en-US">Proceeds from the private placement offering, net of offering costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ProceedsFromThePrivatePlacementOfferingNetOfOfferingCosts" xlink:to="clnn_ProceedsFromThePrivatePlacementOfferingNetOfOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_PropertyPlantAndEquipmentOneTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PropertyPlantAndEquipmentOneTextBlock" xlink:to="clnn_PropertyPlantAndEquipmentOneTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ProposedPublicOfferingCost_lbl0" xml:lang="en-US">Proposed Public Offering Cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ProposedPublicOfferingCost" xlink:to="clnn_ProposedPublicOfferingCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_PurchaseOption_lbl0" xml:lang="en-US">Number of share units purchase.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PurchaseOption" xlink:to="clnn_PurchaseOption_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_RecognizedGainOnOperatingLease_lbl0" xml:lang="en-US">Recognized gain on operating lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RecognizedGainOnOperatingLease" xlink:to="clnn_RecognizedGainOnOperatingLease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock_lbl0" xml:lang="en-US">Redeemable Convertible Preferred Stock [Text Block].</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock" xlink:to="clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_RemainingBalanceOfOperatingLoss_lbl0" xml:lang="en-US">Amount of remaining balance of operating loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RemainingBalanceOfOperatingLoss" xlink:to="clnn_RemainingBalanceOfOperatingLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ResearchAndDevelopmentCreditExpiryTerm_lbl0" xml:lang="en-US">Term of research and development credit expiration.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ResearchAndDevelopmentCreditExpiryTerm" xlink:to="clnn_ResearchAndDevelopmentCreditExpiryTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_RestrictedStockUnitsDescription_lbl0" xml:lang="en-US">Description of Restricted Stock Units.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RestrictedStockUnitsDescription" xlink:to="clnn_RestrictedStockUnitsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_RetainedEarningsAccumulatedDeficit1_lbl0" xml:lang="en-US">The cumulative amount of the reporting entity&apos;s undistributed earnings or deficit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RetainedEarningsAccumulatedDeficit1" xlink:to="clnn_RetainedEarningsAccumulatedDeficit1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ReverseRecapitalizationAndWillExpireYears_lbl0" xml:lang="en-US">Reverse Recapitalization and will expire years.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ReverseRecapitalizationAndWillExpireYears" xlink:to="clnn_ReverseRecapitalizationAndWillExpireYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_RiskAndUncertaintiesPolicyTextBlock_lbl0" xml:lang="en-US">Risk and Uncertainties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RiskAndUncertaintiesPolicyTextBlock" xlink:to="clnn_RiskAndUncertaintiesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised_lbl0" xml:lang="en-US">Number of options shares exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised" xlink:to="clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerms_lbl0" xml:lang="en-US">Expected term of award under share-based payment arrangement, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerms" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm_lbl0" xml:lang="en-US">Expected term of award under share-based payment arrangement, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos;.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants_lbl0" xml:lang="en-US">Gross number of share options (or share units) for future granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_SharesHeldInEscrow_lbl0" xml:lang="en-US">Number of shares held in Escrow.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharesHeldInEscrow" xlink:to="clnn_SharesHeldInEscrow_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_SharesIssuedUponConversionOfConvertiblePromissoryNote_lbl0" xml:lang="en-US">Shares issued upon conversion of convertible promissory note.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharesIssuedUponConversionOfConvertiblePromissoryNote" xlink:to="clnn_SharesIssuedUponConversionOfConvertiblePromissoryNote_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_SharesPerShare_lbl0" xml:lang="en-US">Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharesPerShare" xlink:to="clnn_SharesPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_SimpleInterestExpense_lbl0" xml:lang="en-US">Simple interest expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SimpleInterestExpense" xlink:to="clnn_SimpleInterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_StockIssuedDuringPeriodSharesPrivatePlacement_lbl0" xml:lang="en-US">Number of stock issued shares of private placement during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockIssuedDuringPeriodSharesPrivatePlacement" xlink:to="clnn_StockIssuedDuringPeriodSharesPrivatePlacement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_TemporaryEquitySharesCommonStockIssuableUponConversion_lbl0" xml:lang="en-US">Common Stock Issuable Upon Conversion.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TemporaryEquitySharesCommonStockIssuableUponConversion" xlink:to="clnn_TemporaryEquitySharesCommonStockIssuableUponConversion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_TemporaryEquitySharesIssuedAndOutstanding_lbl0" xml:lang="en-US">Preferred Shares Issued and Outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TemporaryEquitySharesIssuedAndOutstanding" xlink:to="clnn_TemporaryEquitySharesIssuedAndOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_WarrantExercisePrice_lbl0" xml:lang="en-US">Exercise price per warrant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantExercisePrice" xlink:to="clnn_WarrantExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_WarrantsSharesInExercise_lbl0" xml:lang="en-US">Number of warrants shares in exercise.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantsSharesInExercise" xlink:to="clnn_WarrantsSharesInExercise_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_WarrantsToPurchasePreferredStock_lbl0" xml:lang="en-US">Warrants to purchase preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantsToPurchasePreferredStock" xlink:to="clnn_WarrantsToPurchasePreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_weightedAverageFairValuesOfOptionsGranted_lbl0" xml:lang="en-US">Fair value of options granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_weightedAverageFairValuesOfOptionsGranted" xlink:to="clnn_weightedAverageFairValuesOfOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_InitialShareholdersContingentEarnoutMember_lbl0" xml:lang="en-US">Initial Shareholders Contingent Earn-out [Member].</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialShareholdersContingentEarnoutMember" xlink:to="clnn_InitialShareholdersContingentEarnoutMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ExpirationDate_lbl1" xml:lang="en-US">ExpirationDate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExpirationDate" xlink:to="clnn_ExpirationDate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PaycheckProtectionProgramNoteMember_lbl0" xml:lang="en-US">PaycheckProtectionProgramNoteMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PaycheckProtectionProgramNoteMember" xlink:to="clnn_PaycheckProtectionProgramNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DeferredTaxLiabilitiesLeaseLiability_lbl1" xml:lang="en-US">DeferredTaxLiabilitiesLeaseLiability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredTaxLiabilitiesLeaseLiability" xlink:to="clnn_DeferredTaxLiabilitiesLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CommonStockWarrants_lbl0" xml:lang="en-US">CommonStockWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrants" xlink:to="clnn_CommonStockWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_IncreaseInInterestAccruedOnNotesPayable_lbl1" xml:lang="en-US">IncreaseInInterestAccruedOnNotesPayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncreaseInInterestAccruedOnNotesPayable" xlink:to="clnn_IncreaseInInterestAccruedOnNotesPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_AustraliaResearchAndDevelopmentCreditReceivable_lbl1" xml:lang="en-US">AustraliaResearchAndDevelopmentCreditReceivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AustraliaResearchAndDevelopmentCreditReceivable" xlink:to="clnn_AustraliaResearchAndDevelopmentCreditReceivable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CommonStockWarrantsExpiration_lbl1" xml:lang="en-US">CommonStockWarrantsExpiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsExpiration" xlink:to="clnn_CommonStockWarrantsExpiration_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_IncurredNetLosses_lbl1" xml:lang="en-US">IncurredNetLosses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncurredNetLosses" xlink:to="clnn_IncurredNetLosses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_OperatingLeaseObligationsWeightedAverageInterestRate_lbl1" xml:lang="en-US">OperatingLeaseObligationsWeightedAverageInterestRate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OperatingLeaseObligationsWeightedAverageInterestRate" xlink:to="clnn_OperatingLeaseObligationsWeightedAverageInterestRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStock_lbl1" xml:lang="en-US">ConversionOfRedeemableConvertiblePreferredStockIntoCommonStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStock" xlink:to="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_GrantFundingPolicyTextBlock_lbl1" xml:lang="en-US">GrantFundingPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GrantFundingPolicyTextBlock" xlink:to="clnn_GrantFundingPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FinanceLeaseLiabilityGross_lbl1" xml:lang="en-US">FinanceLeaseLiabilityGross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeaseLiabilityGross" xlink:to="clnn_FinanceLeaseLiabilityGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CommonStockWarrantsExercisePrice_lbl1" xml:lang="en-US">CommonStockWarrantsExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsExercisePrice" xlink:to="clnn_CommonStockWarrantsExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_TottenhamsMember_lbl0" xml:lang="en-US">TottenhamsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TottenhamsMember" xlink:to="clnn_TottenhamsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock_lbl1" xml:lang="en-US">RedeemableConvertiblePreferredStockDisclosureTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock" xlink:to="clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SharesIssuedUponConversionOfConvertiblePromissoryNote_lbl1" xml:lang="en-US">SharesIssuedUponConversionOfConvertiblePromissoryNote</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharesIssuedUponConversionOfConvertiblePromissoryNote" xlink:to="clnn_SharesIssuedUponConversionOfConvertiblePromissoryNote_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PercentageOfLoanAmountUsedToPayrollExpenses_lbl1" xml:lang="en-US">PercentageOfLoanAmountUsedToPayrollExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PercentageOfLoanAmountUsedToPayrollExpenses" xlink:to="clnn_PercentageOfLoanAmountUsedToPayrollExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DeferredTaxExpenseAbstract_lbl0" xml:lang="en-US">DeferredTaxExpenseAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredTaxExpenseAbstract" xlink:to="clnn_DeferredTaxExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout_lbl2" xml:lang="en-US">ChangeInFairValueOfInitialShareholdersContingentEarnout</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout" xlink:to="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FairValueExerciseOfSeriesCPreferredStockWarrants_lbl1" xml:lang="en-US">FairValueExerciseOfSeriesCPreferredStockWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueExerciseOfSeriesCPreferredStockWarrants" xlink:to="clnn_FairValueExerciseOfSeriesCPreferredStockWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_EarnOutShare_lbl1" xml:lang="en-US">EarnOutShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_EarnOutShare" xlink:to="clnn_EarnOutShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati_lbl1" xml:lang="en-US">ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati" xlink:to="clnn_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DeferredTaxAssetsTaxDeferredAccruedCompensation_lbl1" xml:lang="en-US">DeferredTaxAssetsTaxDeferredAccruedCompensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredTaxAssetsTaxDeferredAccruedCompensation" xlink:to="clnn_DeferredTaxAssetsTaxDeferredAccruedCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_IssuanceOfCommonStockAsPaymentRelatedOfferingCosts_lbl1" xml:lang="en-US">IssuanceOfCommonStockAsPaymentRelatedOfferingCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IssuanceOfCommonStockAsPaymentRelatedOfferingCosts" xlink:to="clnn_IssuanceOfCommonStockAsPaymentRelatedOfferingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_IncreaseDecreaseOperatingLeaseObligations_lbl1" xml:lang="en-US">IncreaseDecreaseOperatingLeaseObligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncreaseDecreaseOperatingLeaseObligations" xlink:to="clnn_IncreaseDecreaseOperatingLeaseObligations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_OperatingCashFlowsFromFinanceLeases_lbl0" xml:lang="en-US">OperatingCashFlowsFromFinanceLeases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OperatingCashFlowsFromFinanceLeases" xlink:to="clnn_OperatingCashFlowsFromFinanceLeases_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl1" xml:lang="en-US">PrepaidExpensesAndOtherCurrentAssetsTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_MetalsToBeUsedInResearchAndDevelopment_lbl1" xml:lang="en-US">MetalsToBeUsedInResearchAndDevelopment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_MetalsToBeUsedInResearchAndDevelopment" xlink:to="clnn_MetalsToBeUsedInResearchAndDevelopment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_InitialShareholdersContingentEarnoutMember_lbl1" xml:lang="en-US">InitialShareholdersContingentEarnoutMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialShareholdersContingentEarnoutMember" xlink:to="clnn_InitialShareholdersContingentEarnoutMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FairValueMeasurementWithUnobservableInputsNotesPayable_lbl0" xml:lang="en-US">FairValueMeasurementWithUnobservableInputsNotesPayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueMeasurementWithUnobservableInputsNotesPayable" xlink:to="clnn_FairValueMeasurementWithUnobservableInputsNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_WarrantsDateMember_lbl0" xml:lang="en-US">WarrantsDateMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantsDateMember" xlink:to="clnn_WarrantsDateMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_AccumulatedDepreciationDepletionAndAmortizationLeases_lbl1" xml:lang="en-US">AccumulatedDepreciationDepletionAndAmortizationLeases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AccumulatedDepreciationDepletionAndAmortizationLeases" xlink:to="clnn_AccumulatedDepreciationDepletionAndAmortizationLeases_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SimpleInterestExpense_lbl1" xml:lang="en-US">SimpleInterestExpense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SimpleInterestExpense" xlink:to="clnn_SimpleInterestExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts_lbl1" xml:lang="en-US">IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts" xlink:to="clnn_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_EarnoutSharessee_lbl0" xml:lang="en-US">EarnoutSharessee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_EarnoutSharessee" xlink:to="clnn_EarnoutSharessee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ProceedsFromThePrivatePlacementOfferingNetOfOfferingCosts_lbl1" xml:lang="en-US">ProceedsFromThePrivatePlacementOfferingNetOfOfferingCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ProceedsFromThePrivatePlacementOfferingNetOfOfferingCosts" xlink:to="clnn_ProceedsFromThePrivatePlacementOfferingNetOfOfferingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_StockPlan2014Member_lbl1" xml:lang="en-US">StockPlan2014Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockPlan2014Member" xlink:to="clnn_StockPlan2014Member_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN_lbl1" xml:lang="en-US">ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" xlink:to="clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SharesHeldInEscrow_lbl1" xml:lang="en-US">SharesHeldInEscrow</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharesHeldInEscrow" xlink:to="clnn_SharesHeldInEscrow_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NotesPayableBasedOnClosingPrice_lbl1" xml:lang="en-US">NotesPayableBasedOnClosingPrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NotesPayableBasedOnClosingPrice" xlink:to="clnn_NotesPayableBasedOnClosingPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_EntityCommonStockSharesOutstanding1_lbl1" xml:lang="en-US">EntityCommonStockSharesOutstanding1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_EntityCommonStockSharesOutstanding1" xlink:to="clnn_EntityCommonStockSharesOutstanding1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ReverseRecapitalizationAndWillExpireYears_lbl1" xml:lang="en-US">ReverseRecapitalizationAndWillExpireYears</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ReverseRecapitalizationAndWillExpireYears" xlink:to="clnn_ReverseRecapitalizationAndWillExpireYears_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_AggregateGrossProceedWarrantsExercised_lbl0" xml:lang="en-US">AggregateGrossProceedWarrantsExercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AggregateGrossProceedWarrantsExercised" xlink:to="clnn_AggregateGrossProceedWarrantsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable_lbl1" xml:lang="en-US">ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable" xlink:to="clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CommonStockWarrantsPolicyTextBlock_lbl1" xml:lang="en-US">CommonStockWarrantsPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsPolicyTextBlock" xlink:to="clnn_CommonStockWarrantsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ConvertibleNotesDisclosureTextBlock_lbl0" xml:lang="en-US">ConvertibleNotesDisclosureTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConvertibleNotesDisclosureTextBlock" xlink:to="clnn_ConvertibleNotesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DeferredTransactionsCostsInAccruedLiabilities_lbl1" xml:lang="en-US">DeferredTransactionsCostsInAccruedLiabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredTransactionsCostsInAccruedLiabilities" xlink:to="clnn_DeferredTransactionsCostsInAccruedLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted_lbl0" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ServicesLetterAgreementDescription_lbl0" xml:lang="en-US">ServicesLetterAgreementDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ServicesLetterAgreementDescription" xlink:to="clnn_ServicesLetterAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares_lbl0" xml:lang="en-US">SeriesARedeemableConvertiblePreferredStockWarrantsinShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares" xlink:to="clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ContingentEarnoutPolicyTextBlock_lbl1" xml:lang="en-US">ContingentEarnoutPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ContingentEarnoutPolicyTextBlock" xlink:to="clnn_ContingentEarnoutPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ExerciseOfSeriesCPreferredStockWarrant_lbl0" xml:lang="en-US">ExerciseOfSeriesCPreferredStockWarrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExerciseOfSeriesCPreferredStockWarrant" xlink:to="clnn_ExerciseOfSeriesCPreferredStockWarrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SaleOfStockholdersCommonStock_lbl0" xml:lang="en-US">SaleOfStockholdersCommonStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SaleOfStockholdersCommonStock" xlink:to="clnn_SaleOfStockholdersCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ResearchAndDevelopmentCreditExpiryTerm_lbl1" xml:lang="en-US">ResearchAndDevelopmentCreditExpiryTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ResearchAndDevelopmentCreditExpiryTerm" xlink:to="clnn_ResearchAndDevelopmentCreditExpiryTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm_lbl1" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SharesPerShare_lbl1" xml:lang="en-US">SharesPerShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharesPerShare" xlink:to="clnn_SharesPerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_StockPlan2020Member_lbl0" xml:lang="en-US">StockPlan2020Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockPlan2020Member" xlink:to="clnn_StockPlan2020Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DescriptionOfConvertibleNotes_lbl0" xml:lang="en-US">DescriptionOfConvertibleNotes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DescriptionOfConvertibleNotes" xlink:to="clnn_DescriptionOfConvertibleNotes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DeferredTaxLiabilitiesDeferredExpenseDepreciation_lbl1" xml:lang="en-US">DeferredTaxLiabilitiesDeferredExpenseDepreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredTaxLiabilitiesDeferredExpenseDepreciation" xlink:to="clnn_DeferredTaxLiabilitiesDeferredExpenseDepreciation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PreferredStockConvertibleConversionPrice_lbl1" xml:lang="en-US">PreferredStockConvertibleConversionPrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PreferredStockConvertibleConversionPrice" xlink:to="clnn_PreferredStockConvertibleConversionPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_UnrecognizedStockbasedCompensation_lbl0" xml:lang="en-US">UnrecognizedStockbasedCompensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_UnrecognizedStockbasedCompensation" xlink:to="clnn_UnrecognizedStockbasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PreferredStockWarrantsMember_lbl0" xml:lang="en-US">PreferredStockWarrantsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PreferredStockWarrantsMember" xlink:to="clnn_PreferredStockWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CleneNanomedicineContingentEarnout_lbl1" xml:lang="en-US">CleneNanomedicineContingentEarnout</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneNanomedicineContingentEarnout" xlink:to="clnn_CleneNanomedicineContingentEarnout_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_RestrictedStockUnitsDescription_lbl1" xml:lang="en-US">RestrictedStockUnitsDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RestrictedStockUnitsDescription" xlink:to="clnn_RestrictedStockUnitsDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_OperatingLossExpireTerm_lbl1" xml:lang="en-US">OperatingLossExpireTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OperatingLossExpireTerm" xlink:to="clnn_OperatingLossExpireTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DeferredTransactionCostsInAccountsPayable_lbl1" xml:lang="en-US">DeferredTransactionCostsInAccountsPayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredTransactionCostsInAccountsPayable" xlink:to="clnn_DeferredTransactionCostsInAccountsPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DerivativeInstrumentsOfComprehensiveLoss_lbl0" xml:lang="en-US">DerivativeInstrumentsOfComprehensiveLoss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DerivativeInstrumentsOfComprehensiveLoss" xlink:to="clnn_DerivativeInstrumentsOfComprehensiveLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NumberOfSharesIssuable_lbl1" xml:lang="en-US">NumberOfSharesIssuable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NumberOfSharesIssuable" xlink:to="clnn_NumberOfSharesIssuable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_GainOnForgivenessLoan_lbl0" xml:lang="en-US">GainOnForgivenessLoan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GainOnForgivenessLoan" xlink:to="clnn_GainOnForgivenessLoan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FinanceCashFlowsFromFinanceLeases_lbl0" xml:lang="en-US">FinanceCashFlowsFromFinanceLeases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceCashFlowsFromFinanceLeases" xlink:to="clnn_FinanceCashFlowsFromFinanceLeases_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NetOfIssuanceCosts_lbl1" xml:lang="en-US">NetOfIssuanceCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetOfIssuanceCosts" xlink:to="clnn_NetOfIssuanceCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementNumberOfOptionsExercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised" xlink:to="clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_IncreaseDecreaseInPayableToRelatedParties_lbl1" xml:lang="en-US">IncreaseDecreaseInPayableToRelatedParties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncreaseDecreaseInPayableToRelatedParties" xlink:to="clnn_IncreaseDecreaseInPayableToRelatedParties_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_EarnoutSharesDescription_lbl0" xml:lang="en-US">EarnoutSharesDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_EarnoutSharesDescription" xlink:to="clnn_EarnoutSharesDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DerivativeInstrumentMember_lbl0" xml:lang="en-US">DerivativeInstrumentMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DerivativeInstrumentMember" xlink:to="clnn_DerivativeInstrumentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_weightedAverageFairValuesOfOptionsGranted_lbl1" xml:lang="en-US">weightedAverageFairValuesOfOptionsGranted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_weightedAverageFairValuesOfOptionsGranted" xlink:to="clnn_weightedAverageFairValuesOfOptionsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DrugsMember_lbl0" xml:lang="en-US">DrugsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DrugsMember" xlink:to="clnn_DrugsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ClinicalTrialAccrualPolicyTextBlock_lbl1" xml:lang="en-US">ClinicalTrialAccrualPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ClinicalTrialAccrualPolicyTextBlock" xlink:to="clnn_ClinicalTrialAccrualPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NumeratorAbstract_lbl0" xml:lang="en-US">NumeratorAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NumeratorAbstract" xlink:to="clnn_NumeratorAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsExercised_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsExercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsExercised" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ProposedPublicOfferingCost_lbl1" xml:lang="en-US">ProposedPublicOfferingCost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ProposedPublicOfferingCost" xlink:to="clnn_ProposedPublicOfferingCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_OperatingCashFlowsFromOperatingLeases_lbl0" xml:lang="en-US">OperatingCashFlowsFromOperatingLeases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OperatingCashFlowsFromOperatingLeases" xlink:to="clnn_OperatingCashFlowsFromOperatingLeases_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PercentageOfStock_lbl0" xml:lang="en-US">PercentageOfStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PercentageOfStock" xlink:to="clnn_PercentageOfStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NetProceeds_lbl1" xml:lang="en-US">NetProceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetProceeds" xlink:to="clnn_NetProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization_lbl1" xml:lang="en-US">ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization" xlink:to="clnn_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SeriesCRedeemableConvertiblePreferredStock_lbl0" xml:lang="en-US">SeriesCRedeemableConvertiblePreferredStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SeriesCRedeemableConvertiblePreferredStock" xlink:to="clnn_SeriesCRedeemableConvertiblePreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_MergerAgreementPercentage_lbl1" xml:lang="en-US">MergerAgreementPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_MergerAgreementPercentage" xlink:to="clnn_MergerAgreementPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ChardanUnitPurchaseOptionWarrants_lbl1" xml:lang="en-US">ChardanUnitPurchaseOptionWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChardanUnitPurchaseOptionWarrants" xlink:to="clnn_ChardanUnitPurchaseOptionWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_StockIssuedDuringPeriodSharesPrivatePlacement_lbl1" xml:lang="en-US">StockIssuedDuringPeriodSharesPrivatePlacement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockIssuedDuringPeriodSharesPrivatePlacement" xlink:to="clnn_StockIssuedDuringPeriodSharesPrivatePlacement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PaymentsForAdvisoryServicesShares_lbl1" xml:lang="en-US">PaymentsForAdvisoryServicesShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PaymentsForAdvisoryServicesShares" xlink:to="clnn_PaymentsForAdvisoryServicesShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_WeightedAverageExercisePricePerShareOptionsVestedAndExercisableStockOptionsVest_lbl0" xml:lang="en-US">WeightedAverageExercisePricePerShareOptionsVestedAndExercisableStockOptionsVest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WeightedAverageExercisePricePerShareOptionsVestedAndExercisableStockOptionsVest" xlink:to="clnn_WeightedAverageExercisePricePerShareOptionsVestedAndExercisableStockOptionsVest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_IssuanceOfDerivativeInstrumentRelatedToConvertibleNotes_lbl0" xml:lang="en-US">IssuanceOfDerivativeInstrumentRelatedToConvertibleNotes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IssuanceOfDerivativeInstrumentRelatedToConvertibleNotes" xlink:to="clnn_IssuanceOfDerivativeInstrumentRelatedToConvertibleNotes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ConversionOfSecuredPromissoryNotes_lbl1" xml:lang="en-US">ConversionOfSecuredPromissoryNotes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConversionOfSecuredPromissoryNotes" xlink:to="clnn_ConversionOfSecuredPromissoryNotes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NumberOfSharesIssuableOnExerciseOfWarrants_lbl1" xml:lang="en-US">NumberOfSharesIssuableOnExerciseOfWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NumberOfSharesIssuableOnExerciseOfWarrants" xlink:to="clnn_NumberOfSharesIssuableOnExerciseOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_WarrantsToPurchasePreferredStock_lbl1" xml:lang="en-US">WarrantsToPurchasePreferredStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantsToPurchasePreferredStock" xlink:to="clnn_WarrantsToPurchasePreferredStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_RecognizedGainOnOperatingLease_lbl1" xml:lang="en-US">RecognizedGainOnOperatingLease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RecognizedGainOnOperatingLease" xlink:to="clnn_RecognizedGainOnOperatingLease_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ExtinguishmentOfDerivativeLiability_lbl1" xml:lang="en-US">ExtinguishmentOfDerivativeLiability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExtinguishmentOfDerivativeLiability" xlink:to="clnn_ExtinguishmentOfDerivativeLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ContingentEarnoutMember_lbl1" xml:lang="en-US">ContingentEarnoutMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ContingentEarnoutMember" xlink:to="clnn_ContingentEarnoutMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_RemainingRightofuseAsset_lbl0" xml:lang="en-US">RemainingRightofuseAsset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RemainingRightofuseAsset" xlink:to="clnn_RemainingRightofuseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_InitialShareholdersContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization_lbl1" xml:lang="en-US">InitialShareholdersContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialShareholdersContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization" xlink:to="clnn_InitialShareholdersContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DeferredTaxAssetsLiabilitiesAbstract_lbl0" xml:lang="en-US">DeferredTaxAssetsLiabilitiesAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredTaxAssetsLiabilitiesAbstract" xlink:to="clnn_DeferredTaxAssetsLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SeriesBRedeemableConvertiblePreferredStock_lbl0" xml:lang="en-US">SeriesBRedeemableConvertiblePreferredStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SeriesBRedeemableConvertiblePreferredStock" xlink:to="clnn_SeriesBRedeemableConvertiblePreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SupplementsMember_lbl0" xml:lang="en-US">SupplementsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SupplementsMember" xlink:to="clnn_SupplementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ExercisePrice_lbl0" xml:lang="en-US">ExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExercisePrice" xlink:to="clnn_ExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_OperatingLeasesMember_lbl0" xml:lang="en-US">OperatingLeasesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OperatingLeasesMember" xlink:to="clnn_OperatingLeasesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfDrugsAndSupplementsSegmentsTableTextBlock_lbl0" xml:lang="en-US">ScheduleOfDrugsAndSupplementsSegmentsTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfDrugsAndSupplementsSegmentsTableTextBlock" xlink:to="clnn_ScheduleOfDrugsAndSupplementsSegmentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PreferredStockWarrantsOutstandingShares_lbl1" xml:lang="en-US">PreferredStockWarrantsOutstandingShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PreferredStockWarrantsOutstandingShares" xlink:to="clnn_PreferredStockWarrantsOutstandingShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_TwoThousandNineteenCecilLoanMember_lbl0" xml:lang="en-US">TwoThousandNineteenCecilLoanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TwoThousandNineteenCecilLoanMember" xlink:to="clnn_TwoThousandNineteenCecilLoanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection_lbl0" xml:lang="en-US">ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection" xlink:to="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_InstrinsicValueOptionsVestedAndExercisableStockOptionsVestedAndExpectedToVestEnding_lbl0" xml:lang="en-US">InstrinsicValueOptionsVestedAndExercisableStockOptionsVestedAndExpectedToVestEnding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InstrinsicValueOptionsVestedAndExercisableStockOptionsVestedAndExpectedToVestEnding" xlink:to="clnn_InstrinsicValueOptionsVestedAndExercisableStockOptionsVestedAndExpectedToVestEnding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_AcquisitionOfRightofuseAssetsAndLeaseholdImprovementsThroughOperatingLease_lbl0" xml:lang="en-US">AcquisitionOfRightofuseAssetsAndLeaseholdImprovementsThroughOperatingLease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AcquisitionOfRightofuseAssetsAndLeaseholdImprovementsThroughOperatingLease" xlink:to="clnn_AcquisitionOfRightofuseAssetsAndLeaseholdImprovementsThroughOperatingLease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ChardanUnitPurchaseOptionToPurchaseCommonStock_lbl1" xml:lang="en-US">ChardanUnitPurchaseOptionToPurchaseCommonStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChardanUnitPurchaseOptionToPurchaseCommonStock" xlink:to="clnn_ChardanUnitPurchaseOptionToPurchaseCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_IncreseDecreaseInFairValue_lbl1" xml:lang="en-US">IncreseDecreaseInFairValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncreseDecreaseInFairValue" xlink:to="clnn_IncreseDecreaseInFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_RetainedEarningsAccumulatedDeficit1_lbl1" xml:lang="en-US">RetainedEarningsAccumulatedDeficit1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RetainedEarningsAccumulatedDeficit1" xlink:to="clnn_RetainedEarningsAccumulatedDeficit1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ContingentEarnoutRecognizedConnectionWithTheReverseRecapitalization_lbl1" xml:lang="en-US">ContingentEarnoutRecognizedConnectionWithTheReverseRecapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ContingentEarnoutRecognizedConnectionWithTheReverseRecapitalization" xlink:to="clnn_ContingentEarnoutRecognizedConnectionWithTheReverseRecapitalization_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ForeignCurrencyTranslationAdjustment_lbl0" xml:lang="en-US">ForeignCurrencyTranslationAdjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ForeignCurrencyTranslationAdjustment" xlink:to="clnn_ForeignCurrencyTranslationAdjustment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_IssuanceOfCommonStockUponReverseRecapitalization_lbl1" xml:lang="en-US">IssuanceOfCommonStockUponReverseRecapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IssuanceOfCommonStockUponReverseRecapitalization" xlink:to="clnn_IssuanceOfCommonStockUponReverseRecapitalization_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CommonSharesAuthorized_lbl0" xml:lang="en-US">CommonSharesAuthorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonSharesAuthorized" xlink:to="clnn_CommonSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CostsOfRevenue_lbl1" xml:lang="en-US">CostsOfRevenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CostsOfRevenue" xlink:to="clnn_CostsOfRevenue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PurchaseOption_lbl1" xml:lang="en-US">PurchaseOption</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PurchaseOption" xlink:to="clnn_PurchaseOption_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_RemainingBalanceOfOperatingLoss_lbl1" xml:lang="en-US">RemainingBalanceOfOperatingLoss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RemainingBalanceOfOperatingLoss" xlink:to="clnn_RemainingBalanceOfOperatingLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CommonStockWarrantsDisclosureTextBlock_lbl1" xml:lang="en-US">CommonStockWarrantsDisclosureTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsDisclosureTextBlock" xlink:to="clnn_CommonStockWarrantsDisclosureTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FinanceLeaseLiabilityNet_lbl1" xml:lang="en-US">FinanceLeaseLiabilityNet</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeaseLiabilityNet" xlink:to="clnn_FinanceLeaseLiabilityNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FinanceLeaseObligationsWeightedaverageInterestRate_lbl1" xml:lang="en-US">FinanceLeaseObligationsWeightedaverageInterestRate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeaseObligationsWeightedaverageInterestRate" xlink:to="clnn_FinanceLeaseObligationsWeightedaverageInterestRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ExerciseOfSeriesCPreferredStockWarrants_lbl1" xml:lang="en-US">ExerciseOfSeriesCPreferredStockWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExerciseOfSeriesCPreferredStockWarrants" xlink:to="clnn_ExerciseOfSeriesCPreferredStockWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FinanceLeasesMember_lbl0" xml:lang="en-US">FinanceLeasesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeasesMember" xlink:to="clnn_FinanceLeasesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_InvestorsPurchasedShares_lbl1" xml:lang="en-US">InvestorsPurchasedShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InvestorsPurchasedShares" xlink:to="clnn_InvestorsPurchasedShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_TwoThousandNineteenMDLoanMember_lbl0" xml:lang="en-US">TwoThousandNineteenMDLoanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TwoThousandNineteenMDLoanMember" xlink:to="clnn_TwoThousandNineteenMDLoanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CurrentTaxExpenseAbstract_lbl0" xml:lang="en-US">CurrentTaxExpenseAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CurrentTaxExpenseAbstract" xlink:to="clnn_CurrentTaxExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemableConvertibleSreferredStock_lbl1" xml:lang="en-US">ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemableConvertibleSreferredStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemableConvertibleSreferredStock" xlink:to="clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemableConvertibleSreferredStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FairValueIssuanceOfConvertiblePromissoryNotes_lbl1" xml:lang="en-US">FairValueIssuanceOfConvertiblePromissoryNotes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueIssuanceOfConvertiblePromissoryNotes" xlink:to="clnn_FairValueIssuanceOfConvertiblePromissoryNotes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_MinimumFairMarketValueOfOptionGrantDescription_lbl1" xml:lang="en-US">MinimumFairMarketValueOfOptionGrantDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_MinimumFairMarketValueOfOptionGrantDescription" xlink:to="clnn_MinimumFairMarketValueOfOptionGrantDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_December20201Member_lbl0" xml:lang="en-US">December20201Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_December20201Member" xlink:to="clnn_December20201Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerms_lbl1" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerms" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerms_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ChardanMember_lbl0" xml:lang="en-US">ChardanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChardanMember" xlink:to="clnn_ChardanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ContingentEarnoutNetOfCurrentPortion_lbl0" xml:lang="en-US">ContingentEarnoutNetOfCurrentPortion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ContingentEarnoutNetOfCurrentPortion" xlink:to="clnn_ContingentEarnoutNetOfCurrentPortion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock_lbl0" xml:lang="en-US">ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock" xlink:to="clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_LifeSciCapitalLLCMember_lbl0" xml:lang="en-US">LifeSciCapitalLLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LifeSciCapitalLLCMember" xlink:to="clnn_LifeSciCapitalLLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_RecapitalizationShare_lbl0" xml:lang="en-US">RecapitalizationShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RecapitalizationShare" xlink:to="clnn_RecapitalizationShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_TemporaryEquitySharesIssuedAndOutstanding_lbl1" xml:lang="en-US">TemporaryEquitySharesIssuedAndOutstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TemporaryEquitySharesIssuedAndOutstanding" xlink:to="clnn_TemporaryEquitySharesIssuedAndOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ApplicationOfASC842_lbl0" xml:lang="en-US">ApplicationOfASC842</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ApplicationOfASC842" xlink:to="clnn_ApplicationOfASC842_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PropertyPlantAndEquipmentOneTextBlock_lbl1" xml:lang="en-US">PropertyPlantAndEquipmentOneTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PropertyPlantAndEquipmentOneTextBlock" xlink:to="clnn_PropertyPlantAndEquipmentOneTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PaycheckProtectionProgramLoan_lbl0" xml:lang="en-US">PaycheckProtectionProgramLoan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PaycheckProtectionProgramLoan" xlink:to="clnn_PaycheckProtectionProgramLoan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ChangeInFairValueOfPreferredStockWarrantLiability_lbl0" xml:lang="en-US">ChangeInFairValueOfPreferredStockWarrantLiability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangeInFairValueOfPreferredStockWarrantLiability" xlink:to="clnn_ChangeInFairValueOfPreferredStockWarrantLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PerShareUnit_lbl1" xml:lang="en-US">PerShareUnit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PerShareUnit" xlink:to="clnn_PerShareUnit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_WarrantLiabilitySettledOnExercise_lbl0" xml:lang="en-US">WarrantLiabilitySettledOnExercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantLiabilitySettledOnExercise" xlink:to="clnn_WarrantLiabilitySettledOnExercise_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodIntrinsicValue_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodIntrinsicValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodIntrinsicValue" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_RedeemableConvertiblePreferredStockWarrantLiability_lbl0" xml:lang="en-US">RedeemableConvertiblePreferredStockWarrantLiability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RedeemableConvertiblePreferredStockWarrantLiability" xlink:to="clnn_RedeemableConvertiblePreferredStockWarrantLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes_lbl1" xml:lang="en-US">IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes" xlink:to="clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DeferredTaxAssetsTaxDeferredNonqualifiedStockOptions_lbl1" xml:lang="en-US">DeferredTaxAssetsTaxDeferredNonqualifiedStockOptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredTaxAssetsTaxDeferredNonqualifiedStockOptions" xlink:to="clnn_DeferredTaxAssetsTaxDeferredNonqualifiedStockOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis_lbl0" xml:lang="en-US">IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis" xlink:to="clnn_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DescriptionOfOperatingLease_lbl0" xml:lang="en-US">DescriptionOfOperatingLease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DescriptionOfOperatingLease" xlink:to="clnn_DescriptionOfOperatingLease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_AccruedTransactionCosts_lbl1" xml:lang="en-US">AccruedTransactionCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AccruedTransactionCosts" xlink:to="clnn_AccruedTransactionCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_RiskAndUncertaintiesPolicyTextBlock_lbl1" xml:lang="en-US">RiskAndUncertaintiesPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RiskAndUncertaintiesPolicyTextBlock" xlink:to="clnn_RiskAndUncertaintiesPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_LeaseLiabilitySettledThroughTerminationOfLease_lbl0" xml:lang="en-US">LeaseLiabilitySettledThroughTerminationOfLease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LeaseLiabilitySettledThroughTerminationOfLease" xlink:to="clnn_LeaseLiabilitySettledThroughTerminationOfLease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CommonStockWarrantsClassification_lbl0" xml:lang="en-US">CommonStockWarrantsClassification</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsClassification" xlink:to="clnn_CommonStockWarrantsClassification_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SeriesCRedeemableConvertiblePreferredStockWarrantsinShares_lbl0" xml:lang="en-US">SeriesCRedeemableConvertiblePreferredStockWarrantsinShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SeriesCRedeemableConvertiblePreferredStockWarrantsinShares" xlink:to="clnn_SeriesCRedeemableConvertiblePreferredStockWarrantsinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DeferredTaxAssetsRightofUseAsset_lbl1" xml:lang="en-US">DeferredTaxAssetsRightofUseAsset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredTaxAssetsRightofUseAsset" xlink:to="clnn_DeferredTaxAssetsRightofUseAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FoundationGrantCost_lbl0" xml:lang="en-US">FoundationGrantCost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FoundationGrantCost" xlink:to="clnn_FoundationGrantCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts_lbl1" xml:lang="en-US">IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts" xlink:to="clnn_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DeferredGrantFunds_lbl1" xml:lang="en-US">DeferredGrantFunds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredGrantFunds" xlink:to="clnn_DeferredGrantFunds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_WarrantsDate2Member_lbl0" xml:lang="en-US">WarrantsDate2Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantsDate2Member" xlink:to="clnn_WarrantsDate2Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_GrantFundingMember_lbl0" xml:lang="en-US">GrantFundingMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GrantFundingMember" xlink:to="clnn_GrantFundingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock_lbl0" xml:lang="en-US">ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock" xlink:to="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SeriesARedeemableConvertiblePreferredStock_lbl0" xml:lang="en-US">SeriesARedeemableConvertiblePreferredStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SeriesARedeemableConvertiblePreferredStock" xlink:to="clnn_SeriesARedeemableConvertiblePreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CommonStockWarrantsExercisable_lbl0" xml:lang="en-US">CommonStockWarrantsExercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsExercisable" xlink:to="clnn_CommonStockWarrantsExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_IncomeTaxReconciliationNondeductibleExpensesResearchAndDevelopment_lbl1" xml:lang="en-US">IncomeTaxReconciliationNondeductibleExpensesResearchAndDevelopment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncomeTaxReconciliationNondeductibleExpensesResearchAndDevelopment" xlink:to="clnn_IncomeTaxReconciliationNondeductibleExpensesResearchAndDevelopment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PreferredStockWarrantMember_lbl0" xml:lang="en-US">PreferredStockWarrantMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PreferredStockWarrantMember" xlink:to="clnn_PreferredStockWarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CashConsiderationReceived_lbl1" xml:lang="en-US">CashConsiderationReceived</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CashConsiderationReceived" xlink:to="clnn_CashConsiderationReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe_lbl0" xml:lang="en-US">ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe" xlink:to="clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_TemporaryEquitySharesCommonStockIssuableUponConversion_lbl1" xml:lang="en-US">TemporaryEquitySharesCommonStockIssuableUponConversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TemporaryEquitySharesCommonStockIssuableUponConversion" xlink:to="clnn_TemporaryEquitySharesCommonStockIssuableUponConversion_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NetIssuanceCosts_lbl1" xml:lang="en-US">NetIssuanceCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetIssuanceCosts" xlink:to="clnn_NetIssuanceCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FairValueOfIssuanceOfNotesPayable_lbl1" xml:lang="en-US">FairValueOfIssuanceOfNotesPayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueOfIssuanceOfNotesPayable" xlink:to="clnn_FairValueOfIssuanceOfNotesPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_InitialShareholdersContingentEarnout_lbl1" xml:lang="en-US">InitialShareholdersContingentEarnout</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialShareholdersContingentEarnout" xlink:to="clnn_InitialShareholdersContingentEarnout_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_WarrantsDate1Member_lbl0" xml:lang="en-US">WarrantsDate1Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantsDate1Member" xlink:to="clnn_WarrantsDate1Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ChangeInFairValueOfContingentEarnout_lbl2" xml:lang="en-US">ChangeInFairValueOfContingentEarnout</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangeInFairValueOfContingentEarnout" xlink:to="clnn_ChangeInFairValueOfContingentEarnout_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ProceedsFromReverseRecapitalizationNet_lbl1" xml:lang="en-US">ProceedsFromReverseRecapitalizationNet</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ProceedsFromReverseRecapitalizationNet" xlink:to="clnn_ProceedsFromReverseRecapitalizationNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants_lbl1" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PreferredStockShares_lbl1" xml:lang="en-US">PreferredStockShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PreferredStockShares" xlink:to="clnn_PreferredStockShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts_lbl0" xml:lang="en-US">IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts" xlink:to="clnn_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_WarrantsSharesInExercise_lbl1" xml:lang="en-US">WarrantsSharesInExercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantsSharesInExercise" xlink:to="clnn_WarrantsSharesInExercise_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_InstrinsicValueOptionsVestedAndExercisableEnding_lbl0" xml:lang="en-US">InstrinsicValueOptionsVestedAndExercisableEnding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InstrinsicValueOptionsVestedAndExercisableEnding" xlink:to="clnn_InstrinsicValueOptionsVestedAndExercisableEnding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl1" xml:lang="en-US">NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:to="clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsForfeited_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsForfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsForfeited" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsForfeited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_WeightedAverageRemainingTermOptionsVestedAndExercisableStockOptionsVestedAndExercisable_lbl0" xml:lang="en-US">WeightedAverageRemainingTermOptionsVestedAndExercisableStockOptionsVestedAndExercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WeightedAverageRemainingTermOptionsVestedAndExercisableStockOptionsVestedAndExercisable" xlink:to="clnn_WeightedAverageRemainingTermOptionsVestedAndExercisableStockOptionsVestedAndExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl1" xml:lang="en-US">PrepaidExpensesAndOtherCurrentAssetsTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_WarrantExercisePrice_lbl1" xml:lang="en-US">WarrantExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantExercisePrice" xlink:to="clnn_WarrantExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_OptionsToPurchaseCommonStockinShares_lbl0" xml:lang="en-US">OptionsToPurchaseCommonStockinShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OptionsToPurchaseCommonStockinShares" xlink:to="clnn_OptionsToPurchaseCommonStockinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_IncomeTaxReconciliationWarrantLiability_lbl1" xml:lang="en-US">IncomeTaxReconciliationWarrantLiability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncomeTaxReconciliationWarrantLiability" xlink:to="clnn_IncomeTaxReconciliationWarrantLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DenominatorAbstract_lbl0" xml:lang="en-US">DenominatorAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DenominatorAbstract" xlink:to="clnn_DenominatorAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_WorkInProcessMember_lbl0" xml:lang="en-US">WorkInProcessMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WorkInProcessMember" xlink:to="clnn_WorkInProcessMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_IssuanceOfSeriesDPreferredStockInConnectionExtinguishmentOfConvertiblePromis_lbl0" xml:lang="en-US">IssuanceOfSeriesDPreferredStockInConnectionExtinguishmentOfConvertiblePromis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IssuanceOfSeriesDPreferredStockInConnectionExtinguishmentOfConvertiblePromis" xlink:to="clnn_IssuanceOfSeriesDPreferredStockInConnectionExtinguishmentOfConvertiblePromis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_InitialFairValueOfInstrument_lbl1" xml:lang="en-US">InitialFairValueOfInstrument</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialFairValueOfInstrument" xlink:to="clnn_InitialFairValueOfInstrument_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_TottenhamMember_lbl0" xml:lang="en-US">TottenhamMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TottenhamMember" xlink:to="clnn_TottenhamMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_AustraliaResearchAndDevelopmentCredit_lbl0" xml:lang="en-US">AustraliaResearchAndDevelopmentCredit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AustraliaResearchAndDevelopmentCredit" xlink:to="clnn_AustraliaResearchAndDevelopmentCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CleneNanomedicineMember_lbl0" xml:lang="en-US">CleneNanomedicineMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneNanomedicineMember" xlink:to="clnn_CleneNanomedicineMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_AccruedCROFees_lbl1" xml:lang="en-US">AccruedCROFees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AccruedCROFees" xlink:to="clnn_AccruedCROFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CROPrepayments_lbl0" xml:lang="en-US">CROPrepayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CROPrepayments" xlink:to="clnn_CROPrepayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_IssuanceOfCommonStockPaymentOfRelatedOfferingCosts_lbl0" xml:lang="en-US">IssuanceOfCommonStockPaymentOfRelatedOfferingCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IssuanceOfCommonStockPaymentOfRelatedOfferingCosts" xlink:to="clnn_IssuanceOfCommonStockPaymentOfRelatedOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl0" xml:lang="en-US">Investor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl0" xml:lang="en-US">Warrant, Exercise Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl1" xml:lang="en-US">Temporary Equity, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl0" xml:lang="en-US">Debt Conversion, Converted Instrument, Warrants or Options Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl1" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyMember_lbl0" xml:lang="en-US">Royalty [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Income Tax Liabilities, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfMediumTermNotes_lbl0" xml:lang="en-US">Proceeds from Issuance of Medium-term Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:to="us-gaap_ProceedsFromIssuanceOfMediumTermNotes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl0" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl0" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockTextBlock_lbl0" xml:lang="en-US">Preferred Stock [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl0" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl0" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Two Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl0" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableToBank_lbl0" xml:lang="en-US">Notes Payable to Bank</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableToBank" xlink:to="us-gaap_NotesPayableToBank_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl0" xml:lang="en-US">Accounts Payable, Related Parties, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Inventory, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl0" xml:lang="en-US">Board of Directors Chairman [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl0" xml:lang="en-US">Line of Credit Facility, Interest Rate During Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl0" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees_lbl0" xml:lang="en-US">Warrant or Right, Reason for Issuance, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:to="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl0" xml:lang="en-US">Capital Lease Obligations, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl0" xml:lang="en-US">Property, Plant and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate During Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl1" xml:lang="en-US">Convertible Notes Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl0" xml:lang="en-US">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl2" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtCurrent_lbl0" xml:lang="en-US">Long-term Debt, Current Maturities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Redeemable Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl0" xml:lang="en-US">Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl1" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl0" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl2" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl1" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl0" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl0" xml:lang="en-US">Finance Lease, Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl0" xml:lang="en-US">Repayments of Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl0" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl1" xml:lang="en-US">Series C Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl0" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl0" xml:lang="en-US">Other Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl1" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl0" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl0" xml:lang="en-US">Finance Lease, Principal Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl0" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl0" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_lbl0" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Five Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl0" xml:lang="en-US">Series B Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl1" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl0" xml:lang="en-US">Leasehold Improvements, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl1" xml:lang="en-US">Temporary Equity, Liquidation Preference</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl0" xml:lang="en-US">Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract_lbl0" xml:lang="en-US">Finance Lease Liability [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_lbl0" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl0" xml:lang="en-US">Warrants and Rights Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl0" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl2" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl0" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl0" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl0" xml:lang="en-US">Debt Instrument, Unamortized Discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl0" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="exch_PIPE_lbl0" xml:lang="en-US">ARITAS SECURITIES LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="exch_PIPE" xlink:to="exch_PIPE_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl0" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accrued Salaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedSalariesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts_lbl0" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives and Commodity Contracts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts" xlink:to="us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnContractTermination_lbl0" xml:lang="en-US">Gain (Loss) on Contract Termination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnContractTermination" xlink:to="us-gaap_GainLossOnContractTermination_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl0" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl2" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_lbl0" xml:lang="en-US">Related Party Transaction, Other Revenues from Transactions with Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl0" xml:lang="en-US">Inventory, Finished Goods, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl0" xml:lang="en-US">Other Operating Income (Expense), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0" xml:lang="en-US">Schedule of Stockholders&apos; Equity Note, Warrants or Rights [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl0" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl1" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RedeemablePreferredStockMember_lbl0" xml:lang="en-US">Redeemable Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemablePreferredStockMember" xlink:to="us-gaap_RedeemablePreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl0" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl0" xml:lang="en-US">Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CumulativeEarningsDeficit_lbl0" xml:lang="en-US">Cumulative Earnings (Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CumulativeEarningsDeficit" xlink:to="us-gaap_CumulativeEarningsDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl0" xml:lang="en-US">Conversion of Stock, Amount Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockDescription_lbl0" xml:lang="en-US">Conversion of Stock, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockDescription" xlink:to="us-gaap_ConversionOfStockDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accounts Payable, Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Finance Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl0" xml:lang="en-US">Accrued Salaries, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl0" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl0" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Three Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl0" xml:lang="en-US">UNITED STATES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl0" xml:lang="en-US">Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl0" xml:lang="en-US">Prepaid Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl0" xml:lang="en-US">Domestic Tax Authority [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl0" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl0" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl1" xml:lang="en-US">Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl1" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_lbl0" xml:lang="en-US">Line of Credit Facility, Fair Value of Amount Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:to="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl0" xml:lang="en-US">Capital Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl0" xml:lang="en-US">Accrued Employee Benefits, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl1" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescription_lbl0" xml:lang="en-US">Debt Instrument, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl0" xml:lang="en-US">Operating Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering_lbl0" xml:lang="en-US">Partners&apos; Capital Account, Units, Sold in Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering" xlink:to="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl0" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease_lbl0" xml:lang="en-US">Common Stock, Convertible, Conversion Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:to="us-gaap_CommonStockConvertibleConversionPriceIncrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl1" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentExpense_lbl0" xml:lang="en-US">Equipment Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentExpense" xlink:to="us-gaap_EquipmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl0" xml:lang="en-US">Long-term Line of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl0" xml:lang="en-US">Other Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesAndLoansPayable_lbl0" xml:lang="en-US">Notes and Loans Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansPayable" xlink:to="us-gaap_NotesAndLoansPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_lbl0" xml:lang="en-US">Long-lived Assets by Geographic Areas [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl0" xml:lang="en-US">Fair Value of Assets Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfAssetsAcquired" xlink:to="us-gaap_FairValueOfAssetsAcquired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossRecognizedOnAssetsTransferredToSeparateAccountGross_lbl0" xml:lang="en-US">Loss Recognized on Assets Transferred to Separate Account, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossRecognizedOnAssetsTransferredToSeparateAccountGross" xlink:to="us-gaap_LossRecognizedOnAssetsTransferredToSeparateAccountGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl0" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl0" xml:lang="en-US">Related Party Transaction, Description of Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GuarantyLiabilities_lbl0" xml:lang="en-US">Guaranty Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuarantyLiabilities" xlink:to="us-gaap_GuarantyLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl1" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl0" xml:lang="en-US">Proceeds from Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPreferredUnitsTextBlock_lbl0" xml:lang="en-US">Schedule of Preferred Units [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPreferredUnitsTextBlock" xlink:to="us-gaap_ScheduleOfPreferredUnitsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl0" xml:lang="en-US">Leases of Lessee Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExchangeClearedMember_lbl0" xml:lang="en-US">Exchange Cleared [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExchangeClearedMember" xlink:to="us-gaap_ExchangeClearedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet_lbl0" xml:lang="en-US">Derivative, Fair Value, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeNet" xlink:to="us-gaap_DerivativeFairValueOfDerivativeNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl0" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl2" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl0" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl0" xml:lang="en-US">Redeemable Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl0" xml:lang="en-US">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl0" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherUnderwritingExpense_lbl0" xml:lang="en-US">Other Underwriting Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherUnderwritingExpense" xlink:to="us-gaap_OtherUnderwritingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConversionBasis_lbl0" xml:lang="en-US">Preferred Stock, Conversion Basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConversionBasis" xlink:to="us-gaap_PreferredStockConversionBasis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl0" xml:lang="en-US">Variable Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl0" xml:lang="en-US">Deferred Tax Assets, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReportingUnitAmountOfFairValueInExcessOfCarryingAmount_lbl0" xml:lang="en-US">Reporting Unit, Amount of Fair Value in Excess of Carrying Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReportingUnitAmountOfFairValueInExcessOfCarryingAmount" xlink:to="us-gaap_ReportingUnitAmountOfFairValueInExcessOfCarryingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl0" xml:lang="en-US">Temporary Equity, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl0" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl0" xml:lang="en-US">Convertible Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl2" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Finance Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNet_lbl0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl0" xml:lang="en-US">Inventory, Raw Materials, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_lbl0" xml:lang="en-US">Capital Leases, Future Minimum Payments Due Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl0" xml:lang="en-US">Warrant, Exercise Price, Decrease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl0" xml:lang="en-US">Notes Payable, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl1" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_lbl0" xml:lang="en-US">Expense Related to Distribution or Servicing and Underwriting Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:to="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl0" xml:lang="en-US">Deferred Revenue, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock_lbl0" xml:lang="en-US">Shares Subject to Mandatory Redemption, Changes in Redemption Value, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl0" xml:lang="en-US">Revenues [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl0" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_AU_lbl0" xml:lang="en-US">AUSTRALIA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_AU" xlink:to="country_AU_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventDescription_lbl0" xml:lang="en-US">Subsequent Event, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventDescription" xlink:to="us-gaap_SubsequentEventDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableOtherPayablesMember_lbl0" xml:lang="en-US">Notes Payable, Other Payables [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableOtherPayablesMember" xlink:to="us-gaap_NotesPayableOtherPayablesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl0" xml:lang="en-US">Number of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl2" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl1" xml:lang="en-US">Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl0" xml:lang="en-US">Product [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl0" xml:lang="en-US">Series D Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod_lbl0" xml:lang="en-US">Line of Credit Facility, Expiration Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:to="us-gaap_LineOfCreditFacilityExpirationPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl0" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl0" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_lbl0" xml:lang="en-US">Long-term Debt and Lease Obligation, Including Current Maturities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableFairValueDisclosure_lbl0" xml:lang="en-US">Notes Payable, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableFairValueDisclosure" xlink:to="us-gaap_NotesPayableFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl0" xml:lang="en-US">Gain (Loss) on Termination of Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnTerminationOfLease" xlink:to="us-gaap_GainLossOnTerminationOfLease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl1" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl0" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Other Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherSharesOutstanding" xlink:to="us-gaap_CommonStockOtherSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_lbl0" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Four Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl0" xml:lang="en-US">Taxes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl2" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressGross_lbl0" xml:lang="en-US">Construction in Progress, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressGross" xlink:to="us-gaap_ConstructionInProgressGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl0" xml:lang="en-US">Temporary Equity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityTableTextBlock" xlink:to="us-gaap_TemporaryEquityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl1" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl0" xml:lang="en-US">Capital Leases, Future Minimum Payments, Interest Included in Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl0" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl2" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl0" xml:lang="en-US">Short-term Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl0" xml:lang="en-US">Furniture and Fixtures, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl1" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl0" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>clnn-20201231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Mar 26 16:52:33 EDT 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ConsolidatedBalanceSheet" roleURI="http://www.cleaninccom/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.cleaninccom/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ConsolidatedIncomeStatement" roleURI="http://www.cleaninccom/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ShareholdersEquityType2or3" roleURI="http://www.cleaninccom/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ShareholdersEquityType2or3_Parentheticals" roleURI="http://www.cleaninccom/role/ShareholdersEquityType2or3_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ConsolidatedCashFlow" roleURI="http://www.cleaninccom/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_NatureoftheBusinessandBasisofPresentation" roleURI="http://www.cleaninccom/role/NatureoftheBusinessandBasisofPresentation"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.cleaninccom/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ReverseRecapitalizationwithTottenhamandCleneNanomedicine" roleURI="http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicine"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_Prepaidexpensesandothercurrentassets" roleURI="http://www.cleaninccom/role/Prepaidexpensesandothercurrentassets"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_PropertyandEquipmentNet" roleURI="http://www.cleaninccom/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_AccruedLiabilities" roleURI="http://www.cleaninccom/role/AccruedLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_Leases" roleURI="http://www.cleaninccom/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_NotesPayable" roleURI="http://www.cleaninccom/role/NotesPayable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_PreferredStockWarrantLiability" roleURI="http://www.cleaninccom/role/PreferredStockWarrantLiability"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_CommonStockWarrants" roleURI="http://www.cleaninccom/role/CommonStockWarrants"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ConvertibleNotes" roleURI="http://www.cleaninccom/role/ConvertibleNotes"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_DerivativeInstruments" roleURI="http://www.cleaninccom/role/DerivativeInstruments"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_CommitmentsandContingencies" roleURI="http://www.cleaninccom/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_IncomeTaxes" roleURI="http://www.cleaninccom/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_StockBasedCompensation" roleURI="http://www.cleaninccom/role/StockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_FairValue" roleURI="http://www.cleaninccom/role/FairValue"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_RedeemableConvertiblePreferredStock" roleURI="http://www.cleaninccom/role/RedeemableConvertiblePreferredStock"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_CommonStock" roleURI="http://www.cleaninccom/role/CommonStock"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_NetLossPerShareAttributabletoCommonShareholders" roleURI="http://www.cleaninccom/role/NetLossPerShareAttributabletoCommonShareholders"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_RelatedPartyTransactions" roleURI="http://www.cleaninccom/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_GeographicandSegmentInformation" roleURI="http://www.cleaninccom/role/GeographicandSegmentInformation"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_SubsequentEvents" roleURI="http://www.cleaninccom/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_AccountingPoliciesByPolicy" roleURI="http://www.cleaninccom/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_PrepaidexpensesandothercurrentassetsTables" roleURI="http://www.cleaninccom/role/PrepaidexpensesandothercurrentassetsTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_PropertyandEquipmentNetTables" roleURI="http://www.cleaninccom/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_AccruedLiabilitiesTables" roleURI="http://www.cleaninccom/role/AccruedLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_LeasesTables" roleURI="http://www.cleaninccom/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_PreferredStockWarrantLiabilityTables" roleURI="http://www.cleaninccom/role/PreferredStockWarrantLiabilityTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_CommonStockWarrantsTables" roleURI="http://www.cleaninccom/role/CommonStockWarrantsTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_IncomeTaxesTables" roleURI="http://www.cleaninccom/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_StockBasedCompensationTables" roleURI="http://www.cleaninccom/role/StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_FairValueTables" roleURI="http://www.cleaninccom/role/FairValueTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_RedeemableConvertiblePreferredStockTables" roleURI="http://www.cleaninccom/role/RedeemableConvertiblePreferredStockTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_NetLossPerShareAttributabletoCommonShareholdersTables" roleURI="http://www.cleaninccom/role/NetLossPerShareAttributabletoCommonShareholdersTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_GeographicandSegmentInformationTables" roleURI="http://www.cleaninccom/role/GeographicandSegmentInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofprepaidexpensesandothercurrentassetsTable" roleURI="http://www.cleaninccom/role/ScheduleofprepaidexpensesandothercurrentassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofpropertyandequipmentnetTable" roleURI="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofaccruedliabilitiesTable" roleURI="http://www.cleaninccom/role/ScheduleofaccruedliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofnoncancelableoperatingleasearrangementsTable" roleURI="http://www.cleaninccom/role/ScheduleofnoncancelableoperatingleasearrangementsTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleoffinanceleaseobligationsandincludedpropertyandequipmentTable" roleURI="http://www.cleaninccom/role/ScheduleoffinanceleaseobligationsandincludedpropertyandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleoffinanceandoperatingleasecostsTable" roleURI="http://www.cleaninccom/role/ScheduleoffinanceandoperatingleasecostsTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofsupplementalcashflowinformationTable" roleURI="http://www.cleaninccom/role/ScheduleofsupplementalcashflowinformationTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_SchedulefairvalueoftheoutstandingwarrantsTable" roleURI="http://www.cleaninccom/role/SchedulefairvalueoftheoutstandingwarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable" roleURI="http://www.cleaninccom/role/ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofcomponentsofincomelossbeforeincometaxesTable" roleURI="http://www.cleaninccom/role/ScheduleofcomponentsofincomelossbeforeincometaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofincometaxexpensebenefitTable" roleURI="http://www.cleaninccom/role/ScheduleofincometaxexpensebenefitTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofincometaxreconciliationTable" roleURI="http://www.cleaninccom/role/ScheduleofincometaxreconciliationTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofdeferredtaxassetsandliabilitiesTable" roleURI="http://www.cleaninccom/role/ScheduleofdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofstockbasedcompensationexpenseTable" roleURI="http://www.cleaninccom/role/ScheduleofstockbasedcompensationexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable" roleURI="http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleoffairvalueofthesestockoptionsawardsgrantedTable" roleURI="http://www.cleaninccom/role/ScheduleoffairvalueofthesestockoptionsawardsgrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofrestrictedcommonstockactivityTable" roleURI="http://www.cleaninccom/role/ScheduleofrestrictedcommonstockactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable" roleURI="http://www.cleaninccom/role/ScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleoffairvalueoftheinitialcontingentearnoutTable" roleURI="http://www.cleaninccom/role/ScheduleoffairvalueoftheinitialcontingentearnoutTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleoffinancialliabilityrelatedtothenotespayablethederivativeinstrumentthePreferredStockwarrantsandthecontingentearnoutmeasuredatfairvalueTable" roleURI="http://www.cleaninccom/role/ScheduleoffinancialliabilityrelatedtothenotespayablethederivativeinstrumentthePreferredStockwarrantsandthecontingentearnoutmeasuredatfairvalueTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofPreferredStockTable" roleURI="http://www.cleaninccom/role/ScheduleofPreferredStockTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofbasicanddilutednetlosspershareTable" roleURI="http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofdilutivesecuritieswereexcludedfromthecomputationofdilutednetlosspershareTable" roleURI="http://www.cleaninccom/role/ScheduleofdilutivesecuritieswereexcludedfromthecomputationofdilutednetlosspershareTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofpropertyandequipmentnetbylocationTable" roleURI="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbylocationTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofdrugsandsupplementssegmentsTable" roleURI="http://www.cleaninccom/role/ScheduleofdrugsandsupplementssegmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ScheduleofpropertyandequipmentnetbysegmentTable" roleURI="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbysegmentTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_NatureoftheBusinessandBasisofPresentationDetails" roleURI="http://www.cleaninccom/role/NatureoftheBusinessandBasisofPresentationDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails" roleURI="http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_PropertyandEquipmentNetDetails" roleURI="http://www.cleaninccom/role/PropertyandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_LeasesDetails" roleURI="http://www.cleaninccom/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_NotesPayableDetails" roleURI="http://www.cleaninccom/role/NotesPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_PreferredStockWarrantLiabilityDetails" roleURI="http://www.cleaninccom/role/PreferredStockWarrantLiabilityDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_CommonStockWarrantsDetails" roleURI="http://www.cleaninccom/role/CommonStockWarrantsDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_ConvertibleNotesDetails" roleURI="http://www.cleaninccom/role/ConvertibleNotesDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_DerivativeInstrumentsDetails" roleURI="http://www.cleaninccom/role/DerivativeInstrumentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_IncomeTaxesDetails" roleURI="http://www.cleaninccom/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_StockBasedCompensationDetails" roleURI="http://www.cleaninccom/role/StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_FairValueDetails" roleURI="http://www.cleaninccom/role/FairValueDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_RedeemableConvertiblePreferredStockDetails" roleURI="http://www.cleaninccom/role/RedeemableConvertiblePreferredStockDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_CommonStockDetails" roleURI="http://www.cleaninccom/role/CommonStockDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_NetLossPerShareAttributabletoCommonShareholdersDetails" roleURI="http://www.cleaninccom/role/NetLossPerShareAttributabletoCommonShareholdersDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_RelatedPartyTransactionsDetails" roleURI="http://www.cleaninccom/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#clnn_r_SubsequentEventsDetails" roleURI="http://www.cleaninccom/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20201231.xsd#DocumentAndEntityInformation" roleURI="http://www.cleaninccom/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LongTermNotesPayable" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RedeemableConvertiblePreferredStockWarrantLiability" xlink:href="clnn-20201231.xsd#clnn_RedeemableConvertiblePreferredStockWarrantLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="RedeemableConvertiblePreferredStockWarrantLiability" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContingentEarnoutNetOfCurrentPortion" xlink:href="clnn-20201231.xsd#clnn_ContingentEarnoutNetOfCurrentPortion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="ContingentEarnoutNetOfCurrentPortion" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InitialShareholdersContingentEarnout" xlink:href="clnn-20201231.xsd#clnn_InitialShareholdersContingentEarnout"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="InitialShareholdersContingentEarnout" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_ProductMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_RoyaltyMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CostsOfRevenue" xlink:href="clnn-20201231.xsd#clnn_CostsOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="CostsOfRevenue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnContractTermination" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnContractTermination"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnContractTermination" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInFairValueOfPreferredStockWarrantLiability" xlink:href="clnn-20201231.xsd#clnn_ChangeInFairValueOfPreferredStockWarrantLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="ChangeInFairValueOfPreferredStockWarrantLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInFairValueOfContingentEarnout" xlink:href="clnn-20201231.xsd#clnn_ChangeInFairValueOfContingentEarnout"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="ChangeInFairValueOfContingentEarnout" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInFairValueOfInitialShareholdersContingentEarnout" xlink:href="clnn-20201231.xsd#clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="ChangeInFairValueOfInitialShareholdersContingentEarnout" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AustraliaResearchAndDevelopmentCredit" xlink:href="clnn-20201231.xsd#clnn_AustraliaResearchAndDevelopmentCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="AustraliaResearchAndDevelopmentCredit" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTax" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ApplicationOfASC842" xlink:href="clnn-20201231.xsd#clnn_ApplicationOfASC842"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ApplicationOfASC842" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfSeriesCPreferredStockWarrants" xlink:href="clnn-20201231.xsd#clnn_ExerciseOfSeriesCPreferredStockWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ExerciseOfSeriesCPreferredStockWarrants" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfSeriesCPreferredStockWarrant" xlink:href="clnn-20201231.xsd#clnn_ExerciseOfSeriesCPreferredStockWarrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ExerciseOfSeriesCPreferredStockWarrant" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe" xlink:href="clnn-20201231.xsd#clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection" xlink:href="clnn-20201231.xsd#clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable" xlink:href="clnn-20201231.xsd#clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockPaymentOfRelatedOfferingCosts" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfCommonStockPaymentOfRelatedOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockPaymentOfRelatedOfferingCosts" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati" xlink:href="clnn-20201231.xsd#clnn_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization" xlink:href="clnn-20201231.xsd#clnn_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForeignCurrencyTranslationAdjustment" xlink:href="clnn-20201231.xsd#clnn_ForeignCurrencyTranslationAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ForeignCurrencyTranslationAdjustment" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfSeriesDPreferredStockInConnectionExtinguishmentOfConvertiblePromis" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfSeriesDPreferredStockInConnectionExtinguishmentOfConvertiblePromis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfSeriesDPreferredStockInConnectionExtinguishmentOfConvertiblePromis" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ShareholdersEquityType2or3_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="NetIssuanceCosts" xlink:href="clnn-20201231.xsd#clnn_NetIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="NetIssuanceCosts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInFairValueOfContingentEarnout" xlink:href="clnn-20201231.xsd#clnn_ChangeInFairValueOfContingentEarnout"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ChangeInFairValueOfContingentEarnout" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInFairValueOfInitialShareholdersContingentEarnout" xlink:href="clnn-20201231.xsd#clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ChangeInFairValueOfInitialShareholdersContingentEarnout" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnTerminationOfLease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnTerminationOfLease" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseInInterestAccruedOnNotesPayable" xlink:href="clnn-20201231.xsd#clnn_IncreaseInInterestAccruedOnNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseInInterestAccruedOnNotesPayable" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInPayableToRelatedParties" xlink:href="clnn-20201231.xsd#clnn_IncreaseDecreaseInPayableToRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInPayableToRelatedParties" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" order="18.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseOperatingLeaseObligations" xlink:href="clnn-20201231.xsd#clnn_IncreaseDecreaseOperatingLeaseObligations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseOperatingLeaseObligations" order="19.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseOperatingLeaseObligations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromThePrivatePlacementOfferingNetOfOfferingCosts" xlink:href="clnn-20201231.xsd#clnn_ProceedsFromThePrivatePlacementOfferingNetOfOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="ProceedsFromThePrivatePlacementOfferingNetOfOfferingCosts" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfMediumTermNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfMediumTermNotes" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_FairValueOfAssetsAcquired" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AcquisitionOfRightofuseAssetsAndLeaseholdImprovementsThroughOperatingLease" xlink:href="clnn-20201231.xsd#clnn_AcquisitionOfRightofuseAssetsAndLeaseholdImprovementsThroughOperatingLease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="AcquisitionOfRightofuseAssetsAndLeaseholdImprovementsThroughOperatingLease" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantLiabilitySettledOnExercise" xlink:href="clnn-20201231.xsd#clnn_WarrantLiabilitySettledOnExercise"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="WarrantLiabilitySettledOnExercise" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseLiabilitySettledThroughTerminationOfLease" xlink:href="clnn-20201231.xsd#clnn_LeaseLiabilitySettledThroughTerminationOfLease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="LeaseLiabilitySettledThroughTerminationOfLease" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfDerivativeInstrumentRelatedToConvertibleNotes" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfDerivativeInstrumentRelatedToConvertibleNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="IssuanceOfDerivativeInstrumentRelatedToConvertibleNotes" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" xlink:href="clnn-20201231.xsd#clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTransactionCostsInAccountsPayable" xlink:href="clnn-20201231.xsd#clnn_DeferredTransactionCostsInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="DeferredTransactionCostsInAccountsPayable" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTransactionsCostsInAccruedLiabilities" xlink:href="clnn-20201231.xsd#clnn_DeferredTransactionsCostsInAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="DeferredTransactionsCostsInAccruedLiabilities" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfRedeemableConvertiblePreferredStockIntoCommonStock" xlink:href="clnn-20201231.xsd#clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="ConversionOfRedeemableConvertiblePreferredStockIntoCommonStock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemableConvertibleSreferredStock" xlink:href="clnn-20201231.xsd#clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemableConvertibleSreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemableConvertibleSreferredStock" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockAsPaymentRelatedOfferingCosts" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfCommonStockAsPaymentRelatedOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="IssuanceOfCommonStockAsPaymentRelatedOfferingCosts" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContingentEarnoutRecognizedConnectionWithTheReverseRecapitalization" xlink:href="clnn-20201231.xsd#clnn_ContingentEarnoutRecognizedConnectionWithTheReverseRecapitalization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="ContingentEarnoutRecognizedConnectionWithTheReverseRecapitalization" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InitialShareholdersContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization" xlink:href="clnn-20201231.xsd#clnn_InitialShareholdersContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="InitialShareholdersContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_InterestPaid" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/NatureoftheBusinessandBasisofPresentation">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicine">
    <loc xlink:type="locator" xlink:label="ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract" xlink:href="clnn-20201231.xsd#clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract"/>
    <loc xlink:type="locator" xlink:label="ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock" xlink:href="clnn-20201231.xsd#clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract" xlink:to="ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/Prepaidexpensesandothercurrentassets">
    <loc xlink:type="locator" xlink:label="PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="clnn-20201231.xsd#clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:href="clnn-20201231.xsd#clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="PrepaidExpensesAndOtherCurrentAssetsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/PropertyandEquipmentNet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/AccruedLiabilities">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/NotesPayable">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/PreferredStockWarrantLiability">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/CommonStockWarrants">
    <loc xlink:type="locator" xlink:label="CommonStockWarrantsDisclosureAbstract" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrantsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CommonStockWarrantsDisclosureTextBlock" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrantsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDisclosureAbstract" xlink:to="CommonStockWarrantsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ConvertibleNotes">
    <loc xlink:type="locator" xlink:label="ConvertibleNotesDisclosureAbstract" xlink:href="clnn-20201231.xsd#clnn_ConvertibleNotesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesDisclosureTextBlock" xlink:href="clnn-20201231.xsd#clnn_ConvertibleNotesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDisclosureAbstract" xlink:to="ConvertibleNotesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/DerivativeInstruments">
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/StockBasedCompensation">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/FairValue">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/RedeemableConvertiblePreferredStock">
    <loc xlink:type="locator" xlink:label="RedeemableConvertiblePreferredStockDisclosureAbstract" xlink:href="clnn-20201231.xsd#clnn_RedeemableConvertiblePreferredStockDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="RedeemableConvertiblePreferredStockDisclosureTextBlock" xlink:href="clnn-20201231.xsd#clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemableConvertiblePreferredStockDisclosureAbstract" xlink:to="RedeemableConvertiblePreferredStockDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/CommonStock">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/NetLossPerShareAttributabletoCommonShareholders">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/GeographicandSegmentInformation">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RiskAndUncertaintiesPolicyTextBlock" xlink:href="clnn-20201231.xsd#clnn_RiskAndUncertaintiesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="RiskAndUncertaintiesPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContingentEarnoutPolicyTextBlock" xlink:href="clnn-20201231.xsd#clnn_ContingentEarnoutPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ContingentEarnoutPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockWarrantsPolicyTextBlock" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrantsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="CommonStockWarrantsPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantFundingPolicyTextBlock" xlink:href="clnn-20201231.xsd#clnn_GrantFundingPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="GrantFundingPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClinicalTrialAccrualPolicyTextBlock" xlink:href="clnn-20201231.xsd#clnn_ClinicalTrialAccrualPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ClinicalTrialAccrualPolicyTextBlock" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:href="clnn-20201231.xsd#clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/PrepaidexpensesandothercurrentassetsTables">
    <loc xlink:type="locator" xlink:label="PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="clnn-20201231.xsd#clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:href="clnn-20201231.xsd#clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/PropertyandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/AccruedLiabilitiesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PropertyPlantAndEquipmentOneTextBlock" xlink:href="clnn-20201231.xsd#clnn_PropertyPlantAndEquipmentOneTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="PropertyPlantAndEquipmentOneTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/PreferredStockWarrantLiabilityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPreferredUnitsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPreferredUnitsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ScheduleOfPreferredUnitsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/CommonStockWarrantsTables">
    <loc xlink:type="locator" xlink:label="CommonStockWarrantsDisclosureAbstract" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrantsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/StockBasedCompensationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/FairValueTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/RedeemableConvertiblePreferredStockTables">
    <loc xlink:type="locator" xlink:label="RedeemableConvertiblePreferredStockDisclosureAbstract" xlink:href="clnn-20201231.xsd#clnn_RedeemableConvertiblePreferredStockDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemableConvertiblePreferredStockDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/NetLossPerShareAttributabletoCommonShareholdersTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/GeographicandSegmentInformationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfDrugsAndSupplementsSegmentsTableTextBlock" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfDrugsAndSupplementsSegmentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="ScheduleOfDrugsAndSupplementsSegmentsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofprepaidexpensesandothercurrentassetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="AustraliaResearchAndDevelopmentCreditReceivable" xlink:href="clnn-20201231.xsd#clnn_AustraliaResearchAndDevelopmentCreditReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="AustraliaResearchAndDevelopmentCreditReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CROPrepayments" xlink:href="clnn-20201231.xsd#clnn_CROPrepayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="CROPrepayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_AccountsReceivableNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MetalsToBeUsedInResearchAndDevelopment" xlink:href="clnn-20201231.xsd#clnn_MetalsToBeUsedInResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="MetalsToBeUsedInResearchAndDevelopment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_EquipmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_FurnitureAndFixturesGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_LeaseholdImprovementsGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_ConstructionInProgressGross" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofaccruedliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAccruedLiabilitiesAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfAccruedLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedLiabilitiesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedLiabilitiesAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedCROFees" xlink:href="clnn-20201231.xsd#clnn_AccruedCROFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedLiabilitiesAbstract" xlink:to="AccruedCROFees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredGrantFunds" xlink:href="clnn-20201231.xsd#clnn_DeferredGrantFunds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedLiabilitiesAbstract" xlink:to="DeferredGrantFunds" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedLiabilitiesAbstract" xlink:to="us-gaap_AccruedSalariesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedTransactionCosts" xlink:href="clnn-20201231.xsd#clnn_AccruedTransactionCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedLiabilitiesAbstract" xlink:to="AccruedTransactionCosts" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedLiabilitiesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedLiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofnoncancelableoperatingleasearrangementsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfNoncancelableOperatingLeaseArrangementsAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfNoncancelableOperatingLeaseArrangementsAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsTable" xlink:href="clnn-20201231.xsd#clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsTable"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems" xlink:href="clnn-20201231.xsd#clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNoncancelableOperatingLeaseArrangementsAbstract" xlink:to="LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="FinanceLeasesMember" xlink:href="clnn-20201231.xsd#clnn_FinanceLeasesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="FinanceLeasesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesMember" xlink:href="clnn-20201231.xsd#clnn_OperatingLeasesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="OperatingLeasesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsTable" xlink:to="LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleoffinanceleaseobligationsandincludedpropertyandequipmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinanceLeaseObligationsAndIncludedPropertyAndEquipmentAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfFinanceLeaseObligationsAndIncludedPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentTable" xlink:href="clnn-20201231.xsd#clnn_LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentTable"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentLineItems" xlink:href="clnn-20201231.xsd#clnn_LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinanceLeaseObligationsAndIncludedPropertyAndEquipmentAbstract" xlink:to="LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_EquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WorkInProcessMember" xlink:href="clnn-20201231.xsd#clnn_WorkInProcessMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="WorkInProcessMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentTable" xlink:to="LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="FinanceLeaseLiabilityGross" xlink:href="clnn-20201231.xsd#clnn_FinanceLeaseLiabilityGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentLineItems" xlink:to="FinanceLeaseLiabilityGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccumulatedDepreciationDepletionAndAmortizationLeases" xlink:href="clnn-20201231.xsd#clnn_AccumulatedDepreciationDepletionAndAmortizationLeases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentLineItems" xlink:to="AccumulatedDepreciationDepletionAndAmortizationLeases" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceLeaseLiabilityNet" xlink:href="clnn-20201231.xsd#clnn_FinanceLeaseLiabilityNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentLineItems" xlink:to="FinanceLeaseLiabilityNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleoffinanceandoperatingleasecostsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinanceAndOperatingLeaseCostsAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfFinanceAndOperatingLeaseCostsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinanceAndOperatingLeaseCostsAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_VariableLeaseCost" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_LeaseCost" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofsupplementalcashflowinformationTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSupplementalCashFlowInformationAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfSupplementalCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingCashFlowsFromOperatingLeases" xlink:href="clnn-20201231.xsd#clnn_OperatingCashFlowsFromOperatingLeases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalCashFlowInformationAbstract" xlink:to="OperatingCashFlowsFromOperatingLeases" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingCashFlowsFromFinanceLeases" xlink:href="clnn-20201231.xsd#clnn_OperatingCashFlowsFromFinanceLeases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalCashFlowInformationAbstract" xlink:to="OperatingCashFlowsFromFinanceLeases" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceCashFlowsFromFinanceLeases" xlink:href="clnn-20201231.xsd#clnn_FinanceCashFlowsFromFinanceLeases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalCashFlowInformationAbstract" xlink:to="FinanceCashFlowsFromFinanceLeases" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/SchedulefairvalueoftheoutstandingwarrantsTable">
    <loc xlink:type="locator" xlink:label="ScheduleFairValueOfTheOutstandingWarrantsAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleFairValueOfTheOutstandingWarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPreferredUnitsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPreferredUnitsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredUnitsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredUnitsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleFairValueOfTheOutstandingWarrantsAbstract" xlink:to="us-gaap_ScheduleOfPreferredUnitsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPreferredUnitsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesCPreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPreferredUnitsTable" xlink:to="us-gaap_PreferredUnitsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="ExpirationDate" xlink:href="clnn-20201231.xsd#clnn_ExpirationDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredUnitsLineItems" xlink:to="ExpirationDate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredUnitsLineItems" xlink:to="us-gaap_WarrantExercisePriceIncrease" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredUnitsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="WarrantsDateMember" xlink:href="clnn-20201231.xsd#clnn_WarrantsDateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="WarrantsDateMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsDate1Member" xlink:href="clnn-20201231.xsd#clnn_WarrantsDate1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="WarrantsDate1Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="December20201Member" xlink:href="clnn-20201231.xsd#clnn_December20201Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="December20201Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsDate2Member" xlink:href="clnn-20201231.xsd#clnn_WarrantsDate2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="WarrantsDate2Member" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesIssuable" xlink:href="clnn-20201231.xsd#clnn_NumberOfSharesIssuable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="NumberOfSharesIssuable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockWarrantsExercisePrice" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrantsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="CommonStockWarrantsExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockWarrantsExercisable" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrantsExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="CommonStockWarrantsExercisable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockWarrantsClassification" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrantsClassification"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="CommonStockWarrantsClassification" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockWarrantsExpiration" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrantsExpiration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="CommonStockWarrantsExpiration" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofcomponentsofincomelossbeforeincometaxesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofincometaxexpensebenefitTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfIncomeTaxExpenseBenefitAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfIncomeTaxExpenseBenefitAbstract"/>
    <loc xlink:type="locator" xlink:label="CurrentTaxExpenseAbstract" xlink:href="clnn-20201231.xsd#clnn_CurrentTaxExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxExpenseBenefitAbstract" xlink:to="CurrentTaxExpenseAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentTaxExpenseAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentTaxExpenseAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentTaxExpenseAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentTaxExpenseAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxExpenseAbstract" xlink:href="clnn-20201231.xsd#clnn_DeferredTaxExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxExpenseBenefitAbstract" xlink:to="DeferredTaxExpenseAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxExpenseAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxExpenseAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxExpenseAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxExpenseAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxExpenseBenefitAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofincometaxreconciliationTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfIncomeTaxReconciliationAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfIncomeTaxReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxReconciliationWarrantLiability" xlink:href="clnn-20201231.xsd#clnn_IncomeTaxReconciliationWarrantLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="IncomeTaxReconciliationWarrantLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingencies" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxReconciliationNondeductibleExpensesResearchAndDevelopment" xlink:href="clnn-20201231.xsd#clnn_IncomeTaxReconciliationNondeductibleExpensesResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="IncomeTaxReconciliationNondeductibleExpensesResearchAndDevelopment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofdeferredtaxassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsLiabilitiesAbstract" xlink:href="clnn-20201231.xsd#clnn_DeferredTaxAssetsLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsLiabilitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxLiabilitiesDeferredExpenseDepreciation" xlink:href="clnn-20201231.xsd#clnn_DeferredTaxLiabilitiesDeferredExpenseDepreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsLiabilitiesAbstract" xlink:to="DeferredTaxLiabilitiesDeferredExpenseDepreciation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxLiabilitiesLeaseLiability" xlink:href="clnn-20201231.xsd#clnn_DeferredTaxLiabilitiesLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsLiabilitiesAbstract" xlink:to="DeferredTaxLiabilitiesLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsRightofUseAsset" xlink:href="clnn-20201231.xsd#clnn_DeferredTaxAssetsRightofUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsLiabilitiesAbstract" xlink:to="DeferredTaxAssetsRightofUseAsset" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsTaxDeferredNonqualifiedStockOptions" xlink:href="clnn-20201231.xsd#clnn_DeferredTaxAssetsTaxDeferredNonqualifiedStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsLiabilitiesAbstract" xlink:to="DeferredTaxAssetsTaxDeferredNonqualifiedStockOptions" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsTaxDeferredAccruedCompensation" xlink:href="clnn-20201231.xsd#clnn_DeferredTaxAssetsTaxDeferredAccruedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsLiabilitiesAbstract" xlink:to="DeferredTaxAssetsTaxDeferredAccruedCompensation" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofstockbasedcompensationexpenseTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockBasedCompensationExpenseAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfStockBasedCompensationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable" xlink:href="clnn-20201231.xsd#clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems" xlink:href="clnn-20201231.xsd#clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockBasedCompensationExpenseAbstract" xlink:to="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable" xlink:to="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InstrinsicValueOptionsVestedAndExercisableEnding" xlink:href="clnn-20201231.xsd#clnn_InstrinsicValueOptionsVestedAndExercisableEnding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="InstrinsicValueOptionsVestedAndExercisableEnding" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePricePerShareOptionsVestedAndExercisableStockOptionsVest" xlink:href="clnn-20201231.xsd#clnn_WeightedAverageExercisePricePerShareOptionsVestedAndExercisableStockOptionsVest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="WeightedAverageExercisePricePerShareOptionsVestedAndExercisableStockOptionsVest" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingTermOptionsVestedAndExercisableStockOptionsVestedAndExercisable" xlink:href="clnn-20201231.xsd#clnn_WeightedAverageRemainingTermOptionsVestedAndExercisableStockOptionsVestedAndExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="WeightedAverageRemainingTermOptionsVestedAndExercisableStockOptionsVestedAndExercisable" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InstrinsicValueOptionsVestedAndExercisableStockOptionsVestedAndExpectedToVestEnding" xlink:href="clnn-20201231.xsd#clnn_InstrinsicValueOptionsVestedAndExercisableStockOptionsVestedAndExpectedToVestEnding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="InstrinsicValueOptionsVestedAndExercisableStockOptionsVestedAndExpectedToVestEnding" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:href="clnn-20201231.xsd#clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodIntrinsicValue" xlink:href="clnn-20201231.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodIntrinsicValue"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraqWjSnTNF4jeT3oaMW8W5R0MkiIXXy8k2PQbBklJ1lYf+6GCuiY/lJFjk6uDeNN+gvvgD/ctbqbBhZgNg1qNU0EiFrWvY1hT6GmZd73HE7TJaI9wGp4wAxzd2UaTwEVsbp/IQFhRTHB/tg6uRHFmIlGtAq3Qm2BGSLl2WSERQ17mrXKB1xi6zH] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodIntrinsicValue" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementNumberOfOptionsExercised" xlink:href="clnn-20201231.xsd#clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="ShareBasedCompensationArrangementNumberOfOptionsExercised" order="20.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsExercised" xlink:href="clnn-20201231.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsExercised" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue" xlink:href="clnn-20201231.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="24.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsForfeited" xlink:href="clnn-20201231.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsForfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsForfeited" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue" xlink:href="clnn-20201231.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleoffairvalueofthesestockoptionsawardsgrantedTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfTheseStockOptionsAwardsGrantedAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfFairValueOfTheseStockOptionsAwardsGrantedAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedTable" xlink:href="clnn-20201231.xsd#clnn_StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedTable"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedLineItems" xlink:href="clnn-20201231.xsd#clnn_StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheseStockOptionsAwardsGrantedAbstract" xlink:to="StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedTable" xlink:to="StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofrestrictedcommonstockactivityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfRestrictedCommonStockActivityAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfRestrictedCommonStockActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable" xlink:href="clnn-20201231.xsd#clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:href="clnn-20201231.xsd#clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestrictedCommonStockActivityAbstract" xlink:to="StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable" xlink:to="StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueHierarchyOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfFairValueHierarchyOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable" xlink:href="clnn-20201231.xsd#clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable"/>
    <loc xlink:type="locator" xlink:label="FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems" xlink:href="clnn-20201231.xsd#clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueHierarchyOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" xlink:to="FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable" xlink:to="FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems" xlink:to="us-gaap_NotesPayableFairValueDisclosure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CleneNanomedicineContingentEarnout" xlink:href="clnn-20201231.xsd#clnn_CleneNanomedicineContingentEarnout"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems" xlink:to="CleneNanomedicineContingentEarnout" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InitialShareholdersContingentEarnout" xlink:href="clnn-20201231.xsd#clnn_InitialShareholdersContingentEarnout"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems" xlink:to="InitialShareholdersContingentEarnout" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RedeemableConvertiblePreferredStockWarrantLiability" xlink:href="clnn-20201231.xsd#clnn_RedeemableConvertiblePreferredStockWarrantLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems" xlink:to="RedeemableConvertiblePreferredStockWarrantLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleoffairvalueoftheinitialcontingentearnoutTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfTheInitialContingentEarnOutAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfFairValueOfTheInitialContingentEarnOutAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheInitialContingentEarnOutAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ContingentEarnoutMember" xlink:href="clnn-20201231.xsd#clnn_ContingentEarnoutMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ContingentEarnoutMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleoffinancialliabilityrelatedtothenotespayablethederivativeinstrumentthePreferredStockwarrantsandthecontingentearnoutmeasuredatfairvalueTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialLiabilityRelatedToTheNotesPayableTheDerivativeInstrumentThePreferredStockWarrantsAndTheContingentEarnOutMeasuredAtFairValueAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfFinancialLiabilityRelatedToTheNotesPayableTheDerivativeInstrumentThePreferredStockWarrantsAndTheContingentEarnOutMeasuredAtFairValueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialLiabilityRelatedToTheNotesPayableTheDerivativeInstrumentThePreferredStockWarrantsAndTheContingentEarnOutMeasuredAtFairValueAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableOtherPayablesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_NotesPayableOtherPayablesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DerivativeInstrumentMember" xlink:href="clnn-20201231.xsd#clnn_DerivativeInstrumentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="DerivativeInstrumentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreferredStockWarrantsMember" xlink:href="clnn-20201231.xsd#clnn_PreferredStockWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="PreferredStockWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContingentEarnoutMember" xlink:href="clnn-20201231.xsd#clnn_ContingentEarnoutMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="ContingentEarnoutMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="InitialShareholdersContingentEarnoutMember" xlink:href="clnn-20201231.xsd#clnn_InitialShareholdersContingentEarnoutMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="InitialShareholdersContingentEarnoutMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueIssuanceOfConvertiblePromissoryNotes" xlink:href="clnn-20201231.xsd#clnn_FairValueIssuanceOfConvertiblePromissoryNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FairValueIssuanceOfConvertiblePromissoryNotes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InitialFairValueOfInstrument" xlink:href="clnn-20201231.xsd#clnn_InitialFairValueOfInstrument"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueIssuanceOfConvertiblePromissoryNotes" xlink:to="InitialFairValueOfInstrument" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable" xlink:href="clnn-20201231.xsd#clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueIssuanceOfConvertiblePromissoryNotes" xlink:to="ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExtinguishmentOfDerivativeLiability" xlink:href="clnn-20201231.xsd#clnn_ExtinguishmentOfDerivativeLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueIssuanceOfConvertiblePromissoryNotes" xlink:to="ExtinguishmentOfDerivativeLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfIssuanceOfNotesPayable" xlink:href="clnn-20201231.xsd#clnn_FairValueOfIssuanceOfNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FairValueOfIssuanceOfNotesPayable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreseDecreaseInFairValue" xlink:href="clnn-20201231.xsd#clnn_IncreseDecreaseInFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="IncreseDecreaseInFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueExerciseOfSeriesCPreferredStockWarrants" xlink:href="clnn-20201231.xsd#clnn_FairValueExerciseOfSeriesCPreferredStockWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FairValueExerciseOfSeriesCPreferredStockWarrants" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofPreferredStockTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPreferredStockAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfPreferredStockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPreferredStockAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesCPreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="TemporaryEquitySharesIssuedAndOutstanding" xlink:href="clnn-20201231.xsd#clnn_TemporaryEquitySharesIssuedAndOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="TemporaryEquitySharesIssuedAndOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="TemporaryEquitySharesCommonStockIssuableUponConversion" xlink:href="clnn-20201231.xsd#clnn_TemporaryEquitySharesCommonStockIssuableUponConversion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="TemporaryEquitySharesCommonStockIssuableUponConversion" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfBasicAndDilutedNetLossPerShareAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfBasicAndDilutedNetLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="NumeratorAbstract" xlink:href="clnn-20201231.xsd#clnn_NumeratorAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedNetLossPerShareAbstract" xlink:to="NumeratorAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumeratorAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="DenominatorAbstract" xlink:href="clnn-20201231.xsd#clnn_DenominatorAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedNetLossPerShareAbstract" xlink:to="DenominatorAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DenominatorAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedNetLossPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofdilutivesecuritieswereexcludedfromthecomputationofdilutednetlosspershareTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="SeriesCRedeemableConvertiblePreferredStock" xlink:href="clnn-20201231.xsd#clnn_SeriesCRedeemableConvertiblePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract" xlink:to="SeriesCRedeemableConvertiblePreferredStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBRedeemableConvertiblePreferredStock" xlink:href="clnn-20201231.xsd#clnn_SeriesBRedeemableConvertiblePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract" xlink:to="SeriesBRedeemableConvertiblePreferredStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesARedeemableConvertiblePreferredStock" xlink:href="clnn-20201231.xsd#clnn_SeriesARedeemableConvertiblePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract" xlink:to="SeriesARedeemableConvertiblePreferredStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesCRedeemableConvertiblePreferredStockWarrantsinShares" xlink:href="clnn-20201231.xsd#clnn_SeriesCRedeemableConvertiblePreferredStockWarrantsinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract" xlink:to="SeriesCRedeemableConvertiblePreferredStockWarrantsinShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesARedeemableConvertiblePreferredStockWarrantsinShares" xlink:href="clnn-20201231.xsd#clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract" xlink:to="SeriesARedeemableConvertiblePreferredStockWarrantsinShares" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockWarrants" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract" xlink:to="CommonStockWarrants" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsToPurchaseCommonStockinShares" xlink:href="clnn-20201231.xsd#clnn_OptionsToPurchaseCommonStockinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract" xlink:to="OptionsToPurchaseCommonStockinShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChardanUnitPurchaseOptionToPurchaseCommonStock" xlink:href="clnn-20201231.xsd#clnn_ChardanUnitPurchaseOptionToPurchaseCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract" xlink:to="ChardanUnitPurchaseOptionToPurchaseCommonStock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChardanUnitPurchaseOptionWarrants" xlink:href="clnn-20201231.xsd#clnn_ChardanUnitPurchaseOptionWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract" xlink:to="ChardanUnitPurchaseOptionWarrants" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EarnoutSharessee" xlink:href="clnn-20201231.xsd#clnn_EarnoutSharessee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract" xlink:to="EarnoutSharessee" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbylocationTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentNetByLocationAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfPropertyAndEquipmentNetByLocationAbstract"/>
    <loc xlink:type="locator" xlink:label="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable" xlink:href="clnn-20201231.xsd#clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable"/>
    <loc xlink:type="locator" xlink:label="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems" xlink:href="clnn-20201231.xsd#clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetByLocationAbstract" xlink:to="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_AU" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_AU"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_AU" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable" xlink:to="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofdrugsandsupplementssegmentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDrugsAndSupplementsSegmentsAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfDrugsAndSupplementsSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsTable" xlink:href="clnn-20201231.xsd#clnn_GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsTable"/>
    <loc xlink:type="locator" xlink:label="GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsLineItems" xlink:href="clnn-20201231.xsd#clnn_GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDrugsAndSupplementsSegmentsAbstract" xlink:to="GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DrugsMember" xlink:href="clnn-20201231.xsd#clnn_DrugsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="DrugsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SupplementsMember" xlink:href="clnn-20201231.xsd#clnn_SupplementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="SupplementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsTable" xlink:to="GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsLineItems" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbysegmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentNetBySegmentAbstract" xlink:href="clnn-20201231.xsd#clnn_ScheduleOfPropertyAndEquipmentNetBySegmentAbstract"/>
    <loc xlink:type="locator" xlink:label="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable" xlink:href="clnn-20201231.xsd#clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable"/>
    <loc xlink:type="locator" xlink:label="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems" xlink:href="clnn-20201231.xsd#clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetBySegmentAbstract" xlink:to="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DrugsMember" xlink:href="clnn-20201231.xsd#clnn_DrugsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="DrugsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SupplementsMember" xlink:href="clnn-20201231.xsd#clnn_SupplementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="SupplementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable" xlink:to="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/NatureoftheBusinessandBasisofPresentationDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:href="clnn-20201231.xsd#clnn_NatureoftheBusinessandBasisofPresentationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="NatureoftheBusinessandBasisofPresentationDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfFreshStartAdjustmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfFreshStartAdjustmentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:to="us-gaap_TypeOfFreshStartAdjustmentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExchangeClearedMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExchangeClearedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:to="us-gaap_ExchangeClearedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CleneNanomedicineMember" xlink:href="clnn-20201231.xsd#clnn_CleneNanomedicineMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="CleneNanomedicineMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ChardanMember" xlink:href="clnn-20201231.xsd#clnn_ChardanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ChardanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LifeSciCapitalLLCMember" xlink:href="clnn-20201231.xsd#clnn_LifeSciCapitalLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="LifeSciCapitalLLCMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="NatureoftheBusinessandBasisofPresentationDetailsLineItems" order="6.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="MergerAgreementPercentage" xlink:href="clnn-20201231.xsd#clnn_MergerAgreementPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="MergerAgreementPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromReverseRecapitalizationNet" xlink:href="clnn-20201231.xsd#clnn_ProceedsFromReverseRecapitalizationNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="ProceedsFromReverseRecapitalizationNet" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOption" xlink:href="clnn-20201231.xsd#clnn_PurchaseOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="PurchaseOption" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PerShareUnit" xlink:href="clnn-20201231.xsd#clnn_PerShareUnit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="PerShareUnit" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentsForAdvisoryServicesShares" xlink:href="clnn-20201231.xsd#clnn_PaymentsForAdvisoryServicesShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="PaymentsForAdvisoryServicesShares" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesPrivatePlacement" xlink:href="clnn-20201231.xsd#clnn_StockIssuedDuringPeriodSharesPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="StockIssuedDuringPeriodSharesPrivatePlacement" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncurredNetLosses" xlink:href="clnn-20201231.xsd#clnn_IncurredNetLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="IncurredNetLosses" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_Cash" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RetainedEarningsAccumulatedDeficit1" xlink:href="clnn-20201231.xsd#clnn_RetainedEarningsAccumulatedDeficit1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="RetainedEarningsAccumulatedDeficit1" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="clnn-20201231.xsd#clnn_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RedeemablePreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemablePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_RedeemablePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollateralAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_CollateralAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollateralDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_CollateralDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_EquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="GrantFundingMember" xlink:href="clnn-20201231.xsd#clnn_GrantFundingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="GrantFundingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PreferredStockWarrantMember" xlink:href="clnn-20201231.xsd#clnn_PreferredStockWarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="PreferredStockWarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsLineItems" order="8.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_InventoryRawMaterials" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_InventoryFinishedGoods" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProposedPublicOfferingCost" xlink:href="clnn-20201231.xsd#clnn_ProposedPublicOfferingCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="ProposedPublicOfferingCost" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DeferredRevenue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails">
    <loc xlink:type="locator" xlink:label="ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract" xlink:href="clnn-20201231.xsd#clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract"/>
    <loc xlink:type="locator" xlink:label="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" xlink:href="clnn-20201231.xsd#clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract" xlink:to="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" xlink:to="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfFreshStartAdjustmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfFreshStartAdjustmentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:to="us-gaap_TypeOfFreshStartAdjustmentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExchangeClearedMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExchangeClearedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:to="us-gaap_ExchangeClearedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CleneNanomedicineMember" xlink:href="clnn-20201231.xsd#clnn_CleneNanomedicineMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="CleneNanomedicineMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LifeSciCapitalLLCMember" xlink:href="clnn-20201231.xsd#clnn_LifeSciCapitalLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="LifeSciCapitalLLCMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TottenhamMember" xlink:href="clnn-20201231.xsd#clnn_TottenhamMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="TottenhamMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="exch_PIPE" xlink:href="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd#exch_PIPE"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="exch_PIPE" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" xlink:to="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" order="5.0"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockUponReverseRecapitalization" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfCommonStockUponReverseRecapitalization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="IssuanceOfCommonStockUponReverseRecapitalization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EarnOutShare" xlink:href="clnn-20201231.xsd#clnn_EarnOutShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="EarnOutShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EntityCommonStockSharesOutstanding1" xlink:href="clnn-20201231.xsd#clnn_EntityCommonStockSharesOutstanding1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="EntityCommonStockSharesOutstanding1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesHeldInEscrow" xlink:href="clnn-20201231.xsd#clnn_SharesHeldInEscrow"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="SharesHeldInEscrow" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ServicesLetterAgreementDescription" xlink:href="clnn-20201231.xsd#clnn_ServicesLetterAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="ServicesLetterAgreementDescription" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherUnderwritingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherUnderwritingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_OtherUnderwritingExpense" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestorsPurchasedShares" xlink:href="clnn-20201231.xsd#clnn_InvestorsPurchasedShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="InvestorsPurchasedShares" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesPerShare" xlink:href="clnn-20201231.xsd#clnn_SharesPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="SharesPerShare" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePrice" xlink:href="clnn-20201231.xsd#clnn_ExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="ExercisePrice" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetProceeds" xlink:href="clnn-20201231.xsd#clnn_NetProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="NetProceeds" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EarnoutSharesDescription" xlink:href="clnn-20201231.xsd#clnn_EarnoutSharesDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="EarnoutSharesDescription" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/PropertyandEquipmentNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentNetDetailsTable" xlink:href="clnn-20201231.xsd#clnn_PropertyandEquipmentNetDetailsTable"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentNetDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_PropertyandEquipmentNetDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="PropertyandEquipmentNetDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsTable" xlink:to="PropertyandEquipmentNetDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsLineItems" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CumulativeEarningsDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CumulativeEarningsDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CumulativeEarningsDeficit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RemainingRightofuseAsset" xlink:href="clnn-20201231.xsd#clnn_RemainingRightofuseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="RemainingRightofuseAsset" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RecognizedGainOnOperatingLease" xlink:href="clnn-20201231.xsd#clnn_RecognizedGainOnOperatingLease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="RecognizedGainOnOperatingLease" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfOperatingLease" xlink:href="clnn-20201231.xsd#clnn_DescriptionOfOperatingLease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="DescriptionOfOperatingLease" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceLeaseObligationsWeightedaverageInterestRate" xlink:href="clnn-20201231.xsd#clnn_FinanceLeaseObligationsWeightedaverageInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="FinanceLeaseObligationsWeightedaverageInterestRate" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeaseObligationsWeightedAverageInterestRate" xlink:href="clnn-20201231.xsd#clnn_OperatingLeaseObligationsWeightedAverageInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="OperatingLeaseObligationsWeightedAverageInterestRate" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/NotesPayableDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="NotesPayableDetailsTable" xlink:href="clnn-20201231.xsd#clnn_NotesPayableDetailsTable"/>
    <loc xlink:type="locator" xlink:label="NotesPayableDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_NotesPayableDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="NotesPayableDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="TwoThousandNineteenMDLoanMember" xlink:href="clnn-20201231.xsd#clnn_TwoThousandNineteenMDLoanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="TwoThousandNineteenMDLoanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandNineteenCecilLoanMember" xlink:href="clnn-20201231.xsd#clnn_TwoThousandNineteenCecilLoanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="TwoThousandNineteenCecilLoanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaycheckProtectionProgramNoteMember" xlink:href="clnn-20201231.xsd#clnn_PaycheckProtectionProgramNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaycheckProtectionProgramNoteMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="NotesPayableDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_LineOfCredit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SimpleInterestExpense" xlink:href="clnn-20201231.xsd#clnn_SimpleInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="SimpleInterestExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesAndLoansPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAndLoansPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_NotesAndLoansPayable" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfLoanAmountUsedToPayrollExpenses" xlink:href="clnn-20201231.xsd#clnn_PercentageOfLoanAmountUsedToPayrollExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="PercentageOfLoanAmountUsedToPayrollExpenses" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_AccruedSalariesCurrentAndNoncurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableToBank" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBank"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_NotesPayableToBank" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/PreferredStockWarrantLiabilityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="PreferredStockWarrantLiabilityDetailsTable" xlink:href="clnn-20201231.xsd#clnn_PreferredStockWarrantLiabilityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="PreferredStockWarrantLiabilityDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_PreferredStockWarrantLiabilityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="PreferredStockWarrantLiabilityDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockWarrantLiabilityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesCPreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesDPreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockWarrantLiabilityDetailsTable" xlink:to="PreferredStockWarrantLiabilityDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockWarrantLiabilityDetailsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockWarrantLiabilityDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockWarrantLiabilityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockWarrantLiabilityDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LossRecognizedOnAssetsTransferredToSeparateAccountGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossRecognizedOnAssetsTransferredToSeparateAccountGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockWarrantLiabilityDetailsLineItems" xlink:to="us-gaap_LossRecognizedOnAssetsTransferredToSeparateAccountGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockWarrantLiabilityDetailsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/CommonStockWarrantsDetails">
    <loc xlink:type="locator" xlink:label="CommonStockWarrantsDisclosureAbstract" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrantsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CommonStockWarrantsDetailsTable" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrantsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="CommonStockWarrantsDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_CommonStockWarrantsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDisclosureAbstract" xlink:to="CommonStockWarrantsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesDPreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TottenhamsMember" xlink:href="clnn-20201231.xsd#clnn_TottenhamsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="TottenhamsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ChardanMember" xlink:href="clnn-20201231.xsd#clnn_ChardanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ChardanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDetailsTable" xlink:to="CommonStockWarrantsDetailsLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReverseRecapitalizationAndWillExpireYears" xlink:href="clnn-20201231.xsd#clnn_ReverseRecapitalizationAndWillExpireYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDetailsLineItems" xlink:to="ReverseRecapitalizationAndWillExpireYears" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantExercisePrice" xlink:href="clnn-20201231.xsd#clnn_WarrantExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDetailsLineItems" xlink:to="WarrantExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDetailsLineItems" xlink:to="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PreferredStockWarrantsOutstandingShares" xlink:href="clnn-20201231.xsd#clnn_PreferredStockWarrantsOutstandingShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDetailsLineItems" xlink:to="PreferredStockWarrantsOutstandingShares" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDetailsLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ConvertibleNotesDetails">
    <loc xlink:type="locator" xlink:label="ConvertibleNotesDisclosureAbstract" xlink:href="clnn-20201231.xsd#clnn_ConvertibleNotesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesDetailsTable" xlink:href="clnn-20201231.xsd#clnn_ConvertibleNotesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_ConvertibleNotesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDisclosureAbstract" xlink:to="ConvertibleNotesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesDPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsTable" xlink:to="ConvertibleNotesDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfConvertibleNotes" xlink:href="clnn-20201231.xsd#clnn_DescriptionOfConvertibleNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsLineItems" xlink:to="DescriptionOfConvertibleNotes" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_InterestExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfStock" xlink:href="clnn-20201231.xsd#clnn_PercentageOfStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsLineItems" xlink:to="PercentageOfStock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreferredStockConvertibleConversionPrice" xlink:href="clnn-20201231.xsd#clnn_PreferredStockConvertibleConversionPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsLineItems" xlink:to="PreferredStockConvertibleConversionPrice" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/DerivativeInstrumentsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeFairValueOfDerivativeNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DerivativeInstrumentsOfComprehensiveLoss" xlink:href="clnn-20201231.xsd#clnn_DerivativeInstrumentsOfComprehensiveLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="DerivativeInstrumentsOfComprehensiveLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GuarantyLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GuarantyLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_GuarantyLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReportingUnitAmountOfFairValueInExcessOfCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitAmountOfFairValueInExcessOfCarryingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_ReportingUnitAmountOfFairValueInExcessOfCarryingAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsTable" xlink:href="clnn-20201231.xsd#clnn_IncomeTaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_IncomeTaxesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="IncomeTaxesDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLossExpireTerm" xlink:href="clnn-20201231.xsd#clnn_OperatingLossExpireTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="OperatingLossExpireTerm" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RemainingBalanceOfOperatingLoss" xlink:href="clnn-20201231.xsd#clnn_RemainingBalanceOfOperatingLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="RemainingBalanceOfOperatingLoss" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentCreditExpiryTerm" xlink:href="clnn-20201231.xsd#clnn_ResearchAndDevelopmentCreditExpiryTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="ResearchAndDevelopmentCreditExpiryTerm" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/StockBasedCompensationDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsTable" xlink:href="clnn-20201231.xsd#clnn_StockBasedCompensationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_StockBasedCompensationDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="StockBasedCompensationDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="StockPlan2020Member" xlink:href="clnn-20201231.xsd#clnn_StockPlan2020Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="StockPlan2020Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockPlan2014Member" xlink:href="clnn-20201231.xsd#clnn_StockPlan2014Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="StockPlan2014Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="StockBasedCompensationDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MinimumFairMarketValueOfOptionGrantDescription" xlink:href="clnn-20201231.xsd#clnn_MinimumFairMarketValueOfOptionGrantDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="MinimumFairMarketValueOfOptionGrantDescription" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants" xlink:href="clnn-20201231.xsd#clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockOtherSharesOutstanding" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="CommonSharesAuthorized" xlink:href="clnn-20201231.xsd#clnn_CommonSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="CommonSharesAuthorized" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross" xlink:href="clnn-20201231.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="11.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="UnrecognizedStockbasedCompensation" xlink:href="clnn-20201231.xsd#clnn_UnrecognizedStockbasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="UnrecognizedStockbasedCompensation" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="weightedAverageFairValuesOfOptionsGranted" xlink:href="clnn-20201231.xsd#clnn_weightedAverageFairValuesOfOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="weightedAverageFairValuesOfOptionsGranted" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedStockUnitsDescription" xlink:href="clnn-20201231.xsd#clnn_RestrictedStockUnitsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="RestrictedStockUnitsDescription" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerms" xlink:href="clnn-20201231.xsd#clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerms" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm" xlink:href="clnn-20201231.xsd#clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/FairValueDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueDetailsTable" xlink:href="clnn-20201231.xsd#clnn_FairValueDetailsTable"/>
    <loc xlink:type="locator" xlink:label="FairValueDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_FairValueDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="FairValueDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesCPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsTable" xlink:to="FairValueDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementWithUnobservableInputsNotesPayable" xlink:href="clnn-20201231.xsd#clnn_FairValueMeasurementWithUnobservableInputsNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsLineItems" xlink:to="FairValueMeasurementWithUnobservableInputsNotesPayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NotesPayableBasedOnClosingPrice" xlink:href="clnn-20201231.xsd#clnn_NotesPayableBasedOnClosingPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsLineItems" xlink:to="NotesPayableBasedOnClosingPrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsToPurchasePreferredStock" xlink:href="clnn-20201231.xsd#clnn_WarrantsToPurchasePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsLineItems" xlink:to="WarrantsToPurchasePreferredStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/RedeemableConvertiblePreferredStockDetails">
    <loc xlink:type="locator" xlink:label="RedeemableConvertiblePreferredStockDisclosureAbstract" xlink:href="clnn-20201231.xsd#clnn_RedeemableConvertiblePreferredStockDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="RedeemableConvertiblePreferredStockDetailsTable" xlink:href="clnn-20201231.xsd#clnn_RedeemableConvertiblePreferredStockDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RedeemableConvertiblePreferredStockDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_RedeemableConvertiblePreferredStockDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemableConvertiblePreferredStockDisclosureAbstract" xlink:to="RedeemableConvertiblePreferredStockDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemableConvertiblePreferredStockDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesCPreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesDPreferredStockMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemableConvertiblePreferredStockDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestorMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="us-gaap_InvestorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemableConvertiblePreferredStockDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemableConvertiblePreferredStockDetailsTable" xlink:to="RedeemableConvertiblePreferredStockDetailsLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfSecuredPromissoryNotes" xlink:href="clnn-20201231.xsd#clnn_ConversionOfSecuredPromissoryNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="ConversionOfSecuredPromissoryNotes" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetOfIssuanceCosts" xlink:href="clnn-20201231.xsd#clnn_NetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="NetOfIssuanceCosts" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashConsiderationReceived" xlink:href="clnn-20201231.xsd#clnn_CashConsiderationReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="CashConsiderationReceived" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="us-gaap_AdditionalPaidInCapital" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesIssuedUponConversionOfConvertiblePromissoryNote" xlink:href="clnn-20201231.xsd#clnn_SharesIssuedUponConversionOfConvertiblePromissoryNote"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="SharesIssuedUponConversionOfConvertiblePromissoryNote" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsSharesInExercise" xlink:href="clnn-20201231.xsd#clnn_WarrantsSharesInExercise"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="WarrantsSharesInExercise" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConversionBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockConversionBasis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="us-gaap_PreferredStockConversionBasis" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="us-gaap_CommonStockConvertibleConversionPriceIncrease" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="us-gaap_ConversionOfStockDescription" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/CommonStockDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="PreferredStockShares" xlink:href="clnn-20201231.xsd#clnn_PreferredStockShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="PreferredStockShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockUponReverseRecapitalization" xlink:href="clnn-20201231.xsd#clnn_IssuanceOfCommonStockUponReverseRecapitalization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="IssuanceOfCommonStockUponReverseRecapitalization" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="RecapitalizationShare" xlink:href="clnn-20201231.xsd#clnn_RecapitalizationShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="RecapitalizationShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestorsPurchasedShares" xlink:href="clnn-20201231.xsd#clnn_InvestorsPurchasedShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="InvestorsPurchasedShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SharePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="NetProceeds" xlink:href="clnn-20201231.xsd#clnn_NetProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="NetProceeds" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/NetLossPerShareAttributabletoCommonShareholdersDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesIssuableOnExerciseOfWarrants" xlink:href="clnn-20201231.xsd#clnn_NumberOfSharesIssuableOnExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="NumberOfSharesIssuableOnExerciseOfWarrants" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChardanUnitPurchaseOptionToPurchaseCommonStock" xlink:href="clnn-20201231.xsd#clnn_ChardanUnitPurchaseOptionToPurchaseCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="ChardanUnitPurchaseOptionToPurchaseCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ChardanUnitPurchaseOptionWarrants" xlink:href="clnn-20201231.xsd#clnn_ChardanUnitPurchaseOptionWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="ChardanUnitPurchaseOptionWarrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsTable" xlink:href="clnn-20201231.xsd#clnn_RelatedPartyTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_RelatedPartyTransactionsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_BoardOfDirectorsChairmanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="RelatedPartyTransactionsDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="clnn-20201231.xsd#clnn_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsLineItems" xlink:href="clnn-20201231.xsd#clnn_SubsequentEventsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="SubsequentEventsDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="PaycheckProtectionProgramLoan" xlink:href="clnn-20201231.xsd#clnn_PaycheckProtectionProgramLoan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="PaycheckProtectionProgramLoan" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GainOnForgivenessLoan" xlink:href="clnn-20201231.xsd#clnn_GainOnForgivenessLoan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="GainOnForgivenessLoan" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FoundationGrantCost" xlink:href="clnn-20201231.xsd#clnn_FoundationGrantCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="FoundationGrantCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SubsequentEventDescription" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateGrossProceedWarrantsExercised" xlink:href="clnn-20201231.xsd#clnn_AggregateGrossProceedWarrantsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="AggregateGrossProceedWarrantsExercised" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SaleOfStockholdersCommonStock" xlink:href="clnn-20201231.xsd#clnn_SaleOfStockholdersCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="SaleOfStockholdersCommonStock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="clnn-20201231.xsd#clnn_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $Z D0# 2(  A$! Q$!_\0
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M/BOX;GO?VC?V6[33?@KX;_XK+PU!?ZC<_ [0OCCXO^!GB\>*M'NM%B\3>*_
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M5]8H7DDVDY/ENDW=Z+F@[QG%/3EDU*22YGS+^1]>BUMLUY/=?DC]I?\ A'M
M_P"@'H__ (+++VQ_RP_SFC_A'M _Z >C_P#@LLO_ (Q7Y9?LE:#_ ,%!=!_:
M)MM/_:!?Q9K?P'O=-_;)\>:=XGUGQ1X,N)?#^O\ C7]JB)OA+\&?$'A_2=9U
M#6M6T?PG\)=/B\9? [Q>!<RZ3\/?&6L?##QK_9NO>!M'DUO]9?\ /YUA5A[*
M?)STY^ZI<U.7-'5R5KV7O+ENTU=76][E*S5[6\FDF>?7^A:(OBWP_$NC:2(G
MT_66>,:;9!791:E2P\CDK_#GIDXQDYZ@>'O#^3_Q(]&S_P!@RRZ=O^6'3U]\
MUEZA_P CCX=_[!VM?RM?\G\*ZLD CD GUZXS].YP.<=<]1BLW:U^[TMUOY_K
MMHM= TUT7X&3_P ([X?'30M'_P#!99?_ !BC_A'M _Z >C_^"RR_^,5^:'CK
MPY^V/:0_$2ZTZ3XB7MCJWQ+T34] LO#NOKK-U'X%M/&>NQZQ&-.B^(_P[UC3
M)FT"70OLN@>#?''AFUU+1%^V7-Y'KEOJ&GS=#XXL_P!I9?%7B1="TSXO:CX3
M;XZ:9K,^N1WL]OJ<W@B1=?M9O".A>#-%^-?A*.3P9X?":+>6'B[P_K_@^ZUN
MWO8(_&'@/Q%JVEZC>:KO[#5?OJ<KJUU)NUN6][N[?O:+=VDEU#3M^'X[?\'R
M/T._X1[0/^@'H_\ X+++_P",4?\ ".^'_P#H!Z/_ ."RR_\ C%?F]XBT?]N3
M7CXAM[31]0T:/Q+X]U#XA>$&M/BI'#'X9\-)\+/BYH>G?#[Q1=Z?#H-[H-U:
M^,K+X0^)++P_IEQXY\+:EXBU/43XC\13Z"NMV,'H*VO[2-S>^(_[)MOB-9^.
M[KQ9\/;W0_$WC:[TBY^$H^'$:>'SJ-I>^"?"OCK2EM/$\4B:Y)XWTW3(M-U&
M:^EG@TKQ!J&AKI@*]C9?Q:3TOI*RMIJ]K13NGH[-/W6K,-/Y?_)5_5S[@'AW
MP_VT+1OPTRR_^,5')X>T$-%C0M(.9,$C3+' 'ER<MFW)QD 9!!R1SC(/G?P)
MM_B39?#'1K;XOSK<_$*/6/'!UVYC.+6>&3QWXEET&;38?[2UF6TT:7PX^DR:
M+8W>JW^H:?I)LK'4;J:^M[EJ]9D8%H< MB7LVT*?*DP7X.4YV]L.5[C%92:4
MG'F4K-KF3;4DM.9-ZV?2^K70=O+\%_D9W_"/:!_T ]'_ /!99?\ QBC_ (1W
MP_\ ] /1QT_YAEE_\8_#^5>7?M 6'Q$U;X4^)--^%#72^.;RXT*'2&M-9F\/
MR+"_B#3#JS2:U:S6]_IML-)%]]JN=,E&IQV_F?8 UT8T/QYXM\%_MA:#>_$$
M:7XC\8^+K)?AGK?A7PSK&AZ[!!>ZSXOL_A#X4N=+U6'PE>^)M(L-&TN[\9P^
M,8[3Q-IVN:1X]N/&L.D:3J>HVWA+6Y?$.F:4Z:FK^UIP>ONRD[NW+MT=W+1-
MIOED]D)Z?9OZ)?Y'Z*?\([X?_P"@'H__ (+++_XQ1_PCV@?] /1__!99?_&*
M_/Z^M_VB(=*\27L.A_&^]\2)X.\&WGPZ_L76K#2_#]MI6G:QH5UXVT'7O#7B
M7XK:_?-\4=2@BUA+67Q?XF\6P3:?+;6FF^-8"]VJ:'C)?VM-?O?%'CKX?Z3X
MWT6"'5M?\5>#OAKXHUOPEH[:YHMW\ _A+HMKX UMK77=4MO#>I_\+#E^)6H:
M-J$6HW-EI?C;3HM3N[N?P_>))>/V+32=6FEKJV[)Z<J3N[)N^MDDU*]N5MFE
MK\OX*_Y:_P##?+[Q_P"$=\/_ /0"T?\ \%EE_P#&*/\ A'?#^,#0]''I_P 2
MRRX_\@5\2>';;X^Z;XG\&WOQ&T;XQ^(O"]G=ZM=VECX'\2^&K:]@\4P7^GSZ
M=+\188_%FBOJ_@N[T-);/2]+AO=5T=-5.M'Q%ID7FZ'>MB_#'5?VNO">J^!9
MOC!X)\7>(X=1\<^*-=\11_#[Q9X:\9:5I6B?$W1!J.F:#K1UYOA]?6>F?"GQ
M:NI:7'IVEV'B2/2?#]QH<>FZYXI$%U>*>R=FU4INRNDFKR^*ZC=V;BXWD]$G
M*-KZL/E^'_ \]/F?>$OA_00BXT'2&/FP@A=+L.AE0%CNMR J@EFP,X!VD'!$
M@\.Z!@9T/1B?7^R[+]/W-:<K J!AFQ+#PIP01,AW'C&Q,;FZY4$<<&I-Z]C^
MA_PK'FTNM_5+M?KY]/R"R[+[E_D9/_"/:!_T ]'_ /!99?\ QBC_ (1[0/\
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MW^'GA3QAX=U#7/#*II:3_%CQGKFH?$73YFU$M+=>&O#B^'_#_CW1+:4R>)O
M7B"*XT9;SQ!X,MM)U5^R72K2LTVFY-)M-W75WTOJM;JSN[!_VZ^G3NKGVW_P
MCOA__H!Z/_X+++_XQ4%SX?T 02$:#I+$ 85=,L=Q^8=-UNP_,&OG?]G"7XK0
M/XHTWXF^&/'5A?0PZ3<ZGXJ\;>*K/6(/$'C"9[U/$D/@K1-+\0:UHVC>![4I
M;3>'&TBR\.QS:;<6L.J:-#K5O?N?IZYP\$B@,^0/E0[6(#*2%.#@XYZ'Z5G)
M<LG'F3M;5/1W2=UKY^O<++M^'_ *'_"/:!_T ]'_ /!99?\ QBC_ (1[P_\
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MVKW2LT3=?RO_ ,!M^:/T=_X1[0/^@'H__@LLO_C%'_"/>'_^@'H_'_4,LO\
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MV;W_ .>1_P"^O_K4;W_YY'_OK_ZU?DK_ ,/7_")Z?!7QL><?\C%X1H_X>O\
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M?=<_XF;\#/\ HO\  ?\ AHXC_P#H>_K7L[?K-*TABD @=B8W&U7"LV5(PK$
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M\?$7A+U]O\_2F_!CQ4:Y7PGC&M%9YCE%GRJT79YSTN[.WS'_ ,3->!:_YK[
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M4XIQY4HTN?*VYTY-2E.59PK:QC!0Y97Z6P^$^KMXAM_#^LZOI&E2G4%TR_\
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M1>"9O#NF07TU\L]T&L4U"U2/,,+:A+J<-O-9W2E?M%N'TN53YD22$2QMA07
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M:'\.M/U/6KS5CX>NY++5-*UJ/5)VTG2]0N;?5$:RALY["-M2.+\3_P!KG5?
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M  +OI_S4_&RZV7K9MKJEN:;ND*-+(Z1QHC2222,J)'&BJ7=W8A51%4LSL0%
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M/_#BV'_S)4?\/6;3_HWZX_\ #BV'_P R5?D-Q_>'YG_XNCC^\/S/_P 71_Q
MOPN_Z)RK_P")%GG_ ,\0_P")H/''_HKJ'_B(<,__ #E/UY_X>LVG_1OUQ_X<
M6P_^9*C_ (>LVG_1OUQ_X<6P_P#F2K\AN/[P_,__ !='']X?F?\ XNC_ (@7
MX7?]$Y5_\2+//_GB'_$T'CC_ -%=0_\ $0X9_P#G*?KP?^"J]HP(_P"&?[D
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M4@X.>QT?* ZL?S/_ ,54,D69(/E9@'<E@>(_W; ,V3D@Y*@#N17X->?\S_\
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MG2G1J15.G'#PG3ES5*B79?V_HG7^UM-R2"?].@&<8QP)0.,>G-+_ ,)#HO\
MT%],'!QB\MN/?F0\CMVYY!KA?^$#T8<_8;,<\?O$R?;_ %/?OSGTSTH_X0/1
M><6-D?I(GX?\L?Q_^O7']4RS2^)Q;T;5\/2T7;\?PZZGJ_6L]?\ S!9;V_WO
M$]-#N_\ A(=%(P=6TS![&\MS_P"U:/\ A(=%_P"@MIGI_P ?L&./;S<?Y]A7
M"#P'HO7[#9_]_$]QC_4]_P N?PI?^$"T7O8V>,?\]$X)Z ?N?7\^>:7U3+/^
M@G%_^$]';?O_ %U%]9SS_H"R[_PKQ)W/_"0:)T_M;3/3_C]@X&,8'[WCCTQ^
M=<EXXO;'5/#LUM8WMI<S-J&CML@N(I9&6/4[:1B$C<GY%#,S;<;>3TJG_P (
M'HPZ6-F,@Y_>*/\ VC^O:K]AX1TRRE5X+.W5AD )*G#'D=(L@$#N.>@SCG2E
M3R_#5:>(IU\5.=&I"K&$J%*,92A=I-Q=U?:Z\K&>(><8S#UL)6PV ITL32G1
MJ3IXG$3G"%1*+E&,O<DTM4I-+36Q#9QM'KWA12"#_9.NCDG.=EGGDX.<^HK\
M>_\ @IGX,\9>(OCAX$O?#WA'Q/K]G#\)X+6:[T31-0U.V@N?^$Q\2S&VEGM(
M)(UG$,L4IB+!Q'(CE=KH:_9BY5X_%?AH)&N%TS7 J^;P?EM",GR\Y)ZG! SW
MY-=@6GX_<J, CB?'7CM%U';T[5[G!'&=?@?BFEQ/AL!1S&K1PN9X582OB*^%
MI2CF.'6&E4=;#1G54J27/&*34V^6>FI\KXH^&N&\4N!J_!.,S;$9/0Q&/R7'
M2S#"X/"XZM"638R6-A2CAL9.G0E&O*;ISG*2E"*YH)MV/YY?V;_B]\3/@G;6
MOA_QC^SIXW^*7A'3-6DUOPU976DZU;W?@O5+J:*:^U#0]+O]+N?#]Q=S2K)<
MPW]S%:ZQ9W$TJ6FKV]J[1)ZIK_[3/BV'P/)H'@']E#Q[H?BY-7^(>HZ+X]U/
M2KS3M1\)1>.O&7B#Q.\>C#P[I;7URT5OK:VUWI]Q?VFCW5Q;JMU:WUL 6_<7
M]_\ \\@>G6Y;M_VS[]Z7,_\ SQ7IC_CX;_XWU]Z^TS#Q6R'-,WJ9YC?#?+:N
M.KXBEB\0H<6<44,%B<11E4E"KB,OHN.#J.<JDY8F')&EBVV\53JN4^?\NRGZ
M/G%.29#0X;RWQFS>EEF%P6(R[!SJ\ <"XK,\%@L5&E&IA\)G&)C5S*A&E&E"
M.#G&M*K@(>Y@:E&,::I_R@6'ACX]:68&TW0?C-IKVKB:V?3;/QCIS6TO]I-K
M/G6HL/LZ6D@UF1]85K183'JS-J"!+G]Y6A)IW[2,S1226GQXE>#5_P#A(('D
M?QY(\&O>4(/[=C+3,R:Q]G46YU($7;P?NFF,9*G^J[,__/(?^!!],?\ //\
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M:N3_ ))?^%8?$_/'PW\?9.!D>$M;5O;#"U4@YP<J005!&,"K ^'7Q;62:5?
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MY2K5,QJ5YR:T<IUZDVM)3E=W_DE'PN^)Z@A?AOX_51@;%\)Z\J==WW!; ??
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M=_T3;Q]_X26M?_(E?UN?Z1DYB'7C%RW]8AWSCVQ1^_\ ^>7_ ),G_P"-T_\
MB:+./^B/RO\ \/.;?_*!?\2*\/\ _1QLZ_\ $7X>_P#FL_DC_P"%7?$[_HFW
MC[_PDM:_^1*/^%7?$[_HFWC[_P )+6O_ )$K^MS]_P#\\O\ R9/_ ,;H_?\
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M:S^2/_A5WQ._Z)MX^_\ "2UK_P"1*/\ A5WQ._Z)MX^_\)+6O_D2OZW/W_\
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M!C:0,Y*DYYJ;?<?\\$_[_P#_ -KH GHJ#?<?\\$_[_?_ &JC?<?\\$_[_?\
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M[2YFJ^JX>ROAZ-]MI6>EWUTU775Z^1^A3?&[]G1!K[/\9_ 83PHOA>3Q0_\
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M&R,C@G/A[.#C/..^!VH'[?O[81Z?&J]/ /'A+P/C!Z'/_"/=Z\1OK_X<F_\
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M?WL]A_X;\_;"_P"BTWO;KX2\#_\ S/>H./;K1_PWY^V'_P!%IO?_  DO _\
M\SM>+6E]\+K]7^VZ!9Z7=3V.B22HD_BM+<ZAJ%O?7'BBST6:&]FBL;O3=:ET
MO3_#,NI0_P#"/VOAVVU":\-]>R12#H?$^G?"[1=3TO3/[,TJRBN+O3;BYU!;
MWQ-K<D&AV5CK%Q<"[LX+V*.RO/$&O6^E:/<2I#JCQ>'97\0Z;:IY\EN"T-%R
M+57^%?=L%WW?WL]'/[??[83 J?C3?8((/_%)>" <$8."/#H(]5/;@\TO_#?G
M[87_ $6F]_'PEX'_ /F=Y_'GU)/->,3:E\)(9;NVM?#OVNSN-0U$PZG<2^+$
MU"PT^:YOA9FU6/4[:VF-K:"P-H+S3GE63S'O$G)>)/)ES@;N3Z^OH3TY(Y/
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M[.'_ "L!_P#!1G_LQ#]B#_U(OBE7[>:'_P B[H7_ &"--_\ 3?%7XA_LX?\
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M;K5IM?LI;?6)+R35-/LKH2M?9C%M%;Q;+53#7MO_  DWA[_GH_K_ ,>AY/\
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M()(&:N'Q-X>/_+1__ 0_U@-:%GKVC3.!$[)G: 7A$:G)  R\*@DY*J"3QD
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M*VF\LL<DB+R,)(P'!Q7[F_\ "P_A[_T4#PAQU_XJCP[_ /)G%,?XA?#XF/\
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M+R 2 2.A('I7[Q?\+#^'G_10/"'_ (5/AW_Y+H_X6'\//^B@>$/_  J?#O\
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M.P&-I'J">]354CC/FW&&E7,B$OF,^81#$H('E\  ;2!U*D]34WEM_P ]I?\
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M0:WX7@#* IV7/B'3H'&1@C*R,#[-[FO6NN"#QC\_0Y_SUKQ3]H'_ ))M=_\
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MI?F\,-@/88><L97=6I1<ZU.G1;5&HJL(*DYSDEK";J<^J7LY1M^\IM?(NM_
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MNF_Y_-0_\&-__P#)-&Z;_G\U#_P8W_\ \DTF/]H_I_A[48/J?T_PHM3[4_\
MRA_\B%Y_US?Y"[IO^?S4/_!C?_\ R31NF_Y_-0_\&-__ /)-)@^I_3_"C!]3
M^G^%%J?:G_Y0_P#D0O/^N;_(7=-_S^:A_P"#&_\ _DFC=-_S^:A_X,;_ /\
MDFDP?4_I_A1@^I_3_"BU/M3_ /*'_P B%Y_US?Y"[IO^?S4/_!C?_P#R31NF
M_P"?S4/_  8W_P#\DTWOC)_(>^.W?!_*EP?4_I_A1:GVI_\ E#_Y$=Y_US?Y
M"[IO^?S4/_!C?_\ R31NF_Y_-0_\&5__ /)-)@^I_3_"@@X/)_#&?PXHM3[4
M_P#RA_\ (A>??_TK_(_5S_@EC_P4U\6?L%_$U?#7C:\U/Q)^R[\1M<MV^)OA
MZ3[=J^J> -3GB2R3XJ>"(5:XO'N--C%L/&?AJUCE7Q-H$#W%A;2>)-,TI;K^
M]GPCXN\+^/O#'A[QMX*U_2?%7A'Q7I%CKWAOQ'H5[!J.D:WHVJ017>GZEIU[
M;N\-S:7,$BRQ2(Q^4X(#*P'^9C^SK^S[\4/VIOC)X,^!?P>T-M9\;>,;LYN9
M8I_[$\)^';*2,Z[XW\67D$4G]E^%_#MO*LMY=.!+>WLMCHNF1W.K:E9VLO\
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M;R72;#3]0\:?$'1_B)J9^P:1)865_;QZIH\=K#:ZG;WEJ8;B>YD@:]VW ?\
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M!H?_ "+NA?\ 8(TW_P!-\5?B'^SA_P K ?\ P49_[,0_8@_]2+XI5^WFA_\
M(NZ%_P!@C3?_ $WQ5^(?[.'_ "L!_P#!1G_LQ#]B#_U(OBE0)=/3_(_=FBBB
M@84444 %%%% !1110 5YOH8#2ZP&1I ;W4!L5C&S@S,-JN#E3QC<, 'KTP/2
M*\WT1=TNKKM,F;W4%$8)5I,RN=BL.03ZCGOV-'1_+]0Z_?\ H?ES_P %UO\
ME&)^U7_V)_A+_P!6-X0K]:/!O_(H^%?^Q=T/_P!--K7Y+_\ !=;_ )1B?M6?
M]B?X2_\ 5C>$*_6CP;_R*/A7_L7=#_\ 33:U]CC_ /DA.'?^RGXC_P#51PZ?
M-8;_ )*S-_\ LGLA_P#5KGAE?%&?PM;?#7X@3>./$EGX.\&CP9XF3Q5XLU"\
ML=/LO#?A^71KR'5M<N;[4U?3K6+3+&2:\:>^22TC\G=/')&&1OS"\$_L6_LW
M_#C3_#6D_#W]J+Q?HK_$34=!'AN75+WX9:]>ZQ\,_!NG:C=>&_A?H,6H>#8A
MIG@_P?X(M6\/>$;\0KJ_A_PYIC^7J-U>M<7C?J%\2/ VE_$[P!XP^'FNI:OH
MOC;P[JGAG6(;W2].UNSFTS6;22RO[>ZTK5[>YTW4+>XM9I8)K:[@DBDCD;A6
MVLOP1K?_  2_^#OB?PGJ'A'Q)\0_B[KD6I6&C6][XFO_ !+:R^.[R\T?P78^
M"(KC4/&QT[_A(-1TZ33--M)/^$>O+R;1HI3?(EL8]4U$7/R]"K&G&495ZE)2
MG%RC"FJD9**=I-/K&3VV:MU6GT4DVU:*>F[=K?AV/G[Q_P#\$I?A._@3Q1X.
M^%WQOM= \4^.O&7PP\3W&I?$#0OAWXMM-9OK'P9\,?AG>6OB+1K32-'/C?1M
M8^'7PJM[_P %^"]6\S1(O%^J>+[RX;4_#WB>_P!(L?9_A5^P-^SU\-_CE\+?
MB=HGQI\7>*O%OPLM+ZWTGPUXB\6Z*^DR7.OZ3J&@07VG:5X4C\+VUIJ3_P#$
MSL/LDUOK.F3Z'8Z9X>72((/#VFW$'4I_P3$^ =IX:T/PQI6J^-M+M-%U[0-4
M%]#JEO=ZP^E^'_A3\/?A/::!8ZMJ-K>:AH<%MI7PXTW6M$U32+BVUCPOKFN>
M+KKP]>Z>OB74TFM^%/\ @FS\'_"'B#P1XETWQ=X_;4?A_P#$G2?B7X926^TO
M[%H][I>N>(=;?0=(LETT6^FZ!J8\3ZKI6IP0H][<:5,+=;V.11,-WBFX3B\;
M7=_:7_V>*<^=<KYI7<N622T>L;RY7>]THV=^1*R5FI:KKVMU?_#'Z)=Q]#].
MW;I]/3G'4UXK^T#_ ,DVN_;Q#X/_ /4HTD5[6.G/![CKBO%?V@/^2:WG_8P>
M#_\ U*M(J,L_Y&. O_T%4?SF*OI1J_X)?C9?J6/"_P#R$?!H_P"H-K?_ *!8
MU^5/_!2O]CW_ ()N_M!_&_P3XQ_;%_:=UGX)_$G1OA3:^&/#7AC3?C%\/?AY
M!JG@6/Q=XEU6'7I-&\7>$]?U"]E?Q!J&LZ=_:=O=PV;)8K:"V$]O-+)^JWA<
M?\3#P<?31M;_ %2QK^0G_@Y(@@D_;8^"C2P0R,/V6--4-)$CD#_A;OQ'PNYE
M)"Y)( (&3SC.:_1/"C*\9G/B'A\OR_/LSX9Q53+L^JQS?)_J_P!>I0H8*-2I
MAX_6OW/L<7!JC7O[_LTN3WKGA\18BEA<GG6K8/#XZ"KX2+P^)YW2DY5I1C-J
MG[W-3?O0LK7;OH?2?_#L?_@A85Q_PW[XH.>Y_:=^"7./I\-L#OSCUYXX!_P3
M&_X(6 _\G^^* ?\ LYSX) \?]TV'0<#OCCJ :_E<%E%=WEGHNF6^GR^(-;N;
M?3- TYHK=Y]0U?49DL=+MHK4%9KCS[^:"%O+^4*S,[QQJSI^P_AC_@E>/VK[
M#XG^+_V,=1T[PYHO[/>EVGP^^.'@3XY:Y8:UJ\WQ]\(:#<7OQ!C^%OQ-^&B>
M,?AMXW\#:Q=6\BZ+J=MK=I'I]_"YDABT74]+GB_IG.>',SX=]A4SGQR\0<!A
MJ_-?'58Y.L)0;KX?"X=8JK!3G0^O8S$4\)@9NA5I5\4IT93P]HUJGPF%QM#&
M\ZPW"F359P2_=16)]K.T)U)*G%VC+V5.#J58N<)1IM2BIW<(_HV/^"8__!"S
MC_C/WQ3C' _X:=^"8'TS_P *V!^G?\Z=_P .Q_\ @A;S_P 9^^*,CL?VGO@G
MVZ#_ ))MGICCK]><_P UUE\('U'1-,O;77/"<GB;6/!/BGXB6'@ :;XBD\13
M^$_!;>(V\1W::I;:!=>%EOK.S\):YJ$5A=:Q:+=06L-M%=_VG?Z=87<=C\#?
MBCJEY-8:9\,=9O[F".R:X-I;:-/:02:C=R:=86,VJ)J']E0:W>:FCZ1!X;EO
ME\1MKBG0SI*ZQML3Z$>",]DZEO''CE<DW"?-5R2FURMIV]I:4E=2]Z"DI<K3
M4G&T<?[5PJ2_XQ3*-4FN6&+DKNUTU%.VZLG9ZK777^E7_AV/_P $+NO_  W]
MXHYZ9_:>^"7<$?\ 1-N,DG/;.">:;_P[&_X(6 X_X;]\48S_ -'/?!/@$$YX
M^&WKUR=OJ20!7\S&G_"WQ/?V]O>/X7GMK"Z75!#=_P!FIJ4T=YI>GZK?_P!G
M:EHVD&]U[0+N^_L34[?3G\1:9I4%S)8:E-#)+;Z7J,MM[KX/_89_:+\?^#KC
MQ=X4^%_]IW=A\7/"'P:U?P,RP0>/?#^O>.+'3+S0O%7B317A^S^'_AQ!)K&G
MV?B7Q?J][:6?A&2XCN_$<6FZ<ZWARQ7!^;8&FZN-\>.-<+352%)U*V)R"$(U
M*CJJ,'-N2BVZ-6/O.$8R2C*?/4I1Q%4\RP]:2C1X2RJI+ENHQI8N4FDHW:2L
MW;FB]+OE;=K1DX?OE_P[&_X(6YP?V_/$YXQS^T[\$B1GM_R3;ID9R>.!D&E_
MX=C_ /!"S_H_WQ0O?C]IWX) 9.>.?AL!W]LGKR!7X1_%7]A[QK\%O"&O>,/B
M'X\^#&BVFF?%+XA?"CPY9BX\=W0^(NJ?"SQ7%X+\:ZWX,\2VGP]N/!'V2TU>
MX2[T?PYXB\3:'XW\1>'8YO$>E>'9=.2)[CY&O]*L+&_O+-)-'U2.SNI[9-2T
MM#+I=^L,C1K=V$EW:6EU)9W 59;9[BTMIFB8&2")@5HR_@_.<TA4J9;XY\>8
MRE"<J4ZE'^RG!5(1I3G!3J4*"E*,:]*_*M)24)-SC45,K9GA:#C&OPID]*32
MDHRCB%+E?-9M*4FKN$K7?331J_\ 4K_P['_X(6=OV_O%'I_R<[\$NOO_ ,6V
MXI?^'8__  0M[_M^^*/?'[3OP2.>>1D?#;/MQ@_3K7\L L;1FC5+.V=Y9HHH
MU%O%EY9Y4BB0?)CYY'1=QX&23QG'UKK'[!W[1VE+XI6P^'FB>/KGP=::S<ZO
M9?"+7=-^+%Z;KPG\2+?X3?$#0;2V\%VNHS/XH^&7CB]M-/\ B/H=PEI+X<M+
MJVOQ+>PRIF\5P7G.!J4:6-\=>-L)/$*;H0Q.(R&@ZRA.C3GR>T:C)0GB*$)M
MSC&#JT^9I2YXJGF>&K1E*EPGE550MSRIT\7-1NI25U'5-J$VM&WRNU[6?[T_
M\.QO^"%O_1_WBC/_ &<]\$N/K_Q;<#D>H^E'_#L?_@A9U_X;]\4<_P#5SWP2
M_#@_#?\ +U/'-?S6Z1\"/B]X@C\+S:#\$_B+K</C>WU2[\'7.D^ M:U"U\3V
MNAPP7.MW.C7=MI[VUU!HUO=6D^J2--$+&&\M)+CRUNH/,Y_4/AKXQT;1?#OB
M76_A_P"(- \,>+;^?2_#'BK7_#=[HOA?7+ZUNKFRNH=/\0:A:6^EW L[BRO1
M=3)<^3%#8:A=AWM;*XECU7 >?N7)'QQXXE-S]FJ<<1P]*;J)S7LU3C5<_:7I
MU+4U#VC<)VI2<??F6;X.*3?"N4I6OS.GC%'E:6MW&R7O)W;Y;-/F5_=_IR/_
M  3(_P""%R_\W^>*.H''[3WP4/WB >GPU/&#D=L\$A<D'_#L?_@A;_T?]XI_
M\2=^"7_SMJ_FA^(/PGUOX9S>%T\1#P/J^G>-O"T?C7P?XE\!^*="\=>$?$OA
MJ36]<\,3:AI/B'1"]K.UCXC\-:]H6HVSI%+:ZAI=R@\Z PW$WG_V*S;G[+;>
MG_'O!QQZ[#GUZ]_6JH\ <28FE"OAO&SCZK1JING4IO)7":C.=.33<:;TG3G!
MKV=-QE"490C*+0I9Q@82E"?"^3QG&R<91Q-U=)ZJ\EJFFGS.Z::;31_4]_P[
M'_X(6_\ 1_WBG_Q)SX)?_.VH_P"'8_\ P0M_Z/\ O%/_ (DY\$O_ )VU?RP_
M8++_ )];;_P'@_\ C='V"R_Y];;_ ,!X/_C=:?\ $.>*_P#H]'B!]^2_YD_V
MWE__ $3&2_=B3^I[_AV/_P $+?\ H_[Q3_XDY\$O_G;4?\.Q_P#@A;_T?]XI
M_P#$G/@E_P#.VK^6'[!9?\^MM_X#P?\ QNC[!9?\^MM_X#P?_&Z/^(<\5_\
M1Z/$#[\E_P P_MO+_P#HF,E^[$G]3W_#L?\ X(6_]'_>*?\ Q)SX)?\ SMJ1
MO^"9'_!"X D?M^^*21T!_:=^"8S^(^&C']#7\L7V"R_Y];;_ ,!X/_C='V"R
M_P"?6V_\!X/_ (W1_P 0YXK_ .CT^('WY(']MY?_ -$QDOW8D_J>_P"'8_\
MP0LY_P",_O%/_B3OP2^G_1-N!QVX/6C_ (=C_P#!"W_H_P"\4_\ B3GP2_\
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MII?A73;>ZE7492L\-T\T_P#98?\ @B9_P3!Q_P FVZ3GL?\ A/\ XD?AD?\
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M8/\ T;;I'_A??$C_ .;&C_B9C@?_ *%?%?\ X3Y9_P#/@/\ 4C-/^?\ @?\
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M"_Z-MTC_ ,+[XD?_ #8U/_$S' __ $*^*_\ PGRS_P"? O\ 4C-/^?\ @?\
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MOUJ"2> RVQWQOAY#O$JJ(QY;@,0<[\\)@$')!QV'Y4?1EZBH/M5O_P ]XO\
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M%]J(/?L01]110!['H?\ R+NA?]@C3?\ TWQ5^(?[.'_*P'_P49_[,0_8@_\
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MXGT2YLY]7U#0 WB[2+SPT[7,.LVT]H#<?!))(/X@\C'Z@=/3CIR>F>G \ <
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M_P#B:-P_O'\A_P#$T?\ $,N"?^A._P#PLS'_ .3#_B&?!?\ T)W_ .%V._\
MDS^F?_B(CM?^C5M2_P##DZ;_ /*"HY/^#B"SE1D;]E?42&'3_A9>G#N#U70@
M1Z\'K7\S@89'S'\A_P#$T_\ SZ?RH_XAEP3_ -"9_P#A;F"_]O%_Q#3@M?\
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MX:GNA+)I6J6US D2ZMX;UV"&5]*UB&WB1KBWO=.GCBO+*1&^Z!@XX'/7CU)
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M9KL]1B8'H/R%&!Z#\A2T5('@7Q4_Y&&S_P"P-;_^EVHT4?%3_D8;/_L#6_\
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M"G_$1#K_ /T:M;?^'1D_^9^C_B(AU_\ Z-6MO_#I2?\ S/T?V]X@?]$!A/\
MQ(L/_P#(!_;O'RVX#PG_ (D%#_Y2?SU_\*V^)_\ T23XN_\ AIOB)_\ ,S1_
MPK;XG_\ 1)/B[_X:;XB?_,S7]"G_ !$0Z_\ ]&K6W_ATI/\ YGZ/^(B'7_\
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MK'2JLP_?6OR[@))#NW8,9,;\X_B!'R@#D?>SA3GY ^0+5%%% !1110 4444
M01IB2X;81ND0[BV0^V&,;@/X0.5QW(+=ZGJ", 2W!V[<R1Y;.=_[J-0<?PX^
MY@]2I/>IZ "BBB@"K!8V5LI2VL[6W0G<5@MX8E+?+R5C103\B<D9^1?[HPUM
M.T]WDD>QLVDF>&69VMH&>62VE$]O)(Q0EW@G FA=B6BE D0JX!JY11_6[_S
MKQ6=I!N\BUMX=TAF;RH(H]TS AI6V*N9&#,"YRQ#$$\FK%%% !1110!X%\5/
M^1AL_P#L#6__ *7:C11\5/\ D8;/_L#6_P#Z7:C10![!H?\ R+NA?]@C3?\
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M_"OH_P#X8]_:_P#^C3_VC_\ PSGCC_Y44?\ #'O[7_\ T:?^T?\ ^&<\<?\
MRHH_M?*?^AME7_ATRW_YYA_:F4_]#7*__#ME_P#\\3YPR?[_ .K?X49/]_\
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M-EJVK^#M74QM:W#9C&J:4DLTMZOAW7D1=:\.C58[?5AHU]:"^@$P,TO\Z_\
MP2K_ ."3_BCQ3XOT[]H;]K#P#JOA;PCX-U:2;X>_!CQSHESIFL^+O$NF2E8?
M%?CKP]J<<<]IX4T:\3[1H/A^_MPWB+48(-2U&%M'MH;:_P#ZKDPI('3@  #
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M4'Q7K9!'H1]JZ4?\3\</?]&TX@_\27AK_P"9@_XD8XC_ .CB\/\ _B.<1?\
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M%XLT6W8O!\/;B%VB2!GALM!B9H(X9+=(69) 3%';RRVZ1D[!#+)$JA'92_\
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M6'^N56=>O5C5KU:/"7&"52:A.*?+7P,G"[J5*LX4^2C*O5G6C2I248GXW'C
M&2#@XSSP3_B.>.!C->_^&OCO?>&M&\ Z!8Z8JZ=X5TW4HM:E;=<WFLZD^L^+
M=6T*2WBN[F72K>PTN7Q)&\T+:=]IO9(9XKB>6U=(3^B/_#I:!O\ FO6IGH>?
MAQIA[9_Z'/N.G^%'_#I: ]/CUJ>0>?\ BV^F=<CO_P )E[>O&/SO)?HU_26X
M=KXC$Y-PE#!U\32HT*]6GQ-PE.4Z%'%TL;&E[^,GRPGB*5)U8Q475IQC3E)0
M1&>?2)^C?Q+AZ&%SKB;$XW#X:K6KT*<^%^+J<85Z^#J8"=6U+ QO4AAZM149
M2YO8U6ZT8NHE;X)M?C1X#_L/Q<FI>"9K[Q/XPT'2M-U*\GL- ET5M?TO0_#=
MO8^,8M+BM[."VU&V\0:3K6IWUI"$BU:#6HH@MJT5ZUS-XA^-O@?4M%^(.G:?
MX)@&J>,X85?6=3TC3;@M(VFI:/'8VT#POX;M=(O8QJ/AT0O>S61DDAFFN%*
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MHZA?SA!:V\?G"XQQW)/Z_P"'6OV/_P"'2L/'_%^M4_\ #<:9Q_Y>7X_B:/\
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M&PR5'#Y^Z!G@G/85_8Q_*)8HHHH **** "BBB@"&,8EN#L*[I$.[.0^(8QN
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M6GU73[G1O#.DWFI1K!=^(-=U?P;HMJNU+[QGHK20?:/J+XL?#OPI\6O!.N^
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M!.) L*@$.WU_H?\ R+NA>^D:;G_P BK\0_V<3C_@X"_X*-8'3]@_]B# '?\
MXJ+XI'_ZU DKJWE^B/V^^Q:A_?LO^^)?\*/L6H_\]++_ +YF_P *VLGK@GJ,
M<9XSSU[X 'U%>._M!^&_B'XT^!GQ;\)?"'Q)#X3^*'B3X?>+=$\ ^));E[2/
M1_%=]H]W;:3>&]BAN9;%H;UT'VZ*WGET]R+M(G> *6M6E=1O)+F=[*[2;=NB
M3;?DF%EV_%_YGHJVM\X)2:P8!G0E1(P#HQ1U;;P&1P59<@A@0<$$!_V/41_'
M9?\ ?,O^'X<9^E?ACXA_90_:K'A;X+^.OV<OA/XD^!7C7X!_ _\ :!6X^#/C
MKX^V%_X:^.OQ>\=6OP>T75_"7CC7?#7B;QK97.B_%/PYHOQ E\%_%+4)+76O
MAQ\0M/\ "?CG4_#=A%>:WHMWPGB3]A']O:?1]1\':'XAOF\*^/K3]E/Q;X^O
MI_CGJUKXET[QU^RQ\(_V9?"]IHOAN1#(EOH/Q6\2:!\5O^%C-;7EI;ZD_@_2
M=2N;?46\8SL.I8:DVKXNC!-VDG>\;2:=U&4D[Q2G%QDTW+D=I7(;M]AO;J]=
M$^_?1W7F?T$?9;[(4RV08@LJA90Q",JL0.N%+J"P!"EESC<*7['J/(,EEUS]
MV;\<]>?RX.!T-?F3\4?V2/VB?B]^V!X>^+^M_$+3/!O@GP)\)/A0VDZOX!NM
M<L-4U+XB^ ?CQ\5?'UYX/T/2]0\27D'A30?&7@34/ ?A;XN>(-1TOQ#-XWT.
MYNM#T5/#\>FK(/FSP7^SU_P4TF\:?LF?$34-2M=-7X!?"+0/A%X\TOXE_%VX
M\1_$'XA^)/B)H6N:'\:_B?)=>$+^[^'&LZ7X5\3Q^!O%O@N/Q9IMYXJO_#/A
MJZTS3K?P[K&J7-F\QP].<8OZU1BW#GE&5X\L[3<:?-=*3DX\MTFH\RYDDU<O
MK\$K7LGOIHN:U]%9WU[/J?N,\%Y$4#W&GQF0[8PYD4NW7:@8@L>^U<GOBG_8
M]0//F61R2<[93GG\:_%V'X _MR_M&?"9_!7[3?@VWT[7+O6?V3?">G^(]1^(
M'A9/$/@"PT+X6^&;7]L'XQ>$Y?AIJZP2:AXM\>Z?XDL?AQI5[?R:A=1:GI_B
M*^TCPS;&;0[#]MK:WALK:WM+="EO:P16T"%Y)62&",1Q*9)6>60JB*I=W>1S
M\SLS$M6,X1IV2G&<FY<W(U**4;6?,F]W*UFD]&]AJSUM9>K3>^ZT_IF8MGJ
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M(-&MX/B'X0\1^)++P]IE](L6JRVHUS*%1K3:LGNW%?:WDU:*W;LMVKGL:?\
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MGP9XTX&/^11\2C_W$_Y_6D_X1#QA_P!"7XT_\)'Q+_\ *FO[U/L-E_SYVO\
MX#Q?_$4?8;+_ )\[7_P'B_\ B*_+/^((1_Z*:K_X:J7_ ,W'\Y+Z(-))+_7^
MOHDO^2<PW1)?]#?R/X*_^$0\8?\ 0E^-/_"1\2__ "IH_P"$0\8?]"7XT_\
M"1\2_P#RIK^]3[#9?\^=K_X#Q?\ Q%'V&R_Y\[7_ ,!XO_B*/^((1_Z*:K_X
M::7_ ,W!_P 2A4O^B_K_ /B.8;_Y[G\:_P"R'^Q?\1OVJ/B='X6?3-?\&>!/
M#XM-4^(7C+5M$U+3/[.TB68K#I&A)J5M;"_\2:V(9X=/ABWQ64<5QJ-ZZ16Z
M++_7?\.?ASX.^$_@WPQ\// 6A6GA_P )>%;*#3='TNS4(D,,4<N^ZN''-YJ%
MY.SW.H7LH-Q=W<\MS,[.<COHX((=WDPQ1;B"WE1I'N(& 6" 9(' )R0.!Q22
M+EX2$W;9"2<D!!Y<@W8!&[D[<$$?-G&0"/T3@W@C+N$,/7]C4>.S#%2?UC,:
MM*%*I*@I<U+#4*<9550H0=IU%&I)UZ_[VK)J%&G2_<_"KPAR/PNP6+^K5WF^
M>9C)K'Y[B<-3P]:>$A4Y\-E^%H0J5XX/"4K*K6A"M*>,Q3^L8B<E2PU'#S44
M45]M<_7 HHHH **** (9@2J_(''FP'!;;C]\F7SWV<.%_B(VGKFIOZ]:AF4L
M%PI?$D!QNP %E4EN"#\@^8CHV #N&14U !1110 4444 %5[L;K>0;0^0HVEM
MH/SKU;L.Y^E6*@N5+02*$$A.WY"=H;YE)&[(QQSG(H FY[]SQ[#'?\0?S%+1
M10 4444)W_K^NX!1110!#<#,,WRB3,; 1D[0QVL,;LC;N!VDY&!^-2K]U>,?
M*.,YQQTSWQZU'."T4JA0Y,;84DJ&)! 7((QGG)W CCUXD484 C& !CTXZ=_Y
MF@!:*** "BBB@!#T/T/3K4$PS+;'8&Q(_P Q?;LS&PR%_C)^[CMG=V-6*KRH
M3+;$(7".Y9RQ'E@QL-V 0&+$A1D$#.<9P0 6**** "BBB@ HHHH @C&);@[0
M,R)D@Y+_ +J,!B,_+MP5QW W=ZG_ ,_X5!&K"6X.P*&D0[LD^8!"@W8R0"&&
MS&!D+G!)!,XX&/3UZ_C0 4444 %%%% !1110 444'@$^GIUH \"^*G_(PV?_
M &!K?_TNU&BKOQ%TZ]U+7H7L+6[OEMM-@MKAK.".X6"X^T7=Q]GF/VB(QS"W
MN()O+9-WDS0R9(D%% 'L$NF6<S.[0E'D8O(8)I[<22$;3)(+>6(.[+@,[@N5
M"@L=BX\8\2?%CX?^$O%]MX.\0Z?XPTN>[UC3-"M_$-_IVLV'@R>^U70KS7;2
M.U\5WUY;:3?3&*R;3?[/T^>[U>76)HK"UTZX=;A[?W>L#6_"WACQ0L$7B;PY
MH/B**RG\ZSCUW2-/U=+28^1(9;9-0M[A8)3)#"_F1!&WQ1-G=&I#C:_OIM?W
M79_BK/T>C#T/GJ3]I_\ 9LM[C5H+[XA6>E_V+XJU7P9=SZI<:YI]K-K^B3QV
MFI6FF3W1C361:WSM82MI)O3%=P7$<JQB%FK=E^.OP732M7UZ#5]?O]"T72_#
MNLW.MZ?H/CJ[TF[TSQ5X@U+PUHEYHVHQ6!M=>@O-1TF^E271I;Z-M,B&K1L^
MG,MR='4/@_\ "2V\4>$;&V^%WPZM[*5?$^H2V<'@GPS%:R7\::7+'>R6\>F+
M$]W'*[R)<LAF61V=7#,2?1[?X?> ;.TOK"T\$>$+6QU,(NI65OX:T6"TU!8[
MN6_C%];Q62PW82^GFO$$Z2!;N:6X7$TCN=)>Q5N55==?>E#:]K7C&^R?EJNQ
M*OKMIZ]KGF%Y\<?@/8:99ZQ=^.K2#3[^>]MH)F?Q,9%FL+BVLY$N[5;=KNP%
MU?7VG:?I3W\%LFMZEJFE:=HS7]]JNGV]SF/^T3^SW'=7FGGQV@U'3["[U.]T
M]K?Q?#>6MKICVL6K-=17%E"+670KJ_LK+Q%!=-#+X;O[RVLM?33;F9(CZ^/A
MS\/1%9P#P)X-$&G7-W>:?"/"^B"*QN[^2*:^NK.,6.RUN;V6&&6[G@5);B2*
M)YF=HT(^=?!GP\\ >(/VB?VC;W7O W@_6[RU7X4K;7>K^&=%U*YMUOO#5_J%
MZL$][932PK>7ZB^NA&ZBXO +F7?, ].,:34VU4]V+E92AK[T4OL]I:^>P-M6
M6FM^CZ*_<ZOPW^T1^SSXMU/1]%\/^/K;4=6UV\33].L(O^$H2>2\N-+\4ZWI
M\,YEMTAM$UK2O!'C*]\/7=W+#8^(X?"VO-H5SJ!TRZ$=*7]H/X76=K8:CJVE
M^-M%TF_BTNZ76-1MI%TVVL-=@N=0T'4;R6TU^[D@L-7T*QU3Q'#<&)Q9:)I.
MHW.KC3;BV^RMB^*_ O@BP_:<_9\:P\'>%;(V7@OXQWUF;3P]I%L;2^T^Q\):
M/87EL8;-#!=66D>(O$&EVEQ%LFMM.UW6+&%TMM3O8I_>X_A5\+X1&(?AOX"B
M$-E>Z;"(_!_AY!%IVI6L]CJ-A&%TX".RO[*ZN;.]M5Q!=6MQ/;SQR12R(SG"
ME#D=JC52"FDY13C[THVNE9_#?56UUZ@G)WVT=NO]=3Q#1/VFO@GKVO7>BVLW
MB2VL["]\/:=>^*=0CN;/PO;7OC**YN_ \+WLFL&]>/QMIEM_:_AN]ATZ6PN=
M+N+*ZNKJS%W CLT#]J/X Z[=:_9G7-9T>3PW#X3GU+^V+;6HR%\;^.%^&_A@
M00:?<ZC=2_VIXSEM]%@D-ND+27,=TLILEGN8?>K/X:_#G3M=LO%.G^ /!-CX
MFTS3X=(TWQ%9^%="MM=T_2K:QATRWTRRU>"P34+33[?3;:WT^&R@N([:*Q@A
MM(XE@B2-;MMX(\%V<EQ+9^$/"]K+=SZ==74EMH&DP27-UI&IKK6DW-P\5HC3
M3Z7K")JVG32%I++4T6_MFBNE$HANCK[M3:-O?CH[^\W[NJ:T5K6;OTU?O>7W
M,^=A^U9^S3):O?67CMM6TYI-"CLM0T2'Q/K5MJ@\123I83::=+CNYY[41VTU
MU+>/##:FSC>ZMIKB"-W77T[]I']G?6;V2VT3QU'K5M:^$_&WC74-:TK_ (22
M]T'3-$^'DO@U/%0O=6AC-JNK:=%X_P#"=^=#@:?6&TK6++5OL2Z==V=S<>KV
M_P (OA/:+$EK\,/AY;)!!;VL*6_@KPW"L-K9R/-:6T2QZ8HC@M99));>% (X
M)'=XE5F8FS8?"_X9Z7)-+IGP[\"Z=+<:7J&ASR6'A+0+.2?1-7;3GU71YGM]
M/C:72]3;1]);4-/<M:7K:7IQN8938VQB;='I&JGTO.%NF]HW[O2RU[!KUM;R
M3_S/,]"^.WP,\0>*U\$V7BT1>);G4$T[2K"^EURT37Y7T0^(EN/#]](WV#6+
M$:0DES)>V=U);Q-%+;RNEPC1#"M_VH?V7[FW:Z3XKZ!' EI]NF:ZO_$-BT%N
MUE%J$7VB&^AMYX;F>VFB^S6,L:7UU.YMK>VDN4>)?<;7X<_#VQO=-U*R\">#
M;/4=&B:#1[^U\,:);WNE0/9G3WATVZAL4GL8FL";%H[62)&LR;8@P_)5*Z^%
M'PMOI9Y[WX:^ +R:ZN+>[N9KKP=X=N);B[M+*+3;2ZGDFTYWEN+73H8;"WFD
M+206445K$RP1K&"]&_PU4O*=.][OO&VUM];WZ6!WZ-?-/R[/U_ \ZM?CO\!=
M0U&/1]+\<0:OJLSQ1P:=HW_"4:O=S">W2]BN(H]-M[G?9R:<[ZH+X'[(NE6>
MIZF\ZV.DZI/9X=I^TU^SA<^'?"/B>X^(%OI.F>-M-34M#35SXFL+U@W]F9LK
MZU>)GT_4T;5]/4:?=F.XN5N8I[%+NU=9S[/;_"_X:6D-Q;VGP[\#6MO=WUCJ
MEU!;^$M AAN=3TRWEL]-U&XBCT]4FOM/M)IK6QNY%:XM+>66"WDCBD=3/<?#
MGX>W=JEA=>!/!MS8QF,QV=QX7T2:UC,7V;RBEO)8M"AC^Q6?EE4&S[);;<>1
M%L7[GM5M?^:%[6?]VV]OE?OH:]U]S_S/%)OVE?V>K:"_OIO&<T.E:?=Z!:2Z
MW/;>*H-"DD\00Z//;/!K,\$>GR1Z<OB#18M=S.LFBWFK:9INH1P:EJ6GV=U(
MW[1OP!MY/$"ZMXIU#PY%X7O+^QUFX\4:7XT\.16;Z5;VMUJMU*FL65G<1:7I
M2W]A!J>KSP0Z787VH6.F75W%J-W!:O[*OPW^':6%_I2> O!::7JBVZZGIJ^%
MM#6PU%;2YCO+5;^S%B+>[6VO(HKJW%Q'((;F..>/;*BL(Y?AC\-9XF@G^'O@
M>:!YOM#PR^$] DB>XVQKY[1OI[(TVV*)?-(+[8HQNPB@%Z/\M7_P*'ETY;7W
M\M5V#7NON_X)YY9?&OX'ZCINKZK9^,/.M=!&D_VO%Y/BV+4["76[S4M.T^TF
MT6:TCUD7[ZAH^J6%UIRV!O;"^L+NSU"WMKF"6)<!?VEOV:'TR]UJ/XH:-+HN
MGL(;O68KSQ#+H\5W)?6>F6FF_P!K)$VG/J^J:A?VMGHNCI<MJ>MW+R1:5:7C
MV]R(J7[3W@_PE9_!GXA7]IX6\.6M]K":/!JUY;Z)ID%WJD$_BNVU":'4;B*U
M6:]BFO[Z]OI8[EY4DO+RZN74S7$SO[38?#7X<Q^'SH:> /!2:+J'V&]O](3P
MKH2Z7?7EMY4]M=WFGBP%I<W-O,B303S0O+%*JR1NKJ"':ERJ357632LZ::22
MO?W6FW?39=PU[K[G_F>1WO[1G[/UMI]OK$/BR;4]/DU)=+CO=.M_$L\*R2:]
M<^&;BXBFEC@2XLK75[&Z@O)[)KC;;V[7RI+8F.X?1U+X^? ;2M1T32[KQBTM
MSXET=-?\/?V9!XLUM-:T9]3U?2/[4T\:+:ZA++I@O=$O@NJ&)-,F@-K=6UY-
M;WEO))U7C_P-X)T[P%XXOM/\'>%K&]M?"/B2[M;RS\/:3:W5M=6VEZA>V]S!
M<06B2PW$%XS7<,T;K)%<DSHRRDO6WX-\&>#[;P_X*O+;PIX:M[O2/!>B:%I-
MU!H6EQ7.EZ)'IT031M.GCM5ELM*02RA-/MFBM%$D@$(WMD_=6O:I\37Q0O;E
M37V;73O?NMK,-;VTVOM\NYY6?VD?V;TBAN)_B1IMG;W-T]C9S:A<^(M/^W74
M8O7=;&WOHK>\O(!#IUS<+J%O;2:;- J2P7LJR)NI0_M1_LQ311R+\3K!)9EN
M'BT^>/QC;:S)';20P32)H=Q81:RT8N)TM$D6P,<UX)K2%I+FWGBC[OP#\+?A
ME'X1TVWC^'7@2.WBU;6M1B@3PCX?6&+4'UG5@]_'$NGA$O7$\X:Z51.PFE!D
M(D?/9R?#+X;RW<.H2_#[P1)?V\9BM[V3PGH+W<$1=9#'#<M8&:*,NJN41U4N
MJL1D @?L4VFJVCMI*G;_ -)#7NON?^9XXW[2/[.ZAX_^$Y!U 6VH7T&B>5XJ
M&O7NGZ:VH&YU*QT=K<7UUIHLM+OM96_CA-H/#T#>(9)H]%_TX=%_PN7X-1ZS
MXLT&]\0WFEZEX)OM9T_Q"FJ6GBRQM+670?#UGXIU22#4IK<:=>6\6B7J74$U
MK=2B]:"\@L1<3V=Q''W-W\*/A;?R+-??#7P!>2HB1I+=^#?#MQ(J137%Q&BO
M-ISLJ1W%Y=SHH("375Q*H#SRLV?XX\ ^!+S1O&&MW?@KPE=:S=^&?$\-WJ]Q
MX<T>?4[J'4=!N-.U"*XOY;-KJ>._T]%L;V.65ENK-5MIQ)  @7[EV2577KS0
MT;DK;1LXVO>^M]5IH'O>7XGF-Y^TK^SK966NWK^-YYU\,Z8FK:];6NF>.9[_
M $BWDGO;6.#5+)=-%QINI->61LSI5^EMJ,-U?:+#<VT+:]HOV]T7[2'[/MU9
MPWNE^+K[73)X@\)>%;FS\/Z5XWUK4=*UWQMXBT7PKX>T_7;#3K&XGT*6[US7
MK&S?^UELUB>._P!Q)TR_%OZG8?"OX8/H^CV;_#CP&]I8Q0W5E:MX/\/-;V=S
M+!&)+BU@.G&*WGD  >:%4D< !F-7+?X6?#&U=);7X<^ [:2*XAO(Y+?PAX?A
M>.[M[VWU*WND>/3E9+B#4;2TU"&=2)8KVUM[I&6>&.16_8ZJU6Z;^U"VB:_E
M[ZZ=-!+F\ON?^9X)<?M4_ :#QMJOP]%[XJF\4Z!XEN?"WB&U&E:_;6&@ZA;^
M(M,\,P3ZKKM_<6>AVVG:E?:M:2Z7>_VB\=];&18@;U/L;=1XD_:#^ ?A2#7I
M=5\83FX\.7%]9ZEIEA9>,=1U<W5A'KS/'8Z79V<MYJ,5U<^&-?TK3;ZQBGTW
M4]>TJZ\/V-Y/K2+8-[3>^"O!NI2P3ZCX2\,7\]M<W-[;37N@Z5=2V]Y>7D>H
MW=W!)/:2/%<W6H117US/&RRSWD<=U*[3HKCA_#7PP^&MU9WM_<_#SP-<7VH:
MKXD>_O9_"6@37=\]_K.H37SWES)I[37+7LLLLMVTSN;B261YB[.Q(E1:NXU5
M;E32G%\S>[NX>ZM'HKM76MUJ]=KJ[N[VVVTW\]SS&Z_:H_9HM-,U;4W^("7!
MT/2]5U;5M.TZ+Q5JNJV,.BZ=)J=_:W-EIMO=-!J4=N@A33Y62YFOY8--C1K^
M:*W;IK[XZ_!#3O[#>X\27YMM>O/'VGV]Y!I_C"XMK"^^&4/G^,[+76BM7ET&
M[TS_ %4%KJT5I/J<[11:7'>&>W\WTR'X7?#.W6^6W^'?@6!=422/4UA\(Z!$
MNHQRHD4L=\$T]1=I)''''(MP)%=$1&!50!+/\-?AU<VSV=SX \%7%G+?7FIR
M6L_A70I;:34M1MH+/4-0>"2P:)[Z^M+6VM;R[9#<75M;P03R/%#&JK]SI:-6
MW6\H=GM:/>SUOU[A[W=?<_\ ,\=C_:/_ &=);.#4Q\1=,_L>Y:]2'6TO=;N=
M#\S342348I]8LS<Z=:FS$]E"\EY<P027VHV.EV\LVJS?8EZ,?&#X.O'I+Q>(
M;N>36Y=7BLK.*U\5C44/AWQ+=>#_ !$]]ITD$=[IL?AWQ+8WFD:[)?P6RZ5<
M6TS7WDP*9:W?%?P^\!:;X$\6VNG>"/"%A;1^%]7V6]EX:T:U@3['I+?9-D,%
ME'&OV7[%9_9\*/(^R6WE;?(BV>?_ +/7P_\  =_\ ?@G-?>"?"-[,_PH\)[Y
M;OPWHUS(_P#;6EVNN:SN>:R=F_M;6[V\UC4\D_;]4N[K4+KS;NXEF>FJ7*Y)
M5$E-1LW!MIQDU=J*U36MNFPKN]M-K[/OZF3>?M4_LSVUO--;_$%-6EA>R#66
MDP>++N]:WNM6\/Z)<:BD1MXD_L?0=3\6>'+/Q7K+2KI?A*YUW2;;Q)=Z9=ZI
M86]SH3_M*?L\Q:C%I,7C.>\O_P#A)+3PI>P6MGXO*:+J][;7MY&FO7,UK#::
M1;)!87+2W5]/%$L@CA4O/-#&_K#_  @^$LEK;6,GPN^'4EE9^9]DLW\$^&GM
M;7SKBRNYOLUNVF&&#S;K3M/N9/*1=]Q864S9DM8&CT8?AO\ #NVN+.[M_ 7@
MN"ZT[4VUK3[F'PMH<5Q8ZRT9A;5K.9+%9+74VA)B:_@9+HQDH92I(J;T-^6K
MI?[<%T=K^X_PUN^RLW[W=?<_\SR&W_:%^ EWJRZ7:>,!<P_V#J/B&;7(WUU/
M#]O966J:1I%E$=3E:)+JZ\37.K-+X073X[N'Q1::/KMUH\]S'IDNZ77OVA?V
M>/"U[>:;XE^(=AH&HZ?;65Y?:?K$GBC3[ZRM]1>WBL7O+2ZMX[BU:ZN;E;&"
M&>..9]0@OM/6,WNG7\%M[%!X$\#VT>JPVW@WPI;PZZES'K<4'AW2(H]92\9'
MO$U5([-5U!+IXXWN5NQ,)V1&E#%5(S?^%5_##%^/^%<> L:K!IEKJ@_X0_P]
MC4K;1;Q]1T:WOQ_9V+R#2=0DDOM,AN/,CL+QWNK58IV9R+V6EU5V5[2AJ^KU
MCHK[+MYMAKW7W/\ S/*M9_:)_9Z\.:_K/AC7_'D.E:QH+A=3AN/^$GFM8%>Q
M748)#J=E!=:6!<V9,UK"]XES<*,Q6[B2(R0C]I']G$Z8=6_X6%$EJMUI5D(I
M;7QK#J;W>N0ZQ<:+;QZ/-I\>L2RZO!H&KS::L=BWVZ&RDDMS+')$9/:[WP#X
M$U*:]N-1\%>$M0GU.59]1GO?#FCW4VH3K&(5FO9)[.1[N580(EDG:1Q& @;:
M *J7'PR^&UUJ5IK-U\/? ]SK&GK"MAJUQX3T&;4K);>.2&!;2^DL&NK98(99
M8H1#*@CCED1 JNP(O8V5U5O;7WJ>_7[(:]U]S_S/*[']H3]G34S&-/\ B7HM
MVL]H=0M9(=0UUX;[3\.4U'3I]GE:EI\ZQ3-:W]B]Q:7:P7!MII1!+LR;C]I_
M]F>VM8;^Z^(\-O97,/VN"\GL_',-K+:OK\'A>SNEN'TM8OLVK>(YX]&T"XW^
M3XAOUF@T-]0:VN!%ZU+\&_A#-;?8IOA7\-Y;,QM$;27P/X8DMO*<*KQ^0^EF
M+RW555DV;6"J"" *\5^&7PD^%-IX@TBYM/AE\/;6XCT3QU/'/;^"_#<,T<S_
M !4EU!YDECTU765K^""^:16#M>0Q7))FC1Q<8T7&3M5]VWVJ>N[_ )>R^_R%
M[U[:;/OTM_F;:?M)?LWS6TUW9_$O2+V*%9RK6M_KCQSR6]IXAO'B@N)/*M))
M&B\+ZU''FX6-[FW@M?,%QJ.G172Q?M'?L[W5IJ]UIOQ M-8ET/PS_P )=JNE
M:/)XCU/7+;0PEM))+_8UI%)J#WMO]JC6ZTF.!M5M94N8+BSCFM+J.'U>3X3_
M  LF""7X:^ )1$LJQB3P;X=<1K/>+J,RH&TT[%FU!$OI0N!)>(MT^9U#BY;?
M#GX>V<UW<VG@/P9:W%_#J-M?SVWA?1()KVWU>^FU35H+N6*Q5[F'5-3N;C4=
M1BF9TO;ZXFN[E9;B621H_<]%5Z;RI_I'M?;6X]>Z^Y_YG@VE_M4_LS:G_9<#
M?$2UTS5M7U"RTJT\.ZL_B*S\2+?ZKJMGH^BP7&B;)+Z!->NKZWET*Y>(6FL6
M*WFH6$\]EINISV=Z\_:9_9JL(8KF[^)6F6]K-=W-@MU/=>(;>W-]:17<EQ8Q
M3W$<45UJ$;VA@.G63W.H>?=:<@M2NH6CR^R?\*O^&?VR#4?^%=^!?[0MHH(;
M:^_X1'0/MEO#:B 6T,%U_9_GQ16PM;401QNJ0BV@\L+Y,>WEM-^"_P '8K[Q
M!;1_"?X:1V\SV,<L">!/"R0RQ_8D;9)$NE!'3<[MM92N68XRQS7[EW=JUDKV
MYJ?>RL^7LU>^[3>E[![W=?<_\S>\$>*/A[\2-)N==\#Z[#XDTBTU*YTB>_T_
M4=3:!-0M(K>>:#,LT3G_ $>[M;F&4(8;JTN;>[M9)K6X@FD['^QK#^Y<?^!]
M_P#_ "34>B^'?#_AN&YMO#NA:/H-O>W?V^\@T73++2X;N^^RVMC]MN8K&"!)
M[O[%8V5G]HE5YOLMG:V^_P FWA1-BLG:[Y;VZ<S3=O-I)-^B2&9?]C6']RX_
M\#[_ /\ DFC^QK#^Y<?^!]__ /)-:E%(#+_L:P_N7'_@??\ _P DT?V-8?W+
MC_P/O_\ Y)K4HH R_P"QK#^Y<?\ @??_ /R31_8UA_<N/_ ^_P#_ ))K4HH
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?..)-S.0 <N[G+R.W+/([<O(Y9W;+,Q)S14]% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $D ZH# 2(  A$! Q$!_\0
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M\A1_:US_ - JZ_(4 :M%97]K7/\ T"KK\A1_:US_ - JZ_(4 :M%97]K7/\
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M_"@#5HK)\W6_^?6U_P"_A_PH\[6_^?6V_P"_G_UJ -:BLKS=;_Y];7_OX?\
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M_P#6I?-UO_GUMO\ OX?\* -6BLKS=;_Y];;_ +^?_6H\W6_^?6V_[^?_ %J
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M>BN7E\90PP^8UNV*BA\<6\_W;=_SH ZVBN3/C5/-"?9&^N:N'Q/$(PYA/TH
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M(48H T:*I?;'(X49I/MDG]T4 7J*H_;6_NBG?;&]!0!<HJI]L]A36O<#@#-
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M.63&X_G4"LIX[TA!)P*0"<A\CI3RP:D,9 H\OC(ZT ( <\T[@=:#4;O@\<T
M2M$'4XJMCRSBIHIF)P:D**QSWI@0JQQS2LB[<BG2IQ@4U5P.32 9O(J>)NY%
M1[ 3FIBN5P* (9B&/%0@'-3O'@8HV;5R: &+G.*DE8!*$P:;)R,8H :F":L=
M1@5# @+5.5YXZ4P$ 7-#P@C(J-CM.:0S$\"@ ("C J,OM-.P332G/-("PH++
MD4I.T8[U-$5\KCK55FP_-,!K%CVIJ %N:G!3&2144C+D8H F>/(XZ4P1MTJ2
M+D<FEFF"#BD!5:,*]*^*:/G.XFE+8YH 8D.Y\FKMNFV4573+<U-;L?/ H U*
MY;4O^1STW_<?^5=37+:E_P CGIO^X_\ *F!U"?=%+34^Z*=0 U_N&N2TG_D>
M=1_W!76O]PUR6D_\CSJ/^X* .OKFM3_X_6%=+7-ZF/\ 3FH I#C@TBGYL"G!
M<FFE2K BD [ WT-[4%@#3L9% #0W%+]:85*G-*3D9H ;+P,U'N^7-+*_&#4&
MX4 !?GFJ\TI4]:?(W%9]U+@=>:8$=S<8'!K.EEW#K23S$]:INYH 1Y3FH&?G
M-#O4#R 9S0!'='=&:Y>]7YS722OE36!=C+F@#)84W)J=UP3416@!N[%.61@:
M;C%)0!;CG(/6KL-V5QS62N>M3*YH Z6WU%@!\U:]KK3( "QKBXY2.]68YFSU
MH ]$M=85\;C6K#=)*,@UYM!>,.]:UGJCHP&>* /08FR,BK$;9KGM.U0/A<YK
M:CDR010!=5\G%3*.]0+TS4JM2 EZFEV\5'GFI ?EI@7-)&+S\*WZP-*(-W[U
MOT <7_S4<_\ 7N:D\4_\A+2/^N]1_P#-1S_U[FI/%'_(1TC_ *[T@.O7[HKD
M?&T'G"VXZ&NN7[HKG?%.,0 ]<\4P.,:!X0I8?+2D1,<KC-3:E,P@VCFL6.1F
M8 $@T 74BW7&6&<=*C:-6N"'3(S6I:VS/$I;J*CNH2KAE&<4 6XVCC@"[ H]
M:A,2%]P&5J)IA-$$8X--+2Q1X'W: ++202.$7M56["(I(&:K'(.]3R:F+;8\
MGYB>U %2-W\P,F1S6^CA[<?WL52TV".5V9N,<XJW*55@(QB@#*D8_:"O-:=M
M<+#%@KGWIGDJKEF7D]Z([=VR#]V@!\D\;C<HYIEO$DLN34UM9-E@J$BJLRR6
M\_'% %Z2S5FPM-CLU@D#4MI<ALY/S8J-[H"4@T :4A@1 00&;J*SIX[=P2<9
MK+N[TF8LASMI@N)+C&>!0!:M[)(I?.1>M/FDWMCH15NWG1K81]QTJNEN99&/
M:@!UO'YT3<XQ6?+J1BE,0YQ6EA8%(K/:TA:7S1UH 2&42;B1@U"PC9SQFK'E
MC)8<5'Y!9LJ,B@!%*L=JKTHE1D );\*LQ6Y4;@*JS(96()XH :=\NW!HF1TC
MSNP:EMH61/[WI3I;<RC#<4 ,MX$FC#R-DT27GV8[$%"V;QC"DXI9[%_),AY(
MH FCD:>/Y^M5"LC3%'.%%-@9U(/85>DF691A.10 ZWDCB0@#-(29&R#@5&HX
MX&*LQ6Y;ITH V/"F/[1F"C^$5V?:N5\-P"*\E(/85U5 '%I_R42X_P"N(I_B
M;_D,:/\ ]=:8G_)1+C_KB*?XF_Y"^C_]=: .QJK>?=%6ATJG>R! N: *6P [
MJ<6 -.D8,HVBH5'S<T@)2Q(I-Q6GM&<!A2#!%,""1S31TSUI\PROI3(AG@T
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MI%^Z*Y?QA+Y44+=>: .7@M79\!AN-,NH'C?YA^-%O*\DPD7C%+>7,LHV <T
M1VL&Z<.064&KEQ(D<@/\-6=.:.VL2'P7:J5Q;,YW]J )U5'4.F,54FD$$O/4
MU4>XDB<(F0*CN&DG=0H)/K0!LI(3#\YR/2I;;RY&^9>*S;3S NR3K4T<C*V
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MJQ/2KUW9@2,3U-46C\L$KUH TY)1,%]13=Q! 2HK.>)5_>?>-2*H:YW*?EH
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M-PU "6D\C7&Q\X-5+]HK6YWRL G7FDOKX6DBR$80=37G_C+Q.+U_(M7X[D4
M=#XG^(*65A]CTULNPP2.U>73W$M[,9KABSDYYJ( DY8DGWIU !1110 4444
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MSTW_ ''_ )5U-<MJ7_(YZ;_N/_*@#IT^Z*=34^Z*=0 U_N&N2TG_ )'G4?\
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MA^E=!6%I('VK(K=I@<7_ ,U(/_7 U)XH_P"0EI'_ %VIG_-1S_UP-/\ %/\
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M [LXH @\KM3UAJ^+3< 1UJS':C'(H RA",5(D7;M6DUJN<BG"W7'2@"M%;Y
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M.>U6$(V<T 5Y%YSBA)"1BG.5)P*>H0)[T@()5./>HHPP;DU)(V#Q2Q+E<FF
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MLG!I/L&6K25..E/"X- %6.U54QWIZ0[6Z58"\U*$ %(!JQKMHZ<4I]J:&R:
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M@TX,,4 (PQR*<IR.:0X(ZTH&!0 IQBF$XIV>#49(- "^9D8I5.13!BD+8[T
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M?F/_ +Z%']J6/_/S'_WT* ,8^#+ G)=Z9-X)LIP 9Y0!Z8K<_M2R_P"?F/\
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MF/\ [Z%']IV1X%S'G_>% '+)_P E#N/^N(I_B;_D,:/_ -=:8F&^($SHP93
M.0<BI/$H!U?2"2 !)R: .P'2F21+*,-58ZI9*=IN8\C_ &A1_:MC_P _4?\
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MC^U;'_GYC_[Z% $GV1,<DTTV$1ZYIO\ :MC_ ,_4?_?0H_M6Q_Y^HO\ OH4
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M_P!]5Z/Y:^E'EKZ4 <UH/AN'2I/-7<\I&-S'G%6M=TB/4[<1R[@1T*G!%;@
M'04%0W44 >9/X&3<<37!]R]-_P"$&7_GM<?]]UZ884]*/)3TH \S_P"$&7_G
MM<?]]T?\(,O_ #VN/^^Z],\E/2CR4]* /,_^$&7_ )[7'_?='_"#+_SVN/\
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MP16Z$4=!2E0>HH \R;P/'N.);C_OND_X0=/^>MQ_WU7IGDIZ4GDKZ4 >:?\
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2BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )* ZH# 2(  A$! Q$!_\0
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M5K8$9&^K=QK=W%=2QJ(=JN5'[L= :LDQ^*7-:?\ ;U[Z0_\ ?L4?V]>^D/\
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M>12&I:&,II%2$4TBIL RBEQ25(Q*#110,0T4I%)2$PHHHH$%%%% PI,T9HH
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MZA8VK2)"H$R0@G8.QQZ5A2PR02%)4:-QU5P01^!J6K&SM>R9'1112$%&:**
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M9@Z5IZ+_ *VX_P"N1K-'2OH4CRKA12XI0*JPAN*7%. HQ18+C<4N*=BEQ3L
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MH7(L4F*EV4TJ:EQ'<C(I,5)BD(J7$I2(\4F*DQ28J7$I2(\4N*=BC%+E'S"
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MH]QIP- $@-*#3*4'F@"0'BG U'2@TP),T9IN:* -+2/^0O;?[]0WG_']<?\
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M#_OG/))SC!K8T;XB0S"."YVK$!AV;J?6M&\TGP[XIL23;QVEL'#&6)0CL>N
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MV^6/,!R),]O3%.UB=P8!H1\A$@/+;NOX4R-F)ZC(/0\TB%F')&13YP\KM,
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M!\O/S!>OX5&6\IRJYV9X)ZXH?$<A\L$(3P#U%2#!C8%58GHQZK]*! 0&B(V
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M;VXJ$&G TFKH%H]1"R1*6 D&,X:0"0_C_+-)%+J$VGH]^(K>5G*I;[0Y,0&
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M^]>)B<'.G>70]*E74M.HW9N50J@OC^$<FG1R;8BI8_-PP]:@BD53T/UJ8C>
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MT444 %%%% !2TE+0!HTHI**[SG'THIHIPIHECQ3UZ5$O6I!5C1(*>*C%/%-
M2"I%-0@U*IJT!,*D!J%34@-:(EDP-.!J,&G UJF9M$P-/#8J &G UHF0T3@U
M(K57#4]6JTQ%D-4JM58-3U:J$7$:I%:JBO4H>E8"R&I=U0!Z7=2L!-NI,U&&
MI=U%ACB:WM"\(7VO6CW:7%M;6ZL4#S$_,1V '\ZY[-=3X:FG;39D6Y98T?A!
M[\US8JI.G3YH;FM&,92M(YV_LIM.O9;2X"^9&<$J<@CL0?2J^,U:U)B^HS$M
MNP<?2JU;4I.4$WN1-)2:04H6@#-/ JR05:D44**D I"!14JBD44\"D(7%+BC
M%+BD F */2E/%7-/OK>T%PEQ#N\Q1L<+NQ[>U3)V5S.I-PCS)7-$M96EJL4T
M:K.L>UQNR&)[_6F:?I^C7EW&KWMRL>,N@52WX'_ZU9D5E>WOF2PQ/<  ON7D
M[?7%+#8WZS1,MK.FX_*64J"/J:YU"R=I:GIRQE.<8.K3M&RUZE_4(;&SN%@T
MV">:YWYC>0[CUXP!5&XO+EK^*2YB7S8&P8I%.,]P0:CN6O+.\$Q:2&4<HP;E
M>/6H;6PU?7?$.GL)A<VMN<W"SG"QQ#))8]QGMUJ9.4(7:O\ ,PC1PU>O[2F[
M=B34)7GO&FDBCB9P"4C4*!^ JH3717MUI5[,(+@"W12?GMU&0?Q[46WANSEB
MDN?[6CEB3E(UC*M)Z@Y/'ZU=.LHP2D=.(P<_:OV>J_+U,.6RNX;6&YFM9H[>
M;_5RLN%?Z&H!5S4=;BNI#IQ-P)8W.V-EQ$JKQA><YJG6E"JZL>:W4YL11=&?
M(QPIP-,%*#6Q@/W4N:9FC- B3--S29K2MM(%QHMQJ1N@GDMM$?E$AC_O=!43
MFH*[*C%RT1GTHI!3U%42.11FJ<^CW,NI"\L;F.%B49T:,G)7J01ZCKFM!!4B
M7$32/;+.N_&6C#<D5C6BI1L_D:T*DJ<^9;=?0NZK)I[R6$S31)Y*&.%))/F5
ML98@=_K2H0RAE(*D9!!R#6=KND7$VGS.[^9<H!+;.6!,1'1<]A[58TFW^S:7
M;0'[R)AN<\]_UK"C-\W([=_Q-\=!6]IJGM;IM=6+@%.HQ2XKJ/,8 4M%&: &
MM4;"I3R*81Q0!!]QRX"DD%3D9R*KN*M,.*A<4TE>Y295<<U XJRXJ!Q5#15<
M54N[2&[A,4Z;EZCG!!]0:O,*B89IM*2LRTVM4<AJFB_8(#<6\C.@(WAQR/RK
M/C<G&6&!ZUW+('4JRAE88(/((KGM5T.*WMWNK4N-G+1GD8]1]*\?&8#[=-:'
M;1Q'V9&6P)!= 1'GYBO04\MY\00-G:.,G&*BC?*@*OXU8MX7>Y2WCP=[8#$=
M!ZXKR$FWRK<['9*[V);&WEO':&WC+/C+<X&/>NQT33QI=LP+!II#ERO3V JO
MIUA#I\;+&Q=VY=SU/_UJOAZ^@PF"5+WY?$>1B*SJ>ZMB^LE2K+[UGK)4BRUV
MLXW$T5EJ42>]9JR^]2"7WJ62XFB)!ZTHD]ZH";WIPE]ZEBY"]YF>])YGO502
M>]+YE0V'*6"]1,]1F3WJ)I*BY:B.=ZKN](\E5Y).M*YHHCGDJN\E,>3WJ!Y*
M5S51)&DJ)I*B:2H7DJ6:*),TE1F3-0-)[TPR5#-5$G+^E1LU1;Z:7J66HDC-
M43&D+TTM4EI#7-5WJ5C4#GK4LM(KR54<5;>JSCFI9:*KBH6%6'%0LO-2RB$U
M&14Q%,(K-H9"13"*F(IA%2!$:0BGD8IM2 RDIY&::1B@0E%+24 %%%% &E2T
MHHKN1SBTHI*6J$Q1UIXIE.!JA(D%.%-!IPJACQ4BFHA3Q30,F4U(#4*FI :T
M3$R8&G U$#3P:M,FQ)3@:C!IV:T3):'@TX-48I0:M2,VB=6J0-58&GAJM,DL
MAJD5ZK!J>&Q5B+0>GAJJAZ<&HL%RR'I=U0!JL6EM<7MPEO:023S/]V.-=Q-)
MZ:LI"YKKO"EA<QVLUW^["3X$89L$XSSTZ57@\#:C&D4NJE;2-\DQ[@9 /<=!
M5_3]5@L(?[/DD7?!\H[9':N6I44U:#.'&U5']VSG=;L[BUU*1YT 61LJP.0:
MSP*[%[2S\2*S?:<2QG:I1@0#[BJTG@'6Q=I!:1Q7BN,B6)\*/KGI3C6C%<LF
M;X-RJ4MMM#F15BVMWNKF.WB&9)#A03BM[_A ]>2\^SS011*!EIFE&Q1^'/X5
M*-,M]"VW+7'FW"Y&5X4#UQZ<=?>FZT7\+N7B)2I1O;?8;<>$WAM=\-X)I@,E
M-FU3]#FL( @E3U!P:ZF37K>2)5#H/,(7[P[U"_A26X;=ILJRY!8K(V,GV/\
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M*3;0!I4O:DHKN.<6E[4E**8F+2@TVE%6(D!IXJ,4\&F,>*>*C!IX-4AD@-2
MU$*<#5(1,#3@:B!IP-4F23 T[-0@TX&K3%8ES2YJ,&G U28FB0&ES48-.!JT
MR&B0'%/#U"#3LUHI$-$P:G!J@!IP;%6F38L*_-=%X2\0_P#"/ZA--@#S8O+W
M]UYS7,*V:E5JFK352#@^I4)N$E)'5ZUXHGO9F\F<D-R6YX^E8! D.7&XYSEN
M34"M4BM44J$*4>6(ZD^>7.UJ7+6>2SG6:!MCCTZ'ZUZ;X;\2N-(#;@))/O\
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MA=(9&5>K!"0*MVMC=72[X+>1TSM+@?*#]>E=CDNYY$M%=ES06(OVB^8HT>2
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M"^L=T$$)A^0.< 'VK& VG!ZC@TSH>"1]*454*;C.3Z,QG4<XQB^A-&AD=$!
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M$AK&H6-/-,:I+2(F/-,/2I"M-(I-C(Z::EVTTK4E#*44[;2A:0P%.% %. I
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5* %I*** "BEI* "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &L ZH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+JYGN9&U00J5FV2(,G"R<<G'45MWOBJ[2]OXM-TK[9#IW_'U*9@F#C)"C')
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M@ ;EWN%C8Y&<(I^\0*GV,]K%>VAW.LHKF-6\53V<$5S:64,MJ]N)_.GNEB#
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MH>:*:(A]IZ$ 9SFF6?BRTNIIH9+6\M9X[<W(CN(]I>,=UYHO6^X=J/WE+QA
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MK5BT$R!T)&#BK593E*3]XUA&,5[H4445!84444 %%%% !1110 4444 %%%%
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M9#:*S>(K35?/&+>U:W\O;][)!SG/M6P***S<F]S112V"BBBD,**** "BBB@
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M3Z3X<L;"YV&:&/:^PY&<GI6M1164FY-MFD4HJR"BBBD,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH YF?PU]M\6WE_>PP36$]DMN$;EMV[
M).,<<=ZRI/"6L-H;Z2T\$L5G=+/8.[D%D&?D?'(Z]17=T5LJ\U^'X&+H0?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !129QUJ)[J%.L@^@YHM<+DU%4VOU_@0GZ\5$UY*W3"CV%4H,GG1HTQI4
M7JPK.WNY^9B:<*?)W%SELW*_P@FFF=STP*A'6EI\J%=BEV;JQI***8!1110
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH SM2UO3-'\O^T;V*W\W.S>?O8ZU1_P"$V\-?]!BV
M_,_X5YW\4;PS^)XK;/R6T X]V.3_ $KB:]2C@(SIJ4GN>96Q\H5'&*V/>O\
MA-O#7_08MOS/^%'_  FWAK_H,6WYG_"O!:*T_LVG_,S+^T:G9'O7_";>&O\
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MC_PE_AW_ *#-K^9_PH_X2_P[_P!!FU_,_P"%>'44?V?#^9A_:$^R/<?^$O\
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M=#2U%;S">WCF7HZAOSJ2N78[4[ZBT444#"BBB@ HHHH **** "BBB@ HHHH
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M 692QO;\_P#+5Q"GN!RQ_/%==7F8AWJ,]*@K4T%+24M8FPM/A_U\8/0L!3*
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M_0/L_P#P'3_"IQ3A2&DB#^SM/_Z!]G_X#I_A2C3=/_Z!]G_X#I_A4K2(GWF
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MHHN^X<L>Q3_LC2_^@99?^ Z?X4?V1I?_ $#++_P'3_"KE%%V'+'L4_['TO\
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MR3A7SUS0!?O+:QLYTB2/)/)/I5#]W)<22$;47UJAJ6M$E3C>1T<=ZQ[K78Q
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MB]'^AOT445F:!1110 45S_B/Q;8^&7MTNXYI&G!*B( X ]<GWK#_ .%K:/\
M\^E[_P!\K_C6T,/5FN:,=#&6(I0?+*6IWE%<'_PM;1_^?2]_[Y7_ !I#\5=(
MQ\MI>9]U7_&J^JUOY63]:H_S'>TC,%&6( ]S7G,OQ.L9.GVQ!Z+$O^-5'\>:
M3(<R?V@Q]T4_^S52P=7JB'C*71GH\NI6D6<S*2.R\U2EUU!_JH6;W8XK@O\
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M '[7_&C_ (3?1?\ GG>_]^U_QH]G/^5A[2'\R.AHKGO^$WT7_GG>_P#?M?\
M&C_A-]%_YYWO_?M?\:/9S_E8>TAW1T- KGO^$WT7_GG>_P#?M?\ &C_A-]%_
MYYWW_?M?\:/9S_E8_:0[HZ*BN=_X3C1?^>=]_P!^U_QH_P"$XT7_ )YWW_?M
M?\:/9S_E8>TAW1T=%<Y_PG&B_P#/.]_[]K_C2_\ "<:+_P \[[_OVO\ C1[.
M?\K#VD.Z.CHJKIVH6VJV*7EH7\IF9")  RD?3\*M5F_,N]]@I:2EH&+1110
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M@#1OID(\N/&_ ! J6!V:%4 P(^2U8<<@FG$RKM5>N.]6_P"U028V8JK#GU-
M%R74(Q.!-SD<"J,UUY<^0.#Z'I5=YK>1T+@AEZ>E12S1LCJ#CWH 2:_9]P)Z
MG&*R[ACYR;N1UZU-"%:1@<[@O K&O9I%N"N?;% '4VTWG(MNJC+<FM2XBEMK
M(2(F !TK&T9-[@$C*K707 >&)//G^5N .M %6QE>6!7X&.F3UKH+8-?1B.1M
MLG0;:PKF-(9HTM_F4C/%65NWBN-R-MQ@8% %W5+)HU>*-QE1R!ZUC01SK PG
MDPJG(QWK=BOK9R%<$RD9;U-9$RBXG+-E5W8V>U &UHUR]V1%MVJO3WKJC:PI
MMD3E_2N%A26S;SK=\QDXP3716&H"0*S2#.<$9H T+B(W,+ACR*Q0IYC;..F:
MN7UT\$X"*0&I86$Q5)%Y)[4 =EX#A\BUN$]C6UX*_P"10T__ '6_]#-4?"T0
MA%PH.1LJMX7U>2#PO911Q+E5;YF/^T:VA!R@TO+]3&<U&:;[,[:F/*D8R[JH
M]SBN:EU*\EX,Q4>B\559BYRQ+'U-4L.^K)>(71'22ZM9Q<>9O/H@S5.77CSY
M4/'JQK&H/2M%0BC)UYLX3XA7LMYXD19"/W5N@P.@)^8_S%<I6YXP??XLO_\
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M?JW_ %[/_*I[G/\ 8JXZ^0/Y5!XO_P"1/U;_ *]G_E5J0@:7$3T$(S^5:?\
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M($ZC+#J* .R\%LS6]T6.3M-9OAW_ ) %K]&_]"-7? 4XN+"Y<#'RFJ7AW_D
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M_OO_ -]&CS)/[[_]]&K^MR[$?58]SR+^RM2_Z!]U_P!^6_PH_LK4O^@?=?\
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M&>:ZSYME_P" LZ[08CIOB#4M)BFE>SCBBFB25RYC+9! )YQQ6_<QB:UEC/\
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MU^O[I\/CE&X(K-U(*2@WJRE"37,EH7:***T)"JE\S%$A4X,K;?P[U;JE=?\
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M$P?]_FH_X6!+_P! F#_O\U<;15?5Z?8GZQ4[G9?\+ E_Z!,'_?YJ/^%@2_\
M0)@_[_-7-Z-8+JFM6=@\AC6XE"%P,D9K3O- M)+*XN=&N;FY:UN%MYH9H@K9
M8X4K@G(R,5$H48RY6OS-(SK2CS)_D:/_  L"7_H$P?\ ?YJ/^%@2_P#0)@_[
M_-6%+X:U>&Y@MVM=TL[,B".17&Y?O D' ([YZ5*OA/67=U6WB(1!(9!.FS:2
M1G=G'4&ER8?R^\.>O_2-C_A8$O\ T"8/^_S4?\+ E_Z!,'_?YJP7\.ZJEFMT
M;7]VP4X#J6 8X5BN<@$]#TI[^%]72>"'[,CO.65#',K#*C+ D' QWS3Y,/\
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M_P!^4J]#I7B>RA2VM=8LI((AMC:XMB7VCH"0<'ZU)]E\7_\ 03TO_P !F_\
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M-)V JI9Q/=2"-I#E1D+ZUJ62AK@A,(%.#F@#2M[=S;H99,2'^'TJS:13M<@
MEE4X^E4KF(FY3RI"P[BNATRW,3;,$EN] &C-J+Q^5! I+'[QJR\\V.<@"K5E
MIGEN))!G-/O8A#&P=<9Z&@#JO H_T2Y.>H)_2J7AW_D 6OT;_P!"-7/ +B2Q
MN,'@ C]*;X:TZY?PU9RQH'5@V,'G[QKJH-*+OY?J<N(3<E;S+5%/DBDB.)(V
M0_[0Q3*W.>P4'I10>E,1YIXO??XLU#_9<+^2BL2MSQ@FSQ9?\?>97_-16'7J
M4?X<?0\VK\;]34\.@_V[:G!QD_R-'B,'^W;DX./EY_X"*N>%M1$%V;.4CRYC
M\A/9O_KTOBG41/="RB(*1'+D=V]/PKP?:5O[:MR:<EKWZ7O?[]+'K\E+^RK\
M^O->WG:UOUN<]1117T1XA<TF_P#[+U>TO_+\W[/('V9QNQVS6Q_PE,5HI&DZ
M<;4R7274S2SF4R,IR%Z#"YKFZ#P,UG*E"3O(TC5E%6B==/XX9[ZVGBLW\M'D
M>6*6;(?>NT@8 QP3@\FLV;6[)=*O=-L--:W@N8XTWM,7?*ONR>,'TXQ2S>%K
MF&TDD:[MC<10K<36H)\R.,X^8\8/!!P#4[>#+I9K:(W]ENO,_9,,3YXV[LCC
M@=N>]<Z6'CL_S-VZ\MRQ)XU:73XH)+(O*L<<4@,O[IT0C^'&<D#!YQ2W'C2.
M:YM)$L9D2VFDE7%QM8!QC"[5&,=OUK-@\,7,D<4DUS!;HUJUW*9<_N8PVT%@
M!U)Z 5:C\$WTEP\8N[8Q)%')YZAF4^9]T  9_3BDXX9?TQJ6(9<'CH?:9<V+
M"&6)$=E=1*S*20Q.W!ZXZ567Q;%+*7OM.:<QWOVVWQ.5*-@##''S# %,B\%7
MK.D4MY:03R3201Q.6R[IU P,<CO6;HNAW.MW<UO Z1M#&9'W DX!Q@ 9)/TI
MJ&'LVA.=>Z3);/73::_=ZI]GW&X68>7OQM\P'OCMFKMMXND@\/QZ<8'\V&W>
MWCE27:NUN[#&21SWP:KQ^&)&:],NHVD$5G*D3RR;L$OTP,9_2K?_  @6K!)=
M[PK(K.L:?,?-V#)((& /3.,TY/#OXGV%%5U\*[DZ>.!;VB16NFB(KY)"^8/+
M5HR#PH'?'.3GFJ4/B#3K35X+VTTAHU5I6F#7!9G\Q2" <8 &3CBJDN@/;V$5
MS/?6D<TD2SK:,Q$C(QP".,9]LYK7F\#7L]Y<_9C#!&LIBAC9F?>0H)&[''U.
M*FV'C\_4J]>7R*5OXG%K=Z;)'9!K>SMWMGA>3(FC8DX)QQU'Y5<LO',\/VG[
M3 \K27372&.4(58C&T\'Y>!TP>*S9?#%U!H*:M)/$L;IO6/:Q.,XQNQMS[9K
M$K14J-1::F;JUH/70=(YEE>1OO.Q8_4FFT45T'.%%%%, HHHH Z3P+(4\2A
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MC#5/:/E3:.55BK!E)!!R".U#$LQ9B2Q.23WKJO\ A7/B;_GSB_[_ *_XT?\
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MWAY3D7=E_P!_E_QIPB\/CI>60_[;K_C5W_A&]#_Z!%C_ -^%_P */^$:T/\
MZ!%C_P!^%_PH]SS_  #]YY?B4C#X?/6\LO\ O^O^--^S^'LY^V67_?\ 7_&K
M_P#PC6A_] BQ_P"_"_X4?\(UH?\ T"+'_OPO^%'N>?X!^\\OQ*8B\/@?\?EE
M_P!_E_QIAMO#K=;NR_[_ "_XU?\ ^$:T/_H$6/\ WX7_  H_X1K0_P#H$6/_
M 'X7_"CW//\  /WGE^)G?8_#A.?M=E_W_7_&E^R^'?\ G\L_^_Z_XUH?\(UH
M?_0(L?\ OPO^%'_"-:'_ - BQ_[\+_A1[GG^ ?O/+\2A]F\/?\_MG_W_ %_Q
MH^R^'?\ G\L_^_Z_XU?_ .$:T/\ Z!%C_P!^%_PH_P"$:T/_ *!%C_WX7_"C
MW//\ _>>7XF8;#PV6W?;+/=Z^>O^-*;+PZ1@WMH1_P!=U_QK2_X1K0_^@18_
M]^%_PH_X1K0_^@18_P#?A?\ "CW//\ _>>7XF0VD^%W/S75F?^VZ_P"-/73O
M#"]+NS'TG7_&M3_A&M#_ .@18_\ ?A?\*/\ A&]#_P"@18_]^%_PH]SS_ /W
MGE^)G&Q\,$@FZM/_  (7_&I/LWAD];FS/_;<?XU=_P"$;T/_ *!%C_WX7_"C
M_A&]#_Z!%C_WX7_"CW//\ _>>7XE7RO#6,>?8D>\R_XT+'X:0Y$VG_\ ?U?\
M:M?\(WH?_0(L?^_"_P"%'_"-Z'_T"+'_ +\+_A1[GG^ ?O/+\3/U+Q#IUE;F
MUTPQ7>H2C9!;6Q#$D]SCH!U)-:>A:<VDZ'9V+L&>&,!V'0MU/ZFI[33;&P#"
MSLX+?=U\J,+G\JM4I25N6(XQ=^:04445!84444 >'_$2?SO&EV,\1HB#_OG/
M]:Y:MSQDQ?QEJI/:?'Z"L.OI:"M2BO)'S==WJ2?F6;"S>_O8K:/JQY/H.YHU
M"S?3[Z2VDS\I^4_WAV-;'A6ZMX+HP&-S<3G ?C"J!G%+XJNK::Z\@1N+F @;
M^,,I&<5Y'U_$?VI]6Y/<Y?Z?IT/1^IT?[/\ ;\WO7_I>O4YVBBN@\-Z?;W]I
MK"S1JSI;IY;D9*$N!D?@:]F<U"/,SS(0<Y<J.?HKKI?!L$ER;:QU"1Y([_[%
M*98@H!P3N&#SP*K6GA_2KZ[=;?4[H6T=O++*\EMAE,9YQS@@^QS6?UBG:YI]
M7G>QS5%=7-X0MQHQOX;]_G@:YA6554,@/"GG.X]>!BDN/",$.G0W/VZ6)C+#
M'-Y\84*)/X@ 2P ]\9H^LT^X?5ZG8Y6BNS?P*GV^.**ZG-MY4DKRLJ'(3'W"
M&VDG/<C'>J=SX6M;+[=-<ZC)]CMXXF5HHP\A,G0$9QQ@YY^E)8FF]F#PU1;H
MYBBNJU#0[:[\?G1X"+:W?: R+]W]V#G'O_6EL_"EC?+;W$&HSBSECG+.\(#J
MT6">,\@Y^M/ZQ!)-]=0]A-MI'*45T]GX9L+Q+,KJ$Z-J4DB6(,(((7C,G/&3
MZ9JY'X5L+ZVTL6\LT4AL7NKIB%)<!MORY.,YX&<#'-)XFF@6'FSC**ZJX\*6
M=@);B]U*066^*.)H8U>0LXSAAG QWY^E2Q>" 1>Q/>/)=6\KQB*!%)P!D,5)
M!(.>V<4?6:>]P^KU.QR%%=;_ ,(]IES:Z*L#7:23VLD]PRQ@D[3CN<+SQSQB
MGQ^#+5M7NK-M1<B..*2)5""20.,]SM./8\]J/K-/J/ZO/H<?177+X9ADCTZU
MGG6V+S7*-(T01VV$8!R<9/;/2L37M)_L;4OLP,Q0QJZF50"0?H2#]150K0D^
M5;D3HRBN9F91116QD%%%% '8_#^;%YJ%MGAX5D ]U;'\FKN*\[\! OXLAB#8
M\V*1/_'?_K5Z?)IEW%_RSW#U4YKR\2U&J[GI89.5--%2EH960X=2I]QBBLC8
M6GPX\Y,]-P)IE&=H9AU"L?T-)[#1XU=S&XO;B<_\M)6?\R34MII=]?('M[=G
M3.-V0 #52MFW=Y?"MS'$[*\$P=@IQE2,5VXRK4HTX^SMJTKO97TN<&&IPJSE
MSWT3>G6P\:7IB+]CEU!1?GG>O,:G^Z35&[T>_LD:2: ^4O612"I_&J-;,3-#
MX5G:1V(GF5(E)XP.217/-8C"N+]IS<S2::[]K;:=-3>#HXA27)R\J;NGV[WW
M]3&KL=-\165GHUC&+ADNH+*[CX4_+(YRF#6!HNEIJ<]R9IVAMK6!KB9U7<VT
M=E'<\UM6G@^"_P!0AM;:_D_TRU%U:.\6,KG#!P.A';'!KLKRIOW9O8YZ*J+6
M"W+%UXGAO-/FMI;V24R:7#%M8'!N P+$^^.]:^LZW96.JW<-WJ#7&ZZMF2W\
MLXM0F"S ].1Z=<UA6'ANVU*V>"WG*QKJ#1&>2'$FQ(RS=_8X%/DT+3;ZTT;[
M(]SY,D$\LDXA'FN%; W9.T8Z9)Q7,XT;]3H4JMNA/#XHCNY=2$NLRV4KWHEA
MN?++;H%)_=C'(]<4D?BK2R^I7'E,DD$\D^E+M^ZSKM;/IS\U03>&],TZVUM9
MYIII;9+=H) HX$G(SS@GL?;I4EUX1CO=8NTMIUC$%X(KE$C"K#$4#>8!GIP?
MQH_<7ZV_X;^O^'%^^2Z7)E\3:8/#D$.8V*6RPRV;HY+N&R6'.WGKN/-1>(-=
MLKS2-3ABU9[HW5S'-;P-$RB!!U7)XX]N*JW/@Z*'1VO4OB9#;_:HU<*%://
MZYW$<],=JY[2[,:AJMG9,Y07$JQE@,E<G&:TITZ3O.+>G_#D3J55:$EN=+I'
MB:VT[3M!MI)7:&"YE>\A5>"I/R$^N#SCVJ^_B:R76;5Q?6[A()8VN&BE8$.0
M0I8G</J.G2J$?A'3IFB2+5+DM-+-;IF  >9&"23S]WCZU(=%TS^S[J6Y5A+'
MI4,\9A0 !F;&3SR<X'TJ)*BW?7_ARXNLE;0F;Q#I,6H:E+!=R'SC:E))8S*"
MR-EL9P2H'KS5F3Q-IB>(--NDU&0%5F2XDC,AB4,#MP&^;[V"1T%8MQX2B0W-
MK;WSOJ%GY7VA'BVQ_O"!\K9R<%AUZU8T_0=*A\4VMD+B6[,=P\%S'-!M3(4G
M*D'D9['FAQHVO=[?H"E6O:RW_4L#6],B\,7%D=4>XEEM'CVR!SF7=G('W0#U
MSUYIM[XIM+F;4TEG:XLFCM3;P,IVED92^/0X!Y[U13PM:7"V]W;W\OV!X9YY
M7>(!T$1PP50><]J4^%]/33WU1]1N/[/,,<T9$(\PAGV%2,XSGOG%'+0ZMBO6
MZ)&Q_P )+IL>M&ZFUB6\@EDE:&)H2%LPRX4YZ@CIA>W-<UXEU2.]U2WGM9TD
M>"%$^T1!@68=\L<DCU-:2^%+.QOG:]O9&MTOH;:()""9"X#?,,\#!P<4_4?#
M^FV]VUT\[Q&;4I+>"U2(,GRN!R<_=P:<'1C.ZN] FJLHV=EJ7[KQ'8W-[?M!
MKDEK)<F"2.Z$3$JJCYHCWZ\^AS7(:]>VVHZ]>W=G'Y=O+)N12,=NN.V3D_C7
M0Q>$8-0O]04W$MN5NIHH=D2B+Y,GN<GZ+G%8WB*V@MI]/$$2QB33X9'"CJQ'
M)_&KH>RC.T=[$5O:.%Y;&-1117:<84444 >M_#2Z:;PP\+'/V>X91[ @'_&N
MRKSOX52DP:K#V#1O^8(_I7HE>!BE:M)'NX9WHQ'"EI!2USG2/%!H%+C)%(8J
M#O4E &!14E(J)IEE'!<0);1B*X9FF3'#ENI/UJ"70-)FTV+3I+"!K.+_ %<1
M7A/IZ5I44^:7<GE78S3H&DG2_P"S?[/@^Q9W>3MXSZ_7WIL7AW1X(98HM.@2
M.:,12*%^^GH?6M2BGSR[AR1[%.[TJPOK);.ZM(IK=0 L;KD#'3'I67JGA>VF
M\,W.CZ9%#9K,0<A>,@@Y/<]*Z#-)0IR6S$X1>Z,S3_#^EZ<9'MK&"*65-DKH
MN-P[CZ59CTZRBTX:>EM$+,+L\G;E<>F*Q_$/C/2O#P,<KF>[QQ;Q'+#ZGM7F
MVJ_$;7=0)6WD2QB[+",M^+'^E=-+#5JVO3NSGJXBC1TZ^1ZWI^A:5I/F?8;"
M& R##E5Y(]/I4'_"+:&+-[3^R[?[.\GFE-O&[ID>GX5X\NL:I;:6]Y/J5V]S
M=YB@W3-\J#[[X_\ '1^-5;3Q1KMDP,&K70QV=]X_(YK=8&J[M2_,P>-I*R<?
MR/=(]&TV+36TY+&!;-NL.WY3]:CM_#VD6EE/9P:? EO.,2H%^_\ 7UKC-(^)
M+0Z?;2ZY$"9Y&19(%Y"KC+,OU../2N]LK^UU&U2YLYTFA?HZ'(_^M7)4IU:?
MQ'73G2J?"06NB:;9/;O;V<4;6Z&.%@.44G) ^M1P>'-&M]0^WPZ;;QW6=WF*
MG(/J.P-:E%9<\NYKR1[% Z-IQM;FU-G%Y%RY>9,<2,>I/Y5>50B!5&% P!Z"
MEHI-M[C22V"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PCQU'Y7C34A_>
M=6_-17.UV7Q-MC#XN,N/EG@1@?ID'^5<;7TF'=Z47Y'SF(5JLEYE_19XK;6+
M>:9PD:DY8]N*76YXKK6;B6%P\9(PP[X K/HK/ZI#ZS]9OKR\OE:]ROK$O8>P
MMI>_X6"K-IJ%U8B46TS1B8!9, ?, <C]:K45TM)Z,P3:=T7_ .V]2WR.+R0/
M)<"Z9A@$RCHWUJ:X\2:O=2%Y;QLF)H<*BJ-C?>& ,<]S6514^SAV*]I/N:"Z
MYJ*:;_9ZW)^S;2@4J"0I.2H;&0,]JEE\2ZQ.@5[P\,C9"*"63[I)QDD5E44>
MSAO8/:3[FLWB;6&GCE^U[6CW858U"G=][*@8.>^::GB/5H[J:Y6[(DF0)(-B
M[2HZ#;C'':LNBE[*'9#]K/NS7L-?N+?Q)#K5X7NID.6.0"WR[13)?$>KSR*[
MWK;EC:(850 K?>X QD]SUK+HH]E"]["]I.UKFE9:_JFG69M+2[:.$Y(& 2N>
MNTD97/M2P>(=5MH;>**Z(CMPRQ@HIPK=5.1R/8UF44W3@]T"J36S-:+Q-K$-
MS-<)>$/-MW@HI7Y?NX7&!CMBFP>(]7MPXCO6W.[2%V4,P9NI!(R"?:LNBE[*
M'9![6?=FI;^(M5M;>*"*Z_=1*R*K(K#:W53D<CV-.7Q+JZSO,;H,[JJMOB5@
M=OW>,8R.QK)HH]E#L@]K/N::^(=6$J2F]=G1G8%P&R7^_G(YS56^U"ZU*<37
M<OF.JA%X "J.@ ' %5J*:A%.Z0G.35FPHHHJR0HHHH ZCX>(7\;6?^RDC?\
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MOZ2^IP79GTI)VF13N\F,O\IZ@C!X^M7#J?B.<SW:M=GS(P'DCA( 13P 0/E
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M^@M#_P!^3_C1_P *ENO^@M#_ -^3_C7J=%'UZOW#ZE0['EG_  J6Z_Z"T/\
MWY/^-'_"I;K_ *"T/_?D_P"->IT4?7J_</J5#L>6?\*ENO\ H+0_]^3_ (T?
M\*ENO^@M#_WY/^->IT4?7J_</J5#L>6?\*ENO^@M#_WY/^-'_"I;K_H+0_\
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MD5VCBD=4&7*J2%'OZ4_JM#L'UJOW.^_X6I<?] B'_O\ '_"C_A:EQ_T"(?\
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M:1I"/3)S6GV_D<_V/F3:;J$VEW\=W"%++D,K='4\$'ZUUJ>)]%>+S&:[B?\
MYX^4&/T#9Q63;Z996MG;O<VYN)YXQ*<R%513T QU..<U#>Z'!')%/'>P6]G,
MNY1.^77!P1@#+8(ZXKR\=E^"Q\E[>-VMG^FAZ6&Q&,P<+TGH^@[Q3>/>W5M)
M&,6!BS:\YR#][=_M9X/T%;5FQM]'L5MF,<+Q!R4.-[_Q$D=2#Q6'%<Z2+5M*
M9YY(97W"[D&T0OC 94ZX/0Y/3MQ5076J:)-+9I<20$'+*I!4^C#MR.XK6>$4
MJ*H4_=4=O0XZLY3DZDG=O=^9>\5JOVJTE8 7,D.Z;U/)VD^Y']*P.3P!DG@#
MUI\DLMS.TDKO+-(>23EF->@^!_ MP]W#JVK0F**,AX8''S.W9F'8>U='-'#4
M4IN]B84Y5IVB>@^'; Z9X>L+-AAHH5##_:/)_4FM2BBO D^9ML^ABN5)(***
M*0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "D(I:* /._%_P\2Z\S4-%14G^]);#A7]
MU]#[=*Z'P(LD?@ZPCEC:-T#JRL,$$.>M='2  5M*O.=-4Y=#"-",*G/'2XM%
2%%8FX4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *F ZH# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC/S'''K098PH8NH5NASP:\I^(ITT?$_PP-7M)KO3C8W7GPQQ-)E>#ED7E@"
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MQ*Y89CV@DM@9PS<F@#V3[3!OB3SX]TPS&N\9<=<CU_"FW5[:6,8DN[F&W0G
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M110 4444 %&!G..M%% !BDP/2EK..HN/$:Z9Y:[#:&XWYYR'"X_6@#1P/2C
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MQQ^&>35^SMNR>?L=A-K^EP9W7L9([)\Q_2J$OC'3T^Y'<.?]T+_,U':>#[=
M#=W#RG^Y'\B_XUM6VEV-FH$%K$F.^W)_,\TO=0_>9CKXBU&Y_P"/31)G!Z,[
M8'\JLI-XBE_Y=+&$?[<C,1^5;5%3?R'8SD@U9O\ 67MLOM' ?ZM226VK#F+4
M(#[/;_X&M*BBX6,,GQ)&>18S#_8RI_4U$^KZO!Q-8 8[[&Q^8S70T4[^0K>9
MS\'B1Y#AK5&(Z^7,"?R(%6DU^UW8EBN(?=H\C\QFKT]C:W(/GV\;Y[E1G\ZS
MY= C _T6XEA_V6.]?UY_6G[CW%[R+T&H6=R<0W,;M_=#<_E5JN5NM-NH<F>T
M6=!TDA&X_EU'X9J.VN)H@?L=XX /*.=ZCVP>15>S3^%BY[;HZZBL2#760XO8
M"H_YZPY9?Q'4?K6O#<17$8DAD61#T93D5FXM;EII[&=K7^K@_P!X_P J9I%H
MP;[89#\P9 F.,9Z_I4NM(3:QR ?<D&?H>/\ "I=)(.G(/0L/U-7?]V1;WR]4
M<<T<KR(CAFC.UP/X3C-25@"<V[:U(LZ0-YZ@2,N[&47H.Y]!4QC<<I<IO45S
M]E?SIJR0-+=2P20L_P#I,00Y7'W< >M36)O[JUM]0-^%\U@QA91Y80G[H[Y]
M\]:ITVMV2JJ>R-E9$?.U@VTX.#G!]*6N;L6DL],U.47OEG[4ZAY%!"G=UP!R
M3Z5+97EQ_:T=J9KMX9H7;=<Q!"&&.5X'KW%#I[V8E5VNMS=21)%W(P89(R#G
MD=:=7*VES/I_AZ,PR2/)-=M$IV!BF7;) [GC\S6CIES=M?O XNGMS'N$ES&$
M96STXZBG*DU=A&JG9=S:HHHK(V"BBB@ HK@=5\?Z==3Q:; ^N:?<&\CB$XTM
MRK'> 4RPQANF?0UWU ''>,_%VH>';W2K>RTMIHKJ\@@GNY>(HUD?;M'.6?\
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M-N90%(D8@GOP/7FNB\&[?^$7M-HF ^;B:^%XWWCUE!(;\^.E &_12,RHI9B
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M^4?@#[5=.I.[YE]PJN'CR1E$Z>;7M,M[JWMI;R)9K@XC0MRU66O[8''G*3Z
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MIQQM]SN%Z*/2N^\.6(MX-^!P-H/K618:&MO(B1Q!"W3YMQ^I-=C!"L$*QJ.
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M86L-K;K]V*% BC\!66W_ "/J?]@QO_1JUNUA-_R/J?\ 8,;_ -&K0!NT444
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MAG!)"I)[QG'\ZK/J4EL"LR';_=(SBJE&E5U@[,CZK6@^:GJ=7:7>YA%*1O\
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M_A"O#?\ T"+;\C_C7GG@O/\ PG%B$S_;(FU+^W/O9V>8/)WYX_N[?;.*]A%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH P_%OAT^*O#T^CG4+BQBN"!+) !N9>Z\]CWK)@\#7D.A)
MIS>*=3,D$R2VEPBQQF#8,!-J@*R>JD5V5% '#GX:VT=G ]KJ]];ZS%=2W?\
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M% "!%#%@H!/4XY-+110 4444 %(J*BA54*!V Q2T4 %%%% !2$!NH![\TM%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'&!FLG4->U"PT2"Q/BJ*[U*74VLTGL+%9)I !DQ[<[%D ZL>/:@#T5F51EB
M/4FEKPG5M8\0>(/!EJ+K56@N+3Q7'8^;Y,>Y@&&QG"G:2I.2!P<5L>,?&6MZ
M7<ZI<Z3K,LZ:5+;PRQ"RC6!6;:&$CL=S,<Y 0<4 >L1W=M-<2V\=Q$\\./-B
M5P63/3<.HS[U-7CSRZK!XT^*%SH;A-2AM[&:'*!MQ6+<5P>N0"/QJRWCK7/$
M.G:[JWANZM8[.VM[:"T6<H@DN'VO*0S8&Y5.T*3C- 'J=S<P6EN]Q<S1PPH,
MO)*X55'N3P*D5E=0RL"I&00>"*\;O/%M]-X!\8P7L]S-J.GQ1.;/5=/C5X5<
MC&[;E) >2#@5:\3>*/$NEWIEBN9K?1[>Q@D,NGV\-P8&*Y8SQL0P7TVXXH ]
M;HKFO%&MSV?PZU'7--G'G)IYN8)=G&=N0=I_D:YB?5M>M-&T"WN/$DTNJZRQ
MG1+/3HVD*>6&,:;CM4*3DLU 'I98+U(';FEKPR;6=>\3Z/X)N;C5OLUU_;\M
MJ\J0H0Q3<%<@':2 ",#@YS6JWC3Q7=Z[J5S9;Q:V.L"P^Q-%"L+1@@-ND9@X
MD.<C QT'- 'KU%>3:KXN\0Z5XMN7U"]FM]%CU!((IK2VBN;81G V3$'S$D)/
MX9Z5ZS0 4444 %9?B218_#6IEMQS:RJ JEB25(  ')K4HH \(^$MMIMCX*6+
MQ!:7-G?66I_;(C)92>9P%QM.W)!Y&*]>\-:VWB'3I;_[)<6L)G=($N(C&Y1>
M-Q4\C)R?IBMFB@ HHHH **** "BBB@ HHHH **X'XQRRP^ )'BD>-OMEL-R,
M5/\ K5[BLW6_'WB2SD\6SV5KI9L_#L\083!]\Z,JD@8. 1D\_3B@#U"BO(+[
MQ9XBT_Q3XMU6":UEL++1H+N&UF#G;N4E< '&<YW>O&*W+GQ7XDL_#^EW5Y/H
M=O=ZF_F1HL<TK+$4#!5B7YI'R>2, "@#T.BO+M+^(FNZ[9Z!8V5I8V^KZG+=
MI)+.K^3&MN<,0F0V6XX)XYJQKGCO7-&CT+3;FUL8=8U%IO.EA26ZAC6+J51!
MO).1QVYS0!Z317C<WB*_U_Q3X$O+NVGL)W34XY[?#HK,D0PP#8)4\$9Z9]JL
M_#/Q/?1V/@O0F"2PWVFW-Q+-(6,FY)"  <]* /6Z*\;7Q1?>)-6\ ZA<[('D
MU:^A=("P1EC!49!//2M?1?B%JMYXPTK3;C^S;FRU)YXP]E%-MA,:EAB9L++P
M.=HX- 'IM%<5\/\ Q%X@\56DNJ:A'IT.G%Y888X _FETD*[F). , \5P,^NZ
MEX=\<^,M2GN';0)KK[!<KDG[-(T(,4@]!N)4X]10![G17AFIZ_#'\(_!>AW>
MJM8G6%C%S>,Y#1P)\SMGKD_*!]:E_P"$F;5_V?-<C6^\Z\TH&R:XC8@R*LB[
M'SU^9<<_6@#VZBO*;C1[?P3XM\(2:#)=Q+JDKV]W:/<O*DR^7NW8<G!![BK&
MC>./$]Y\0[W3+CPS>QV@BM\P--#FT#,P,K$'Y@1V!)^6@#TZBN'\:SS1>,_
MT<<LB))J$H=58@./*)P1WJSX]\77'A>#3(;.)&NM1NO(222)Y5B &68HGS,<
M= * .OHKS6S^(>KK!I=UJ>GQV]FVIMIU[,\,D0(*YBF0/@JI/!#9P:JW/Q-U
M1="TR]2TMXWUO498K!C!)*([9/\ EHR)EG8XR ,=?:@#U2BO';GQ+J6O:MX(
MFO;:6RN(];FMI5"21)<!4!5U5\':P(X/0Y%:WACX@:OJ7BJ'2M9CLM.DF:93
M8S6\T4RE2=NR0Y27(&3C'M0!Z91110 4444 %%%% !7@6O?8+_\ :?T^&X:"
M:V-N(Y S#;GR7X/OTKWVJ9TK3RY<V%J7)SN\E<Y]>E %7PYH-IX:T==+L5VV
MD<CM$F2=BLQ;&?;-:U XHH **** "BBB@ HHHH **** "BBB@ HHKSSQI'_;
MGQ \/>%[VYGATBYMY[F:*&4QFY=,;4+#!P,DX!H ]#HKQ&XGTO2M%\<Z/I,?
MB#3I$TM[@65^W[J( E=\1+%OF/OVK87X@WGAO1Y;2[MX9'CT.TN]*SNW7+NJ
MQE6YY(<KT[&@#U:BO/7\3^+;[6-1T[2K?1_.T:&W-]]J9U$\LB[F5"#\B@9Y
M.>:?J?BSQ'<Z]JVGZ!;:8BZ-:1W%T;UG8RNZE@B%<8& ?F.>: ._HKQL>)]1
MU3QBFO:-#_I$WA+[9!9SLQ0OYN2I (R>" ?I5G7_ (@ZCKGAW6)/#LD$-K;:
M"E[/=?-YD4TG(C4@\,%#'V.* /6Z*\F'B*YT76=&NM7@AN;FW\,SWLLT#R#<
MJ8(4*6QDC&203G/:NJ\*ZKXIU%K.ZU>'2!87]H+F,6KN)82<$*0V=XP1DC'-
M '7T5XU\8->@N-;M/#O]N#2OLMI+J#RARI:<#$$>1ZG)Q5/QK+IOBKX6:?XT
MC$RZI+]FMY)([B1 I\S;(NT''4MSC/2@#W&BO'/'VAZ9H5_X0TJUTW4KO39+
MJY>6QM+B1I9CY8/!+@G! /7L:Z3X8Z7JVG)K#W5K>V&DSW"MIMA?3>9-"H7#
M9.3@$XP,\8H [^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO?6-IJ5G
M+9WUM%<VTHVR12J&5A[@U8HH R-(\+:%H$,T.E:3:6D<_$HBC WCT/J/:F:3
MX1\/:%<33Z5H]G9RSC;(\,04L/3V'M6U7,^+;FZDGT?1K2X>U_M2Z,<T\;;7
M2)$9V"'LQVXSVR: -*+PYHMO%811:9;)'I[E[150 0L<Y*^F<FL/7OA_IFL2
MZ8L4%M!:VVHM?W-OY(9;EF4AL^YSUJ8Z7IOA:XFU&TOIK>*"REEN+)IVD$RJ
M,^9AB2",$9'7.#7'V]]JND^"[S1+R_F?4-1M(;BRF+DR W#*DB@_[#OD>@8>
ME 'H">$?#R:&VBKH]F--9MYMA&-I;.=WU]^M-A\'>'((VCBT6S1'DCF8",?,
MZ?<8^I&>M<?8ZQ+IWQ&U6\NKV;^QH[62T2-B656MEB9FQZGS&'J<4>'/$@TW
M5]=U;Q-?2VYO+F."WMRLDBP[8PQ0!00"!(H)XR0: ._ET?3I]2_M&:R@DO/(
M-OYS("WE$Y*?3/:J>E>$O#^AW+7.F:1:VLS+LWQI@A<YVCT'L*XCXA>)XIKJ
M\TV#5OL0TJW%Y)MD*///]Z.('T !9A[J*[5=?677H;*)8_LQT\WTLQ/*@L @
M'U&X_A0 :?X0\.:5JDFIV&BV5M>R9W310@-SUQZ9]JD7POH265O9KI5J+:VN
M!=0Q",;8Y@2=X'9LD\^]<5>Z[<Z^-,N&TV[O85T^2]N;"SN#"(PY_<NS$C<2
MJM\N>#SCI72:7?W=E\-H-1%PFHW,6G?:%E<D";"%ADGGI@9ZT ;VH:=9:K8R
MV6H6L5U:RC#Q2J&5OP-9]MX1\/6>C3Z1;Z/9QZ?.<S6ZQC;(>/O>O0=:R[[Q
M;>>5=S:3IXO(;2TCEF<;F(DDVD*%7D[4)=L<XP!UK3\,ZO<:S8RW,S6<L0DV
MPSVCDK*N >5;YD8$D%3Z4 :TMM#/:O;2QJ\$B&-HR."I&"/IBJ4GA_2)K:PM
MI--MGAT]D>T1HP1 5&%*^F!67XLN+J6?2-&M+A[7^T[HQS3QMM=(D1G8(>S'
M &>V352]L[#P:9-3T^>XRD!5M,^T%_M3,RJC?.25.X@;A_>YH Z6QTJPTQKE
MK&TBMVNIC/.8UP9)#U8^IK-N/!7AF[L4LKC0[*2UCE:9(FB&U7;[S >IK,O?
M%.J:)]OCU:WLFFATN34(C;,VW*$ QL#SR67!'7GBH)/$WB2*6>":RTR*2+3%
MU"5C([+;]<HW=B=IP1CH>M '0V_A;0;32)])M](LXM/G&);=(@$D_P!X=ZLS
M:-IMP]B\UE"[6#;K4LN?).,97TXKCIO'&K/97UW:Z?:+#8Z=;7<WG.V6EE4N
M8E [XVX)[GI4]_XVO-#;4SJUG;XMK2&XCCMV8LKRN46-CCDY'4#UXH ZO5='
MT[7+%K'5+*&[M6()BF0,,CH?K5!O!OAMM(ATDZ+9_8(9/-CA$8 1_P"\,<Y]
MZYD?$&\6PU*1+6"]F@BB:!H8YHHWD>0((CY@!SD@Y';L*U?[9\2SZA>:;:6N
MF-=V48EF9G<1G?DI$.^[ R6Z#(XH T6\'>'&TJ?2SHMF+">02R6XB 1G&/FQ
MZ\#FH[GP/X7O+AY[G0K&661%1V>('<%&%S[@# /6L:]\2R6FIZA<^3;P7,(M
M[0?:+EV0,R&5QL7.\J"/N#)SV JK!XHO/$4FFV2@1N-;\B26 21K+'#'YK$!
ML,O.U2#[^M '5WFBB&/4;O0X[.SUB]1%>[EAWA]HPN\ @M@9 YK/\-^!]-T/
MP8GARZCAOX7+/=&6(;9G8Y)*_ECTP*@\=:]#8P6>BC4%LKC5'*-<;]I@@',C
M@]CCY1[L/2L_PSXCEMO!?AV.)_ML]Q?G3A)+(6+*KN&?/4D(F>: .DM_"'AZ
MUTVZT^'1[1;2[Q]HCV9$N.F[/)Q2:AX.\.:K<1W%]HUI/-&@C#O'R4'13Z@>
MAKF/%&IWVO//H%I)):)+J\-@ES;N5DPL7G2M[ 8 X]ZKS^*KJ9M/NY6>*72=
M-O;G4(@VT&>/$04CN"VXC\* /0KJPM+VPDL+FWCEM)4\MX67Y67IC'I5/4/#
M6BZK;6MM?:;;SPVF/LZNG^JP,?+Z<<5P&F:;=7&FZ*FFZ;KEOK"O;R76H7<C
MI& "#*2&<A]PW#:!W[8KIM+\3ZC?>)9=-EMK6$1RR(]M(62X2,9V2C/RR*V!
M]WIN% &E+X.\.3:4-+DT6S-BLWGK;^4 BR?W@.QIT_A#P[<ZRNKS:-9R:@K*
MPG:(%MPZ'W(['K6U10!B3^#_  [<ZM_:DVC6;WI<2&4QC)<=&(Z$CU/-;=%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!E^(/#]AXFTLZ=J2.UN9$D
M(1RIW*=PY^HJC=>"=&NX-=AECF*:X5:]Q(1N*@ ;?3@5T5% '*7_ ,/-!U&Z
MGN)ENE:XL183+'<,JR1 8&X="0.AJUJ?@S2M4BTM9#=02Z6NRTGMIVCD12H4
MKN'."  :Z&B@#D&^&OATZ7;V$4=W EK<27%O-#<NLL+2??VOG.#Z'-/N/ 7A
MV+1+.T5)[*+3"\T%U!<-'-$6!WL9,Y.[G.>M=97-^-CNT.&W9BL-S?6T$Y!Q
MB-I5##Z'I^- %*P\.^%)]0TR"TN#+>:)"[11_:6:1$N%Y9P3D[AR":AM_!/A
M.ZBLM+L;B99O#Y:)3:WC+-")/F*.P.<,.QK'N;N/0?'^M^(7 $$-Q%:79](G
MMU*'\)%4?\"JA'/J?A^Q\1SPX34KI[![N4,J>6TQ;>VYN%P&P">!@'M0!VUI
M\/\ P_8KI:06\JIIEQ-<6RF4D*TN=^?4<]*ATSX<:#I%Y875J;W=I\CO9I)=
M.Z0!P0RJIX"G)XKFUUG5;.WU"PNKN[A1Y;:.!8[^*YNEDD9@4\P@! P (+<C
MG':JD&L:T]U/I(U2[M@NM6=OG[4EQ+&DD;%T,F,'I[XH ]*T'0;'PYI@T[3D
M=+<2/( [ECN=BQY^I-5'\(:-+%K<4MNTD>M-NO%=R0QVA>/3@#\:J>%);J/5
M/$&E37L]W#874:P27#;I KQ*Y4MWP2<9K"NYO$?_  L. QZ]HZVPM9E :%MJ
MCS4^1OWG,F.A]CQ0!M0^%_#/A5[75I7\A-/LA80R7,V4CBW9P >-Q/?J>E49
MM(\$:[9>(M1%Y$;34(D35'BN-BJ(^5+#^$X[]Q6IXT2TDL].2YU Z=,+U&M+
MIHP\:3 -M#@\8(R.<<D8.<5QVMWDS:5XNM;]-+N=0&CAWU+3\A9$RP5)%).U
MAR1R<@]J -;POI_@2SUN.XTW5?[0U,1LD+W5Z\[QIC+!-QPO YQ776%UHU[
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MJ07,D(7R7E9PV]5X.%0L!QZ&KMUJ6J:,L4ESJUI>6R:E'#/*(U5HXF0@J^.
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MHHH **** "BBB@ HHIK.B %V502 ,G'/I0 ZBFB1"Y0.I=1DKGD4Z@ HHHH
M**** ,V[T#2[^6YDNK*.5[F..*8MGYT1BRJ?8$DU:6QMDOY+Y8E%U)&L3R]R
MBDD#Z9)_.K%% &3=^&M&OX[V.ZL(I4OI$EN0Q/[UDQM)Y[;1Q5J+2K&&>\GC
MMHQ)>;1<$C/F!5V@$'C '&*N44 8ECX1T+3KJ&YMK!5D@SY.Z1W6'/78K$A/
MP J5_#.COJ'VYK)#,91.1N;89!T<IG:6]\9K6K(\57$]IX2U>XM<B>.SE9".
MH(4\_AUH K0W?AN)8])CN(0-6>X\N%G8FX;GS<$]>_3\*?>P^'WDL/#EUY(E
M\OS+.V#%758QC<A'(P.,YKA_%&GJNI>$AIYS)I^E7%U:%>=QB$) ]]PR/^!5
M5OM3:\\36WB[3D,DEQ:7XT_<,[XX81M('HSEC^5 'JFG:99Z5;&WLH%AC+%V
MP22S'JS$\DGU-9][X1T+4;N:YN;!6DGQYVV1T6;'3>JD!OQ!KC=%UC4;2:&>
M;4@]K)IDMS<EM0%W(VU0PECC"#;R2",@'(&.*H)K>I6D@\K4+M?M.B7EP!<W
MZ7#LR(K)+M48C.2> <>W% 'I5SX?TF[=GGL8G+1QQ'C V(V]%QTP&YQ7,ZEX
M(GU?7'GO$TW[(]W'</*B.)9%0AE1ESL)R -_7'%.T07EAXETJ"35KV\2_P!+
M>>=;F3</,4Q_,HQ\OWR,#CI4/CU]6-YI:V.L6%M&E[;NT,J9=<,<R,=XRG3(
MQ^- '23^'=$^V/J4]I&)!(+AV9R(]ZCAV7.W<,?>([5BVC^!O$FLS&VDM;J]
M+I<.@=P'>,C;(%.%8C ^8 ]JT-6:&3P)>G6)S>6[V;BYET]/OJ002BY/;W/2
MN=M+V:UUG0()M1TKQ!:R2&.SF@C"75OF-OWF%)4KM&&.%ZCZ4 6(M;^'E[K,
M=S#=VTMY+<!U"B0HTW0/MQL+?[6,^];UC!X<NI9M*LEMY)-+NA/+ K',,S$N
M&/N2Q-<CX!N[]/#&AC_A)=&2U$:C[*T(\T+G[N[S.OOM_"JHOV\.>)=>UV,*
M4FU&:PD0_P <ODQ/ /Q;<O\ P.@#JUM?!US?W%ZOV9YK;45$K"1MD=YQ@E<[
M0_(YQUZUM/H6ER:4=,:SC-F7+^5SPQ;?N!Z@[B3GKFN"TG2TT[PSXXL9=ADB
M!DE8=YOLJ.S?7?DUW^B7$UWH&G7-Q_KYK6*23C'S%03^M %<>&-'^PRV9L@8
MI91,[,[%VD&,-OSNW# P<\5FZKX1BOK*#18(;2'1))A/>H=S33,&#8S[D#+$
MYQ74T4 46T>PDU1-3:V7[8D)MQ("1^[)SM(S@C/J*J6GA70[$OY&GQ@/$T&U
MRSA8SU10Q(53Z# K9HH S--\/:7I,QEL[;9)Y8B#M(SE4!SM!8G"^PXK3HHH
M **** "BBB@ HHHH ***Y_6=)U_5;IDM-?\ [*L0HQ]FMU>9SWRSY 'I@?C0
M!T%>9V?AG4D\?6][:: NDB*^GGO=0BN]Z7L+@[5VDYW$D$@@!<<5T7AR+58=
M0G@/B=-9M;:0PW*7%LJ30R;00 R8!ZC(([]:ZJ@#+UB'47A,MAJ*V@C1F96M
MQ)N.,CJ1BG>'KV;4O#>EWUP5,]Q:12R%1@;F4$X';DU;O?\ CPN/^N3?R-9G
M@_\ Y$K0O^P?!_Z+% &U1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5Y3\2;C67\1Z1G2K^32K+4+
M1X6MW39/*9/FW G/ X'&,DDGI7JU(0#U - 'CWA@-_PL6T!5AK0O]2;5.&W?
M9R/W.X]-OW-O;TKT:'7YO[=M]*O=+GM'N4E>"0R(ZN$QG[IR.&!YK;V@,3@9
M/4US>K?\C_X;_P"O>\_E%0!TM%%% !1110 4444 %%%% !3)8TFB>*10\;J5
M92."#U%/HH SM-TB#3K.UMR%F-JABAE=!O2/LN?H /? JU'96D7D^7:PIY *
MP[8P/+!ZA?3\*GHH J6VEZ?9/*]K8VT#S?ZQHHE4O]<#FF0Z+I5NA2'3;.)3
MNR$@4#YA@]!W'!J]10!&+>$2)((8P\:E$;:,JIQP#V' _*JEYHFDZA,)KW3+
M*YE"[=\]NCMCTR1TJ_10!%!;P6L"06\,<,*#"QQJ%51Z #@57M='TRPFDFL]
M.M+>63[\D,"HS?4@<U=HH RQX9T%9!(NB::) =P86D>0?7.*N-8VCA@UK"P:
M02L#&#EQC#'WX'/7@58HH SM3T>#4K*>T)$,=RRFX,:@-*HQE2?<#&?2M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^\WK_=/K4T7^\B32^->IZ[7EGB^]NXO%%W'%=SQH-@"I(0!E?2O5*\D\9?\
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MZ9/ SC-:]><^-3J%WXDM].C\-7]QH[>5+?W5G%&7N61@R1$D@[ >2>O88YH
M[*W\2:-=ZU/H]OJ,$FH0 F2!6^88QD>A(R,@=,\UG:K_ ,C_ .&_^O>\_E%7
M*>'] UBV\86$-Q83I#I^H:C>27S;?+F2<?(%.<D_-R,<;:W)DU5?B'H)U&>S
MDC-O>>4+>)D(_P!7]XECGC'3% ':4444 %%%% !1110 4444 -E_U3_[IKR8
M]3]:]9E_U3_[IKR8]3]:\;-OL?,YL1T$HHHKQCF"G)_K$_WA_.FTY/\ 6)_O
M#^=-;H#UE?NCZ4M(OW1]*6OL%L>D>(:B,ZM>\9_TB3^'_:-5MO\ L_\ CM6=
M1&=5O?ES_I$G\.?XC5;;_L_^._\ UZ\*?Q,\&7Q,-O\ L_\ CM&W_9_\=HV_
M[/\ X[_]>C;_ +/_ ([_ /7J1#9%_=M\O;^[7M^F?\@JS_ZX)_Z"*\0D'[MO
ME[?W:]OTS_D%6?\ UP3_ -!%=^!WD=V!WD6Z***]$]$**** "BBB@ HHHH *
M*** "BBB@ KCO'[03Z?;VR6[W5\LP:(0ZD+-[<[3^\+Y! [=#G/2NQKSWXDZ
M3;,MG<VOA[1KW4[N;R#<ZA9^<% 1F53CG)*A1SC)H ?X.C\:65U:Q:IJ]AK>
MG2^8)I(6#26A R@,@QYF>A^4'O74V_BC0[O6I='M]4MI-1BR'MU?Y@1U'N1W
M':N5^%%S#<:)?B"+2T5;H9.EV9MX23&A(P>2P)P?IBLK2[VTU;XCP(=)O=-L
M=,N9OL,2Z;(BW,[@AYWDV[0O7 SR3D]A0!Z=>_\ 'A<?]<F_D:S/!_\ R)6A
M?]@^#_T6*DURZU&WM'%EIJW:M$^]C<"+9Q[@YJ/P?_R)6A?]@^#_ -%B@#:H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH BN?^/67_ '#_ "KY<KZCN?\ CUE_W#_*OERL:O0\G-/L_,*GL?\
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M)M/]W_QT4;3_ '?_ !T4N!Z?^.BC ]/_ !T5(ADBGRV^7M_=%>XZ9_R"K/\
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MP?!_Z+%:=[_QX7'_ %R;^1K,\'_\B5H7_8/@_P#18H VJ*** "BBB@ HHHH
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M #\1?]]BC[9;?\_$7_?8KA !CI2X'I3$=FEU;B]E;SX\%%&=P]34_P!LMO\
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M_P#R)6A?]@^#_P!%BKFJ7EK;64RW%S#$S1-M$D@7/';-4_!__(E:%_V#X/\
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M[BATRZU%+>:-5S),2DC$$G@*-HX'))]J[.J=[I=EJ,MI)=P"5[.<7$!)(V2
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MV/\ YZ+^=/!!&1TKCCTKJ[7_ (](?]P?RKJP>->);7+:QC7H>R2=[G-^._\
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M=ASGYF[Y_A-31_B1]14OXB]3UZO)/&7_ "-EY]8__0:];KR3QE_R-EY]8_\
MT&O0QO\ #^9Z&-_A_,P5Z#_@/\Z0?Y_.E7H/^ _SI!_G\Z\P\LZ3P-_R-D/_
M %SEKU:O*? W_(V0_P#7.6O5J]3!_P (]3!_P_F?/?C/_D<]6_Z[G^0K"K=\
M9_\ (YZM_P!=S_(5A5C/XF<D_B85WGPF_P"1GN?^O4_^A"N#KO/A-_R,]S_U
MZG_T(55+XT71_B(]EKX>\;?\CUKW_80G_P#0S7W#7P]XV_Y'K7O^PA/_ .AF
MN\],P:*** /=/V:?^0OX@_ZX1?\ H35]%U\Z?LT_\A?Q!_UPB_\ 0FKZ+H *
M*** .<\7Z1K.MV"V.FS:6MM("MU%J%NTJR#C  5A5/P/X5O?#(O!=+I"K-L"
M#3;9XL;<_>W,<]>,8[UU]% !1110 5S6K?\ (_\ AO\ Z][S^45=+7-:M_R/
M_AO_ *][S^45 '2U#=_\>4__ %S;^535#=_\>4__ %S;^5 '"#I10.E%,044
M44 6+'_D(6__ %T7^==S7#6/_(0M_P#KHO\ .NYI#&R_ZI_]TUY,>I^M>LR_
MZI_]TUY,>I^M>-FWV/F<V(Z"4445XQS!3D_UB?[P_G3:<G^L3_>'\Z:W0'K*
M_='TI:1?NCZ4M?8+8](\/U'_ )"M[S_R\/\ Q ?Q&JV?]K_QX59U$XU:]Y_Y
M>)/XL?Q&JV[W_P#'J\*?Q,\&7Q,,_P"U_P"/"C/^U_X\*-WO_P"/4;O?_P >
MJ1#7/R-SV_O"O<=,_P"059_]<4_]!%>'2-^[;GM_>KW#3/\ D%6?_7!/_017
M?@=Y'=@=Y%NO&_%'_(S:C_UU;_T$5[)7C?BC_D9M1_ZZM_Z"*TQOP+U-,;\"
M]3*/?ZG^5 [?7^E![_4_RH';Z_TKS#S1$_A_X#_*A>W_  &A/X?^ _RH7M_P
M&FP/8?"O_(K:?_UR_J:V:QO"O_(K:?\ ]<OZFMFO<A\*/<I_ O0****LL***
M* "O./'VM^+]/U$PV,,UEH7DY?4[.T^US!\=-F?D&?XL'UKT>B@#B?A9-:77
M@Z&\AU2?4;VX(>_DGG,CI/M&Y"#]W''R\5VU116T$#2-##'&TK;I"B@%VZ9.
M.IKE]/\ '^GZAXD&DI:721R3S6UO>.H\J>:(9D0<Y&.>2,'!H Z:]_X\+C_K
MDW\C69X0_P"1*T+_ *\(/_18K3O?^/"X_P"N3?R-9GA#_D2M"_Z\(/\ T6*
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M5Z#_ (#_ #I!_G\Z%Z#_ (#_ #H'^?SKS#RSI/ W_(V0_P#7.6O5J\I\#?\
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M0QLO^J?_ '37DQZGZUZQ+_JG_P!TUY.>I^M>-FWV/F<V(Z"4445XQS!3H_\
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M44 %%%% !7D_Q.M'?7+EKFRENDNM%:TTSR[=I-EX90>"!\K8V'/'"GFO6**
M.;UC0=3UK38;-]4CMXP(7<?9M[&2-E?.=W0LHJW]BU__ *#-K_X _P#V=;-%
M ',WWA_6+]T:76X 4&!MLO\ [.JO_"(:G_T'(O\ P"'_ ,5785Q/B/X@6NG:
M>[:8\4ERE^+"8W".%MI,$@NH&[!QA<<$D<T 4M!T;5M9T^2Y;5X(BES-!M6S
M!R(Y&3/WN^W-:L?A/58Y$D77(<J01FR'_P 56EX5U<ZQH_FS6\5O=PR&&[BA
M.Z-)A@L%;^+KU]<CM6Y0!C?8M?\ ^@S:_P#@#_\ 9UE:EX4U75+A9Y]<A5E7
M:-MD.F?][WKKJ*B=.-1<LE=":35F<+_P@-]_T'D_\ A_\56;X?\ "VH:WH-I
MJ3:S'$TZEBBV@(')'7=[5UVH^*+?2?$-GIFH6\EO;WHVV]\Q'E--_P \C_=8
MCD9Z]!5^RU/3KJ\N]/LIHWEL2JSQQCB(L,A2>F?;M6/U.A_*B?9P['-6W@G4
M;2ZBN(]=C+QMN -D,?\ H5;?V+7_ /H,VO\ X __ &=;-%:TZ4*:M!6*45'8
MXC5_ VHZS??:[C7D238$Q'9@# _X%[UF7/PVNX+6:;_A(23&C/C[(.<#/]ZO
M2JY_3O%-I>ZMJ&D7D+V%_9Y<PW##$L':9#T*GOZ'@TG1IR=VC-T:;=VCB]$\
M WFKZ#I^I-KWEM=VT<Y1;4$+N4'&=WO6SIW@"_TS4(KV'7PTD6=H>S!'(Q_>
MKKM)U"QU73(+S39%ELI!^Z=%*J0#C@'MQQ5VA4*:=T@5"FG=(QOL6O\ _09M
M?_ '_P"SKGM2\!7^JZA)>SZ\BR2;<A+(8X&/[U=U2,P12QS@#/ S5RA&:M)%
MRA&:M)'ENM> ;O2-!U#45UP2-:6TDX1K0 -L4M@G=[5-8?#JZO=.M;HZZ%,T
M*2%19@XR <?>]Z[O2]9TSQ!I/VZRG2>T?<K[AC:1PRNIY!'<&K\11HE,14QD
M J5Z8[8]JS^KTOY3/ZO2_E.*TKP)J&D:@MY;Z\C2*K* ]D,<]?XJW_L6O_\
M09M?_ '_ .SK9HK2,%%6B:1A&*M%'FVI_"N?5=3N+^?Q 5EG?>P2S& ?;YJP
M/$OPRDT#PY?ZJFN-,UK$9!&UJ &]B=U>T5S]IXEL[W6[_0;^V:TO( 9$CN""
MMU!_SU0]"/4=1WI>SCV)=*#UL<6OP=9D5O\ A(7Y&?\ CT7_ .*K7\/_  \O
M?#=])=V>O*\CQ^61+9@C&0>S>U=CIFJ66L6"7NGSK/:N6"2J#M;!(./49'7I
M5RA4XIW2!4H)W2,;[%K_ /T&;7_P!_\ LZ\NU/\ 9ZM-6U6[U&X\1W FNIFF
M<):J &8Y./FZ<U[54-U<I9VDUS*',<*-(P12S8 R< <D^U6:'SYXC^ %AH>C
MM?)K]Q*PFABVM H'SR*F>O;=FM7_ (9IT[_H9+K_ ,!E_P :]DL=4TW6M'BU
M*UN(;BPF42+(<;<#UST(([]"*O@@C(Y% 'FO@KX42^ [B[FTK7S(UTBH_GV@
M. I)&,,/6NR^Q:_C_D,VO_@#_P#9ULT4 ,B#K$@D8.X #,!@$]SCM3Z** "B
MBB@ HHHH \TT#POK=EXML8[BS*V.FWU_>"],RD3BXSL4+][(W'.>.!UKJ)O!
MUM<7\5[)JFKFXA#B)A=GY ^-P''0X'Y5T=% &%_PC _Z#>M?^!A_PI&\+JZE
M6UK6B",$?;#_ (5O44 <M_P@EA_T$M7_ / P_P"%'_""6'_02U?_ ,##_A74
MU@:OXMT[3=*GOH98[LQ72V92.55"S%@NUV/"8SR3T% &5;^!D.I7BS:AJPM0
M(_(/VP\G!W?KBK?_  @EA_T$M7_\##_A5_PUXAC\0V#3&W:UN8R!-;.X9DSR
MIR.S###ID$'%;5 ',)X'LHW5TU/5PRG(/VP\'\JM?\(P/^@WK7_@8?\ "MVB
M@#!/A@$8_MO6O_ P_P"%9_\ PKO2O^?[5?\ P,-==4-U+)#:32PPF:5(V9(@
M<%R!PN??I4RA&7Q*XFD]SE_^%=Z3_P _VJ_^!AJA_P *^A_M_9]KU3^S?LN=
MWVLY\[?T]?NU5\,_$'49K_[-X@LI$CFFA@2YBM'B2WN'7)MY QW9&5 8#!SV
MKT>H]A2_E7W"Y8]CD?\ A7>D_P#/]JO_ (&&@?#S2@01?:MD<_\ 'X:ZZBCV
M%/\ E7W!RQ[&%_PC _Z#>M?^!A_PH_X1D?\ 0;UK_P ##_A6[16I1QK_  UT
M:21Y'N]5+NQ9C]L;DGJ:3_A66B?\_6J_^!C5V=>?O\3K:T\57>GW\,5OI]N\
ML3R[V::(QX_>21A?EB;/RMG^=1[.'8CV<.Q'<_#6U&O6"03ZH=.:*8W+?;#D
M.-GE^_\ ?Z5H_P#"LM$_Y^M5_P# QJ[&-TEC62-@R, RL#D$'H13J/9P[(/9
MP[(XL_#'0R,&ZU7'_7XU:J>%4CC6--9UE44 *!>'@#\*WZ*:BH[(:C&.R,+_
M (1D?]!O6O\ P,/^%9=Q\-](N[AYY[W5GED.68W9Y/Y5V-%-Q4MT-Q4MT<3_
M ,*OT3_G[U7_ ,##_A5&_P#AE9I=:<+.XU0PM<8NB;O[L>QN>1_>VCBI_'^O
M^(]&OK(:3&5MG"A9!"LBS7#2*JPR$D>6I!^]Z_KTWA[74U^QFG%M-:S6]P]M
M<6\N"T<B=1D$@CD'(]:GV<.Q/LX=D8'_  K#1.UWJH_[>S_A1_PK#1.UWJH_
M[?#_ (5VU%'LX=D'LX=D<[;^$8;6W2"#5]9CB0851>' 'Y5+_P (P/\ H-ZU
M_P"!A_PK=HJRRKI]E]@MO)^TW-Q\Q;?<2;V^F?2K5%% !1110 4444 %%%%
M!2$X&:"R[MN1N(R!GFO)4U'Q#J/C^'3;NZOK;4Q=,9M/4@6)TX @N#UD9LCG
MJ#G@ 4 -\4ZI;:GJLUW::XUYI]LZ2>?:#-QHTOW1,@ _>P-C#CGO71>&_"$T
MU]_;.O(@N1(LBV4>UK9944(L\7&Y<J,A3]TDU+X7\!S>'=0CD?5WNK2V5H[:
M,Q[7*$!561LG<$484  <D]:S/&?B6:YU'[)H6JR[;-)5U2UMX2TKPMA#)%Q\
M[1MU"G(Z=: .HM_$CIXA&DZA!'&+EG-A=0R;XI]O+(3_  R 9..X!P>#70UY
MIX,\$7T6F+)J+V\&9[>[A^SJ1N>,_P"L*D#863"E>O4DDFO0[ZZ2PT^YO)%9
MD@B:5E09)"@D@>_% $Y(4$DX ZDUY9XF\2W>HQZAI$.JZ?)9WDZ+8:A;3?NE
M<$$VEP5)*%\$!NAW8J+5O%&K/X0>\UGS9M.UVT!7^S+;*Z9#)\H=Y"?WC?.O
MR@ GYL5T'AGPA>P:E+?ZY;:0I^QQV?D6,1\N<(VX2NK# 88X&.,GF@"7P-H-
M[I,]_<O8G1K&Y*F/1EE65(7 &Z167A=Q_A''?BNTHK/U'6K#29[.*^G\DWDO
MDPLRG:7QD*6Z GMGJ>* +5U=065K+<W,J101*7DD<X"J.I)KRVYU?Q%>:M:Q
M?\)&]K973.^BZ@EILBN92W$%RK#(P!A<8W#G.>*+V:Y\5Z7K-YI5G))92W4E
MGJFE!B+IU4*JRKN_U<JX!"'Y2/<UU>D:4VD:I]L\0Z_'?:A<PI!;B2-8!LC.
M<[-Q!DR_)'KP!0!T6F2WLVF6\FHV\=M>L@\Z*.3>JMWPW<5;KRJ;6H?$VO/<
M:49M(OBQ@L]36XW)-*K$"">'I\VUB!RVT9XXKT'P_J<NKZ)!=W%N;:Z.8[B
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M01G;R <*2<9Q4FBV&I:M:Z;X@CR^L6,XMVO)$\G^TK4X#[EP..25R.J9XW4
M>B56GO[6VN[:UFF5)[HLL*'JY49./PI;VX%K8W%P9(HQ%&S[YFVHN!G+'L/6
MO)K[Q5+XL>Q@U.UGATQ%\G5;2U+K-%(YQ%<#C<\&<$,HR#UZ4 6O$AC\4WMQ
MJ42VEE-IU\NFVDLKM(;N82#]Q/$!CRF;!!)R.&KI-)33_!UA-?W:3Z;%>[9Y
M]-3]]#92$'>R[ =J$]3]W/IFG:7X5L-&SK?B$V-SJ=IN_P")HR^66C'"O(,[
M?,"\%L5QGBGQ);7_ (I75=*U:&VEM+7&EW$41D349<GS+64C_@.$Z_-N% 'K
MUI=V]]:QW5I/'/;RKNCEC8,K#U!%)=7EM9(CW4\<*O(L2F1@ SL<!1[DUS?A
M71[W2;R>46:65A?PK<R6*RAA:W1^^J8XVL.>.X/K7,:OX]75X8MD)CTVRNVA
MU^*-EDGMEY"L,9!C)Y+J<C''0T 7O&TT&O3:A817$VFOHD)EFUA9]@M6DC)"
ME!RZLO!],\<BI?">F0^'K*37)H&T*V,16]TV'$EL[K@"XCQDJ"/0<@\\C-+I
M?P^MKBX,FN%-3A@"+8W?FNLL\'WECN ,+)M/0G.1UK.\<:[87^K:1#8:[9Z?
M]G>5TUA9-Z6\Z@8A< A0'!;(;J!QS0!Z/97UKJ5I'=V5S%<V\@RDL3AE;\15
MBN \&VNH-=6FO0Z:MA;ZI&PU&S1QY7F 92XC'8..".IR">F:Z[54MM1T"]B-
MZL%O<0/&;E) H0$$;@V>,4 )J^L6NDQ0BXN88)KI_(M?/)"/*02JDCIG%>0:
M=X>O=;U:>#3;<V-[8LL<L4M](&TB<R>8[P@<212 Y S]:L>$=%\2:UI]SI;W
M4<FDV;BPO[#5V,_F3(?WC1,,/&N-K+DGD]AS7H4LFE>!-'BM+*WFN)YY"+>U
M$N^>[D[_ #.>2!U)/ % &O;:WIMWJ,^G07L37MO_ *VW)VN!Z[3R1[CBM"O(
M[$ZQXSBAFE>.XN,M):ZA!"(9]'NT&6MY5SDH?N\]<\CD&O5+"6XGT^VENX/(
MN7B5I8LYV.1R,]\&@"Q1110 4444 %%%% !1110 44R::.W@DFFD6.*-2[NQ
MP%4#))/I7'>-?$EI;Z=#;VFL7%G>R".Y@N;6 SHBE@$:4 ']TQ(7WSQTH O>
M(?$D^G)>V-M JZL\#MI<<K#%XZIDA?<$]#@GZ5QVCV%GXPU:WEMY[J[:"V4:
ME?WEL +G+_-9S1%5!*CD'DKQ3=%\+7GB!'BU&6\219MNL6UW([;;@#<ES9RC
M[I/&,<8X(R.?5XT\N-4W,VT 98Y)]S0!%965KI]I':65O%;V\0VI%$H55'L!
M4]%% !7(^*O&7]AVVH116THNK98F,KQ[HTB<X,Y .2B'(;'(X['-7?$'BBUT
MT7&G6=S:R^(&M7FL]/>3#3, 2HQ[D=.]>;Z9K-U>^(]*E.J3:G#-<JC7,]ML
M>SGE!\RT9.,QL%/')0A2<B@#1T+PE<ZM<W4>H@D3-G4)P3+9ZQ ^626/G]W*
MO&,?=QW&*](T71;#P_I<6G:= (H(\GKEG8]68GEF)Y)-6+&QM=-LXK.R@CM[
M:(;8XHQA5'H!5B@ HHKC/&'B^#3[?[+8ZC;1/]H6VO[I6$ATY74XD9 >/FP,
MG@$\T 5->\;W-Q:6FGZ(B6VIZ@\ULLE_E(X)D!!B++TE)QM'3OS65H'@NW\0
MP0MJEM=-I43%OL.I._VFSN00)$63_EI"_)()(/;K@-\*"W\4ZCJ.G:T(;L36
MX>5TCQ#J*H^R.[C(/R-\I5A[*17JBJ%4*.@&!0 D<:11K'&BHB@*JJ,  = !
M3J** ([BXBM;:6XGD6.&)2[NQP%4#))KCO&'C0:=;2VFDB6XNUA6>XGMD67[
M% Q \XH3EN"2 ,],]*O>*/$-U975MHVDV4%YJM[%)+#%<R;(62,KO!/<D-@#
M\3Q7+>#+*Q\3>3>VK7%J^DS!;6=6 F2)N7LY@>JJ>!G@KM(/6@"/1_"-SX@N
MKB>\U"065R$:ZN=/95M]<A(RC,H.8Y!C#[?O ^]>H00Q6\$<$,:QQ1J$1%&
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MS\O- $.C>!9-4D>XU826-M+-OO\ 2K9P;._E7!6=<<A&ZE>Y STY]( "@
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M64 A\\EN.E;OA7P78VUG#+?6EI=Q(8Y].:YME-S:J0#Y;OC+;3P#UQUH I^
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M;@!P1R0!NZY- '<ZOH6FZ]!%!J=OY\,4@D5#(R@GW (W#V.16@JJBA5 50,
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M-L=.N=.O&,=RTLGEB\D#,'A1P1M=51F+G., #FI/"7@^WU'3K&?4[6&ZTF&
M#3([RV:.\@C)SY<ISAE&...>":L>#/#8NO#[V.L:8\FC17 ETVSU6$&XM^I*
MMR00"3M/4CK7H   P!@4 (  , 8 I:** "BBB@ HHHH **** "BBB@ HHHH
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M"1YN0<+@J2%P>,>M4O"7P\BDFLKZ]>_AFTQU>QO+2];R+R)AD,(V),>1@,O
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-+I<V5G<%A<V$H)#1EL_/'Z!L\'TQ7=T %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !5*_U&*R,,+.@N;HM';)(2!)(%+!
M<]N :NUE^(-$AU_2FLY)I+>1766"YB^_!*IRKK[@_F,CO0!Y=/JGB?5]"M+?
M4[>ZMKB?51&+B?8(1<ALK T&,O;Y&W=DG//2N^\.>%[6Q_XF$M@MI<SL+AK$
M.LD-I.00[1<?+NSSC@TS2=(N[G5HK[Q'I-G)JEG'Y<&I02$I(.>1&>4;D^O7
M@UU5 !36=5(5F +' !/4TZN!UVT3Q5XC/A_4KV73;NQE^WZ;+;_*TR^65#J3
M_$CD[AW&,\&@#$UGQ3KEY;>*+"]AO[*.&40-+:1*181'A9"6YE#@[FV_=7WK
M9\,^"+9HTN;_ $F+3CN N=,AVM:RS1D;+F,=4/';!(/.:UK30;C7=/MD\76D
M<EY8S$*T$S"*Z QB1D![X'RMG!![5U5 !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !6;K.@:=KT$<6H6_F&)_,AE5
MBDD3?WD<8*GZ444 7+:#[-;1P^;++L4+OE;<S>Y/<U-110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
%10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &I ZH# 2(  A$! Q$!_\0
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M/QS7>4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 <]XH\8V/A&T-YJ=I?FS7&^X@AWHI)
MP ><CGV[U@V/Q>T#4[":^L-/URZM(#MEF@T]G5#C/)!]*=\:/^22ZY_NP_\
MHY*X_P#9WN8+3P3JTMS/%#&M]DO(X4 ;%[F@#T;PS\0O#'BZ4P:/J:2W(7<;
M=U*28[D!AS^%=/7RGHMC/K_QW:_\*0O]@CU,S_:(D*QI$&^<YZ $9P.^:^K!
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** .!^-/_))=<_W8?\ T<E><_ WP;X>\3^$=3?6=,BN
MW6\V*SD@J-@Z8/O7J?Q&\/ZSXL\+W6@Z9]BB2ZV>9/<2,"H5@V H4\Y KD_
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M+Z!<WIO9]%T^2Z)W&5[9"Q/KG'6K]W8VM_:M:W=M%<6[XW12H&4XZ<'BIZ*
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MT?\  37MM-1%C0(BA5 P !@ 4Z@ HHHH **** "BBB@ HHHH **** "BBB@
MK+\1)K$F@W8T&6"+5-F;<SKN0MZ'Z],]JU** /'+JQ\:>/\ 5/#EIK7AS^R+
M?2;I+J[O'G5O.=,<1@=,_P!>O%>PM&CG+(K'W&:=10!CZFB)K.A[54?Z3)T'
M_3&2MBLC5?\ D,Z'_P!?,G_HF2M>@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)(N >5''3(/KFM/4_"_BSP-XZU'Q-X0L(M6L-4.Z[L&<*ZMG.1^.2",]2,5
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV@GJ?4GW)YK/LP-2UB6_.&@M=UO;G/!;_EHWYC;^!]:V*;T5@"BBBD 4444
M%%%% !1110 4444 >=^)/B3>Z5K.K6^F:*M_9Z'%'+JDK7&QE#\XC&.2!R<U
MV\>I0SZ,NJ6ZO/ ]N+B-8QEG4KN  [DBO'O%5EJ>D:WX[LDTB_O#XG@A73Y+
M:$NA?;L8,W1<9SSVKT#3]3/A?3K#0)M.O[B2PT99GGAA+1L8U"F,$=7)' H
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MD:K_ ,AG0_\ KYD_]$R5KUD:K_R&=#_Z^9/_ $3)6O0 4444 %%%% !1110
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M <;6Z  CMFO<QJ=BW2]M_P#OZ/\ &O._'/PH\-^.-675?[5-C>LH69X61UE
MX!()ZXXS57,^5]C4^&_Q!_X3'PDFHWMNT5Y%(T,XAB=D+  Y& <9!'%=5_;=
MD.3]H ][:3_XFJ/A/P[I/A#0(=(TI\P1DLSNX9I'/5B?6MX,#T(- 69GKK=@
MQQYDH^L#C^E..LV ZS$?6-O\*OT4",N3Q%I43;7NPIQG!1O\*X3XG_%1/"F@
MP/HC0W-_=2%$+@E8@!DL1QD] !7I]<UXV\$Z9XZT4:=J1DC,;>9!/%]Z-L8S
MSU'J* /.OA#\6]6\7:]+H>N1PO,T3303PIL^[C*L.G0\'VKVJO._ WPR\/\
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MB\^3:;>9W;=Y+]BHXZUU%9&J_P#(9T/_ *^9/_1,E:] !1110 4444 %%%%
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MK7'>%])D\3VD\L;FT>!]C1S1G/U!KT36N+O1S_T_ ?\ D-Z;:3PVGB*\TXR
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M)?4K)%OM7$'FA;Q7EE:3;G9N9=H.>,@5Z'XNO/MUQJ>C7G@ZXU:RATYKF.8
MXE<G'E(=N0Y'<'-<7#XPNK>&.*/X,7@2-0JYMP2 !QR8\T >@>'])T[6=1L/
M'BVTUKJ%[IB1& L-JHV'Y&.6Z#/H*ZRJ6D7<M_H]E=S6CV<L\"2/;2?>A) )
M0^XZ5=H **** "BBB@#(U7_D,Z'_ -?,G_HF2M>LC5?^0SH?_7S)_P"B9*UZ
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %9.LNUP8-*B+!KLGS67^"$??/X\+^-:K,$4LQ 4#))["LK1U:Z>?595
M(:Z($(/\,(^[^?+?C[4UW U$140(H 51@ =A3J**0!1110 4444 %%%% !11
M10 4444 %<?\2%M/^$;AEN+UK66*[C>U*VOVDR3<A4\K^/.3Q^/:NPKAO'^J
M:4\,FG75_?V,VGPC5'N[.(,8 I*J,MP&8D@#OS0!'\+X;=-,OF^VRW%^)(X;
MI);(VK0[(PJ*8SD_= .XGG-;'BC7-%TR:SMM3T][Z6X8;$2V$WEKN"[VSPJY
M8#/J:YOX>6,ESJM]J1USQ";F.0)>Z?JL42,6*#86VCIM((P:T/&FEZ=X@\0:
M9I$ZWL5VUO-.+NUNQ 4C0H=IS]_+[.,<8S0!U.BZA9:GI45UIZ%+<ED$9CV%
M"K%64KV(((Q6A7.>!)K*?PA9-8VTEM$ID1HY)?-;S%=@Y+_QDL"=W?-='0 4
M444 %%%% &/K_P![2O\ L(1?R:MBL;Q#P-+(Z_VA#_,ULT 5=1MYKO3[BWM[
MC[/+*A190N[9GOBN/\+^&)O!&I^6VH&YLK_Y"63;MF'*YY[C(^N*[JJU]9Q7
M]G);2YVN.HZJ>H(]P<&DUU,YTU*2GU19HK/TJ\EN(7@N<"\MF\N< 8!/9A[,
M.?S':M"F6G=7"BBB@84444 0SVT-RFR>)7';(Z?3TJO]ENK?)M;G>O:*?YA^
M#=1^M7J*3BF*R*(U#RL"\@D@)_C^\G_?0Z?CBJ5WXJTJRN#!)*[, #F-=PY]
MQ6U7GOB;1[Z?79I+6QD>(JN&C3@G'-<^(G4IPO#4QK3G"-XZG8:7KMEK#R+:
M,Y,8!;<N.M:=<1X2L-5L)[IFM-@95XFRN[KT-=2-1$9Q<V\T&/XBNY?S%50J
MN4$YZ,JE-RC>6Y>HJ*&XAN%W0RI(OJK9J6M[FH4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 4=4U33=)LGN-4O+>UM@#N:=PH(].>OTKPF]\0?#Z;Q,L?@KP,FNZT[%XR
M%9( PYW!"<$#K]T#WKK/B7\+=2\4^(;?Q#IEW:336\:I_9]\A,+X)[@]\]/U
MKD3XBU#PM\0]&U7Q3X3.AV.GVDMJ6T^'= V[.&7''?IDF@#WC1Y+Z;1K*34X
M4AOW@1KB*/[J2$#<!UX!S5ZJNG7]MJFG6VH6<GF6US$LT3X(W*PR#@^QJU0
M4444 %%%% &1JO\ R&=#_P"OF3_T3)6O61JO_(9T/_KYD_\ 1,E:] !1110
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M4<6IPFW$C.$X!1LC:2.#UKJK72+VQU6S-KJ(CT:VLA;#3_)'+C 5]_7@#&*
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M"'Q,[>BLCP]J[ZS8O<21+$5D*84Y[#_&M>M(24XJ2V9<9*2N@HHHJAA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!6O\ 4;+2[1KJ
M_NX+6W7K),X11^)K)L/%OA;Q%(]A9:QIM\[@@P"56+CO\IZUP/BC2K+Q?\:H
M-%UZ4OI&GZ6+I+8R[$>1GQD\CM_*H?'_ ,.O!FF^"]1U30[6"PU.PC^T036]
MRVX,I!_O'MF@#UZW@AM;>.WMXDBAC4(D:#"J!T '85+61X5U&75_"6CZC/\
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M*^MC'G<:G);3O^AV=%)2TS8**** "BBB@ HHHH **** "BBB@ HHHH ****
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M7M$>YU6>[4SR ))%&H!\E^<J ?\ ]==-0 4444 %%%% !1110 4444 %%%%
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M%6EZ?;Z5'<16-M'*E]:MO6)0P_?IWQ74U@^,/^1?_P"WNU_]*(ZWJ "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP+_O2 5SH\+7?<Z.W^]8NW\Y*D3P[?1C"?V$OTTP_P#Q=&@&P=9TQ>NH6O\
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ML45C_9O$7_02T[_P"?\ ^.4?9O$7_02T[_P"?_XY0!L45C_9O$7_ $$M._\
M )__ (Y1]F\1?]!+3O\ P"?_ ..4 ;%%8_V;Q%_T$M._\ G_ /CE)]F\1?\
M02T[_P  G_\ CE &S17-Q2^(I-6N+'[?IH\F*.3?]C?G<6&,>9_L_K5O[-XB
M_P"@EIW_ (!/_P#'* -FBL?[-XB_Z"6G?^ 3_P#QRC[-XB_Z"6G?^ 3_ /QR
M@#8HK'^S>(O^@EIW_@$__P <H^S>(O\ H):=_P" 3_\ QR@#8HK'^S>(O^@E
MIW_@$_\ \<H^S>(O^@EIW_@$_P#\<H V**Q_LWB+_H):=_X!/_\ '*J_;-9L
M_$.F6-W<64\%X)BQCMV1EV*",$N?6@#HJ*** "BBB@ HHHH **** .%\1?$N
MVT'6+RRCTB]OX=-C274[FW*[;57^[P3ECCD@=!78B^MCIW]H>:OV7RO/\SML
MQNS^5>(>*[A=!USXC6%['/\ :?$%M -+58F;[2=A0JN!U!/-=\DT=OX4@\#,
MTG]N-X?^6,(=O$?EGYNF=W&* #P_\3+77-7LK.72+VPM]361],NIRNR["=>
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M/2O1J "BBB@ HHHH ***Q?%FL7N@^'+F_P!.TN?4[Q,"&UA4DLQ.,G'.!U-
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MLC+_ *PP1A2WU-:U !1110 4444 %8WBCQ-8^$=$DU?48[A[6-U5_(CWE<G
M)'8>];-17%O#=V\EO<0QS0R#:\<BAE8>A!ZT >+6\^EZ5\9]%N/"^IC5CK:2
M'4 \HN#"GW@5;J@]O08JEHVK:?X;M_BIINJ7<-O=O<3RQ1R,%:57#[=H/7J.
MGK7L6C^$] \/RR2Z1H]G92R##O#$%8CTSZ>U)J?A+P]K5]'>ZGHUC=W4>-LL
MT(9N.F3W_&@#$^$=G-8_"W089U*NT+2;3V#NS#]"*[6D50BA5 "@8  X I:
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MM-5N9[B=9,9!EZ@8[#M72T4 <7X=^'5GH6H?;;K4[[598[3[#;B\92((/[@
M SZ9-0Z)\,-/T75[*[_M/4+JUTYI&TZQG<&*U+]<<9/4XSTKNJ* "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5=1NI[#4QJ9GGD#-++Z'C"K[+B@#)T[XK0W^LV\:V,7]E7=ZUC!<)=!IBX)
M=H@,JA(QG/I5WQUJ&HR:]X:\-6%_-IRZM/+]HNH,"01QIN*H2."?6K6F> ;?
M2-36:SU6_BTY+E[I-.0J(E=N2,@;BN23MSBM+Q-X6M/$]M;K--<6MU:2^=:W
M=L^V6!^F0>G(Z@]: ,%Y9OAUI6L:A?Z[>ZSI\0C-M:W)#W$;L=H4R<9#$C&1
MQ3H?'=_:7%_8Z]H:V.H0:=)J4$<5R)4FC3[R[L## ^U20?#32SIVK6^IWM_J
MESJJHMS>7,@\S"<IMP %VGD<5)9_#Z"-K^?4=7U#4[Z[LFL!=7)7=# PY5
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M(3;DC;:?E5?X<9Z?2O/? 6HW7@;38=,U*?=HGB73&N;.9N%BN-A#(3VSP/\
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MIMO$.H0SF1Q8Q;8;>)0#N;'\1P<DXZ 8KT:W\ WR?"[5?#<MW;G4M2>>66<
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M;Y$602FR/(POWMF2N0.U&EL-1U37-$TX7QTZ\UNQBBCN/,S';JGFOP_*J0G
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXI^+;R#Q+'8Z7KD>GMHUI_:,T;3"/[5)N7;!UY)4,<>XKM[7QM#?ZYX>LK2
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M=4&%SE3_ )-2Z?X?O%\;IJ-T\LEKINFK96LT[AI)W<AI)&QW^51T'.:ZVDH
'6BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (/ ZH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?(+D;&B7<"0P[$5V?@WQSJ?BV74=7.GP6?A:W+BWNI2WG3;>K8Z!1@Y_+UH
M[VBO'D^*7B[4])O_ !-HWAJRE\-V;N"TTY6>1$^\P'08'/3\ZT?%OQ:.C^&/
M#FO:18)>6^KR8,4A(=0 ,J,?Q9R/PH ]0HKF_"%_XHU"VN9?$^DVNFOO7[/%
M!+O)0C)W<GD=/SKG_''Q#O=!\4:?X;TFWT_[==Q&9KC4IS% BY( SW)VG]*
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MLJRD9!![BO&O$7C(^.?V?M7U=[46TP=898U;<H99$.0?3!%>E>!_^1"\/?\
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M]'VVJZ?>23QVM];3O;G$RQRJQC/^U@\?C45IKND7]RUM9ZI97$Z]8XIU=A^
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M,0@12<,_]T-C:3[ UU5>(_&#2-/TNU\$-86<%LT6H1QHT2!2%^4XR/H*]NH
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M07RQ"MW&: /!O#%EX,31K.Z\7Z#KW^DSLLFJ+N2W!)X'O[D>]>C^-8[3Q/\
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M/!#>"(_ &I)JKVHL2K0XMT.-N\'';J.V>]>I^.X)[KP-K$%JMVT[VY$8L_\
M6ELC&W_/2N#T;XC^+K'1K.TO/AUK4UQ!"L;RJ6^<J,;N5SDXS0!Z1X8TJ31/
M"VE:5-()9;.UCA=QT)50#6M532[N6_TJTO)[62TEGA61[>3[T1(R5/N.E6Z
M"BBB@ K#\7?\B[+_ -=[?_T<E;E8?B[_ )%V7_KO;_\ HY* -RBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "L;Q7_R*VH_]<OZBMFL;Q7_ ,BMJ/\
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M 4444 %%%% !1110 5C>*_\ D5M1_P"N7]16S6-XK_Y%;4?^N7]10!LT444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1167/X
MET&UG>"XUK3HID.UXY+I%93Z$$\4 :E%8_\ PEGAO_H8-*_\#(_\:/\ A+/#
M?_0P:5_X&1_XT ;%%8__  EGAO\ Z&#2O_ R/_&C_A+/#?\ T,&E?^!D?^-
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M&_\ H8-*_P# R/\ QH V**Q_^$L\-_\ 0P:5_P"!D?\ C1_PEGAO_H8-*_\
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MQ\$?]"QIO_?D5UE% ')_\*Q\$?\ 0L:;_P!^11_PK'P1_P!"QIO_ 'YKK**
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M.66']EW?"2'_ +,*\>A?!_0F@#2LOCEH%WJL,+Z?J5OIMQ-Y$.IS18A=\X_
M?R[@5TWC/QYIO@N"U%S#<7E[>,5MK.U7=)*1C/'IR*\F\50P#]F#0B0%96A9
M,=V+-G]"35Z666Z^.G@<7.6"Z/&Z[A_$8W)/YT >E^"_'FF^-8+D6T-Q:7MH
MP2YL[E=LD1.<?AP:T?%?_(K:C_UR_J*\ST$.O[1GBJ"TF,0FT_+LN#M?$>&P
M>"03WKL_$>E:Q%X>O7F\1SS1JF6C-K$ XR.,@9% '94444 %9U]J-W:SB.#2
M+J[0KGS(GC !]/F8&J%G<ZUJ3W<D%S90Q174L"(UNS'"-C).\=?I5G[/K_\
MT$+#_P !&_\ BZ *L/B2\N)9XXO#NH%X'\N0>9",-@'^_P"A%;-G<2W-LLLU
MK):N2<Q2,I8?]\DC]:Q[;2M;M9[N9-2LBUS*)6!M&X.T+Q\_^R*L_9]?_P"@
MA8?^ C?_ != &O16/I=W?MJU_87TEO)Y$<4B/#&4^_OR""3_ '?UK8H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN4444 %%%% !1110 4444 >/_&#_ )&'1O\ KTF_]#2O/J]!^,'_ ",.C?\
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M_P#GEK'_ (*Y_P#XFC_A:_AO_GEK'_@KG_\ B: .EU_1(?$6B7.E7,]Q#!<
M*[6\FQB,Y(SZ'H?8U4T;PCIWA^PU"QTQ[FVM;QVD$22D"W+#!\K^[Z_6L7_A
M:_AO_GEK'_@KG_\ B:/^%K^&_P#GEK'_ (*Y_P#XF@#2\,^!=)\)W+SZ6URA
MDMTAF1I,K*RDGS6'=SGDU#IOP]TC2M>36[>:]_M#S9I)9GGRTXDQ\LG]Y5P,
M#MBJ?_"U_#?_ #RUC_P5S_\ Q-'_  M?PW_SRUC_ ,%<_P#\30!<U+X>Z1JN
MOOK=S->_VAYL,D,RSD&W\O/RQ_W5;)W#O765P_\ PM?PW_SRUC_P5S__ !-'
M_"U_#?\ SRUC_P %<_\ \30!W%%</_PM?PW_ ,\M8_\ !7/_ /$T?\+7\-_\
M\M8_\%<__P 30!W%%</_ ,+7\-_\\M8_\%<__P 372:%KUGXBL#>V*W"Q!S&
M1<0-$V1CLP!QSUH U**** "BBB@ HHHH **** "BBB@#S?XBZ1I?B?6=!TV7
MQ7+I-YNDDM4MT#%W4 EMV?E('N,YJA9^'6\,^)]$;4/B/JUZUS<^7#9R99)V
M ^ZV&.!]:Q?B7X)^'^B:[:Z[K-S>6XNY9&DL+12[7+$=5Y&P G)]<U0\$3?#
M(>,]+_LG0_$2ZB9=MO)>#,:-@\GYS0![/XLT>;Q!X3U32()$BEO+9X4>3.U2
M1U.*S] \)"Q^'-OX4U.1)U%HUM,\6<,&SDC/UKJ:* /%H_@_XFN+*Q\-:GXC
MMI_"ME<^<D21$3.N20I...I[G&:ZSQQX!N];U'1]<\/7T6G:SI/RP-*FZ-X_
M[I'MS^9KO:* .$\!^!;[P_JNK:_KU_%?ZYJ; 2R0IM2-!_"OY#\A71>*_P#D
M5M1_ZY?U%;-8WBO_ )%;4?\ KE_44 ;-%%% &+X;_P!1J/\ V$;G_P!#-;58
MOAO_ %&H_P#81N?_ $,UM4 %%%% &-9?\C;J_P#U[6W\Y:V:QK+_ )&W5_\
MKVMOYRULT %%%% !1110 4444 %8/C.^U#2_"M]J&F7$,%Q:IYVZ:!I057DK
MM7G)Z9[9K>HQF@#R/X8WGC&XTK5[+49H[.:VB=XDN8)))%DE_>(Y8G#* 2-H
MYXYJG\.-<\7ZCXRN#?M'%9:@3=[Y+>7%Q&F8OW0)Q%\PW$'DYKVBC% 'A]MK
M7C<_% H;B%K5I/[+^VFTE$!=3YA CSPV#MW]*]P%&** "BBB@ HHHH ****
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M5I7S:QGYCU_#BN;^TL/W?W =Q:W<%];1W-M()(9!E6 ZU-7$?:]=_P"@X?\
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MMC"\9/UKM:X7X3_\BG/_ -?TO\EKNJ]"'PH].'PH\?\ V@O^1=T?_K\;_P!
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M<YQ[9H ]3\+:C<ZOX5TG4;R/R[FZM(Y94QC#,H)XK7J"TGM[FTAGM)(Y+:1
MT3QD%64C@C';%3T %%%% !6'XN_Y%V7_ *[V_P#Z.2MRL/Q=_P B[+_UWM__
M $<E &Y1110 4444 %%%% !1110!X_\ &#_D8=&_Z])O_0TKSZO0?C!_R,.C
M?]>DW_H:5Y]7EXG^(S] R#_<8^K_ #"BBBN<]HZ'P)_R/FC_ /71_P#T6]?0
M%?/_ ($_Y'S1_P#KH_\ Z+>OH"O3PO\ #/@N(O\ ??DOU"O.]$_Y UM]&_\
M0C7HE>=Z)_R!K;Z-_P"A&N/-OX<?4\(OT445X(!6AX._U.K?]A!__0$K/K0\
M'?ZG5O\ L(/_ .@)7IY5_&?H!TM>=^,_^1RMO^P<?_1E>B5YWXS_ .1RMO\
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M1FE,0O(3&),9VGJ#^8%>83V_Q9OO#Y\(3:1ID<+P_9)-5$HP8<;2=N>I7V_
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M-8UE_P C;J__ %[6W\Y:V: /+/C)UT'_ *Z3_P#H*UYC7IWQDZZ#_P!=)_\
MT%:\QKS,5_$/O>'?]R^;_0****YCW32\.?\ (W:%_P!A"+^=?1]?.'AS_D;M
M"_["$7\Z^CZ]+"? ?#<2?[VO1?J%>?Z?_J)O^OJ?_P!&-7H%>?Z?_J)O^OJ?
M_P!&-7+FO\)>I\\6Z***\  JYX2_Y".M_P#76+_T6*IU<\)?\A'6_P#KK%_Z
M+%>EE?\ '^0'4UY[XY_Y&[2O^O&X_P#0XZ]"KSWQS_R-VE?]>-Q_Z''7KXW_
M '>?H14^%F11117RQQA1:_\ (QZ#_P!?X_\ 1<E%%K_R,>@_]?X_]%R5TX+_
M 'B'J5#XD>LT445]4=I\PQ?=;_KH_P#Z$:DJ.+[K?]='_P#0C4E>9+=GE2^)
MA1112)/8/A/_ ,BG/_U_2_R6NZKA?A/_ ,BG/_U_2_R6NZKTH?"CU*?P(\?_
M &@O^1<T?_K\;_T UX!7OW[07_(N:/\ ]?A_] -> ]ZF6Y,]P_"C_/2BC!_R
M*D@W_ __ "/WA_\ Z_XOYU]@5\?^!O\ D?O#_K]OB_G7V!6D-C6&QX9^TM_R
M!= _Z^)?_05KYSKZ,_:6_P"0+H'_ %\2_P#H*U\YU184444 ==\+?^2G^'?^
MOQ?ZU]HU\7?"W_DI_AW_ *_%_K7VC0 4444 0W5U!96LMU=3)#!$I>21SA54
M=237"3?&SP!#*T9ULL5.,I;2L#]"%K9^(\"77PZUV!Q.0]JP @3>^<C&!WYQ
M^%>8:+\0/#%EHMG;7'PVO5FBA5'V::C@L!@G)&3GWH ]>N]2BU'P=<:IITAD
MBGL'GMW"D%@8R5.#SZ5XKX/CB/[,GB$N ,M.2?5ALQ^N*]ST>XM]1T&RN(;1
MK:WN+='2W= AC5EX4KVP.,5Y5/\ !S78(-0T+2/$\=KX6O[@32VKP[I4&<E5
M/IP.XS@?B =G\*'D?X6^'S(23]FP.>P8@?IBH_&&M>&/ /G>([BQ@.LW2&&(
M1(//N3Q\N>N.%R>W%2ZYX3U4Z-HFE^%]7.DP:=(@DP3^]B48VG'K7)>,?A9X
MI\2>.CXCM/$=I;>05%E&\3,8 !Z'(SG)_&@#1^%_A35;>SUO7]<\RSU/Q!-Y
MS11?*T"9)'T/S'Z<>];OB71FMM%,QU74IMEQ;GRY9@5;]\G4;:3P3H/BW1IK
MQO$WB1-7215$"K'M\LC.3T'7C\JU?%W_ "+LO_7>W_\ 1R4 ;E%%% '->$K.
MVET21Y+:%F-]=Y+1@D_Z1)6[]@L_^?2#_OV/\*R?!_\ R G_ .OZ[_\ 2B2M
MZ@"O]@L_^?2#_OV*/L%G_P ^D'_?L?X58HH YW0XHXO%/B18XU1?,M^%&!_J
MA715S^C?\C7XD_ZZ6_\ Z)%=!0!X_P#&#_D8=&_Z])O_ $-*\^KT'XP?\C#H
MW_7I-_Z&E>?5Y>)_B,_0<@_W&/J_S"BBBN<]DZ'P)_R/FC_]='_]%O7T!7S_
M .!/^1\T?_KH_P#Z+>OH"O3PO\,^"XB_WWY+]0KSO1/^0-;?1O\ T(UZ)7G>
MB?\ (&MOHW_H1KCS;^''U/"+]%%%>" 5H>#O]3JW_80?_P! 2L^M#P=_J=6_
M["#_ /H"5Z>5?QGZ =+7G?C/_D<K;_L''_T97HE>=^,_^1RMO^P<?_1E>IC_
M /=Y?UU,ZGPLRJ***^7.0*M:+_R-NB_]=9?_ $4]5:M:+_R-NB_]=9?_ $4]
M=6"_WB'J73^)'I]07O\ QX7'_7)OY&IZ@O?^/"X_ZY-_(U]4=A\SVW_'K%_N
M#^52U%;?\>L7^X/Y5+7EO<\E[A1112$>T_"__D1;;_KM-_Z,:NQKCOA?_P B
M+;?]=IO_ $8U=C7IQ^%'JP^%'B/[0W^I\/\ ^_/_ "6O#J]R_:%_U/A__?F_
MDM>&]_\ ZU3+<SGN!'^<444=:DDZKX:'_BY>@?\ 7R?_ $!J^M:^2OAIS\2]
M _Z^3_Z U?6M:1V-8;!7R9\>O^2J7G_7O#_Z!7UG7R9\>O\ DJEY_P!>\/\
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M<E &Y1110!@^#_\ D!/_ -?UW_Z425O5@^#_ /D!/_U_7?\ Z425O4 %%%%
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M5Z65_P ?Y =37GOCG_D;M*_Z\;C_ -#CKT*O/?'/_(W:5_UXW'_H<=>OC?\
M=Y^A%3X69%%%%?+'&%%K_P C'H/_ %_C_P!%R446O_(QZ#_U_C_T7)73@O\
M>(>I4/B1ZS1117U1VGS#%]UO^NC_ /H1J2HXONM_UT?_ -"-25YDMV>5+XF%
M%%%(D]@^$_\ R*<__7]+_):[JN%^$_\ R*<__7]+_):[JO2A\*/4I_ CQ_\
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M'@O5K^\LX[V""W+-;2#*R>@/MG%<Y?:OXNTWX3VVM00::NJ6T0NKB #$7V<
ML57T.S;W[&@#JO"AE;PEI!FL$L)#9Q;K1%*K"=H^0 \@#IBMBL[0=6CUW0-/
MU:)&1+RW2<(W5=P!Q6C0 4444 %8?B[_ )%V7_KO;_\ HY*W*P_%W_(NR_\
M7>W_ /1R4 ;E%%% &#X/_P"0$_\ U_7?_I1)6]6#X/\ ^0$__7]=_P#I1)6]
M0 4444 <_HW_ "-?B3_KI;_^B1705S^C?\C7XD_ZZ6__ *)%=!0!X_\ &#_D
M8=&_Z])O_0TKSZO0?C!_R,.C?]>DW_H:5Y]7EXG^(S]!R#_<8^K_ #"BBBN<
M]DZ'P)_R/FC_ /71_P#T6]?0%?/_ ($_Y'S1_P#KH_\ Z+>OH"O3PO\ #/@N
M(O\ ??DOU"O.]$_Y UM]&_\ 0C7HE>=Z)_R!K;Z-_P"A&N/-OX<?4\(OT445
MX(!6AX._U.K?]A!__0$K/K0\'?ZG5O\ L(/_ .@)7IY5_&?H!TM>=^,_^1RM
MO^P<?_1E>B5YWXS_ .1RMO\ L''_ -&5ZF/_ -WE_74SJ?"S*HHHKY<Y JUH
MO_(VZ+_UUE_]%/56K6B_\C;HO_767_T4]=6"_P!XAZET_B1Z?4%[_P >%Q_U
MR;^1J>H+W_CPN/\ KDW\C7U1V'S/;?\ 'K%_N#^52U%;?\>L7^X/Y5+7EO<\
ME[A1112$>T_"_P#Y$6V_Z[3?^C&KL:X[X7_\B+;?]=IO_1C5V->G'X4>K#X4
M>(_M#?ZGP_\ [\W\EKPZO<OVA?\ 5>'_ /?F_DM>&U,MS.>X#_/%'>C'^<45
M))U7PS_Y*5H'_7S_ .R-7UK7R5\,_P#DI6@?]?/_ +(U?6M:1V-8;!7R9\>O
M^2J7G_7O#_Z!7UG7R9\>O^2J7G_7O#_Z!5%GF=%%% !7M7[-O_(VZQ_UXC_T
M8M>*U[5^S;_R-NL?]>(_]&+0!]*T444 %%%% !1110 4444 %%%% !1110 4
M444 %8WBO_D5M1_ZY?U%;-8WBO\ Y%;4?^N7]10!LT444 8OAO\ U&H_]A&Y
M_P#0S6U6+X;_ -1J/_81N?\ T,UM4 %%%% &-9?\C;J__7M;?SEK9K&LO^1M
MU?\ Z]K;^<M;- 'EGQDZZ#_UTG_]!6O,:].^,G70?^ND_P#Z"M>8UYF*_B'W
MO#O^Y?-_H%%%%<Q[II>'/^1NT+_L(1?SKZ/KYP\.?\C=H7_80B_G7T?7I83X
M#X;B3_>UZ+]0KS_3_P#43?\ 7U/_ .C&KT"O/]/_ -1-_P!?4_\ Z,:N7-?X
M2]3YXMT445X !5SPE_R$=;_ZZQ?^BQ5.KGA+_D(ZW_UUB_\ 18KTLK_C_(#J
M:\]\<_\ (W:5_P!>-Q_Z''7H5>>^.?\ D;M*_P"O&X_]#CKU\;_N\_0BI\+,
MBBBBOECC"BU_Y&/0?^O\?^BY**+7_D8]!_Z_Q_Z+DKIP7^\0]2H?$CUFBBBO
MJCM/F&+[K?\ 71__ $(U)4<7W6_ZZ/\ ^A&I*\R6[/*E\3"BBBD2>P?"?_D4
MY_\ K^E_DM=U7"_"?_D4Y_\ K^E_DM=U7I0^%'J4_@1X_P#M!?\ (NZ-_P!?
MK?\ H!KP"O?OV@O^1<T?_K\;_P! -> GWJ9;DSW"CL:*,<U)!O\ @<?\5]X?
M_P"O^+^=?8%?'_@;_D?O#_\ U_Q?SK[ K2&QK#8\,_:6_P"0+H'_ %\2_P#H
M*U\YU]&?M+?\@70/^OB7_P!!6OG.J+"BBB@#KOA;_P E/\._]?B_UK[1KXN^
M%O\ R4_P[_U^+_6OM&@ HHHH S=?M]-N_#]_!K!0::\#"Y9VV@)CDY[8KY[<
M^#FMO[-N?BMJUQH2'_D'B"3+(.B;NF/P_"O=/'>D7.O^!M8TNR*_:;FW*Q!C
M@%N"!GMG&/QKR76-'O\ 3-/2Y'@%KJ/6=&CM)+2&(%K.[CRJN<#(!!!R,'CK
M0![7H$EA-X>TZ72H_+T][:,VR;=N(]HVC';C%:-9/AR.^M/"NF1ZNZ_;XK2,
M7+9&-X4;NG%>7S_&/7IH;_7M)\,1W7A6PN/)ENFFQ*XR 64>G(/0]1F@#V:B
MJ>EZE;:QI-IJ5H^^WNHEEC/LPS7$>+?'^JV/BV#PIX5TB'4]8:$SS>=+L2)>
MH!Y'..>O<>M 'H=8?B[_ )%V7_KO;_\ HY*S/A]XW'C72[IY[,V6I6,QM[RV
M+9V..X/H<'\C6GXN_P"1=E_Z[V__ *.2@#<HHHH P?!__("?_K^N_P#THDK>
MK \'_P#("?\ Z_KO_P!*)*WZ "BBB@#G]&_Y&OQ)_P!=+?\ ]$BN@KG]&_Y&
MOQ)_UTM__1(KH* /'_C!_P C#HW_ %Z3?^AI7GU>@_&'_D8=&_Z])O\ T-*\
M^KR\5_$9^@Y!_N,?5_F%%%%<Y[)T/@3_ )'S1_\ KH__ *+>OH"OG_P)_P C
MYH__ %T?_P!%O7T!7IX3^&?!<1?[[\E^H5YWHG_(&MOHW_H1KT2O.]$_Y UM
M]&_]"-<>;?PX^IX1?HHHKP0"M#P=_J=6_P"P@_\ Z E9]:'@[_4:M_V$'_\
M0$KT\J_C/T Z6O._&?\ R.5M_P!@X_\ HRO1*\[\9_\ (Y6W_8./_HRO4Q_^
M[R_KJ9U/A9E4445\P<@5:T7_ )&W1?\ KK+_ .BGJK5K1?\ D;=%_P"NLO\
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M!5%GF=%%% !7M7[-O_(VZQ_UXC_T8M>*U[5^S;_R-NL?]>(_]&+0!]*T444
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M:-X8FM3CRPFTO)L\NUGX8Z'8S:4L-QJ.+F^6"3-QGY2CGCCU45J_\*B\.?\
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M^!1_PKO]4T]=4TZ6S>1HUDVY91DC# _TJY19!9'GVG?!OPOI6H07]C)J4-U
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MIX&M(PP35M74,S.0+@=2<D_=]37444I0C-6DKF9S/_"%6_\ T%]7_P# @?\
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M2U8_[6>4_&O1HY$FB62-U=' 964Y# ]"#6+XI;P_/I:Z7XBFMEM=1<6T<<[
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M22-&PG7C#D'Y6ST].AJ#QOXW\>>&_B;%;Q"TCTR5=ME!+Q%=C(R"Y^[)GCJ
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MEYK^JM>?\(E\5].LUT[5P/LE]:\1QR=E+=B#CGM[@UCZ5I%AXS\1>(?#OC^
M6WB^8J;6Z7(7RU4!?)YQCC..X)]#79>&_#VKZ_X<U#P?X^TTW-O8.J6VHA\?
M:%ZJRGKN QS[X/>@#G]-^'?C6=W\&ZGK+#P9;.)%N(R!+<Q'D0@]0/7L/?BO
M5SX9T8^&_P#A'A81+I1C$1ME&%*]?KG/.>M:-I:PV-I#:VZ;(84$<:Y)PH&
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M;41;QB\:(0F?'S% <A<^F235FB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KR<_%+4(/B/=^"[VPA$DM[Y4%TERL?EP,N03G.7Z$#WQ
M6KXK\87FH:_'X-\(:A;0ZZS-]JGG0D6R!-V0",,QR!WQ7'!$\63W/@7Q_##8
M^*8R)+#5HD"_:2!\K!@!DX&,=QZ$4 2^')I?AMX_O]'\6M]KM=<(^RZS.NXR
M8^7RY"?8@$=C[&NNA^#'@N+5/MJV4YC\SS19F<FWW>NSN/8G%'A7PIXEN8&B
M\?W5AJL%N8Q9P"(/AD)Q,S$ [CG&/SKT&@!%4*H50 !P .U+137)",5&6 X&
M>IH =69=:_I=MK-OHDNH0Q:G=1L\$#'YF [X_/ZX-</\-_BO#XPNKC2M4BBL
M=7C=S'&I.V9 3]W/\0Z$>V?7&UX_\!V_C+3HY(9/L>M69\RQO4X:-AS@D<[2
M?RZT <'>74UQJEW\/_B8Z31WTAETG6%0(-Q/ '92"<?H>"*OZ+\.;K7[:?1/
M'NFK=#2Y%2PUB*7;+<1=E..2 ,=?IU&:DLO"?BGQQ=6,'Q#TVR33]+1P!#+E
M[N4X <[3\H 'MDGIZ>L(BQQJB#"J  /04 -AACMX(X(EVQQJ$1<] !@"I***
M "BBN)UO6]2\.>/M/-W<A]!U>,6D6Y0%M;H9*Y/</T^HH V/%/BS2O"FES75
M_=V\<XB=X+>24*\[ 9"J#ZGBO.6\9Z_IU[%IGQ,TJQ_L#7$V13VXS' 6'W)#
M^(YZCJ">V-::?:^)?'6N>'OB3;HFO74:)IMTF5C$:[L>5SC)R#[X(/-=;X5\
M.:U=Z1JO@3QI8?;M)M5"V>I9 \U#]T#ON7U[=#[@&!!\//&FEW]QX4T/63%X
M-OOWYNR0TD$9^]&ASG)]N".>.:]2TSP?H>E>%V\.VMB@TV2)HY8SR90PPQ8]
M23ZUI:;IUMI.FVVG6:%+:VC$4:EB<*!@<FK= $=O!%:V\5O @2*) B(.BJ!@
M#\JDHKGO&NEZCJWA>YAT>[EM=2B*W%L\;[=TB'<%;U4XP1[T 7M?U_3O#6CS
M:IJD_DVL6 2 26)X  '4FO)!JOB3XDW6KZYX1\3367]E2JMEI939YP"@DR#/
M5CD#.1QVI/$U]K.OZ3H?Q"TAIKRVT]U;4="DY6.2,D.P7U!)Z\@8-:MOHD/B
M76=+^('P^OX+2>XD5-3@D^Y(G\8=1_&/3OP<]R 8$5C+\19D\1>&)QX?\<:>
MXM]4@;*A@?E+$8^OY8/(!KU/P;X*T[P;IS0VQ:>]G.^[O9>9)W[DGT]!6_#9
M6MO///!;11RW#!IG1 &D(& 6/?@5/0 U(DCW;$5=QW-M&,GU/O3J*9++'#$\
MLKJD: LSL<!0.Y- $:W=LXF*7$3"!BLI#C$9 R0WH<'O7CGQ'^(,]Y;W&G0Z
M5>IX96^CM+[687X8!@9%3 Z$97.>:UM:M=/TGQ8;B7RY_"?C%!;7A1_W<=R1
M\D@8'@..,^O-9GA^RO? .NMX!UNS?5/"VL,XL)_*+["WWD<#I[^G4=\ $#:)
M-\/;VWU3PO!+KG@G6=L=UIRGSBF_@,@/4'/?Z'L1UWA/X3>'_"^NSZO")9W+
M%K.*?D68/)"CUSW_ /UUM>"O!T/@K3KG3[6_N;FTDN&EACG.1 I_@7_'O734
M &**** "FR2)%$\DCJB("S,QP !U)-4]8M[R[T:\M].NS:7DD++!<!0WEOC@
MX/O7D7B76?%/BKX7M+IX'VS3V>T\0:8$_>2;>&VGJ 1\V!U!]L4 :^K>,]:\
M8ZQ+I?PXU?3B+*U^TW%Q(N[S7W8$2Y&,<9W=.1S7.S)_PLZT^WV8_L7XCZ"<
M21_<,NWM[@]NN,X/!J<:+::WIVG>/OA='%9ZI:@1W&FIA5E4?>C9>F[^8YZX
M->J6?A_3WU>+Q'<Z7!#KKVRQ32H=Q7CE0>A],XSB@#C_  EX)U75=4A\6>/7
M2YU=5 M+$ >39CUV\C>>OM]>GH0T^T&I'4?L\?VPQ>29\?-Y><[<^F>:LT4
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MO+9<F1>F&&1GZUT/ACPY;>&-%BTZWEDG92SRW$QS),[$LS,?<DULT4 %%%%
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MIFR<1J#]"?SI_@SQWJT7B-_!GC6*.#6T&;:Z08CO%]1VS@=NN#P"*Y"Z>_\
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M($SKC"Y^51[ >M+X0\.GPOX8L-(DO9+Y[1"@GE4 X)S@>BCH!Z 5O4 %%%%
M!5'6EO6T._737V7QMY/L[8SB3:=O'UQ7)>*?B-)H^L3:/HFA76N7]K#]HO$@
M;:MO'U&3@Y8CG KI?#>O6WB?P[9:U9HZ07<>\)(/F4YP0?H010!QNF0VWQ7\
M$>'KJ\N65[&\CEOK<J"))HLAD<=@<Y_&L2XT[4_A'XH%]H]O/>^$=3G"W%E$
M"[VDK' *#TST_(]C6AK/AW7O _BBY\4^$+4W^G7K;]3T=3@LW>2/WZG _4'C
MLO"_C/1_%L4G]GRR)=0 ?:+2XC,<T)_VE/\ ,4 -3P)X5_MQ==70K1=1SO$N
MS&&_O;>F[WQFNCHHH **YCQSXO3P?HL5PEM]JOKN=;6SM]VT22MTR>PK%\,>
M-]8/B:]\.>,;33].OXK=+F&6"?\ =R(S;<?,>N?Y&@"E!-;S^/O$/@CQ3B\L
MM39-0T];ACM=>-T8_P!TKD >AH^(D'PWLM3MYO&"$W$]FT%N@$C!(U.<J%X5
MLG -=%XY\$6_C&P@>*X:QU>R?S;&^C^]$_H?53@5CZ)XBUR&\M=#\;^&Y7O"
MP2#4K2#S[>8^IP/W9_SQ0!2^&'A@:E\-;&T\1V;W%M%>M<V$-V/F2,']WD?F
M<=,&O4    . *6B@ J"ZO;6Q6)KJ>.$2R+#&7;&YV. H]S4]<I\1M!N?$/@R
M[MK!BNH6[)=VA'7S8SN 'UP1^- ''?$[Q)XFTGQSHT?AII;AK2REO;RP4_)+
M$& .1U)QG'IVINK:=#\2].T[QSX'O%M/$5CQM8@%L=8I/<9.">"#Z'CL/ OB
MC3?&NDP:NL,2:M GV>[C*XD@?C<OJ%)&1_B#5&U^'LFB_$,>(?#]\MCI]VK?
MVE8;,K*W8J.@Y.?;MUH YC3[/Q1XO^(/A[6]1\,2:%-I*.+ZZ=QBYR,!$'4C
MKZXR>:]CHHH **** (YIH[>"2:5ML<:EV;T &2:\CB^+FNR7%AK3>'8D\(7U
MX+.&Z,O[_)8KO(SP,@\8[=:Z/Q3KUQX>^(&A_;YF_P"$?U6"2PD5C^[2<D%6
M/U'R_G1XNT'P)H/A"RCURT6WT/3[D/%!'O*EVR,%1RW4DYH J:E\+/#^OZ/J
M_P!FO3+>WU\U]#J <.T$N  H8=5'I[^H%3^!KC6=;TJ_\.>-]&$USIKK$US/
M$'ANQCAAGJV,9/N.^:POA';6H\5^)[SPVEQ'X2F,8M1*&5&E_B*!N<#D?E7K
MU %6PTVQTJU6UT^S@M+=3D101A%S]!5JBJ6K:O8:'IDVHZE<QV]K"NYY'/Z#
MU/M0!=KA?&7B*Z\+>+_#5]/<%-"NVDLKM2<+'(V#'(3^!'TS4?A'Q3KOB*\O
M/$%_%!I7A39LLDNAMEE.?]:23\H/3'?C'J>I\1>']/\ %.@W.D:C'YEM<+C(
MZJ>H93Z@\T >;:S\.-$T?Q5>^)-8O8(_!^?M<NGREC&;IOEW;1P1SD#U.,8J
MGX"TS0[WXB>(;;PY&E[X-GM$:XBD3=;BY)&%4,.<#/TS]*T+'4=>\"6O]A>,
M],EUOPZGR6^J00^>5C'19H^3QZ_SKTW24T]=-@;2X(H;.11)&L47EK@\YVX&
M/RH -,T?3=%M?LNEV-O9P9SY=O&$!/KQ5VBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#SOXI_$/4/ <&GFPTD7
M1NI<-/,<0J!U3(_B/;/'UKSCQUKOA[QC%:^(?L1AU33AY.K:3<C;+);,>60_
MQ;<Y##IG/:O>];T6P\0Z1<:7J=NL]I.NUU/4>A![$=C7A[^!=FNQ>!/$UI<7
MEI,KG1-<MT_>P*.3'(1U4>AX';@\ %[P^PB6'X>^)U?5_#>K1!]#U-4))3&5
M4D?=9?7M]#7IO@7PQ<^$/#B:1<:K+J*Q2,87D7'EQY^5!]/Z^E+X'\*GP?X7
MM='DOGOVMV8K+(N-H8YVJ.P_'UKI* "BBB@ J&[69K.=;9@DYC81L1T;'!_.
MN0\5^/I=$U=-$T;1+G6]8\G[1);P-M$47]YFP>3V'_UJV?"7B:V\7>'+;6+6
M*6%92RO%*/FC=3AE/T(ZT <9HX'Q5^'5I9:E>-%J%C>1IJ2;02TD3\JP]&'/
MU^E9FLZ1J?PH\1OXC\.6TMUX:OI -2TR(9,+$XWQC\>/RZ8QJ>)/#&N^&?%4
MOC'P9"+K[3C^U-)+8%QC^-/]K^OKDBNH\+>.-(\6!X;8S6VH0J#<6%U&4FB^
MH/49[B@ ;P/X4U#5H=?ET"U-^<2B22,J<]067H6^HS73444 %%<[XV\5P^#O
M#DFIR0-<2LZPV\"G'F2M]T$]AZGVKG?#_CC78?%DGA[QG8:?IL\EI]LMYH)_
MD*[MI4ECUS_*@"#7KJ.T^)CZ)XA;S_#_ (ELDBACE8B..>,_<'INR#]2*?X_
MM/AUIUQI<WBZ)0JV[VEI#ARB(,$D*O0C@ ^]=1XP\):=XUT%M.O24.1);W$?
MWX9!T93_ )R*Y#3-9\2^&S#HWC;1)=7M58);:Q90^>&[#S$QD'W_ )]: *OP
MK\-1:IX!N['6+.2XT.74FFTV"\!W>0I!0D>A(SCOSZUZNB+&BHBA548"@8 '
MH*5<;1@8&.!C&*6@ J"[O;:PA$UW/'!$65-\C8&YB !]22!4]<[XZT!_$_@S
M4M*@(6YECWP,3C$BD,O/;D"@#C?BMKOB33?$/ANV\+22R7W[^YDLU^[/&BC(
M8=^-W'Y<U4U&UM/BYH%CXG\,77]G>*-*;Y0S8:-QR8G]L]#TZ^IKJ/A[XIL_
M&.E07%W#''X@TU3;W<4BCS8GZ,1GD!L?T[5#-\/)+/XA6_BGP]?KIRS$C5+;
M9N2Y7KD#H"3_ (^N0#E([3Q=XS\6>%[G5?"S:1>Z-/YEYJ9<;9D'\*#ODYXY
M R:]HHHH **** $9@JDDX &2:\@N/BYKNX:[:>'(G\("\%F;IY<3N=VW>%SP
M,]L?C73>-?$-UX7\5>&K^>X9=!N9)+*]7'R([@&-S]"#^&:=XGT#P3HO@DPZ
MM:K;Z#:W"W311;B'D)[@<MDGI0!5U'X9^&_$MMK\GVK[1/JEPLXNE=7:UE5=
MHVD=ASQZ'%,\!2Z]<PZCX1\9:9]K.G!52^EC#PW49^[G/5L?_7YZX'POM].D
M^(NN7_A".>/PI):HIW*RQ-<9'W W/ S],_2O9* *>G:3I^D6WV?3;&WLX<Y\
MNWB"*3ZX%7**K:AJ%II5A-?7]Q';VL*EY)9#@*!0!9KAO'VO7GA;5?#FLF9Q
MHHNFMM1C'W0)%PDA_P!T@_G5?PMXOUKQ1J]UKGDPZ;X-AC9(9+M=LERW_/7)
M^ZOZ?CT[#6-)T_Q'HEQIM_&L]G=1[6 /4=0P/J."#0!YOXB^'&DIXMG\3WU]
M%#X4=!>ZC9ESY<TR@[6P."#G/N?K67X.L?#]Y\5]0C\(HESX6N=-SJ,.PFV$
MQ;Y5 88ST..V6K1L)O$/PXA;1/$.G3:_X3'R6]]!%YLD$?998^I4?_J]*]*T
M+^RGTF"XT:WAAL9U\R,10^4"#W*X&#]10 _2M#TK0[=H-*TZULHF.YDMX@@8
M^IQUJ_110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4F
M*6B@ HHHH *9+*D,3RN<(BEF.,X ZUR>G?$[PAJFM3Z1;ZS"+N*0Q@2_(LA'
M78QX:LKQSXI\0^"]?LM9>%+OPDRB*[2&/][ Q/\ K">X].W4=2#0!QWB=[?4
MM%UWXC> _$-W!+)$(+^U2$'?M(7<0>4(7YL^G/'-4=*72M!\0>#&\!^([R_:
M]D6*]T]YS(OE$9=V3^#'/';MT-:%Y'%;?$JPU+X;S6NH+J\!FU33HY!Y!BW
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MS2*N.6QTSC!]<9XKT]5"J%'0# H 6BBB@ HHHH **** "BBB@ HHHH ****
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M!TBZ:^L-$L;.]E'[R2&(!LGJ <=* -FD\M!(9-J[R,%L<X^M.HH **XCQO\
M$[2O NIZ?8ZA:7<[78+EH$R(T!QGGJ?858FU+1_B1X3O;30/$!C:>/;YUJ^V
M6(]1N7[P'8],C- &-\2=;T,WUEX6\4Z9<+H^ICY=4#!4AF!^4 ]B.Y/KT(S7
MF\]EX1T'Q+XETGQTFH7C&)!I-Y<L\SO#M. C#^+)&.W&/KJWWC )X6U/P'\0
MM.GN-:AC\NQDBB+_ &QND;*<<-G'/?ZY%>D^ /"^HZ'X5M+'Q#=0ZC<0'-NS
MQ9:W3 PFX\D@YH 9\)[75K/X<:7#K E6X 8HDWWUB+'8#^&.*[6BB@ HHK'U
MB^NY]+U2W\/7%G)K5O'\D4KY".1E0P'3(Z9H \1\0>+=3U";Q-J<WB^XT34M
M'NS!I^C1D*)54\%EZN6_(?2O5?!OQ"TGQ6W]GI)-#J\$"/<6UQ"8F)P-Q4'J
M,_TKSFYO+CXA:/#<6.EV=MX\T"\CGO+.:)4>X\O@X)Y(SC@GV]#73^'='\0^
M)/B%;>,==T6/0EL;0VT=N) \D[-G+,1T49.,^U &OXF^'4>I:TOB/0-1DT7Q
M HP;B)<QSCTD7O\ 7^==#X<;Q"=/9?$D5@MXC[0]D[%)%_O88?*3Z<UL44 %
M%%% %#6]7MM!T.]U:\W?9[2%I7"C)( Z#W-><Z9\1O$L>JZ)<>(-(T^ST'72
M1:2QS_O(?EW*9"3CD?3^E=+\0?$^D^'M*@@UVPN+G2]2D-I<2(N4A5AR7/\
MASUKRG4M%\)^$?&NGQ^(/MVH>#I]/SITUQ,T\,4I.3C;VVXQCU!^@![?KFC:
M9XN\.SZ;>;+BQNDX>-@<'LRGU!Y%>?:9JOB3X=1?V-XIL+C6?#T8V6^K6L1E
M:./LLR=< =_YU8^"UI/;:5K,ENETGAZ:^9](2YR&\KG) /(!X_(UZA0!6L)+
M6>P@FL@HM9$#Q;4V#:>1Q@8JS16;K.OZ3X>LQ=ZQJ$%G 3M#2MC<?0#J?PH
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M;Q]<>;?V2[+&Q7&R$C@R-C@N<9_R /4* "BBB@ HHHH **** "BBB@ HHHH
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M^@W"W*\9W1D@.#ZCH3[ UQ.C^ [GXB:M-XPTF/\ X1"Q9?\ 03:C]Y.^>9&
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS=VAG6.X>#'[A#U<^OTH V)-0MI;JXTVVOK<:DD6_P DN&= <[6*YSC-?/\
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MGO3Z* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M *Y_QO+IT/@O56U:>Y@L?((EDM<^8H/3;COG'MZ\5T%-=%D0HZAE(P01D$4
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M'T&#_A["NX\"^#8_!NCRP/<M>7]W*;B]NF&#+*>N!V'I7444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
0% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (/ ZH# 2(  A$! Q$!_\0
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MD);_ &D;!_Q'L16G7SA\ ?$<NC^*-0\)W^4^TEGC5C]V=.&'X@'_ +YKZ/H
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MJW4=Q#'<VTL$J[HY4*./4$8- 'B_P7\*Z5XAT"]\4Z[:0ZGJ=]=R!I+M!(%
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MYQ[5:L_B#XI\/^(-(LO&,>CRV>K2>5'/ILA)MY#C"N,G(R1_B<5S^L^'M?\
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M +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6T5YX!UVWFDECC>SD!:)"[#CLHZ_2O(-%\8?#^VT6S@OOAQ<?:HXE24C2XY
MS 8)W-@G/7F@#W+0HM/AT'3XM*8-IR6\8MF!R#'M&TY/MBM"J&BSVUUH=A<6
M5L;:UDMT>&!D"&-"H(7:.F!QBK] !1110 4444 %%%% !6?9:YI>I-=K97]O
M.UFVRX$;@F)N>&].A_*M"OGSQQJ/_"O?'/BT0[HHO$6E>9;E>@G)VG^;G\:
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M< YVG:YP?P(_.LCX7Z7I'B3Q3XWN?$EK;7NI+>,C)=J'\N++ X!Z#@#/; H
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M.9]+F\ZW\N3:-V0>1W^Z*WZ* ..\4_#/P]XNU>#5=06ZBO84$8EMIO++*#D
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MVR3QHV,X9P#0!+144EU;Q0>?)/$D/_/1G 7\Z>CI(@=&#*PR&4Y!H =1110
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M:ZY=VDC1SB#8KH<%=S!20>W!-=?63XGT*'Q-X:U#19Y#''=PF/>!DJ>H/X$
MT >0V>C67@SQ7\.+K1D>W?5H##?[7)%QN13E@>^6S7??%K>?AEK(344L&\M?
MWKL1N^8?)QSEON_C6-H'@+Q,_B'0KWQ/J-A+:^'X6BL8[-6#2DKM#/GIP!T]
M*TM:\':]XL\&ZCI&O:G;"\:[\^QGMH\+&JD% XQSWS]: .'^'BV,?Q/L?[/T
MBX\,1'2/WEE=%@U^Q_B4'@XZYZ\=.M=U/\4;."XEA/AGQ0YC<H633&*M@XR#
MGD53TGP9XFU'QKIOB/Q=>:<SZ5 T5K%8*PWLPP78M]3P*]'H Y_PKXPT_P 7
M07;V,-Y;R6DODSP7</ER(V,\CZ5T%>?_  ]_Y&WQ[_V%A_Z *] H **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M 9*RI"[N,JJDD8SQ7C.A> U\1Z0]]X0\9:OI?AR_ED+6!CP4.XAPOS<#(/\
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M* "BBB@ HHHH R_$O_(JZQ_UY3?^@&LGX:?\DS\.?]>,?\JUO$O_ "*NL?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_KQC_E6MXE_Y%76/^O*;_P! -9/PT_Y)GX<_Z\8_Y4 =51110 4444 %%%%
M!7SQ\0?^2NZQ_P!>=O\ ^@U]#U\\?$'_ )*[K'_7G;_^@UE7_AL]+)_]^I^O
MZ,QZ***\H_0PK8^'G_)7=*_Z\KC^58];'P\_Y*[I7_7E<?RKHPW\1'CY]_N,
MO5?F?0]%%%>D?!&'XDL?$%];0)X?UF'2YE<F1Y;43!UQT )&.:\]\6S_ !&\
M*:=:7<GB^RN1<WL5H%&F*NTN2-W4],=*]>XKSSXQ?\BWH_\ V&[3_P!"- $G
M_"/?$G/_ "/-AC_L$K_\57>QAEC4.VY@ &;&,GUQ3J,B@ HHIDLT<$+S32)'
M$@+,[L %'J2>E #Z*;'+'-$DL3J\;@,KJ<A@>A![TR"ZM[I7:WGBF",48QN&
MVL.H..A'I0!+14275O)<R6Z3Q-/$ 9(E<%D!Z$CJ,T-=6Z7,=L\\2SR LD1<
M!F ZD#J<4 2T444 %%%% !1110 4444 17%Q#:6\EQ<2I%#$I=Y';"J!U)/8
M5AZ=XSTC4M6O]/CN$C>TFBA61Y%VSM(NY?+.?FXK9O[2*_L)[2>&*:*5"C1S
M+N1L]F'<5Y=X0^$3>'_$=IK%Y'I=P[K(]U$(<+;RALQFWX^4 <'/I0!V]QXT
MT:#7;72_M,;F>.9VN%E3RX?*QO#G/RGD4NL>,](T?[*&G2Y>>Y@M_+@D5F3S
M?N.PSPI]:X37/@\^K>++G78TTB,+<Q-;V?V<^3-'DF4SCJSG/!'I5SQQ\)H_
M%FIPR6RZ?86UO:%8WB@_>O, !&KGO$ !QUH ]*M;NVO81-:SQ3Q$D!XG#*2#
M@\CWJ:LKPWI*Z)H%I8BUL[9XT!ECLT*Q>8?O%0>Q.:U: "O._B?X]O?!^G2K
M:V5U$[I&8=1,(D@#E_FC;G@[037HE8^K^%])UZ_L;S4[;[2]EO\ *C=B8_G7
M:25Z$XZ$]* .8O\ XD/#X7?6D\/:Q%9DNJW$D ^1-@*3E<_<)/Z5!X.^(E]K
MO@[^T/[#U.^N;>T5Y)8H B7,V[#)'SSC^AKHW\#Z))X7MO#DD4[Z9;.KI&T[
M$G:VX G/*^QXQ5K3_"^E:5;ZE;V4+PPZC(\L\:2$*&88.P#[GX8H X;P7\4)
M_$7B'4=/&G:A=*+_ &1E;8(+.#;_ ,M3GKN!'X5ZE7-Z+X&T+P_>6MUIML\,
MUM:?8U(<_.F[=EQ_$V<\GUKI* "BBB@#AOB7X;\2>(M#D@\/ZP+4-"\=Q:.J
M[;A2.!N/W3U&<]ZX0>'_ !9=:$NDWOQ2T>*T>W%O+;CRR53;@INSSQQG->H>
M/XS+\/\ 7D%V+3-E)^_.<+QWQS@]/QKQ+2;_ .!HT>S%]93K=B%1,'2=COQ\
MW*G!YSTH ]_\/V$.E>'=-T^VN/M$%M;1Q)-D'S % #<>O6M*L[0&T]O#VFMI
M(QIIMHS:C!XBVC;UYZ8ZUHT %%%% !1110 4444 >?\ P]_Y&WQ[_P!A8?\
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MRO./BO\ \??@W_L-Q_\ H#5WU':#:[,^",3_ (5IX:S_ *N__P# Z7_&FO\
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M.$;3R2H8 XZ^]=[H\6I0:5!'J]U#=7Z@^;-!'L1CDXPO;C% %^BBB@ HHHH
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M^29^'/\ KQC_ )4 =#J/_(,N_P#KB_\ Z":^;?"/_(J:?_N'_P!"-?26H_\
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M U\YZ9_R"K/_ *XI_*O7R[XY>A5?9%JBBBO6.80]#]*]D^!__)*M._ZZS_\
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M^6/X'( ^;V[5V/\ ;VC_ /06L?\ P(3_ !J>VO[.]W?9+N"XV_>\J0/CZX-
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MO_(J:O\ ]ABX_DM 'I]?/'Q!_P"2NZQ_UYV__H-?0]?/'Q!_Y*[K'_7G;_\
MH-95_P"&STLG_P!^I^OZ,QZ***\H_0PK8^'G_)7=*_Z\KC^58];'P\_Y*[I7
M_7E<?RKHPW\1'CY]_N,O5?F?0]><?%?_ (^_!O\ V&X__0&KT>O./BO_ ,??
M@W_L-Q_^@-7=5_AR]'^1\$:9ZT4'K17R8@KD?B;_ ,B#??\ 76'_ -&+775R
M/Q-_Y$&^_P"NL/\ Z,6ML-_&CZH#U^+_ %*?[HK+\5?\BAK?_7A/_P"BVK4B
M_P!2G^Z*R_%7_(H:W_UX3_\ HMJ^J&>/^$/^1.TC_KU6MJL7PA_R)VD?]>JU
MM5\E6_B2]7^9Y\OB84HZBDI1U%9$FM\%/^1%G_["5S_Z%7HU><_!3_D19_\
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M_P#9:]ZI\#-Z_P##EZ'/4445Y9X 51NO^1@\+_\ 8:MO_0JO51NO^1@\+_\
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M+_\ H)KYM\(_\BII_P#N'_T(U]):C_R#+O\ ZXO_ .@FOFWPC_R*FG_[A_\
M0C0!MT444 *OWA]:[#X&_P#(J:O_ -ABX_DM<>OWA]:[#X&_\BIJ_P#V&+C^
M2T >GU\\?$'_ )*[K'_7G;_^@U]#U\\?$'_DKNL?]>=O_P"@UE7_ (;/2R?_
M 'ZGZ_HS'HHHKRC]#"MCX>?\E=TK_KRN/Y5CUL?#S_DKNE?]>5Q_*NC#?Q$>
M/GW^XR]5^9]#UYQ\5_\ C[\&_P#8;C_] :O1Z\X^*_\ Q]^#?^PW'_Z U=U7
M^'+T?Y'P1IGK10>M%?)B"N1^)O\ R(-]_P!=8?\ T8M==7(_$W_D0;[_ *ZP
M_P#HQ:VPW\:/J@/7XO\ 4I_NBLOQ5_R*&M_]>$__ *+:M2+_ %*?[HK+\5?\
MBAK?_7A/_P"BVKZH9X_X0_Y$[2/^O5:VJQ?"'_(G:1_UZK6U7R5;^)+U?YGG
MR^)A2CJ*2E'45D2:WP4_Y$6?_L)7/_H5>C5YS\$_^1%G_P"PE<_^A5Z-7V,=
MD>BMCYUUS_DJGC#_ *[0?^BA24NN?\E4\8?]=H/_ $4*2O/Q'\1GBXO^,PHH
MHK$YC8^&G_)69O\ L#G_ -&"O<Z\,^&G_)69O^P.?_1@KW.O3H_ CW<-_"B>
M0?''_C[\)_\ 7U-_Z *X*N]^./\ Q]^$_P#KZF_] %<%6&(^)'-B_B04445@
M<I1U'_7Z7_V$;?\ ]#%?55?*NH_Z_2_^PC;_ /H8KZJKLH? >CA?X9S/Q$_Y
M)OXD_P"P=/\ ^@&OG/3/^059_P#7%/Y5]&?$3_DF_B3_ +!T_P#Z :^<],_Y
M!5G_ -<4_E7KY=\<O0JOLBU1117K',(>A^E>R? __DE6G?\ 76?_ -&M7C9Z
M'Z5[)\#_ /DE6G?]=9__ $:U>9F/V3HH=3T6BBBO+.@*KWM]:Z;9R7=[<16]
MM$,O+*P55&<<DU,TB1C+LJCU8XKD-#\0:5\0M,UBROM/C%K;WSV,D$T@<3;"
M#N[<9Q^5 '3:=JFGZO;?:=.O;>[@SM\R"0.,^F15NJ&FZ)IFCJRZ;8P6@=41
MA"@4$(,+G'H.*OT %%%<_P".=>E\,>"M5UB!5:>V@)B##(WDA5S^)% '045X
M]HNK^)_#?B;PDNK:])JMIXEA)FBF15^SR[0PV8Z#Y@,?6O1O%H\0-X=N$\,"
MW&JOA8GG;"H">6Z') Z4 ;=%>3Z->^(O#7Q2T[PQ<^(9M>@O;-I[M9T4-:N
M3N!'120, ^M>L4 >?_#W_D;?'O\ V%A_Z *] KS_ .'O_(V^/?\ L+#_ - %
M>@4 %%%% !1110 4444 >0_''_CY\*?]?<W_ * *\^KT'XX_\?/A3_K[F_\
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M!F]?^'+T.>HHHKRSP JC=?\ (P>%_P#L-6W_ *%5ZJ-U_P C!X7_ .PU;?\
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M_B2]6=T?A04445F4%%%% %+5=)T_7-.ET_4[2*ZM)?OQ2#(/O['WKB[7X*>
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MG_T8*]SKTZ/P(]W#?PHGD'QQ_P"/OPG_ -?4W_H K@J[WXX_\??A/_KZF_\
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M^%'V:W_Y]X?^_8_PJ6B@"_\ #=$C^+<X1%0?V.>% '_+05[C7B'PZ_Y*Y/\
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MSW[F03F- @1Q(P*8']W&/?&:ZB@ HHHH **** "BBB@#+\2_\BKK'_7E-_Z
M:R?AI_R3/PY_UXQ_RK6\2_\ (JZQ_P!>4W_H!K)^&G_),_#G_7C'_*@#H=1_
MY!EW_P!<7_\ 037S;X1_Y%33_P#</_H1KZ2U'_D&7?\ UQ?_ -!-?-OA'_D5
M-/\ ]P_^A&@#;HHHH 5?O#ZUV'P-_P"14U?_ +#%Q_):X]?O#ZUV'P-_Y%35
M_P#L,7'\EH ]/KYX^(/_ "5W6/\ KSM__0:^AZ^>/B#_ ,E=UC_KSM__ $&L
MJ_\ #9Z63_[]3]?T9CT445Y1^AA6Q\//^2NZ5_UY7'\JQZV/AY_R5W2O^O*X
M_E71AOXB/'S[_<9>J_,^AZ\X^*__ !]^#?\ L-Q_^@-7H]><?%?_ (^_!O\
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M#X#T<+_#.9^(G_)-_$G_ &#I_P#T U\YZ9_R"K/_ *XI_*OHSXB?\DW\2?\
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MJ^4=5^Y9?]?T'_H8KZNKT<+_  SX?B'_ 'S_ +=7ZG,?$?\ Y)MXC_[!\O\
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M/_HP5[G7IT?@1[N&_A1/(/CC_P ??A/_ *^IO_0!7!5WOQQ_X^_"?_7U-_Z
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M VOR0W-G';K&L(# J<DG)QBNW 8:K2J\TXV5C6E"497:/=:\6^,'_(_>%_\
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MZ]1_Z$:[&O)/!GBG7/#?@_2]'G\!>(I9;2'RV=(E"L<D\9.>];O_  L35_\
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M7)K>9 \<J1@JZGH0?2IAJOB+/_(B:_\ ]^A6?U'$?R_D+V4^QV7P3_Y$6?\
M["5S_P"A5Z-7B_P_UW7_  GX<DTZZ\">()I&NY9]T42@8<Y Y(KJO^%BZO\
M]$]\2_\ ?I/_ (JOIEL=R/,]<_Y*IXP_Z[0?^BA25#J4'B>[\9:YK*>"]<$.
MH/&R1F'YEVH%.<<4WR?$_P#T)6M_]^:XZU*<IMI'E8G#U)U7**T+%%9UK>:U
M?3W4%KX4U>:6TD\N=$C!,;8S@^AQ5GR?$_\ T)6N?]^:R]A4[&'U6M_*=!\-
M/^2LS?\ 8'/_ *,%>YU\^>$9O$F@^-9-;G\$Z[)"UB;81I"-V[>&SR0,<5Z+
M_P +$U?_ *)[XE_[])_\57?334$F>O0BXTTGN<]\<?\ C[\)_P#7U-_Z *X*
MNE^(>H>(O%TVBR6O@?7X/L$TDCB6$'<&4#C!-<U_9_BG_H3-:_[\UE6A*3T1
MAB*<IR3B@HJK(VNPZC!I\GA75DO+A&>* Q_,ZK]X@>U6O[/\4_\ 0F:U_P!^
M:Q]E/L<_L*G8HZC_ *_2_P#L(V__ *&*^JJ^6[G1O%=Q+9L/!VM 0744YS#U
M"MDBO9O^%B:O_P!$]\2_]^D_^*KII1<8V9VX>+C"TC8^(G_)-_$G_8.G_P#0
M#7SGIO\ R"K3_KBG\J]>\4>+];UWPIJVE0^ ?$<<MY:20([Q)A2RD G!SCFO
M*K30O%EO9PPMX.UDF.-5)$/7 KTL%5A3DW-V*JQ<DK"T4Z73?$\$+S2^$-82
M.-2S,T.  .2345E:^(M1LH;RS\*:M/;3+OCECBRK#U!KTOK='^8P]E/L./0_
M2O9/@?\ \DKT[_KK/_Z-:O(#I'BO!_XHW6?^_-=[\/=>U_PAX-M-&NO GB">
M:%Y&+Q1*%.YRPZD'O7GXZM"IR\CN;4HN-[GL]%<#_P +%U?_ *)[XE_[])_\
M51_PL75_^B>^)?\ OTG_ ,57 ;&SXWUE].\+:JNGW]M!JXM':V1Y55]V." 3
MR>N/>O+=*\$6FJZ3:Z@WQ:U$/<1+(X%\!AB,D8+Y&#QS7H?C3P;X,U)+CQ#X
MGL%D^R6_[R8R.N(UR<84C/4_G7CP;P((1J$OPMUJ/1#@_P!H>;*0$S][&<8_
M&@#Z'T>V6ST6QMENVO!# B"Y=MQFPH&\GOGK5ZL_1!IZZ%IXTK;_ &<+>,6N
MTDCR]HV]?;%:% !5+5M+M-;TFZTR^C\RUNHS%(H."0?0]C5VB@#@?#GPQAT7
M6K+4K[6[[5FTV$P:=%<A0MLA&.W4XXS_ /6J^G@*VN/#&JZ#J^I7FJ6^H3O-
MOG;YX<D%0A). I (KKZ* .(\+_#M-!UL:QJ&M7FL7\5L+2VDN5"B"(=@!U/O
M]:[>BB@ HHHH **** .%T>RNX_C%XEO'MIEM9;"U6.=D(1V&<@-T)%=U110
M4444 %%%07=[:6$/G7ES#;Q9"[YI BY/09- ''^/;*ZN];\&/;6TTR0:RDDS
M1H6$:[&^9L=![FNWI%974,I!4C((.0:6@ HHHH ***0D $GH* ,/QK!-<^!]
M=@MXGEFDL9E2.-2S,2AP !U-.\'PRV_@O0X)XWBECL85>-QAE(09!'8T[2/%
MF@:]/);Z7JUK<SQ$AX5?#KCKE3S^E;- !1110 4444 %<-\/;*[M-4\9/<VT
MT*SZY++$9$*B1"JX9<]1[BNHCU_2)M5ETJ/4[1M0BQOMA,OF#O\ =ZUHT %%
M%% !1110 5Q&IV5T_P 8M!O$MIFM8],N$><(2BL6& 6Z GTKI]1UW2=(EMXM
M2U*UM'N"1$L\H3>1UQFKZLK*&4@J1D$=#0 M%%% !1110 5POQ<L;O4/ 4MO
M96LUS,;JW81PH7; D4DX'H*[AY$BC:21E1%!+,QP /4FH[6[MKZW6XM+B*XA
M;[LD3AU/T(XH FHHHH **** "BBJ\-_9W%Q-;0W<$L\)Q+$D@9D/^T!R/QH
MXSP'8W=IXK\<2W-K-#'<:FKPO)&5$B[>JD]1[BN[HHH **** "BBB@ HHHH
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MO^NNI <)$C#/7CIUR*U!X@NO'FH7>EVWAVWN_"8F>TN[^ZGV[RH^8QIU.#@
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M3MX]\,;=:TYQ;O?QNR)?*!PWRD;N,9^OX#U*VMH;.VBMK:)(H(E")&@PJ@=
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M 'A^G2O3+6%X+6&*69IY4C5'F8 %R!U./7K^- $>GV?V*SBB>9KB=8U22YD
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M* &>#?!$N@0ZAIDVH1:IX8F99=/M;A/,:('YB"3P5SC'Y\5W0&*  !@# %%
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MADF*#[C*06]N.QKZ'KG=!\#^'_#>HW>HZ=9$7MVQ:6XFD:23DY(#,20*Z*@
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M !1110 4444 %%%% !1110 445GZWK=AX=T>XU74YQ!:6Z[G<\GV '<D\ 4
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M6V$Q!D<L7=\=,LQ)P/2MZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCX,\/RZI?;R/N1*J%@TA!*@D= 2.IKRF>[UG1-<L/$WCV*RUO0=6L1:M<6\
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MQ01+%#&D<:]$10 /P%/HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1<_P1EB>.Q/'<UZC:VEM8VZ6]I;Q6\"#"QQ($5?H!P*FHH ***0L 0,C)Z4
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M&,\G];_@GP_>>)UN- OK;4-#UGP_,)M,U H2]O$S9\EFXWCJ1Z@GMP0#M)?
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M/#*R]>V&SP<5O^ ?"GB>ZTJ_\&^.=&6;0(U#6TLDX9HVSPL; Y('//&/H<4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MD>)[?4KOPW?VVD+:-?2Q%(A=C,1SP<CZ9]JUZ* /+_AY\-=4^'^ONT%[:7>F
M7=JOVMGCVS),.R$?P<GK_.O4*** "BBB@ HHHH \9;X7>)F\6GQH+O21K?\
M:&\6GD_Z/Y'W<YQG?CG/7/?->RC..>M+10 4444 %%%% !1110 4444 %%%%
H !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,* L0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "O*/BKXEUSP]XF\+VVE:G+;0:E/Y5P@56R-Z
M#C(.#AC7J]>'?'&ZMU\8^"0TT8,-T7E&X?(N^/D^@X/Y4 =-K/B_5/ WCS2-
M)U2Z_M#1=8.R&:1%6:WDW 8)4 ,N67J,\^U=EJ7BK1=(NVMKV^2.5%5Y>"PA
M5CA6D(&$!/ )Q7FOCS3G^(/Q$\+V>C@W%EICFXO;U!F) 64[0_0MA.@]162T
M-J?B3XZT+Q1JLFFP:R(VA<A?](B&=JJS \@$  >A':@#V'4?%>A:3J$%A?ZG
M!;W5PNZ&.0D>8/8XP:S1\1_"C6%Y>#55\NS<I.AB<2(?=,;L>^,5PGBX6ME\
M3OAI:&X++;(R$SD;P-JA2WH3C\ZQ[:ZM!XI^+CF>'+V;A&W#YOE8$ ]^<#ZX
MH ]??QKX;233XVU:#=J*J]F.3YX)P-O'/-6;GQ+HUF;_ .TW\4/V *;HOD"/
M=]W/'.>P'6O&_P"R9-6_9ZT+5=-E']IZ#F\A9.2I1VWK^7./85?^)HU:\^&6
MEZZ\#QF6_@U"_BC&[RX]N%!]0OR_C0!Z%K'B*"\\'Z_=Z1>/%>:?;2LP*;9(
M9%0NH96'&>#R.0:X^'Q+J6H?"OPUJ-WXLAT;4;R<&2[FA!$P#L"F , D ?7%
M2RPZ$_ASQIXDTW7)-0;4]+<7$A*B(,(F" 8 PV#C'6N"UJZM_P#A0/@Q!/'N
M34$W*&&1AI,Y'MD?G0![G=^,?#^GZE+IMUJD4=]%'YC6Y#;]N,Y  YX],U)9
M>+-!U#P^=>M]3@.F#.ZX8[54@X(.<$'/:O.9;VT/[2,$OVF QC12 ^\8!Y/7
MZ<_2N5\-:GI%I\#_ !/)JEB-4MDU=R+42%<EBFPDCE5SSGV- 'N-CXHT?4=0
MN=/@N\7MJ@DEMY$9'5#R&PP&1R.17.:/\2M(\17&O6UK=_9DL=R0W#QL2VU2
M6DQCH#V/7%<)X3O5N/CW#=27\-R+G15\N6)"D;':ORIGD@8([G@U;\"R#3[+
MXE6=[N@N#=7,NR12IV%6PWT/K0!W'A+7(+#P''J>L^*K;58HW</J078C?-@+
MCN1TZ9-;EKXFTF[2\*7)1[)0]S#)&R21*1D%D(S@CD'%?/-I;W5S\#O#<]LQ
M:VL-;,E\JG/EKO.&8=@,_J*[YDGG^-OB+5;6=?[*MM%$=U,&_=EB@*KGIGO]
M![T =L/B-X1*6CKK=N\=W+Y,4B!BI?\ NDXPI^N*ZFOELW$"_LZV,:RQB;^V
M\[0PW<$G..O3%?4,4B2Q))&ZNC*&5E.00>X- #Z*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \G
MUG7]<B^.6G>%X=7N(M*N[7SGC54W*VU^C%<@?**M:/XLUJQ^,-UX*O+O^TK$
MV_GQ3O&JRP_+NPQ7 (YQT]*YCQ2UC>?M(:3'+=A(38^4\L4^PHQ67 W \-R/
MTJ3P/<-\.OB3J/AWQ(5E;5&\VRUF<?/,.RLY[''3/##W% 'K$OBO1(-3&GR7
MZ"?SEMR<$HLK#*QEL8#D= 3FH[SQEX>L-4DTRYU.*._C3>UN0Q<C&> !S^%>
M->&+"QU%O$/A;Q)K%U8:BNMM>);1A1+.^<JZ$@ENG;M@UT5Q<0+^TS:EYH_D
MTDH2S#AL,<?7% ':'XE^$!I,>IG68_LCR>47\M\HV<8<8RG7OBM0>*M#.MQZ
M*-1A.I2J'CMQDLRD9!'&",=Z^=[.>W_X5!X_42Q^9)JZE0",L"ZXQZC@_K7<
M>*K6YM_"G@;QQHP-Q>Z5';Q2+&<^="ZJI4GZ\?\  C0!ZB_BC18[2YNGOXQ#
M;3_9I&((Q+G&P#&2V2.!FN6\?>+FC^&VJZUX=U!HKJRE6-B$PT;AU5D=6'!P
M>A%8'Q5@N])T?PKJ+B1+>SU9;J_>)=_ELQSO([X);K[5G^-+/18/AIXOU72M
M9DU$:O+!)+*2OE-*''"8 YQU'/2@#K;O6+J>;P1N\50Z;/=1Q2W%K)#DW^Y5
MRJGH.21_P+-;MU\0/"UE)?13:O$)K$$W,2JS/& <'*@9KR[Q+>VIU;X22"YB
M,:B(LP<848C&3Z<@C\*CMKJV7XD_%*1IX@ITR10Q88.$ ('X\4 >S_\ "0Z1
M_8L.L?VA -.F"F*X+?*^XX '<DGC'6J]OXNT2Y_M%5O=DNFC==PR1LLD(Z@E
M2,X/;'6O&M/U?2K#]G/1I=4L%U';>-'%&\C*L4OFN59RO( ';OG'>M/PG=?:
M?C%XJ+:@M[+=Z0ABE5-@F.U/N+Z#H.O2@#I[;XB6'BKP3K%[9:JNCR(9$ANI
M8F;R4W;4D88QSZ=LUT.F:]9Z9X2TFZU36HKY[B..-+N-.;N0CC8@Y)/H!7DF
M@7$=O^S?KUA.QBNX3.LD4@*LC%QA3GN?2EBBN6C^$>J"0-I-OMAF<'Y(I3C&
M[TSC'/I0![1#XGT>?2[O4DO4^S6;,MTS AH&7[P=<94CW%9\7Q#\)SW%A#%K
M4#F_<QV[*&V.V<;=V, Y[$UYQHT5RFJ?%?5S)MTB59HHY2WR22!6SM/?&<?C
M7&75Q"GP>\!*)8UD36&9@& *X=LD^F,C\Q0!]0T4@(8 @@@\@CO2T %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,
M:*-CEHU)/<BGT4 (JJJA5  '0 5%+:6T\T<TMO%)+$<QNZ LA]CVJ:B@!K1Q
MLVYD4GU(I/)B_P">:?\ ?(I]% '.ZKHFJWFNV\MMJ<<.CM;O!>6+1?ZS)SO4
MCOCCGMFM_P I#%Y113'C;LQQCTQ3Z* (8;6WMX!!!;Q10CI&B!5'X"G^3%C'
MEIC_ '13Z* &>3%G_5I_WR*:]M!)$\3PQM&XPR,@(8>XJ6B@"(6MN)4E$$0D
M1=B.$&57T!["I"JG.5!SUR.M+10 SRH]K+L7:W!&.#38;6WMH?)@@BBBZ[$0
M*OY"I:* &>3%_P \T_[Y%/    & .PHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 888B<F
M-">OW12M&CXW(K8]1FG44 0FTMC="Z-O$;@#:)2@W@>F>N*D,49;<47/KBG4
M4 ,\F+&/+3_OD5S[Z'JLOB>>XEU1'T*1(BNG^7@QR(<Y#>A/)S71T4 -DCCF
MC:.5%=&&&5AD$>XID=M!#"D,4$:1)]U%0!5^@J6B@!GDQ<?NTX_V11Y,?/[M
M.>ORBGT4 126T$T1BD@C>,G)1D!!_"@6T"S><(8Q+MV;PHW;?3/I4M% #2B,
M,%003G!%->"&2%H9(HVB;[R,H*GZBI** (XX(8H1#'$B1*,!%4!1^%+Y,6,>
M6G_?(I]% !THHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DS2TQV
M" EC@4 +FL+Q-XPTGPI:"?49_F;[D*$%W^@KGO%_B'7W1K'0+9DE?Y1+CY_J
MO;\ZXFT^$.O:O(U]JMZJ3R\NTI/F9]^,5O"DK<TW9?B9NIK9(ZU/C5X;=E7[
M/?C/<QKQ^M=1X?\ %^F^(YIH;0R)+'SLE !8>H]N:\8\6?#+4?#&G_VBES'<
MVB'$@&=Z^_3&*AT#Q$^FSV>JQD[[8A9E'\<?I_*NKZO2J4W*EN<[K5(32GL?
M1N:9)*(HR[ D#TIEM/'=VL4\3!HY%# BI2 1@]*\X[!D4\<PRC U)S7*:]]K
MT*1=1LU:2WS^\0?PULZ-K5KK=DMQ;N">CKW4^E4XZ<RV)4M;,O>>OF&,@@U+
M5:X94:,GN<9J=>!UJ2AU%%(2,4 'XT!@>A%4Y<,3\QXZKZUG6.H/+K4FG94%
M(_-P.RYQ^=)-,#=HS1VJ.61(8GED8+&@+,Q[ =:8"RS1PQEY'"K[TD,RSIO3
ME?6N L-6G\;^(YOLV5TFS<J&_P">ASC/T.*]!CC6)%11A5& *N<.71[DQES:
MK8?11FBH*"FDTIKCO$WCJVTF<:9ID1O]8E.U+>/G:?5O:JC%R=D)M+<ZB^U"
MUTZV:XNYTBB7JS&F:;J*:G:BYBCD6-ONEQC</45R&C^#K[4[M=7\5W)N+G.Z
M.T!_=PCL/7-=TH"@*H  ]*J:C%66K)BY-W>PM4;C5K:VO4M'8^:^.!VS5T]:
M\ZTB\_M[XB7<F/W-OF,X]4) I0C>[[!.7+9=ST;FEI*6H+"HY9A$,G)/8#J:
MD(R*B5#N)( ':@!X;<*CGN!;JK,K%2<$CM]:E  Z56O95CMV7&XL,!?6@"5)
MUD/!^GO4M9M@)H;41RJ Z#Y5'9>V:L27<5N%,T@3>< 'O4I]&!9) H!S5*6\
MMU1I3*-B#+'TJ:UE6>/S%.5;D&G<"Q11WHI@%%%% !1110 4444 %%%% !2$
MT9YJIJ.IV6DV<EW?W*001C+.W:@"WSGK1SFO%_$OQIE%V(/#MM&\*MAKB;.'
M'JN#_.LVW^,7B*2X17M[+:QQQN_QKHAA:DE>QE.K".[/>AUI:X_P/XLFU];J
MVOD1+R!LG9]UD.=N,_2NPS6,X.$G&6Y<9*2YD)1FJ]W)+#'YL:[@OWAWQ4=E
MJ4%\,1L-XZBE9VN.^MBY2TAJ"*1PQ63''<4AEBBDSGFEH **1FVC-0M=1YX^
M;UQVH GHIBR*W0YI^: "DS02 "21BLBUUI=0OGALQOC3AI.U-)L3=C7I:04M
M(8449HH 3-!-9^KZWI^AVANM1N4AB'&6[GTK)T+6=2\07#7<=K]ETL']V9/O
MR^X[8JU!M<W0ER2=CIJ,T5B^)];70=#FO/E\P<1ANA-2DV[(;=E=FU2UFZ#>
MS:CHUO>3*%>5=V!VK2H:L[ G=7"BBHW<@<+S2&24E1Q;\?.1G/.*>X)0@'!Q
MP: %I:H6]U-([HRC=&<-[U=#CH:5P'44QG"TBR;FHN!)1113 **** "BBB@
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M:Z*>'D^EWV_S,9UXKK8Z/1/ DEQ=IK'BFX.HZ@3O6)^8X>X 'M_2NY4!5"J
M . !7A]Y\1?%EX4MXI;2W:9Q'&5C((9C@9.:TO$'C7Q7HNH6^FN]GYJ0AGE"
M'$AP#TS[TJE*HZL:4MWLAPJ0Y');(]@KR+XNZJ]Q?Z=H<."=PG8@]\XQ^1IE
MI\1O$PB#R06<^>@1-I_4US<]S]J\4VVMZH0HEG#SA1D*,8X'Y5O1PM2G/FDM
ME<YYXNE-<L7OH>_6<2P6D42*%54  %3U6M;NWNHE:WFCE7 ^XP.*GW5Y[.X=
M3#&&8,>HIU+0 8J*9V1?D7<QZ"I:0]: ,V*U6VG$LC9FDX/L*;?W[6$ 98VE
ME=PB(.YJ'5[Q[>_M!' TQP6*@XP,]:Q8=?&I:I,OEF.2W0^7 >2YXYS1RMN_
M05UL;]M?7%S<&!K8J57+.>@/I4MG+/YS1W2A9,_+M'!%0Z/*Q,PE4+([;BOI
M6IN'I1:S'<?129I: "BBB@ HHHH ***:X)&!0 CRQQC+NJCU8XK+O/$NBV"%
MY]2MACJ!("?RIM_HS7R,IG90??-<G>_"R"\<LUU #ZF#)_G6D(P?Q2L9RE-?
M"C-\1?&.WCC>W\.VDES.P(\^5"JQGUVD?-^=>7V'G3:LUY=S/-<SR;Y))#DD
MUZJ/A&Z >7JZ*1_T[\?^A5YSKNDZAX<\6+87JKACOBD7HZ],X[<UZ.']A%VI
MO4XZ_MI+WE9&]H)*^.]$(.!]H.??Y37N38SBO"]&R/&>BL!R9SC_ +Y->XN?
MF_"L,P_BKT-<%_#?J9.JB$W=M;%=KSG"G]3^E;,2)!$D4:X1!M4>U9]U;"YU
M*RDQ_J"S9^HQ6CG-<)UF;J6DOJT;P7,BM:N,-$1D,/>O.KG2]?\ AUJ4NHV0
M%UX?)'F0IUB'?C\^<<5ZSCWKE?$>K++)]@!W6;@QW&T9+Y_A7W/(IQ6KTO?=
M":N:&F:S::QIR7MI,K1.H)Y^[[&I9;@"%G$B';_M"O*/["U'P+J"7UT;@^'I
MY,RQPN=T2GH2!Z"NGUN'Y+:[TF5Y]+O4VEE?=AOPZ<#GWKCJ8.K>\9>Z]BU)
M/3J4/'?B2_DT6?3;33#/]H_=M-'^\$:]<D#Z5B>!O%B>&+>XBU6=[H"/;;W&
M"S#T0CKUYKUZUAM;2V5(;>-0R#=A<;OK7#>+?AY#?)+?Z$JQ7/WGMNB2?3T-
M=F#I4*:Y*BWZF-9U-Z?W$W@S0;O5-2;Q=KGS7,W-K$>?*0^GIU/%=7K6O6VC
M/:).<-=2;(QZGC_&N6^'VO7"PIH>M7,(OP,P0]'5/[K<Y)&#5;XE7%K'XE\+
M"\F$4$<TLCL3Z*#T_"G.?/*_W&E."V9Z5D("20 .22< 5R=]XMGOM4&D>&H1
M=7/_ "VN3_JH1]>C'V![5DSRZ]X]F,5H9-*T#?\ -,01+<+GMT(!_'K75P66
MG^$_#]PUC;B.*WB,C?WGP,Y)[FKM&G\6K[?YD:STB>.7-C/HWBS5[2QU ?:,
MJUW/&"K$N-V%/;K72>'['5-:232)I3)ILO,[ORX_W3V/-<_X?VZM+?:FR2J\
M\K.QD!&\ G&#W '%>M>%K V.D*\BA9ICE\>G;]*XES5:CE+8]O$JC0PL8))S
M?5?UN5[7P)H=HX+1/.!_#,VX?RKC_$L%EX+\6Z?>VUC''8.<A%7 $G(X].*]
M2)KD_B)HAUKPG-Y:%[FU/G0@?WNA_3-:N"M9'!#$S]IS5&W?1^C.L29985EC
M8,CC((I=QKC/AIK@UCPC C,#+:_N2,\D#O\ K78U;33LSFTZ$5Q:6MU_Q\6\
M<O&/G7-5)-'MT3-BJVLB_=V#"_B*T**32>XK''>(&CTK1[R]UW1[?48HXVWR
M1Q_?&/NE>3CWKB=#U+6(HUN+35)PY;=';.Y,2+V7;],5[-)&DT3Q3(LD3@JZ
M,,AAZ$5YGXP\,MX?6/4M)8>1).J2V['&T'/*G\.E93@XJ\#MP7L74Y:JWV.V
MT'Q/;:LJP38@OU'SPL>_MZ_A6^#7C4&G/<FWN+:]$6H6K;X'8?>/7#'/(YKT
M7PQXC37K(B5!!?PG;<6Y.2I]1ZCI5TY\R,L31E1J<K5ET.AIK'@GL*,T,-PQ
M5F!S+1X6_4C&Z1GY]#5336:R!=+ORD<_<;D9]AZUHZCE-5D3H)8@!]1FLK21
M ^NQQW*[B WE@] 1UK9*],Q?QF\A>91)OE<CV*_SJ_#NV_.I!^N:D/''3% K
M$V)%IU-6G4 %%%% !1110 4444 %%%% !137<(I)[5BZEXA^P(2EL96'8OM_
MI346]A-I;FY63XBO;.QT&^>^F2*%H'7YF W94\#WKS[6/B7K:;DLM)BA(_C:
M42?I@5YWK%WJ_B*X\_6M1+]Q$%*QCZ+G%=-/!U)OL83Q,(^96\.B-GG\E2L+
MG,888.WM7IWPMN%AU35;-OO2*CK^&<_SKS?1W1;HHI'3%=S\.CCQK(/6W?\
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MPP2,#V&!73ZW,=/\-:G=>69##;.^P#.[ Z5Y/\/-'L-4FU"[U6)\V7[QH"2
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MH)('UJ'X5Z[_ &QX42WD8FXM#M?/H<D#\!71+WZ2?6.G^1FO=DUW.U I0M/
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MXDR709,9)Z$=<<UZ[5*ZM$NMR3JLD3#!1AD$>XJ904MS2E6E2?-$\7B\FXP
MRO&_IS220R:7*IM[A#NY$+,,G\*ZS5? GV:ZDO-$;"J-TEHPX;_=/1:XC2[R
MPO=7>#7;.[M&PZI.T3 1,#@9;'3WK%TFMST?K\5%3COU1LV^H07)\N0>5+Z-
MWJ9H@.U5KKPW<6]A)=F[BOXT&[?",$+Z@Y.:H6^IR6R)YA\ZW8?*XZU@X]4>
MGAL;3K747L:$D8]*JSQ!DPV,5=66*XB\R)P1UQW%/735:V-[?.T-KG:@527E
M/HHZFKI5)1>A.*I0<>:;T.93[1H]W]LTJ[-K/U.#\K?[P[UV&B?%RWRMKXFB
M%N^=HNHES&Y^@SC\:O6'A!KN$RBUCM8W&5^T@2L1].,5:D^'EE<P>7(;5CZ&
M#C\JZ98CFWW/$F\-M%/U.NLGTS4(5NK-K>YC89$D;!OY5H @=,"O(;W1->\!
M2C4=%3S;&)@9H(1A"I^]B,=\9YKT_3]0BU+3X+R$_++&KE<Y*DC.#[BJC)21
MS3@HO1W-'.:*B5J>&ID$=W:6]];/;74*302##QN,AA7G_BGP7<I<VMYH\9EM
M8"2=/W (#@C*YX%>B9HSD\5,H*2LRX3<)*2W1X]J>C)IR6]U)IT[^;!^\C2,
MLR2<YY Z=!4UAX?35=$@NHS/;W 7/DM"RD<?=Y%>M;CSS29-9^Q70Z%CL0E;
MF/*_#_@B.YO9+_4])<*NZ-+1F&V4'@L_8^HK;TCP5=6\DEI>RQ?V2LGF06\0
MP5!.=A/<#I7<9/K28JU3BC*5>I*3DWJS!U?P=HVKZ:;,VJ08Y1XQ@J:X^UU#
MQ!\/;@VVL%]1T9S^ZN!DM&/?KQ7I^*BNK6"]MGM[F)98G&&5AD&K22=S)RDU
M:Y5TK6M/UFW$UC<)(",[<X8?4=:P?%_AA;]#J-I'_I4?^L0<>:O^/^%<KK/A
M:Z\*:A]LT^:9+!VR)8V(,1]'QU'Y#I70:=XHU>WM@U];1WL1X\R$A3CZ<YKH
MC&4;3INY@Y*7N5$5O#WB&72HTCGWS:8YQ&>KP^Q]O;'>N\BEAO+;?$ZR12*1
ME3GK7"W6MZ+9LQ2VG2WNV+L3 <H_?MTXQ3=,_MMKJ.ZTI5L]/;EDF^;>/4+Q
MM-*:4_>BK,<&XZ,ATW37-QJ-G(2(8KN10JCGRR<#]*J6JS7WVK2(MSZ;8RF1
M),_?;/W?^ X_6NC72;K^TKN]-X0URNUE0$ =>1[\TMII<.GVWV>WW!2Q8L3R
MQ/4FM8RO:_0AQM>W4HZ%I(A\2VER9DD'DR$H.JGC&:[C=\U<1ILSZ/K]U<WD
M#?99%58Y4&2O'.0*Z&[\0:?:V@FCN(Y9'.V.-6&XD^H[?6L*S<IW9K224;%;
MQ3XHB\/V?EQ#SM1F&V"%1DD^I'I7EUEH]QK>LIIJ3M++<MYMY.1\RCIG^0KI
M%W:=XCFU>^7[=)(N%=N%4<<+G.!71^"M(>U@N=6NX5CN[Y]^P#_5KTV_IFMK
M*C3UW9FI.I/39'4PPQVUO'!"@2.-0JJO %/I <TX5R'0)1BG8IP6@1&1N!4C
M((P1533]&T[2Y9Y+&SBMWG(:4HN-Q]ZO[:<!3 1:=112&(:\:_:+LIKGPAIT
M\:Y2WNBTA] 5P/UKV6N ^-,7F?"K6,)N9?*(P,D?O%H \%^$/CF3PGXJBM[B
M55TR]813A@3M/\)'ISC)]*^N$=9$5T965AD,IR"*^ P2""#@BOJ+X)>/QXAT
M-=$OYHQJ%B@2/^$R1@8&!W( Y- 'KE%-YIU !37^XWTIU!&10!XOJ/G7;S"T
M$,L8<[BI!Q]::LT<=N8F!#XZ <5T7BGX?SW5T=0\,W8T^Y',D&/W4WX @ ^]
M8-K+<VJ_9=7L_LM]'][?RC?1^E>E2Q$7&SW/!KX2I1UW7];A:"%=EK<1Y)^:
MJEYI<4TDTT#[ F>#2W-V#JZM-$R+C *FIKX--ICF,A/F[\$BNE<RDGW.9-IJ
MQE6\</V5I96);.!3)+.5(!*RX1NE322P1Z8ENF&?.2:B:[S9")R>#QS70KFJ
MONBG&L]E=+>6$[V]RO\ &AQGV/M7=Z'\4$4QVWB"$Q/T^TQJ2C'Z#)'UKB88
MKB[#>0F54<NQVJ/QJTOA>]OE$>\Y;TA++^8XKEQ4<.U^\=F==&O.F[+7R/;8
M[J._M?-L+F*9".'C<,/TKF]8\")XAD']I7\K1#^!&Q7GUCX;\6>%9Q/I-^\4
M0Y,!A9XS_P !!Q7H7A?QS!K=R=.O(_LNI(,^63D./;T/M7EIN#O3E?S.]5*=
M1J,E9]GH6M*^'WAO2X51-.CG=>DDZAF_.NDAMXK>,1PQJB#HJC H#8IX;-1*
M4I?$S9)+86O/?$/P\>^\<0^)[69' 0+/92#B7 &,=@>O6O0LTAZ5/2R8]'N>
M%#QCJ5OJ4\&D1PZ7:02D)9,N/FS\Q(XSD\U+X@\6:EXBTA=/O(X I<.9$7'3
M/;/O7J&M>#M$US+75H$E;K-#A'/U.*YBZ^$]BY_T6_GC Z"1BV*[Z%7#0C%2
MCJNIQ5:6)<VXRT?0P--^(EYI&AV^G0V"F2$$>:S @\D]/QJ#Q#J^O^)?#-OK
M?FH-/0;;NP@&YP<GE@#R.G&,UO0?"2(3[KG57DB[J@*G\\UV.@>%]+\.64MK
M8QLR2MOD,IW%CC%9UYTDU*ANG?U-J4:C3C5VL>2:#X2U+Q66:%6L[%>&FE4@
ML<= .OXUTMIX@U?X=O#I6NVGGZ,@$<%[ O"#MNZ_TKTU%6.-4C4(B\!0, 5%
M>6EMJ%H]K>0I-!(,,CKD&IJ8F55^^M!TJ$:2M$;8:A::I:)=6-PDT+C(*-G\
M_2L/Q?X5B\06)DC4"]B&4/\ ?']T_P JX[4O#6K>!+YM4\/W#MIC-F6W(+!"
M>^.X_E73Z/X_M+M(UOX7MI&P R_.C>^1P*A1E%\],IRC+W)F+X4U^XT&/[%?
MJYM%?9DG+1'/3'7'^%>DQ2QSPK+$X>-AD$'K7):QI%M?W:ZK83PNI^6Y4$,-
MOK^ S56&[F\,!F2X2:Q)W"-FP?\ @/\ @*J:C4]Z._5$P<H/EEMT&>+X!#XK
MLK@*0D\!4X[ON&/T%-T>\70=8N;F=1:Z=>)N&>GFC 'Z U-KFLV^LZ=IU[I\
M$\KQ7(?8T94X (/7WJKJ&GR:O?V:/"PTZ#]Z0YSNDZ8QZ8-5%\U/D8I*U3F1
MEZG>7E[;/+-;A)&;>Q1>>>.:]#T*V-CH-E:D8,404BN2U6Y:R7"!(Q.1&=XR
M.N:[HC(78<KC@BIQ$E:,%LAT8[R>Y("3]*\H^)7BMKUI-#L6_P!&B.ZZG4]2
M/X0?P(-=1XQ\075I;C3M+'^D3'9)<'[L([_4]?I7%OX2BDUJPT>SO/M(EQ-=
MOUQC!.X^K<U6&A'^)/9"K3?P0W9T'PK\-BTT^36KF,":X^6 $<I&,\CZ@C\J
M]%-1011VT$=O"NV*)0B+Z <"I:PJ3=23D^IM&*C%)#32 $4^C;4#,76_"VE>
M((R+VW EQA9TX=?H:Y?0?AW>Z!XMBU&*_2>R7(VN#O YZFO0]II0.U:QJSBG
M%/1D2IPD[M:CEIU- IU9&@4444 %%%% !28%+10!!(<?='/M5"ZL8;R-X[J"
M*2-QAE= <UJ$<=*A9,T7L*R.0;PBMBC_ -BSNBL"#;RON!SZ$]*\VTW?'8OI
M=_!Y-W;.RLI[9)/]:]Q9"#D=:Y[7?".GZ],+IBUM>@8$R=_J.]9SIWU6YTX6
MLJ,[M:,\XL=->75$2.78H^9^>H%;6F37>HWO]MRL&M[=C%80E?E"CJ^.F3DC
M\*RM;L-5\,:G;R7,9>VD0Q_:(QE1U/S>E;_ARXMKKP;IAMG#>7%LD _A;)X/
MOR*Q:Y%YFV,K^ULHO0['2]>@OP(Y2([CNK=#]*TG4JV17#?9#(04R&SP1UJK
MJ/C>ZTR4:-:%+K4"OWV/$(]3[_6L[7.2$93DH15VSO+S4+33H#)?W4-O&1C,
MSA0?SKA-1\;:+ILLMQHAN9KKJ8(H6,4GL".!GUKFWTF6ZN6NM4GENIWY;>3L
M_!>E0V/]I:KK<VC^'K6)#;@&XN&&%3(R,<8]:J#UT/4EEU.C3]IB)_=_F=M8
M?%72I5@&HV5[8O)PVZ!BJ'W;'3WKNK:YAN[=+BWE26%QE71@0?Q%>2ZIX:\4
MZ?:F218-1C49>/:,G\A67H'B:XAED71I6M[V,_O=.N. WL,].W05T1J=SAE1
MIS_@N_DSW//-.%<KX7\:6?B'_1)E-IJ:#]Y:R<$^ZYY(KJ!6B9S--.S'8I,4
M T^F(9BC;4@%+0!'MHVU)1B@""6&.>)X9D62-QAE89!%<,UH/#6M16#O_H5T
MV+1G/(;^Y[\ FN_-<7>K'K7B&?STW163>7%ST?KN'O@XJZ;:EH1-*VIJI!'(
MFV6&.3/]Y0:N1P@(   H[#BFP+4EVYCB4#C-6W=DZ)7$,?&5YJ%XAWX-3Z<&
M=78].U/GA+/O!X[TKV=@W7,C)GB!SD9%<^OA^RCOY[M>)I!U8_*/H.U=5<IA
M#4?]FPW$.&R'(^]6L9VW)DCD(;&;6]?L].D<BSM/W\@'?!^[^.<UZ '!.!P!
MP*\YF6;PYXUBU4RG[.Z_9KF,] "0=_X "N^+?-D'(/(-95[\^OR-*22CH7%-
M2"J\;9%6%-8FA*!2@4"EH$%%%% PHHHH 0C-9/B>RAO_  QJ5O.,QFW=B#Z@
M9'ZBM>H;J$7-I- >DL;(?Q&* /@:M?PQK]UX9\0V>K6C;9('&>,Y4\,/Q&:/
M%.G+I/BK5-/7&VVN7C&/8XK)H ^Z]!UJU\0:)::I9R1O%<1J_P CAMK$<J2.
MXZ&M.OF?X$^//[)U3_A'+^5%L[ILP.[8V2<\#UW$BOIB@ HHHH 8RUF:CI5E
MJ%L]O>1"6-_[W4?0]JUJA>,$YZT >2:WX#U73KG[7HLK7EDK;FMY6^=![$Y+
M5FW]_%J-OY<689H_OQ2C8X_X">:]H8%3QQ6#KGA;2M>0_:81%<?PSQ?*<^^.
MOXUU4L7*+7/JD<-? QG[U/1_@>1V\!E0G(XJ33K#^T;\Q.VV",;I7[ ?6K.N
M^%M9\,.SA'O; _\ +>)<L!_M =!5+0]2CGT_4+>,Y\V:* L.P?=7HSQ,/9.<
M'<XW1J1E:2.MT""QU"^#W2^3IL3[;>/[HE8=2WMGUZYKTB.*.*("!41,<!!@
M?I7$7%FD%O# B@*L:C'X5/IFIW6G2!#NE@/53R1]*^7G-U&YS/:C2C27)$[%
M96#8:L+5/"=A?ZE:ZG;(+;4+5]\4D8P"<$?,!UZ]ZKZ]XWTG1;8,7\Z\;[MJ
MG+@_[0[#WKSJ_P#%WB76F;?.MC;-_P N\7./^!<&M\-A:U;6GMW(JU84_C/6
MH=9BMW2VU:6&TNS]T22 "3_=)ZGV%:L;K(N^-U=>F5.17SK)IZSNC7$\\K*<
MAGE8E?ID\5IQOJ'AJ]@O=(OYC(ZC?%(Y=6'I@YQ]:]/ZA42UDFSF^O4[I-,]
M[#4X'BN,\.^/['52EMJ"?8+TG;LDX1SZ*3U-=ATKDE%Q?++<ZHRC)7B[H<12
M$4H-+Q4C&8I-M2;:-M,"/;1MJ7;2[:0$+(&5D=0R,,,I&017!ZUX>30KK[;:
MQA],D;]]$1GR2>X']WGZ "O02N*H:U-#;Z1<M. 49"FT_P 1(P!5PFX.\291
M4E9G)VVC6LB,\4DJ+,I!$3E5(/L.*FTWPE:V-P9)9GNP/N+,2P3Z9S4GANSN
M;335AN9!(<EU/H#R%_#I7111@#/I6TGK<B**ZVRH,(@4>BC%->$,.]2FY/FA
M5Z9Q5F>,K'E1S47:W#1ZKH8=Y90SQ;)HE<>C#.*Q;S^VM. 32)RRR':XF.[8
M/4$UU3IN3.*HM:R3L50@8[FM%9Z2)U6J.8G:.STZ9-0+R;1N4DD9<^OUXKH?
M!^F?8M+2^N(E2\ND5F]0O50?<9KF?&/VVSM$F-MYYCEC+H.Z[AD_@,FN\2[B
MNX8KFW;,,J!T(]".*6(EHHK8=&.KD]RZK9J0&JT;\583D5S&Y*!FG 4B]*=0
M 8HQ110 4444 %%%% !1110 4444 %-9<TZB@"!DS4+)S_*K#?+UZ>M,9,;>
M: *DT,5Q"T%Q$DL3=5<9%<@?AW865[+>Z+<S64KC)@W%HV/T)./P%=TT?M4#
MI2:3T8'EWB#Q#<^&M*GCN[4Q:G(?)M_[CDG!93WQG/X5R5EIS00[II&DNY#O
MFE)Y9N_X5Z1\3=#OM7TO3KJR@^T&QE,DD0'S,I &1].M<-;2)<=,ANX/4&N:
MI'E=EL>OED8*,I_:_0?;:O-%/!I\I$DEPWE0!N.3QGZ#(KT_P[X9A\-PW#JY
MDN;HJT[^I'8>PS7E]]9,RQWL:?Z799FA8=R.<'ZXKO?"GC<:_H\5W<Q>7EC&
M[?W6!P?UJ7I'0RS&<^=)_#T]3K5+'W%<3XX\"+K=N=0T41VFM1#,<@^4/[-_
M^JNYCVE05((/((I_!J$VM3SUIJCPV^TSQ/:::+O7M,CW0XS>V;,)4_VN,#'U
MKI_#GQ&DM9(;77KA+JSE^6#58@-A]I,8"GZ>U>C2HLD;1RJ'C<893T(KRGQ3
M\/;C1?,U'PK")+(C-UIC$MO]2I/?IW'2MJ=3H:^T51VJ?>>O)(LB*\9#(PR"
M.]2 UX7X.\73:3(QT^X>XTP']_I\Y_>6_NOKVZFO9-,U:RU>S2ZLIUDC;MGD
M'T-=*9G4IN&^QI@TZHE8T_=00.HI,TQYDC4L[JH SDF@!S\(Q]C7#^&)%>&>
M:7EI)"23ZUKW?C+2HI?(MW:\F/'EP\D?GBL#18+FWFN'E8+#(^Z.$?P#WK:E
M%ZW,JC6QU<1R" :NHJM&%D ;'K69&6CV[A@&IW<N@ -#0725S1 5$ 0#'H*B
MG"NN#QS5!&DB/RL?I4KW!9!G@U/*TP4TU8BN,%2!5--32U4B92<=,5))<%"2
M*R]T<E_$)?N%N:VC&^Y$F8^O#^TK>\9UV^:I 7O6WX7U:#6]!M9H90TRKMD0
MGYE(/>F^*KBU%O#$A0.""6'85A2V-G;!H;>]A1W3S%N(V(*'TQTJYT_:P5M&
M3&HJ;=]COHP0>0:M(:\OM?%OB+3@$(@U)/60X?'X<5T&F?$?1[DA+Y9-/DZ$
MSXP3[8S6$L/5CNC6->G+9G;KTIU5+.^M;V$2VMQ'+&>C*:M YK$U0M%)2T %
M%%% !45R[1VLSJ<,J,0??%2U!>?\>-Q_US;^5 'P_P"*YY+KQ9JL\S;I9+EV
M9L8R2:R,UI^(O^1CU#_KNW\ZRZ 'Q2O!,DT3%9$8,K#J".0:^P?A3XS7QEX1
MBEEV"^M L-PBMGH,*QSW.":^/*['X9^++KPGXOM9X4,L,["&:+/56(R1[CM0
M!]F"EJ."4301RJ"!(H8 ]1D9J2@ H-%% $;+UJ!XZM$<5$W.?Y4 52,*48!D
M/56&0:XO7_AY87\T]]I.+*_E'SA3A'(Z''0$>P[UW93+].HJ-HJ%H3**FN66
MQYI"VNZ5 (_$5M&(X\*EU"25(_VNF*=XBUQ=#T2.XMPDUY='9:KU!)S\Q]AC
M]:]$>-7!CE4/&W!5AD&O%O&]A!IOCV%8U>. 0-Y2,<KR5R1^-13PJJU8Q6SW
M"<^2#EV,N&V*NT\[&6Y?EY&Y.:L=J,YY%%?3QBHKECL>%*3D[L0UJVJ0W%NT
MLLBH8U^49K.D,9"A <XYJ$$"10P)&>0.]$E=$VYD7=)ACU.XGMKH;HR"0W0J
M?4$<BNATGQ5J/A&1;757?4-)Z).O,D([9]1ZDG/%.M&MX].+0PB-MN!FJ<6G
MA-MU=OO+L %ZCFN"JHU6^96'3KRI2O3^X]5T_4;35+*.\LITFMY!\KH<BKBM
M7CWV>^\+7KZEH,ZA).9K*0G9)]/0_EUKO_#'BVP\3VA> -#<Q\36\GWT/X=J
M\Z5.45?H>S1Q$*NBW['2@TZH5:I0V:S-A:*2C- Q:Y?Q=,V;"S RLTNX_P#
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MF(>/:G9J2A:*** "BBB@ HHHH **** "D#!LX(...#2UYJ?B%H.B>)+JR#W
MC:9EG!4E8W!Y8<=_Z4>\W9)L&TMSTJBL_3-8T_6(//T^Z2=.^."/J#R*OYHV
M " :JNXCD$)X#?=/OZ5;J*:%9D*M^!'44 -AF68$'AU.&7TI6050<.TP0OY5
MVG1OX9!5E[O9$1(I67ICUH 7/) YQUKD_$W@J#5\WFGD6VH+W'W9/8__ %O6
MNHE/V6U&>6) )]234I0@ =Q0TFK,J,I0?-%V9XU;->6>HBQU&W:"Z4_=;HWN
M#Z4S1C/;^,+FTL;=3I=R,R+W1^Y'XDUZOJVD66M6WD7L>2.4D7[R'U'O7F<O
MP\\8:?K"W&DZM;.JN2CR[LE2>0^.OX5DZ=D['34Q/MJ?+-:G56.K3:3.8)\R
M6N< ]UKK89XKB)98F#*W((KSTW<PNOL.JV_V:]'?^"3W4_XU>LKVYT:3Y1OM
MVY9/ZBN9I[,Y4SM)&&,4U6VGGH:@L[R"_@$T#Y]5[BIC4 >>^/? #WDQ\0^'
M46/4X^985X$Z]QCUY-<!'<Q76HH\%Y-HNKQC!C7CYNXYR*^@E8KTK!\0^#=$
M\3)F^M56X'W9T'S*:Z*=?ET9K&JTN5ZH\_MM;\60*RW&O3EP, ,%P?TJ2/Q%
MXJX+:PY_ ?X5G:_X=U_P;_I+DZII*GF1?];&/?\ ^L*;:ZWI\]K]H\]43&?F
MXKTJ4J<U=('",E>)NKKGB23&=8G7_="_X4CHUR?,U&[DG8<YD;'\JQ+.\U77
MYS;^'].DGQ]Z=QM1??G!/X5UFG_#.YND$GB/56=NOD6IPGT.X9K5U*4.FIRR
MIO:YF?V[I%C)'!;[I+DGA(U))_&K6L^)-:T33[>XDT-X[>5]OF38(3CJ<'I7
M?:5H>CZ&FS3;&*#(P2HY-6;ZVM=4LIK*]A66WF7:Z,.#6$L0Y,%32.7T#4]1
MU6S,URL>$Z"/I6M%<.1E1D"N*DTOQ!X$NI#IZ/J&BO\ W3\\0]^F?PK;T/Q'
M97@;[/.A;HT3MAE/XU2:>P-,Z*.ZA?[S;6]#45U=1X"HV3WK-NB\DQ<+M!IP
M59$01 [P"6STJE!&;5A)[TB+R\9R?QK-N)]X*JA#XX#=S3FU2RM-4B66XB\Q
M&#&,MR16QJFI:1=Z9*WFJ9-N4P#G-:KW6K(AZG V\*>-K\VQ>6"PLS_I2C[S
MOV7Z$&MN+P!X5Z"TD!]=Y_QJM8Z?/#K!O;:5(Y6B+20D\3#C_P >KI;&6&^M
MEN;5P\9X..Q]ZY*_.IZLWI<KCHC"/PNTAVWVFK7]H>P3:<?G5&\^%6I#'V'6
MEF7_ *>A_P#$BN]@&*OQ$T0KU8[282HTY;Q/&F\">+-)O!+#"92#GS+1^G_?
M1KK]!U_6[27[/J$LCMTQ<K\P_P"^>*] 5C3RB2+\R@_A53Q#FO?29,:,8/W7
M8AM+HW$89EP3Z=*MU$D$:?<4#Z5+6#-@HHHH *@O/^/&X_ZYM_*IZ9+L\I_,
MQLVG=GT[T ?"_B/CQ)J(_P"F[?SK+K?\;F ^.-;-J (/MDGEA>FW/%8- "5[
M7\"_AZ-5O?\ A)=4M=UG;M_H@<\/(#]X8_ND=_6O,O"'AB[\7>([72[5'(D<
M&5E_@0'YCS[9K[/T31[30-'MM,LHPL,"!1_M''+'W/6@#1'3BEH%(>AH 6BL
M+3=:C^UR6%Y>VK7 YC*2#YE]^>M;@.1FIC)25T M,=-W(.#3Z2J @,@SNR,K
MPU2%01D=*@N8RC&95W C#KZBH(IV@*[<R6S=&'5/8T 660$]*R=;\/:;XBM/
ML^H0!B.8Y!]Y#ZBM>:0>6!&<LYP*C<A&2/\ B-";6J%Y,\1\0^&M1\)S;Y0U
MQIS'"7"\E?9O>J$<JRJ"IR#7ODL:2Q-#*@>-AAE/0UY?XL^'L]D6U'PU#YD8
M^:2R!Q_WQ_\ 7KTJ&.^S5^__ #.&M@T_>I_<<UY?E2(7&0:G4PV]TLDB_(W2
MLN"^%UE6RDJ<,C##*:T=/C@GO$^TM^['2O0;O'FZ'FRBU\185;BXG/E2,$<X
M'':K:63$FV6^S*#N"GUHN=;,%[]GMD7RU&,U$UW:,CO+\ET.0Z]ZQ]]K:QFT
MRC<K*966[N#N!Z"KMM FF,+VSD=;C'$B]16:Y2=7ED<F3M5NR>1X=QR0G8>E
M:RC>-GL.2=DT[6-.+XH:]ILRP:CI\%Q%_!-$#EOKD]:VO^%M0)$C-HEXS$<A
M2O'ZU@7MW97NER*$ 9.!FL!=H7GBN6.#I36J:.V&-JVU._'Q<MF'&B7RGW9/
M\::?B7?W)Q:Z=''_ -=L_P!#7!R%8UW,0!ZTMA)?:A<_9]*L9KJ;_9&T#\3B
MG+"4(*[_ !9K#$U9NR.VEU/6-7=DN-0\F%QS'%POTYYI+:[TS2U"S3*H7)8\
ML?ZU#I_P_P!>U##:SJ:VD!_Y8VN1)^).178Z1X1T+10K6]FC3@8,[C+M]:XI
MUJ<=(([(TY/63,#3?&^BW$ICM)&N S;<J" #T[UT27( SZ\XKAO$'AF[\*ZJ
M^M:3";C3&?S)K9?O1GJ2/U)K<T[Q'8:X(Y[0@<#?&PPP/T-2FI:HKEL=-'*D
MHX(S3R JD]JS;J2'RU:(D/Z5!')+.&#38 &>>]"B9N/4M-<IN.\_+69/,CAO
MF ]!22OE#Z^]:%CI5A?:>K%L2D?,V>0:UTBKLEW>B.;U/Q!):Z;-#YY8IA5A
M'5B3@?AFJ%GHGC.6R5)=5M;9'(<V_/RGKCH:C\0:0T>MP75OB2[LW^3/W74\
M8/OBNMMYS>1^:%*/_P M(SU1NXK*O.<&N71%THQDG?5G*W/A/QG(Q>.YTRY!
MQD-NR?TK#O?#/BM9O,/AYRP_BM6  ]^6KU:W9@>M:44KX )S2CBJL>MPEAJ;
MZ6/%8?&7BGP[,D=PUPJC@0W294?]\\UW?A_XB3W^U;ZR7+?QP< ?7<<UW&U)
M5*NBLI'((K,E\*:)-)YHL8HY2<^8@YHE6A/XHV?D"I3C\,OO-.VOH+I08WR3
MVJS5"TTU;0 )*[*.S5?' K!VZ&ROU%HHHI#"BBB@ HHHH *^>=702>*]7)Y'
MVE_YFOH:OF^XGQXUUR%CUO)"O_?1KT,O=I2.+')N"+FA:E+X6\00ZE Q6W<A
M+N/^%D/\1'J!G%>^VUS%=VT=Q"X>*10RD'L:^?Y8PT;(ZY##!R*[/X8^(6AG
M?P]=R9 !>U+>G<9_$8K3'4+KVL?F9X.M_P NW\CU,<TM1ACG%+NKRST2.YMH
M[F/:XY'(8=0?:J27*K>+8W0'FXW1,>CCV]^*TZS=:L/MMF'C;9/ =\;CJI[_
M *4 1ZI>1V\]DD@.V60C.. 0.]:;#DUC/*NJZ,'P Y4,!_=<<@?RJSHU^-0T
M]7;_ %T9\N4>CCK3:$6F7-0LA'2K1%,*TAF3J6F6FK6IMKZ(2)_"V.4/J*X^
MZM+[PT_EW9>[TMC^[N0"S1^S=S^5>@M'FHVC#(T;J&C8896&014RBI*S X>*
M26SE6\L9 5;G@Y#"NKTW4HM2ARORRC[R'K7,ZUH5UHH>]TF,SV6<S6F>4]U_
MP JG97R3*MW8R$,O48PRGT([5RS@XNS&=]BD[UG:7K,6HKY<F([D=5/?Z5I=
M*R:L!)L22)D8!E888'H1Z5X3\2/!UCHE_P"8+=QI=VWF;D'$$@['V)/Z5[F&
M*]*BNK6WO[=H+N".>%NJ2+D'\*TIU'!W*C*SN<WX'\4Z3J6B0:?9F*WGMXPH
MAW ;@!C</KU_&NC,K%N2?QKB]9^&=BT\6J^'RUCJ5LV^)$.(SC^' QUK?TS4
MUU"V!/$\>$F0\%6^GO77&:GL3*U]#85LTX_6H$/%3+S5")$D,<4CGHJEOR%>
M"7.E6%_=ZGJCM):S2W3RB2%MK $\5ZWXUU!M/\/-%"Y2XN6"(1U'()_3->?Z
M?X976O$%M;Q7+/"N);G@_+CD#\Q51:1M"DW!U'LBYX?\*>(V\,2ZD==NF<YE
MMHIV)W1CD9^HJ6XAGUJZTAFU.>R@FC:.<0/M/FC;Q^9->FG:DBQHH6-?E"CH
M!Z5Y#XD:XT/7KVQC!*+*M]#[DDL0/TJH-NZN91AS.QT/_"#:%!*WG0/<W&"#
M/,0SCZ&JLGAV]TR99].;[= IR;:8Y;'L3@5U=I/'JNDVNH1D$2H-V.S <C\Z
MD6,ALBHC*47=,EI-6://TO(IY'$BM;S _P"K<$$'T'K3]+U.3PU?O<HC26,Q
M_?PCM_M"NZU#1;#6H3'>18D(PLZ<.OXUPFJ:'K/AYB;A#>Z?G"W$0^9?J.2:
MUG6YHV:"G2CS6N>F6S6]Y:QW=G*LL$@RK+5N/([5Y-H6O77A^;SK']_I[G,M
MN#]WW7TKU+3-3L]9LUN[&821D<CH5]B.U<ZDGL;5:,Z3]Y%]*E6HU&*D6J,1
M]+0**!A1110 51UE]FAW[[MI%O(0?^ FKU<9\5]0FTOX:ZO=P'$BHBCZ,ZJ?
MYT ?&TDKS2M)(Q9V.23W-(JL[!54LQ.  ,DFFUZM\$_ 9\1^(1J]XN-/L6#
M%?\ 6/VP>V#@T >M_!GP*GA;PRNH7*N-1U!5D<.,;$ZJ .H.#S7IN*!UI:
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MUNQ2\L)5>-AR.ZGT([5RUJ$J,K/;N=%*K&HKK<T$Z5*M1J*E6L30>*,4HHH
M**** "BBB@ HHHH *^8-;)3QMK+J<$7DG_H1KZ?KYCUHC_A,M;R,_P"ER?\
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MTVH1*182M_I"+TC/]X>@_P :W8F5D#(P92,@CO7;&2DKHDP/$MA_:-TCD$I
M/E'^U5OPKHJZ3ISRL@%Q<MO8]P.P_"M<1(YR0#5CM5&CJ/DY.A"R\YK@_B79
M!%T[5E7F-S#(?7?@#/Y&O0BN:P_&&GKJ'A2^C*EFB0S(!W902*-M@I2Y:D9/
MN<I\/=0"7%UH<I^5LRVX/YM_,5VYAVL1BO&+&^FLC9:K"I\VV(+J.K ?>7\<
M5[;9W$.I6,-Y"P*2*&R#D ]Q40FIG9F.%="I=?#(B$>*GCS@H>5/4'O61?>*
M]#TZ3RWNA+(#AEAPQ7ZU*FKR:KIIGT6(.9%_=O+\HIN45NSA<))*36C,?6O
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M;[FFP26X$:G^M<G;BUNM1V6D;ZKJ*-^]FE'[N)O<=OP%=A::=.8P;ZXWL?\
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MZQ>S.;"8N=.3:TDKIKR,_P *>&KC6?$D6L7:N+&!6&'X\QSTQ],5ZJ<* J
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M[',Q(P  !T IO-*!3PE<IT" <T\+3@M2!* (MM."U+M&*4** (PAIP6GXHH
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M;KMY?6%YI.I73W-U9/F*1^6:' QN/<YSS7!'C@U-HFM?\(QXC@U$AC;R8BN
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M*^;[1I5#VUP-EQ QCE7^ZPX(KZKKPKXJ^&)-$UP:]9PM]ANSBXVCB-\_>/\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***,T
M%%%% !1110 4444 %%&:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTR5RD3N!DJI./6OG?6?V@O$.FZW?64>E:<8[>=XUWA]V <<\]: /HNBOF?\
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MNP3^="U=C6%*4TVK:'N5M9VMDA2UMH8%/)$480'\J62VMY9XYI((GEC^Y(R
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M(&.:U46J7-S==B?M6L4>*.,=**.M9%!QBM+PL,>-]#_Z_H?_ $,5G5H^%O\
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M#_T,5%10NN0J33DW%670^XJ^=/VE/^0WX?\ ^O>7_P!"%?1=?.?[2O\ R&M
M_P"O>7_T):R)/&.U% ^Z**T *55>1PB#)-)4UG<BSNUG*;]O\--)-I/80ZXL
M;FT17F0JK=*@JYJ6J3:E("PVQKT6J554Y%*T-@5[:BCFC&*,XJ:U7S+A >A/
M)/:H;L5&/,TC0T1O+N!(0@"G@L<5)J%DFHW@:RMV7<-SG'R_44NW3[ZV\E&,
M-TIQDG"M[5UFBQH-,43J%E5>G0]:YK2E)RCH_,^BPU"%2$</-WCW6NOZ%5M+
M$>E&UM&= W.&8GFL>\\-3!(3%(&Q_K0QQCU-=-ILC7[NQ4QI&V"I'+#%9^L1
M>7:7/V9G9G.223Q^%<\?;0M*3W/7Q6%P=6DW&-U%=';;_@[G+ZE/;0S"*Q'R
MH,-(1R3[5"-/N[@[\;R1N)SG ]Z986DUU<Q^5$9%##=CH/K73W<$FD6%S<*0
MY?@^P)Z5T3J*G:,=SYZAA98I3KU%:"[;(Y.:.-%78V3WK<71OM.F1WLCA9 .
M XQGTJ2VL-.@L$OKY"&=LA?\]:=JYN-1DAMK-T,!4, IZ?7TJ95.9I+3S-J.
M"C1A*I42E=*T5OKLWV.;DSYC!@ 0<<4RM"739OM&R2:$-P"=U5;B'R'V[@WN
M*Z8R3T1XU2A4C>4E8@HQZ\FG"DJS 56*G(J:.X9/XV(SRG8BH*=&-T@4'%2T
MNI<)--6+VJM&7B,4)C4QJW7CD5K^&-,^U0M<S#*YQ'S5:"Q2^7?+-M2%/G '
M8#C%.7Q3):*(;&%4B084D=?>L8<L[0>W4]F/+0J?6:EM=EW?HNPVYT7['>R3
M7\H$!;*@')8>E5=0ELY+E9;>-]N.<DTV;4I=6<"\D&\'Y6Q@"JLJ/&^S[WTJ
MHQUU9SUZU-I^QC[K=]=7<]E^ ;V4OBB_>V1D;[*05)R/O+7T+7SI^SY)YGB?
M4,Q!"+8]/]Y:^BA2BK(Y,3+FDGY+;0^,/B5_R5'Q#_U^O7-5TOQ*_P"2H^(?
M^OUZYHUHC M6%K'>70BEG6%<$EV[5J3:"DT<<6GW44\@R6!8 U@D5H:;9F4-
M.+D0!2!G=MZ^]9U$U[R=CMPDH/\ =2I\S?6]G;\C=^PF:SM=-OI"EVI+)*3G
MOT!K-T]6WW8GN)!/&"%!SDBMBPGGN;H0S75O+Y8RK( 3CZULK96IF,S1C>1R
M<?>KGI3CS^SJ2LF>_+!2K05?#QNXZ6?:UM6GNN_4XDP*T9F>WD8@XS@A3^-,
MBM0ZS'!55/S,!D"N^>W2"':T82(<@,.*YZ_A^T^9'97$#P.V61" 0?PZTE6?
M,XV(Q&5*E!3NF^R[_?KJ8$5M%Y(D8MO)*H,<,/K5E+BSM[(QB/=.>N1TI\EM
M<VTRPW850H_=@?TJO_95ZUNUWY!"@DE3UKLH5W3;DM3Q:V&;2BDTUOWT*[ZE
M=2V8M&?]T#PNVDL+(SW.9<[ ?F]JKHC2')(4YYW'%6O/>V@>$$?,>2.].+4)
M)I'/=U-:C=E_2)=7^RQRJEKT P:SMP[T$$\DY-:^BKIK;Q=X#_PEC@8K?^-5
MTLKG/\,3*3$DBID#)ZUHB]>WA>W4$Q#UY%9]T(Q>N(,[,_+70^'EB%M<DJ)Y
ME&?+(SGI7+7?*M=;'H9?!U:GLXNS?7Y;%33;NY:4VEO"JO+P6QVK6T_PPB9:
M]=I2#E5SP*N6L4D#/>W"I'%Y?W-@!0YZ9K)&I7>KZI&EL2D8)Z'&!ZFN.4I3
M;Y-%U/>IT:.'C#ZRG.3?NK;3O8ZXSVMO;%&CB0;<!> &K@;][(7OR0"2,=2K
MX!_*KOB!)5D2"(2NL: LQSWK$50?E S@=JZ:;E.*E)['%FN)BZCI0A:S]?N+
MJ6<%_P";]D4QNJ[@C-D8[\U18(L14_?!HBO9+>1Q$<%@5/':D,A:/:0.N<XK
M2*=_(\BI.E**LK2UOV(R>E:IT5O[+-VDNX@9VBLHCBM2V>,:)<%KIEF'"1YZ
MUO"<(7YU<PA2E4=HNUM=?(S!]>:$_P"/RW_ZZ+_.A:$_X_+;_KHO\ZS>Q)]Q
MZ-G^QK/G_ED*O52TG_D$VG_7(5=J!!1110 4444 %?$GC/\ Y'_7_P#K_F_]
M#-?;=?$GC3CX@:^/^G^;_P!#-- 8^:*3K2U0!2;1Z4N1G%% !2%@.M+4MAY#
M:A&MSCRCUS515VD#(/,7UI0X/0UL:Q!IR7-L+;;RPW!3VJSK.CP)IXN+:,J0
M,D5O]6E[UG>Q'.M/,YYUW*15TZQ>&R%KN CQC@515OE&:7#8R5('K6$9RC?E
M9;2>X*N!2THI*0!2T44 %%%% !112'L!U- "T5;FTJ[M[(7;K\A[=ZIJ=R@U
M4HRC\2$+111BI 0BG,\CJ%>1BHZ GI244]1@,"M+PM_R/&A_]?T'_H8K-K2\
M+?\ ([Z'_P!?T'_H8J7L!]P5\Z?M*_\ (;T#_KWE_P#0EKZ*S7SI^TK_ ,AK
M0/\ KWE_]"%0!XP.@HH'045H(*.*#5BSTV?468Q?<3EOI51BY.T5=A>Q6X[&
MEK<U#1+>ST[[3%*2.,JU82G(S55*<J;Y9"335T*/>G(YC8,M-I0!FLRDVG=$
MY*SS*!\C'N/6N_TJ\M=19H@71D7!R.M<1811CS9)"&"H6 'K5WPY<RQWTS9_
M=;?F)[<USU%&_-)72/<RW$5*4TD[<^^E]CJ-/U&.RD>!HSP=HD;@-6-KZR+=
M1K:R,TTIYC!Z=\UF3:E<?9Y;(QK()#E6SRM7C/9Z;IEM+(A:^QP">1]?:IJ3
MJ3DI3U[(ZXU:+I3HP]U+5O5==O-]C7T"[M(-L5SY<4['E1U;WK6NS [,0!Y>
M,D,.*YAKS3;VQBO[V'RWW^6&7JI'<?G5F1;&XFCGAU'>D0_>-ZCW%2J<JE*2
MT5M?/Y'?3Q\:/+!6E>R5GT?62*^LR:7?11,UYM6+("18.:P)KV)5,=JC1+TW
M[CD_X5I:K:V'VJ">VES;SM\^SD+SUK+U"W@CG8VLF^+L3UJJ*C9+4\7,:E65
M24[13T3MN].GE;L5"Q)R68GW-&X[<'FK5GI<UY.L?W01G)]*9>6+V$[0NP)'
M>NSD?)SVT/$?,G9[E>@&BI(%#RA2.IQ4MVU"*N[(:F"X# D'TJQ>VZVY0*'4
ME02&'-6)H9M$O 2!N(##/:M'P_:OJVI27%P ZI\PS[UFG*3O!7.V&'BOW-1V
ME?ML5$\[3]%8RKM-T?ESUP._ZUEI;O/,(8 9#CM6YKT>JWTTA%FPMX&*J5Z8
M]:P[">:"Z#0G;(.,^E.DFO>J*UQ8UKVBI4]5%65_Q^]D]WIDVG;#.>&&1BIG
MD>]5$MHL;1R!R33GU3S+HM=1BX &!N./Y5-%<QVP%U' (P?X<]:*LES7@M.E
MRL/3333DDNO<]&_9Y25/&6HAP0/LAZ_[RU])"OGWX#7D=[XJU&1$"G[,>!_O
M+7T$*E-M:G/B(1A.T'='QC\2O^2H^(?^OUZYJND^)7_)4?$/_7Z]<V:M&)9L
M8'FN 4C\P)RR^HKH+NW-I91S:;:%0WS2HXW8 YSS^-<]8W36EP"K%5;Y6QZ=
MZT;&":[UD1V]R6CQDL3_  ^F/7%854[W;T1ZN!G#V?)&-Y2=NEUZ?J2:"+JY
MU?[1!&$C7B0XXP>H^IKT&T,3*T;8RU<TVJVMM!,;9,^5\K\8.[M5&PU6_CU"
M#[3,DD-SG:.A7G%8QG+G]IRZ=F>_AIT<)35!S<G)W;6R=[?F='KMW;VH2*\E
MS')\GICZUR9T2"*YDA%Y)"Y^:/=P'^E:=]I/VZ^GDO)P+=R/*QR0<#_Z]%ZL
M%FC27MSO@'RQQJ,LP]*3J\TFXO?YBQ5*53WJ\4HQV;T];V?7=%.[\.W5R]O*
MMX9=HY+'^5;EU?1V6E-'=O&C,NW(.=WTK.A\0:7:P0QQ+(%8<*.=OUYK&UA_
M[1OIIHW\Q8. !TQ3I2K:P>D7Y&->6#H0]K0M*H^EVTM-_/0J 6\5MYB3;W9L
M[7 JD[F1RQ[TGWF)-%=D8V/EZE7GTM9!5[2M-6_F*M)M4=35&K6GF7SBL<H0
M'K[UI!PC*\]B(QE)\L=V5[V 6]XT:L6"G -:<>IR6^FI#;J%+'YI .<>E9\]
MM()OO;R3^)K7TVS?3)8[J_4HH/R1X!+'_"L:K@]5\D=N#IUHU&EIT;[?,T;&
MUE;2/(FN&\Z[;*Y.<#\?I5.>U?2XH[" M)=3$-(4'.WT'Y4:=JTM[XAC>0A$
M;*J@Z =:CN]3V>)1<+M9(25'H1@_XUS*,U)I^IZTZV&E0C*+U3Y+];=7\R*\
M:\LY9)"&59!MVOR1[<UG1.D;Q<@;B PJ^=9D?5FN9,.G(5&Z 8K+N&6XF+HF
MW)S@5T4XM:-'D8JI"3<J<KZNU_S^9J:O9V$5M');NIF/)P<YK)'2E%O*R@[L
M^U/: I@%AS714G&4KI6.)0GNR,G%(&!.,<U/:%(;^)IQF,'FKFN263SQO:8&
M1\V/6JC"\'.^Q+=G8SJ(_P#C\MO^NJ_SH'2A/^/RW_ZZ+_.LGL!]R:5_R"K7
M_KF*NU1T?G1K3_KD*O"H **** "BBB@ KYE\2?!CQ5J_BK5]0@CB6&XNY)8]
MQ/(+$BOIJB@#Y1/P,\8@_<B/XF@? OQBQP4B'U)KZNHH ^67^ GBGRE*-#O[
M@DU7/P,\8@X"1?@37U=152=P/E'_ (4;XR_N1?F:0? GQ@QYCB'N2:^KZ*D#
MY53X$>,%=7!@# Y!)/\ A5^;X/\ CV: Q//;E#QC)_PKZ;Q15*<HZ)B:3/E#
M_A1'B_ILAQ]36S=?!GQ/)HT=K'# ) >3S7TM1BJA4<$TNH-7/E ? WQB./+B
M_,TO_"C?&7]R+\S7U=168SY1_P"%&^,O[D7YFC_A1OC+^Y%^9KZNHIW ^4?^
M%&^,O[D7YFC_ (4;XR_N1?F:^KJ*+@?*/_"C?&7]R+\S2CX%>,&(RL(QZDU]
M6T4K@?--S\(_'%QIXM&6S"@ %@6R16/_ ,*+\8KP$BQ[$U]748JY5)3=Y.XD
MDMCY1_X4;XR_N1?F:/\ A1OC+^Y%^9KZNHJ+C/E'_A1WC+^Y%^9H_P"%&^,O
M[D7YU]744[@?*/\ PHWQD?X(OS-:&@_!7Q7IOB72[V>.(Q074<KE2> K FOI
MZBD VO'_ (S_  _UKQIJ>DS:4B,EO#(CENQ)!'\J]BQ1B@#Y1/P+\8KP$B/T
M)H_X4;XR_N1?F:^KL44 ?*!^!GC'O'%^9K1T[X.>-K&*1(EM@'&/F)XKZ>HQ
M51G*+O%B:3W/EF7X%^,I =\MNV><;C_A5?\ X47XQ3@)"?H37U=BBDVWN,^5
M8?@3XN:13((57//)I\_P)\6"3]UY)7MR:^I\44^;2P'S!8_ _P 4+;W*SI#N
M9"$.3UJ?3O@[XOT^"2W^SVDJ2GYV);('M7TQ16;BGN;PQ$X<KAHU^I\QZA\%
M/%:/Y=F(6B(ZG.15:3X(>-+F-%D:WP@P,DY_E7U+1BFHI$U*TYMMO<^7W^!_
MB]]-CM#]EPDA?.6R<CZ46OP.\8VT,PCDM1O&""6Y_2OJ"BBRV%[25U*_2Q\O
M6/P-\7V\X8M;;=I&&+8Y_"HG^!_B\SY*P% > ">:^IL48HMK<7M'RJ)\P0_!
MKQS'(&CD@0#H#GC]*KW7P0\:7$QEE:!W/<$_X5]3XI,57,^7EZ$MMN[/E+_A
M1OC+^Y%^9J2'X(>-(Y RB)2.Y)KZJQ1BD)-IW1\ZVGP>\374<B:LEK(/X2,Y
MK2M/A1KUDH@A6!8,=1G->\45G[*-[GI4LUKT[6M?O;7T9XK!\--:B@:%HX6C
M;.1S7%:G\#O%(OI)++RC$YR!SD5]/T8K1745%NZ1CB<;/$.\DD_)6/ENS^!7
MBSSE>8V^T')5B>:T=2^#'BNXMECC%H,>A;BOI/%%2XW=V90Q$H4W3CU/&OA!
M\.-<\&ZW>7>I^4(I(#&H4G.<@_TKV/-.HQ5&4I7/FOQE\(/%.N^-M8U*WAC$
M%Q<M)&Q)Y!K$_P"%&>,?^><7YFOJ_%%!)\H#X%^,"?\ 5Q?F:NZ?\$_&5C=I
M<I]GW+V)/-?45&*&KJS*C*4)*479H^=C\'_$>HV,T%\L,3LX8/'G)ING_!+7
M[<P&X:W=H&)1@3D<U]%XHK+V4;61VK,*O,IR2;76WYG@,GPR\7/9SAEM1.21
M$4SQ[G-<L_P)\8S,6DDMR3R<L?\ "OJ>BJA3C#X49XK'5\5;VLKV/E;_ (4'
MXNS]^V_,_P"%/C^"7C2V$H3[.?,&&Y-?4V*,5=KG+&3B[H^4?^%&^,O^><?Y
MFC_A1OC+^Y'^9KZNHH$?*/\ PHWQE_<B_,TJ_ _QFC!E2/(]S7U;10%^Q\L_
M\*4\9RR(YCMU9.G)YJR_P8\:W-S%/=26\NS@*2>!^5?3N**5D:*M-:7/F33?
M@AXIM=52X?[.(USP">XJN_P+\7,S2,;5FQ@<G_"OJ/%%%M;C]J^7EZ7N?*/_
M  HSQC_SSB_,TJ_ [QB#_JXOQ)KZMHQ3,CY;C^"WC*.V,0B@R3]XDY%,;X)>
M,"BGRH2R^YYKZFP*7%*QHZDFK'RI<? _QA(PQ##@#L347_"B_&&?]7'^9KZP
MQ1BF0W=W/E'_ (4=XR_N1?F:>GP,\7QS1RE(6VL#@$^M?5=&*!%+2X);72K6
M"<KYL<85]O3-7!2XHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!YS\<I+J/X6:A]E+ -)$LQ7_GF6&?
MPSBM_P"'(B'PX\.^3C9]@BZ>NWG]<UOWME;:C936=Y D]M.A22)QE64]0:YW
M0_!LGAJT-AI&MWD6F@DQ6TR)+Y.3G",1D#KP<T <Y\:-2O\ PWX.CU#1;R:P
MNGOT$CP'&_<I!SZ_='Y4RQUS57^.\NBM?SMIITE9_LQ;Y0Y"\CTKI_$G@73O
M$_A8Z%>7%T(_-$PN-^Z3S 2=Q)X/4\=/I4&G^ ;33?%B^*)-4OKC41;?9Y6E
M*;'0 #[H48Z#I0!Y=:ZSX@OO"'CO4'\1:HMQH=\?L3+-@*%8\-Q\P(XP:V/$
M/B[7KJP^'&I6.H2V4^L2*ETB?ZM\E,DK]2?SJAX \+OXFA\:Z;=7E[96=[J?
MF.BQ!3/%N8C!9>,\<CM7I6K_  ]TO56T$">XM8M#*M9Q0%=H(VXW9!)^Z* .
M2^(J:WX'^'%Y=6OB?4[F\?44=+F9@'C1N"@P,;>,]*O^/]?F\->&DU;^T;N3
M4+ZVAM=/LHI"H,YR6DP/O'YA^0'>NL\8>$K/QIH?]DW]Q/%;F19&,! 8E>G)
M!K.O_A[9ZEK^E:S<ZC>/<:7$L=JC;#&I ^_M(^]T.?8>E '%7.J>)=#OO WA
M34]5NIKS59_/U.X\S#XR/W*L.@'0XY_.K.E^*=3>]^(OA][NY*Z1'+/8W.\F
M2(;3A=W4X(&,Y[UV-WX#M+YK2YN+^[EU.SO3>07S[2Z,<#9C&-F !MJ2T\#6
M%I8Z[$)YFNM<9VO;O"AVW C"C&  "<#WH \=7Q5XCM/ O@OQ.^O:A/>76J-!
M/&\O[J2,.PVE0.>%Z]>:[+5M=UO7?'7BG0M.:]5]-TY18I:3+'BX89$CDL,C
M.!CD8SQS6O+\(]&E\-:5H)O[\6>F7#7,!#)NWDD\G;R 2?SK0U3X?V][XLC\
M2V.JWNEZF8A#<26NPB=/1@P(SP.?8>E &]H<FJR^'K*35H$AU4P+]HC# J),
M<\C(QGTK@/$C^-3XD\*?:8-!$POI?L_ER3;=WD29W9'3&>G?%>G00K;P)"A8
MJ@P"QR3[D]S4-SIUI>7-I<7$"R36CF2!SUC8J5)'X$C\: (M(.K-9$ZREFEU
MO/%FS%-O;[W.>M7Z** "BBB@ HHHH **** "BBB@ HHHH YW6/''A_P_J]MI
MFK7WV2YN<>3YL;!'R<?>QCK[\5IZAJUMIC6RW"S$W,@BB\J)GRQZ XZ=#UKD
M_'O@RR\<3_V7=829;)Y+:?&3%)O7!^AZ$>E<AX!\8:BM]:^!/$ZNFMZ;>((7
M?GSXE#=^Y P0>X^E 'M5%>67'C/6-6U#QPVGW@LX/#46VW18U;SI5#%C)D=,
MH1@8]:HZG\2-<N-/\":KI#P1KKLWD7-J\89=X8*V&/(&=WX8H ]AHKS#QGJG
MC'P7\/\ 4=6GURUN;^.]5H6CM%5!"Q"A"#W!).:K77B3Q58>._#&F'5X)8=>
MLR[H;50MNP7.Y,<G\30!ZQ17F?@SQ1XEU"U\9V+O%JFI:+=R0V3R(L7G'YMH
M;&!U7]:S;#Q]K4/C_P ,:/<7<=RNIVQ&H0 (RV]P V0CJ,'!&",G\Z /1M,\
M4:3K&K:AI=E<%[W3R!<Q-&RF,GIU'/3M6C>WMMIUG+>7D\<%M"I>261MJJ!W
M)KR[X?\ _)9/B#_UTB_K6?\ 'R^N"WAC1R6&GWEYNN,='VLH /\ WT30!Z+!
MXVTFXTQM41+T:8%W_;6M'$97^\.,[??&*V[&]M]2L(+VTD\RWN(Q)$^,;E(R
M#4BPQI"(511$J[ @' 7&,8],5Y_=Z_-'\1],\!:3(;&RBL6N)Y8U!? !V(N0
M0 , GCVH ]$HKQ&X^*.N3?##5=5M[F*+6-'U 6DS>0I2=2V VT]"1Z=Q706?
MB;Q!:?$[0='OM1CNK+6-,-RT2VZH(9 I/RGJ1\O?UH ]+,J>:(MZ^85W!,\X
M]<>E/KQOPW)KFI_'+Q3"^N.@LH4C7_1U8>42"$4'[N"W7G/>K7@37O&WC+3#
M>-J]E;PV.JM%<,;4%KB%=I90!PO&>??VY /6JQKSQ1I.G^(;/0KJY,>H7H+6
M\1C;$@&<X.,=C7E[?$G7+SP;K_C.UG2.'3M36VM[$H"CP@H#O/7<=^<@\8I_
MB'48M7^,'PXU*#/DW5HTR ]@RD_UH ]FHHHH **** "BBB@#'UGQ/I6A3VUM
M>W!-Y=';;VL*&264_P"RJ\X]^E,7Q5IHU.STRX^T6M]>DBW@G@92^%+'!Z<
M'/->9> )Y-7^._C*\OP6N+-6@MPYSY<8?;QZ< ?F?6O7KNPM[V2VEE3,MM(9
M87[HQ4KG\F- %JBO#T^(?BG_ (0?QEJ)OX3>:+J*P6\GV9,,F_:0PZ<]<UL^
M+?&7B+3!X#:PO88SKC0Q72O;JPW-Y>6'<??/% 'J]%>8:%XLUD>+O%GA&_U
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MHQC/]:HGXJ: -9&G R'*[C-T51[T :?COPF_C7PO+H@OELUED1GE\GS#A3G
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MJ\_G3E%VH@&<(OKC)Y/6N<7XV>&B266=$'5R.*DL_C+H%XY*P7"PC/[XC@T
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M*[AA,"(8_NH ,\\4[3[2-Y [Q HO7Z5P>A^-M9L=)BAO]%;4XD/EK=Q'EE'
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MC6\$WV2)_EVLVUMW<4 5H+J#4-#-U)#&RPJ5D &#G_(J&]F\/.EM#?&TR_\
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M;%@".N<4 >#ZC=W'B.^BT5IHTTNW.^XE4XW>V?QKK]3T^VN-&%A90QQKM#*
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M^U9(AP1^%=186UA=6ABO;>!T"9\UU&3^-93WMOHUH\=CIZP7 ;*S!,'&?7%
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MOS19G6(9V\]3CZ"J_B'Q(C:MI)M[1VOXG5#,.1C- 'TBG"+]*=34YC7Z"G4
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ML7INX9+:*T&YG=?E8<],_2O)_%^KVWBSQ1$+9&:TM055P..W/Z5H^)/%FO\
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MD=A-J=F@N_L=B5+%G ^5N.!62-*FUW49=.&J2C3(&WD _P"N_P YJ6^F2VU
MEH2\48*MO[CVIMO:S6&K65_!/LM)00RGIR>] '1I]FLH0D*! @P*2#?.!)DY
M-5YTW@[6!R>,&M+3?L;V$H:39,G1?6@#G/%?A]=4T^2:$%+N$;E*]216OX(\
M76&JZ%;QWMY%;:G$!%(DAP7Q_P#KJKK.H3Z?I$DT+9D8[<GWJTO@7PY)X622
M^B'F/'YIN<X;=[8^E &3\1[A!XKT&>UF$DL6X2%.B@C'^-6KN)GT^W@MM16:
M*ZF)GC4#>HR..GN:YFTT;3+&:TGL[N>[S+EXY.F..];ESKGEWQU?3HXK:2)O
M)6W8$^8>E $*Z%;P3.T,\D5NKX#/USGI2+J<%HSK-QLZ'L:LZQ;:D^GB6;+W
M$@\]HAT'<"LS2%MDT4R7-RK73RX$3@_NQD\GB@"_X?L9S::CIVR(6U^=[2S=
M4R/X<5BW6EW>F(_AYK/?.3F.X7H?QK>LV33IYP)\H1S<*#M.1G'^?2K4!,EG
M/8(7N)YFW1-P"Q]R: ,N\\/74H:&]?RI[6$<N2#UZK^=0?V#J$>D0ZY9>()H
M5,R*(Y".1N'M5P6U[KBS+IT;W-Q&-MR96&58<X'Z5>TC2+:6&&XOYRE]'<8^
MRL?E'2@#N_&+VW_""Z@^H*\D'D9D"=37B<%]8RGPQK6D.([6WQ:RP_Q)D*O/
MYU] ZPJ/HUPL@5D*8(/0U\[^(M"LM/\ %-E#8L8+:_4*0#P).Q_,T >I7UG!
M!=C9(^XG<,G@YY%230:?KFG3Z5J"J8IEVJ.X;&,BN=\,>(XGN+CPYKL@6^MC
MY23_ -Y1D#^5=5H^CR13H94WJLF4;VS0!Y;:ZMJ6A>%-:\.13LD]O<^6KMU6
M-@2/T(K=\.^"?"FH:>\5S->37J@%[AGP-QYXP?Z4\6FGZ_XV\:P7DT<%G+%'
M$)2?NMY:C(_(UBZ'K%I-?6FA:K?F.XTZ7=!-'PLZ\\'\_P!* *WB*QUCP+XC
ML;K+W$"M^[N1]XKSP:[H?$/P[!I3W3/MN9D*&+/+L1Q5OQO?6T7@:>>22.21
M3F'D$Y_SFO/O"_@N/QWIDVN3*L.#MA"_P'K^= '1K\,[GQ+X#C\]([;4)7-P
MA?(9,@8''TK.L_$'C/P)HXL-0LRL40*QR$<''<53EUO7_#DO]D->32$'$=P?
MO*OI]>M:0EC\3:U966M:G+);C[C2\;_TH R_!7B"ULWU/Q#K6DW4L6H3[);Q
M0-D?)Z\^];NL:3:MJ&GPZ0V^6=Q<P2*>-G!_J*[*\L[9M!O]#@MDCLS"T<7
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MM'\3M!#W4:V^E0--<,[#(W!UQ]>E4KW5OB2;.1F@M+:%4W/=&1,8]165X \
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M/$>C:;87-MITBO<SH5<IPJ CGV)KSS2-*2_OH+=F_P!#FF42.>_K0!V>D:-
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M/"<:>,?B)=W]_$ATZPS%##C@[<C/Z"NN\1>!=#\3P2I;6RV-ZH+0R1#;SVH
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M Q<Q-QAN3Q[4 1'[79FVU;4XIF2=\O*1P!ZXZ=!5_P"(E@NIKI<]C.&O0!Y
M4#+'FNBOOM-[X5ED;RR7@#I&?88XKE_!$L-QX@MUD&^^5#N]%&>@S0!+X3^*
M217QT+Q5:-9ZF/W?G2#"GZ__ *JT_$:SVDQC@2)+F>5/*N0QV[-PX_G65XVT
M"PU?4L)+']JN?];#)QSZ@COP*Y>;X;SQ-IEO)?7LMZTRL@9AL50<_7L: /<_
M%<OV/P=?/("Y2'G'>O'+#Q:TF@FRT^QE>:>(1EF'"@C'K7L?BQS:^#KPJ =D
M8&#WYKRZUNTBLK5HH%1)57>0.F: .?O-+G\*MI^NZ$6EN8UQJ-N.0PXR1^&:
MZK3_ (@^'+Y5GD:2%@,LK8X/<=:W].EAV )$'A/RG(Y->=^([71?[<FT:S@W
M.#YLTHZKGG:/S_2@"WX=T:U\?^)-8U+4T==+V&&!^^< 9'Y&JFE>+)?!.J3:
M%KX>ZLD)^S3IR5'H>GK3[_7M6\'Z;!IZ,5L+H8CRH#(3WK.;[%/:1NL >2,[
MFE?DNQ[4 =-JWQ+T--$GCTA7GO)QY:JW1<]SS7-:7I.G:3;6[RWB;YX\NX./
M+DZX_2I)](G\1^*HM*:SM[98%#,(P1D>I_.NHU#X9Z%J5H;:W:6"=!E)2>&:
M@#G]3\:+=VMM%>2&41_*OE_Q&ND\#Z1=VM]>ZE>Q"%[^':L>/NJ0>OYUD^%-
M'T^::6SU!4M[G3G*2@]&Q_%^)K8\0ZT;'1KBX@(CD:3RH".IYP/YT <=X=,G
M@GXI7EE=OLM+LEE8].<X_G7K<^JV.D(]]<W,*P1KY@;/WAUQ7F'B#P/J-QHM
MEKVJ7>]BJF8+]Y5./;ZUDZAX(CF%M%;ZD\ZRJ'(9CA4/_P!:@#4\-,=5TOQM
MXCD@9;692D&/XC@@']*Z:37$TS2]*G9O-O64-&BG@8X^:J=OKLUAI1\'FUMU
MCEA*PLF<2$]?QYJK;VMC<PPV!M/LM^"5:9VX SU'/TH SM1TR;Q1+?/>,!J9
M_?6LZ\<\# JS%\3=9T>P%EK&D&2_C7:D^/E8>M:3:;/HDXN=1O \%JX,;>IQ
MFM%O$FA:[:R3:='%-*H^:!AR#[4 <CIVG^(?&6OV>KZK)Y=O V^)<8 _2M'X
M@ZG':^-]!UU8E/ER"*8KTYXS^M=/!JB2:8LS6A22+@(O%49["Q\1:3?0R1+'
M(Y.T.<8/;% '7W$JO.MW&59)?W@QZ&O+_B-I5MINH6^O6I!M+K-M=J.V[ S^
MIJSX)\1RV-Q-X3UJ8+<1 K:3$_>'0#/X5T'C[3(=/^%-VE^8_-:564YY)R<8
MH XR+Q1JOAJ&VT_68I/LLF/LMV@^4(>F<^@Q7N/B/,_@*^V9<O99'OE17@M[
MXRO?%?AS3=!T;2#<F%46:9AZ#'7->]:WYT'@*Z")^^2Q "^X44 >/1Z3IQLK
M:."1_.9?WK.<*ISTXJK;PK;))+IUTH=OE8MZ^U3Z5X=EU2(MJEPR1MV0\BK_
M /PC.F6UY;V=E(R,P^=F/)^E '*ZM;:YJ-M9V-Y*9[ 2[B<]*[+6=!MK>RL[
M>VCCA498MD_= SS^59EI=-I>HW6E7WS.GS1L?XQ6M;74^H7QLKPA+6]MS';N
M?X&P2* ,*+Q=JEK;O8:7L3# (2,ELG (JY#X.U;5Y5NO$MZ^TD$HOWL?2L31
M/#9\,>,HS>W+7+6[ N>VWM7J6O\ B30(/(NI+U71W4M&G4<B@#G+B[N/!?B"
MVM(KCS-)N$ 1'X9>F<X^M5K]]1\?7SZ=;DPV$)YESQ^=<YXLU;_A)O%L!M25
MMI'6*//\/05ZQ%8)H=K!8V<:A1$-Q[EB 2: .53P'=60^PIX@=8\?,>,GVZ5
MG:S::[X:T9X9IE:RG.P3(?Y_E77W;--+#</,RM#UQR#5;6+1O$_@N^\J4+&H
MWA7]0<4 1?#UM.M/#@F4,MTTFUVP#V]ZEU_2I+^<[KF6*-B.(^_-<9X8\17/
MA[3Y7%B;U'/*8X4_I1+\0+O3]3>\4 L_^K@89P?PH ]'L(CI-K]HN"J6D:A2
MTAYKS[7M7L/$WCG3_)A"V\9\MG/!8<#-9LUWXO\ &#!&MIW!;('"J*ZS0_!F
MFP934[G&J8Z)_ : $TC2]"/B34X$"LZ+B(,<@YS63=^++C<NB:;8K)=PR,K%
M1D%<]*I>*+.RT[7ELM.ED-T4S*Y/WL]/ZUU'@O18+3PR]VBJ;V>?:S]6&":
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M,[BWMQ6;I<@\36$W]IQ+_9TL(PK#@ CM[TRU\$>%]/MH+L6,1Q+P\I P,]:
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M=?1&N2>=X&NI ,;[+< >V5% 'E-M.\-B)21MQR36A;7"/<VUXN'5^%:LK3[
MRPA[J4F#&/+'0UHV-HUEIAC@52L;_+GHHH Q/&NG7']J_P!JEB+6W0!0.K$G
MO^=1:M))/H=I);95ED5D<=AD59\9:W'>6PT2R8.YP;B4=%YZ9_"J<!1='C6\
MN%B@3Y5YY;Z4 5=3UF;4[B.QTZUWWQP'G[M["M#2_AY=W,GGZE>^2P_Y9$'@
M_E62+R32=7BO]+0HR\*QX_&NNLO'T\+-)J$8N@PX*(<YH Y[Q3I4OA*XM)@R
MW%O*0#(@^XW&*]1T_4HI_"MOJ3E))SA&4L.!TR?RK@-<\16_B:VDM([)DW8
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M1SSBJEOX>USPMX8ETVV!N+JX?>\BCJQR>?SK=TK2M>M_")BDN&6_=LD^@]J
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MXL2)O"E\LO$?E\@=J\.FTBZ%G%=Z?'YD00$!F'I7MWBNSEU+P??6R*ZRR0G
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MJXOPUX6\6^'[2/4K72%,S2,)8BP&Y"2>?TH HR0ZJ_AR:SFL/(@LR<3GC/\
MCUK>\2WFFZ5X2TBZN]-AGU6\C"!W4=<GG]*A\06OC_Q/J<=LNE_9;%2#L# *
M?KZUF^,/#GC+4[.RT^;2]\MK<ATEC/&S'3CIS0!<E\*^*-2@2&XC\B$KD-G@
M _C7)ZK\.-1L_.'VIMR\Y#Y%>YA]>N;6V1[5MWE .">,UR<GA_Q.+NY^T6'F
MQROF,J^,#/0T <K\./$EWI,EUX:O$3SI5W6\^,$]>,UZ(-0T^ZT>33;Q4$Y5
MO,8]01WKCD\">(7\?6UZ=."6,2C)##.>]=)JWA;55U.=[2Q$\<R8#.>5/XT
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MC\S;)MB_3% &]K6OV>C66ZW*R79&(T!S^)K@M(T"Y\4>(DN]4N_,P?,D!;G
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,@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (1 ZP# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HJO=WEM86LES=S)#!&,L[G %9N@>)],\2)<-I\C-Y#
M[65UVG'9L>AJE"3BY):(ESBI*+>K-JBBBI*"BBH;NZALK26YN)%CAB4N[MT
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M'%WJ$0PEQ8L^/0XY'YUC?%R:)?#-M$Q'FR70*?0 Y_G2:3&\?P7D$F<FSE8
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M6XTU+5ZLW]6N+'P=X&N)]&1$BQFWVL64NYX.3U]?PKA? /@Z'Q*;C5]8:2:
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MGH$&UK3D8ZY!S71&I&&%@YQYM7N<TZ<IXJ:A+ET6Q4\"^,SXIMYX;F)(KVW
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M 8K;T;2Y-+\.6NF22+))#!Y1=1@$XZUJ45SNK-P4&]%J="HP4W-+5Z'#>"_
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MQ^-0^(_^/2S_ .OZ#_T,5K JZGC*]#D53^%$+XG\BEIMU+=:6)IF4-\P$@7
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M_"X_:2T];'05@W?C'0[&YDM[F[>.2-]C#R),;O3.W!K=KG?&/&FV/_81M_\
MT,5--*4K,NJY1BW$NV_B/2KFPGODNMEM <222HT87_OH#-+IOB+2]6G:"SN=
MTRKO\MT9&*^H# 9'N*MWUK9W,*F]CC>*%Q*/-^ZI7D-^%<_9LWB+Q);:Q!&4
MTVQ21()F&#<LW!(_V!CKW-.,8M-DRE--(M2^--!AFEB:\<O$Y1]MO(P# X(R
M%Q5G4/$NE:6T"W=RR-<)YD:B)F++QS@ XZBL2&T\2>']/NYH)-,GMTEFN?)(
M</(K,6/SYP#^%0WNHWEUXGT2_P!)LTN'GTR20132^7A2R'K@\]*T]E%O3;U,
M_:S2UWTZ>?KJ;D'BW1KE+AX[F3;;Q&:4M!(NU!U/(YK2FO[:WT][^695M4C\
MTR=MN,Y_*J5@^J7T=Q#K&FV]M$R[0(Y_,W@Y!!X&*Y*%WNM+M?!TS%IH[XVT
MXSR;:/YP?H5VBI5-2?I\]"I5916O7;IJ=T]_;)IQOVF46HB\XRGILQG/Y5##
MK%A->16B7 $\L0FC1@5+H>XSU^G45Q:223Z9!X/8DS+?FVD]?LR?O,_0KM6N
MB\96\?\ PC%S=+A+BQ7[1;2#@QNO(Q]>GXT.DDTGU_I JLI1<ET_IG145#:2
MM/9P2L-K21JQ'H2,U-6.QNG?4****!A6)J^LF$M;6GS3 $NP&=@'7\:U+N0Q
MVLC*ZH^TA2QP,]JY:PO+2WM+F.9'-S*K*7QGJ.E;487]ZU[&%:=O=O8\]_X2
MB,:W/="*1K>50K<_,Q'\7-=+X3\1?VCXJM[:V$B6YB?S4DZ,1@K@>H-<8/"V
MJ@@&% ,XSY@XKKO"^D0Z(8[QI@]YY^Q@.@3M@>_.:]:NJ?LVEN>50=3VB;.W
MEU6/3=1^Q,KNLC@J?[F[M[\UMBN=GGMKGQ-"3+%LACR6W#K6]'-%+GRY$?'7
M:P->*Z?(E9'L0GS-W9)11FBI-#&\1_\ 'K9_]?T'_H8K75MPS@CZUD>(_P#C
MUL_^OZ#_ -#%:O[W_8_6J?PHA?$_D5KL6]HKWQME=T&6=5&['<_E45S?+;QV
M]P]F[R.C$!5RR<9Q5[]YWV?K5-#?A9UE>#?C,.._)X/X8J2Q)[N-;B")K<-]
MH49+>F>![XSFFRW<,NII9S69<A_DE905SMW''H>E.\VZ:2T*2PLC?ZP@CD]\
M?KTI2]YBXQ+ -QQ;DGC/O0 Q9K?4;R6VGLT?R2<&0!L<XZ=L]O45HJH50J@
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M%X'0+UP1CH0>Q'7-7J*E-K8MQ3W.<UFQUF72)-*L8X+B&2V,+7%U.5DR1C)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_?S_ .M6UM']T?E2[5_NC\J=X=@M/NC)_P"$DT/_ *"%O^='_"2:)_T$;?\
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M_0W_ /DBG^-')'^9?C_D'M9?R/\ #_,ZRBN3_L#Q7_T-_P#Y()_C1_8'BO\
MZ&__ ,D4_P :.2/\R_'_ "#VLOY'^'^9UE%<G_8'BO\ Z&__ ,D$_P :/[ \
M5_\ 0W_^2*?XT<D?YE^/^0>UE_(_P_S.LHKD_P"P/%?_ $-__D@G^-']@>*_
M^AO_ /)%/\:.2/\ ,OQ_R#VLOY'^'^9UE%<G_8'BO_H;_P#R03_&C^P/%?\
MT-__ )()_C1R1_F7X_Y![67\C_#_ #.LHKD_[ \5_P#0W_\ D@G^-']@>*_^
MAO\ _)!/\:.2/\R_'_(/:R_D?X?YG645R?\ 8'BO_H;_ /R03_&C^P/%?_0W
M_P#D@G^-')'^9?C_ )![67\C_#_,ZRBN3_L#Q7_T-_\ Y(I_C1_8'BO_ *&_
M_P D$_QHY(_S+\?\@]K+^1_A_F=917)_V!XK_P"AO_\ )!/\:/[ \5_]#?\
M^2"?XT<D?YE^/^0>UE_(_P /\SK**Y/^P/%?_0W_ /D@G^-']@>*_P#H;_\
MR03_ !HY(_S+\?\ (/:R_D?X?YG645R?]@>*_P#H;_\ R03_ !H_L#Q7_P!#
M?_Y()_C1R1_F7X_Y![67\C_#_,ZRBN3_ + \5_\ 0W_^2"?XT?V!XK_Z&_\
M\D$_QHY(_P R_'_(/:R_D?X?YG645R?]@>*_^AO_ /)!/\:/[ \5_P#0W_\
MDBG^-')'^9?C_D'M9?R/\/\ ,ZRBN3_L#Q7_ -#?_P"2"?XT?V!XK_Z&_P#\
MD$_QHY(_S+\?\@]K+^1_A_F=917)_P!@>*_^AO\ _)%/\:/[ \5_]#?_ .2"
M?XT<D?YE^/\ D'M9?R/\/\SK**Y/^P/%?_0W_P#D@G^-']@>*_\ H;__ "03
M_&CDC_,OQ_R#VLOY'^'^9UE%<G_8'BO_ *&__P D$_QH_L#Q7_T-_P#Y()_C
M1R1_F7X_Y![67\C_  _S.LHKD_[ \5_]#?\ ^2*?XT?V!XK_ .AO_P#)!/\
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MYE^/^0>UE_(_P_S.LHKD_P"P/%?_ $-__D@G^-']@>*_^AO_ /)%/\:.2/\
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MW=M(\4.0=B$_=&0* .1'B'7=-\*RW4.I>(#>7MS:V,4FM6D<:0&5N9(PH^;
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MR1VXM)/)NV3[3%G.R4_Q DGWYK1;P+H+VVL6S6K&WU98TN(MY"@1J%39C[N
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M+BZ%Y%>M<W-R7FDDB&$#,>J@'I6YI.B6>BM?M9B0&^NGNYM[9_>-C./0<=*
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M/Y5K#6O#HGNF%[IXFM5Q.VY<HH.,$^@/'UXH XC3/&'B#5=0CTN&]M$DEGA
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M#P%<W4VD6$.E/+*C1/"D0Q*H.64'&& (Z G&*DTJ7P/=ZX4TQ=,?4@Q=3'&
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MN<*A&0#_ +7/TKMAIEDL9C%I"$;;E0@P=OW?R[4DFEV,K.TEI"Y?.\E =V<
MY^N!^5'(^Y/UFE_)_7]7.5N->U6SO)M-EO(Y+@O#Y3QVV78.K$JJYQD;>I/2
MH],UO7M9:*WM[J""58YV=F@#%V23:HP#@>^,UUMSI.GWF[[39PR[MNXL@).W
MIS[9-$6FVMJC?8X(;9]C*KI&/ESST^O-'*[[C^L4N7X-?E8RO#FN7&N2RR;5
M2""%(Y5V\_:.2XSZ#@?C7&Z:CVJ:7?FWMHU:_9&N(9R;B3+L I3H1Z^PKK=
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M>QT\7(AQ&1-()F#?.<XX]NO6NPHH X+4O 5[J,$]B;VT2S\ZYN('\H^:7F#
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M%C4*<\G[K'/L*S_!_AR]M+5Y;R&*S\^T\AH8R69VW,?,D!&-V#COWYQB@#M
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MA[50D\ :%)#+$5NPLL$5NVVZ<'9&<KCG@^I[T =11344(BH.BC IU !1110
M4444 %%%% !1110!R<W_ "56V_[!+_\ HP5UE<G+_P E5MO^P2__ *,%=96M
M7[/HOU,:/VO5_H>;67Q)O+GQXV@/:6@4W9MQ K/]I1!O!D88QCY5;_=8<YKT
MFO)-"O[ZQ\=O'%J5[_8MSJ<T*32Z;&8Y)26)A67<7 !! .,97%>MUD;&?K>L
MVF@:1<ZG>F3R($+,(T+LWL .]9VK>,+'2-'L=1DM[J<7JAX8($#2;=AD8D9
MPJ@D\]JV-1LUU'3+NQ=V1;F%X2R]5#*1D?G7-:IX'_M*PM;3^V+F$6<:Q6[)
M&A*+Y1BD'(YWJW?H>E '4V]S%=6D5S"X:&5!(C>JD9!_*N6U>ZM[GQYX4$%Q
M%*1]KR$<-C]T/2NGMK.&UL(;*-?W$40B56Y^4# !_"N+N?#VC:)X_P#"[Z7I
M=G9/+]K#M;PJA8>4.#CK0!W=%%% !1110 4444 %%%% !1110 4444 %%%%
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MH [&BBB@ HHHH **** "BBB@ HHHH ***0L 0"0">@]: %HI%8,,@@@]Q2T
M%%%% !1110 5C:KJNIV5Z(;/1)KV,VTDOG+*% D7[L?/<^M;-% &+I.JZI>W
MQ@O=$ELHOLT<HF:4,/,/WH\#N/6MJBB@ HHHH **** ,I_#>CR2,[V*%F)).
M3R3^-9EKX?TI]>U&!K-#'''"47<V 3NSW]A745DV?_(RZK_UR@_]GH EM="T
MVRN%GMK1(Y5R P)XS^-:-%% !1110 4444 %%%% !1110!R<O_)5;;_L$O\
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MC_\ (]^)_P#KG9_^@/72US6C_P#(]^)_^N=G_P"@/0!TM%%% !1110 4444
M%%%% !1110 5F:GH-AJ]W9W-VCM+9LS1%9"H!88.0.O'K6G10!1T?2;70],B
MT^R$@MXL[?,<NW)SR3R:O444 %%%% !1110 452O;:]GD0VNH?95 ^9?)5]Q
M]>:R=036;);8KK.[SKA(3FU3@,<9H Z.BLC^S]7_ .@X?_ 1*U8PRQJKMN8
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MSK6K)U[[FG?]?\/\Z -:BBB@ HHHH RO$W_(L:E_U[O_ "KS0?='TKTKQ/\
M\BQJ7_7N_P#*O-5^Z/H*^8XBWI_,^6XCWI_/]!:***^:/F J.;[@_P!]/_0A
M4E1S?<'^^G_H0K?"_P >'JOS.C"?QX>J_,]CHHHK]%/T@**** "BBB@ HHHH
M Y.;_DJMM_V"7_\ 1@KK*Y.7_DJMM_V"7_\ 1@KK*UJ_9]%^IC1^UZO]#PO5
M1XBB\47]Q8MK,>LK<3DB/3H"GD $Q;)2N7S\@VYR<D<8KVRP:X?3[9KM0ETT
M2F95Z!\#<!^.:\:T33M&N?B-'=PZWIJZC'JT_G07)/VIBKO@(-Q!R&QGT5<<
MU[;61L%%%% !7+:[_P CWX3^MY_Z*%=37+Z[_P CWX3^MY_Z*% '44444 %%
M%% !1110 4444 %%%% !1110 4444 %%%(: $) &20!ZFJ?FS74A6$&.)69)
M"X(8\<%:27%].]N<&!,K/&Z'YLC(P:NJH50!T P*SUEZ&>LO0KP6,,6&(,D@
M01F1^68#UJS@"EHJU%+8M)+83%5Y;."1T?9M>,DHR\8)&"?>K-%#BGN#2>YG
M^?)8*!=/N@5543'EF8G'( J^"&7(.1ZBD=%=2K %2,$&J4/^A3I;9 A?Y8$1
M#\@ YR:C6+\B-8OR+]%(*6M#0\=^)VCZ;::]+J*_96NKJT_>6D_VMC<8)P%$
M1V\],'O7HVM2M;^$)I4ANU*0(?*LU;S0.,A I!SC/0UYS\1$BTGQ([1WEU 9
M8#>,LVI7*"Z;=CR(%0X5N/U''6O3-5_M!_#,QTQY;:^, ,3>6)70\?PL0"?J
M: .+^'TTMUK=Q<HMSY+QMO:7<"6R,;P7/S?45Z57(>&/"U]IFJMJNI7=O>W<
MT.QYWA83]CMR7*@>P KKZ "BBB@ KF-3_P"2C>'_ /KRO/YQ5T]<QJ?_ "4;
MP_\ ]>5Y_.*@#IZ*** "L3^VS<:I<:9#$R2JK!)3TR!Z>E;=<X^EZA#J]YJ'
MV@F)HSM5/O'C@5M14'?F[:>IO04'S<_;3U+FA0:G#;RC4I-[E_DRV2!]:ORW
MEM#.D,DZ)+)]U6/)KEK>36-6TR5[>:>.5) ,,0H8>QQUJA.DSZO;QWHFFN%<
M1F1.V,=..V:Z/J_/-N37HCK^J^TG)SDD]=$=38:['?:I/9+"Z&+/S'O@X_"M
M:N2M$U.XU*_M]TD/RL%E* 9/;)QS6WHEE=6%AY5W-YLFXD<DX'IDUC6IPCJG
MVT.?$4H0UBUTTWZ;FG1117.<H&LN74YH]72S%N2C8^?^M:;' )]*Y^6[N#K"
M2H[BV&,CRST[]JUI14F[]C@Q]:5.,.5M7DMK/3KOT-N2XAB=$DD56<X4$]:S
M]<>V6VC^T $EQMX_/]*H:K<64][;.ZS$CK@8XS[U+K-[:2V\:M$[D.",J5QZ
M]:TITFI1>NIQ8K'1G2K0O'W;6W?;?0TKRS34-/$,;[$."I'3%26L*V%BD329
M6,<LU9U[>B73A'9&2-\# V$<>F:=%<Q2Z8+:\:5G9<.0A_PJ>27+9[7-U7HJ
MNY17O<N_3T_I;&K#/'<1AXG#J>XJ2LS2A:V\?V>!I3DEB74C-:=935I61WX>
MI*I34I6OUMJK@:Q=?T^_OXH5L;CRBK98;BN?3D5M4F*QJTE5@X2V?8JK2C5@
MX2V?;0YO5(-?2SB6&[B9@0&*?(3^)INK0:TVGQYOK=&R-V#LS^)J]K^D_P!J
MV\2?:O(V-G)Z&C4]"74].M[5IW4PXP^,YXQS7GU</-NHHW>BM[V_^1Y]7#U&
MZBBF]%;WM_\ (P;Z62U6X^WO!-DQ@@QEMQV]1S5Z[OI[71H;B26V>UD "1^0
M>?08S5RTTVVDN;NSGC$T4:Q ;^>@ZT>)8)?[%$5I!&P5@"I X'MFLW2J0ISJ
M)]-.KO?KW,W2J4Z<ZB?33J[WZ]Q]FVI7=G%/#=6PC=05'DD<?G6K )5B43LK
M2=RHP*@TM95TRW69$20( RIT%7*]*C&T4VWL>E1C:*;;O8****V-@HHHH Y+
MPW_R.GBS_KM!_P"BZI>/[GP[I!LK[5M LM0GN9! )K@(@C0<G+L/?@=^:N^&
M_P#D=/%G_7:#_P!%UG?$SS631H[25UOFN)/)C/D^4X$9+;_-^3@<CC.>E:UO
MB^2_)&-#X/F_S9T>D3Z=J/A"TN(M-$>GR6X=;,Q!@JCG 4<'IQCKQ5+PCXBM
MO$'VB6WT[[&3%%/(2FUG9]PYX&<!!S_A5C2=:W^!+?609;O;9>?\R+&\F%SC
M"_*.G;CTI/"^IPZG%+)%'IB81!BQE+D#D@-\JXQDX_&LC8M>(M<&@V$4XM9+
MN:>=+>""-@I=VS@9/ & 3GVK'U+Q_9V.C:5J<5E<7,=_ UUL4JIBA10SL<GD
M@,.!UK=UO1+37K 6EV9559%ECDAD*/&Z]&4CH>OYUE77@+1;RTM[6070@MP%
MBC2X8!8]H4Q_[C #<.YYH Z">[M[6S>[N9XX;=%WM+(P55'J2>E<1I7BSP[%
MXT\13OKNG+%+':>6YN4 ;"OG!SSC(KO&C1H_+9%*$8VD9&*Y32;&T?QSXE5[
M6!E6.SP#&#CY'H T/^$U\+?]#%I?_@6G^-'_  FOA?\ Z&+2_P#P+3_&M/\
MLRP_Y\K;_OTO^%5[_3;$:==$65L"(G_Y9+Z'VH6H%7_A,_#'_0PZ7_X%)_C1
M_P )GX8_Z&'2_P#P*3_&OCRX1?M,WRK]]NWO4>U?[H_*OM(<'RE%2]KOY?\
M!.9XCR/L?_A,_#'_ $,.E_\ @4G^-'_"9^&/^AATO_P*3_&OCC8O]T?E1L7^
MZ/RJ_P#4V7_/[\/^"'UCR/L?_A,_#'_0PZ7_ .!2?XTG_":^%O\ H8M+_P#
MM/\ &OD"S1#?6X*+_K5[>]?9MKIMB;2$FRML^6O_ "R7T^E>!G&4O+9Q@Y<W
M,K[6-:=3G*/_  FOA;_H8M+_ / M/\:/^$T\+GIXBTO_ ,"T_P :T_[,L/\
MGRMO^_2_X5R7CBQLXTTW9:6ZYF?.(E_N'VKRJ<.>:CW.BE3]I44.YM_\)GX8
M_P"AATO_ ,"D_P :/^$S\,?]##IG_@4G^->=_9;;_GWA_P"_8_PH^RVW_/M#
M_P!^Q_A7I_V6_P"8]?\ L9_S_@>B?\)GX8_Z&'3/_ I/\:/^$S\,?]##I?\
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MFO0TI</TJ<U-3>COT,O_ (37PO\ ]#%I7_@6G^-'_":^%O\ H8M+_P# M/\
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M?_OX*)2@UJQ2E!K5[D]O(TMNCO&8V89*$Y*GTJ:LJTNK2TA?=);PPM(3&WG
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MH;8OS.>E1[J@N]S=NL\1*SM#ETVLG^?Z#-,OCJ%KYQCV'.,=C5ZH;>:&:(/
MRM'VV]*EJ)?$[*QU4$U2CS2YG;?N+1114FQB>(M,74K6)7NQ;;'SECP<_P!:
MUK>/R;:./<7V*%W'O[UG:WHJ:S#'&TS1&-L@@9_2J6HV^MV-E$EA<&?;A2HC
M ( Z?6N&3=&K.KR-JRU6K?R.&3=&K.K[-M66JU;^0S4[^[T^YOI;.'S7+Q@Y
M&=HP>U7;[3Y=>T:!)F:VE.'88S@^A%9FI:5=/IYGNM32"24J9 PVKD#ID5L6
M5I>Q0P9U+S8U4?\ +,'</K6--3G4G"I%\K6UUU?K<QIJ=2I.%2+Y6MKKJ_6Y
M;L+465E#;!R_EJ%W'J:LT@I:].,5%)(].,5%)+H%%%%,84444 <EX;_Y'3Q9
M_P!=H/\ T76;\2[ZUBM+:.Z%C=VD!,U[8SRQ([(P*1N-X(&'(]S[\BM+PW_R
M.GBS_KM!_P"BZR_%^@0W>NR:IIUVTVM6\,4@TQ6C.XAF6.8AN<)O=L="5%:U
MOB^2_)&-#X/F_P V;=@UPOPWB:[U&%9QIN6O+?!1?DX9=O7 QT_"LGX>Q^5>
M:B-TJ!TC98IFD+XW.-QWDXP05P/[H)Y-6KF*ST?X<VUOIFO65K911)&E[>(L
ML<JG@@C(!W<]/RJM\-H8H;?4!'#M&]<2A%"2CGE3]_'LP'M61L=W1110 5S6
MC_\ (]^)_P#KG9_^@/72US6C_P#(]^)_^N=G_P"@/0!TM5K_ /Y!MU_UQ?\
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M;-I_QYP?]<U_E4V*RAA*,(>S4=#*G@Z$(>S4=#!M/".C61E,=HK>: &WX/\
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MGZT3W3.?)M3F5PVV3&Y%([-BI;>V2W5BJ@-(V^3&>6[FLV^;1;&;?-HMB<
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MMK7] HHHK0T"BBB@ HHHH Y+PW_R.GBS_KM!_P"BZZVN2\-_\CIXL_Z[0?\
MHNNM%:UOB^2_)&-#X/F_S84445D;'&>.[G6EMHX+2TNTTWSHS=7EC*?/$>3N
M544;O[O([9K"UK4-7D\)Z%:RMKD.M 1I/-;Q2!(G* F27:I+X'\(X+'!Z5ZA
M10!6N3=?87-D(FNMG[OS\A"?]K'(KF/"IU$^+_$QU1;5;K9:9%JS%,;'Q]X
MYKL*YK1_^1[\3_\ 7.S_ /0'H Z6JU__ ,@ZZ_ZXO_(U9JMJ'_(.NO\ KB_\
MC36X'Q7<_P#'U-_OM_.HJL7$4IN92(W(WM_"?6HO)E_YY2?]\FOV:C7I>RC[
MRV75=EYGG-.XRBG^3+_SRD_[Y-'DR_\ /*3_ +Y-:^WI?S+[U_F*S)++_C_M
MO^NJ_P Z^U;3_CS@_P"N:_RKXMLXI!?6Y,;@"5>2I]:^TK3_ (\X/^N:_P J
M^#XOG&=:ERN^C_,ZL/LR:BBBOCSH([AY(X'>&(S2 ?+&&"[OQ-9W]H:K_P!
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MX428/_9K-&#D6[W,K0C_ +9EMN/;&*ZM$6-%1%"HHPJJ, #T%.HK(V"BBB@
MKE]=_P"1[\)_6\_]%"NHKE]=_P"1[\)_6\_]%"@#J**** "BBB@ HHHH ***
M* "BBB@ HHI&W%3M(#8X)Z9H H67_(4U/_KI'_Z *T*S+.RU""]FGFN;=TF8
M,ZK"5/"X&#N/I6G0 4444 %%%% !1110 4444 %%%% !1110 5F>(([&31+@
M:E=_8[4;6:YWA/*8,"K!CP"&QUK3JAK.EIK.F/8R,%1W1FRH8$*X;!!ZYQC\
M: ,#0M)AL-=VS33G[.CI8>;*&^T!]LDT_ Y8LV#V ' YKKJYJP\*'3/$$%W:
MWK#388I5BL77=Y+.5SL;J$^7[O;M@<5TM !1110 5S&I_P#)1O#_ /UY7G\X
MJZ>N8U/_ )*-X?\ ^O*\_G%0!T]%%% !1110 5##<P3EQ#*DA0X8*<X-2D @
M@]#67I6B0:3).\4CN93_ !=AZ524>5W>O0N*ARMMZ]#5HHHJ2 HHHH ****
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M]"C[1#_SUC_[Z%<[_P *[\(?]"_9?]\4?\*[\(?]"_9?]\4 =%]HA_YZQ_\
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MQ]MC,=K>A^3@T =717+_ /"PO#W_ #UO?_!?/_\ $4?\+"\/?\];W_P7S_\
MQ% '445R_P#PL+P]_P ];W_P7S__ !%'_"PO#W_/6]_\%\__ ,10!U%%<O\
M\+"\/?\ /6]_\%\__P 11_PL+P]_SUO?_!?/_P#$4 =117+_ /"PO#W_ #UO
M?_!?/_\ $4R7XC^&H4WRW-U&N0-SV,P&2< ?<[F@#JZ*Y?\ X6%X>_YZWO\
MX+Y__B*/^%A>'O\ GK>_^"^?_P"(H ZBBN7_ .%A>'O^>M[_ ."^?_XBC_A8
M7A[_ )ZWO_@OG_\ B* .HHKE_P#A87A[_GK>_P#@OG_^(H_X6%X>_P">M[_X
M+Y__ (B@#J*0US'_  L+P]_SUO?_  7S_P#Q%'_"PO#W_/6]_P#!?/\ _$4
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M.W.3TSQ7<44 5[FQM[VQDLKN,3V\B;'23G</>L(?#[PD"2-!LP3U.SDUTM%
M'-_\*_\ "?\ T K3_OD_XT?\*_\ "?\ T K3_OD_XUTE% '-_P#"O_"?_0"M
M/^^3_C1_PK_PG_T K3_OD_XUTE9VO:LFA:!?ZM)$TJ6D+3-&IP6 &< F@#FU
M^'.A#Q')<'2+/^SC:+&L7/$H=B6Q_ND#/M6C_P (!X3_ .@%:?\ ?)_QK.T/
MXB6VM7%M;K8NDD]Y]EW).LJ ^29<AAUX&".QKM: .;_X5_X3_P"@%:?]\G_&
MC_A7_A/_ * 5I_WR?\:Z2B@#F_\ A7_A/_H!6G_?)_QH_P"%?^$_^@%:?]\G
M_&NDHH YO_A7_A/_ * 5I_WR?\:/^%?^$_\ H!6G_?)_QK3U[5ET+1+K4W@>
M=+90[1H<$KD G\!S^%<<_P 6=-Q=F*PG<6T\J,=ZJ&B3;^^!/\!+8% %S0?A
MQH5KHEM#J>D6<UZ@(EDY;)W''/TQ6E_PK_PG_P! *T_[Y/\ C3'\;6+ZCI=K
M9VMW=QZC'+)#<1QXC8(I; +8W%L<8]CTJWX:\0GQ!;W;26,ME/:7!MY8G=7
M8 'AEX.-V#Z$$4 5_P#A7_A/_H!6G_?)_P :/^%?^$_^@%:?]\G_ !KI** .
M;_X5_P"$_P#H!6G_ 'R?\:/^%?\ A/\ Z 5I_P!\G_&NDHH YO\ X5_X3_Z
M5I_WR?\ &LS6/AQH=P+#^S](LXO+O(Y)^HW0C.Y??/'%7/%GCBW\)2F.XL9[
MAFM6GA$1&96#JIC ]?G!^F:K:?\ $G2K[5UL?*EC6;(M9<[OM+ J"%4<\$GG
MH-IH T/^$ \)_P#0"M/^^3_C1_PK_P )_P#0"M/^^3_C65<_$JVL--U"XOM*
MN8+FTG2$6HD1VD+ -U4X!5>6'\/XUW"G*@^M '.?\*_\)_\ 0"M/^^3_ (T?
M\*_\)_\ 0"M/^^3_ (UTE% '-_\ "O\ PG_T K3_ +Y/^-'_  K_ ,)_] *T
M_P"^3_C7244 <W_PK_PG_P! *T_[Y/\ C6;:?#C0TUW4IY](LVL94A%M'R=A
M ;?QVSE?RJM+\5-/AN6MI-/N1.L<VY-PXE20QB+_ 'FP2/:K7_"Q;.7P]>ZG
M:V,MQ+8LPN[=9%'D!68$LYXSA<X'/(XYH T?^%?^$_\ H!6G_?)_QH_X5_X3
M_P"@%:?]\G_&H=&\<V>M^))]'MK>13#&&:2210=VU6*[,YX#CGUS754 <W_P
MK_PG_P! *T_[Y/\ C1_PK_PG_P! *T_[Y/\ C7244 9FE>'=(T-I6TRPAM3+
M@.8QC=CI_.M.BB@ HHHH **** .3F_Y*K;?]@E__ $8*ZRN3F_Y*K;?]@E__
M $8*ZRM:OV?1?J8T?M>K_0****R-@HHHH **** "BB@D 9/2@ KE_%OBE](A
MFL-,A:ZUMK5[J*W1-Y6-2 SXR,GDX'<C%6M6\2V]I-:V5KFXNKU)'B:(JR1H
MF TCDD#:I(SC)]JXGPEX?OM4O[75]8>]6&WA2=;J:]63S+G/S20L.D+IU4X!
MR..,T =;X%UN_P!=T'[1J"[I$D*+<"$Q+,,9R%/((SM/;(..*Z>O./&7B6[C
MUIM.*WMI;VR^=*;9ML[Q<?Z1"1D2*AR'C(SCG!KI?">JWM_:SVNI,DUU:LNV
MZB3:EU$Z[HY0.Q(ZCL0: .BHHHH ***9)-%#M\V1$W,%7<P&2>@'O0 ^O,]>
M^(.H'4;*70(FETMI'C,WV8RK<RHV&B!!RI(X4]SUP!5GQ-K\VMI';:9%?FTB
MU!K:<6TZP37FU7WK V<Y1AD@[<@'!J]X<TJX\*>&+K5;U'?5IH#+<PF8!995
MW;,_PB1AM5F'4B@#LHV9XD9D*,5!*GJI]*?7EB:YKXU.[DDNXH=>MC&3I22,
M8+Z,Q"4HJ-DI(JY&X<$@9ZUZ99W4=]8P7<.[RIXUD3<,'!&1D=C0!/1110 4
M45F:SKUCHFGW%W</O\C:&BBPSEG(5%QGJ20!G% #M;UNQT#3Q>7\A6-I$B15
M&6=V.%4#U)KD?!WBCQ!JGB2^L-6M"BQE]T8MRGV4J>,L3AU8$;3U.">!BLF^
ML-9\4^)YX9H;J2T:XB2:)KE#;0VQ0&2"6,'_ %N3D,,\E2",5TGBB^OO"^B:
M39:=;W5Y!),EI-.299E3& .H)9CA=Q("YR: .QHK@?".N7JZC'9S/>SZ?<22
MVZ"] :XLKF+EX9'7AU(Y5NO&,GBN^H **** "BBB@ HHHH **** &&)&<.44
MNO1B.1^-8TG@_0I=/6P:Q'V58O*6,2. J[]XQSP0W(;J/6MRB@"M86%KIEC#
M964*PVT"A(XUZ**LT44 %%%% !115+6+JXL=%OKNTA6:Y@@>2.)B0'95) X]
M<4 7:SM*TE=+DU!EF:3[;=M=$$8V%E4;1_WS7GT?Q9GNYY([+3(G$K1_8F:0
MXG0(S3-_P J16F/B3]K\)V.MZ9IKW237,%M/*6"Q1,Q0.03RP!;:..2/2@#O
MZ*YC3/$.I77C*_T6ZLK98((C*DL$Q=HQNPHEXPK.,L #D <UT] !1110 444
M4 %9NN:0NMZ<+-IVA FBFW*,GY'5\?CMQ7-^-O'%UX4O([:'3TNI;JU9[-=Q
M!EG#JOE_3:V?PK-L_BM!<:E9"2T7^S[Z1H+5XB6DEE58OE Z?>D8?\!H ](H
MKS^[^(5WI-QK<>IZ?; 62 VXM[C<6E9B(X7)  =@ ^ 3A3S77>'M3.M>'-.U
M-E1&N[=)F6-MRJ6 ) /L>* -*BBB@ HHHH **;(7$3F, R;3M!Z$]LUY;#\6
MKB>6*%-+B\V:&**/]X<&]+JLD/\ P$-G\* /0K+2%L];U/4Q,SM?^5F,CA/+
M4KP>^<UI5Y_;?$*ZU7PE>ZGI-A%->:>Q%VKE_*0C<2J[069L!> /XAS3]#^(
M;ZUXJATQ;2"&U>-09&D8L9C$)2JD#8V <8SG@F@#O:*** "BBB@ HHHH Y+P
MW_R.GBS_ *[0?^BZZVN2\-_\CIXL_P"NT'_HNNM%:UOB^2_)&-#X/F_S8444
M5D;!1110 4449% !1110 53U73+;6=)NM-NPQM[J,Q2!&VG:>N#VJY39'6*-
MI'8*B@LQ/0 4 <F/AUI Q(+O5!=B99OM@NV\[*H4 W>@4D8]ZZJWA^SV\</F
M22>6H7?(VYFQW)[FLV/Q-H\FF/J7VU4LT94,TB,@RQ 7&X#.<CIZUK4 %%%%
M !1110!!>6D-_93V=PNZ&>-HI%]588(_(US0^''AI81$MHX7^STTX_O#S"C;
M@#ZG(Y/>NLJCJ&L6&EO EY.8WG8K$JHSEB.O"@^HYH SH_"&EQ0V<41N42R,
MWV;;,1Y0E!5@OH "<#MQ5CP[X=L_#&F#3K&6Y>W5BR+<2[RF>H!],\_4U/9Z
MWIVH7L]G:W22W$&?,0 \8.#@]#@\'&<'BM"@ HHHH **** ,O5/#^G:Q?:=>
M7L)DFTZ4S6YSP&*[3D=QBL>W^''AVTBL4MX)HFL%(M9$E(>+,GF$@^I)(^G%
M=95&ZUG3K*XE@N+N..6*W-TZ$\K$#@L1Z9XH YM?AAX:.DRZ9<Q7-W;N[2+]
MIG+M$S'+%&Z@L>OK781QK%&L:#"* JCT J"QO[;4K5;FU=FB8D LC(?R8 U9
MH **** "BBB@#F9O /A^XO9KN2U8S2ZC'J3'>?\ 7H,*?IZCOFHA\/=$C@NH
MK9KVT%TV^9K>Y9"[%F))QU)WLI]L#L*ZNL9O%>AK%!+_ &E$8[@L(W4%E.UM
MC$D#@!N,GB@"OIG@K1=(U9=1LH98W1-D<7FDQH2JJ6"]F*HH)]JZ&BB@ HHH
MH **** "BBB@ HHHH Y.7_DJMM_V"7_]&"NLKDYO^2JVW_8)?_T8*ZRM:OV?
M1?J8T?M>K_0****R-@HHHH **** "N)\0^(-#\1^$M?@M-<6".TD6VN+A(V=
M0^5.P!>7#?=.T\Y(%:OB7Q-HFC".QU:1]EV-DH121%&V5WR$?<3/&X]S7-Z3
MHFH?\)GJ7]B/%8>'6>V\QXTP[/"FWRD!& I&TE^XZ'J0 9OASP9<ZIJ#P:S;
M7?\ 9%K&PB26%;14F+<_9UC.Y8BN0P8_-D9Z&N@\:);FQ7PS=QQ6FBZE:&TM
M[D?*L%PN#&C=@I &/=<=Z[>H+RSMM0M);2\MX[BWE&UXI5#*P]P: /._ W@R
MXET^PU+69[I?+D,T6E2@E+.13M!C9LN!P3C.TANF*]*  Z57L;&WTVSCM+1"
MD$0PBERV!Z9))JS0 4444 9VMZYIWAW29M3U2Y6WM8A\S'DD]@ .23Z"N#\<
M6\>KZ[IUS97UQ-/'9"=;.VL1<3)&7!$T18A$<],MDX''2M'6]=\*^(UU&QE)
MEN[.VE^SRM"S*^]3&SPX^_M)VD@'%2:&^N^&?!L^J^( 99[2Q18]-M<,$6)<
M?>QEG;J3T';I0!7\,:+IN@1Z?J?B22&#Q!>2NJ&XG 9W8D+E0=AFV;0S*.:R
M?'%B+G5+JSUB%)6F>.33)[B0K#)&"&>W!)V)+D$!F'*M[5FSZ@WB_5K:Z O7
MU9[=XHXM//D6UY$KAF6*XE7(9=PW%<9 X->E>&='N[+PI:Z;K<JWLZJ?,\T^
M: "Q(0EN6VC R>N* (_#OAW[%<S:UJ26TNO7B 7$\*85$'W8T_V5&!GJ<9-=
M$!B@    8 [44 %%%4=6U:UT73WO+QV$:\*B+N>1CT15'+,>@% $,OB+2X?$
M,&@O=I_:4T33+ .2$7J3Z>V>N#7DUEX<O=2O!%IES<:E8WUR3<79LEBM[F$2
MMYGGNQ+R.!D+MP!P1TKH+_RM9U#1-7\$16YU">>:XN))T8! T?E.TG^TAV_N
M\YX]*VKWQE8>%;JUT6^N)+E[>%&O;Z>1(Q&K9"L1QN9B#\J \4 1ZC?:+X)L
M;72K%X+=;]YO,N)[DDIM0[I&8DLQ#;%QG/( Z4WP[;^(3IAT2\OEO[,P(]OK
M.T-YJ$C?%(I(.[&0&]#SR*IWFBS37,NHZ0D>HZ3J69K>ZMA&USI\DF-[PE^"
MK8R><J<D9KN=*TJST738=/L8O+MX1A02223R22>22<DGN30 NG:99:391V6G
MVT=O;1YVQQC &>I^OO5NBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *0@,"",@\$4M% '.VW@;PY:164<&G(BV44T-OAV^19L^8.O.<FI(O!NA06,
MEE%9;+622&5HE=@N^+;L;&>ORKGUQSFM6_U"TTRU-S>W"00@A=[G R3@#ZDU
M63Q!I+W-M;K?P^=<J&A0M@L#G'YX./7!H KZ7X4TK1]7O=3LHYTN;UVDN,W#
MLKL3DG:3C/'7'3BMJBB@ HHHH **** ,^_T33]3O;"\O+=99]/D,MLY)^1B,
M$^_'K66O@'PTMG!:+IJB&#S?*4.WR&1P[$'.0=R@@]L<5TE1O/#'(D;RHKN"
M55F + =<#VH YZU\!>';3[:!8F9+UFDGCN)6E1G8Y+A6) ;W'-;>FZ=::1IM
MOI]C"L-K;H(XHUZ*HI;/4++4(V>RN[>Y13M9H9 X!]#@U9H **** "BBB@ K
M B\%>'X989(]/17AOWU%#N;BX889^OZ=*WZ* .8;X?\ APVSP1V4D*.%!,,[
MQME2Q!R"#GYV&>X.*M6G@W0;'58-2M;!8KB",1Q!7;8N%V!@F<;MOR[L9Q6[
M10 4444 %%%% !1110!R7AO_ )'3Q9_UV@_]%UUM<EX;_P"1T\6?]=H/_1==
M;6M;XODOR1C0^#YO\V%%%%9&P4444 -894@=2*Y;0?"DFDQ30L\:I<6,<,VP
MEMTP+[G(/7(8<^U=710!DZ#H4>A6\L4<WFB1@V?+5,<8_AK6HHH *KWT!NM/
MN;<;,RQ,@W@E>01SCG'TJQ10!YW<^ =3OM-FB.HQ67S!H+*,F:"(A57<"XSG
M@D8Z9]>:]#0$(H9MQ Y.,9I:* "BBB@ HHHH *YKQ/H-WJ\]O+:+;"6.-XUG
MDDD22W+%3O0KU(V]#[<]:Z6B@#E] \/7VF:C&]S+ ]O:Q30P,F=\HDD$A9QC
M (P!QG/)KJ*** "BBB@ HHHH *XN]\%W<VL:A?+?17,=Y!)&\%U'@,69"J%E
MPVP!<#N/?FNTHH Q_#FFW6F:?)%=R*6DG>5(DD9U@4]$5FY('7MU-;%%% !1
M110 4444 4]5L6U+2[BR2YDMC,FSS8P"RCOC/MQ^-<>GA/7+6PL],6>QNM.2
M>66XC;,)D4R;D3Y5/R <D=SQTZ]Y10 "BBB@ HHHH **** "BBB@ HHHH Y.
M;_DJMM_V"7_]&"NLKDYO^2JVW_8)?_T8*ZRM:OV?1?J8T?M>K_0****R-@HH
MHH *Y#Q%\0-.T'4[G2I@\%W';K,ES<QL+4%R0H>102HR,9QBM'Q9XGM_"^C2
M7TBI+(K(HC,FT#<VT,YP2JYZG!K#BTZT\>W&B>()K=()M/EDBO+.7]XK<9V$
MCAMK[6&<@'/&: ,&R\/:OXM76+N[62UFD.VUF^V+-;7=O)\S0LR??C5@V,8(
M#8XYKT3P[HXT#P_9:4)VG^S1[-Y&,\YP!V S@#L !5^WMX+2!(+:&.&%!A8X
MU"JOT XJ6@ HHHH ***K7^H6>EV4EY?W4-M;1#+RS.%51[DT 332"&%Y2K,$
M4L0HR3@=AZUYCJWQ$;Q)I*VWA@-%?W$)>.WN9?LMUD'*-$&&V12000&SC(KI
MX/'NDAM034F^P2V:^:%=@XN("?DEB*_?#<# YR<4GAOP;I^E7>H7WD0SB\NO
MM=KYL/SVRD9V#=]W#%R ,8W&@#D;_P -Q:(=#UR:2X@BBE66WTHOOFCN9#N-
MO;XX 9LALD\ ]!5/77.HW]WJ=Y'?WYNL0Z3=Z7(S-IUX@YM\+\IR_P#RTY4X
M(->J:YHEAXATJ;3=1A\V"4=CAD;LRGLP[&LCPIX2?P^HDO-0:^N8XA:P,$$:
M10*?E4(.-QX+-U)H FT#PS#83+JUXKR:U- JW#O,SI&Q +K$"<(I8=![5T5%
M% !116)KOB2WT93#$JWFI>7YL>G12J)Y8P?F9%/WL#)QWQ0 >)/%%GX7ALY;
MRWO)ENIQ GV6$R$,03R!ST!Z<UPSW=YX[\16GV<B?1,NOVS3+T'[,ZG?#*48
M!HY005((((:M[6KW0O'^@+HMAJ0-SJ%N;JUEB5MT!0C#MCE"&XP<'J*9XJN5
M\#^%XGTRSAL8G,<%WJ%O;!A:Q@8\PH.7/89R 2,\4 <T)D\&IKUA;:W$WB'4
M9%"N$;R4D).#+(1L69P3R<#(7C J/P]!?^(-=.G-+;I<643G^TX\7EW9'?CR
M9)I%VEFRQ&T?+M]*G@TF[UI]0TW2);>VAU>,2:S877[[[*9/NS(RC:)74 E,
MX!(/:O5;:W2VMXX8\[44+D]3@8R3W/% $&CZ5::'I%KIEBA2VMD"(&.3]2>Y
M)YJ[110 4444 %%%% !1110 4444 %%%% !1110 5R'AO3M8M-22:]EO'2>V
MF,XGG+JLGG?)@9^7Y">G:NOHH YSP]HNJ:9>7$M_?FYCD7"+Y\LFTYST<D#\
M*Z.BB@ HHHH PO%6G/J6FP(EBU[Y-RDQA2Y,#';GE6&.02#@D?6N7M/"_B!)
M(X;M5G^TS6D\UVTP+0"!RVP]W.-H!'4DD^_HM% !1110 4444 %%%%  :X#6
M?#^O7/C :BT,%S:M;W,"&.5D>*)HP @!&T,S9.?IGI7?T4 <KX)LKNPMKJ%X
M+J"P4QBU2\5!,,( ^=G!&>F??MBNJHHH **** "BBB@ K,U^ZOK/2)9=.M9+
MFZ)5$6, E<G!?!(S@9..^*TZ* /)(=46;2]#M)]5U"VUAP=LE[<>4(D68YE8
M X=VQM"G/T YKUNF&.-B"44XZ9%/H **** "BBB@ HHHH Y+PW_R.GBS_KM!
M_P"BZZVN2\-_\CIXL_Z[0?\ HNNMK6M\7R7Y(QH?!\W^;"BBBLC8**** "BB
MB@ HHHH *.E%5-4D,6DW;BT>\(A<_9DQNFX/R#/'/2@"RKJWW6!^AI5=6SM8
M'!P<'H:\K\'Z-JMAI-_)I^@_8M3OG#WT5RK6\21X(6*W*D\K_>/4G)K)T/2?
M$NB6URFFZ9J=M9L;=;F=8$2\*@MO"KN*2L/ES( "03UH ]KHKRR:Y\?_ &T&
M"/4MVQ/)26*'RC#Y1WF4KTFWXP!QT[9J6Q7Q[;>(]&BGN;R>R:*![AY(D*DL
M"9U? &T@X"_UYH ]-W*&"DC<>@SUI001D&O-KG1IQXYO;C4?#]YJ5Q->PR:=
M?Q2[([6 * 06R-NTAB5Q\V>]9%C9^-]$\.065NNINLEM&2%$>ZUD,K[@."2-
MNW(Y//6@#V"BO*K:;XA".VO;B2Y22/[.DD$L<8B(,#^:[\9X<)T/&:PK+Q'X
MUU>UG71[Z_NTB%N;B39$\B.T3D[-@(*^8%]\8Z"@#W$LJ]2!]32UY5X]T/6-
M8D\/2SV$UTT>GSI=&&T6<),RICY"P .0V#GBJL3_ !!MFT^VM[74;9(;!89%
M^2= WD'# G&6W@9R<Y]J /7Z3(SC/->0QW7Q*-MIJB*]0++('D9%9I&W)MWJ
M0"L>TOUQTZ]*U_#%KXEE\;B^UJ&^W1VES%(TJH+=7,RE!%MY*E .3_C0!Z12
M%@HR2 /<UY5:/\0KB>*&5]1A$DT*WTCQ1 0L92'\CUC\ON<]N^:F\0:9K^K>
M ]&AU"UN;N\@U/=<CR%E=H5:0*S1Y ;*[>..M 'IP=#C#*<].>M+O4L5##<.
M2,\UXIJ'AJZFDD%OX:OY)'TE8-.E2V6V^S7(E<[R _[O&5.<G(%3?\(WK<?B
M6^D72;^>2XCN5NIV*QM\T6 T-P&^8,W1&7Y<]L4 >R*ZN,JP8>H.:7<N.H_.
MO.?A]H-W!I>MZ;=V-Q9V%PJ)%,T7V:9\Q[7)C#,JD<?.,;CSBN0UGP9XH?5]
M8AM;.[?3;J]%SG>,L8-HCQST;<3_ , H ]U# ]"#^- (/0@UX_;Z;XNL;Y[J
M.RO;>-PL=P]I&GF"+[5,Q\M3QNVE">.A-;NB>&;FV^&EVD]I??VM=V+0S1),
ML<QPS[0I^Z&PQ]J /0E=77<K!@>X.:=7B5I8^--'TR2'0].NK6S:ZSYJ6HBF
MD(B&W=#N95&\8)7 ;J<=:WK\_$9%U**%G9;:-9(98T3=<>:R;E4>L8$@'KD=
M: /3B0!DG I:\H:T\<:CISB]>\=([6$QP-#&!,YN#G>",[EC"GMZ^U5M,N/%
M&E:CI>@?;KSS]2N[@2K=%6DMT2<R&5.Y1XR5R>_2@#V"BBB@ HHHH **** "
MBBB@ HHHH Y.7_DJMM_V"7_]&"NLKDY?^2JVW_8)?_T8*ZRM:OV?1?J8T?M>
MK_0****R-@KEO&FOSZ';0-"PBB9LSW2D,;8 C#.F"3&3\K,/N@YK0\1^((M!
MTR>94%Q>",O#9HW[R7&,D*/F(&<G )P*\ZTC3+SQMXL?Q C):B!HDN5GARZD
M(-PB.3\CKP4?E=Q)&30!/HGAV?Q3K=WJ6IV[QLTH=YF(+Q, H:V!QMGMG4[E
M/;/KS7J%G96NGVD=K9V\5O;QC"11*%51[ 46=E;:?9PV=I D%M"H2.)!A44=
M !4] !1110 4444 %<?X^\-ZCKFGV]WI,ZB_L&>6&WF4-%,2N#E3QO ^ZQZ&
MNPJ,7$+2F(31F0?PAAG\J .#\#^#(H+6*\U+3I(TAE632[.^D\Z6Q4(%)W'H
M6/S;1PO&.:] HHH **8)8V;:LBEN> >>.M/H **1G5%+.P51U). *6@ KR3Q
M3X&UG_A(II;%;B^M]0F:>&9)A%+9717:K/(/F,*KN*J._'.:];HH R=$T"RT
M2!S!#$+RXVM>7*1A6N) H!=L=SR?Q-:<L4<\3Q2HLD;J59&&0P/4$=Q3ZB2Y
M@D?8D\;-_=5P30!3T;0M,\/:>MAI5I':VRL6V)W)ZDD\FM&F&:(3"(R()",A
M-PR1]*?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7"67B[5A
MXJU*WOYM(&@Z8I-Y?H'C$+D_+$68X+ $%L<#/K7=UR^D^ -#T6X,MH+TQLSN
MUO+=O)"S/]XE&.TGOR* ,%OB%>P^*S;W*65OHK2$0SR+)^_B\O?YD<HS&QX/
MR<' K67XA6KVMM(NBZQYUXW^AVQMP'N4V;]Z?-C 7DY((X&.:LOX!\/2:JU^
MUI(=TAF-MYS?9_,*[=_E9V[L<9Q4*_#CP\EH+=$O5*.'BF%[)YL("E0J/G*K
MM)&!Q@T 4G^*^@B*6>*"^EMT2$^<(@$+RXV1Y+##'G.>!@Y-6;[QPMQX7T[4
M]#A66?4[Q+&W6ZRJQR,Q!+X[#:W3KQ@\U;/@'P[]@N;)+$QP3^22$D8%#$,1
MLIS\I'KW[U;E\)Z1/X=30I8)'LD(9"TK>8K@[@X?.X-GG.: .:O?&VM>'KJS
MM];TVWN"PNGF;3"7)CB56#A6(V\,<@DGCCK5JZ^*.A6=Y-!+#>;8[5KI9%12
M)$5 YP-V0=K#&0,\UH6_@+0+: 1I;2L=DZO(\[,\GG "0LQ.6) ')Z8K/B^'
M/A&YENO)AE<#?!*BW+[5+(JN,9X)4+F@!S?$G3E+1'3-4^V+*\;6?DKYJJD8
MD9R-V-NUE/7/.,4[2?B9H.LZS;:9:_:?,N579(Z +O,8DV'G(.T]<8SQFH/%
M/P\BUG,NFSQVEU),TLTD@=BV8A&0"K*0-H&1T..:OZ+X%T70)K:]A$OVBV@2
M-G,I5'94">84SC<5'6@#G9_B+JL'C*?3#;6ALHM5CL"3%*#M95.\R_ZL'+?=
M/)_&M"3XL:'%%>L]K?*]I+'&R%$YWE@K%MV%'R'.XC''K38M(\":UJ=QJD>H
M?:3+=1SS0B]?R7F.%1C'G!.0,''458_X5[X5TZ$6P:ZM_M12"/\ TQPQV[F5
M%Y[9;CTH '^*7AV+4(K24W$>Z))'E* K$70NJM@YS@=0"!QSS3]"\=C6-4U7
MS[*6QTZSL(;U'N4VR,CAB6(!(QA01WZYJS;?#OPU:7$,L%BT:Q0B'R1*WER*
M%*@NN<,<,1D^M6=&\%:)H?VH6D,SBZ@6WE%Q.TN8E!"I\Q.  2,>E &6GQ,T
MQXXP=-U1;B=H1;VS0*))DE#>6Z_-C:=IZD$=Z9KWCN2#P=IFNZ/ #]OO([8)
M<PNS1[BRME$.205/ JIIUC\/;&4FWU!'DLI%N/,ENG<Q"'(5=Q/"+N/R].:N
M2VO@J]\(1VHU%5TJQN1*DD5TR/%+N+#Y@=P.6.!0!FCQAXJN+J"TLH=*>?\
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M<$T^?QEXS>VT=H#>0*\3[))X WVJ83;=IVQG<NSI@(2#GM7IY\:^&Q=Q6O\
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ML@#:Z%RF]B.$ (YSV(K8O?%CRZ1X?NM-1 ^L74<2;R'$:89W.5."=J$=>IH
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M+^OD/VK_ )7^'^9UM8_B?0D\1^'[G36F,$D@#0SJ,F&12&1Q[@@5E?8/'?\
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M?F^8 GS]NGS;O7K7J"@*H Z#@5R?V#QW_P!!O2?_  $;_&C[!X[_ .@WI/\
MX"-_C1[-?S+^OD+VK_E?X?YG6T5R7V#QW_T&])_\!&_QH_L_QU_T&])_\!&_
MQH]FOYE_7R#VK_E?X?YG6T5R7]G^.O\ H-Z3_P" C?XT?V?XZ_Z#>D_^ C?X
MT>S7\R_KY#]J_P"5_A_F=;17)?8/'?\ T&])_P# 1O\ &C^S_'7_ $&])_\
M 1O\:/9K^9?U\A>U?\K_  _S.MHKD?[/\=?]!O2?_ 1O\:7^S_'7_0;TG_P$
M;_&CV:_F7]?(?M7_ "O\/\SK:*Y+[!X[_P"@WI/_ ("-_C1]@\=_]!O2?_ 1
MO\:/9K^9?U\A>U?\K_#_ #.MHKDOL'CO_H-Z3_X"-_C1_9_CK_H-Z3_X"-_C
M1[-?S+^OD'M7_*_P_P SK:*Y+^S_ !U_T&])_P# 1O\ &C^S_'7_ $&])_\
M 1O\:/9K^9?U\A^U?\K_  _S.@U'2K'5D@CO[=9T@F6>-'S@.OW21WQ[UF77
M@GPY>3W$TVEQ%[C=YNTE0VY/+)P#C)7BJ7V#QW_T&])_\!&_QH_L_P =?]!O
M2?\ P$;_ !H]FOYE_7R%[5_RO\/\S9;P]I,E]]LDL8I)_LPM0T@W8B!SM /
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M6/3<)(\;EC-(7!3[@5RVY0,G !QS37^'GAD"%H-,BCE@0)"=[E5VL74,N[#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
L% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &I ZH# 2(  A$! Q$!_\0
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MXVL1S@]#0!WJNKC*L&'J#FG5XOHETOAK4O&-_.+7P[=65G'$=.@1IHN6^2Y
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MFD9L3H$VJ@;A&P2 .* /8**\$LK_ %L:9XB>PGU?RY= \^)'>XD9+D/@@-(
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MF.IN+"TO)(I+FUAF>+=Y;21ABFX8;!/3(X/J*KZ?H.CZ3(TFG:596;N,,UO
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M#*J;0G16#$+DXYV^_>CF92H0EK>WEH=MD>O2JESJEI:%Q++AD*J5523EON@
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MY+6.,?9%4C>-['*<Y;@'=G%3:+I6J)XMM+^?2#:GS;D7<D:J%(;)3Y]Q>0'
M/( !["@#T*DV*&+;1N(QG'.*6B@ HHHH **** "BBB@ HHHH 0HI8,5!8=#C
MD4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHH **** "@C/6BB@"*"V@ME*V\$<2DY(C0*"?7BI:** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** &R(LD;1N,JP((]0:YRZ\ ^&[S[%YVGL/L,'V>V,=
MQ(ACC_NC:PKI:* $10B*J]%&!7"_$/\ Y#/@C_L/1_\ H#UW=<)\0_\ D,^"
M/^P]'_Z ] '=T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>M6ZI7L,XEBNK=OGCX="<*Z'K^(ZUSEEVBHX9H[B%)H7#QN,JP[U)0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<)\0_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYRH''/TJ>@ HHHH **** "BBB@#A+;_DNE__ -@"+_T<:[NN$MO^2Z7_ /V
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MF1!LE":L5SG8%%%% !1110 4444 %%%% !1110 4444 %%%% &9X?_Y T?\
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MW_A5&@?\_P!KO_@TF_QH [JBN%_X51H'_/\ :[_X-)O\:/\ A5&@?\_VN_\
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MU2)[>\MK61I$E9,F&1,Y.",JPY]^:-%\5:'XAFFATG4([J2!5:155@5!Z$Y
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MW#6TOV9) ,"4HP4C/ .3UK'UW2]7N_#^EVEOI[/+I;V5YM\Y0+AHV^>(9/!
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MBB@ HHHH **** "@C/6BB@!NQ?[H_*C8O]T?E3J* &[%_NC\J-B_W1^5.HH
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M#WJ]7*> = .B>'T>:/;=W>)9<CE1_"OX#^==70*A*<Z:E-6;"BBB@U"BBB@
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M2OM.^099@7P0/FP,-@ <B@#T^RD66QMY$,A1XE9?,^]@@=?>IZBMFE:UA:=
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MH *X3XA_\AGP1_V'H_\ T!Z[NN$^(?\ R&?!'_8>C_\ 0'H [NBBB@ HHHH
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M?;O#-\K#O@=,BMCQ#XITCPM;0W&L7+013/L0B)GR<9_A!H YRV_Y+I?_ /8
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPH ;IFE-;2/>7<@N-0E&))<<*/[J#LH_6M.BB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#X,O\ ZU=_10!P']M?$_\ Z%+1_P#P9?\ UJ/[:^)__0I:/_X,O_K5W]%
M' ?VU\3_ /H4M'_\&7_UJ/[:^)__ $*6C_\ @R_^M7?T4 <!_;7Q/_Z%+1__
M  9?_6H_MKXG_P#0I:/_ .#+_P"M7?T4 >?:?XP\61>,=)T/Q#H-A9)J*S-'
M);W9E(\M<GC'N*]!K#U'PW#J/BG1]=>XD273$F5(@!M?S% .3[8K<H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X
M2V_Y+I?_ /8 B_\ 1QKNZX2V_P"2Z7__ & (O_1QKNZ "BBB@ HHHH ****
M"JNI3O:Z7=W$>/,BA=USTR%)%6JANH$N[2:VD)"31M&Q7K@C!H \P\(^/]9U
M'4M COKFWN8M4M9)IHQ826QA94W 1NQ(E)/&!VYK:;XI:7#;:A)=6-Y;R62P
MLT3&-B5E8JI+*Q5.1SN(Q4FG_#'3+..UAN=5UC4+>SB:*T@NKA=D *%,KL5>
M=I(!.<4ZS^&UA8PR)#JNJ*[VL=J)!(@*HC;DX"8..AR"".N: )I_B!8P:7IU
MT;*X:XU!Y$M[59(MSA!EF#[MFW&.<\Y%8M[\1C)_:-[8SJNEQZ1;7T$GD;Y
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MFCO5,VHS?:_MQ#2A[;;-^[$@)V$,I&W & .]>LTF "3@9/6@!:*** "BBB@
MHHHH **** "BBB@#D/B*J?\ ".V\D]Q'%:QWL+7"2NZ1S)G!1G4$J,D')XXY
MJ3X;MJ+>!=/.I;_-S)Y>\DGRM[>7R>3\FW&><8KJB 1@@$>]+0 4444 %%%%
M !1110 4444 %,F5WA=8W\N0J0K[<[3V..]/HH \J74(]-\$^(I/$&N:B\=I
MKDD9FBDV2W&"F(@1]U6/'&,#/(KL/ 9G/A&T-QJ,=_(2Y,D<_G",%B1'YG\>
MP$+GOBMZ2SMI8VCDMX71FWE60$%O4CUI\%O#;1B."*.*,=%C4*/R% $E%%%
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M1QQQXAAG:-L@MCC;QZU:3XGZ'+JMO9Q+,T4KP1&?*@(\RAHP5SN(P1D@8!-
M';T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD\5Z1J?BT626T_A\JT=X<!+@3%74?[0(;WH ]#MO >AVC.L;7&6M+BU(,O\
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MA<@F0D'!/&#6[;NTMO%(PPS("1]12E'E*A/FZ$M%%%0:!1110 4444 %%%%
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>SDC/TJ^*6DIN3>XE%+9"T444B@HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &@ ZP# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%8WBGQ!'X7\/7&KRV[W"PLB^4C!2Q9PHY/
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MGL?E1_LGF!U^4G'F< EN>FWC-2MXE\96@6WO-0G$$K:?)-?+IP+VZS1N9%1
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M0RHT048CF^\B$KDJ/4^M=V8D,@D*+O P&QR!Z9KR3XBVZ3>/M/DNQ ;/^R6
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M[.<X4@\'TKH_"^I7VI65Y_:)MS<6M[-:EX$**P0X!P22/SH W**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH YG4O'6CZ7)JR3_:<Z7'$]P1%@'S&V*%+$!C
MGKV'KUK3L]?TV\M[:3[5#"]PBND,LR;\-TX!.<^V:AU#PW;W]W=78NKJWN;B
M"*'S(7 *"-V=2 01G+'.<@CM7/>(O"^CZ+X/MHK6QA,EM<6B1W$D:M+_ ,?"
M<[\9SR>GK0!W5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S
M'@[_ %WB3_L-3_\ H$==/7,>#O\ 7>)/^PU/_P"@1UT] !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)]2@AC$JK)8B7A67#AS&#A2.N>*TO!+Z8VB-_95WJMS;"4@-J?F^8#M' \P
M[<8QCCK0!TE%54U.PEO&LX[ZV>Z7K"LJEQ_P'.:M4 <*?AR[_;))/$%X]W<7
M8NTN3!&9(Y-K)C./F78Q4*>!VKIH_#NE#0;319[.*ZL;6-(XXKE!(,(,*3D8
MS6I10!R7@2UM[*/Q!;6L$<$$>LS*D4:A54;4X '2NMKF/!W^N\2?]AJ?_P!
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M.=(/*5R44NJC/S*CDJ''WL4 =91110 5SGCC_D66_P"ORT_]*(ZZ.N<\<?\
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MXD_[#4__ *!'73US'@[_ %WB3_L-3_\ H$==/0 4444 %%%% !1110 4444
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M86X'XG'O6A=:/IE]'-'=Z=:3I.RM*LL*L)"HP"V1R0.E6T1(T5$5510 JJ,
M#T% ')^ KC[7#K]P8)H/,UB9O*G7:Z_(G!'8UUU<QX._UWB3_L-3?^@1UT]
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% &'IO_(VZY_N6_P#Z"U;E8>F_\C;KG^Y;_P#H+5N5
M$-OO%$BN(%N;:6!RX212A*,58 C'!'(/N*\N^&^GZE8>)Y8;[3KV&..TD$+W
M,UQ+Y:F1<+N<[,GG[HS\N>AY]6KRWP1XRU"^\7WFG:OK=A*A:18HUGB/F/N&
MT1!?FP '^]SR.^:L9)?W5Y%X\C$Q-M(\L8EV7)570/A2P60+R"!@C/(]:].K
MS+Q05'Q!M5*0*WF0$(]SM6Y!91ADWC+ C.=IXC7[V<#TV@ KF_!_^KUO_L,7
M7_H0KI*YOP?_ *O6_P#L,77_ *$* .DHHHH **9--';Q-+,X2-1EF8\"E21)
M4#QLKHW(93D&@!U8LNBR6DS76BS+:RL=SV[#,$I]U'W3_M+^(-;5%)Q3W$XI
M[F1::] \AMK]#I]XHR89V # =2C=&'TY]0*U4=74,C!E(R"#D$5R?Q"\-WWB
M;0([;3WC\Z*82^7(<!Q@C&>QYS5;PMI^N>#] AM[V(7UN"6=+<EI+?)Z '[Z
M^PP1DXS6/M)*?*UIW,?:34^5K3N=I+%'/$T4J*\;C#*PR"*HA9]-("#S;!$.
M1EFDCQSQUW#MCJ/>K%E?6NH6XGM)TFB)QN4]#Z$=C[&K-;IWV-T[[$<%Q%=0
MK-!(LD;C*LIR#4E4YK-EG^TVLACD"D&+/[N3KC(['/<<_6EM;X3%8ID^SW1!
M)@=@3@'&1CJ/>@"W1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!GZ[8S:EH-]96\X@FG@9$E(R$)'6N>\&>'KS2M*U.WNM56^AN93Y
M$JW#SE4VXY+GK[#C\ZU?&30IX+UEKCS/)%G(7\I@K8VGH3P/QX]:X3X47\=A
M?WN@20G[2^9C+'-"\7RJGRJL7 P'7GOT[8H M>%YROCV>V>1I98I)(V! #@
M'YW4#Y0=O'/\2^O'IM>9:!<F3XC2;IKMQY]PB22.H#+\_P FW>3C<'Y*C[B=
M._IM  0""",@]JYSQQ_R+#?]?=I_Z41UT=<YXX_Y%EO^ORT_]*(Z .CHHHH
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MPK*5"J1GYCE!\W<GT('::-'J$6CVBZK.D]_Y8,[H@52QY( '8=/PH O4444
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M0K:@U.PN;R>SM[VWEN8/];"D@9X_]X#D?C6+X/\ ]7K?_88NO_0A0!TE%%%
M 0",$53.G1K+');N]OL_@C.$;ORO3J>HP:N44 9WVRZLX@;^#S/FQYMJI88]
M2O4?AFKT<L<H)C=7P<':<X/H:?52;3H9'DDBS;SN #-#@,<'//K^- %NC%41
M+>VS[9HA<0*F3-'P^0.<IWS[58M;N"\A$L$@=#QTP0>X(/(- &?>Z*DMRU[8
MS&ROR.9HQE9/:1>C#]?0TR#6WMYTM-9A%G.QPDP.8)C_ ++=C_LM@^F:V:CG
M@BN8'AGB26)QAD=<@CW%0X]8DN/6(_O44]K#<[3(@+(<H^/F0XQD'L:QQ9:A
MHN#IA:\LAULI7^=!_P!,W/\ Z"WX$5H:=JMKJ:OY#L)(SB6&1=LD9]&4\C^5
M-2Z/<%+H]QL<US8^5#=>9<HS%1<(GW?3>!_,<?2KR.LB!T8,K#(93D&G50-@
M]MAM-:. &3?)$RY1\]?]T_3\JHHOT55MKY)W>)HY(94;!208SZ$'H1QVJU0
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M_P# R/\ QH VJ*Q?^$O\-?\ 0PZ5_P"!D?\ C1_PE_AK_H8=*_\  R/_ !H
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M9]E_SYV__?I?\*LT4 5O[/LO^?.W_P"_2_X4&PL0,FTM\?\ 7-:LT$ C!Y%
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M;S_Q.=,/IBR;GZ?-29\6_P#09TSI_P ^3?E]ZBX>T?\ *_P_S.QHKC\^+?\
MH,Z8/7_0FX_\>I,^+N/^)QI@]<V3<?7YJ+A[1_RO\/\ ,[$UYKXS\=KH_BRS
MMDLC,-/;S96+[=V]",+] V<^M;.?%V/^0QIGT^Q-^?WJXCQ7<!/$5F-8OM+G
MNXR#)(MBQ5%Q\N_YOF&><5,V['-BJLU3]W35;V_S/8[>9;FVBG3.R1 ZYZX(
MS4M<:I\5E 4UK2RA *E;)L$>WS4N?%O_ $&=,Z?\^3?E][K57.E5'_*_P_S.
MQHKC\^+>/^)SI@]<V3<?7YJ3/BWC_B<Z8/K9-Q]?FHN'M'_*_P /\SL:*X[/
MBW'_ "&-,^GV)OS^]1GQ=S_Q.-,/TLFY^GS47#VC_E?X?YG8T5Q^?%W_ $&=
M,/IBR;GZ?-5_PIJ5_J-O?IJ,D4D]K>/;[XH]@8 #G&3ZT7&JEVDTU<Z&BBBF
M:!1110 4444 %%%% &'IO_(VZY_N6_\ Z"U;E8>F_P#(VZY_N6__ *"U;E1#
M;[Q1,W7X[R;0+Z/3VD6\:%A$8]N[=CMN(&?J17&^"U.FRV]M#I&OBY8%;N2:
MW^SVW+9W$,Q!(' *9)[]:[^XCDEMY(XIC#(RD+*H!*''!P>#CWKSOX=:CJNH
MZ@QOM9O+^&*"1$$\ELNXB3&YHXR7#<8^;IR.]6,3Q/$K^-4N3/(([>>V$TKO
MA;?<5P%3S!NR0.=I WMG/;TD$, 0<@]".]>=:S;V5[\09(M0AM9 /LZQK/*L
M98'J OEMY@SZL/3CK7HD<:11K'&JHB@*JJ,  = !0 ZN;\'_ .KUO_L,77_H
M0KI*YOP?_J];_P"PQ=?^A"@#I**** "BBB@ HHHH **** "BBB@ JK+8QO.E
MQ&[PRKW1L!O9AT/\_>K5% &'J7B&/P]IK7>MKL53M#VZEQ(>P [$^A].M2>'
M?$FG^)[!KS3V?:C['21<,A]"*EU[0[/Q%I,FG7P?RG(8,APRL.A%9VB>%X_"
MFGM#HS&1G</*+EO]9QC@@?*?P(XK-^T]I_=,G[3VG]W\38U#3+34X5CNHMVP
M[HW4E7C;U5AR#]*S?M&IZ(,7@?4;$?\ +S&G[Z(?[:#[P]UY]JU;>]AN)I(
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M1110 4444 %-=%D0HPRI&"*=10!G1F73#' WFS6ASB9FR8NX#?[./XOS]:T
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M7'_CGO1VQ@^N/_9J9H'7T.>F>_7D^] ZCOGIG^+ZT=>Q.><?WNO-')_VL_\
MC_M0 G&,Y]L_T^E<7XH\(6.J>(K&YDFEB-W(8IUC (^5"01^  KM>V<^V?\
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M5!110 4444 <QX._UWB3_L-3_P#H$==/7,>#O]=XD_[#4_\ Z!'73T %%%%
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M<?W>O-=E110 4444 %%%% !1110 4444 %%%% !1110!AZ;_ ,C;KG^Y;_\
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M-Z\#+=>.*AT[XEK,S+=V$CR-*(88+-2[NYEF0?>(&"(<^V::VG_#NU94-O\
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MW,KS(YNI9X601,-@58VW%74\]!QCMTKMZ ,:>75=,5+FXN[:Y@\Q$D1;<QL
MS!<@[CT)'&.:V:S/$'_((?\ Z[0_^C5K3H **** "F2S1P0O--(D<2#<SNP
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M_P"@M6Y6'IO_ "-NN?[EO_Z"U;E1#;[Q1"BBBK&%%%% !1110 4444 %%%%
M!1110 4444 %(Z[D9<D9&,CM2T4 >?V_@2>ZTT&YE\B[BM;>VC3<QB9H&?\
MUB X='R.#S@GO40^'.H+)=2+J<7FN[LDDBL^[<7;+KP#C?COQGIG%>BT4 >=
MV?PYN8I@UQ<6<D;R$RJ$.50O$Q13QU\M@> /FZ4LWPXNY1:L^J":92RRN^Y?
MEW((V7'.Y4C5>HR<G(KT.B@#GKO1M5CUF\O-*N[6)+](TN/M$1=HRF1N3!P<
MJ>AXR,^HK$M/A\Z7MN]Y+9S6\#89/))-T/G(>7/!?+_S]0!WE% '':%X3O\
M1+M)1-83E5'[^2)O./RHI3=GA0%)'7MTZG;\/6<]GI\IN$,<D]U-<>42#Y8>
M0L%X[X(S[DUK44 %%%% !69H'_()'_7>?_T:]:=9F@?\@D?]=I__ $:] &G1
M17&Z3/K%SXRO3OO6LH;J6.3S2OD",1KL"#KNW$Y/IGVH [*D) QD]:Q-%TW5
M[._N9=0OOM$+@^6GFEMO/H5&.*R/&FEW]_>0M;VDMR#:R0VS1D#[-<ET*RG)
M&, 'YATP1WH [+(R!GDT9'7(ZXZUQ&N:=J.H:X9[>QN!.XA6SNFP!:^7(_FD
M\\!EQC'W@0.U83:!?-H5S -"O$9X8HH@ C&.Z6,B27:6Q\Q(7S.H(W>] 'JM
M%<?H6FZ_#XRNM0U2*$Q3V2H'BN&=4(<[4"D#D DD]R<^P["@#,\0?\@A_P#K
MM#_Z-6M.LOQ!_P @A_\ KM#_ .C5K4H **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@# \3W5Q -/B@DDC6:9P[QG!.V)W5?Q91]>G>N'M=5\2Z%!
M%),LY:>SMC^^FDN4^8_O)B7QL9>%*=/G![5ZG-!%<*HFC5PCAUW#.&!R"/<5
M)0!Y<?&7B&TW2O;-YT\B2"%H'9-OEQ95"2",[F; !/7T-6--\1^(;9IE>.2^
M=I1:!VA<;9F>0(2.@4;0&([$'->DU2M]7TV[-P+:_MIC;_Z[RY0WE]?O8/'0
M_D: .5T'Q'XAU9=7CFLHHIX(':% I!CF!8*C9X.< ]NOH16?:ZV;.V@DL=2U
M.221(UU">_ADEBM'.<L5."KY^7:I"C.2!@9[.;Q%I,6DW>II?0SVMHA>5H'#
MXP,XX/6K.F7\>J6$=Y%')&DF=HDQG&>O!(_6@#AQXM\3BS^VO81*I?R?(^RR
M;D_<K)YI.<D9)^7'3C.:UI=:EET:TN(K[SKJ.]A :*%X5N$>7R_NMU!4L>I&
M5R*ZVHY;>&9HFEC5S$^^,L,[6P1D>^"?SH DHHHH 9+_ *E_]TU3T3_D Z=_
MU[1_^@BKDO\ J7_W35/1/^0#IW_7M'_Z"* +]11W5O*9!'/$YC.'"N#M^OI4
MM<?X6\*W.GO-<7WD1-)'-"(H$ +*\S/N=LD,V",>F3ZT =9%<0W )AFCD Z[
M&!Q^54DUS3Y-7;2UG)NER,;#M+ !BH;&"P4@D9S@U'H?A^TT"*:.T:5A*0S>
M85[#V K.'AJ[BUM[Z"[A\D7$EY%&\1)$SQB,[B#RN,G P<GVH N/XKTA'G3[
M0Y:%MFU87)E;=LQ'Q\_S?+\N<&GVOB;2KV[@M[:X:5YE#*RQ,4&06"LV,*V
M3@X/%8C>#+L7$4T=_#FQE:2P#1' W2^8PDYY_NC&/6JMO\./)N<_VB427+SS
M0J4G+%"C*C9(5#G.,'D?D =AINJ66KV[W%A<+/"LKQ%UZ;E.U@/7D=:N5C^'
M-"/A^QGM?M<ERCW#S(9%4%%;HOR@#BMB@#,UG[^F_P#7ZG\FK3K,UG[^F_\
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M^(I/M&K_ /0.M?\ P+/_ ,16E10!G?:-7_Z!UK_X%G_XBD^T:O\ ] ZU_P#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" && ZH# 2(  A$! Q$!_\0
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MN[@@C(+!I9 H('4\T <'X<^&VH:#>64/]O12Z18N6A@6PC6:09)"R2\D@9[
M&K"?#AE^&5[X/_M($W,CO]I\K[NZ3?C;G\.M=C;:KI]ZL+6M_:SB<,8C'*K>
M9M^]MP><=_2K"7$,DLD4<L;R1$"158$H2,@$=N.: //+[X9WPUB]O=&UN"S3
M4!']K6:P2=E=5"[XF;[I(^O-7/$7@35-5*16FMVWV/[,('MM0T^.X12!@NG3
M:Q[]LUH/XFU;4M0O;?P[I$-W!8RF":ZN[DPH\H^\D>%8G&<$G SQS37\<?\
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M8B9HIU;A?*? R2WR[2 0<?6J]QXK\0:78_VMJ_AI(-*4!YO)O/,N+=/[[IM
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M'MZ]* (?%WAA/%6B"Q^V3V4\4JSV]S ?FBD7H<=Q[5SEO\.]3U+6[?4_%WB
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MO[9+FSN(KB!_NR1.&4_B* )Z*** "BBB@ HHHH **** "BBB@ HHHH ****
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MU:.W\EVU!F,K)OW*X[J,C@^IJYXY?3_L]C#K6D/>Z/)*?/N8@Q>S<#Y'PGS
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M6=4O8K*^BN1:7%L(VL8HLG;,P W,,!!GKG//6O8*,44 %%%% !1110 4444
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M@:33XK4.+Z1D"AH'P2"<!6QTQGCK7IU59-1L8;I;66\MX[AONQ-*H<_0$YH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M065W"D-W;#8ZR*J!#MW*2A*C!VX]>M=-:VL5E:0VMNNR&&-8XUSG"J, ?D*
M)J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\O+/3"EZ(8+:^M72.ZAR!O6XSMWGG [< ^M:=QX%^VJT]WKFH3:F)898KPA
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117*?$
M""T7PW/JE[J>JV4.GHTN-.N?):4D8"G@YR< ?6@#JZ*\=N?#_C2W\-^'+"&?
M6M0GFDEN]3DAU$0NF4&R(2MT )]#D@^M=WX"U&TU#P=;3VLNH2JC21R?VA)Y
MDZR*Q#*S=\'@>V* .GHJE%JEM+<1P#SDDDSL$D+J#@9/)%7: "BBB@ HHHH
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M .2@T*XM?&.D_8M-2VT72[&:WCD$P.XN8\ +UXV')/6NMHHH **** "BBB@
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M]%45Q'PQN[B\T&Z>XN))V%R0&D<L0-HXYKMZY9QY9.)SRCRRL%%%%22%%%%
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M;7%6FIS<D<E62E*Z/&OB;_R-_P#V[1_S:N.KU[Q7X<L-4UK[3<B7S/*5?E?
MP":Q/^$+TGTG_P"_E=5/$PC!)G13KPC%)GGE;'A/_D;M)_Z^5KJ_^$+TGTG_
M ._E7M'\*:9::U9W$0F\R*4,N7R,U4L5!Q:'+$0::/1JR?$$4<U@BRQI(OF
MX=01T/K6M69KG_'DO^^/Y&O/.(YC[#9_\^EO_P!^E_PH^PV?_/I;_P#?I?\
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M Z2*RAE'+ D 8'K7"?#:XT>[\46:6NKR7=U#!=7,^=/DA\VXF<&1MS# 4 *
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M-J2WFC:]JEO-!&ND-IUQL@MWVX;S!D8._G)SQ73^ ="U70-5U2SDCNHM(2&
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M +14;W$,<9D>5%0<%F8 ?G4E &=??\A;2_\ ?D_] -:-9U]_R%M+_P!^3_T
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M_8UD()O/B$"!93U<  9/O5VL'HRPHHHH **** "BBB@ HHHH **** "BBB@
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MVO\ U\Q_SJ]5'4_NVO\ U\Q_SJ]0!CZ]]R#ZFL2MO7ON0?4UB4@"@=:*!UH
M[)/N+]*K:E_R#I_]VK*?<7Z56U+_ )!T_P#NTP.6HHHI %=)H_\ R#D^I_G7
M-UTFC_\ (.3ZG^= %^N0G_X^)?\ ?/\ .NOKD)_^/B7_ 'S_ #I@1T444@-;
M0?\ 7S?[H_G6[6%H/^OF_P!T?SK=I@<[K7_(0_X /ZUG5HZU_P A#_@ _K6=
M2 *L6'_(0M_]\57JQ8?\A"W_ -\4 =769KG_ !Y+_OC^1K3K,US_ (\E_P!\
M?R-,#GZ***0!VKKK7_CTA_ZYK_*N1[5UUK_QZ0_]<U_E0 7/_'K+_N'^5<B.
ME==<_P#'K+_N'^5<B.E, HHHI ;^A?\ 'I)_O_T%:E9>A?\ 'I)_O_T%:E,#
MB]9^'5IK.KW&H27\\;S$$HJ@@8&*H'X36!'_ "$[G_OA:]#HK55JB5DS159I
M63*]C:K8V%O:*Q988UC#'J<#&:ATG2+/1+'['8QE(O,>4[F+%G=BS$D\DDDU
M>K.L-<TW4[^_L;.Z26ZL)!'<Q#(,;$9&<_SK(S%TO1;'1HKF*QC,<=S</<NF
MXD;W.6(ST!/.!6'8_#O0]-DA:TEU2)87#I$NHS>6#G.-N[&,]JZ&PU.TU-9V
MLYA*+>=[>7 (VR+]Y>?2K= &#-X.T:;3EL3#*D2WAOD:.9E=)BQ8L&!R.6/'
MH:/^$/T<7]S>"&4/<W4=Y(@F;9YR'(<+G /3..O>K.L>(M-T(P)?3L)K@D00
M11M++*1UVHH)..YZ"JT'C'0[C2[W41>&.&P_X^UEB9)(/]Y"-P_+F@"/4/ ^
MAZG?375Q!./M)!N88KAXXKDCC,B A6X '(Y[UT"(L:*B*%51A5 P /04JL&4
M,#D$9%+0!EZ/X=TO0;.XM-.MA#!<3//(F207?[W7M[5!;^$M$MO#*^'8[%?[
M+4$"%F)QEMV<YSG/.<Y%;=% &!9>#='LH+U EQ/)>PFWGGN;AY96B((V!V)(
M7D\"IM1\+:7J=G96\T<J&Q %K-!,T<L/&WY74@C(X/K6S574-1MM,M1<73E(
MS(D0P"26=@J@ =2210!E?\(;HG]CC3#;.81-]H$IF?SO._YZ>9G=O]\U;T7P
M]I^@I/\ 8TD,MPP>>>>5I992!@;G8DG X'I3])US3=<CN7TV[2X%M.UO-MR"
MDB]5(-3:;J5IJ]C'>V,PFMY"P5P",X)4]?<&@"W14%U>6]F(C<S)$)95ACW'
M[SMT4>YJ>@ HHHH \W\8Z+JMCK%SK\4GAF[L9-NZSUFV2,KA0#MGQGMGYJL?
M#7Q7H_B7^T$T[P_#I=Q;%5G>V1##+UQMD0#=T/YUS_BG24USXAWR:3X:CUZ_
MM$B-S+JMVPM+4LHVHD8X+$ ,?K78^"O$,U\]YH6I:-'H^JZ:$,EK"086C;.U
MXR.-O!&.U %WQS82ZGX1O;2*SNKPR;=T%I.L,KJ&!.UF&,X_.N)\&:IX6TS7
ME@FU_P 1V>J>7Y?]F^(+D@#=CH"-I/'!!KIO&&MVLEVOADS:E;O-:O>75Y8,
M$-I;IDEF8]-Q4KQ7#^%++PEXEB?0[GPA<Z?_ &M:-<6FHW<HGGNHP1EPYR48
M9!Q0![514<$0@@CA4L5C4*"QR3@8YJ2@ HHHH SK[_D+:7_OR?\ H!K1K.OO
M^0MI?^_)_P"@&M&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "L?5XI+2:/6+9"TENNV>,?\M8>IX[E?O#\1WK8HIIV8$<
M,T<\*31.'CD4,C#H0>AJ2L2R_P")/JATUN+2Y+26A)^XW5H__9A[9':MNAJP
MD%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWQ_(UIUF:Y_QY+_OC^1I@<_1112 .U==:_\ 'I#_ -<U_E7(]JZZU_X](?\
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M9#T)Y&:]= P /3UK';PGH3:/_9!TR#[#Y@F\H C]YG._.<[L]\YK850JA1T
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M?BKU% %'4_NVO_7S'_.KU4=3^[:_]?,?\ZO4 8^O?<@^IK$K;U[[D'U-8E(
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MWIT6H:;<I<VDN=DJ9PV#@]?<&O&HM/\ #::=H#W'C=+:<W=Y=OJ%G&IMWNI
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MXH^TP_WQ6;17![%'F?6I=CU/P%(LFD7!4Y'GG_T$5U=<;\./^0)<_P#7P?\
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M10J@*H&  , "EHH SK[_ )"VE_[\G_H!K1K.OO\ D+:7_OR?^@&M&@ HHHH
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M-M\I0HPPP=V,'&*Z3X>ZO=WUQJ%KJ6M:E=7\"QF2SU&P2V>$$$A@%^\K?TH
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MJA(^Z*Q#:7.#_HTW_?L_X5[QBC'M6$L(I2;N<E3+%.;ES;^12T4%=$L0001
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M,J&&1\A[5J4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[V_O-^=&]O[S?G245XUD?)W8N]O[S?G7K7@8D^%;?)S\S_\ H1KR2O6O O\
MR*EM_O/_ .A&NK"?'\CTLK;]L_0Z2O"=0_Y"5W_UV?\ ]"->[5X3J'_(2N_^
MNS_^A&M<9LCHS;X8^I7HHHK@/$.X^&O_ !_W_P#UR7^9KT:O.?AK_P ?]_\
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M:/J,%_N\/0****U.H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **YSQ/XNB\.SV=G%I]UJ6HWN\P6=J!O94&78DD
M #\SQ6EH.MV7B/1+75M/=FMKE-R[AAAS@@CL000?I0 7W_(6TO\ WY/_ $ U
MHUG7W_(6TO\ WY/_ $ UHT %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P#0C7DM>M>!?^14MO\ >?\ ]"-=6$^/Y'I97_&?H=)7A.H?\A*[_P"NS_\
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MLFFNV8V8<HZ,2>.S=#0!TGV74?\ H)#_ ,!Q_C1]EU'_ *"0_P# <?XU?HH
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MX_X_[G\E_P *[:BB4(R^)!4HTZGQJYP4OP\LX[BWC%]<D2,P8[5XP"?2I_\
MA6UC_P _]S^2_P"%5/%>O>-M&UFUM]/CT">/4+H06,#^=YY&,LS8^4!0"2?3
M%>@)NV#=C=CG'3-3[&GV,_J=#^1&)HWAXZ':O;VE[(4=]YWQJ3G&/Z5H^1=_
M\_O_ )"%6Z*T225D;QBHKEBK(0 @#)R?6EHHIE!1110 4444 %%%% !1110
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MQ8#GL!V%=O10 4444 %%%% '.>.-"O?$OAI])LY8H_/FB\_S6(#1!PSKP#U
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M;K.,[Y)B-S#KC Z5U%<E\-O#<OA?P396=VI&H2YN+QF;<QE?DY/<@8'X5UM
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 5H+"VMKNYNH8]DMT5:8@G#%1@''3.,#/L*LT44 %%%% !5:WL;:
MUGN9X8@LMRX>9^I<@ #GT & *** +-%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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$H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img_014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'T ZH# 2(  A$! Q$!_\0
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MY+J\O)[9HHXD7/<]^3^E 'M-%%% !1110 4444 %%%% !1110 4444 %%%%
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MAKT4$?\ ;4%J\%O+(S>600?E=0<,N3S0!XCJMDMA\)=)\2V_B?5&U;49H3<
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MMY/,@AEN9)(HFZY5"2 10!V=%%% !1110 4444 %%%% !1110 4444 %%%%
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M#')J,YN+DEBV]SU//3Z"N>'PG\&#5?MXTD;O-\[R/-?R=_\ >\O.W],4 <3
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M-(M70SM<_<P1*WWG!'()[^M.C\*:!%!+#'H]HD4RHDB+& '"-N7/K@\ULT4
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M=N?3/--N]+L;^YM+BZM8I9[1_,MY&7YHFQ@E3VXJY10 4444 %%%% !1110
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MA*I&?+)D0A2>F0.,>U>I4E '-^,M0GTZQMY'T==4TAY"FI1"(RR)$1PZI_$
M<9'/%<):_P#"-+XFTFY^'\=S RW DU3[/'+':BU"G?YBL N[IMP,YKV"DQ0!
MYAX;\-ZOXCTS5-<FUJYTY?$,KO):?9(G_<<I&I+J2/D X]ZP18/JFG^%?"VM
M6DET-'UQ]/N-Z-MEB6)_+?/H5V]^HKVZB@#RW4/"VE_#OQ18^)=+TE&TJ5A;
M7L>PRO:%N%FBSD@9.& [&I-;U'PS>:I>V7Q T*"&2*5OL%Y]ED=)[<\J5D4$
MANN5R.>E>G44 >:^$]*U^]T.[BTW6]2TK2UO2VF/=P+-.UOM'!$H)"[LE<\X
MJ>^2\\'^+[/Q!J+W.HV$VFBPO[R*#+QNKETD9$'"G<P.!QQ7H=% '#3>*I_%
M5]_9GA>)I[%K>87NH2PO''&2A"+&3C+[B">H KEI=3MKSX41^"K>PN5\0FU2
MQ_L_[.P:*4$ R%L;0H(W[L_K7L5% 'GWC-KOPK?:7XJM+>2ZDBMGT^\6)=S2
MAES$<>TH _X&:NZ;X1UBQ\*:5I]CXAFTRZB5I+R6.VCE\^5SN<G>#CYBU=I1
M0!Y)XF\7V]QK$GA35-6O+/3+2-$O[R*TD\Z_?'S(A12$7^\1US@>M>C^'KO2
M[S0;2715":<$V0*(FC"JO&-K $=*TZ,4 >5>"? VF:OI-_=:B-365]4N\QI?
M3PH5\UL?(K 8(]N:V?$6AKX:NO#6LZ)I;-8Z*\L4]G:H2PMY5PS(O\14@,1U
M/-=[10!Q,WCZ+5[JSL/"43ZA>33)Y\DEO(D-K#GYV<D#G&0!US6!H_@/0?$^
MJ>,9M9TPO<-K$L<5QED=4\M,%2#V)/->J4N* /.?!VF6HT_4? FM:;$LEA('
M#PQF)+V$G*2Y7'S\ -SU%:'ACX>Z9HFI7UZ]BJS?;WFLW6=VVQE0!D$XS][K
MFNVHH XOXDQR2:;H0CC=R-=LF.U2< 2<D^U<G\5M%O\ 2+/4[_2+=IM/ULQ1
MZC;H"3%,KJ4G4#U VMZ\&O8** //+'5[/P=XK\3_ -NB:#^T;I+NTN!"[K<1
M^6J[ 5!^92I&WW&.M8OA/2;RSUSP@;VRE@+OJMTD4B<P)(P* _W3@]/>O7*,
M4 >>6VEZI?>./&:Z=JL^D.;BR;STMDD\P?9\$ .,=>X]*AU'PW'J/Q#\/V.O
M*-92+2;DR3W$"J&?S$P2%&T'&17I.*6@#S/6O">EZ1X[\)'0]+AL9)C>I)-!
M%C&;9@I8CW-9/]IV_P#PJ5O!(L+D>(OLAL/[.^SMN\WIYF[&W;GY]V?UKV*B
M@#Q_6#!HVK:J8=8U31-69$WP26OVFUU1A&%#JFTY)QM."#Q5O3_$,.D>.8+[
MQ%:&PGF\.6HF:.%F2V?S')C. 2H)Z?3%>JUF1Z)!'XFGUP2R&>:U2U9.-H56
M9@?7/S&@#SC0+6Z;QGINJFUGAM-2UF^N[9)(RI$1MPH=A_#N()YP>165INM3
MZ5HUAIG_ !XR6NKW@O[^6Q,SZ>'>1HRH(P-^<;N1S7MU+0!X9J/FW5UXQFCN
M=2U&.?P\@ANKJWV>?B1L^6 H^4;AVZYKH[CQ$WA&[\6ZFUG-/([V,5N@C;:\
MAMQC) X48))]O6O4** /&+U=/U?P3JVGZ9J<NK^*+\QW=Y(L$B-/Y;JS1Q[E
M "A00J_XFM""6U\2:_HT=KK>N:K<6\C7&&M4A2R.QES*?+4CKMV@Y/X5ZO10
M!XCJ&JVUK\%Y_"<UE=#7+6 0RV8MG9E99 3+G&"I^]N![^M>W444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 4]6NYK'1[V[MX#<300/)'".LC!20OXFO.-%O?$>
MNZ!'KNC>-(-0U9H5F?2/*A$ 8@$PD??0CD;B>O->C:NVH+I%VVE+"VH")C;K
M-]QGQP#[$UY3KEWX7U[3Y/,\):G;>+6C*QI;6$D,Z7&.")5 4J&_B)QB@#U"
MPUNVOM1NM,R8]0LXXGN82#\N\9&#T8<$9'I62_Q T!3 J37,TESYHMHX;9W:
M?RFV/L '//?V)KE/%R:[X>MM$UJ/$^K75@-%O2G\<\BCRW]]LFX_1JV+'0%T
M7QOX9LK>%VM;#19X!-M. VZ+J>Q/)_.@"X?B9X<^R-<J]Z\<)(NMMG(39X.#
MYPQ\G?K]>E7;WQMI%GJ+Z<OVJ[O5B6?R+2W:5C&PR'&!TKF;&RN%\)_$53:R
MB6XU"_:,>6<R@Q* 1Z@]JJ:+KUKX<\5WAU&TN@C:/IZF>*W>4HP1OW;!02,]
MN,9% &SJWQ#@BO\ PO\ V4KWECJT\BR216[NP"J?E '1@PY!Y !K2N_B!H-G
M<7$;R73P6LGE7-W%:N\$#]P\@&!COZ=ZX2"ROM&_X1[7;[3[J&T;Q!>WTD2P
MEY+:*=7$>Y5R1U&?3-7+'4SH7@74?"%WI5^^M$74$,45J[K=^:SE9%<#;@[Q
MDDC&#0!VNH>-]&T_4'T_==75XL*7'D6EN\S-&V<.-HP1QU^GK56+XD>&YUM9
M8;BXDM+ATC%VMJ_DI(QP$=\85LD#!Z'KBLGP1HUWI'BN6WNXG,EOH-A;-,5.
MUG7>& ;O@X_2L?3]/ND^ \5H;.=;C[0&,/E'?_Q]YSMZ].: .VU'QSI&G7=W
M;E+ZZ-G_ ,?;VEH\J6YQG#LHQG!S@9(K,N?':OXTTK2[)7FTV^TY[M;F*!GW
M$E=C ]-H!.?0XS7/7NH:A<ZEX@LM1N-9M+G[1*ECIFEV>U;B/'R2&4(<ENY+
M#&*I^'DGTF;P/<WEG=I"V@RV!98&;RYRRX5\#Y<X/)]* .ZMO%^G6/A[1Y[J
M_GU*XOX_]'\BT/FW1 R6$2YP .O85LZ+KMAK]K)/8R.?*D,4T4J%)(G'564\
M@\BO-M!6;PW_ ,(EKNHV5V;!-$>PF:.!G:UD+JX9D + $*1D#TKOO#>J-K*W
MUZNEM96CSXMY9$V272A1^\92 1SD#/) H Y+^UM1\0^*]8TZ3Q;_ ,([)8W)
M@M;".*+S9DV@B5C(#N#9X"XP!72Z9K&H:;I]G!XI\I=0GO3902VZY2YZE'P,
M[,@'(/0BN8UC5-)EN[W3O'_AKS7CF;['=1:>\\<T'5-KJ"5?L1QS63;VFHZ7
MX<L-0:PU/^Q[/Q"EW:6LJM)<6]EL*Y9>6QN8D+U H [CQ9XHCTW3=<M+*<IK
M%GI3WZ QY55Y ;)X/(Z4:+XZTG4CIUNTEPDE[&/L\\UL\<-R^W)$;D8)Z\=\
M<9KB=<GE\0ZQXIU&PT^]:SF\+O;V\DMNZ>>X=B0H(SWQTYK2O=0/BFW\,Z'I
M^FW\%Y9WMK=7@FMFC6S2(98%B "3T 4G.: .AM?%VGV&D^?>:G+?R37TUM D
M5H1+(ZN08UC7);:!C=[9J];^,M%GTR_OY+EK6/3^+Q+J-HI(#C(#*1GGC&.O
M:O,;:TFC?3=;=M2CT^UU'58+B?3EW2VYDF^5]NULK\I!P,C(JS>Z/+KNG:UJ
M6D6VMWH2:R<3WY"M?)#)O98XRJG@$X)ZGB@#IO$'Q,L[#P[J5S96]Y'J4-H;
MBV@O+.2/S5R!O (&5!(SZ9&:UE\;6,=I8"2WU"6]N;;[1]EALW:54'!=EQ\J
MYZ9Z]JYKQ;KI\8^&]4T_0='N[H_V=.TMQ-;/$86P,1H&4%G;!R!Z55U2\TN^
M?2-5<Z]I#G3Q%#K%E%)G*M\T$L6P]",C<,'G% 'I.D:O9:YID6H:?-YUM+G:
MVTJ00<$$'D$$$$'TKD+&YU[QS/>WECK4FC:+;W+VUM]EA1YK@H2K2,S@@+NS
M@ =N:UO =SJ]UX:$NLH?.,\GDR/ (7FAW?)(Z#[K,.<5@:'J0^'BWFAZS9W@
ML1=2SV%];V[S1R1R,7V-L!*NI)'/7@T 6;7QA<>&=3U#1_%MVDWV6&.Z@U&*
M';YL#OY>74=&5L9(XP<\5UE[K=CI^H6-C<3;;B]WF%0,@A%W,Q/0 #N?6N-M
M-'D\;Z_JVM7]C<6>E7&EG2K6.Y39+*C,6>4J>5&<;<\\9K*\/Z3KOB6PUF35
M+9[>]LM+?0K,S KYD@4^9*/9CLY] : .QM/'VAWMS;QQO=+!=2>5;7DELZ6\
M[]@DA&#GMZ]JF@\9Z3=:_)HMN;J:[BF:&;R[9RD+ 9P[XP,]O6O-[6&"_P!!
MTGP],OBN?4$-O#/IC?NHK8QE<L9?+QL4KD$$D\>M=_X,MG@NO$[20-&9=:F=
M2RXWKL0 CU''6@#0\1ZEJFGV*KH^F&]O)MRH7<)%#@9WR-UQ[#D]*H^$=>>X
M^'&F:[K-VNYK(7%S.X"CIDG XKH[D$VLP&22C?RKSG1O#&IZU\*_"MA'>#3W
MMHXIIX;FU\Q9=O(1T)' ;!Q["@#3\$^)]7\0>)/$,6HP_9K:W%M):6S* \<<
MB%AO[[B,$CMTJWX\U+4K"UT6'2[W['-?ZM#9O,(ED*HZN3@-QG@5S6@Z'XH?
MQWXN6YUOR?-AME:[@L AD;RSM:/<2!MZ$<YSVJ7Q;I^H>']'T*XO]3U+7!;:
M_;W,DAM@TD<81P<+&O(_QH O:W=>)O!5O%K5UKBZOI,<R)?0SVJ1/'&S!?,1
MDQ]TD$@CIFMO4O&VDZ;>W-ILOKN6U :Z^QVCS+ ",C>5& <<XZXKF/$6MM\0
MM(/AO1-,U,1WLJ)>7=U:/!'! &#/RX&6(& !ZU6O-0OGUW7+#4+G6;%UF*6%
MAI5G@7<>P;9#,%.6)R#EAC% '>:?XHTC5+ZWM+.Z$LES9B]@(4[9(2=N0?4'
M&1U&:IS^.-&BNI+2)KJZNDG>W\BUMVD=F0 O@ <A=P!/0$XZUY]"MYX9^%_A
M/Q1%92&^T1&BN;=EVNT,A*,A!_VMA_"KMYH=KH>D>'DU5-7M+I8II9=:TPL7
M@N)2'D1U522K$]P1\H% 'H^BZW8Z_8F[L)&:-9&BD5T*/&Z_>5E/((]*T:Y#
MX?7>KWFEWKZF\D\ NF6RNY[86\MS%@?.Z8&#G(S@9 KKZ "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHK@O'6N75EK^D:7+K+Z!I%W'(TVIJJY:0$;8@S
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M#@EBBG@L> /3.:Y&^\37_@[4=>M9]3DUBVL=)^WJ9T4202EMJQLR  ANHXR
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M$:)@/NMD C/'/7BMKP%I%UHWA2"*^B$5Y<2RW<\0.?+:1R^W/J 0#[@UTU%
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M@$=*6LVQU%I9C9W<8@OD&3&#\KK_ 'D/<?J*T:Z$[GDRBXNS%HHHIB"BBB@
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M?&YVP7AX#GLK^C>_0_6M>A.XI1<1:***9(4444 %%%% !1110 4444 %%%%
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M110 8HHHH **** "C%%% !BC%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5+7_ (_+[_KHO_H"
MU;JI:_\ 'Y??]=%_] 6@"W1110!'/;Q7,#PSQK)$XPRL,@BLE9IM#<173M-I
MQ.([AN6@_P!ESW7T;\_6MJFLH=2K*&4C!!&012:+C*VCV%!! (((/0BEK$*3
M: 2T2O+I?5HQRUO[KZI[=1VK8BECGB26)U>-QE64Y!%"82A;5;#Z***9 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !113))%BC:1V"H@+,
M3V H ?17F^H_&'3H--TRZT[2-1U&343,\-O&FU_)B)#28YX."1[9KN](U2VU
MK2+34[-BUM=1++&2,'!&>?>@"[1110 4444 %5=._P"/)?\ >;_T(U:JKIW_
M !Y+_O-_Z$: +5%%% "8K-/_ !*[G/\ RY3-SZ1.>_\ NG]#]:TZ9+&DL31R
M*&1AAE/<5$HWVW*C*VCV'9I:SK21[2<6$[%AC,$A_C4?PGW'ZBM&G&5T$HV8
M44451(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !115&XUG2[29H;G4K.&5>J23JK#\": +U%5%U33WM&NTOK9K9#AI
MA,I13[MG'>BUU33[YV2SOK6X=1DK#,KD#U.#0!;JI:_\?E]_UT7_ - 6K=5+
M7_C\OO\ KHO_ * M %NBBB@ HHHH 0UCRVD^D2O<Z?&9+5CNFM%[>K1^_JO?
MZULT4FKE1DX^A!:W4-[;I/;R!XWZ$?R/H?:IZR;JQGM;A[_3 /-;F:W)PL_O
M[/[]^]7+&_AOX/,A)!4[71AAD;N".QH3Z,<HJW-';\BU1113("BBB@ HHHH
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M@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?69"0WV QR0.5!/WDZ< ]<UZI0 4444 %%%% !5*U_Y"5]]4_P#0:NU2M?\
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MNA.G-;HM44@8,,@@CVI:9 4444 %%1I-'(2$D1BO4*P.*DH#8**** "BBB@
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MQ26Z*7LY(O+:->V!TQ]*\QN9OAWX#\226MSI&I^(=2MPLE]?SK]H^S9Y!;/
MZ^GXUZQIVB:->Z[!XPL&S+<:>L$;1X$;Q$[PQ&.O3\* .AHHHH **** "JNG
M?\>2_P"\W_H1JU573O\ CR7_ 'F_]"- %JBBB@ HHHH **** "BBB@ HHHH
M**** *]U9PW:KY@(9>4D4X93[&JHNKBP^6]_>0=!<H.G^^.WU''TK2I" :AP
MUNM&4I='JA$=74,C!E(R"#D&G5G-8RVKF73V50>6MV/R-]/[I_2JUWXGL;!
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M&'4,X!J+3&5K!&4@J2Q!!R#\QH MT444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD:D5.#NB:E.5.3C-69Y?X_UU+S5+K0O^$=TO4HK&%)YY+^^6V9=P)'E$_-D
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MA*^^J?\ H- %VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MI6O_ "$K[ZI_Z#5VJ%JQ_M;4%[#RS_X[_P#6H OT444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK4PN#M\AHU]=ZD_R-9=JM]_;&H8EM\XB_@/H?>@#:HJIMU#_ )ZV_P#W[/\
MC1MU#_GK;_\ ?L_XT 6Z*J;;_P#YZV__ '[/^-,,>IDG%Q:@=AY+?_%4 7J*
MH^7JG_/S:_\ ?EO_ (JCR]4_Y^;7_ORW_P 50!>HJCY>J?\ /S:_]^6_^*H\
MO5/^?FU_[\M_\50!>HJCY>J?\_-K_P!^6_\ BJAC;59+B:+[1:#RR!GR6YR,
M_P!Z@#4HJCY>J?\ /S:_]^6_^*IRQZACYKBWS[1'_P"*H N455\N^_Y^(/\
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M3:@E]#;[[8^8CMG8W&,>_O4^W4/^>MO_ -^S_C0!;HJIMU#_ )ZV_P#W[/\
MC4=P^H06TDOF6QV*6QL;G]: +]%5 M^0#YMO_P!\-_C1MU#_ )ZV_P#W[/\
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M4."4))(_' K*TS3[+P?\>+71]%MOLMAJ&D$RP1_<WH6(?'K\N,^] 'KM%%%
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M'!56<!L'Z9'XUR/@RWT;1?&N@QS^%KKP_=7=DRZ?.MV'6\&T%O.4='[XR>U
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MA3+X*U.\24R^8?M$*'"L7WJ0#Z'%,\.> =<A\3:=K/B;6+6^;2;4VMA':PE
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MY4740U",>7NZ<D8/X5V^B:]=7_\ :#:GIZZ8EK<>3&TEPKB4?WN/N\]C7$>
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M4[&74Y=-CNHGO8HQ+) K99%)P"1VS4&NZ]IOAO2WU+5KD6]HC!6D*EL$G X
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 >/> M:U#0M1D?4[J2?1=9U2Z@AED8G[)<K*RJA)_A=1Q
MZ$>]:VE>)7T2X\4L89[^ZN/$9L[*U5\%W:*,A<GA5 #$GM@UJZ'X-,G@G4=
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M(D;V[E0&1]P.4R,@CGD\4V[\):G'I]C8W_A?1-=L5M_FM[54LVM9RQ9C&3_
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MJR0E!@=^37GNJWVMP_"R'28&TRZTU3;V]OJ<-UN:[C\U51$BQD/C@Y.!@_@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4+71=,LM2NM1MK&
M"*]N\>?.J?/)CIDU?HHH **** "BBB@ HHHH **** "BBB@ HHHH *Q(/!_A
MRUU7^TX-$L8[W>7$RP@,&/4CT/O110!MT444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
G %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img_015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !2 &@# 2(  A$! Q$!_\0
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<0 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881015806296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 25, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Clene Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,526,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001822791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">01-39834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881015897512">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 59,275<span></span>
</td>
<td class="nump">$ 8,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">191<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,523<span></span>
</td>
<td class="nump">661<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">62,989<span></span>
</td>
<td class="nump">9,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,029<span></span>
</td>
<td class="nump">1,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,225<span></span>
</td>
<td class="nump">4,319<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">68,243<span></span>
</td>
<td class="nump">14,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,124<span></span>
</td>
<td class="nump">889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,960<span></span>
</td>
<td class="nump">2,878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income tax payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">164<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Payable to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue from related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">112<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease obligations, current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">194<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease obligations, current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">190<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Clene Nanomedicine contingent earn-out, current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,924<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,668<span></span>
</td>
<td class="nump">4,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease obligations, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,785<span></span>
</td>
<td class="nump">1,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease obligations, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">205<span></span>
</td>
<td class="nump">389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,949<span></span>
</td>
<td class="nump">640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">260<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RedeemableConvertiblePreferredStockWarrantLiability', window );">Redeemable convertible preferred stock warrant liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ContingentEarnoutNetOfCurrentPortion', window );">Clene Nanomedicine contingent earn-out, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">46,129<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InitialShareholdersContingentEarnout', window );">Initial Shareholders contingent earn-out</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,906<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">67,902<span></span>
</td>
<td class="nump">9,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 13)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock (Series A, B, C and D), $0.0001 par value; 0 and 31,036,008 shares authorized as of December 31, 2020 and 2019, respectively; 0 and 27,499,837 shares issued and outstanding as of December 31, 2020 and 2019, respectively; liquidation preference of $0 and $78,875 as of December 31, 2020 and 2019, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">72,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit): (1)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value: 100,000,000 shares authorized; 59,526,171 and 17,357,505 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">153,571<span></span>
</td>
<td class="nump">1,754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(153,561)<span></span>
</td>
<td class="num">(69,571)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">325<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS&#8217; EQUITY (DEFICIT)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">341<span></span>
</td>
<td class="num">(67,774)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 68,243<span></span>
</td>
<td class="nump">$ 14,877<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Retroactively restated for the reverse recapitalization as described in Note 1</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ContingentEarnoutNetOfCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ContingentEarnoutNetOfCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_InitialShareholdersContingentEarnout">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial Shareholders contingent earn-out.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_InitialShareholdersContingentEarnout</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_RedeemableConvertiblePreferredStockWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_RedeemableConvertiblePreferredStockWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881011867576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible preferred stock, per value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable convertible preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,036,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,499,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,499,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation preference (in Dollars)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 78,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">59,526,171<span></span>
</td>
<td class="nump">17,357,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">59,526,171<span></span>
</td>
<td class="nump">17,357,505<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881011657128">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 206<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CostsOfRevenue', window );">Cost of revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">65<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,204<span></span>
</td>
<td class="nump">9,563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,151<span></span>
</td>
<td class="nump">6,769<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,420<span></span>
</td>
<td class="nump">16,332<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(20,214)<span></span>
</td>
<td class="num">(16,332)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(950)<span></span>
</td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnContractTermination', window );">Gain on termination of lease</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">51<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ChangeInFairValueOfPreferredStockWarrantLiability', window );">Change in fair value of preferred stock warrant liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(14,615)<span></span>
</td>
<td class="num">(361)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts', window );">Change in fair value of derivative liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ChangeInFairValueOfContingentEarnout', window );">Change in fair value of Clene Nanomedicine contingent earn-out</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,659<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout', window );">Change in fair value of Initial Shareholders contingent earn-out</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,465<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_AustraliaResearchAndDevelopmentCredit', window );">Australia research and development credit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,210<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertibles notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(540)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,343<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(18,871)<span></span>
</td>
<td class="num">(16,155)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(406)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(19,277)<span></span>
</td>
<td class="num">(16,155)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">284<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Total other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">284<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (18,993)<span></span>
</td>
<td class="num">$ (16,158)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share-- basic and diluted (Note 19) (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (1.10)<span></span>
</td>
<td class="num">$ (0.93)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares used to compute basic and diluted net loss per share (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">17,503,992<span></span>
</td>
<td class="nump">17,357,505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 176<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 30<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Retroactively restated for the reverse recapitalization as described in Note 1</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_AustraliaResearchAndDevelopmentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_AustraliaResearchAndDevelopmentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ChangeInFairValueOfContingentEarnout">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the period ended Change in fair value of contingent earn-out.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ChangeInFairValueOfContingentEarnout</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of Initial Shareholders contingent earn-out

..</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ChangeInFairValueOfPreferredStockWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ChangeInFairValueOfPreferredStockWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CostsOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CostsOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of open derivatives, commodity, or energy contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881013545016">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Redeemable Convertible Preferred Stock</div></th>
<th class="th" colspan="2"><div>Common Stock</div></th>
<th class="th" colspan="2"><div>Additional Paid-In Capital</div></th>
<th class="th" colspan="2"><div>Accumulated Deficit</div></th>
<th class="th" colspan="2"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th" colspan="2"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 62,926<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,345<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (53,430)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 44<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (52,039)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in Shares) at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">25,165,036<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">17,345,002<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ApplicationOfASC842', window );">Application of ASC 842</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts', window );">Issuance of Series C preferred stock, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 8,069<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of Series C preferred stock, net of issuance costs (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,935,111<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ExerciseOfSeriesCPreferredStockWarrants', window );">Exercise of Series C preferred stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,666<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ExerciseOfSeriesCPreferredStockWarrant', window );">Exercise of Series C preferred stock warrants (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">399,690<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12,503<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">399<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">399<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ForeignCurrencyTranslationAdjustment', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(16,155)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(16,155)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 72,661<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,754<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(69,571)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">41<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(67,774)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in Shares) at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">27,499,837<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">17,357,505<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">78<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">78<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">87,613<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe', window );">Conversion of redeemable convertible preferred stock into common stock in connection with the Reverse Recapitalization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (114,603)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">114,599<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">114,603<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection', window );">Conversion of redeemable convertible preferred stock into common stock in connection with the Reverse Recapitalization (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(36,893,894)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">36,893,894<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable', window );">Extinguishment of preferred stock warrant liability in connection with the conversion of redeemable convertible preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">17,828<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">17,828<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts', window );">Issuance of common stock upon the Reverse Recapitalization and the private offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">31,833<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">31,833<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon the Reverse Recapitalization and the private offering (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,542,995<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Offering costs in connection with the Reverse Recapitalization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,911)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,911)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts', window );">Issuance of common stock as payment of related offering costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IssuanceOfCommonStockPaymentOfRelatedOfferingCosts', window );">Issuance of common stock as payment of related offering costs (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">644,164<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati', window );">Clene Nanomedicine contingent earn-out recognized in connection with the Reverse Recapitalization (see Note 12)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(64,713)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(64,713)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization', window );">Initial Shareholders contingent earn-out recognized in connection with the Reverse Recapitalization (see Note 12)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,371)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,371)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">761<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">761<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ForeignCurrencyTranslationAdjustment', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">284<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">284<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(19,277)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(19,277)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">153,571<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(153,561)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">325<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">341<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in Shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">59,526,171<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of Series D Preferred Stock, net of issuance costs of $1.3 million</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 35,051<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of Series D Preferred Stock, net of issuance costs of $1.3 million (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">7,896,922<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis', window );">Issuance of Series D Preferred Stock in connection with the extinguishment of convertible promissory notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 6,891<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IssuanceOfSeriesDPreferredStockInConnectionExtinguishmentOfConvertiblePromis', window );">Issuance of Series D Preferred Stock in connection with the extinguishment of convertible promissory notes (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,497,135<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="13"></td></tr>
<tr><td colspan="13"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Retroactively restated for the reverse recapitalization as described in Note 1</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Retroactively restated for the reverse recapitalization as described in Note 1</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ApplicationOfASC842">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ApplicationOfASC842</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent earn-out recognized in connection with the Reverse Recapitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent earn-out recognized in connection with the Reverse Recapitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ExerciseOfSeriesCPreferredStockWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ExerciseOfSeriesCPreferredStockWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ExerciseOfSeriesCPreferredStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of Series C preferred stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ExerciseOfSeriesCPreferredStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extinguishment of preferred stock warrant liability in connection with the conversion of redeemable convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ForeignCurrencyTranslationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ForeignCurrencyTranslationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock as payment of related offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_IssuanceOfCommonStockPaymentOfRelatedOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_IssuanceOfCommonStockPaymentOfRelatedOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Series C preferred stock, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_IssuanceOfSeriesCPreferredStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_IssuanceOfSeriesDPreferredStockInConnectionExtinguishmentOfConvertiblePromis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_IssuanceOfSeriesDPreferredStockInConnectionExtinguishmentOfConvertiblePromis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_IssuanceOfSeriesDPreferredStockInConnectionWithTheExtinguishmentOfConvertiblePromis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881014429256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) (Parentheticals)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NetIssuanceCosts', window );">Net issuance costs</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Retroactively restated for the reverse recapitalization as described in Note 1</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_NetIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Issuance Costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_NetIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881010220600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (19,277)<span></span>
</td>
<td class="num">$ (16,155)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">963<span></span>
</td>
<td class="nump">848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash lease expense</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of preferred stock warrant liability</a></td>
<td class="nump">14,615<span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ChangeInFairValueOfContingentEarnout', window );">Change in fair value of Clene Nanomedicine contingent earn-out</a></td>
<td class="num">(12,659)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout', window );">Change in fair value of Initial Shareholders contingent earn-out</a></td>
<td class="num">(1,465)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">761<span></span>
</td>
<td class="nump">399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of derivative</a></td>
<td class="num">(29)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible notes</a></td>
<td class="nump">540<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain on termination of lease</a></td>
<td class="num">(51)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Accretion of debt discount</a></td>
<td class="nump">179<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IncreaseInInterestAccruedOnNotesPayable', window );">Increase in interest accrued on notes payable</a></td>
<td class="nump">732<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(163)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(2,862)<span></span>
</td>
<td class="num">(354)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(312)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(272)<span></span>
</td>
<td class="nump">1,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax payable</a></td>
<td class="nump">164<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IncreaseDecreaseInPayableToRelatedParties', window );">Payable to related parties</a></td>
<td class="num">(131)<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue from related parties</a></td>
<td class="nump">112<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income tax</a></td>
<td class="nump">260<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IncreaseDecreaseOperatingLeaseObligations', window );">Operating lease obligations</a></td>
<td class="num">(142)<span></span>
</td>
<td class="num">(237)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(18,929)<span></span>
</td>
<td class="num">(13,197)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(387)<span></span>
</td>
<td class="num">(294)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(387)<span></span>
</td>
<td class="num">(294)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of Series C Preferred Stock, net of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments of finance lease obligations</a></td>
<td class="num">(194)<span></span>
</td>
<td class="num">(176)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from the issuance of note payable</a></td>
<td class="nump">652<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments of notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of offering costs</a></td>
<td class="num">(4,011)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ProceedsFromThePrivatePlacementOfferingNetOfOfferingCosts', window );">Proceeds from the Reverse Recapitalization and from the private placement</a></td>
<td class="nump">31,833<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of Series D Preferred Stock, net of issuance costs</a></td>
<td class="nump">35,051<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfMediumTermNotes', window );">Proceeds from the issuance of convertible notes payable</a></td>
<td class="nump">6,125<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">69,534<span></span>
</td>
<td class="nump">5,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of foreign exchange rate changes on cash</a></td>
<td class="nump">269<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash</a></td>
<td class="nump">50,487<span></span>
</td>
<td class="num">(7,989)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash &#8211; beginning of year</a></td>
<td class="nump">8,788<span></span>
</td>
<td class="nump">16,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash &#8211; end of year</a></td>
<td class="nump">59,275<span></span>
</td>
<td class="nump">8,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Acquisition of property and equipment through finance lease</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_AcquisitionOfRightofuseAssetsAndLeaseholdImprovementsThroughOperatingLease', window );">Acquisition of right-of-use assets and leasehold improvements through operating lease</a></td>
<td class="nump">820<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_WarrantLiabilitySettledOnExercise', window );">Warrant liability settled on exercise</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_LeaseLiabilitySettledThroughTerminationOfLease', window );">Lease liability settled through termination of lease</a></td>
<td class="nump">348<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IssuanceOfDerivativeInstrumentRelatedToConvertibleNotes', window );">Issuance of derivative instrument related to convertible notes</a></td>
<td class="nump">705<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes', window );">Issuance of Series D Preferred Stock upon extinguishment of convertible promissory notes</a></td>
<td class="nump">5,675<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN', window );">Extinguishment of derivative liability in connection with extinguishment of convertible promissory notes</a></td>
<td class="nump">676<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_DeferredTransactionCostsInAccountsPayable', window );">Deferred transaction costs in accounts payable</a></td>
<td class="nump">546<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_DeferredTransactionsCostsInAccruedLiabilities', window );">Deferred transaction costs in accrued liabilities</a></td>
<td class="nump">1,354<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStock', window );">Conversion of redeemable convertible preferred stock into common stock</a></td>
<td class="nump">114,603<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemableConvertibleSreferredStock', window );">Extinguishment of preferred stock warrant liability in connection with the conversion of redeemable convertible preferred stock</a></td>
<td class="nump">17,828<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IssuanceOfCommonStockAsPaymentRelatedOfferingCosts', window );">Issuance of common stock as payment of related offering costs</a></td>
<td class="nump">6,442<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ContingentEarnoutRecognizedConnectionWithTheReverseRecapitalization', window );">Clene Nanomedicine contingent earn-out recognized in connection with the Reverse Recapitalization</a></td>
<td class="nump">64,713<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InitialShareholdersContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization', window );">Initial Shareholders contingent earn-out recognized in connection with the Reverse Recapitalization</a></td>
<td class="nump">7,371<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest expense</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_AcquisitionOfRightofuseAssetsAndLeaseholdImprovementsThroughOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_AcquisitionOfRightofuseAssetsAndLeaseholdImprovementsThroughOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ChangeInFairValueOfContingentEarnout">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the period ended Change in fair value of contingent earn-out.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ChangeInFairValueOfContingentEarnout</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of Initial Shareholders contingent earn-out

..</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ContingentEarnoutRecognizedConnectionWithTheReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent earn-out recognized in connection with the Reverse Recapitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ContingentEarnoutRecognizedConnectionWithTheReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of redeemable convertible preferred stock into common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_DeferredTransactionCostsInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Thereafter, it is classified as an expense within the current accounting period. Deferred charges often stem from a business making payments for goods and services it has not yet received, such as prepaid insurance premiums or rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_DeferredTransactionCostsInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_DeferredTransactionsCostsInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred transactions costs in accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_DeferredTransactionsCostsInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extinguishment of derivative liability in connection with extinguishment of convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemableConvertibleSreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extinguishment of preferred stock warrant liability in connection with the conversion of redeemable convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemableConvertibleSreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_IncreaseDecreaseInPayableToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payable to related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_IncreaseDecreaseInPayableToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_IncreaseDecreaseOperatingLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_IncreaseDecreaseOperatingLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_IncreaseInInterestAccruedOnNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in interest accrued on notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_IncreaseInInterestAccruedOnNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_InitialShareholdersContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial Shareholders contingent earn-out recognized in connection with the Reverse Recapitalization,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_InitialShareholdersContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_IssuanceOfCommonStockAsPaymentRelatedOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock as payment of related offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_IssuanceOfCommonStockAsPaymentRelatedOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_IssuanceOfDerivativeInstrumentRelatedToConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_IssuanceOfDerivativeInstrumentRelatedToConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Series D Preferred Stock upon extinguishment of convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_LeaseLiabilitySettledThroughTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_LeaseLiabilitySettledThroughTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ProceedsFromThePrivatePlacementOfferingNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from the private placement offering, net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ProceedsFromThePrivatePlacementOfferingNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_WarrantLiabilitySettledOnExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_WarrantLiabilitySettledOnExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of assets acquired in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 40<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121604053&amp;loc=SL77918607-209975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfMediumTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt funding received on a regular basis with maturities ranging from 5-10 years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfMediumTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881027695848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of the Business and Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
Nature of the Business and Basis of Presentation</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clene Inc. (formerly
Chelsea Worldwide, Inc.) (the &#x201c;Company&#x201d;) is a biopharmaceutical company focused on the development of clean-surfaced
nanocrystal drugs. The Company has developed an electrocrystal chemistry drug development platform, in which nanocrystals within
a suspension are the therapeutic drug. Utilizing technology to create nanocrystal drug suspensions, the Company&#x2019;s platform
has produced multiple drug assets, of which its lead assets are currently in development for use in neurological and infectious
diseases, among others, such as a study for treatment of COVID-19 coronavirus pandemic. Secondary to the Company&#x2019;s drug development,
as part of the Company&#x2019;s identification of potential drug assets, the Company has also identified certain mineral solutions
as dietary supplements. The Company&#x2019;s dietary supplements may also be commercialized by a related party, as discussed in
Note 20.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying consolidated
financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America
(&#x201c;GAAP&#x201d;) and include the accounts of the Company and its wholly owned subsidiaries, Clene Nanomedicine, Inc. (&#x201c;Clene
Nanomedicine&#x201d;), a subsidiary incorporated in Delaware, Clene Australia Pty Ltd, a subsidiary incorporated in Australia, and
dOrbital, Inc., a subsidiary incorporated in Delaware, after elimination of all intercompany accounts and transactions. Certain
prior period balances have been reclassified to conform to the current year presentation.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Recapitalization with Tottenham Acquisition 1 Limited</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 30, 2020 (the &#x201c;Closing Date&#x201d;), Chelsea Worldwide, Inc., our predecessor company, consummated the previously
announced business combination (referred to as the &#x201c;Reverse Recapitalization&#x201d;) pursuant to a merger agreement, dated
as of September 1, 2020 (the &#x201c;Merger Agreement&#x201d;), by and among Clene Nanomedicine, Tottenham Acquisition I Limited
(&#x201c;Tottenham&#x201d; or &#x201c;TOTA&#x201d;), Chelsea Worldwide Inc., a Delaware corporation and wholly owned subsidiary of
Tottenham (&#x201c;PubCo&#x201d;), Creative Worldwide Inc., a Delaware corporation and wholly owned subsidiary of PubCo (&#x201c;Merger
Sub&#x201d;), and Fortis Advisors LLC, a Delaware limited liability company as the representative of the Company&#x2019;s stockholders
(&#x201c;Stockholders&#x2019; Representative&#x201d;). Prior to the Reincorporation Merger discussed below, Tottenham was incorporated
in the British Virgin Islands as a blank check company for the purpose of entering into a merger, share exchange, asset acquisition,
stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Reverse Recapitalization
was effected in two steps: (i) Tottenham was reincorporated to the state of Delaware by merging with and into PubCo (the &#x201c;Reincorporation
Merger&#x201d;); (ii) promptly following the Reincorporation Merger, Merger Sub was merged with and into Clene Nanomedicine, resulting
in Clene Nanomedicine becoming a wholly owned subsidiary of PubCo (the &#x201c;Acquisition Merger&#x201d;). On the Closing Date,
PubCo changed its name from Chelsea Worldwide Inc. to Clene Inc. and listed its shares of common stock, par value $0.0001 per share
(&#x201c;Common Stock&#x201d;) on the Nasdaq under the symbol &#x201c;CLNN.&#x201d;</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the consummation
of the Reverse Recapitalization, each Tottenham ordinary share issued and outstanding immediately prior to the effective time of
the Reincorporation Merger (excluding certain shares to be canceled pursuant to the Merger Agreement, any redeemed shares and any
dissenting), was automatically cancelled and cease to exist and (i) for each Tottenham ordinary share, the Company issued to each
shareholder one validly issued share of the Company&#x2019;s Common Stock; (ii) each warrant to purchase one half (1/2) of one Tottenham
Ordinary Share converted into a warrant to purchase one-half of one share of the Company&#x2019;s Common Stock; (iii) each right
exchangeable into one-tenth (1/10) of one Tottenham ordinary share converted into a right exchangeable for one-tenth (1/10) of
one share of the Company&#x2019;s Common Stock; provided, however, that no fractional shares were issued and all fractional shares
were rounded down to the nearest whole share.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On the Closing Date,
each share of Clene Nanomedicine common stock was cancelled and the holders thereof in exchange received 0.1389 newly issued shares
of Clene Inc. Common Stock, which is the exchange ratio (the &#x201c;Exchange Ratio&#x201d;). Pursuant to the Merger Agreement, 5%
of the aggregate amount of the closing payment shares, or 2,716,958 shares will be held in escrow to satisfy any indemnification
obligation incurred and will be released six months after the closing of the Reverse Recapitalization. In addition, each share
of Clene Nanomedicine&#x2019;s preferred stock outstanding immediately prior to the closing of the Reverse Recapitalization was
converted into the right to receive the Company&#x2019;s Common Stock based on the same Exchange Ratio. In addition, all outstanding
warrants exercisable for common stock in Clene Nanomedicine (other than warrants that expired, were exercised or were deemed automatically
net exercised immediately prior to the Acquisition Merger) were exchanged for warrants exercisable for the Company Common Stock
with the same terms and conditions except adjusted by the aforementioned Exchange Ratio. At the closing of the Reverse Recapitalization,
each stock option of Clene Nanomedicine common stock was cancelled and the holders thereof in exchange received 0.1320 newly issued
stock options of the Company&#x2019;s Common Stock, which is 95% of the Exchange Ratio. Pursuant to the Merger Agreement, the Company
issued 370,101 of restricted stock units (&#x201c;RSUs&#x201d;) to the option holders which complements the 5% closing payment shares
held in escrow for Clene Nanomedicine common shareholders. The modification of the stock options did not result in a material incremental
compensation expense upon closing of the Reverse Recapitalization.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the Company
issued 1,136,961 RSUs to option holders to complement the earn-out payments that would contingently be issued to certain current
Clene Nanomedicine&#x2019;s shareholders upon the achievement of milestones. See Note 3 for the milestones detail.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The proceeds received from
the Reverse Recapitalization is $3.7&#xa0;million, net of offering costs of $5.9 million which excludes the fair value of common
shares issued as a payment of related offering costs.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
Tottenham&#x2019;s initial public offering in August 2018, Tottenham issued to Chardan Capital Markets, LLC (&#x201c;Chardan&#x201d;),
options to purchase 220,000 units at $10.00 per unit. Each of the units consists of one and one-tenth shares of Tottenham&#x2019;s
ordinary shares for $10.00 per share and one warrant to purchase one-half of one of Tottenham&#x2019;s ordinary shares at an exercise
price of $11.50 per share (the &#x201c;Chardan Unit Purchase Option&#x201d;). In connection with the Reverse Recapitalization, the
Chardan Unit Purchase Option was converted into one Company unit purchase option. The warrants included in the Chardan Unit Purchase
Option (the &#x201c;Chardan Unit Purchase Option Warrants&#x201d;) are exercisable upon the completion of the Reverse Recapitalization
and will expire five years after the consummation of the Reverse Recapitalization (i.e., December 30, 2025) (see Note 10).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also,
in connection with the Reverse Recapitalization, 644,164 shares of the Company&#x2019;s Common stock were issued to LifeSci Capital
LLC (&#x201c;LifeSci&#x201d;), as payment for advisory services rendered in connection with the Reverse Recapitalization (see Notes
3 and 18).</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transaction was
accounted for as a &#x201c;reverse recapitalization&#x201d; in accordance with accounting principles generally accepted in the United
States (&#x201c;GAAP&#x201d;). Under this method of accounting, Tottenham was treated as the &#x201c;acquired&#x201d; company for financial
reporting purposes. This determination is primarily based on the fact that subsequent to the Reverse Recapitalization, Clene Nanomedicine&#x2019;s
stockholders have a majority of the voting power of the combined company, Clene Nanomedicine comprises all of the ongoing operations
of the combined entity, Clene Nanomedicine comprises a majority of the governing body of the combined company, and Clene Nanomedicine&#x2019;s
senior management comprises all of the senior management of the combined company. Accordingly, for accounting purposes, this transaction
was treated as the equivalent of Clene Nanomedicine issuing shares for the net assets of Tottenham, accompanied by a recapitalization.
The shares and net loss per common share, prior to the Reverse Recapitalization, have been retroactively restated as shares reflecting
the Exchange Ratio established in the Reverse Recapitalization (0.1389 Clene Inc. shares for 1 Clene Nanomedicine share). The net
assets of Tottenham were recorded at historical costs, with no goodwill or other intangible assets recorded. Operations prior to
the Reverse Recapitalization are those of Clene Nanomedicine.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
PIPE Offering</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Prior to the completion
of the Reverse Recapitalization on December 30, 2020, the Company entered into a subscription agreement on December 28, 2020, with
various investors. Pursuant to the subscription agreements, the Company issued 2,239,500 shares of the Company&#x2019;s Common Stock
(the &#x201c;PIPE Shares&#x201d;) at a price of $10.00 per share with net proceeds of $22.2 million. The purpose of the PIPE is to
fund general corporate expenses. In addition, investors in the PIPE offering also received warrants to purchase a number of shares
equal to one-half (1/2) of the number of PIPE Shares, totaling 1,119,750 shares of the Company&#x2019;s Common Stock, at an exercise
price of $0.01 per share for each of the PIPE Shares (the &#x201c;PIPE Warrants&#x201d;), subject to a 180-day holding period.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 3 &#x2013; Reverse Recapitalization with Tottenham and Clene Nanomedicine for additional details on Reverse Recapitalization.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has incurred
significant losses and negative cash flows from operations since its inception. The Company incurred net losses of $19.3 million
and $16.2 million for the years ended December 31, 2020 and 2019. As of December 31, 2020, the Company&#x2019;s cash totaled $59.3
million, its accumulated deficit was $153.6 million, and the Company had net cash used in operating activities of $18.9 million.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Reverse Recapitalization, Clene Nanomedicine&#x2019;s
operations were financed through the issuance of equity instruments and the issuance of convertible promissory notes. The Company
has not generated significant revenues to date and does not anticipate generating any significant revenues unless it successfully
completes development and obtains regulatory approval for its drugs or for its COVID-19 study. The Company expects to incur additional
losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional
capital to fully implement its business plan. Additionally, we may attempt to negotiate a collaboration agreement with a third
party for development and commercialization of a drug candidate, which may provide upfront and milestone payments to reduce our
spending going forward.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects to continue investing in product development, sales and marketing and customer support for its products. The long-term
continuation of the Company&#x2019;s business plan is dependent upon the generation of sufficient revenues from its products to
offset expenses and capital expenditures. In the event that the Company does not generate sufficient revenues and is unable to
obtain funding, the Company will be forced to delay, reduce, or eliminate some or all of its research and development programs,
product portfolio expansion, commercialization efforts or capital expenditures, which could adversely affect the Company&#x2019;s
business prospects, ability to meet long-term liquidity needs or the Company may be unable to continue operations.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects that the cash on hand as of December 31, 2020 will be sufficient to fund its operations for a period extending
beyond twelve months from the date the consolidated financial statements are issued.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impact
of the COVID-19 Coronavirus Pandemic</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
COVID-19 pandemic, which began in December&#xa0;2019 and has spread worldwide, has caused many governments to implement measures
to slow the spread of the outbreak. The outbreak and government measures taken in response have had a significant impact, both
direct and indirect, on businesses and commerce, as worker shortages have occurred, supply chains have been disrupted, and facilities
and production have been suspended. The future progression of the pandemic and its effects on the Company&#x2019;s business and
operations remain uncertain. The COVID-19 pandemic may affect the Company&#x2019;s ability to initiate and complete preclinical
studies, delay the initiation of future clinical trials, disrupt regulatory activities, or have other adverse effects on its business
and operations. In particular, the Company and its clinical research organizations (&#x201c;CROs&#x201d;) may face disruptions that
may affect the Company&#x2019;s ability to initiate and complete preclinical studies, manufacturing disruptions, and delays at
clinical trial sites. The pandemic has already caused significant disruptions in the financial markets, and may continue to cause
such disruptions, which could impact the Company&#x2019;s ability to raise additional funds to support its operations. Moreover,
the pandemic has significantly impacted economies worldwide and could result in adverse effects on the Company&#x2019;s business
and operations.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is monitoring the potential impact of the COVID-19 pandemic on the Company&#x2019;s business and financial statements.
While the COVID-19 pandemic has led to various research restrictions and paused certain of Clene Nanomedicine&#x2019;s clinical
trials, these impacts have been temporary and to date, the Company has not experienced material business disruptions or incurred
impairment losses in the carrying values of its assets as a result of the pandemic and the Company is not aware of any specific
related event or circumstance that would require the Company to revise the estimates reflected in these financial statements.
The extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#x2019;s business, results of operations,
cash flows and financial condition, including planned and future clinical trials and research and development costs, will depend
on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19,
the actions taken to contain or treat it, and the duration and intensity of the related effects.</font></p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881014090280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
Summary of Significant Accounting Policies</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use
of Estimates</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets, liabilities and disclosure of contingent assets and liabilities at the date of the
consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and
assumptions made in the accompanying consolidated financial statements include, but are not limited to the valuation of common
stock, stock options, contingent earn-out liability, and Preferred Stock warrants.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual
results may differ from those estimates or assumptions. Estimates are periodically reviewed in light of changes in circumstances,
facts, and experience. Changes in estimates are recorded in the period in which they become known.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
and Uncertainties</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
product candidates developed by the Company require approvals from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) or
foreign regulatory agencies prior to commercial sales. There can be no assurance that the Company&#x2019;s current and future product
candidates will receive the necessary approvals or be commercially successful. If the Company is denied approval or approval is
delayed, it will have a material adverse impact on the Company&#x2019;s business and its consolidated financial statements.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to risks common to companies in the development stage including, but not limited to, dependency on the need
for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by
physicians and patients, significant competition, and untested manufacturing capabilities.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to certain risks and uncertainties and believes that changes in any of the following areas could have a material
adverse effect on future financial position or results of operations: ability to obtain future financing; regulatory approval
and market acceptance of, and reimbursement for, product candidates; performance of third-party clinical research organizations
and manufacturers upon which the Company relies; protection of the Company&#x2019;s intellectual property; litigation or claims
against the Company based on intellectual property, patent, product, regulatory or other factors; and the Company&#x2019;s ability
to attract and retain employees necessary to support its growth.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentrations
of Credit Risk</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments which potentially subject the Company to significant concentrations of credit risk consist primarily of cash. The
Company&#x2019;s cash is mainly held in financial institutions. Amounts on deposit may at times exceed federally insured limits.
The Company has not experienced any losses on its deposits of cash and does not believe that it is subject to unusual credit risk
beyond the normal credit risk associated with commercial banking relationships.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash and Cash Equivalents</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company considers
all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. As of December
31, 2020 and 2019, the Company has no cash equivalents and no restricted cash balances.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Inventory</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Inventory is stated
at historic cost on a first -in first-out basis. The Company&#x2019;s inventory consisted of $71,000 in raw materials and $0.1 million
in finished goods as of December 31, 2020. The Company&#x2019;s inventory consisted of $28,000 in finished goods as of December
31, 2019.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Deferred
Offering Costs</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company capitalizes
certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings,
including the Reverse Recapitalization and the PIPE offering, as deferred costs until such financings are consummated. After consummation
of the equity financing, these costs are recorded in stockholders&#x2019; equity (deficit) as a reduction of proceeds generated
as a result of the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately
as a charge to operating expenses in the consolidated statement of operations.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2020, the Company incurred $5.9 million of offering costs, which excludes the fair value of common shares issued as a payment
of related offering costs, to additional paid in capital in connection with the Reverse Recapitalization.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During 2019, the Company
had offering costs that were directly related to its proposed initial public offering of $1.0 million. In September 2019, the Company
terminated its initial public offering registration process. Accordingly, the Company has written off deferred offering costs previously
capitalized to general and administrative expense within the accompanying consolidated statements of operations and comprehensive
loss as of December 31, 2019.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leases</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
inception of a contract, the Company determines if a contract meets the definition of a lease. A lease is a contract, or part
of a contract, that conveys the right to control the use of identified property, plant, or equipment (an identified asset) for
a period of time in exchange for consideration. The Company determines if the contract conveys the right to control the use of
an identified asset for a period of time. The Company assesses throughout the period of use whether the Company has both of the
following: (1)&#xa0;the right to obtain substantially all of the economic benefits from use of the identified asset, and (2)&#xa0;the
right to direct the use of the identified asset. This determination is reassessed if the terms of the contract are changed. Leases
are classified as operating or finance leases based on the terms of the lease agreement and certain characteristics of the identified
asset. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of the
future lease payments.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases laboratory and office space (real estate), and certain equipment under non-cancellable operating and finance leases.
The carrying value of the Company&#x2019;s right-of-use lease assets is substantially concentrated in its real estate leases, while
the volume of lease agreements is primarily concentrated in equipment leases. The Company&#x2019;s policy is to not record leases
with an original term of twelve months or less on the consolidated balance sheets. The Company recognizes lease expense for these
short-term leases on a straight-line basis over the lease term.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
lease agreements may require the Company to pay additional amounts for taxes, insurance, maintenance and other expenses, which
are generally referred to as non-lease components. Such variable non-lease components are treated as variable lease payments and
recognized in the period in which the obligation for these payments was incurred. Variable lease components and variable non-lease
components are not measured as part of the right-of-use asset and liability. Only when lease components and their associated non-lease
components are fixed are they accounted for as a single lease component and are recognized as part of a right-of-use asset and
liability. Total contract consideration is allocated to the combined fixed lease and non-lease component. This policy election
applies consistently to all asset classes under lease agreements.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
may contain clauses for renewal at the Company&#x2019;s option. Payments to be made in option periods are recognized as part of
the right-of-use lease assets and lease liabilities when it is reasonably certain that the option to extend the lease will be
exercised, or is not at the Company&#x2019;s option. The Company determines whether the reasonably certain threshold is met by
considering contract-, asset-, market-, and entity-based factors. In the consolidated statements of earnings, operating lease
expense, which is recognized on a straight-line basis over the lease term, and the amortization of finance lease ROU assets, which
are included in plant, property, and equipment and depreciated, are included in research and development or general and administrative
expenses consistent with the leased assets&#x2019; primary use. Accretion on the liabilities for finance leases is included in
interest expense.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Property
and Equipment</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Property and equipment
are stated at cost less accumulated depreciation. Property and equipment consist of lab and office equipment and leasehold improvements.
Depreciation is calculated using the straight-line method over the estimated economic useful lives of the assets, which are 3-5&#xa0;years
for lab equipment and 3-7&#xa0;years for furniture and fixtures. Leasehold improvements are amortized over the lesser of the estimated
lease term or the estimated useful life of the assets. Costs for capital assets not yet placed into service are capitalized as
construction in progress and depreciated or amortized in accordance with the above useful lives once placed into service. Upon
retirement or sale, the related cost and accumulated depreciation and amortization are removed from the accounts and any resulting
gain or loss is included in the consolidated statements of operations and comprehensive loss. Maintenance and repairs that do not
improve or extend the lives of the respective assets are expensed to operations as incurred.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impairment
of Long-Lived Assets</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived
assets are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of
the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include
significant underperformance of the business in relation to expectations, significant negative industry or economic trends and
significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate an asset group
for recoverability, the Company compares the forecasted undiscounted cash flows expected to result from the use and eventual disposition
of the asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows
expected to result from the use and eventual disposition of an asset group are less than its carrying amount. The impairment loss
would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted
cash flows using market participant assumptions. The Company did not record any impairment losses on long-lived assets during
the years ended December 31, 2020 or December 31, 2019.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Derivative
Instruments</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
convertible promissory notes issued in February through July&#xa0;2020 (&#x201c;2020 Convertible Notes&#x201d;) contained embedded
features that provide the lenders with multiple settlement alternatives. Certain of these settlement features provided the lenders
a right to a fixed number of the Company&#x2019;s shares upon conversion of the notes. Other settlement features provided the lenders
the right or the obligation to receive cash or a variable number of shares upon the completion of a capital raising transaction,
change of control or default of the Company (the &#x201c;Redemption Features&#x201d;).</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Redemption Features of the 2020 Convertible Notes met the requirements for separate accounting and were accounted for as a single
derivative instrument (the &#x201c;2020 Derivative Instrument&#x201d;). The 2020 Derivative Instrument was recorded at fair value
at inception and was subject to re-measurement to fair value at each balance sheet date and immediately prior to the extinguishment
of derivative liability, with any changes in fair value recognized in the consolidated statements of operations and comprehensive
loss. In August 2020, in connection with the Company&#x2019;s issuance and sale of Series D Preferred Stock, all of the outstanding
principal and accrued interest under the convertible promissory notes was automatically converted into shares of Series D Preferred
Stock and the derivative liability was extinguished (see Notes 11 and 12).</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Redeemable
Convertible Preferred Stock</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Reverse
Recapitalization with Tottenham, the Company recorded all shares of redeemable convertible Preferred Stock at their respective
fair values on the dates of issuance, net of issuance costs. The redeemable convertible Preferred Stock was recorded outside of
permanent equity because while it was not mandatorily redeemable, upon certain events considered not solely within the Company&#x2019;s
control, such as a merger, acquisition, or sale of all or substantially all of the Company&#x2019;s assets (each, a &#x201c;Deemed
Liquidation Event&#x201d;), the redeemable convertible Preferred Stock would become redeemable at the option of the holders of at
least a majority of the then-outstanding shares. The Company did not adjust the carrying values of the redeemable convertible Preferred
Stock to the liquidation preferences of such shares because it was uncertain whether or when a Deemed Liquidation Event would occur
that would obligate the Company to pay the liquidation preferences to holders of shares of redeemable convertible Preferred Stock.
Subsequent adjustments to the carrying values of the liquidation preferences would be made only when it becomes probable that such
a Deemed Liquidation Event will occur.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the Reverse Recapitalization, all shares of redeemable convertible Preferred Stock were converted into shares of the Company&#x2019;s
Common Stock. Accordingly, there was no redeemable convertible Preferred Stock outstanding as of December 31, 2020. As of December
31, 2019, the carrying value of the redeemable convertible Preferred Stock was $72.7 million (see Note 17).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Contingent Earn-out</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the Reverse Recapitalization and pursuant to the Merger Agreement, Clene Nanomedicine&#x2019;s common shareholders and Initial Shareholders
of Tottenham are entitled to receive additional shares of the Company&#x2019;s Common Stock upon the Company achieving certain milestones
described in Note 12. In accordance with ASC 815 &#x2013; <i>Derivatives and hedging</i>, the earn-out shares are not indexed to
the Company&#x2019;s own stock and therefore are accounted for as a liability at the reverse recapitalization date and subsequently
remeasured at each reporting date with changes in fair value recorded as a component of other income (expense), net in the consolidated
statements of operations and comprehensive loss.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The estimated fair
value of the contingent consideration was determined using a Monte Carlo simulation that simulated the future path of the Company&#x2019;s
stock price over the earn-out period. The assumptions utilized in the calculation are based on the achievement of certain stock
price milestones including projected stock price, volatility, and risk-free rate. For potential payments related to a product development
milestone, the fair value was determined based on the Company&#x2019;s expectations of achieving such a milestone and the simulated
estimated stock price on the expected date of achievement.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The contingent earn-out
is categorized as a Level 3 fair value measurement (see Fair Value of Financial Instruments accounting policy) because the Company
estimates projections during the earn-out period utilizing unobservable inputs, including various potential pay-out scenarios.
Contingent earn-out payments involve certain assumptions requiring significant judgment and actual results may differ from assumed
and estimated amounts.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Preferred Stock Warrant Liability</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Reverse
Recapitalization with Tottenham, the Company accounted for freestanding warrants to purchase shares of Preferred Stock as liabilities
on the balance sheet at their estimated fair value as the underlying redeemable convertible Preferred Stock was considered contingently
redeemable and may obligate the Company to transfer assets to the holders at a future date upon the occurrence of a deemed liquidation
event. At the end of each reporting period, changes in the estimated fair value of the warrants to purchase shares of Preferred
Stock were recorded in change in fair value of Preferred Stock warrant liability in the consolidated statements of operations and
comprehensive loss. Changes in the estimated fair value of the Preferred Stock warrant liability were ($14.6) million and ($0.4)
million for the years ended December 31, 2020 and 2019, respectively. In connection with the Reverse Recapitalization, all Clene
Nanomedicine Preferred Stock was converted to the Company&#x2019;s Common Stock and the Clene Nanomedicine Preferred Stock warrants
were converted to warrants to purchase the Company&#x2019;s Common Stock. The Company assessed the features of these warrants and
determined that they qualify for classification as permanent equity. Accordingly, the Company remeasured the warrants to fair value
upon the closing of the Reverse Recapitalization and reclassified the resulting warrant liability to additional paid-in capital
(See Note 16).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Common Stock Warrants</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company accounts for common stock warrants as either equity
instruments or liabilities in accordance with ASC 480, <i>Distinguishing Liabilities from Equity</i> (&#x201c;ASC 480&#x201d;), depending
on the specific terms of the warrant agreement (See Note 10).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue
Recognition</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects
the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition
for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&#xa0;identify
the contract(s) with a customer; (ii)&#xa0;identify the performance obligations in the contract; (iii)&#xa0;determine the transaction
price, including variable consideration, if any; (iv)&#xa0;allocate the transaction price to the performance obligations in the
contract; and (v)&#xa0;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies
the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in
exchange for the goods or services it transfers to the customer.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine
which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes
as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation
is satisfied or as it is satisfied. The Company typically satisfies its performance obligations via delivery of dietary supplements
to the customer. Payments are due upon receipt for commercial transactions or a prepayment is collected for online retail sales.
The Company&#x2019;s revenue for the year ended December 31, 2020 was comprised of sales of dietary supplements.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded deferred revenue of $0.1 million as of December 31, 2020 from the dietary supply agreement with the related party
discussed in Note 20. The deferred revenue is expected to be recognized in the first half of 2021.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Grant
Funding</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company may submit
applications to receive grant funding from governmental and non-governmental entities. Grant funding received that involves no
conditions or continuing performance obligations of the Company is recognized upon receipt. Grant funding with conditions or obligations
of the Company is recognized as the conditions or obligations are fulfilled. The Company has made an accounting policy election
to record such unconditional grants, such as the Australian Research and Development Credit, as other income in the consolidated
statements of operations and comprehensive loss. Income from grants is recognized in the period during which the related qualifying
expenses are incurred, provided that the conditions under which the grants were provided have been met. The Company recognizes
Australian Research and Development Credit in an amount equal to the qualifying expenses incurred in each period multiplied by
the applicable reimbursement percentage. During the years ended December 31, 2020 and 2019, the Company recognized $3.2 million
and $0.6 million, respectively, of Australian Research and Development Credit within other income (expense), net in the consolidated
statement of operations and comprehensive loss. As of December 31, 2020 and 2019, the Company recorded $2.1 million and $0, respectively,
of Australian Research and Development Credit receivable in prepaid expenses and other current assets on the consolidated balance
sheets.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
amount received in advance of fulfilling such conditions or obligations is recorded in accrued liabilities in the consolidated
balance sheets if the conditions or obligations are expected to be met within the next twelve months. As of December 31, 2020
and 2019, the Company recorded $0.3 million and $0.1 million, respectively, of Australian Research and Development Credit received
in advance in accrued liabilities.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant
funding recognized on conditional grants is included as a reduction in research and development expenses in the consolidated statements
of operations and comprehensive loss as the conditions are tied to the Company&#x2019;s research and development efforts, and as
the arrangement between the Company and the organizations are not part of the Company&#x2019;s on-going, major, or central operations.
During the years ended December 31, 2020 and 2019, the Company recorded $0.8 million and $0.1 million, respectively of grant funding
as a reduction of research and development expenses.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value of Financial Instruments</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the price that would be received for
an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value
must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried
at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy:</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level
1</b>&#xa0;&#x2014; Inputs based upon quoted market prices for identical assets or liabilities in active markets at the measurement
date.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level
2</b>&#xa0;&#x2014; Observable inputs other than quoted market prices included in Level 1, such as quoted prices for similar assets
and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active;
or other inputs that are observable or can be corroborated by observable market data.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level
3</b>&#xa0;&#x2014; Inputs that are management&#x2019;s best estimate of what market participants would use in pricing the asset
or liability at the measurement date. The inputs are unobservable in the market and significant to the instrument&#x2019;s valuation.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews the fair value hierarchy classification as of the actual date of the event or change in circumstances that caused
the transfer. There was a transfer to Level 1 from Level 3 as of December 31, 2020 for the Notes payable.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 16 for information on the Company&#x2019;s assets and liabilities measured at fair value as of December 31, 2020 and 2019.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Foreign
Currency Translation and Transactions</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
functional currency of the Company is the United&#xa0;States dollar. The Company&#x2019;s Australian subsidiary determined its
functional currency to be the Australian dollar. The Company uses the United&#xa0;States dollar as its reporting currency for
the consolidated financial statements. The results of its non-U.S. dollar based functional currency operations are translated
to U.S. dollars at the average exchange rates during the period. The Company&#x2019;s assets and liabilities are translated using
the current exchange rate as of the consolidated balance sheet date and shareholders&#x2019; equity is translated using historical
rates.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
resulting from the translation of the consolidated financial statements of the Company&#x2019;s foreign functional currency subsidiaries
into U.S. dollars are excluded from the determination of net loss and are accumulated in a separate component of shareholders&#x2019;
equity. These foreign currency translation gains and losses are currently the only component of other comprehensive income.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also incurs foreign exchange transaction gains and losses for purchases denominated in foreign currencies. Foreign exchange
transaction gains and losses are included in other income (expense) in the Company&#x2019;s consolidated results of operations
as incurred.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comprehensive
Loss</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss includes net loss as well as other changes in stockholders&#x2019; equity (deficit) that result from transactions and economic
events other than those with stockholders. The Company&#x2019;s only element of other comprehensive income (loss) in any period
presented was translation of Australian dollar denominated balances of the Company&#x2019;s Australian subsidiary to U.S. dollars
for consolidation.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
Loss Per Share Attributable to Common Shareholders</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company calculated basic and diluted net loss per share attributable to common shareholders in conformity with the two-class method
required for companies with participating securities. The Company considered all series of redeemable convertible Preferred Stock
to have been participating securities as the holders were entitled to receive non-cumulative dividends on a pari passu basis in
the event that a dividend had been paid on common stock. See Note 19, Net Loss Per Share Attributable to Common Shareholders,
for further details on the Company&#x2019;s historical participating securities, including warrants to purchase redeemable convertible
Preferred Stock and common stock.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the two-class method, basic net loss per share attributable to common shareholders was calculated by dividing the net loss by
the weighted-average number of shares of common stock outstanding during the period, less shares subject to repurchase. The net
loss attributable to common shareholders was not allocated to the redeemable convertible Preferred Stock as the holders of redeemable
convertible Preferred Stock did not have a contractual obligation to share in losses. Diluted net loss per share attributable
to common shareholders was computed by giving effect to all potentially dilutive common stock equivalents outstanding for the
period. For purposes of this calculation, redeemable convertible Preferred Stock, stock options to purchase common stock, early
exercised stock options, and warrants to purchase redeemable convertible Preferred Stock and common stock were considered common
shares equivalents but had been excluded from the calculation of diluted net loss per share attributable to common shareholders
as their effect was anti-dilutive. In periods in which the Company reports a net loss attributable to common shareholders, diluted
net loss per share attributable to common shareholders is the same as basic net loss per share attributable to common shareholders,
since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net
loss attributable to common shareholders during the years ended December 31, 2020 and 2019.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Segment
Information</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has determined that its chief executive officer is the chief operating decision maker (&#x201c;CODM&#x201d;). Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the CODM in making decisions regarding resource allocation and assessing performance. The Company views its operations and
manages its business in two operating segments, the first being that of the development and commercialization of proprietary nanotechnology
drug suspensions, and the second being the development and commercialization of dietary supplements (See Note 21).</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
Taxes</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets
and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements
or in the Company&#x2019;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between
the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences
are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company
assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes,
based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets
will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred
tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process
to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood
that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not
to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial
statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being
realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized
tax benefits, that are considered appropriate as well as the related net interest and penalties.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based
Compensation</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company accounts
for stock-based compensation arrangements with employees using a fair value-based method for costs related to all share-based payments
including stock options and restricted common stock. Stock-based compensation expense is recorded in research and development and
general and administrative expenses based on the classification of the work performed by the grantees.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the Reverse Recapitalization, there was not a public market for the shares of Clene Nanomedicine, Inc. common stock. The Company&#x2019;s
determination of the fair value of stock options on the date of grant utilized the Black-Scholes option-pricing model and was
impacted by its common stock price, as determined by the Board of Directors with input from the Company&#x2019;s management, as
well as changes in assumptions regarding a number of subjective variables. These variables included, but were not limited to,
the expected term that options remained outstanding, the expected common stock price volatility over the term of the option awards,
risk-free interest rates, and expected dividends.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value was recognized over the period during which an
optionee was required to provide services in exchange for the option award and service-based RSUs, known as the requisite service
period (usually the vesting period), on a straight-line basis. For the RSUs with market conditions, the fair value is recognized
over the period based on the expected milestone achievement dates as the derived service period (usually the vesting period), on
a straight-line basis. For the RSUs with performance conditions, the grant date fair value of these awards is the market price
on the applicable grant date, and compensation expense will be recognized when the conditions become probable of being satisfied.
The Company will recognize a cumulative true-up adjustment once the conditions become probable of being satisfied as the related
service period had been completed in a prior period.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stock-based compensation
expense recognized at fair value included the impact of estimated forfeitures. The Company elected to account for forfeitures as
they occurred, rather than estimating expected forfeitures.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After the closing
of the Reverse Recapitalization, the Company determined the fair value of each share of Common Stock underlying stock-based awards
based on the closing price of the Company&#x2019;s Common Stock as reported by Nasdaq on the date of grant. The fair value of the
RSUs with market conditions are determined using a Monte Carlo valuation model. Forfeitures are estimated at the time of grant
and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are charged to expense as incurred. The Company accounts for nonrefundable advance payments for goods and
services that will be used in future research and development activities as expenses when the goods have been received or when
the service has been performed. Research and development expenses consist of costs incurred by the Company for the discovery and
development of the Company&#x2019;s product candidates. Research and development costs include, but are not limited to, payroll
and personnel expenses including stock-based compensation, clinical trial supplies, fees for clinical trial services, consulting
costs, and allocated overhead, including rent, equipment, and utilities.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Accrual</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#x2019;s
clinical trial accrual process accounts for expenses resulting from obligations under contracts with CROs, consultants, and under
clinical site agreements in connection with conducting clinical trials. Clinical trial costs are charged to research and development
expense as incurred. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and
may result in payment flows that do not match the periods over which materials or services are provided to the Company under such
contracts. The Company reflects the appropriate clinical trial expense in the consolidated financial statements by matching the
appropriate expenses with the period in which services and efforts are expended. In the event advance payments are made to a CRO,
the payments will be recorded as a prepaid asset which will be amortized over the period of time the contracted services are performed.
In addition to pass-through costs, the Company generally incurs costs in clinical trials in four distinct groups as follows:</p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRO
Start-up&#xa0;&#x2014; These costs include the initial set-up of the clinical trial and usually occurs within a few months after
the contract has been executed and includes costs which are expensed ratably over the start-up period when such period is identifiable
and expensed as incurred when no such period exists. Start-up phase activities include study initiation, site recruitment, regulatory
applications, investigator meetings, screening, preparation, pre-study visits, and training.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRO
Site and Study Management&#xa0;&#x2014; These costs include medical and safety monitoring, and patient administration and data
management. These costs are usually calculated on a per patient basis and expensed ratably over the treatment period beginning
on the date that the patient enrolls.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRO
Close Down and Reporting&#xa0;&#x2014; These costs include analyzing the data obtained and reporting results, which occurs after
patients have ceased treatment and the database of information collected is locked. These costs are expensed as incurred over
the course of any close down and reporting period.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
Party Contracts&#xa0;&#x2014; These costs include fees charged by third parties for various support services which are not provided
by CROs and include such items as lab fees, data quality review costs, and fees incurred for investigational product monitoring
and inventory control. These items are expensed ratably over any identifiable service period with the engaged third-party vendors.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CRO contracts generally include pass-through fees including, but not limited to, regulatory expenses, investigator fees, travel
costs and other miscellaneous costs, including shipping and printing fees. The Company determines accrual estimates through reports
from and discussion with applicable personnel and outside services providers as to the progress or state of completion of trials,
or the services completed. The Company makes estimates of accrued expenses as of each balance sheet date in the consolidated financial
statements based on the facts and circumstances known to the Company at that time.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently
Adopted Accounting Pronouncements</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitating of the Effects of Reference Rate Reform
on Financial Reporting, which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships,
and other transactions in which the reference LIBOR or another reference rate is expected to be discontinued as a result of the
Reference Rate Reform. This ASU is intended to ease the potential burden in accounting for (or recognizing the effects of) reference
rate reform on financial reporting. The new guidance was effective immediately, and through December 31, 2022. As a result of
the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section
107(b) of the JOBS Act, ASU 2016-02 is effective for the Company for fiscal years beginning after December 15, 2020, and all interim
periods thereafter. Early adoption is permitted. The Company early adopted this guidance on March 1, 2020. The adoption of this
guidance did not have a material impact on its consolidated financial statements.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recent
Accounting Pronouncements Not Yet Adopted</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2016, the FASB
issued ASU No. 2016-13, <i>Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>.
The amendments in this ASU, among other things, require the measurement of all expected credit losses for financial assets held
at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions
and other organizations will now use forward-looking information to better inform their credit loss estimates. The guidance is
effective for fiscal years beginning after December 15, 2022. The Company is currently evaluating the expected impact of the new
guidance.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2018, the FASB issued ASU No. 2018-15, <i>Intangibles &#x2013; Goodwill and Other &#x2013; Internal-Use Software (Subtopic
350-40): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract</i>.
The new guidance provides for the deferral of implementation costs for cloud computing arrangements and expensing those costs
over the term of the cloud services arrangement. The new guidance is effective for fiscal years beginning after December 15, 2020.
The Company is currently evaluating the expected impact of the new guidance.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2019, the
FASB issued ASU No. 2019-12, <i>Income Taxes</i> (Topic 740), which amends the existing guidance relating to the accounting for
income taxes. This ASU is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles
of accounting for income taxes and to improve the consistent application of GAAP for other areas of accounting for income taxes
by clarifying and amending existing guidance. The new guidance is effective for fiscal years beginning after December 15, 2021.
The Company does not expect that the adoption of this new guidance will have a material impact on its consolidated statements.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881014083016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reverse Recapitalization with Tottenham and Clene Nanomedicine<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract', window );"><strong>Reverse Recapitalization With Tottenham And Clene Nanomedicine [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock', window );">Reverse Recapitalization with Tottenham and Clene Nanomedicine</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
Reverse Recapitalization with Tottenham and Clene Nanomedicine</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 30, 2020,
the Company consummated the Reverse Recapitalization, pursuant to which Tottenham merged with and into PubCo in connection with
the Reincorporation Merger and PubCo merged with and into Clene Nanomedicine, resulting in Clene Nanomedicine becoming a wholly
owned subsidiary of PubCo. On the Closing Date, PubCo changed its name from Chelsea Worldwide, Inc. to Clene Inc. (see Note 1).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the consummation
of the Reverse Recapitalization, each Tottenham ordinary share issued and outstanding immediately prior to the effective time of
the Reincorporation Merger was automatically cancelled and ceased to exist and (i) for each Tottenham ordinary share, the Company
issued one validly issued share of the Company&#x2019;s Common Stock; (ii) each warrant to purchase one half of one Tottenham Ordinary
Share was converted into a warrant to purchase one-half of one share of the Company&#x2019;s Common Stock; and (iii) each Tottenham
right exchangeable into one-tenth (1/10) of one Tottenham ordinary share was converted into a right exchangeable for one-tenth
(1/10) of one share of the Company&#x2019;s Common Stock. As a result of the Reverse Recapitalization, all outstanding shares of
Tottenham ordinary shares of 2,303,495 held by the Initial Shareholders and Tottenham public shareholders were converted into the
same number of the Company&#x2019;s Common Stock. In addition, pursuant to the Merger Agreement, the Initial Shareholders are entitled
to receive up to 750,000 of the company common shares as earn-out shares upon the achievement of certain milestones described in
below. The contingent earn-out with the Initial Shareholders is accounted for as a contingent liability and is included in the
line item of &#x201c;Contingent Earn-out&#x201d; on the consolidated balance sheets.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with
the Merger Agreement, on the closing of the Reverse Recapitalization, each share of Clene Nanomedicine preferred stock and common
stock then issued and outstanding was automatically cancelled, extinguished and exchanged for 0.1389 newly issued shares of Clene
Inc. Common Stock. At the closing of the Reverse Recapitalization, Clene Inc. acquired 100% of the issued and outstanding Clene
Nanomedicine common stock, in exchange for 54,339,012 shares of Clene Inc. Common Stock issued to the Clene Nanomedicine common
shareholders, among which 2,716,958 shares of the Clene Inc. Common Stock are to be issued and held in escrow to satisfy any indemnification
obligations incurred under the Merger Agreement. In addition, all outstanding warrants (other than warrants that expired, were
exercised or were deemed automatically net exercised immediately prior to the Acquisition Merger) exercisable for common stock
in Clene Nanomedicine were assumed by the Company with no changes to the terms and conditions of the awards. The awards have been
retroactively restated to reflect the Exchange Ratio established in the Reverse Recapitalization.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the Reverse Recapitalization, a total of 53,286,115 stock options of Clene Nanomedicine common stock was cancelled and the holders
thereof in exchange received 0.1320 newly issued stock options of Clene Inc. Common Stock for a total of 7,032,590, which is 95%
of the Exchange Ratio. Pursuant to the Merger Agreement, the Company issued RSUs to the option holders which complements the 5%
closing payment shares held in escrow for Clene Nanomedicine common shareholders. In addition, the Company issued 1,136,961 RSUs
to option holders to complement the earn-out payments that would contingently be issued to certain current Clene Nanomedicine&#x2019;s
shareholders upon the achievement of milestones described in below.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Also, in connection
with the Reverse Recapitalization, Clene Nanomedicine entered into a letter agreement with LifeSci Capital LLC (&#x201c;LifeSci&#x201d;)
on July 2, 2020, according to which LifeSci was engaged to act as Clene Nanomedicine&#x2019;s financial advisor with respect to
identifying and soliciting special purpose acquisition companies for the purpose of entering into a merger or similar transaction
with Clene Nanomedicine and its shareholders. Under this agreement, Clene Nanomedicine agreed that if it consummated a merger with
Tottenham, LifeSci would receive consideration of (i) 3% of the amount by which the total transaction consideration exceeded $350
million, plus (ii) 7% of cash and cash-equivalents received by Clene Nanomedicine from the Tottenham&#x2019;s trust account. Clene
Nanomedicine could elect to pay LifeSci either in cash, equity interests of the surviving company, or a combination of the two.
Upon the consummation of the Reverse Recapitalization, 644,164 shares of the Company&#x2019;s Common Stock were issued to LifeSci
as consideration for its services as pursuant to the letter agreement (see Note 18).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Immediately after giving
effect to the Reverse Recapitalization, there were 59,526,171 shares of Common Stock issued and outstanding, and warrants to purchase
5,566,363 shares of Common Stock issued and outstanding (see Note 10).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During Tottenham&#x2019;s
IPO, Tottenham incurred deferred underwriters&#x2019; fees which were payable to Chardan from the amounts held in the trust account
upon completion of the Reverse Recapitalization. Upon the closing of the Reverse Recapitalization, the Company paid $2.1 million
to Chardan as the settlement of the deferred underwriting and advisory fees which amount was included in the total offering costs
of the Reverse Recapitalization transaction.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2020, the Company recorded $5.9 million of offering costs, which excludes the fair value of common shares issued as a payment
of related offering costs and Chardan underwriting fees discussed above. Those offering costs were related to third-party legal,
accounting services and other professional services to consummate the Reverse Recapitalization. These offering costs are recorded
in additional paid-in capital upon the close of the Reverse Recapitalization in the Company&#x2019;s consolidated balance sheets.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 28, 2020 and
prior to the close of the Reverse Recapitalization on December 30, 2020, various PIPE investors purchased 2,239,500 shares of the
Company&#x2019;s Common Stock at a price of $10.00 per share and 1,119,750 warrants with an exercise price of $0.01 per share, to
purchase one share of the Company&#x2019;s Common Stock, for net proceeds of $22.2 million (see Notes 10 and 18).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Earn-out
shares</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain of Clene Nanomedicine&#x2019;s
current stockholders are entitled to receive earn-out shares as follows (the &#x201c;Clene Nanomedicine Contingent Earn-Out&#x201d;):
(i) 3,333,333 shares of the Company&#x2019;s Common Stock if (A) the volume-weighted average price (&#x201c;VWAP&#x201d;) of the shares
of the Company&#x2019;s Common Stock equals or exceeds $15.00 (or any foreign currency equivalent) (the &#x201c;Milestone 1 Price&#x201d;)
in any twenty trading days within a thirty trading day period within the three years following the closing of the Reverse Recapitalization
on any securities exchange or securities market on which the shares of the Company&#x2019;s Common Stock are then traded or (B)
the change of control price equals or exceeds the Milestone 1 Price if a change of control transaction occurs within the three
years following the closing of the Reverse Recapitalization (the requirements set forth in clause (A) and (B), &#x201c;Milestone
1&#x201d;); (ii) 2,500,000 shares of the Company&#x2019;s Common Stock if (A) the VWAP of the shares of the Company&#x2019;s Common
Stock equals or exceeds $20.00 (or any foreign currency equivalent) (the &#x201c;Milestone 2 Price&#x201d;) in any twenty trading
days within a thirty trading day period within the five years following the closing of the Reverse Recapitalization on any securities
exchange or securities market on which the shares of the Company&#x2019;s Common Stock are then traded or (B) the change of control
price equals or exceeds the Milestone 2 Price if a change of control transaction occurs within the five years following the closing
of the Reverse Recapitalization (the requirements set forth in clause (A) or (B), &#x201c;Milestone 1&#x201d;); and (iii) 2,500,000
shares of the Company&#x2019;s Common Stock if Clene Nanomedicine completes a randomized placebo-controlled study for treatment
of COVID-19 which results in a statistically significant finding of clinical efficacy within twelve months after the closing of
the Reverse Recapitalization (&#x201c;Milestone 3&#x201d;). If Milestone 1 is not achieved but Milestone 2 is achieved, the Clene
Nanomedicine stockholders will receive a catch-up issuance equal to the shares issued upon satisfaction of Milestone 1. Upon the
consummation of the Reverse Recapitalization, the earn-out shares that certain Clene Nanomedicine stockholders are entitled to
receive increased by 12,852 as a result of the exercise of stock options during November 2020. Therefore, the total Clene Nanomedicine
earn-out shares has increased to 8,346,185 shares of the Company&#x2019;s Common Stock.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Initial Shareholders of Tottenham may be entitled to receive earn-out shares as follows (the &#x201c;Initial Shareholders Contingent
Earn-Out&#x201d;): (i) 375,000 shares of the Company&#x2019;s Common Stock upon satisfaction of the requirements of Milestone 1;
and (ii) another 375,000 shares of the Company&#x2019;s Common Stock upon satisfaction of the requirements of Milestone 2. If Milestone
1 is not achieved but Milestone 2 is achieved, the Initial Shareholders shall receive a catch-up issuance equal to the shares
granted upon satisfaction of the requirements of Milestone 1.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clene Nanomedicine
and Initial Shareholders earn-out payments (collectively, referred to as &#x201c;Earn-out Shares&#x201d;) have been classified as
liabilities in the consolidated balance sheets as of December 31, 2020 and were initially measured at fair value on the date of
the Reverse Recapitalization and will be subsequently remeasured to fair value at each reporting date (see Note 16).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the
Reverse Recapitalization and the PIPE offering, Clene Nanomedicine&#x2019;s stockholders own approximately 91% of the Common Stock
of the Company, Tottenham public stockholders own approximately 4% of the Common Stock of the Company, and investors from the PIPE
own approximately 4% of the Common Stock of the Company, based on the number of shares of Clene Inc. Common Stock outstanding on
December 30, 2020 (in each case, not giving effect to any shares issuable upon exercise of Clene Inc. warrants, options, or earn-out
shares).</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881027695848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid expenses and other current assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Prepaid Expenses And Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">Prepaid expenses and other current assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
Prepaid expenses and other current assets</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets consisted of the following as of December 31, 2020 and 2019:</font></p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Australia research and development credit receivable</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,148</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">CRO prepayments</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,211</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">413</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accounts receivable</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">21</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Metals to be used in research and development</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">31</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">191</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">112</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">57</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,523</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">661</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for Prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881014031608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
Property and Equipment, Net</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment, net consisted of the following as of December 31, 2020 and 2019:</font></p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif;  width: 100%">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(in
    thousands)</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.25in; padding-left: 0.25in; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Lab
    equipment</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">3,077</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2,707</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Furniture
    and fixtures</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">147</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">162</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Leasehold
    improvements</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">3,889</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">3,430</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Construction
    in progress</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">490</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">410</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.25in; padding-left: 0.25in; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">7,603</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">6,709</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Less
    accumulated depreciation</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(3,378</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
    <td>&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(2,390</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Total
    property and equipment, net</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">4,225</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">4,319</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense related to property and equipment, net for the years ended December 31, 2020 and 2019 was approximately $1.0 million ($0.9
million in Research and Development expense and $0.1 million in General and Administrative expense) and $0.9 million ($0.8 million
in Research and Development expense and $0.1 million in General and Administrative expense), respectively.</font></p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881018482952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Disclosure Text Block Supplement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
Accrued Liabilities</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
liabilities consisted of the following as of December 31, 2020 and 2019:</font></p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued professional fees</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">189</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,826</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued compensation and benefits</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,225</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">817</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued CRO fees</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">788</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">95</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Deferred grant funds</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">301</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">80</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued expense reimbursements</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">33</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">36</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued transaction costs</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,354</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">70</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">24</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,960</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,878</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881018483512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
Leases</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted ASC 842 on January 1, 2019 using the modified retrospective approach. Upon adoption of the new leasing standards,
the Company (i) recognized an operating lease right of use asset of approximately $1.2 million and a corresponding operating lease
liability of approximately $1.7 million, which are included in the Company&#x2019;s consolidated balance sheet, and with a $14
thousand cumulative adjustment to accumulated deficit and (ii) elected the package of transition practical expedients, which allowed
the Company to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the
lease classification for any expired or existing leases and initial direct costs for existing leases.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also made an accounting policy election not to recognize leases with an initial term of 12 months or less within its consolidated
balance sheets and to recognize those lease payments on a straight-line basis in its consolidated statements of operations and
comprehensive loss over the lease term.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the lease commencement date, the discount rate implicit in the lease is used to discount the lease liability if readily determinable.
If not readily determinable or leases do not contain an implicit rate, the Company&#x2019;s incremental borrowing rate is used
as the discount rate.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April&#xa0;2020, the Company terminated an existing operating lease for office space. At the time of termination, the Company
removed the remaining right-of-use asset of $0.3 million, lease liability of $0.3 million, and recognized a gain of $51 thousand.
Further, in April&#xa0;2020, the Company commenced a new operating lease. At the time of commencement, the Company recorded the
right-of-use asset value of $0.4 million, leasehold improvements of $0.4 million, and a lease liability of $0.8 million. The net
effect of the change in leases being an increase in right-of-use assets of $56 thousand, an increase in leasehold improvements
of $0.5 million, an increase in lease liability of $0.4 million, and a gain on termination of $51 thousand.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has noncancelable operating lease arrangements primarily for office and lab space. The Company also has noncancelable
finance leases for certain lab equipment. The maturity analysis of finance and operating lease liabilities as of December 31,
2020 are as follows:</font></p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif;  width: 100%">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(in
    thousands)</font></td><td style="text-align: center; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif">Finance <font style="font-family: Times New Roman, Times, Serif">Leases</font></td><td style="text-align: center; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif">Operating <font style="font-family: Times New Roman, Times, Serif">Leases</font></td><td style="text-align: center; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2021</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">165</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">376</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2022</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">135</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">421</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2023</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">82</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">433</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2024</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">20</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">442</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2025</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">454</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Thereafter</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">530</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.375in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Total
    undiscounted cash flows</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">403</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2,656</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Less
    amount representing interest/discounting</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(8</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
    <td>&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(677</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.375in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Present
    value of future lease payments</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">395</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">1,979</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Less
    lease obligations, current portion</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(190</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
    <td>&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(194</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Lease
    obligations&#xa0;&#x2013; long term portion</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">205</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">1,785</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects that, in the normal course of business, the existing leases will be renewed or replaced by similar leases.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Finance
Leases</i></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
recorded under finance lease obligations and included with property and equipment as of December 31, 2020 and 2019 are summarized
as follows:</font></p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif;  width: 100%">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(in
    thousands)</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 76%; text-align: left; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><font style="font-family: Times New Roman, Times, Serif">Lab
    equipment</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">920</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">920</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><font style="font-family: Times New Roman, Times, Serif">Furniture
    and fixtures</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">46</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">46</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><font style="font-family: Times New Roman, Times, Serif">Work
    in process</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">228</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">228</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><font style="font-family: Times New Roman, Times, Serif">Total</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">1,194</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">1,194</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><font style="font-family: Times New Roman, Times, Serif">Less
    accumulated depreciation</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(593</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(418</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><font style="font-family: Times New Roman, Times, Serif">Net</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">601</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">776</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2020, the Company&#x2019;s finance lease obligations had a weighted-average interest rate of 8.1% and had a weighted-average
remaining term of 2.7 years. As of December 31, 2019, the Company&#x2019;s finance lease obligations had a weighted-average interest
rate of 8.1% and had a weighted-average remaining term of 3.7 years.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating
Leases</i></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#x2019;s balance of right-of-use assets on the face of the balance sheet pertain to operating leases. As of December 31,
2020, the Company&#x2019;s operating lease obligations had a weighted-average discount rate of 9.6% and had a weighted-average
remaining term of 6.3 years. As of December 31, 2019, the Company&#x2019;s operating lease obligations had a weighted-average discount
rate of 9.6% and a weighted-average remaining term of 6.0 years.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Components
of Lease Cost</i></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of finance and operating lease costs for the years ended December 31, 2020 and 2019 were as follows:</font></p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif;  width: 100%">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(in
    thousands)</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Finance
    lease costs:</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Amortization</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">175</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">182</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Interest
    on lease liabilities</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">37</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">29</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Operating
    lease costs</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">293</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">325</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Short-term
    lease costs</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">249</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">283</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Variable
    lease costs</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">92</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">103</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Total
    lease costs</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">846</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">922</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Supplemental
Cash Flow Information</i></font></p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif;  width: 100%">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(in
    thousands)</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Operating
    cash flows from operating leases</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(635</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(711</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Operating
    cash flows from finance leases</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(37</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(29</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Finance
    cash flows from finance leases</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(194</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(176</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
</table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881014092520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes Payable</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
Notes Payable</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February&#xa0;2019, the Company entered into a loan agreement (the &#x201c;2019 MD Loan&#x201d;) with the Department of Housing
and Community Development, a principal department of the State of Maryland (&#x201c;Maryland&#x201d;). Pursuant to the 2019 MD Loan,
Maryland agreed to provide a $0.5 million term loan. Amounts outstanding under the 2019 MD Loan bear simple interest at an annual
rate of 8.00%. Under the 2019 MD Loan, the Company has agreed to affirmative and negative covenants to which it will remain subject
until maturity. These covenants include providing information about the Company and its operations; limitations on the Company&#x2019;s
ability to retire, repurchase, or redeem the Company&#x2019;s common or preferred stock, options, and warrants other than per the
terms of the securities; and limitations on the Company&#x2019;s ability to pay dividends of cash or property. There are no financial
covenants associated with the Loan Agreement. Events of default under the Loan Agreement include failure to make payments when
due, insolvency events, failure to comply with covenants, and material adverse effects with respect to the Company. The Company
is not in violation of any affirmative or negative covenants. Repayment of the full balance outstanding is due on February 22,
2034. The 2019 MD Loan establishes &#x201c;Phantom Shares,&#x201d; based on 119,906 shares of the Company&#x2019;s common stock (based
on 863,110 Series C Preferred Shares prior to the Reverse Recapitalization), determined at issuance. The Loan Agreement states
the repayment amount is to be the greater of the balance of principal and accrued interest or the Phantom Share value. The Company
determined that the note should be accounted for at fair value. The Company records the fair value of the debt at the end of each
reporting period. In order to value the note, the Company considers the amount of the simple interest expense that would be due
and considers the value of Phantom Shares. Expense of $0.5 million and $34 thousand was recognized during the years ended December
31, 2020 and 2019, respectively. The fair value of $1.1 million and $0.5 million of principal and accrued interest is included
in long-term notes payable as of December 31, 2020 and December 31, 2019, respectively.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April&#xa0;2019,
the Company entered into a loan agreement (the &#x201c;2019 Cecil Loan&#x201d;) with Cecil County, Maryland (&#x201c;Cecil&#x201d;).
Pursuant to the 2019 Cecil Loan, Cecil agreed to provide a $0.1 million term loan. Amounts outstanding under the 2019 Cecil Loan
bear simple interest at an annual rate of 8.00%. Under the 2019 Cecil Loan, the Company has agreed to affirmative and negative
covenants to which it will remain subject until maturity. These covenants include providing information about the Company and its
operations; limitations on the Company&#x2019;s ability to retire, repurchase, or redeem the Company&#x2019;s common or preferred
stock, options, and warrants other than per the terms of the securities; and limitations on the Company&#x2019;s ability to pay
dividends of cash or property. There are no financial covenants associated with the Loan Agreement. Events of default under the
Loan Agreement include failure to make payments when due, insolvency events, failure to comply with covenants, and material adverse
effects with respect to the Company. The Company is not in violation of any affirmative or negative covenants. Repayment of the
full balance outstanding is due on April 30, 2034. The 2019 Cecil Loan establishes &#x201c;Phantom Shares,&#x201d; based on 23,981
shares of the Company&#x2019;s common stock (based on 172,622 Series C Preferred Shares prior to the Reverse Recapitalization),
determined at issuance. The 2019 Cecil Loan states the repayment amount is to be the greater of the balance of principal and accrued
interest or the Phantom Share value. The Company determined that the note should be accounted for at fair value. The Company records
the fair value of the debt at the end of each reporting period. In order to value the note, the Company considers the amount of
the simple interest expense that would be due and considers the value of Phantom Shares. Expense of $0.1 million and $6 thousand
was recognized during the years ended December 31, 2020 and 2019, respectively. The fair value of $0.2 million and $0.1 million
of principal and accrued interest is included in long-term notes payable as of December 31, 2020 and December 31, 2019, respectively.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May&#xa0;2020, the
Company entered into a note payable in the amount of $0.6 million (the &#x201c;PPP Note&#x201d;) under the Paycheck Protection Program
of the CARES Act (the &#x201c;PPP&#x201d;). As amended, the PPP permits forgiveness of amounts loaned for payments of payroll and
other qualifying expenses within 24 weeks of receipt of loaned funds, given that at least 60% of the total loan is used for payroll.
Amounts not forgiven by the PPP have a repayment period of five years. The Company expects the full $0.6 million balance of the
PPP Note to be forgiven. The Company will record any forgiveness after approval by the issuer. Until then, the PPP balance is included
in long-term notes payable as of December 31, 2020. On January 11, 2021, the U.S. Small Business Administration notified the Company
that the Company&#x2019;s PPP loan of $0.6 million had been forgiven (see Note 22).</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881015804968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock Warrant Liability<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Disclosure Text Block Supplement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Preferred Stock Warrant Liability</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
Preferred Stock Warrant Liability</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Reverse
Recapitalization, the Company issued Series A Preferred Stock Warrants in 2013 in connection with certain note purchase agreements.
The warrants expire 10&#xa0;years from issuance. These warrants are exercisable at a fixed exercise price of $1.97, which is equal
to the price per share of the Series A Preferred Stock by the Company. As of December 31, 2019, these warrants were exercisable
into 1,608,672 shares of the Series A Preferred Stock.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Reverse
Recapitalization, on April 8, 2013, the Company issued 10-year warrants to purchase units of the Company&#x2019;s most senior equity
equal to 0.50% of the Company&#x2019;s fully diluted equity at the time of exercise in connection with certain note purchase agreements.
As of December 31, 2019, these warrants were exercisable into 271,439 shares of the Company&#x2019;s most senior equity, Series
C Preferred Stock, at a fixed exercise price of $1.97 per share. On August 11, 2020, in connection with the Company&#x2019;s issuance
of Series D Preferred Stock, these warrants became exercisable into 320,441 shares of the Company&#x2019;s most senior equity, Series
D Preferred Stock, at a fixed exercise price of $1.97 per share.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Reverse
Recapitalization, the Company classified its Preferred Stock warrants as a liability on its consolidated balance sheet because
the warrants are freestanding financial instruments that may have required to the Company to transfer assets upon exercise. The
liability associated with each of these warrants was initially recorded at fair value upon the issuance date of each warrant and
is subsequently remeasured to fair value as a component of other income (expense), net in the consolidated statement of operations
and comprehensive loss. Upon the closing of the Reverse Recapitalization (see Note 1), and as pursuant to the Merger Agreement,
all of the outstanding Clene Nanomedicine Preferred Stock was converted to the Company&#x2019;s Common Stock and the Clene Nanomedicine
Preferred Stock warrants to purchase Clene Nanomedicine Preferred Stock were converted to warrants to purchase the Company&#x2019;s
Common Stock (see Note 10). Upon conversion, the Company assessed the features of the warrants and determined that they qualify
for classification as permanent equity upon the closing of the Reverse Recapitalization. Accordingly, the Company remeasured the
warrants to fair value one final time upon the close of the Reverse Recapitalization, and recognized a loss of $14.6 million for
the year ended December 31, 2020, within other income, (expense), net on the consolidated statements of operations and comprehensive
loss. Upon the closing of the Reverse Recapitalization, the warrant liability was reclassified to additional paid-in capital (see
Notes 1 and 17).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2020, the Company does not have any Preferred Stock warrants outstanding.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2019,&#xa0;the fair value of the outstanding warrants was $3.2 million with the changes in fair value recorded
as a component of other income (expense), net on the consolidated statements of operations and comprehensive&#xa0;loss. As of
December 31, 2019, the Company had Preferred Stock warrants outstanding and exercisable as follows:</font></p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif;  width: 100%">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: center; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Expiration</font></td>
    <td style="text-align: center; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td><td colspan="2" style="vertical-align: bottom; text-align: center; font-weight: bold; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Exercise&#xa0;Price</font></td><td style="text-align: center; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Warrant</font>s</td>
    <td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Date</font></td>
    <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td><td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Per&#xa0;Share<sup>(1)</sup></font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Outstanding<sup>(1)</sup></font></td>
    <td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 66%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    C preferred stock warrants<sup>(2)</sup></font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 9%; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2023</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%">&#xa0;</td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; width: 9%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">1.9658</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%">&#xa0;</td>
    <td style="text-align: right; width: 9%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">271,439</font></td>
    <td style="width: 1%">&#xa0;</td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Series
    A preferred stock warrants</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2023</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">1.9658</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">1,608,672</font></td>
    <td>&#xa0;</td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         exercise price per share and warrants outstanding, prior to the Reverse Recapitalization,
                                         have been retroactively restated as shares reflecting the Exchange Ratio established
                                         in the Reverse Recapitalization (See Note 1).</font></td></tr></table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                         of December 31, 2019, the most senior equity preferred stock warrants were convertible
                                         into Series C Preferred Stock.</font></td></tr></table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881021987272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsDisclosureAbstract', window );"><strong>Common Stock Warrants Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsDisclosureTextBlock', window );">Common Stock Warrants</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
Common Stock Warrants</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2020, outstanding warrants to purchase shares of the Company&#x2019;s Common Stock consisted of the following:</font></p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; padding-left: 9pt; text-align: center"><font style="font-size: 10pt"><b>Date Exercisable</b></font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number of</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Shares Issuable</b></p></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Exercise Price</b></font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Exercisable for</b></font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td>&#xa0;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Classification</b></font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Expiration</b></font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#xa0;</td></tr>
<tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; width: 28%; padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">June 2021</font></td>
    <td style="vertical-align: bottom; width: 1%">&#xa0;</td>
    <td style="vertical-align: bottom; width: 1%">&#xa0;</td>
    <td style="vertical-align: bottom; width: 12%; text-align: right"><font style="font-size: 10pt">1,119,750</font></td>
    <td style="vertical-align: bottom; width: 1%">&#xa0;</td>
    <td style="vertical-align: bottom; width: 1%">&#xa0;</td>
    <td style="vertical-align: bottom; width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="vertical-align: bottom; width: 12%; text-align: right"><font style="font-size: 10pt">0.01</font></td>
    <td style="vertical-align: bottom; width: 1%">&#xa0;</td>
    <td style="vertical-align: bottom; width: 1%">&#xa0;</td>
    <td style="vertical-align: bottom; width: 12%; text-align: center"><font style="font-size: 10pt">Common Stock</font></td>
    <td style="vertical-align: bottom; width: 1%">&#xa0;</td>
    <td style="vertical-align: bottom; width: 1%">&#xa0;</td>
    <td style="vertical-align: bottom; width: 12%; text-align: center"><font style="font-size: 10pt">Equity</font></td>
    <td style="vertical-align: bottom; width: 1%">&#xa0;</td>
    <td style="vertical-align: bottom; width: 1%">&#xa0;</td>
    <td style="vertical-align: bottom; width: 12%; text-align: center"><font style="font-size: 10pt">December 2021</font></td>
    <td style="vertical-align: bottom; width: 1%">&#xa0;</td></tr>
<tr>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">December 2020</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">2,407,500</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">$</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">11.50</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt">Common Stock</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt">Equity</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt">December 2025</font></td>
    <td style="vertical-align: bottom">&#xa0;</td></tr>
<tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">December 2020</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">110,000</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">$</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">11.50</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt">Common Stock</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt">Equity</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt">December 2025</font></td>
    <td style="vertical-align: bottom">&#xa0;</td></tr>
<tr>
    <td style="vertical-align: top; padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">December 2020</font></td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid">&#xa0;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,929,113</font></td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt"><font style="font-size: 10pt">$</font></td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: right"><font style="font-size: 10pt">1.97</font></td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><font style="font-size: 10pt">Common Stock</font></td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><font style="font-size: 10pt">Equity</font></td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><font style="font-size: 10pt">April 2023</font></td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt">&#xa0;</td></tr>
<tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">Total</font></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#xa0;</td>
    <td style="vertical-align: bottom; border-bottom: black 4.5pt double">&#xa0;</td>
    <td style="vertical-align: bottom; border-bottom: black 4.5pt double; text-align: right"><font style="font-size: 10pt">5,566,363</font></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 2pt; text-align: right">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 4pt; text-align: center">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#xa0;</td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 2pt; text-align: center">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 2pt; text-align: center">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On December 28, 2020, the Company entered into a subscription agreement
(the &#x201c;Subscription Agreement&#x201d;) with various investors for the private purchase of 2,239,500 shares of the Company&#x2019;s
Common Stock at a price of $10.00 per share with net proceeds of $22.2 million. Investors in the PIPE offering also received warrants
(&#x201c;PIPE Warrants&#x201d;) to purchase a number of shares equal to one-half (1/2) of the number of PIPE Shares, totaling 1,119,750
shares of the Company&#x2019;s Common Stock, at an exercise price of $0.01 per share. Also, pursuant to the Subscription Agreement,
the 1,119,750 PIPE Warrants are subject to a 180-day holding period. A holder of the PIPE Warrants may not exercise the PIPE Warrant
if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of the Company&#x2019;s
Common Stock outstanding immediately after giving effect to such exercise. As of December 31, 2020, none of the warrants had been
exercised.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the Reverse Recapitalization, all of Tottenham&#x2019;s issued and outstanding warrants to purchase one-half (1/2) of one share
of Tottenham&#x2019;s ordinary shares totaling 4,815,000 shares issued in connection with Tottenham&#x2019;s initial public offering,
were automatically converted into 2,407,500 warrants to purchase the Company&#x2019;s Common Stock. The warrants became exercisable
upon the completion of the Reverse Recapitalization and will expire five years after the consummation of the Reverse Recapitalization
(i.e., December 2025). The Company may redeem those outstanding warrants, in whole and not in part, at a price of $0.01 per warrant
if, and only if, the last sales price of the Company&#x2019;s Common Stock equals or exceeds $16.50 per share for any 20 trading
days within a 30-trading day period ending three business days before the Company sends the notice of redemption. As of December
31, 2020, none of the warrants had been exercised.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
Tottenham&#x2019;s initial public offering in August 2018, Tottenham issued to Chardan options to purchase 220,000 units at $10.00
per unit. Each of Tottenham&#x2019;s units consists of one and one-tenth shares of Tottenham&#x2019;s ordinary shares for $10.00
per share and one warrant to purchase one-half of one Tottenham ordinary share at an exercise price of $11.50 per share. In connection
with the Reverse Recapitalization, the Chardan Unit Purchase Option was converted into one Company unit purchase option. The Chardan
Unit Purchase Option Warrants are exercisable upon the completion of the Reverse Recapitalization and will expire in December
2025. As of December 31, 2020, no Chardan Unit Purchase Options were exercised.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Reverse Recapitalization, all of the 1,929,113 outstanding Series A and Series D Preferred Stock Warrants
were converted automatically into 1,929,113 warrants to purchase shares of the Company Common Stock at $1.97 per share (See Note
9).</font></p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CommonStockWarrantsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CommonStockWarrantsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CommonStockWarrantsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>he entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CommonStockWarrantsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881021987272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ConvertibleNotesDisclosureAbstract', window );"><strong>Convertible Notes Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ConvertibleNotesDisclosureTextBlock', window );">Convertible Notes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.
Convertible Notes</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February through July 2020, the Company issued convertible promissory notes (the &#x201c;2020 Convertible Notes&#x201d;) in an aggregate
principal amount of $6.1 million, bearing interest at an annual rate of 5%. The 2020 Convertible Notes were convertible at the
earlier of (i)&#xa0;one year, at which point the notes would be convertible into Series C preferred shares at the Series C preferred
share issuance price, and (ii)&#xa0;next equity financing of no less than $10.0 million, at which point the notes would be convertible
into shares issued in the next equity financing at 90% of the per share issuance price of the next equity financing. The 2020
Convertible Notes contained redemption features that met the requirements for separate accounting and were accounted for as a
single derivative instrument. Accordingly, the 2020 derivative instrument of $0.7 million was recorded at fair value at inception
as redeemable convertible preferred stock derivative liability in the consolidated balance sheets (see Note 12).</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized interest expense of $0.2 million, including amortization of debt discount of $0.2 million during the year ended
December 31, 2020, in connection with the 2020 Convertible Notes.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 11, 2020, in connection with the Company&#x2019;s issuance and sale of Series D Preferred Stock, all of the outstanding
principal and accrued interest under the 2020 Convertible Notes, totaling $6.9 million, was automatically converted into 1,497,135
shares of Series D Preferred Stock at a price equal to 90% of $4.60 per share, the per share price paid in cash by investors in
the Series D preferred stock financing.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounted for the conversion of the 2020 Convertible Notes as a debt extinguishment and recognized a loss on extinguishment
of debt of $0.5 million within other income (expense), net in the consolidated statement of operations and comprehensive loss.
As of the date of conversion, the unamortized discount on the 2020 Convertible Notes was $0.5 million. The loss on extinguishment
was calculated as the difference between (i) the fair value of the 1,497,135 shares of Series D Preferred Stock issued to settle
the 2020 Convertible Notes of $6.9 million and (ii) the carrying value of the 2020 Convertible Notes, including the principal
balance of the 2020 Convertible Notes of $6.1 million and accrued but unpaid interest of $76 thousand, net of the unamortized
debt discount of $5.7 million, plus the then-current fair value of derivative liability associated with the 2020 Convertible Notes
at the time of the extinguishment of $0.7 million.</font></p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ConvertibleNotesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ConvertibleNotesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ConvertibleNotesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ConvertibleNotesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881010026680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.
Derivative Instruments</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Derivative
instrument in connection with the 2020 Convertible Notes</i></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">One of the redemption
features of the 2020 Convertible Notes met the requirements for separate accounting and was accounted for as a derivative instrument.
The 2020 Derivative Instrument was recorded at fair value, which was $0.7 million at issuance. In August 2020, in connection with
the Company&#x2019;s issuance and sale of Series D Preferred Stock, all of the outstanding principal and accrued interest under
the 2020 Convertible Notes was automatically converted into shares of Series D Preferred Stock and the derivative liability was
extinguished. Prior to the extinguishment of derivative liability, the 2020 Derivative Instrument was marked at fair value and
the Company recorded the change in the 2020 Derivative Instrument of ($29) thousand in the consolidated statements of operations
and comprehensive loss (see Note 11).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Derivative instrument in connection
with the Contingent Earn-out</i></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Earn-out Shares
issued in connection with the Reverse Recapitalization met the requirements for separate accounting and is therefore accounted
for as a derivative instrument. Accordingly, upon the consummation of the Reverse Recapitalization, the Company recorded a liability
in the consolidated balance sheets and a debit to additional paid-in capital for the earn-out provision associated with the Initial
Shareholders Contingent Earn-out and a debit to accumulated deficit for the earn-out provisions associated with the Clene Nanomedicine
Contingent Earn-out. The contingent shares to be issued to the Clene Nanomedicine shareholders immediately prior to the Reverse
Capitalization were treated as a deemed distribution. The contingent earn-out was subsequently remeasured to fair value at each
reporting date as a component of other income (expense), net in the Company&#x2019;s consolidated statements of operations and comprehensive
loss.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing of the Reverse Recapitalization, the Company recognized the contingent earn-out liability at its fair value of $72.1
million in the consolidated balance sheets. As of December 31, 2020, the carrying value of the contingent earn-out was $58.0 million.
During the year ended of December 31, 2020, the Company recognized a gain of $14.1 million in change in fair value of contingent
earn-out as a component of other income (expense), net in the Company&#x2019;s consolidated statements of operations and comprehensive
loss. To date, none of the milestones has been achieved.</font></p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881011617032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.
Commitments and Contingencies</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Litigation</b>&#xa0;&#x2014;
From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business activities.
The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures
can be reasonably estimated. The Company is not aware of any current pending legal matters or claims.</font></p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881018459976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.
Income Taxes</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not recorded income tax benefits for the net operating losses incurred during the years ended December 31, 2020 and
2019 nor for research and development tax credits and other deferred tax assets generated, due to its uncertainty of realizing
a benefit from those items.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The components of income
(loss) before income taxes for the years ended December 31, 2020 and 2019 were as follows (in thousands):</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">United&#xa0;States</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(18,985</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(13,812</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Foreign</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">114</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,343</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Loss before provision for income taxes</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(18,871</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(16,155</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Income tax expense
(benefit) for the years ended December 31, 2020 and 2019 were as follows (in thousands):</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td>Provision for income taxes:</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td>Current tax expense:</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-left: 9pt">Federal</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;-</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;-</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">State</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Foreign</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">146</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total current tax expense (benefit)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">146</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred tax expense:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Federal</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">State</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Foreign</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">260</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total deferred tax expense (benefit)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">260</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total income tax expense (benefit)</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">406</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A reconciliation of
the income tax computed at the U.S. federal statutory rate of 21% to the expense for income taxes for the years ended December
31, 2020 and 2019 is as follows (in thousands):</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Income tax expense (benefit) at federal statutory rate</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">(3,963</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">(3,393</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">State income taxes (net of federal benefit)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(917</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(721</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Warrant liability</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3,069</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Contingent consideration</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(2,966</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Research and development credits</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(425</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">326</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Other</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">242</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,205</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,366</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,583</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Income tax expense (benefit)</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">406</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#x2019;s
effective tax rate was (2.15)% and 0.00% for the years ended December 31, 2020 and 2019, respectively. Significant components of
the Company&#x2019;s deferred tax assets (liabilities) as of December 31, 2020 and 2019 were as follows (in thousands):</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">Deferred tax assets (liabilities):</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Net operating loss carryforwards</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">17,958</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">13,502</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Depreciation and amortization</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,810</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,814</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Research &amp; development credits</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,682</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">882</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Lease liability</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">520</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">436</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Right-of-use asset</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(270</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(48</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Accrued interest</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">160</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Non-qualified stock options</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">146</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">130</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Accrued compensation</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">115</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">62</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Other</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(260</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">Total</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">21,861</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">16,755</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(22,121</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,755</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net deferred tax assets (liabilities)</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">(260</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In
assessing the realizability of deferred tax assets, management considers whether it is more-likely-than-not that some portion
or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the
generation of future taxable income during periods in which those temporary differences become deductible. Management considers
the scheduled reversal of deferred tax liabilities, projected future taxable income, carry back opportunities and tax planning
strategies in making the assessment. The Company believes it is more likely than not it will not realize the benefits of these
deductible differences and has applied a full valuation allowance against them. As the Company has no deferred tax assets in Australia,
it has recognized a deferred tax liability and expense for $0.3 million for temporary differences that will reverse in future
periods.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The
Company has federal and state net operating losses (NOLs) of approximately $72.2 million and $59.8 million as of December 31,
2020, respectively that, subject to limitation, may be available in future tax years to offset taxable income. Of the available
federal NOLs, approximately $38.8 million can be carried forward indefinitely but utilization is limited to 80% of the Company's
taxable income in any given tax year based on current federal tax laws. The remaining balance of $33.4 million will begin to expire
after 2034. Of the available state NOLs, approximately $39.4 million can be carried forward indefinitely but utilization is limited
to 80% of the Company's taxable income in any given tax year based on current tax laws. The remaining balance of $20.4 million
will begin to expire after 2032. Additionally, the Company has approximately $1.7 million of research and development (R&amp;D)
credit carryforwards that will begin to expire after 2034 if not utilized.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the provisions
of &#xa7;382 of the Internal Revenue Code, substantial changes in the Company's ownership may result in limitations on the amount
of NOL carryforwards and R&amp;D credits that can be utilized in future years. NOL carryforwards and R&amp;D credits are subject
to examination in the year they are utilized regardless of whether the tax year in which they are generated has been closed by
statute. The amount subject to disallowance is limited to the amount utilized. Accordingly, the Company may be subject to examination
for prior NOLs and credits generated as such tax attributes are utilized.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has not
recorded any amounts for unrecognized tax benefits as of December 31, 2020 and 2019. The Company&#x2019;s practice is to recognize
interest and penalties related to income tax matters in income tax expense. The Company had no accrual of interest and penalties
on the Company&#x2019;s balance sheets and has not recognized interest and penalties in the consolidated statements of operations
and comprehensive loss for the years ended December 31, 2020 and 2019.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is subject to taxation in the United States and
Australia. The Company&#x2019;s tax returns from 2014 to present are subject to examination by the United States and state authorities
due to the carry forward of unutilized net operating losses and R&amp;D credits. There are currently no pending examinations.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881027608152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15.
Stock-Based Compensation</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2020
Stock Plan</i></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In December 2020, in connection with the Reverse Recapitalization,
the Company&#x2019;s board of directors approved the 2020 Stock Plan (the &#x201c;2020 Stock Plan&#x201d;) and reserved 12,000,000
shares of Common Stock for issuance thereunder, all of which may be issued pursuant to incentive stock options or any other type
of award under the 2020 Stock Plan. The 2020 Stock Plan became effective immediately upon the closing of the Reverse Recapitalization.
The maximum number of shares of Common Stock that may be issued pursuant to the exercise of incentive stock options under the 2020
Stock Plan is 12,000,000. The Company&#x2019;s selected employees, officers, directors and consultants are eligible to participate
in the traditional stock option grants, stock appreciation rights, restricted stock awards, restricted stock unit awards, other
stock awards, and performance awards under the 2020 Stock Plan. The purpose of this 2020 Stock Plan is to enable the Company to
offer competitive equity compensation packages in order to attract and retain the talent necessary for the Combined Company.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The 2020 Stock Plan is administered by the Company&#x2019;s Board
of Directors. The exercise prices, vesting periods and other restrictions are determined at the discretion of the Company&#x2019;s
Board of Directors, except that the exercise price per share of options may not be less than 100% of the fair market value of the
Common Stock on the date of grant. Stock options awarded under the 2020 Stock Plan expire ten years after the grant date, unless
the Company&#x2019;s Board of Directors sets a shorter term. Stock options and restricted stock granted to employees, officers,
members of the Company&#x2019;s Board of Directors and consultants generally vest over a four-year period. If an option or other
award granted under the 2020 Stock Plan expires, terminates or is cancelled, the unissued shares subject to that option or award
shall again be available under the 2020 Stock Plan. If shares awarded pursuant to the 2020 Stock Plan are forfeited to or repurchased
at original cost by the Company, the number of shares forfeited or repurchased at original cost shall again be available under
the 2020 Stock Plan.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 30, 2020, the Company granted 1,507,062 restricted
stock units under the 2020 Stock Plan. As of December 31, 2020, 10,492,938 shares remained available for future grant.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2014
Stock Plan</i></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the closing of the Reverse Recapitalization, the 2014 Stock Plan is administered by the Company&#x2019;s Board of Directors. Stock
options awarded under the 2014 Stock Plan expire ten years after the grant date. Stock options and restricted stock granted to
employees, officers, members of the Company&#x2019;s Board of Directors and consultants typically vest over a four-year period.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of
                                                                                                                                                                                                     the Reverse Recapitalization (as described in Note 1), stock options outstanding under the 2014 Stock Plan of 53,286,115 were
                                                                                                                                                                                                     converted into 7,032,590 of stock options of the Company based on the Exchange Ratio determined in accordance with the terms
                                                                                                                                                                                                     of the Merger Agreement. The exchange of Clene Nanomedicine&#x2019;s stock options for Clene Inc. stock options was treated as
                                                                                                                                                                                                     a modification of the awards. The modification of the stock options did not result in a material incremental compensation
                                                                                                                                                                                                     expense to be recognized at the closing of the Reverse Recapitalization.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2020, the Company granted stock options for 270,555 shares under the 2014 Stock Plan.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31,
2019, there were 6,720,065 common shares authorized for grant to employees, officers, directors, and consultants under the 2014
Stock Plan. Effective as of the closing of the Reverse Recapitalization on December 30, 2020, no additional awards may be made
under the 2014 Stock Plan and as a result, (i) any shares in respect of stock options that are expired or terminated under the
2014 Stock Plan without having been fully exercised will not be available for future awards; (ii) any shares in respect of restricted
stock that are forfeited to, or otherwise repurchased by the Company, will not be available for future awards; and (iii) any shares
of Common Stock that are tendered to the Company by a participant to exercise an award will not be available for future awards.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2019, the Company granted stock options for 1,440,717 shares under the 2014 Stock Plan. There were 388,283 shares
available for grant under the 2014 Stock Plan as of December 31, 2019.</p><br/><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation for the years ended December 31, 2020 and 2019 was approximately $0.8 million and $0.4 million, respectively, and
is recorded in research and development and general and administrative expenses in the consolidated statement of operations and
comprehensive loss as follows:</font></p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif;  width: 100%">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(In
    thousands)</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">General
    and administrative</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">281</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">161</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Research
    and development</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">480</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">238</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Total
    stock-based compensation</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">761</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">399</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><br/><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2020, the Company had approximately $2.4 million of unrecognized stock-based compensation costs related to non-vested
awards which is expected to be recognized over a weighted-average period of 2.04 years.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following sets
forth the outstanding Common Stock options and related activity for the year ended December 31, 2020 (in thousands, except share
and per share data):</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Equity</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&#xa0;of<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price <br/> Per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Term <br/> (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Instrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -9pt; padding-left: 9pt">Outstanding - December 31, 2018</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">5,698,090</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.38</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">6.62</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,089</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">Granted</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,440,717</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2.42</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.66</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">Exercised</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(11,878</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">0.83</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">31</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Forfeited</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(248,757</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.44</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Outstanding - December 31, 2019</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6,878,172</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">0.83</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.36</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">18,105</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">Granted</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">270,555</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.48</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.32</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">Exercised</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(83,232</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">0.94</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">740</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Forfeited</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(32,904</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.65</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Outstanding - December 31, 2020</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">7,032,591</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.97</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">5.34</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">62,462</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td>&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Options vested and exercisable - December 31, 2020</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">5,896,034</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.55</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">4.86</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">52,694</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Options vested and exercisable - Stock options vested and expected to vest December 31, 2020</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">7,032,591</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.97</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">5.34</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">62,462</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the consummation
of the Reverse Recapitalization, the exercise price of the stock options granted was based on the fair market value of the common
shares of the Company as of the grant date as determined by the Board of Directors, with input from the Company&#x2019;s management.
The Board of Directors determined the fair value of the common stock at the time of grant of the options by considering a number
of objective and subjective factors, including third-party valuation reports, valuations of comparable companies, sales of redeemable
convertible Preferred Stock, sales of common stock to unrelated third parties, operating and financial performance, the lack of
liquidity of the Company&#x2019;s capital stock, and general and industry-specific economic outlook.</p><br/><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
options are valued using the Black-Scholes option pricing model. Since the Company has limited trading history of its common stock,
the expected volatility is derived from the average historical stock volatilities of several unrelated public companies within
the Company&#x2019;s industry that the Company considers to be comparable to its own business over a period equivalent to the expected
term of the stock option grants. The risk-free interest rate for periods within the contractual life of the stock options is based
on the U.S. Treasury yield curve in effect at the time of the grant. The expected dividend is assumed to be zero as the Company
has never paid dividends and has no current plans to do so. The expected term represents the period that stock-based awards are
expected to be outstanding. For option grants that are considered to be &#x201c;plain vanilla,&#x201d; the Company determines the
expected term using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the
contractual life of the options. For other option grants, the Company estimates the expected term using historical data on employee
exercises and post-vesting employment termination behavior taking into account the contractual life of the award.</font></p><br/><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assumptions used to calculate the value of the stock option awards granted in 2020 and 2019 are presented as follows:</font></p><br/><table cellpadding="0" cellspacing="0" style=" width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.25in; padding-left: 0.25in; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif">&#xa0;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.25in; padding-left: 0.25in; width: 72%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Expected
    stock price volatility</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 12%; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">75.00%
- 119.30%</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#xa0;</td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 12%; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">75.00%</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#xa0;</td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Risk-free
    interest rate</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">0.39%
                                         - 0.53%</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#xa0;</td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">1.46%</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Expected
    dividend yield</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">0%</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#xa0;</td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">0%</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#xa0;</td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Expected
    term of options</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">6
years</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#xa0;</td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">6
                                         years</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average grant-date fair value of options granted during the years ended December 31, 2020 and 2019 was $2.3923 and $1.5806,
respectively.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Restricted Stock Units</i></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 30, 2020,
the Company granted the following shares of restricted common stock under the 2020 Stock Plan:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 48px">&#xa0;</td>
    <td style="width: 24px; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify; font-size: 10pt"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">370,101 shares to various employees and non-employee directors,
which vest on June 30, 2021, subject to the employee&#x2019;s continuous employment through such vesting date. The award represents
5% of the converted stock options under 2014 Stock Plan as a result of the Reverse Recapitalization and complements the 5% closing
payment shares held in escrow for Clene Nanomedicine common shareholders (as described in Note 1). The grant-date fair value of
these awards was $4.0 million.</p></td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 48px">&#xa0;</td>
    <td style="width: 24px; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">454,781 shares to various employees and non-employee directors, which were eligible to vest based on certain market conditions, subject to the employee&#x2019;s continuous employment through such vesting date. The award complements the Milestone 1 earn-out share entitlement of Clene Nanomedicine shareholders and vests based on the same market condition (as described in Note 3). The grant-date fair value of these awards, using a Monte Carlo simulation, was $4.3 million. Based on the outcome of the market condition as of the December 31, 2020 measurement date, no shares were vested.</font></td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 48px">&#xa0;</td>
    <td style="width: 24px; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">341,090 shares to various employees and non-employee directors, which were eligible to vest based on certain market conditions, subject to the employee&#x2019;s continuous employment through such vesting date. The award complements the Milestone 2 earn-out share entitlement of Clene Nanomedicine. shareholders and vests based on the same market condition (as described in Note 3). The grant-date fair value of these awards, using a Monte Carlo simulation, was $3.5 million. Based on the outcome of the market condition as of the December 31, 2020 measurement date, no shares were vested.</font></td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 48px">&#xa0;</td>
    <td style="width: 24px; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify; font-size: 10pt"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">341,090 shares to various employees and non-employee directors,
which were eligible vest based on certain performance conditions tied to the completion of the COVID-19 coronavirus treatment study,
subject to the employee&#x2019;s continuous employment through such vesting date. The award complements the Milestone 3 earn-out
share entitlement of Clene Nanomedicine shareholders and vests based on the same performance condition (as described in Note 3).
The grant-date fair value of these awards was $3.7 million based on a weighted average grant date fair value of $10.82 per share.
The Company did not recognize compensation expense because the occurrence of achieving this milestone was not probable. As of the
December 31, 2020 measurement date, no shares were vested.</p></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
summarizes the restricted common stock activity during the year ended December 31, 2020:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td>&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&#xa0;of<br/> RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Unvested balance as of December 31, 2019</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="width: 76%; text-indent: -9pt; padding-left: 0.25in">Granted</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">1,507,062</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">10.30</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Vested</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Unvested balance as of December 31, 2020</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">1,507,062</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10.30</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The assumptions used
to calculate the value of the restricted stock units granted in 2020 in the Monte Carlo valuation model include projected stock
price, volatility and risk-free rate based on the achievement of certain stock price milestones. Our significant unobservable inputs
as of December 31, 2020 were as follows: (i) 85% of expected stock price volatility, (ii) risk-free interest rate of 0.4%, and
(iii) expected term of 5 years. The weighted average grant-date fair value of RSUs granted during the years ended December 31,
2020 and 2019 was $10.3034 and $0, respectively.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The stock-based compensation
expense associated with the RSUs were immaterial for the years ended December 31, 2020 and 2019. As of December 31, 2020, total
unrecognized compensation cost related to the unvested stock-based awards was $15.5 million, which is expected to be recognized
over a weighted average period of 8 months.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881027624008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16.
Fair Value</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The carrying amount
of cash and accounts payable approximates fair value because of the immediate, short-term maturity of these financial instruments.</p><br/><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liabilities
with Fair Value Measurements on a Recurring Basis&#xa0;&#x2014; </b>The following tables present the Company&#x2019;s fair value
hierarchy for its liabilities measured at fair value on a recurring basis as of December 31, 2020 and 2019 (in thousands):</font></p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value Measurements on a Recurring Basis<br/> December&#xa0;31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -9pt; padding-left: 9pt">Notes payable</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,296</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,296</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Clene Nanomedicine contingent earn-out</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">52,053</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">52,053</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Initial Shareholders contingent earn-out</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5,906</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5,906</td><td style="text-align: left">&#xa0;</td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif;  width: 100%">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="14" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Fair
    Value Measurements on a Recurring Basis<br/>
December&#xa0;31, 2019</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Level
                                         1</font></td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Level
                                         2</font></td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Level
                                         3</font></td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Total</font></td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Redeemable
    convertible preferred stock warrant liability</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">3,213</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">3,213</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Notes
    payable</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">640</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">640</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended
December 31, 2020, there was a transfer to Level 1 from Level 3 of the Company&#x2019;s notes payable as the fair value of the notes
payable is determined based on the Company&#x2019;s stock price listed on the Nasdaq. There were no other transfers between Level
1, Level 2 or Level 3. For the years ended December 31, 2019, there were no transfers between Level 1, Level 2, or Level 3.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Valuation
of the Notes Payable</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The carrying value
of the notes payable includes certain notes remeasured at fair value on a recurring basis in the balance sheet as of December 31,
2020 and 2019. In order to value the note, the Company considers the amount of simple interest expense that would be due and considers
the value of Phantom Shares.</p><br/><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to becoming a public company, the Company&#x2019;s notes payable contained unobservable inputs that reflected the Company&#x2019;s
own assumptions. Accordingly, the Company&#x2019;s notes payable were measured at fair value on a recurring basis using unobservable
inputs. Significant unobservable inputs as of December 31, 2019 were the fair value of Series C Preferred Stock of $4.1699 per
share.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31,
2020, the fair value of the Company&#x2019;s Notes payable is determined based on the closing price of $9.01 per share for CLNN
listed on the Nasdaq.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Valuation
of Warrants to Purchase Preferred Stock</i></b></font></p><br/><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#x2019;s Preferred Stock warrant liabilities contain unobservable inputs that reflect the Company&#x2019;s own assumptions.
Accordingly, the Company&#x2019;s Preferred Stock warrant liabilities were measured at fair value on a recurring basis using unobservable
inputs. Prior to the extinguishment of the Preferred Stock warrant liabilities on December 30, 2020 and on December 31, 2019,
the Preferred Stock warrant liability was valued using a Black-Scholes valuation model.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Significant unobservable
inputs at December 30, 2020 were the fair value of Series D Preferred Stock warrants of $10.82 per share, the fair value of Series
A Preferred Stock warrants of $10.82 per share, expected term of 2.3&#xa0;years, expected volatility of Series D Preferred Stock
warrants of 101%, and expected volatility of Series A Preferred Stock warrants of 101%. Significant unobservable inputs at December
31, 2019 were the fair value of Series C Preferred Stock warrants of $4.1699 per share, the fair value of Series A Preferred Stock
warrants of $3.1046 per share, expected term of 2&#xa0;years, expected volatility of Series C Preferred Stock warrants of 49%,
and expected volatility of Series A Preferred Stock warrants of 71%.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors
determines the fair value of the Preferred Stock by considering a number of objective and subjective factors, including third-party
valuations, valuations of comparable companies, sales of redeemable convertible Preferred Stock, sales of common stock to unrelated
third parties, operating and financial performance, the lack of liquidity of the Company&#x2019;s capital stock, and general and
industry-specific economic outlook. The Company estimated the volatility of its Preferred Stock based on comparable peer companies&#x2019;
historical volatility. The risk-free interest rate for periods within the contractual life of the warrants is based on the U.S.
Treasury yield curve in effect at the valuation date. The Company has no plans to declare any future dividends. The determination
of the fair value of the Preferred Stock warrant liability could change in future periods based upon changes in the value of the
Company&#x2019;s Preferred Stock and other assumptions as presented above. The Company records any such change in fair value to
the change in fair value of Preferred Stock warrant liability expense line in the consolidated statements of operations and comprehensive
loss.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the closing of
the Reverse Recapitalization (see Note 1), all of the outstanding Clene Nanomedicine Preferred Stock was converted to Clene Inc.
Common Stock and the Clene Nanomedicine Preferred Stock warrants were converted to warrants for the purchase of Clene Inc. Common
Stock. Accordingly, the Preferred Stock warrant liabilities were extinguished in connection with the conversion of Clene Nanomedicine
Preferred Stock on December 30, 2020 (see Note 9).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Valuation
of the Contingent Earn-out</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Merger
Agreement, Clene Nanomedicine&#x2019;s common shareholders immediately prior to the Reverse Recapitalization and Initial Shareholders
of Totttenham were entitled to receive additional shares of up to 8,333,333 shares and 750,000 shares of the Company&#x2019;s Common
Stock, respectively, upon the Company achieving certain milestones described in Note 3. Upon the consummation of the Reverse Recapitalization,
Clene Nanomedicine and the Initial Shareholders are entitled to receive additional shares up to 8,346,185 shares as a result of
the exercise of the stock options in November 2020, and 750,000 shares of the Company&#x2019;s Common Stock. The Clene Nanomedicine
Contingent Earn-out and the Initial Shareholders Contingent Earn-out are recorded at fair value as contingent earn-out on the closing
of the Reverse Recapitalization on December 30, 2020 and remeasured at each reporting period. As of December 31, 2020, no milestone
has been achieved.</p><br/><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair value of the initial contingent earn-out is determined using a Monte Carlo analysis in order to simulate the future
path of the Company&#x2019;s stock price over the earn-out period. The carrying amount of the liability may fluctuate significantly
and actual amounts paid may be materially different from the liability&#x2019;s estimated value. As of December 31, 2020, the contingent
earn-out was revalued using a similar Monte Carlo analysis. The unobservable inputs to the model were as follows:</font></p><br/><table cellpadding="0" cellspacing="0" style=" width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2019</font></td>
    <td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 72%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Expected
    stock price volatility</font></td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 12%; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">85.00</font>%</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"></font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; width: 12%"><font style="font-family: Times New Roman, Times, Serif">N/A</font></td>
    <td style="width: 1%">&#xa0;</td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Risk-free
    interest rate</font></td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">0.40%</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">N/A</font></td>
    <td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Expected
    term</font></td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">5
                                         years</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">N/A</font></td>
    <td>&#xa0;</td></tr>
</table><br/><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of changes in the fair value of the Company&#x2019;s financial liability related to the notes payable, the
derivative instrument, the Preferred Stock warrants, and the contingent earn-out measured at fair value as of December 31, 2020
and 2019 (in thousands):</font></p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#xa0;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Notes Payable</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#xa0;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Derivative Instrument</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#xa0;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Preferred Stock Warrants</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#xa0;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Clene Nanomedicine Contingent Earn-out</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#xa0;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Initial Shareholders Contingent Earn-out</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Balance - December 31, 2018</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,518</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Issuance of notes payable</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">600</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Change in fair value</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">40</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">361</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; padding-bottom: 1.5pt; text-align: left">Exercise of Series C preferred stock warrants</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,666</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance - December 31, 2019</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">640</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3,213</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Issuance of convertible promissory notes</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">705</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Initial fair value of instrument</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">64,712</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7,371</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Change in fair value</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">656</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(29</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">14,615</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(12,659</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(1,465</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Extinguishment of preferred stock warrant liability in connection with the conversion of redeemable convertible preferred stock</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(17,828</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1.5pt; text-align: left">Extinguishment of derivative liability in connection with extinguishment of the 2020 Convertible Notes (Note 12)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(676</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance - December 31, 2020</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,296</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">52,053</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,906</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881027563976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RedeemableConvertiblePreferredStockDisclosureAbstract', window );"><strong>Redeemable Convertible Preferred Stock Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17.
Redeemable Convertible Preferred Stock</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Reverse
Recapitalization, the Company had issued Series A, B, C, and D Preferred Stock to various investors. Preferred stock is convertible
into common stock at the option of the holder at the conversion price. The Company evaluated the Preferred Stock and concluded
that it did not meet the criteria for being classified as a liability. However, the Company had determined that the Preferred Stock
should be classified as temporary equity, as the Company might be required to redeem the outstanding Preferred Stock in cash. The
Company had concluded that a redemption event is not probable. Accordingly, the value of Preferred Stock had not been adjusted
to its redemption amount.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of Preferred
Stock vote together with the holders of common stock as a single class. Voting rights are in proportion to the number of votes
equal to common stock shares into which preferred shares would be converted.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Redeemable
Preferred Stock</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Between February and
April&#xa0;2015, the Company issued 16,066,503 shares of Series A Preferred Stock to several investors, at a price of $1.9658 per
share, for proceeds of $9.5 million in cash and $18.0 million by conversion of convertible promissory notes.</p><br/><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December&#xa0;2016, the Company issued 4,168,815 shares of Series B Preferred Stock at a price of $4.0778 per share and a buyout
option for proceeds of $16.6 million, net of issuance costs of $0.4 million. The Agreement provided the buyer with an exclusive
right and option to acquire all of the issued and outstanding stock of the Company on a fully diluted basis at a set price and
provides for future milestone payments to be made to existing shareholders of the Company based on achievement of certain milestones
defined within the Agreement. The purchase option was not exercised and was terminated by written notice received from the buyer
on September 21, 2017. The Company allocated the total cash consideration received of $16.6 million between the Series B Preferred
Stock and the buyout option based on the relative fair value of each instrument. The $3.4 million assigned to the buyout option
was treated as a contribution and recorded into additional paid-in capital.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Between August and
October&#xa0;2018, the Company issued 4,929,718 shares of Series C Preferred Stock to several investors. The Company issued 3,849,011
shares, at a price of $4.1699 per share, for proceeds of $15.9 million in cash, net of issuance costs of $0.2 million. $1.5 million
of the proceeds were allocated to the Series C Preferred Stock Warrants issued (see Note 9). The Company issued 1,080,707 shares
upon conversion of the convertible promissory notes (see Note 11).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Between March and July&#xa0;2019,
the Company issued 2,334,801 shares of Series C Preferred Stock to several investors. The Company issued 1,935,111 shares, at a
price of $4.1699 per share, for proceeds of $8.1 million in cash, net of immaterial issuance costs. The Company issued 399,690
shares on exercise of Series C Preferred Stock Warrants (see Note 9).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020, the
Company issued 9,394,057 shares of Series D Preferred Stock to several investors. The Company issued 7,896,922 shares, at a price
of $4.6018 per share, for proceeds of $35.1 million in cash, net of $1.3 million issuance costs. In addition, in connection with
the Company&#x2019;s issuance and sale of Series D preferred stock, all of the outstanding principal and accrued interest under
the 2020 Convertible Notes was automatically converted into an aggregate of 1,497,135 shares of Series D Preferred Stock. The Company
determined the fair value of the shares issued upon conversion to be $6.9 million, based on the preferred stock financing cash
price per share (see Note 11).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Series A Preferred
Stock, Series B Preferred Stock, Series C Preferred Stock, and Series D Preferred Stock are collectively referred as the &#x201c;Preferred
Stock.&#x201d; In connection with the closing of the Reverse Recapitalization, the Preferred Stock converted into 36,893,894 shares
of Common Stock on a 1:0.1389 basis (see Note 1).</p><br/><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2020, there was no Preferred Stock outstanding.</font></p><br/><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
Stock consisted of the following as of December 31, 2019 (in thousands, except share amounts):</font></p><br/><table cellpadding="0" cellspacing="0" style=" width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="18" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">December
    31, 2019</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Preferred<br/>
    Shares<br/> Authorized</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Preferred<br/>
    Shares<br/> Issued and<br/> Outstanding</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Carrying<br/>
    Value</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Liquidation<br/>
    Value</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Common
    Stock<br/> Issuable Upon<br/> Conversion</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 40%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Series
    A Preferred Stock</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">17,675,175</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">16,066,503</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">27,485</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">31,584</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">16,066,503</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Series
    B Preferred Stock</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">4,168,815</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">4,168,815</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">16,582</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">16,999</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">4,168,815</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Series
    C Preferred Stock</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">9,192,018</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">7,264,519</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">28,594</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">30,292</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">7,264,519</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Total</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">31,036,008</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">27,499,837</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">72,661</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">78,875</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">27,499,837</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><br/><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rights and preferences of Series A, Series B, Series C, and Series D Preferred Stock are as follows:</font></p><br/><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Voting
Rights&#xa0;&#x2014; </b>The holder of each share of Series A, Series B, Series C, and Series D Preferred Stock shall have the
right to one vote for each share of common stock into which such Series A, Series B, Series C, and Series D Preferred Stock could
then be converted.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Right to Elect Directors&#xa0;&#x2014;
</b>As long as the majority of the Series A Preferred Stock issued remains outstanding, its holders shall be entitled to elect
two directors of the Company. The holders of Series B Preferred Stock are entitled to elect one director of the Company. The holders
of Series C Preferred Stock are entitled to elect one director of the Company. The holders of Preferred Stock and common stock
(voting together as a single class&#xa0;and not as separate series and on as-converted basis) shall be entitled to elect any remaining
director of the Company.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Dividend Rights&#xa0;&#x2014;
</b>The holders of Preferred Stock are entitled to receive, when, as and if declared by the Board of Directors, out of any assets
of the Company legally available therefore, any dividends as may be declared from time to time by the Board of Directors. No dividend
may be declared or paid on the common stock (other than dividends payable in shares of common stock) unless any and all such dividends
or distributions are distributed among all holders of common stock and Preferred Stock in proportion as if the Preferred Stock
were converted to common stock at the effective conversion rate. The debt covenants of the Company&#x2019;s outstanding note payable
prohibit the issuance of dividends, see Note 8.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Preferred Stock
Protective Provisions&#xa0;&#x2014; </b>As long as Preferred Stock originally issued remains outstanding, the Company shall not
without first obtaining the approval of the holders of at least a majority of the outstanding shares of Preferred Stock: (i)&#xa0;consummate
a liquidation event or effect any other merger or consolidation, (ii)&#xa0;amend, alter, or repeal any provision of the Certificate
of Incorporation, (iii)&#xa0;increase or decrease (other than redemption or conversion) the total number of authorized shares of
common stock or Preferred Stock, (iv)&#xa0;authorize or issue any equity security having a preference over, or being on a parity
of any series of Preferred Stock, (v)&#xa0;redeem, purchase, or acquire any shares of Preferred Stock or common stock, (vi)&#xa0;pay
or declare any dividend on any shares of capital stock of the Company, other than dividends payable in shares of common stock,
(vii)&#xa0;create or hold capital stock in any subsidiary that is not wholly owned by the Company or permit any direct or indirect
subsidiary to sell, lease, transfer, exclusively license, or otherwise dispose the assets of such subsidiary.</p><br/><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, Series B, Series C, and Series D Preferred Stock have protective provisions that prevent the Company from amending,
altering, or repealing any provision of the Certificate of Incorporation or Bylaws to adversely alter or change the powers, preferences
or special rights without first obtaining the approval of the holders of at least a majority of the outstanding shares of Series
B, Series C, and Series D Preferred Stock, respectively.</font></p><br/><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidation
Preference&#xa0;&#x2014; </b>In case of any liquidation event, either voluntary or involuntary, the holders of Series D Preferred
Stock shall be entitled to receive out of the proceeds or assets of the Company available for distribution to its shareholders
prior and in preference to any distribution of the proceeds of such liquidation event to the holders of Series C Preferred Stock,
Series B Preferred Stock, Series A Preferred Stock, and common stock by reason of their ownership thereof, an amount per share
equal to the sum of the applicable original issue price for the Series D Preferred Stock plus declared but unpaid dividends on
such share. If, upon the occurrence of such event, the proceeds thus distributed among the holders of the Series D Preferred Stock
shall be insufficient to permit the payment to such holders of the full amounts, then the entire Proceeds legally available for
distribution shall be distributed ratably among the holders of the Series D Preferred Stock in proportion to the full preferential
amount that each such holder is entitled to receive.</font></p><br/><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
case of any liquidation event, either voluntary or involuntary, the holders of Series C Preferred Stock shall be entitled to receive
out of the proceeds or assets of the Company available for distribution to its shareholders prior and in preference to any distribution
of the proceeds of such liquidation event to the holders of Series B Preferred Stock, Series A Preferred Stock, and common stock
by reason of their ownership thereof, an amount per share equal to the sum of the applicable original issue price for the Series
C Preferred Stock plus declared but unpaid dividends on such share. If, upon the occurrence of such event, the proceeds thus distributed
among the holders of the Series C Preferred Stock shall be insufficient to permit the payment to such holders of the full amounts,
then the entire Proceeds legally available for distribution shall be distributed ratably among the holders of the Series C Preferred
Stock in proportion to the full preferential amount that each such holder is entitled to receive.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In case of any liquidation
event, either voluntary or involuntary, the holders of Series B Preferred Stock shall be entitled to receive out of the proceeds
or assets of the Company available for distribution to its shareholders prior and in preference to any distribution of the proceeds
of such liquidation event to the holders of Series A Preferred Stock, and common stock by reason of their ownership thereof, an
amount per share equal to the sum of the applicable original issue price for the Series B Preferred Stock plus declared but unpaid
dividends on such share. If, upon the occurrence of such event, the proceeds thus distributed among the holders of the Series B
Preferred Stock shall be insufficient to permit the payment to such holders of the full preferential amounts, then the remaining
Proceeds legally available for distribution after distribution to holders of the Series D Preferred Stock and Series C Preferred
Stock shall be distributed ratably among the holders of the Series B Preferred Stock in proportion to the full preferential amount
that each such holder is entitled to receive.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In case of any liquidation
event, either voluntary or involuntary, the holders of Series A Preferred Stock shall be entitled to receive out of the proceeds
or assets of the Company available for distribution to its shareholders prior and in preference to any distribution of the proceeds
of such liquidation event to the holders of common stock by reason of their ownership thereof, an amount per share equal to the
sum of the applicable original issue price for the Series A Preferred Stock plus declared but unpaid dividends on such share. If,
upon the occurrence of such event, the proceeds thus distributed among the holders of the Series A Preferred Stock shall be insufficient
to permit the payment to such holders of the full preferential amounts, then the remaining Proceeds legally available for distribution
after distribution to holders of the Series D Preferred Stock, Series C Preferred Stock and Series B Preferred Stock shall be distributed
ratably among the holders of the Series A Preferred Stock in proportion to the full preferential amount that each such holder is
entitled to receive For purposes of determining the amount each holder of shares of Preferred Stock is entitled to receive in a
liquidation event, each such holder shall be deemed to have converted into shares of common stock immediately prior to the Liquidation
Event if, as a result of an actual conversion, such holder would receive, in the aggregate, an amount greater than the amount that
would be distributed otherwise.</p><br/><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Redemption&#xa0;&#x2014;
</b>The Series A, Series B, Series C, and Series D Preferred Stock are not redeemable at the option of the holder. However, so
long as a majority of the Preferred Stock originally issued remains outstanding, the Company shall not, without first obtaining
the approval of the holders of at least a majority of the then outstanding shares of Preferred Stock, redeem, purchase, or acquire
any share or shares of Preferred Stock or common stock, except the repurchase, if any, of shares of common stock from employees,
officers, directors, consultants, or other persons performing services for the Company.</font></p><br/><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Conversion
Rights &#x2014;</b></font></p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.5in">&#xa0;</td>
    <td style="width: 0.25in; font-size: 10pt"><font style="font-size: 10pt">(a)</font></td>
    <td style="font-size: 10pt; text-align: justify"><font style="font-size: 10pt">Right to Convert.&#xa0;Each share of Preferred Stock shall be convertible, at the option of the holder thereof, at any time, into such number of fully paid and non-assessable shares of common stock as is determined by dividing the applicable original issue price by the applicable conversion price. The initial conversion price per share of Series A, Series B, Series C, and Series D Preferred Stock shall be $1.9658, $4.0778, $4.1699, and $4.6018, respectively, provided, however, that the conversion price shall be subject to adjustment as set forth below.</font></td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.5in">&#xa0;</td>
    <td style="width: 0.25in; font-size: 10pt"><font style="font-size: 10pt">(b)</font></td>
    <td style="font-size: 10pt; text-align: justify"><font style="font-size: 10pt">Automatic Conversion.&#xa0;Each share of Series A, Series B, Series C, and Series D Preferred Stock shall automatically be converted into shares of common stock upon the earlier of (i)&#xa0;the closing of the sale of common stock in an underwritten public offering pursuant to a registration statement under the Securities Act of 1933, the public offering price of which is not less than $30.0 million in the aggregate, (ii)&#xa0;the date, or the occurrence of an event, specified by vote or written consent, or agreement of the holders of a majority of the then outstanding shares of Preferred Stock (voting together as a single class&#xa0;and not as separate series and on an as-converted basis), or (iii) a closing of a merger with a publicly-traded entity that has no operations other than searching for an operating company with which to merge (a &#x201c;SPAC&#x201d;) at a value per share in accordance with the restated certification incorporation, resulting in at least $30.0 million of proceeds to the Company (including any cash acquired in the merger with the SPAC).</font></td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion
Price Adjustment.&#xa0;The conversion Price of Preferred Stock shall be subject to adjustment as follows: If the Company shall
issue any additional stock (as defined in the associated agreement) without consideration or for a consideration per share less
than the Conversion Price in effect immediately prior to the issuance of such additional stock, the Conversion Price shall be
adjusted.</font></td>
</tr></table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_RedeemableConvertiblePreferredStockDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_RedeemableConvertiblePreferredStockDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeemable Convertible Preferred Stock [Text Block].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881011627624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>18.
Common Stock</b></font></p><br/><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2020, the Company&#x2019;s certificate of incorporation, as amended and restated, authorized the Company to issue
100,000,000 shares of the Company&#x2019;s Common Stock, par value $0.0001 per share and 1,000,000 shares of the Company&#x2019;s
Preferred Stock, par value $0.0001 per share.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#x2019;s
common shareholders are entitled to one vote per share and to notice of any shareholders&#x2019; meeting. Voting, dividend and liquidation
rights of the holders of Common Stock are subject to the prior rights of holders of all classes of stock and are qualified by the
rights, powers, preferences and privileges of the holders of Preferred Stock. No distributions shall be made with respect to Common
Stock until all declared dividends to Preferred Shares have been paid or set aside for payment to the holders of Preferred Stock.
Common Stock is not redeemable at the option of the holder.</p><br/><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the closing of the Reverse Recapitalization, the total 2,303,495 of the Tottenham ordinary shares held by the Initial Shareholders
and public shareholders were converted into the same number of Company&#x2019;s Common Stock (see Note 3).</font></p><br/><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the closing of the Reverse Recapitalization, 644,164 shares of the Company&#x2019;s Common Stock were issued to LifeSci as financial
advisor to the Reverse Recapitalization (see Note 3).</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 28, 2020 and
prior to the closing of the Reverse Recapitalization, various PIPE investors purchased 2,239,500 shares of the Company&#x2019;s
Common Stock at a price of $10.00 per share and 1,119,750 warrants to purchase, at an exercise price of $0.01 per share, one share
of the Company&#x2019;s Common Stock for net proceeds of $22.2 million (see Notes 1 and 3).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31,
2020, the Company&#x2019;s common shares issued and outstanding are 59,526,171 and there are no preferred shares issued and outstanding
(see Note 17).</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881027572520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Shareholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share Attributable to Common Shareholders</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>19.
Net Loss Per Share Attributable to Common Shareholders</b></font></p><br/><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the computation of basic and diluted net loss per share attributable to common shareholders (in thousands,
except share and per share data):</font></p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">Numerator:</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -0.125in; padding-left: 0.25in">Net loss attributable to common shareholders</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(19,277</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(16,155</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Denominator:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">Weighted average shares outstanding</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,503,992</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,357,505</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Net loss per share attributable to common shareholders, basic and diluted</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1.10</td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.93</td><td style="padding-bottom: 2pt; text-align: left">)</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Included within weighted
average common shares outstanding are 1,119,750 common shares issuable upon the exercise of the PIPE warrants as the warrants are
exercisable at any time for nominal consideration, and as such, the shares are considered outstanding for the purpose of calculating
basic and diluted net loss per share attributable to common shareholders.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has not
considered the effect of the Chardan Unit Purchase Option that would convert to 242,000 shares of the Company&#x2019;s Common Stock
and warrants to purchase 110,000 shares of the Company&#x2019;s Commons Stock, in the calculation of diluted loss per share, since
the conversion of the Chardan Unit Purchase Option and the exercise of the Chardan Unit Purchase Option Warrants into the Company&#x2019;s
Commons Stock would be anti-dilutive (see Notes 1 and 10).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share
attributable to common shareholders for the periods presented because including them would have been antidilutive:</font></p><br/><table cellpadding="0" cellspacing="0" style=" width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">As
    of<br/>
December&#xa0;31,</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Series
    C redeemable convertible preferred stock</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">7,264,519</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Series
    B redeemable convertible preferred stock</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">4,168,815</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Series
    A redeemable convertible preferred stock</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">16,066,503</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Series
    C redeemable convertible preferred stock warrants</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">271,439</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Series
    A redeemable convertible preferred stock warrants</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">1,608,672</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Common
    stock warrants (see Note 10)</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">4,336,613</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Options
    to purchase common stock</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">7,032,591</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">6,878,172</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Chardan
    Unit Purchase Option to purchase common stock (see Note 1)</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">242,000</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Chardan
    Unit Purchase Option Warrants (see Notes 1 and 10)</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">110,000</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Earn-out
    shares (see Note 3 and 12)</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">9,096,185</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 4pt; vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Total</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">20,817,389</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">36,258,120</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881018562328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>20.
Related Party Transactions</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Related
Party Payables</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
years prior to 2020, the Company incurred expenses for compensation for consulting services provided by a member of the Board
of Directors. These expenses were fully paid as of December 31, 2020. As of December 31, 2019, the outstanding balance of $0.1
million was recorded in accounts payable.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Supply
Agreement</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In August&#xa0;2018, in
conjunction with an investment made in the Company&#x2019;s Series C Preferred Stock and Series C Preferred Stock Warrants by 4Life,
LLC, an investor, the Company entered into a supply agreement with the investor. Under the terms of this agreement, the Company
granted the investor an exclusive license to pursue development of dietary supplements using certain of the Company&#x2019;s intellectual
property (IP). The exclusive rights to the IP will be for a term of 5&#xa0;years from the commencement of sales of licensed product
by the investor, with a deemed commencement date of January 1, 2023 if sales have not yet commenced, and is subject to annual minimum
sales. The agreement may be renewed for additional 5-year terms. If the investor fails to meet the annual minimum sales requirements,
the investor may pay an additional fee to maintain exclusivity or have the investor&#x2019;s license converted to non-exclusive
rights. As part of this agreement, the Company will provide non-pharmaceutical product to the investor for development efforts
and potential future production, and the investor is to pay royalties of 3% of incremental sales, as defined in the agreement.
As of December 31, 2020, the Company had sold $70 thousand of product under this agreement, as well as $62 thousand of product
not under this agreement, and received $0.1 million in advance to be applied against future sales of product under this agreement.
The Company recorded this advanced amount as deferred revenue as of December 31, 2020 within accrued liabilities, and the Company
expects to fulfil the performance obligations to release the deferred revenue in the first half of 2021 as the investor purchases
product. As of December 31, 2020, the investor has made commercial sales of their products under the agreement which the Company
recognized as royalty revenues of $30 thousand. As of and for the year ended December 31, 2019, the Company had not sold any product
under this agreement, and there were no balances outstanding due to or from the investor.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881027644376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic and Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Geographic and Segment Information</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>21.
Geographic and Segment Information</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Geographic
Information</i></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#x2019;s long-lived assets, which were composed of property and equipment, net by location was as follows (in thousands):</font></p><br/><table cellpadding="0" cellspacing="0" style=" width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: bottom; padding-left: 0.125in; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">As
    of<br/>
December&#xa0;31,</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: bottom; padding-left: 0.125in; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">United
    States</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">3,997</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">3,908</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Australia</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">228</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">411</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Total
    property and equipment, net</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">4,225</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">4,319</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Segment
Information</i></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31,
2019, the Company had a single operating segment, development and commercialization of proprietary nanotechnology drug suspensions
(&#x201c;Drugs&#x201d;). The Company identified a second segment, development and commercialization of proprietary dietary supplements
(&#x201c;Supplements&#x201d;), in January&#xa0;2020. The Company&#x2019;s chief operating decision maker, the CEO, now obtains and
reviews separate financial information for Supplements in deciding how to allocate resources to the segments and in assessing performance.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
operating results of the Company&#x2019;s Drugs and Supplements segments for the years ended December 31, 2020 and 2019 were as
follows (in thousands):</font></p><br/><table cellpadding="0" cellspacing="0" style=" width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">As
    of<br/>
December 31,<br/>
2020</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Drugs</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Supplements</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Total</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Revenue
    from external customers</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">206</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">206</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(Loss)
    Income from operations</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(20,355</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">141</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(20,214</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style=" width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/>
December&#xa0;31,<br/>
2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Drugs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Supplements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Revenue from external customers</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="width: 64%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Loss from operations</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(16,332</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(16,332</td><td style="width: 1%; text-align: left">)</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The
Company&#x2019;s long-lived assets, which were composed of property and equipment, net by segment was as follows (in thousands):</font></p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/> December&#xa0;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-indent: -9pt; padding-left: 9pt">Drugs</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,990</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,319</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Supplements</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">235</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#x2014;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total property and equipment, net</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,225</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,319</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881018391784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>22.
Subsequent Events</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">On
January 11, 2021, the U.S. Small Business Administration notified the Company that the PPP loan of $0.6 million was forgiven.
On that date, the Company recorded a gain on forgiveness of the PPP loan of $0.6 million in its consolidated statement of operations
and comprehensive loss.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 27, 2021,
the Company was awarded the Michael J. Fox Foundation grant for $0.5 million and funding is milestone based. On that date, the
grant was recorded in accrued liabilities in the consolidated balance sheets, and as the associated conditions or obligations are
met, the grant funding will be recognized as a reduction in research and development expenses in the consolidated statements of
operations and comprehensive loss.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 16, 2021,
the Company filed a registration statement on Form S-1 to register 4,541,481 shares of Common Stock underlying outstanding warrants
that the Company had issued, among which 2,517,500 and 904,231 warrants were originally issued by Tottenham and Clene Nanomedicine,
respectively, prior to the closing of the Reverse Recapitalization, and 1,119,750 warrants were issued as part of the PIPE offering
in connection with the closing of the Reverse Recapitalization. The Company will receive aggregate gross proceeds of $30.7 million
if all of these warrants are exercised. In addition, the registration statement on Form S-1 included 23,251,553 shares of the Common
Stock to be registered for possible sale by the selling shareholders. The Company will not receive any proceeds from the sales
by the selling shareholders. Incident to the registration of the Common Stock, the Company incurred certain offering costs, which
will be recognized as an expense within general and administrative expenses on the consolidated statement of operations and comprehensive
loss in the first quarter of 2021.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881016004024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use
of Estimates</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets, liabilities and disclosure of contingent assets and liabilities at the date of the
consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and
assumptions made in the accompanying consolidated financial statements include, but are not limited to the valuation of common
stock, stock options, contingent earn-out liability, and Preferred Stock warrants.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual
results may differ from those estimates or assumptions. Estimates are periodically reviewed in light of changes in circumstances,
facts, and experience. Changes in estimates are recorded in the period in which they become known.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RiskAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
and Uncertainties</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
product candidates developed by the Company require approvals from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) or
foreign regulatory agencies prior to commercial sales. There can be no assurance that the Company&#x2019;s current and future product
candidates will receive the necessary approvals or be commercially successful. If the Company is denied approval or approval is
delayed, it will have a material adverse impact on the Company&#x2019;s business and its consolidated financial statements.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to risks common to companies in the development stage including, but not limited to, dependency on the need
for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by
physicians and patients, significant competition, and untested manufacturing capabilities.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to certain risks and uncertainties and believes that changes in any of the following areas could have a material
adverse effect on future financial position or results of operations: ability to obtain future financing; regulatory approval
and market acceptance of, and reimbursement for, product candidates; performance of third-party clinical research organizations
and manufacturers upon which the Company relies; protection of the Company&#x2019;s intellectual property; litigation or claims
against the Company based on intellectual property, patent, product, regulatory or other factors; and the Company&#x2019;s ability
to attract and retain employees necessary to support its growth.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentrations
of Credit Risk</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments which potentially subject the Company to significant concentrations of credit risk consist primarily of cash. The
Company&#x2019;s cash is mainly held in financial institutions. Amounts on deposit may at times exceed federally insured limits.
The Company has not experienced any losses on its deposits of cash and does not believe that it is subject to unusual credit risk
beyond the normal credit risk associated with commercial banking relationships.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash and Cash Equivalents</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company considers
all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. As of December
31, 2020 and 2019, the Company has no cash equivalents and no restricted cash balances.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Inventory</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Inventory is stated
at historic cost on a first -in first-out basis. The Company&#x2019;s inventory consisted of $71,000 in raw materials and $0.1 million
in finished goods as of December 31, 2020. The Company&#x2019;s inventory consisted of $28,000 in finished goods as of December
31, 2019.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Deferred
Offering Costs</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company capitalizes
certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings,
including the Reverse Recapitalization and the PIPE offering, as deferred costs until such financings are consummated. After consummation
of the equity financing, these costs are recorded in stockholders&#x2019; equity (deficit) as a reduction of proceeds generated
as a result of the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately
as a charge to operating expenses in the consolidated statement of operations.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2020, the Company incurred $5.9 million of offering costs, which excludes the fair value of common shares issued as a payment
of related offering costs, to additional paid in capital in connection with the Reverse Recapitalization.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During 2019, the Company
had offering costs that were directly related to its proposed initial public offering of $1.0 million. In September 2019, the Company
terminated its initial public offering registration process. Accordingly, the Company has written off deferred offering costs previously
capitalized to general and administrative expense within the accompanying consolidated statements of operations and comprehensive
loss as of December 31, 2019.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leases</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
inception of a contract, the Company determines if a contract meets the definition of a lease. A lease is a contract, or part
of a contract, that conveys the right to control the use of identified property, plant, or equipment (an identified asset) for
a period of time in exchange for consideration. The Company determines if the contract conveys the right to control the use of
an identified asset for a period of time. The Company assesses throughout the period of use whether the Company has both of the
following: (1)&#xa0;the right to obtain substantially all of the economic benefits from use of the identified asset, and (2)&#xa0;the
right to direct the use of the identified asset. This determination is reassessed if the terms of the contract are changed. Leases
are classified as operating or finance leases based on the terms of the lease agreement and certain characteristics of the identified
asset. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of the
future lease payments.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases laboratory and office space (real estate), and certain equipment under non-cancellable operating and finance leases.
The carrying value of the Company&#x2019;s right-of-use lease assets is substantially concentrated in its real estate leases, while
the volume of lease agreements is primarily concentrated in equipment leases. The Company&#x2019;s policy is to not record leases
with an original term of twelve months or less on the consolidated balance sheets. The Company recognizes lease expense for these
short-term leases on a straight-line basis over the lease term.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
lease agreements may require the Company to pay additional amounts for taxes, insurance, maintenance and other expenses, which
are generally referred to as non-lease components. Such variable non-lease components are treated as variable lease payments and
recognized in the period in which the obligation for these payments was incurred. Variable lease components and variable non-lease
components are not measured as part of the right-of-use asset and liability. Only when lease components and their associated non-lease
components are fixed are they accounted for as a single lease component and are recognized as part of a right-of-use asset and
liability. Total contract consideration is allocated to the combined fixed lease and non-lease component. This policy election
applies consistently to all asset classes under lease agreements.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
may contain clauses for renewal at the Company&#x2019;s option. Payments to be made in option periods are recognized as part of
the right-of-use lease assets and lease liabilities when it is reasonably certain that the option to extend the lease will be
exercised, or is not at the Company&#x2019;s option. The Company determines whether the reasonably certain threshold is met by
considering contract-, asset-, market-, and entity-based factors. In the consolidated statements of earnings, operating lease
expense, which is recognized on a straight-line basis over the lease term, and the amortization of finance lease ROU assets, which
are included in plant, property, and equipment and depreciated, are included in research and development or general and administrative
expenses consistent with the leased assets&#x2019; primary use. Accretion on the liabilities for finance leases is included in
interest expense.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Property
and Equipment</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Property and equipment
are stated at cost less accumulated depreciation. Property and equipment consist of lab and office equipment and leasehold improvements.
Depreciation is calculated using the straight-line method over the estimated economic useful lives of the assets, which are 3-5&#xa0;years
for lab equipment and 3-7&#xa0;years for furniture and fixtures. Leasehold improvements are amortized over the lesser of the estimated
lease term or the estimated useful life of the assets. Costs for capital assets not yet placed into service are capitalized as
construction in progress and depreciated or amortized in accordance with the above useful lives once placed into service. Upon
retirement or sale, the related cost and accumulated depreciation and amortization are removed from the accounts and any resulting
gain or loss is included in the consolidated statements of operations and comprehensive loss. Maintenance and repairs that do not
improve or extend the lives of the respective assets are expensed to operations as incurred.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impairment
of Long-Lived Assets</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived
assets are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of
the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include
significant underperformance of the business in relation to expectations, significant negative industry or economic trends and
significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate an asset group
for recoverability, the Company compares the forecasted undiscounted cash flows expected to result from the use and eventual disposition
of the asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows
expected to result from the use and eventual disposition of an asset group are less than its carrying amount. The impairment loss
would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted
cash flows using market participant assumptions. The Company did not record any impairment losses on long-lived assets during
the years ended December 31, 2020 or December 31, 2019.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Derivative
Instruments</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
convertible promissory notes issued in February through July&#xa0;2020 (&#x201c;2020 Convertible Notes&#x201d;) contained embedded
features that provide the lenders with multiple settlement alternatives. Certain of these settlement features provided the lenders
a right to a fixed number of the Company&#x2019;s shares upon conversion of the notes. Other settlement features provided the lenders
the right or the obligation to receive cash or a variable number of shares upon the completion of a capital raising transaction,
change of control or default of the Company (the &#x201c;Redemption Features&#x201d;).</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Redemption Features of the 2020 Convertible Notes met the requirements for separate accounting and were accounted for as a single
derivative instrument (the &#x201c;2020 Derivative Instrument&#x201d;). The 2020 Derivative Instrument was recorded at fair value
at inception and was subject to re-measurement to fair value at each balance sheet date and immediately prior to the extinguishment
of derivative liability, with any changes in fair value recognized in the consolidated statements of operations and comprehensive
loss. In August 2020, in connection with the Company&#x2019;s issuance and sale of Series D Preferred Stock, all of the outstanding
principal and accrued interest under the convertible promissory notes was automatically converted into shares of Series D Preferred
Stock and the derivative liability was extinguished (see Notes 11 and 12).</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Redeemable
Convertible Preferred Stock</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Reverse
Recapitalization with Tottenham, the Company recorded all shares of redeemable convertible Preferred Stock at their respective
fair values on the dates of issuance, net of issuance costs. The redeemable convertible Preferred Stock was recorded outside of
permanent equity because while it was not mandatorily redeemable, upon certain events considered not solely within the Company&#x2019;s
control, such as a merger, acquisition, or sale of all or substantially all of the Company&#x2019;s assets (each, a &#x201c;Deemed
Liquidation Event&#x201d;), the redeemable convertible Preferred Stock would become redeemable at the option of the holders of at
least a majority of the then-outstanding shares. The Company did not adjust the carrying values of the redeemable convertible Preferred
Stock to the liquidation preferences of such shares because it was uncertain whether or when a Deemed Liquidation Event would occur
that would obligate the Company to pay the liquidation preferences to holders of shares of redeemable convertible Preferred Stock.
Subsequent adjustments to the carrying values of the liquidation preferences would be made only when it becomes probable that such
a Deemed Liquidation Event will occur.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the Reverse Recapitalization, all shares of redeemable convertible Preferred Stock were converted into shares of the Company&#x2019;s
Common Stock. Accordingly, there was no redeemable convertible Preferred Stock outstanding as of December 31, 2020. As of December
31, 2019, the carrying value of the redeemable convertible Preferred Stock was $72.7 million (see Note 17).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ContingentEarnoutPolicyTextBlock', window );">Contingent Earn-out</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Contingent Earn-out</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the Reverse Recapitalization and pursuant to the Merger Agreement, Clene Nanomedicine&#x2019;s common shareholders and Initial Shareholders
of Tottenham are entitled to receive additional shares of the Company&#x2019;s Common Stock upon the Company achieving certain milestones
described in Note 12. In accordance with ASC 815 &#x2013; <i>Derivatives and hedging</i>, the earn-out shares are not indexed to
the Company&#x2019;s own stock and therefore are accounted for as a liability at the reverse recapitalization date and subsequently
remeasured at each reporting date with changes in fair value recorded as a component of other income (expense), net in the consolidated
statements of operations and comprehensive loss.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The estimated fair
value of the contingent consideration was determined using a Monte Carlo simulation that simulated the future path of the Company&#x2019;s
stock price over the earn-out period. The assumptions utilized in the calculation are based on the achievement of certain stock
price milestones including projected stock price, volatility, and risk-free rate. For potential payments related to a product development
milestone, the fair value was determined based on the Company&#x2019;s expectations of achieving such a milestone and the simulated
estimated stock price on the expected date of achievement.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The contingent earn-out
is categorized as a Level 3 fair value measurement (see Fair Value of Financial Instruments accounting policy) because the Company
estimates projections during the earn-out period utilizing unobservable inputs, including various potential pay-out scenarios.
Contingent earn-out payments involve certain assumptions requiring significant judgment and actual results may differ from assumed
and estimated amounts.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Preferred Stock Warrant Liability</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Preferred Stock Warrant Liability</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Reverse
Recapitalization with Tottenham, the Company accounted for freestanding warrants to purchase shares of Preferred Stock as liabilities
on the balance sheet at their estimated fair value as the underlying redeemable convertible Preferred Stock was considered contingently
redeemable and may obligate the Company to transfer assets to the holders at a future date upon the occurrence of a deemed liquidation
event. At the end of each reporting period, changes in the estimated fair value of the warrants to purchase shares of Preferred
Stock were recorded in change in fair value of Preferred Stock warrant liability in the consolidated statements of operations and
comprehensive loss. Changes in the estimated fair value of the Preferred Stock warrant liability were ($14.6) million and ($0.4)
million for the years ended December 31, 2020 and 2019, respectively. In connection with the Reverse Recapitalization, all Clene
Nanomedicine Preferred Stock was converted to the Company&#x2019;s Common Stock and the Clene Nanomedicine Preferred Stock warrants
were converted to warrants to purchase the Company&#x2019;s Common Stock. The Company assessed the features of these warrants and
determined that they qualify for classification as permanent equity. Accordingly, the Company remeasured the warrants to fair value
upon the closing of the Reverse Recapitalization and reclassified the resulting warrant liability to additional paid-in capital
(See Note 16).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsPolicyTextBlock', window );">Common Stock Warrants</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Common Stock Warrants</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company accounts for common stock warrants as either equity
instruments or liabilities in accordance with ASC 480, <i>Distinguishing Liabilities from Equity</i> (&#x201c;ASC 480&#x201d;), depending
on the specific terms of the warrant agreement (See Note 10).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue
Recognition</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects
the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition
for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&#xa0;identify
the contract(s) with a customer; (ii)&#xa0;identify the performance obligations in the contract; (iii)&#xa0;determine the transaction
price, including variable consideration, if any; (iv)&#xa0;allocate the transaction price to the performance obligations in the
contract; and (v)&#xa0;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies
the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in
exchange for the goods or services it transfers to the customer.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine
which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes
as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation
is satisfied or as it is satisfied. The Company typically satisfies its performance obligations via delivery of dietary supplements
to the customer. Payments are due upon receipt for commercial transactions or a prepayment is collected for online retail sales.
The Company&#x2019;s revenue for the year ended December 31, 2020 was comprised of sales of dietary supplements.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded deferred revenue of $0.1 million as of December 31, 2020 from the dietary supply agreement with the related party
discussed in Note 20. The deferred revenue is expected to be recognized in the first half of 2021.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_GrantFundingPolicyTextBlock', window );">Grant Funding</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Grant
Funding</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company may submit
applications to receive grant funding from governmental and non-governmental entities. Grant funding received that involves no
conditions or continuing performance obligations of the Company is recognized upon receipt. Grant funding with conditions or obligations
of the Company is recognized as the conditions or obligations are fulfilled. The Company has made an accounting policy election
to record such unconditional grants, such as the Australian Research and Development Credit, as other income in the consolidated
statements of operations and comprehensive loss. Income from grants is recognized in the period during which the related qualifying
expenses are incurred, provided that the conditions under which the grants were provided have been met. The Company recognizes
Australian Research and Development Credit in an amount equal to the qualifying expenses incurred in each period multiplied by
the applicable reimbursement percentage. During the years ended December 31, 2020 and 2019, the Company recognized $3.2 million
and $0.6 million, respectively, of Australian Research and Development Credit within other income (expense), net in the consolidated
statement of operations and comprehensive loss. As of December 31, 2020 and 2019, the Company recorded $2.1 million and $0, respectively,
of Australian Research and Development Credit receivable in prepaid expenses and other current assets on the consolidated balance
sheets.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
amount received in advance of fulfilling such conditions or obligations is recorded in accrued liabilities in the consolidated
balance sheets if the conditions or obligations are expected to be met within the next twelve months. As of December 31, 2020
and 2019, the Company recorded $0.3 million and $0.1 million, respectively, of Australian Research and Development Credit received
in advance in accrued liabilities.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant
funding recognized on conditional grants is included as a reduction in research and development expenses in the consolidated statements
of operations and comprehensive loss as the conditions are tied to the Company&#x2019;s research and development efforts, and as
the arrangement between the Company and the organizations are not part of the Company&#x2019;s on-going, major, or central operations.
During the years ended December 31, 2020 and 2019, the Company recorded $0.8 million and $0.1 million, respectively of grant funding
as a reduction of research and development expenses.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value of Financial Instruments</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the price that would be received for
an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value
must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried
at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy:</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level
1</b>&#xa0;&#x2014; Inputs based upon quoted market prices for identical assets or liabilities in active markets at the measurement
date.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level
2</b>&#xa0;&#x2014; Observable inputs other than quoted market prices included in Level 1, such as quoted prices for similar assets
and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active;
or other inputs that are observable or can be corroborated by observable market data.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level
3</b>&#xa0;&#x2014; Inputs that are management&#x2019;s best estimate of what market participants would use in pricing the asset
or liability at the measurement date. The inputs are unobservable in the market and significant to the instrument&#x2019;s valuation.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews the fair value hierarchy classification as of the actual date of the event or change in circumstances that caused
the transfer. There was a transfer to Level 1 from Level 3 as of December 31, 2020 for the Notes payable.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 16 for information on the Company&#x2019;s assets and liabilities measured at fair value as of December 31, 2020 and 2019.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation and Transactions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Foreign
Currency Translation and Transactions</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
functional currency of the Company is the United&#xa0;States dollar. The Company&#x2019;s Australian subsidiary determined its
functional currency to be the Australian dollar. The Company uses the United&#xa0;States dollar as its reporting currency for
the consolidated financial statements. The results of its non-U.S. dollar based functional currency operations are translated
to U.S. dollars at the average exchange rates during the period. The Company&#x2019;s assets and liabilities are translated using
the current exchange rate as of the consolidated balance sheet date and shareholders&#x2019; equity is translated using historical
rates.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
resulting from the translation of the consolidated financial statements of the Company&#x2019;s foreign functional currency subsidiaries
into U.S. dollars are excluded from the determination of net loss and are accumulated in a separate component of shareholders&#x2019;
equity. These foreign currency translation gains and losses are currently the only component of other comprehensive income.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also incurs foreign exchange transaction gains and losses for purchases denominated in foreign currencies. Foreign exchange
transaction gains and losses are included in other income (expense) in the Company&#x2019;s consolidated results of operations
as incurred.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comprehensive
Loss</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss includes net loss as well as other changes in stockholders&#x2019; equity (deficit) that result from transactions and economic
events other than those with stockholders. The Company&#x2019;s only element of other comprehensive income (loss) in any period
presented was translation of Australian dollar denominated balances of the Company&#x2019;s Australian subsidiary to U.S. dollars
for consolidation.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share Attributable to Common Shareholders</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
Loss Per Share Attributable to Common Shareholders</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company calculated basic and diluted net loss per share attributable to common shareholders in conformity with the two-class method
required for companies with participating securities. The Company considered all series of redeemable convertible Preferred Stock
to have been participating securities as the holders were entitled to receive non-cumulative dividends on a pari passu basis in
the event that a dividend had been paid on common stock. See Note 19, Net Loss Per Share Attributable to Common Shareholders,
for further details on the Company&#x2019;s historical participating securities, including warrants to purchase redeemable convertible
Preferred Stock and common stock.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the two-class method, basic net loss per share attributable to common shareholders was calculated by dividing the net loss by
the weighted-average number of shares of common stock outstanding during the period, less shares subject to repurchase. The net
loss attributable to common shareholders was not allocated to the redeemable convertible Preferred Stock as the holders of redeemable
convertible Preferred Stock did not have a contractual obligation to share in losses. Diluted net loss per share attributable
to common shareholders was computed by giving effect to all potentially dilutive common stock equivalents outstanding for the
period. For purposes of this calculation, redeemable convertible Preferred Stock, stock options to purchase common stock, early
exercised stock options, and warrants to purchase redeemable convertible Preferred Stock and common stock were considered common
shares equivalents but had been excluded from the calculation of diluted net loss per share attributable to common shareholders
as their effect was anti-dilutive. In periods in which the Company reports a net loss attributable to common shareholders, diluted
net loss per share attributable to common shareholders is the same as basic net loss per share attributable to common shareholders,
since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net
loss attributable to common shareholders during the years ended December 31, 2020 and 2019.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Segment
Information</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has determined that its chief executive officer is the chief operating decision maker (&#x201c;CODM&#x201d;). Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the CODM in making decisions regarding resource allocation and assessing performance. The Company views its operations and
manages its business in two operating segments, the first being that of the development and commercialization of proprietary nanotechnology
drug suspensions, and the second being the development and commercialization of dietary supplements (See Note 21).</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
Taxes</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets
and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements
or in the Company&#x2019;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between
the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences
are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company
assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes,
based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets
will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred
tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process
to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood
that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not
to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial
statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being
realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized
tax benefits, that are considered appropriate as well as the related net interest and penalties.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based
Compensation</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company accounts
for stock-based compensation arrangements with employees using a fair value-based method for costs related to all share-based payments
including stock options and restricted common stock. Stock-based compensation expense is recorded in research and development and
general and administrative expenses based on the classification of the work performed by the grantees.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the Reverse Recapitalization, there was not a public market for the shares of Clene Nanomedicine, Inc. common stock. The Company&#x2019;s
determination of the fair value of stock options on the date of grant utilized the Black-Scholes option-pricing model and was
impacted by its common stock price, as determined by the Board of Directors with input from the Company&#x2019;s management, as
well as changes in assumptions regarding a number of subjective variables. These variables included, but were not limited to,
the expected term that options remained outstanding, the expected common stock price volatility over the term of the option awards,
risk-free interest rates, and expected dividends.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value was recognized over the period during which an
optionee was required to provide services in exchange for the option award and service-based RSUs, known as the requisite service
period (usually the vesting period), on a straight-line basis. For the RSUs with market conditions, the fair value is recognized
over the period based on the expected milestone achievement dates as the derived service period (usually the vesting period), on
a straight-line basis. For the RSUs with performance conditions, the grant date fair value of these awards is the market price
on the applicable grant date, and compensation expense will be recognized when the conditions become probable of being satisfied.
The Company will recognize a cumulative true-up adjustment once the conditions become probable of being satisfied as the related
service period had been completed in a prior period.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stock-based compensation
expense recognized at fair value included the impact of estimated forfeitures. The Company elected to account for forfeitures as
they occurred, rather than estimating expected forfeitures.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After the closing
of the Reverse Recapitalization, the Company determined the fair value of each share of Common Stock underlying stock-based awards
based on the closing price of the Company&#x2019;s Common Stock as reported by Nasdaq on the date of grant. The fair value of the
RSUs with market conditions are determined using a Monte Carlo valuation model. Forfeitures are estimated at the time of grant
and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are charged to expense as incurred. The Company accounts for nonrefundable advance payments for goods and
services that will be used in future research and development activities as expenses when the goods have been received or when
the service has been performed. Research and development expenses consist of costs incurred by the Company for the discovery and
development of the Company&#x2019;s product candidates. Research and development costs include, but are not limited to, payroll
and personnel expenses including stock-based compensation, clinical trial supplies, fees for clinical trial services, consulting
costs, and allocated overhead, including rent, equipment, and utilities.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ClinicalTrialAccrualPolicyTextBlock', window );">Clinical Trial Accrual</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Accrual</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#x2019;s
clinical trial accrual process accounts for expenses resulting from obligations under contracts with CROs, consultants, and under
clinical site agreements in connection with conducting clinical trials. Clinical trial costs are charged to research and development
expense as incurred. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and
may result in payment flows that do not match the periods over which materials or services are provided to the Company under such
contracts. The Company reflects the appropriate clinical trial expense in the consolidated financial statements by matching the
appropriate expenses with the period in which services and efforts are expended. In the event advance payments are made to a CRO,
the payments will be recorded as a prepaid asset which will be amortized over the period of time the contracted services are performed.
In addition to pass-through costs, the Company generally incurs costs in clinical trials in four distinct groups as follows:</p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRO
Start-up&#xa0;&#x2014; These costs include the initial set-up of the clinical trial and usually occurs within a few months after
the contract has been executed and includes costs which are expensed ratably over the start-up period when such period is identifiable
and expensed as incurred when no such period exists. Start-up phase activities include study initiation, site recruitment, regulatory
applications, investigator meetings, screening, preparation, pre-study visits, and training.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRO
Site and Study Management&#xa0;&#x2014; These costs include medical and safety monitoring, and patient administration and data
management. These costs are usually calculated on a per patient basis and expensed ratably over the treatment period beginning
on the date that the patient enrolls.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRO
Close Down and Reporting&#xa0;&#x2014; These costs include analyzing the data obtained and reporting results, which occurs after
patients have ceased treatment and the database of information collected is locked. These costs are expensed as incurred over
the course of any close down and reporting period.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
Party Contracts&#xa0;&#x2014; These costs include fees charged by third parties for various support services which are not provided
by CROs and include such items as lab fees, data quality review costs, and fees incurred for investigational product monitoring
and inventory control. These items are expensed ratably over any identifiable service period with the engaged third-party vendors.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CRO contracts generally include pass-through fees including, but not limited to, regulatory expenses, investigator fees, travel
costs and other miscellaneous costs, including shipping and printing fees. The Company determines accrual estimates through reports
from and discussion with applicable personnel and outside services providers as to the progress or state of completion of trials,
or the services completed. The Company makes estimates of accrued expenses as of each balance sheet date in the consolidated financial
statements based on the facts and circumstances known to the Company at that time.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently
Adopted Accounting Pronouncements</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitating of the Effects of Reference Rate Reform
on Financial Reporting, which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships,
and other transactions in which the reference LIBOR or another reference rate is expected to be discontinued as a result of the
Reference Rate Reform. This ASU is intended to ease the potential burden in accounting for (or recognizing the effects of) reference
rate reform on financial reporting. The new guidance was effective immediately, and through December 31, 2022. As a result of
the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section
107(b) of the JOBS Act, ASU 2016-02 is effective for the Company for fiscal years beginning after December 15, 2020, and all interim
periods thereafter. Early adoption is permitted. The Company early adopted this guidance on March 1, 2020. The adoption of this
guidance did not have a material impact on its consolidated financial statements.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recent
Accounting Pronouncements Not Yet Adopted</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2016, the FASB
issued ASU No. 2016-13, <i>Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>.
The amendments in this ASU, among other things, require the measurement of all expected credit losses for financial assets held
at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions
and other organizations will now use forward-looking information to better inform their credit loss estimates. The guidance is
effective for fiscal years beginning after December 15, 2022. The Company is currently evaluating the expected impact of the new
guidance.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2018, the FASB issued ASU No. 2018-15, <i>Intangibles &#x2013; Goodwill and Other &#x2013; Internal-Use Software (Subtopic
350-40): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract</i>.
The new guidance provides for the deferral of implementation costs for cloud computing arrangements and expensing those costs
over the term of the cloud services arrangement. The new guidance is effective for fiscal years beginning after December 15, 2020.
The Company is currently evaluating the expected impact of the new guidance.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2019, the
FASB issued ASU No. 2019-12, <i>Income Taxes</i> (Topic 740), which amends the existing guidance relating to the accounting for
income taxes. This ASU is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles
of accounting for income taxes and to improve the consistent application of GAAP for other areas of accounting for income taxes
by clarifying and amending existing guidance. The new guidance is effective for fiscal years beginning after December 15, 2021.
The Company does not expect that the adoption of this new guidance will have a material impact on its consolidated statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ClinicalTrialAccrualPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical Trial Accrual Policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ClinicalTrialAccrualPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CommonStockWarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for Common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CommonStockWarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ContingentEarnoutPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Earn-out Policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ContingentEarnoutPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_GrantFundingPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Funding Policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_GrantFundingPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>New Accounting Pronouncements Not Yet Adopted Policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_RiskAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk and Uncertainties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_RiskAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognition of changes in redemption value of mandatorily redeemable shares. Provides the period over which changes in redemption value are accreted, usually from the issuance date (or from the date that it becomes probable that the security will become redeemable, if later) to the earliest redemption date of the security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21459-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881022197672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid expenses and other current assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Prepaid Expenses And Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Schedule of prepaid expenses and other current assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Australia research and development credit receivable</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,148</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">CRO prepayments</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,211</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">413</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accounts receivable</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">21</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Metals to be used in research and development</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">31</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">191</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">112</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">57</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,523</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">661</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses And Other Current Assets [TableTextBlock]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881015286760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif;  width: 100%">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(in
    thousands)</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.25in; padding-left: 0.25in; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Lab
    equipment</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">3,077</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2,707</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Furniture
    and fixtures</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">147</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">162</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Leasehold
    improvements</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">3,889</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">3,430</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Construction
    in progress</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">490</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">410</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.25in; padding-left: 0.25in; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">7,603</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">6,709</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Less
    accumulated depreciation</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(3,378</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
    <td>&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(2,390</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Total
    property and equipment, net</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">4,225</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">4,319</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881018289528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Disclosure Text Block Supplement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued professional fees</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">189</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,826</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued compensation and benefits</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,225</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">817</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued CRO fees</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">788</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">95</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Deferred grant funds</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">301</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">80</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued expense reimbursements</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">33</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">36</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued transaction costs</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,354</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">70</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">24</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,960</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,878</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881022006856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of noncancelable operating lease arrangements</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif;  width: 100%">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(in
    thousands)</font></td><td style="text-align: center; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif">Finance <font style="font-family: Times New Roman, Times, Serif">Leases</font></td><td style="text-align: center; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif">Operating <font style="font-family: Times New Roman, Times, Serif">Leases</font></td><td style="text-align: center; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2021</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">165</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">376</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2022</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">135</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">421</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2023</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">82</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">433</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2024</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">20</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">442</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2025</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">454</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Thereafter</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">530</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.375in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Total
    undiscounted cash flows</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">403</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2,656</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Less
    amount representing interest/discounting</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(8</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
    <td>&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(677</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.375in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Present
    value of future lease payments</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">395</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">1,979</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: bottom; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Less
    lease obligations, current portion</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(190</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
    <td>&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(194</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Lease
    obligations&#xa0;&#x2013; long term portion</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">205</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">1,785</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PropertyPlantAndEquipmentOneTextBlock', window );">Schedule of finance lease obligations and included property and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif;  width: 100%">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(in
    thousands)</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 76%; text-align: left; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><font style="font-family: Times New Roman, Times, Serif">Lab
    equipment</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">920</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">920</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><font style="font-family: Times New Roman, Times, Serif">Furniture
    and fixtures</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">46</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">46</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><font style="font-family: Times New Roman, Times, Serif">Work
    in process</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">228</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">228</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><font style="font-family: Times New Roman, Times, Serif">Total</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">1,194</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">1,194</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><font style="font-family: Times New Roman, Times, Serif">Less
    accumulated depreciation</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(593</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(418</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><font style="font-family: Times New Roman, Times, Serif">Net</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">601</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">776</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of finance and operating lease costs</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif;  width: 100%">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(in
    thousands)</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Finance
    lease costs:</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Amortization</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">175</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">182</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Interest
    on lease liabilities</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">37</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">29</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Operating
    lease costs</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">293</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">325</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Short-term
    lease costs</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">249</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">283</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Variable
    lease costs</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">92</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">103</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Total
    lease costs</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">846</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">922</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of supplemental cash flow information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif;  width: 100%">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(in
    thousands)</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Operating
    cash flows from operating leases</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(635</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(711</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Operating
    cash flows from finance leases</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(37</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(29</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Finance
    cash flows from finance leases</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(194</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(176</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_PropertyPlantAndEquipmentOneTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_PropertyPlantAndEquipmentOneTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881027594232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock Warrant Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Disclosure Text Block Supplement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfPreferredUnitsTextBlock', window );">Schedule fair value of the outstanding warrants</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif;  width: 100%">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: center; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Expiration</font></td>
    <td style="text-align: center; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td><td colspan="2" style="vertical-align: bottom; text-align: center; font-weight: bold; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Exercise&#xa0;Price</font></td><td style="text-align: center; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Warrant</font>s</td>
    <td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Date</font></td>
    <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td><td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Per&#xa0;Share<sup>(1)</sup></font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Outstanding<sup>(1)</sup></font></td>
    <td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 66%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    C preferred stock warrants<sup>(2)</sup></font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 9%; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2023</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%">&#xa0;</td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; width: 9%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">1.9658</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%">&#xa0;</td>
    <td style="text-align: right; width: 9%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">271,439</font></td>
    <td style="width: 1%">&#xa0;</td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Series
    A preferred stock warrants</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2023</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">1.9658</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td>&#xa0;</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">1,608,672</font></td>
    <td>&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfPreferredUnitsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of preferred units of master limited partnerships that have priority over limited partner units in areas including liquidation, redemption, conversion, tax status of distribution or sharing in distributions. This schedule ordinarily includes a description of the preferred units that details various rights including redemption, conversion, liquidation, and sharing in distributions; capital contributed by preferred partners; number of preferred units authorized to be issued, issued, and outstanding; aggregate cumulative cash distributions made to the preferred partners; aggregate cumulative net income earned by the preferred partners; capital account balance of the preferred partners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB TOPIC 4.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfPreferredUnitsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881027619032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsDisclosureAbstract', window );"><strong>Common Stock Warrants Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of outstanding warrants to purchase shares of common stock</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; padding-left: 9pt; text-align: center"><font style="font-size: 10pt"><b>Date Exercisable</b></font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number of</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Shares Issuable</b></p></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Exercise Price</b></font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Exercisable for</b></font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td>&#xa0;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Classification</b></font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Expiration</b></font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#xa0;</td></tr>
<tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; width: 28%; padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">June 2021</font></td>
    <td style="vertical-align: bottom; width: 1%">&#xa0;</td>
    <td style="vertical-align: bottom; width: 1%">&#xa0;</td>
    <td style="vertical-align: bottom; width: 12%; text-align: right"><font style="font-size: 10pt">1,119,750</font></td>
    <td style="vertical-align: bottom; width: 1%">&#xa0;</td>
    <td style="vertical-align: bottom; width: 1%">&#xa0;</td>
    <td style="vertical-align: bottom; width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="vertical-align: bottom; width: 12%; text-align: right"><font style="font-size: 10pt">0.01</font></td>
    <td style="vertical-align: bottom; width: 1%">&#xa0;</td>
    <td style="vertical-align: bottom; width: 1%">&#xa0;</td>
    <td style="vertical-align: bottom; width: 12%; text-align: center"><font style="font-size: 10pt">Common Stock</font></td>
    <td style="vertical-align: bottom; width: 1%">&#xa0;</td>
    <td style="vertical-align: bottom; width: 1%">&#xa0;</td>
    <td style="vertical-align: bottom; width: 12%; text-align: center"><font style="font-size: 10pt">Equity</font></td>
    <td style="vertical-align: bottom; width: 1%">&#xa0;</td>
    <td style="vertical-align: bottom; width: 1%">&#xa0;</td>
    <td style="vertical-align: bottom; width: 12%; text-align: center"><font style="font-size: 10pt">December 2021</font></td>
    <td style="vertical-align: bottom; width: 1%">&#xa0;</td></tr>
<tr>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">December 2020</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">2,407,500</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">$</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">11.50</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt">Common Stock</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt">Equity</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt">December 2025</font></td>
    <td style="vertical-align: bottom">&#xa0;</td></tr>
<tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">December 2020</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">110,000</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">$</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">11.50</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt">Common Stock</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt">Equity</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt">December 2025</font></td>
    <td style="vertical-align: bottom">&#xa0;</td></tr>
<tr>
    <td style="vertical-align: top; padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">December 2020</font></td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid">&#xa0;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,929,113</font></td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt"><font style="font-size: 10pt">$</font></td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: right"><font style="font-size: 10pt">1.97</font></td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><font style="font-size: 10pt">Common Stock</font></td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><font style="font-size: 10pt">Equity</font></td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><font style="font-size: 10pt">April 2023</font></td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt">&#xa0;</td></tr>
<tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">Total</font></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#xa0;</td>
    <td style="vertical-align: bottom; border-bottom: black 4.5pt double">&#xa0;</td>
    <td style="vertical-align: bottom; border-bottom: black 4.5pt double; text-align: right"><font style="font-size: 10pt">5,566,363</font></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 2pt; text-align: right">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 4pt; text-align: center">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#xa0;</td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 2pt; text-align: center">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 2pt; text-align: center">&#xa0;</td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CommonStockWarrantsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CommonStockWarrantsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881046275496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of components of income (loss) before income taxes</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">United&#xa0;States</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(18,985</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(13,812</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Foreign</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">114</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,343</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Loss before provision for income taxes</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(18,871</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(16,155</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of income tax expense (benefit)</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td>Provision for income taxes:</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td>Current tax expense:</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-left: 9pt">Federal</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;-</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;-</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">State</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Foreign</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">146</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total current tax expense (benefit)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">146</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred tax expense:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Federal</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">State</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Foreign</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">260</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total deferred tax expense (benefit)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">260</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total income tax expense (benefit)</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">406</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of income tax reconciliation</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Income tax expense (benefit) at federal statutory rate</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">(3,963</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">(3,393</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">State income taxes (net of federal benefit)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(917</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(721</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Warrant liability</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3,069</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Contingent consideration</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(2,966</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Research and development credits</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(425</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">326</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Other</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">242</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,205</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,366</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,583</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Income tax expense (benefit)</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">406</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">Deferred tax assets (liabilities):</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Net operating loss carryforwards</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">17,958</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">13,502</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Depreciation and amortization</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,810</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,814</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Research &amp; development credits</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,682</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">882</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Lease liability</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">520</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">436</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Right-of-use asset</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(270</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(48</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Accrued interest</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">160</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Non-qualified stock options</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">146</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">130</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Accrued compensation</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">115</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">62</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Other</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(260</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">Total</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">21,861</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">16,755</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(22,121</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,755</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net deferred tax assets (liabilities)</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">(260</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881014125400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif;  width: 100%">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(In
    thousands)</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">General
    and administrative</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">281</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">161</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Research
    and development</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">480</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">238</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Total
    stock-based compensation</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">761</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">399</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of outstanding common stock options and related activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Equity</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&#xa0;of<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price <br/> Per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Term <br/> (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Instrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -9pt; padding-left: 9pt">Outstanding - December 31, 2018</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">5,698,090</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.38</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">6.62</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,089</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">Granted</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,440,717</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2.42</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.66</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">Exercised</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(11,878</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">0.83</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">31</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Forfeited</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(248,757</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.44</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Outstanding - December 31, 2019</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6,878,172</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">0.83</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.36</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">18,105</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">Granted</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">270,555</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.48</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.32</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">Exercised</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(83,232</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">0.94</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">740</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Forfeited</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(32,904</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.65</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Outstanding - December 31, 2020</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">7,032,591</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.97</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">5.34</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">62,462</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td>&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Options vested and exercisable - December 31, 2020</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">5,896,034</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.55</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">4.86</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">52,694</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Options vested and exercisable - Stock options vested and expected to vest December 31, 2020</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">7,032,591</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.97</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">5.34</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">62,462</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of fair value of these stock options awards granted</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style=" width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.25in; padding-left: 0.25in; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif">&#xa0;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.25in; padding-left: 0.25in; width: 72%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Expected
    stock price volatility</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 12%; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">75.00%
- 119.30%</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#xa0;</td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 12%; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">75.00%</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#xa0;</td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Risk-free
    interest rate</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">0.39%
                                         - 0.53%</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#xa0;</td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">1.46%</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Expected
    dividend yield</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">0%</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#xa0;</td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">0%</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#xa0;</td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Expected
    term of options</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">6
years</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#xa0;</td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">6
                                         years</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of restricted common stock activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td>&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&#xa0;of<br/> RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Unvested balance as of December 31, 2019</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="width: 76%; text-indent: -9pt; padding-left: 0.25in">Granted</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">1,507,062</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">10.30</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Vested</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Unvested balance as of December 31, 2020</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">1,507,062</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10.30</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881014111704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value Measurements on a Recurring Basis<br/> December&#xa0;31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -9pt; padding-left: 9pt">Notes payable</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,296</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,296</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Clene Nanomedicine contingent earn-out</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">52,053</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">52,053</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Initial Shareholders contingent earn-out</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5,906</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5,906</td><td style="text-align: left">&#xa0;</td></tr>
</table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif;  width: 100%">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="14" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Fair
    Value Measurements on a Recurring Basis<br/>
December&#xa0;31, 2019</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Level
                                         1</font></td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Level
                                         2</font></td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Level
                                         3</font></td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Total</font></td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Redeemable
    convertible preferred stock warrant liability</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">3,213</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">3,213</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Notes
    payable</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">640</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">640</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of fair value of the initial contingent earn-out</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style=" width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2019</font></td>
    <td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 72%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Expected
    stock price volatility</font></td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 12%; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">85.00</font>%</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"></font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; width: 12%"><font style="font-family: Times New Roman, Times, Serif">N/A</font></td>
    <td style="width: 1%">&#xa0;</td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Risk-free
    interest rate</font></td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">0.40%</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">N/A</font></td>
    <td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Expected
    term</font></td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">5
                                         years</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">N/A</font></td>
    <td>&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of financial liability related to the notes payable, the derivative instrument, the Preferred Stock warrants, and the contingent earn-out measured at fair value</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#xa0;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Notes Payable</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#xa0;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Derivative Instrument</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#xa0;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Preferred Stock Warrants</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#xa0;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Clene Nanomedicine Contingent Earn-out</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#xa0;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Initial Shareholders Contingent Earn-out</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Balance - December 31, 2018</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,518</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Issuance of notes payable</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">600</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Change in fair value</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">40</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">361</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; padding-bottom: 1.5pt; text-align: left">Exercise of Series C preferred stock warrants</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,666</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance - December 31, 2019</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">640</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3,213</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Issuance of convertible promissory notes</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">705</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Initial fair value of instrument</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">64,712</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7,371</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Change in fair value</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">656</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(29</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">14,615</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(12,659</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(1,465</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Extinguishment of preferred stock warrant liability in connection with the conversion of redeemable convertible preferred stock</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(17,828</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1.5pt; text-align: left">Extinguishment of derivative liability in connection with extinguishment of the 2020 Convertible Notes (Note 12)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(676</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance - December 31, 2020</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,296</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">52,053</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,906</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881022047928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RedeemableConvertiblePreferredStockDisclosureAbstract', window );"><strong>Redeemable Convertible Preferred Stock Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Schedule of Preferred Stock</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style=" width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="18" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">December
    31, 2019</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Preferred<br/>
    Shares<br/> Authorized</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Preferred<br/>
    Shares<br/> Issued and<br/> Outstanding</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Carrying<br/>
    Value</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Liquidation<br/>
    Value</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Common
    Stock<br/> Issuable Upon<br/> Conversion</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 40%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Series
    A Preferred Stock</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">17,675,175</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">16,066,503</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">27,485</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">31,584</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">16,066,503</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Series
    B Preferred Stock</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">4,168,815</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">4,168,815</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">16,582</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">16,999</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">4,168,815</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Series
    C Preferred Stock</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">9,192,018</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">7,264,519</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">28,594</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">30,292</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">7,264,519</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Total</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">31,036,008</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">27,499,837</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">72,661</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">78,875</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">27,499,837</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_RedeemableConvertiblePreferredStockDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_RedeemableConvertiblePreferredStockDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881021987272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Shareholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted net loss per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">Numerator:</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -0.125in; padding-left: 0.25in">Net loss attributable to common shareholders</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(19,277</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(16,155</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Denominator:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">Weighted average shares outstanding</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,503,992</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,357,505</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Net loss per share attributable to common shareholders, basic and diluted</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1.10</td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.93</td><td style="padding-bottom: 2pt; text-align: left">)</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of dilutive securities were excluded from the computation of diluted net loss per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style=" width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">As
    of<br/>
December&#xa0;31,</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Series
    C redeemable convertible preferred stock</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">7,264,519</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Series
    B redeemable convertible preferred stock</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">4,168,815</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Series
    A redeemable convertible preferred stock</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">16,066,503</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Series
    C redeemable convertible preferred stock warrants</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">271,439</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Series
    A redeemable convertible preferred stock warrants</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">1,608,672</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Common
    stock warrants (see Note 10)</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">4,336,613</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Options
    to purchase common stock</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">7,032,591</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">6,878,172</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Chardan
    Unit Purchase Option to purchase common stock (see Note 1)</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">242,000</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Chardan
    Unit Purchase Option Warrants (see Notes 1 and 10)</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">110,000</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Earn-out
    shares (see Note 3 and 12)</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">9,096,185</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 4pt; vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Total</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">20,817,389</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">36,258,120</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881018482952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic and Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Schedule of property and equipment, net by location</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style=" width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: bottom; padding-left: 0.125in; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">As
    of<br/>
December&#xa0;31,</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: bottom; padding-left: 0.125in; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">United
    States</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">3,997</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">3,908</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Australia</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">228</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">411</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Total
    property and equipment, net</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">4,225</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">4,319</font></td><td style="padding-bottom: 2pt; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ScheduleOfDrugsAndSupplementsSegmentsTableTextBlock', window );">Schedule of drugs and supplements segments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style=" width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">As
    of<br/>
December 31,<br/>
2020</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Drugs</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Supplements</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Total</font></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Revenue
    from external customers</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">206</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">206</font></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(Loss)
    Income from operations</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(20,355</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">141</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(20,214</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
</table><table cellpadding="0" cellspacing="0" style=" width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/>
December&#xa0;31,<br/>
2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Drugs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Supplements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Revenue from external customers</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="width: 64%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Loss from operations</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(16,332</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(16,332</td><td style="width: 1%; text-align: left">)</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock', window );">Schedule of property and equipment, net by segment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/> December&#xa0;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-indent: -9pt; padding-left: 9pt">Drugs</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,990</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,319</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Supplements</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">235</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#x2014;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total property and equipment, net</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,225</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,319</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ScheduleOfDrugsAndSupplementsSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ScheduleOfDrugsAndSupplementsSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881012637800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 28, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2018 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems', window );"><strong>Nature of the Business and Basis of Presentation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_MergerAgreementPercentage', window );">Merger agreement percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares aggregate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,716,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ProceedsFromReverseRecapitalizationNet', window );">Net proceeds from the reverse recapitalization | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockIssuedDuringPeriodSharesPrivatePlacement', window );">Private placement shares issued</a></td>
<td class="nump">2,239,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from equity issuance | $</a></td>
<td class="nump">$ 22.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Warrants purchase shares</a></td>
<td class="nump">1,119,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IncurredNetLosses', window );">Incurred net losses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.3<span></span>
</td>
<td class="nump">$ 16.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RetainedEarningsAccumulatedDeficit1', window );">Accumulated deficit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=clnn_ChardanMember', window );">Chardan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems', window );"><strong>Nature of the Business and Basis of Presentation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PurchaseOption', window );">Purchase option (in Units)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PerShareUnit', window );">Purchase option (in Dollars per unit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase option | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=clnn_LifeSciCapitalLLCMember', window );">LifeSci Capital LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems', window );"><strong>Nature of the Business and Basis of Presentation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PaymentsForAdvisoryServicesShares', window );">Advisory payment share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">644,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=clnn_CleneNanomedicineMember', window );">Clene Nanomedicine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems', window );"><strong>Nature of the Business and Basis of Presentation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=clnn_CleneNanomedicineMember', window );">Clene Nanomedicine [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems', window );"><strong>Nature of the Business and Basis of Presentation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,136,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems', window );"><strong>Nature of the Business and Basis of Presentation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase option | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap_ExchangeClearedMember', window );">Exchange Ratio [Member] | Clene Nanomedicine [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems', window );"><strong>Nature of the Business and Basis of Presentation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap_ExchangeClearedMember', window );">Exchange Ratio [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems', window );"><strong>Nature of the Business and Basis of Presentation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Newly issued share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap_ExchangeClearedMember', window );">Exchange Ratio [Member] | Common Stock [Member] | Clene Nanomedicine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems', window );"><strong>Nature of the Business and Basis of Presentation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Newly issued share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,032,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_IncurredNetLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incurred net losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_IncurredNetLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_MergerAgreementPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Merger agreement percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_MergerAgreementPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_NatureoftheBusinessandBasisofPresentationDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_PaymentsForAdvisoryServicesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to advisory services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_PaymentsForAdvisoryServicesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_PerShareUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_PerShareUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ProceedsFromReverseRecapitalizationNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the reverse recapitalization net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ProceedsFromReverseRecapitalizationNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_PurchaseOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share units purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_PurchaseOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_RetainedEarningsAccumulatedDeficit1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_RetainedEarningsAccumulatedDeficit1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_StockIssuedDuringPeriodSharesPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of stock issued shares of private placement during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_StockIssuedDuringPeriodSharesPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1828-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=clnn_ChardanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=clnn_ChardanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=clnn_LifeSciCapitalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=clnn_LifeSciCapitalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=clnn_CleneNanomedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=clnn_CleneNanomedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap_ExchangeClearedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap_ExchangeClearedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881012689816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Inventory in raw materials</a></td>
<td class="nump">$ 71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 28,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering costs</a></td>
<td class="nump">5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ProposedPublicOfferingCost', window );">Proposed public offering cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of preferred stock warrant liability</a></td>
<td class="nump">14,615,000<span></span>
</td>
<td class="nump">361,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 15,204,000<span></span>
</td>
<td class="nump">9,563,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=clnn_PreferredStockWarrantMember', window );">Preferred Stock Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of preferred stock warrant liability</a></td>
<td class="nump">$ 14,600,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=clnn_GrantFundingMember', window );">Grant Funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income and expenses</a></td>
<td class="nump">3,200,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid expenses</a></td>
<td class="nump">2,100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAxis=us-gaap_EquipmentMember', window );">Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives of asset</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAxis=us-gaap_EquipmentMember', window );">Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives of asset</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives of asset</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives of asset</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemablePreferredStockMember', window );">Redeemable Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Convertible preferred stock value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,700,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ProposedPublicOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proposed Public Offering Cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ProposedPublicOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=clnn_PreferredStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=clnn_PreferredStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=clnn_GrantFundingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=clnn_GrantFundingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemablePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemablePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881013752072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems', window );"><strong>Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IssuanceOfCommonStockUponReverseRecapitalization', window );">Issuance of common stock upon the Reverse Recapitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,303,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_EarnOutShare', window );">Earn out share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Acquired percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_EntityCommonStockSharesOutstanding1', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,339,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SharesHeldInEscrow', window );">Shares held in Escrow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,716,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Common stock, shares cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,904<span></span>
</td>
<td class="nump">248,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,526,171<span></span>
</td>
<td class="nump">17,357,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherUnderwritingExpense', window );">Deferred underwriting fees (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees', window );">Underwriting fees (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InvestorsPurchasedShares', window );">Investors purchased shares</a></td>
<td class="nump">2,239,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SharesPerShare', window );">Shares per share (in Dollars per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Warrants shares</a></td>
<td class="nump">1,119,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NetProceeds', window );">Net proceeds (in Dollars)</a></td>
<td class="nump">$ 22.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_EarnoutSharesDescription', window );">Earn-out shares, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) 375,000 shares of the Company&#x2019;s Common Stock upon satisfaction of the requirements of Milestone 1; and (ii) another 375,000 shares of the Company&#x2019;s Common Stock upon satisfaction of the requirements of Milestone 2. If Milestone 1 is not achieved but Milestone 2 is achieved, the Initial Shareholders shall receive a catch-up issuance equal to the shares granted upon satisfaction of the requirements of Milestone 1.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=clnn_CleneNanomedicineMember', window );">Clene Nanomedicine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems', window );"><strong>Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_EarnoutSharesDescription', window );">Earn-out shares, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) 3,333,333 shares of the Company&#x2019;s Common Stock if (A) the volume-weighted average price (&#x201c;VWAP&#x201d;) of the shares of the Company&#x2019;s Common Stock equals or exceeds $15.00 (or any foreign currency equivalent) (the &#x201c;Milestone 1 Price&#x201d;) in any twenty trading days within a thirty trading day period within the three years following the closing of the Reverse Recapitalization on any securities exchange or securities market on which the shares of the Company&#x2019;s Common Stock are then traded or (B) the change of control price equals or exceeds the Milestone 1 Price if a change of control transaction occurs within the three years following the closing of the Reverse Recapitalization (the requirements set forth in clause (A) and (B), &#x201c;Milestone 1&#x201d;); (ii) 2,500,000 shares of the Company&#x2019;s Common Stock if (A) the VWAP of the shares of the Company&#x2019;s Common Stock equals or exceeds $20.00 (or any foreign currency equivalent) (the &#x201c;Milestone 2 Price&#x201d;) in any twenty trading days within a thirty trading day period within the five years following the closing of the Reverse Recapitalization on any securities exchange or securities market on which the shares of the Company&#x2019;s Common Stock are then traded or (B) the change of control price equals or exceeds the Milestone 2 Price if a change of control transaction occurs within the five years following the closing of the Reverse Recapitalization (the requirements set forth in clause (A) or (B), &#x201c;Milestone 1&#x201d;); and (iii) 2,500,000 shares of the Company&#x2019;s Common Stock if Clene Nanomedicine completes a randomized placebo-controlled study for treatment of COVID-19 which results in a statistically significant finding of clinical efficacy within twelve months after the closing of the Reverse Recapitalization (&#x201c;Milestone 3&#x201d;). If Milestone 1 is not achieved but Milestone 2 is achieved, the Clene Nanomedicine stockholders will receive a catch-up issuance equal to the shares issued upon satisfaction of Milestone 1. Upon the consummation of the Reverse Recapitalization, the earn-out shares that certain Clene Nanomedicine stockholders are entitled to receive increased by 12,852 as a result of the exercise of stock options during November 2020. Therefore, the total Clene Nanomedicine earn-out shares has increased to 8,346,185 shares of the Company&#x2019;s Common Stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=clnn_CleneNanomedicineMember', window );">Clene Nanomedicine [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems', window );"><strong>Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,136,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=clnn_LifeSciCapitalLLCMember', window );">LifeSci Capital LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems', window );"><strong>Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ServicesLetterAgreementDescription', window );">Services letter agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) 3% of the amount by which the total transaction consideration exceeded $350 million, plus (ii) 7% of cash and cash-equivalents received by Clene Nanomedicine from the Tottenham&#x2019;s trust account. Clene Nanomedicine could elect to pay LifeSci either in cash, equity interests of the surviving company, or a combination of the two. Upon the consummation of the Reverse Recapitalization, 644,164 shares of the Company&#x2019;s Common Stock were issued to LifeSci as consideration for its services as pursuant to the letter agreement (see Note 18).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=clnn_TottenhamMember', window );">Tottenham [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems', window );"><strong>Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=exch_PIPE', window );">PIPE Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems', window );"><strong>Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap_ExchangeClearedMember', window );">Exchange Ratio [Member] | Clene Nanomedicine [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems', window );"><strong>Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems', window );"><strong>Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IssuanceOfCommonStockUponReverseRecapitalization', window );">Issuance of common stock upon the Reverse Recapitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,303,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,566,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Clene Nanomedicine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems', window );"><strong>Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Common stock, shares cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,286,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Exchange Ratio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems', window );"><strong>Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Newly issued share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Exchange Ratio [Member] | Clene Nanomedicine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems', window );"><strong>Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Newly issued share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,032,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_EarnOutShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>the amount of the earn out share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_EarnOutShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_EarnoutSharesDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_EarnoutSharesDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_EntityCommonStockSharesOutstanding1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_EntityCommonStockSharesOutstanding1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_InvestorsPurchasedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of share investors purchased shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_InvestorsPurchasedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_IssuanceOfCommonStockUponReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_IssuanceOfCommonStockUponReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_NetProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_NetProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ServicesLetterAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ServicesLetterAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SharesHeldInEscrow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares held in Escrow.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SharesHeldInEscrow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SharesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SharesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense related to distribution, servicing and underwriting fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1828-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherUnderwritingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred during the period, such as those relating to general administration and policy maintenance that do not vary with and are not primarily related to the acquisition or renewal of insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 720<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35755714&amp;loc=d3e28434-158551<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherUnderwritingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=clnn_CleneNanomedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=clnn_CleneNanomedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=clnn_LifeSciCapitalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=clnn_LifeSciCapitalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=clnn_TottenhamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=clnn_TottenhamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=exch_PIPE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=exch_PIPE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap_ExchangeClearedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap_ExchangeClearedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881011769912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid expenses and other current assets (Details) - Schedule of prepaid expenses and other current assets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Schedule of prepaid expenses and other current assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_AustraliaResearchAndDevelopmentCreditReceivable', window );">Australia research and development credit receivable</a></td>
<td class="nump">$ 2,148<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CROPrepayments', window );">CRO prepayments</a></td>
<td class="nump">1,211<span></span>
</td>
<td class="nump">413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">21<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_MetalsToBeUsedInResearchAndDevelopment', window );">Metals to be used in research and development</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Total</a></td>
<td class="nump">$ 3,523<span></span>
</td>
<td class="nump">$ 661<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_AustraliaResearchAndDevelopmentCreditReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Australia research and development credit receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_AustraliaResearchAndDevelopmentCreditReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CROPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CROPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_MetalsToBeUsedInResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Metals to be used in research and development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_MetalsToBeUsedInResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881011780104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - Property, Plant and Equipment [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PropertyandEquipmentNetDetailsLineItems', window );"><strong>Property and Equipment, Net (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_PropertyandEquipmentNetDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_PropertyandEquipmentNetDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881010179048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - Schedule of property and equipment, net - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ScheduleOfPropertyAndEquipmentNetAbstract', window );"><strong>Schedule of property and equipment, net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquipmentExpense', window );">Lab equipment</a></td>
<td class="nump">$ 3,077<span></span>
</td>
<td class="nump">$ 2,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Furniture and fixtures</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">3,889<span></span>
</td>
<td class="nump">3,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">490<span></span>
</td>
<td class="nump">410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">7,603<span></span>
</td>
<td class="nump">6,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(3,378)<span></span>
</td>
<td class="num">(2,390)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">$ 4,225<span></span>
</td>
<td class="nump">$ 4,319<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ScheduleOfPropertyAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ScheduleOfPropertyAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquipmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents equipment expense including depreciation, repairs, rentals, and service contract costs. This item also includes equipment purchases which do not qualify for capitalization in accordance with the entity's accounting policy. This item may also include furniture expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquipmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881013162952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities (Details) - Schedule of accrued liabilities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ScheduleOfAccruedLiabilitiesAbstract', window );"><strong>Schedule of accrued liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">$ 189<span></span>
</td>
<td class="nump">$ 1,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">1,225<span></span>
</td>
<td class="nump">817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_AccruedCROFees', window );">Accrued CRO fees</a></td>
<td class="nump">788<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_DeferredGrantFunds', window );">Deferred grant funds</a></td>
<td class="nump">301<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued expense reimbursements</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_AccruedTransactionCosts', window );">Accrued transaction costs</a></td>
<td class="nump">1,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 3,960<span></span>
</td>
<td class="nump">$ 2,878<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_AccruedCROFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued CRO fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_AccruedCROFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_AccruedTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued transaction costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_AccruedTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_DeferredGrantFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred grant funds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_DeferredGrantFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ScheduleOfAccruedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ScheduleOfAccruedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881010058360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 02, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,029<span></span>
</td>
<td class="nump">$ 1,081<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEarningsDeficit', window );">Cumulative adjustment to accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RemainingRightofuseAsset', window );">Remaining right-of-use asset</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RecognizedGainOnOperatingLease', window );">Recognized gain on operating lease</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_DescriptionOfOperatingLease', window );">Description of operating lease</a></td>
<td class="text">the Company recorded the right-of-use asset value of $0.4 million, leasehold improvements of $0.4 million, and a lease liability of $0.8 million. The net effect of the change in leases being an increase in right-of-use assets of $56 thousand, an increase in leasehold improvements of $0.5 million, an increase in lease liability of $0.4 million, and a gain on termination of $51 thousand.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FinanceLeaseObligationsWeightedaverageInterestRate', window );">Finance lease obligations weighted-average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.10%<span></span>
</td>
<td class="nump">8.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance lease weighted-average remaining term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 255 days<span></span>
</td>
<td class="text">3 years 255 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_OperatingLeaseObligationsWeightedAverageInterestRate', window );">Operating lease obligations weighted average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.60%<span></span>
</td>
<td class="nump">9.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease weighted-average remaining term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 109 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_DescriptionOfOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_DescriptionOfOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FinanceLeaseObligationsWeightedaverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance lease obligations weighted-average interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FinanceLeaseObligationsWeightedaverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_OperatingLeaseObligationsWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease obligations weighted average interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_OperatingLeaseObligationsWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_RecognizedGainOnOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recognized gain on operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_RecognizedGainOnOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_RemainingRightofuseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_RemainingRightofuseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEarningsDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative earnings (deficits) for relevant time periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEarningsDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881012666616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of noncancelable operating lease arrangements<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=clnn_FinanceLeasesMember', window );">Finance Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems', window );"><strong>Leases (Details) - Schedule of noncancelable operating lease arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent', window );">2021</a></td>
<td class="nump">$ 165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears', window );">2022</a></td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears', window );">2023</a></td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears', window );">2024</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears', window );">2025</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter', window );">Total undiscounted cash flows</a></td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments', window );">Less amount representing interest/discounting</a></td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments', window );">Present value of future lease payments</a></td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Less lease obligations, current portion</a></td>
<td class="num">(190)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities', window );">Lease obligations &#8211; long term portion</a></td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=clnn_OperatingLeasesMember', window );">Operating Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems', window );"><strong>Leases (Details) - Schedule of noncancelable operating lease arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent', window );">2021</a></td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears', window );">2022</a></td>
<td class="nump">421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears', window );">2023</a></td>
<td class="nump">433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears', window );">2024</a></td>
<td class="nump">442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears', window );">2025</a></td>
<td class="nump">454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter', window );">Total undiscounted cash flows</a></td>
<td class="nump">2,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments', window );">Less amount representing interest/discounting</a></td>
<td class="num">(677)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments', window );">Present value of future lease payments</a></td>
<td class="nump">1,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Less lease obligations, current portion</a></td>
<td class="num">(194)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities', window );">Lease obligations &#8211; long term portion</a></td>
<td class="nump">$ 1,785<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_LeasesDetailsScheduleofnoncancelableoperatingleasearrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121569800&amp;loc=d3e45023-112735<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121616839&amp;loc=d3e45280-112737<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121616839&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121616839&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121616839&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121616839&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121616839&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121616839&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount necessary to reduce net minimum lease payments to present value for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121616839&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of minimum lease payments for capital leases net of executory costs, including amounts paid by the lessee to the lessor for insurance, maintenance and taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121616839&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, including portion classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=clnn_FinanceLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=clnn_FinanceLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=clnn_OperatingLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=clnn_OperatingLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881013150936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of finance lease obligations and included property and equipment - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentLineItems', window );"><strong>Leases (Details) - Schedule of finance lease obligations and included property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FinanceLeaseLiabilityGross', window );">Total</a></td>
<td class="nump">$ 1,194<span></span>
</td>
<td class="nump">$ 1,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_AccumulatedDepreciationDepletionAndAmortizationLeases', window );">Less accumulated depreciation</a></td>
<td class="num">(593)<span></span>
</td>
<td class="num">(418)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FinanceLeaseLiabilityNet', window );">Net</a></td>
<td class="nump">601<span></span>
</td>
<td class="nump">776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentLineItems', window );"><strong>Leases (Details) - Schedule of finance lease obligations and included property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FinanceLeaseLiabilityGross', window );">Total</a></td>
<td class="nump">920<span></span>
</td>
<td class="nump">920<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentLineItems', window );"><strong>Leases (Details) - Schedule of finance lease obligations and included property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FinanceLeaseLiabilityGross', window );">Total</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=clnn_WorkInProcessMember', window );">Work in process [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentLineItems', window );"><strong>Leases (Details) - Schedule of finance lease obligations and included property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FinanceLeaseLiabilityGross', window );">Total</a></td>
<td class="nump">$ 228<span></span>
</td>
<td class="nump">$ 228<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_AccumulatedDepreciationDepletionAndAmortizationLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_AccumulatedDepreciationDepletionAndAmortizationLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FinanceLeaseLiabilityGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FinanceLeaseLiabilityGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FinanceLeaseLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance lease liability, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FinanceLeaseLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_LeasesDetailsScheduleoffinanceleaseobligationsandincludedpropertyandequipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=clnn_WorkInProcessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=clnn_WorkInProcessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881014984136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of finance and operating lease costs - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityAbstract', window );"><strong>Finance lease costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization</a></td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">$ 182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">293<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease costs</a></td>
<td class="nump">249<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 846<span></span>
</td>
<td class="nump">$ 922<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881013988088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of supplemental cash flow information - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ScheduleOfSupplementalCashFlowInformationAbstract', window );"><strong>Schedule of supplemental cash flow information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_OperatingCashFlowsFromOperatingLeases', window );">Operating cash flows from operating leases</a></td>
<td class="num">$ (635)<span></span>
</td>
<td class="num">$ (711)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_OperatingCashFlowsFromFinanceLeases', window );">Operating cash flows from finance leases</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FinanceCashFlowsFromFinanceLeases', window );">Finance cash flows from finance leases</a></td>
<td class="num">$ (194)<span></span>
</td>
<td class="num">$ (176)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FinanceCashFlowsFromFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FinanceCashFlowsFromFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_OperatingCashFlowsFromFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_OperatingCashFlowsFromFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_OperatingCashFlowsFromOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_OperatingCashFlowsFromOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ScheduleOfSupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ScheduleOfSupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881012058280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 11, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=clnn_TwoThousandNineteenMDLoanMember', window );">2019 MD Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NotesPayableDetailsLineItems', window );"><strong>Notes Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Outstanding due date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 22,  2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Loan, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The 2019 MD Loan establishes &#x201c;Phantom Shares,&#x201d; based on 119,906 shares of the Company&#x2019;s common stock (based on 863,110 Series C Preferred Shares prior to the Reverse Recapitalization), determined at issuance.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SimpleInterestExpense', window );">Simple interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding', window );">Fair value of long-term notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=clnn_TwoThousandNineteenCecilLoanMember', window );">2019 Cecil Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NotesPayableDetailsLineItems', window );"><strong>Notes Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Outstanding due date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 30,  2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Loan, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The 2019 Cecil Loan establishes &#x201c;Phantom Shares,&#x201d; based on 23,981 shares of the Company&#x2019;s common stock (based on 172,622 Series C Preferred Shares prior to the Reverse Recapitalization), determined at issuance.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SimpleInterestExpense', window );">Simple interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding', window );">Fair value of long-term notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=clnn_PaycheckProtectionProgramNoteMember', window );">PPP Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NotesPayableDetailsLineItems', window );"><strong>Notes Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansPayable', window );">Note payable</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PercentageOfLoanAmountUsedToPayrollExpenses', window );">Percentage of loan amount used for payroll expenses</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Repayment period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrentAndNoncurrent', window );">Payroll expenses</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=clnn_PaycheckProtectionProgramNoteMember', window );">PPP Note [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NotesPayableDetailsLineItems', window );"><strong>Notes Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableToBank', window );">Long term note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_NotesPayableDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_NotesPayableDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_PercentageOfLoanAmountUsedToPayrollExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of loan amount used to payroll expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_PercentageOfLoanAmountUsedToPayrollExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SimpleInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Simple interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SimpleInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the amount outstanding under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableToBank">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, the carrying value as of the balance sheet date of notes payable to banks, excluding mortgage notes, initially due beyond one year or beyond the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableToBank</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=clnn_TwoThousandNineteenMDLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=clnn_TwoThousandNineteenMDLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=clnn_TwoThousandNineteenCecilLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=clnn_TwoThousandNineteenCecilLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=clnn_PaycheckProtectionProgramNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=clnn_PaycheckProtectionProgramNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881012501416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock Warrant Liability (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 11, 2020</div></th>
<th class="th"><div>Apr. 08, 2013</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PreferredStockWarrantLiabilityDetailsLineItems', window );"><strong>Preferred Stock Warrant Liability (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossRecognizedOnAssetsTransferredToSeparateAccountGross', window );">Recognized a loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Outstanding warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PreferredStockWarrantLiabilityDetailsLineItems', window );"><strong>Preferred Stock Warrant Liability (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants expire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,608,672<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PreferredStockWarrantLiabilityDetailsLineItems', window );"><strong>Preferred Stock Warrant Liability (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants expire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Senior equity equal percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PreferredStockWarrantLiabilityDetailsLineItems', window );"><strong>Preferred Stock Warrant Liability (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Exercise price</a></td>
<td class="nump">$ 1.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants</a></td>
<td class="nump">320,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_PreferredStockWarrantLiabilityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_PreferredStockWarrantLiabilityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossRecognizedOnAssetsTransferredToSeparateAccountGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss recognized during the reporting period on assets that were transferred into separate accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 80<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641442&amp;loc=d3e19393-158473<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossRecognizedOnAssetsTransferredToSeparateAccountGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881011774136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock Warrant Liability (Details) - Schedule fair value of the outstanding warrants<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C preferred stock warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredUnitsLineItems', window );"><strong>Preferred Units [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">April 2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Exercise Price Per Share | $ / shares</a></td>
<td class="nump">$ 1.9658<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding | shares</a></td>
<td class="nump">271,439<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A preferred stock warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredUnitsLineItems', window );"><strong>Preferred Units [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">April 2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Exercise Price Per Share | $ / shares</a></td>
<td class="nump">$ 1.9658<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding | shares</a></td>
<td class="nump">1,608,672<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As of December 31, 2019, the most senior equity preferred stock warrants were convertible into Series C Preferred Stock.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The exercise price per share and warrants outstanding, prior to the Reverse Recapitalization, have been retroactively restated as shares reflecting the Exchange Ratio established in the Reverse Recapitalization (See Note 1).</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration Date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredUnitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredUnitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881013109272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Apr. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsDetailsLineItems', window );"><strong>Common Stock Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares, issued</a></td>
<td class="nump">2,239,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Common stock, net proceeds (in Dollars)</a></td>
<td class="nump">$ 22.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Warrants, description</a></td>
<td class="text">Investors in the PIPE offering also received warrants (&#x201c;PIPE Warrants&#x201d;) to purchase a number of shares equal to one-half (1/2) of the number of PIPE Shares, totaling 1,119,750 shares of the Company&#x2019;s Common Stock, at an exercise price of $0.01 per share. Also, pursuant to the Subscription Agreement, the 1,119,750 PIPE Warrants are subject to a 180-day holding period. A holder of the PIPE Warrants may not exercise the PIPE Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of the Company&#x2019;s Common Stock outstanding immediately after giving effect to such exercise.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,893,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in Dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Conversion of warrants into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,929,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Converted price, per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.97<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=clnn_ChardanMember', window );">Chardan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsDetailsLineItems', window );"><strong>Common Stock Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering', window );">Initial public offering purchase unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Initial public offering price, per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Ordinary price, per shares (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=clnn_TottenhamsMember', window );">Tottenham&#8217;s [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsDetailsLineItems', window );"><strong>Common Stock Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,815,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsDetailsLineItems', window );"><strong>Common Stock Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Warrants, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company may redeem those outstanding warrants, in whole and not in part, at a price of $0.01 per warrant if, and only if, the last sales price of the Company&#x2019;s Common Stock equals or exceeds $16.50 per share for any 20 trading days within a 30-trading day period ending three business days before the Company sends the notice of redemption.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,407,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationAndWillExpireYears', window );">Reverse Recapitalization and will expire years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_WarrantExercisePrice', window );">Warrant Exercise Price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsDetailsLineItems', window );"><strong>Common Stock Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Common stock, net proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Initial public offering price, per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.9658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PreferredStockWarrantsOutstandingShares', window );">Preferred stock warrants, outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,929,113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsDetailsLineItems', window );"><strong>Common Stock Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Common stock, net proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Initial public offering price, per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.6018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PreferredStockWarrantsOutstandingShares', window );">Preferred stock warrants, outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,929,113<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CommonStockWarrantsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CommonStockWarrantsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_PreferredStockWarrantsOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock warrants, outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_PreferredStockWarrantsOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ReverseRecapitalizationAndWillExpireYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization and will expire years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ReverseRecapitalizationAndWillExpireYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_WarrantExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_WarrantExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of reason for issuing warrant or right.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of units sold in a public offering of each class of partners' capital account. Units represent shares of ownership of the general, limited, and preferred partners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=clnn_ChardanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=clnn_ChardanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=clnn_TottenhamsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=clnn_TottenhamsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881013060872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants (Details) - Schedule of outstanding warrants to purchase shares of common stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NumberOfSharesIssuable', window );">Number of Shares Issuable</a></td>
<td class="nump">5,566,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=clnn_WarrantsDateMember', window );">June 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NumberOfSharesIssuable', window );">Number of Shares Issuable</a></td>
<td class="nump">1,119,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsExercisable', window );">Exercisable for</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsClassification', window );">Classification</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsExpiration', window );">Expiration</a></td>
<td class="text">December 2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=clnn_WarrantsDate1Member', window );">December 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NumberOfSharesIssuable', window );">Number of Shares Issuable</a></td>
<td class="nump">2,407,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsExercisable', window );">Exercisable for</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsClassification', window );">Classification</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsExpiration', window );">Expiration</a></td>
<td class="text">December 2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=clnn_December20201Member', window );">December 2020 One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NumberOfSharesIssuable', window );">Number of Shares Issuable</a></td>
<td class="nump">110,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsExercisable', window );">Exercisable for</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsClassification', window );">Classification</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsExpiration', window );">Expiration</a></td>
<td class="text">December 2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=clnn_WarrantsDate2Member', window );">December 2020 Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NumberOfSharesIssuable', window );">Number of Shares Issuable</a></td>
<td class="nump">1,929,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsExercisable', window );">Exercisable for</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsClassification', window );">Classification</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsExpiration', window );">Expiration</a></td>
<td class="text">April 2023<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CommonStockWarrantsClassification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CommonStockWarrantsClassification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CommonStockWarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CommonStockWarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CommonStockWarrantsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise Price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CommonStockWarrantsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CommonStockWarrantsExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CommonStockWarrantsExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_NumberOfSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Shares Issuable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_NumberOfSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=clnn_WarrantsDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=clnn_WarrantsDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=clnn_WarrantsDate1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=clnn_WarrantsDate1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=clnn_December20201Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=clnn_December20201Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=clnn_WarrantsDate2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=clnn_WarrantsDate2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881013454168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes (Details) - 2020 Convertible Notes [Member] - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 11, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ConvertibleNotesDetailsLineItems', window );"><strong>Convertible Notes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Annual debt interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_DescriptionOfConvertibleNotes', window );">Description of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The 2020 Convertible Notes were convertible at the earlier of (i) one year, at which point the notes would be convertible into Series C preferred shares at the Series C preferred share issuance price, and (ii) next equity financing of no less than $10.0 million, at which point the notes would be convertible into shares issued in the next equity financing at 90% of the per share issuance price of the next equity financing. The 2020 Convertible Notes contained redemption features that met the requirements for separate accounting and were accounted for as a single derivative instrument. Accordingly, the 2020 derivative instrument of $0.7 million was recorded at fair value at inception as redeemable convertible preferred stock derivative liability in the consolidated balance sheets (see Note 12).<span></span>
</td>
<td class="text">The loss on extinguishment was calculated as the difference between (i) the fair value of the 1,497,135 shares of Series D Preferred Stock issued to settle the 2020 Convertible Notes of $6.9 million and (ii) the carrying value of the 2020 Convertible Notes, including the principal balance of the 2020 Convertible Notes of $6.1 million and accrued but unpaid interest of $76 thousand, net of the unamortized debt discount of $5.7 million, plus the then-current fair value of derivative liability associated with the 2020 Convertible Notes at the time of the extinguishment of $0.7 million.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ConvertibleNotesDetailsLineItems', window );"><strong>Convertible Notes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Stock issued</a></td>
<td class="nump">$ 6.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Convertible shares (in Shares)</a></td>
<td class="nump">1,497,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PercentageOfStock', window );">Percentage of stock</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PreferredStockConvertibleConversionPrice', window );">Convertible per share (in Dollars per share)</a></td>
<td class="nump">$ 4.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ConvertibleNotesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ConvertibleNotesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_DescriptionOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_DescriptionOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_PercentageOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_PercentageOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881015842264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Issuance of derivative instrument</a></td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_DerivativeInstrumentsOfComprehensiveLoss', window );">Derivative instruments of comprehensive loss</a></td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuarantyLiabilities', window );">Contingent earn-out liability fair value</a></td>
<td class="nump">72,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAmountOfFairValueInExcessOfCarryingAmount', window );">Carrying value contingent earn-out</a></td>
<td class="nump">58,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain in fair value of contingent</a></td>
<td class="nump">$ 14,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_DerivativeInstrumentsOfComprehensiveLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_DerivativeInstrumentsOfComprehensiveLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the assets less the liabilities of a derivative or group of derivatives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuarantyLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents a non-contingent liability for the fair value of an obligation to stand ready to perform over the term of a guaranty issued in the event that specified triggering events or conditions occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121555860&amp;loc=d3e11019-110243<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121555860&amp;loc=d3e11049-110243<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuarantyLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAmountOfFairValueInExcessOfCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fair value of reporting unit in excess of carrying amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAmountOfFairValueInExcessOfCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881013060152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax U.S. federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">Effective tax rate</a></td>
<td class="num">(2.15%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpense', window );">Deferred tax liability and expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net operating loss</a></td>
<td class="num">$ (20,214)<span></span>
</td>
<td class="num">(16,332)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ResearchAndDevelopmentCreditExpiryTerm', window );">Term of research and development credit expiration</a></td>
<td class="text">Additionally, the Company has approximately $1.7 million of research and development (R&amp;D) credit carryforwards that will begin to expire after 2034 if not utilized.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">$ 1,682<span></span>
</td>
<td class="nump">$ 882<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net operating loss</a></td>
<td class="num">(72,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 38,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Percentage of taxable income limit</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_OperatingLossExpireTerm', window );">Term of operating loss expiration</a></td>
<td class="text">The remaining balance of $33.4 million will begin to expire after 2034.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RemainingBalanceOfOperatingLoss', window );">Remaining balance of operating loss</a></td>
<td class="nump">$ 33,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net operating loss</a></td>
<td class="num">(59,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 39,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Percentage of taxable income limit</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RemainingBalanceOfOperatingLoss', window );">Remaining balance of operating loss</a></td>
<td class="nump">$ 20,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_IncomeTaxesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_IncomeTaxesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_OperatingLossExpireTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The term of operating loss expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_OperatingLossExpireTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_RemainingBalanceOfOperatingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of remaining balance of operating loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_RemainingBalanceOfOperatingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ResearchAndDevelopmentCreditExpiryTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of research and development credit expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ResearchAndDevelopmentCreditExpiryTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from capitalized costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881014059176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of components of income (loss) before income taxes - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract', window );"><strong>Schedule of components of income (loss) before income taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (18,985)<span></span>
</td>
<td class="num">$ (13,812)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">114<span></span>
</td>
<td class="num">(2,343)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">$ (18,871)<span></span>
</td>
<td class="num">$ (16,155)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881012913784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of income tax expense (benefit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CurrentTaxExpenseAbstract', window );"><strong>Current tax expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">146<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense (benefit)</a></td>
<td class="nump">146<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_DeferredTaxExpenseAbstract', window );"><strong>Deferred tax expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">260<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax expense (benefit)</a></td>
<td class="nump">260<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense (benefit)</a></td>
<td class="nump">$ 406<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CurrentTaxExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CurrentTaxExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_DeferredTaxExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_DeferredTaxExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881015038776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of income tax reconciliation - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ScheduleOfIncomeTaxReconciliationAbstract', window );"><strong>Schedule of income tax reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax expense (benefit) at federal statutory rate</a></td>
<td class="num">$ (3,963)<span></span>
</td>
<td class="num">$ (3,393)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes (net of federal benefit)</a></td>
<td class="num">(917)<span></span>
</td>
<td class="num">(721)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IncomeTaxReconciliationWarrantLiability', window );">Warrant liability</a></td>
<td class="nump">3,069<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingencies', window );">Contingent consideration</a></td>
<td class="num">(2,966)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IncomeTaxReconciliationNondeductibleExpensesResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="num">(425)<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other</a></td>
<td class="nump">242<span></span>
</td>
<td class="nump">1,205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">5,366<span></span>
</td>
<td class="nump">2,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 406<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_IncomeTaxReconciliationNondeductibleExpensesResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of research and development credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_IncomeTaxReconciliationNondeductibleExpensesResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_IncomeTaxReconciliationWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax reconciliation warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_IncomeTaxReconciliationWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ScheduleOfIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ScheduleOfIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881012656536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of deferred tax assets and liabilities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_DeferredTaxAssetsLiabilitiesAbstract', window );"><strong>Deferred tax assets (liabilities):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 17,958<span></span>
</td>
<td class="nump">$ 13,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_DeferredTaxLiabilitiesDeferredExpenseDepreciation', window );">Depreciation and amortization</a></td>
<td class="nump">1,810<span></span>
</td>
<td class="nump">1,814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research &amp; development credits</a></td>
<td class="nump">1,682<span></span>
</td>
<td class="nump">882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_DeferredTaxLiabilitiesLeaseLiability', window );">Lease liability</a></td>
<td class="nump">520<span></span>
</td>
<td class="nump">436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_DeferredTaxAssetsRightofUseAsset', window );">Right-of-use asset</a></td>
<td class="num">(270)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves', window );">Accrued interest</a></td>
<td class="nump">160<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_DeferredTaxAssetsTaxDeferredNonqualifiedStockOptions', window );">Non-qualified stock options</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_DeferredTaxAssetsTaxDeferredAccruedCompensation', window );">Accrued compensation</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="num">(260)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total</a></td>
<td class="nump">21,861<span></span>
</td>
<td class="nump">16,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(22,121)<span></span>
</td>
<td class="num">(16,755)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets (liabilities)</a></td>
<td class="num">$ (260)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_DeferredTaxAssetsLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_DeferredTaxAssetsLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_DeferredTaxAssetsRightofUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets right of use of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_DeferredTaxAssetsRightofUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_DeferredTaxAssetsTaxDeferredAccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_DeferredTaxAssetsTaxDeferredAccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_DeferredTaxAssetsTaxDeferredNonqualifiedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-qualified stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_DeferredTaxAssetsTaxDeferredNonqualifiedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_DeferredTaxLiabilitiesDeferredExpenseDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_DeferredTaxLiabilitiesDeferredExpenseDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_DeferredTaxLiabilitiesLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_DeferredTaxLiabilitiesLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881012593064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,555<span></span>
</td>
<td class="nump">1,440,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 761<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_UnrecognizedStockbasedCompensation', window );">Unrecognized stock-based compensation (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_weightedAverageFairValuesOfOptionsGranted', window );">Fair value of options granted (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.3923<span></span>
</td>
<td class="nump">$ 1.5806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm', window );">Weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=clnn_StockPlan2020Member', window );">2020 Stock Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares authorized</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available to be issued</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_MinimumFairMarketValueOfOptionGrantDescription', window );">Minimum fair market value of option grant, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The exercise prices, vesting periods and other restrictions are determined at the discretion of the Company&#x2019;s Board of Directors, except that the exercise price per share of options may not be less than 100% of the fair market value of the Common Stock on the date of grant.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=clnn_StockPlan2014Member', window );">2014 Stock Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Stock option outstanding (pre-conversion)</a></td>
<td class="nump">53,286,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,286,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock option outstanding (post-conversion)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,032,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,555<span></span>
</td>
<td class="nump">1,440,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonSharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,720,065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Shares granted</a></td>
<td class="nump">1,507,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,507,062<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants', window );">Shares for future grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,492,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,507,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RestrictedStockUnitsDescription', window );">Restricted stock units shares,description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company granted the following shares of restricted common stock under the 2020 Stock Plan: &#x25cf; 370,101 shares to various employees and non-employee directors, which vest on June 30, 2021, subject to the employee&#x2019;s continuous employment through such vesting date. The award represents 5% of the converted stock options under 2014 Stock Plan as a result of the Reverse Recapitalization and complements the 5% closing payment shares held in escrow for Clene Nanomedicine common shareholders (as described in Note 1). The grant-date fair value of these awards was $4.0 million. &#x25cf; 454,781 shares to various employees and non-employee directors, which were eligible to vest based on certain market conditions, subject to the employee&#x2019;s continuous employment through such vesting date. The award complements the Milestone 1 earn-out share entitlement of Clene Nanomedicine shareholders and vests based on the same market condition (as described in Note 3). The grant-date fair value of these awards, using a Monte Carlo simulation, was $4.3 million. Based on the outcome of the market condition as of the December 31, 2020 measurement date, no shares were vested. &#x25cf; 341,090 shares to various employees and non-employee directors, which were eligible to vest based on certain market conditions, subject to the employee&#x2019;s continuous employment through such vesting date. The award complements the Milestone 2 earn-out share entitlement of Clene Nanomedicine. shareholders and vests based on the same market condition (as described in Note 3). The grant-date fair value of these awards, using a Monte Carlo simulation, was $3.5 million. Based on the outcome of the market condition as of the December 31, 2020 measurement date, no shares were vested. &#x25cf; 341,090 shares to various employees and non-employee directors, which were eligible vest based on certain performance conditions tied to the completion of the COVID-19 coronavirus treatment study, subject to the employee&#x2019;s continuous employment through such vesting date. The award complements the Milestone 3 earn-out share entitlement of Clene Nanomedicine shareholders and vests based on the same performance condition (as described in Note 3). The grant-date fair value of these awards was $3.7 million based on a weighted average grant date fair value of $10.82 per share. The Company did not recognize compensation expense because the occurrence of achieving this milestone was not probable. As of the December 31, 2020 measurement date, no shares were vested.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value of RSUs granted (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.3034<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost (in Dollars)</a></td>
<td class="nump">$ 15,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerms', window );">Weighted average period for recognition of unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CommonSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CommonSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_MinimumFairMarketValueOfOptionGrantDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of minimum fair market value of option grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_MinimumFairMarketValueOfOptionGrantDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_RestrictedStockUnitsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of Restricted Stock Units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_RestrictedStockUnitsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) for future granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_StockBasedCompensationDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_StockBasedCompensationDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_UnrecognizedStockbasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_UnrecognizedStockbasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_weightedAverageFairValuesOfOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_weightedAverageFairValuesOfOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=clnn_StockPlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=clnn_StockPlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=clnn_StockPlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=clnn_StockPlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881027751336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Schedule of stock-based compensation expense - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems', window );"><strong>Stock-Based Compensation (Details) - Schedule of stock-based compensation expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">$ 761<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems', window );"><strong>Stock-Based Compensation (Details) - Schedule of stock-based compensation expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems', window );"><strong>Stock-Based Compensation (Details) - Schedule of stock-based compensation expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">$ 480<span></span>
</td>
<td class="nump">$ 238<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881013618440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Schedule of outstanding common stock options and related activity - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract', window );"><strong>Schedule of outstanding common stock options and related activity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding - beginning</a></td>
<td class="nump">5,698,090<span></span>
</td>
<td class="nump">6,878,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Outstanding - beginning</a></td>
<td class="nump">$ 0.38<span></span>
</td>
<td class="nump">$ 0.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Term (Years), Outstanding - beginning</a></td>
<td class="text">6 years 226 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Instrinsic Value, Outstanding - beginning</a></td>
<td class="nump">$ 11,089<span></span>
</td>
<td class="nump">$ 18,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding - ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,032,591<span></span>
</td>
<td class="nump">6,878,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Outstanding - ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.97<span></span>
</td>
<td class="nump">$ 0.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Term (Years), Outstanding - ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 124 days<span></span>
</td>
<td class="text">6 years 131 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Instrinsic Value, Outstanding - ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,462<span></span>
</td>
<td class="nump">$ 18,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of Options, Options vested and exercisable ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,896,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Options vested and exercisable ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Term (Years), Options vested and exercisable ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 313 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InstrinsicValueOptionsVestedAndExercisableEnding', window );">Instrinsic Value, Options vested and exercisable ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Options vested and exercisable - Stock options vested and expected to vest ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,032,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_WeightedAverageExercisePricePerShareOptionsVestedAndExercisableStockOptionsVest', window );">Weighted Average Exercise Price Per Share, Options vested and exercisable - Stock options vested and expected to vest ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_WeightedAverageRemainingTermOptionsVestedAndExercisableStockOptionsVestedAndExercisable', window );">Weighted Average Remaining Term (Years), Options vested and exercisable - Stock options vested and expected to vest ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 124 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InstrinsicValueOptionsVestedAndExercisableStockOptionsVestedAndExpectedToVestEnding', window );">Instrinsic Value, Options vested and exercisable - Stock options vested and expected to vest ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,555<span></span>
</td>
<td class="nump">1,440,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.48<span></span>
</td>
<td class="nump">$ 2.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted', window );">Weighted Average Remaining Term (Years), Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 116 days<span></span>
</td>
<td class="text">9 years 240 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodIntrinsicValue', window );">Instrinsic Value, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83,232)<span></span>
</td>
<td class="num">(11,878)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.94<span></span>
</td>
<td class="nump">$ 0.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsExercised', window );">Weighted Average Remaining Term (Years), Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue', window );">Instrinsic Value, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 740<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,904)<span></span>
</td>
<td class="num">(248,757)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="nump">$ 1.44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsForfeited', window );">Weighted Average Remaining Term (Years) Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue', window );">Instrinsic Value, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_InstrinsicValueOptionsVestedAndExercisableEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_InstrinsicValueOptionsVestedAndExercisableEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_InstrinsicValueOptionsVestedAndExercisableStockOptionsVestedAndExpectedToVestEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_InstrinsicValueOptionsVestedAndExercisableStockOptionsVestedAndExpectedToVestEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options shares exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_WeightedAverageExercisePricePerShareOptionsVestedAndExercisableStockOptionsVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_WeightedAverageExercisePricePerShareOptionsVestedAndExercisableStockOptionsVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_WeightedAverageRemainingTermOptionsVestedAndExercisableStockOptionsVestedAndExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_WeightedAverageRemainingTermOptionsVestedAndExercisableStockOptionsVestedAndExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881013213528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Schedule of fair value of these stock options awards granted - Equity Option [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedLineItems', window );"><strong>Schedule of assumptions used to calculate the fair value of stock option awards granted [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.46%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedLineItems', window );"><strong>Schedule of assumptions used to calculate the fair value of stock option awards granted [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.39%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedLineItems', window );"><strong>Schedule of assumptions used to calculate the fair value of stock option awards granted [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">119.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_StockBasedCompensationDetailsScheduleoffairvalueofthesestockoptionsawardsgrantedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881011891848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Schedule of restricted common stock activity - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems', window );"><strong>Stock-Based Compensation (Details) - Schedule of restricted common stock activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Beginning balance, Number of RSUs, Unvested balance | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance, Weighted Average Grant Date Fair Value, Unvested balance | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of RSUs, Granted | shares</a></td>
<td class="nump">1,507,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">$ 10.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of RSUs, Vested | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of RSUs, Unvested balance | shares</a></td>
<td class="nump">1,507,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Unvested balance | $ / shares</a></td>
<td class="nump">$ 10.30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881015005336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueDetailsLineItems', window );"><strong>Fair Value (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NotesPayableBasedOnClosingPrice', window );">Notes payable based on closing price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_WarrantsToPurchasePreferredStock', window );">Warrants to purchase preferred stock, description</a></td>
<td class="text">Significant unobservable inputs at December 30, 2020 were the fair value of Series D Preferred Stock warrants of $10.82 per share, the fair value of Series A Preferred Stock warrants of $10.82 per share, expected term of 2.3 years, expected volatility of Series D Preferred Stock warrants of 101%, and expected volatility of Series A Preferred Stock warrants of 101%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Significant unobservable inputs at December 31, 2019 were the fair value of Series C Preferred Stock warrants of $4.1699 per share, the fair value of Series A Preferred Stock warrants of $3.1046 per share, expected term of 2 years, expected volatility of Series C Preferred Stock warrants of 49%, and expected volatility of Series A Preferred Stock warrants of 71%.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription', window );">Contingent earn-out, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Pursuant to the Merger Agreement, Clene Nanomedicine&#x2019;s common shareholders immediately prior to the Reverse Recapitalization and Initial Shareholders of Totttenham were entitled to receive additional shares of up to 8,333,333 shares and 750,000 shares of the Company&#x2019;s Common Stock, respectively, upon the Company achieving certain milestones described in Note 3. Upon the consummation of the Reverse Recapitalization, Clene Nanomedicine and the Initial Shareholders are entitled to receive additional shares up to 8,346,185 shares as a result of the exercise of the stock options in November 2020, and 750,000 shares of the Company&#x2019;s Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueDetailsLineItems', window );"><strong>Fair Value (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueMeasurementWithUnobservableInputsNotesPayable', window );">Unobservable inputs fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.1699<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FairValueDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FairValueDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FairValueMeasurementWithUnobservableInputsNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FairValueMeasurementWithUnobservableInputsNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_NotesPayableBasedOnClosingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Notes payable based on closing price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_NotesPayableBasedOnClosingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_WarrantsToPurchasePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants to purchase preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_WarrantsToPurchasePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents a description of such arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881013582488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value (Details) - Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems', window );"><strong>Fair Value (Details) - Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable</a></td>
<td class="nump">$ 1,296<span></span>
</td>
<td class="nump">$ 640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CleneNanomedicineContingentEarnout', window );">Clene Nanomedicine contingent earn-out</a></td>
<td class="nump">52,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InitialShareholdersContingentEarnout', window );">Initial Shareholders contingent earn-out</a></td>
<td class="nump">5,906<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RedeemableConvertiblePreferredStockWarrantLiability', window );">Redeemable convertible preferred stock warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems', window );"><strong>Fair Value (Details) - Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable</a></td>
<td class="nump">1,296<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CleneNanomedicineContingentEarnout', window );">Clene Nanomedicine contingent earn-out</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InitialShareholdersContingentEarnout', window );">Initial Shareholders contingent earn-out</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RedeemableConvertiblePreferredStockWarrantLiability', window );">Redeemable convertible preferred stock warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems', window );"><strong>Fair Value (Details) - Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CleneNanomedicineContingentEarnout', window );">Clene Nanomedicine contingent earn-out</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InitialShareholdersContingentEarnout', window );">Initial Shareholders contingent earn-out</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RedeemableConvertiblePreferredStockWarrantLiability', window );">Redeemable convertible preferred stock warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems', window );"><strong>Fair Value (Details) - Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CleneNanomedicineContingentEarnout', window );">Clene Nanomedicine contingent earn-out</a></td>
<td class="nump">52,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InitialShareholdersContingentEarnout', window );">Initial Shareholders contingent earn-out</a></td>
<td class="nump">$ 5,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RedeemableConvertiblePreferredStockWarrantLiability', window );">Redeemable convertible preferred stock warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,213<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CleneNanomedicineContingentEarnout">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clene Nanomedicine contingent earn-out.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CleneNanomedicineContingentEarnout</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_InitialShareholdersContingentEarnout">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial Shareholders contingent earn-out.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_InitialShareholdersContingentEarnout</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_RedeemableConvertiblePreferredStockWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_RedeemableConvertiblePreferredStockWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881014088696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Details) - Schedule of fair value of the initial contingent earn-out - Contingent earn-out [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=clnn_ContingentEarnoutMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=clnn_ContingentEarnoutMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881012065144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Details) - Schedule of financial liability related to the notes payable, the derivative instrument, the Preferred Stock warrants, and the contingent earn-out measured at fair value - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">$ 640<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueIssuanceOfConvertiblePromissoryNotes', window );">Issuance of convertible promissory notes</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InitialFairValueOfInstrument', window );">Initial fair value of instrument</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable', window );">Extinguishment of preferred stock warrant liability in connection with the conversion of redeemable convertible preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ExtinguishmentOfDerivativeLiability', window );">Extinguishment of derivative liability in connection with extinguishment of the 2020 Convertible Notes (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueOfIssuanceOfNotesPayable', window );">Issuance of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IncreseDecreaseInFairValue', window );">Change in fair value</a></td>
<td class="nump">656<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueExerciseOfSeriesCPreferredStockWarrants', window );">Exercise of Series C preferred stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">1,296<span></span>
</td>
<td class="nump">640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=clnn_DerivativeInstrumentMember', window );">Derivative Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueIssuanceOfConvertiblePromissoryNotes', window );">Issuance of convertible promissory notes</a></td>
<td class="nump">705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InitialFairValueOfInstrument', window );">Initial fair value of instrument</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable', window );">Extinguishment of preferred stock warrant liability in connection with the conversion of redeemable convertible preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ExtinguishmentOfDerivativeLiability', window );">Extinguishment of derivative liability in connection with extinguishment of the 2020 Convertible Notes (Note 12)</a></td>
<td class="num">(676)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueOfIssuanceOfNotesPayable', window );">Issuance of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IncreseDecreaseInFairValue', window );">Change in fair value</a></td>
<td class="num">(29)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueExerciseOfSeriesCPreferredStockWarrants', window );">Exercise of Series C preferred stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=clnn_PreferredStockWarrantsMember', window );">Preferred Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">3,213<span></span>
</td>
<td class="nump">4,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueIssuanceOfConvertiblePromissoryNotes', window );">Issuance of convertible promissory notes</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InitialFairValueOfInstrument', window );">Initial fair value of instrument</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable', window );">Extinguishment of preferred stock warrant liability in connection with the conversion of redeemable convertible preferred stock</a></td>
<td class="num">(17,828)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ExtinguishmentOfDerivativeLiability', window );">Extinguishment of derivative liability in connection with extinguishment of the 2020 Convertible Notes (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueOfIssuanceOfNotesPayable', window );">Issuance of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IncreseDecreaseInFairValue', window );">Change in fair value</a></td>
<td class="nump">14,615<span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueExerciseOfSeriesCPreferredStockWarrants', window );">Exercise of Series C preferred stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,666)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=clnn_ContingentEarnoutMember', window );">Contingent Earn-out [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueIssuanceOfConvertiblePromissoryNotes', window );">Issuance of convertible promissory notes</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InitialFairValueOfInstrument', window );">Initial fair value of instrument</a></td>
<td class="nump">64,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable', window );">Extinguishment of preferred stock warrant liability in connection with the conversion of redeemable convertible preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ExtinguishmentOfDerivativeLiability', window );">Extinguishment of derivative liability in connection with extinguishment of the 2020 Convertible Notes (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueOfIssuanceOfNotesPayable', window );">Issuance of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IncreseDecreaseInFairValue', window );">Change in fair value</a></td>
<td class="num">(12,659)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueExerciseOfSeriesCPreferredStockWarrants', window );">Exercise of Series C preferred stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">52,053<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=clnn_InitialShareholdersContingentEarnoutMember', window );">Initial Shareholders Contingent Earn-out [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueIssuanceOfConvertiblePromissoryNotes', window );">Issuance of convertible promissory notes</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InitialFairValueOfInstrument', window );">Initial fair value of instrument</a></td>
<td class="nump">7,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable', window );">Extinguishment of preferred stock warrant liability in connection with the conversion of redeemable convertible preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ExtinguishmentOfDerivativeLiability', window );">Extinguishment of derivative liability in connection with extinguishment of the 2020 Convertible Notes (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueOfIssuanceOfNotesPayable', window );">Issuance of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IncreseDecreaseInFairValue', window );">Change in fair value</a></td>
<td class="num">(1,465)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueExerciseOfSeriesCPreferredStockWarrants', window );">Exercise of Series C preferred stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">$ 5,906<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ExtinguishmentOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extinguishment of derivative liability in connection with extinguishment of the 2020 Convertible Notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ExtinguishmentOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extinguishment of preferred stock warrant liability in connection with the conversion of redeemable convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FairValueExerciseOfSeriesCPreferredStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This value for exercise of Series C preferred stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FairValueExerciseOfSeriesCPreferredStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FairValueIssuanceOfConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This value for issuance of convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FairValueIssuanceOfConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FairValueOfIssuanceOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This value for issuance of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FairValueOfIssuanceOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_IncreseDecreaseInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This value for change in fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_IncreseDecreaseInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_InitialFairValueOfInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This value for initial fair value of instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_InitialFairValueOfInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=clnn_DerivativeInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=clnn_DerivativeInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=clnn_PreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=clnn_PreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=clnn_ContingentEarnoutMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=clnn_ContingentEarnoutMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=clnn_InitialShareholdersContingentEarnoutMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=clnn_InitialShareholdersContingentEarnoutMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880938539272">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Apr. 30, 2015</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RedeemableConvertiblePreferredStockDetailsLineItems', window );"><strong>Redeemable Convertible Preferred Stock (Details) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from private offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 22,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 153,571<span></span>
</td>
<td class="nump">$ 1,754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Aggregate of converted shares (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,893,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConversionBasis', window );">Shares conversion basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#x201d; In connection with the closing of the Reverse Recapitalization, the Preferred Stock converted into 36,893,894 shares of Common Stock on a 1:0.1389 basis (see Note 1).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockDescription', window );">Conversion rights, description</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each share of Series A, Series B, Series C, and Series D Preferred Stock shall automatically be converted into shares of common stock upon the earlier of (i) the closing of the sale of common stock in an underwritten public offering pursuant to a registration statement under the Securities Act of 1933, the public offering price of which is not less than $30.0 million in the aggregate, (ii) the date, or the occurrence of an event, specified by vote or written consent, or agreement of the holders of a majority of the then outstanding shares of Preferred Stock (voting together as a single class and not as separate series and on an as-converted basis), or (iii) a closing of a merger with a publicly-traded entity that has no operations other than searching for an operating company with which to merge (a &#x201c;SPAC&#x201d;) at a value per share in accordance with the restated certification incorporation, resulting in at least $30.0 million of proceeds to the Company (including any cash acquired in the merger with the SPAC).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RedeemableConvertiblePreferredStockDetailsLineItems', window );"><strong>Redeemable Convertible Preferred Stock (Details) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares of common stock issued (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,066,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.9658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from private offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ConversionOfSecuredPromissoryNotes', window );">Conversion of secured promissory notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceIncrease', window );">Conversion price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.9658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RedeemableConvertiblePreferredStockDetailsLineItems', window );"><strong>Redeemable Convertible Preferred Stock (Details) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares of common stock issued (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,168,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from private offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NetOfIssuanceCosts', window );">Issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CashConsiderationReceived', window );">Cash consideration received</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceIncrease', window );">Conversion price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.0778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RedeemableConvertiblePreferredStockDetailsLineItems', window );"><strong>Redeemable Convertible Preferred Stock (Details) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares of common stock issued (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,849,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,935,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.1699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.1699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from private offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NetOfIssuanceCosts', window );">Issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Warrants issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SharesIssuedUponConversionOfConvertiblePromissoryNote', window );">Shares issued upon conversion of convertible promissory note (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,080,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_WarrantsSharesInExercise', window );">Warrants shares in exercise (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceIncrease', window );">Conversion price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.1699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member] | Investor [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RedeemableConvertiblePreferredStockDetailsLineItems', window );"><strong>Redeemable Convertible Preferred Stock (Details) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares of common stock issued (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,929,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,334,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RedeemableConvertiblePreferredStockDetailsLineItems', window );"><strong>Redeemable Convertible Preferred Stock (Details) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares of common stock issued (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,896,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.6018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from private offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NetOfIssuanceCosts', window );">Issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Aggregate of converted Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceIncrease', window );">Conversion price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.6018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member] | Convertible Notes Payable [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RedeemableConvertiblePreferredStockDetailsLineItems', window );"><strong>Redeemable Convertible Preferred Stock (Details) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Aggregate of converted shares (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,497,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member] | Investor [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RedeemableConvertiblePreferredStockDetailsLineItems', window );"><strong>Redeemable Convertible Preferred Stock (Details) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares of common stock issued (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,394,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Retroactively restated for the reverse recapitalization as described in Note 1</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CashConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash consideration received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CashConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ConversionOfSecuredPromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of secured promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ConversionOfSecuredPromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_NetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_NetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_RedeemableConvertiblePreferredStockDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_RedeemableConvertiblePreferredStockDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SharesIssuedUponConversionOfConvertiblePromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued upon conversion of convertible promissory note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SharesIssuedUponConversionOfConvertiblePromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_WarrantsSharesInExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants shares in exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_WarrantsSharesInExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConvertibleConversionPriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share increase in conversion price of convertible common stock. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConvertibleConversionPriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881013186344">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock (Details) - Schedule of Preferred Stock - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred Shares Authorized (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">31,036,008<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TemporaryEquitySharesIssuedAndOutstanding', window );">Preferred Shares Issued and Outstanding (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,499,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 78,875<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TemporaryEquitySharesCommonStockIssuableUponConversion', window );">Common Stock Issuable Upon Conversion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,499,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 72,661<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred Shares Authorized (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,675,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TemporaryEquitySharesIssuedAndOutstanding', window );">Preferred Shares Issued and Outstanding (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,066,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 31,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TemporaryEquitySharesCommonStockIssuableUponConversion', window );">Common Stock Issuable Upon Conversion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,066,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 27,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred Shares Authorized (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,168,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TemporaryEquitySharesIssuedAndOutstanding', window );">Preferred Shares Issued and Outstanding (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,168,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 16,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TemporaryEquitySharesCommonStockIssuableUponConversion', window );">Common Stock Issuable Upon Conversion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,168,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 16,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred Shares Authorized (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,192,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TemporaryEquitySharesIssuedAndOutstanding', window );">Preferred Shares Issued and Outstanding (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,264,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 30,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TemporaryEquitySharesCommonStockIssuableUponConversion', window );">Common Stock Issuable Upon Conversion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,264,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 28,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Retroactively restated for the reverse recapitalization as described in Note 1</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_TemporaryEquitySharesCommonStockIssuableUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Issuable Upon Conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_TemporaryEquitySharesCommonStockIssuableUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_TemporaryEquitySharesIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Shares Issued and Outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_TemporaryEquitySharesIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881012583512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common share, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PreferredStockShares', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IssuanceOfCommonStockUponReverseRecapitalization', window );">Issuance of common stock upon the reverse recapitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,303,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RecapitalizationShare', window );">Recapitalization share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">644,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InvestorsPurchasedShares', window );">Investors purchased shares</a></td>
<td class="nump">2,239,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Shares price (in Dollars per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Warrants purchase shares</a></td>
<td class="nump">1,119,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in Dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NetProceeds', window );">Net proceeds (in Dollars)</a></td>
<td class="nump">$ 22.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,526,171<span></span>
</td>
<td class="nump">17,357,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,526,171<span></span>
</td>
<td class="nump">17,357,505<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_InvestorsPurchasedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of share investors purchased shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_InvestorsPurchasedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_IssuanceOfCommonStockUponReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_IssuanceOfCommonStockUponReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_NetProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_NetProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_PreferredStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock Shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_PreferredStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_RecapitalizationShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_RecapitalizationShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1828-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881015804968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Shareholders (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NumberOfSharesIssuableOnExerciseOfWarrants', window );">Number of shares issuable on exercise of PIPE warrants</a></td>
<td class="nump">1,119,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ChardanUnitPurchaseOptionToPurchaseCommonStock', window );">Purchase option to common stock</a></td>
<td class="nump">242,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ChardanUnitPurchaseOptionWarrants', window );">Purchase of warrants</a></td>
<td class="nump">110,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ChardanUnitPurchaseOptionToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ChardanUnitPurchaseOptionToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ChardanUnitPurchaseOptionWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ChardanUnitPurchaseOptionWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_NumberOfSharesIssuableOnExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issuable on exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_NumberOfSharesIssuableOnExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881018513400">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Shareholders (Details) - Schedule of basic and diluted net loss per share - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (19,277)<span></span>
</td>
<td class="num">$ (16,155)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">17,503,992<span></span>
</td>
<td class="nump">17,357,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common shareholders, basic and diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (1.10)<span></span>
</td>
<td class="num">$ (0.93)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Retroactively restated for the reverse recapitalization as described in Note 1</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881014907496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Shareholders (Details) - Schedule of dilutive securities were excluded from the computation of diluted net loss per share - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract', window );"><strong>Schedule of dilutive securities were excluded from the computation of diluted net loss per share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SeriesCRedeemableConvertiblePreferredStock', window );">Series C redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,264,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SeriesBRedeemableConvertiblePreferredStock', window );">Series B redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,168,815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SeriesARedeemableConvertiblePreferredStock', window );">Series A redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,066,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SeriesCRedeemableConvertiblePreferredStockWarrantsinShares', window );">Series C redeemable convertible preferred stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares', window );">Series A redeemable convertible preferred stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,608,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrants', window );">Common stock warrants (see Note 10)</a></td>
<td class="nump">4,336,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_OptionsToPurchaseCommonStockinShares', window );">Options to purchase common stock</a></td>
<td class="nump">7,032,591<span></span>
</td>
<td class="nump">6,878,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ChardanUnitPurchaseOptionToPurchaseCommonStock', window );">Chardan Unit Purchase Option to purchase common stock (see Note 1)</a></td>
<td class="nump">242,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ChardanUnitPurchaseOptionWarrants', window );">Chardan Unit Purchase Option Warrants (see Notes 1 and 10)</a></td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_EarnoutSharessee', window );">Earn-out shares (see Note 3 and 12)</a></td>
<td class="nump">9,096,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Total</a></td>
<td class="nump">20,817,389<span></span>
</td>
<td class="nump">36,258,120<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ChardanUnitPurchaseOptionToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ChardanUnitPurchaseOptionToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ChardanUnitPurchaseOptionWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ChardanUnitPurchaseOptionWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_EarnoutSharessee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_EarnoutSharessee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_OptionsToPurchaseCommonStockinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_OptionsToPurchaseCommonStockinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ScheduleOfDilutiveSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SeriesARedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SeriesARedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SeriesBRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SeriesBRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SeriesCRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SeriesCRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SeriesCRedeemableConvertiblePreferredStockWarrantsinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SeriesCRedeemableConvertiblePreferredStockWarrantsinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881014972616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Related party transaction, description</a></td>
<td class="text">Under the terms of this agreement, the Company granted the investor an exclusive license to pursue development of dietary supplements using certain of the Company&#x2019;s intellectual property (IP). The exclusive rights to the IP will be for a term of 5 years from the commencement of sales of licensed product by the investor, with a deemed commencement date of January 1, 2023 if sales have not yet commenced, and is subject to annual minimum sales. The agreement may be renewed for additional 5-year terms. If the investor fails to meet the annual minimum sales requirements, the investor may pay an additional fee to maintain exclusivity or have the investor&#x2019;s license converted to non-exclusive rights. As part of this agreement, the Company will provide non-pharmaceutical product to the investor for development efforts and potential future production, and the investor is to pay royalties of 3% of incremental sales, as defined in the agreement. As of December 31, 2020, the Company had sold $70 thousand of product under this agreement, as well as $62 thousand of product not under this agreement, and received $0.1 million in advance to be applied against future sales of product under this agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Commercial sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_RelatedPartyTransactionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_RelatedPartyTransactionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919370-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121603689&amp;loc=d3e36975-112693<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918703-209980<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121606570&amp;loc=SL77919784-209982<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881012641112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Geographic and Segment Information (Details) - Schedule of property and equipment, net by location - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems', window );"><strong>Geographic and Segment Information (Details) - Schedule of property and equipment, net by location [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">$ 4,225<span></span>
</td>
<td class="nump">$ 4,319<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems', window );"><strong>Geographic and Segment Information (Details) - Schedule of property and equipment, net by location [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">3,997<span></span>
</td>
<td class="nump">3,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_AU', window );">Australia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems', window );"><strong>Geographic and Segment Information (Details) - Schedule of property and equipment, net by location [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">$ 228<span></span>
</td>
<td class="nump">$ 411<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881013302120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic and Segment Information (Details) - Schedule of drugs and supplements segments - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsLineItems', window );"><strong>Geographic and Segment Information (Details) - Schedule of drugs and supplements segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue from external customers</a></td>
<td class="nump">$ 206<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(Loss) Income from operations</a></td>
<td class="num">(20,214)<span></span>
</td>
<td class="num">(16,332)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=clnn_DrugsMember', window );">Drugs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsLineItems', window );"><strong>Geographic and Segment Information (Details) - Schedule of drugs and supplements segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue from external customers</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(Loss) Income from operations</a></td>
<td class="num">(20,355)<span></span>
</td>
<td class="num">(16,332)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=clnn_SupplementsMember', window );">Supplements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsLineItems', window );"><strong>Geographic and Segment Information (Details) - Schedule of drugs and supplements segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue from external customers</a></td>
<td class="nump">206<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(Loss) Income from operations</a></td>
<td class="nump">$ 141<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_GeographicandSegmentInformationDetailsScheduleofdrugsandsupplementssegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=clnn_DrugsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=clnn_DrugsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=clnn_SupplementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=clnn_SupplementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881010237944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Geographic and Segment Information (Details) - Schedule of property and equipment, net by segment - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems', window );"><strong>Geographic and Segment Information (Details) - Schedule of property and equipment, net by segment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">$ 4,225<span></span>
</td>
<td class="nump">$ 4,319<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=clnn_DrugsMember', window );">Drugs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems', window );"><strong>Geographic and Segment Information (Details) - Schedule of property and equipment, net by segment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">3,990<span></span>
</td>
<td class="nump">4,319<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=clnn_SupplementsMember', window );">Supplements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems', window );"><strong>Geographic and Segment Information (Details) - Schedule of property and equipment, net by segment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">$ 235<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=clnn_DrugsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=clnn_DrugsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=clnn_SupplementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=clnn_SupplementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881011825256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 11, 2021</div></th>
<th class="th"><div>Feb. 16, 2021</div></th>
<th class="th"><div>Jan. 27, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PaycheckProtectionProgramLoan', window );">PPP loan forgiven</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_GainOnForgivenessLoan', window );">Gain on forgiveness PPP loan</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FoundationGrantCost', window );">Foundation grant amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventDescription', window );">Subsequent events, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On February 16, 2021, the Company filed a registration statement on Form S-1 to register 4,541,481 shares of Common Stock underlying outstanding warrants that the Company had issued, among which 2,517,500 and 904,231 warrants were originally issued by Tottenham and Clene Nanomedicine, respectively, prior to the closing of the Reverse Recapitalization, and 1,119,750 warrants were issued as part of the PIPE offering in connection with the closing of the Reverse Recapitalization.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_AggregateGrossProceedWarrantsExercised', window );">Aggregate gross proceed warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SaleOfStockholdersCommonStock', window );">Sale of stockholders common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,251,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_AggregateGrossProceedWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_AggregateGrossProceedWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FoundationGrantCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FoundationGrantCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_GainOnForgivenessLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_GainOnForgivenessLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_PaycheckProtectionProgramLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_PaycheckProtectionProgramLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SaleOfStockholdersCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SaleOfStockholdersCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SubsequentEventsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SubsequentEventsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>113
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M,W![59VQJQLCM^[4^2@-G&'=Y8;1C"G[ GR_DM*\W=@$S2\=D_\!4$L#!!0
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MZ$%E_(WQ?&!ZM0P(#U#@&[%SJ.1JJ YZ7M!%HYH)KG;U64$M(2+[XRM!2 M
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MCP1X:92MB0 W4./^EG7J-*.TVW,/[;F'*AQ#@G,1)F$:D0*$):UD]!Y@^ M
M<^@(BG2AAOHW_(^(1CLCJS)B;[W'<PNYR#J=/1Z2HIL*M5,LNBD@-LQV(J^;
M:&IB \_;R?QN,L-H)PE$2&B.W7VREKOQWMWX.'>_I:WO=A7FI'AWE.O5L!+7
M[XS,0Z>:T#+GF/=^-R&TJ7/G<R2NKK&OKJ$LUX?-)HFCL!I1T-[LP^TE< PD
MJI\:1U(_I1$;H9T4FS B9Q/:X J2/Y+).1#U2)IP%IIP/*,;#HZ>OJ:L F56
MK9B;^YB;REAY1;%E'&<!OR5Y3,E^"3;[UT+!.O9?0$J'T#1!_)(XRHI2]!:Z
M4&<F(8;9:;S.W'(YTBN1!T1=$XZG"<?7A!.\'J?%'VO/'^MG\>>P5Q5Q29VQ
MA$M6MX6XV(00<G12@@]WE[UWEZTL]?4/DD=QH707> KS/$S%#4P-+W&*W7T9
M6Q;_5E$B#VA@FG \33B^)IS@]3@MQCA[QCCZ&-/7I-192=CC=)H4=EW+Y49I
MUTKLX?YQ]_YQC_;/SAG9AHU@A*U'#26IO])HP+A%$\["[79Q7"P\35GYFG "
M99%;88?S9AH^'Q?XOD;0@RMA@=IJ  UJH)8S$!WE2_QQ($M 9;FK.?B4J7A+
M^GY=;^B4=3>4)S_8M6C6>M$#*7.%TFJ(*S0!+6H@KH_B&H6NW'Q=0$%/L=M$
M:#0"J)[9?\QR$C^D(-K2-T0:/8.2OAN*9$>&</G?;5$RQ4K(AU&:@=IJ"!\T
M 2UT 7FZ@/P:Z##44\R)&.HT;38T$@94BPTW=.B=9(7P==AC*@NWTFI(N#4!
M+70!>; KK4RA!4U.N/)U91CT9]@.>R/E0+4&(U,*76%$C<X$P4:6Q<V9KGJR
M%-/E6@#.B84?1P$OH$ -L4U.>ODT"ML38$\MU[0YEWP>A>X+T T.^<LHY$!8
M;MNV.:_<]*$C#KW-PD9<@FK!YQ@!5<3(BQY<6<]D=B54VW!=!]O<9$60$MK8
MM,VYK.4U@@A4"Q.#)B0]6+)ZOEZ]J-V@"6@!N[J+[?#C+TV9^;J  G6IV_%O
M%!YXO,0S;%XR2MM16PWA@MUQAF-;4#8 :?0+J%85=NN-1;VHD#<+D='!0B0O
M:,1IF;%9#%M<?+G##-)ZP\-37*Y N2+@&V'@['^T6SF,_ZP&ND('CY(_:JO6
MVA*$AC7'?)_23<AUNPO8U5(HE-F=JKQ>3*F;BB:@0%QR2SIM;>0;J!9=_C_T
MZ&V+HY0BV-4YIMAR7.RX!D^6;M).RO82<2.,H#YAI(S3AVU<K-@TCWE5(A>"
M) [OXH3M.9"X+QH1'.%2]"C)16TUH&O3!;1  NW&=A#_IM.5GZ\+*.@M>)MK
MC>B$U K1X?)/JSUN-_12V0+9+AB68)/'CV')$"B+*'&%_!FE4ZFMAO!'ETZ%
M!((/=##F^:-+J=(%%/06O,V?@_TL:D7I)_"GKVOO*9&,2[HT+M05>0S30*XK
MF7B@1NE!:KGFUQ<'[%97-0R8>C*4N4J7/J0+:($$*HOI\FO"GJ[\?%U 06_!
MVU1IU"&DGM]+FUU8@$WX_#)NR,EN*US68I:0*:-V!*FMAC!%UYX@74">+B!?
M%U"@ :C-MD8%0L?O,1K,MM[N?)12I+8:PKRND&09!K1DH_A&1D)JZ><R(2D!
M-V&:K<DRCNA3UIVSD3US%PGS=)IM2^JT*'M(XS^IWP9/@0I",\CHJQ,BL6M'
MB5-JJR&NU25.Z0+R4%<OFEJ&#;GQFZ\KPZ _PS:[&I$*J<4D+XW+.$QV#:O>
MAOZ_Y]<HP4MM-81?NG8\H:YR-K4QOU;@Z<K/UP44]!:\S:Y&\D-J)6W,5H0>
M2!D9-.E;U[J %J@KE-G\2IJG*S=?%U#04^PV$1IQ#ZEULE=L1>A!EO%!UV8M
M74 +74">+B ?=:5'Y'0.5*@3M8]3--(D5@M]JLT(/::R0Q.Z-$)=0 M=0![N
M:G93Z"*;6\OT=648]&?8#GNC$F*U/B?9C(#FPHAJTJRN>@HEV:Y06[5.0'';
M%48!+W!70H,F[FPI^#0*W1.@3QD\_^KY/ K>%\!CQ.V*^3(*.A!!\[LA;OJ@
ME?L5<"-'XB//U\GW*PA)>]&#*^N\=(F*N"LJFJZ)+"@;R^&#(W!JD4]PP..*
M/S<J.^!![[R![S%8QTDBD1A[<I<Y#G<:*3;G)G_(0PT^I$_7M<%,%Y"O"RC0
M -1F5B-"XN-%R%<RJT\DZBF)C&7=S52VXUHN0CS/-$MKN)'6\.#C>QT?RB;N
MI+-.W%[5S=;4Z5G^#%(ZAQ</V49I;[A[WL]RW$[;U77@3Q>0IPO(UP44: !J
M\ZY1)_'@8W\_B7>]37N42(D%YP0-UX;8Y&FH^: @9A)=^TXCJ^ Q&LA%C]4W
M4N;9[@,QR3.@A2PKE?T^RZMHY+5\EW?65PNP)$64QW<[[6^GY*FJUL@"N&?R
MS@_7ZHJHK7Y^168'7P59D_RA^J(.TT6W:5D?3=K?WG^VYZ+ZW@EW_Q*>7(GN
M7\.3CZ+["WCR273?@R>?1?=]>/)%=#^ )S>B^Q^P?1)@6_"$TH<^<81/7/JD
M^F;,K/'&[HM&09@_Q&D!$G)//3-_;].6E.\^$K3[46:;ZA,J=UE99NOJ<D7"
M)<E9 OK\/J-1J'^P#/:?:CK_"U!+ P04    " #NG'I2^II>?[L"  !?!@
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MI*]-(#H-4#K0 #<-<+]!/-" - V( 5I[9F#=T8I>7TKQ$DEM#6_37TQL3&M
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M8C>I/H-DDDI_YG3+*UKP/^O5N::.UFIK-E;@LP"WAKB$N)Q,T(ST%UQA%\]
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MOL>$FK;:=WVU8W$=K3;NY/7[W][\^'CV AOOVD;?6M=C)9".+8&3?31EVU1
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MI'V;LE%;1YVM(J*XGM=&YB3I5&ZM2.79V5V=]QWRCLXL68TDTV8=$%Q\H_H
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MR^3APK"=JT(< ?G=\UF+< )90W :_A(> <<5LL EQ*UT>W4W@KT4PS'N#ZK
M5UDH<+EG0]-S1'),<*V<BXP'?[!@*>Y=F5KO)F&#^>PQ7LS$=.V:KQ6%$LLR
M&SX203# TNFUGQ1Q;VFK%FU-1<%G3.X99^_ZJ%E F8[AX9"1)NE$@1K>NF(
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MP.^+%B@7/M $Z7\&\.K_ 5!+ P04    " #NG'I2NG<=H/LH  #)A0  &
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MFU7;-4 M_W-B@R_#!E_2!E_^OZ#W]-K72_/XY;/WK3/PV$]M5P MPR_N=LX
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MV?OENV7VJ@9 <)N73;_-;G+00 5*1Z*EL__XMV^OKR^_?_7RAGZZ^OX<L&I
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M^MLBH3>^E]$R]#3\'B1(!^8FHH@>6=F2K#10Z7"6BO@O_H07@IH4C/,NF*J
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M6[)(1/3T1;OS5HY"@RKRE;#F46M1M?TX5O97DF'D;=_T6]#VDJZ=R7Z.BAM
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M-@?D)M2%?^VK>H4Q>!*(177HJ<LH4(CO54RNFU9JUZ["/[9+<SO131FHHJB
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M>N>)W=#/WDG;L]]X.KX=#SUEOIGW#\]GIG=<&A"X)==D,KT-0?=DW@M6M9Y
M-\H2'?MM3>\?:F= ^JU2=A!<@/%%7?T%4$L#!!0    ( .Z<>E)I&BFROP(
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MM'91.P>R%TK9D^ 2](M\_0=02P,$%     @ [IQZ4E#%&;M_"   718  !D
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M#[98BD086="( ^! 5CCT!74D) 2C%-*8WSNVNP4AZ$N]4DY&?/F0>NL3R&$
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M -'('#-N:XU*A.R?F3!]>U0BKY$2GQH*5Y:>G1W-K9"( 4""(2E!E=!NC?G
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MH<Q4G2>$ [X)&%: B2@T-*A^P!="B97&#+INZ-:TV!,ZK)L=,*IT6_ X"Y
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M421H^ #]/M7DI>J"%30OUR[^!5!+ P04    " #NG'I2%P4B>9D&   ?$@
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MOD _:1U' ^CQOI$FIQ2FQ%FS1N=%)],=Q"4<W(6M:FGN?_[I:+EX\:L?#,2
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MB6L?.1; ]Y7%7M>]L(/A(GGZ#U!+ P04    " #NG'I2TD3*/_4!  ";!
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M6^I;-XS"8*!M8_L=+5(SQVU#KP>X$$#G)VOQ;(0$TWM4_ )02P,$%     @
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M$3=-DSLD%A4RW>FV,H"P;#P%M11SM&1?=3SH_T ^'J:^)MQVXA90%*U'?%.
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MU@8Y+/B!\AXZ7B?S/YI<13^Y,I7@OAS2W^I!.>0'$T P6/C_^PD J$S'#T@
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M#R@"2ZPMGUKQ2?3@/RPOP0 OC\1T-<'_D^4D^.3D"8[EF:] :+8*?BV0LVS
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MC10 D!;@^5I#ZO"%#FA^57+U7U!+ P04    " #NG'I2J[=-27(.  "D+P
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M[&:AX,E:#Z$F8M4"\* =T,[X)%';PK&T51$I-6V%/QL'N*)YS/.0IT 4&H9
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M#^(S9 OJJ7%_0,K<>H\N"9V<5S"^\@"B)22-CT_$'A?Z9T @^#(0Z&?XQT!
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MIQ=V(N^_E/F.[V&O\A*8SA\W"L%6T MXOLZ!/>X+;5!?S'_]'U!+ P04
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M-<#?MQ)U-1L;H/N@6OT%4$L#!!0    ( .Z<>E+BZP]>T 4  -T-   9
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MWKRY'>[\&GO82X1!-J2(5DOH+"<E9)]4B)H-.O.1^("-:L,83$L7VZ?<SNC
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M]_A+B<&MK!LFUM]_=Y'$Y]<:*BF6)Q452@Y,:S1Z "N2*V&%"B&CVU+3.UE
MHZ@S*+-V6O%;RQNK=P"".LEB34"9U[)BFJ"@D!4U  U'7( I9:M)3!]?!7,=
MR"*P<:7@QI?!5\$-YL&C808U?(!T<'EY[I_113!O;90JSB!)+F 4Q\$7:5@5
M'"+S 4:#)!F[9QI?;CRTYXJYMB91FF&]0&53+;!L!D05H?,1E(R< IK2I4*P
M^IA+'>WQ!M0,GJG).<V.!WFK1I5QXON75].Y37$TU %!,"$-9J60E5RN(5<M
MH;6Z\3U/!T<V+$ET?4<OM%O'U\>G-FX])YZ3-EYP=-0PDZ3WWQ/*NZ=NFZ9"
M*[<E\;@]VU 9  7S9R9:*V-#N,>MSZFLY%CL."S'C+NF7K,G5)V//_Y*T:(R
MDPM#GQ)M^08*GVT7)H,:1K((!2>76?ZD>!L\6L$..TO*JLBMKI(@C016N7Q$
M^HYHV:J,4HM.K>+.64ZAE;19KVV,@?@Z'2)#9U>PM8!0J.N[G#&O&.SBY:MQ
MAU:OR?*U8FMD2@/:'KF7>LZ53MSFH*\\IH/#%>1U[NKSE?% .2!:# HE:\ 7
M@TJ0^_R7!96ML!/Z)=&9_P^.?I%:'U-Q4+*0PZU49S=E)-TY2J)!.A[#,:WC
M4=R=)/$(C@-71>\Q@<-,W"^P)%Y3'I\-TC1QRD_V]O]K+^LB]WXK@[U6YAWA
M6UBT:3_!KF.2= R.;G+M&]E!)O]L9*]]J88[HP!Y=>D&'BI!V0KCIX+^M)^I
MYGZ4V%[W ]EGII:V$BLL2#0Z/:<11ODAQV^,;-Q@L9"&0NB6)<V%J.P%>E](
MZF[=QBKH)\W9WU!+ P04    " #NG'I2<:L!'?D$  "$"P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970R.2YX;6RE5DUOVS@0O>M7$$:/6MN2[:8MD@!)VF)3
MH*U1M[N'Q1XH:2P1H4B7I.*XOWX?25FQMXG1Q1XL4]3,FS>?Y/E6FSO;$#GV
MT$IE+T:-<YLWDXDM&VJY'>L-*7Q9:]-RAU=33^S&$*^"4BLG^73Z<M)RH4:7
MYV%O:2[/=>>D4+0TS'9MR\WNFJ3>7HRRT7[CBZ@;YS<FE^<;7M.*W+?-TN!M
M,J!4HB5EA5;,T/IB=)6]N9Y[^2#PAZ"M/5@S[TFA]9U_N:TN1E-/B"25SB-P
M_-W3#4GI@4#C>X\Y&DQZQ</U'OU]\!V^%-S2C99_BLHU%Z-7(U;1FG?2?=';
MWZGW9^'Q2BUM>+)ME,U?CUC96:?;7AD,6J'B/W_HXW"@\&KZC$+>*^2!=S04
M6+[ECE^>&[UEQDL#S2^"JT$;Y(3R25DY@Z\">NYRU166OG>D''MWCZ<]GSC
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M5]D\N<NW9;[)URDL+8*$49  0&46@8MCI(!,^T-:'G&8<XYD7729!6+K8/,
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M)%H$JF@-X:4GHP,HP$0'=V@&8'B-<'7L&:+(%M"G92[B'XY)BB*7BG!/AZR
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M$FQ&V>^Y QDU$'D$R;4-@$27 HBE?0ZF?4U\+P3&@-#?V%7=4>82^ZB3?W;
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MM6@OR>GGR('G$P  E0-WP[28$)&C]:9Q\J^]$F>=*Q11D>H4*P_6N]C7RV$
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M1$M6EO[T1H1G")$4"BH'>L22:8L* !Z4D(##&<$67_+@G>)P3F2)I F#.QF
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M>H)=$ORWR$RQ;>#W-\LG3^'-\/C//QY C05BW&+9;V$W\.KU_.7S)WP-I/L
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M:<BR;EK2&XG* NB\D-(<%C9!_^HN_@%02P,$%     @ [IQZ4IAHBKE+!
MC H  !D   !X;"]W;W)K<VAE971S+W-H965T,S0N>&ULE5;;;MM&$'WG5PQ8
MH[  Q^)5E%Q)@)W4:("D-6(W>2CZL"*7TL)++K.[M.Q^?6>6%".GENH -K6W
MN9XS@YEOE;XW&\XM/%:R-@M_8VUS,1Z;?,,K9LY5PVN\*96NF,6M7H]-HSDK
MG% EQU$03,85$[6_G+NS&[V<J]9*4?,;#::M*J:?KKA4VX4?^KN#3V*]L70P
M7LX;MN:WW/[9W&C<C0<MA:AX;82J0?-RX5^&%U<9O7<//@N^-7MKH$A62MW3
MYGVQ\ -RB$N>6]+ \.>!O^52DB)TXVNOTQ],DN#^>J?]VL6.L:R8X6^5_"(*
MNUGX4Q\*7K)6VD]J^QOOXTE)7ZZD<5_8=F^SQ(>\-595O3!Z4(FZ^V6/?1[V
M!*;! 8&H%XB<WYTAY^4[9MERKM46-+U&;;1PH3II=$[4!,JMU7@K4,XN/W ,
MR<#I'5M);D;SL46E=#7.>P57G8+H@((P@H^JMAL#O]8%+YXK&*,W@TO1SJ6K
MZ*C&=SP_AS@\@RB(@B/ZXB'$V.F+#^D3)I?*M)K#'7^T<"55?@]_7:Z,U4B*
MOX^82 83B3.1'#!QB[52M)*#*J%6=<[JG$O**&#U:&9%O09)F0:F-:O7'&EM
MS4O)/FJ'*O3"-"SG"Q]+T'#]P/WEJ:@]NU&M875A1G M:C(//;)_# YT!QYF
M-803""<I?N-L0@<1A'$*2132)H9I!$D<TSI!$"!)(EJG\ :2-/'N-AS+O[1<
MXT$:!]Z=LDQZ;5U@HE5;6UY SLP&2JQX TD00W0V22?>!VZ,QRIZ@O7L JB=
M9P)E<&?'.PUT>#J%$9Q.L@Q&WDWWUGM@LG5)+EM+>'8Y;=B3RR?$LQ3"LUDV
MZTQUMVHEQ9I1"S!G6%%:XU-HE'9-X32<!60FG"5HQF7(VQ. GW^:1F'X"TB%
M'J&3U2!Y@IFA#(9GV32%(QQ*!PZEK^90V6/XGP@ ,<9TY;+%6H-&$[WLDSOE
M7UO14!Y>HM51TZ^B%14C?D+,+5MY@S',P POW->[;G4M"!B/'"K%(ZV1 1/\
M\[Y@=_9$34[GB Y$T93^._9@&@D"]^UYDN=MU4I&;"J(++E@'63I+";(DA )
MXOW.R85)0)3.LLDQ("8#$),?!H+B^;Z4<V5>KN&CZG\PV7TU>WLF+[S+BDCX
M#^N)&&:.B-/(>]\7DH?GG804;"6DL )QB#.(9M[0$/9UXD4,<91ZMQM4_8:8
M_OPZF4$TC;W/3 OJ:\\N9]@^@KAO _L7)S!%[(D;T3%@L@&8[-7 F+9II&NC
M2)ZAVV!I=',*)N8E9([K/PC"MY3M];52J^I[3E#(IQ-LI2-:9&&(##TL_*S*
MG2@BY"2C&0KNH/]_,=>]W (K8/12IL=[$T+%]=K-009<L^V&A>%T&+4NNPGC
MV_-N3OO(]%I@)Y*\1-'@/,/>HKO9I]M8U;AY8Z4L3B]NN<%QD6MZ@/>E4G:W
M(0/# +K\%U!+ P04    " #NG'I2-@Q\6H\"  !B!0  &0   'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q]5-]OVC 0?N>O.$5[:"5$?D IK2 2=)TV:=50
MZ=:':0\F.8A5Q\[.3D/_^]D.9%0JO,0^Y[[OOCO?>=HH>M$%HH%=*:2>!84Q
MU6T8ZJS DNF!JE#:/QM%)3/6I&VH*T*6>U IPB2*QF')N S2J3];4CI5M1%<
MXI) UV7)Z&V!0C6S( X.!X]\6QAW$*;3BFUQA>9GM21KA1U+SDN4FBL)A)M9
M,(]O%R/G[QU^<6STT1Y<)FNE7ISQ+9\%D1.$ C/C&)A=7O$.A7!$5L;?/6?0
MA73 X_V!_8O/W>:R9AKOE'CFN2EFP22 '#>L%N91-5]QG\^5X\N4T/X+3>L[
MLLY9K8TJ]V"KH.2R7=EN7X<CP"0Z 4CV@,3K;@-YE9^98>F45 /DO"V;V_A4
M/=J*X])=RLJ0_<LMSJ1+6P0DPAQ61F4O\,R(F#3PG;,U%]R\P<436PO4E]/0
MV'@.%69[[D7+G9S@CA-X4-(4&NYECOE[@M *[=0F![6+Y"SC9\P&,(S[D$1)
M=(9OV&4_]'S#4WQ<9T+IFA"><&=@(5P-5G55";2=9^#W?*T-V=;Y<R;:J(LV
M\M%&)Z*M[$3EM4#8,$[PRD2-H#9@"KO41ALF<RZWT+17H#\J^-D ;H!O=<4R
MG 5V0C72*P;I_:[BQ/P(W.^0,JX1EL0S/-QUSS:./4*"5<%L)2[B2_AQI,?:
MO1421]V[@ZKK%^W[Y2 6+I)+F%?$1<_>S1 ^03RX&5]-(+F.^Z/AS8%A?IK!
MH^$].NZ/HTE_?)W 1_4/C_J^1-KZZ=:0J5J:=@2ZT^X!F;=S\]^]?7T>&&VY
MU"!P8Z'1X/HJ &HGNC6,JOP4K96Q,^FWA7T$D9R#_;]1RAP,%Z![5M-_4$L#
M!!0    ( .Z<>E)DCZ,"N@(  !0&   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,V+GAM;*55WV_:,!!^[U]QBO:P21%Q$GZ4"I" ,FV3.J'2K0_3'DQR$*N.
MG=I.H?_]; <R.K5,TUZ(S[[ON^]\OF.TD^I!%X@&]B47>AP4QE174:2S DNJ
M.[)"84\V4I746%-M(UTII+D'E3Q*".E')64BF(S\WE)-1K(VG E<*M!U65+U
M/$,N=^,@#HX;MVQ;&+<13485W>(*S;=JJ:P5M2PY*U%H)@4HW(R#:7PUZSI_
M[_"=X4Z?K,%ELI;RP1F?\W% G"#DF!G'0.WG">?(N2.R,AX/G$$;T@%/UT?V
MCSYWF\N::IQ+?L]R4XR#RP!RW-":FUNY^X2'?'J.+Y-<^U_8-;Y]ZYS5VLCR
M +8*2B::+]T?[N$$<$G> "0'0.)U-X&\RFMJZ&2DY Z4\[9L;N%3]6@KC@E7
ME)51]I19G)G,95G:RUD9F3W /56*"J/A_1U=<]0?1I&Q,9QGE!WX9@U?\@9?
MG,"-%*;0L! YYB\)(BNN59@<%<Z2LXS7F'4@C4-(2$+.\*5MQJGG2_\IXVNF
M,RYUK1!^3-?:*/M<?IZ)UFVC=7VT[AO15K:+\IHCR W8GM"&BIR)+>R.@8V$
MJE9985\6Z((JU,XU:T1J)_*U(IP-ZAKY2E<TPW%@.U6C>L)@8I\'PF*/*F/:
M5??B:UVN4;EHJR;N9ZUK=W+T0E@JEKT @1T#,.=4:[9A&?6-M=A73/GEQ9=:
MH*M3#'$8Q\-PT"/P#DB'Q/#BVA>/-3//8$N+7H.#7)Q:!)*P2P9ACSB"..Y8
MHK\Q]/Y@B&,2DO_!A\-D:--('4-G.'B58%HIQIU_>G$G#>70"WO]?ICV4WCM
M]40GG5JBVOIYI&VY:V&:IFUWVY$W;3K]MWLS+V^HVC*A@>/&0DEGT M -3.H
M,8RL?-^OI;%3Q"\+.[91.0=[OI'2' T7H/TCF/P"4$L#!!0    ( .Z<>E(Y
MT9@K>00  $ +   9    >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;)U6;6_C
M-@S^GE\A!,.0 DYCRR]QLC1 7W98@;M;T?9V'X9]4&PF$<Z6?)+<M/OUHV3'
M2;'4O>U+(LGD0_(A17&QD^J;W@(8\EP60E\,M\94\\E$9ULHF3Z7%0C\LI:J
M9 :W:C/1E0*6.Z6RF%#?3R8EXV*X7+BS.[5<R-H47,"=(KHN2Z9>KJ"0NXMA
M,-P?W//-UMB#R7)1L0T\@/E2W2G<33J4G)<@-)>"*%A?#"^#^=74RCN!/SCL
M]-&:V$A64GZSF]O\8NA;AZ" S%@$AG]/< U%88'0C>\MYK S:16/UWOT#RYV
MC&7%-%S+XBO/S?9BF Y)#FM6%^9>[GZ#-I[8XF6RT.Z7[!K9Q!^2K-9&EJTR
M>E!RT?RSYY:'(X7T+07:*E#G=V/(>7G##%LNE-P19:41S2Y<J$X;G>/")N7!
M*/S*4<\L;T4F2R"/[!DT&3VR50'Z;#$Q"&T%)ED+<]7 T#=@ DH^26&VFOPJ
M<LA? TS0I\XQNG?LBO8BWD!V3L+ (]2G?@]>V 4:.KSPW4#)#==9(76M@/QY
MN=)&86G\U6,BZDQ$SD3TAHD'O#%Y70"1:X+&*BE &&UWO#$^0JOZC*P +Q/L
M#XVE_A3C_<8L+<A-,!M\$=Q 3AX,,YC#G\@H2+U9&I,SMPZ]%)-S-L :Q@H5
M) @B,J)>&(5X^!']V;M3*?G$W5W#[2OG6LQT&K28B1?$B-]#6=Q1%O\P90>3
M!)ZQZ6@D; 4"UMR<K,A>9-O,YKIB&5P,L5MI4$\P7-Z]&>.<' B]KI7"S!U[
M,A]\@!P4*\B8C >.:K?J6(T2W#U*@Q+9O]4/@;22-[ &E,K_BPV:^)V-_(3^
MD9%CT3Y:2>2C-Z0GD4F7R.3_)%)!)D7&"\YL#SZ5Q5[8TUD\9.JV+S9FR+HE
M5".9M9'JA2C+ZBCT9@G6OUV$,WL1&K9?%?U(X).(T>PQ.MS1+)A:W2G%^S#X
MRI1BF&T,<85QFA<2>GXR0_JOL2%RL;&E@"1H;F'<2X37;Y8D"#$>W&-,3&5;
MPD2.27W"1[(JG08FEV/S&$74WN20)H/?S184H1$E@4?]>'"]98B.3I,G5M0-
M-"OPE64B Q)[(=J@7IR&_32]6P+3K@2F/UP"K^J3:0T8B@UQSQ(_W?)Z#;Q7
M##<G;(Z.#)[-!Y]M2BN7![$AMAN3#//W@MU@QU2N23#U9G%*L&O&/D5$M)/Q
MEEITGY52&?YW<Q!@9_7=;W3(X\^LK'XYF<G 2U)*TI0./@*.$4<%$V,$49@,
MW$0TENMQC9]= %@J4]_66I1BJ5UFF:HQ/BX,8/R&!.Z:?Y9B_+UF!5]S_(@3
M0_8-@[0N:M=M@M#O5.VSA/EO PABDM"VKD:V9Z E:J]#TSDHQI8$:,6;QC%Z
MK;%+GBJU$:5>8"^#>QJF]FEP3)\J@E<)V1L]77Z3HZFF!+5QLQLF3-;"- -.
M=]J-AY?-5'00;V;+3TQM.-)1P!I5_?,IOAVJF=>:C9&5FY%6TN#$Y99;''%!
M60'\OI;2[#?60#<T+_\!4$L#!!0    ( .Z<>E)O/%WS?P0  #L+   9
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MK26Z2R.(#@-X6G*E&^]UWV)GQ!F$GQ$)?D/8Q_[+?(8^_=*D:WIVE&#4&.5
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M&/NC:3AIGW^ZFG^ZOQHB[<1IVJZ)Z080@J=>L()1$L+F6SB8C,-Q.UK?LPG
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MX&7QOYP>#]#E&AS@:P0P8!>5<*B'8G0'FFV\KY_7S_I&^"64Y9RFR 1J4J1
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M&.7(ZNJJ!EH4]O1?"XUWB7U,\;8':0)P?B.$?AN8"Z7Y_Q#] 5!+ P04
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MA8;V:8<IW'"H- ;P?"&$WDU,@.K.-/H+4$L#!!0    ( .Z<>E(SBFTWW@(
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M%LH@QQ55]_SP&=J$ N,OY536O^C0VCH62BNI>-F*-4%)6/./G]M"] 3N[(3
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M]G"G-_ @S WZ^H9S]3 P>\K^7P++?P!02P,$%     @ [IQZ4K<%[MWQ @
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M" I!<*@@+ 2A#71-9L.:4$U' RE61!IK]&86-C=6C=&PS)1QJB4^9:C3HVO
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M.\%\7PNA'SKVUEK]!TU_ %!+ P04    " #NG'I2&0:%2=H#  #$#   &0
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MN"'=XV87W44:)LO(F[0^L1$W6DCW:+EA1N(P=,,BFG/SV/ O+5Z5P6IN>)+
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MD=J?*T9C)LT-<'TAA-X>& ?5]['C_P!02P,$%     @ [IQZ4G&>R?+Z P
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MN!Z@[N\8D\<3/4&[,;7^'U!+ P04    " #NG'I2/*YAA$\%  "Q$   &0
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ML9._GJ!%66B4[>,1,K6+0M!,HO5_4==U\91I5]1.:WRLOS[)>5&F W_$^Z1
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MW\?EBY&Y^V)<28/?G^YQ"Q2[N!7 _;7$4JU>[$=H\U^*^7]02P,$%     @
M[IQZ4GK[FF6K @  Q@8  !D   !X;"]W;W)K<VAE971S+W-H965T-C$N>&UL
ME95+;]LP#,>_BF#TT )K_<ASA6,@J;<UAP)%NVZ'80?%IF.ALI1)<M)^^U%R
MXF:(8V"71 _RSY\HBHYW4KWJ$L"0MXH+/?-*8S:WOJ^S$BJJ;^0&!.X44E74
MX%2M?;U10'/G5'$_"H*Q7U$FO"1V:X\JB65M.!/PJ(BNJXJJ]P5PN9MYH7=8
M>&+KTM@%/XDW= W/8%XVCPIG?JN2LPJ$9E(0!<7,FX>WBZFU=P8_&.STT9C8
MDZRD?+6393[S @L$'#)C%2C^;>$..+="B/%GK^FU(:WC\?B@_M6='<^RHAKN
M)/_)<E/.O*E'<BAHS<V3W-W#_CPCJY=)KMTOV36V8S3.:FUDM7=&@HJ)YI^^
M[?-PY!"%9QRBO4/DN)M CC*EAB:QDCNBK#6JV8$[JO-&.";LI3P;A;L,_4R2
M@F);:C-#ED(;56/"C2:7*1C*N+XB%X0)\KV4M:8BU[%O,*AU];-]@$43(#H3
M((S(@Q2FU.2+R"'_5\!'VA8Y.B OHE[%%+(;,@@_D2B(@I?GE%Q>7/7(#MI,
M#)SLX/\R@:<F]Y"OF5B3N2TA9AAHDC*=<:EK!>37?(7F6%Z_>RB&+<7040S/
M4"RUKJG(@,@"BZLE8BU1UPTTDF,G:5_A-ID$0>QO.SA&+<>HER/MBJTM528K
M?/ZE?9>XB3GH+(I&?72$=!U][D8:MTCC7J0[+".\!>0@0)6XQA9#.*,KQIEY
M)P5EBFPIKZ$+9WR",XG"<SF:M$"3?B"JU+NM"Q<6$W/"UX4R.4$938-S*-,6
M9=J+\@W;KWVH'UEHKNI U 4R/:F:<'B:$_^HMU2@UJZ#:I2NA6G:3+O:-NEY
MTYL^S)L._T 5/B--.!3H&MQ,, FJZ9K-Q,B-ZU0K:;#ON6&)'QI0U@#W"RG-
M86(#M)^NY"]02P,$%     @ [IQZ4@D9,P9F!   FQ   !D   !X;"]W;W)K
M<VAE971S+W-H965T-C(N>&ULM5AM;]LV$/XKA)$."=!:(N77SC'0."T:8-F"
MO&P?BGV@I9,ME!(]DH[M_?H=)5FR8YE.N_:#;5'B/??<\?B<Z-%*JJ]Z#F#(
M.A69OFS-C5F\]SP=SB'ENBT7D.&36*J4&QRJF:<7"GB4&Z7"8[[?\U*>9*WQ
M*+]WI\8CN30BR>!.$;U,4ZXV5R#DZK)%6]L;]\EL;NP-;SQ:\!D\@'E:W"D<
M>15*E*20Z41F1$%\V?I WT]88 WR&7\FL-([U\2&,I7RJQW<1)<MWS(" :&Q
M$!Q_GF$"0E@DY/%/"=JJ?%K#W>LM^J<\> QFRC5,I/@KB<S\LC5HD0ABOA3F
M7JX^0QE0U^*%4NC\FZR*N5WT&"ZUD6EIC.,TR8I?OBX3L6,P\(\8L-* O3"@
MG2,&06F09\XKF.5A77/#QR,E5T39V8AF+_+<Y-8839+997PP"I\F:&?&-UDH
M4R"/? V:G%^#X8G0%^0=>7JX)N=G%^2,)!EYG,NEYEFD1YY!I];4"TL'5X4#
M=L0!9>169F:NR<<L@F@?P$.V%66VI7S%G(C7$+9)0-\2YC._@=#DU>9TZ* 3
M5!D,<KS@VS+XY3><1VX,I/IOAY=.Y:63>^FXO1B^)D_MAS:)(0+%!=&&FZ61
M:D,4-]"T/&Y<1MN^_Z8IB]]NMQ=8MPJLZP3Z&,>0;^4\MF-!N#'.69MVWUPT
M1>$V]$\$T:N"Z#EQKB$&I2#*8Q )GR8B,1N".X; &A57-P4U*3![.::5V^=Q
MX&-!/S<0Z5=$^DXBOZ/PH\1C&I-L1H34C3NV?^#X'>XEVJE\%_R*:=W=:;07
M!*R9XJ"B.'!2? 25$AEC#]# 53C/LQ3!,W:4!?8'0T),9&)LXA(;A\R:0G#[
M^! A EIR(39OB9D#F<ATP;,-F7--^&*AY#K!'@!B0\YHNX_**H3M*BY>Y_>_
M\'3QJ_U<7VQ9AERI#7;3%5>11D_<H( +0:8P0]TTL@@#"(\-*)2<H$.2F&32
MD*7!(OD7HK:C_H953H?.>.]/Y'*/95,ZAP<507L#]J(>#B<-!D>*@?IU__&=
MU#^50O;E%M(I*)=6TIVF1G^B)E-6^V$_8+N5('L;J<_8L;U.Z\Y# Z?[/_9<
MGU[E$FY/<0:#HSSJWD3=S> .5(C5AJ]]=@.A!O*I 'QOR!=!)&EB&MFX00>G
MQ)G6+8:Z97XK.?M+=4)A3F&BJ"BP+\H6;\H%S\(\_+,@:'<J03DA!J[-3^ON
M0]WMY[Z)QROJLJ$!!9VCY5#W(.IN0O];C>AAYZ']H[SJQD/=7>$!WY7@54)3
MZRX=_D2A8;5*,K=*ODYH2I ]H>D.CVYP5NLIHS]4:$JXO<H:'JTL5NLM<^OM
M]PG-"="30L-J069N0?[.C<@.=9GYA^GR=HYY*:A9?OK%U9#+S!3'I^IN=<+^
MD)\K7]R_PI-W<4ZN88IC^RU7*%6:"(@1TF_WL994<1(N!D8N\L/D5!H\FN:7
M<^#8PNT$?!Y+:;8#ZZ#Z/V+\'U!+ P04    " #NG'I2Z@PMAI<"  "Q!@
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M;PI($X#S*R'TWC +=*]4\AM02P,$%     @ [IQZ4AGW<9(& P  ,@P  !D
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M$NB9L\O(--84"QP,&5TCIGI+-U70<Z/5DB8EZC/.!)-O4ZD3P1,):0[H#6^
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M!F?[#V9XLA/ *TPU>7V@<LNX(CEL$-*[G6"&937,5 LM=G8>6 N-TX5]S'
M!&D,\/U&"'U:F #-2+GX!5!+ P04    " #NG'I2'4 \H9L#  #N"P  &0
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M"_3VS3OT!@V1C(B@$K$4/:5,R3[<A.N?(YY)DH;R:J@ E98]# H$\QP!/H+
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M6">.0Q[SIE,\]8[ J%D,V\GEBPOT0FZSR)WNT^]=QZ"CA3"NTS6V)]N'@N$
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MYR>2\H2&+-"YJ-PT/2?B,4"$Y B@<@]:4B/B)PYEM/LN5]UXQ(6IK%>M/@/
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M +;_R+._$'2=?O:84B%HG Y7!,\)4P+R^8)2<;A07U+R3VVC_P%02P,$%
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M*K? SL^E-(\=MT'[!V#Z!U!+ P04    " #NG'I2PP9*[0$#   &"@  &0
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M('(%H<#$.@9&ORTN4 A'1&6\U)Q!D](!#\=[]FNOG;0LF<&%$G]X:M?3X"R
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M*'VY$!Q6$',!?#]/8%+E;TP'Q='CT?]02P,$%     @ [IQZ4E=:<HXU"0
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MY[6"3I(XZ?*D1?O@;T#[H!7MNTLQL&@?_"#:H_^A&[  P)'OTP$"VP&"U^D
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ME8K3844-G4^5/!!EO9'-+IR8#HWI,V'+OC8*GS+$F?DG[*P/4FMR XJL<ZJ
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MV-A8:?0F*\TQWFN)JQG*Z>5'S)0_A%)D"Y+<IUP"66DMLUVM^2X'H@79B*+
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MM+R OJ>&]O9NP 3-)7[V#U!+ P04    " #NG'I2]XO$9H@"  !T"   &0
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M6MRSE=FTTRK#-?=.4//?S?.<2::IV!9M>_\U9_G%BJ.K?R6Y^JVR+]BKL=Z
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M49+X$<#\"J((0^!MQ!%, 6C D"BJ]L&]_2C<[%-A^Q^T\2]02P,$%     @
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MB=4#,8/AG2/UY,3JP9C^\,Z1>G)B]>#%]  3J2<G?V, 8091"+Z8?,@YS^@
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M>@_CYZ$.MYZO-5[_.ZD>+^?6V^6ORZ^=DWO\BG.XKQB>_P)02P,$%     @
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M:6_:X3D_6_X\<?,+4$L! A0#%     @ [IQZ4@=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #NG'I2
M H1E?^\    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " #NG'I2F5R<(Q &  "<)P  $P              @ '-
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( .Z<>E+4=#2J7@0
M /40   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    " #NG'I2665^D+@'  "I(   &               @(&B
M#   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ [IQZ4E._
MT# @ P  FPH  !@              ("!D!0  'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    ( .Z<>E*,*A=UI08  /(;   8
M  " @>87  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #N
MG'I29?!: SX*  "V20  &               @('!'@  >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @ [IQZ4OJ:7G^[ @  7P8  !@
M         ("!-2D  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   ( .Z<>E(^D9 'S D  #PP   8              " @28L  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #NG'I2 _\0O,\5   80
M&               @($H-@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @ [IQZ4KIW':#[*   R84  !@              ("!+4P  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( .Z<>E(-4I+%7 X
M )4N   9              " @5YU  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @ [IQZ4IP' JZO @  #@8  !D              ("!
M\8,  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #NG'I2
M$S(]RS0#  !=!P  &0              @('7A@  >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    ( .Z<>E)I&BFROP(  -0%   9
M      " @4**  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @ [IQZ4E#%&;M_"   718  !D              ("!.(T  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " #NG'I2&V3J!>H'  !8&0
M&0              @('NE0  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    ( .Z<>E)O6FZHKP8  &@3   9              " @0^>  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ [IQZ4A<%(GF9
M!@  'Q(  !D              ("!]:0  'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    " #NG'I2JQF0/;8%  "+#@  &0
M@('%JP  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( .Z<
M>E(IE8Z<5 4  %0.   9              " @;*Q  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @ [IQZ4M)$RC_U 0  FP0  !D
M         ("!/;<  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    " #NG'I273?99*()  ##&0  &0              @(%IN0  >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( .Z<>E)N)\')I1   *LT
M   9              " @4+#  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @ [IQZ4A:8+.U6"P  82(  !D              ("!'M0
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #NG'I2J[=-
M27(.  "D+P  &0              @(&KWP  >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    ( .Z<>E)RNL"UP@0  *X+   9
M  " @53N  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
M[IQZ4I/FF^,9!0  7 T  !D              ("!3?,  'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    " #NG'I2XNL/7M %  #=#0  &0
M            @(&=^   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    ( .Z<>E*5J=^$200  '4*   9              " @:3^  !X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ [IQZ4G&K 1WY!
MA L  !D              ("!) ,! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    " #NG'I2$I?"ZP Q  ""I@  &0              @(%4
M" $ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( .Z<>E+(
M[>F[E (  (\%   9              " @8LY 0!X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @ [IQZ4H9W5-RN @  D@4  !D
M     ("!5CP! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
M" #NG'I24)G25*T"  "!!0  &0              @($[/P$ >&PO=V]R:W-H
M965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( .Z<>E*8:(JY2P0  (P*   9
M              " @1]" 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L!
M A0#%     @ [IQZ4C8,?%J/ @  8@4  !D              ("!H48! 'AL
M+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " #NG'I29(^C KH"
M   4!@  &0              @(%G20$ >&PO=V]R:W-H965T<R]S:&5E=#,V
M+GAM;%!+ 0(4 Q0    ( .Z<>E(YT9@K>00  $ +   9              "
M@5A, 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ [IQZ
M4F\\7?-_!   .PL  !D              ("!"%$! 'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6Q02P$"% ,4    " #NG'I20[/X2)0$   (#   &0
M        @(&^50$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0
M   ( .Z<>E*(O6=HM (  /0%   9              " @8E: 0!X;"]W;W)K
M<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ [IQZ4N6F_W&] P  # D
M !D              ("!=%T! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q0
M2P$"% ,4    " #NG'I2@@@(71$#  #2!P  &0              @(%H80$
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( .Z<>E)K5Q4X
M%08  -0<   9              " @;!D 0!X;"]W;W)K<VAE971S+W-H965T
M-#,N>&UL4$L! A0#%     @ [IQZ4MD\:%KK!   &Q<  !D
M ("!_&H! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " #N
MG'I2^:*Q%N$)  !]+@  &0              @($>< $ >&PO=V]R:W-H965T
M<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( .Z<>E)$("T'T (  $L(   9
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M970U,"YX;6Q02P$"% ,4    " #NG'I2[)U#BO8#   >$   &0
M    @('#B@$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    (
M .Z<>E*W!>[=\0(  .\*   9              " @?". 0!X;"]W;W)K<VAE
M971S+W-H965T-3(N>&UL4$L! A0#%     @ [IQZ4F_*,*[0 @  .@@  !D
M             ("!&)(! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"
M% ,4    " #NG'I2EK(R3E0"   @!@  &0              @($?E0$ >&PO
M=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( .Z<>E*'7<;J$04
M +$4   9              " @:J7 0!X;"]W;W)K<VAE971S+W-H965T-34N
M>&UL4$L! A0#%     @ [IQZ4O;EF+-4 P  $PT  !D              ("!
M\IP! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " #NG'I2
M&0:%2=H#  #$#   &0              @(%]H $ >&PO=V]R:W-H965T<R]S
M:&5E=#4W+GAM;%!+ 0(4 Q0    ( .Z<>E)R"8ZHT@8  "L;   9
M      " @8ZD 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%
M  @ [IQZ4G&>R?+Z P  I!(  !D              ("!EZL! 'AL+W=O<FMS
M:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " #NG'I2/*YAA$\%  "Q$
M&0              @('(KP$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+
M 0(4 Q0    ( .Z<>E)Z^YIEJP(  ,8&   9              " @4ZU 0!X
M;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ [IQZ4@D9,P9F
M!   FQ   !D              ("!,+@! 'AL+W=O<FMS:&5E=',O<VAE970V
M,BYX;6Q02P$"% ,4    " #NG'I2Z@PMAI<"  "Q!@  &0
M@('-O $ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( .Z<
M>E(9]W&2!@,  #(,   9              " @9N_ 0!X;"]W;W)K<VAE971S
M+W-H965T-C0N>&UL4$L! A0#%     @ [IQZ4BX?B$UF P  7@H  !D
M         ("!V,(! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4
M    " #NG'I2'4 \H9L#  #N"P  &0              @(%UQ@$ >&PO=V]R
M:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( .Z<>E(YIMEAO@@  (HD
M   9              " @4?* 0!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL
M4$L! A0#%     @ [IQZ4LO#=/R_ @  Z0@  !D              ("!/-,!
M 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4    " #NG'I2+4]^
M&CH%  !V&P  &0              @($RU@$ >&PO=V]R:W-H965T<R]S:&5E
M=#8Y+GAM;%!+ 0(4 Q0    ( .Z<>E)IB3TG-P,   P,   9
M  " @:/; 0!X;"]W;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%     @
M[IQZ4L,&2NT! P  !@H  !D              ("!$=\! 'AL+W=O<FMS:&5E
M=',O<VAE970W,2YX;6Q02P$"% ,4    " #NG'I2;M9XXSD$  #O#   &0
M            @(%)X@$ >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4
M Q0    ( .Z<>E+U^NB/Q@,  "D3   9              " @;GF 0!X;"]W
M;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%     @ [IQZ4B+ 4D*L @
M2P<  !D              ("!MNH! 'AL+W=O<FMS:&5E=',O<VAE970W-"YX
M;6Q02P$"% ,4    " #NG'I2A%38];H&  "&+   &0              @(&9
M[0$ >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    ( .Z<>E)7
M6G*.-0D  .\H   9              " @8KT 0!X;"]W;W)K<VAE971S+W-H
M965T-S8N>&UL4$L! A0#%     @ [IQZ4K39A':>!   T!,  !D
M     ("!]OT! 'AL+W=O<FMS:&5E=',O<VAE970W-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .Z<>E(0 <0FG 0  - +   9              "
M@;P0 @!X;"]W;W)K<VAE971S+W-H965T.#(N>&UL4$L! A0#%     @ [IQZ
M4O>+Q&:( @  = @  !D              ("!CQ4" 'AL+W=O<FMS:&5E=',O
M<VAE970X,RYX;6Q02P$"% ,4    " #NG'I2U&L0+A4#  "J"P  &0
M        @(%.& ( >&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+ 0(4 Q0
M   ( .Z<>E*KG2GOC@(  (X(   9              " @9H; @!X;"]W;W)K
M<VAE971S+W-H965T.#4N>&UL4$L! A0#%     @ [IQZ4C[P-H^R P  ;PD
M !D              ("!7QX" 'AL+W=O<FMS:&5E=',O<VAE970X-BYX;6Q0
M2P$"% ,4    " #NG'I28IRJ4RX#  !.$P  #0              @ %((@(
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( .Z<>E*7BKL<P    !,"   +
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4!08     7@!> ,D9  #8,0(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>219</ContextCount>
  <ElementCount>588</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>65</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders??? Equity (Deficit) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ShareholdersEquityType2or3_Parentheticals</Role>
      <ShortName>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders??? Equity (Deficit) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Nature of the Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/NatureoftheBusinessandBasisofPresentation</Role>
      <ShortName>Nature of the Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Reverse Recapitalization with Tottenham and Clene Nanomedicine</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicine</Role>
      <ShortName>Reverse Recapitalization with Tottenham and Clene Nanomedicine</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Prepaid expenses and other current assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/Prepaidexpensesandothercurrentassets</Role>
      <ShortName>Prepaid expenses and other current assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.cleaninccom/role/NotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Preferred Stock Warrant Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/PreferredStockWarrantLiability</Role>
      <ShortName>Preferred Stock Warrant Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Common Stock Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/CommonStockWarrants</Role>
      <ShortName>Common Stock Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Convertible Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.cleaninccom/role/ConvertibleNotes</Role>
      <ShortName>Convertible Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Derivative Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/DerivativeInstruments</Role>
      <ShortName>Derivative Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/FairValue</Role>
      <ShortName>Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Redeemable Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/RedeemableConvertiblePreferredStock</Role>
      <ShortName>Redeemable Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Net Loss Per Share Attributable to Common Shareholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/NetLossPerShareAttributabletoCommonShareholders</Role>
      <ShortName>Net Loss Per Share Attributable to Common Shareholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Geographic and Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/GeographicandSegmentInformation</Role>
      <ShortName>Geographic and Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Prepaid expenses and other current assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/PrepaidexpensesandothercurrentassetsTables</Role>
      <ShortName>Prepaid expenses and other current assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/Prepaidexpensesandothercurrentassets</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/PropertyandEquipmentNet</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/AccruedLiabilities</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/Leases</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Preferred Stock Warrant Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/PreferredStockWarrantLiabilityTables</Role>
      <ShortName>Preferred Stock Warrant Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/PreferredStockWarrantLiability</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Common Stock Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/CommonStockWarrantsTables</Role>
      <ShortName>Common Stock Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/CommonStockWarrants</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/IncomeTaxes</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/StockBasedCompensation</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/FairValueTables</Role>
      <ShortName>Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/FairValue</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Redeemable Convertible Preferred Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/RedeemableConvertiblePreferredStockTables</Role>
      <ShortName>Redeemable Convertible Preferred Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/RedeemableConvertiblePreferredStock</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Net Loss Per Share Attributable to Common Shareholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/NetLossPerShareAttributabletoCommonShareholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Common Shareholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/NetLossPerShareAttributabletoCommonShareholders</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Geographic and Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/GeographicandSegmentInformationTables</Role>
      <ShortName>Geographic and Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/GeographicandSegmentInformation</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Nature of the Business and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/NatureoftheBusinessandBasisofPresentationDetails</Role>
      <ShortName>Nature of the Business and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/NatureoftheBusinessandBasisofPresentation</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails</Role>
      <ShortName>Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicine</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Prepaid expenses and other current assets (Details) - Schedule of prepaid expenses and other current assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofprepaidexpensesandothercurrentassetsTable</Role>
      <ShortName>Prepaid expenses and other current assets (Details) - Schedule of prepaid expenses and other current assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/PrepaidexpensesandothercurrentassetsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Property and Equipment, Net (Details) - Schedule of property and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetTable</Role>
      <ShortName>Property and Equipment, Net (Details) - Schedule of property and equipment, net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Accrued Liabilities (Details) - Schedule of accrued liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofaccruedliabilitiesTable</Role>
      <ShortName>Accrued Liabilities (Details) - Schedule of accrued liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/AccruedLiabilitiesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/LeasesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Leases (Details) - Schedule of noncancelable operating lease arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofnoncancelableoperatingleasearrangementsTable</Role>
      <ShortName>Leases (Details) - Schedule of noncancelable operating lease arrangements</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/LeasesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Leases (Details) - Schedule of finance lease obligations and included property and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleoffinanceleaseobligationsandincludedpropertyandequipmentTable</Role>
      <ShortName>Leases (Details) - Schedule of finance lease obligations and included property and equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/LeasesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Leases (Details) - Schedule of finance and operating lease costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleoffinanceandoperatingleasecostsTable</Role>
      <ShortName>Leases (Details) - Schedule of finance and operating lease costs</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/LeasesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Leases (Details) - Schedule of supplemental cash flow information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofsupplementalcashflowinformationTable</Role>
      <ShortName>Leases (Details) - Schedule of supplemental cash flow information</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/LeasesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.cleaninccom/role/NotesPayableDetails</Role>
      <ShortName>Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/NotesPayable</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Preferred Stock Warrant Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/PreferredStockWarrantLiabilityDetails</Role>
      <ShortName>Preferred Stock Warrant Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/PreferredStockWarrantLiabilityTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Preferred Stock Warrant Liability (Details) - Schedule fair value of the outstanding warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/SchedulefairvalueoftheoutstandingwarrantsTable</Role>
      <ShortName>Preferred Stock Warrant Liability (Details) - Schedule fair value of the outstanding warrants</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/PreferredStockWarrantLiabilityTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>057 - Disclosure - Common Stock Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/CommonStockWarrantsDetails</Role>
      <ShortName>Common Stock Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/CommonStockWarrantsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>058 - Disclosure - Common Stock Warrants (Details) - Schedule of outstanding warrants to purchase shares of common stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable</Role>
      <ShortName>Common Stock Warrants (Details) - Schedule of outstanding warrants to purchase shares of common stock</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/CommonStockWarrantsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>059 - Disclosure - Convertible Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.cleaninccom/role/ConvertibleNotesDetails</Role>
      <ShortName>Convertible Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/ConvertibleNotes</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>060 - Disclosure - Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/DerivativeInstrumentsDetails</Role>
      <ShortName>Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/DerivativeInstruments</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>061 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/IncomeTaxesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>062 - Disclosure - Income Taxes (Details) - Schedule of components of income (loss) before income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofcomponentsofincomelossbeforeincometaxesTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of components of income (loss) before income taxes</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/IncomeTaxesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>063 - Disclosure - Income Taxes (Details) - Schedule of income tax expense (benefit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofincometaxexpensebenefitTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of income tax expense (benefit)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/IncomeTaxesTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>064 - Disclosure - Income Taxes (Details) - Schedule of income tax reconciliation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofincometaxreconciliationTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of income tax reconciliation</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/IncomeTaxesTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>065 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofdeferredtaxassetsandliabilitiesTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of deferred tax assets and liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/IncomeTaxesTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>066 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/StockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/StockBasedCompensationTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>067 - Disclosure - Stock-Based Compensation (Details) - Schedule of stock-based compensation expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofstockbasedcompensationexpenseTable</Role>
      <ShortName>Stock-Based Compensation (Details) - Schedule of stock-based compensation expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/StockBasedCompensationTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>068 - Disclosure - Stock-Based Compensation (Details) - Schedule of outstanding common stock options and related activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable</Role>
      <ShortName>Stock-Based Compensation (Details) - Schedule of outstanding common stock options and related activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/StockBasedCompensationTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>069 - Disclosure - Stock-Based Compensation (Details) - Schedule of fair value of these stock options awards granted</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleoffairvalueofthesestockoptionsawardsgrantedTable</Role>
      <ShortName>Stock-Based Compensation (Details) - Schedule of fair value of these stock options awards granted</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/StockBasedCompensationTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>070 - Disclosure - Stock-Based Compensation (Details) - Schedule of restricted common stock activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofrestrictedcommonstockactivityTable</Role>
      <ShortName>Stock-Based Compensation (Details) - Schedule of restricted common stock activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/StockBasedCompensationTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>071 - Disclosure - Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/FairValueDetails</Role>
      <ShortName>Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/FairValueTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>072 - Disclosure - Fair Value (Details) - Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable</Role>
      <ShortName>Fair Value (Details) - Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/FairValueTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>073 - Disclosure - Fair Value (Details) - Schedule of fair value of the initial contingent earn-out</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleoffairvalueoftheinitialcontingentearnoutTable</Role>
      <ShortName>Fair Value (Details) - Schedule of fair value of the initial contingent earn-out</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/FairValueTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>074 - Disclosure - Fair Value (Details) - Schedule of financial liability related to the notes payable, the derivative instrument, the Preferred Stock warrants, and the contingent earn-out measured at fair value</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleoffinancialliabilityrelatedtothenotespayablethederivativeinstrumentthePreferredStockwarrantsandthecontingentearnoutmeasuredatfairvalueTable</Role>
      <ShortName>Fair Value (Details) - Schedule of financial liability related to the notes payable, the derivative instrument, the Preferred Stock warrants, and the contingent earn-out measured at fair value</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/FairValueTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>075 - Disclosure - Redeemable Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/RedeemableConvertiblePreferredStockDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/RedeemableConvertiblePreferredStockTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>076 - Disclosure - Redeemable Convertible Preferred Stock (Details) - Schedule of Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofPreferredStockTable</Role>
      <ShortName>Redeemable Convertible Preferred Stock (Details) - Schedule of Preferred Stock</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/RedeemableConvertiblePreferredStockTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>077 - Disclosure - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/CommonStockDetails</Role>
      <ShortName>Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/CommonStockWarrantsTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>078 - Disclosure - Net Loss Per Share Attributable to Common Shareholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/NetLossPerShareAttributabletoCommonShareholdersDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Common Shareholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/NetLossPerShareAttributabletoCommonShareholdersTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>079 - Disclosure - Net Loss Per Share Attributable to Common Shareholders (Details) - Schedule of basic and diluted net loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable</Role>
      <ShortName>Net Loss Per Share Attributable to Common Shareholders (Details) - Schedule of basic and diluted net loss per share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/NetLossPerShareAttributabletoCommonShareholdersTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>080 - Disclosure - Net Loss Per Share Attributable to Common Shareholders (Details) - Schedule of dilutive securities were excluded from the computation of diluted net loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofdilutivesecuritieswereexcludedfromthecomputationofdilutednetlosspershareTable</Role>
      <ShortName>Net Loss Per Share Attributable to Common Shareholders (Details) - Schedule of dilutive securities were excluded from the computation of diluted net loss per share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/NetLossPerShareAttributabletoCommonShareholdersTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>081 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/RelatedPartyTransactions</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>082 - Disclosure - Geographic and Segment Information (Details) - Schedule of property and equipment, net by location</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbylocationTable</Role>
      <ShortName>Geographic and Segment Information (Details) - Schedule of property and equipment, net by location</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/GeographicandSegmentInformationTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>083 - Disclosure - Geographic and Segment Information (Details) - Schedule of drugs and supplements segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofdrugsandsupplementssegmentsTable</Role>
      <ShortName>Geographic and Segment Information (Details) - Schedule of drugs and supplements segments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/GeographicandSegmentInformationTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>084 - Disclosure - Geographic and Segment Information (Details) - Schedule of property and equipment, net by segment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbysegmentTable</Role>
      <ShortName>Geographic and Segment Information (Details) - Schedule of property and equipment, net by segment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/GeographicandSegmentInformationTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="clnn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>085 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/SubsequentEvents</ParentRole>
      <Position>86</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>clnn-20201231.xml</File>
    <File>clnn-20201231.xsd</File>
    <File>clnn-20201231_cal.xml</File>
    <File>clnn-20201231_def.xml</File>
    <File>clnn-20201231_lab.xml</File>
    <File>clnn-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/exch/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>118
<FILENAME>0001213900-21-018061-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-21-018061-xbrl.zip
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MI@T\/C"Y';:VV>MEZ=:KOP/?,I'LB'(U>VI:TR;&'3C7EA/7SXTJ'GCX MM
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M?MIV#<BE-DPF";^\3>!TD8GII9]DH^5/!<STGQM0Y9]X.Z>0GZ@HS^EEHET
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M7_TM=C_*(5#)A="QY-[< (WTT&K*W_C>W YALF-]!GLM>^PKLZ-.@NG+XDA
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M/.6IQ!O;5H+G'_3B :/[VOU L(P=U6] C3@,:%,]1:V]T/JA)["1!+#LWC6
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MFV&GAZC#GO*V6!&*E*.F$8OJ'GDQ$+^1F;U:P#,H'GH]>M]4,H]*;5W.^JP
M[_:DRC&9V=6JW]D838:#4C9[!@ UP5[Z'AD.>X,=0)<A_TAUR93JE(\_IH^6
M^T"^4:US[<)BU)Z&_X!O^&0YVNRZOF+:5P'@HA;0*T0S=H!<%1GX@/*A;]0W
M].UI2&9\D>0OI$^R2LQTI''JK" +6(:(0:DG^:-WICCHS2+19B)6>"J<C"<O
MAXA%-$GD$6=X^>?CL3Y"7#2#DYG(%#;'Z?>_\W.-9T15U[7AI22WIX[^I'\^
MU(I69HKF]9QE&_ XY;81F<(<N:TVJY ZE+R9<W=+6/_XR\!F^5_?[(?'T)NO
M L*_X<XPL !9Y)\72WK'$Q;.??2]U<-C\NE"BZ(7S^Z:85.\N&:0+A_3,6O#
M.4)9G4AZ2\+0@50R$6C3*?"[[UB>=J/1**;>QCV31$$ZJ1_FQ*PIC75P)@V1
MK;9_7;!OG:41>6E9Z<8\]>#.D_Q>?3[G>6^8-8ZL$B#9O>.UX;+M8WH$R2V!
M%,4/R6#!]Z5'A3DY>S@16? 6=A!X_EH?K8>C\TQB:X OFP4U(UXQ-I4Y[CF6
MDMP9S^6 U1-1.)=T8&V@*L=_+R2I=*@B4$4:#/:(L! <C&#6DSPZ/).X47KK
MI!;0 O&VBCUC\R#>O8[44%.D"E???Q.CMX-\2^5]E3G4/3?R^]D-/:E,65.Z
M'16_9&?S'4!J"CT=.CFYN6H*9O1VW8C.K?[7!O-\W!_G*^NZ<;@HTN#[). V
M E \MB=SW(^6V_8LD8%8&8@*HZ^JXK"]VLIKB9SB>5Y3:#V4+3N4H2Q897N*
MZT!S*Q&&=H:\"R*OU2^ LD*/;CVU<^>)Q/AZ0%4S<YLGR+8UKZ(L#YIPZ D.
M),/S\OIJ;4FYG<L'#]6BN;R=WZ\"VR5!\($$4]_&7*U+=_;>"NP +Y" L@D)
M?D>!>.^ UB])BXO_<L*?ET80KAWRZW_]M?+"G^?TF^\,L[<,C3M[02VVK^39
M^.8M+/>8_>+8 %]Q_K.QL/P'VST)O>4[@WX\^L6]%X;>@O\.H#BA$O'@OC,<
M,@_9)O_U0/_?89NE=C^96PO;6;_;M#]^-J BR<!-KGP/_S!/J?!\M<*53PQO
M;H2/Q!"T-"QW9B )X2\R$>';;^_%.F]AE^B'9;2\_U;\<S?R(9F,7I)0T$?
MGJ_Y+VUW1F#1WNG0=F,LKQSB$N.S.STU7L\]?T%\9TW1O7HD3D LXW?/=V;/
M]HP<XV?>&*\!_?^R%LN?__</*H[3GZ$0WW+7\:]F/[\Q*#TLX][VEE09+*PI
M687VU'*H/.%G*<VG*\A*I(<;EIO1@^]X+)>9DG'J$,L]"5;^G'YSACK&M5QO
MZJ\#JA6,F;]Z"$X-JC ,OK?Q: 5B$?H%RS6(0S6+'WUE^DBHBQKZ:_QR8K\E
MO:8![V/#=HWG1WOZ:$B;!<8SU4WT+P"$902K ,H<02E1)8>P0[6CM40$<?%3
MXWM(C:[_0#^HD$P?7<_Q'M9&Z!GPRA820T5%6I1R-8RQBBDZ^3F(X$1( -^E
M[\U60)_%R@GM)?4G<34+P\W'0$>&C4WM#DK0&?\+ C[%SHLAY31%3:8&W<&@
MG(%?NV3E ^S(.!!SVYVCNEX% ,+,#B Z27>RJ.WS8'A "/I3L*)[6L#^(%S-
MUKAB")@+[EY=_^OSAQ-S0H7!]USKR?;I@A3?&641%<);>D.X,\M'DN520V7C
M,6,0+.2'XI!F?M.&4V#/*59XM]"/+KT0?B78(0@8*O)%A<&+ODW)/J6&LD7I
MM*"*P*=?#CQGQ0I/!"PSFX2 2+!:4O9@N#\AM@I*Z4_3P[UF^]X3.#L+B(3#
MO4BWOZ=_,7QF9"+6ZV,#]PSHT8*S!4)[!!$UH]\[;9W: 3)84ZX/X*Q0KE,*
MVC/$AT(^9VDH0%BJ4#D]'JTG0FE!7"K]A"+-T(1U_!F8XGA:\><5&A[T8YA7
MZU!4J!4"?*(R3_].EB'[+G#Y.[V%Z4^WL _J\4M*:"H@%(K7LJ;[Q^7E35+-
ML6,!S^9,&?"= T4"V>?HKY^I740!\)Y=NE^PN@_LF6U!Q/388'KX*U4."S*S
MIU2HCKE63BA;_!0*F/S1!%3'</;$VG#"*766GF]QC#]0F7FFI!-;7E)V4;K8
MEG$3KHTOX6S#]Z//'R-:",OLVK\'BXV!7!H :TYM%:JK;?'D 72C+**?HG\0
MET5$5-@NE,)#I\85/X,4!,IIJFF6F-E@W%L.B(,L,#Z9.O1HL[,+VMAS49UR
M+<,UHK$FE@_"%=WC=1V="@8//U"-VCSP#QO^P8UR2N&478Z'[8Y"3=Q':V%(
M[Y^&:7RA3*4,1^K9D>73@$&4UCKM)OFU:QQ10QH;PQF#WK$!)G6&F>5X 6BT
M#_08*<<]QU:C-L *99GZ"P3B\\+\.D9ENUHL\$3"1O1#3W"Q@^D'=Y=+?347
M;(M[8>?2K]Z+0_I:A(;@\- [1P55B(PJ,$G=N5SY$#\)<1&#:MP'BK_UX!/"
M+G1Q$^!52O7"+>AL))*91Z/?V"*78A&%3O=,$3-[)4O?9LOR9R'+ZGT0?5S>
MQZ!T3GSH^NYR$[\BK2E4HR$T)EJ:%.;LBV,-=#&.8K 3X-VL[J\\=6NPQ&RJ
M$_7LC5LD=^4\H&#=KN[5>XFN]@FZ%@7&Y>S)IB(9&%^^7"5V=SBM'1&\C)P&
M+FD^B=7S$RFT]0*ICZ*A<D]NLBA_C8JMO$$"A5/JXL$UPR^-;R2^VX!:'/?8
M!KNG]NFS+%?/%(G$?6@<<2/DO4^E+7@T_F6#9C(^!_0&FP7,DKZG__X3G!AT
MR84+Y;.CNZ)K!4@' K<F]J%UI3-%37*(R!B$9_4=,PN77JN1B(/U?(3$@N7H
MQP+Z*5\YO? ;SW^P7*'^*0!H]!L!99E#K\U,98&7A$>/&OWXPJ-PB$^!J>4#
MS/BB<]IN+_D.N9VMUE!' 6,)YDIRN_+9HZ"29?#.>&V_423 )PD9X-*$=B[P
M,3H+5&$!#X&ES+!%<Y-^G)^[M.)-RB, QF0R(<4_4Y H3-2!7"S!!YS3\^T]
MH\.:*]3'0KCIJ48<4+AF"EQ92I6>)7!0Z>H&D_;TA^@YH2(#'[%*:!L5:UE7
M9V![:ERS$R;?H%3BC]AR[% P\]RU%L284[+DJ&@C0A%_ K0=.PCYMUG'9@Q@
MX'L 4S_'X)P93S@OZ*?>::_7,\%*Y8=2T4GL(<% U92\+7FDY*L5S*R_C!65
M4G;\@_7BWG.2EL*7KU]/Y6^W[C1!0@BSNH4= KP[XJH\[YP=&\2:R@8G=?JH
ME@&7&6EI!\$*HS\S:OA(3;D7(&:4YU2JEK+V9L<5[I"08H=7*>5'@5Y_354H
MRY".G'_.\Y!YZ.!S..".2Z8-K*?:)7 3K@T?G]U RMDB:)NX:^Y146P(^K#T
MWH3S9JVHI6IA&(TBPK9R.+I3S!.CFY$?5!SQ5Z!TX(HH)%DRR,'I!\O EQ",
M( [FHQ*G<FS/G.BSC/!%5[ LT5SOX.K/[(D2=A-7#F[P:#ESX[7YMO\&EH7?
MQ, ?70OH\8T!I =>*\E,7'@YBY[@HGRY+4 6,/N0TPE4$5<I9G'@WK +1)$>
M 7:SEP&\(JPIV-GBB96!?UD+TY.R!2)+7N=S;#QZSW#$@/M6:+@>57G,HX9@
M"Y/%9Y(\4."4IS_%;C[XJ.^!2IH9,ZJWA=2[!#X4HD;GX+8O#I5Y-QPANR,"
M9UQ8LH;'XYD\D+"DL#O!1")T%:HM!'?!MB)4\<PH-.9@/*&D>E8.56"@/I1N
M&YF;QR*VRTSB>%W05^D;4A1T&-_@[ZI%NU%9#?\/,IJ+FO5 __( I@IUI%9N
M%&V=<A+RXF2.QC$8>?WC<W-T/!F.(_&RJ3Q1C4EO6;26X$7*>P8(H*%O,%^C
M(@26+=PX5HM 1%UVP(Y>H1>*3@I?T:<*&-H#4Z/T![4WZ<$)>)A)AG'#37-*
M*6Y8O%,_OW;$?9TI#TJH/O*/F7R4NHU*@H;"9APIZ@/](E0@] <N7.7T@H$#
M_(1Y$8 !E)06A1:@"&1\P/+E7;$)2]2.5%?BC&3;?:^9 T'UD&M$ZZ!6(C^6
M4/!PS#01B?I8T'7Q-_SJ3-Z*^%)$0NGCN>1.&XUOQ%;"(@0<<I&3+\X$/8$B
M8!-'Y*2RMV"7.SQLV.R)@.Y"J,:RL-<WB^;CV:)+XZ&C'Z*_53EQ&581%;!Q
MF>@R*5R*"&O-^JS?2^HSX5HR -38>+YH2DIN0E40_YI*D\WJ2V85>" ,JL%Y
M[]BDMCA=UH\JCC@!X%D^2(8UOMU^#Y(6.=^/DU50AX$,3KIXPX$/4?"SU2.\
MY25U( A7 8.DY KVEK3P9HG7+.9)RO2>V3-ZR8?<$<,'$P-"?SX\KMA0! @
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M#3+?2/O'_<'D>$@=P/)F(@\/'Z5<%.0Y&\JL."(A1!EB?T_Q.-GQI3H@BIW
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M21!WR>=Y#I*!( )3+(25&(,.X^[S@^^MEH:X59/,/U9H3?_KBT0%#^85H]#
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M?I+]!X2$QAT() 'LU2: W7EVI-?W*C*TX-D<CNXALVL3*;_C8[MQ!/(YZHW
MX>8%=G(IO,_)R]\28.0"/7(+>'+!=B)!G.8SYR_U1+10Q'P2-FSSF/4M%]G/
M>('0.P_J7(,X4I:,ED3)SAPJYAL'<GQ1;?7"!L6D=H?BW=C%CW#R8W'AZ;]6
M/+E8=/"+B"+5.4(D1'J-#*;4F +\(U)*4//T8Y$U+-JUSP'\("3+X)WQVI8:
MJ/#>(6N9*%@4^3IXP]-&(AY036-G?A>^E\CACA+!Y(YTN"RN(2\2TPF?!^/\
M+A'143UAX0G$K!,3!V#M)VEI42*=6IG%0+@EM0%P_L:+H*/I*.\026Y2<%]C
M'/6-S!<851W,L=M*SHY)<PE?U$0U=L0<8.,)L-%8>#/B1#V"8(*07*F;?'J3
MP,!'MJF';=^-C#/@B<)47":*L=LN)FDG1#]#\.%KPG^*'Q:Y]!R2Z1+Z\!JX
MCZEC<9&_G8@,LC+O@H//2A7%=T7ZF6KH0F%"D#B#V"DI.G:0]\YZGN<=A-!8
MP#,\%3@;(KN8WH;?B*SWO*^RAJ1@SDS#W/8G1U:L]S'.&Y6LY)Q;;">N=$!
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M;0_FLGE8ZK?LU:%NX%FLAL<(VSR:3=%$(,B^Y*?OW@X4_$#L<)6Z<=J934M
MLJY9,ABF!#GK4.Z$>AR^K' &,B(8)",'I= #3R1HM"L,@WN&BG9<]&KM"6+:
M%J-R4RZA4*E16A''&F-UH4;@WPO3TPC8)KQ!R:9H]Z%@D%<N426FLH6#9U'+
M9QHBE+X>1M83O&^"TQ)(,<E785.!89U*TB7I;#1GXI'EA%I"7+]XYJ=DQ\3>
M+42?HIB@.LW!%V#_8&3O%O[N3#P/= =,6A@*-1-B4!LOKYQM)O[1H7="LEEJ
M*X@ PH>;PI+<G6A=^0Q@<H5D^Y@%A5OE@F NB?D_<<<>5 ]&XLRC&$\([6QQ
M0"2V==Z0RX4!X$_J3OGR7>L]B K']\KHT*(V0R]6#Z?J.8N5<]<CA:*&B0Y(
MB$LGSB/DV)(1?5%C+.33O1#\AJ8ZJ8")S@ NUGF+B0E!_4\2>*@"#XFC#^9_
MJTIJX F:8LF24(,9,<J$-,Q8T$JARJ?%7O#00^=-'[JLW887@&.'J$9&>;R>
M^B4X2;AC7]B*M'BQ4% BA[%,AV$@LH(%H72%U7<?9O9A!K@;=E+NCA^/G-8E
M3M,ZDT9L!3Y"!URZ#!B0@ =B[RY[YI!H!>1H<-K%46B#36M7!*F7EK;LB@!7
MR%3*I!*%^)R@J16X-_CR-C$OSI=));RB8[CYN$+%-E0-)94<#[;FL(<6HE)%
MPR=#5)4\VE4R)R^CU#) C#-3ZV=R,<HN]\);%[TMH%N'IIJ)=XZBN)%\)769
M0@)J5](RVY%-+$-?'CX%=2A*E8U0&0:1])LRAA#QF7@CP;^V6#2IB343/QEZ
M0>"&")'.O&?$M>[\Z123 2%" =/4*WBH[2V:8W4YNJ"B\JKT6'9,.BWTCB6
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M_@M5?.MC2;QULW^)HA&R%/#;!?*;]??SD%H .Y\%NUU%X_0>XB([5[.;%(4
MK&FPW^WL=84L.!-+BR9>G(&XM.VD\PE#-1";GJ&[?6Y,"W:=LR":C9!]9OBU
M4V-"XC6V+((]<\51%QG9LH1**V<]*4M7E=)@MRZ 9XV!^\Q%40R 2D]@*4.U
M%*M;24?'B9TC%4%K%=;\T\.,I*9Z5H&UE[-[JMDYNW:=\IIWT+Y_=59^B@!Z
M+&6KY&X<=WI]ZVY@_74&$D-JN4/!V=)90@W%K97??"J25^=%#@^0E"(.&?=
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MU^0'%,4Z6E7KLVIW0:^M*D"DDM.RE)PQ!,-NY+AW$S-'1CDPU_D(PM0Y<^,
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MPN/RCA)T0R+G8\G?VAM(YU,NC=57&S'%2TCQU7<E!;'T:N1[*71QP""_@%4
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M,6-2NB/H+$;; 0)5"O7(FLJ8:?B1,RRB^(L,U)"- []% ![/:W#6>%*<5'9
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M*L^8:6LZ 7S36QDKEY;& \(7%&];KW!E_R(9*+^YR<C]=Z&I1)R0'ZH*I[U
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M3[OSIU/,B80(9$[38N&AMK>H<BB)BBZHY(2J!)<=Q$X+O6,Y_F"6),KM-W+
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M#FH[6PZTEQ*F)('S_=#K[HHG&:,50W0J>\?M0V$I*L7(&5854#*>(![0TP_
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M$MIMV27)WA!=>J.OB0[!5[LKQ?D)[)C'.ACQKFB" &C3P!UZ-U&'R1=@=@=
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MERR8LDGH1AO6@>7V]JL8[EMY MOG]>7)7((=5,NRI^L[+_;<<<I07*MQUB)
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M\M!0 PC1 $*LZ! W3>WZ00T@Q(-+'[ZGJ]/<G080XDD (39J U0#PJV9DC<
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MN[(F+AXV+6W.G8YDR9D8C>!ND-!/Q?NU\3;A*Y%6.>4[^0L.0JA9(-AV.:#
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MG9$%^!IIER61%H38G I''SS:Y%%C;2VE,U!<<ZYO-$/2UMC,B';9&O<4;VJ
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M#=D2SWU:($X::Y&/ &&[?INLX W4V0%$/=1FOP?R@L>$ ?I,*%V3VV)X?V"
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M_+FAZ6N1^N]PJ581$Q*WDS<TMKG7?G3F)LO<#)D$,FI)0*[.O@C=PL P%;7
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MD_V3]^.I$DNGAT\@$SZQI#M#8^31#T\>BKEN+HA)#^Y&NED%R6Y,"22=K!_
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M:X]H4D"TM"=--ZC]RK"%-[XO\X0D[K#B** L@VU:$IVSQD(]@V_-5S0"IN0
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M8" Q&?:/F*"H.4,A;C$&ZJQ?1$-*)2@:GY\0-2=X?[[+3PCG)^JR)WOE)PH
M76=^8A#>-R4H]J0_4$<SY=7F)S+HP^*""M.R[<U/Y.P'U.&KST]DR!&&%6-U
M.%;;F9_XG=8-7YF+C[QJ^-["CT)LJL00C::S<7]088PA"G>UPI._ZL%-5I4)
MG_W022#M'H:A,"P5&+?A'P-E4*%QJPZ'< (D&'!'+<#N6O[;/[+&+N4-V4@=
MSX;!#JGHRM4' RD4;7R<) KW9<#F+%6[XV.R,S@0KOK%OU<6'QT"N'2T?8U
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MX@3@+R1%F?4&_7?E&%21) IZI79)1HL%HY'"4,ZJUVBR&V:FO^K.7Q=+FY#
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M*( .USW'@ Y] 5ZR!OO)LBS@!US3)L!A3!^=49@DA(DN8H'@:5N*)* 3S".
MCR'26^.&E DWO=< [S;TOUU]$4PQ2'9Z<VVC;^$U#H,,W_U(3%C*H#]3T[@
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M&=*;S(^/1_Y<R9!?L0*>#)7)05:RCRP>-2.>YG,&F/(<R)>3N)R4)ZFE.]Y
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M65_]3#A9'YQL+L]K':\73M8A-D['R43Y^ H\+GVM](_TQO[HLU<(H1 #[4;
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M,5QG1F;H-.\X]&H[H.A%*-<8SX.3'0@DY8HPS@84XEOSB6<X&@:_2\V"\DI
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MC7>Y<'N$]>(UW"&AP;?2_KLLE6[-GL7;I_ANC4U:\K=!UGZ8 )*A35H2R>D
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M*A\X2P&C%78JE5^>5@&Y;\O(F6;S-$#>-$?*.<]M H27J1 Y@T@5B_4ZSXK
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M_0'R<.E[\-.5QWS1])(?I9\ )#P@5? 0?APDB>#"@&<^$<D"5P=O#5OWO8!
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MLFCL@D9MB&$%I0;U<E8=N %\W3+U>].B2Z6)6I/P":+ 8L9@00DJF:5IT:]
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M%G+Q#)Q)]X32]F"#L]/A=?CW(C#\T&!<XA'=-1[ITQ?DB5@.#<,2^7L-5E%
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MR4YHVULV[A6M=PI5+=)+P)RH=+L;^/,H\>/H.^_^)DJF0Y0D $[]&9TGAS&
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MF:BT!8WR>M'P?,F3575":QF0+A.5Y+-90 V/4S4HO1-+FP63O<N((!O0B%+
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M'@/J4:19A&NW=;$X]V?<HT8P8<X [C&X 1B V^R2Y1BC&;?O9_,TXTM>H]6
MVFP?!IONY<82]*FB#G)JO"4Y'J/'*PCR&$7Y-J&DJ:QI.U*[<:IY<DF^+="7
MU;K?7C9\L>KWE[H+%YO(!3-:Q"@PAI)95C::ER\;[E6;M([MT\2PMVL*:-VD
M-BX^.)TP%]+RQB\AF1ST 6>F:J8EHN$T76,P<#"\E@#'*_!TANKJ^B'GX4KJ
MH5+7-!P:3L>[TPTYKFX7:_\:G#Q'J+R,>1UH>/P:[\-UO@:KNU8HX![S 0R/
M81(EB\8SB]H2ABFYPXWXO 'QSP%+YL9;^XN]K/BF=TM>^_,YRX*1_YC]!"'*
M*"ELSS?TUV@V1SCQH#]C)SL!J,CR=H3CIPA/>KL[.WL]=OC!$JQL>82JL9G_
M(;=>-%78?]M%O6WVTW9_=WNO__26A%N]=ZN@8$2SP,>V*(IZJZ 8^V3$FTO)
M=D)Y36B[NSO;.WW:B!('QR#6G/C^G%?L@3@A95O;R[9*0.WX$B:XQYKJ03KT
M<138L:9>BS'F%6-,_\7:.!#<7A$+@F<:.&9 HN2?\__"Q'JH%!58W\_MF5 *
MF>!DU?%!JPICHVQ(,CBL.$! \'2"KGLD"HQ8B*H2^T,W.D%FPW(,;[<4&9D_
MBQF9!Y*,S(,123#=,&]YC.*W6PQ*])J%G<'):0)F3+EM>7Y>ZNU6@E/Z?U:*
M&E 1"H>\7ICB?$V!4<Q3QQ5E"5VXZ4*0LJ_O,4KG12<1;5ZP%M:F0- E5=[D
M.8./\X2_M)%SEN[W,,OV.^ 74MSA0RNT2IH+6_=\_+BH7Q&W%1\RBW]0S4/L
M)NEZJ$L]I"*V^6"EBW1J4)I)/!/S5)X7&>=XSK*!D*321;K;0E>K_66;)UG^
M/=[(^3(7(QU"IWDF1MFH<I$[:U+2@EE,IU2X?\@2%3K,$P-@&]*OA*Q]ASZ9
MGL3H1MBBN4B\+63C(E#&?9^/AU-POKR?4Z3J<8]Z>\A*ZF5YK4K/BCL4V\&T
M&>(2+@W119Y4B9\=DO.QT)T[/-@ #:J%LY'VR,DA8,1H8>@=ECE$SL?9_71V
MJGS LX<(:6K<(7MUZ#:SH:R76]('65(-%\DW034;A64+EY7<$DX3JX!J)O8H
M#X*D;>3;(>BZQ6\+V6*:RY,=Y"/'1=KM +=<X(0EX'Q>V,EY3,0@OR;H(C-6
M):$GNL^5YGW%:*+KI=@VOT3[/KM#ZR)GVH.WF"R7Y4U2T69P>'S8 ;;:ZQ7\
M_*FX>G<^%E3.Q_PZR"!9,AY>%E?N^*N2+O)G@U19#)_JF#S-;J$=EI=KCGT,
MZ81VFD]VR,V+[DEQBZE,V9RKJB&B'8AYV^F_L@26P_H=K7(G!T/ZK8%-(DHG
M&>T27S2KA,VM) >W1JO!KA[;:4X(A&;<H=F(T$;],UT7T"%TE 7UUB]..$BL
M)6([V1[E4=!791#T9X#!<1X"?8+1C,^M,OXYK_$H&+5QVJR,2\7AS,&B.-=U
MD57VH"VVG2R2DC:T=,N2//+.24O)!NYZ@L^;<Y%X:\P:#N0GKDNWC#N$JJ%I
MZ!%\$,X1I,&FFI@-EXJ3+B KE"H2>5"2GR#L#CU-2&ICY A -*/FL5,$R$ I
M=X(6UF?]^:,JA70'#Q(?+V0TCOV82(G,0A>3XM/(C]D9*,5/^XR2.[6E&]1H
MCE6$;0E*F78]'^=ZZ0+A3$C.LL(*OHKV?#<MWL9KM.<P[5;PU7(G[)"&!:U!
MUNG:5"YG=(W,$(S6DW %J/J4>,KB3DZAX#"Y\PFNI'GM8=V:&+7VEK1U%Z/\
M/GDA'>;6U-_3M+]/AMBJ J5-.4@9/7'D7P+V1',P9?MW.N5BQ$WNPQRRLUK"
M#K]ZD@SHWBH*\EWVX.KPY;-=EX> #*Z:N%-"4M;O^?B*@@/DL*I+^))9E.'J
MUF72VQ.C9LSQ+<!!1%1M%0Y<E]EA2\*Z3*@9_#R 9T4.W"VI2HOGA#T"-(&9
M;1AD5_>S6U*#\ ^J/EA1AS6<%7REI5N;-$=5UIU"NEI $)3W%:;@^):M'FE$
MIJP9ON0N=QITX^7TI+@+<C? VI8\?9!)ME%R-"&=K"CARY?%;O84EDFA%/)S
M>31NGMA[X*L#0W&#Q.A6O^H@UF^S),*0HW1Y/-X5R1J7]5*KZ$?V!3]6!Q>Q
M'X ,'$5&P7*KKOCG$9FH&Z.V+6\'+%@A:S,/8WC<W#/1TY8_+;CSP,NP-6C=
M]K[A#& QNQ,8?0=A?5Q*K[&Z/%[6IDWC.K-OFDYGQ07@/PGO- 2J&4@UV;TY
M%M;<7S6@JD\-*-=] DXAM3@ >^(DOP9Z#L4H,8=)M:5 :686#1R!HJ$B- X)
MV?'H[N$1,,%,@VD@%"U4;S8*-S]=U@#V1&C2$Z  @)#D 4MNV'!KCH[5:=+X
MF(-OU.B.,J?M9329)FB<$K"\1\(XSKSWI[,Y1M=9J,]P2E%.IE6QN#R@-DBE
MFI7U3<H52)*8Z:_"1^@RA\S@51J'LZ5>+^?=$& >#L'Y[OPH:4F)>B4J[619
M2'89P5V_F.DR:U8E26?_&[QZG^86WCR"\.(1,6\3A&IVE?56EK)2>D[L.G:9
MNW='M"[X+ ^\6V9&Y@OM*:1&*TKIXG$/!O>ZC+,G0JGI)$V091NU-#2/C!<:
M0@Q>C34<Q"[S:$W*6NBM#3E_!6A7E19=YO*]\V)E+^Z?RX>[2??EG]P+U\X'
MMWJ8ZY_-L7EG-*NV9JMF?QR"V^0@%A0EI$C2V>ND^/V>#Q[6IT,S$FU2(KK&
MD':8==>0=/FA7*/:$JS9.I,E0W*/6#/23=W(=HWV%<&K;]I$Y"N=(Y^H%L>)
M'T%FQ%^@. H6SE%N@50[G6O+B9M4&F'J3C\;.L!5&HU E>.5YZ(Y27DB'S>I
MTR'4""^.8!3X\1!3,XCOJ_W83?ILD&KFX1FXR7THC#\8T3$.LT,:0I7Y%Y ,
M0C1GIWF\23=9L!X-*I/4RG+A)YZ.L6,%X%JC,[M"?D&W%HEXC_S</>O;#JM-
MVA!-U@ G9;X*<G.J!U/Z ,=9T1*^BA]6EZ/HC@]$UQMRI-_5E=>VE&C6Q\MS
MKF:X0VH3OC05R>M>?ZWB5(GX(P4<DR$Z )\(\V?(^>,NF9;X-6H^/SN@_#H!
M&SD N;,Q7 5J// I[3^7B9* U5XWS7A0/PYSF$ 58AV5/':A>#-N^9@@%%]/
M0$7(2\P*^\+K"<.F+KZ'/!MA\GI*:^(@'8%32<S&FN2H%?)ZK7^(((=;C]U^
M@,0DFR)$&P34;'^<O;# &T3+L#V>HC9+*"9[Q/*Q#+)UJ&L]YE;KS/TAN"Y=
MRINUPH,GY7$IQ4<<MJLTF T+5SI+^?'E$9AC$&1)S^G?,6!_4'ME,&-I9[)C
MDTP0[G)A-7(T5IB4K73+XBX+E(A5H[T,4BV><N%!PM7059<M&3O\:J4IKR^R
M\?%17T5O'M^/DG0S=IWF.[Z=1]FZ=$35A>T:=Z?I("J -)>0TMD(X/-Q]NH,
M#TUI&CWM+_F58EHC!9\,5ZL#F2)D_ )'04D2<U[-\]RP]TN2$>$JQ+4Q4>_W
ME$D$J#\*;U0]C'U"HG&>Q,=-\FH8U:GD)(PIYJ:;E GX-&F3Y _<W&<>N?7O
MN%E1H+OH)VO@#-']09@&/%B@.*:Y,Y?C/7.G#7$6.6V%8.;BU[Q1T>)VV&QH
M3XLYAKW25-7T?G2<J,&W3G.<WXW[E-^-<W>'9$1N(^_BU/:V^(U.LV^I']/E
M)0\SRI\(>D1\L*%F)=X41P3",UN/DRTR0M3/]4C?%VMXL0@K-F+% J$8R/20
M<_[,S1&E?2]C [TXY+_<+#F:< FV0QK5^Q&>L#Y8+(ODEQ?X$V;Y[!8?.05,
M*=(1?PVP/P&78.9'D%]N@)Q=5#FP>ZWYTV=5%A<,N^\X@P>C7O=<!>NQ(?HF
MJ ,%*-[%*;S@G#J%;/"2*.!I<ATV1>^2:F64C*G/PC^1]U%LY,.U/2<;&KHK
M8;^+H<=B<]C]L.*.-N'A:L.I#U>>*2IN/Z2J<(\U:E-BS?E4=O&7TR0FRA_+
M_#E!> PBIY9:]UAS9_,G[R)E*\-?;0:9:=>Y'(E8,F_Q%T"86&$H^)N/N<C=
MW16VID2C6&H#NW*B<)&?<V@Z$/?C[/O#'Y-LFB#E/%:I!*8'6G10_^Z$3KTK
MVM3IWFQ'M**+.0AXYA[VTY]G^MH3JS,=[#;\8S_"UPP/&B?L:7'N $!9WSY_
M6GR2[3 ?JQNH)8'WR-''YQU:@;1U79.X?/0]X&>.O$L_?_3]L8Y)"Z(VX)K4
M]O+X!I\E.6I+L'S<23VNIQ%=^' P7:!QO#R.FN7/BOO)<@) S%X89LP:^21R
M+[+\[HE]&$8[-&[OATQEB$@]7<AC>F?1 KQRX1#?:"MS(MU7FNBU P:-X+6I
MD<7<RF53+M.K06T6\)_@+;'6M"@O!!0-B7G 'F,ZT7:$:#.P9@FI*F\V%DX]
MESF@Q:V2OT6>4)=IMH&OD_40S.:(+J6+S'N[C._E>V/!8^O 29H]5J4*E#8A
MOGR31S:SY+O+C(GN^CY6I$=YSIJI4(M$2PX,AQ9@=<X'WLK!8R+9"JR1Y,%C
M(MD*K)%DF[%2& P1S":3,RQ8";Q^HMMPU5E^K 2^Q;T !PB5H=)==N/^PB&Z
M2.G.F&X*A.H.2<\*INZ-=!SZ\!,U]8KZ68/2]AP@MR7@]H2[-%Z-&)56>.:<
MR*1/0-WC]R!/.-<AJ?/R 33!_GP:!=3\S-,=G<(QPC.YPU5V<YV:E*-%C++K
M2\XY/>^(0M5HV'AW#CDW[Y VC?W3MM>0)3:C1<DRL1D1$YL]YL%II.U^^/B(
MQZ0557>O+HF06>XQ#T@[ C<X*DT=/N*A:4^:<GR>^2P@CI_$'Z1TZT!7?]K:
M 3L]0NS=#4*+BIT[-_Y6(T#G)6S;HD,#:'7HZIW61X G  \F&/!?+Z@46"N3
M<A3DX7KLUWNV6M70]&EGRQ<D%8\J;"8OSGT\@:DA0#?$JQN66M0@"**9']^S
M*&N(=/++XS#9QFM]Y&N'C%;@Z&#GF4)/$!Z$UQ$[G+H"^#H* ''&6V'&J'2Q
M%?YW$!ZE3.]E\=59K?HCK0Y0V@ZO_OR015R D$ZY#XAL)M'071ZDU\!JG\]@
MKR^ D/D&*(=()2?9. JBI.]P<(@->IT//9W-*"EH?!5-($^U A,A%3S+]!Z5
MF?R<,XI60+\I7CAD#:V(6_>>]ARQNR7IB%857TES><YK4*L?BY&;%3?B8U.^
MY+$I5^?#1NC1K0)K=N#0I-D8)9K+5+)'"-FAO=5[=@]B+[2&K//]G^>.]H?/
M=%=!HQ;8,568R4*@/+.3A""4O@.T6( T79(E/X$X/(7'),#HQH%A)P&E.>3F
MAOH'0"?I<D]\!&BU2++->Y",;Q8@=7<PK]E=$4R*O6+HS,9)"<V0XH04N\>'
MO_I8PZ,T#1Q+;"G)8JE\CRHI/"<NFVLB3+40Q.-:MZ:X$IIZ*EPLW=CB:SJN
M&I,V<"V>O9)7=\@2M 6JV47D-W_SO'2I\QGUE(C5KPL73Q6_IQ7/835;M\MZ
MQH!<ITF%6<T2^:@I?A %I$-GF2#_?/D&0W&9W<\NLY]":K?0I?Y22+6]ZOG'
MVFO?"I MLL>KFALXR(&50*O/0H4;5*XN/DJ,;:AR:)'1HM->7XYF\[@4;)[M
MUN%3.SE>Y1.AY5'F^?@#\N%@QKR6[ FV(:+<PBB.BPS(#W\,VP:L]E12%LY<
MWNQQ=4:V0*TS@2T:<6C:ML3;(A+=53&;H+8GT2%QVH#4GA1*G: #&'Z.^-R/
M,/@"?%RC]('R$]FCU:6^RMCDF#=$BDJ[%Y5=(!%<IAORL*T?96$)5'VC8'EK
MAIL<[JH9#4[]4R;2BDXI&0-"]?)8V=/5VW%MS]G IUGV!<NI<H?'#6-.N&EH
MH3X$NI>W;S>C&#=ML&B@ZAT?Q7US,?$G.Q*<8S"E!BZ[B;Z9UQ7O:AMB38)F
MU2C?9W%7C:H@&B*Y:G4<4IXZ<#9.'2K2S+)A61@=T)@J9&I':^Z9/<@F@NC:
MN^,9M[ZG50]=XS^7O6UTR.%PEBT<$:8E4&WPJ"IUFW.JQ0+M:ND*'=(VECAU
MVO0C'?*S=,;RTWST\5>0Y%EJL@!O_BZ"6P>7+0'K4W2O\7K'2<KN<+QWY9KS
M1LG1;,^X X(3.$B3*<+L9.KA]YT*7(:PCDT]&")YJMO-5SW:$Z4Q+S^Q+(;Y
MV>15^9+0AM_<NBO[V@*\<A+<5 ^MRM1>I'PNI?9*T0/NI^RQZLR;/!5K%DT)
MH\2Q6!83PLVO 24?!X2DL^+ECSQG-WLCP@&NW"%QV@._5;L]0SPZKS9B,V4D
M=N^$<_KNJ33FAG35\)8#M"7'(>M:#4T7GU)4^ICE_66?/D?)]!-$(P+P-0-R
M"N=I0F19;!]PI5@1N.;9>*$8MSC.X6&,"+O2XXBST810_2Q(?K"Q3)>D35'W
M$-K?"%%[3FA,8N:J\FD+73U\[5MR2&6M EI](EYXW%D:XX#E,+_'S,-KVO<6
MX-616"!9)NQF%_!<)E0"5GO\Z),IY0V)0I#AN00!B*[K>WBG2%1C-MX3RJZ.
M5Q/-:E)0N[*';XU;-8>+52!O%181!PX0JH1F>X[IS*TB*2S]+=1J2,MF;AEN
M8O60X5+KR?R-V.6099V>PV7V>X?20+8 J[6,>&:""Q\GBR$M3=B3-%0UN6L.
M6>!5G^5I*SME]E@BU69/H-N<;RG]X?@:.!S@J,6I=<S(*SHD1B-"S=+@+X(I
M"+[2=3$!7/CTKPGV9RS0V>539SUP-<'9;: 3A"?4$F()Q%PG5 Y8_2X,2F'H
MET=Z=YV]8TT358962=I@,L%@0A46/V+);Y$6JX_BW7*GJ+4D0*N,_+@(7)NB
MF!KVQ*T,V7I\ZFF99YO^")BU4;JX$&1>KA"Q )-[#N:LX+%^7LP=_ ID&J=%
M]6DQ=RA1(%-1<D0WN:S [L[N3M\9*F2H=/' S2A&ATA1@E.J[B.69-@="@0T
MZH54N'WJ#G09*HVQPU:6DY3?('"&! DH]7-^_!$POO<LEQ-7%54+L)KMU(=H
M#*Z"Z#!S*'SX<.@,?2ID*N%5+R^[,X7DN-19\50;#>9 =(8H&Y2M[Z:Z0YT&
M7>OK7VY310RSBI>]H/L1:D<\<X84&2I-$.&R].Z.BS24J#0T+)]+<(>"!B;-
MY"BS'3H#OXY(^]1E4=8=[C<@J1^NO$'#*4I9[OHSNC5+ ("'((ABYMEQAQPS
M2/7LD%3^>.0Z>16$QAB6(S\![NPO9:C4XA%+[SI)PVXK&IPDP;"0?T;XZRGD
M3D#BCA*3H=+X*5# M_\#&![S]*3":RZ#'.W#'X]8H61B>M.C%!)J1\]\3O)_
M 5!+ P04    " #NG'I2<?J!5MP/  !CQ   %0   &-L;FXM,C R,#$R,S%?
M8V%L+GAM;.U=;7/:N!;^OK^"F_UR[^Q00M(F;:?='?)"2S<-+)"^[,[.CK%%
M4&O+5+()]-=?2;8!@V7+MH0AVP^=(=3H'#^/='1T='3TZK>Y8]=F !/HHM='
MS2?'1S6 3->"Z/[UT=V@WAI<=CI'O_U:J_WTZC_U>NT-0  ;'K!JHT7MTG6F
M Q/6AMA 9.QBI_9?S_E?K5Z;>-[T9:/Q\/#PQ*3/$!-B0%P?FX"P+VKU.FTP
M:O(2 ];@RUH;P]I[ ]=.SFK-LY?/3EZ>GM:NKX:UD^.39O"3GU[9$'T=&034
MJ-Z(O#Y:DS0?8?N)B^\;)\?'IXWHP:/@R9=S]D7L^8=3_G3SQ8L7#?Z_RT<)
M3'J0-MML?'I_,S GP#'J$!'/0"830.!+PK^\<4W#XTAFZE43/L'^JD>/U=E7
M]>9)_;3Y9$ZLHP"W6NT5=FW0!^,:U_REMYB"UT<$.E.;*<2_FV P?GUDV@C1
M1DZ.FR=!$S^S;_[!_URZB+@VM!CV%X;-7F4P < [JK&F[_J=V$N8-C 01"9E
MK\'^OR'\>4./BAW:*QTP\.AG!Z B6FZV$"BJ7M-+@TS:MOM00,7E3ZEN2O1B
M?=7R;>".V3AT$7UOXHXA1\)V"1D!.FQ!\+=GS $9&B/6N)3F!1M7V$%6&JRD
MS*< $3"B=FH,O6*OD]H84U^Q\A:T?0_.  &FCZ$' 7D &("Y:?L6L,;8=;P)
M8!C['C<OX2^ A8#'@)Y2^STQ,"CVMFJEKXTJT[!-W^:_N:%XQ) "<P\@VGR$
M%=.IH,'Y-1!'!=JN&1-B,W/LXDB&;8R _?K()_5[PYC^TR($>.32QYC;DW7.
M0CVX71X;9,2-<_B[!N.R 6R/1-]P=NO'S=!&_YPL8 5,;DV966@A;AVNO_EP
M9MALJ+6\2P/C!9VI/QBV#W2\@9S@QHJ!-<I;./Z*!C8C%>G'+;[C<V#X1(/X
MCL-;JT-JM:/?LSZ9P:/GYH;/Q1; U <ZJCT >#_QV,? #N<FK(-F5(2+%[=
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M"F'Y6G%,ZE6#-3JBC+'YZ/]02P,$%     @ [IQZ4M@K&NW":P  O-P& !4
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M7A1!0+D#EI!R'2#4D8P4+G4"A8ET;ME#Q(@LF)-)S6HZ\_U\D_/K9GH&#_P
MQ;0!J#K=JG0$!D$0+]>B(L6SU]D#='J 8(_UV&-^%CIAKWSY(>_>>T9*N]!B
MP:V#J;40=<%5IF/8<3F&<34F93-%(*FS-7L>E>E98QCA*&E.\="F!K+:[[JO
M^/_^MOF@]O! >9"'ML?=I%_>W<H.;A2H><+I+;C'696>&.!@+"4]_>.P'%6
M/V]!JIQ8.LNS=9P$?QQ6%*(T6R2G=QA6@@A)EK8GOJLTS0<474ENBKM6)WQ*
M)]^:P.:'8NB#2:U.\V1$UP 2Q7\_(OLIH/];\,HZQ=THH9[$ #(4TYV\Y93
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MM$KA='1:,4R(+:Y$SM=>LE+L2;927CLI3F#W@F)7BJRSWXK9^UKV)K1X(3J
MP+K(3<<&=H)62DI>%-)J*8\!9 :F/:'E!L>S%*>\&8KAPKO:;+T@X;5'DXL@
MW<:I%\Z7G^)H]2EX)(NB[LX0^YP)']-9JF8PET*7]S3I]UYDF*U12LW=G;+N
MGB@'K)20O;8F^[ 4NZE+[_*'?Q$_NX\_>]&"_?:.98%L>#73<]X%-KV*#C_B
MV5,#"-4><Y.JDFE/)%4(P&I IE7,VR0:HQQD_#87"$8E ^L]OMOY)T,L2271
M22TU-82 IKE6WLB;+2+E,*,_OH/Q4/>N-<MW>"113LI^! R= 1:1FNB4%A$
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MW.GUYW*3SC>*H[+=7ESCK6+4[E34;W6<:BN(.W]-%GE(YDL)8KAA0#AUE[%
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MG54EANNR\,PO1@_KE'E$#>_L+R;DM-@P2&&/'VD(P$)).!+2PHD 2$4SCBA
M+^F@E1@NEW7*O'R=QQGMS]RZSYT&X/ @0S!;VR:I1>B=(:[OW#]ZT4?UG<;)
MVZC;E\_'Y\AIX"KZ;O2X"B=K/;&M)<+WAOKZ?BJX"B=K/3>-D[K.V>CSY1T_
M*EVE:0XN_R#Y= 0!.8!WWSEYN[$D3NJ<'T%YZ*^2;B,\ D)<.<B$L%<#@M"+
M44X4K/6*(9R^B;8F@L8RL&QQ!%0YW\$R\ 4/->!B.!K%K;O77Q3'H&"T9A1J
M0!57-U\.^Q$<[K0VUL(!"6"MX,'#G_[^M!;3\>G?".4K?2#+."'%WS/OF5AY
MUW<X&,Z75WSH3Y34&2=5_/V>D3+,D=4=W?CJ\C XRU]C34F"* ^B59EY&$=M
MHM1+(VD6^,TIV8D)]&''_3M!0YVH1Q-ZR0,E(F3 T25;;BN4>%X/;D:1;>I&
M1?8"06L:8\#4AV<Z1<I0$'G)CF]#UW'$;@PHI)3$JGJW-Q(U K/KJ *':QV#
MBQ/6J&9PY^'@(!0/11](1 EE)E>D1P+9HU0^03TK1C;T#52CF63\EQ55#X-J
M\2;_>@R/+X#H'WQ?.198:; %Q4M"1_?"%J<H=] *DHZ,F%(/&U?1*MA0_*&2
M*K\GFD6+3_27!Q69@K"S!VDFHE.!B-3GL-2;PBD:=+G)2$YIN4EALUJ"Z8BJ
MQ(@CRDI&T=V69B(M*6XXT<R+,L7.T)'H^-RY5ZWK1G1!@56!I*)9;HD#+AH@
M98=G<+5JUI</%$FL!*F+?79\;8=T($\0?5>1-S.1PB!%BY3L-:O81UVLT6[*
MTUNC"B2Q,NPK^@Y$V"&[Z<BMAV]B'J(<1$PC7%I&CHP2NG%6.*C%\A+BQY$?
MA$&C+(Z-6-YM8^2^L3S):+WN;%K#RB1?A5#8SIC347>'[ULOYBPO$"L,CJ (
M#U MA(O*CI"08I,2+L5.%$['-%T67*9]H:P\@-;(Y:'6"VUK*.&AS!39UU<#
MV4+H6 YS9]!DJ@>FU3I/BKG1'Q27?BM"?SCHLFZ1/D7):\./TH5"0OTZ9FY7
M[F<!]9;**::WA/5S]-?4QER01Q+&VTVK/ZK>$M<AXZYMBY/%KR4!V%-D6Y9A
MGJU)LO]1M$)[[*M%_QNT$1)!8-6(E7!QOF8=7J^B6@2 UT9/62/GP@4.P_B)
M5<4;4$ETN#I!TV)39I#JMR^A& >G1I. M8M0S*+4LLQ[]KB6>=$B++W:@)@6
MFSP"LJ7*["AT(&(8G8&.:G2(:@UNRB]H(.?7IYH2$EVC=L!D]Y!['*C>TSX4
M1X[3])R>T';+.'GRD@6*!Z1#?AR7-DI%%ET#@-!%>?5=XZ#&<_73TL#6FY#I
MKD?@J".X/P5)SA0TG#2N%O?LU$S_'F0-W:F.38.L4 4+S@+5UM:H"F-8;K>-
M9=KLY=!C91X-Y/X*M>]:/$8&DNK5WWWA+PKC?7,L,]?E>)#)+!@@)I#3N35C
M>&23V2)-'@ESO&:^G^1>F%8_&LHV:G T&<G;D@#@36W_15KCZ3J.?J<<!,N@
MK,$ZW_*'/68+%S+P9$3: [M2BG^QML"5O'!-(@OVZ(OJF)&;"AKS=*0G1*P4
MW _XEID';H<Y+W)*DQ&<"K%21'^U?-'1(B?HPXXDH'W+]HD+J-F!_4=L 0US
MMP"\/'"7:]*MN)T"ZXCT=X98[,BOU40=26!5OW7787Z#V&<W=F.-]?.:T@_T
M]+GP:YMK^9ZZ1]45-NP9&[:^9[=ZV7=2_R0N3"V[ [!*T<QYM\&#H(8UXHSO
M:S6_AJECC:<>>T_2HACZ=\3J<W>_KVS+<@2Y1) *9'>10_-UE/6Q<=94^VI6
M C-B;9X61;QRVMT$!VC@U%%7&Z#E &G!^VM9%QA.F6VUR)S6V[8I-6C5;2/1
M?201R[YAL;O%AN+$?+8L>*S2\_#:/<$(NT]Z5YBANA2!6&(]KA5G4J(+$D+6
MZ8%26XX@()&:XK$BQ:V='$-L$DKN'AUAN;LJ:,=ZZJPU/?(/K8WB(B1/?YZ0
MD&KT@IZP@\<@V]4RSOJDG-7:09T?JJ66%P%T0=P65&<E5<,4-%,JYL91+/T9
M>XVRXF;A;'?XE1MOQWXT8UD )5,UCHN"XL.MR3Y,.D^0ZZE/Z@7<2X0HQQ>+
M?'XE[*J=PO-('8L5Z2@F/SH%[&1]%&G*XU3-;I%;[B3:X/]!S?^#-O^WA(F#
M0QQQ^'(OO"?)YCV:^@X\C3%$XFUK\M":8+V;#,*ZO*),!_3D[[-+IK$;WR-F
MW=<0'Z>M/9:I[91"6XNJUK #N*C>C=&\FDSCQ;SVUP2T],R^2_%GDK()1#R3
MT*=_O(_9CVJ3'.]9"\S[B_$UDCBP&<L(=79JA[:>,WH),=A3#F6>K0OO0WM2
MDW)*+,[N)*,:XX 6DLAL4"@FK?O_;:[W?'[@>(*"W-J#GHK6&$(*2'\>U48_
MB8L ,.\OSJF1Q $IX?KFJ,LUN"$)9[UC0=5Q^[G58$IBK6S3/ E]PI%&%;JW
M6;)0MG^R35.#N>-_-U$=:[1'4/8428?LB:?2)<M][>&[MX3%AIN'X3/!Z7ZC
M;I6&8"HELMO9IN\F_)&WY;V*J(T-X@7:HS4,-D]%Y5!%66D=SB5+%[>I%KNC
MB^)99/\TME@G@J_4UVJ']N$OW?F4#WF)W6E[SK@[A="R:P%7"FOM(N4PH;Y;
M0[7BNE(KNG02B?YI:1V6D"J]ZJP)8E^OB@@,Q:AQ'ZYCR8Q&/XT=LR_$E<SM
MEQ/IO8=77$[7?].;P2GFQ0PH_TJ3Y=<.PVV)'W[/*3K\B)_SJ?+",/=K+S+>
M_6W;13>LGXB.CQGB_4*P5=W&BN.QY\^AAZCBX44Y->15)7C;;N/5E_'+.%F2
M(,N3P[XQQF"CB,V78"- E)7>66])W=M?$; [.8]5=PZG<8ARIP*5-ELM0STJ
MQZ2$9(INZX'U%\\ 7SNJI6"K/9@5-TBPH!TXKFHN3L,.#R6R2M64SV<&KQ"Q
M](+DD3$9+^GB2DFC0 3O8+ J;@%Z=2."U>4 \_()HV*A 76C?"O;[%@O9*A)
M&6^KZE73T%R9=.L;ZDK*0JU#':5+D^S76V;*@$4-Z>_7_'_ZMV/?OSD@TDV7
MU:*%9FN)Z<$1>%9K?>S'!M?5@HNF43/+0>5!H=(U -6H9/9O?_]O;]Z\^C]?
M/__\Y__[?_[3W^;/OT1__G'QQP^/JU]VT9>+_.GC#\F//_S'^W]]N=^EX0^/
M_A_?A?_,WF9WY)]__/#];\_O_$_9=_]U>?G^[C_>/CZ?G?_RW>/B+O%^__JO
MN^C^^O+?_T7NOX^]SU__^O7/M]]]_BVX^L__W/WUM_<W__OA[+?PG^_"7Y;_
MXR\?S_/@E[?A/R__]=M?\@MR??T_5H^/JXNW?O;P^\/9^K]6UZMWOU]_^>Y#
M<)E\??SEW?K^+Q\W_[7XX?M_?/CA_I_>U8]/'[?__C1[_F/Q_HMW__3AY_1A
M^_;J?U^N;^__<?8V6_TEO_W'Y>:*JNT/F\5WT<U?O_\:T@F??__;Y_7EV_C'
MFZ??K^[^\E?R?U^=W]V^>:.Y\QS!#JJG:*1M#NHE0G4-5 /1K(IW$CSR*GV'
ML\IMD/Z&546VDQ[BDA^)38;!#BS)UD/8U='RGGZ%5U>VDYXS^ZZC^F*9B=##
MZE4IIXE36%8I,X=596U*#+6J;.TTCU=XM$W$9;58B&UIA(_;$$'<*4V_X3,%
M89-O['JIS4&=A#LE_G?E.1Q-VW;%74[">T9 MC'H*)%M3AMKIS:.ZUU2UX0'
M[F9IFF^JZ^GB^<O/<4B'8=TCZZWE1W'1J\&VLR>60\1N!I4_9C%%6[RS[?TR
M(73#STA"P9R$Y@J9'GMEZ1$JKECXRFJ)SI6V6G 7P6.P(-%B$DHK9/I%:2T)
M7UE:<=#*1EU\CZ]2D9I;ARD'@^LIDKPA11)=7/(RNY\$C-%:%X!6T7^LF\Q.
MZBA7N4"*J,WG )@/->-Q-Y_34P_=RUF(&%PUG^-FA45XL"X*F@2F<C, 7SEU
MNWX$)DXHV3Q?\\!>M+@)O>C:VR!>&J#PZ;:'G7"QV,FE[9*-Y7@J)K,X=QEH
MJN3T%L2)-J%=0-_N+28WL5\HG.GMW1?4?FT=!!U$%X<PT$?MW;H0Q^L)U*,
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M]AS_AM7>_^,^Y1S',S1B9(+>HAG@UBM_R)-=Z_FJA4J"G!;H6!,QGWKXP.J
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MV;'=55X2_)1]ZS"G1"<,*IVZW1I\945-QC>E=>:%177B!G40W*HQQFT@83!
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M]F2W\+"X-05>:MHD.*T=R2[65I.T!#[U/%N7_0WK'=60#RL2HI/<7P!8*E/
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M0KN$#*!*)MWISY)TD[^_990>O)2P7_M_4$L#!!0    ( .Z<>E)'V-5TMO8
M %*]#  5    8VQN;BTR,#(P,3(S,5]L86(N>&UL['WK<^2XD>?GN[\"-[OA
MZ(Z3W%+WCN=AKR]*K[9LM:25U-,[ZW X*!9*10^+K"%9>LQ??WCP 9( "( $
M0(W]86+4$H%,(']()!*)S#_\O^=-#!YAED=I\I]?'?[VX"L DS!=1LG#?W[U
M^79_<7M\?O[5__LC /_[#_]G?Q]\A G,@@(NP?T+.$XWV]LP G=9D.2K--N
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M!4=_6._^. H$]J0_M3I1%+E(UE=WBPNPN+T]O;N=@XS%PAVYMB^BX#Z*D;:
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M;[O?L,IAH0OB*@=FR!2.V(C(KW8%CF['SP"L0*]'Q-O=?I<3 ;JJ2V?P)DH
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M_Q(5Z[NT*&"R#C8(P\<(L/ R2-(-7"+:">0##7=)X'/XO@3/-$1<N/<GX52
MP;);T.T7X(Y!W3- 70/2-V [%[S<<XC82:&"03W=9!OB_CJ#VR!:5F^%$!D:
MQ$4SAM#<,EH8U^K0&9YUN!*^%21=@*H/ E+2"RB[ ;0?[[G$C 5;(U)[N@S1
MAU,[+G<QO%I-CD/#KITATHP_T1U8V1FV+[<E3JL'B^1Q:QEJVDI:-H.'T!.
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M,WCZ',:[)5SBXG_$';E!IUYRUBU;3 7BR<E[N9"8>A0J90U*DB"O:8(G1!3
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MZE(6O5$J/R&1?#["#T03CH7,'8/V"0[W<KS+,M3)690C:_]'&&2GR1(G!IE
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M_2&-$1"#C.Q^V12F*[]?/W9*APLY3NJ/ ?W:O\4B$$X;%[PQ&MLNY7&Y#M[
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M*;C#<7$OK=(#=F\)9.3\Q+T(N%'2YC.[!5"0I0!<(N__)(BRYTP6D?+Q3DS
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M(7%!%II[ F>L8C.J\#6CE^0J*H)M)5@9G(<1YMT-+*/+\JN5N-CH- @3TO(
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M;_SA/O%_"P#B)7Q?**M6+#Y_D,8(^2'((FRO6P5(GXC[O:?'@P <U7=\:'C
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MWEO^0Q#OR!>+.$Z?<()FAS#5X<KU]?MXED5V!.D!'9U(&E2:_C*HVLSTK&0
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M,N74N%39 Y*/A6#,E>OHL_$L:];_"YD"?]6AG?CC,ZHY05!2\7FQ,AV\!#4
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M%S:-$1:KUG0?]%?<T$BJ??0ISY%)!9!S>GYE=]W:6%;<%24=>,B)(.9&F-R
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M:U 2:\=T&YB'$2 ["Z(,O_J#Y\EV5^07V#;DNA0G"N*2D'-OR4FX$3[_1)\
MWW<+&L)K!0H-#-?06\#KENNJM >A][."D-S;22'T?L80XO@[58<[(80^N(70
MAUE!Z(,"A#[,&$(?]"#TP1Q"9:$?DL$&>S1H FZ-FQ)16_<%#OB,"&LS55\#
M6.5,G\%MZ( DF-),XL$Z+U(@YH7_LJ^>^5/AS+_">1_A^R.%,ZZ#%YR]\:I8
MPZS\V>)S@"&2KM\$#/ C>EM,*HZ4G\Y$GRL*D]7I*H,WCG7(HD=RO76>H'/0
M3O2\2QCR(&SN]$V?F _AI7C5 #0MYJ#AAP7"Q$)(!VV6E)A?T%$#$M(.G._Z
M,FX$T.A&.'Z1A)^Z1H>*=&I\#([=* KN/(F**(C)R_)U&B_1](^Q#S6Z<URE
M6YTS 9#*#@#; U R;]P#2U^J-<PTYVE,%AA:A]YM0#V?G*^ >BXW\H#Z(Y68
M;8]1VU)Y]J.VQ3.@>[3%B5FSE[^CJ>J!)Z_0D\/PMP_IX[OR8PJ>\A]=W# =
M.E15-5$!"K!#FT@^*&:0L*(WYT2-M,=@*,?%YXGEB#IT+\?%9X$<%SL<B!9'
M@??EVY]P5HCE $S\3*3HAL[I@_G>[7&C(2PZ7Y!"*?X#;3E3VIP?.J,PK&+2
M5$C1$%V_E6/KKL> L'A#4^?&M_*43G>3I(\[LC&7F&CVUVC_R(K%\A]("]$J
M.*CAU8KWI\5S9"7EO D;$VN%F(.F$>R)TEG@S_?)]X#I"_P5M_&: V4$$EIW
M%(9391[Y+ZC8: NJ,G*3ZSD9*"6,Z-;L[,+/SY%!09 *E3I91$T(I_SHA?V+
M8W3QJ,\!;!R^E+#7Q=M\T":1LTJ96,%\F%:&26/<&7ZQ8@EO'0I3WQ_*(-4F
M+;RKK3X"?X+Q<@;[)%\FK;H5_8%-$69V]$(2A!_'09Y;L\.$Q*:/;94:7"(^
M1 =H_!$@7_7W,I^!'2*A<<,ZN(,USE#2+N^&33!;J!&1LG C) .-@ W%RGT
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M)TYK! P&CW\*4S0"OZ2074Z>AS+9?LOZ=G!IY87&,%$O+HLAKN25$3E)Y_Q
M456B+> IC=W'3J;$&6\G6SP\9/"![EX@[,B(&!ZT)[]VASUIF>QJ93(!;@T+
M=)SZ$I$@B"B#/T)DL2F%QZCWYC0V5)DMH9^&7[:&U!U\BNA%,>H#O.!._&8:
MT10GDU5"9X[,TJ7Q'/E*N.(V=)T+@,>$W&8!]:7+]2R3',KD40-#.&S3,W:0
M%0F:Z&.*L]+_]SF)BOPVQ6GIVU7,K9RX-5GP4-!9CT/A^ZNHB(*X5]B^RIP+
M=HGW-%F&<&B=^PPFRQ"\K*.)K 1^WMWI/81M8AYN/H3,B%S+V3)*@NR%WC?O
M-?HN5\CEZ]G%R)6LR-_8GPRS2.569?'ZKJ_Q9FMD]E;MRVTR-T6NQ&5X6V7H
MGVJW0,I<8O0/9>[CDO4$V<0D:TS/N+>!S8FB/D0T+\F:6^8KXFDI46[%-6#.
MC/L=V9A7J2,A+Q..56C&;]+25F5%[R\21Z&E^V+1? 8--^SV,\F2:'0?PX83
MHL"MX5N-N-^GUA+.!MU@W>U]9IGZC7$@?FL[-%MC_;.D9S88UYY7MD_*GR^V
MQXL<>OAKX;M);[X]H>SZ'CW^>(W#%=H8=9G&1)&R#V2IL28J)9HD.W1X7J(^
MZJ?B?C&F)V.Q!AO.7#(N>VP7X$J'%GD/;H\J4E[44LB&737E,9.GDG#X662Y
M@S>\:V!?77*B:12>W#+A,'Z>U<HB7]J/9SO&N]?GL;V("<FX3',$MX^O8AO)
MP($AZ<SU'8 J8PJVB[+%[->!,2Q)@0=C8'(F.<]]3H)-BFC\ I<G44[<OO8M
M'!Y1_\8-ARMA3<;Z2[ L/YV372,1JMBD$0U_A#U-PN&B1\CD+6E^>=DMI#$5
MT@:I.D\$.,R3Z/JIC,'#V^&R_A[9TI70//NV5 7<1IW29)CNHDU/#;1S$L.X
MS> :)CGZRT7O&8[0HE;LS/4NJLJ8T-+F8"FG1C?30_M%C7N;6T^2C/FM,3F&
MN^C'78 ]K2]5_:K(3J JCXQS]<5A0FR=X53#.,T(K*K<U17*P*K.W>7YIE(B
M/%93B<8](C/I#=SB/39YP'?K90ZO5:T'SY/3YQ#BD-;C(,M><+'CC2V+S) 3
MY^ SXU.$S_*C,H-<V(>K7S-N'#Q8[(Z8ME&)=RO-BPLK81U[E3BT^$1$_9PM
M!K@20!1_C39E1EF6OK 2J?ZO@11%S+?Y9)-A?-(X7:U@2/=[9+_ N^ 9^V7Q
M\]D$)XFB89C%&40F=!#?%D&Q0WV]M#ZV <PIV')_33\!U\)@.OP-*()G\/FW
MM[\%*]H'R*M.NO6:O !\0C"Q2V"J:36T5U7(8ZJ0)(X,@[C^SHYA.XH?#\%[
M8_@5Y9.INB0KPE^ILBDAHHMXZ929YC$X*9VHJ"?&=*]^R\W*/94EHD+81^25
M E]"5T$9-(A!VISE\+L-CTF_C43=MDA4I\10X39U=Y"U0ZSL59H]!=G2BCJ5
M4',=&"5F9;@H$VH!0K:)9T?!L!#YI9:X(S>/:E+1I,=K-*?H P;8-&<,/O!1
MZR*.TR?L3?:UG^NPZ-S/,/$ E&ZXD4K%84OHN$<,XSC:1)X=$):0IFL6Z$ZT
MZ65!:\72%WK]O)J#=2';;9TG+1<P(JM/UB[0C+4NK-,H>XRX&! 'IU1C?\1&
M3T?J.GA'04QS7K1(*.%AJ _'[W6ES A?Z5;5#^]ILSY0/*)#44C,>]SA.3 +
MU;N!.41<K]'!Y00^PCC=DJAFDI><P/%%68LH=N5<J:CQ-:!CLK(3<EI8-MV
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M,*UPOL8I6IL&V!=.6GA=_$/B:-:\=,"F9<JS-(1PF9\ACBJ 7:VJ4X4-$V:
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M/M.8H'H57O$FRW?UE_4SWQQVO-P6 OI,(+ #RSA$AF:0BKZ#CZ6C[$EEHS_
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M #)U2RSA^4GA3&AKC!^:&7(,W_)*".6RK,E?,V@\U9@*/6\SQ.+DZ? ,+^E
M>24:/8$N:J.G:.M!O2W,N#B=J99D,XE6<XOL)RTS58J>-"56/8EI8)UB R[$
M?#>/Q=,VHD/2GKP5+V43(WN5Z5[QV!Q8FRT"AS=D0K:\ZFVM1?FU$UG4[IT4
M,IQZLTR[K%+F030?)8 S=^\L0<Z:P+6$/32Z=&;LHN*55TTN]J*4ZF;<-X$)
M,"7R$"#^VA%F"%/2^;*$IQ3F6+LD@O\LH=PSZ]0K)C()G@ > V7.3EF(E)/*
MJMB.<=D,9QD-;XIUN></V?>+0_-<5ODY<X2\:V$FG/F \&PJ]3D3W[-VP$)<
M<S'6V;;"(-9SM;)VTAE/DF\LYFOD@2&Z$Q;W!D48T5XF(81GO3SC":<].J'Q
M>.]- (J)>V$AKTP"6P)[XNBW1459AKH#GZCC.[)[(0[+_ ;3I)VB)C(LK0/T
MT8Z(X.S3[IG$J3 ?GS20CMA0SKMH49O*?RE-(,Y)6C#/;YN,:[!SKCZEB2EU
M#FB0\-Z.H,>:X8;S3;L\_*,136Y>("9QWR.?D&\#_TT0QGNB-0WJIS_D#?0K
MO"DV^6N^.62[O^;-LRRK "T+G_.7A_)#T4S1@Y,*Y$]=%D.HF0&7KQH"S (9
M1=T\I"40CF"TJ;,_AS#S;J=[ON%\#U><9>SI^[-F) )-FQ,SK6$29-[L!3,+
ML\U^0\?GLM3TF8RV$A&FDVZN^I:^UK3'=,Z\6-+5#-A.MCT78CDX@NTSMJG#
MTC!CHSIK9TVW2"9-A+<5X\!,K8ZV*!_]%+99.RN1*F?92E,ONL3)$)6(5)B.
MVEFNFVQANRMT=TV@T+PJ!KV@[3D5-0(3H!JP H D!M\OS8^2PARKC$ $_UF6
M*<^L$\V=L4GPQ/T8*'-VRD)DI516Q7:,0PHZ+7,VY?JP-W6D7$RZ6*^K ]]<
MWM]><R[!^+.#)_HK)CYC6_'=G^BDAS[ (T*[\"&DJ_607)9U$R5P8U6T7<,
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MJV!H-8S.3C]&P<TJ!Y;X)J,N#8EOH)")W3G,6\3$QY(O7>:6>"UD"9E^Y[=
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MEV_9KGD+2U_Z(Q>]22C> ]I%9 =6N,^]J6K7^B&-RS'GM<X2<C\;:IA1/\1
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M7><[[N_AJCYF[==,?4[!""_L-MDC".)VF)0K7V8-?RJK6(M)^2TS'Y.\L![
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MNF 995#8V:CGVD]G9A5FGY+-1CIHH#QV+HZ$KH88C@OO!C$8]4X(AJ9\I"M
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MZ>^+O?FBJ'H#1^+T(4M+<6;E#Y6#.#/UA%(%"]8U6#FTL4AV+FW^R30".;?
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MB.4V8SZ"5N%G\&@FT-1+32B-2MPA(%RDT56<$?,40G-1@0V4;K_BKWQ7#IO
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MXJMWFWS]\G!_\?'F@D1>Z>"S63&$&E4]ZFO(5[Q>5[E\YU)- Q!>T0Y:D&7
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MF8ZA%(*]2X#=UO?NHA1N[:^@F"G@'4KA*;Z>-6]/:C]J:X,)RX W)+45L;5
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MB!B->43JN0G>I#-1$'G=?B% #D\O0+N&5YFO U2TD<-ZNO:B%;J,]N-5YTN
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MP6I]4ZAFH>W$33-V;/5#G3"396AG8\+&^0M*_"#E"6%9'"VFG:)K39A=PN2
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M<+Q7P^+" /]-VQ8>2RRU9N@>G 5"A#"TX<"-EW1-S,"-9WBU8S8<$C2%:]\
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MU4<B HV$@[_R&AP(9RJ<83%H.+*5&2'D49L=IQSTF,*D3_&+[\0E7M".OZJ
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MO0WVGB;^<3.J]%Q$E5(O6N!_Z\1>&/&L?3A&,1I3;6$?R"J'Q=S'^!Y:?^K
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M-9FM$D1%_ SA(S_8"L>J!)8YFHN+",DLEXAV/.WB9FXX\;@!ZAA=%BY9X>I
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M!AQD5&)VPDHBN-3$=4:4(' YL9H7DG*BLO=2X-@XT:O-&+Z:"*'@VB5%C*Z
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MT"%D."=B&+PS_H!)%E0IA./.0E'>4:D[K;!38=/K.S,K6\)8N'+\CL"/2M"
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M3?3PH248_00 O'[)L.63%T3SZ *O&. =H#059@?[2QMZ+L,%SGZAKCDRI+_
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MZWN"T*.7(O*W_P]02P$"% ,4    " #NG'I2!E@_6PJO 0 -1Q0 $0
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64$L%!@     &  8 B@$  !FR P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
